PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Franci, C; Takkunen, M; Dave, N; Alameda, F; Gomez, S; Rodriguez, R; Escriva, M; Montserrat-Sentis, B; Baro, T; Garrido, M; Bonilla, F; Virtanen, I; de Herreros, AG				Franci, C.; Takkunen, M.; Dave, N.; Alameda, F.; Gomez, S.; Rodriguez, R.; Escriva, M.; Montserrat-Sentis, B.; Baro, T.; Garrido, M.; Bonilla, F.; Virtanen, I.; Garcia de Herreros, A.			Expression of Snail protein in tumor-stroma interface	ONCOGENE			English	Article						Snail transcriptional factor; fibroblast; epithelial-mesenchymal transition	TRANSCRIPTION FACTOR SNAIL; EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN EXPRESSION; MAMMARY-CARCINOMA; REPRESSOR SNAIL; BREAST-CANCER; GROWTH; PHOSPHORYLATION; FIBROBLASTS; CELLS	The product of Snail gene is a repressor of E-cadherin transcription and an inductor of the epithelial-to-mesenchymal transition in several epithelial tumor cell lines. In order to examine Snail expression in animal and human tissues, we have raised a monoclonal antibody(MAb) that reacts with the regulatory domain of this protein. Analysis of murine embryos shows that Snail is expressed in extraembryonic tissues and embryonic mesoderm, in mesenchymal cells of lungs and dermis as well as in cartilage. Little reactivity was detected in adult tissues as Snail was not constitutively expressed in most mesenchymal cells. However, Snail expression was observed in activated fibroblasts involved in wound healing in mice skin. Moreover, Snail was detected in pathological conditions causing hyperstimulation of fibroblasts, such as fibromatosis. Analysis of Snail expression in tumors revealed that it was highly expressed in sarcomas and. brosarcomas. In epithelial tumors, it presented a more limited distribution, restricted to stromal cells placed in the vicinity of the tumor and to tumoral cells in the same areas. These results demonstrate that Snail is present in activated mesenchymal cells, indicate its relevance in the communication between tumor and stroma and suggest that it can promote the conversion of carcinoma cells to stromal cells.	Univ Helsinki, Inst Biomed Anat, Biomedicum, FIN-00014 Helsinki, Finland; Univ Pompea Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona, Spain; Hosp Mar, Serv Anat Patol, E-08003 Barcelona, Spain; Univ Autonoma Barcelona, Fac Med, E-08193 Barcelona, Spain; Univ Pompau Fabra, Inst Municipal Invest Med, Serv Estab, Barcelona, Spain; Hosp Virgen Salud, Dept Patol, Toledo, Spain; Hosp Univ Puerta Hierro, Med Oncol Serv, Madrid, Spain	University of Helsinki; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; University of Barcelona; Complejo Hospitalario de Toledo; Hospital Puerta de Hierro-Majadahonda	Virtanen, I (corresponding author), Univ Helsinki, Inst Biomed Anat, Biomedicum, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	ismo.virtanen@helsinki.fi; agarcia@imim.es	de Herreros, A Garcia/H-3104-2014	de Herreros, A Garcia/0000-0001-5270-0808				Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Galie M, 2005, CARCINOGENESIS, V26, P1868, DOI 10.1093/carcin/bgi158; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; Jamora C, 2005, PLOS BIOL, V3, P131, DOI 10.1371/journal.pbio.0030011; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Moinfar F, 2000, CANCER RES, V60, P2562; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; NIETO MA, 1992, DEVELOPMENT, V116, P227; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Pena C, 2005, HUM MOL GENET, V14, P3361, DOI 10.1093/hmg/ddi366; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5; Rosivatz E, 2006, VIRCHOWS ARCH, V448, P277, DOI 10.1007/s00428-005-0118-9; Rosivatz E, 2004, INT J CANCER, V111, P711, DOI 10.1002/ijc.20317; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Shekhar MPV, 2001, CANCER RES, V61, P1320; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	43	186	188	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5134	5144		10.1038/sj.onc.1209519	http://dx.doi.org/10.1038/sj.onc.1209519			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16568079				2022-12-25	WOS:000240063700006
J	Mochizuki, T; Furuta, S; Mitsushita, J; Shang, W; Ito, M; Yokoo, Y; Yamaura, M; Ishizone, S; Nakayama, J; Konagai, A; Hirose, K; Kiyosawa, K; Kamata, T				Mochizuki, T.; Furuta, S.; Mitsushita, J.; Shang, W. H.; Ito, M.; Yokoo, Y.; Yamaura, M.; Ishizone, S.; Nakayama, J.; Konagai, A.; Hirose, K.; Kiyosawa, K.; Kamata, T.			Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells	ONCOGENE			English	Article						Nox4; apoptosis; AKT; ASK1	PROTEIN-KINASE B; NAD(P)H OXIDASE; ANGIOTENSIN-II; NADPH OXIDASE; SUPEROXIDE; INSULIN; PHOSPHORYLATES; EXPRESSION; MECHANISM; HOMOLOGS	Pancreatic adenocarcinoma is an aggressive human malignancy and is characterized by resistance to apoptosis. Recently, NADPH oxidase ( Nox) 4-mediated generation of intracellular reactive oxygen species ( ROS) was proposed to confer antiapoptotic activity and thus a growth advantage to pancreatic cancer cells. The signaling mechanism by which Nox4 transmits cell survival signals remains unclear. Here, we show that both a flavoprotein inhibitor, diphenylene iodonium ( DPI), and small interfering RNAs designed to target Nox4 mRNA ( siNox4R-NAs) inhibited superoxide production in PANC-1 pancreatic cancer cells, and depletion of ROS by DPI or siNox4RNAs induced apoptosis. Parallely, DPI treatment and siNox4RNA transfection blocked activation of the cell survival kinase AKT by attenuating phosphorylation of AKT. Furthermore, AKT phosphorylation of apoptosis signal-regulating kinase 1 ( ASK1) on Ser-83 was reduced by DPI and siNox4RNAs. When ASK1Ser83Ala ( an AKT phosphorylation-defective ASK1 mutant) was introduced into PANC-1 cells, this mutant alone induced apoptosis. But, addition of DPI or co-transfection of siNox4RNA had no additive effect, indicating that the mutant can substitute for these reagents in apoptosis induction. Taken together, these findings suggest that ROS generated by Nox4, at least in part, transmit cell survival signals through the AKT ASK1 pathway in pancreatic cancer cells and their depletion leads to apoptosis.	Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Grad Sch Med, Dept Internal Med 2, Nagano, Japan; Shinshu Univ, Grad Sch Med, Dept Dermatol, Matsumoto, Nagano, Japan; Shinshu Univ, Grad Sch Med, Dept Surg, Matsumoto, Nagano, Japan; Shinshu Univ, Grad Sch Med, Inst Organ Transplants Reconstruct Med & Tissue E, Nagano, Japan; Kureha Chem Ind Co Ltd, Biomed Res Inst, Tokyo, Japan	Shinshu University; Shinshu University; Shinshu University; Shinshu University; Shinshu University	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp	Mitsushita, Junji/D-7688-2016	Mitsushita, Junji/0000-0001-9402-4318				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Djordjevic T, 2005, ARTERIOSCL THROM VAS, V25, P519, DOI 10.1161/01.ATV.0000154279.98244.eb; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gorin Y, 2004, BIOCHEM J, V381, P231, DOI 10.1042/BJ20031614; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lin KI, 1999, J BIOL CHEM, V274, P13650, DOI 10.1074/jbc.274.19.13650; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P49, DOI 10.1210/en.2003-0792; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Miura K, 2001, J BIOL CHEM, V276, P46276, DOI 10.1074/jbc.M102387200; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Yu WP, 2003, CANCER RES, V63, P2483	37	187	196	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3699	3707		10.1038/sj.onc.1209406	http://dx.doi.org/10.1038/sj.onc.1209406			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16532036				2022-12-25	WOS:000238448300009
J	Compton, MA; Graham, LA; Stevens, TH				Compton, Mark A.; Graham, Laurie A.; Stevens, Tom H.			Vma9p (subunit e) is an integral membrane V-o subunit of the yeast V-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ENDOPLASMIC-RETICULUM; VACUOLAR ATPASE; GENE ENCODES; PROTEIN; PUMP; TRANSFORMATION; TRANSPORT; ROTATION; DIVERSE	The Saccharomyces cerevisiae vacuolar proton-translocating ATPase (V-ATPase) is composed of 14 subunits distributed between a peripheral V-1 subcomplex and an integral membrane V-0 subcomplex. Genome-wide screens have led to the identification of the newest yeast V-ATPase subunit, Vma9p. Vma9p ( subunit e) is a small hydrophobic protein that is conserved from fungi to animals. We demonstrate that disruption of yeast VMA9 results in the failure of V-1 and V-0 V-ATPase subunits to assemble onto the vacuole and in decreased levels of the subunit a isoforms Vph1p and Stv1p. We also show that Vma9p is an integral membrane protein, synthesized and inserted into the endoplasmic reticulum ( ER), which then localizes to the limiting membrane of the vacuole. All V-0 subunits and V-ATPase assembly factors are required for Vma9p to efficiently exit the ER. In the ER, Vma9p and the V-0 subunits interact with the V-ATPase assembly factor Vma21p. Interestingly, the association of Vma9p with the V-0-Vma21p assembly complex is disrupted with the loss of any single V-0 subunit. Similarly, Vma9p is required for V-0 subunits Vph1p and Vma6p to associate with the V-0-Vma21p complex. In contrast, the proteolipids associate with Vma21p even in the absence of Vma9p. These results demonstrate that Vma9p is an integral membrane subunit of the yeast V-ATPase V-0 subcomplex and suggest a model for the arrangement of polypeptides within the V-0 subcomplex.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Stevens, TH (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	stevens@molbio.uoregon.edu		Stevens, Tom/0000-0001-6427-6848	NIGMS NIH HHS [GM38006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUERLE C, 1993, J BIOL CHEM, V268, P12749; Conibear E, 2002, METHOD ENZYMOL, V351, P408; Davis-Kaplan SR, 2004, J BIOL CHEM, V279, P4322, DOI 10.1074/jbc.M310680200; Flannery AR, 2004, J BIOL CHEM, V279, P39856, DOI 10.1074/jbc.M406767200; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Graham LA, 2003, J BIOENERG BIOMEMBR, V35, P301, DOI 10.1023/A:1025772730586; Graham LA, 1999, J BIOENERG BIOMEMBR, V31, P39, DOI 10.1023/A:1005492429471; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; Graham LA, 2000, J EXP BIOL, V203, P61; Hiesinger PR, 2005, CELL, V121, P607, DOI 10.1016/j.cell.2005.03.012; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; Imamura H, 2005, P NATL ACAD SCI USA, V102, P17929, DOI 10.1073/pnas.0507764102; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Jackson DD, 1997, J BIOL CHEM, V272, P25928, DOI 10.1074/jbc.272.41.25928; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; KANE PM, 1992, J BIOL CHEM, V267, P447; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kontani K, 2005, DEV CELL, V8, P787, DOI 10.1016/j.devcel.2005.02.018; Ludwig J, 1998, J BIOL CHEM, V273, P10939, DOI 10.1074/jbc.273.18.10939; Malkus P, 2004, MOL BIOL CELL, V15, P5075, DOI 10.1091/mbc.E04-06-0514; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; Merzendorfer H, 1999, J BIOL CHEM, V274, P17372, DOI 10.1074/jbc.274.24.17372; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sambade M, 2005, GENETICS, V170, P1539, DOI 10.1534/genetics.105.042812; Sambade M, 2004, J BIOL CHEM, V279, P17361, DOI 10.1074/jbc.M314104200; SAMBROOK J, 2001, MOL CLONING LAB METH; SIKORSKI RS, 1989, GENETICS, V122, P19; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sun-Wada GH, 2004, BBA-BIOENERGETICS, V1658, P106, DOI 10.1016/j.bbabio.2004.04.013; Sun-Wada GH, 2003, J BIOENERG BIOMEMBR, V35, P347, DOI 10.1023/A:1025780932403; Sze H, 2002, TRENDS PLANT SCI, V7, P157, DOI 10.1016/S1360-1385(02)02240-9; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	48	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15312	15319		10.1074/jbc.M600890200	http://dx.doi.org/10.1074/jbc.M600890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16569636	hybrid			2022-12-25	WOS:000237922200035
J	Keiser, M; Alfalah, M; Propsting, MJ; Castelletti, D; Naim, HY				Keiser, Markus; Alfalah, Marwan; Proepsting, Marcus J.; Castelletti, Deborah; Naim, Hassan Y.			Altered folding, turnover, and polarized sorting act in concert to define a novel pathomechanism of congenital sucrase-isomaltase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; INTESTINAL EPITHELIAL-CELLS; GPI-ANCHORED PROTEINS; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; APICAL MEMBRANE; ENZYME; BIOSYNTHESIS; EXPRESSION	Naturally occurring mutants of membrane and secretory proteins are often associated with the pathogenesis of human diseases. Here, we describe the molecular basis of a novel phenotype of congenital sucrase-isomaltase deficiency (CSID), a disaccharide malabsorption disorder of the human intestine in which several structural features and functional capacities of the brush-border enzyme complex sucrase-isomaltase (SI) are affected. The cDNA encoding SI from a patient with CSID reveals a mutation in the isomaltase subunit of SI that results in the substitution of a cysteine by an arginine at amino acid residue 635 (C635R). When this mutation is introduced into the wild type cDNA of SI a mutant enzyme, SIC635R, is generated that shows a predominant localization in the endoplasmic reticulum. Nevertheless, a definite localization of SIC635R in the Golgi apparatus and at the cell surface could be also observed. Epitope mapping with conformation-specific mAbs protease sensitivity assays, and enzymatic activity measurements demonstrate an altered folding pattern of SIC635R that is responsible for a substantially increased turnover rate and an aberrant sorting profile. Thus, SIC635R becomes distributed also at the basolateral membrane in contrast to wild type SI. Concomitant with the altered sorting pattern, the partial detergent extractability of wild type SI shifts to a complete detergent solubility with Triton X-100. The mutation has therefore affected an epitope responsible for the apical targeting fidelity of SI. Altogether, the combined effects of the C635R mutation on the turnover rate, function, polarized sorting, and detergent solubility of SI constitute a unique and novel pathomechanism of CSID.	Univ Vet Med Hannover, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Univ Vet Med Hannover, Dept Physiol Chem, D-30559 Hannover, Germany.	hassan.naim@tiho-hannover.de	Al Falah, Dr. Marwan/C-6281-2011	Keiser, Markus/0000-0003-4842-6273				Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Alfalah M, 2002, J BIOL CHEM, V277, P10683, DOI 10.1074/jbc.M109357200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; GORVEL JP, 1991, GASTROENTEROLOGY, V101, P618, DOI 10.1016/0016-5085(91)90517-O; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 2000, J CLIN INVEST, V106, P281, DOI 10.1172/JCI9677; Jacob R, 2000, J BIOL CHEM, V275, P10630, DOI 10.1074/jbc.275.14.10630; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; JACOB R, 1994, J BIOL CHEM, V269, P2712; KERRY K. R., 1965, Australian Paediatric Journal, V1, P223; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; LLOYD ML, 1987, NEW ENGL J MED, V316, P438, DOI 10.1056/NEJM198702193160804; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; Moolenaar CEC, 1997, J CELL SCI, V110, P557; NAIM HY, 1988, J CLIN INVEST, V82, P667, DOI 10.1172/JCI113646; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; Propsting MJ, 2003, J BIOL CHEM, V278, P16310, DOI 10.1074/jbc.C300093200; Ritz V, 2003, GASTROENTEROLOGY, V125, P1678, DOI 10.1053/j.gastro.2003.09.022; SEMENZA G, 1983, CIBA F SYMP, V95, P92; Spodsberg N, 2001, J BIOL CHEM, V276, P23506, DOI 10.1074/jbc.C100219200; TREEM WR, 1995, J PEDIATR GASTR NUTR, V21, P1, DOI 10.1097/00005176-199507000-00001	28	19	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14393	14399		10.1074/jbc.M513631200	http://dx.doi.org/10.1074/jbc.M513631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543230	hybrid			2022-12-25	WOS:000237512300066
J	Kijas, AW; Harris, JL; Harris, JM; Lavin, MF				Kijas, Amanda W.; Harris, Janelle L.; Harris, Jonathan M.; Lavin, Martin F.			Aprataxin forms a discrete branch in the HIT (histidine triad) superfamily of proteins with both DNA/RNA binding and nucleotide hydrolase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-LYSINE HYDROLASE; DNA-DAMAGE; ATAXIA; RNA; HINT; PURIFICATION; NUCLEOLUS; MUTATIONS; MECHANISM; INTERACTS	Ataxia with oculomotor apraxia type 1 (AOA1) is an early onset autosomal recessive spinocerebellar ataxia with a defect in the protein Aprataxin, implicated in the response of cells to DNA damage. We describe here the expression of a recombinant form of Aprataxin and show that it has dual DNA binding and nucleotide hydrolase activities. This protein binds to double-stranded DNA with high affinity but is also capable of binding double-stranded RNA and single-strand DNA, with increased affinity for hairpin structures. No increased binding was observed with a variety of DNA structures mimicking intermediates in DNA repair. The DNA binding observed here was not dependent on zinc, and the addition of exogenous zinc abolished DNA binding. We also demonstrate that Aprataxin hydrolyzes with similar efficiency the model histidine triad nucleotide-binding protein substrate, AMPNH(2), and the Fragile histidine triad protein substrate, Ap(4)A. These activities were significantly reduced in the presence of duplex DNA and to a lesser extent in the presence of single-strand DNA, and removal of the N-terminal Forkhead associated domain did not alter activity. Finally, comparison of sequence relationships between the histidine triad superfamily members shows that Aprataxin forms a distinct branch in this superfamily. In addition to its capacity for nucleotide binding and hydrolysis, the observation that it also binds DNA and RNA adds a new dimension to this superfamily of proteins and provides further support for a role for Aprataxin in the cellular response to DNA damage.	Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Queensland Univ Technol, Sch Life Sci, Brisbane, Qld 4000, Australia; Univ Queensland, Cent Clin Sch, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Queensland University of Technology (QUT); University of Queensland	Lavin, MF (corresponding author), Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.	Martin.Lavin@qimr.edu.au	Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Harris, Jonathan/0000-0003-4209-2380; Kijas, Amanda/0000-0001-8538-7766; Hancock, Janelle/0000-0001-6703-7228				Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; CHI NW, 1994, J BIOL CHEM, V269, P29984; Clements PM, 2004, DNA REPAIR, V3, P1493, DOI 10.1016/j.dnarep.2004.06.017; Date H, 2004, BIOCHEM BIOPH RES CO, V325, P1279, DOI 10.1016/j.bbrc.2004.10.162; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Draganescu A, 2000, J BIOL CHEM, V275, P4555, DOI 10.1074/jbc.275.7.4555; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Gueven N, 2004, HUM MOL GENET, V13, P1081, DOI 10.1093/hmg/ddh122; Hall MC, 2001, PROTEIN EXPRES PURIF, V21, P333, DOI 10.1006/prep.2000.1379; Hirano M, 2004, BIOCHEM BIOPH RES CO, V322, P380, DOI 10.1016/j.bbrc.2004.07.135; Krakowiak A, 2004, J BIOL CHEM, V279, P18711, DOI 10.1074/jbc.M314271200; Kwasnicka DA, 2003, J BIOL CHEM, V278, P39051, DOI 10.1074/jbc.M306355200; Le Ber I, 2004, BRAIN, V127, P759, DOI 10.1093/brain/awh080; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Matt T, 2004, BIOCHEM J, V381, P685, DOI 10.1042/BJ20040564; Mendez-Vidal C, 2002, NUCLEIC ACIDS RES, V30, P1991, DOI 10.1093/nar/30.9.1991; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Mosesso P, 2005, CELL MOL LIFE SCI, V62, P485, DOI 10.1007/s00018-004-4441-0; Olson Mark O J, 2004, Sci STKE, V2004, ppe10; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Sano Y, 2004, ANN NEUROL, V55, P241, DOI 10.1002/ana.10808; Seidle HF, 2005, J BIOL CHEM, V280, P20927, DOI 10.1074/jbc.M502889200; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; Shaw P, 2005, CELL CYCLE, V4, P102, DOI 10.4161/cc.4.1.1467; Stefl R, 2005, EMBO REP, V6, P33, DOI 10.1038/sj.embor.7400325; Tranchant C, 2003, NEUROLOGY, V60, P868, DOI 10.1212/01.WNL.0000048562.88536.A4; Weinberg RL, 2004, J MOL BIOL, V342, P801, DOI 10.1016/j.jmb.2004.07.042; Wesierska-Gadek J, 2003, ANN NY ACAD SCI, V1010, P266, DOI 10.1196/annals.1299.046; Yung TMC, 2004, J BIOL CHEM, V279, P39686, DOI 10.1074/jbc.M402729200	32	60	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13939	13948		10.1074/jbc.M507946200	http://dx.doi.org/10.1074/jbc.M507946200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16547001	hybrid, Green Published			2022-12-25	WOS:000237512300015
J	Muresanu, L; Pristovsek, P; Lohr, F; Maneg, O; Mukrasch, MD; Rurterjans, H; Ludwig, B; Lucke, C				Muresanu, Lucia; Pristovsek, Primoz; Loehr, Frank; Maneg, Oliver; Mukrasch, Marco D.; Ruerterjans, Heinz; Ludwig, Bernd; Luecke, Christian			The Electron Transfer Complex between Cytochrome c(552) and the Cu-A Domain of the Thermus thermophilus ba(3) Oxidase A COMBINED NMR AND COMPUTATIONAL APPROACH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The structural analysis of the redox complex between the soluble cytochrome c(552) and the membrane-integral cytochrome ba(3) oxidase of Thermus thermophilus is complicated by the transient nature of this protein-protein interaction. Using NMR-based chemical shift perturbation mapping, however, we identified the contact regions between cytochrome c(552) and the Cu-A domain, the fully functional water-soluble fragment of subunit II of the ba(3) oxidase. First we determined the complete backbone resonance assignments of both proteins for each redox state. Subsequently, two-dimensional [N-15, H-1]TROSY spectra recorded for each redox partner both in free and complexed state indicated those surface residues affected by complex formation between the two proteins. This chemical shift analysis performed for both redox states provided a topological description of the contact surface on each partner molecule. Remarkably, very pronounced indirect effects, which were observed on the back side of the heme cleft only in the reduced state, suggested that alterations of the electron distribution in the porphyrin ring due to formation of the protein-protein complex are apparently sensed even beyond the heme propionate groups. The contact residues of each redox partner, as derived from the chemical shift perturbation mapping, were employed for a protein-protein docking calculation that provided a structure ensemble of 10 closely related conformers representing the complex between cytochrome c(552) and the Cu-A domain. Based on these structures, the electron transfer pathway from the heme of cytochrome c(552) to the Cu-A center of the ba(3) oxidase has been predicted.	[Muresanu, Lucia; Loehr, Frank; Mukrasch, Marco D.; Ruerterjans, Heinz; Luecke, Christian] Univ Frankfurt, Ctr Biomol Magnet Resonance, Inst Biophys Chem, D-60439 Frankfurt, Germany; [Pristovsek, Primoz] Natl Inst Chem, SI-1000 Ljubljana, Slovenia; [Maneg, Oliver; Ludwig, Bernd] Univ Frankfurt, Inst Biochem, D-60439 Frankfurt, Germany	Goethe University Frankfurt; National Institute of Chemistry - Slovenia; Goethe University Frankfurt	Lucke, C (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle, Saale, Germany.	luecke@enzyme-halle.mpg.de		Pristovsek, Primoz/0000-0002-2304-1791	Deutsche Forschungsgemeinschaft [SFB 472]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported in part by the Deutsche Forschungsgemeinschaft (SFB 472). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	ANTHOLINE WE, 1992, EUR J BIOCHEM, V209, P875, DOI 10.1111/j.1432-1033.1992.tb17360.x; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; Bertini I, 1996, J AM CHEM SOC, V118, P11658, DOI 10.1021/ja9621410; Bertini I., 2001, SOLUTION NMR PARAMAG; Bresser A., 1993, Biological Chemistry Hoppe-Seyler, V374, P736; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cunha CA, 1999, J BIOL INORG CHEM, V4, P360, DOI 10.1007/s007750050323; Diaz-Moreno I, 2005, J BIOL CHEM, V280, P18908, DOI 10.1074/jbc.M413298200; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Drosou V, 2002, EUR J BIOCHEM, V269, P2980, DOI 10.1046/j.1432-1033.2002.02979.x; Drosou V, 2002, BIOCHEMISTRY-US, V41, P10629, DOI 10.1021/bi020094k; FEE JA, 1980, P NATL ACAD SCI-BIOL, V77, P147, DOI 10.1073/pnas.77.1.147; Fee JA, 2000, PROTEIN SCI, V9, P2074, DOI 10.1110/ps.9.11.2074; Gray HB, 2005, P NATL ACAD SCI USA, V102, P3534, DOI 10.1073/pnas.0408029102; Harrenga A, 2000, J MOL BIOL, V295, P667, DOI 10.1006/jmbi.1999.3382; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Johansson MP, 2002, J AM CHEM SOC, V124, P11771, DOI 10.1021/ja026523j; Johansson MP, 2002, BBA-BIOENERGETICS, V1553, P183, DOI 10.1016/S0005-2728(02)00182-2; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kannt A, 1998, FEBS LETT, V434, P17, DOI 10.1016/S0014-5793(98)00942-9; KELLY M, 1993, J BIOL CHEM, V268, P16781; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Maneg O, 2004, BBA-BIOENERGETICS, V1655, P274, DOI 10.1016/j.bbabio.2003.10.010; Maneg O, 2003, J BIOL CHEM, V278, P46734, DOI 10.1074/jbc.M307594200; Moore G. R., 1990, CYTOCHROMES C EVOLUT; Mooser D, 2005, BBA-BIOENERGETICS, V1708, P262, DOI 10.1016/j.bbabio.2005.03.008; Morelli X, 2000, J BIOL CHEM, V275, P23204, DOI 10.1074/jbc.M909835199; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Mukrasch MD, 2004, J BIOMOL NMR, V28, P297, DOI 10.1023/B:JNMR.0000013687.83263.b5; Mulder FAA, 1999, J MOL BIOL, V292, P111, DOI 10.1006/jmbi.1999.3034; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Pristovsek P, 2000, EUR J BIOCHEM, V267, P4205, DOI 10.1046/j.1432-1327.2000.01456.x; REGAN JJ, 1993, J PHYS CHEM-US, V97, P13083, DOI 10.1021/j100152a009; Reincke B, 2001, BIOCHEMISTRY-US, V40, P12312, DOI 10.1021/bi010615o; SCOTT RA, 1996, CYTOCHROME C MULTIDI; SIDDARTH P, 1993, J PHYS CHEM-US, V97, P2400, DOI 10.1021/j100112a047; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Soulimane T, 1997, BIOCHEM BIOPH RES CO, V237, P572, DOI 10.1006/bbrc.1997.7041; SOULIMANE T, 1995, FEBS LETT, V368, P132, DOI 10.1016/0014-5793(95)00623-H; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; Ubbink M, 1997, BIOCHEMISTRY-US, V36, P6326, DOI 10.1021/bi963199u; Wienk H, 2003, BIOCHEMISTRY-US, V42, P6005, DOI 10.1021/bi027198f; Williams PA, 1999, NAT STRUCT BIOL, V6, P509; WILLIAMS RAD, 1989, FEMS SYMP, V49, P82; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Witt H, 1998, J BIOL CHEM, V273, P5132, DOI 10.1074/jbc.273.9.5132; Worrall JAR, 2001, BIOCHEMISTRY-US, V40, P7069, DOI 10.1021/bi0025823; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yano T, 1997, J BIOL CHEM, V272, P4201, DOI 10.1074/jbc.272.7.4201; ZIMMERMANN BH, 1988, P NATL ACAD SCI USA, V85, P5779, DOI 10.1073/pnas.85.16.5779	54	39	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14503	14513		10.1074/jbc.M601108200	http://dx.doi.org/10.1074/jbc.M601108200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16554303	hybrid			2022-12-25	WOS:000207179300009
J	Parker, ET; Doering, CB; Lollar, P				Parker, Ernest T.; Doering, Christopher B.; Lollar, Pete			A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; MILD HEMOPHILIA-A; HIGH-LEVEL EXPRESSION; PROCOAGULANT ACTIVITY; VONWILLEBRAND FACTOR; INHIBITORY EPITOPE; MAJOR DETERMINANT; LIGHT-CHAIN; FACTOR-X; INACTIVATION	Factor VIII (fVIII) is the plasma protein that is missing or deficient in hemophilia A. In contrast, elevated levels of fVIII are associated with an increased risk of arterial and venous thrombosis. fVIII is activated by thrombin to form a non-covalently linked A1/A2/A3-C1-C2 heterotrimer. At physiological concentrations, fVIIIa decays as a result of A2 subunit dissociation, which may help regulate the balance between hemostasis and thrombosis. A2 subunit dissociation is faster in human fVIIIa than in porcine fVIIIa, which may represent an evolutionary adaptation associated with the development of the upright posture and venous stasis in the lower extremities. To investigate the basis for the different decay kinetics of human and porcine fVIIIa, hybrid fVIII molecules representing all possible combinations of human and porcine A domains were isolated. The kinetics of fVIIIa decay were measured and fit to a model describing a reversible bimolecular reaction in which the dissociation rate constant, k, and dissociation constant, K-d, were the fitted parameters. Substitution of the porcine A1 domain into human fVIIIa produced a dissociation rate constant indistinguishable from porcine fVIIIa. Subsequently, substitution of the second cupredoxin-like A1 subdomain resulted in a dissociation rate constant similar to porcine fVIIIa, whereas substitution of the first cupredoxin-like A1 subdomain resulted in a dissociation rate constant intermediate between human and porcine fVIIIa. We propose that cupredoxin-like A1 subdomains in fVIII contain inter-species differences that are a result of selective pressure on the dissociation rate constant.	Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; Childrens Healthcare Atlanta, Aflac Canc Ctr & Blood Disorders Serv, Atlanta, GA 30322 USA	Emory University; Children's Healthcare of Atlanta (CHOA)	Lollar, P (corresponding author), Emory Childrens Ctr, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	jlollar@emory.edu	Doering, Christopher/W-2064-2019		NHLBI NIH HHS [R01-HL40921] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALY AM, 1992, J CLIN INVEST, V89, P1382, DOI 10.1172/JCI115726; ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; Barrow RT, 2000, BLOOD, V95, P564, DOI 10.1182/blood.V95.2.564; BARROW RT, 1994, J BIOL CHEM, V269, P26796; Bevington P. R., 1969, DATA REDUCTION ERROR; Doering CB, 2004, J BIOL CHEM, V279, P6546, DOI 10.1074/jbc.M312451200; Doering CB, 2002, J BIOL CHEM, V277, P38345, DOI 10.1074/jbc.M206959200; Doering CB, 2002, THROMB HAEMOSTASIS, V88, P450; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ESMON CT, 1979, J BIOL CHEM, V254, P964; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; Evans E, 2001, ANNU REV BIOPH BIOM, V30, P105, DOI 10.1146/annurev.biophys.30.1.105; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Hakeos WH, 2002, THROMB HAEMOSTASIS, V88, P781, DOI 10.1055/s-0037-1613302; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; Healey JF, 1998, BLOOD, V92, P3701, DOI 10.1182/blood.V92.10.3701.422k22_3701_3709; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HULTIN MB, 1981, BLOOD, V57, P476; Kamphuisen PW, 2001, ARTERIOSCL THROM VAS, V21, P731, DOI 10.1161/01.ATV.21.5.731; Keeling DM, 1999, BRIT J HAEMATOL, V105, P1123, DOI 10.1046/j.1365-2141.1999.01460.x; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LIND P, 1995, EUR J BIOCHEM, V232, P19, DOI 10.1111/j.1432-1033.1995.tb20776.x; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MERTENS K, 1993, BRIT J HAEMATOL, V85, P133, DOI 10.1111/j.1365-2141.1993.tb08656.x; Moore J.W., 1981, KINETICS MECH, V3rd, P284; Moore W. J., 1972, PHYSICAL CHEM, P324; OBRIEN DP, 1990, BLOOD, V75, P1664; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARQUETGERNEZ A, 1988, THROMB HAEMOSTASIS, V59, P202; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Pipe SW, 1999, BLOOD, V93, P176, DOI 10.1182/blood.V93.1.176.401k07_176_183; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Rudzki Z, 1996, BRIT J HAEMATOL, V94, P400, DOI 10.1046/j.1365-2141.1996.d01-1792.x; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SHIMA M, 1989, BLOOD, V74, P1612; SHOEMAKER DP, 1989, EXPT PHYS CHEM, P801; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	51	20	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13922	13930		10.1074/jbc.M513124200	http://dx.doi.org/10.1074/jbc.M513124200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16513639	hybrid			2022-12-25	WOS:000237512300013
J	Shabalina, IG; Petrovic, N; Kramarova, TV; Hoeks, J; Cannon, B; Nedergaard, J				Shabalina, Irina G.; Petrovic, Natasa; Kramarova, Tatiana V.; Hoeks, Joris; Cannon, Barbara; Nedergaard, Jan			UCP1 and defense against oxidative stress - 4-hydroxy-2-nonenal effects on brown fat mitochondria are uncoupling protein 1-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTIVE NONSHIVERING THERMOGENESIS; ADIPOSE-TISSUE; LIPID-PEROXIDATION; SUPEROXIDE ANION; SIMPLE ASSAY; RAT; NUCLEOTIDES; TARGET; MUSCLE; MICE	Uncoupling proteins have been ascribed a role in defense against oxidative stress, particularly by being activated by products of oxidative stress such as 4-hydroxy-2-nonenal (HNE). We have investigated here the ability of HNE to activate UCP1. Using brown fat mitochondria from UCP1(+/+) and UCP1(+/+) mice to allow for identification of UCP1-dependent effects, we found that HNE could neither ( re) activate purine nucleotide-inhibited UCP1, nor induce additional activation of innately active UCP1. The aldehyde nonenal had a ( re) activating effect only if converted to the corresponding fatty acid by aldehyde dehydrogenase; the presence of a carboxyl group was thus an absolute requirement for (re)activation. The UCP1-dependent proton leak was not increased by HNE but HNE changed basal proton leak characteristics in a UCP1-independent manner. In agreement with the in vitro results, we found, as compared with UCP1(+/+) mice, no increase in HNE/protein adducts in brown fat mitochondria isolated from UCP1(-/-) mice, irrespective of whether they were adapted to thermoneutral temperature (30 degrees C) or to the cold (4 degrees C). The absence of oxidative damage in UCP1(-/-) mitochondria was not due to enhanced activity of antioxidant enzymes. Thus, HNE did not affect UCP1 activity, and UCP1 would appear not to be physiologically involved in defense against oxidative stress. Additionally, it was concluded that at least in brown adipose tissue, conditions of high mitochondrial membrane potential, high oxygen tension, and high substrate supply do not necessarily lead to increased oxidative damage.	Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden	Stockholm University	Nedergaard, J (corresponding author), Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	jan@metabol.su.se	Shabalina, Irina/AAC-3720-2019; Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Shabalina, Irina G/A-4225-2011; Cannon, Barbara/B-3089-2016	Shabalina, Irina/0000-0002-2915-6450; Shabalina, Irina G/0000-0002-2915-6450; Hoeks, Joris/0000-0002-0265-0870; Nedergaard, Jan/0000-0003-2070-1587; Cannon, Barbara/0000-0001-6594-2363				AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; ALP PR, 1976, BIOCHEM J, V154, P689, DOI 10.1042/bj1540689; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Bernal-Mizrachi C, 2005, NATURE, V435, P502, DOI 10.1038/nature03527; Beutler E., 1982, RED CELL METABOLISM, P105; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Cadenas S, 2000, BIOCHEM J, V348, P209, DOI 10.1042/0264-6021:3480209; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 2000, METH MOL B, V155, P295; Chen JJ, 1998, BBA-GEN SUBJECTS, V1380, P336, DOI 10.1016/S0304-4165(98)00002-6; Choksi KB, 2004, BBA-MOL BASIS DIS, V1688, P95, DOI 10.1016/j.bbadis.2003.11.007; Cohn JA, 1996, ARCH BIOCHEM BIOPHYS, V328, P158, DOI 10.1006/abbi.1996.0156; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; DEQUIROGA GB, 1991, BIOCHEM J, V277, P289, DOI 10.1042/bj2770289; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Esteves TC, 2005, BBA-BIOENERGETICS, V1709, P35, DOI 10.1016/j.bbabio.2005.06.002; FOSTER DO, 1978, CAN J PHYSIOL PHARM, V56, P110, DOI 10.1139/y78-015; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; Golozoubova V, 2001, FASEB J, V15, P2048, DOI 10.1096/fj.00-0536fje; Jaburek M, 2004, J BIOL CHEM, V279, P53097, DOI 10.1074/jbc.M405339200; Jaburek M, 2003, J BIOL CHEM, V278, P25825, DOI 10.1074/jbc.M302126200; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; Matthias A, 1999, J BIOL CHEM, V274, P28150, DOI 10.1074/jbc.274.40.28150; Meyer MJ, 2004, CHEM RES TOXICOL, V17, P1272, DOI 10.1021/tx049843k; MISRA HP, 1972, J BIOL CHEM, V247, P3170; Murphy MP, 2003, J BIOL CHEM, V278, P48534, DOI 10.1074/jbc.M308529200; Murphy TC, 2003, J NEUROCHEM, V84, P1313, DOI 10.1046/j.1471-4159.2003.01628.x; Nedergaard J, 2005, EMBO REP, V6, P917, DOI 10.1038/sj.embor.7400532; Nedergaard J, 2003, EXP PHYSIOL, V88, P65, DOI 10.1113/eph8802502; NEDERGAARD J, 1983, EUR J BIOCHEM, V133, P185, DOI 10.1111/j.1432-1033.1983.tb07446.x; Nedergaard J, 2001, BBA-BIOENERGETICS, V1504, P82, DOI 10.1016/S0005-2728(00)00247-4; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Ohta S, 2004, ANN NY ACAD SCI, V1011, P36, DOI 10.1196/annals.1293.004; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Petersen DR, 2004, FREE RADICAL BIO MED, V37, P937, DOI 10.1016/j.freeradbiomed.2004.06.012; Reinheckel T, 1998, FREE RADICAL RES, V29, P297, DOI 10.1080/10715769800300331; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RICQUIER D, 1978, J PHYSIOL-PARIS, V74, P695; Shabalina IG, 2004, J BIOL CHEM, V279, P38236, DOI 10.1074/jbc.M402375200; Siems Werner, 2003, Molecular Aspects of Medicine, V24, P167, DOI 10.1016/S0098-2997(03)00011-6; Silva JP, 2005, EMBO J, V24, P4061, DOI 10.1038/sj.emboj.7600866; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; ULLRICH O, 1994, FEBS LETT, V352, P84, DOI 10.1016/0014-5793(94)00922-8; Unami A, 2004, BIOCHEM PHARMACOL, V67, P555, DOI 10.1016/j.bcp.2003.09.010; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Waeg G, 1996, FREE RADICAL RES, V25, P149, DOI 10.3109/10715769609149920; Yagi K, 1998, Methods Mol Biol, V108, P101	55	76	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13882	13893		10.1074/jbc.M601387200	http://dx.doi.org/10.1074/jbc.M601387200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543238	hybrid			2022-12-25	WOS:000237512300008
J	Boix-Chornet, M; Fraga, MF; Villar-Garea, A; Caballero, R; Espada, J; Nunez, A; Casado, J; Largo, C; Casal, JI; Cigudosa, JC; Franco, L; Esteller, M; Ballestar, E				Boix-Chornet, M; Fraga, MF; Villar-Garea, A; Caballero, R; Espada, J; Nunez, A; Casado, J; Largo, C; Casal, JI; Cigudosa, JC; Franco, L; Esteller, M; Ballestar, E			Release of hypoacetylated and trimethylated histone H4 is an epigenetic marker of early apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; CHROMATIN CONDENSATION; NUCLEAR EVENTS; PHOSPHORYLATION; CANCER; H3; HETEROCHROMATIN; FRAGMENTATION; NUCLEOSOME; LYSINE-20	Nuclear events such as chromatin condensation, DNAcleavage at internucleosomal sites, and histone release from chromatin are recognized as hallmarks of apoptosis. However, there is no complete understanding of the molecular events underlying these changes. It is likely that epigenetic changes such as DNA methylation and histone modifications that are involved in chromatin dynamics and structure are also involved in the nuclear events described. In this report we have shown that apoptosis is associated with global DNA hypomethylation and histone deacetylation events in leukemia cells. Most importantly, we have observed a particular epigenetic signature for early apoptosis defined by a release of hypoacetylated and trimethylated histone H4 and internucleosomal fragmented DNA that is hypermethylated and originates from perinuclear heterochromatin. These findings provide one of the first links between apoptotic nuclear events and epigenetic markers.	Spanish Natl Canc Ctr, Canc Epigenet Lab, Mol Pathol Programme, Madrid 28029, Spain; Spanish Natl Canc Ctr, Prot Technol Unit, Biotechnol Programme, Madrid 28029, Spain; Spanish Natl Canc Ctr, Human Canc Genet Programme, Mol Cytogenet Grp, Madrid 28029, Spain; Univ Salamanca, Canc Res Ctr, Lab 14, Salamanca 37007, Spain; Univ Valencia, Dept Biochem & Mol Biol, Valencia 46100, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); University of Salamanca; University of Valencia	Esteller, M (corresponding author), Spanish Natl Canc Ctr, Canc Epigenet Lab, Mol Pathol Programme, Melchor Fernandez Almgro 3, Madrid 28029, Spain.	mesteller@cnio.es; eballestar@cnio.es	Ballestar, Esteban/ABG-8561-2020; Espada, Jesús/AAA-3198-2019; Casal, Ignacio/M-2312-2014; Cigudosa, Juan C/E-4105-2016; Esteller, Manel/L-5956-2014; Fraga, Mario F/H-7824-2017; Casado-Vela, Juan/C-5086-2013	Espada, Jesús/0000-0002-4202-4938; Casal, Ignacio/0000-0003-1085-2840; Esteller, Manel/0000-0003-4490-6093; Fraga, Mario F/0000-0001-8450-2603; Casado-Vela, Juan/0000-0001-5924-6601; Villar Garea, Ana/0000-0001-8960-1635; Franco, Luis/0000-0001-9610-6448; Ballestar, Esteban/0000-0002-1400-2440				Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; Allera C, 1997, J BIOL CHEM, V272, P10817; ARENDS MJ, 1990, AM J PATHOL, V136, P593; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; Bonaldi T, 2004, METHOD ENZYMOL, V377, P111; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; Cigudosa JC, 1998, BLOOD, V91, P3007, DOI 10.1182/blood.V91.8.3007.3007_3007_3010; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Gilchrist Susan, 2004, Chromosome Res, V12, P505; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; Hengartner MO, 2001, NATURE, V412, P27, DOI 10.1038/35083663; Johnson CA, 2001, J BIOL CHEM, V276, P4539, DOI 10.1074/jbc.C000824200; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Kratzmeier M, 2000, J BIOL CHEM, V275, P30478, DOI 10.1074/jbc.M003956200; Krystosek A, 1999, HISTOCHEM CELL BIOL, V111, P265, DOI 10.1007/s004180050357; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lawen A, 2003, BIOESSAYS, V25, P888, DOI 10.1002/bies.10329; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Lee E, 1999, IUBMB LIFE, V48, P79, DOI 10.1080/152165499307459; LINDNER H, 1992, BIOCHEM J, V283, P467, DOI 10.1042/bj2830467; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Lund G, 2004, J BIOL CHEM, V279, P29147, DOI 10.1074/jbc.M403618200; Makatsori D, 2004, J BIOL CHEM, V279, P25567, DOI 10.1074/jbc.M313606200; Martelli AM, 2001, J CELL BIOCHEM, V82, P634, DOI 10.1002/jcb.1186; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Okamoto I, 2004, SCIENCE, V303, P644, DOI 10.1126/science.1092727; Paz MF, 2003, CANCER RES, V63, P1114; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Polioudaki H, 2001, EMBO REP, V2, P920, DOI 10.1093/embo-reports/kve199; Pyrpasopoulou A, 1996, EMBO J, V15, P7108, DOI 10.1002/j.1460-2075.1996.tb01102.x; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Robertson JD, 2000, J STRUCT BIOL, V129, P346, DOI 10.1006/jsbi.2000.4254; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; SHELTON ER, 1980, J BIOL CHEM, V255, P771; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; van Holde K.E., 1988, CHROMATIN; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Weaver VM, 1996, J CELL SCI, V109, P45; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Wojciechowski J, 2003, INT J CANCER, V106, P486, DOI 10.1002/ijc.11290; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; Wu DC, 2002, J BIOL CHEM, V277, P12001, DOI 10.1074/jbc.M109219200	56	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13540	13547		10.1074/jbc.M601136200	http://dx.doi.org/10.1074/jbc.M601136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531610	Green Published, hybrid			2022-12-25	WOS:000237336600062
J	Iwakura, M; Maki, K; Takahashi, H; Takenawa, T; Yokota, A; Katayanagi, K; Kamiyama, T; Gekko, K				Iwakura, M; Maki, K; Takahashi, H; Takenawa, T; Yokota, A; Katayanagi, K; Kamiyama, T; Gekko, K			Evolutional design of a hyperactive cysteine- and methionine-free mutant of Escherichia coli dihydrofolate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LOCAL FITNESS LANDSCAPE; AMINO-ACID; OXIDATIVE RESISTANCE; CIRCULAR PERMUTATION; MOLECULAR DISSECTION; CRYSTAL-STRUCTURES; FOLDING ELEMENTS; PROTEIN; BINDING	We developed a strategy for finding out the adapted variants of enzymes, and we applied it to an enzyme, dihydrofolate reductase ( DHFR), in terms of its catalytic activity so that we successfully obtained several hyperactive cysteine- and methionine-free variants of DHFR in which all five methionyl and two cysteinyl residues were replaced by other amino acid residues. Among them, a variant ( M1A/M16N/M20L/M42Y/C85A/M92F/C152S), named as ANLYF, has an approximately seven times higher k(cat) value than wild type DHFR. Enzyme kinetics and crystal structures of the variant were investigated for elucidating the mechanism of the hyperactivity. Steady-state and transient binding kinetics of the variant indicated that the kinetic scheme of the catalytic cycle of ANLYF was essentially the same as that of wild type, showing that the hyperactivity was brought about by an increase of the dissociation rate constants of tetrahydrofolate from the enzyme-NADPH-tetrahydrofolate ternary complex. The crystal structure of the variant, solved and refined to an R factor of 0.205 at 1.9-A resolution, indicated that an increased structural flexibility of the variant and an increased size of the N-( p-aminobenzoyl)-L-glutamate binding cleft induced the increase of the dissociation constant. This was consistent with a large compressibility ( volume fluctuation) of the variant. A comparison of folding kinetics between wild type and the variant showed that the folding of these two enzymes was similar to each other, suggesting that the activity enhancement of the enzyme can be attained without drastic changes of the folding mechanism.	Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058566, Japan; Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Hiroshima University	Iwakura, M (corresponding author), Natl Inst Adv Ind Sci & Technol, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	masa-iwakura@aist.go.jp	Takenawa, Tatsuyuki/M-5439-2018; Yokota, Akiko/M-1807-2018	Takenawa, Tatsuyuki/0000-0001-5642-0117; Yokota, Akiko/0000-0002-5896-9899				ADAMS J, 1989, BIOCHEMISTRY-US, V28, P6611, DOI 10.1021/bi00442a012; ADAMS JA, 1991, BIOCHEMISTRY-US, V30, P11046, DOI 10.1021/bi00110a006; Aita T, 1996, J THEOR BIOL, V182, P469, DOI 10.1006/jtbi.1996.0189; Aita T, 1998, J THEOR BIOL, V193, P383, DOI 10.1006/jtbi.1998.0709; Aita T, 2000, BIOPOLYMERS, V54, P64, DOI 10.1002/(SICI)1097-0282(200007)54:1<64::AID-BIP70>3.0.CO;2-R; Aita T, 2002, BIOPOLYMERS, V64, P95, DOI 10.1002/bip.10126; Aita T, 2001, PROTEIN ENG, V14, P633, DOI 10.1093/protein/14.9.633; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Arai M, 2005, J MOL BIOL, V347, P337, DOI 10.1016/j.jmb.2005.01.033; Arai M, 2003, J MOL BIOL, V329, P779, DOI 10.1016/S0022-2836(03)00511-4; Arai M, 2003, J MOL BIOL, V328, P273, DOI 10.1016/S0022-2836(03)00212-2; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BOLES JO, 1992, J BIOL CHEM, V267, P22217; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; BYSTROFF C, 1991, BIOCHEMISTRY-US, V30, P2227, DOI 10.1021/bi00222a028; CAYLEY PJ, 1981, BIOCHEMISTRY-US, V20, P874, DOI 10.1021/bi00507a034; Chelius D, 2000, BIOCHEMISTRY-US, V39, P9687, DOI 10.1021/bi000274z; CHEN JT, 1987, BIOCHEMISTRY-US, V26, P4093, DOI 10.1021/bi00387a053; CHEN KQ, 1993, P NATL ACAD SCI USA, V90, P5618, DOI 10.1073/pnas.90.12.5618; Chien HCR, 2002, BIOCHEM BIOPH RES CO, V297, P282, DOI 10.1016/S0006-291X(02)02184-8; COOPER A, 1976, P NATL ACAD SCI USA, V73, P2740, DOI 10.1073/pnas.73.8.2740; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; Gegg CV, 1997, PROTEIN SCI, V6, P1885, DOI 10.1002/pro.5560060909; GEKKO K, 1986, BIOCHEMISTRY-US, V25, P6563, DOI 10.1021/bi00369a034; Gekko K, 2000, J BIOCHEM, V128, P21, DOI 10.1093/oxfordjournals.jbchem.a022726; GREEN SM, 1993, BIOCHEMISTRY-US, V32, P10131, DOI 10.1021/bi00089a032; Hager AJ, 1996, CHEM BIOL, V3, P717, DOI 10.1016/S1074-5521(96)90246-X; HILLCOAT BL, 1967, ANAL BIOCHEM, V21, P178, DOI 10.1016/0003-2697(67)90179-0; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HUANG Z, 1994, BIOCHEMISTRY-US, V33, P11576, DOI 10.1021/bi00204a020; IWAKURA M, 1992, J BIOCHEM-TOKYO, V111, P31, DOI 10.1093/oxfordjournals.jbchem.a123714; IWAKURA M, 1995, J BIOCHEM, V117, P480, DOI 10.1093/oxfordjournals.jbchem.a124733; IWAKURA M, 1992, J BIOCHEM-TOKYO, V111, P37, DOI 10.1093/oxfordjournals.jbchem.a123715; Iwakura M, 2000, NAT STRUCT BIOL, V7, P580, DOI 10.1038/76811; Iwakura M, 2001, PROTEIN ENG, V14, P583, DOI 10.1093/protein/14.8.583; JENNINGS PA, 1993, BIOCHEMISTRY-US, V32, P3783, DOI 10.1021/bi00065a034; JOYCE GF, 1992, SCI AM, V267, P90, DOI 10.1038/scientificamerican1292-90; Kamiyama T, 2000, BBA-PROTEIN STRUCT M, V1478, P257, DOI 10.1016/S0167-4838(00)00019-4; Kim YH, 2001, PROTEIN ENG, V14, P343, DOI 10.1093/protein/14.5.343; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; KUWAJIMA K, 1991, BIOCHEMISTRY-US, V30, P7693, DOI 10.1021/bi00245a005; Miller GP, 1998, CHEM BIOL, V5, pR105, DOI 10.1016/S1074-5521(98)90616-0; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; MURPHY DJ, 1989, BIOCHEMISTRY-US, V28, P3025, DOI 10.1021/bi00433a043; Nakamura T, 1999, J BIOL CHEM, V274, P19041, DOI 10.1074/jbc.274.27.19041; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohmae E, 1998, J BIOCHEM, V123, P839; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; PENNER MH, 1985, J BIOL CHEM, V260, P5366; PERRY KM, 1989, BIOCHEMISTRY-US, V28, P7961, DOI 10.1021/bi00445a061; REYES VM, 1995, BIOCHEMISTRY-US, V34, P2710, DOI 10.1021/bi00008a039; RICHARDS FM, 1985, METHOD ENZYMOL, V115, P440; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P586, DOI 10.1021/bi962337c; SCHUSTER P, 1994, COMPUT CHEM, V18, P295, DOI 10.1016/0097-8485(94)85025-9; Slusarczyk H, 2000, EUR J BIOCHEM, V267, P1280, DOI 10.1046/j.1432-1327.2000.01123.x; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Takenawa T, 1998, J BIOCHEM-TOKYO, V123, P1137; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; UWAJIMA T, 1990, BIOCHEM BIOPH RES CO, V171, P684, DOI 10.1016/0006-291X(90)91200-C; WAGNER CR, 1995, BIOCHEMISTRY-US, V34, P15671, DOI 10.1021/bi00048a011; WAGNER CR, 1992, BIOCHEMISTRY-US, V31, P7834, DOI 10.1021/bi00149a013; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; Yano T, 1998, P NATL ACAD SCI USA, V95, P5511, DOI 10.1073/pnas.95.10.5511	68	29	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13234	13246		10.1074/jbc.M508823200	http://dx.doi.org/10.1074/jbc.M508823200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16510443	hybrid			2022-12-25	WOS:000237336600029
J	Weider, M; Machnik, A; Klebl, F; Sauer, N				Weider, M; Machnik, A; Klebl, F; Sauer, N			Vhr1p, a new transcription factor from budding yeast, regulates biotin-dependent expression of VHT1 and BIO5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; GENE FAMILY; ARABIDOPSIS-THALIANA; FACTOR IIH; CLUSTER; IDENTIFICATION; REPRESSOR; SYSTEM	Transcription of the Saccharomyces cerevisiae vitamin H transporter gene VHT1 is enhanced by low extracellular biotin. Here we present the identification and characterization of Vhr1p as a transcriptional regulator of VHT1 ( VHR1 ( YIL056w); VHT1 regulator 1) and the identification of the cis- regulatory target sequences for Vhr1p in two yeast promoters. VHR1 was identified in a complementation screening of mutagenized yeast cells that had lost the capacity to express the gene of the green fluorescent protein ( GFP) from the VHT1 promoter. Delta vhr1 deletion mutants fail to induce VHT1 on low biotin concentrations. In yeast one- hybrid analyses performed with fusions of Vhr1p N- terminal and C- terminal fragments to the Gal4p activation domain or to the Gal4p DNA- binding domain, the Vhr1p N terminus mediated biotin- dependent DNA binding, and the Vhr1p C terminus triggered biotin- dependent transcriptional activation. The analyzed Vhr1p N- terminal fragment has previously been described as a domain of unknown function ( DUF352). Deletion and linker scanning analyses of the VHT1 promoter revealed the palindromic 18- nucleotide sequence AATCA-N-8-TGAYT as the vitamin H- responsive element. This sequence was identified also in the BIO5 promoter that is also transcriptionally activated on low biotin concentrations. Bio5p mediates the transport of 7- keto- 8- aminopelargonic acid across the yeast plasma membrane, a compound that is used as a precursor in biotin biosynthesis. Delta vhr1 deletion mutants fail to induce BIO5 on low biotin concentrations. The presented data characterize Vhr1p as an essential component of the biotin- dependent signal transduction cascade in yeast.	Univ Erlangen Nurnberg, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Sauer, N (corresponding author), Univ Erlangen Nurnberg, Staudtstr 5, D-91058 Erlangen, Germany.	nsauer@biologie.uni-erlangen.de	Weider, Matthias/AAV-9240-2021					ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; Belli G, 2004, J BIOL CHEM, V279, P12386, DOI 10.1074/jbc.M311879200; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; Brachmann CB, 1998, YEAST, V14, P115; BROWN T, 1994, CURRENT PROTOCOLS MO; BURKE D, 2000, METHODS YEAST GENETI, P159; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CRONAN JE, 1995, FEMS MICROBIOL LETT, V130, P221, DOI 10.1016/0378-1097(95)00210-V; Ding WV, 1997, MOL CELL BIOL, V17, P2538, DOI 10.1128/MCB.17.5.2538; Eisenstein E, 1999, BIOCHEMISTRY-US, V38, P13077, DOI 10.1021/bi991241q; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; Grunewald S, 2004, NEUROPEDIATRICS, V35, P211, DOI 10.1055/s-2004-821080; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Ha N, 1996, NUCLEIC ACIDS RES, V24, P1453, DOI 10.1093/nar/24.8.1453; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; James P, 1996, GENETICS, V144, P1425; Jona G, 2002, J BIOL CHEM, V277, P39409, DOI 10.1074/jbc.M202733200; Jorgensen MU, 1997, CURR GENET, V31, P241, DOI 10.1007/s002940050201; Klebl F, 2000, FEBS LETT, V481, P86, DOI 10.1016/S0014-5793(00)01959-1; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Llorente B, 2000, FEBS LETT, V475, P237, DOI 10.1016/S0014-5793(00)01698-7; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; McMahon RJ, 2002, ANNU REV NUTR, V22, P221, DOI 10.1146/annurev.nutr.22.121101.112819; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MINET M, 1992, PLANT J, V2, P417; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Nikolau BJ, 2003, ARCH BIOCHEM BIOPHYS, V414, P211, DOI 10.1016/S0003-9861(03)00156-5; Noel J, 1998, J BIOL CHEM, V273, P17463, DOI 10.1074/jbc.273.28.17463; Phalip V, 1999, GENE, V232, P43, DOI 10.1016/S0378-1119(99)00117-1; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAI R, 1988, J BACTERIOL, V170, P266, DOI 10.1128/jb.170.1.266-271.1988; REMBOUTSIKA E, 1994, MOL CELL BIOL, V14, P5547, DOI 10.1128/MCB.14.8.5547; ROGERS TO, 1969, J BACTERIOL, V100, P565, DOI 10.1128/JB.100.2.565-572.1969; ROGERS TO, 1969, J BACTERIOL, V100, P557, DOI 10.1128/JB.100.2.557-564.1969; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Said HM, 2004, ANNU REV PHYSIOL, V66, P419, DOI 10.1146/annurev.physiol.66.032102.144611; SAUER N, 1994, PLANT J, V6, P67, DOI 10.1046/j.1365-313X.1994.6010067.x; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; Sellick CA, 2005, TRENDS BIOCHEM SCI, V30, P405, DOI 10.1016/j.tibs.2005.05.007; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SONI R, 1993, CURR GENET, V24, P455, DOI 10.1007/BF00351857; Stephan J, 2004, GENE, V343, P181, DOI 10.1016/j.gene.2004.08.028; Stolz J, 1999, J BIOL CHEM, V274, P18747, DOI 10.1074/jbc.274.26.18747; Stolz J, 1999, J BIOL CHEM, V274, P18741, DOI 10.1074/jbc.274.26.18741; Stolz J, 2004, EUKARYOT CELL, V3, P406, DOI 10.1128/EC.3.2.406-412.2004; Stolz J, 2003, YEAST, V20, P221, DOI 10.1002/yea.959; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Weaver LH, 2001, P NATL ACAD SCI USA, V98, P6045, DOI 10.1073/pnas.111128198	67	20	21	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13513	13524		10.1074/jbc.M512158200	http://dx.doi.org/10.1074/jbc.M512158200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533810	hybrid			2022-12-25	WOS:000237336600059
J	Ferrer, T; Rupp, J; Piper, DR; Tristani-Firouzi, M				Ferrer, T; Rupp, J; Piper, DR; Tristani-Firouzi, M			The S4-S5 linker directly couples voltage sensor movement to the activation gate in the human ether-a '-go-go-related gene (hERG) K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNELS; ION CHANNELS; CHARGE DISPLACEMENT; CRYSTAL-STRUCTURE; INACTIVATION; PORE; CONDUCTION; MUTATIONS; SEGMENT; FAMILY	A key unresolved question regarding the basic function of voltage-gated ion channels is how movement of the voltage sensor is coupled to channel opening. We previously proposed that the S4-S5 linker couples voltage sensor movement to the S6 domain in the human ether-a'-go-go- related gene (hERG) K+ channel. The recently solved crystal structure of the voltage-gated Kv1.2 channel reveals that the S4-S5 linker is the structural link between the voltage sensing and pore domains. In this study, we used chimeras constructed from hERG and ether-a'-go-go (EAG) channels to identify interactions between residues in the S4-S5 linker and S6 domain that were critical for stabilizing the channel in a closed state. To verify the spatial proximity of these regions, we introduced cysteines in the S4-S5 linker and at the C-terminal end of the S6 domain and then probed for the effect of oxidation. The D540C-L666C channel current decreased in an oxidizing environment in a state-dependent manner consistent with formation of a disulfide bond that locked the channel in a closed state. Disulfide bond formation also restricted movement of the voltage sensor, as measured by gating currents. Taken together, these data confirm that the S4-S5 linker directly couples voltage sensor movement to the activation gate. Moreover, rather than functioning simply as a mechanical lever, these findings imply that specific interactions between the S4-S5 linker and the activation gate stabilize the closed channel conformation.	Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84113 USA; Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84113 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84113 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Tristani-Firouzi, M (corresponding author), Univ Utah, Sch Med, Dept Pediat, Suite 1500 PCMC, Salt Lake City, UT 84113 USA.	mfirouzi@cvrti.utah.edu			NHLBI NIH HHS [HL03816] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; Chanda B, 2005, NATURE, V436, P852, DOI 10.1038/nature03888; Chen J, 2001, P NATL ACAD SCI USA, V98, P11277, DOI 10.1073/pnas.201250598; CREIGHTON TE, 1997, PROTEINS STRUCTURES, P18; Ding SH, 2003, BIOPHYS J, V84, P295, DOI 10.1016/S0006-3495(03)74850-4; Ding SH, 2002, J GEN PHYSIOL, V120, P87, DOI 10.1085/jgp.20028611; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ficker E, 1998, CIRC RES, V82, P386, DOI 10.1161/01.RES.82.3.386; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Horn R, 2000, BIOCHEMISTRY-US, V39, P15653, DOI 10.1021/bi0020473; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Piper DR, 2005, J BIOL CHEM, V280, P7206, DOI 10.1074/jbc.M411042200; Piper DR, 2003, P NATL ACAD SCI USA, V100, P10534, DOI 10.1073/pnas.1832721100; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Shieh CC, 1997, J GEN PHYSIOL, V109, P767, DOI 10.1085/jgp.109.6.767; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; Stefani E, 1998, METHOD ENZYMOL, V293, P300; Sukhareva M, 2003, J GEN PHYSIOL, V122, P541, DOI 10.1085/jgp.200308905; Tristani-Firouzi M, 2002, J BIOL CHEM, V277, P18994, DOI 10.1074/jbc.M200410200; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438	31	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12858	12864		10.1074/jbc.M513518200	http://dx.doi.org/10.1074/jbc.M513518200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524878	hybrid			2022-12-25	WOS:000237134700081
J	Dutt, S; Kleber, M; Matasci, M; Sommer, L; Zimmermann, DR				Dutt, S; Kleber, M; Matasci, M; Sommer, L; Zimmermann, DR			Versican V0 and V1 guide migratory neural crest cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HYALURONAN-BINDING PROTEOGLYCANS; AVIAN EMBRYO; NERVOUS-SYSTEM; PG-M; COMMISSURAL AXONS; DEVELOPING BRAIN; AGGRECAN GENE; CHICK-EMBRYO; EXPRESSION	We previously showed the selective expression of the chondroitin sulfate proteoglycans versican V0 and V1 in barrier tissues that impede the migration of neural crest cells during embryonic trunk development (Landolt, R. M., Vaughan, L., Winterhalter, K. H., and Zimmermann, D. R. ( 1995) Development 212, 2303 - 2312). To test for an active involvement of these isoforms in the guidance process, we have now established protocols to isolate intact versican V0 and V1 in quantities sufficient for functional experiments. Using stripe choice assays, we demonstrate that pure preparations of either a mixture of versican V0/V1 or V1 alone strongly inhibit the migration of multipotent Sox10/p75NTR double-positive early neural crest stem cells on fibronectin by interfering with cell-substrate adhesion. We show that this inhibition is largely core glycoprotein-dependent, as the complete removal of the glycosaminoglycan chains has only a minor effect on the inhibitory capacity. Our findings support the notion that versican variants V0 and V1 act, possibly in concert with other inhibitory molecules such as aggrecan and ephrins, in directing the migratory streams of neural crest cells to their appropriate target tissues.	Univ Zurich Hosp, Dept Pathol, Mol Biol Lab, CH-8091 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich	Zimmermann, DR (corresponding author), Univ Zurich Hosp, Dept Pathol, Mol Biol Lab, CH-8091 Zurich, Switzerland.	maurice.kleber@gmx.ch; dieterzi@patho.unizh.ch		Sommer, Lukas/0000-0002-1143-7908				Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Bronner-Fraser Marianne, 1993, Trends in Cell Biology, V3, P392, DOI 10.1016/0962-8924(93)90089-J; BRONNERFRASER M, 1991, DEV BIOL, V143, P213, DOI 10.1016/0012-1606(91)90071-A; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; Debby-Brafman A, 1999, NEURON, V22, P475, DOI 10.1016/S0896-6273(00)80703-5; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOMOWICZ M, 1995, DEV BIOL, V171, P655, DOI 10.1006/dbio.1995.1312; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; Erickson CA, 1998, CURR TOP DEV BIOL, V40, P177, DOI 10.1016/S0070-2153(08)60367-1; ERICKSON CA, 1992, DEV BIOL, V151, P251, DOI 10.1016/0012-1606(92)90231-5; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Henderson DJ, 1997, MECH DEVELOP, V69, P39, DOI 10.1016/S0925-4773(97)00151-2; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Kasemeier-Kulesa JC, 2005, DEVELOPMENT, V132, P235, DOI 10.1242/dev.01553; Kawasaki T, 2002, DEVELOPMENT, V129, P671; Kil SH, 1998, DEV BIOL, V202, P29, DOI 10.1006/dbio.1998.8985; KIMATA K, 1986, J BIOL CHEM, V261, P3517; Kleber M, 2005, J CELL BIOL, V169, P309, DOI 10.1083/jcb.200411095; KLEBER M, 2006, CELL BIOL LAB HDB, P69; Krull CE, 2001, MECH DEVELOP, V105, P37, DOI 10.1016/S0925-4773(01)00395-1; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Kubota Y, 1999, DEV DYNAM, V214, P55, DOI 10.1002/(SICI)1097-0177(199901)214:1<55::AID-DVDY6>3.0.CO;2-E; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; Le Douarin NM, 2004, MECH DEVELOP, V121, P1089, DOI 10.1016/j.mod.2004.06.003; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Li S, 2005, ANNU REV BIOMED ENG, V7, P105, DOI 10.1146/annurev.bioeng.7.060804.100340; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; NEWGREEN DF, 1990, DEV BIOL, V139, P100, DOI 10.1016/0012-1606(90)90282-N; OAKLEY RA, 1994, DEVELOPMENT, V120, P103; OAKLEY RA, 1991, DEV BIOL, V147, P187, DOI 10.1016/S0012-1606(05)80017-X; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Paratore C, 2001, DEVELOPMENT, V128, P3949; Perissinotto D, 2000, DEVELOPMENT, V127, P2823; Perris R, 1996, FASEB J, V10, P293, DOI 10.1096/fasebj.10.2.8641562; PERRIS R, 1991, DEVELOPMENT, V111, P583; Pettway Z, 1996, EXP CELL RES, V225, P195, DOI 10.1006/excr.1996.0170; PETTWAY Z, 1990, DEV BIOL, V142, P335, DOI 10.1016/0012-1606(90)90354-L; RANSCHT B, 1991, DEVELOPMENT, V111, P15; RICKMANN M, 1985, J EMBRYOL EXP MORPH, V90, P437; Ring C, 1996, DEV BIOL, V180, P41, DOI 10.1006/dbio.1996.0283; ROVASIO RA, 1983, J CELL BIOL, V96, P462, DOI 10.1083/jcb.96.2.462; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Santiago A, 2002, DEVELOPMENT, V129, P3621; Schmalfeldt M, 1998, J BIOL CHEM, V273, P15758, DOI 10.1074/jbc.273.25.15758; Schmalfeldt M, 2000, J CELL SCI, V113, P807; Schweigreiter R, 2004, MOL CELL NEUROSCI, V27, P163, DOI 10.1016/j.mcn.2004.06.004; Talts JF, 1999, METH MOL B, V129, P153; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; Testaz S, 2001, DEV DYNAM, V222, P127, DOI 10.1002/dvdy.1181; Testaz S, 1999, J CELL SCI, V112, P4715; Tosney KW, 2004, DEV DYNAM, V229, P99, DOI 10.1002/dvdy.10492; VIELMETTER J, 1990, EXP BRAIN RES, V81, P283; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; Westling J, 2004, BIOCHEM J, V377, P787, DOI 10.1042/bj20030896; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	68	71	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12123	12131		10.1074/jbc.M510834200	http://dx.doi.org/10.1074/jbc.M510834200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16510447	hybrid			2022-12-25	WOS:000236988100082
J	Wendt, MK; Johanesen, PA; Kang-Decker, N; Binion, DG; Shah, V; Dwinell, MB				Wendt, M. K.; Johanesen, P. A.; Kang-Decker, N.; Binion, D. G.; Shah, V.; Dwinell, M. B.			Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis	ONCOGENE			English	Article						chemokine; intestinal mucosa; epithelial cell; epigenetic	CHEMOKINE RECEPTOR CXCR4; FACTOR-I; CPG METHYLATION; BREAST-CANCER; CELLS; SDF-1; METHYLTRANSFERASES; LOCALIZATION; LACKING; GROWTH	Cellular metastasis is the most detrimental step in carcinoma disease progression, yet the mechanisms that regulate this process are poorly understood. CXCL12 and its receptor CXCR4 are co-expressed in several tissues and cell types throughout the body and play essential roles in development. Disruption of either gene causes embryonic lethality due to similar defects. Post-natally, CXCL12 signaling has a wide range of effects on CXCR4-expressing cells, including the directed migration of leukocytes, lymphocytes and hematopoietic stem cells. Recently, this signaling axis has also been described as an important regulator of directed carcinoma cell metastasis. We show herein that while CXCR4 expression remains consistent, constitutive colonic epithelial expression of CXCL12 is silenced by DNA hypermethylation in primary colorectal carcinomas as well as colorectal carcinoma-derived cell lines. Inhibition of DNA methyltransferase (Dnmt) enzymes with 5-aza-2'-deoxycytidine or genetic ablation of both Dnmt1 and Dnmt3b prevented promoter methylation and restored CXCL12 expression. Re-expression of functional, endogenous CXCL12 in colorectal carcinoma cells dramatically reduced metastatic tumor formation in mice, as well as foci formation in soft agar. Decreased metastasis was correlated with increased caspase activity in cells re-expressing CXCL12. These data constitute the unique observation that silencing CXCL12 within colonic carcinoma cells greatly enhances their metastatic potential.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Mayo Clin Fdn, GI Res Unit, Dept Med, Rochester, MN USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Mayo Clinic; Medical College of Wisconsin	Dwinell, MB (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mdwinell@mcw.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062066, R56DK062066, K01DK002808] Funding Source: NIH RePORTER; NIDDK NIH HHS [R56 DK062066, DK002808, DK062066, R01 DK062066] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Arya M, 2003, CURR MED RES OPIN, V19, P557, DOI 10.1185/030079903125002216; Begum NA, 1996, BIOCHEM BIOPH RES CO, V229, P864, DOI 10.1006/bbrc.1996.1893; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Binion DG, 1997, GASTROENTEROLOGY, V112, P1895, DOI 10.1053/gast.1997.v112.pm9178682; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Derdeyn CA, 1999, AIDS RES HUM RETROV, V15, P1063, DOI 10.1089/088922299310359; Dwinell MB, 1999, GASTROENTEROLOGY, V117, P359, DOI 10.1053/gast.1999.0029900359; Dwinell MB, 2001, GASTROENTEROLOGY, V120, P49, DOI 10.1053/gast.2001.20914; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Garcia-Moruja C, 2005, J MOL BIOL, V348, P43, DOI 10.1016/j.jmb.2005.02.016; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; Haviv YS, 2004, MOL CANCER THER, V3, P687; Heidemann J, 2004, AM J PHYSIOL-GASTR L, V286, pG1059, DOI 10.1152/ajpgi.00417.2003; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Izadpanah A, 2001, AM J PHYSIOL-GASTR L, V280, pG710, DOI 10.1152/ajpgi.2001.280.4.G710; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jordan NJ, 1999, J CLIN INVEST, V104, P1061, DOI 10.1172/JCI6685; Jubb AM, 2003, ANN NY ACAD SCI, V983, P251, DOI 10.1111/j.1749-6632.2003.tb05980.x; Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022; Kimura R, 2003, GENES IMMUN, V4, P356, DOI 10.1038/sj.gene.6363978; Lenhard K, 2005, CLIN GASTROENTEROL H, V3, P142, DOI 10.1016/S1542-3565(04)00624-X; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; PANIS Y, 1990, J HEPATOL, V11, P53, DOI 10.1016/0168-8278(90)90271-R; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; Schrader AJ, 2002, BRIT J CANCER, V86, P1250, DOI 10.1038/sj.bjc.6600221; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Smith JM, 2005, AM J PHYSIOL-GASTR L, V288, pG316, DOI 10.1152/ajpgi.00208.2004; Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	45	119	123	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4986	4997		10.1038/sj.onc.1209505	http://dx.doi.org/10.1038/sj.onc.1209505			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568088	Green Accepted			2022-12-25	WOS:000239921300004
J	Han, SW; Roman, J				Han, S. W.; Roman, J.			Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B	ONCOGENE			English	Article						fibronectin; PI3-K; NF-kappa B; cell cycle; tumor suppressor gene; human bronchial epithelial cells	TUMOR-SUPPRESSOR PTEN; SMOOTH-MUSCLE-CELLS; C-MYC; EXTRACELLULAR-MATRIX; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; CYCLE PROGRESSION; GENE-EXPRESSION; GROWTH-FACTORS; CANCER CELLS	The extracellular matrix glycoprotein, fibronectin, influences a variety of cellular functions including adhesion, migration, survival, differentiation, and growth. Fibronectin has also been shown to increase the migration and proliferation of human lung carcinoma cells. However, the role of fibronectin in controlling lung airway epithelial cell phenotype remains unknown. Here, we demonstrate that fibronectin stimulates the proliferation of human bronchial epithelial cells (BEAS-2B and 16-HBE). Of note, fibronectin induced the mRNA and protein expression of c-Myc and cyclin D1, while it decreased the expressions of cyclin-dependent kinase inhibitor p21 (WAF-1/CIP1/MDA-6) (p21) and the tumor suppressor gene phosphatase and tensin homolog deleted on chromosome ten ( PTEN). Fibronectin also stimulated the phosphorylation of the phosphatidylinositol 3 kinase (PI3-K) downstream signal Akt. The inhibitor of PI3-K, Wortmannin, and anti-alpha 5 beta 1 integrin antibodies abrogated the effect of fibronectin on c-Myc, cyclin D1, p21, and PTEN expression. The stimulatory effect of. bronectin was mediated by nuclear factor kappaB (NF-kappa B) since. bronectin induced the expression of the p65 component of NF-kappa B and enhanced NF-kappa B DNA binding. Furthermore, we found that p65 small interfering RNA inhibited the effect of. bronectin on c-Myc, cyclin D1, p21, PTEN expression, and on fibronectin-induced cell proliferation. Finally, we found that. bronectin inhibits apoptosis by reducing DNA fragmentation and inhibiting the activities of caspases 3/7. Taken together, our findings demonstrate that fibronectin stimulates human bronchial epithelial cell growth and inhibits apoptosis through activation of NF-kappa B, which, in turn, increases the expression of c-Myc and cyclin D1 and decreases p21 and PTEN via alpha 5 beta 1 integrin-dependent signals that include PI3-K/Akt. Therefore, alternations in the extracellular matrix composition of the lung, with increased. bronectin, might promote epithelial cell growth and thereby contribute to oncogenesis in certain settings.	Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, Atlanta, GA 30322 USA; Atlanta Vet Affairs Med Ctr, Atlanta, GA USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Han, SW (corresponding author), Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, Whitehead Biomed Res Bldg,615 Michael St,Suite 20, Atlanta, GA 30322 USA.	shan2@emory.edu						AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V273, pL684, DOI 10.1152/ajplung.1997.273.3.L684; Arcuri C, 2005, J BIOL CHEM, V280, P4402, DOI 10.1074/jbc.M406440200; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Benaud CM, 2001, ONCOGENE, V20, P759, DOI 10.1038/sj.onc.1204152; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Chen F, 2001, J BIOL CHEM, V276, P11414, DOI 10.1074/jbc.M011682200; Cordes N, 2004, INT J RADIAT ONCOL, V58, P453, DOI 10.1016/j.ijrobp.2003.09.069; Cordes N, 2004, CANCER BIOL THER, V3, P47, DOI 10.4161/cbt.3.1.570; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Dai R, 2005, APOPTOSIS, V10, P503, DOI 10.1007/s10495-005-1880-5; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; de Jong-Hesse Y, 2005, GRAEF ARCH CLIN EXP, V243, P695, DOI 10.1007/s00417-004-1116-3; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Galmozzi E, 2004, J CELL PHYSIOL, V200, P82, DOI 10.1002/jcp.20012; Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003; Garl PJ, 2004, CIRC RES, V94, P175, DOI 10.1161/01.RES.0000109791.69181.B6; Gordon AH, 2005, CANCER RES, V65, P3209, DOI 10.1158/0008-5472.CAN-04-4017; Halder SK, 2005, EXP CELL RES, V307, P231, DOI 10.1016/j.yexcr.2005.03.009; Han SW, 2005, CANCER LETT, V219, P71, DOI 10.1016/j.canlet.2004.07.040; Han SW, 2004, INT J CANCER, V111, P322, DOI 10.1002/ijc.20281; Han SW, 2003, J CLIN ENDOCR METAB, V88, P713, DOI 10.1210/jc.2002-020876; Han SW, 1996, ENDOCRINOLOGY, V137, P1791, DOI 10.1210/en.137.5.1791; Illario M, 2005, J CLIN ENDOCR METAB, V90, P2865, DOI 10.1210/jc.2004-1520; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Kijima T, 2003, J CELL MOL MED, V7, P157; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Liu B, 2004, J SURG RES, V120, P256, DOI 10.1016/j.jss.2003.12.015; Loeser RF, 2002, BIORHEOLOGY, V39, P119; Moon SK, 2004, ARCH BIOCHEM BIOPHYS, V421, P267, DOI 10.1016/j.abb.2003.11.007; Nasu-Tada K, 2005, GLIA, V52, P98, DOI 10.1002/glia.20224; Orend G, 2003, ONCOGENE, V22, P3917, DOI 10.1038/sj.onc.1206618; Pulai JI, 2005, J IMMUNOL, V174, P5781, DOI 10.4049/jimmunol.174.9.5781; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; TAKIZAWA H, 1991, AM J RESP CELL MOL, V5, P548, DOI 10.1165/ajrcmb/5.6.548; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tang CH, 2004, MOL PHARMACOL, V66, P440; Tell G, 2004, ENDOCRINOLOGY, V145, P4660, DOI 10.1210/en.2004-0282; Vignola AM, 2001, J ALLERGY CLIN IMMUN, V108, P738, DOI 10.1067/mai.2001.119160; Wadsworth SJ, 2004, AM J PHYSIOL-LUNG C, V286, pL596, DOI 10.1152/ajplung.00217.2003; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zhao YL, 2002, BRIT J CANCER, V86, P1923, DOI 10.1038/sj.bjc.6600304	49	79	82	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4341	4349		10.1038/sj.onc.1209460	http://dx.doi.org/10.1038/sj.onc.1209460			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518410				2022-12-25	WOS:000239240100009
J	Hariharan, P; Liang, WC; Chou, SH; Chin, DH				Hariharan, Parameswaran; Liang, Wenchuan; Chou, Shan-Ho; Chin, Der-Hang			A new model for ligand release - Role of side chain in gating the enediyne antibiotic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-PROTEIN CHROMOPHORE; NEOCARZINOSTATIN CHROMOPHORE; APO-NEOCARZINOSTATIN; CRYSTAL-STRUCTURE; DEOXYRIBONUCLEIC-ACID; ESCHERICHIA-COLI; BINDING; APOPROTEIN; CHROMOPROTEIN; COMPLEX	Antitumor antibiotic chromoproteins such as neocarzinostatin involve a labile toxin that is tightly bound by a protective protein with very high affinity but must also be freed to exert its function. Contrary to the prevalent concept of ligand release, we established that toxin release from neocarzinostatin requires no major backbone conformational changes. We report, herein, that subtle changes in the side chains of specific amino acid residues are adequate to gate the release of chromophore. A recombinant wild type aponeocarzinostatin and its variants mutated around the opening of the chromophore binding cleft are employed to identify specific side chains likely to affect chromophore release. Preliminary, biophysical characterization of mutant apoproteins by circular dichroism and thermal denaturation indicate that the fundamental structural characteristics of wild type protein are conserved in these mutants. The chromophore reconstitution studies further show that all mutants are able to bind chromophore efficiently with similar complex structures. NMR studies on N-15-labeled mutants also suggest the intactness of binding pocket structure. Kinetic studies of chromophore release monitored by time course fluorescence and quantitative high pressure liquid chromatography analyses show that the ligand release rate is significantly enhanced only in Phe(78) mutants. The extent of DNA cleavage in vitro corresponds well to the rate of chromophore release. The results provide the first clearcut indication of how toxin release can be controlled by a specific side chain of a carrier protein.	Natl Chung Hsing Univ, Dept Chem, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Inst Biochem, Taichung 40227, Taiwan; Stanford Univ, Sch Med, Dept Biochem, Beckman Ctr, Stanford, CA 94305 USA	National Chung Hsing University; National Chung Hsing University; Stanford University	Chin, DH (corresponding author), Natl Chung Hsing Univ, Dept Chem, 250 Kuo Kuang Rd, Taichung 40227, Taiwan.	chdhchin@dragon.nchu.edu.tw	Parameswaran, Hariharan/P-2496-2015	Parameswaran, Hariharan/0000-0002-6020-1547; CHOU, Shan-Ho/0000-0002-5202-8238				Abe Shintaro, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P715, DOI 10.2174/1568011023353679; Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Beglova N, 2005, TRENDS BIOCHEM SCI, V30, P309, DOI 10.1016/j.tibs.2005.03.007; Chin DH, 1997, BBA-GEN SUBJECTS, V1336, P43, DOI 10.1016/S0304-4165(97)00008-1; Chin DH, 1999, CHEM-EUR J, V5, P1084, DOI 10.1002/(SICI)1521-3765(19990301)5:3<1084::AID-CHEM1084>3.0.CO;2-K; De Wolf FA, 2000, PHARMACOL REV, V52, P207; GAO XL, 1992, J MOL BIOL, V225, P125, DOI 10.1016/0022-2836(92)91030-S; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gerstein M, 1998, NUCLEIC ACIDS RES, V26, P4280, DOI 10.1093/nar/26.18.4280; GOLDBERG IH, 1991, ACCOUNTS CHEM RES, V24, P191, DOI 10.1021/ar00007a001; Heyd B, 2000, J BACTERIOL, V182, P1812, DOI 10.1128/JB.182.7.1812-1818.2000; Heyd B, 2003, BIOCHEMISTRY-US, V42, P5674, DOI 10.1021/bi0273664; IMAJO S, 1995, BIOORGAN MED CHEM, V3, P429, DOI 10.1016/0968-0896(95)00032-C; ISHIDA N, 1965, J ANTIBIOT, V18, P68; Ishiguro M, 1996, J SYN ORG CHEM JPN, V54, P427, DOI 10.5059/yukigoseikyokaishi.54.427; Jayachithra K, 2005, BIOPHYS J, V88, P4252, DOI 10.1529/biophysj.104.051722; JUNG G, 1981, BIOCHEM BIOPH RES CO, V98, P176, DOI 10.1016/0006-291X(81)91885-4; KAPPEN LS, 1980, P NATL ACAD SCI-BIOL, V77, P1970, DOI 10.1073/pnas.77.4.1970; KEMPNER ES, 1993, FEBS LETT, V326, P4, DOI 10.1016/0014-5793(93)81749-P; KIM KH, 1993, SCIENCE, V262, P1042, DOI 10.1126/science.8235619; KOSHLAND DE, 1963, SCIENCE, V142, P1533, DOI 10.1126/science.142.3599.1533; Kuo HM, 2002, BIOCHEMISTRY-US, V41, P897, DOI 10.1021/bi015771+; Leal WS, 2005, P NATL ACAD SCI USA, V102, P5386, DOI 10.1073/pnas.0501447102; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; Min KC, 2003, P NATL ACAD SCI USA, V100, P14713, DOI 10.1073/pnas.2136684100; MISPELTER J, 1995, J BIOMOL NMR, V5, P233; MOHANTY S, 1994, BIOCHEMISTRY-US, V33, P10579, DOI 10.1021/bi00201a003; Nakamura Y, 1996, NUCLEIC ACIDS RES, V24, P214, DOI 10.1093/nar/24.1.214; NAPIER MA, 1980, BIOCHEMISTRY-US, V19, P1767, DOI 10.1021/bi00550a007; NAPIER MA, 1981, BIOCHEMISTRY-US, V20, P5602, DOI 10.1021/bi00522a038; NAPIER MA, 1979, BIOCHEM BIOPH RES CO, V89, P635, DOI 10.1016/0006-291X(79)90677-6; Nicaise M, 2003, PROTEIN ENG, V16, P733, DOI 10.1093/protein/gzg099; Nozaki S, 2002, J BIOCHEM, V131, P729, DOI 10.1093/oxfordjournals.jbchem.a003158; Perez J, 2001, J MOL BIOL, V308, P721, DOI 10.1006/jmbi.2001.4611; POVIRK LF, 1980, BIOCHEMISTRY-US, V19, P4773, DOI 10.1021/bi00562a009; POVIRK LF, 1981, BIOCHEMISTRY-US, V20, P4007, DOI 10.1021/bi00517a009; SAKATA N, 1993, BIOL PHARM BULL, V16, P26; Shen B, 2003, CURR MED CHEM, V10, P2317, DOI 10.2174/0929867033456701; STUB C, 2004, BMC BIOCH, V5, P1; SUDHAHAR CG, 2006, IN PRESS BIOORG MED; Sudhahar GCP, 2000, J BIOL CHEM, V275, P39900; TAKAHASHI K, 1994, TETRAHEDRON, V50, P1327, DOI 10.1016/S0040-4020(01)80621-9; Takashima H, 2005, J BIOL CHEM, V280, P11340, DOI 10.1074/jbc.M411579200; TANAKA T, 1993, J CHEM SOC CHEM COMM, P1205, DOI 10.1039/c39930001205; TEPLYAKOV A, 1993, EUR J BIOCHEM, V213, P737, DOI 10.1111/j.1432-1033.1993.tb17814.x; Urbaniak MD, 2004, J MED CHEM, V47, P4710, DOI 10.1021/jm040790d; Urbaniak MD, 2002, BIOCHEMISTRY-US, V41, P11731, DOI 10.1021/bi0262146; Vaillancourt P, 2000, METHOD ENZYMOL, V326, P340; Valerio-Lepiniec M, 2002, PROTEIN ENG, V15, P861, DOI 10.1093/protein/15.11.861; Wyborski DL, 1999, PROTEIN EXPRES PURIF, V16, P1, DOI 10.1006/prep.1999.1064; Xi Z., 1999, COMPREHENSIVE NATURA, V7, P553; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	52	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16025	16033		10.1074/jbc.M600841200	http://dx.doi.org/10.1074/jbc.M600841200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16567802	hybrid			2022-12-25	WOS:000237996000054
J	Weng, J; Cao, Y; Moss, N; Zhou, M				Weng, Jun; Cao, Yu; Moss, Noah; Zhou, Ming			Modulation of voltage-dependent Shaker family potassium channels by an aldo-keto reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; BETA-SUBUNIT; RAT-BRAIN; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; FUNCTIONAL-CHARACTERIZATION; O-2-SENSING MECHANISMS; LIPID-PEROXIDATION; KINETIC MECHANISM; ALPHA-SUBUNITS; BOVINE BRAIN	The beta subunit (Kv beta) of the Shaker family voltage-dependent potassium channels (Kv1) is a cytosolic protein that forms a permanent complex with the channel. Sequence and structural conservation indicates that Kv beta resembles an aldo-keto reductase (AKR), an enzyme that catalyzes a redox reaction using an NADPH cofactor. A putative AKR in complex with a Kv channel has led to the hypothesis that intracellular redox potential may dynamically influence the excitability of a cell through Kv beta. Since the AKR function of Kv beta has never been demonstrated, a direct functional coupling between the two has not been established. We report here the identification of Kv beta substrates and the demonstration that Kv beta is a functional AKR. We have also found that channel function is modulated when the Kv beta-bound NADPH is oxidized. Further studies of the enzymatic properties of Kv beta seem to favor the role of Kv beta as a redox sensor. These results suggest that Kv beta may couple the excitability of the cell to its metabolic state and present a new avenue of research that may lead to understanding of the physiological functions of Kv beta.	Columbia Univ, Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Columbia University	Zhou, M (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Physiol & Cellular Biophys, 630 W 168th St, New York, NY 10032 USA.	mz2140@columbia.edu	Cao, Yu/GNP-6653-2022	Cao, Yu/0000-0003-1409-2068; Moss, Noah/0000-0001-6247-3477	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086392] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL086392, R01 HL086392-01, HL086392] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accili EA, 1998, J PHYSIOL-LONDON, V512, P325, DOI 10.1111/j.1469-7793.1998.325be.x; Accili EA, 1997, J BIOL CHEM, V272, P25824, DOI 10.1074/jbc.272.41.25824; ASKONAS LJ, 1991, BIOCHEM J, V278, P835, DOI 10.1042/bj2780835; BARSKI OA, 1995, BIOCHEMISTRY-US, V34, P11264, DOI 10.1021/bi00035a036; CASTELLINO RC, 1995, AM J PHYSIOL-HEART C, V269, pH385, DOI 10.1152/ajpheart.1995.269.1.H385; Coppock EA, 2001, AM J PHYSIOL-LUNG C, V281, pL1, DOI 10.1152/ajplung.2001.281.1.L1; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Haddad GG, 1997, ANNU REV PHYSIOL, V59, P23, DOI 10.1146/annurev.physiol.59.1.23; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; Heredia VV, 2004, BIOCHEMISTRY-US, V43, P12028, DOI 10.1021/bi0489762; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Hyndman D, 2003, CHEM-BIOL INTERACT, V143, P621, DOI 10.1016/S0009-2797(02)00193-X; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Jez JM, 1996, J BIOL CHEM, V271, P30190, DOI 10.1074/jbc.271.47.30190; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; Lee SH, 2000, CHEM RES TOXICOL, V13, P698, DOI 10.1021/tx000101a; Liu SQ, 2001, J BIOL CHEM, V276, P11812, DOI 10.1074/jbc.M008259200; Liu YP, 2002, CLIN EXP PHARMACOL P, V29, P305, DOI 10.1046/j.1440-1681.2002.03649.x; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; Patel AJ, 2001, EUR RESPIR J, V18, P221, DOI 10.1183/09031936.01.00204001; Penning TM, 2001, CHEM-BIOL INTERACT, V130, P659, DOI 10.1016/S0009-2797(00)00257-X; Rasmusson RL, 1995, J PHYSIOL-LONDON, V489, P709, DOI 10.1113/jphysiol.1995.sp021085; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rindgen D, 1999, CHEM RES TOXICOL, V12, P1195, DOI 10.1021/tx990034o; Rozanski GJ, 2002, CLIN EXP PHARMACOL P, V29, P132, DOI 10.1046/j.1440-1681.2002.03618.x; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; Schlegel BP, 1998, BIOCHEMISTRY-US, V37, P3538, DOI 10.1021/bi9723055; Schultz D, 1996, GENOMICS, V31, P389, DOI 10.1006/geno.1996.0065; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; TARLE I, 1993, J BIOL CHEM, V268, P25687; TSENGCRANK J, 1993, J GEN PHYSIOL, V102, P1057, DOI 10.1085/jgp.102.6.1057; Weir EK, 2005, NEW ENGL J MED, V353, P2042, DOI 10.1056/NEJMra050002; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	43	83	86	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15194	15200		10.1074/jbc.M513809200	http://dx.doi.org/10.1074/jbc.M513809200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16569641	hybrid, Green Accepted			2022-12-25	WOS:000237922200022
J	Slepenkov, SV; Darzynkiewicz, E; Rhoads, RE				Slepenkov, Sergey V.; Darzynkiewicz, Edward; Rhoads, Robert E.			Stopped-flow kinetic analysis of eIF4E and phosphorylated eIF4E binding to cap analogs and capped oligoribonucleotides - Evidence for a one-step binding mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; MESSENGER-RNA-CAP; ACTIVATED PROTEIN-KINASE; TRANSLATION FACTOR EIF4E; EUKARYOTIC TRANSLATION; FACTOR EIF-4E; SECONDARY STRUCTURE; 4E-BINDING PROTEIN; CIRCULAR-DICHROISM; HYPERTONIC STRESS	Recruitment of eukaryotic mRNA to the 48 S initiation complex is rate-limiting for protein synthesis under normal conditions. Binding of the 5'-terminal cap structure of mRNA to eIF4E is a critical event during this process. Mammalian eIF4E is phosphorylated at Ser-209 by Mnk1 and Mnk2 kinases. We investigated the interaction of both eIF4E and phosphorylated eIF4E(eIF4E(P)) with cap analogs and capped oligoribonucleotides by stopped-flow kinetics. For m7GpppG, the rate constant of association, k(on), was dependent on ionic strength, decreasing progressively up to 350 mM KCl, but the rate constant of dissociation, k(off), was independent of ionic strength. Phosphorylation of eIF4E decreased k(on) by 2.1-2.3fold at 50 - 100 mM KCl but had progressively less effect at higher ionic strengths, being negligible at 350 mM. Contrary to published evidence, eIF4E phosphorylation had no effect on k(off). Several observations supported a simple one-step binding mechanism, in contrast to published reports of a two-step mechanism. The kinetic function that best fit the data changed from single- to double-exponential as the eIF4E concentration was increased. However, measuring koff for dissociation of a pre-formed eIF4E(.)m7GpppG complex suggested that the double-exponential kinetics were caused by dissociation of eIF4E dimers, not a two-step mechanism. Addition of a 12-nucleotide chain to the cap structure increased affinity at high ionic strength for both eIF4E (24-fold) and eIF4E(P) (7-fold), primarily due to a decrease in k(off). This suggests that additional stabilizing interactions between capped oligoribonucleotides and eIF4E, which do not occur with cap analogs alone, act to slow dissociation.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ Warsaw, Dept Biophys, PL-02089 Warsaw, Poland	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Warsaw	Rhoads, RE (corresponding author), 1501 Kings Highway, Shreveport, LA 71130 USA.	rrhoad@lsuhsc.edu	Slepenkov, Sergey/D-4039-2016		FOGARTY INTERNATIONAL CENTER [R03TW006446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020818] Funding Source: NIH RePORTER; FIC NIH HHS [1R03 TW 006446] Funding Source: Medline; NIGMS NIH HHS [2R01 GM 20818] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arquier N, 2005, CURR BIOL, V15, P19, DOI 10.1016/j.cub.2004.12.037; Bevington PR, 1969, DATA REDUCTION ERROR; Blachut-Okrasinska E, 2000, EUR BIOPHYS J BIOPHY, V29, P487, DOI 10.1007/s002490000096; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P1624, DOI 10.1021/bi00220a026; CARBERRY SE, 1990, BIOCHEMISTRY-US, V29, P3337, DOI 10.1021/bi00465a027; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P4542, DOI 10.1021/bi00232a025; CARBERRY SE, 1992, BIOCHEMISTRY-US, V31, P1427, DOI 10.1021/bi00120a020; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P6977, DOI 10.1021/bi00242a024; Cuesta R, 2000, EMBO J, V19, P3465, DOI 10.1093/emboj/19.13.3465; DARNBROUGH C, 1973, J MOL BIOL, V76, P379; Dlugosz M, 2003, EUR BIOPHYS J BIOPHY, V31, P608, DOI 10.1007/s00249-002-0258-7; Dyer JR, 1998, J BIOL CHEM, V273, P29469, DOI 10.1074/jbc.273.45.29469; Fechter P, 2005, J GEN VIROL, V86, P1239, DOI 10.1099/vir.0.80755-0; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GOSS DJ, 1990, BIOCHEMISTRY-US, V29, P5008, DOI 10.1021/bi00473a002; GOSS DJ, 1990, BIOCHIM BIOPHYS ACTA, V1050, P163, DOI 10.1016/0167-4781(90)90160-4; Grudzien E, 2004, RNA, V10, P1479, DOI 10.1261/rna.7380904; Grudzien E, 2006, J BIOL CHEM, V281, P1857, DOI 10.1074/jbc.M509121200; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; Hong-Brown LQ, 2004, AM J PHYSIOL-CELL PH, V287, pC1482, DOI 10.1152/ajpcell.00038.2004; Hu GH, 2003, J BIOL CHEM, V278, P51515, DOI 10.1074/jbc.M307654200; Jankowska-Anyszka M, 1998, J BIOL CHEM, V273, P10538, DOI 10.1074/jbc.273.17.10538; Jemielity J, 2003, RNA, V9, P1108, DOI 10.1261/rna.5430403; Joshi B, 2004, EUR J BIOCHEM, V271, P2189, DOI 10.1111/j.1432-1033.2004.04149.x; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; Khan MA, 2004, BIOCHEMISTRY-US, V43, P9092, DOI 10.1021/bi049602b; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; MCCUBBIN WD, 1988, J BIOL CHEM, V263, P17663; McKendrick L, 2001, EUR J BIOCHEM, V268, P5375, DOI 10.1046/j.0014-2956.2001.02478.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Morley SJ, 2002, J BIOL CHEM, V277, P32855, DOI 10.1074/jbc.C200376200; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Naegele S, 2004, J BIOL CHEM, V279, P46023, DOI 10.1074/jbc.M404945200; Niedzwiecka A, 2002, BIOCHEMISTRY-US, V41, P12140, DOI 10.1021/bi0258142; Niedzwiecka A, 2002, J MOL BIOL, V319, P615, DOI 10.1016/S0022-2836(02)00328-5; Orton KC, 2004, J BIOL CHEM, V279, P38649, DOI 10.1074/jbc.M407337200; Ptushkina M, 1999, EMBO J, V18, P4068, DOI 10.1093/emboj/18.14.4068; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Reiling JH, 2005, CURR BIOL, V15, P24, DOI 10.1016/j.cub.2004.12.034; Ren JH, 1996, NUCLEIC ACIDS RES, V24, P3629, DOI 10.1093/nar/24.18.3629; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Righetti P.G., 1983, ISOELECTRIC FOCUSING; Robalino J, 2004, J BIOL CHEM, V279, P10532, DOI 10.1074/jbc.M313688200; Rodriguez CM, 1998, PLANT J, V13, P465, DOI 10.1046/j.1365-313X.1998.00047.x; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; RYCHLIK W, 1990, J BIOL CHEM, V265, P19467; SAFER B, 1978, J BIOL CHEM, V253, P3384; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; SHA M, 1995, J BIOL CHEM, V270, P29904; Stepinski J, 2001, RNA, V7, P1486; STERN BD, 1993, PROTEIN EXPRES PURIF, V4, P320, DOI 10.1006/prep.1993.1041; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Tomoo K, 2005, BBA-PROTEINS PROTEOM, V1753, P191, DOI 10.1016/j.bbapap.2005.07.023; Tomoo K, 2003, J MOL BIOL, V328, P365, DOI 10.1016/S0022-2836(03)00314-0; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; von der Haar T, 2000, J BIOL CHEM, V275, P30551, DOI 10.1074/jbc.M004565200; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Wang YH, 1996, BBA-PROTEIN STRUCT M, V1297, P207, DOI 10.1016/S0167-4838(96)00119-7; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WEBB NR, 1984, BIOCHEMISTRY-US, V23, P177, DOI 10.1021/bi00297a001; Wieczorek Z, 1999, Z NATURFORSCH C, V54, P278; Wieczorek Z, 1997, BBA-GENE STRUCT EXPR, V1354, P145, DOI 10.1016/S0167-4781(97)00116-4; Wieczorek Z, 1998, J PHOTOCH PHOTOBIO B, V43, P158, DOI 10.1016/S1011-1344(98)00100-6; Worch J, 2004, ONCOGENE, V23, P9162, DOI 10.1038/sj.onc.1208164; ZAWADZKI V, 1991, NUCLEIC ACIDS RES, V19, P1948, DOI 10.1093/nar/19.8.1948; Zuberek J, 2004, BIOCHEMISTRY-US, V43, P5370, DOI 10.1021/bi030266t; Zuberek J, 2003, NUCLEOS NUCLEOT NUCL, V22, P1703, DOI 10.1081/NCN-120023118; Zuberek J, 2003, RNA, V9, P52, DOI 10.1261/rna.2133403; 1994, BIAPPLICATIONS HDB	87	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14927	14938		10.1074/jbc.M601653200	http://dx.doi.org/10.1074/jbc.M601653200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16540463	hybrid			2022-12-25	WOS:000237671300046
J	Sunesen, M; De Carvalho, LP; Dufresne, V; Grailhe, R; Savatier-Duclert, N; Gibor, G; Peretz, A; Attali, B; Changeux, JP; Paas, Y				Sunesen, Morten; De Carvalho, Lia Prado; Dufresne, Virginie; Grailhe, Regis; Savatier-Duclert, Nathalie; Gibor, Gilad; Peretz, Asher; Attali, Bernard; Changeux, Jean-Pierre; Paas, Yoav			Mechanism of Cl- selection by a glutamate-gated chloride (GluCl) receptor revealed through mutations in the selectivity filter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGED AMINO-ACIDS; ACETYLCHOLINE-RECEPTOR; ION SELECTIVITY; NICOTINIC RECEPTOR; GATING MECHANISM; ANION PERMEATION; CHANNEL; GLYCINE; PORE; CONDUCTANCE	To learn about the mechanism of ion charge selectivity by invertebrate glutamate-gated chloride ( GluCl) channels, we swapped segments between the GluCl beta receptor of Caenorhabditis elegans and the vertebrate cationic alpha 7-acetylcholine receptor and monitored anionic/cationic permeability ratios. Complete conversion of the ion charge selectivity in a set of receptor microchimeras indicates that the selectivity filter of the GluCl beta receptor is created by a sequence connecting the first with the second transmembrane segments. A single substitution of a negatively charged residue within this sequence converted the selectivity of the GluCl beta receptor's pore from anionic to cationic. Unexpectedly, elimination of the charge of each basic residue of the selectivity filter, one at a time or concomitantly, moderately reduced the P-Cl/P-Na ratios, but the GluCl beta receptor's mutants retained high capacity to select Cl- over Na+. These results indicate that, unlike the proposed case of anionic Gly- and gamma-aminobutyric acid-gated ion channels, positively charged residues do not play the key role in the selection of ionic charge by the GluCl beta receptor. Taken together with measurements of the effective open pore diameter and with structural modeling, the study presented here collectively indicates that in the most constricted part of the open GluCl beta receptor's channel, Cl- interacts with backbone amides, where it undergoes partial dehydration necessary for traversing the pore.	Inst Pasteur, CNRS, UMR 2182, Unit Receptors & Cognit, F-75724 Paris 15, France; Sophion Biosci AS, DK-2750 Ballerup, Denmark; Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Tel Aviv University; Sackler Faculty of Medicine	Paas, Y (corresponding author), Inst Pasteur, CNRS, UMR 2182, Unit Receptors & Cognit, 25 Rue Dr Roux, F-75724 Paris 15, France.	yopaas@netvision.net.il						Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; BORMANN J, 1993, EMBO J, V12, P3729, DOI 10.1002/j.1460-2075.1993.tb06050.x; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; Carland JE, 2004, J BIOL CHEM, V279, P54153, DOI 10.1074/jbc.M410625200; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; FATIMASHAD K, 1993, P ROY SOC B-BIOL SCI, V253, P69, DOI 10.1098/rspb.1993.0083; Fuchs S, 2003, ANN NY ACAD SCI, V998, P93, DOI 10.1196/annals.1254.011; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Jensen ML, 2005, J NEUROCHEM, V92, P962, DOI 10.1111/j.1471-4159.2004.02970.x; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; Keramidas A, 2004, PROG BIOPHYS MOL BIO, V86, P161, DOI 10.1016/j.pbiomolbio.2003.09.002; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Lee DJS, 2003, NEUROSCI LETT, V351, P196, DOI 10.1016/j.neulet.2003.08.005; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; MacInnes D.A., 1961, PRINCIPLES ELECTROCH; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; Menard C, 2005, J BIOL CHEM, V280, P27502, DOI 10.1074/jbc.M501624200; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moorhouse AJ, 2002, J GEN PHYSIOL, V119, P411, DOI 10.1085/jgp.20028553; Paas Y, 2005, P NATL ACAD SCI USA, V102, P15877, DOI 10.1073/pnas.0507599102; Pitzer K.S, 1991, ION INTERACTION APPR, Vsecond; RUNDSTROM N, 1994, P NATL ACAD SCI USA, V91, P8950, DOI 10.1073/pnas.91.19.8950; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; TAYLOR P, 2000, HANDB EXP PHARM, V144, P79; Thompson AJ, 2003, BRIT J PHARMACOL, V140, P359, DOI 10.1038/sj.bjp.0705424; VILLARROEL A, 1992, BIOPHYS J, V62, P196, DOI 10.1016/S0006-3495(92)81805-2; Wilson GG, 2000, J GEN PHYSIOL, V115, P93, DOI 10.1085/jgp.115.2.93; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Wotring VE, 2003, J PHYSIOL-LONDON, V548, P527, DOI 10.1113/jphysiol.2002.032045; Wotring VE, 1999, J PHYSIOL-LONDON, V521, P327, DOI 10.1111/j.1469-7793.1999.00327.x; [No title captured]	41	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14875	14881		10.1074/jbc.M511657200	http://dx.doi.org/10.1074/jbc.M511657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16527818	hybrid			2022-12-25	WOS:000237671300041
J	Ulvila, J; Parikka, M; Kleino, A; Sormunen, R; Ezekowitz, RA; Kocks, C; Ramet, M				Ulvila, Johanna; Parikka, Mataleena; Kleino, Anni; Sormunen, Raija; Ezekowitz, R. Alan; Kocks, Christine; Ramet, Mika			Double-stranded RNA is internalized by scavenger receptor-mediated endocytosis in Drosophila S2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTEIN; PROTEASOME; COMPONENTS; INITIATION; CLEAVAGE; IDENTIFICATION; INTERFERENCE; PHAGOCYTOSIS; ARGONAUTE2	Double-stranded RNA ( dsRNA) fragments are readily internalized and processed by Drosophila S2 cells, making these cells a widely used tool for the analysis of gene function by gene silencing through RNA interference (RNAi). The underlying mechanisms are insufficiently understood. To identify components of the RNAi pathway in S2 cells, we developed a screen based on rescue from RNAi-induced lethality. We identified Argonaute 2, a core component of the RNAi machinery, and three gene products previously unknown to be involved in RNAi in Drosophila: DEAD-box RNA helicase Belle, 26 S proteasome regulatory subunit 8 (Pros45), and clathrin heavy chain, a component of the endocytic machinery. Blocking endocytosis in S2 cells impaired RNAi, suggesting that dsRNA fragments are internalized by receptor-mediated endocytosis. Indeed, using a candidate gene approach, we identified two Drosophila scavenger receptors, SR-CI and Eater, which together accounted for more than 90% of the dsRNA uptake into S2 cells. When expressed in mammalian cells, SR-CI was sufficient to mediate internalization of dsRNA fragments. Our data provide insight into the mechanism of dsRNA internalization by Drosophila cells. These results have implications for dsRNA delivery into mammalian cells.	Tampere Univ, Inst Med Technol, FIN-30014 Tampere, Finland; Oulu Univ, Dept Pediat, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat,Lab Dev Immunol, Boston, MA 02115 USA; Tampere Univ Hosp, Dept Pediat, FIN-33521 Tampere, Finland	Tampere University; University of Oulu; University of Oulu; University of Oulu; Harvard University; Harvard Medical School; Massachusetts General Hospital; Tampere University; Tampere University Hospital	Ramet, M (corresponding author), Tampere Univ, Inst Med Technol, FIN-30014 Tampere, Finland.	Mika.Ramet@uta.fi	Parikka, Mataleena/D-4364-2014	Parikka, Mataleena/0000-0001-5555-3815	NIAID NIH HHS [P01 AI 44220] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044220] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baker SP, 2005, CELL, V123, P361, DOI 10.1016/j.cell.2005.10.013; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; Goto A, 2003, NUCLEIC ACIDS RES, V31, P6619, DOI 10.1093/nar/gkg852; Greaves DR, 2005, J LIPID RES, V46, P11, DOI 10.1194/jlr.R400011-JLR200; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Iost I, 1999, J BIOL CHEM, V274, P17677, DOI 10.1074/jbc.274.25.17677; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Johnson ME, 2004, J SOUND VIB, V277, P101, DOI 10.1016/j.jsv.2003.08.031; Kallio J, 2005, MICROBES INFECT, V7, P811, DOI 10.1016/j.micinf.2005.03.014; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Kleino A, 2005, EMBO J, V24, P3423, DOI 10.1038/sj.emboj.7600807; Kocks C, 2005, CELL, V123, P335, DOI 10.1016/j.cell.2005.08.034; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Miyoshi K, 2005, GENE DEV, V19, P2837, DOI 10.1101/gad.1370605; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; Preall JB, 2005, CELL, V123, P543, DOI 10.1016/j.cell.2005.11.006; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020; Rand TA, 2004, P NATL ACAD SCI USA, V101, P14385, DOI 10.1073/pnas.0405913101; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	42	208	215	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14370	14375		10.1074/jbc.M513868200	http://dx.doi.org/10.1074/jbc.M513868200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16531407	hybrid			2022-12-25	WOS:000237512300063
J	Yamaguchi, T; Matsushita, S; Motojima, K; Hirose, F; Osumi, T				Yamaguchi, Tomohiro; Matsushita, Shuhei; Motojima, Kiyoto; Hirose, Fumiko; Osumi, Takashi			MLDP, a novel PAT family protein localized to lipid droplets and enriched in the heart, is regulated by peroxisome proliferator-activated receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-RELATED PROTEIN; ANCHOR PERILIPIN-A; GENE-EXPRESSION; PPAR-ALPHA; GAMMA; IDENTIFICATION; ACCUMULATION; ADIPOPHILIN; METABOLISM; HORMONE	Cytosolic lipid droplets (LDs) are multifunctional organelles that exist in all types of eukaryotic cells and control lipid homeostasis. In mammalian cells LDs contain a class of proteins in their surface layers that share a homologous sequence called the PAT domain, including perilipin, adipose differentiation-related protein ( ADRP), a tail-interacting protein of 47 kDa (TIP47), and S3-12, which are distributed tissue- or cell type-selectively. Expression in some cases is regulated by peroxisome proliferator-activated receptors (PPARs). In this study we identified a new PAT family member named MLDP (myocardial LD protein) in a murine cDNA data base and showed the mRNA and protein to be highly enriched in the heart and also expressed at lower levels in the liver and adrenals. Upon subcellular fractionation, a substantial amount of MLDP was detected in the top fraction enriched with LDs. Furthermore, over-expressed MLDP tagged with green fluorescent protein accumulated at the surfaces of LDs and co-localized with perilipin and ADRP. Deletion analysis demonstrated the N-terminal region containing a PAT-1 domain and the following 33-mer domain to be required for targeting of MLDP to LDs. MLDP was found to be up-regulated at both mRNA and protein levels in the heart and liver by a selective ligand for PPAR alpha, Wy14,643, but not in PPAR alpha knock-out mice. MLDP expression was also increased upon fasting in parallel with ADRP. These results indicate that MLDP is a bona fide new PAT family member localized in LDs. Its expression depends on the physiological conditions and the action of PPAR alpha.	Univ Hyogo, Grad Sch Life Sci, Kamigori, Hyogo 6781297, Japan; Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan	University of Hyogo; Meiji Pharmaceutical University	Osumi, T (corresponding author), Univ Hyogo, Grad Sch Life Sci, 3-2-1 Koto, Kamigori, Hyogo 6781297, Japan.	osumi@sci.u-hyogo.ac.jp		Hirose, Fumiko/0000-0003-4586-4892				Arimura N, 2004, J BIOL CHEM, V279, P10070, DOI 10.1074/jbc.M308522200; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Buechler C, 2001, BBA-MOL CELL BIOL L, V1532, P97, DOI 10.1016/S1388-1981(01)00121-4; Chang BHJ, 2006, MOL CELL BIOL, V26, P1063, DOI 10.1128/MCB.26.3.1063-1076.2006; Corsini E, 2003, J INVEST DERMATOL, V121, P337, DOI 10.1046/j.1523-1747.2003.12371.x; Dalen KT, 2004, DIABETES, V53, P1243, DOI 10.2337/diabetes.53.5.1243; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Edvardsson U, 2006, J LIPID RES, V47, P329, DOI 10.1194/jlr.M500203-JLR200; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; Gazouli M, 2002, ENDOCRINOLOGY, V143, P2571, DOI 10.1210/en.143.7.2571; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Gupta RA, 2001, J BIOL CHEM, V276, P29681, DOI 10.1074/jbc.M103779200; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Hodgkinson CP, 2003, BIOCHEM BIOPH RES CO, V308, P505, DOI 10.1016/S0006-291X(03)01416-5; Huss JM, 2004, CIRC RES, V95, P568, DOI 10.1161/01.RES.0000141774.29937.e3; Imamura M, 2002, AM J PHYSIOL-ENDOC M, V283, pE775, DOI 10.1152/ajpendo.00040.2002; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Londos C, 2005, BIOCHIMIE, V87, P45, DOI 10.1016/j.biochi.2004.12.010; Masuda Y, 2006, J LIPID RES, V47, P87, DOI 10.1194/jlr.M500170-JLR200; McManaman JL, 2003, J LIPID RES, V44, P668, DOI 10.1194/jlr.C200021-JLR200; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Nagai S, 2004, ENDOCRINOLOGY, V145, P2346, DOI 10.1210/en.2003-1180; Nakamura N, 2003, BIOCHEM BIOPH RES CO, V306, P333, DOI 10.1016/S0006-291X(03)00979-3; Robenek H, 2005, J BIOL CHEM, V280, P26330, DOI 10.1074/jbc.M413312200; Robenek H, 2005, J LIPID RES, V46, P1331, DOI 10.1194/jlr.M400323-JLR200; Rosenbaum SE, 1998, MOL ENDOCRINOL, V12, P1150, DOI 10.1210/me.12.8.1150; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Shimizu M, 2004, MOL CELL BIOL, V24, P1313, DOI 10.1128/MCB.24.3.1313-1323.2004; Stanley WC, 2005, PHYSIOL REV, V85, P1093, DOI 10.1152/physrev.00006.2004; Subramanian V, 2004, J LIPID RES, V45, P1983, DOI 10.1194/jlr.M400291-JLR200; SUZUKI J, 2002, AM J PHYSIOL-ENDOC M, V283, P94; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tachibana Keisuke, 2005, Nucl Recept, V3, P3, DOI 10.1186/1478-1336-3-3; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Targett-Adams P, 2005, BBA-GENE STRUCT EXPR, V1728, P95, DOI 10.1016/j.bbaexp.2005.01.017; Targett-Adams P, 2003, J BIOL CHEM, V278, P15998, DOI 10.1074/jbc.M211289200; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Tominaga S, 2002, J BIOCHEM, V132, P881, DOI 10.1093/oxfordjournals.jbchem.a003301; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; Wolins NE, 2005, J BIOL CHEM, V280, P19146, DOI 10.1074/jbc.M500978200; Wolins NE, 2003, J BIOL CHEM, V278, P37713, DOI 10.1074/jbc.M304025200; Wu CC, 2000, ELECTROPHORESIS, V21, P3470, DOI 10.1002/1522-2683(20001001)21:16<3470::AID-ELPS3470>3.3.CO;2-7; Xu GH, 2005, J BIOL CHEM, V280, P42841, DOI 10.1074/jbc.M506569200; Yamaguchi T, 2004, J BIOL CHEM, V279, P30490, DOI 10.1074/jbc.M403920200; Yue TL, 2003, CIRCULATION, V108, P2393, DOI 10.1161/01.CIR.0000093187.42015.6C; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	60	163	168	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14232	14240		10.1074/jbc.M601682200	http://dx.doi.org/10.1074/jbc.M601682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16571721	hybrid			2022-12-25	WOS:000237512300047
J	Kalamvoki, M; Georgopoulou, U; Mavromara, P				Kalamvoki, M; Georgopoulou, U; Mavromara, P			The NS5A protein of the hepatitis C virus genotype 1a is cleaved by caspases to produce C-terminal-truncated forms of the protein that reside mainly in the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NONSTRUCTURAL 5A PROTEIN; NF-KAPPA-B; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATOR; HEPATOCELLULAR-CARCINOMA; PROTEOLYTIC CLEAVAGE; NUCLEAR-LOCALIZATION; DEPENDENT ACTIVATION; MEDIATED CLEAVAGE; CALPAIN PROTEASES	The nonstructural 5A ( NS5A) protein of the hepatitis C virus ( HCV) is a multifunctional protein that is implicated in viral replication and pathogenesis. We report here that NS5A of HCV- 1a is cleaved at multiple sites by caspase proteases in transfected cells. Two cleavage sites at positions Asp(154) and (DXXD251)-D-248 were mapped. Cleavage at Asp(154) has been previously recognized as one of the caspase cleavage sites for the NS5A protein of HCV genotype 1b ( 1, 2) and results in the production of a 17- kDa fragment. The sequence (DXXD251)-D-248 is a novel caspase recognition motif for NS5A and is responsible for the production of a 31- kDa fragment. Furthermore, we show that Arg(217) is implicated in the production of the previously described 24- kDa product, whose accumulation is affected by both calpain and caspase inhibitors. We also showed that caspase- mediated cleavage occurs in the absence of exogenous proapoptotic stimuli and is not related to the accumulation of the protein in the endoplasmic reticulum. Interestingly, our data indicate that NS5A is targeted by at least two different caspases and suggest that caspase 6 is implicated in the production of the 17- kDa fragment. Most importantly, we report that, all the detectable NS5A fragments following caspase- mediated cleavage are C- terminal-truncated forms of NS5A and are mainly localized in the cytosol. Thus, in sharp contrast to the current view we found no evidence supporting a role for caspase- mediated cleavage in the transport of the NS5A protein to the nucleus, which could lead to transcriptional activation.	Hellenic Pasteur Inst, Mol Virol Lab, Athens 11521, Greece		Mavromara, P (corresponding author), Hellenic Pasteur Inst, Mol Virol Lab, 127,Vas Sofias Ave, Athens 11521, Greece.	penelopm@hol.gr	Georgopoulou, Urania/AAQ-3831-2020					Al-Molawi N, 2003, J GEN VIROL, V84, P1237, DOI 10.1099/vir.0.18840-0; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Algeciras-Schimnich A, 2002, CURR OPIN CELL BIOL, V14, P721, DOI 10.1016/S0955-0674(02)00384-8; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Arima N, 2001, J BIOL CHEM, V276, P12675, DOI 10.1074/jbc.M008329200; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Best SM, 2004, VIROLOGY, V320, P191, DOI 10.1016/j.virol.2003.11.025; Best SM, 2003, J VIROL, V77, P5305, DOI 10.1128/JVI.77.9.5305-5312.2003; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Carlile GW, 2004, BLOOD, V103, P4310, DOI 10.1182/blood-2003-09-3362; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHOI YW, 2004, BIOCHEM BIOPH RES CO, V38, P514; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Chung KM, 1997, MOL CELLS, V7, P661; Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000; Chung YL, 2003, INT J CANCER, V107, P65, DOI 10.1002/ijc.11303; Cicala C, 2000, P NATL ACAD SCI USA, V97, P1178, DOI 10.1073/pnas.97.3.1178; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Di Bisceglie AM, 2000, HEPATOLOGY, V31, P1014, DOI 10.1053/he.2000.5762; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eckhart L, 2001, BIOCHEM BIOPH RES CO, V289, P777, DOI 10.1006/bbrc.2001.6055; Eleouet JF, 2000, J VIROL, V74, P3975, DOI 10.1128/JVI.74.9.3975-3983.2000; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Francois F, 2000, FEBS LETT, V486, P281, DOI 10.1016/S0014-5793(00)02316-4; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Gao L, 2004, J VIROL, V78, P3480, DOI 10.1128/JVI.78.7.3480-3488.2004; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Ghosh AK, 2000, VIRUS RES, V67, P173, DOI 10.1016/S0168-1702(00)00141-6; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Ghosh AK, 2003, VIROLOGY, V306, P51, DOI 10.1016/S0042-6822(02)00029-6; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Goh PY, 2001, VIROLOGY, V290, P224, DOI 10.1006/viro.2001.1195; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Grand RJA, 2002, VIROLOGY, V301, P255, DOI 10.1006/viro.2002.1586; Hasnain SE, 2003, J BIOSCIENCES, V28, P349, DOI 10.1007/BF02970153; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; He YP, 2002, VIRAL IMMUNOL, V15, P95, DOI 10.1089/088282402317340260; Hidajat Rachmat, 2004, Kobe Journal of Medical Sciences, V50, P153; Hirota M, 1999, VIROLOGY, V257, P130, DOI 10.1006/viro.1999.9658; Hofmann TG, 2000, ONCOGENE, V19, P1153, DOI 10.1038/sj.onc.1203406; Houshmand H, 2003, BIOCHEM BIOPH RES CO, V309, P695, DOI 10.1016/j.bbrc.2003.08.054; Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0; Irusta PM, 2003, CURR OPIN CELL BIOL, V15, P700, DOI 10.1016/j.ceb.2003.10.007; Kalamvoki M, 2004, J VIROL, V78, P11865, DOI 10.1128/JVI.78.21.11865-11878.2004; Kalamvoki M, 2002, ARCH VIROL, V147, P1733, DOI 10.1007/s00705-002-0836-0; Kalliampakou KI, 2005, J GEN VIROL, V86, P1015, DOI 10.1099/vir.0.80728-0; Kang KH, 2001, J BIOL CHEM, V276, P24638, DOI 10.1074/jbc.M101291200; Kato N, 1997, J VIROL, V71, P8856, DOI 10.1128/JVI.71.11.8856-8859.1997; King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; LeBlanc AC, 2003, PROG NEURO-PSYCHOPH, V27, P215, DOI 10.1016/S0278-5846(03)00017-4; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Los M, 2001, TRENDS IMMUNOL, V22, P31, DOI 10.1016/S1471-4906(00)01814-7; Macdonald A, 2004, J GEN VIROL, V85, P2485, DOI 10.1099/vir.0.80204-0; Macdonald A, 2004, J GEN VIROL, V85, P721, DOI 10.1099/vir.0.19691-0; Majumder M, 2002, VIROLOGY, V294, P94, DOI 10.1006/viro.2001.1309; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mendez E, 2004, J VIROL, V78, P8601, DOI 10.1128/JVI.78.16.8601-8608.2004; Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200; Munger J, 2003, VIROLOGY, V305, P364, DOI 10.1006/viro.2002.1728; MURPHY FA, 1995, VIRUS TAXONOMY, P424; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; PANARETAKIS T, 2005, MOL BIOL CELL; Park KJ, 2003, J BIOL CHEM, V278, P30711, DOI 10.1074/jbc.M209623200; Park KJ, 2002, J BIOL CHEM, V277, P13122, DOI 10.1074/jbc.M111599200; Polyak SJ, 2001, J VIROL, V75, P6095, DOI 10.1128/JVI.75.13.6095-6106.2001; Qadri I, 2002, BBA-MOL CELL RES, V1592, P193, DOI 10.1016/S0167-4889(02)00315-4; Ravi R, 1998, CANCER RES, V58, P882; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Reed KE, 1997, J VIROL, V71, P7187, DOI 10.1128/JVI.71.10.7187-7197.1997; Rendl M, 2002, J INVEST DERMATOL, V119, P1150, DOI 10.1046/j.1523-1747.2002.19532.x; Reyes GR, 2002, J BIOMED SCI, V9, P187, DOI 10.1007/BF02256065; Rotter B, 2004, BIOCHEM J, V378, P161, DOI 10.1042/BJ20030955; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Satoh S, 2000, VIROLOGY, V270, P476, DOI 10.1006/viro.2000.0287; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; Shirota Y, 2002, J BIOL CHEM, V277, P11149, DOI 10.1074/jbc.M111392200; Shisler JL, 1998, TRENDS MICROBIOL, V6, P337, DOI 10.1016/S0966-842X(98)01342-0; Song J, 2000, VIRUS RES, V69, P109, DOI 10.1016/S0168-1702(00)00206-9; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Taguchi T, 2004, J GEN VIROL, V85, P959, DOI 10.1099/vir.0.19513-0; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885; Tang GL, 2001, MOL CELL, V8, P1005, DOI 10.1016/S1097-2765(01)00380-X; Tanimoto A, 1997, BIOCHEM BIOPH RES CO, V236, P360, DOI 10.1006/bbrc.1997.6967; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Varaklioti A, 2002, J BIOL CHEM, V277, P17713, DOI 10.1074/jbc.M201722200; Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Waris G, 2002, BIOCHEM PHARMACOL, V64, P1425, DOI 10.1016/S0006-2952(02)01300-X; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Woo M, 2003, NAT IMMUNOL, V4, P1016, DOI 10.1038/ni976; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; Yeh CT, 2005, BIOCHEM BIOPH RES CO, V327, P516, DOI 10.1016/j.bbrc.2004.11.165; Zech B, 2003, J GEN VIROL, V84, P555, DOI 10.1099/vir.0.18801-0; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	117	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13449	13462		10.1074/jbc.M601124200	http://dx.doi.org/10.1074/jbc.M601124200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16517592	hybrid			2022-12-25	WOS:000237336600052
J	Duncan, EA; Anest, V; Cogswell, P; Baldwin, AS				Duncan, EA; Anest, V; Cogswell, P; Baldwin, AS			The kinases MSK1 and MSK2 are required for epidermal growth factor-induced, but not tumor necrosis factor-induced, histone H3 Ser(10) phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; C-FOS; ACTIVATION; ALPHA	Phosphorylation of histone H3 protein at serine 10 is an important step in chromatin remodeling during transcriptional transactivation. IkB kinase-alpha (IKK-alpha) and Mitogen- and Stress- activated protein Kinases 1 and 2 (MSK1/2) have been shown to play key roles in the transcriptional regulation of immediate early genes such as c-fos. Interestingly, IKK-alpha and MSK1/2 have also been implicated as histone H3-Ser(10) kinases. In this work, we have shown that MSK1/2 are required for epidermal growth factor (EGF)-induced, but not tumor necrosis factor-induced, histone H3-Ser(10) phosphorylation, both globally and at specific promoters. Consistent with this, MSK1/2 are required for optimal immediate early c-fos transcription in response to EGF potentially through control of both H3-Ser(10) and promoter-associated cAMP-response element-binding protein phosphorylation. Furthermore, MSK1/2 control EGF-induced IKB alpha promoter H3-Ser(10) phosphorylation in the absence of elevated transcription. These studies demonstrate the existence of pathway-specific mechanisms to control histone H3-Ser(10) phosphorylation and gene expression.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Canc Ctr 22 000, CB 7295, Chapel Hill, NC 27599 USA.	abaldwin@med.unc.edu			NCI NIH HHS [R01 CA73756] Funding Source: Medline; NIAID NIH HHS [R01 AI35098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	18	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12521	12525		10.1074/jbc.M513333200	http://dx.doi.org/10.1074/jbc.M513333200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517600	hybrid, Green Published			2022-12-25	WOS:000237134700040
J	Leiblich, A; Cross, SS; Catto, JWF; Phillips, JT; Leung, HY; Hamdy, FC; Rehman, I				Leiblich, A.; Cross, S. S.; Catto, J. W. F.; Phillips, J. T.; Leung, H. Y.; Hamdy, F. C.; Rehman, I.			Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer	ONCOGENE			English	Article						prostate cancer; hypermethylation; proteomic; benign prostatic hyperplasia; metastatic	PROTEOMIC ANALYSIS; EXPRESSION; HYPOXIA; GROWTH; TISSUE; SITES; LDH	In order to identify novel candidates associated with prostate cancer metastasis, we compared the proteomic pro. le of the poorly metastatic human prostate cancer cell line LNCaP, with its highly metastatic variant LNCaP-LN3, by two- dimensional gel electrophoresis. A major protein spot ( pI of 5.9 and molecular weight of 37 kDa) was seen in LNCaP cells, but not in LNCaP- LN3 cells and was identified as lactate dehydrogenase- B ( LDHB), by tandem mass spectrometry. Furthermore, enzyme kinetic assays and zymography showed a higher LDH enzyme activity in LNCaP cells compared with LNCaP-LN3. Bisulphite- modified DNA sequencing showed promoter hypermethylation in LNCaP- LN3 cells but not in LNCaP, Du145, PC3, CWR22 or BPH45 cells. Treatment of LNCaP- LN3 cells with 5'- azacytidine caused re-expression of LDHB transcripts. In tissues, LDHB promoter hypermethylation occurred at a higher frequency in prostate cancer, 14/ 31 ( 45%), compared to adjacent nonmalignant or benign tissue, 2/ 19 ( 11%) ( P < 0.025). Immunohistochemistry showed a higher frequency of LDHB expression in benign or nonmalignant tissues, 59/ 73 ( 81%), compared to cancer cases, 3/ 53 ( 6%) ( P < 0.001). Absent LDHB expression was also seen in 7/ 7 ( 100%) cases of metastatic cancer in bone. Our data are the first to show loss of LDHB expression in prostate cancer, the mechanism of which appears to involve promoter hypermethylation.	Univ Sheffield, Div Clin Sci S, Acad Urol Unit, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Div Genom Med, Acad Unit Pathol, Sheffield S10 2JF, S Yorkshire, England; Univ Newcastle, No Inst Canc Res, Urol Res Grp, Newcastle Upon Tyne, Tyne & Wear, England	University of Sheffield; University of Sheffield; Newcastle University - UK	Rehman, I (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Acad Urol Unit, Glossop Rd,Floor K, Sheffield S10 2JF, S Yorkshire, England.	i.rehman@sheffield.ac.uk		Cross, Simon/0000-0003-2044-1754; catto, james/0000-0003-2787-8828; Leung, Hing Y./0000-0002-3933-3975; Hamdy, Freddie/0000-0003-2627-2154	Medical Research Council [G0100444] Funding Source: Medline; MRC [G0100444] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahram M, 2002, MOL CARCINOGEN, V33, P9, DOI 10.1002/mc.10019; Allen S, 2003, J BIOL CHEM, V278, P6371, DOI 10.1074/jbc.M209915200; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P574; Bhandari MS, 2005, EUR J CANCER, V41, P941, DOI 10.1016/j.ejca.2005.02.008; Brizel DM, 2001, INT J RADIAT ONCOL, V51, P349, DOI 10.1016/S0360-3016(01)01630-3; Cheung PK, 2004, CANCER RES, V64, P5929, DOI 10.1158/0008-5472.CAN-04-1216; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Chu LW, 2001, CANCER GENET CYTOGEN, V127, P161, DOI 10.1016/S0165-4608(01)00389-2; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Ding SJ, 2004, PROTEOMICS, V4, P982, DOI 10.1002/pmic.200300653; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Graves PR, 2002, MICROBIOL MOL BIOL R, V66, P39, DOI 10.1128/MMBR.66.1.39-63.2002; Grayhack J T, 1980, Prostate, V1, P227, DOI 10.1002/pros.2990010208; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Hamdy FC, 2001, CANCER TREAT REV, V27, P143, DOI 10.1053/ctrv.2000.0208; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; HOLBROOK JJ, 1975, LACTATE DEHYDROGENAS, P191; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Klingler HC, 1999, PROSTATE, V41, P110; Koukourakis MI, 2005, NEOPLASIA, V7, P1, DOI 10.1593/neo.04373; Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010; Liu XH, 2003, ELECTROPHORESIS, V24, P3445, DOI 10.1002/elps.200305574; Maekawa M, 2003, CLIN CHEM, V49, P1518, DOI 10.1373/49.9.1518; MARKERT CL, 1975, SCIENCE, V189, P102, DOI 10.1126/science.1138367; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Meehan KL, 2002, PROSTATE, V50, P54, DOI 10.1002/pros.10032; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Rehman I, 2005, PROSTATE, V65, P322, DOI 10.1002/pros.20302; Rehman I, 2004, UROLOGY, V64, P1238, DOI 10.1016/j.urology.2004.06.063; Rehman I, 2004, HUM PATHOL, V35, P1385, DOI 10.1016/j.humpath.2004.07.015; Rehman I, 1996, ONCOGENE, V12, P2483; RETHORE MO, 1976, ANN GENET-PARIS, V19, P140; Salplachta J, 2000, ACTA VET BRNO, V69, P267, DOI 10.2754/avb200069040267; Schulz WA, 2003, MOL HUM REPROD, V9, P437, DOI 10.1093/molehr/gag064; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Shi Q, 2001, ONCOGENE, V20, P3751, DOI 10.1038/sj.onc.1204500; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Stern R, 2002, EXP CELL RES, V276, P24, DOI 10.1006/excr.2002.5508; TAKENO T, 1989, BIOCHEM J, V257, P921, DOI 10.1042/bj2570921; Tsoi SCM, 2001, PLACENTA, V22, P317, DOI 10.1053/plac.2000.0620; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711	45	95	102	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2953	2960		10.1038/sj.onc.1209262	http://dx.doi.org/10.1038/sj.onc.1209262			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16547507				2022-12-25	WOS:000237448200015
J	Sun, JC; Duffy, KE; Ranjith-Kumar, CT; Xiong, J; Lamb, RJ; Santos, J; Masarapu, H; Cunningham, M; Holzenburg, A; Sarisky, RT; Mbow, ML; Kao, C				Sun, JC; Duffy, KE; Ranjith-Kumar, CT; Xiong, J; Lamb, RJ; Santos, J; Masarapu, H; Cunningham, M; Holzenburg, A; Sarisky, RT; Mbow, ML; Kao, C			Structural and functional analyses of the human Toll-like receptor 3 - Role of glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SUBCELLULAR-LOCALIZATION; BIOSYNTHESIS; ACTIVATION; IMMUNITY; LIGAND; RNA; RECOGNITION; SUPPRESSION; EXPRESSION	Toll-like receptors (TLRs) play critical roles in bridging the innate and adaptive immune responses. The human TLR3 recognizes foreign-derived double-stranded RNA and endogenous necrotic cell RNA as ligands. Herein we characterized the contribution of glycosylation to TLR3 structure and function. Exogenous addition of purified extracellular domain of TLR3 (hTLR3 ECD) expressed in human embryonic kidney cells was found to inhibit TLR3-dependent signaling, thus providing a reagent for structural and functional characterization. Approximately 35% of the mass of the hTLR3 ECD was due to posttranslational modification, with N-linked glycosyl groups contributing substantially to the additional mass. Cells treated with tunicamycin, an inhibitor of glycosylation, prevented TLR3-induced NF-kappa B activation, confirming that N-linked glycosylation is required for bioactivity of this receptor. Further, mutations in two of these predicted glycosylation sites impaired TLR3 signaling without obviously affecting the expression of the protein. Single-particle structures reconstructed from electron microscopy images and two-dimensional crystallization revealed that hTLR3 ECD forms a horseshoe structure similar to the recently elucidated x-ray structure of the protein expressed in insect cells using baculovirus vectors (Choe, J., Kelker, M. S., and Wilson, I. A. ( 2005) Science 309, 581 - 585 and Bell, J. K., Botos, I., Hall, P. R., Askins, J., Shiloach, J., Segal, D. M., and Davies, D. R. ( 2005) Proc. Natl. Acad. Sci. U. S. A. 102, 10976 - 10980). There are, however, notable differences between the human cell-derived and insect cell-derived structures, including features attributable to glycosylation.	Centocor Res & Dev Inc, Discovery Res, Radnor, PA 19087 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Texas A&M Univ, Microscopy & Imaging Ctr, College Stn, TX 77843 USA	Johnson & Johnson; Johnson & Johnson USA; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Mbow, ML (corresponding author), Centocor Res & Dev Inc, Discovery Res, Radnor, PA 19087 USA.	Lmbow@cntus.jnj.com; ckao@tamu.edu	Kumar CT, Ranjith/J-5701-2016; Masarapu, Hema/AAV-9120-2021	Masarapu, Hema/0000-0002-1262-5978				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Belkhadir Y, 2004, CURR OPIN PLANT BIOL, V7, P391, DOI 10.1016/j.pbi.2004.05.009; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; DEBOUTEILLER O, 2005, J BIOL CHEM; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; Guo HB, 2003, J BIOL CHEM, V278, P52412, DOI 10.1074/jbc.M308837200; Harris JR, 2002, MICRON, V33, P461, DOI 10.1016/S0968-4328(01)00039-7; Hoppert M., 2003, MICROSCOPIC TECHNIQU; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V41, P121, DOI 10.1016/0304-3991(92)90102-P; JANS DA, 1992, ARCH BIOCHEM BIOPHYS, V294, P64, DOI 10.1016/0003-9861(92)90137-L; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Lemaitre B, 2004, NAT REV IMMUNOL, V4, P521, DOI 10.1038/nri1390; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Mbow ML, 2005, DRUG NEWS PERSPECT, V18, P179, DOI 10.1358/dnp.2005.18.3.892763; McGettrick AF, 2004, MOL IMMUNOL, V41, P577, DOI 10.1016/j.molimm.2004.04.006; Moremen KW, 2002, BBA-GEN SUBJECTS, V1573, P225, DOI 10.1016/S0304-4165(02)00388-4; Moynagh PN, 2005, TRENDS IMMUNOL, V26, P469, DOI 10.1016/j.it.2005.06.009; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; Patel RN, 1999, J IMMUNOL, V163, P3459; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x; Schroder M, 2005, TRENDS IMMUNOL, V26, P462, DOI 10.1016/j.it.2005.07.002; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Underhill DM, 2004, MICROBES INFECT, V6, P1368, DOI 10.1016/j.micinf.2004.08.016; Weber ANR, 2004, J BIOL CHEM, V279, P34589, DOI 10.1074/jbc.M403830200; Zambon RA, 2005, P NATL ACAD SCI USA, V102, P7257, DOI 10.1073/pnas.0409181102	32	97	109	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11144	11151		10.1074/jbc.M510442200	http://dx.doi.org/10.1074/jbc.M510442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16533755	hybrid			2022-12-25	WOS:000236822200057
J	Hui, AS; Bauer, AL; Striet, JB; Schnell, PO; Czyzyk-Krzeska, MF				Hui, Anna S.; Bauer, Amy L.; Striet, Justin B.; Schnell, Phillip O.; Czyzyk-Krzeska, Maria F.			Calcium signaling stimulates translation of HIF-alpha during hypoxia	FASEB JOURNAL			English	Article						protein kinase C; oxygen-sensitive cells; protein translation; carotid body; PC12 cells	TUMOR-SUPPRESSOR PROTEIN; TYROSINE-HYDROXYLASE; MESSENGER-RNA; GENE-EXPRESSION; INDUCIBLE FACTOR-1-ALPHA; MAMMALIAN TARGET; CHANNEL ACTIVITY; K+ CHANNEL; ACTIVATION; CELLS	Hypoxia-inducible factors (HIFs) are ubiquitous transcription factors that mediate adaptation to hypoxia by inducing specific sets of target genes. It is well accepted that hypoxia induces accumulation and activity of HIFs by causing stabilization of their alpha subunits. We have demonstrated that hypoxia stimulates translation of HIF-1 alpha and -2 alpha proteins by distributing HIF-alpha mRNAs to larger polysome fractions. This requires influx of extracellular calcium, stimulation of classical protein kinase C-alpha (cPKC-alpha), and the activity of mammalian target of rapamycin, mTOR. The translational component contributes to similar to 40-50% of HIF-alpha proteins accumulation after 3 h of 1% O-2. Hypoxia also inhibits general protein synthesis and mTOR activity; however, cPKC-alpha inhibitors or rapamycin reduce mTOR activity and total protein synthesis beyond the effects of hypoxia alone. These data show that during general inhibition of protein synthesis by hypoxia, cap-mediated translation of selected mRNAs is induced through the mTOR pathway. We propose that calcium-induced activation of cPKC-alpha hypoxia partially protects an activity of mTOR from hypoxic inhibition. These results provide an important physiologic insight into the mechanism by which hypoxia-stimulated influx of calcium selectively induces the translation of mRNAs necessary for adaptation to hypoxia under conditions repressing general protein synthesis.	Univ Cincinnati, Coll Med, Dept Genome Sci, Genome Res Inst, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Czyzyk-Krzeska, MF (corresponding author), Univ Cincinnati, Coll Med, Dept Genome Sci, Genome Res Inst, 2180 E Galbraith Rd, Cincinnati, OH 45267 USA.	maria.czyzykkrzeska@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066312, R01HL058687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66312, HL58687] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKER H, 1989, ANNU REV PHYSIOL, V51, P835, DOI 10.1146/annurev.physiol.51.1.835; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Avila G, 2004, CELL MOL NEUROBIOL, V24, P317, DOI 10.1023/B:CEMN.0000022765.52109.26; Berchner-Pfannschmidt U, 2004, J BIOL CHEM, V279, P44976, DOI 10.1074/jbc.M313995200; Berjukow S, 1996, BRIT J PHARMACOL, V118, P748, DOI 10.1111/j.1476-5381.1996.tb15463.x; BLENIS J, 1986, P NATL ACAD SCI USA, V83, P1733, DOI 10.1073/pnas.83.6.1733; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; Fontainhas AM, 2005, NEUROSCIENCE, V133, P393, DOI 10.1016/j.neuroscience.2005.02.026; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jiang B, 2002, MOL CELL BIOCHEM, V238, P69, DOI 10.1023/A:1019907104763; Kim W, 2003, CURR OPIN GENET DEV, V13, P55, DOI 10.1016/S0959-437X(02)00010-2; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Levites Y, 2003, FASEB J, V17, P952, DOI 10.1096/fj.02-0881fje; Liu LP, 2004, CANCER BIOL THER, V3, P492, DOI 10.4161/cbt.3.6.1010; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Lopez-Barneo J, 1999, RESP PHYSIOL, V115, P215, DOI 10.1016/S0034-5687(99)00016-X; Maher P, 2001, J NEUROSCI, V21, P2929, DOI 10.1523/JNEUROSCI.21-09-02929.2001; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Millhorn DE, 1997, KIDNEY INT, V51, P527, DOI 10.1038/ki.1997.73; MochizukiOda N, 1997, J NEUROCHEM, V69, P377; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Mottet D, 2003, J CELL PHYSIOL, V194, P30, DOI 10.1002/jcp.10176; Nakashima S, 2002, J BIOCHEM, V132, P669, DOI 10.1093/oxfordjournals.jbchem.a003272; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Premkumar DRD, 2000, J APPL PHYSIOL, V88, P1898, DOI 10.1152/jappl.2000.88.5.1898; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Schnell PO, 2003, J NEUROCHEM, V85, P483, DOI 10.1046/j.1471-4159.2003.01696.x; Schwab MS, 1999, MOL CELL BIOL, V19, P2485; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; Tinton SA, 1999, FEBS LETT, V446, P55, DOI 10.1016/S0014-5793(99)00185-4; Weinreb O, 2004, FASEB J, V18, P1471, DOI 10.1096/fj.04-1916fje; Yu SP, 1998, J NEUROSCI RES, V52, P612, DOI 10.1002/(SICI)1097-4547(19980601)52:5<612::AID-JNR13>3.0.CO;2-3; Zakrzewska A, 2005, J NEUROCHEM, V94, P1288, DOI 10.1111/j.1471-4159.2005.03293.x; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	50	100	103	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					466	475		10.1096/fj.05-5086com	http://dx.doi.org/10.1096/fj.05-5086com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507764				2022-12-25	WOS:000239815100010
J	Andrews, P; He, YJ; Xiong, Y				Andrews, P.; He, Y. J.; Xiong, Y.			Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function	ONCOGENE			English	Article						cullin 7; p53; ROC1; cytoplasmic localization	LARGE T-ANTIGEN; PROTEIN UBIQUITINATION; NUCLEAR EXPORT; RING FINGER; F-BOX; COMPLEX; FAMILY; DOMAIN; SCF; DEGRADATION	Cullins are a family of evolutionarily conserved proteins that bind to the small RING finger protein, ROC1, to constitute potentially a large number of distinct E3 ubiquitin ligases. CUL7 mediates an essential function for mouse embryo development and has been linked with cell transformation by its physical association with the SV40 large T antigen. We report here that, like its closely related homolog PARC, CUL7 is localized predominantly in the cytoplasm and binds directly to p53. In contrast to PARC, however, CUL7, even when overexpressed, did not sequester p53 in the cytoplasm. We have identified a sequence in the N-terminal region of CUL7 that is highly conserved in PARC and a sequence spanning the tetramerization domain in p53 that are required for CUL7-p53 binding. CUL7 and MDM2 did not form a detectable tertiary complex with p53. In vitro, CUL7 caused only mono- or di-ubiquitination of p53 under the conditions MDM2 polyubiquitinated p53. Co-expression of CUL7 reduced the transactivating activity of p53. Constitutive ectopic expression of CUL7 increased the rate of cell proliferation and delayed UV-induced G2 accumulation in U2OS cells expressing functional p53, but had no detectable effect in p53-deficient H1299 cells. Deletion of the N-terminal domain of CUL7 or a mutation disrupting p53 binding abolished the ability of CUL7 to increase the rate of U2OS cell proliferation. Our results suggest that CUL7 functions to promote cell growth through, in part, antagonizing the function of p53.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27514 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27514 USA.	yxiong@email.unc.edu		He, Yizhou/0000-0002-1396-7275	NCI NIH HHS [CA65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2004, J VIROL, V78, P2749, DOI 10.1128/JVI.78.6.2749-2757.2004; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Arai T, 2003, P NATL ACAD SCI USA, V100, P9855, DOI 10.1073/pnas.1733908100; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baptiste N, 2004, CELL, V116, P487, DOI 10.1016/S0092-8674(04)00164-3; Chipuk JE, 2004, CELL CYCLE, V3, P429; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Marin I, 2004, PHYSIOL GENOMICS, V17, P253, DOI 10.1152/physiolgenomics.00226.2003; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	43	75	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4534	4548		10.1038/sj.onc.1209490	http://dx.doi.org/10.1038/sj.onc.1209490			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16547496				2022-12-25	WOS:000239457500004
J	Koturbash, I; Rugo, RE; Hendricks, CA; Loree, J; Thibault, B; Kutanzi, K; Pogribny, I; Yanch, JC; Engelward, BP; Kovalchuk, O				Koturbash, I.; Rugo, R. E.; Hendricks, C. A.; Loree, J.; Thibault, B.; Kutanzi, K.; Pogribny, I.; Yanch, J. C.; Engelward, B. P.; Kovalchuk, O.			Irradiation induces DNA damage and modulates epigenetic effectors in distant bystander tissue in vivo	ONCOGENE			English	Article						radiation; bystander effect; DNA damage; epigenetics	INDUCED GENOMIC INSTABILITY; DOUBLE-STRAND BREAKS; HUMAN RAD51 PROTEIN; IONIZING-RADIATION; MAMMALIAN-CELLS; ALPHA-PARTICLES; HOMOLOGOUS RECOMBINATION; HUMAN FIBROBLASTS; HISTONE H2AX; GLOBAL DNA	Irradiated cells induce chromosomal instability in unirradiated bystander cells in vitro. Although bystander effects are thought to be linked to radiation-induced secondary cancers, almost no studies have evaluated bystander effects in vivo. Furthermore, it has been proposed that epigenetic changes mediate bystander effects, but few studies have evaluated epigenetic factors in bystander tissues in vivo. Here, we describe studies in which mice were unilaterally exposed to X-irradiation and the levels of DNA damage, DNA methylation and protein expression were evaluated in irradiated and bystander cutaneous tissue. The data show that X-ray exposure to one side of the animal body induces DNA strand breaks and causes an increase in the levels of Rad51 in unexposed bystander tissue. In terms of epigenetic changes, unilateral radiation suppresses global methylation in directly irradiated tissue, but not in bystander tissue at given time-points studied. Intriguingly, however, we observed a significant reduction in the levels of the de novo DNA methyltransferases DNMT3a and 3b and a concurrent increase in the levels of the maintenance DNA methyltransferase DNMT1 in bystander tissues. Further more, the levels of two methyl-binding proteins known to be involved in transcriptional silencing, MeCP2 and MBD2, were also increased in bystander tissue. Together, these results show that irradiation induces DNA damage in bystander tissue more than a centimeter away from directly irradiated tissues, and suggests that epigenetic transcriptional regulation may be involved in the etiology of radiation-induced bystander effects.	Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada; MIT, Div Biol Engn, Cambridge, MA 02139 USA; Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA; MIT, Dept Nucl Sci & Engn, Cambridge, MA 02139 USA	University of Lethbridge; Massachusetts Institute of Technology (MIT); US Food & Drug Administration (FDA); Massachusetts Institute of Technology (MIT)	Kovalchuk, O (corresponding author), Univ Lethbridge, Dept Biol Sci, 4401 Univ Dr,HH127, Lethbridge, AB T1K 3M4, Canada.	olga.kovalchuk@uleth.ca		Loree, Jonathan/0000-0001-8189-2132	NCI NIH HHS [R01CA79827, R01 CA079827, R21 CA084740, P01-CA26731] Funding Source: Medline; NIEHS NIH HHS [P30-ES02109, P30 ES001209-26A1, P30 ES002109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA084740, R01CA079827, P01CA026731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 2003, MCNP GEN MONT CARL N; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Basnakian AG, 1996, DNA CELL BIOL, V15, P255, DOI 10.1089/dna.1996.15.255; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bowen NJ, 2004, CELL MOL LIFE SCI, V61, P2163, DOI 10.1007/s00018-004-4177-x; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Goldberg Z, 2003, ONCOGENE, V22, P7011, DOI 10.1038/sj.onc.1206990; Goldberg Z, 2002, INT J ONCOL, V21, P337; Gonzalgo ML, 1997, MUTAT RES-REV MUTAT, V386, P107, DOI 10.1016/S1383-5742(96)00047-6; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hall EJ, 2003, HEALTH PHYS, V85, P31, DOI 10.1097/00004032-200307000-00008; Helleday T, 2003, MUTAT RES-FUND MOL M, V532, P103, DOI 10.1016/j.mrfmmm.2003.08.013; Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang L, 2003, ONCOGENE, V22, P5848, DOI 10.1038/sj.onc.1206697; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; Ichijima Y, 2005, BIOCHEM BIOPH RES CO, V336, P807, DOI 10.1016/j.bbrc.2005.08.164; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; KALINICH JF, 1989, RADIAT RES, V117, P185, DOI 10.2307/3577319; Kashino G, 2004, MUTAT RES-FUND MOL M, V556, P209, DOI 10.1016/j.mrfmmm.2004.08.009; Koturbash I, 2005, BIOCHEM BIOPH RES CO, V337, P526, DOI 10.1016/j.bbrc.2005.09.084; Kovalchuk O, 2004, MOL CANCER RES, V2, P567; Little JB, 1999, CR ACAD SCI III-VIE, V322, P127, DOI 10.1016/S0764-4469(99)80034-1; Little JB, 1998, INT J RADIAT BIOL, V74, P663, DOI 10.1080/095530098140925; Lundin C, 2003, J MOL BIOL, V328, P521, DOI 10.1016/S0022-2836(03)00313-9; Maguire P, 2005, RADIAT RES, V163, P384, DOI 10.1667/RR3325; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Minamoto T, 1999, CARCINOGENESIS, V20, P519, DOI 10.1093/carcin/20.4.519; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Mothersill C, 2005, RADIAT RES, V163, P391, DOI 10.1667/RR3320; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Mothersill C, 2002, RADIAT RES, V158, P626, DOI 10.1667/0033-7587(2002)158[0626:BADEAF]2.0.CO;2; Mothersill CE, 2004, INT J RADIAT ONCOL, V58, P575, DOI 10.1016/j.ijrobp.2003.09.038; Nagar S, 2003, CANCER RES, V63, P324; NAGASAWA H, 1992, CANCER RES, V52, P6394; Panayiotidis MI, 2004, ANTIOXID REDOX SIGN, V6, P129, DOI 10.1089/152308604771978435; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; Pogribny I, 2004, BIOCHEM BIOPH RES CO, V320, P1253, DOI 10.1016/j.bbrc.2004.06.081; Pogrlbny I, 2005, MOL CANCER RES, V3, P553, DOI 10.1158/1541-7786.MCR-05-0074; Ponnaiya B, 2004, MUTAT RES-FUND MOL M, V568, P41, DOI 10.1016/j.mrfmmm.2004.06.045; Raiche J, 2004, BIOCHEM BIOPH RES CO, V325, P39, DOI 10.1016/j.bbrc.2004.10.002; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Rothkamm K, 2002, INT J ONCOL, V21, P433; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Rugo RE, 2005, ONCOGENE, V24, P5016, DOI 10.1038/sj.onc.1208690; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Sigurdson AJ, 2003, ONCOGENE, V22, P7018, DOI 10.1038/sj.onc.1206989; Sokolov MV, 2005, ONCOGENE, V24, P7257, DOI 10.1038/sj.onc.1208886; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Tawa R, 1998, J RADIAT RES, V39, P271, DOI 10.1269/jrr.39.271; TURK PW, 1995, CARCINOGENESIS, V16, P1253, DOI 10.1093/carcin/16.5.1253; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Ward JF, 2002, MUTAT RES-FUND MOL M, V499, P151, DOI 10.1016/S0027-5107(01)00286-X; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Xue LY, 2002, P NATL ACAD SCI USA, V99, P13765, DOI 10.1073/pnas.182209699; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2002, MUTAT RES-FUND MOL M, V499, P135, DOI 10.1016/S0027-5107(01)00285-8	68	165	185	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4267	4275		10.1038/sj.onc.1209467	http://dx.doi.org/10.1038/sj.onc.1209467			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16532033				2022-12-25	WOS:000239240100002
J	Lingohr, MK; Briaud, I; Dickson, LM; McCuaig, JF; Alarcon, C; Wicksteed, BL; Rhodes, CJ				Lingohr, Melissa K.; Briaud, Isabelle; Dickson, Lorna M.; McCuaig, Jill F.; Alarcon, Cristina; Wicksteed, Barton L.; Rhodes, Christopher J.			Specific regulation of IRS-2 expression by glucose in rat primary pancreatic islet beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-EXPRESSION; PROTEIN-KINASE-B; GLUCAGON-LIKE PEPTIDE-1; SIGNAL-TRANSDUCTION; DIFFERENTIAL ACTIVATION; PROINSULIN BIOSYNTHESIS; RECEPTOR SUBSTRATE-2; CAMP; APOPTOSIS; TRANSPORT	Insulin receptor substrate 2 (IRS-2) plays a critical role in pancreatic beta-cells. Increased IRS-2 expression promotes beta-cell growth and survival, whereas decreased IRS-2 levels lead to apoptosis. It was found that IRS-2 turnover in rat islet beta-cells was rapid, with mRNA and protein half-lives of similar to 90 min and similar to 2 h, respectively. However, this was countered by specific glucose-regulated IRS-2 expression mediated at the transcriptional level. Glucose (>= 6 mM) increased IRS-2 mRNA and protein levels in a dose-dependent manner, reaching a maximum 4-fold increase in IRS-2mRNAand a 5-6-fold increase in IRS-2 protein levels at >= 12mM glucose (p <= 0.01). Glucose ( 15 mM) regulation of islet beta-cell IRS-2 gene expression was rapid, with a significant increase in IRS-2 mRNA levels within 2 h that reached a maximum 4-fold increase by 4 h. IRS-2 protein expression in beta-cells followed that of IRS-2 mRNA. Glucose metabolism was necessary for increased IRS-2 expression in beta-cells. Moreover, inhibition of a glucose-induced rise in islet beta-cell cytosolic [Ca2+](i) prevented an increase in IRS-2 expression, indicating this was Ca2+-dependent. The glucose-induced rise in IRS-2 levels correlated with increased IRS- 2 tyrosine phosphorylation and downstream activation of protein kinase B. These data indicate that fluctuations of glucose in the normal physiological range (5-15 mM) promote beta-cell survival via regulation of IRS-2 expression and a subsequent parallel protein kinase B activation. Given that the onset of type-2 diabetes is marked by loss of beta-cells, these data further the idea that controlled IRS-2 expression in beta-cells could be a therapeutic means to promote beta-cell survival and delay the onset of the disease.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA	University of Washington; University of Washington Seattle	Rhodes, CJ (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	cjr@pnri.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK060266] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 60266, DK 55269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Briaud I, 2005, J BIOL CHEM, V280, P2282, DOI 10.1074/jbc.M412179200; Briaud I, 2003, DIABETES, V52, P974, DOI 10.2337/diabetes.52.4.974; Buteau J, 2004, DIABETOLOGIA, V47, P806, DOI 10.1007/s00125-004-1379-6; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Dickson LM, 2004, AM J PHYSIOL-ENDOC M, V287, pE192, DOI 10.1152/ajpendo.00031.2004; Dickson LM, 2001, J BIOL CHEM, V276, P21110, DOI 10.1074/jbc.M101257200; Easom RA, 2000, SEMIN CELL DEV BIOL, V11, P253, DOI 10.1006/scdb.2000.0174; ERMAN M, 2004, DIABETES MELLITUS FU, P15; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; Hagman DK, 2005, J BIOL CHEM, V280, P32413, DOI 10.1074/jbc.M506000200; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103; Kelpe CL, 2003, J BIOL CHEM, V278, P30015, DOI 10.1074/jbc.M302548200; Landa LR, 2005, J BIOL CHEM, V280, P31294, DOI 10.1074/jbc.M505657200; Leibiger IB, 2002, FEBS LETT, V532, P1, DOI 10.1016/S0014-5793(02)03627-X; LeRoith D, 2002, AM J MED, V113, p3S; Lingohr MK, 2003, MOL CELL ENDOCRINOL, V209, P17, DOI 10.1016/j.mce.2003.08.003; Lingohr MK, 2003, MOL CELL ENDOCRINOL, V204, P85, DOI 10.1016/S0303-7207(03)00124-2; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P1; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x; Sander M, 1998, P NATL ACAD SCI USA, V95, P11572, DOI 10.1073/pnas.95.20.11572; SHI SR, 1993, J HISTOCHEM CYTOCHEM, V41, P1599, DOI 10.1177/41.11.7691930; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; SWENNE I, 1980, DIABETES, V29, P686, DOI 10.2337/diab.29.9.686; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Wang Q, 2004, DIABETOLOGIA, V47, P478, DOI 10.1007/s00125-004-1327-5; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; WELSH M, 1985, J BIOL CHEM, V260, P3590; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wicksteed B, 2003, J BIOL CHEM, V278, P42080, DOI 10.1074/jbc.M303509200; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wrede CE, 2002, J BIOL CHEM, V277, P49676, DOI 10.1074/jbc.M208756200; Zawalich WS, 2002, J BIOL CHEM, V277, P26233, DOI 10.1074/jbc.M202291200	51	70	74	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15884	15892		10.1074/jbc.M600356200	http://dx.doi.org/10.1074/jbc.M600356200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16574657	hybrid			2022-12-25	WOS:000237996000038
J	Nicholls, DG				Nicholls, David G.			Simultaneous monitoring of ionophore- and inhibitor-mediated plasma and mitochondrial membrane potential changes in cultured neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FLUORESCENT DYE; GLUTAMATE EXCITOTOXICITY; PERMEABILITY TRANSITION; HIPPOCAMPAL-NEURONS; INTACT SYNAPTOSOMES; CYTOCHROME-C; NITRIC-OXIDE; CALCIUM; DEPOLARIZATION; RESPIRATION	Although natural and synthetic ionophores are widely exploited in cellstudies, for example, to influence cytoplasmic free calcium concentrations and to depolarize in situ mitochondria, their inherent lack of membrane selectivity means that they affect the ion permeability of both plasma and mitochondrial membranes. A similar ambiguity affects the interpretation of signals from fluorescent membrane-permeant cations (usually termed "mitochondrial membrane potential indicators"), because the accumulation of these probes is influenced by both plasma and mitochondrial membrane potentials. To resolve some of these problems a technique is developed to allow simultaneous monitoring of plasma and mitochondrial membrane potentials at single-cell resolution using a cationic and anionic fluorescent probe. A computer program is described that transforms the fluorescence changes into dynamic estimates of changes in plasma and mitochondrial potentials. Exploiting this technique, primary cultures of rat cerebellar granule neurons display a concentration-dependent response to ionomycin: low concentrations mimic nigericin by hyperpolarizing the mitochondria while slowly depolarizing the plasma membrane and maintaining a stable elevated cytoplasmic calcium. Higher ionomycin concentrations induce a stochastic failure of calcium homeostasis that precedes both mitochondrial depolarization and an enhanced rate of plasma membrane depolarization. In addition, the protonophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone only selectively depolarizes mitochondria at submicromolar concentrations. ATP synthase reversal following respiratory chain inhibition depolarizes the mitochondria by 26 mV.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Nicholls, DG (corresponding author), 8001 Redwood Blvd, Novato, CA 94945 USA.	dnicholls@buckinstitute.org	NICHOLLS, DAVID G/K-4300-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041908] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 41908] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abad MFC, 2004, J BIOL CHEM, V279, P11521, DOI 10.1074/jbc.M306766200; Abramov AY, 2003, CELL CALCIUM, V33, P101, DOI 10.1016/S0143-4160(02)00203-8; AKERMAN KEO, 1981, EUR J BIOCHEM, V115, P67; APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; Baxter DF, 2002, J BIOMOL SCREEN, V7, P79, DOI 10.1177/108705710200700110; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; CIVITELLI R, 1987, J CELL PHYSIOL, V131, P434, DOI 10.1002/jcp.1041310316; COURTNEY MJ, 1992, J NEUROCHEM, V59, P983, DOI 10.1111/j.1471-4159.1992.tb08339.x; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Dussmann H, 2003, J CELL SCI, V116, P525, DOI 10.1242/jcs.00236; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; EPPS DE, 1994, CHEM PHYS LIPIDS, V69, P137, DOI 10.1016/0009-3084(94)90035-3; FARKAS DL, 1989, BIOPHYS J, V56, P1053, DOI 10.1016/S0006-3495(89)82754-7; Fink C, 1998, BIOPHYS J, V75, P1648, DOI 10.1016/S0006-3495(98)77607-6; Jekabsons MB, 2004, J BIOL CHEM, V279, P32989, DOI 10.1074/jbc.M401540200; Keelan J, 1999, J PHYSIOL-LONDON, V520, P797, DOI 10.1111/j.1469-7793.1999.00797.x; Kiedrowski L, 2001, NEUROREPORT, V12, P3579, DOI 10.1097/00001756-200111160-00041; Kiedrowski L, 2001, NEUROREPORT, V12, P59, DOI 10.1097/00001756-200101220-00020; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lambert AJ, 2004, BIOCHEM J, V382, P511, DOI 10.1042/BJ20040485; Lauritzen I, 2003, J BIOL CHEM, V278, P32068, DOI 10.1074/jbc.M302631200; MALOFF BL, 1978, J CELL BIOL, V78, P214, DOI 10.1083/jcb.78.1.214; Marks JD, 2005, J NEUROSCI, V25, P6561, DOI 10.1523/JNEUROSCI.1450-05.2005; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Petersen A, 2000, BRAIN RES, V857, P20, DOI 10.1016/S0006-8993(99)02320-3; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; Rego AC, 2001, J NEUROSCI, V21, P1893, DOI 10.1523/JNEUROSCI.21-06-01893.2001; Rego AC, 2001, CELL DEATH DIFFER, V8, P995, DOI 10.1038/sj.cdd.4400916; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; Safiulina D, 2006, J CELL PHYSIOL, V206, P347, DOI 10.1002/jcp.20476; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; Toescu EC, 2000, PFLUG ARCH EUR J PHY, V440, P941, DOI 10.1007/s004240000390; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; Vergun O, 2001, J PHYSIOL-LONDON, V531, P147, DOI 10.1111/j.1469-7793.2001.0147j.x; Ward MW, 2000, J NEUROSCI, V20, P7208; Whiteaker KL, 2001, J BIOMOL SCREEN, V6, P305, DOI 10.1177/108705710100600504; Yamada A, 2001, JPN J PHARMACOL, V86, P342, DOI 10.1254/jjp.86.342	43	144	145	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14864	14874		10.1074/jbc.M510916200	http://dx.doi.org/10.1074/jbc.M510916200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551630	hybrid			2022-12-25	WOS:000237671300040
J	Zhu, H; Shuman, S				Zhu, Hui; Shuman, Stewart			Substrate specificity and structure-function analysis of the 3 '-phosphoesterase component of the bacterial NHEJ protein, DNA ligase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYNUCLEOTIDE KINASE; 3'-PHOSPHATASE; MYCOBACTERIA; ARCHITECTURE; PHOSPHATASE; ENZYME; KU	DNA ligase D (LigD) performs end remodeling and end sealing reactions during nonhomologous end joining in bacteria. Pseudomonas aeruginosa LigD consists of a central ATP-dependent ligase domain fused to a C-terminal polymerase domain and an N-terminal phosphoesterase (PE) module. The PE domain catalyzes manganese-dependent phosphodiesterase and phosphomonoesterase reactions at the 3' end of the primer strand of a primer-template. The phosphodiesterase cleaves a 3'-terminal diribonucleotide to yield a primer strand with a ribonucleoside 3'-PO4 terminus. The phosphomonoesterase converts a terminal ribonucleoside 3'-PO4 or deoxyribonucleoside 3'-PO4 of a primer-template to a 3'-OH. Here we report that the phosphodiesterase and phosphomonoesterase activities are both dependent on the presence and length of the 5' single-strand tail of the primer-template substrate. Although the phosphodiesterase activity is strictly dependent on the 2'-OH of the penultimate ribose, it is indifferent to a 2'-OH versus a 2'-H on the terminal nucleoside. Incision at the ribonucleotide linkage is suppressed when the 2'-OH is moved by 1 nucleotide in the 5' direction, suggesting that LigD is an exoribonuclease that cleaves the 3'-terminal phosphodiester. We report the effects of conservative amino acid substitutions at residues: (i) His(42), His(48), Asp(50), Arg(52), His(84), and Tyr(88), which are essential for both the ribonuclease and 3'-phosphatase activities; (ii) Arg(14), Asp(15), Glu(21), and Glu(82), which are critical for 3'-phosphatase activity but not 3'-ribonucleoside removal; and (iii) at Lys(66) and Arg(76), which participate selectively in the 3'-ribonuclease reaction. The results suggest roles for individual functional groups in metal binding and/or phosphoesterase chemistry.	Sloan Kettering Inst, Mol Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Mol Biol Program, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NIGMS NIH HHS [GM63611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernstein NK, 2005, MOL CELL, V17, P657, DOI 10.1016/j.molcel.2005.02.012; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; RICHARDSON CC, 1964, J BIOL CHEM, V239, P242; Vance JR, 2001, J BIOL CHEM, V276, P15073, DOI 10.1074/jbc.M011075200; Voegtli WC, 2000, BIOCHEMISTRY-US, V39, P15365, DOI 10.1021/bi0021030; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Zhu H, 2006, P NATL ACAD SCI USA, V103, P1711, DOI 10.1073/pnas.0509083103; Zhu H, 2005, J BIOL CHEM, V280, P33707, DOI 10.1074/jbc.M506838200; Zhu H, 2005, J BIOL CHEM, V280, P25973, DOI 10.1074/jbc.M504002200; Zhu H, 2005, J BIOL CHEM, V280, P418, DOI 10.1074/jbc.M410110200; Zhu H, 2004, J BIOL CHEM, V279, P26358, DOI 10.1074/jbc.M403200200	15	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13873	13881		10.1074/jbc.M600055200	http://dx.doi.org/10.1074/jbc.M600055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16540477	hybrid			2022-12-25	WOS:000237512300007
J	Izaguirre, G; Olson, ST				Izaguirre, G; Olson, ST			Residues Tyr(253) and Glu(255) in strand 3 of beta-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; SERPIN-PROTEINASE COMPLEX; BLOOD-COAGULATION; TERNARY COMPLEX; BASIC RESIDUES; AUTOLYSIS LOOP; HIGH-AFFINITY; MECHANISM; THROMBIN; BINDING	We previously showed that conformational activation of the anticoagulant serpin, antithrombin, by heparin generates new exosites in strand 3 of beta- sheet C, which promote the reaction of the inhibitor with the target proteases, factor Xa and factor IXa. To determine which residues comprise the exosites, we mutated strand 3C residues that are conserved in all vertebrate antithrombins. Combined mutations of the three conserved surface- accessible residues, Tyr(253), Glu(255), and Lys(257), or of just Tyr(253) and Glu(255), but not any of these residues alone, was sufficient to reproduce the exosite defects of a strand 3C antithrombin- alpha(1)- proteinase inhibitor chimera in reactions of the heparin- activated variants with both factor Xa and factor IXa. Importantly, the exosite- defective antithrombins bound heparin with nearly wild- type affinities, and the heparin- activated mutants showed near normal reactivities with thrombin, a protease that does not utilize the exosite. Mutation of the conserved but partially buried strand 3C residue, Gln(254), the reactive loop P6 ' residue, Arg(399), which interacts with Glu(255), or a residue proposed to constitute the exosite from modeling studies, Glu(237), all produced minimal effects on antithrombin reactivity with thrombin, factor Xa, and factor IXa in the absence or presence of heparin. Together, these results indicate that Tyr(253) and Glu(255) are key exosite determinants responsible for promoting the reactions of conformationally activated antithrombin with both factor Xa and factor IXa.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Olson, ST (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, Rm 530E,Dent M-C 860,801 S Paulina St, Chicago, IL 60612 USA.	stolson@uic.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 2001, J BIOL CHEM, V276, P43809, DOI 10.1074/jbc.M105294200; Backovic M, 2002, J PROTEOME RES, V1, P367, DOI 10.1021/pr025515z; Bedsted T, 2003, BIOCHEMISTRY-US, V42, P8143, DOI 10.1021/bi034363y; Bjork I, 1997, ADV EXP MED BIOL, V425, P17; Calugaru SV, 2001, J BIOL CHEM, V276, P32446, DOI 10.1074/jbc.M104731200; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Izaguirre G, 2003, J BIOL CHEM, V278, P51433, DOI 10.1074/jbc.M309266200; IZAGUIRRE G, 2005, 4 INT C SERP STRUCT, P45; Jairajpuri MA, 2002, J BIOL CHEM, V277, P24460, DOI 10.1074/jbc.M203127200; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langdown J, 2004, J BIOL CHEM, V279, P47288, DOI 10.1074/jbc.M408961200; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; MILETICH JP, 1981, METHOD ENZYMOL, V80, P221; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; Olson ST, 2004, THROMB HAEMOSTASIS, V92, P929, DOI 10.1160/TH04-06-0384; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; Quinsey NS, 2002, J BIOL CHEM, V277, P15971, DOI 10.1074/jbc.M108131200; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2004, BIOCHEMISTRY-US, V43, P2898, DOI 10.1021/bi036145a; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Yang LK, 2003, J BIOL CHEM, V278, P25032, DOI 10.1074/jbc.M302174200; Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200	43	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13424	13432		10.1074/jbc.M600415200	http://dx.doi.org/10.1074/jbc.M600415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16517611	hybrid			2022-12-25	WOS:000237336600049
J	Kawaguchi, M; Minami, K; Nagashima, K; Seino, S				Kawaguchi, M; Minami, K; Nagashima, K; Seino, S			Essential role of ubiquitin-proteasome system in normal regulation of insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; SENSITIVE POTASSIUM CHANNELS; UNRESPONSIVE MIN6 SUBLINES; CYCLIN-DEPENDENT KINASE-5; CALCIUM-CHANNELS; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; QUALITY-CONTROL; GLUCOSE	Insulin secretion from pancreatic beta-cells occurs by sequential cellular processes, including glucose metabolism, electrical activity, Ca2+ entry, and regulated exocytosis. Abnormalities in any of these functions can impair insulin secretion. In the present study, we demonstrate that inhibition of proteasome activity severely reduces insulin secretion in the mouse pancreatic beta-cell line MIN6-m9. Although no significant effects on glucose metabolism including ATP production were found in the presence of proteasome inhibitors, both glucose- and KCl-induced Ca2+ entry were drastically reduced. As Ca2+-ionophore-induced insulin secretion was unaffected by proteasome inhibition, a defect in Ca2+ entry through voltage-dependent calcium channels (VDCCs) is the likely cause of the impaired insulin secretion. We found that the pore-forming alpha-subunit of VDCCs undergoes ubiquitination, which does not decrease but slightly increases expression of the alpha-subunit protein at the plasma membrane. However, electrophysiological analysis revealed that treatment with proteasome inhibitors results in a severe reduction in VDCC activity in MIN6-m9 cells, indicating that VDCC function is suppressed by proteasome inhibition. Furthermore, insulin secretion in isolated mouse pancreatic islets was also decreased by proteasome inhibition. These results demonstrate that the ubiquitin-proteasome system plays a critical role in insulin secretion by maintaining normal function of VDCCs.	Kobe Univ, Grad Sch Med, Div Cellular & Mol Med, Kobe, Hyogo 6500017, Japan; Kyoto Univ Hosp, Dept Expt Therapeut Translat Res Ctr, Kyoto 6068507, Japan; Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan; Kyoto Univ, Grad Sch Med, Dept Diabet & Clin Nutr, Kyoto 6068507, Japan	Kobe University; Kyoto University; Chiba University; Kyoto University	Seino, S (corresponding author), Kobe Univ, Grad Sch Med, Div Cellular & Mol Med, Kobe, Hyogo 6500017, Japan.	seino@med.kobe-u.ac.jp		Minami, Kohtaro/0000-0003-4698-6250				Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Ahren B, 2000, DIABETOLOGIA, V43, P393, DOI 10.1007/s001250051322; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Cornet V, 2002, EUR J NEUROSCI, V16, P883, DOI 10.1046/j.1460-9568.2002.02168.x; Cuesta-Munoz AL, 2004, DIABETES, V53, P2164, DOI 10.2337/diabetes.53.8.2164; Dolphin AC, 2003, PHARMACOL REV, V55, P607, DOI 10.1124/pr.55.4.3; Dupre S, 2004, BBA-MOL CELL RES, V1695, P89, DOI 10.1016/j.bbamcr.2004.09.024; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; GLASER B, 1994, NAT GENET, V7, P185, DOI 10.1038/ng0694-185; Gloyn AL, 2003, DIABETES, V52, P568, DOI 10.2337/diabetes.52.2.568; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huopio H, 2000, J CLIN INVEST, V106, P897, DOI 10.1172/JCI9804; ISHIHARA H, 1994, J BIOL CHEM, V269, P3081; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kasai K, 2005, J CLIN INVEST, V115, P388, DOI 10.1172/JCI200522955; Kitiphongspattana K, 2005, J BIOL CHEM, V280, P15727, DOI 10.1074/jbc.M410876200; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Miki T, 1999, J MOL ENDOCRINOL, V22, P113, DOI 10.1677/jme.0.0220113; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; Minami K, 2002, J BIOL CHEM, V277, P25277, DOI 10.1074/jbc.M203988200; Minami K, 2001, DIABETES, V50, pA336; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; REED PW, 1972, J BIOL CHEM, V247, P6970; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Rougier JS, 2005, AM J PHYSIOL-CELL PH, V288, pC692, DOI 10.1152/ajpcell.00460.2004; SAITO Y, 1990, NEUROSCI LETT, V120, P1, DOI 10.1016/0304-3940(90)90153-Z; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Wei FY, 2005, NAT MED, V11, P1104, DOI 10.1038/nm1299; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; Yada T, 1996, ANN NY ACAD SCI, V805, P329; Yan FF, 2005, AM J PHYSIOL-CELL PH, V289, pC1351, DOI 10.1152/ajpcell.00240.2005; ZAWALICH WS, 1993, REGUL PEPTIDES, V44, P277, DOI 10.1016/0167-0115(93)90137-W; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	45	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13015	13020		10.1074/jbc.M601228200	http://dx.doi.org/10.1074/jbc.M601228200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543239	hybrid			2022-12-25	WOS:000237336600004
J	Nam, JS; Turcotte, TJ; Smith, PF; Choi, S; Yoon, JK				Nam, JS; Turcotte, TJ; Smith, PF; Choi, S; Yoon, JK			Mouse cristin/R-spondin family proteins are novel ligands for the frizzled 8 and LRP6 receptors and activate beta-catenin-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; WNT SIGNALING PATHWAY; PARAXIAL MESODERM; NORRIE DISEASE; CANDIDATE GENE; GROWTH-FACTOR; DROSOPHILA; SUPERFAMILY; PMESOGENIN1; DICKKOPF-1	Wnt signaling plays critical biological roles during normal embryonic development and homeostasis in adults. In the canonical pathway, binding of Wnt ligands to the Frizzled ( Fzd) receptor and the low density lipoprotein-related receptor ( LRP) 5 or LRP6 coreceptor initiates downstream signaling events leading to gene activation by beta-catenin and the T-cell factor ( TCF)-lymphoid enhancer factor ( LEF) family transcription factor complex. In this study, we provide several lines of evidence that the mouse Cristin/R-spondin family proteins function as Fzd8 and LRP6 receptor ligands and induce the canonical Wnt/beta-catenin signaling pathway, leading to TCF-dependent gene activation. First, conditioned medium containing Cristin/R-spondin proteins effectively induced reporter activity in a TCF-binding site-dependent manner. Second, stimulation of cells with Cristin/R-spondin was accompanied by stabilization of endogenous beta-catenin proteins and induction of canonical Wnt target genes. Third, Cristin/R-spondin proteins physically interacted with the extracellular domains of the LRP6 and Fzd8 receptors in vivo and in vitro. Interestingly, unlike canonical Wnt ligands, Cristin/R-spondin failed to form a ternary complex with both LRP6 and Fzd8 receptors, suggesting that R-spondin may activate the canonical Wnt signaling pathway by different mechanisms. Furthermore, Cristin/R-spondin proteins possess an intriguing positive modulatory activity on Wnt ligands, possibly through a direct interaction. Our findings expand the repertoire of ligands that induce beta-catenin/TCF-dependent gene activation and implicate the presence of active beta-catenin-dependent gene activation in a Wnt-free biological context.	Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	Maine Medical Center; California Institute of Technology	Yoon, JK (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	yoonje@mmc.org			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018789] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR018789] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams JC, 2000, DEV DYNAM, V218, P280; Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; Brennan K, 2004, ONCOGENE, V23, P4873, DOI 10.1038/sj.onc.1207642; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; CHEN ZY, 1992, NAT GENET, V1, P204, DOI 10.1038/ng0692-204; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Inoue T, 2004, CELL, V118, P795, DOI 10.1016/j.cell.2004.09.001; Kamata T, 2004, BBA-GENE STRUCT EXPR, V1676, P51, DOI 10.1016/j.bbaexp.2003.10.009; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Kuhl M, 2004, FRONT BIOSCI-LANDMRK, V9, P967; Latinkic BV, 2003, DEVELOPMENT, V130, P2429, DOI 10.1242/dev.00449; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Lin XH, 2000, MATRIX BIOL, V19, P303, DOI 10.1016/S0945-053X(00)00073-1; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; Malbon CC, 2004, FRONT BIOSCI-LANDMRK, V9, P1048, DOI 10.2741/1308; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mercurio S, 2004, DEVELOPMENT, V131, P2137, DOI 10.1242/dev.01045; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Polakis P, 2000, GENE DEV, V14, P1837; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Wang HY, 2004, FRONT BIOSCI-LANDMRK, V9, P1043, DOI 10.2741/1310; Wiedlocha A, 2004, CURR TOP MICROBIOL, V286, P45; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8; Yoon JK, 2000, DEV BIOL, V222, P376, DOI 10.1006/dbio.2000.9717; Yoon JK, 2000, GENE DEV, V14, P3204, DOI 10.1101/gad.850000; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522	44	218	249	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13247	13257		10.1074/jbc.M508324200	http://dx.doi.org/10.1074/jbc.M508324200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543246	hybrid, Green Accepted			2022-12-25	WOS:000237336600030
J	Qiu, LY; Swarts, HGP; Tonk, ECM; Willems, PHGM; Koenderink, JB; De Pont, JJHHM				Qiu, LY; Swarts, HGP; Tonk, ECM; Willems, PHGM; Koenderink, JB; De Pont, JJHHM			Conversion of the low affinity ouabain-binding site of non-gastric H,K-ATPase into a high affinity binding site by substitution of only five amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; H-K-ATPASE; FUNCTIONAL EXPRESSION; DISTAL COLON; BETA-SUBUNITS; H+,K+-ATPASE; TRANSMEMBRANE; NA+,K+-ATPASE; KIDNEY; DETERMINANT	P- type ATPases of the IIC subfamily exhibit large differences in sensitivity toward ouabain. This allows a strategy in which ouabaininsensitive members of this subfamily are used as template for mutational elucidation of the ouabain-binding site. With this strategy, we recently identified seven amino acids in Na, K-ATPase that conferred high affinity ouabain binding to gastric H, K-ATPase (Qiu, L. Y., Krieger, E., Schaftenaar, G., Swarts, H. G. P., Willems, P. H. G. M., De Pont, J. J. H. H. M., and Koenderink, J. B. (2005) J. Biol. Chem. 280, 32349 - 32355). Because important, but identical, amino acids were not recognized in that study, here we used the non-gastric H, K-ATPase, which is rather ouabain-insensitive, as template. The catalytic subunit of this enzyme, in which several amino acids from Na, K-ATPase were incorporated, was expressed with the Na, K-ATPase beta 1 subunit in Xenopus laevis oocytes. A chimera containing 14 amino acids, located in M4, M5, and M6, which are unique to Na, K-ATPase, displayed high affinity ouabain binding. Four of these residues, all located in M5, appeared dispensable for high affinity binding. Individual mutation of the remaining 10 residues to their non-gastric H, K-ATPase counterparts yielded five amino acids (Glu(312), Gly(319), Pro(778), Leu(795), and Cys(802)) whose mutation resulted in a loss of ouabain binding. In a final gain-of-function experiment, we introduced these five amino acids in different combinations in non-gastric H, K-ATPase and demonstrated that all five were essential for high affinity ouabain binding. The non-gastric H, K-ATPase with these five mutations had a similar apparent affinity for ouabain as the wild type Na, K-ATPase and showed a 2000 times increased affinity for ouabain in theNH(4)(+)-stimulated ATPase activity in membranes of transfected Sf9 cells.	Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Biochem 286, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Pharmacol Toxicol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	De Pont, JJHHM (corresponding author), Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Biochem 286, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.dePont@ncmls.ru.nl	Koenderink, Jan/N-3578-2014; Willems, P.H.G.M./L-4759-2015	Willems, P.H.G.M./0000-0002-0915-1599				Asano S, 1998, AM J PHYSIOL-CELL PH, V275, pC669, DOI 10.1152/ajpcell.1998.275.3.C669; Burns EL, 1996, J BIOL CHEM, V271, P15879, DOI 10.1074/jbc.271.27.15879; Campbell WG, 1999, AM J PHYSIOL-RENAL, V276, pF237, DOI 10.1152/ajprenal.1999.276.2.F237; Codina J, 1998, J BIOL CHEM, V273, P7894, DOI 10.1074/jbc.273.14.7894; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Jaisser F, 1999, AM J PHYSIOL-RENAL, V276, pF812, DOI 10.1152/ajprenal.1999.276.6.F812; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; KANO I, 1990, BIOCHEM CELL BIOL, V68, P1262, DOI 10.1139/o90-187; KLAASSEN CHW, 1995, BIOCHEM BIOPH RES CO, V210, P907, DOI 10.1006/bbrc.1995.1743; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; Koenderink JB, 2000, P NATL ACAD SCI USA, V97, P11209, DOI 10.1073/pnas.200109597; Koenderink JB, 2003, J BIOL CHEM, V278, P51213, DOI 10.1074/jbc.M306384200; Kraut JA, 1998, KIDNEY INT, V53, P958, DOI 10.1111/j.1523-1755.1998.00841.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; MATSUI H, 1968, BIOCHIM BIOPHYS ACTA, V151, P655, DOI 10.1016/0005-2744(68)90013-2; MODYANOV NN, 1995, AM J PHYSIOL, V269, pC922; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; Qiu LY, 2005, J BIOL CHEM, V280, P32349, DOI 10.1074/jbc.M505168200; Qiu LY, 2003, J BIOL CHEM, V278, P47240, DOI 10.1074/jbc.M308833200; Sangan P, 2000, AM J PHYSIOL-CELL PH, V278, pC182, DOI 10.1152/ajpcell.2000.278.1.C182; SWARTS HGP, 1995, J BIOL CHEM, V270, P7890, DOI 10.1074/jbc.270.14.7890; Swarts HGP, 1998, EMBO J, V17, P3029, DOI 10.1093/emboj/17.11.3029; Swarts HGP, 2005, J BIOL CHEM, V280, P33115, DOI 10.1074/jbc.M504535200; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOOLFSON DN, 1990, FEBS LETT, V277, P185, DOI 10.1016/0014-5793(90)80839-B	33	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13533	13539		10.1074/jbc.M600551200	http://dx.doi.org/10.1074/jbc.M600551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531406	hybrid, Green Published			2022-12-25	WOS:000237336600061
J	Sanematsu, F; Takami, Y; Barman, HK; Fukagawa, T; Ono, T; Shibahara, KI; Nakayama, T				Sanematsu, F; Takami, Y; Barman, HK; Fukagawa, T; Ono, T; Shibahara, KI; Nakayama, T			Asf1 is required for viability and chromatin assembly during DNA replication in vertebrate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WD DIPEPTIDE MOTIFS; HISTONE CHAPERONES; DAMAGE CHECKPOINT; CHICKEN HIRA; LXXLL MOTIF; FACTOR-I; PROTEIN; GENE; TRANSCRIPTION; PHASE	Asf1 ( anti- silencing function 1), a well conserved protein from yeast to humans, acts as a histone chaperone and is predicted to participate in a variety of chromatin- mediated cellular processes. To investigate the physiological role of vertebrate Asf1 in vivo, we generated a conditional Asf1- deficient mutant from chicken DT40 cells. Induction of Asf1 depletion resulted in the accumulation of cells in S phase with decreased DNA replication and increased mitotic aberrancy forming multipolar spindles, leading to cell death. In addition, nascent chromatin in Asf1- depleted cells showed increased nuclease sensitivity, indicating impaired nucleosome assembly during DNA replication. Complementation analyses revealed that the functional domain of Asf1 for cell viability was confined to the N- terminal core domain ( amino acids 1 - 155) that is a binding platform for histones H3/ H4, CAF- 1p60, and HIRA, whereas Asf1 mutant proteins, abolishing binding abilities with both p60 and HIRA, exhibit no effect on viability. These results together indicate that the vertebrate Asf1 plays a crucial role in replication- coupled chromatin assembly, cell cycle progression, and cellular viability and provide a clue of a possible role in a CAF- 1- and HIRA- independent chromatin- modulating process for cell proliferation.	Miyazaki Univ, Coll Med, Dept Med Sci, Sect Biochem & Mol Biol, Kiyotake, Miyazaki 8891692, Japan; Natl Inst Genet, Dept Integrated Genet, Mishima, Shizuoka 4118540, Japan; Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan; Miyazaki Univ, Dept Life Sci, Frontier Sci Res Ctr, Miyazaki 8891692, Japan	University of Miyazaki; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; University of Miyazaki	Nakayama, T (corresponding author), Miyazaki Univ, Coll Med, Dept Med Sci, Sect Biochem & Mol Biol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	tnakayam@med.miyazaki-u.ac.jp	Fukagawa, Tatsuo/AAK-3922-2021					Adkins MW, 2004, J BIOL CHEM, V279, P52069, DOI 10.1074/jbc.M406113200; Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Ahmad A, 2005, J BIOL CHEM, V280, P32090, DOI 10.1074/jbc.M501426200; Ahmad A, 2004, GENE, V342, P125, DOI 10.1016/j.gene.2004.07.031; Ahmad A, 2003, BIOCHEM BIOPH RES CO, V312, P1266, DOI 10.1016/j.bbrc.2003.11.073; Ahmad K, 2002, P NATL ACAD SCI USA, V99, P16477, DOI 10.1073/pnas.172403699; Carrera P, 2003, GENE DEV, V17, P2578, DOI 10.1101/gad.276703; Chimura T, 2002, P NATL ACAD SCI USA, V99, P9334, DOI 10.1073/pnas.142627899; Daganzo SM, 2003, CURR BIOL, V13, P2148, DOI 10.1016/j.cub.2003.11.027; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Emili A, 2001, MOL CELL, V7, P13, DOI 10.1016/S1097-2765(01)00150-2; Franco AA, 2005, GENE DEV, V19, P1365, DOI 10.1101/gad.1305005; Fukagawa T, 1999, NUCLEIC ACIDS RES, V27, P1966, DOI 10.1093/nar/27.9.1966; Fukagawa T, 2001, EMBO J, V20, P4603, DOI 10.1093/emboj/20.16.4603; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Groth A, 2005, MOL CELL, V17, P301, DOI 10.1016/j.molcel.2004.12.018; Groth A, 2003, EMBO J, V22, P1676, DOI 10.1093/emboj/cdg151; Gunjan A, 2005, BIOCHIMIE, V87, P625, DOI 10.1016/j.biochi.2005.02.008; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Hu FH, 2001, GENE DEV, V15, P1061, DOI 10.1101/gad.873201; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Krawitz DC, 2002, MOL CELL BIOL, V22, P614, DOI 10.1128/MCB.22.2.614-625.2002; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Mousson F, 2005, P NATL ACAD SCI USA, V102, P5975, DOI 10.1073/pnas.0500149102; Myung K, 2003, P NATL ACAD SCI USA, V100, P6640, DOI 10.1073/pnas.1232239100; Nabatiyan A, 2004, MOL CELL BIOL, V24, P2853, DOI 10.1128/MCB.24.7.2853-2862.2004; Polo SE, 2005, CANCER LETT, V220, P1, DOI 10.1016/j.canlet.2004.08.024; Prado F, 2004, EMBO REP, V5, P497, DOI 10.1038/sj.embor.7400128; Ramey CJ, 2004, MOL CELL BIOL, V24, P10313, DOI 10.1128/MCB.24.23.10313-10327.2004; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Schulz LL, 2006, FASEB J, V20, P488, DOI 10.1096/fj.05-5020fje; Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Sillje HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6; Sutton A, 2001, GENETICS, V158, P587; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Takami Y, 2000, J BIOL CHEM, V275, P16191, DOI 10.1074/jbc.M908066199; Takami Y, 1997, GENES CELLS, V2, P711, DOI 10.1046/j.1365-2443.1997.1550353.x; Takami Y, 1999, J BIOL CHEM, V274, P23977, DOI 10.1074/jbc.274.34.23977; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Zabaronick SR, 2005, MOL CELL BIOL, V25, P652, DOI 10.1128/MCB.25.2.652-660.2005; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019	49	73	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13817	13827		10.1074/jbc.M511590200	http://dx.doi.org/10.1074/jbc.M511590200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537536	hybrid			2022-12-25	WOS:000237336600092
J	Joselin, AP; Schulze-Osthoff, K; Schwerk, C				Joselin, AP; Schulze-Osthoff, K; Schwerk, C			Loss of acinus inhibits oligonucleosomal DNA fragmentation but not chromatin condensation during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; PROTEOMIC ANALYSIS; CELL-DEATH; ENDONUCLEASE-G; PROTEIN; NUCLEASE; CLEAVAGE; REVEALS; HISTONE; DIFFERENTIATION	Chromatin condensation and oligonucleosomal DNA fragmentation are the nuclear hallmarks of apoptosis. A proteolytic fragment of the apoptotic chromatin condensation inducer in the nucleus ( Acinus), which is generated by caspase cleavage, has been implicated in mediating apoptotic chromatin condensation prior to DNA fragmentation. Acinus is also involved in mRNA splicing and a component of the apoptosis and splicing-associated protein ( ASAP) complex. To study the role of Acinus for apoptotic nuclear alterations, we generated stable cell lines in which Acinus isoforms were knocked down by inducible and reversible RNA interference. We show that Acinus is not required for nuclear localization and interaction of the other ASAP subunits SAP18 and RNPS1; however, knockdown of Acinus leads to a reduction in cell growth. Most strikingly, down-regulation of Acinus did not inhibit apoptotic chromatin condensation either in intact cells or in a cell-free system. In contrast, although apoptosis proceeds rapidly, analysis of nuclear DNA from apoptotic Acinus knockdown cells shows inhibition of oligonucleosomal DNA fragmentation. Our results therefore suggest that Acinus is not involved in DNA condensation but rather point to a contribution of Acinus in internucleosomal DNA cleavage during programmed cell death.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schwerk, C (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	Christian.Schwerk@uni-duesseldorf.de	Schwerk, Christian/GNP-5375-2022; Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Joselin, Alvin/0000-0002-9010-0421				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Korn C, 2005, J BIOL CHEM, V280, P6005, DOI 10.1074/jbc.M413035200; Lechardeur D, 2004, J CELL BIOL, V167, P851, DOI 10.1083/jcb.200404105; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Longman D, 2000, EMBO J, V19, P1625, DOI 10.1093/emboj/19.7.1625; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Saitoh N, 2004, MOL BIOL CELL, V15, P3876, DOI 10.1091/mbc.E04-03-0253; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Samejima K, 2005, NAT REV MOL CELL BIO, V6, P677, DOI 10.1038/nrm1715; Samejima K, 2000, EXP CELL RES, V255, P314, DOI 10.1006/excr.2000.4801; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Schwerk C, 2003, MOL CELL BIOL, V23, P2981, DOI 10.1128/MCB.23.8.2981-2990.2003; Strack S, 2004, J BIOL CHEM, V279, P47732, DOI 10.1074/jbc.M408015200; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tange TO, 2005, RNA, V11, P1869, DOI 10.1261/rna.2155905; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zamzami N, 1999, NATURE, V401, P127, DOI 10.1038/43591; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	48	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12475	12484		10.1074/jbc.M509859200	http://dx.doi.org/10.1074/jbc.M509859200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16537548	hybrid			2022-12-25	WOS:000237134700035
J	Li, KY; Tong, WH; Hughes, RM; Rouault, TA				Li, KY; Tong, WH; Hughes, RM; Rouault, TA			Roles of the mammalian cytosolic cysteine desulfurase, ISCS, and scaffold protein, ISCU, in iron-sulfur cluster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; YEAST NFS1P; MITOCHONDRIAL; BIOGENESIS; IDENTIFICATION; PURIFICATION; HOMEOSTASIS; FRATAXIN; ABILITY	Iron-sulfur clusters are prosthetic groups composed of sulfur and iron that are found in respiratory chain complexes and numerous enzymes. Iron-sulfur clusters are synthesized in a multistep process that utilizes cysteine desulfurases, scaffold proteins, chaperones, and iron donors. Assembly of iron-sulfur clusters occurs in the mitochondrial matrix of mammalian cells, but cytosolic isoforms of three major mammalian iron-sulfur cluster (ISC) assembly components have been found, raising the possibility that de novo iron-sulfur cluster biogenesis also occurs in cytosol. The human cysteine desulfurase, ISCS, has two isoforms, one of which targets to the mitochondria, whereas the other less abundant form is cytosolic and nuclear. The open-reading frame of cytosolic mammalian ISCS begins at the second AUG of the transcript and lacks mitochondrial targeting information. Yeast complementation experiments have suggested that the human cytosolic ISCS isoform (c-ISCS) cannot be functional. To evaluate function of c-ISCS, we overexpressed the human cytosolic ISCS in yeast Pichia pastoris and showed that the cytosolic form of ISCS is an active cysteine desulfurase that covalently binds S-35 acquired from desulfuration of radiolabeled cysteine. Human cytosolic ISCS dimerized as efficiently as bacterial ISCS and formed a complex in vitro with overexpressed cytosolic human ISCU. When incubated with iron regulatory protein 1, cysteine, and iron, the cytosolic forms of ISCS and ISCU facilitated efficient formation of a [4Fe-4S] cluster on IRP1. Thus, the cytosolic form of ISCS is a functional cysteine desulfurase that can collaborate with cytosolic ISCU to promote de novo iron-sulfur cluster formation.	NICHD, Cell Biol & Metab Branch, NIH, Intramural Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Rouault, TA (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Intramural Program, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.	Rouault@mail.nih.gov	Li, Kuanyu/AAL-2051-2020	Hughes, Robert M./0000-0002-4182-9136	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008814] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008814] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Allerson CR, 2003, RNA, V9, P364, DOI 10.1261/rna.2143303; Cupp-Vickery JR, 2003, J MOL BIOL, V330, P1049, DOI 10.1016/S0022-2836(03)00690-9; Dos Santos PC, 2004, J BIOL CHEM, V279, P19705, DOI 10.1074/jbc.M400278200; Flint DH, 1996, J BIOL CHEM, V271, P16053, DOI 10.1074/jbc.271.27.16053; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Muhlenhoff U, 2004, J BIOL CHEM, V279, P36906, DOI 10.1074/jbc.M406516200; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Nakai Y, 2004, J BIOL CHEM, V279, P12363, DOI 10.1074/jbc.M312448200; Nakai Y, 2001, J BIOL CHEM, V276, P8314, DOI 10.1074/jbc.M007878200; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620; Sun GF, 2003, J HUM GENET, V48, P415, DOI 10.1007/s10038-003-0048-9; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Tong WH, 2006, CELL METAB, V3, P199, DOI 10.1016/j.cmet.2006.02.003; Tong WH, 2003, P NATL ACAD SCI USA, V100, P9762, DOI 10.1073/pnas.1732541100; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	24	76	83	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12344	12351		10.1074/jbc.M600582200	http://dx.doi.org/10.1074/jbc.M600582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527810	hybrid			2022-12-25	WOS:000237134700019
J	Ducrot, C; Lefebvre, O; Landrieux, E; Guirouilh-Barbat, J; Sentenac, A; Acker, J				Ducrot, C; Lefebvre, O; Landrieux, E; Guirouilh-Barbat, J; Sentenac, A; Acker, J			Reconstitution of the yeast RNA polymerase III transcription system with all recombinant factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; CASEIN KINASE-II; SACCHAROMYCES-CEREVISIAE; FACTOR-TAU; SUBUNIT; GENE; TFIIIB; PURIFICATION; COMPONENTS; EXPRESSION	Transcription factor TFIIIC is a multisubunit complex required for promoter recognition and transcriptional activation of class III genes. We describe here the reconstitution of complete recombinant yeast TFIIIC and the molecular characterization of its two DNA-binding domains, tau A and tau B, using the baculovirus expression system. The B block-binding module, r tau B, was reconstituted with r tau 138, r tau 91, and r tau 60 subunits. r tau 131, r tau 95, and r tau 55 formed also a stable complex, r tau A, that displayed nonspecific DNA binding activity. Recombinant rTFIIIC was functionally equivalent to purified yeast TFIIIC, suggesting that the six recombinant subunits are necessary and sufficient to reconstitute a transcriptionally active TFIIIC complex. The formation and the properties of rTFIIIC-DNA complexes were affected by dephosphorylation treatments. The combination of complete recombinant rTFIIIC and rTFIIIB directed a low level of basal transcription, much weaker than with the crude B" fraction, suggesting the existence of auxiliary factors that could modulate the yeast RNA polymerase III transcription system.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Acker, J (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Batiment 144, F-91191 Gif Sur Yvette, France.	joel.acker@cea.fr	LEFEBVRE, Olivier/C-3847-2014; Acker, Joël/F-5138-2010; guirouilh-barbat, josee/O-7286-2017	LEFEBVRE, Olivier/0000-0002-3903-9450; Acker, Joël/0000-0002-0855-875X; guirouilh-barbat, josee/0000-0002-8845-7333				Andrau JC, 2001, EUR J BIOCHEM, V268, P5167, DOI 10.1046/j.0014-2956.2001.02445.x; Arrebola R, 1998, MOL CELL BIOL, V18, P1; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BIDWAI AP, 1992, J BIOL CHEM, V267, P18790; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; Brown TRP, 2000, GENE EXPRESSION, V9, P15; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; CAMIER S, 1985, EMBO J, V4, P491, DOI 10.1002/j.1460-2075.1985.tb03655.x; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Chong SS, 2001, J BIOL CHEM, V276, P20727, DOI 10.1074/jbc.M100088200; CONESA C, 1993, J BIOL CHEM, V268, P18047; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dieci G, 2003, TRENDS BIOCHEM SCI, V28, P202, DOI 10.1016/S0968-0004(03)00054-9; DIECI G, 1993, J BIOL CHEM, V268, P11199; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; Ferrari R, 2004, P NATL ACAD SCI USA, V101, P13442, DOI 10.1073/pnas.0403851101; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Ghavidel A, 1997, GENE DEV, V11, P2780, DOI 10.1101/gad.11.21.2780; Harismendy O, 2003, EMBO J, V22, P4738, DOI 10.1093/emboj/cdg466; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Hu P, 2003, MOL CELL, V12, P699, DOI 10.1016/j.molcel.2003.08.011; Huet J, 1997, J BIOL CHEM, V272, P18341, DOI 10.1074/jbc.272.29.18341; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3432, DOI 10.1093/nar/22.16.3432; Jourdain S, 2003, J BIOL CHEM, V278, P10450, DOI 10.1074/jbc.M213310200; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; Kruppa M, 2001, MOL CELL, V7, P309, DOI 10.1016/S1097-2765(01)00179-4; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; Lopez S, 2001, MOL CELL BIOL, V21, P3096, DOI 10.1128/MCB.21.9.3096-3104.2001; MARSOLIER MC, 1994, P NATL ACAD SCI USA, V91, P11938, DOI 10.1073/pnas.91.25.11938; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; Moqtaderi Z, 2004, MOL CELL BIOL, V24, P4118, DOI 10.1128/MCB.24.10.4118-4127.2004; Mylona A, 2006, PROTEIN EXPRES PURIF, V45, P255, DOI 10.1016/j.pep.2005.06.013; OTTONELLO S, 1994, BIOCHEM BIOPH RES CO, V203, P1217, DOI 10.1006/bbrc.1994.2312; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Ptacek J, 2005, NATURE, V438, P679, DOI 10.1038/nature04187; Roberts DN, 2003, P NATL ACAD SCI USA, V100, P14695, DOI 10.1073/pnas.2435566100; Roberts S, 1996, J BIOL CHEM, V271, P14903, DOI 10.1074/jbc.271.25.14903; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726	57	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11685	11692		10.1074/jbc.M600101200	http://dx.doi.org/10.1074/jbc.M600101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16517597	hybrid			2022-12-25	WOS:000236988100032
J	Lund, P; Weisshaupt, K; Mikeska, T; Jammas, D; Chen, X; Kuban, RJ; Ungethum, U; Krapfenbauer, U; Herzel, HP; Schafer, R; Walter, J; Sers, C				Lund, P.; Weisshaupt, K.; Mikeska, T.; Jammas, D.; Chen, X.; Kuban, R-J; Ungethum, U.; Krapfenbauer, U.; Herzel, H-P; Schafer, R.; Walter, J.; Sers, C.			Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation	ONCOGENE			English	Article						HRAS(G12V); MEK/ERK signalling; gene expression; CpG methylation; clusterin; Mmp2	PROGRAMMED CELL-DEATH; DNA-METHYLTRANSFERASE; HA-RAS; TRANSFORMED PHENOTYPE; GENE-EXPRESSION; METHYLATION; CANCER; TIMP-2; ACTIVATION; TRANSCRIPTION	Silencing of gene expression by methylation of CpG islands in regulatory elements is frequently observed in cancer. However, an influence of the most common oncogenic signalling pathways onto DNA methylation has not yet been investigated thoroughly. To address this issue, we identified genes suppressed in HRAS-transformed rat fibroblasts but upregulated after treatment with the demethylating agent 5-Aza-2-deoxycytidine and with the MEK1,2 inhibitor U0126. Analysis of gene expression by microarray and Northern blot analysis revealed the MEK/ERK target genes clusterin, matrix metalloproteinase 2 (Mmp2), peptidylpropyl isomerase C-associated protein, syndecan 4, Timp2 and Thbs1 to be repressed in the HRAS-transformed FE-8 cells in a MEK/ERK- and methylation-dependent manner. Hypermethylation of putative regulatory elements in HRAS-transformed cells as compared to immortalized fibroblasts was detected within a CpG island 14.5 kb upstream of clusterin, within the clusterin promoter and within a CpG island of the Mmp2 promoter by bisulphite sequencing. Furthermore, hypermethylation of the clusterin promoter was observed 10 days after induction of HRAS in immortalized rat fibroblasts and a clear correlation between reduced clusterin expression and hypermethlyation could also be observed in distinct rat tissues. These results suggest that silencing of individual genes by DNA methylation is controlled by oncogenic signalling pathways, yet the mechanisms responsible for initial target gene suppression are variable.	Inst Pathol, Lab Mol Tumorpathol, Charite, D-10117 Berlin, Germany; Univ Saarland, Dept Nat Sci, Tech Fac Biol Sci 3 FR 8 3, Inst Genet Epigenet, D-6600 Saarbrucken, Germany; Lab Funct Genome Res, Charite, Berlin, Germany; Humboldt Univ, Inst Theoret Biol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Saarland University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Sers, C (corresponding author), Inst Pathol, Lab Mol Tumorpathol, Charite, Schumannstr 20-21, D-10117 Berlin, Germany.	christine.sers@charite.de	Schäfer, Reinhold/AAB-5110-2021; Mikeska, Thomas/B-4876-2008; Sers, Christine/B-5438-2010; Lund, Per G/M-9019-2017; Lund, Per/Q-6737-2017	Mikeska, Thomas/0000-0003-1318-0859; Lund, Per/0000-0002-7457-4360; Sers, christine/0000-0002-6219-1514				Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Behrens P, 2001, PATHOBIOLOGY, V69, P19, DOI 10.1159/000048753; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BOS JL, 1989, CANCER RES, V49, P4682; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Brem R, 2001, ONCOGENE, V20, P2854, DOI 10.1038/sj.onc.1204403; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cappabianca L, 2003, EXP CELL RES, V286, P209, DOI 10.1016/S0014-4827(03)00072-7; Chen TG, 2004, CANCER RES, V64, P7412, DOI 10.1158/0008-5472.CAN-04-2077; Criswell T, 2005, J BIOL CHEM, V280, P14212, DOI 10.1074/jbc.M412569200; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 1997, ANTICANCER RES, V17, P3201; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Gadal F, 2003, NUCLEIC ACIDS RES, V31, P5789, DOI 10.1093/nar/gkg762; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Itoh T, 1998, CANCER RES, V58, P1048; Ivanova T, 2004, INT J CANCER, V108, P882, DOI 10.1002/ijc.11652; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Klock G, 1998, J CELL PHYSIOL, V177, P593, DOI 10.1002/(SICI)1097-4652(199812)177:4<593::AID-JCP10>3.3.CO;2-6; KYPRIANOU N, 1991, CANCER RES, V51, P162; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Laduron S, 2004, NUCLEIC ACIDS RES, V32, P4340, DOI 10.1093/nar/gkh735; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; LIU HS, 1992, CANCER RES, V52, P983; Lopes S, 2003, HUM MOL GENET, V12, P295, DOI 10.1093/hmg/ddg022; Lymar ES, 2000, BIOL REPROD, V63, P1341, DOI 10.1095/biolreprod63.5.1341; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Raudies O, 2005, ADV ENZYME REGUL, V45, P63, DOI 10.1016/j.advenzreg.2005.02.004; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; ROSEMBLIT N, 1994, J MOL ENDOCRINOL, V13, P69, DOI 10.1677/jme.0.0130069; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Scaltriti M, 2004, INT J CANCER, V108, P23, DOI 10.1002/ijc.11496; Scaltriti M, 2004, CANCER RES, V64, P6174, DOI 10.1158/0008-5472.CAN-04-0920; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; Schneider-Stock R, 2005, J PHARMACOL EXP THER, V312, P525, DOI 10.1124/jpet.104.074195; SCHWARTEWALDHOFF I, 1994, ONCOGENE, V9, P899; Sers C, 2002, ADV ENZYME REGUL, V42, P63, DOI 10.1016/S0065-2571(01)00024-3; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Taraboletti G, 2000, FASEB J, V14, P1674; Tchernitsa OI, 2004, ONCOGENE, V23, P4536, DOI 10.1038/sj.onc.1207585; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wei G, 2003, ANTICANCER RES, V23, P2173; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	68	49	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4890	4903		10.1038/sj.onc.1209502	http://dx.doi.org/10.1038/sj.onc.1209502			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16568090				2022-12-25	WOS:000239687100007
J	Longworth, MS; Laimins, LA				Longworth, M. S.; Laimins, L. A.			Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src	ONCOGENE			English	Article						HDAC3; c-Src; plasma membrane; tyrosine; phosphorylation	HUMAN-PAPILLOMAVIRUS TYPE-31; PP60C-SRC PROTEIN-KINASE; TYROSINE KINASE; C-SRC; ACTIVATION; EXPRESSION; HDAC3; DIFFERENTIATION; TRANSCRIPTION; PROGRESSION	Histone deacetylases (HDACs) negatively regulate gene expression by removing acetyl groups from lysine residues present in histones and other proteins. Histone deacetylase 3 is unique among the Class I family of HDACs, as it is able to shuttle between the nucleus and the cytoplasm, whereas the other family members remain in the nucleus. Histone deacetylase 3 often forms complexes with corepressor proteins that do not associate with the other Class I HDACs, and its phosphorylation correlates with increased enzymatic activity. Here we show that HDAC3 also localizes to the plasma membrane in multiple cell types. Furthermore, c-Src is shown to form a complex with HDAC3 at the plasma membrane and to use HDAC3 as a substrate for phosphorylation. Our results describe a novel localization and binding partner for the HDAC3 protein, as well as implicate c-Src in HDAC3 regulation.	Northwestern Univ, Dept Microbiol & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Laimins, LA (corresponding author), Northwestern Univ, Dept Microbiol & Immunol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	l-laimins@northwestern.edu	longworth, michelle/S-8456-2019		NATIONAL CANCER INSTITUTE [R01CA059655, T32CA009560] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA059655-12, T32CA09560, R01 CA059655] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Dib K, 2003, J BIOL CHEM, V278, P24181, DOI 10.1074/jbc.M302300200; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; FANNING P, 1992, CANCER RES, V52, P1457; Fehrmann F, 2003, J VIROL, V77, P2819, DOI 10.1128/JVI.77.5.2819-2831.2003; FEHRMANN F, 2004, METHOD MOL BIOL, V292, P317; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Guenther MG, 2000, GENE DEV, V14, P1048; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; JACOBS C, 1983, CANCER RES, V43, P1696; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Longworth MS, 2005, EMBO J, V24, P1821, DOI 10.1038/sj.emboj.7600651; Longworth MS, 2004, J VIROL, V78, P3533, DOI 10.1128/JVI.78.7.3533-3541.2004; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; Olszewska-Pazdrak B, 2004, J BIOL CHEM, V279, P40400, DOI 10.1074/jbc.C400208200; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zhang XH, 2005, GENE DEV, V19, P827, DOI 10.1101/gad.1286005; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	27	87	93	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4495	4500		10.1038/sj.onc.1209473	http://dx.doi.org/10.1038/sj.onc.1209473			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16532030				2022-12-25	WOS:000239326000013
J	Fountain, SJ; North, RA				Fountain, Samuel J.; North, R. Alan			A C-terminal lysine that controls human P2X(4) receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST SYNAPTIC TRANSMISSION; RAT SPINAL-CORD; DORSAL-HORN; ION-CHANNEL; ATP-BINDING; IDENTIFICATION; ECTODOMAIN; RESIDUES; DOMAIN; SUBUNITS	Receptor desensitization can determine the time course of transmitter action and profoundly alter sensitivity to drugs. Among P2X receptors, ion currents through homomeric P2X(4) receptors exhibit intermediate desensitization when compared with P2X(1) and P2X(3) ( much faster) and P2X(2) and P2X(7) ( slower). We recorded membrane currents in HEK293 cells transfected to express the human P2X4 receptor. The decline in current during a 4-s application of ATP ( 100 mu M) was about 30%; this was not different during whole-cell or perforated patch recording. Alanine-scanning mutagenesis of the intracellular C terminus identified two positions with much accelerated desensitization kinetics (Lys(373): 92% and Tyr(374): 74%). At position 373, substitution of Arg or Cys also strongly accelerated desensitization: however, in the case of K373C the wild-type phenotype was fully restored by adding ethylammonium methanethiosulfonate. At position 374, phenylalanine could replace tyrosine. These results indicate that wild-type desensitization properties requires an aromatic moiety at position 374 and an amino rather than a guanidino group at position 373. These residues lie between previously identified motifs involved in membrane trafficking (YXXXK and YXXGL) and implicates the C-terminal also in rearrangements leading to channel closing during the presence of agonist.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Fountain, SJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg, Manchester M13 9PT, Lancs, England.	Samuel.fountain@manchester.ac.uk	Fountain, Samuel J/C-2142-2011; North, Richard/GQA-6156-2022		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bardoni R, 1997, J NEUROSCI, V17, P5297; Barrera NP, 2005, J BIOL CHEM, V280, P10759, DOI 10.1074/jbc.M412265200; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; Egan TM, 1998, J NEUROSCI, V18, P2350; Ennion SJ, 2002, BIOCHEM BIOPH RES CO, V291, P611, DOI 10.1006/bbrc.2002.6488; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; Fabbretti E, 2004, J BIOL CHEM, V279, P53109, DOI 10.1074/jbc.M409772200; He ML, 2002, MOL PHARMACOL, V62, P1187, DOI 10.1124/mol.62.5.1187; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Hugel S, 2000, J NEUROSCI, V20, P2121; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Jiang LH, 2003, J NEUROSCI, V23, P8903; Khakh BS, 1999, J NEUROSCI, V19, P7289, DOI 10.1523/JNEUROSCI.19-17-07289.1999; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; King B, 1997, NEUROREPORT, V8, P1099, DOI 10.1097/00001756-199703240-00007; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; Lewis CJ, 2000, BRIT J PHARMACOL, V131, P1659, DOI 10.1038/sj.bjp.0703744; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pankratov YV, 2002, J NEUROSCI, V22, P8363; Priel A, 2004, J GEN PHYSIOL, V123, P281, DOI 10.1085/jgp.200308986; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Roberts JA, 2004, J BIOL CHEM, V279, P9043, DOI 10.1074/jbc.M308964200; Royle SJ, 2005, J CELL SCI, V118, P3073, DOI 10.1242/jcs.02451; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Seguela P, 1996, J NEUROSCI, V16, P448; Soto M, 1996, BIOCHEM BIOPH RES CO, V223, P456, DOI 10.1006/bbrc.1996.0915; Stojilkovic SS, 2005, ANN NY ACAD SCI, V1048, P116, DOI 10.1196/annals.1342.011; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Wang Y, 2004, NEUROREPORT, V15, P633, DOI 10.1097/00001756-200403220-00012; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Zemkova H, 2004, J NEUROSCI, V24, P6968, DOI 10.1523/JNEUROSCI.1471-04.2004	36	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15044	15049		10.1074/jbc.M600442200	http://dx.doi.org/10.1074/jbc.M600442200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16533808	hybrid			2022-12-25	WOS:000237922200005
J	Ruban, AV; Solovieva, S; Lee, PJ; Ilioaia, C; Wentworth, M; Ganeteg, U; Klimmek, F; Chow, WS; Anderson, JM; Jansson, S; Horton, P				Ruban, Alexander V.; Solovieva, Svetlana; Lee, Pamela J.; Ilioaia, Cristian; Wentworth, Mark; Ganeteg, Ulrika; Klimmek, Frank; Chow, Wah Soon; Anderson, Jan M.; Jansson, Stefan; Horton, Peter			Plasticity in the composition of the light harvesting antenna of higher plants preserves structural integrity and biological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A/B-BINDING-PROTEINS; PHOTOSYSTEM-II; SUPRAMOLECULAR ORGANIZATION; SPECTROSCOPIC ANALYSIS; CRYSTAL-STRUCTURE; COMPLEX-II; ACCLIMATION; ARABIDOPSIS; ENERGY; XANTHOPHYLLS	Arabidopsis plants in which the major trimeric light harvesting complex ( LHCIIb) is eliminated by antisense expression still exhibit the typical macrostructure of photosystem II in the granal membranes. Here the detailed analysis of the composition and the functional state of the light harvesting antennae of both photosystem I and II of these plants is presented. Two new populations of trimers were found, both functional in energy transfer to the PSII reaction center, a homotrimer of CP26 and a heterotrimer of CP26 and Lhcb3. These trimers possess characteristic features thought to be specific for the native LHCIIb trimers they are replacing: the long wavelength form of lutein and at least one extra chlorophyll b, but they were less stable. A new population of loosely bound LHCI was also found, contributing to an increased antenna size for photosystem I, which may in part compensate for the loss of the phosphorylated LHCIIb that can associate with this photosystem. Thus, the loss of LHCIIb has triggered concerted compensatory responses in the composition of antennae of both photosystems. These responses clearly show the importance of LHCIIb in the structure and assembly of the photosynthetic membrane and illustrate the extreme plasticity at the level of the composition of the light harvesting system.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Umea Univ, Dept Plant Physiol, Plant Sci Ctr, S-90187 Umea, Sweden; Australian Natl Univ, Res Sch Biol Sci, Photobioenerget Grp, Canberra, ACT 2601, Australia	University of Sheffield; Umea University; Australian National University	Ruban, AV (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	a.ruban@sheffield.ac.uk	Chow, Wah Soon/D-2010-2009; Jansson, Stefan/A-1119-2009; Horton, Peter/A-3958-2012	Jansson, Stefan/0000-0002-7906-6891; Horton, Peter/0000-0002-6095-1460; ILIOAIA, Cristian/0000-0001-7505-1900				Allemeersch J, 2005, PLANT PHYSIOL, V137, P588, DOI 10.1104/pp.104.051300; Anderson JM, 1995, PHOTOSYNTH RES, V46, P129, DOI 10.1007/BF00020423; Andersson J, 2003, PLANT J, V35, P350, DOI 10.1046/j.1365-313X.2003.01811.x; Andersson J, 2001, PLANT CELL, V13, P1193, DOI 10.1105/tpc.13.5.1193; Bailey S, 2001, PLANTA, V213, P794, DOI 10.1007/s004250100556; Bassi R, 1997, PHYSIOL PLANTARUM, V100, P769, DOI 10.1034/j.1399-3054.1997.1000404.x; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Boekema EJ, 1999, EUR J BIOCHEM, V266, P444, DOI 10.1046/j.1432-1327.1999.00876.x; Caffarri S, 2004, BIOCHEMISTRY-US, V43, P9467, DOI 10.1021/bi036265i; Croce R, 1998, BIOCHEMISTRY-US, V37, P17355, DOI 10.1021/bi9813227; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; Davison PA, 2002, NATURE, V418, P203, DOI 10.1038/nature00861; de Weerd FL, 2002, BIOCHEMISTRY-US, V41, P15224, DOI 10.1021/bi0261948; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; Dudley AM, 2002, P NATL ACAD SCI USA, V99, P7554, DOI 10.1073/pnas.112683499; Ganeteg U, 2004, PLANT MOL BIOL, V54, P641, DOI 10.1023/B:PLAN.0000040813.05224.94; Ganeteg U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/pp.127.1.150; Haldrup A, 2001, TRENDS PLANT SCI, V6, P301, DOI 10.1016/S1360-1385(01)01953-7; Hilson P, 2004, GENOME RES, V14, P2176, DOI 10.1101/gr.2544504; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Huner NPA, 1998, TRENDS PLANT SCI, V3, P224, DOI 10.1016/S1360-1385(98)01248-5; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; KITAJIMA M, 1975, BIOCHIM BIOPHYS ACTA, V408, P297, DOI 10.1016/0005-2728(75)90131-0; Klimmek F, 2005, BIOCHEMISTRY-US, V44, P3065, DOI 10.1021/bi047873g; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; Novoderezhkin VI, 2005, J PHYS CHEM B, V109, P10493, DOI 10.1021/jp044082f; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; Palacios MA, 2003, BBA-BIOENERGETICS, V1605, P83, DOI 10.1016/S0005-2728(03)00080-X; Pascal AA, 2005, NATURE, V436, P134, DOI 10.1038/nature03795; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Rodermel S, 2001, TRENDS PLANT SCI, V6, P471, DOI 10.1016/S1360-1385(01)02085-4; Ruban AV, 2000, FEBS LETT, V477, P181, DOI 10.1016/S0014-5793(00)01799-3; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 2003, NATURE, V421, P648, DOI 10.1038/nature01344; RUBAN AV, 1991, BIOCHIM BIOPHYS ACTA, V1058, P411, DOI 10.1016/S0005-2728(05)80137-9; RUBAN AV, 1991, PHOTOSYNTH RES, V29, P157, DOI 10.1007/BF00036219; RUBAN AV, 1992, BIOCHIM BIOPHYS ACTA, V1102, P30, DOI 10.1016/0005-2728(92)90061-6; Ruban AV, 2001, J BIOL CHEM, V276, P24862, DOI 10.1074/jbc.M103263200; SJODIN A, 2005, UPSC BASE; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Standfuss R, 2005, EMBO J, V24, P919, DOI 10.1038/sj.emboj.7600585; van Amerongen H, 2001, J PHYS CHEM B, V105, P604, DOI 10.1021/jp0028406; Wentworth M, 2004, BIOCHEMISTRY-US, V43, P501, DOI 10.1021/bi034975i; Yakushevska AE, 2003, BIOCHEMISTRY-US, V42, P608, DOI 10.1021/bi027109z; Zelisko A, 2005, P NATL ACAD SCI USA, V102, P13699, DOI 10.1073/pnas.0503472102	50	41	43	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14981	14990		10.1074/jbc.M511415200	http://dx.doi.org/10.1074/jbc.M511415200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551629	Green Published, hybrid			2022-12-25	WOS:000237671300051
J	Simpson, GIC; Leonard, DM; Leonard, JL				Simpson, Gregory I. C.; Leonard, Deborah M.; Leonard, Jack L.			Identification of the key residues responsible for the assembly of selenodeiodinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IODOTHYRONINE DEIODINASE; RAT; 5-DEIODINASE; SELENOCYSTEINE; DIMERIZATION; SUBUNIT; PROTEIN; ENZYME; FAMILY	Type I deiodinase is the best characterized member of a small family of seleno enzymes catalyzing the bioactivation and disposal of thyroid hormone. This enzyme is an integral membrane protein composed of two 27-kDa subunits that assemble into a functional enzyme after translation using a highly conserved sequence of 16 amino acids in the C-terminal half of the polypeptide, (148)DFLXXYIXEAHXXDGW(163). In this study, we used alanine scanning mutagenesis to identify the key residues in this domain required for holoenzyme assembly. Overexpression of sequential alanine-substituted mutants of a dimerization domain-green fluorescent protein fusion showed that sequence (IYI154)-I-152 was required for type I enzyme assembly and that a catalytically active monomer was generated by a single I152A substitution. Overexpression of the sequential alanine-substituted dimerization domain mutants in type II selenodeiodinase-expressing cells showed that five residues ((FLIVY157)-F-153) at the beginning and three residues ((164)SDG(166)) at the end of this region were required for the assembly of the type II enzyme. In vitro binding analysis revealed a free energy of association of -60 +/- 5kJ/mol for the noncovalent interaction between dimerization domain monomers. These data identify and characterize the essential residues in the dimerization domain that are responsible for the post-translational assembly of selenodeiodinases.	Univ Massachusetts, Sch Med, Dept Cell & Mol Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Leonard, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Cell & Mol Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	jack.leonard@umassmed.edu						BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1992, J BIOL CHEM, V267, P18055; Bianco AC, 2005, THYROID, V15, P777, DOI 10.1089/thy.2005.15.777; Callebaut I, 2003, J BIOL CHEM, V278, P36887, DOI 10.1074/jbc.M305725200; Curcio-Morelli C, 2003, ENDOCRINOLOGY, V144, P937, DOI 10.1210/en.2002-220960; Farwell AP, 1996, J BIOL CHEM, V271, P16369, DOI 10.1074/jbc.271.27.16369; Kohrle J, 2000, CELL MOL LIFE SCI, V57, P1853, DOI 10.1007/PL00000667; LEONARD JL, 1991, J BIOL CHEM, V266, P11262; Leonard JL, 1999, ENDOCRINOLOGY, V140, P2206, DOI 10.1210/en.140.5.2206; Leonard JL, 2005, J BIOL CHEM, V280, P11093, DOI 10.1074/jbc.M500011200; Leonard JL, 2001, J BIOL CHEM, V276, P2600, DOI 10.1074/jbc.M006973200; MOL JA, 1984, BIOCHEM BIOPH RES CO, V120, P28, DOI 10.1016/0006-291X(84)91409-8; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080; WEEKE J, 1973, SCAND J CLIN LAB INV, V32, P357, DOI 10.3109/00365517309084359	17	6	6	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14615	14621		10.1074/jbc.M600783200	http://dx.doi.org/10.1074/jbc.M600783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16565517	hybrid			2022-12-25	WOS:000237671300013
J	Page, S; Judson, A; Melford, K; Bensadoun, A				Page, Shallee; Judson, Andrea; Melford, Kristan; Bensadoun, Andre			Interaction of lipoprotein lipase and receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; PLASMON RESONANCE BIOSENSORS; RAT HEPATOMA-CELLS; ALPHA-2-MACROGLOBULIN RECEPTOR; IN-VIVO; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; CULTURED ADIPOCYTES; BINDING DOMAIN; ER RETENTION	Receptor-associated protein ( RAP) is a recognized chaperone/escort protein for members of the low density lipoprotein receptor family. In this report, we show that RAP binds to lipoprotein lipase (LPL) and may play a role in the maturation of LPL. Binding of highly purified RAP to LPL was demonstrated in vitro by solid phase assays, surface plasmon resonance, and rate zonal centrifugation. The dissociation constant for this interaction measured by the first two techniques ranged between 2.4 and 13 nM, values similar to those reported for the binding of RAP to LRP or gp330. The specificity of the interaction was demonstrated by competition with a panel of LPL monoclonal antibodies. Rate zonal centrifugation demonstrated the presence of a stable complex with an apparent M-r consistent with the formation of a complex between monomeric LPL and RAP.RAP center dot LPL complexes were co-immunoprecipitated in adipocyte lysates or from solutions of purified LPL and RAP. The interaction was also demonstrated in whole cells by cross-linking experiments. RAP-deficient adipocytes secreted LPL with a specific activity 2.5-fold lower than the lipase secreted by control cells. Heparin addition to cultured RAP-deficient adipocytes failed to stimulate LPL secretion in the medium, suggesting defective binding of the lipase to the plasma membrane. These studies demonstrate that RAP binds to LPL with high affinity both in purified systems and cell extracts and that RAP-deficient adipocytes secrete poorly assembled LPL. A function of RAP may be to prevent premature interaction of LPL with binding partners in the secretory pathway, namely LRP and heparan sulfate proteoglycan.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Bensadoun, A (corresponding author), Cornell Univ, Div Nutr Sci, 321 Savage Hall, Ithaca, NY 14853 USA.	ab55@cornell.edu	Page, Shallee/AAA-6855-2019	Page, Shallee/0000-0002-3557-4122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007158] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14990] Funding Source: Medline; NIDDK NIH HHS [DK7158] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Ben-Zeev O, 2002, J BIOL CHEM, V277, P10727, DOI 10.1074/jbc.M108128200; Bensadoun A, 1999, METH MOL B, V109, P145; BENSADOUN A, 1986, BIOCHIM BIOPHYS ACTA, V879, P253, DOI 10.1016/0005-2760(86)90214-6; BENSADOUN A, 1991, ANNU REV NUTR, V11, P217, DOI 10.1146/annurev.nu.11.070191.001245; BENZEEV O, 1992, J BIOL CHEM, V267, P6219; Briquet-Laugier V, 1999, J LIPID RES, V40, P2044; Bu GJ, 1997, J CELL SCI, V110, P65; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; CISAR LA, 1987, BIOCHIM BIOPHYS ACTA, V927, P305, DOI 10.1016/0167-4889(87)90094-2; CISAR LA, 1989, J BIOL CHEM, V264, P1767; FIELDING CJ, 1973, BIOCHIM BIOPHYS ACTA, V316, P66, DOI 10.1016/0005-2760(73)90167-7; GERSHENWALD JE, 1985, BIOCHIM BIOPHYS ACTA, V836, P286, DOI 10.1016/0005-2760(85)90132-8; Goldberg IJ, 1996, J LIPID RES, V37, P693; Hall DB, 2002, J BIOL CHEM, V277, P46043, DOI 10.1074/jbc.M208911200; HATA A, 1992, J BIOL CHEM, V267, P20132; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; JI ZS, 1994, J BIOL CHEM, V269, P13429; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Landry R, 2001, CELL GROWTH DIFFER, V12, P497; LITTHAUER D, 1992, COMP BIOCHEM PHYS A, V101, P59, DOI 10.1016/0300-9629(92)90628-4; Mahley RW, 1999, J LIPID RES, V40, P1; Mason T, 1999, MATH BIOSCI, V159, P123, DOI 10.1016/S0025-5564(99)00023-1; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OLIVECRONA T, 1993, BIOCHEM SOC T, V21, P509, DOI 10.1042/bst0210509; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PETERSON J, 1992, J LIPID RES, V33, P1165; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; Schuck P, 1997, CURR OPIN BIOTECH, V8, P498, DOI 10.1016/S0958-1669(97)80074-2; Sendak RA, 1998, J LIPID RES, V39, P1310; Sendak RA, 1998, J LIPID RES, V39, P633; STEIN O, 1983, BIOCHIM BIOPHYS ACTA, V750, P306, DOI 10.1016/0005-2760(83)90033-4; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; van Vlijmen BJM, 1999, J BIOL CHEM, V274, P35219, DOI 10.1074/jbc.274.49.35219; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; Wong H, 1997, P NATL ACAD SCI USA, V94, P5594, DOI 10.1073/pnas.94.11.5594; Zhang LY, 2003, J BIOL CHEM, V278, P29344, DOI 10.1074/jbc.M300455200	51	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13931	13938		10.1074/jbc.M600995200	http://dx.doi.org/10.1074/jbc.M600995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16517593	hybrid			2022-12-25	WOS:000237512300014
J	Wang, BX; Zhou, J; Lodder, M; Anderson, RD; Hecht, SM				Wang, Bixun; Zhou, Jia; Lodder, Michiel; Anderson, Raymond D., III; Hecht, Sidney M.			Tandemly activated tRNAs as participants in protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISACYLATED TRANSFER-RNAS; TRANSFER RIBONUCLEIC-ACID; THERMUS-THERMOPHILUS; CRYSTAL-STRUCTURE; TERNARY COMPLEX; AMINOACYLATION; ELABORATION; SYNTHETASE	While all studies of protein synthesis to date have employed monoaminoacylated transfer RNAs, there have been reports that bisphenylalanyl-tRNA is formed by Thermus thermophilus phenylalanyl-tRNA synthetase. Such tandemly activated tRNAs have now been prepared by chemicoenzymatic techniques and are shown to function in both prokaryotic and mammalian protein synthesizing systems. They exhibit characteristics consistent with their possible utility under extreme conditions in natural systems and have important potential advantages for protein elaboration in cell free systems. Mechanistically, the bisaminoacylated tRNAs bind to the ribosomal A-site and utilize the aminoacyl moiety attached to the 3'-position of the terminal adenosine for addition to the growing polypeptide chain. Following translocation to the P-site and transfer of the formed peptidyl moiety, the donor tRNA dissociates from the ribosome as a monoaminoacylated tRNA capable of functioning in a subsequent polypeptide elongation step.	Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA	University of Virginia; University of Virginia	Hecht, SM (corresponding author), Univ Virginia, Dept Chem, McCormick Rd,POB 400319, Charlottesville, VA 22904 USA.	sidhecht@virginia.edu			NCI NIH HHS [CA77359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS JP, 1988, NUCLEIC ACIDS RES, V16, P10099, DOI 10.1093/nar/16.21.10099; CRICK F, 1970, NATURE, V227, P561, DOI 10.1038/227561a0; GRIFFIN BE, 1966, BIOCHEMISTRY-US, V5, P3638, DOI 10.1021/bi00875a037; HECHT SM, 1992, ACCOUNTS CHEM RES, V25, P545, DOI 10.1021/ar00024a001; HECHT SM, 1977, ACCOUNTS CHEM RES, V10, P239, DOI 10.1021/ar50115a002; HECHT SM, 1977, TETRAHEDRON, V33, P1671, DOI 10.1016/0040-4020(77)84042-8; HECHT SM, 1978, J BIOL CHEM, V253, P4517; HECHT SM, 1998, NUCL ACIDS RES S SER, V39, P15; Karginov VA, 1997, J AM CHEM SOC, V119, P8166, DOI 10.1021/ja971099l; Lodder M, 1998, J ORG CHEM, V63, P794, DOI 10.1021/jo971692l; Lodder M, 1997, J ORG CHEM, V62, P778, DOI 10.1021/jo962170t; Mamaev SV, 1996, J AM CHEM SOC, V118, P7243, DOI 10.1021/ja961053c; NATHANS D, 1963, NATURE, V197, P1076, DOI 10.1038/1971076a0; NEUMANN H, 1968, P NATL ACAD SCI USA, V61, P1207, DOI 10.1073/pnas.61.4.1207; Nissen P, 1999, STRUCTURE, V7, P143, DOI 10.1016/S0969-2126(99)80021-5; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Short GF, 1999, BIOCHEMISTRY-US, V38, P8808, DOI 10.1021/bi990281r; STEPANOV VG, 1992, FEBS LETT, V311, P192, DOI 10.1016/0014-5793(92)81099-8; Stepanov VG, 1998, BBA-PROTEIN STRUCT M, V1386, P1, DOI 10.1016/S0167-4838(98)00054-5; TAIJI M, 1983, BIOCHEMISTRY-US, V22, P3220, DOI 10.1021/bi00282a028; Trobro S, 2005, P NATL ACAD SCI USA, V102, P12395, DOI 10.1073/pnas.0504043102; WAGNER T, 1982, BIOCHEMISTRY-US, V21, P1521, DOI 10.1021/bi00536a009; Wang BX, 2000, J AM CHEM SOC, V122, P7402, DOI 10.1021/ja0002262	23	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13865	13868		10.1074/jbc.C600018200	http://dx.doi.org/10.1074/jbc.C600018200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16556606	hybrid			2022-12-25	WOS:000237512300005
J	Alone, PV; Dever, TE				Alone, PV; Dever, TE			Direct binding of translation initiation factor eIF2 gamma-G domain to its GTPase- activating and GDP-GTP exchange factors eIF5 and eIF2B epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; TERMINAL DOMAIN; TRANSFER-RNA; FACTOR 2B; RECOGNITION; COMPLEX; ARCHAEAL; RELEASE; IDENTIFICATION; EIF2-ALPHA	The GTP-binding eukaryotic translation initiation factor eIF2 delivers initiator methionyl-tRNA to the 40 S ribosomal subunit. The factor eIF5 stimulates hydrolysis of GTP by eIF2 upon AUG codon recognition, whereas the factor eIF2B promotes guanine nucleotide exchange on eIF2 to recycle the factor for additional rounds of translation initiation. The GTP-binding (G) domain resides in the gamma subunit of the heterotrimeric eIF2; however, only eIF2 beta, and not eIF2 gamma, has been reported to directly bind to eIF5 or eIF2B. Using proteins expressed in yeast or recombinant systems we show that full-length yeast eIF2 gamma, as well as its isolated G domain, binds directly to eIF5 and the epsilon subunit of eIF2B, and we map the interaction sites to the catalytically important regions of these factors. Consistently, an internal deletion of residues 50-100 of yeast eIF5 impairs the interaction with recombinant eIF2 gamma-G domain and abolishes the ability of eIF5 to stimulate eIF2 GTPase activity in translation initiation complexes in vitro. Thus, rather than allosterically regulating eIF2 gamma-G domain function via eIF2 beta, our data support a model in which the GTPase-activating factor eIF5 and the guanine-nucleotide exchange factor eIF2B modulate eIF2 function through direct interactions with the eIF2 gamma-G domain.	NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dever, TE (corresponding author), NICHD, Lab Gene Regulat & Dev, NIH, Bldg 6A,Rm B1A-03, Bethesda, MD 20892 USA.	tdever@nih.gov	Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Algire MA, 2005, MOL CELL, V20, P251, DOI 10.1016/j.molcel.2005.09.008; Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; Aravind L, 2000, GENOME RES, V10, P1172, DOI 10.1101/gr.10.8.1172; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 2001, EMBO J, V20, P2326, DOI 10.1093/emboj/20.9.2326; Boesen T, 2004, J BIOL CHEM, V279, P10584, DOI 10.1074/jbc.M311055200; Das S, 2000, MOL CELL BIOL, V20, P3942, DOI 10.1128/MCB.20.11.3942-3950.2000; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; Das S, 2001, J BIOL CHEM, V276, P6720, DOI 10.1074/jbc.M008863200; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; Gomez E, 2002, EMBO J, V21, P5292, DOI 10.1093/emboj/cdf515; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Kapp LD, 2004, J MOL BIOL, V335, P923, DOI 10.1016/j.jmb.2003.11.025; Krishnamoorthy T, 2001, MOL CELL BIOL, V21, P5018, DOI 10.1128/MCB.21.15.5018-5030.2001; Maag D, 2005, MOL CELL, V17, P265, DOI 10.1016/j.molcel.2004.11.051; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Nielsen KH, 2004, EMBO J, V23, P1166, DOI 10.1038/sj.emboj.7600116; Paulin FEM, 2001, CURR BIOL, V11, P55, DOI 10.1016/S0960-9822(00)00025-7; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Pedulla N, 2005, NUCLEIC ACIDS RES, V33, P1804, DOI 10.1093/nar/gki321; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Roll-Mecak A, 2004, J BIOL CHEM, V279, P10634, DOI 10.1074/jbc.M310418200; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schmitt E, 2002, EMBO J, V21, P1821, DOI 10.1093/emboj/21.7.1821; Singh CR, 2004, J BIOL CHEM, V279, P49644, DOI 10.1074/jbc.M409609200; Thompson GM, 2000, BIOCHEM J, V347, P703, DOI 10.1042/0264-6021:3470703; Unbehaun A, 2004, GENE DEV, V18, P3078, DOI 10.1101/gad.1255704; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; Valasek L, 2001, EMBO J, V20, P891, DOI 10.1093/emboj/20.4.891; Yatime L, 2004, J BIOL CHEM, V279, P15984, DOI 10.1074/jbc.M311561200	34	50	53	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12636	12644		10.1074/jbc.M511700200	http://dx.doi.org/10.1074/jbc.M511700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522633	hybrid			2022-12-25	WOS:000237134700054
J	Irazusta, V; Cabiscol, E; Reverter-Branchat, G; Ros, J; Tamarit, J				Irazusta, V; Cabiscol, E; Reverter-Branchat, G; Ros, J; Tamarit, J			Manganese is the link between frataxin and iron-sulfur deficiency in the yeast model of Friedreich ataxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVELY DAMAGED PROTEINS; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; MITOCHONDRIAL ACONITASE; STRESS; CELLS; ACCUMULATION; EXPRESSION; HOMOLOG; STRAIN	Friedreich ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin. Proteomic analysis of the mutant yeast model of Friedreich ataxia presented in this paper reveals that these cells display increased amounts of proteins involved in antioxidant defenses, including manganese-superoxide dismutase. This enzyme shows, however, lower activity than that found in wild type cells. Our results indicate that this lack of activity is a consequence of cellular manganese deficiency, because in manganese-supplemented cultures, cell manganese content, and manganese-superoxide dismutase activity were restored. One of the hallmarks of Friedreich ataxia is the decreased activity of iron/sulfur-containing enzymes. The activities of four enzymes of this group (aconitase, glutamate synthase, succinate dehydrogenase, and isopropylmalate dehydratase) have been analyzed for the effects of manganese supplementation. Enzyme activities were recovered by manganese treatment, except for aconitase, for which, a specific interaction with frataxin has been demonstrated previously. Similar results were obtained when cells were grown in iron-limited media suggesting that manganese-superoxide dismutase deficiency is a consequence of iron overload. In conclusion, these data indicate that generalized deficiency of iron-sulfur protein activity could be a consequence of manganese-superoxide dismutase deficiency, and consequently, it opens new strategies for Friedreich ataxia treatment.	Univ Lleida, Dept Ciencies Med Basiques, Fac Med, Grp Bioquim Estres Oxidatiu, Lleida 25008, Spain	Universitat de Lleida	Ros, J (corresponding author), Univ Lleida, Dept Ciencies Med Basiques, Fac Med, Grp Bioquim Estres Oxidatiu, Montserrat Roig,2, Lleida 25008, Spain.	joaquim.ros@cmb.udl.es	Cabiscol, Elisa/A-4584-2009; Ros, Joaquim/A-7507-2010; Tamarit, Jordi/C-6316-2008; ROS, Joaquim/ABG-7487-2020	Cabiscol, Elisa/0000-0003-2795-7999; Tamarit, Jordi/0000-0003-3227-6928; ROS, Joaquim/0000-0003-0901-8648; Irazusta, Veronica/0000-0001-7436-8543				Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bulteau AL, 2005, P NATL ACAD SCI USA, V102, P5987, DOI 10.1073/pnas.0501519102; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Campanella A, 2004, HUM MOL GENET, V13, P2279, DOI 10.1093/hmg/ddh232; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cavadini P, 2000, HUM MOL GENET, V9, P2523, DOI 10.1093/hmg/9.17.2523; Chantrel-Groussard K, 2001, HUM MOL GENET, V10, P2061, DOI 10.1093/hmg/10.19.2061; Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391; COGONI C, 1995, J BACTERIOL, V177, P792, DOI 10.1128/jb.177.3.792-798.1995; de Nobel H, 2001, YEAST, V18, P1413, DOI 10.1002/yea.793; Ding HG, 2005, J BIOL CHEM, V280, P30432, DOI 10.1074/jbc.M504638200; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Finley JW, 2004, NUTR REV, V62, P148, DOI 10.1301/nr.2004.apr.148-153; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gonzalez-Cabo P, 2005, HUM MOL GENET, V14, P2091, DOI 10.1093/hmg/ddi214; KOHLHAW GB, 1988, METHOD ENZYMOL, V166, P423; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Luk EEC, 2001, J BIOL CHEM, V276, P47556, DOI 10.1074/jbc.M108923200; MacEvilly CJ, 1997, RESTOR NEUROL NEUROS, V11, P131, DOI 10.3233/RNN-1997-11303; O'Neill HA, 2005, BIOCHEMISTRY-US, V44, P537, DOI 10.1021/bi048459j; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Pastore A, 2003, J BIOL CHEM, V278, P42588, DOI 10.1074/jbc.M301872200; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Reverter-Branchat G, 2004, J BIOL CHEM, V279, P31983, DOI 10.1074/jbc.M404849200; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Rotig A, 2002, TRENDS MOL MED, V8, P221, DOI 10.1016/S1471-4914(02)02330-4; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; Rutherford JC, 2005, J BIOL CHEM, V280, P10135, DOI 10.1074/jbc.M413731200; Santos MM, 2001, HUM MOL GENET, V10, P1935, DOI 10.1093/hmg/10.18.1935; Seznec H, 2005, HUM MOL GENET, V14, P463, DOI 10.1093/hmg/ddi042; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Sturm B, 2005, J BIOL CHEM, V280, P6701, DOI 10.1074/jbc.M408717200; Takeda A, 2003, BRAIN RES REV, V41, P79, DOI 10.1016/S0165-0173(02)00234-5; Tamarit J, 2006, ANAL BIOCHEM, V351, P149, DOI 10.1016/j.ab.2005.12.001; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; Tan GL, 2003, HUM MOL GENET, V12, P1699, DOI 10.1093/hmg/ddg187; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Yoon T, 2004, J BIOL CHEM, V279, P25943, DOI 10.1074/jbc.C400107200; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i; Zhang Y, 2005, J BIOL CHEM, V280, P19794, DOI 10.1074/jbc.M500397200	50	56	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12227	12232		10.1074/jbc.M511649200	http://dx.doi.org/10.1074/jbc.M511649200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16510442	Green Published, hybrid			2022-12-25	WOS:000237134700005
J	Shukla, A; Barrett, TF; Nakayama, KI; Nakayama, K; Mossman, BT; Lounsbury, KM				Shukla, Arti; Barrett, Trisha F.; Nakayama, Keiichi I.; Nakayama, Kieko; Mossman, Brooke T.; Lounsbury, Karen M.			Transcriptional up-regulation of MMP12 and MMP13 by asbestos occurs via a PKC delta-dependent pathway in murine lung	FASEB JOURNAL			English	Article						TIMP; fibrosis; lung cancer; lung epithelium	PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; IDIOPATHIC PULMONARY-FIBROSIS; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; TISSUE INHIBITORS; CIGARETTE-SMOKE; ACTIVATION; MICE; PROLIFERATION	Asbestos is a known inflammatory, carcinogenic, and fibrotic agent, but the mechanisms leading to asbestos-induced lung diseases are unclear. Using a murine inhalation model of fibrogenesis, we show that asbestos causes significant increases in mRNA levels of lung matrix metalloproteinases (MMPs 12 and 13) and tissue inhibitor of metalloproteinases (TIMP1), as well as increased activities of MMP 2, 9, and 12 in bronchoalveolar lavage fluids (BALF). Asbestos-exposed PKC delta knockout (PKC delta-/-) mice exhibited decreased expression of lung MMP12 and MMP13 compared with asbestos-exposed wild-type mice. Studies using small molecule inhibitors in murine alveolar epithelial type II cells (C10) and primary lung fibroblasts confirmed that asbestos transcriptionally upregulates MMPs via an EGFR (or other growth factor receptors)/PI3K/PKC delta/ERK1/2 pathway. Moreover, use of a broad-spectrum MMP inhibitor showed that MMPs play an important role in further enhancing asbestos-induced signaling events by activating EGFR. These data reveal a potentially important link between asbestos signaling and integrity of the extracellular matrix (ECM) that likely contributes to asbestos-induced lung remodeling and diseases.	Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; Kyushu Univ, Dept Mol Genet, Med Inst Bioregulat, Fukuoka 812, Japan	University of Vermont; University of Vermont; Kyushu University	Lounsbury, KM (corresponding author), Univ Vermont, Coll Med, Dept Pharmacol, 89 Beaumont Ave, Burlington, VT 05405 USA.	karen.lounsbury@uvm.edu			NCI NIH HHS [P30CA22435] Funding Source: Medline; NHLBI NIH HHS [P01 HL067004, P01HL67004] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA022435] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067004] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burch PM, 2004, MOL CELL BIOL, V24, P4696, DOI 10.1128/MCB.24.11.4696-4709.2004; Corbel M, 2001, J PATHOL, V193, P538, DOI 10.1002/path.826; Ellerbroek SM, 2001, CANCER RES, V61, P1855; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Fukuda Y, 1998, LAB INVEST, V78, P687; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hayashi T, 1996, AM J PATHOL, V149, P1241; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Lavigne MC, 2005, BIOCHEM BIOPH RES CO, V330, P194, DOI 10.1016/j.bbrc.2005.02.144; Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260; Lounsbury KM, 2002, AM J PATHOL, V160, P1991, DOI 10.1016/S0002-9440(10)61149-2; Lucchesi PA, 2004, CIRCULATION, V110, P3587, DOI 10.1161/01.CIR.0000148780.36121.47; Malkinson AM, 1997, TOXICOLOGY, V123, P53, DOI 10.1016/S0300-483X(97)00108-X; Manning CB, 2002, CANCER RES, V62, P4169; Manning CB, 2002, INT IMMUNOPHARMACOL, V2, P191, DOI 10.1016/S1567-5769(01)00172-2; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; MOSSMAN BT, 1989, NEW ENGL J MED, V320, P1721, DOI 10.1056/NEJM198906293202604; MOSSMAN BT, 1990, AM REV RESPIR DIS, V141, P1266, DOI 10.1164/ajrccm/141.5_Pt_1.1266; Muscella A, 2003, J CELL PHYSIOL, V195, P234, DOI 10.1002/jcp.10242; Ortiz LA, 2001, AM J RESP CRIT CARE, V163, P244, DOI 10.1164/ajrccm.163.1.2002123; Perez-Ramos J, 1999, AM J RESP CRIT CARE, V160, P1274, DOI 10.1164/ajrccm.160.4.9808006; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Robledo RF, 2000, AM J PATHOL, V156, P1307, DOI 10.1016/S0002-9440(10)65001-8; Sabo-Attwood T, 2005, AM J PATHOL, V167, P1243, DOI 10.1016/S0002-9440(10)61212-6; Scapoli L, 2004, ONCOGENE, V23, P805, DOI 10.1038/sj.onc.1207163; Selman M, 2000, AM J PHYSIOL-LUNG C, V279, pL562, DOI 10.1152/ajplung.2000.279.3.L562; Shapiro SD, 1999, THROMB HAEMOSTASIS, V82, P846; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; Shapiro SD, 1999, AM J RESP CELL MOL, V20, P1100, DOI 10.1165/ajrcmb.20.6.f151; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Shukla A, 2005, FASEB J, V19, pA491; Shukla A, 2003, AM J RESP CELL MOL, V29, P198, DOI 10.1165/rcmb.2002-0248OC; Shukla A, 2003, FREE RADICAL BIO MED, V34, P1117, DOI 10.1016/S0891-5849(03)00060-1; Shukla A, 2001, CANCER RES, V61, P1791; Shukla A, 2000, AM J RESP CELL MOL, V23, P182, DOI 10.1165/ajrcmb.23.2.4035; Shum JKS, 2002, J BIOL CHEM, V277, P42830, DOI 10.1074/jbc.M205094200; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Vincenti MP, 2000, METH MOL B, V151, P121, DOI 10.1385/1-59259-046-2:121; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Winkler MK, 2002, AM J PHYSIOL-LUNG C, V283, pL1, DOI 10.1152/ajplung.00489.2001; Woo JH, 2004, ONCOGENE, V23, P1845, DOI 10.1038/sj.onc.1207307; Wylie AG, 1997, TOXICOL APPL PHARM, V147, P143, DOI 10.1006/taap.1997.8276; Yoshisue H, 2004, BIOSCI BIOTECH BIOCH, V68, P2024, DOI 10.1271/bbb.68.2024; Zanella CL, 1996, CANCER RES, V56, P5334; Zanella CL, 1999, AM J PHYSIOL-LUNG C, V277, pL684, DOI 10.1152/ajplung.1999.277.4.L684; Zhang Q, 2005, AM J RESP CELL MOL, V32, P72, DOI 10.1165/rcmb.2004-0198OC; Zuo FR, 2002, P NATL ACAD SCI USA, V99, P6292, DOI 10.1073/pnas.092134099	51	33	33	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					997	+		10.1096/fj.05-4554fje	http://dx.doi.org/10.1096/fj.05-4554fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571779				2022-12-25	WOS:000240157700034
J	Aboulaich, N; Vener, AV; Stralfors, P				Aboulaich, N; Vener, AV; Stralfors, P			Hormonal control of reversible translocation of perilipin B to the plasma membrane in primary human adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SENSITIVE LIPASE; RAT ADIPOCYTES; STIMULATED LIPOLYSIS; LIPID DROPLETS; PHOSPHORYLATION; CAVEOLAE; INSULIN; DOMAINS	In adipocytes, perilipin coats and protects the central lipid droplet, which stores triacylglycerol. Alternative mRNA splicing gives rise to perilipin A and B. Hormones such as catecholamines and insulin regulate triacylglycerol metabolism through reversible serine phosphorylation of perilipin A. It was recently shown that perilipin was also located in triacylglycerol-synthesizing caveolae of the plasma membrane. We now report that perilipin at the plasma membrane of primary human adipocytes was phosphorylated on a cluster of threonine residues ( 299, 301, and 306) within an acidic domain that forms part of the lipid targeting domain. Perilipin B comprised <10% of total perilipin but was the major isoform associated with the plasma membrane of human adipocytes. This association was controlled by insulin and catecholamine: perilipin B was specifically depleted from the plasma membrane in response to the catecholamine isoproterenol, while insulin increased the amount of threonine phosphorylated perilipin at the plasma membrane. The reversible translocation of perilipin B to and from the plasma membrane in response to insulin and isoproterenol, respectively, suggests a specific function for perilipin B to protect newly synthesized triacylglycerol in the plasma membrane.	Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden; Linkoping Univ, Ctr Diabet Res, SE-58185 Linkoping, Sweden	Linkoping University; Linkoping University	Stralfors, P (corresponding author), Linkoping Univ, Dept Cell Biol, SE-58185 Linkoping, Sweden.	peter.stralfors@ibk.liu.se		Stralfors, Peter/0000-0002-1196-1806				Aboulaich N, 2004, BIOCHEM J, V383, P237, DOI 10.1042/BJ20040647; Clifford GM, 1997, BIOCHEM SOC T, V25, pS672, DOI 10.1042/bst025s672; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; MOONEY RA, 1991, BIOCHEM J, V274, P433, DOI 10.1042/bj2740433; OKA Y, 1984, J BIOL CHEM, V259, P8125; Ost A, 2005, J BIOL CHEM, V280, P5, DOI 10.1074/jbc.C400429200; Robenek H, 2005, J BIOL CHEM, V280, P26330, DOI 10.1074/jbc.M413312200; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Sowa G, 2003, P NATL ACAD SCI USA, V100, P6511, DOI 10.1073/pnas.1031672100; STRALFORS P, 1983, J BIOL CHEM, V258, P5146; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Vainonen JP, 2004, BIOCHEM BIOPH RES CO, V320, P480, DOI 10.1016/j.bbrc.2004.05.196; Vener AV, 2001, J BIOL CHEM, V276, P6959, DOI 10.1074/jbc.M009394200; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200	22	31	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11446	11449		10.1074/jbc.C500461200	http://dx.doi.org/10.1074/jbc.C500461200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16527823	hybrid			2022-12-25	WOS:000236988100004
J	Leger, B; Vergani, L; Soraru, G; Hespel, P; Derave, W; Gobelet, C; D'Ascenzio, C; Angelini, C; Russell, AP				Leger, B; Vergani, L; Soraru, G; Hespel, P; Derave, W; Gobelet, C; D'Ascenzio, C; Angelini, C; Russell, AP			Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1	FASEB JOURNAL			English	Article						E3 ligase; neurodegenerative disease	TRANSCRIPTION FACTORS; UBIQUITIN LIGASES; MESSENGER-RNAS; EXPRESSION; INSULIN; ACTIVATION; PATHWAY; KINASE; GROWTH; GENES	The molecular mechanisms influencing muscle atrophy in humans are poorly understood. Atrogin-1 and MuRF1, two ubiquitin E3-ligases, mediate rodent and cell muscle atrophy and are suggested to be regulated by an Akt/Forkhead (FKHR) signaling pathway. Here we investigated the expression of atrogin-1, MuRF1, and the activity of Akt and its catabolic (FKHR and FKHRL1) and anabolic (p70(s6k) and GSK-3 beta) targets in human skeletal muscle atrophy. The muscle atrophy model used was amyotrophic lateral sclerosis (ALS). All measurements were performed in biopsies from 22 ALS patients and 16 healthy controls as well as in G93A ALS mice. ALS patients had a significant increase in atrogin-1 mRNA and protein content, which was associated with a decrease in Akt activity. There was no difference in the mRNA and protein content of FKHR, FKHRL1, p70(s6k), and GSK-3 beta. Similar observations were made in the G93A ALS mice. Human skeletal muscle atrophy, as seen in the ALS model, is associated with an increase in atrogin-1 and a decrease in Akt. The transcriptional regulation of human atrogin-1 may be controlled by an Akt-mediated transcription factor other than FKHR or via another signaling pathway.	Clin Romande Readaptat SuvaCare, CH-1951 Sion, Switzerland; Univ Padua, Dipartimento Sci Neurol, Ist Veneto Med Mol, I-35129 Padua, Italy; Katholieke Univ Leuven, Fac Kinesiol & Rehabil Sci, Res Ctr Exercise & Hlth, B-3001 Heverlee, Belgium	University of Padua; Veneto Institute Molecular Medicine; KU Leuven	Russell, AP (corresponding author), Clin Romande Readaptat SuvaCare, Av Gd Champsec 90, CH-1951 Sion, Switzerland.	aaron.russell@crr-suva.ch	Léger, Bertrand/AAK-4356-2020; Derave, Wim/B-2554-2014; Sorarù, Gianni/AAB-8891-2019; Angelini, Corrado I/J-3655-2019	Derave, Wim/0000-0002-2225-5587; Angelini, Corrado I/0000-0002-9554-8794; Soraru, Gianni/0000-0001-9691-6328; Leger, Bertrand/0000-0003-2782-1442; Hespel, Peter/0000-0003-1283-2229; Russell, Aaron/0000-0002-7323-9501	Telethon [GTF02009] Funding Source: Medline	Telethon(Fondazione Telethon)		Blough E, 1999, BIOTECHNIQUES, V26, P202, DOI 10.2144/99262bm05; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Cartoni R, 2005, J PHYSIOL-LONDON, V567, P349, DOI 10.1113/jphysiol.2005.092031; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Dehoux M, 2004, ENDOCRINOLOGY, V145, P4806, DOI 10.1210/en.2004-0406; Dehoux MJM, 2003, FEBS LETT, V544, P214, DOI 10.1016/S0014-5793(03)00505-2; Derave W, 2003, NEUROBIOL DIS, V13, P264, DOI 10.1016/S0969-9961(03)00041-X; Di Giovanni S, 2004, ANN NEUROL, V55, P195, DOI 10.1002/ana.10811; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; Jones SW, 2004, FASEB J, V18, P1025, DOI 10.1096/fj.03-1228fje; Kumamoto T, 2000, ACTA NEUROPATHOL, V100, P595, DOI 10.1007/s004010000229; Lai KMV, 2004, MOL CELL BIOL, V24, P9295, DOI 10.1128/MCB.24.21.9295-9304.2004; Latres E, 2005, J BIOL CHEM, V280, P2737, DOI 10.1074/jbc.M407517200; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lee SW, 2004, J AM SOC NEPHROL, V15, P1537, DOI 10.1097/01.ASN.0000127211.86206.E1; Li YP, 2005, FASEB J, V19, P362, DOI 10.1096/fj.04-2364com; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; Lynch G S, 2001, Exerc Sport Sci Rev, V29, P141, DOI 10.1097/00003677-200110000-00002; McGee SL, 2003, DIABETES, V52, P926, DOI 10.2337/diabetes.52.4.926; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Nikawa T, 2004, FASEB J, V18, P522, DOI 10.1096/fj.03-0419fje; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; RUSSELL AP, 2005, FASEB J; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; SWASH M, 1999, CLIN FEATURES DIAGNO; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Zinna EM, 2003, CURR OPIN CLIN NUTR, V6, P87, DOI 10.1097/00075197-200301000-00013	41	109	115	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					583	+		10.1096/fj.05-5249fje	http://dx.doi.org/10.1096/fj.05-5249fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16507768				2022-12-25	WOS:000235996000015
J	Yang, G; Wu, LY; Wang, R				Yang, G; Wu, LY; Wang, R			Pro-apoptotic effect of endogenous H2S on human aorta smooth muscle cells	FASEB JOURNAL			English	Article						cystathionine gamma-lyase; proliferation; MAPK; cell cycle protein	CYSTATHIONINE-GAMMA-LYASE; HYDROGEN-SULFIDE; RAT; INHIBITION; EXPRESSION; KINASES; PROLIFERATION; HYPERTENSION; PATHOGENESIS; MODULATION	Cystathionine gamma-lyase (CSE) is a key enzyme in the trans-sulfuration pathway, which uses L-cysteine to produce hydrogen sulfide (H2S). The CSE/H2S system has been shown to play an important role in regulating cellular functions in different systems. In the present study, we overexpressed CSE in human aorta smooth muscle cells (HASMCs) using a recombinant defective adenovirus containing CSE gene (Ad-CSE). Infection of HASMCs with Ad-CSE resulted in a significant increase in the expression of CSE protein and H2S production. Ad-CSE transfection inhibited cell growth and stimulated apoptosis, as evidenced by cell viability assay, Hoechst 33258 staining, TUNEL, and caspase 3 activation. CSE-mediated apoptosis was associated with an increased ERK and p38 MAPK activation, up-regulation of p21(Cip/WAK-1), and down-regulation of cyclin D1 expression. After inhibiting endogenous background CSE gene expression, direct administration of H2S at 100 mu M induced apoptosis of HASMCs. The other two endproducts of CSE-catalyzed enzymatic reaction, ammonium and pyruvate, failed to do so. These results demonstrate that overexpression of CSE stimulates SMC apoptosis due to an increased endogenous production of H2S. Adenovirus-mediated transfer of CSE gene may provide a novel therapeutic approach in treating vascular diseases linked to abnormal cellular proliferation and vascular remodeling.	Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 0W0, Canada	University of Saskatchewan; University of Saskatchewan	Wang, R (corresponding author), Lakehead Univ, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.	rwang@lakeheadu.ca	Wang, Rui/C-7824-2012; Yang, Guangdong/G-4129-2011	Wang, Rui/0000-0003-3825-3620; 				Barber T, 1999, J NUTR, V129, P928, DOI 10.1093/jn/129.5.928; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Deplancke B, 2003, FASEB J, V17, P1310, DOI 10.1096/fj.02-0883fje; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; ERICKSON PF, 1990, BIOCHEM J, V269, P335, DOI 10.1042/bj2690335; Eto K, 2002, J NEUROCHEM, V83, P80, DOI 10.1046/j.1471-4159.2002.01097.x; Geng B, 2004, BIOCHEM BIOPH RES CO, V318, P756, DOI 10.1016/j.bbrc.2004.04.094; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hershenson MB, 1997, CAN J PHYSIOL PHARM, V75, P898, DOI 10.1139/cjpp-75-7-898; Hou YZ, 2004, EUR J PHARMACOL, V499, P85, DOI 10.1016/j.ejphar.2004.07.107; Hui Y, 2003, J INFECTION, V47, P155, DOI 10.1016/S0163-4453(03)00043-4; Ishii I, 2004, BIOCHEM J, V381, P113, DOI 10.1042/BJ20040243; KERY V, 1994, J BIOL CHEM, V269, P25283; Kobayashi T, 2004, BIOL PHARM BULL, V27, P587, DOI 10.1248/bpb.27.587; Mason DP, 1999, CIRC RES, V85, P1179; Mok YYP, 2004, BRIT J PHARMACOL, V143, P881, DOI 10.1038/sj.bjp.0706014; NISHI N, 1994, J BIOL CHEM, V269, P1015; Park WH, 2003, INT J ONCOL, V23, P197; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sun XF, 2004, BIOCHEM PHARMACOL, V67, P147, DOI 10.1016/j.bcp.2003.08.041; Todd DE, 2004, ONCOGENE, V23, P3284, DOI 10.1038/sj.onc.1207467; Ullmannova V, 2003, LEUKEMIA RES, V27, P1115, DOI 10.1016/S0145-2126(03)00103-6; Wang R, 2003, ANTIOXID REDOX SIGN, V5, P493, DOI 10.1089/152308603768295249; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan H, 2004, BIOCHEM BIOPH RES CO, V313, P22, DOI 10.1016/j.bbrc.2003.11.081; Yang GD, 2004, FASEB J, V18, P1782, DOI 10.1096/fj.04-2279fje; Yang GD, 2004, J BIOL CHEM, V279, P49199, DOI 10.1074/jbc.M408997200; Zhang CY, 2003, BIOCHEM BIOPH RES CO, V302, P810, DOI 10.1016/S0006-291X(03)00256-0; Zhao WM, 2003, CAN J PHYSIOL PHARM, V81, P848, DOI 10.1139/Y03-077; Zhao WM, 2002, AM J PHYSIOL-HEART C, V283, pH474, DOI 10.1152/ajpheart.00013.2002; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008; Zhong GZ, 2003, J HYPERTENS, V21, P1879, DOI 10.1097/00004872-200310000-00015	35	263	281	1	35	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					553	+		10.1096/fj.05-4712fje	http://dx.doi.org/10.1096/fj.05-4712fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16507767				2022-12-25	WOS:000235996000014
J	Hirohashi, Y; Wang, Q; Liu, Q; Du, X; Zhang, H; Sato, N; Greene, MI				Hirohashi, Y.; Wang, Q.; Liu, Q.; Du, X.; Zhang, H.; Sato, N.; Greene, M. I.			p78/MCRS1 forms a complex with centrosomal protein Nde1 and is essential for cell viability	ONCOGENE			English	Article						centrosome; cancer; mitosis; spindle; microtubule	GAMMA-TUBULIN; CYTOPLASMIC DYNEIN; TRANSFORMING ACTIVITY; CANCER PROGRESSION; MITOTIC SPINDLE; LIVING CELLS; RING COMPLEX; FHA DOMAIN; DYNAMICS; DEFECTS	The centrosome, an organelle that functions as the major microtubule-organizing center, plays an essential role in the formation of the mitotic spindle and guiding accurate chromosome segregation. Centrosome aberrations are frequently associated with various forms of human cancers and it is thought that defects in this organelle contribute to genomic instability and malignant transformation. We recently identified and characterized a centrosome-localized protein complex that is comprised of Su48 and Nde1. Disruption of the normal function of these proteins leads to abnormal cell division. To extend our understanding of how this protein complex operates, we sought to identify Nde1-interacting molecules by the yeast two-hybrid screening method. Here, we demonstrate that both Nde1 and Su48 can associate with p78/MCRS1, a protein implicated in cancer development. We found that, whereas the majority of p78 localizes to the nucleus as reported in earlier studies, a fraction of the p78 protein can be detected in the centrosome. Moreover, we determined that a region containing the forkhead-associated domain of p78 is involved in association with Nde1 and Su48, as well as in centrosomal localization. We also provide evidence that the association between p78 and Nde1 is regulated by phosphorylation on Nde1. Furthermore, abrogation of the endogenous p78 function by small interfering RNA knockdown causes cell death and a modest delay in mitosis. These results indicate that a subset of the p78 proteins comprises a component of the centrosome and that p78 is essential for cell viability.	Univ Penn, Dept Pathol & Lab Med, Sch Med, Philadelphia, PA 19104 USA; Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido, Japan	University of Pennsylvania; Sapporo Medical University	Greene, MI (corresponding author), Univ Penn, Dept Pathol & Lab Med, Sch Med, 252 John Morgan Bldg,36th Hamilton Walk, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu	Hirohashi, Yoshihiko/AFQ-4227-2022; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049				Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bruni R, 1998, J VIROL, V72, P8525, DOI 10.1128/JVI.72.11.8525-8531.1998; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681; ENGEL E, 1969, NATURE, V223, P152, DOI 10.1038/223152a0; ENGEL E, 1969, J CELL SCI, V5, P93; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2004, NEURON, V44, P279, DOI 10.1016/j.neuron.2004.09.023; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Paluh JL, 2000, MOL BIOL CELL, V11, P1225, DOI 10.1091/mbc.11.4.1225; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 1998, CANCER RES, V58, P3974; Prigozhina NL, 2004, MOL BIOL CELL, V15, P1374, DOI 10.1091/mbc.E03-06-0405; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Sato N, 1999, CLIN CANCER RES, V5, P963; Schnackenberg BJ, 1998, P NATL ACAD SCI USA, V95, P9295, DOI 10.1073/pnas.95.16.9295; Shono M, 2001, LAB INVEST, V81, P945, DOI 10.1038/labinvest.3780306; Song H, 2004, BIOCHEM BIOPH RES CO, V316, P1116, DOI 10.1016/j.bbrc.2004.02.166; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Strome S, 2001, MOL BIOL CELL, V12, P1751, DOI 10.1091/mbc.12.6.1751; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Wang Q, 2004, DNA CELL BIOL, V23, P475, DOI 10.1089/1044549041562276; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	39	29	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4937	4946		10.1038/sj.onc.1209500	http://dx.doi.org/10.1038/sj.onc.1209500			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547491				2022-12-25	WOS:000239687100011
J	Castro, P; Soares, P; Gusmao, L; Seruca, R; Sobrinho-Simoes, M				Castro, P.; Soares, P.; Gusmao, L.; Seruca, R.; Sobrinho-Simoes, M.			H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid	ONCOGENE			English	Article						aneuploidy; RAS mutations; H-RAS polymorphism; H-RAS splicing	SPORADIC COLORECTAL ADENOMAS; GENOMIC INSTABILITY; PROTO-ONCOGENE; DNA ANEUPLOIDY; BRAF MUTATIONS; P21 PROTEIN; CELL-CYCLE; CANCER; CARCINOMA; ACTIVATION	Follicular thyroid tumors are often aneuploid. It was advanced that chromosomal instability is closely associated to RAS mutations, but such association remains unproven. H-RAS can be alternatively spliced in two different proteins, p21 and p19, the former being the active protein. In order to investigate the relationship between RAS mutational status and ploidy in thyroid tumors, we analysed RAS genes in a series of 99 follicular lesions (14 nodular goiters, 70 follicular adenomas and 15 follicular carcinomas), eight thyroid carcinoma cell lines and a control group of 102 blood donors, correlating the presence of RAS mutations with the ploidy of the tumors and evaluating the two spliced forms of H-RAS. Overall, 20% of the follicular tumors harbored RAS mutations and 62% of the patients with follicular tumors (and 51% of blood donors) harbored the H-RA S 81T -> C polymorphism. The presence of RAS mutations was not associated with aneuploidy. The H-RAS polymorphism did not seem to confer a higher propensity for neoplastic transformation as it was also found in hyperplastic lesions, but was strongly associated with aneuploidy (P < 0.0001). The presence of the H-RAS 81T -> C polymorphism was associated with significantly higher amounts of total H-RAS mRNA expression, higher amounts of p21 isoform and a higher fraction of neoplastic cells in S phase. Our results suggest that the H-RAS 81T -> C polymorphism may induce aneuploidy through overexpression of the active p21 isoform of H-RAS.	IPATIMUP, P-4200465 Oporto, Portugal; Fac Med Porto, Dept Pathol, Oporto, Portugal	Universidade do Porto	Sobrinho-Simoes, M (corresponding author), IPATIMUP, Rua Dr Roberto Frias S-N, P-4200465 Oporto, Portugal.	ssimoes@ipatimup.pt	Castro, Patricia/J-8537-2013; Sobrinho-Simões, Manuel/J-8290-2013; Gusmão, Leonor/L-8931-2019; Gusmao, Leonor/B-3122-2013; seruca, raquel/F-8187-2011; Soares, Paula/B-6054-2008	Gusmão, Leonor/0000-0003-0432-6481; Gusmao, Leonor/0000-0003-0432-6481; Soares, Paula/0000-0001-9607-6998; Castro, Patricia/0000-0001-9588-9065; Sobrinho-Simoes, Manuel/0000-0003-1613-1235; Seruca, Raquel/0000-0002-8851-4166				BOS JL, 1989, CANCER RES, V49, P4682; Castro P, 2005, J PATHOL, V206, P305, DOI 10.1002/path.1772; Castro P, 2001, VIRCHOWS ARCH, V438, P336, DOI 10.1007/s004280000354; Codony C, 2001, ONCOGENE, V20, P3683, DOI 10.1038/sj.onc.1204473; COHEN JB, 1993, MOL CELL BIOL, V13, P2666, DOI 10.1128/MCB.13.5.2666; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; CUSICK EL, 1991, BRIT J SURG, V78, P94, DOI 10.1002/bjs.1800780129; DEITCH AD, 1982, J HISTOCHEM CYTOCHEM, V30, P967, DOI 10.1177/30.9.6182188; DeLellis R, 2004, PATHOLOGY GENETICS T; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Esapa CT, 1999, CLIN ENDOCRINOL, V50, P529, DOI 10.1046/j.1365-2265.1999.00704.x; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; Giaretti W, 2004, CELL ONCOL, V26, P301; GIARETTI W, 1995, GASTROENTEROLOGY, V108, P1040, DOI 10.1016/0016-5085(95)90201-5; Giaretti W, 1998, AM J PATHOL, V153, P1201, DOI 10.1016/S0002-9440(10)65664-7; Guil S, 2003, CANCER RES, V63, P5178; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; HARA H, 1994, SURGERY, V116, P1010; HOSTETTER AL, 1988, AM J CLIN PATHOL, V89, P760, DOI 10.1093/ajcp/89.6.760; Huang MY, 1997, ONCOL RES, V9, P611; Illmer T, 2005, CLIN CANCER RES, V11, P3217, DOI 10.1158/1078-0432.CCR-04-2232; JOENSUU H, 1988, AM J CLIN PATHOL, V89, P35, DOI 10.1093/ajcp/89.1.35; JOHANNESSEN JV, 1982, AM J CLIN PATHOL, V77, P20; Johne A, 2003, CANCER EPIDEM BIOMAR, V12, P68; Kimura ET, 2003, CANCER RES, V63, P1454; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; LIWO A, 1994, J PROTEIN CHEM, V13, P237, DOI 10.1007/BF01891982; Mammas IN, 2004, GYNECOL ONCOL, V92, P941, DOI 10.1016/j.ygyno.2003.11.040; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; MONACO R, 1995, J PROTEIN CHEM, V14, P457, DOI 10.1007/BF01888140; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; NOONAN T, 1991, J MED CHEM, V34, P1302, DOI 10.1021/jm00108a010; Pastinen T, 2004, SCIENCE, V306, P647, DOI 10.1126/science.1101659; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; Rosai J, 1993, TUMORS THYROID GLAND; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; SCHELFHOUT LJDM, 1990, INT J CANCER, V45, P16, DOI 10.1002/ijc.2910450105; Schneider S., 2000, ARLEQUIN SOFTWARE PO, V2, P2496; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Sugg SL, 1999, SURGERY, V125, P46, DOI 10.1067/msy.2099.92118; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Wang B, 1997, ANTICANCER RES, V17, P4387	46	25	27	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4620	4627		10.1038/sj.onc.1209491	http://dx.doi.org/10.1038/sj.onc.1209491			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16532025				2022-12-25	WOS:000239457500012
J	Cuilliere-Dartigues, P; El-Bchiri, J; Krimi, A; Buhard, O; Fontanges, P; Flejou, JF; Hamelin, R; Duval, A				Cuilliere-Dartigues, P.; El-Bchiri, J.; Krimi, A.; Buhard, O.; Fontanges, P.; Flejou, J-F; Hamelin, R.; Duval, A.			TCF-4 isoforms absent in TCF-4 mutated MSI-H colorectal cancer cells colocalize with nuclear CtBP and repress TCF-4-mediated transcription	ONCOGENE			English	Article						TCF-4 isoforms; CtBP; corepressor; alternative splicing; MSI-H cancer; Wnt/Wingless signalling	NONSENSE-MEDIATED DECAY; BETA-CATENIN; MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; SEQUENCES; GENE	TCF-4 is the main effector of the Wnt/Wingless signalling pathway. As with other TCF/LEF factors, numerous alternative splicings at its 30 end affect its expression. Such a mechanism leads to the synthesis of numerous TCF-4 isoforms among which some contain binding domains for CtBP, an ubiquitous transcriptional corepressor. Of interest, we described a frequent TCF-4 frameshift mutation in mismatch-repair deficient colorectal cancers (MSI-H cancers) that leads to the selective loss of TCF-4 isoforms with CtBP binding abilities. We provide here data that argue for a partial colocalization of CtBP with TCF-4 isoforms containing CtBP binding domains in cellulo, and for a functional role of CtBP in repressing TCF-4 mediated transcription. We also demonstrate that such a colocalization is not observed in MSI-H colorectal cancer cells that harbour the TCF-4 frameshift mutation, and that CtBP is not able to repress TCF-4-mediated transcription in this context. Taken together, our results strongly suggest that CtBP would play a role in regulating TCF-4 mediated transcription upon its binding with some TCF-4 isoforms encoded by alternatively spliced mRNA. They also suggest a role for TCF-4 frameshift mutation during MSI-H colorectal tumour progression, by regulating the relative proportion of the different TCF-4 isoforms.	INSERM, U762, F-75010 Paris, France; Univ Paris 06, F-75005 Paris, France; Hop Tenon, IFR65, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Duval, A (corresponding author), INSERM, U762, 27 Rue Juliette Dodu, F-75010 Paris, France.	alex.duval@cephb.fr						AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2002, CANCER RES, V62, P2447; Duval A, 2000, CANCER RES, V60, P3872; El-Bchiri J, 2005, HUM MOL GENET, V14, P2435, DOI 10.1093/hmg/ddi245; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jourdan F, 2003, VIRCHOWS ARCH, V443, P115, DOI 10.1007/s00428-003-0833-z; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Ruckert S, 2002, CANCER RES, V62, P3009; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Valenta T, 2003, NUCLEIC ACIDS RES, V31, P2369, DOI 10.1093/nar/gkg346	19	49	50	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4441	4448		10.1038/sj.onc.1209471	http://dx.doi.org/10.1038/sj.onc.1209471			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547505				2022-12-25	WOS:000239326000007
J	Pantic, M; Zimmermann, S; El Daly, H; Opitz, OG; Popp, S; Boukamp, P; Martens, UM				Pantic, M.; Zimmermann, S.; El Daly, H.; Opitz, O. G.; Popp, S.; Boukamp, P.; Martens, U. M.			Telomere dysfunction and loss of p53 cooperate in defective mitotic segregation of chromosomes in cancer cells	ONCOGENE			English	Article						telomere dysfunction; Q-FISH; telomerase inhibition; chromosomal instability; hyperdiploidy	SPINDLE CHECKPOINT; INSTABILITY; ANEUPLOIDY; INACTIVATION; PROGRESSION; CARCINOMA; DAMAGE; REQUIREMENT; CENTROSOME; MUTATIONS	Aneuploidy is a fundamental principle of many cancer cells and is mostly related to defects in mitotic segregation of chromosomes. Many solid tumors as well as some preneoplastic lesions have been shown to contain polyploid chromosome numbers. The exact mechanisms behind whole-genome duplications are not known but have been linked to compromised mitotic checkpoint genes. We now report that the telomere checkpoint plays a key role for polyploidy in colon cancer cells. Telomerase suppression by a dominant-negative mutant of hTERT and consecutive telomere dysfunction in wild-type HCT116 colon cancer cells resulted in only minor stable chromosomal alterations. However, higher ploidy levels with up to 350 chromosomes were found when the cell-cycle checkpoint proteins p53 or p21 were absent. These findings indicate that telomere dysfunction in the absence of cell-cycle control may explain the high frequency of alterations in chromosome numbers found in many solid tumors.	Univ Freiburg, Med Ctr, Dept Hematol Oncol, D-79106 Freiburg, Germany; Univ Freiburg, Med Ctr, Dept Gastroenterol, Freiburg, Germany; German Canc Res Ctr, D-6900 Heidelberg, Germany	University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ)	Martens, UM (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	uwe.martens@uniklinik-freiburg.de						Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; DELANGE T, 1995, TELOMERES, P265; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; El-Daly H, 2005, BLOOD, V105, P1742, DOI 10.1182/blood-2003-12-4322; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Fernandez-Capetillo O, 2004, NAT GENET, V36, P672, DOI 10.1038/ng0704-672; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; Fukasawa K, 2002, ONCOGENE, V21, P6140, DOI 10.1038/sj.onc.1205771; Gisselsson D, 2005, SEMIN CANCER BIOL, V15, P13, DOI 10.1016/j.semcancer.2004.09.002; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Gordon KE, 2003, CANCER RES, V63, P458; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Hansemann D., 1890, ARCH PATHOL ANAT PH, V119, P299, DOI DOI 10.1007/BF01882039; Hede K, 2005, J NATL CANCER I, V97, P87, DOI 10.1093/jnci/97.2.87; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Pantic M, 2005, INT J ONCOL, V26, P1227; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Shichiri M, 2002, CANCER RES, V62, P13; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Zimmermann S, 2004, STEM CELLS, V22, P741, DOI 10.1634/stemcells.22-5-741	40	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4413	4420		10.1038/sj.onc.1209486	http://dx.doi.org/10.1038/sj.onc.1209486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547498				2022-12-25	WOS:000239326000004
J	Mazurkiewicz, J; Kepert, JF; Rippe, K				Mazurkiewicz, Jacek; Kepert, J. Felix; Rippe, Karsten			On the mechanism of nucleosome assembly by histone chaperone NAP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED HISTONES; DNA-REPLICATION; CORE PARTICLE; H2A-H2B DIMERS; H2A/H2B DIMER; IN-VITRO; CHROMATIN; PROTEIN; H2A.Z; VARIANT	The process of mononucleosome assembly mediated by histone chaperone NAP1 was investigated using DNA fragments 146 and 207 bp in length containing the Lytechinus variegatus 5 S rDNA nucleosome positioning sequence. A quantitative description was derived using gel electrophoresis and fluorescent anisotropy data. First, NAP1-bound H3.H4 was released forming a DNA-histone tetramer complex with a time constant of k(1) = (2.5 +/- 0.7) . 10(M)(4)(-1) s(-1). The tetrasome was converted quickly (k(2) = (4.1 +/- 3.5) . 10(5) (-1)(M) s(-1)), by the addition of a single H2A.H2B dimer, into a "hexasome," i.e. a nucleosome lacking one H2A.H2B dimer. From this intermediate a nucleosome was formed by the addition of a second H2A.H2B dimer with an average rate constant k(3) = (6.6 +/- 1.4) . 10(3) M-1 s(-1). For the back-reaction, significant differences were observed between the 146- and 207-bp DNA upon substitution of the canonical H2A histone with H2A.Z. The distinct nucleosome/ hexasome ratios were reflected in the corresponding equilibrium dissociation constants and revealed some differences in nucleosome stability. In a fourth reaction, NAP1 mediated the binding of linker histone H1 to the nucleosome, completing the chromatosome structure with k(4) = (7.7 +/- 3.7) . 10(M)(3)(-1) s(-1). The activity of the chromatin remodeling complex ACF did not increase the kinetics of the mononucleosome assembly process.	Heidelberg Univ, Kirchhoff Inst Phys, Mol Biophys Grp, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Rippe, K (corresponding author), Heidelberg Univ, Kirchhoff Inst Phys, Mol Biophys Grp, Neuenheimer Feld 227, D-69120 Heidelberg, Germany.	Karsten.Rippe@kip.uni-heidelberg.de	Rippe, Karsten/A-3562-2012	Rippe, Karsten/0000-0001-9951-9395				Abbott DW, 2001, J BIOL CHEM, V276, P41945, DOI 10.1074/jbc.M108217200; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; Annunziato AT, 2005, J BIOL CHEM, V280, P12065, DOI 10.1074/jbc.R400039200; ANNUNZIATO AT, 1984, NUCLEIC ACIDS RES, V12, P6179, DOI 10.1093/nar/12.15.6179; Arnan C, 2003, J BIOL CHEM, V278, P31319, DOI 10.1074/jbc.M305560200; BAXEVANIS AD, 1991, BIOCHEMISTRY-US, V30, P8817, DOI 10.1021/bi00100a013; BONNER WM, 1975, J CELL BIOL, V64, P431, DOI 10.1083/jcb.64.2.431; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CREMISI C, 1980, BIOCHEM BIOPH RES CO, V92, P1117, DOI 10.1016/0006-291X(80)90402-7; DABAN JR, 1982, J MOL BIOL, V156, P749, DOI 10.1016/0022-2836(82)90140-1; DABAN JR, 1982, J MOL BIOL, V156, P771, DOI 10.1016/0022-2836(82)90141-3; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; Dryhurst D, 2004, BIOCHEM CELL BIOL, V82, P490, DOI 10.1139/O04-043; English CM, 2005, BIOCHEMISTRY-US, V44, P13673, DOI 10.1021/bi051333h; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Farris SD, 2005, J BIOL CHEM, V280, P25298, DOI 10.1074/jbc.M501784200; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; Haushalter KA, 2003, NAT REV MOL CELL BIO, V4, P613, DOI 10.1038/nrm1177; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JACKSON V, 1988, BIOCHEMISTRY-US, V27, P2109, DOI 10.1021/bi00406a044; JACKSON V, 1987, BIOCHEMISTRY-US, V26, P2315, DOI 10.1021/bi00382a037; JACKSON V, 1985, BIOCHEMISTRY-US, V24, P6930, DOI 10.1021/bi00345a027; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; JORCANO JL, 1979, BIOCHEMISTRY-US, V18, P768, DOI 10.1021/bi00572a005; Kepert JF, 2005, J BIOL CHEM, V280, P34063, DOI 10.1074/jbc.M507322200; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; Krude T, 1999, EUR J BIOCHEM, V263, P1, DOI 10.1046/j.1432-1327.1999.00508.x; Ladoux B, 2000, P NATL ACAD SCI USA, V97, P14251, DOI 10.1073/pnas.250471597; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P308; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; Levchenko V, 2005, BIOCHEMISTRY-US, V44, P5357, DOI 10.1021/bi047786o; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; McBryant SJ, 2003, J BIOL CHEM, V278, P44574, DOI 10.1074/jbc.M305636200; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Nakagawa T, 2001, J BIOL CHEM, V276, P27384, DOI 10.1074/jbc.M101331200; Nightingale K, 1996, EMBO J, V15, P548, DOI 10.1002/j.1460-2075.1996.tb00387.x; Okuwaki M, 2005, MOL CELL BIOL, V25, P10639, DOI 10.1128/MCB.25.23.10639-10651.2005; Park YJ, 2006, P NATL ACAD SCI USA, V103, P1248, DOI 10.1073/pnas.0508002103; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; PARK YJ, 2004, J BIOL CHEM; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; Pennings S, 1997, METHODS, V12, P20, DOI 10.1006/meth.1997.0443; Pennings S, 1999, METHOD ENZYMOL, V304, P298; Prado A, 2004, BIOCHEM CELL BIOL, V82, P437, DOI 10.1139/O04-042; Rangasamy D, 2004, NAT STRUCT MOL BIOL, V11, P650, DOI 10.1038/nsmb786; Rangasamy D, 2003, EMBO J, V22, P1599, DOI 10.1093/emboj/cdg160; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; RICHMOND TJ, 1988, J MOL BIOL, V199, P161, DOI 10.1016/0022-2836(88)90386-5; RUIZCARRILLO A, 1979, P NATL ACAD SCI USA, V76, P3284, DOI 10.1073/pnas.76.7.3284; SENSHU T, 1978, J BIOCHEM-TOKYO, V84, P985, DOI 10.1093/oxfordjournals.jbchem.a132213; SHERWOOD PW, 1991, GENETICS, V128, P729; Shintomi K, 2005, P NATL ACAD SCI USA, V102, P8210, DOI 10.1073/pnas.0500822102; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; Strohner R, 2005, NAT STRUCT MOL BIOL, V12, P683, DOI 10.1038/nsmb966; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; Thiriet C, 2005, GENE DEV, V19, P677, DOI 10.1101/gad.1265205; Toth KF, 2005, J BIOL CHEM, V280, P15690, DOI 10.1074/jbc.M413329200; Toth KF, 2004, J CELL SCI, V117, P4277, DOI 10.1242/jcs.01293; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; VANHOLDE KE, 1989, CHROMATIN, P241; Verreault A, 2000, GENE DEV, V14, P1430; Vogel SK, 2002, NUCLEIC ACIDS RES, V30, P4094, DOI 10.1093/nar/gkf519; Wagner G, 2005, BIOPHYS J, V89, P3647, DOI 10.1529/biophysj.105.062786; Weidemann T, 2003, J MOL BIOL, V334, P229, DOI 10.1016/j.jmb.2003.08.063; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WILHELM FX, 1978, NUCLEIC ACIDS RES, V5, P505, DOI 10.1093/nar/5.2.505; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; Yodh JG, 2002, BIOCHEMISTRY-US, V41, P3565, DOI 10.1021/bi011612e; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9; Zlatanova J, 1999, CRIT REV EUKAR GENE, V9, P245, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.90	89	78	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16462	16472		10.1074/jbc.M511619200	http://dx.doi.org/10.1074/jbc.M511619200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16531623	Green Submitted, hybrid			2022-12-25	WOS:000238165700036
J	Wajapeyee, N; Britto, R; Ravishankar, HM; Somasundaram, K				Wajapeyee, Narendra; Britto, Ramona; Ravishankar, Halasahalli M.; Somasundaram, Kumaravel			Apoptosis induction by activator protein 2 alpha involves transcriptional repression of Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; FACTOR AP-2; DNA-BINDING; SIGNAL-TRANSDUCTION; PHOSPHATASE 2A; HUMAN-MELANOMA; UP-REGULATION; CYCLE ARREST; TUMOR-GROWTH; KINASE-C	Activator protein 2 alpha ( AP-2 alpha) induces cytotoxicity by inducing cell cycle arrest and apoptosis. In this study we investigated the mechanism of apoptosis induction by AP-2 alpha. We found that AP-2 alpha induced apoptosis efficiently in cells treated with benzyloxycarbonyl-IETD-fluoromethyl ketone or FADD-silenced cells but failed to do so in benzyloxycarbonyl-LEHD-fluoromethyl ketone-treated or apoptosis protease activation factor-1 ( Apaf1)-silenced cells, suggesting the central role of mitochondria in AP-2 alpha-induced apoptosis. In good correlation, cells overexpressing AP-2 alpha showed a reduction in mitochondrial membrane potential ( Delta Psi(m)), cytochrome c and Smac/DIABLO release into cytosol, and Bax translocation into mitochondria. We found that the pro-apoptotic protein Bax is important for AP-2 alpha-induced apoptosis as adenovirus AP2 failed to induce apoptosis in HCT116 Bax(-/-) cells. However, we found the IAP ( inhibitor of apoptosis) inhibitor Smac/DIABLO may have a limited role in AP-2 alpha-induced apoptosis as we found the IAP member Survivin down-regulated by AP-2 alpha. Although the total Bax level remains unaltered, we found a time-dependent increase in the activated form of Bax in adenovirus AP2-infected cells. In addition, we show that AP-2 alpha transcriptionally represses Bcl-2 by binding to its promoter both in vitro and in vivo and that this is essential for AP-2 alpha-induced apoptosis as ectopic expression of Bcl-2 efficiently inhibited apoptosis induced by AP-2 alpha. Furthermore, we show that chemotherapy-induced endogenous AP-2 alpha down-regulates Bcl-2 and induces apoptosis in an AP-2 alpha-dependent manner. Moreover, we demonstrate that inhibition of okadaic acid or staurosporine-sensitive pathways in AP-2 alpha overexpressing breast cancer cells resulted in AP-2 alpha-dependent apoptosis induction. These results suggest that AP-2 alpha induces apoptosis by down-regulating Bcl-2 and utilizing a bax/cytochrome c/Apaf1/caspase 9-dependent mitochondrial pathway.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in	Wajapeyee, Narendra/F-3011-2012	Britto, Ramona/0000-0003-1011-5410				Anttila MA, 2000, BRIT J CANCER, V82, P1974; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burlacu A, 2003, J CELL MOL MED, V7, P249, DOI 10.1111/j.1582-4934.2003.tb00225.x; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2; FORBES IJ, 1992, EXP CELL RES, V198, P367, DOI 10.1016/0014-4827(92)90393-M; Garcia MA, 2000, J MOL BIOL, V301, P807, DOI 10.1006/jmbi.2000.4019; Garcia-Quesada JC, 1999, J VINYL ADDIT TECHN, V5, P31, DOI 10.1002/vnl.10303; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Heimberger AB, 2005, CLIN CANCER RES, V11, P267; HIGLEREVERSHEIM K, 2000, GENE, V260, P1; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li M, 2006, INT J CANCER, V118, P802, DOI 10.1002/ijc.21426; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lu B, 2004, CANCER RES, V64, P2840, DOI 10.1158/0008-5472.CAN-03-3547; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MacLachlan Timothy K, 2003, Methods Mol Biol, V223, P129; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Mohibullah N, 1999, NUCLEIC ACIDS RES, V27, P2760, DOI 10.1093/nar/27.13.2760; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; Piao Z, 2001, GENE CHROMOSOME CANC, V30, P113, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1069>3.3.CO;2-Y; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Somasundaram K, 2005, ONCOGENE, V24, P7073, DOI 10.1038/sj.onc.1208865; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Wajapeyee N, 2005, CANCER RES, V65, P8628, DOI 10.1158/0008-5472.CAN-05-1059; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Wankhade S, 2000, J BIOL CHEM, V275, P29701, DOI 10.1074/jbc.M000931200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Yamaguchi H, 2002, CANCER RES, V62, P466; Yang XH, 2001, CANCER RES, V61, P348; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	55	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16207	16219		10.1074/jbc.M600539200	http://dx.doi.org/10.1074/jbc.M600539200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16533807	hybrid			2022-12-25	WOS:000238165700006
J	Leszczyniecka, M; Bhatia, U; Cueto, M; Nirmala, NR; Towbin, H; Vattay, A; Wang, B; Zabludoff, S; Phillips, PE				Leszczyniecka, M; Bhatia, U; Cueto, M; Nirmala, NR; Towbin, H; Vattay, A; Wang, B; Zabludoff, S; Phillips, PE			MAP1D, a novel methionine aminopeptidase family member is overexpressed in colon cancer	ONCOGENE			English	Article						methionine aminopeptidase; MAP1D; colon cancer; shRNA	EUKARYOTIC PEPTIDE DEFORMYLASES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CELL-GROWTH; PROTEIN; IDENTIFICATION; UNIVERSALITY; EXPRESSION; INITIATION; EXCISION	N-terminal methionine removal is an important cellular process required for proper biological activity, subcellular localization, and eventual degradation of many proteins. The enzymes that catalyze this reaction are called Methionine Aminopeptidases (MAPs). To date, only two MAP family members, MAP1A and MAP2, have been well characterized and studied in mammals. In our studies, we have cloned a full length MAP1D gene. Expression and purification of full length recombinant protein shows that the sequence encodes an enzyme with MAP activity. MAP1D is overexpressed in colon cancer cell lines and in colon tumors as compared to matched normal tissue samples. Downregulation of MAP1D expression by shRNA in HCT-116 colon carcinoma cells reduces anchorage-independant growth in soft agar. These data suggest that MAP1D is a potentially oncogenic, novel member of the MAP gene family that may play an important role in colon tumorigenesis.	Novartis Inst Biomed Res, Cambridge, MA 02139 USA; Novartis Pharma AG, Basel, Switzerland	Novartis; Novartis	Leszczyniecka, M (corresponding author), Novartis Inst Biomed Res, Cambridge, MA 02139 USA.	magdalena.leszczyniecka@novartis.com		Nirmala, Nanguneri/0000-0003-0267-9793				Addlagatta A, 2005, BIOCHEMISTRY-US, V44, P7166, DOI 10.1021/bi0501176; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; Bradshaw RA, 2002, ESSAYS BIOCHEM, V38, P65, DOI 10.1042/bse0380065; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; CHANG SYP, 1989, J BACTERIOL, V171, P4071, DOI 10.1128/jb.171.7.4071-4072.1989; CHANG YH, 1990, J BIOL CHEM, V265, P19892; Chen SP, 2002, ARCH BIOCHEM BIOPHYS, V398, P87, DOI 10.1006/abbi.2001.2675; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cutforth T, 1999, MECH DEVELOP, V82, P23, DOI 10.1016/S0925-4773(99)00006-4; Endo H, 2002, J BIOL CHEM, V277, P26396, DOI 10.1074/jbc.M202244200; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; Garrabrant Thomas, 2004, Angiogenesis, V7, P91, DOI 10.1007/s10456-004-6089-7; Giglione C, 2003, EMBO J, V22, P13, DOI 10.1093/emboj/cdg007; Giglione C, 2001, TRENDS PLANT SCI, V6, P566, DOI 10.1016/S1360-1385(01)02151-3; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Kanno T, 2002, LAB INVEST, V82, P893, DOI 10.1097/01.LAB.0000020419.25365.C4; Kinder FR, 2001, J MED CHEM, V44, P3692; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; MEINNEL T, 1993, BIOCHIMIE, V75, P1061, DOI 10.1016/0300-9084(93)90005-D; MILLER CG, 1987, P NATL ACAD SCI USA, V84, P2718, DOI 10.1073/pnas.84.9.2718; Serero A, 2003, J BIOL CHEM, V278, P52953, DOI 10.1074/jbc.M309770200; Serero A, 2001, J MOL BIOL, V314, P695, DOI 10.1006/jmbi.2001.5175; SING N, 1997, P NATL ACAD SCI USA, V94, P6099; Towbin H, 2003, J BIOL CHEM, V278, P52964, DOI 10.1074/jbc.M309039200; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142	30	21	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2006	25	24					3471	3478		10.1038/sj.onc.1209383	http://dx.doi.org/10.1038/sj.onc.1209383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16568094				2022-12-25	WOS:000238448100012
J	Song, JH; Waataja, JJ; Martemyanov, KA				Song, Joseph H.; Waataja, Jonathan J.; Martemyanov, Kirill A.			Subcellular targeting of RGS9-2 is controlled by multiple molecular determinants on its membrane anchor, R7BP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN BETA-SUBUNIT; GTPASE-ACTIVATING PROTEINS; RAT-BRAIN; NUCLEAR-LOCALIZATION; COUPLED RECEPTORS; POLYBASIC REGION; PLASMA-MEMBRANE; ALPHA-SUBUNITS; DEP DOMAIN; FAMILY	RGS9-2, a member of the R7 regulators of G protein signaling (RGS) protein family of neuronal RGS, is a critical regulator of G protein signaling. In striatal neurons, RGS9-2 is tightly associated with a novel palmitoylated protein, R7BP (R7 family binding protein). Here we report that R7BP acts to target the localization of RGS9-2 to the plasma membrane. Examination of the subcellular distribution in native striatal neurons revealed that both R7BP and RGS9-2 are almost entirely associated with the neuronal membranes. In addition to the plasma membrane, a large portion of RGS9-2 was found in the neuronal specializations, the postsynaptic densities, where it forms complexes with R7BP and its constitutive partner G beta 5. Using site-directed mutagenesis we found that the molecular determinants that specify the subcellular targeting of RGS9-2(.)G beta 5(.)R7BP complex are contained within the 21 C-terminal amino acids of R7BP. This function of the C terminus was found to require the synergistic contributions of its two distinct elements, a polybasic motif and palmitoylated cysteines, which when combined are sufficient for directing the intracellular localization of the constituent protein. In differentiated neurons, the C-terminal targeting motif of R7BP was found to be essential for mediating its postsynaptic localization. In addition to the plasma membrane targeting elements, we identified two functional nuclear localization sequences that can mediate the import of R7BP into the nucleus upon depalmitoylation. These findings provide a mechanism for the subcellular targeting of RGS9-2 in neurons.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Grad Program Neurosci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Martemyanov, KA (corresponding author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	martemyanov@umn.edu						Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; Bouhamdan M, 2004, BBA-MOL CELL RES, V1691, P141, DOI 10.1016/j.bbamcr.2004.01.005; Burchett SA, 2005, NEUROMOL MED, V7, P101, DOI 10.1385/NMM:7:1-2:101; Burchett SA, 2000, J NEUROCHEM, V75, P1335, DOI 10.1046/j.1471-4159.2000.0751335.x; Cabrera-Vera TM, 2004, P NATL ACAD SCI USA, V101, P16339, DOI 10.1073/pnas.0407416101; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; Chen CK, 2003, P NATL ACAD SCI USA, V100, P6604, DOI 10.1073/pnas.0631825100; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Drenan RM, 2005, J CELL BIOL, V169, P623, DOI 10.1083/jcb.200502007; Duvernay MT, 2005, CELL SIGNAL, V17, P1457, DOI 10.1016/j.cellsig.2005.05.020; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Garzon J, 2005, NEUROPHARMACOLOGY, V48, P853, DOI 10.1016/j.neuropharm.2005.01.004; Gold SJ, 1997, J NEUROSCI, V17, P8024; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hu G, 2003, J BIOL CHEM, V278, P14550, DOI 10.1074/jbc.M212046200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Jones MB, 2004, MOL INTERV, V4, P200, DOI 10.1124/mi.4.4.4; Keresztes G, 2004, J BIOL CHEM, V279, P1581, DOI 10.1074/jbc.C300456200; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kovoor A, 2005, J NEUROSCI, V25, P2157, DOI 10.1523/JNEUROSCI.2840-04.2005; Kreienkamp HJ, 2002, CURR OPIN PHARMACOL, V2, P581, DOI 10.1016/S1471-4892(02)00203-5; Kurachi Y, 2004, J PHYSIOL-LONDON, V554, P285, DOI 10.1113/jphysiol.2003.048439; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Martemyanov KA, 2005, J BIOL CHEM, V280, P5133, DOI 10.1074/jbc.C400596200; Martemyanov KA, 2003, J NEUROSCI, V23, P10175; MCGEE R, 1980, MOL CELL BIOCHEM, V33, P121; Nishiguchi KM, 2004, NATURE, V427, P75, DOI 10.1038/nature02170; Rahman Z, 2003, NEURON, V38, P941, DOI 10.1016/S0896-6273(03)00321-0; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Resh MD, 2004, SUB CELL BIOCHEM, V37, P217; Silvius JR, 2002, J MEMBRANE BIOL, V190, P83, DOI 10.1007/s00232-002-1026-4; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Tekumalla PK, 2001, BIOL PSYCHIAT, V50, P813, DOI 10.1016/S0006-3223(01)01234-3; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6; Zachariou V, 2003, P NATL ACAD SCI USA, V100, P13656, DOI 10.1073/pnas.2232594100	44	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15361	15369		10.1074/jbc.M600749200	http://dx.doi.org/10.1074/jbc.M600749200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574655	hybrid			2022-12-25	WOS:000237922200041
J	Boll, R; Hofmann, C; Heitmann, B; Hauser, G; Glaser, S; Koslowski, T; Friedrich, T; Bechthold, A				Boll, Raija; Hofmann, Carsten; Heitmann, Bjoern; Hauser, Gerd; Glaser, Steffen; Koslowski, Thorsten; Friedrich, Thorsten; Bechthold, Andreas			The active conformation of avilamycin A is conferred by AviX12, a radical AdoMet enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							23S RIBOSOMAL-RNA; ESCHERICHIA-COLI; H-1-NMR SPECTRA; BIOSYNTHESIS; STREPTOMYCES; EVERNIMICIN; SUBUNIT; SPECTROSCOPY; ANTIBIOTICS; EUREKANATE	The antibiotic avilamycin A is produced by Streptomyces virido-chromogenes Tu57. Avilamycin belongs to the family of orthosomycins with a linear heptasaccharide chain linked to a terminal dichloroisoeverninic acid as aglycone. The gene cluster for avilamycin biosynthesis contains 54 open reading frames. Inactivation of one of these genes, namely aviX12, led to the formation of a novel avilamycin derivative named gavibamycin N1. The structure of the new metabolite was confirmed by mass spectrometry ( MS) and NMR analysis. It harbors glucose as a component of the heptasaccharide chain instead of a mannose moiety in avilamycin A. Antibacterial activity tests against a spectrum of Gram-positive organisms showed that the new derivative possesses drastically decreased biological activity in comparison to avilamycin A. Thus, AviX12 seems to be implicated in converting avilamycin to its bioactive conformation by catalyzing an unusual epimerization reaction. Sequence comparisons grouped AviX12 in the radical S-adenosylmethionine protein family. AviX12 engineered with a His tag was overexpressed in Escherichia coli and purified by affinity chromatography. The iron sulfur cluster [Fe-S] present in radical AdoMet enzymes was detected in purified AviX12 by means of electron paramagnetic resonance spectroscopy.	Univ Freiburg, Inst Pharmazeut Wissensch Pharmazeut Biol & Biote, D-79104 Freiburg, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Freiburg, Inst Phys Chem, D-79104 Freiburg, Germany; Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany	University of Freiburg; Technical University of Munich; University of Freiburg; University of Freiburg	Bechthold, A (corresponding author), Univ Freiburg, Inst Pharmazeut Wissensch Pharmazeut Biol & Biote, Stefan Meier Str 19, D-79104 Freiburg, Germany.	andreas.bechthold@pharmazie.uni-freiburg.de	Bechthold, Andreas/P-4199-2019; Glaser, Steffen J/B-7335-2009	Glaser, Steffen J/0000-0003-4099-3177; Heitmann, Berit Lilienthal/0000-0002-6809-4504				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Belova L, 2001, P NATL ACAD SCI USA, V98, P3726, DOI 10.1073/pnas.071527498; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEWIT CJ, 1992, J AM CHEM SOC, V114, P10035, DOI 10.1021/ja00051a041; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; Hoffmeister D, 2001, CHEM BIOL, V8, P557, DOI 10.1016/S1074-5521(01)00039-4; Hofmann C, 2005, CHEM BIOL, V12, P1137, DOI 10.1016/j.chembiol.2005.08.016; Hopwood D. A., 1985, GENETIC MANIPULATION; Kofoed CB, 2002, ANTIMICROB AGENTS CH, V46, P3339, DOI 10.1128/AAC.46.11.3339-3342.2002; Liu A, 2000, J BIOL CHEM, V275, P12367, DOI 10.1074/jbc.275.17.12367; MACNEIL DJ, 1992, GENE, V111, P61, DOI 10.1016/0378-1119(92)90603-M; McNicholas PM, 2000, ANTIMICROB AGENTS CH, V44, P1121, DOI 10.1128/AAC.44.5.1121-1126.2000; McNicholas PM, 2001, ANTIMICROB AGENTS CH, V45, P79, DOI 10.1128/AAC.45.1.79-83.2001; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; Pelter S, 1997, J BIOTECHNOL, V56, P115, DOI 10.1016/S0168-1656(97)00082-5; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; THOMPSON MA, 1994, J PHYS CHEM-US, V98, P10465, DOI 10.1021/j100092a015; THOMPSON MA, 1991, J AM CHEM SOC, V113, P8210, DOI 10.1021/ja00022a003; Treede I, 2005, APPL ENVIRON MICROB, V71, P400, DOI 10.1128/AEM.71.1.400-406.2005; Treede I, 2003, MOL MICROBIOL, V49, P309, DOI 10.1046/j.1365-2958.2003.03558.x; Weitnauer G, 2004, CHEM BIOL, V11, P1403, DOI 10.1016/j.chembiol.2004.08.016; Weitnauer G, 2001, CHEM BIOL, V8, P569, DOI 10.1016/S1074-5521(01)00040-0; WRIGHT DE, 1979, TETRAHEDRON, V35, P1207, DOI 10.1016/0040-4020(79)80046-0; Wu WM, 2000, BIOCHEMISTRY-US, V39, P9561, DOI 10.1021/bi000658p	30	23	26	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14756	14763		10.1074/jbc.M601508200	http://dx.doi.org/10.1074/jbc.M601508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16537546	Green Published, hybrid			2022-12-25	WOS:000237671300029
J	Dittmer, A; Vetter, M; Schunke, D; Span, PN; Sweep, F; Thomssen, C; Dittmer, J				Dittmer, Angela; Vetter, Martina; Schunke, Dario; Span, Paul N.; Sweep, Fred; Thomssen, Christoph; Dittmer, Jurgen			Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND DEVELOPMENT; PTH-RELATED PROTEIN; BONE METASTASES; NUCLEAR-LOCALIZATION; INTRACRINE PATHWAY; CARCINOMA INVASION; IMPORTIN BETA; SMOOTH-MUSCLE; EXPRESSION; RECEPTOR	The effect of endogenous parathyroid hormone-related protein (PTHrP) on gene expression in breast cancer cells was studied. We suppressed PTHrP expression in MDA-MB-231 cells by RNA interference and analyzed changes in gene expression by microarray analysis. More than 200 genes showed altered expression in response to a PTHrP-specific small interfering (si) RNA (siPTHrP). Cell cycle-regulating gene CDC2 and genes (CDC25B and Tome-1) that control CDC2 activity showed increased expression in the presence of siPTHrP. CDC2 activity was also found to be higher in siPTHrP-treated cells. Studies with PTHrP peptides 1-34 and 67-86, forskolin, and a PTH1 receptor (PTH1R)-specific siRNA showed that PTHrP regulates CDC2 and CDC25B, at least in part, via PTH1R in a cAMP-independent manner. Other siPTHrP-responsive genes included integrin alpha 6 (ITGA6), KISS-1, and PAI-1. When combined, siRNAs against ITGA6, PAI-1, and KISS-1 could mimic the negative effect of siPTHrP on migration, whereas siKISS-1 and siPTHrP similarly reduced the proliferative activity of the cells. Comparative expression analyses with 50 primary breast carcinomas revealed that the RNA level of ITGA6 correlates with that of PTHrP, and higher CDC2 and CDC25B values are found at low PTHrP expression. Our data suggest that PTHrP has a profound effect on gene expression in breast cancer cells and, as a consequence, contributes to the regulation of important cellular activities, such as migration and proliferation.	Univ Halle, Klin Gynakol, D-06120 Halle, Germany; Radboud Univ, Nijmegen Med Ctr, Dept Chem Endocrinol, NL-6500 HB Nijmegen, Netherlands	Martin Luther University Halle Wittenberg; Radboud University Nijmegen	Dittmer, J (corresponding author), Univ Halle, Klin Gynakol, Ernst Grube Str 40, D-06120 Halle, Germany.	juergen.dittmer@medizin.uni-halle.de	Dittmer, Juergen/G-1160-2011; Sweep, C.G.J./H-8096-2014; Span, Paul/G-4710-2012; Thomssen, Christoph/ABC-3102-2021; Span, Paul N./A-3143-2009	Sweep, C.G.J./0000-0003-1103-3070; Span, Paul/0000-0002-1930-6638; 				Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756-3282(03)00086-3; Carlier MF, 2003, BIOESSAYS, V25, P336, DOI 10.1002/bies.10257; Cataisson C, 2000, J BONE MINER RES, V15, P2129, DOI 10.1359/jbmr.2000.15.11.2129; Cazales M, 2005, CELL CYCLE, V4, P1233, DOI 10.4161/cc.4.9.1964; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Conlan LA, 2002, FEBS LETT, V527, P71, DOI 10.1016/S0014-5793(02)03164-2; de Witte JH, 1999, BRIT J CANCER, V79, P1190, DOI 10.1038/sj.bjc.6690191; DEPAPP AE, 1993, TRENDS ENDOCRIN MET, V4, P181, DOI 10.1016/1043-2760(93)90114-T; DIEFENBACHJAGGER H, 1995, EUR J BIOCHEM, V229, P91, DOI 10.1111/j.1432-1033.1995.0091l.x; Ditmer LS, 1996, ENDOCRINOLOGY, V137, P1608, DOI 10.1210/en.137.5.1608; DITTMER A, 2006, IN PRESS ELECTROPHOR; Dittmer J., 2004, GENE THER MOL BIOL, V8, P451; Doree M, 2002, J CELL SCI, V115, P2461; Falzon M, 2000, ENDOCRINOLOGY, V141, P1882, DOI 10.1210/en.141.5.1882; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Fiaschi-Taesch N, 2004, CIRCULATION, V110, P177, DOI 10.1161/01.CIR.0000134483.30849.B7; FRIEDRICHS K, 1995, CANCER RES, V55, P901; Givant-Horwitz V, 2004, CANCER RES, V64, P3572, DOI 10.1158/0008-5472.CAN-03-3424; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Guerra L, 2005, J BIOL CHEM, V280, P40925, DOI 10.1074/jbc.M505103200; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Guise TA, 1997, CANCER-AM CANCER SOC, V80, P1572, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.3.CO;2-D; Han SJ, 2006, CELL CYCLE, V5, P227, DOI 10.4161/cc.5.3.2395; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; Harbeck Nadia, 2002, Clin Breast Cancer, V3, P196, DOI 10.3816/CBC.2002.n.023; HASTINGS RH, 2003, AM J PHYSIOL, V285, P61312; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Henderson MA, 2001, JNCI-J NATL CANCER I, V93, P234, DOI 10.1093/jnci/93.3.234; Hoey RP, 2003, BRIT J CANCER, V88, P567, DOI 10.1038/sj.bjc.6600757; Hsu JM, 2004, J BIOL CHEM, V279, P32592, DOI 10.1074/jbc.M404950200; Ito J, 2004, REPRODUCTION, V128, P409, DOI 10.1530/rep.1.00230; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Juliano R, 2003, NAT CELL BIOL, V5, P589, DOI 10.1038/ncb0703-589; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kakonen SM, 2003, CANCER-AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kikkawa Y, 2004, EXP CELL RES, V300, P94, DOI 10.1016/j.yexcr.2004.06.031; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; Klymkowsky MW, 2005, HUM PATHOL, V36, P225, DOI 10.1016/j.humpath.2005.02.002; Kodama R, 2005, GENES CELLS, V10, P1211, DOI 10.1111/j.1365-2443.2005.00911.x; Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506; Lam MHC, 1999, J BIOL CHEM, V274, P18559, DOI 10.1074/jbc.274.26.18559; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lim HH, 2003, MOL CELL, V11, P845, DOI 10.1016/S1097-2765(03)00149-7; Lindemann RK, 2003, INT J ONCOL, V22, P799; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; Linforth R, 2002, CLIN CANCER RES, V8, P3172; Maioli E, 2004, CELL MOL LIFE SCI, V61, P257, DOI 10.1007/s00018-003-3233-2; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Martin TA, 2005, CLIN EXP METASTAS, V22, P503, DOI 10.1007/s10585-005-4180-0; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; Masui T, 2004, BIOCHEM BIOPH RES CO, V315, P85, DOI 10.1016/j.bbrc.2004.01.021; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Orloff JJ, 1996, ENDOCRINOLOGY, V137, P5376, DOI 10.1210/en.137.12.5376; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; Rankin W, 1997, CANCER, V80, P1564, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1564::AID-CNCR6>3.3.CO;2-H; Richard V, 2005, CRIT REV EUKAR GENE, V15, P115, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.30; Seddighzadeh M, 1999, CLIN EXP METASTAS, V17, P649, DOI 10.1023/A:1006741228402; Seeliger MA, 2002, BIOCHEMISTRY-US, V41, P1202, DOI 10.1021/bi0113465; Sepulveda VAT, 2002, ENDOCRINOLOGY, V143, P596, DOI 10.1210/en.143.2.596; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shen XL, 2004, EXP CELL RES, V294, P420, DOI 10.1016/j.yexcr.2003.11.028; Shen XL, 2003, REGUL PEPTIDES, V113, P17, DOI 10.1016/S0167-0115(02)00293-8; Skog S, 2004, TUMOR BIOL, V25, P41, DOI 10.1159/000077722; SOUTHBY J, 1995, BRIT J CANCER, V72, P702, DOI 10.1038/bjc.1995.397; Stafford LJ, 2002, CANCER RES, V62, P5399; Stathatos N, 2005, J CLIN ENDOCR METAB, V90, P5432, DOI 10.1210/jc.2005-0963; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Truong NU, 2003, AM J MED, V115, P115, DOI 10.1016/S0002-9343(03)00310-3; Vetter M, 2005, ONCOGENE, V24, P650, DOI 10.1038/sj.onc.1208234; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87; Whitley BR, 2005, INT J ONCOL, V27, P749; Wu TL, 1996, J BIOL CHEM, V271, P24371, DOI 10.1074/jbc.271.40.24371; Wysolmerski JJ, 1998, DEVELOPMENT, V125, P1285; WYSOLMERSKI JJ, 1994, ANNU REV MED, V45, P189, DOI 10.1146/annurev.med.45.1.189; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	86	36	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14563	14572		10.1074/jbc.M510527200	http://dx.doi.org/10.1074/jbc.M510527200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551631	hybrid, Green Published			2022-12-25	WOS:000237671300007
J	Rhee, J; Ge, HF; Yang, WL; Fan, M; Handschin, C; Cooper, M; Lin, JD; Li, C; Spiegelman, BM				Rhee, James; Ge, Hongfei; Yang, Wenli; Fan, Melina; Handschin, Christoph; Cooper, Marcus; Lin, Jiandie; Li, Cai; Spiegelman, Bruce M.			Partnership of PGC-1 alpha and HNF4 alpha in the regulation of lipoprotein metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-IV; AIV GENE-CLUSTER; FAMILIAL COMBINED HYPERLIPIDEMIA; DEDIFFERENTIATED HEPATOMA-CELLS; DEPENDENT NUCLEAR RECEPTORS; APOC-III; TRANSCRIPTIONAL REGULATION; GAMMA COACTIVATOR-1-ALPHA; TRIGLYCERIDE-METABOLISM; VISCERAL ENDODERM	Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) is a transcriptional coactivator involved in several aspects of energy metabolism. It is induced or activated under different stimuli in a highly tissue-specific manner and subsequently partners with certain transcription factors in those tissues to execute various biological programs. In the fasted liver, PGC-1 alpha is induced and interacts with hepatocyte nuclear factor 4 alpha(HNF4 alpha) and other transcription factors to activate gluconeogenesis and increase hepatic glucose output. Given the broad spectrum of liver genes responsive to HNF4 alpha, we sought to determine those that were specifically targeted by the combination of PGC-1 alpha and HNF4 alpha. Co-expression of these two molecules in murine stem cells reveals a high induction of mRNA for apolipoproteins A-IV and C-II. Forced expression of PGC-1 alpha in mouse and human hepatoma cells increases the mRNA of a subset of apolipoproteins implicated in very low density lipoprotein and triglyceride metabolism, including apolipoproteins A-IV, C-II, and C-III. Coactivation of the apoC-III/ A-IV promoter region by PGC-1 alpha occurs through a highly conserved HNF4 alpha response element, the loss of which completely abolishes activation by PGC-1 alpha and HNF4 alpha. Adenoviral infusion of PGC-1 alpha into live mice increases hepatic expression of apolipoproteins A-IV, C-II, and C-III and increases serum and very low density lipoprotein triglyceride levels. Conversely, knock down of PGC-1 alpha in vivo causes a decrease in both apolipoprotein expression and serum triglyceride levels. These data point to a crucial role for the PGC-1 alpha/HNF4 alpha partnership in hepatic lipoprotein metabolism.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Spiegelman, BM (corresponding author), Dana Farber Canc Inst, 1 Jimmy Fund Way, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu	Handschin, Christoph/E-6886-2015; Rhee, James/V-9973-2019	Handschin, Christoph/0000-0003-0603-1097; Fan, Melina/0000-0002-6196-8408	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061562, R01DK054477, R56DK054477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 61562, DK 54477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO A, 1991, International Journal of Developmental Biology, V35, P389; Altomonte J, 2004, J CLIN INVEST, V114, P1493, DOI 10.1172/JCI200419992; Bhalla S, 2004, J BIOL CHEM, V279, P45139, DOI 10.1074/jbc.M405423200; Carrier JC, 2004, J BIOL CHEM, V279, P52052, DOI 10.1074/jbc.M410337200; CHEN M, 1994, J LIPID RES, V35, P1918; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Coghlan MJ, 2003, MOL ENDOCRINOL, V17, P860, DOI 10.1210/me.2002-0355; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Duncan SA, 1997, DEVELOPMENT, V124, P279; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Groenendijk M, 2001, J LIPID RES, V42, P188; HA YC, 1985, J CHROMATOGR, V341, P154, DOI 10.1016/S0378-4347(00)84020-7; Handschin C, 2005, CELL, V122, P505, DOI 10.1016/j.cell.2005.06.040; Harnish DC, 1996, J BIOL CHEM, V271, P13621, DOI 10.1074/jbc.271.23.13621; Hashimoto T, 2000, J BIOL CHEM, V275, P28918, DOI 10.1074/jbc.M910350199; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Heijboer AC, 2005, J LIPID RES, V46, P582, DOI 10.1194/jlr.M400440-JLR200; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; LEBOEUF RC, 1994, J LIPID RES, V35, P121; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Lewis GF, 1996, DIABETES CARE, V19, P390, DOI 10.2337/diacare.19.4.390; Li JX, 2000, GENE DEV, V14, P464; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; METZGER S, 1993, J BIOL CHEM, V268, P16831; Oberkofler H, 2003, BIOCHEM J, V371, P89, DOI 10.1042/BJ20021665; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; OMORI K, 1995, GENE, V159, P231, DOI 10.1016/0378-1119(95)00063-C; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Podvinec M, 2002, MOL ENDOCRINOL, V16, P1269, DOI 10.1210/me.16.6.1269; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; SHACHTER NS, 1994, J CLIN INVEST, V93, P1683, DOI 10.1172/JCI117151; Shin DJ, 2003, J BIOL CHEM, V278, P50047, DOI 10.1074/jbc.M309736200; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, RECEPTOR, V4, P64; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Teusink B, 2003, DIABETES, V52, P614, DOI 10.2337/diabetes.52.3.614; Vergnes L, 1997, BBA-LIPID LIPID MET, V1348, P299, DOI 10.1016/S0005-2760(97)00071-4; Weinstock PH, 1997, J LIPID RES, V38, P1782; WOJCIECHOWSKI AP, 1991, NATURE, V349, P161, DOI 10.1038/349161a0; XU CF, 1994, CLIN GENET, V46, P385; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang YQ, 2004, GENE DEV, V18, P157, DOI 10.1101/gad.1138104	55	63	64	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14683	14690		10.1074/jbc.M512636200	http://dx.doi.org/10.1074/jbc.M512636200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16574644	hybrid, Green Accepted			2022-12-25	WOS:000237671300021
J	Boston-Howes, W; Gibb, SL; Williams, EO; Pasinelli, P; Brown, RH; Trotti, D				Boston-Howes, William; Gibb, Stuart L.; Williams, Eric O.; Pasinelli, Piera; Brown, Robert H., Jr.; Trotti, Davide			Caspase-3 cleaves and inactivates the glutamate transporter EAAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MOUSE MODEL; MOTOR-NEURON DEATH; SUPEROXIDE-DISMUTASE; CELL-DEATH; VITAL FUNCTIONS; EXPRESSION; MUTANT; DISEASE; MICE	EAAT2 is a high affinity, Na+-dependent glutamate transporter with predominant astroglial localization. It accounts for the clearance of the bulk of glutamate released at central nervous system synapses and therefore has a crucial role in shaping glutamatergic neurotransmission and limiting excitotoxicity. Caspase-3 activation and impairment in expression and activity of EAAT2 are two distinct molecular mechanisms occurring in human amyotrophic lateral sclerosis (ALS) and in the transgenic rodent model of the disease. Excitotoxicity caused by down-regulation of EAAT2 is thought to be a contributing factor to motor neuron death in ALS. In this study, we report the novel evidence that caspase-3 cleaves EAAT2 at a unique site located in the cytosolic C-terminal domain of the transporter, a finding that links excitotoxicity and activation of caspase-3 as converging mechanisms in the pathogenesis of ALS. Caspase-3 cleavage of EAAT2 leads to a drastic and selective inhibition of this transporter. Heterologous expression of mutant SOD1 proteins linked to the familial form of ALS leads to inhibition of EAAT2 through a mechanism that largely involves activation of caspase-3 and cleavage of the transporter. In addition, we found evidence in spinal cord homogenates of mutant SOD1 ALS mice of a truncated form of EAAT2, likely deriving from caspase-3-mediated proteolytic cleavage, which appeared concurrently to the loss of EAAT2 immunoreactivity and to increased expression of activated caspase-3. Taken together, our findings suggest that caspase-3 cleavage of EAAT2 is one mechanism responsible for the impairment of glutamate uptake in mutant SOD1-linked ALS.	Harvard Univ, MassGen Inst Neurodegenerat Dis, Dept Neurol, Massachusetts Gen Hosp,Med Sch, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Cecil B Day Lab Neuromuscular Res, Massachusetts Gen Hosp, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Trotti, D (corresponding author), Harvard Univ, MassGen Inst Neurodegenerat Dis, Dept Neurol, Massachusetts Gen Hosp,Med Sch, Bldg 114, Charlestown, MA 02129 USA.	dtrotti@partners.org		Trotti, Davide/0000-0001-6338-6404; Pasinelli, Piera/0000-0002-3385-2707	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044292] Funding Source: NIH RePORTER; NINDS NIH HHS [NS44292] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersen PM, 2006, CURR NEUROL NEUROSCI, V6, P37, DOI 10.1007/s11910-996-0008-9; Ando Y, 2003, NEUROCHEM RES, V28, P839, DOI 10.1023/A:1023258923002; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Ganel R, 2006, NEUROBIOL DIS, V21, P556, DOI 10.1016/j.nbd.2005.08.014; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Guegan C, 2003, J CLIN INVEST, V111, P153, DOI 10.1172/JCI200317610; Guo H, 2002, MOL CELL NEUROSCI, V21, P546, DOI 10.1006/mcne.2002.1198; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Lavrik IN, 2005, J CLIN INVEST, V115, P2665, DOI 10.1172/JCI26252; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; Maragakis NJ, 2004, NEUROBIOL DIS, V15, P461, DOI 10.1016/j.nbd.2003.12.007; Noyan-Ashraf MH, 2005, GLIA, V49, P588, DOI 10.1002/glia.20140; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; Rao SD, 2003, J NEUROSCI, V23, P2627; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Seal RP, 1999, ANNU REV PHARMACOL, V39, P431, DOI 10.1146/annurev.pharmtox.39.1.431; Swanson RA, 1997, J NEUROSCI, V17, P932; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Trotti D, 2001, J BIOL CHEM, V276, P576, DOI 10.1074/jbc.M003779200; Trotti D, 1999, NAT NEUROSCI, V2, P427, DOI 10.1038/8091; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Williams SM, 2005, GLIA, V49, P520, DOI 10.1002/glia.20139; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Yuan JY, 1999, NAT CELL BIOL, V1, pE44, DOI 10.1038/10037	38	111	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14076	14084		10.1074/jbc.M600653200	http://dx.doi.org/10.1074/jbc.M600653200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16567804	hybrid			2022-12-25	WOS:000237512300030
J	Chen, ZH; Yoshida, Y; Saito, Y; Sekine, A; Noguchi, N; Niki, E				Chen, Zhi-Hua; Yoshida, Yasukazu; Saito, Yoshiro; Sekine, Azusa; Noguchi, Noriko; Niki, Etsuo			Induction of Adaptive Response and Enhancement of PC12 Cell Tolerance by 7-Hydroxycholesterol and 15-Deoxy-Delta(12,14)-Prostaglandin J(2) through Up-regulation of Cellular Glutathione via Different Mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE-CYSTEINE LIGASE; TRANSCRIPTION FACTOR NRF2; CYCLOPENTENONE PROSTAGLANDINS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; DEATH; INHIBITION; ADAPTATION; SYNTHETASE; ACTIVATION	Increasing evidence suggests an adaptive response induced by reactive oxygen species and other physiologically existing oxidative stimuli. We have recently reported that a variety of lipid peroxidation products at sublethal concentrations could induce adaptive response and enhance PC12 cell tolerance, although the detailed underlying molecular mechanisms have not been clearly clarified. In the present study, we found that both 7-hydroxycholesterol (7-OHCh) and 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) at sublethal concentrations significantly increased the cellular GSH as well as the enzyme activity of glutamate-cysteine ligase (GCL), the rate-limiting enzyme of GSH synthesis. Depletion of cellular GSH by buthionine sulfoximine completely abolished the adaptive response. Interestingly, treatment with 15d-PGJ(2) significantly increased the gene expression of both subunits of GCL in an NF-E2-related factor 2 (Nrf2)-dependent manner, whereas neither 7-OHCh induced any considerable changes on the GCL gene expression nor did the Nrf2-small interfering RNA treatment exert any appreciable effects on the GSH elevation and subsequent adaptive response induced by 7-OHCh. These results demonstrate that the adaptive response induced by both 7-OHCh and 15d-PGJ(2) is mediated similarly through the up-regulation of GSH but via different mechanisms.	[Chen, Zhi-Hua; Yoshida, Yasukazu; Saito, Yoshiro; Niki, Etsuo] Natl Inst Adv Ind Sci & Technol, Human Stress Signal Res Ctr, Osaka 5638577, Japan; [Sekine, Azusa; Noguchi, Noriko] Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; [Noguchi, Noriko] Doshisha Univ, Dept Engn Sci, Kyoto 6100394, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo; Doshisha University	Chen, ZH (corresponding author), Natl Inst Adv Ind Sci & Technol, Human Stress Signal Res Ctr, 1-8-31 Midorigaoka, Osaka 5638577, Japan.	zhihua-chen@aist.go.jp	Saito, Yoshiro/H-4597-2019; YOSHIDA, YASUKAZU/H-8510-2016	Saito, Yoshiro/0000-0002-0559-5889; YOSHIDA, YASUKAZU/0000-0001-6034-2502	National Institute of Biomedical Innovation; New Energy and Industrial Technology Development Organization (NEDO); New Frontier of Biomedical Engineering Research; Ministry of Education, Culture, Sports, Science and Technology	National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); New Energy and Industrial Technology Development Organization (NEDO)(New Energy and Industrial Technology Development Organization (NEDO)); New Frontier of Biomedical Engineering Research; Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by grants from the Program of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation, the Focus 21 project of New Energy and Industrial Technology Development Organization (NEDO), the Academic Frontier Research Project on "New Frontier of Biomedical Engineering Research," and the Special Coordination Fund for Science and Technology from Ministry of Education, Culture, Sports, Science and Technology. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Bea F, 2003, CIRC RES, V92, P386, DOI 10.1161/01.RES.0000059561.65545.16; Bjorkhem I, 2002, ARTERIOSCL THROM VAS, V22, P734, DOI 10.1161/01.ATV.0000013312.32196.49; Chen ZH, 2006, FEBS LETT, V580, P479, DOI 10.1016/j.febslet.2005.12.045; Chen ZH, 2005, J BIOL CHEM, V280, P41921, DOI 10.1074/jbc.M508556200; Chen ZH, 2005, NEUROSCI LETT, V383, P256, DOI 10.1016/j.neulet.2005.04.022; Chen ZH, 2004, CARCINOGENESIS, V25, P2005, DOI 10.1093/carcin/bgh183; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; Dickinson DA, 2004, FREE RADICAL BIO MED, V37, P1152, DOI 10.1016/j.freeradbiomed.2004.06.011; Forman HJ, 2004, FREE RADICAL BIO MED, V37, P594, DOI 10.1016/j.freeradbiomed.2004.06.009; Fraser JA, 2002, J BIOL CHEM, V277, P1158, DOI 10.1074/jbc.M106683200; Furuichi T, 2005, J NEUROSCI RES, V79, P816, DOI 10.1002/jnr.20402; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Grunblatt E, 2000, J NEUROL, V247, P95; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Itoh K, 2004, MOL CELL BIOL, V24, P36, DOI 10.1128/MCB.24.1.36-45.2004; Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; Leonarduzzi G, 2004, FREE RADICAL BIO MED, V37, P1694, DOI 10.1016/j.freeradbiomed.2004.08.027; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Levonen AL, 2001, ARTERIOSCL THROM VAS, V21, P1846, DOI 10.1161/hq1101.098488; Lim SY, 2004, J BIOL CHEM, V279, P46263, DOI 10.1074/jbc.M406555200; LU SC, 1991, J CLIN INVEST, V88, P260, DOI 10.1172/JCI115286; Lu SC, 2000, CURR TOP CELL REGUL, V36, P95; McWalter GK, 2004, J NUTR, V134, p3499S, DOI 10.1093/jn/134.12.3499S; MOCHIZUKI M, 2004, AM J RESP CRIT CARE, V121, P1760; Piga R, 2005, ARCH BIOCHEM BIOPHYS, V436, P101, DOI 10.1016/j.abb.2005.01.021; Ravati A, 2001, J NEUROCHEM, V78, P909, DOI 10.1046/j.1471-4159.2001.00463.x; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Rimner A, 2005, FREE RADICAL BIO MED, V38, P535, DOI 10.1016/j.freeradbiomed.2004.11.016; Saito Y, 2003, J BIOL CHEM, V278, P39428, DOI 10.1074/jbc.M305542200; Seo YJ, 2004, FREE RADICAL BIO MED, V37, P1272, DOI 10.1016/j.freeradbiomed.2004.07.012; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; SPITZ DR, 1987, J CELL PHYSIOL, V131, P364, DOI 10.1002/jcp.1041310308; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sun WM, 1996, BIOCHEM J, V320, P321, DOI 10.1042/bj3200321; TATEISHI N, 1974, J BIOCHEM, V75, P93, DOI 10.1093/oxfordjournals.jbchem.a130387; YAN N, 1990, J BIOL CHEM, V265, P1588; Yoshida Y, 2004, FREE RADICAL RES, V38, P787, DOI 10.1080/10715760410001700460; Zernecke A, 2003, FASEB J, V17, P1099, DOI 10.1096/fj.02-0485fje	42	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14440	14445		10.1074/jbc.M600260200	http://dx.doi.org/10.1074/jbc.M600260200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16565077	hybrid			2022-12-25	WOS:000207179300002
J	Decker, BL; Wickner, WT				Decker, Bridget L.; Wickner, William T.			Enolase Activates Homotypic Vacuole Fusion and Protein Transport to the Vacuole in Yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX; THIOREDOXIN; EXPRESSION; ALDOLASE; DELETION; I-2(B); GENES	Membrane fusion and protein trafficking to the vacuole are complex processes involving many proteins and lipids. Cytosol from Saccharomyces cerevisiae contains a high M-r activity, which stimulates the in vitro homotypic fusion of isolated yeast vacuoles. Here we purify this activity and identify it as enolase (Eno1p and Eno2p). Enolase is a cytosolic glycolytic enzyme, but a small portion of enolase is bound to vacuoles. Recombinant Eno1p or Eno2p stimulates in vitro vacuole fusion, as does a catalytically inactive mutant enolase, suggesting a role for enolase in fusion that is separate from its glycolytic function. Either deletion of the non-essential ENO1 gene or diminished expression of the essential ENO2 gene causes vacuole fragmentation in vivo, reflecting reduced fusion. Combining an ENO1 deletion with ENO2-deficient expression causes a more severe fragmentation phenotype. Vacuoles from enolase 1 and 2-deficient cells are unable to fuse in vitro. Immunoblots of vacuoles from wild type and mutant strains reveal that enolase deficiency also prevents normal protein sorting to the vacuole, exacerbating the fusion defect. Band 3 has been shown to bind glycolytic enzymes to membranes of mammalian erythrocytes. Bor1p, the yeast band 3 homolog, localizes to the vacuole. Its loss results in the mislocalization of enolase and other vacuole fusion proteins. These studies show that enolase stimulates vacuole fusion and that enolase and Bor1p regulate selective protein trafficking to the vacuole.	[Decker, Bridget L.; Wickner, William T.] Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, WT (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	Bill.Wickner@Dartmouth.edu						Bone N, 1998, CURR BIOL, V8, P135, DOI 10.1016/S0960-9822(98)00060-8; Campanella ME, 2005, P NATL ACAD SCI USA, V102, P2402, DOI 10.1073/pnas.0409741102; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Frommer WB, 2002, NATURE, V420, P282, DOI 10.1038/420282a; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; HOLLAND MJ, 1981, J BIOL CHEM, V256, P1385; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Kahana JA, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P139; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MCALISTER L, 1982, J BIOL CHEM, V257, P7181; NIEDERACHER D, 1991, EUR J BIOCHEM, V200, P311, DOI 10.1111/j.1432-1033.1991.tb16187.x; Niinaka Y, 1998, CANCER RES, V58, P2667; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; Takano J, 2002, NATURE, V420, P337, DOI 10.1038/nature01139; Vinarov DA, 1999, BIOCHEMISTRY-US, V38, P12138, DOI 10.1021/bi990760q; WADA Y, 1992, J BIOL CHEM, V267, P18665; WALSH TP, 1977, BIOCHEM J, V165, P165, DOI 10.1042/bj1650165; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X	25	52	54	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14523	14528		10.1074/jbc.M600911200	http://dx.doi.org/10.1074/jbc.M600911200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16565073	hybrid			2022-12-25	WOS:000207179300011
J	Machida, K; Ohta, Y; Osada, H				Machida, Kiyotaka; Ohta, Yoshihiro; Osada, Hiroyuki			Suppression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION-PORE; ADENINE-NUCLEOTIDE TRANSLOCASE; CYTOCHROME-C RELEASE; DEPENDENT ANION CHANNEL; BOUND HEXOKINASE; BAX; DEATH; ACTIVATION; INHIBITOR; COMPONENT	The permeability transition pore is involved in the mitochondrial pathway of apoptosis. Cyclophilin D, a pore component, has catalytic activity as a peptidyl prolyl cis, trans-isomerase (PPIase), which is essential to the pore opening. It has been reported that cyclophilin D overexpression suppresses apoptosis in cancer cells. To clarify the mechanism of this effect, we generated glioma cells overexpressing wild-type or a PPIase-deficient mutant of cyclophilin D. Interestingly, we found that the PPIase-dependent apoptosis suppression by cyclophilin D correlated with the amounts of mitochondrial-bound hexokinase II, which has anti-apoptotic activity. Inactivation of endogenous cyclophilin D by small interference RNA or a cyclophilin inhibitor was found to release hexokinase II from mitochondria and to enhance Bax-mediated apoptosis. The anti-apoptotic effects of cyclophilin D were canceled out by the detachment of hexokinase II from mitochondria, demonstrating that mitochondrial binding of hexokinase II is essential to the apoptosis suppression by cyclophilin D. Furthermore, cyclophilin D dysfunction appears to abrogate hexokinase II-mediated apoptosis suppression, indicating that cyclophilin D is required for the anti-apoptotic activity of hexokinase II. Based on the above, we propose here that cyclophilin D suppresses apoptotic cell death via a mitochondrial hexokinase II-dependent mechanism in cancer cells.	RIKEN, Antiobiot Lab, Discovery Res Inst, Saitama 3510198, Japan; Tokyo Univ Agr & Technol, Div Biotechnol & Life Sci, Inst Symbiot Sci & Technol, Koganei, Tokyo 1848588, Japan	RIKEN; Tokyo University of Agriculture & Technology	Osada, H (corresponding author), RIKEN, Antiobiot Lab, Discovery Res Inst, Hirosawa 2-1, Saitama 3510198, Japan.	hisyo@riken.jp	Ohta, Yoshihiro/C-8741-2013; Osada, Hiroyuki/N-4305-2014; Osada, Hiroyuki/AAY-6254-2020	Ohta, Yoshihiro/0000-0001-7416-0507; 				Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hashimoto M, 2000, ARCH BIOCHEM BIOPHYS, V384, P163, DOI 10.1006/abbi.2000.2085; Hursting SD, 2002, MOL CARCINOGEN, V33, P16, DOI 10.1002/mc.10020; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YM, 2004, BIOCHEM J, V383, P101, DOI 10.1042/BJ20040669; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; MAGNANI M, 1994, BBA-PROTEIN STRUCT M, V1206, P180, DOI 10.1016/0167-4838(94)90206-2; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Vyssokikh M, 2004, BBA-MOL CELL RES, V1644, P27, DOI 10.1016/j.bbamcr.2003.10.007; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287	37	103	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14314	14320		10.1074/jbc.M513297200	http://dx.doi.org/10.1074/jbc.M513297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551620	hybrid			2022-12-25	WOS:000237512300057
J	Engel, S; Neumann, S; Kaur, N; Monga, V; Jain, R; Northup, J; Gershengorn, MC				Engel, S; Neumann, S; Kaur, N; Monga, V; Jain, R; Northup, J; Gershengorn, MC			Low affinity analogs of thyrotropin-releasing hormone are super-agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CONFORMATIONAL STATES; EXTRACELLULAR LOOPS; SEQUENTIAL BINDING; DESENSITIZATION; MECHANISMS; INHIBITOR; MODEL; TRH; INTERNALIZATION	We show that several analogs of thyrotropin-releasing hormone (TRH) are more efficacious agonists at TRH receptors R1 and R2 than TRH itself. The apparent efficacies of the analogs were inversely related to their potencies and were independent of the nature of the modifications in TRH structure. In studies in intact cells, we showed that the differences in apparent efficacies were not due to differences in G-protein coupling, receptor desensitization, or recycling. Moreover, the differences in efficacies persisted in experiments using accessory protein-free membranes. We conclude that the efficacy differences of TRH analogs originated from the enhanced ability of TRH-R complexed to the low affinity agonists to directly activate G-protein(s), and not by a modulation of the activity of accessory proteins, and propose possible mechanisms for this phenomenon.	NIDDK, Natl Inst Hlth, Clin Endocrinol Branch, Bethesda, MD 20892 USA; Natl Inst Pharmaceut Educ & Res, Dept Med Chem, Sas Nagar 160062, Punjab, India; NIDCD, Lab Cellular Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institute of Pharmaceutical Education & Research (NIPER); National Institute of Pharmaceutical Education & Research, S.A.S. Nagar (Mohali); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Gershengorn, MC (corresponding author), NIDDK, Natl Inst Hlth, Clin Endocrinol Branch, 50 S Dr,Rm 4134, Bethesda, MD 20892 USA.	marving@intra.niddk.nih.gov	Neumann, Susanne/GPK-6035-2022; Engel, Stanislav/G-2799-2013	Engel, Stanislav/0000-0001-5916-5190; Jain, Rahul/0000-0002-9180-2812; monga, Vikram Deep/0000-0003-4004-6241	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK011006, Z01DK011006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000047, ZIADC000047] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Clark WA, 2001, BIOCHEM J, V358, P389, DOI 10.1042/0264-6021:3580389; Colson AO, 1998, BIOPHYS J, V74, P1087, DOI 10.1016/S0006-3495(98)77827-0; Drmota T, 2000, BIOCHEM J, V346, P711, DOI 10.1042/0264-6021:3460711; Garland AM, 1996, MOL PHARMACOL, V49, P438; GERSHENGORN MC, 1989, ANN NY ACAD SCI, V553, P191; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; Hassan A, 2005, J ENDOCRINOL, V184, P29, DOI 10.1677/joe.1.05654; HINKLE PM, 1982, J BIOL CHEM, V257, P5462; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; Jain R, 2002, BIOORGAN MED CHEM, V10, P189, DOI 10.1016/S0968-0896(01)00265-6; Jarv J, 2005, NEUROSCI LETT, V373, P150, DOI 10.1016/j.neulet.2004.10.003; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; JinsiParimoo A, 1997, ENDOCRINOLOGY, V138, P1471, DOI 10.1210/en.138.4.1471; Kenakin T, 2003, TRENDS PHARMACOL SCI, V24, P346, DOI 10.1016/S0165-6147(03)00167-6; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Liapakis G, 2004, MOL PHARMACOL, V65, P1181, DOI 10.1124/mol.65.5.1181; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Lu XP, 2004, MOL PHARMACOL, V66, P1192, DOI 10.1124/mol.104.000349; Merritt JE, 1997, CELL SIGNAL, V9, P53, DOI 10.1016/S0898-6568(96)00097-6; O'Dowd BF, 2000, MOL ENDOCRINOL, V14, P183, DOI 10.1210/me.14.1.183; Palanche T, 2001, J BIOL CHEM, V276, P34853, DOI 10.1074/jbc.M104363200; Perlman JH, 1997, BIOCHEMISTRY-US, V36, P15670, DOI 10.1021/bi9713310; PERLMAN JH, 1992, J BIOL CHEM, V267, P24413; RAMSDELL JS, 1986, J BIOL CHEM, V261, P5301; Roosterman D, 2004, J BIOL CHEM, V279, P30670, DOI 10.1074/jbc.M402479200; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sasaki Y, 2002, PHARMACOL THERAPEUT, V93, P225, DOI 10.1016/S0163-7258(02)00191-2; Sun Y, 2003, J MOL ENDOCRINOL, V30, P87, DOI 10.1677/jme.0.0300087; Sun YH, 2002, ENDOCRINOLOGY, V143, P2886, DOI 10.1210/en.143.8.2886; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Vauquelin G, 2005, FUND CLIN PHARMACOL, V19, P45, DOI 10.1111/j.1472-8206.2005.00319.x; Wang W, 1999, ENDOCRINOLOGY, V140, P4916, DOI 10.1210/en.140.10.4916; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794	33	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13103	13109		10.1074/jbc.M600440200	http://dx.doi.org/10.1074/jbc.M600440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551618	hybrid			2022-12-25	WOS:000237336600014
J	Hua, H; Zhang, YQ; Dabernat, S; Kritzik, M; Dietz, D; Sterling, L; Sarvetnick, N				Hua, H; Zhang, YQ; Dabernat, S; Kritzik, M; Dietz, D; Sterling, L; Sarvetnick, N			BMP4 regulates pancreatic progenitor cell expansion through Id2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; LOOP-HELIX PROTEINS; SIGNAL-TRANSDUCTION; SELF-RENEWAL; STEM-CELLS; GROWTH; DIFFERENTIATION; EXPRESSION; BETA; PATHWAY	Inhibitor of DNA binding (Id) proteins bind to and inhibit the function of basic helix-loop-helix (bHLH) transcription factors including those that regulate pancreatic development. Moreover, bone morphogenetic proteins (BMPs) regulate the expression of Ids. We hypothesized that BMP4 and Id proteins play a role in the expansion and differentiation of epithelial progenitor cells. We demonstrate that BMP4 induces the expression of Id2 along with the expansion of AR42J pancreatic epithelial cells. Furthermore, neutralization of BMP4 significantly reduced duct epithelial cell expansion in a mouse model of islet regeneration. BMP4 stimulation promotes Id2 binding to the bHLH transcription factor NeuroD, which is required for the differentiation of pancreatic islet cells. Therefore, our results indicate that BMP4 stimulation blocks the differentiation of endocrine progenitor cells and instead promotes their expansion thereby revealing a novel paradigm of signaling explaining the balance between expansion and differentiation of pancreatic duct epithelial progenitors. Understanding the mechanisms of BMPand Id function elucidates a key step during pancreas embryogenesis, which is important knowledge for expanding pancreatic progenitors in vitro.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Sarvetnick, N (corresponding author), Scripps Res Inst, Dept Immunol, IMM 23, La Jolla, CA 90237 USA.	noras@scripps.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK066511, R01DK060746] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK066511, DK060746] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashery-Padan R, 2004, DEV BIOL, V269, P479, DOI 10.1016/j.ydbio.2004.01.040; Benezra R, 2001, TRENDS CARDIOVAS MED, V11, P237, DOI 10.1016/S1050-1738(01)00117-7; Brorson M, 2001, HISTOCHEM CELL BIOL, V116, P263, DOI 10.1007/s004180100316; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chae JH, 2004, MOL CELLS, V18, P271; Chen C, 2005, AM J PHYSIOL-LUNG C, V288, pL1033, DOI 10.1152/ajplung.00277.2004; Dichmann DS, 2003, DEV DYNAM, V226, P663, DOI 10.1002/dvdy.10270; Ghil SH, 2002, EXP MOL MED, V34, P367, DOI 10.1038/emm.2002.52; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; GU DL, 1994, RECENT PROG HORM RES, V49, P161; GU DL, 1993, DEVELOPMENT, V118, P33; Gu GQ, 2004, DEVELOPMENT, V131, P165, DOI 10.1242/dev.00921; Habener JF, 2005, ENDOCRINOLOGY, V146, P1025, DOI 10.1210/en.2004-1576; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Huang HP, 2002, MOL ENDOCRINOL, V16, P541, DOI 10.1210/me.16.3.541; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Jiang FX, 2002, J CELL SCI, V115, P753; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kayali AG, 2005, J ENDOCRINOL, V185, P45, DOI 10.1677/joe.1.05949; Kayali AG, 2003, J CELL BIOL, V163, P859, DOI 10.1083/jcb.200304153; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Liu SY, 2004, EXP NEUROL, V190, P109, DOI 10.1016/j.expneurol.2004.07.015; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Marsich E, 2003, BIOCHEM J, V376, P707, DOI 10.1042/BJ20031021; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Park C, 2004, DEVELOPMENT, V131, P2749, DOI 10.1242/dev.01130; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; ROSEWICZ S, 1992, CLIN INVESTIGATOR, V70, P205; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sadlon TJ, 2004, STEM CELLS, V22, P457, DOI 10.1634/stemcells.22-4-457; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Swarbrick A, 2005, ONCOGENE, V24, P381, DOI 10.1038/sj.onc.1208188; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zhang YQ, 1999, DIABETOLOGIA, V42, P719, DOI 10.1007/s001250051220; Zhang YQ, 2004, DIABETES, V53, P2024, DOI 10.2337/diabetes.53.8.2024; Zhang YQ, 2001, DIABETES, V50, pS10, DOI 10.2337/diabetes.50.2007.S10; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	48	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13574	13580		10.1074/jbc.M600526200	http://dx.doi.org/10.1074/jbc.M600526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547003	hybrid			2022-12-25	WOS:000237336600066
J	Kersting, MC; Carman, GM				Kersting, MC; Carman, GM			Regulation of the Saccharomyces cerevisiae EKI1-encoded ethanolamine kinase by zinc depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL PYROPHOSPHATE PHOSPHATASE; PHOSPHOLIPID BIOSYNTHESIS; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; TRANSCRIPTIONAL ACTIVATOR; TRANSPORTER PROTEIN; GENETIC-REGULATION; YEAST; INOSITOL; ENCODES; VACUOLE	Ethanolamine kinase catalyzes the committed step in the synthesis of phosphatidylethanolamine via the CDP-ethanolamine branch of the Kennedy pathway. Regulation of the EKI1-encoded ethanolamine kinase by the essential nutrient zinc was examined in Saccharomyces cerevisiae. The level of ethanolamine kinase activity increased when zinc was depleted from the growth medium. This regulation correlated with increases in the CDP-ethanolamine pathway intermediates phosphoethanolamine and CDP-ethanolamine, and an increase in the methylated derivative of phosphatidylethanolamine, phosphatidylcholine. The beta-galactosidase activity driven by the P-EKI1-lacZ reporter gene was elevated in zinc-depleted cells, indicating that the increase in ethanolamine kinase activity was attributed to a transcriptional mechanism. The expression level of P-EKI1-lacZ reporter gene activity in the zrt1 Delta zrt2 Delta mutant ( defective in plasma membrane zinc transport) cells grown with zinc was similar to the activity expressed in wild-type cells grown without zinc. This indicated that EKI1 expression was sensitive to intracellular zinc. The zinc-mediated regulation of EKI1 expression was attenuated in the zap1 Delta mutant defective in the zinc-regulated transcription factor Zap1p. Direct interactions between Zap1p and putative zinc-responsive elements in the EKI1 promoter were demonstrated by electrophoretic mobility shift assays. Mutations of these elements to a nonconsensus sequence abolished Zap1p-DNA interactions. Taken together, this work demonstrated that the zinc-mediated regulation of ethanolamine kinase and the synthesis of phospholipids via the CDP-ethanolamine branch of the Kennedy pathway were controlled in part by Zap1p.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028140, R01GM028140] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM028140, GM-28140, R37 GM028140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BECKER GW, 1977, J BIOL CHEM, V252, P8684; Bird A, 2000, J BIOL CHEM, V275, P16160, DOI 10.1074/jbc.M000664200; Birner R, 2003, INT REV CYTOL, V225, P273, DOI 10.1016/S0074-7696(05)25007-6; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 2005, BIOCHEM SOC T, V33, P1150, DOI 10.1042/BST0331150; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHEN CC, 1984, J BIOL CHEM, V259, P150; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; Devirgiliis C, 2004, BIOCHEM BIOPH RES CO, V323, P58, DOI 10.1016/j.bbrc.2004.08.051; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; Dowhan W, 2004, BBA-BIOMEMBRANES, V1666, P19, DOI 10.1016/j.bbamem.2004.04.010; Eide DJ, 2003, J NUTR, V133, p1532S, DOI 10.1093/jn/133.5.1532S; Elabbadi N, 1997, BIOCHEM J, V324, P435, DOI 10.1042/bj3240435; Ellis CD, 2005, J BIOL CHEM, V280, P28811, DOI 10.1074/jbc.M505500200; Ellis CD, 2004, J CELL BIOL, V166, P325, DOI 10.1083/jcb.200401157; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Griac P, 1999, NUCLEIC ACIDS RES, V27, P2043, DOI 10.1093/nar/27.9.2043; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Han GS, 2004, J BIOL CHEM, V279, P5338, DOI 10.1074/jbc.M311779200; Han GS, 2001, J BIOL CHEM, V276, P10126, DOI 10.1074/jbc.M011421200; Han SH, 2005, J BIOL CHEM, V280, P29017, DOI 10.1074/jbc.M505881200; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iwanyshyn WM, 2004, J BIOL CHEM, V279, P21976, DOI 10.1074/jbc.M402047200; Kersting MC, 2004, J BIOL CHEM, V279, P35353, DOI 10.1074/jbc.M405704200; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; LESTER RL, 1993, ADV LIPID RES, V26, P253; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2003, J BIOL CHEM, V278, P15065, DOI 10.1074/jbc.M300568200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MENON AK, 1992, J BIOL CHEM, V267, P15277; Miyabe S, 2001, BIOCHEM BIOPH RES CO, V282, P79, DOI 10.1006/bbrc.2001.4522; Muhlenhoff U, 2003, J BIOL CHEM, V278, P40612, DOI 10.1074/jbc.M307847200; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Yuan DS, 2000, GENETICS, V156, P45; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	69	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13110	13116		10.1074/jbc.M601612200	http://dx.doi.org/10.1074/jbc.M601612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551612	Green Accepted, hybrid			2022-12-25	WOS:000237336600015
J	Poteser, M; Graziani, A; Rosker, C; Eder, P; Derler, I; Kahr, H; Zhu, MX; Romanin, C; Groschner, K				Poteser, M; Graziani, A; Rosker, C; Eder, P; Derler, I; Kahr, H; Zhu, MX; Romanin, C; Groschner, K			TRPC3 and TRPC4 associate to form a redox-sensitive cation channel - Evidence for expression of native TRPC3-TRPC4 heteromeric channels in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATED HTRP3 CHANNELS; CA2+ ENTRY; ACTIVATION; PROTEINS; DIACYLGLYCEROL; RECEPTORS; CALCIUM; STRESS; DOMAIN; BRAIN	Canonical transient receptor potential proteins (TRPC) have been proposed to form homo- or heteromeric cation channels in a variety of tissues, including the vascular endothelium. Assembly of TRPC multimers is incompletely understood. In particular, heteromeric assembly of distantly related TRPC isoforms is still a controversial issue. Because we have previously suggested TRPC proteins as the basis of the redox-activated cation conductance of porcine aortic endothelial cells (PAECs), we set out to analyze the TRPC subunit composition of endogenous endothelial TRPC channels and report here on a redox- sensitive TRPC3-TRPC4 channel complex. The ability of TRPC3 and TRPC4 proteins to associate and to form a cation-conducting pore complex was supported by four lines of evidence as follows: 1) Co-immunoprecipitation experiments in PAECs and in HEK293 cells demonstrated the association of TRPC3andTRPC4in the same complex. 2) Fluorescence resonance energy transfer analysis demonstrated TRPC3-TRPC4 association, involving close proximity between the N terminus of TRPC4 and the C terminus of TRPC3 subunits. 3) Co expression of TRPC3 and TRPC4 in HEK293 cells generated a channel that displayed distinct biophysical and regulatory properties. 4) Expression of dominantnegative TRPC4 proteins suppressed TRPC3-related channel activity in the HEK293 expression system and in native endothelial cells. Specifically, an extracellularly hemagglutinin (HA)-tagged TRPC4 mutant, which is sensitive to blockage by anti-HA-antibody, was found to transfer anti- HA sensitivity to both TRPC3-related currents in the HEK293 expression system and the redox-sensitive cation conductance of PAECs. We propose TRPC3 and TRPC4 as subunits of native endothelial cation channels that are governed by the cellular redox state.	Karl Franzens Univ Graz, Inst Pharmaceut Sci Pharmacol & Toxicol, A-8010 Graz, Austria; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Univ Linz, Inst Biophys, A-4020 Linz, Austria	University of Graz; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Johannes Kepler University Linz	Graziani, A (corresponding author), Karl Franzens Univ Graz, Inst Pharmaceut Sci Pharmacol & Toxicol, Univ Pl 2, A-8010 Graz, Austria.	klaus.groschner@uni-graz.at	Derler, Isabella/B-7871-2019; Romanin, Christoph/D-5399-2009; Groschner, Klaus/A-2550-2010	Derler, Isabella/0000-0002-4768-146X; Romanin, Christoph/0000-0003-3756-4136; Groschner, Klaus/0000-0002-8659-377X; Poteser, Michael/0000-0002-9962-1098				Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Chang AS, 1997, FEBS LETT, V415, P335, DOI 10.1016/S0014-5793(97)01155-1; ELLIOTT SJ, 1989, J BIOL CHEM, V264, P3806; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; Groschner Klaus, 2004, Novartis Found Symp, V258, P222; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kohler R, 2001, CARDIOVASC RES, V51, P160, DOI 10.1016/S0008-6363(01)00281-4; Koliwad SK, 1996, J PHYSIOL-LONDON, V495, P37, DOI 10.1113/jphysiol.1996.sp021572; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Rosker C, 2004, J BIOL CHEM, V279, P13696, DOI 10.1074/jbc.M308108200; Schaefer M, 2005, PFLUG ARCH EUR J PHY, V451, P35, DOI 10.1007/s00424-005-1467-6; Schaefer M, 2002, J BIOL CHEM, V277, P3752, DOI 10.1074/jbc.M109850200; Schilling William P, 2004, Novartis Found Symp, V258, P18; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Zhang ZM, 2001, BIOCHEM J, V354, P717, DOI 10.1042/0264-6021:3540717; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	28	163	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13588	13595		10.1074/jbc.M512205200	http://dx.doi.org/10.1074/jbc.M512205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537542	hybrid			2022-12-25	WOS:000237336600068
J	Urata, Y; Ihara, Y; Murata, H; Goto, S; Koji, T; Yodoi, J; Inoue, S; Kondo, T				Urata, Y; Ihara, Y; Murata, H; Goto, S; Koji, T; Yodoi, J; Inoue, S; Kondo, T			17 beta-estradiol protects against oxidative stress-induced cell death through the glutathione/glutaredoxin-dependent redox regulation of Akt in myocardiac H9c2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; ENDOTHELIAL-CELLS; KINASE-B; BREAST-CANCER; GLUTAREDOXIN; APOPTOSIS; BETA; RESISTANCE; EXPRESSION; THIOREDOXIN	The GSH/glutaredoxin (GRX) system is involved in the redox regulation of certain enzyme activities, and this system protects cells from H2O2-induced apoptosis by regulating the redox state of Akt (Murata, H., Ihara, Y., Nakamura, H., Yodoi, J., Sumikawa, K., and Kondo, T. (2003) J. Biol. Chem. 278, 50226-50233). Estrogens, such as 17 beta-estradiol (E-2), play an important role in development, growth, and differentiation and appear to have protective effects on oxidative stress mediated by estrogen receptor alpha( ER alpha). However, the role of the ER beta-mediated pathway in this cytoprotection and the involvement of E-2 in the redox regulation are not well understood. In the present study, we demonstrated that E-2 protected cardiac H9c2 cells, expressing ER beta from H2O2-induced apoptosis concomitant with an increase in the activity of Akt. E-2 induced the expression of glutaredoxin ( GRX) as well as gamma-glutamylcysteine synthetase, a rate-limiting enzyme for the synthesis of GSH. Inhibitors for both gamma-glutamylcysteine synthetase and GRX and ICI182,780, a specific inhibitor of ERs, abolished the protective effect of E-2 on cell survival as well as the activity of Akt, suggesting that ER beta is involved in the cytoprotection and redox regulation by E-2. Transcription of the GRX gene was enhanced by E-2. The promoter activity of GRX was up-regulated by an ER beta-dependent element. These results suggest that the GRX/GSH system is involved in the cytoprotective and genomic effects of E-2 on the redox state of Akt, a pathway that is mediated, at least in part, by ER beta. This mechanism may also play an antiapoptotic role in cancer cells during carcinogenesis or chemotherapy.	Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Histol & Cell Biol, Nagasaki 8528523, Japan; Kyoto Univ, Grad Sch Med, Inst Viral Res, Dept Biol Responses,Sakyo Ku, Kyoto 6068397, Japan; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan	Nagasaki University; Nagasaki University; Kyoto University; University of Tokyo	Urata, Y (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	urata@net.nagasaki-u.ac.jp	Murata, Hiroaki/AAA-8374-2020	Murata, Hiroaki/0000-0002-6185-5059				Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Baba T, 2005, J BIOL CHEM, V280, P16417, DOI 10.1074/jbc.M500924200; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Connor EE, 2005, J ENDOCRINOL, V185, P593, DOI 10.1677/joe.1.06139; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Ejima K, 1999, EUR J ENDOCRINOL, V140, P608, DOI 10.1530/eje.0.1400608; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FOSTER C, 2004, P NATL ACAD SCI USA, V101, P14233; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; GAN ZR, 1986, J BIOL CHEM, V261, P996; Gibson LL, 2005, CIRC RES, V96, P518, DOI 10.1161/01.RES.0000158967.96231.88; Goto S, 2002, JPN J CANCER RES, V93, P1047, DOI 10.1111/j.1349-7006.2002.tb02482.x; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Huang X, 2003, STRUCTURE, V11, P21, DOI 10.1016/S0969-2126(02)00937-1; Iida T, 2001, CANCER GENE THER, V8, P803, DOI 10.1038/sj.cgt.7700371; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kenchappa RS, 2004, FASEB J, V18, P1102, DOI 10.1096/fj.03-1075fje; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P49, DOI 10.1210/en.2003-0792; MEISTER A, 1973, SCIENCE, V180, P33, DOI 10.1126/science.180.4081.33; Montano MM, 2004, ONCOGENE, V23, P2442, DOI 10.1038/sj.onc.1207358; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; Padilla CA, 1996, GENOMICS, V32, P455, DOI 10.1006/geno.1996.0141; Pham FH, 2000, CIRC RES, V86, P1252, DOI 10.1161/01.RES.86.12.1252; Prokai L, 2003, P NATL ACAD SCI USA, V100, P11741, DOI 10.1073/pnas.2032621100; Qing L, 2004, P NATL ACAD SCI USA, V101, P17126, DOI 10.1073/pnas.0407492101; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schultz JR, 2005, J BIOL CHEM, V280, P347, DOI 10.1074/jbc.M407879200; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Smith LH, 2004, CIRC RES, V95, P269, DOI 10.1161/01.RES.0000136521.70093.f1; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Stoica GE, 2003, ONCOGENE, V22, P7998, DOI 10.1038/sj.onc.1206769; Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11; Tamaru N, 2004, LAB INVEST, V84, P1460, DOI 10.1038/labinvest.3700166; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Yasukawa T, 2005, J BIOL CHEM, V280, P7511, DOI 10.1074/jbc.M411871200; Yasuoka C, 2004, J BIOL CHEM, V279, P51182, DOI 10.1074/jbc.M407225200; Yu XR, 2004, J BIOL CHEM, V279, P13086, DOI 10.1074/jbc.M313283200	50	97	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13092	13102		10.1074/jbc.M601984200	http://dx.doi.org/10.1074/jbc.M601984200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16549430	hybrid			2022-12-25	WOS:000237336600013
J	Yang, XH; Kovalenko, OV; Kolesnikova, TV; Andzelm, MM; Rubinstein, E; Strominger, JL; Hemler, ME				Yang, XH; Kovalenko, OV; Kolesnikova, TV; Andzelm, MM; Rubinstein, E; Strominger, JL; Hemler, ME			Contrasting effects of EWI proteins, integrins, and protein palmitoylation on cell surface CD9 organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE 4 SUPERFAMILY; MHC CLASS-II; MONOCLONAL-ANTIBODIES; TETRASPANIN CD9; TM4SF PROTEINS; MRP-1/CD9 EXPRESSION; CD9-DEFICIENT MICE; BETA(1) INTEGRINS; GM3 GANGLIOSIDE; POOR-PROGNOSIS	CD9, a tetraspanin protein, makes crucial contributions to sperm egg fusion, other cellular fusions, epidermal growth factor receptor signaling, cell motility, and tumor suppression. Here we characterize a low affinity anti-CD9 antibody, C9BB, which binds preferentially to homoclustered CD9. Using mAb C9BB as a tool, we show that cell surface CD9 homoclustering is promoted by expression of alpha 3 beta 1 and alpha 6 beta 4 integrins and by palmitoylation of the CD9 and beta 4 proteins. Conversely, CD9 is shifted toward heteroclusters upon expression of CD9 partner proteins (EWI-2 and EWI-F) or other tetraspanins, or upon ablation of CD9 palmitoylation. Furthermore, unpalmitoylated CD9 showed enhanced EWI-2 association, thereby demonstrating a previously unappreciated role for tetraspanin palmitoylation, and underscoring how depalmitoylation and EWI-2 association may collaborate to shift CD9 from homo- to heteroclusters. In conclusion, we have used a novel molecular probe ( mAb C9BB) to demonstrate the existence of multiple types of CD9 complex on the cell surface. A shift from homo- to heteroclustered CD9 may be functionally significant because the latter was especially obvious on malignant epithelial tumor cells. Hence, because of its specialized properties, C9BB may be more useful than other anti-CD9 antibodies for monitoring CD9 during tumor progression.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Paris 11, INSERM, U268, Inst Andre Lwoff, F-94807 Villejuif, France	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Hemler, ME (corresponding author), Dana Farber Canc Inst, Rm D-1430,44 Binney St, Boston, MA 02115 USA.	Martin_Hemler@DFCI.Harvard.edu	Rubinstein, Eric/B-4650-2019	Rubinstein, Eric/0000-0001-7623-9665	NCI NIH HHS [CA42368] Funding Source: Medline; NIGMS NIH HHS [GM38903] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZORSA DO, 1998, CD9 WORKSH AN ANT RE, V6; Baudoux B, 2000, EUR J CELL BIOL, V79, P41, DOI 10.1078/S0171-9335(04)70006-0; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; Berditchevski F, 2001, J CELL SCI, V114, P4143; Charrin S, 2003, EUR J IMMUNOL, V33, P2479, DOI 10.1002/eji.200323884; Charrin S, 2003, BIOCHEM J, V373, P409, DOI 10.1042/BJ20030343; Charrin S, 2003, BIOCHEM BIOPH RES CO, V304, P107, DOI 10.1016/S0006-291X(03)00545-X; Charrin S, 2002, FEBS LETT, V516, P139, DOI 10.1016/S0014-5793(02)02522-X; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Cherukuri A, 2004, J BIOL CHEM, V279, P31973, DOI 10.1074/jbc.M404410200; CROTHERS DM, 1972, IMMUNOCHEMISTRY, V9, P341, DOI 10.1016/0019-2791(72)90097-3; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; Drbal K, 1999, INT IMMUNOL, V11, P491, DOI 10.1093/intimm/11.4.491; Drbal K, 2000, TISSUE ANTIGENS, V56, P258, DOI 10.1034/j.1399-0039.2000.560308.x; Erovic BM, 2003, HEAD NECK-J SCI SPEC, V25, P848, DOI 10.1002/hed.10306; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; Gutierrez-Lopez MD, 2003, J BIOL CHEM, V278, P208, DOI 10.1074/jbc.M207805200; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Huang CL, 2004, ONCOGENE, V23, P7475, DOI 10.1038/sj.onc.1208063; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Inui S, 1997, J CELL PHYSIOL, V171, P291, DOI 10.1002/(SICI)1097-4652(199706)171:3<291::AID-JCP7>3.0.CO;2-J; Ishibashi T, 2004, J NEUROSCI, V24, P96, DOI 10.1523/JNEUROSCI.1484-03.2004; Kaji K, 2000, NAT GENET, V24, P279, DOI 10.1038/73502; KAUFMAN EN, 1992, CANCER RES, V52, P4157; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Koch C, 1999, INT IMMUNOL, V11, P777, DOI 10.1093/intimm/11.5.777; Kolesnikova TV, 2004, BLOOD, V103, P3013, DOI 10.1182/blood-2003-07-2201; Kovalenko OV, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-11; Kovalenko OV, 2004, BIOCHEM J, V377, P407, DOI 10.1042/BJ20031037; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; Mhawech P, 2004, BRIT J CANCER, V90, P471, DOI 10.1038/sj.bjc.6601542; Mhawech P, 2003, CANCER, V98, P1649, DOI 10.1002/cncr.11698; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1995, CANCER RES, V55, P4127; Miyake M, 1996, CANCER RES, V56, P1244; Mori M, 1998, CLIN CANCER RES, V4, P1507; Murayama Y, 2004, J CELL SCI, V117, P3379, DOI 10.1242/jcs.01201; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; Stipp CS, 2003, J CELL BIOL, V163, P1167, DOI 10.1083/jcb.200309113; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Stipp CS, 2001, J BIOL CHEM, V276, P4853, DOI 10.1074/jbc.M009859200; Szollosi J, 1996, J IMMUNOL, V157, P2939; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; Takeda Y, 2003, J CELL BIOL, V161, P945, DOI 10.1083/jcb.200212031; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; Tang W, 2004, J BIOL CHEM, V279, P11112, DOI 10.1074/jbc.M312947200; TOMLINSON MG, 1993, EUR J IMMUNOL, V23, P136, DOI 10.1002/eji.1830230122; Willett B, 1997, J GEN VIROL, V78, P611, DOI 10.1099/0022-1317-78-3-611; WORTHINGTON RE, 1990, BRIT J HAEMATOL, V74, P216, DOI 10.1111/j.1365-2141.1990.tb02568.x; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yanez-Mo M, 2001, J CELL SCI, V114, P577; Yang XW, 2004, J CELL BIOL, V167, P1231, DOI 10.1083/jcb.200404100; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhou B, 2004, CANCER RES, V64, P7455, DOI 10.1158/0008-5472.CAN-04-1574	67	46	48	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12976	12985		10.1074/jbc.M510617200	http://dx.doi.org/10.1074/jbc.M510617200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16537545	hybrid			2022-12-25	WOS:000237134700093
J	Kuphal, S; Lodermeyer, S; Bataille, F; Schuierer, M; Hoang, BH; Bosserhoff, AK				Kuphal, S.; Lodermeyer, S.; Bataille, F.; Schuierer, M.; Hoang, B. H.; Bosserhoff, A. K.			Expression of Dickkopf genes is strongly reduced in malignant melanoma	ONCOGENE			English	Article						Dickkopf; tumor-suppressor gene; Wnt signaling; malignant melanoma; cancer	BETA-CATENIN; BREAST-CARCINOMA; REPRESSOR SNAIL; CELL-LINES; INVASION; TARGET; GROWTH; CANCER; HYPERMETHYLATION; DIFFERENTIATION	The Dickkopf (DKK) genes were originally identified as factors inducing head formation in Xenopus. The genes code for inhibitors that are involved in Wnt signaling. We speculate that loss of DKK expression plays a role in development or progression of malignant melanoma. Thus, we evaluated melanoma cell lines and tissue samples of malignant melanoma for loss of DKK, especially DKK-3 transcription. We found that DKK-1, -2 and -3 were downregulated or lost in all cell lines and in most of the tumor samples analysed. Reduced DKK-3 expression occurred as early as in primary tumors detected by both immunohistochemical and reverse transcription-polymerase chain reaction RT-PCR analysis. Functional assays with stable DKK-3 transfected cell lines revealed that DKK-3 expression increased cell-cell adhesion and decreased cell migration. Further, downregulation of bronectin, snail-1 and re-expression of E-cadherin was found in the DKK-3 expressing cell clones supporting a role of DKK-3 in tumor progression. Our studies thus indicate that loss of DKK-3 expression may contribute to melanoma progression.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Orthopaed Surg, Irvine, CA 92717 USA	University of Regensburg; University of California System; University of California Irvine	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Behrmann I, 2003, AM J PATHOL, V163, P683, DOI 10.1016/S0002-9440(10)63695-4; Berking C, 2004, CANCER RES, V64, P807, DOI 10.1158/0008-5472.CAN-03-3438; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; De Langhe SP, 2005, DEV BIOL, V277, P316, DOI 10.1016/j.ydbio.2004.09.023; Gilles C, 1997, LAB INVEST, V76, P651; Gilles C, 2003, CANCER RES, V63, P2658; Gilles C, 2001, J CELL SCI, V114, P2967; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Haass NK, 2004, J MOL HISTOL, V35, P309; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Laux H, 2004, LAB INVEST, V84, P1372, DOI 10.1038/labinvest.3700158; Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001; Li G, 2004, EXP CELL RES, V297, P142, DOI 10.1016/j.yexcr.2004.03.012; Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0; Pham K, 2003, J CLIN PATHOL-MOL PA, V56, P280, DOI 10.1136/mp.56.5.280; Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008; Tester AM, 2001, CLIN EXP METASTAS, V18, P553, DOI 10.1023/A:1011953118186; Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; ZIEGLERHEITBROCK HWL, 1985, CANCER RES, V45, P1344	31	140	151	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5027	5036		10.1038/sj.onc.1209508	http://dx.doi.org/10.1038/sj.onc.1209508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568085				2022-12-25	WOS:000239921300008
J	Hecker, CM; Rabiller, M; Haglund, K; Bayer, P; Dikic, I				Hecker, Christina-Maria; Rabiller, Matthias; Haglund, Kaisa; Bayer, Peter; Dikic, Ivan			Specification of SUMO1- and SUMO2-interacting motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-RELATED PROTEIN; SUMO-BINDING MOTIF; COVALENT MODIFICATION; GENE-EXPRESSION; E3 LIGASE; MECHANISM; HELICASE; SYSTEM; PML	SUMO proteins are ubiquitin-related modifiers implicated in the regulation of gene transcription, cell cycle, DNA repair, and protein localization. The molecular mechanisms by which the sumoylation of target proteins regulates diverse cellular functions remain poorly understood. Here we report isolation and characterization of SUMO1- and SUMO2-binding motifs. Using yeast two-hybrid system, bioinformatics, and NMR spectroscopy we define a common SUMO-interacting motif (SIM) and map its binding surfaces on SUMO1 and SUMO2. This motif forms a beta-strand that could bind in parallel or antiparallel orientation to the beta(2)-strand of SUMO due to the environment of the hydrophobic core. A negative charge imposed by a stretch of neighboring acidic amino acids and/or phosphorylated serine residues determines its specificity in binding to distinct SUMO paralogues and can modulate the spatial orientation of SUMO-SIM interactions.	Univ Duisburg Essen, Fachbereich Biol & Geog Strukturelle & Med Bioche, D-45117 Essen, Germany; Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany	University of Duisburg Essen; Goethe University Frankfurt	Bayer, P (corresponding author), Univ Duisburg Essen, Fachbereich Biol & Geog Strukturelle & Med Bioche, Univ Str, D-45117 Essen, Germany.	Peter.Bayer@uni-due.de; Ivan.Dikic@biochem2.de	Bayer, Peter/B-8803-2009; Haglund, Kaisa/B-3927-2017; Dikic, Ivan/O-4650-2015	Bayer, Peter/0000-0003-0435-7202; Haglund, Kaisa/0000-0002-7946-3299; Dikic, Ivan/0000-0001-8156-9511				Ayaydin F, 2004, MOL BIOL CELL, V15, P5208, DOI 10.1091/mbc.E04-07-0589; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P31, DOI 10.1093/nar/25.1.31; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Chupreta S, 2005, MOL CELL BIOL, V25, P4272, DOI 10.1128/MCB.25.10.4272-4282.2005; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eladad S, 2005, HUM MOL GENET, V14, P1351, DOI 10.1093/hmg/ddi145; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Haglund K, 2004, J CELL SCI, V117, P2557, DOI 10.1242/jcs.01148; Hannich JT, 2005, J BIOL CHEM, V280, P4102, DOI 10.1074/jbc.M413209200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hipp MS, 2004, J BIOL CHEM, V279, P16503, DOI 10.1074/jbc.M310114200; Hofmann K, 2000, Brief Bioinform, V1, P167, DOI 10.1093/bib/1.2.167; Huang WC, 2004, EUR J BIOCHEM, V271, P4114, DOI 10.1111/j.1432-1033.2004.04349.x; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kunapuli P, 2003, ONCOGENE, V22, P3417, DOI 10.1038/sj.onc.1206408; Macauley MS, 2004, J BIOL CHEM, V279, P49131, DOI 10.1074/jbc.M408705200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moreira MC, 2004, NAT GENET, V36, P225, DOI 10.1038/ng1303; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Pichler A, 2004, NAT STRUCT MOL BIOL, V11, P984, DOI 10.1038/nsmb834; Pype S, 2000, J BIOL CHEM, V275, P18586, DOI 10.1074/jbc.M000531200; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Shou ZF, 2004, BIOCHEM BIOPH RES CO, V314, P885, DOI 10.1016/j.bbrc.2003.12.162; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Sternsdorf T, 1999, MOL CELL BIOL, V19, P5170; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Tanaka T, 2003, J BIOL CHEM, V278, P32905, DOI 10.1074/jbc.M212057200; Tatham MH, 2005, NAT STRUCT MOL BIOL, V12, P67, DOI 10.1038/nsmb878; Weger S, 2003, EXP CELL RES, V290, P13, DOI 10.1016/S0014-4827(03)00292-1	40	390	403	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16117	16127		10.1074/jbc.M512757200	http://dx.doi.org/10.1074/jbc.M512757200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16524884	hybrid			2022-12-25	WOS:000237996000065
J	Wang, YJ; Singh, R; Lefkowitch, JH; Rigoli, RM; Czaja, MJ				Wang, Yongjun; Singh, Rajat; Lefkowitch, Jay H.; Rigoli, Raina M.; Czaja, Mark J.			Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; INDUCED CELL-DEATH; FACTOR-ALPHA; TNF-ALPHA; HEPATOCYTE APOPTOSIS; MEDIATED APOPTOSIS; SENSITIZES HEPATOCYTES; DISTINCT ROLES; JNK ACTIVATION; KNOCKOUT MICE	In vitro studies of hepatocytes have implicated over-activation of c-Jun N-terminal kinase (JNK) signaling as a mechanism of tumor necrosis factor-alpha (TNF)-induced apoptosis. However, the functional significance of JNK activation and the role of specific JNK isoforms in TNF-induced hepatic apoptosis in vivo remain unclear. JNK1 and JNK2 function was, therefore, investigated in the TNF-dependent, galactosamine/lipopolysaccharide (GalN/LPS) model of liver injury. The toxin GalN converted LPS-induced JNK signaling from a transient to prolonged activation. Liver injury and mortality from GalN/LPS was equivalent in wild-type and jnk1(-/-) mice but markedly decreased in jnk2(-/-) mice. This effect was not secondary to down-regulation of TNF receptor 1 expression or TNF production. In the absence of jnk2, the caspase-dependent, TNF death pathway was blocked, as reflected by the failure of caspase-3 and -7 and poly(ADP-ribose) polymerase cleavage to occur. JNK2 was critical for activation of the mitochondrial death pathway, as in jnk2(-/-) mice Bid cleavage and mitochondrial translocation and cytochrome c release were markedly decreased. This effect was secondary to the failure of jnk2(-/-) mice to activate caspase-8. Liver injury and caspase activation were similarly decreased in jnk2 null mice after GalN/TNF treatment. Ablation of jnk2 did not inhibit GalN/LPS-induced c-Jun kinase activity, although activity was completely blocked in jnk1(-/-) mice. Toxic liver injury is, therefore, associated with JNK over-activation and mediated by JNK2 promotion of caspase-8 activation and the TNF mitochondrial death pathway through a mechanism independent of c-Jun kinase activity.	Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Columbia University	Czaja, MJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	czaja@aecom.yu.edu			NIDDK NIH HHS [R01 DK044234-18, R01 DK044234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Conze D, 2002, J EXP MED, V195, P811, DOI 10.1084/jem.20011508; CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Dietrich N, 2004, CELL DEATH DIFFER, V11, P301, DOI 10.1038/sj.cdd.4401353; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Han ZN, 2002, ARTHRITIS RHEUM, V46, P818, DOI 10.1002/art.10104; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Iocca HA, 2003, AM J PATHOL, V163, P465, DOI 10.1016/S0002-9440(10)63676-0; Jaeschke A, 2005, P NATL ACAD SCI USA, V102, P6931, DOI 10.1073/pnas.0502143102; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Kaiser RA, 2005, J BIOL CHEM, V280, P32602, DOI 10.1074/jbc.M500684200; Kallinowski B, 1998, CLIN EXP IMMUNOL, V111, P269; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim WH, 2003, AM J PHYSIOL-GASTR L, V285, pG761, DOI 10.1152/ajpgi.00224.2003; LEIST M, 1994, J IMMUNOL, V153, P1778; LEIST M, 1995, AM J PATHOL, V146, P1220; Lesage G, 2001, AM J PHYSIOL-GASTR L, V281, pG182, DOI 10.1152/ajpgi.2001.281.1.G182; Liu HL, 2002, HEPATOLOGY, V35, P772, DOI 10.1053/jhep.2002.32534; Liu HL, 2000, J BIOL CHEM, V275, P40155, DOI 10.1074/jbc.M001565200; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Malagarie-Cazenave S, 2004, J BIOL CHEM, V279, P18648, DOI 10.1074/jbc.M314294200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morikawa A, 1996, INFECT IMMUN, V64, P734, DOI 10.1128/IAI.64.3.734-738.1996; Naveau S, 2004, HEPATOLOGY, V39, P1390, DOI 10.1002/hep.20206; Nowak M, 2000, AM J PHYSIOL-REG I, V278, pR1202, DOI 10.1152/ajpregu.2000.278.5.R1202; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Schattenberg JM, 2005, SIGNALING PATHWAYS IN LIVER DISEASES, P115, DOI 10.1007/3-540-27194-5_10; Schattenberg JM, 2004, HEPATOLOGY, V39, P444, DOI 10.1002/hep.20067; Schwabe RF, 2004, FASEB J, V18, P720, DOI 10.1096/fj.03-0771fje; She QB, 2002, CANCER RES, V62, P1343; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Teoh N, 2004, HEPATOLOGY, V39, P412, DOI 10.1002/hep.20035; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Xu Y, 1998, GASTROENTEROLOGY, V115, P1229, DOI 10.1016/S0016-5085(98)70095-2; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yerushalmi B, 2001, HEPATOLOGY, V33, P616, DOI 10.1053/jhep.2001.22702; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9; Yin XM, 2000, J MOL MED-JMM, V78, P203, DOI 10.1007/s001090000099; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200; Zhou WH, 2001, HEPATOLOGY, V33, P902, DOI 10.1053/jhep.2001.23073	60	176	182	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15258	15267		10.1074/jbc.M512953200	http://dx.doi.org/10.1074/jbc.M512953200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16571730	hybrid, Green Accepted			2022-12-25	WOS:000237922200029
J	Serantes, R; Arnalich, F; Figueroa, M; Salinas, M; Andres-Mateos, E; Codoceo, R; Renart, J; Matute, C; Cavada, C; Cuadrado, A; Montiel, C				Serantes, Rocio; Arnalich, Francisco; Figueroa, Maria; Salinas, Marta; Andres-Mateos, Eva; Codoceo, Rosa; Renart, Jaime; Matute, Carlos; Cavada, Carmen; Cuadrado, Antonio; Montiel, Carmen			Interleukin-1 beta enhances GABA(A) receptor cell-surface expression by a phosphatidylinositol 3-kinase/Akt pathway - Relevance to sepsis-associated encephalopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN MESSENGER-RNA; PROTEIN-KINASE-C; NEURONAL NICOTINIC RECEPTORS; INDUCED SICKNESS BEHAVIOR; LONG-TERM POTENTIATION; RAT DENTATE GYRUS; FACTOR-KAPPA-B; XENOPUS-OOCYTES; SEPTIC ENCEPHALOPATHY; SYNAPTIC INHIBITION	Sepsis-associated encephalopathy (SAE) is a frequent but poorly understood neurological complication in sepsis that negatively influences survival. Here we present clinical and experimental evidence that this brain dysfunction may be related to altered neuro-transmission produced by inflammatory mediators. Compared with septic patients, SAE patients had higher interleukin-1 beta (IL-1 beta) plasma levels; interestingly, these levels decreased once the encephalopathy was resolved. A putative IL-1 beta effect on type A gamma-aminobutyric acid receptors (GABAARs), which mediate fast synaptic transmission in most cerebral inhibitory synapses in mammals, was investigated in cultured hippocampal neurons and in Xenopus oocytes expressing native or foreign rat brain GABAARs, respectively. Confocal images in both cell types revealed that IL-1 beta increases recruitment of GABAARs to the cell surface. Moreover, brief applications of IL-1 beta to voltage-clamped oocytes yielded a delayed potentiation of the GABA-elicited chloride currents (I-GABA); this effect was suppressed by IL-1ra, the natural IL- 1 receptor (IL-1RI) antagonist. Western blot analysis combined with IGABA recording and confocal images of GABAARs in oocytes showed that IL-1 beta stimulates the IL-1RI-dependent phosphatidylinositol 3- kinase activation and the consequent facilitation of phospho-Akt-mediated insertion of GABAARs into the cell surface. The interruption of this signaling pathway by specific phosphatidylinositol 3- kinase or Akt inhibitors suppresses the cytokine-mediated effects on GABA(A)R, whereas activation of the conditionally active form of Akt1 (myr-Akt1.ER*) with 4-hydroxytamoxifen reproduces the effects. These findings point to a previously unrecognized signaling pathway that connects IL-1 beta with increased "GABAergic tone." We propose that through this mechanism IL-1 beta might alter synaptic strength at central GABAergic synapses and so contribute to the cognitive dysfunction observed in SAE.	Univ Autonoma Madrid, Dept Farmacol, Fac Med, Madrid 28029, Spain; Univ Autonoma Madrid, Dept Bioquim, Fac Med, Madrid 28029, Spain; Univ Autonoma Madrid, Dept Anat Histol & Neurociencia, Fac Med, Madrid 28029, Spain; Hosp Univ La Paz, Dept Med, Madrid, Spain; Consejo Super Invest Cientificas, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Univ Basque Country, Fac Med, Dept Neurociencias, Leioa 48940, Spain	Autonomous University of Madrid; Autonomous University of Madrid; Autonomous University of Madrid; Hospital Universitario La Paz; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Basque Country	Montiel, C (corresponding author), Univ Autonoma Madrid, Dept Farmacol, Fac Med, Arzobispo Morcillo 4, Madrid 28029, Spain.	carmen.montiel@uam.es	Arnalich, Francisco/AAF-5924-2021; Renart, Jaime/B-7661-2009; Arnalich, Francisco/J-8184-2017; Arnalich, Francisco/K-7723-2014; Montiel, Carmen/L-1407-2017; Matute, Carlos/N-5559-2014; Andres-Mateos, Eva/B-4691-2008; Cavada, Carmen/AAG-7021-2020; Cavada, Carmen/L-4564-2013	Arnalich, Francisco/0000-0003-2943-0373; Renart, Jaime/0000-0001-6620-3706; Montiel, Carmen/0000-0003-4845-0484; Matute, Carlos/0000-0001-8672-711X; Cavada, Carmen/0000-0001-7230-1388; Cavada, Carmen/0000-0001-7230-1388; Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				Arnalich F, 1999, J INFECT DIS, V180, P908, DOI 10.1086/314963; Arnalich F, 2002, CLIN EXP IMMUNOL, V127, P331, DOI 10.1046/j.1365-2249.2002.01743.x; Arnalich F, 2000, INFECT IMMUN, V68, P1942, DOI 10.1128/IAI.68.4.1942-1945.2000; Auriant I, 1998, CRIT CARE MED, V26, P1368, DOI 10.1097/00003246-199808000-00023; Balduzzi R, 2001, BBA-MOL CELL RES, V1539, P93, DOI 10.1016/S0167-4889(01)00097-0; Banks WA, 1997, J NEUROIMMUNOL, V79, P22, DOI 10.1016/S0165-5728(97)00103-3; Basler T, 2002, INTENS CARE MED, V28, P293, DOI 10.1007/s00134-002-1217-6; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; BREDER CD, 1988, SCIENCE, V240, P321, DOI 10.1126/science.3258444; Chang YC, 1996, J NEUROSCI, V16, P5415; Coogan A, 1997, NEUROREPORT, V8, P2107, DOI 10.1097/00001756-199707070-00004; Dantzer R, 2001, ANN NY ACAD SCI, V933, P222; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Davies DC, 2002, J ANAT, V200, P639, DOI 10.1046/j.1469-7580.2002.00065.x; De Simoni MG, 1998, BIOL SIGNAL RECEPT, V7, P33; Diem R, 2003, MOL CELL NEUROSCI, V22, P487, DOI 10.1016/S1044-7431(02)00042-8; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dunn AJ, 1998, ANN NY ACAD SCI, V840, P577, DOI 10.1111/j.1749-6632.1998.tb09596.x; Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470; Filippova N, 2000, MOL PHARMACOL, V57, P847; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hellstrom IC, 2005, HIPPOCAMPUS, V15, P656, DOI 10.1002/hipo.20086; Herrero CJ, 1999, BRIT J PHARMACOL, V127, P1375, DOI 10.1038/sj.bjp.0702692; Herrero CJ, 2002, J NEUROSCI, V22, P377, DOI 10.1523/JNEUROSCI.22-02-00377.2002; HOUAMED KM, 1984, NATURE, V310, P318, DOI 10.1038/310318a0; Ikegaya Y, 2003, SYNAPSE, V47, P54, DOI 10.1002/syn.10154; Jones EA, 1997, J NEUROL NEUROSUR PS, V63, P279, DOI 10.1136/jnnp.63.3.279; Klein D, 2003, SHOCK, V20, P536, DOI 10.1097/01.shk.0000093345.68755.98; Konsman JP, 2002, TRENDS NEUROSCI, V25, P154, DOI 10.1016/S0166-2236(00)02088-9; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; KRUEGER JM, 1984, AM J PHYSIOL, V246, P994; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Luk WP, 1999, J NEUROSCI, V19, P4238; Luscher B, 2004, PHARMACOL THERAPEUT, V102, P195, DOI 10.1016/j.pharmthera.2004.04.003; Matsumoto Y, 2001, EUR J PHARMACOL, V430, P283, DOI 10.1016/S0014-2999(01)01374-7; MILEDI R, 1982, EMBO J, V1, P1307, DOI 10.1002/j.1460-2075.1982.tb01315.x; MILLER LG, 1991, MOL PHARMACOL, V39, P105; Palma E, 2005, P NATL ACAD SCI USA, V102, P1667, DOI 10.1073/pnas.0409442102; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; PETER AB, 1991, J CELL BIOL, V114, P455, DOI 10.1083/jcb.114.3.455; Pintado AJ, 2000, BRIT J PHARMACOL, V130, P1893, DOI 10.1038/sj.bjp.0703519; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004; ROSENBERG SA, 1989, J CLIN ONCOL, V7, P1863, DOI 10.1200/JCO.1989.7.12.1863; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Sanchez-Gonzalez MA, 2005, J NEUROSCI, V25, P6076, DOI 10.1523/JNEUROSCI.0968-05.2005; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; Solis-Garrido LM, 2004, J BIOL CHEM, V279, P52414, DOI 10.1074/jbc.M408872200; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; Tabellini G, 2004, BRIT J HAEMATOL, V126, P574, DOI 10.1111/j.1365-2141.2004.05073.x; TEASDALE G, 1974, LANCET, V2, P81; Thompson SA, 1999, MOL PHARMACOL, V55, P993, DOI 10.1124/mol.55.6.993; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANRENTERGHEM C, 1987, MOL BRAIN RES, V2, P21, DOI 10.1016/0169-328X(87)90017-9; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200; Viviani B, 2003, J NEUROSCI, V23, P8692; Voigt K, 2002, FREE RADICAL RES, V36, P735, DOI 10.1080/10715760290032557; Wang QH, 2003, NEURON, V38, P915, DOI 10.1016/S0896-6273(03)00356-8; Wang S, 2000, J PHARMACOL EXP THER, V292, P497; Wilson JX, 2003, CAN J NEUROL SCI, V30, P98, DOI 10.1017/S031716710005335X; WINGROVE PB, 1994, P NATL ACAD SCI USA, V91, P4569, DOI 10.1073/pnas.91.10.4569; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016; ZEISE ML, 1992, REGUL PEPTIDES, V39, P1, DOI 10.1016/0167-0115(92)90002-C; Zeise ML, 1997, BRAIN RES, V768, P341, DOI 10.1016/S0006-8993(97)00787-7	70	91	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14632	14643		10.1074/jbc.M512489200	http://dx.doi.org/10.1074/jbc.M512489200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16567807	hybrid			2022-12-25	WOS:000237671300015
J	Harris, ES; Rouiller, I; Hanein, D; Higgs, HN				Harris, Elizabeth S.; Rouiller, Isabelle; Hanein, Dorit; Higgs, Henry N.			Mechanistic differences in actin bundling activity of two mammalian formins, FRL1 and mDia2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGY-2 DOMAIN; CAPPING PROTEIN; ALPHA-ACTININ; MOUSE FORMIN; BARBED END; FH2 DOMAIN; F-ACTIN; PROFILIN; POLYMERIZATION; NUCLEATION	Formin proteins are regulators of actin dynamics, mediating assembly of unbranched actin filaments. These multidomain proteins are defined by the presence of a Formin Homology 2 (FH2) domain. Previous work has shown that FH2 domains bind to filament barbed ends and move processively at the barbed end as the filament elongates. Here we report that two FH2 domains, from mammalian FRL1 and mDia2, also bundle filaments, whereas the FH2 domain from mDia1 cannot under similar conditions. The FH2 domain alone is sufficient for bundling. Bundled filaments made by either FRL1 or mDia2 are in both parallel and anti-parallel orientations. A novel property that might contribute to bundling is the ability of the dimeric FH2 domains from both FRL1 and mDia2 to dissociate and recombine. This property is not observed for mDia1. A difference between FRL1 and mDia2 is that FRL1-mediated bundling is competitive with barbed end binding, whereas mDia2-mediated bundling is not. Mutation of a highly conserved isoleucine residue in the FH2 domain does not inhibit bundling by either FRL1 or mDia2, but inhibits barbed end activities. However, the severity of this mutation varies between formins. For mDia1 and mDia2, the mutation strongly inhibits all effects of barbed end binding, but affects FRL1 much less strongly. Furthermore, our results suggest that the Ile mutation affects processivity. Taken together, our data suggest that the bundling activities of FRL1 and mDia2, while producing phenotypically similar bundles, differ in mechanistic detail.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Burnham Inst, Cell Adhes Program, La Jolla, CA 92037 USA	Dartmouth College; Sanford Burnham Prebys Medical Discovery Institute	Higgs, HN (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	henry.higgs@dartmouth.edu	Rouiller, Isabelle/AAE-9637-2019; rouiller, isabelle/K-7679-2012	rouiller, isabelle/0000-0002-1288-8575; Higgs, Henry/0000-0002-2917-9644	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008704, R01GM069818] Funding Source: NIH RePORTER; NIGMS NIH HHS [U54 GM646346, T32 GM08704, GM-069818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Cramer LP, 1997, J CELL BIOL, V136, P1287, DOI 10.1083/jcb.136.6.1287; Gasteier JE, 2003, J BIOL CHEM, V278, P38902, DOI 10.1074/jbc.M306229200; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; HOU L, 1990, J CELL BIOL, V110, P1645, DOI 10.1083/jcb.110.5.1645; Kovar DR, 2006, CELL, V124, P423, DOI 10.1016/j.cell.2005.11.038; Kovar DR, 2005, MOL BIOL CELL, V16, P2313, DOI 10.1091/mbc.E04-09-0781; Kuhn JR, 2005, BIOPHYS J, V88, P1387, DOI 10.1529/biophysj.104.047399; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; MABUCHI I, 1988, P NATL ACAD SCI USA, V85, P5966, DOI 10.1073/pnas.85.16.5966; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Madrid R, 2005, FEBS LETT, V579, P441, DOI 10.1016/j.febslet.2004.12.009; Michelot A, 2005, PLANT CELL, V17, P2296, DOI 10.1105/tpc.105.030908; MOOSEKER MS, 1975, J CELL BIOL, V67, P725, DOI 10.1083/jcb.67.3.725; Moseley JB, 2005, J BIOL CHEM, V280, P28023, DOI 10.1074/jbc.M503094200; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; Nicholson-Dykstra S, 2005, CURR BIOL, V15, pR346, DOI 10.1016/j.cub.2005.04.029; OTOMO T, 2005, NATURE, V13, P511; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; Schirenbeck A, 2005, NAT CELL BIOL, V7, P619, DOI 10.1038/ncb1266; Schirenbeck A, 2005, BIOCHEM SOC T, V33, P1256, DOI 10.1042/BST0331256; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Small J V, 1988, Electron Microsc Rev, V1, P155; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Takeya R, 2003, J CELL SCI, V116, P4567, DOI 10.1242/jcs.00769; Tseng Y, 2004, J BIOL CHEM, V279, P1819, DOI 10.1074/jbc.M306090200; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057	39	134	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14383	14392		10.1074/jbc.M510923200	http://dx.doi.org/10.1074/jbc.M510923200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16556604	hybrid			2022-12-25	WOS:000237512300065
J	Kartvelishvily, E; Shleper, M; Balan, L; Dumin, E; Wolosker, H				Kartvelishvily, Elena; Shleper, Maria; Balan, Livia; Dumin, Elena; Wolosker, Herman			Neuron-derived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATHIONINE BETA-SYNTHASE; GLYCINE TRANSPORTER GLYT1; NEUROMODULATOR D-SERINE; RAT-BRAIN; SYNAPTIC VESICLES; AMINO-ACIDS; POSTNATAL-DEVELOPMENT; HIPPOCAMPAL-NEURONS; PROTON GRADIENT; NMDA RECEPTORS	D-Serine is a coagonist of N-methyl-D-aspartate ( NMDA) receptors that occurs at high levels in the brain. Biosynthesis of D-serine is carried out by serine racemase, which converts L-to D-serine. D-Serine has been demonstrated to occur in glial cells, leading to the proposal that astrocytes are the only source of D-serine. We now report significant amounts of serine racemase and D-serine in primary neuronal cultures and neurons in vivo. Several neuronal culture types expressed serine racemase, and D-serine synthesis was comparable with that in glial cultures. Immunohistochemical staining of brain sections with new antibodies revealed the presence of serine racemase and D-serine in neurons. Cortical neurons expressing serine racemase also expressed the NR2a subunit in situ. Neuron-derived D-serine contributes to NMDA receptor activation in cortical neuronal cultures. Degradation of endogenous D-serine by addition of the recombinant enzyme D-serine deaminase diminished NMDA-elicited excitotoxicity. Release of neuronal D-serine was mediated by ionotropic glutamate receptor agonists such as NMDA, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid, and kainate. Removal of either external Ca2+ or Na+ blocked D-serine release. Release of D-serine was mostly through a cytosolic route because it was insensitive to bafilomycin A(1), a potent inhibitor of vesicular neurotransmitter uptake. D-Serine was also not transported into purified synaptic vesicles under conditions optimal for the uptake of known transmitters. Our results suggest that neurons are a major source of D-serine. Glutamate-induced neuronal D-serine release provides a novel mechanism for activating NMDA receptors by an autocrine or paracrine way.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Wolosker, H (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel.	hwolosker@tx.technion.ac.il		Wolosker, Herman/0000-0001-5508-9194				ADAMS RH, 1995, J NEUROSCI, V15, P2524, DOI 10.1523/JNEUROSCI.15-03-02524.1995; ANDERSON DC, 1982, BIOCHEMISTRY-US, V21, P3037, DOI 10.1021/bi00256a001; Boehning D, 2003, ANNU REV NEUROSCI, V26, P105, DOI 10.1146/annurev.neuro.26.041002.131047; Bradford SE, 2004, NEUROSCIENCE, V128, P751, DOI 10.1016/j.neuroscience.2004.06.065; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CARLSON MD, 1990, NEUROSCI LETT, V110, P325, DOI 10.1016/0304-3940(90)90868-A; Ciriacks CM, 2006, NEUROSCI LETT, V393, P200, DOI 10.1016/j.neulet.2005.09.080; Danysz W, 1998, PHARMACOL REV, V50, P597; De Miranda J, 2000, GENE, V256, P183, DOI 10.1016/S0378-1119(00)00356-5; de Miranda J, 2002, P NATL ACAD SCI USA, V99, P14542, DOI 10.1073/pnas.222421299; de Tomasi JA, 1936, STAIN TECHNOL, V11, P137, DOI 10.3109/10520293609110513; Dravid SM, 2003, NEUROSCI LETT, V351, P145, DOI 10.1016/j.neulet.2003.07.017; Foltyn VN, 2005, J BIOL CHEM, V280, P1754, DOI 10.1074/jbc.M405726200; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; Furuya S, 2000, P NATL ACAD SCI USA, V97, P11528, DOI 10.1073/pnas.200364497; GIUFFRIDA AM, 1975, ITAL J BIOCHEM, V24, P288; Hanada K, 2000, J BIOL CHEM, V275, P8409, DOI 10.1074/jbc.275.12.8409; Harlow E., 1988, ANTIBODIES LAB MANUA, P343; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; HASHIMOTO A, 1993, J NEUROCHEM, V60, P783, DOI 10.1111/j.1471-4159.1993.tb03219.x; HASHIMOTO A, 1992, FEBS LETT, V296, P33, DOI 10.1016/0014-5793(92)80397-Y; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Helboe L, 2003, EUR J NEUROSCI, V18, P2227, DOI 10.1046/j.1460-9568.2003.02966.x; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; Hoyt KR, 1998, MOL PHARMACOL, V53, P742, DOI 10.1124/mol.53.4.742; Janosik M, 2001, BIOCHEMISTRY-US, V40, P10625, DOI 10.1021/bi010711p; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JOHNSON RG, 1981, J BIOL CHEM, V256, P5773; Kim PM, 2005, P NATL ACAD SCI USA, V102, P2105, DOI 10.1073/pnas.0409723102; Lenhard B, 1999, NUCLEIC ACIDS RES, V27, P721, DOI 10.1093/nar/27.3.721; MARCEAU M, 1988, J BIOL CHEM, V263, P16926; Matsuo H, 2004, NEUROSCI LETT, V358, P123, DOI 10.1016/j.neulet.2004.01.014; Molina JA, 1998, J NEURAL TRANSM, V105, P279, DOI 10.1007/s007020050057; Mothet JP, 2005, P NATL ACAD SCI USA, V102, P5606, DOI 10.1073/pnas.0408483102; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; OTTERSEN OP, 1990, GLYCINE NEUROTRANSMI; Panizzutti R, 2001, P NATL ACAD SCI USA, V98, P5294, DOI 10.1073/pnas.091002298; PellegriniGiampietro DE, 1997, TRENDS NEUROSCI, V20, P464, DOI 10.1016/S0166-2236(97)01100-4; RAO VLR, 1995, J NEUROCHEM, V65, P1221; Ribeiro CS, 2002, BRAIN RES, V929, P202, DOI 10.1016/S0006-8993(01)03390-X; Robert K, 2003, J HISTOCHEM CYTOCHEM, V51, P363, DOI 10.1177/002215540305100311; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Schell MJ, 1997, J NEUROSCI, V17, P1604; Schubert D, 2001, J NEUROSCI, V21, P7455, DOI 10.1523/JNEUROSCI.21-19-07455.2001; Shleper M, 2005, J NEUROSCI, V25, P9413, DOI 10.1523/JNEUROSCI.3190-05.2005; Snyder SH, 2000, AM J PSYCHIAT, V157, P1738, DOI 10.1176/appi.ajp.157.11.1738; Stevens ER, 2003, P NATL ACAD SCI USA, V100, P6789, DOI 10.1073/pnas.1237052100; Strisovsky K, 2005, BIOCHEMISTRY-US, V44, P13091, DOI 10.1021/bi051201o; Tagliaferro P, 1997, J NEUROSCI METH, V77, P191, DOI 10.1016/S0165-0270(97)00126-X; Takano T, 2005, P NATL ACAD SCI USA, V102, P16466, DOI 10.1073/pnas.0506382102; Troyer H., 1980, PRINCIPLES TECHNIQUE; Verleysdonk S, 1999, GLIA, V27, P239, DOI 10.1002/(SICI)1098-1136(199909)27:3<239::AID-GLIA5>3.0.CO;2-K; Wang LZ, 2003, ACTA PHARMACOL SIN, V24, P965; Williams SM, 2006, GLIA, V53, P401, DOI 10.1002/glia.20300; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Wolosker H, 2002, NEUROCHEM INT, V41, P327, DOI 10.1016/S0197-0186(02)00055-4; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721; Wolosker H, 1996, J BIOL CHEM, V271, P11726, DOI 10.1074/jbc.271.20.11726; Wood PL, 1996, J NEUROCHEM, V67, P1485; Yamasaki M, 2001, J NEUROSCI, V21, P7691, DOI 10.1523/JNEUROSCI.21-19-07691.2001; Yang YL, 2003, P NATL ACAD SCI USA, V100, P15194, DOI 10.1073/pnas.2431073100; Yasuda E, 2001, NEUROSCI LETT, V299, P162, DOI 10.1016/S0304-3940(01)01502-6; Zafra F, 1997, GLIA, V20, P155, DOI 10.1002/(SICI)1098-1136(199706)20:2<155::AID-GLIA7>3.0.CO;2-8; Zhou Q, 2000, J PHYSIOL-LONDON, V525, P195, DOI 10.1111/j.1469-7793.2000.t01-1-00195.x	65	219	225	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14151	14162		10.1074/jbc.M512927200	http://dx.doi.org/10.1074/jbc.M512927200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551623	hybrid			2022-12-25	WOS:000237512300039
J	Nashchekin, D; Zhao, J; Visa, N; Daneholt, B				Nashchekin, Dmitri; Zhao, Jian; Visa, Neus; Daneholt, Bertil			A novel Ded1-like RNA helicase interacts with the Y-box protein ctYB-1 in nuclear mRNP particles and in polysomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEOPROTEIN PARTICLES; MAJOR CORE PROTEIN; COLD-SHOCK DOMAIN; BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; TRANSLATIONAL REPRESSION; GERM-CELLS; INITIATION	We have characterized a novel mRNA-binding protein, designated hrp84, in the dipteran Chironomus tentans and identified it as a DEAD-box RNA helicase. The protein contains the typical helicase core domain, a glycine-rich C-terminal part and a putative nuclear export signal in the N terminus. The protein belongs to the Ded1 subgroup of DEAD-box helicases, which is highly conserved from yeast (Ded1p) to mammals (DDX3). In tissue culture cells, hrp84 is present both in the nucleus and cytoplasm and, as shown by in vivo UV cross-linking, is bound to mRNA in both compartments. Immunoprecipitation experiments revealed that hpr84 is associated with the C. tentans homologue (ctYB-1) of the vertebrate Y-box protein YB-1 both in the nucleus and cytoplasm, and the two proteins also appear together in polysomes. The interaction is likely to be direct as shown by in vitro binding of purified components. We conclude that the mRNA-bound hrp84.ctYB-1 complex is formed in the nucleus and is translocated with mRNA into the cytoplasm and further into polysomes. As both Ded1 and YB-1 are known to regulate the initiation of translation, we propose that the RNA helicase-Y-box protein complex affects the efficiency of mRNA translation, presumably by modulating the conformation of the mRNP template.	Karolinska Inst, Dept Cell & Mol Biol, Med Nobel Inst, SE-17177 Stockholm, Sweden	Karolinska Institutet	Daneholt, B (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Med Nobel Inst, SE-17177 Stockholm, Sweden.	bertil.daneholt@ki.se	Visa, Neus/C-9459-2016; Visa, Neus/R-8037-2019; Zhao, Jian/F-9991-2019	Visa, Neus/0000-0003-3145-3953; Visa, Neus/0000-0003-3145-3953; Nashchekin, Dmitry/0000-0001-7372-0752; Zhao, Jian/0000-0001-5659-730X				Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Berthelot K, 2004, MOL MICROBIOL, V51, P987, DOI 10.1046/j.1365-2958.2003.03898.x; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Daneholt B, 2001, P NATL ACAD SCI USA, V98, P7012, DOI 10.1073/pnas.111145498; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; delaCruz J, 1997, P NATL ACAD SCI USA, V94, P5201, DOI 10.1073/pnas.94.10.5201; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; Gardiol A, 2001, Results Probl Cell Differ, V34, P105; GEE SL, 1994, GENE, V140, P171, DOI 10.1016/0378-1119(94)90541-X; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GURURAJAN R, 1991, NATURE, V349, P717, DOI 10.1038/349717a0; Hayashi N, 1996, MOL GEN GENET, V253, P149, DOI 10.1007/s004380050307; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; JAMIESON DJ, 1991, MOL MICROBIOL, V5, P805, DOI 10.1111/j.1365-2958.1991.tb00753.x; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; Jiang WN, 1997, J BIOL CHEM, V272, P196; Johnstone O, 2005, DEV BIOL, V277, P92, DOI 10.1016/j.ydbio.2004.09.009; Jones PG, 1996, P NATL ACAD SCI USA, V93, P76, DOI 10.1073/pnas.93.1.76; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kawaoka J, 2004, NAT STRUCT MOL BIOL, V11, P526, DOI 10.1038/nsmb771; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Ladomery M, 1997, NUCLEIC ACIDS RES, V25, P965, DOI 10.1093/nar/25.5.965; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; Linder P, 2003, BIOL CELL, V95, P157, DOI 10.1016/S0248-4900(03)00032-7; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Mansfield JH, 2002, DEVELOPMENT, V129, P197; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; Minshall N, 2004, NUCLEIC ACIDS RES, V32, P1325, DOI 10.1093/nar/gkh303; Nakamura A, 2001, DEVELOPMENT, V128, P3233; Nekrasov MP, 2003, J BIOL CHEM, V278, P13936, DOI 10.1074/jbc.M209145200; Olsen LC, 1997, MECH DEVELOP, V66, P95, DOI 10.1016/S0925-4773(97)00099-3; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; Pisarev AV, 2002, J BIOL CHEM, V277, P15445, DOI 10.1074/jbc.M111954200; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Schwer B, 2001, NAT STRUCT BIOL, V8, P113, DOI 10.1038/84091; Sekiguchi T, 2004, EXP CELL RES, V300, P213, DOI 10.1016/j.yexcr.2004.07.005; Silverman E, 2003, GENE, V312, P1, DOI 10.1016/S0378-1119(03)00626-7; Skabkin MA, 2001, J BIOL CHEM, V276, P44841, DOI 10.1074/jbc.M107581200; Skabkin MA, 2004, NUCLEIC ACIDS RES, V32, P5621, DOI 10.1093/nar/gkh889; Smillie DA, 2002, J CELL SCI, V115, P395; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; Soop T, 2003, J CELL SCI, V116, P1493, DOI 10.1242/jcs.00353; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Sun X, 1998, J CELL BIOL, V142, P1181, DOI 10.1083/jcb.142.5.1181; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; Svitkin YV, 2001, RNA, V7, P1743; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Wang Y, 1998, RNA, V4, P1216, DOI 10.1017/S1355838298980992; Wilhelm JE, 2000, J CELL BIOL, V148, P427, DOI 10.1083/jcb.148.3.427; WOLFFE AP, 1992, NEW BIOL, V4, P290; WYSS C, 1982, EXP CELL RES, V139, P309, DOI 10.1016/0014-4827(82)90255-5; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999	76	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14263	14272		10.1074/jbc.M600262200	http://dx.doi.org/10.1074/jbc.M600262200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16556597	hybrid			2022-12-25	WOS:000237512300051
J	Hawkins, KM; Smolke, CD				Hawkins, KM; Smolke, CD			The regulatory roles of the galactose permease and kinase in the induction response of the GAL network in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; GENE-EXPRESSION; QUANTITATIVE MODEL; ESCHERICHIA-COLI; YEAST; PROMOTER; SYSTEM; TRANSPORTER; SWITCH; GALACTOKINASE	The GAL genetic switch of Saccharomyces cerevisiae exhibits an ultrasensitive response to the inducer galactose as well as the " all-or-none" behavior characteristic of many eukaryotic regulatory networks. We have constructed a strain that allows intermediate levels of gene expression from a tunable GAL1 promoter at both the population and the single cell level by altering the regulation of the galactose permease Gal2p. Similar modifications to other feedback loops regulating the Gal80p repressor and the Gal3p signaling protein did not result in similarly tuned responses, indicating that the level of inducer transport is unique in its ability to control the switch response of the network. In addition, removal of the Gal1p galactokinase from the network resulted in a regimed response due to the dual role of this enzyme in galactose catabolism and transport. These two activities have competing effects on the response of the network to galactose such that the transport effects of Gal1p are dominant at low galactose concentrations, whereas its catabolic effects are dominant at high galactose concentrations. In addition, flow cytometry analysis revealed the unexpected phenomenon of multiple populations in the gal1 Delta strains, which were not present in the isogenic GAL1 background. This result indicates that Gal1p may play a previously undescribed role in the stability of the GAL network response.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Smolke, CD (corresponding author), CALTECH, Dept Chem Engn, 1200 E Calif Blvd,MC 210-41, Pasadena, CA 91125 USA.	smolke@cheme.caltech.edu						Acar M, 2005, NATURE, V435, P228, DOI 10.1038/nature03524; Belli G, 1998, NUCLEIC ACIDS RES, V26, P942, DOI 10.1093/nar/26.4.942; BHAT PJ, 1990, GENETICS, V125, P281; Bhat PJ, 2005, FEBS LETT, V579, P597, DOI 10.1016/j.febslet.2004.12.038; Funk M, 2002, METHOD ENZYMOL, V350, P248, DOI 10.1016/S0076-6879(02)50967-8; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Horak J, 1997, J BACTERIOL, V179, P1541, DOI 10.1128/jb.179.5.1541-1549.1997; JOHNSTON M, 2004, METHOD ENZYMOL, V194, P290; Khlebnikov A, 2001, MICROBIOL-SGM, V147, P3241, DOI 10.1099/00221287-147-12-3241; Koller A, 2000, YEAST, V16, P651, DOI 10.1002/(SICI)1097-0061(200005)16:7<651::AID-YEA580>3.3.CO;2-6; Koshland DE, 1998, SCIENCE, V280, P852, DOI 10.1126/science.280.5365.852; LAMPHIER MS, 1992, P NATL ACAD SCI USA, V89, P5922, DOI 10.1073/pnas.89.13.5922; Li JC, 2000, BIOTECHNOL BIOENG, V70, P187, DOI 10.1002/1097-0290(20001020)70:2<187::AID-BIT8>3.0.CO;2-H; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOUIS M, 2002, SCI STKE, pPE33; MascorroGallardo JO, 1996, GENE, V172, P169, DOI 10.1016/0378-1119(96)00059-5; Mateus C, 2000, YEAST, V16, P1313, DOI 10.1002/1097-0061(200010)16:14<1313::AID-YEA626>3.0.CO;2-O; Morgan-Kiss RM, 2002, P NATL ACAD SCI USA, V99, P7373, DOI 10.1073/pnas.122227599; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; Peng G, 2002, P NATL ACAD SCI USA, V99, P8548, DOI 10.1073/pnas.142100099; RAMOS J, 1989, J BACTERIOL, V171, P3539, DOI 10.1128/jb.171.6.3539-3544.1989; Ruhela A, 2004, FEBS LETT, V576, P119, DOI 10.1016/j.febslet.2004.09.001; SCHELL MA, 1977, J BIOL CHEM, V252, P1162; SIKORSKI RS, 1989, GENETICS, V122, P19; Solow SP, 2005, BIOTECHNOL PROGR, V21, P617, DOI 10.1021/bp049916q; Stagoj MN, 2005, FEMS MICROBIOL LETT, V244, P105, DOI 10.1016/j.femsle.2005.01.041; Thoden JB, 2005, J BIOL CHEM, V280, P36905, DOI 10.1074/jbc.M508446200; Venkatesh KV, 1999, BIOTECHNOL PROGR, V15, P51, DOI 10.1021/bp9801042; Verma M, 2004, BIOTECHNOL APPL BIOC, V39, P89, DOI 10.1042/BA20030119; Verma M, 2003, J BIOL CHEM, V278, P48764, DOI 10.1074/jbc.M303526200; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yen KY, 2003, YEAST, V20, P1255, DOI 10.1002/yea.1037	33	40	48	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13485	13492		10.1074/jbc.M512317200	http://dx.doi.org/10.1074/jbc.M512317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16524886	hybrid, Green Accepted			2022-12-25	WOS:000237336600056
J	Lu, B; Garrido, N; Spelbrink, JN; Suzuki, CK				Lu, B; Garrido, N; Spelbrink, JN; Suzuki, CK			Tid1 isoforms are mitochondrial DnaJ-like chaperones with unique carboxyl termini that determine cytosolic fate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA TUMOR-SUPPRESSOR; MOLECULAR CHAPERONES; CRYSTAL-STRUCTURE; BINDING PROTEIN; HUMAN HOMOLOG; T-ANTIGENS; J-DOMAIN; HTID-1; HSP70; YEAST	Tid1 is a human homolog of bacterial DnaJ and the Drosophila tumor suppressor Tid56 that has two alternatively spliced isoforms, Tid1-long and -short (Tid1-L and -S), which differ only at their carboxyl termini. Although Tid1 proteins localize overwhelmingly to mitochondria, published data demonstrate principally nonmito-chondrial protein interactions and activities. This study was undertaken to determine whether Tid1 proteins function as mitochondrial DnaJ-like chaperones and to resolve the paradox of how proteins targeted primarily to mitochondria function in nonmito-chondrial pathways. Here we demonstrate that Tid1 isoforms exhibit a conserved mitochondrial DnaJ-like function substituting for the yeast mitochondrial DnaJ-like protein Mdj1p. Like Mdj1p, Tid1 localizes to human mitochondrial nucleoids, which are large protein complexes bound to mitochondrial DNA. Unlike other DnaJs, Tid1-L and -S form heterocomplexes; both unassembled and complexed Tid1 are observed in human cells. Results demonstrate that Tid1-L has a longer residency time in the cytosol prior to mitochondrial import as compared with Tid1-S; Tid1-L is also significantly more stable in the cytosol than Tid1-S, which is rapidly degraded. The longer cytosolic residency time and the half-life of Tid1-L are explained by its interaction with cytosolic Hsc70 and potential protein substrates such as the STAT1 and STAT3 transcription factors. We show that the unique carboxyl terminus of Tid1-L is required for interaction with Hsc70 and STAT1 and -3. We propose that the association of Tid1 with chaperones and/or protein substrates in the cytosol provides a mechanism for the alternate fates and functions of Tid1 in mitochondrial and nonmito-chondrial pathways.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Tampere Univ Hosp, Inst Med Technol, FIN-33014 Tampere, Finland; Tampere Univ, FIN-33014 Tampere, Finland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Tampere University; Tampere University Hospital; Tampere University	Suzuki, CK (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	suzukick@umdnj.edu	Spelbrink, Johannes N/L-4661-2015; Lu, Bin/GQQ-3590-2022	Spelbrink, Johannes N/0000-0002-9756-2602; 				Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Asai T, 2004, J BIOL CHEM, V279, P19464, DOI 10.1074/jbc.M401291200; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Duchniewicz M, 1999, MOL CELL BIOL, V19, P8201; Edwards KM, 2004, ONCOGENE, V23, P8419, DOI 10.1038/sj.onc.1207732; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; Fan CY, 2003, CELL STRESS CHAPERON, V8, P309, DOI 10.1379/1466-1268(2003)008<0309:MFROHF>2.0.CO;2; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; Germaniuk A, 2002, J BIOL CHEM, V277, P27801, DOI 10.1074/jbc.M201756200; Gething MJ., 1997, GUIDE BOOK SERIES, P89; Hayashi M, 2006, NAT MED, V12, P128, DOI 10.1038/nm1327; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Kim SW, 2005, CANCER RES, V65, P8784, DOI 10.1158/0008-5472.CAN-04-4422; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; Kurzik-Dumke U, 1998, CELL STRESS CHAPERON, V3, P12, DOI 10.1379/1466-1268(1998)003<0012:MLATEO>2.3.CO;2; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Lemmon SK, 2001, CURR BIOL, V11, pR49, DOI 10.1016/S0960-9822(01)00010-0; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li JZ, 2003, STRUCTURE, V11, P1475, DOI 10.1016/j.str.2003.10.012; Liu HY, 2005, J BIOL CHEM, V280, P19461, DOI 10.1074/jbc.M500313200; Lo JF, 2005, J IMMUNOL, V174, P6105, DOI 10.4049/jimmunol.174.10.6105; Lo JF, 2004, MOL CELL BIOL, V24, P2226, DOI 10.1128/MCB.24.6.2226-2236.2004; Lu B, 2003, GENE, V306, P45, DOI 10.1016/S0378-1119(03)00403-7; McBride Kevin M, 2003, Sci STKE, V2003, pRE13; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Sasaki S, 2002, ONCOGENE, V21, P5024, DOI 10.1038/sj.onc.1205627; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Tarunina M, 2004, MOL CELL BIOL, V24, P10792, DOI 10.1128/MCB.24.24.10792-10801.2004; Torregroza I, 2006, BIOCHEM J, V393, P311, DOI 10.1042/BJ20050785; Trentin GA, 2004, FEBS LETT, V578, P323, DOI 10.1016/j.febslet.2004.11.034; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1; Voos W, 2003, MOL CELL, V11, P1, DOI 10.1016/S1097-2765(03)00002-9; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Westermann B, 1996, MOL CELL BIOL, V16, P7063; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	48	49	50	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13150	13158		10.1074/jbc.M509179200	http://dx.doi.org/10.1074/jbc.M509179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531398	hybrid			2022-12-25	WOS:000237336600020
J	Misra, UK; Deedwania, R; Pizzo, SV				Misra, UK; Deedwania, R; Pizzo, SV			Activation and cross-talk between Akt, NF-kappa B, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; RECEPTOR-RECOGNIZED FORMS; MOLECULAR-MECHANISMS; BINDING-PROTEIN; GROWTH-FACTOR; UP-REGULATION; ER-STRESS; KINASE; ALPHA(2)-MACROGLOBULIN; PHOSPHORYLATION	Binding of activated forms of the proteinase inhibitor alpha(2)-macroglobulin (alpha M-2*) to cell surface-associated GRP78 on 1-LN human prostate cancer cells causes their proliferation. We have now examined the interplay between Akt activation, regulation of apoptosis, the unfolded protein response, and activation of NF-KB in alpha M-2*-induced proliferation of 1-LN cells. Exposure of cells to alpha M-2* (50 pM) induced phosphatidylinositol 3-kinase-dependent activation of Akt by phosphorylation at Thr-308 and Ser-473 with a concomitant 60-80% increase in Akt associated kinase activity. ERK1/2 and p38 MAPK were also activated, but there was only a marginal effect on JNK activation. Treatment of 1-LN cells with alpha M-2* down-regulated apoptosis and promoted NF-KB activation as shown by increases of Bcl-2, p-BadSer-136, p- FOXO1(Ser-) 253, p-GSK3 beta Ser-9, XIAP, NF-KB, cyclin D1, GADD45 beta, p- ASK1Ser-83, and TRAF2 in a time of incubation-dependent manner. alpha 2M* treatment of 1-LN cells, however, showed no increase in the activation of caspase- 3, - 9, or -12. Under these conditions, we observed increased unfolded protein response signaling as evidenced by elevated levels of GRP78, IRE1 alpha, XBP-1, ATF4, ATF6, p- PERK, p-eIF2 alpha, and GADD34 and reduced levels of GADD153. Silencing of GRP78 gene expression by RNAi suppressed activation of Akt(Thr-308), Akt(Ser-473), and IKB kinase alpha kinase. The effects of alpha M-2* on the NF-K B activation, antiapoptotic signaling, unfolded protein response signaling, and proapoptotic signaling were also reversed by this treatment. In conclusion, alpha M-2* promotes cellular proliferation of 1-LN prostate cancer cells by activating MAPK and Akt-dependent signaling, down-regulating apoptotic signaling, and activating unfolded protein response signaling.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	Pizzo001@mc.duke.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Amiri KI, 2005, CANCER METAST REV, V24, P301, DOI 10.1007/s10555-005-1579-7; Arai K, 2004, J NEUROCHEM, V89, P232, DOI 10.1111/j.1471-4159.2004.02317.x; Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Asplin IR, 2000, ARCH BIOCHEM BIOPHYS, V383, P135, DOI 10.1006/abbi.2000.2052; Bhattacharjee G, 2001, J CELL BIOCHEM, V82, P260, DOI 10.1002/jcb.1152; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Chung JY, 2002, J CELL SCI, V115, P679; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Eisenmann KM, 2003, CANCER RES, V63, P8330; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Fotin-Mleczek M, 2004, J BIOL CHEM, V279, P677, DOI 10.1074/jbc.M310969200; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hill MM, 2002, METHOD ENZYMOL, V345, P448; Hung CC, 2003, J BIOL CHEM, V278, P29317, DOI 10.1074/jbc.M302368200; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Jin RG, 2002, DNA CELL BIOL, V21, P491, DOI 10.1089/104454902320219059; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kaneko M, 2003, BIOL PHARM BULL, V26, P931, DOI 10.1248/bpb.26.931; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; LU B, 2006, NAT IMMUNOL, V5, P38; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Mintz PJ, 2003, NAT BIOTECHNOL, V21, P57, DOI 10.1038/nbt774; Misra UK, 1998, CELL SIGNAL, V10, P441, DOI 10.1016/S0898-6568(97)00171-X; Misra UK, 1998, BBA-MOL CELL RES, V1401, P121, DOI 10.1016/S0167-4889(97)00123-7; Misra UK, 1999, J BIOL CHEM, V274, P25785, DOI 10.1074/jbc.274.36.25785; Misra UK, 2005, J BIOL CHEM, V280, P26278, DOI 10.1074/jbc.M414467200; Misra UK, 2005, J LEUKOCYTE BIOL, V78, P187, DOI 10.1189/jlb.1104685; Misra UK, 2005, J IMMUNOL, V174, P2092, DOI 10.4049/jimmunol.174.4.2092; Misra UK, 1998, J BIOL CHEM, V273, P13399, DOI 10.1074/jbc.273.22.13399; MISRA UK, 1994, J BIOL CHEM, V269, P12541; Misra UK, 2004, CELL SIGNAL, V16, P487, DOI 10.1016/j.cellsig.2003.09.010; Misra UK, 2002, J BIOL CHEM, V277, P42082, DOI 10.1074/jbc.M206174200; Misra UK, 2002, J BIOL CHEM, V277, P4069, DOI 10.1074/jbc.M109764200; Misra UK, 2002, J BIOL CHEM, V277, P36509, DOI 10.1074/jbc.M203543200; Montano X, 2004, FEBS LETT, V571, P1, DOI 10.1016/j.febslet.2004.06.088; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakayama K, 2003, BIOCHEM BIOPH RES CO, V308, P353, DOI 10.1016/S0006-291X(03)01393-7; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Otto A, 1998, J UROLOGY, V159, P297, DOI 10.1016/S0022-5347(01)64085-0; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Park HR, 2004, JNCI-J NATL CANCER I, V96, P1300, DOI 10.1093/jnci/djh243; PIZZO SV, 2006, HEMOSTASIS THROMBOSE, P395; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shukla S, 2005, PROSTATE, V64, P224, DOI 10.1002/pros.20217; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Szegezdi E, 2003, ANN NY ACAD SCI, V1010, P186, DOI 10.1196/annals.1299.032; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Twomey C, 2005, J CELL MOL MED, V9, P345, DOI 10.1111/j.1582-4934.2005.tb00360.x; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Uzgare AR, 2003, PROSTATE, V55, P128, DOI 10.1002/pros.10212; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ZQ, 2003, J BIOL CHEM, V278, P11138, DOI 10.1074/jbc.M209108200; Williamson AJK, 2004, J BIOL CHEM, V279, P47912, DOI 10.1074/jbc.M409035200; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Woods YL, 2002, BIOCHEM SOC T, V30, P391, DOI 10.1042/bst0300391; Wu SY, 2004, J BIOL CHEM, V279, P34898, DOI 10.1074/jbc.M405616200; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548; Zhang WM, 1998, CLIN CHEM, V44, P2471; ZU K, 2005, ONCOGENE, V24, P1	91	203	209	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13694	13707		10.1074/jbc.M511694200	http://dx.doi.org/10.1074/jbc.M511694200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543232	hybrid			2022-12-25	WOS:000237336600080
J	Miyagi, S; Nishimoto, M; Saito, T; Ninomiya, M; Sawamoto, K; Okano, H; Muramatsu, M; Oguro, H; Iwama, A; Okuda, A				Miyagi, S; Nishimoto, M; Saito, T; Ninomiya, M; Sawamoto, K; Okano, H; Muramatsu, M; Oguro, H; Iwama, A; Okuda, A			The Sox2 regulatory region 2 functions as a neural stem cell-specific enhancer in the telencephalon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; DIFFERENTIATION; PROLIFERATION; NEUROGENESIS; PRECURSORS; LINEAGES; EMBRYO	Sox2 is expressed at high levels in neuroepithelial stem cells and persists in neural stem/ progenitor cells throughout adulthood. We showed previously that the Sox2 regulatory region 2 ( SRR2) drives strong expression in these cells. Here we generated transgenic mouse strains with the beta- geo reporter gene under the control of the SRR2 in order to examine the spatiotemporal function of this regulatory region. We show that the SRR2 functions specifically in neural stem/ progenitor cells. However, unlike Nestin 2nd intronic enhancer, the SRR2 shows strong regional specificity functioning only in restricted areas of the telencephalon but not in any other portions of the central nervous system such as the spinal cord. We also show by in vitro clonogenic assay that at least some of these SRR2- functioning cells possess the hallmark properties of neural stem cells. In adult brains, we could detect strong beta- geo expression in the subventricular zone of the lateral ventricle and along the rostral migrating stream where actively dividing cells reside. Chromatin immunoprecipitation assays reveal interactions of POU and Sox factors with SRR2 in neural stem/ progenitor cells. Our data also suggest that the specific recruitment of these proteins to the SRR2 in the telencephalon defines the spatiotemporal activity of the enhancer in the developing nervous system.	Saitama Med Univ, Res Ctr Genom Med, Div Dev Biol, Hidaka, Saitama 3501241, Japan; Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Dev Biol, Chiba 2608670, Japan; Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Bridgestone Lab Dev & Regenerat Neurobiol, Shinjuku Ku, Tokyo 1608582, Japan; Saitama Small Enterprise Promot Corp, REDS Grp, Kawaguchi, Saitama 3330844, Japan	Saitama Medical University; Chiba University; Chiba University; Keio University; Keio University	Okuda, A (corresponding author), Saitama Med Univ, Res Ctr Genom Med, Div Dev Biol, 1397-1 Yamane, Hidaka, Saitama 3501241, Japan.	akiokuda@saitama-med.ac.jp	Oguro, Hideyuki/Q-5478-2019; Okano, Hideyuki/I-7584-2019	Oguro, Hideyuki/0000-0002-9070-4575; Saito, Tetsuichiro/0000-0002-1538-1454; Sawamoto, Kazunobu/0000-0003-1984-5129				Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Brazel CY, 2005, AGING CELL, V4, P197, DOI 10.1111/j.1474-9726.2005.00158.x; Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131; Catena R, 2004, J BIOL CHEM, V279, P41846, DOI 10.1074/jbc.M405514200; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; Ellis P, 2004, DEV NEUROSCI-BASEL, V26, P148, DOI 10.1159/000082134; Episkopou V, 2005, TRENDS NEUROSCI, V28, P219, DOI 10.1016/j.tins.2005.03.003; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Hanashima C, 2002, J NEUROSCI, V22, P6526; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; Hitoshi S, 2002, DEVELOPMENT, V129, P233; HOGAN B, 1994, MANIPULATING MOUSE E, P217; Johansson CB, 2002, J NEUROSCI RES, V69, P784, DOI 10.1002/jnr.10376; Josephson R, 1998, DEVELOPMENT, V125, P3087; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Komitova M, 2004, NEUROSCI LETT, V369, P24, DOI 10.1016/j.neulet.2004.07.035; Kondo T, 2004, GENE DEV, V18, P2963, DOI 10.1101/gad.309404; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Miyagi S, 2004, MOL CELL BIOL, V24, P4207, DOI 10.1128/MCB.24.10.4207-4220.2004; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Okano H, 2002, J NEUROSCI RES, V69, P698, DOI 10.1002/jnr.10343; Pevny L, 2005, CURR OPIN NEUROBIOL, V15, P7, DOI 10.1016/j.conb.2005.01.016; Pevny L, 2003, TRENDS NEUROSCI, V26, P351, DOI 10.1016/S0166-2236(03)00169-3; Saba R, 2005, DEVELOPMENT, V132, P2147, DOI 10.1242/dev.01781; SEKI T, 1991, ANAT EMBRYOL, V184, P395, DOI 10.1007/BF00957900; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Tanaka S, 2004, MOL CELL BIOL, V24, P8834, DOI 10.1128/MCB.24.20.8834-8846.2004; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; Uchikawa M, 2003, DEV CELL, V4, P509, DOI 10.1016/S1534-5807(03)00088-1; Wiebe MS, 2000, GENE, V246, P383, DOI 10.1016/S0378-1119(00)00086-X; Yoshizaki T, 2004, NEUROSCI LETT, V363, P33, DOI 10.1016/j.neulet.2004.03.074; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zappone MV, 2000, DEVELOPMENT, V127, P2367	38	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13374	13381		10.1074/jbc.M512669200	http://dx.doi.org/10.1074/jbc.M512669200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547000	hybrid			2022-12-25	WOS:000237336600043
J	Wang, XH; Wang, F; Arterburn, L; Wollmann, R; Ma, JY				Wang, XH; Wang, F; Arterburn, L; Wollmann, R; Ma, JY			The interaction between cytoplasmic prion protein and the hydrophobic lipid core of membrane correlates with neurotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRPSC-LIKE CONFORMATION; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE A(2); PROTEASOMAL DEGRADATION; TRANSGENIC MICE; PRIMARY NEURONS; CELL-DEATH; SCRAPIE; NEURODEGENERATION; CONVERSION	Prion protein ( PrP), normally a cell surface protein, has been detected in the cytosol of a subset of neurons. The appearance of PrP in the cytosol could result from either retro- translocation of misfolded PrP from the endoplasmic reticulum ( ER) or impaired import of PrP into the ER. Transgenic mice expressing cytoplasmic PrP ( cyPrP) developed neurodegeneration in cerebellar granular neurons, although no detectable pathology was observed in other brain regions. In order to understand why granular neurons in the cerebellum were most susceptible to cyPrP- induced degeneration, we investigated the subcellular localization of cyPrP. Interestingly, we found that cyPrP is membrane- bound. In transfected cells, it binds to the ER and plasma/ endocytic vesicular membranes. In transgenic mice, it is associated with synaptic and microsomal membranes. Furthermore, the cerebellar neurodegeneration in transgenic mice correlates with the interaction between cyPrP and the hydrophobic lipid core of the membrane but not with either the aggregation status or the dosage of cyPrP. These results suggest that lipid membrane perturbation could be a cellular mechanism for cyPrP- induced neurotoxicity and explain the seemingly conflicting results concerning cyPrP.	Ohio State Univ, Dept Mol & Cellular Biol, Columbus, OH 43210 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University System of Ohio; Ohio State University; University of Chicago	Ma, JY (corresponding author), Ohio State Univ, Dept Mol & Cellular Biol, 1645 Neil Ave, Columbus, OH 43210 USA.	ma.131@osu.edu	Wang, Fei/D-9550-2013	Ma, Jiyan/0000-0001-7150-1898				Barmada SJ, 2005, J NEUROSCI, V25, P5824, DOI 10.1523/JNEUROSCI.1192-05.2005; Baron GS, 2003, J BIOL CHEM, V278, P14883, DOI 10.1074/jbc.M210840200; Bate C, 2004, J GEN VIROL, V85, P3797, DOI 10.1099/vir.0.80366-0; Bate C, 2004, J BIOL CHEM, V279, P36405, DOI 10.1074/jbc.M404086200; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Critchley P, 2004, BIOCHEM BIOPH RES CO, V313, P559, DOI 10.1016/j.bbrc.2003.12.004; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Dunah AW, 2001, J NEUROSCI, V21, P5546, DOI 10.1523/JNEUROSCI.21-15-05546.2001; Farooqui AA, 2004, NEUROCHEM RES, V29, P1961, DOI 10.1007/s11064-004-6871-3; Farooqui AA, 1997, NEUROCHEM INT, V30, P517; Fioriti L, 2005, J BIOL CHEM, V280, P11320, DOI 10.1074/jbc.M412441200; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Gu YP, 2003, NEUROBIOL DIS, V12, P133, DOI 10.1016/S0969-9961(02)00014-1; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; Heller U, 2003, J BIOL CHEM, V278, P36139, DOI 10.1074/jbc.M304002200; Heske J, 2004, J BIOL CHEM, V279, P5435, DOI 10.1074/jbc.M309570200; Ito D, 2004, MOL CELL BIOL, V24, P9456, DOI 10.1128/MCB.24.21.9456-9469.2004; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kristiansen M, 2005, J BIOL CHEM, V280, P38851, DOI 10.1074/jbc.M506600200; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Mange A, 2004, J CELL SCI, V117, P2411, DOI 10.1242/jcs.01094; Mironov A, 2003, J NEUROSCI, V23, P7183, DOI 10.1523/JNEUROSCI.23-18-07183.2003; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Nishiyama A, 2004, MOL BRAIN RES, V125, P1, DOI 10.1016/j.molbrainres.2004.01.012; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Polymenidou M, 2005, LANCET NEUROL, V4, P805, DOI 10.1016/S1474-4422(05)70225-8; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rane NS, 2004, EMBO J, V23, P4550, DOI 10.1038/sj.emboj.7600462; Roucou X, 2003, J BIOL CHEM, V278, P40877, DOI 10.1074/jbc.M306177200; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Seeger H, 2005, SCIENCE, V310, P324, DOI 10.1126/science.1118829; Smaili SS, 2003, BRAZ J MED BIOL RES, V36, P183, DOI 10.1590/S0100-879X2003000200004; Smaili SS, 2000, J BIOENERG BIOMEMBR, V32, P35, DOI 10.1023/A:1005508311495; Strehler EE, 2004, CURR MOL MED, V4, P323, DOI 10.2174/1566524043360735; Wang XH, 2005, J BIOL CHEM, V280, P317, DOI 10.1074/jbc.M410649200; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396	46	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13559	13565		10.1074/jbc.M512306200	http://dx.doi.org/10.1074/jbc.M512306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537534	hybrid			2022-12-25	WOS:000237336600064
J	Cowburn, AS; Sobolewski, A; Reedo, BJ; Deighton, J; Murray, J; Cadwallader, KA; Bradley, JR; Chilvers, ER				Cowburn, AS; Sobolewski, A; Reedo, BJ; Deighton, J; Murray, J; Cadwallader, KA; Bradley, JR; Chilvers, ER			Aminopeptidase N (CD13) regulates tumor necrosis factor-alpha-induced apoptosis in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD NEUTROPHILS; TNF RECEPTOR; POLYMORPHONUCLEAR LEUKOCYTES; GRANULOCYTE APOPTOSIS; AGING NEUTROPHILS; DOWN-REGULATION; IN-VITRO; BESTATIN; INHIBITION; ACTIVATION	Neutrophil apoptosis plays a central role in the resolution of granulocytic inflammation. We have shown previously that tumor necrosis factor-alpha(TNF alpha) enhances the rate of neutrophil apoptosis at early time points via a mechanism involving both TNF receptor ( TNFR) I and TNFRII. Here we reveal a marked but consistent variation in the magnitude of the pro-apoptotic effect of TNF alpha in neutrophils isolated from healthy donors, and we show that inhibition of cell surface aminopeptidaseN(APN) using actinonin, bestatin, or inhibitory peptides significantly enhanced the efficacy of TNF alpha-induced killing. Notably, an inverse correlation is shown to exist between neutrophil APN activity and the sensitivity of donor cells to TNF alpha-induced apoptosis. Inhibition of cell surface APN appears to interfere with the shedding of TNFRI, and as a consequence results in augmented TNF alpha-induced apoptosis, cell polarization, and TNF alpha-primed, formyl-methionyl-leucyl-phenylalanine-stimulated respiratory burst. Of note, actinonin and bestatin had no effect on TNFRII expression under resting or TNF alpha-stimulated conditions and did not alter CXCRI or CXCRII expression. These data suggest significant variation in the activity of APN/CD13 on the cell surface of neutrophils in normal individuals and reveal a novel mechanism whereby APN/CD13 regulates TNF alpha-induced apoptosis via inhibition of TNFRI shedding. This has therapeutic relevance for driving neutrophil apoptosis in vivo.	Univ Cambridge, Addenbrookes Hosp, Resp Med Div, Dept Med,Sch Clin Med, Cambridge CB2 2QQ, England; Univ Cambridge, Papworth Hosp, Resp Med Div, Dept Med,Sch Clin Med, Cambridge CB2 2QQ, England; Univ Edinburgh, Resp Med Unit, MRC, Ctr Inflammat,Sch Med, Edinburgh EH16 4TJ, Midlothian, Scotland	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Papworth Hospital; University of Cambridge; University of Edinburgh	Cowburn, AS (corresponding author), Univ Cambridge, Addenbrookes Hosp, Resp Med Div, Dept Med,Sch Clin Med, Box 157,Hills Rd, Cambridge CB2 2QQ, England.	asc32@cam.ac.uk		Chilvers, Edwin/0000-0002-4230-9677; Bradley, John/0000-0002-7774-8805; Cowburn, Andrew/0000-0001-9145-4275; Sobolewski, Anastasia/0000-0002-8531-1240	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aleman M, 2001, CLIN IMMUNOL, V100, P87, DOI 10.1006/clim.2001.5044; Amoscato AA, 1998, J IMMUNOL, V161, P4023; BAJAJ MS, 1992, INFLAMMATION, V16, P241, DOI 10.1007/BF00918813; Balog T, 1999, IMMUNOPHARMACOLOGY, V41, P11, DOI 10.1016/S0162-3109(98)00050-2; Bhattacharya C, 1997, INDIAN J BIOCHEM BIO, V34, P214; Bhattacharya C, 1997, J IMMUNOL, V158, P1293; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Chitnis D, 1996, J LEUKOCYTE BIOL, V59, P835, DOI 10.1002/jlb.59.6.835; Cowburn AS, 2005, BLOOD, V105, P2970, DOI 10.1182/blood-2004-07-2870; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; Cui XL, 2002, J CLIN INVEST, V110, P515, DOI 10.1172/JCI200213847; DREXLER HG, 1987, LEUKEMIA, V1, P697; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; Dybkaer K, 2001, BRIT J HAEMATOL, V112, P691, DOI 10.1046/j.1365-2141.2001.02613.x; Ertel W, 1998, J TRAUMA, V44, P767, DOI 10.1097/00005373-199805000-00005; Ezawa K, 1996, BIOMED PHARMACOTHER, V50, P283, DOI 10.1016/0753-3322(96)84827-X; Gon S, 1996, MICROBIOL IMMUNOL, V40, P463, DOI 10.1111/j.1348-0421.1996.tb01095.x; Goodman ER, 1998, ARCH SURG-CHICAGO, V133, P1234, DOI 10.1001/archsurg.133.11.1234; Grujic M, 2005, CANCER LETT, V223, P211, DOI 10.1016/j.canlet.2004.10.048; Grujic M, 2002, CANCER LETT, V182, P113, DOI 10.1016/S0304-3835(02)00086-1; Hart SP, 2000, CELL DEATH DIFFER, V7, P493, DOI 10.1038/sj.cdd.4400680; Haslett C, 1997, BRIT MED BULL, V53, P669; HASLETT C, 1985, AM J PATHOL, V119, P101; Huschak G, 2003, CLIN EXP IMMUNOL, V134, P491, DOI 10.1111/j.1365-2249.2003.02302.x; Jimenez MF, 1997, ARCH SURG-CHICAGO, V132, P1263; Keel M, 1997, BLOOD, V90, P3356, DOI 10.1182/blood.V90.9.3356; Khandaker MH, 1999, BLOOD, V93, P2173, DOI 10.1182/blood.V93.7.2173.407a06_2173_2185; Khreiss T, 2004, CELL SIGNAL, V16, P801, DOI 10.1016/j.cellsig.2003.12.005; Larsen SL, 1996, J EXP MED, V184, P183, DOI 10.1084/jem.184.1.183; Lerche C, 1996, MAMM GENOME, V7, P712, DOI 10.1007/s003359900219; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; MACEY MG, 1994, EXP HEMATOL, V22, P967; Marotti T, 2000, NEUROPEPTIDES, V34, P121, DOI 10.1054/npep.2000.0801; MATHE G, 1991, BIOMED PHARMACOTHER, V45, P49, DOI 10.1016/0753-3322(91)90122-A; MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Nolan B, 2000, SHOCK, V14, P290, DOI 10.1097/00024382-200014030-00008; OCONNELL PJ, 1991, J BIOL CHEM, V266, P4593; ORNING L, 1991, J BIOL CHEM, V266, P16507; Petrovic N, 2003, J BIOL CHEM, V278, P49358, DOI 10.1074/jbc.M308071200; PORTEU F, 1994, J BIOL CHEM, V269, P2834; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; QU J, 1995, J PERIODONTAL RES, V30, P153, DOI 10.1111/j.1600-0765.1995.tb01267.x; Riemann D, 1999, IMMUNOL TODAY, V20, P83, DOI 10.1016/S0167-5699(98)01398-X; SAITO M, 1995, LEUKEMIA, V9, P1508; Salamone G, 2001, J IMMUNOL, V166, P3476, DOI 10.4049/jimmunol.166.5.3476; Santos AN, 2000, CELL IMMUNOL, V201, P22, DOI 10.1006/cimm.2000.1629; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; SCHORLEMMER HU, 1979, CANCER RES, V39, P1847; Scornik OA, 2001, CURR DRUG METAB, V2, P67, DOI 10.2174/1389200013338748; Sekine K, 1999, LEUKEMIA, V13, P729, DOI 10.1038/sj.leu.2401388; Sekine K, 2001, INT J CANCER, V94, P485, DOI 10.1002/ijc.1492; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; TAKEDA Y, 1993, INT IMMUNOL, V5, P691, DOI 10.1093/intimm/5.6.691; TALMADGE JE, 1986, CANCER RES, V46, P4505; TALMADGE JE, 1993, J IMMUNOTHER, V14, P258, DOI 10.1097/00002371-199311000-00002; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TAYLOR A, 1993, BIOCHEMISTRY-US, V32, P784, DOI 10.1021/bi00054a007; TIEKU S, 1992, BIOCHEM PHARMACOL, V44, P1725, DOI 10.1016/0006-2952(92)90065-Q; van der Velden VHJ, 1999, CLIN EXP ALLERGY, V29, P445; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; XU Y, 1995, BIOCHEM BIOPH RES CO, V208, P664, DOI 10.1006/bbrc.1995.1390; Xu Y, 1998, CLIN CANCER RES, V4, P171	68	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12458	12467		10.1074/jbc.M511277200	http://dx.doi.org/10.1074/jbc.M511277200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16533817	hybrid			2022-12-25	WOS:000237134700033
J	Prigge, JR; Schmidt, EE				Prigge, JR; Schmidt, EE			Interaction of protein inhibitor of activated STAT (PIAS) proteins with the TATA-binding protein, TBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; GENE-ACTIVATION; IMMUNE-SYSTEM; YEAST-CELLS; FAMILY; SUMO; SUMOYLATION; COMPLEX; DOMAIN	Transcription activators often recruit promoter-targeted assembly of a pre-initiation complex; many repressors antagonize recruitment. These activities can involve direct interactions with proteins in the pre-initiation complex. We used an optimized yeast two-hybrid system to screen mouse pregnancy-associated libraries for proteins that interact with TATA-binding protein (TBP). Screens revealed an interaction between TBP and a single member of the zinc finger family of transcription factors, ZFP523. Two members of the protein inhibitor of activated STAT (PIAS) family, PIAS1 and PIAS3, also interacted with TBP in screens. Endogenous PIAS1 and TBP co-immunoprecipitated from nuclear extracts, suggesting the interaction occurred in vivo. In vitro-translated PIAS1 and TBP co-immunopreciptated, which indicated that other nuclear proteins were not required for the interaction. Deletion analysis mapped the PIAS-interacting domain of TBP to the conserved TBPCORE and the TBP-interacting domain on PIAS1 to a 39-amino acid C-terminal region. Mammals issue seven known PIAS proteins from four pias genes, pias1, pias3, piasx, and piasy, each with different cell type-specific expression patterns; the TBP-interacting domain reported here is the only part of the PIAS C-terminal region shared by all seven PIAS proteins. Direct analyses indicated that PIASx and PIASy also interacted with TBP. Our results suggest that all PIAS proteins might mediate situation-specific regulatory signaling at the TBP interface and that previously unknown levels of complexity could exist in the gene regulatory interplay between TBP, PIAS proteins, ZFP523, and other transcription factors.	Montana State Univ, Bozeman, MT 59717 USA; Washington State Univ, Ctr Reprod Biol, Pullman, WA 99164 USA	Montana State University System; Montana State University Bozeman; Washington State University	Schmidt, EE (corresponding author), Montana State Univ, Mol Biosci Bldg, Bozeman, MT 59717 USA.	eschmidt@montana.edu			NIAID NIH HHS [R01 AI055739-01A1, R01 AI055739-03, R01 AI055739-02, R01 AI055739] Funding Source: Medline; NICHD NIH HHS [R03 HD035824-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD035824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055739] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Bondareva AA, 2003, MOL BIOL EVOL, V20, P1932, DOI 10.1093/molbev/msg205; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; FIELDS S, 1993, YEAST METHOS ANAL PR; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hobbs NK, 2002, CELL, V110, P43, DOI 10.1016/S0092-8674(02)00806-1; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Klejman MP, 2004, MOL CELL BIOL, V24, P10072, DOI 10.1128/MCB.24.22.10072-10082.2004; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2005, MOL CELL BIOL, V25, P1113, DOI 10.1128/MCB.25.3.1113-1123.2005; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Melchior F, 2000, NAT CELL BIOL, V2, pE161, DOI 10.1038/35023639; Mittal V, 1996, MOL CELL BIOL, V16, P1955; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Ohbayashi T, 1996, BIOCHEM BIOPH RES CO, V225, P275, DOI 10.1006/bbrc.1996.1166; Okubo S, 2004, J BIOL CHEM, V279, P31455, DOI 10.1074/jbc.M403561200; Pereira LA, 2003, GENE, V315, P1, DOI 10.1016/S0378-1119(03)00714-5; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Schmidt EE, 2003, J BIOL CHEM, V278, P6168, DOI 10.1074/jbc.M211205200; SCHMIDT EE, 1995, J CELL BIOL, V128, P467, DOI 10.1083/jcb.128.4.467; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Sturm S, 2000, J MOL NEUROSCI, V14, P107, DOI 10.1385/JMN:14:1-2:107; SUMITA K, 1993, NUCLEIC ACIDS RES, V21, P2769, DOI 10.1093/nar/21.11.2769; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; Zheng G, 2004, J BIOL CHEM, V279, P42410, DOI 10.1074/jbc.M407287200	46	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12260	12269		10.1074/jbc.M510835200	http://dx.doi.org/10.1074/jbc.M510835200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522640	hybrid, Green Accepted			2022-12-25	WOS:000237134700010
J	Liu, ZJ; Xiao, M; Balint, K; Soma, A; Pinnix, CC; Capobianco, AJ; Velazquez, OC; Herlyn, M				Liu, Zhao-Jun; Xiao, Min; Balint, Klara; Soma, Akinobu; Pinnix, Chelsea C.; Capobianco, Anthony J.; Velazquez, Omaida C.; Herlyn, Meenhard			Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1	FASEB JOURNAL			English	Article						cell growth; cell signaling; angiogensis	GROWTH-FACTOR; CYCLE ARREST; PHOSPHATIDYLINOSITOL 3-KINASE; NEOPLASTIC TRANSFORMATION; EMBRYONIC LETHALITY; IN-VITRO; EXPRESSION; LIGAND; GENE; TRANSCRIPTION	The requirement for Notch signaling in vasculogenesis and angiogenesis is well documented. In a previous study, we showed that activation of the Notch pathway in endothelial cells induces differentiation-associated growth arrest; however, the underlying mechanism remains to be elucidated. Here, we show that activation of the Notch pathway by either stimulation of cell surface Notch receptors with crosslinked soluble Delta-like 4 (sDll4)/Jagged1 (sJag1) or constitutive expression of the Notch1 intracellular domain (N(IC)) suppresses endothelial cell proliferation. This suppression is mediated by the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt pathways. Following Notch1 activation, both pathways were suppressed in endothelial cells, and alterations in MAPK or PI3K/Akt pathway activity reversed Notch1-induced growth inhibition. Furthermore, we found the effect of Notch1 on endothelial cells to require Mastermind-like (MAML). Overexpression of a dominant-negative mutant of MAML1 antagonized the effects of activated Notch1 on the MAPK and PI3K/Akt pathways. Ectopic expression of Hairy/Enhancer of Split 1 (HES1) consistently reproduced the inhibitory effect of NIC on endothelial cell proliferation. Together, our data demonstrate that the Notch/MAML-HES signaling cascade can regulate both MAPK and PI3K/Akt pathways, which suggests a molecular mechanism for the inhibitory effect of Notch signaling on endothelial cell proliferation.	Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; Univ Penn, Dept Surg, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.org	Balint, Klara/ABB-8816-2021	Capobianco, Anthony/0000-0002-3706-6797; Pinnix, Chelsea/0000-0003-3982-3664	NATIONAL CANCER INSTITUTE [P30CA010815, R01CA076674, P01CA025874, R01CA047159] Funding Source: NIH RePORTER; NCI NIH HHS [CA76674, CA47159, CA10815, CA25874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Brennan K, 2002, BIOESSAYS, V24, P405, DOI 10.1002/bies.10089; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kobinger GP, 2001, NAT BIOTECHNOL, V19, P225, DOI 10.1038/85664; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Krebs LT, 2000, GENE DEV, V14, P1343; Leimeister C, 2000, MECH DEVELOP, V98, P175, DOI 10.1016/S0925-4773(00)00459-7; Limbourg FP, 2005, CIRCULATION, V111, P1826, DOI 10.1161/01.CIR.0000160870.93058.DD; Liu ZJ, 2003, FASEB J, V17, P1931, DOI 10.1096/fj.02-1171fje; Liu ZJ, 2003, MOL CELL BIOL, V23, P14, DOI 10.1128/MCB.23.1.14-25.2003; Liu ZJ, 2001, P NATL ACAD SCI USA, V98, P7289, DOI 10.1073/pnas.121171998; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; Pear WS, 2003, SEMIN IMMUNOL, V15, P69, DOI 10.1016/S1044-5323(03)00003-4; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Qi RZ, 2003, CANCER RES, V63, P8323; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Shou JY, 2001, CANCER RES, V61, P7291; Shutter JR, 2000, GENE DEV, V14, P1313; Sriuranpong V, 2001, CANCER RES, V61, P3200; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Tsai S, 2000, BLOOD, V96, P950, DOI 10.1182/blood.V96.3.950.015k43_950_957; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Velazquez OC, 2002, FASEB J, V16, P1316, DOI 10.1096/fj.01-1011fje; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	49	84	93	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					1009	+		10.1096/fj.05-4880fje	http://dx.doi.org/10.1096/fj.05-4880fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571776				2022-12-25	WOS:000240157700038
J	Lee, KS; Lee, HK; Hayflick, JS; Lee, YC; Puri, KD				Lee, Kyung S.; Lee, Ho K.; Hayflick, Joel S.; Lee, Yong C.; Puri, Kamal D.			Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model	FASEB JOURNAL			English	Article						allergy; inflammation; cell activation; lung cytokines; signal transduction	MAST-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; NEUTROPHIL TRAFFICKING; ADHESION MOLECULES; TRANSGENIC MICE; PROTEIN-KINASE; IN-VITRO; T-CELLS; B-CELLS; EXPRESSION	P110 delta phosphoinositide 3-kinase (PI3K) plays a pivotal role in the recruitment and activation of certain inflammatory cells. Recent findings revealed that the activity of p110 delta also contributes to allergen-IgE- induced mast cell activation and vascular permeability. We investigated the role of p110 delta in allergic airway inflammation and hyperresponsiveness using IC87114, a selective p110 delta inhibitor, in a mouse asthma model. BALB/c mice were sensitized with OVA and, upon OVA aerosol challenge, developed airway eosinophilia, mucus hypersecretion, elevation in cytokine and chemokine levels, up-regulation of ICAM-1 and VCAM-1 expression, and airway hyperresponsiveness. Intratracheal administration of IC87114 significantly (P < 0.05) attenuated OVA-induced influx into lungs of total leukocytes, eosinophils, neutrophils, and lymphocytes, as well as levels of IL-4, IL-5, IL-13, and RANTES in a dose-dependent manner. IC87114 also significantly (P < 0.05) reduced the serum levels of total IgE and OVA-specific IgE and LTC4 release into the airspace. Histological studies show that IC87114 inhibited OVA-induced lung tissue eosinophilia, airway mucus production, and inflammation score. In addition, IC87114 significantly (P < 0.05) suppressed OVA-induced airway hyperresponsiveness to inhaled methacholine. Western blot analyses of whole lung tissue lysates shows that IC87114 markedly attenuated the OVA-induced increase in expression of IL-4, IL-5, IL-13, ICAM-1, VCAM-1, RANTES, and eotaxin. Furthermore, IC87114 treatment markedly attenuated OVA-induced serine phosphorylation of Akt, a downstream effector of PI3K signaling. Taken together, our findings implicate that inhibition of p110 delta signaling pathway may have therapeutic potential for the treatment of allergic airway inflammation.	ICOS Corp, Bothell, WA 98021 USA; Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Ctr Allerg Immune Dis, Jeonju 561712, South Korea	Icos Corporation; Jeonbuk National University	Puri, KD (corresponding author), ICOS Corp, 22021 20th Ave SE, Bothell, WA 98021 USA.	leeyc@chonbuk.ac.kr; kpuri@icos.com						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; Eum SY, 2003, AM J RESP CELL MOL, V28, P25, DOI 10.1165/rcmb.4532; Ezeamuzie CI, 2001, AM J RESP CRIT CARE, V164, P1633, DOI 10.1164/ajrccm.164.9.2101104; Fernandes DJ, 2003, J APPL PHYSIOL, V95, P844, DOI 10.1152/japplphysiol.00192.2003; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fruman DA, 2002, SEMIN IMMUNOL, V14, P7, DOI 10.1006/smim.2001.0337; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Inami M, 2004, J BIOL CHEM, V279, P23123, DOI 10.1074/jbc.M401248200; Jia GQ, 1999, INT IMMUNOL, V11, P1, DOI 10.1093/intimm/11.1.1; Justice JP, 2002, AM J PHYSIOL-LUNG C, V282, pL1066, DOI 10.1152/ajplung.00195.2001; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Li L, 1999, J IMMUNOL, V162, P2477; Lorentz A, 2003, J ALLERGY CLIN IMMUN, V111, P1062, DOI 10.1067/mai.2003.1342; Lukacs NW, 2001, NAT REV IMMUNOL, V1, P108, DOI 10.1038/35100503; MacLean JA, 2000, J IMMUNOL, V165, P6568, DOI 10.4049/jimmunol.165.11.6568; MONTEFORT S, 1991, RESP MED, V85, P91, DOI 10.1016/S0954-6111(06)80284-2; MOSER R, 1992, J IMMUNOL, V149, P1432; Myou S, 2003, J EXP MED, V198, P1573, DOI 10.1084/jem.20030298; Nadler M J, 2000, Adv Immunol, V76, P325; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2002, SCIENCE, V297, P1031; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Puri KD, 2005, BLOOD, V106, P150, DOI 10.1182/blood-2005-01-0023; Puri KD, 2004, BLOOD, V103, P3448, DOI 10.1182/blood-2003-05-1667; Sadhu C, 2003, BIOCHEM BIOPH RES CO, V308, P764, DOI 10.1016/S0006-291X(03)01480-3; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Tigani B, 2001, EUR J PHARMACOL, V433, P217, DOI 10.1016/S0014-2999(01)01515-1; Trifilieff A, 2000, AM J PHYSIOL-LUNG C, V279, pL1120, DOI 10.1152/ajplung.2000.279.6.L1120; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vargaftig BB, 2003, AM J RESP CELL MOL, V28, P410, DOI 10.1165/rcmb.2002-0032OC; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu XD, 2000, J IMMUNOL METHODS, V240, P157, DOI 10.1016/S0022-1759(00)00192-7	53	208	236	2	44	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					455	465		10.1096/fj.05-5045com	http://dx.doi.org/10.1096/fj.05-5045com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507763				2022-12-25	WOS:000239815100009
J	Linden, D; William-Olsson, L; Ahnmark, A; Ekroos, K; Hallberg, C; Sjogren, HP; Becker, B; Svensson, L; Clapham, JC; Oscarsson, J; Schreyer, S				Linden, Daniel; William-Olsson, Lena; Ahnmark, Andrea; Ekroos, Kim; Hallberg, Carina; Sjogren, Helena P.; Becker, Bruno; Svensson, Lennart; Clapham, John C.; Oscarsson, Jan; Schreyer, Sandra			Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation	FASEB JOURNAL			English	Article						GPAT; stearoyl-CoA desaturase; ADRP; adenovirus; fatty liver	GLYCEROL PHOSPHATE ACYLTRANSFERASE; LOW-DENSITY-LIPOPROTEIN; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; RAT HEPATOCYTES; GENERAL-POPULATION; INSULIN-RESISTANCE; DEFICIENT MICE; EXPRESSION; PREVALENCE; ENZYMES	Glycerol-3-phosphate acyltransferase (GPAT) catalyzes the first committed step in triacylglycerol (TAG) and phospholipid biosynthesis. GPAT activity has been identified in both ER and mitochondrial subcellular fractions. The ER activity dominates in most tissues except in liver, where the mitochondrial isoform (mtGPAT) can constitute up to 50% of the total activity. To study the in vivo effects of hepatic mtGPAT overexpression, mice were transduced with adenoviruses expressing either murine mtGPAT or a catalytically inactive variant of the enzyme. Overexpressing mtGPAT resulted in massive 12- and 7-fold accumulation of liver TAG and diacylglycerol, respectively but had no effect on phospholipid or cholesterol ester content. Histological analysis showed extensive lipid accumulation in hepatocytes. Furthermore, mtGPAT transduction markedly increased adipocyte differentiation-related protein and stearoyl-CoA desaturase-1 (SCD-1) in the liver. In line with increased SCD-1 expression, 18:1 and 16:1 in the hepatic TAG fraction increased. In addition, mtGPAT overexpression decreased ex vivo fatty acid oxidation, increased liver TAG secretion rate 2-fold, and increased plasma TAG and cholesterol levels. These results support the hypothesis that increased hepatic mtGPAT activity associated with obesity and insulin resistance contributes to increased TAG biosynthesis and inhibition of fatty acid oxidation, responses that would promote hepatic steatosis and dyslipidemia.	AstraZeneca R&D, Dept Integrat Pharmacol, S-43183 Molndal, Sweden; Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-41124 Gothenburg, Sweden	AstraZeneca; University of Gothenburg	Linden, D (corresponding author), AstraZeneca R&D, Dept Integrat Pharmacol, S-43183 Molndal, Sweden.	daniel.linden@astrazeneca.com	Clapham, John/AAK-4715-2020					Alemany R, 2000, J GEN VIROL, V81, P2605, DOI 10.1099/0022-1317-81-11-2605; Ameen C, 2004, AM J PHYSIOL-ENDOC M, V287, pE1039, DOI 10.1152/ajpendo.00059.2004; Bedoucha M, 2001, J HEPATOL, V35, P17, DOI 10.1016/S0168-8278(01)00066-6; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bellentani S, 2000, ANN INTERN MED, V132, P112, DOI 10.7326/0003-4819-132-2-200001180-00004; BREMER J, 1976, MOL CELL BIOCHEM, V12, P113, DOI 10.1007/BF01731557; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Dircks LK, 1997, BBA-LIPID LIPID MET, V1348, P17, DOI 10.1016/S0005-2760(97)00106-9; Edvardsson U, 1999, J LIPID RES, V40, P1177; Ekroos K, 2003, J LIPID RES, V44, P2181, DOI 10.1194/jlr.D300020-JLR200; Ekroos K, 2002, ANAL CHEM, V74, P941, DOI 10.1021/ac015655c; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; FOLCH J, 1957, J BIOL CHEM, V226, P497; GIBBONS GF, 1992, BIOCHEM J, V287, P749, DOI 10.1042/bj2870749; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; HALDAR D, 1979, J BIOL CHEM, V254, P4502; Hammond LE, 2005, J BIOL CHEM, V280, P25629, DOI 10.1074/jbc.M503181200; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; Heath RJ, 1998, J BACTERIOL, V180, P1425, DOI 10.1128/JB.180.6.1425-1430.1998; Homan R, 1998, J CHROMATOGR B, V708, P21, DOI 10.1016/S0378-4347(97)00651-8; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; JERKINS AA, 1995, J BIOL CHEM, V270, P1416, DOI 10.1074/jbc.270.38.22135; Lankester DL, 1998, J LIPID RES, V39, P1889; Lewin TM, 2005, AM J PHYSIOL-ENDOC M, V288, pE835, DOI 10.1152/ajpendo.00300.2004; Lewin TM, 2004, J BIOL CHEM, V279, P13488, DOI 10.1074/jbc.M314032200; Lewin TM, 2001, ARCH BIOCHEM BIOPHYS, V396, P119, DOI 10.1006/abbi.2001.2604; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Li XH, 1996, J LIPID RES, V37, P210; Linden D, 2004, J LIPID RES, V45, P1279, DOI 10.1194/jlr.M400010-JLR200; Linden D, 2001, J LIPID RES, V42, P1831; Luyckx FH, 1998, INT J OBESITY, V22, P222, DOI 10.1038/sj.ijo.0800571; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; Marchesini G, 2001, DIABETES, V50, P1844, DOI 10.2337/diabetes.50.8.1844; MONROY G, 1972, J BIOL CHEM, V247, P6884; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Nemoto Y, 2000, J CLIN INVEST, V105, P1819, DOI 10.1172/JCI9575; Neschen S, 2005, CELL METAB, V2, P55, DOI 10.1016/j.cmet.2005.06.006; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; NOMURA H, 1988, JPN J MED, V27, P142, DOI 10.2169/internalmedicine1962.27.142; Ntambi JM, 1999, J LIPID RES, V40, P1549; SAGGERSON ED, 1980, BIOCHEM J, V190, P183, DOI 10.1042/bj1900183; Schadinger SE, 2005, AM J PHYSIOL-ENDOC M, V288, pE1195, DOI 10.1152/ajpendo.00513.2004; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; SHIN DH, 1991, J BIOL CHEM, V266, P23834; Spady DK, 2000, J BIOL CHEM, V275, P27005; Steiner S, 1996, BIOCHEM BIOPH RES CO, V218, P777, DOI 10.1006/bbrc.1996.0138; Szczepaniak LS, 2005, AM J PHYSIOL-ENDOC M, V288, pE462, DOI 10.1152/ajpendo.00064.2004; van der Leij FR, 1999, BIOCHEM J, V341, P777, DOI 10.1042/0264-6021:3410777; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; ZHANG WW, 1995, BIOTECHNIQUES, V18, P444	52	91	108	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2006	20	3					434	443		10.1096/fj.05-4568com	http://dx.doi.org/10.1096/fj.05-4568com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507761				2022-12-25	WOS:000239815100007
J	Kawata, M; Kinoshita, K; Takahashi, S; Ogura, K; Komoto, N; Yamanishi, M; Tobimatsu, T; Toraya, T				Kawata, Masahiro; Kinoshita, Koichiro; Takahashi, Sumihisa; Ogura, Ken-ichi; Komoto, Noriaki; Yamanishi, Mamoru; Tobimatsu, Takamasa; Toraya, Tetsuo			Survey of catalytic residues and essential roles of glutamate-alpha 170 and aspartate-alpha 335 in coenzyme B-12-dependent diol dehydratase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; X-RAY-STRUCTURE; RIBONUCLEOTIDE REDUCTASE; CRYSTAL-STRUCTURE; DIRECT PARTICIPATION; HYDROGEN-TRANSFER; AQUEOUS-SOLUTIONS; DEPENDENT ENZYME; SPIN-RESONANCE; POTASSIUM-ION	The importance of each active-site residue in adenosylcobalamin-dependent diol dehydratase of Klebsiella oxytoca was estimated using mutant enzymes in which one of the residues interacting with substrate and/or K+ was mutated to Ala or another amino acid residue. The E alpha 170A and D alpha 335A mutants were totally inactive, and the H alpha 143A mutant showed only a trace of activity, indicating that Glu-alpha 170, Asp-alpha 335, and His-alpha 143 are catalytic residues. The Q alpha 141A, Q alpha 296A, and S alpha 362A mutants showed partial activity. It was suggested from kinetic parameters that Gln-alpha 296 is important for substrate binding and Gln-alpha 296 and Gln-alpha 141 for preventing the enzyme from mechanism-based inactivation. The E alpha 221A, E alpha 170H, and D alpha 335A did not form the (alpha beta gamma)(2) complex, suggesting that these mutations indirectly disrupt subunit contacts. Among other Glu-alpha 170 and Asp-alpha 335 mutants, E alpha 170D and E alpha 170Q were 2.2 +/- 0.3% and 0.02% as active as the wild-type enzyme, respectively, whereas D alpha 335N was totally inactive. Kinetic analysis indicated that the presence and the position of a carboxyl group in the residue alpha 170 are essential for catalysis as well as for the continuous progress of catalytic cycles. It was suggested that the roles of Glu alpha 170 and Asp-alpha 335 are to participate in the binding of substrate and intermediates and keep them appropriately oriented and to function as a base in the dehydration of the 1,1-diol intermediate. In addition, Glu-alpha 170 seems to stabilize the transition state for the hydroxyl group migration from C2 to C1 by accepting the proton of the spectator hydroxyl group on C1.	Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan	Okayama University	Toraya, T (corresponding author), Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan.	toraya@cc.okayama-u.ac.jp	TOBIMATSU, Takamasa/B-2646-2011					Abeles R. H., 1979, Vitamin B12, P373; Andersson J, 2001, J BIOL CHEM, V276, P40457, DOI 10.1074/jbc.M106863200; Banerjee R., 1999, CHEM BIOCH B 12; BANSAL KM, 1973, J PHYS CHEM-US, V77, P16, DOI 10.1021/j100620a004; BOAS JF, 1978, J CHEM SOC FARAD T 2, V74, P417, DOI 10.1039/f29787400417; Bothe H., 1998, VITAMIN B12 B12 PROT, P237; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dolphin D., 1982, B12, V2; Eda M, 2002, B CHEM SOC JPN, V75, P1469, DOI 10.1246/bcsj.75.1469; ESSENBERG MK, 1971, J AM CHEM SOC, V93, P1242; FINLAY TH, 1973, J BIOL CHEM, V248, P1285; FREY PA, 1967, J BIOL CHEM, V242, P5369; Gerfen GJ, 1996, J AM CHEM SOC, V118, P8192, DOI 10.1021/ja960363s; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDING BT, 1976, J AM CHEM SOC, V98, P6331, DOI 10.1021/ja00436a044; Kamachi T, 2004, J AM CHEM SOC, V126, P16207, DOI 10.1021/ja045572o; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence CC, 1999, P NATL ACAD SCI USA, V96, P8979, DOI 10.1073/pnas.96.16.8979; LEE HA, 1963, J BIOL CHEM, V238, P2367; LIVINGSTONE R, 1966, J AM CHEM SOC, V88, P4333, DOI 10.1021/ja00971a006; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Masuda J, 2000, STRUCTURE, V8, P775, DOI 10.1016/S0969-2126(00)00164-7; MULLER P, 1983, J CHEM SOC CHEM COMM, P1342, DOI 10.1039/c39830001342; Persson AL, 1997, J BIOL CHEM, V272, P31533, DOI 10.1074/jbc.272.50.31533; POZNANSKAJA AA, 1979, ARCH BIOCHEM BIOPHYS, V194, P379, DOI 10.1016/0003-9861(79)90630-1; RETEY J, 1990, ANGEW CHEM INT EDIT, V29, P355, DOI 10.1002/anie.199003551; RETEY J, 1966, EXPERIENTIA, V22, P502, DOI 10.1007/BF01898652; RETEY J, 1966, EXPERIENTIA, V22, P72, DOI 10.1007/BF01900153; SCHEPLER KL, 1975, BIOCHIM BIOPHYS ACTA, V397, P510, DOI 10.1016/0005-2744(75)90141-2; Shibata N, 1999, STRUCTURE, V7, P997, DOI 10.1016/S0969-2126(99)80126-9; Shibata N, 2003, J BIOL CHEM, V278, P22717, DOI 10.1074/jbc.M301513200; Shibata N, 2002, BIOCHEMISTRY-US, V41, P12607, DOI 10.1021/bi026104z; SILVERMAN RB, 1976, J AM CHEM SOC, V98, P4626, DOI 10.1021/ja00431a048; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; Smith DM, 1999, J AM CHEM SOC, V121, P5700, DOI 10.1021/ja990209g; Smith DM, 2001, J AM CHEM SOC, V123, P1664, DOI 10.1021/ja001454z; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Tobimatsu T, 2005, BIOSCI BIOTECH BIOCH, V69, P455, DOI 10.1271/bbb.69.455; Tobimatsu T, 1997, ARCH BIOCHEM BIOPHYS, V347, P132, DOI 10.1006/abbi.1997.0325; TOBIMATSU T, 1995, J BIOL CHEM, V270, P7142, DOI 10.1074/jbc.270.13.7142; Toraya T, 1999, J BIOL CHEM, V274, P3372, DOI 10.1074/jbc.274.6.3372; Toraya T, 2003, CHEM REV, V103, P2095, DOI 10.1021/cr020428b; TORAYA T, 1977, J BIOL CHEM, V252, P963; Toraya T, 2001, J BIOCHEM-TOKYO, V130, P865, DOI 10.1093/oxfordjournals.jbchem.a003059; Toraya T, 1997, BBA-PROTEIN STRUCT M, V1337, P11, DOI 10.1016/S0167-4838(96)00143-4; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; TORAYA T, 1974, BIOCHEMISTRY-US, V13, P3895, DOI 10.1021/bi00716a012; TORAYA T, 1971, BIOCHEMISTRY-US, V10, P3475, DOI 10.1021/bi00794a025; Toraya T, 1999, J BIOCHEM, V126, P650, DOI 10.1093/oxfordjournals.jbchem.a022498; TORAYA T, 1979, BIOCHEMISTRY-US, V18, P417, DOI 10.1021/bi00570a005; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; vanderDonk WA, 1996, BIOCHEMISTRY-US, V35, P8381, DOI 10.1021/bi960190j; WAGNER OW, 1966, J BIOL CHEM, V241, P1751; Yamanishi M, 2005, BIOCHEMISTRY-US, V44, P2113, DOI 10.1021/bi0481850; Yamanishi M, 1998, BIOCHEMISTRY-US, V37, P4799, DOI 10.1021/bi972572a; ZAGALAK B, 1966, J BIOL CHEM, V241, P3028; ZHAO Y, 1992, ANGEW CHEM INT EDIT, V31, P215, DOI 10.1002/anie.199202151	57	19	20	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 7	2006	281	27					18327	18334		10.1074/jbc.M601910200	http://dx.doi.org/10.1074/jbc.M601910200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	058TK	16571729	hybrid			2022-12-25	WOS:000238687300009
J	Chen, G; Ma, CL; Bower, KA; Ke, ZJ; Luo, J				Chen, Gang; Ma, Cuiling; Bower, Kimberly A.; Ke, Zunji; Luo, Jia			Interaction between RAX and PKR modulates the effect of ethanol on protein synthesis and survival of neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; FETAL ALCOHOL SYNDROME; GROWTH-FACTOR; CELL LOSS; KINASE PKR; REGIONAL DIFFERENCES; ACTIVATION; BRAIN; APOPTOSIS; INITIATION	Ethanol exposure inhibits protein synthesis and causes cell death in the developing central nervous system. The double-stranded RNA (dsRNA)-activated protein kinase (PKR), a serine/threonine protein kinase, plays an important role in translational regulation and cell survival. PKR has been well known for its anti-viral response. Upon activation by viral infection or dsRNA, PKR phosphorylates its substrate, the alpha-subunit of eukaryotic translation initiation factor-2 (eIF2 alpha) leading to inhibition of translation initiation. It has recently been shown that, in the absence of a virus or dsRNA, PKR can be activated by direct interactions with its protein activators, PACT, or its mouse homologue, RAX. We have demonstrated that exposure to ethanol increased the phosphorylation of PKR and eIF2 alpha in the developing cerebellum. The effect of ethanol on PKR/eIF2 alpha phosphorylation positively correlated to the expression of PACT/RAX in cultured neuronal cells. Using PKR inhibitors and PKR null mouse fibroblasts, we verified that ethanol-induced eIF2 alpha phosphorylation was mediated by PKR. Overexpression of a wild-type RAX dramatically enhanced sensitivity to ethanol-induced PKR/eIF2 alpha phosphorylation, as well as translational inhibition and cell death. In contrast, overexpression of a mutant (S18A) RAX inhibited ethanol- mediated PKR/eIF2 alpha activation. Ethanol promoted PKR and RAX association in cells expressing wild-type RAX but not in cells expressing S18A RAX. S18A RAX functioned as a dominant negative protein and blocked ethanol-induced inhibition of protein synthesis and cell death. Our results suggest that the interactions between PKR and PACT/RAX modulate the effect of ethanol on protein synthesis and cell survival in the central nervous system.	W Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China	West Virginia University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Luo, J (corresponding author), W Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA.	jluo@hsc.wvu.edu	Ke, Zunji/E-4822-2010; He, Liuge/E-6385-2010; Ke, Zun-Ji/N-5689-2014	Ke, Zunji/0000-0003-4038-2456; Ke, Zun-Ji/0000-0003-4038-2456; Luo, Jia/0000-0002-6968-3618	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA013984, R01AA015407] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA015407, AA013984] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ayoub AE, 2005, J COMP NEUROL, V481, P403, DOI 10.1002/cne.20375; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bando Y, 2005, NEUROCHEM INT, V46, P11, DOI 10.1016/j.neuint.2004.07.005; Barber GN, 2005, CELL DEATH DIFFER, V12, P563, DOI 10.1038/sj.cdd.4401643; BAUERMOFFETT C, 1977, BRAIN RES, V119, P249, DOI 10.1016/0006-8993(77)90310-9; Bennett RL, 2004, J BIOL CHEM, V279, P42687, DOI 10.1074/jbc.M403321200; Bonner AB, 2003, METABOLISM, V52, P389, DOI 10.1053/meta.2003.50009; BONTHIUS DJ, 1990, ALCOHOL CLIN EXP RES, V14, P107, DOI 10.1111/j.1530-0277.1990.tb00455.x; BORGES S, 1983, NEUROPATH APPL NEURO, V9, P53, DOI 10.1111/j.1365-2990.1983.tb00323.x; Chang RCC, 2002, J NEUROCHEM, V83, P1215, DOI 10.1046/j.1471-4159.2002.01237.x; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; COX S, 1988, BIOCHEM PHARMACOL, V37, P2045, DOI 10.1016/0006-2952(88)90555-2; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Goodlett CR, 2001, ALCOHOL RES HEALTH, V25, P175; Green JT, 2002, BRAIN RES, V956, P302, DOI 10.1016/S0006-8993(02)03561-8; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Lang CH, 2001, INT J BIOCHEM CELL B, V33, P457, DOI 10.1016/S1357-2725(00)00081-9; Lang CH, 1999, AM J PHYSIOL-ENDOC M, V277, pE805, DOI 10.1152/ajpendo.1999.277.5.E805; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; Li Z, 2001, DEV BRAIN RES, V132, P47, DOI 10.1016/S0165-3806(01)00294-2; Luo J, 1999, J NEUROSCI, V19, P10014, DOI 10.1523/jneurosci.19-22-10014.1999; Luo J, 1997, ALCOHOL CLIN EXP RES, V21, P1186, DOI 10.1111/j.1530-0277.1997.tb04436.x; Luo J, 1997, ALCOHOL CLIN EXP RES, V21, P1108; Luo J, 1998, BRAIN RES REV, V27, P157, DOI 10.1016/S0165-0173(98)00009-5; Luo J, 1999, ALCOHOL CLIN EXP RES, V23, P644, DOI 10.1111/j.1530-0277.1999.tb04166.x; Maier SE, 2001, ALCOHOL, V23, P49, DOI 10.1016/S0741-8329(00)00133-6; Maier SE, 1999, ALCOHOL CLIN EXP RES, V23, P726, DOI 10.1111/j.1530-0277.1999.tb04176.x; MARCUSSEN BL, 1994, ALCOHOL, V11, P147, DOI 10.1016/0741-8329(94)90056-6; May PA, 2001, ALCOHOL RES HEALTH, V25, P159; Miller MW, 1996, BRAIN RES, V734, P286; NAPPER RMA, 1995, J COMP NEUROL, V362, P283, DOI 10.1002/cne.903620210; NATHANIEL EJH, 1986, EXP NEUROL, V93, P610, DOI 10.1016/0014-4886(86)90180-9; Olney JW, 2004, ADDICT BIOL, V9, P137, DOI 10.1080/13556210410001717006; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Peel AL, 2004, J NEUROPATH EXP NEUR, V63, P97, DOI 10.1093/jnen/63.2.97; Peel AL, 2001, HUM MOL GENET, V10, P1531, DOI 10.1093/hmg/10.15.1531; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; PIERCE DR, 1989, TERATOLOGY, V40, P113, DOI 10.1002/tera.1420400205; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; Ruvolo PP, 2001, J BIOL CHEM, V276, P11754, DOI 10.1074/jbc.M011400200; Saelens X, 2001, J BIOL CHEM, V276, P41620, DOI 10.1074/jbc.M103674200; Suen KC, 2003, J BIOL CHEM, V278, P49819, DOI 10.1074/jbc.M306503200; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; WEST JR, 1993, J NUTR, V123, P382, DOI 10.1093/jn/123.suppl_2.382; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; WU JM, 1981, J BIOL CHEM, V256, P4164; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200	52	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15909	15915		10.1074/jbc.M600612200	http://dx.doi.org/10.1074/jbc.M600612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16574643	Green Published, hybrid			2022-12-25	WOS:000237996000041
J	Bourguignon, LYW; Gilad, E; Brightman, A; Diedrich, F; Singleton, P				Bourguignon, Lilly Y. W.; Gilad, Eli; Brightman, Amy; Diedrich, Falko; Singleton, Patrick			Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NUCLEOTIDE EXCHANGE FACTOR; DEPENDENT PROTEIN-KINASE; ANKYRIN-BINDING DOMAIN; C-EPSILON; CD44 INTERACTION; ACTIN-BINDING; ANGIOGENIC OLIGOSACCHARIDES; TYROSINE PHOSPHORYLATION; IP3 RECEPTOR; PDZ-RHOGEF	In this study we have examined the interaction of CD44 ( a major hyaluronan (HA) receptor) with a RhoA-specific guanine nucleotide exchange factor (leukemia-associated RhoGEF (LARG)) in human head and neck squamous carcinoma cells (HNSCC-HSC-3 cell line). Immunoprecipitation and immunoblot analyses indicate that CD44 and the LARG protein are expressed in HSC-3 cells and that these two proteins are physically associated as a complex. HA-CD44 binding induces LARG-specific RhoA signaling and phospholipase C epsilon(PLC epsilon) activity. In particular, the activation of RhoA-PLC epsilon by HA stimulates inositol 1,4,5- triphosphate production, intracellular Ca2+ mobilization, and the up-regulation of Ca2+/ calmodulin-dependent kinase II (CaMKII), leading to phosphorylation of the cytoskeletal protein, filamin. The phosphorylation of filamin reduces its interaction with filamentous actin, promoting tumor cell migration. The CD44-LARG complex also interacts with the EGF receptor (EGFR). Most importantly, the binding of HA to the CD44-LARG-EGFR complex activates the EGFR receptor kinase, which in turn promotes Ras-mediated stimulation of a downstream kinase cascade including the Raf-1 and ERK pathways leading to HNSCC cell growth. Using a recombinant fragment of LARG (the LARG-PDZ domain) and a binding assay, we have determined that the LARG-PDZ domain serves as a direct linker between CD44 and EGFR. Transfection of the HSC-3 cells with LARG-PDZcDNA significantly reduces LARG association with CD44 and EGFR. Over expression of the LARG-PDZ domain also functions as a dominant-negative mutant (similar to the PLC/Ca2+ calmodulin dependent kinase II (CaMKII) and EGFR/MAPK inhibitor effects) to block HA/CD44-mediated signaling events (e.g. EGFR kinase activation, Ras/RhoA co-activation, Raf-ERK signaling, PLC epsilon-mediated inositol 1,4,5- triphosphate production, intracellular Ca2+ mobilization, CaMKII activity, filamin phosphorylation, and filamin-actin binding) and to abrogate tumor cell growth/migration. Taken together, our findings suggest that CD44 interaction with LARG and EGFR plays a pivotal role in Rho/Ras co-activation, PLC epsilon-Ca2+ signaling, and Raf/ ERK up-regulation required for CaMKII-mediated cytoskeleton function and in head and neck squamous cell carcinoma progression.	Univ Calif San Francisco, Dept Med, Endocrine Unit, Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit, Vet Affairs Med Ctr, 111N,, San Francisco, CA 94121 USA.	lillyb@itsa.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA078633, R01CA066163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA66163, R01 CA78633] Funding Source: Medline; NIAMS NIH HHS [P01 AR39448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham MT, 2001, LARYNGOSCOPE, V111, P1285, DOI 10.1097/00005537-200107000-00027; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Assimakopoulos D, 2002, HISTOL HISTOPATHOL, V17, P1269, DOI 10.14670/HH-17.1269; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLANK JL, 1992, J BIOL CHEM, V267, P23069; Bollinger CR, 2005, BBA-MOL CELL RES, V1746, P284, DOI 10.1016/j.bbamcr.2005.09.001; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Borbiev T, 2001, AM J PHYSIOL-LUNG C, V280, pL983, DOI 10.1152/ajplung.2001.280.5.L983; Bourguignon LYW, 2005, J BIOL CHEM, V280, P11961, DOI 10.1074/jbc.M411985200; Bourguignon LYW, 2004, J BIOL CHEM, V279, P29654, DOI 10.1074/jbc.M403608200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; BOYER JL, 1992, J BIOL CHEM, V267, P25451; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Carinci F, 2002, J CRANIOFAC SURG, V13, P85, DOI 10.1097/00001665-200201000-00020; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen AY, 2001, HEAD NECK-J SCI SPEC, V23, P566, DOI 10.1002/hed.1079; Chikumi H, 2004, ONCOGENE, V23, P233, DOI 10.1038/sj.onc.1207012; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; COHEN S, 1982, J BIOL CHEM, V257, P1523; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Filion MC, 2001, J PHARM PHARMACOL, V53, P555, DOI 10.1211/0022357011775677; Ford AC, 2003, HEAD NECK-J SCI SPEC, V25, P67, DOI 10.1002/hed.10224; Franzmann EJ, 2001, OTOLARYNG HEAD NECK, V124, P426, DOI 10.1067/mhn.2001.114674; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GRANDIS JR, 1993, J CELL BIOCHEM, P188; Hakomori S, 2004, GLYCOCONJUGATE J, V21, P125, DOI 10.1023/B:GLYC.0000044844.95878.cf; Hakomori S, 2004, AN ACAD BRAS CIENC, V76, P553, DOI 10.1590/S0001-37652004000300010; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; Hardisson D, 2003, EUR ARCH OTO-RHINO-L, V260, P502, DOI 10.1007/s00405-003-0581-3; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hicks WL, 1997, HEAD NECK-J SCI SPEC, V19, P400; ISHIDA A, 1995, J BIOL CHEM, V270, P2163, DOI 10.1074/jbc.270.5.2163; Jeffries S, 2001, ORAL ONCOL, V37, P115, DOI 10.1016/S1368-8375(00)00065-8; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Johansson N, 2000, HISTOL HISTOPATHOL, V15, P225, DOI 10.14670/HH-15.225; Kawano K, 2001, EXP CELL RES, V262, P180, DOI 10.1006/excr.2000.5083; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KNUDSON W, 1989, CIBA F SYMP, V143, P150; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Lewis CA, 2001, BIOCHEM J, V357, P843, DOI 10.1042/0264-6021:3570843; Li XY, 2003, ONCOL RES, V13, P323; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MAIER H, 1992, CLIN INVESTIGATOR, V70, P320; Mandic R, 2001, ANTICANCER RES, V21, P3413; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; MEGHA LE, 2004, J BIOL CHEM, V279, P9997; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Ohta Y, 1996, J BIOL CHEM, V271, P11858, DOI 10.1074/jbc.271.20.11858; PESSIN JE, 1999, ENDOCR J, V46, P1; Quon H, 2001, HEAD NECK-J SCI SPEC, V23, P147, DOI 10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Robertson SP, 2005, CURR OPIN GENET DEV, V15, P301, DOI 10.1016/j.gde.2005.04.001; ROONEY P, 1993, J CELL SCI, V105, P213; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Seifert JP, 2004, J BIOL CHEM, V279, P47992, DOI 10.1074/jbc.M407111200; Shen XD, 2004, AM J PATHOL, V165, P1315, DOI 10.1016/S0002-9440(10)63390-1; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Singleton PA, 2004, EXP CELL RES, V295, P102, DOI 10.1016/j.yexcr.2003.12.025; Singleton PA, 2002, CELL MOTIL CYTOSKEL, V53, P293, DOI 10.1002/cm.10078; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UNDERHILL C, 1992, J CELL SCI, V103, P293; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALDO GL, 1991, J BIOL CHEM, V266, P14217; Wang SJ, 2006, ARCH OTOLARYNGOL, V132, P19, DOI 10.1001/archotol.132.1.19; Wing MR, 2003, J BIOL CHEM, V278, P41253, DOI 10.1074/jbc.M306904200; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; YASUTAKA O, 1995, BIOCHEMISTRY-US, V34, P6745, DOI 10.1021/bi00020a020; Yoshioka K, 1999, CANCER RES, V59, P2004; Zhang YY, 2002, CANCER RES, V62, P3962; Zhou H, 2005, J BIOL CHEM, V280, P10624, DOI 10.1074/jbc.M411900200; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	105	179	198	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14026	14040		10.1074/jbc.M507734200	http://dx.doi.org/10.1074/jbc.M507734200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16565089	hybrid			2022-12-25	WOS:000237512300025
J	Dialynas, GK; Makatsori, D; Kourmouli, N; Theodoropoulos, PA; McLean, K; Terjung, S; Singh, PB; Georgatos, SD				Dialynas, George K.; Makatsori, Dimitra; Kourmouli, Niki; Theodoropoulos, Panayiotis A.; McLean, Kevin; Terjung, Stefan; Singh, Prim B.; Georgatos, Spyros D.			Methylation-independent binding to histone H3 and cell cycle-dependent incorporation of HP1 beta into heterochromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HP1 CHROMO DOMAIN; LYSINE-9 METHYLATION; MAMMALIAN-CELLS; PERICENTRIC HETEROCHROMATIN; NUCLEAR-ENVELOPE; DNA INTERACTIONS; NUCLEOSOME; DROSOPHILA; PROTEINS; MECHANISMS	We have examined HP1 beta-chromatin interactions in different molecular contexts in vitro and in vivo. Employing purified components we show that HP1 beta exhibits selective, stoichiometric, and salt-resistant binding to recombinant histone H3, associating primarily with the helical "histone fold" domain. Furthermore, using "bulk" nucleosomes released by MNase digestion, S-phase extracts, and fragments of peripheral heterochromatin, we demonstrate that HP1 beta associates more tightly with destabilized or disrupted nucleosomes (H3/H4 subcomplexes) than with intact particles. Western blotting and mass spectrometry data indicate that HP1 beta-selected H3/H4 particles and subparticles possess a complex pattern of post-translational modifications but are not particularly enriched in me(3)K9-H3. Consistent with these results, mapping of HP1 beta and me(3)K9-H3 sites in vivo reveals overlapping, yet spatially distinct patterns, while transient transfection assays with synchronized cells show that stable incorporation of HP1 beta-gfp into heterochromatin requires passage through the S-phase. The data amassed challenge the dogma that me(3)K9H3 is necessary and sufficient for HP1 binding and unveil a new mode of HP1-chromatin interactions.	Univ Ioannina, Biol Lab, Sch Med, Stem Cell & Chromatin Grp, GR-45110 Ioannina, Greece; Ioannina Biomed Res Inst, Fdn Res & Technol, Ioannina 45110, Greece; Univ Crete, Dept Basic Sci, Sch Med, Iraklion 95110, Crete, Greece; Moredun Res Inst, Funct Genom Unit, Penicuik EH26 0PZ, Midlothian, Scotland; ALMF, European Mol Biol Lab, D-69117 Heidelberg, Germany; Roslin Inst, Nucl Reprogramming Lab, Dept Gen Express & Dev, Edinburgh EH25 9PS, Midlothian, Scotland	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); University of Crete; Moredun Research Institute; European Molecular Biology Laboratory (EMBL); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Georgatos, SD (corresponding author), Univ Ioannina, Biol Lab, Sch Med, Stem Cell & Chromatin Grp, GR-45110 Ioannina, Greece.	sgeorgat@cc.uoi.gr	Singh, Prim/G-1088-2014	Singh, Prim/0000-0002-9571-0974; Terjung, Stefan/0000-0002-0018-1804; Georgatos, Spyros/0000-0002-2078-7467				Ahmad K, 2004, MOL CELL, V15, P494, DOI 10.1016/j.molcel.2004.08.012; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; CARTWRIGHT IL, 1986, MOL CELL BIOL, V6, P779, DOI 10.1128/MCB.6.3.779; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Cheutin T, 2004, MOL CELL BIOL, V24, P3157, DOI 10.1128/MCB.24.8.3157-3167.2004; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; Cowieson NP, 2000, CURR BIOL, V10, P517, DOI 10.1016/S0960-9822(00)00467-X; Daniel JA, 2005, CELL CYCLE, V4, P919, DOI 10.4161/cc.4.7.1824; Danzer JR, 2004, DEVELOPMENT, V131, P3571, DOI 10.1242/dev.01223; Fan JY, 2004, MOL CELL, V16, P655, DOI 10.1016/j.molcel.2004.10.023; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Flaus A, 2004, CURR OPIN GENET DEV, V14, P165, DOI 10.1016/j.gde.2004.01.007; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; Greil F, 2003, GENE DEV, V17, P2825, DOI 10.1101/gad.281503; GRUSS C, 1993, EMBO J, V12, P4533, DOI 10.1002/j.1460-2075.1993.tb06142.x; Huang DW, 1998, J CELL BIOL, V142, P307, DOI 10.1083/jcb.142.2.307; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Korber P, 2004, J BIOL CHEM, V279, P35113, DOI 10.1074/jbc.M405446200; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Kourmouli N, 2000, EMBO J, V19, P6558, DOI 10.1093/emboj/19.23.6558; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Luger K, 2005, CURR OPIN STRUC BIOL, V15, P188, DOI 10.1016/j.sbi.2005.03.006; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; MAISON C, 1993, J CELL BIOL, V123, P1491, DOI 10.1083/jcb.123.6.1491; Makatsori D, 2004, J BIOL CHEM, V279, P25567, DOI 10.1074/jbc.M313606200; Mateescu B, 2004, EMBO REP, V5, P490, DOI 10.1038/sj.embor.7400139; Muchardt C, 2002, EMBO REP, V3, P975, DOI 10.1093/embo-reports/kvf194; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; OOHARA I, 1987, J MOL BIOL, V196, P399, DOI 10.1016/0022-2836(87)90700-5; OOHARA I, 1987, J MOL BIOL, V196, P389, DOI 10.1016/0022-2836(87)90699-1; Oudet P, 1978, Cold Spring Harb Symp Quant Biol, V42 Pt 1, P287; Park YJ, 2004, J BIOL CHEM, V279, P24274, DOI 10.1074/jbc.M313152200; Perrini B, 2004, MOL CELL, V15, P467, DOI 10.1016/j.molcel.2004.06.036; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Quivy JP, 2004, EMBO J, V23, P3516, DOI 10.1038/sj.emboj.7600362; Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015; Schmiedeberg L, 2004, MOL BIOL CELL, V15, P2819, DOI 10.1091/mbc.E03-11-0827; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; Singh PB, 2002, J STRUCT BIOL, V140, P10, DOI 10.1016/S1047-8477(02)00536-1; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Wang GZ, 2000, MOL CELL BIOL, V20, P6970, DOI 10.1128/MCB.20.18.6970-6983.2000; YAGER TD, 1984, J BIOL CHEM, V259, P4212	57	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14350	14360		10.1074/jbc.M600558200	http://dx.doi.org/10.1074/jbc.M600558200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16547356	hybrid			2022-12-25	WOS:000237512300061
J	Falomir-Lockhart, LJ; Laborde, L; Kahn, PC; Storch, J; Corsico, B				Falomir-Lockhart, Lisandro J.; Laborde, Lisandro; Kahn, Peter C.; Storch, Judith; Corsico, Betina			Protein-membrane interaction and fatty acid transfer from intestinal fatty acid-binding protein to membranes - Support for a multistep process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE LYSINE RESIDUES; PHOSPHOLIPID-MEMBRANES; HELICAL DOMAIN; COLLISIONAL TRANSFER; DIFFERENT MECHANISMS; LIVER; ADIPOCYTE; VESICLES; HEART; STABILITY	Fatty acid transfer from intestinal fatty acid-binding protein ( IFABP) to phospholipid membranes occurs during protein-membrane collisions. Electrostatic interactions involving the alpha-helical "portal" region of the protein have been shown to be of great importance. In the present study, the role of specific lysine residues in the alpha-helical region of IFABP was directly examined. A series of point mutants in rat IFABP was engineered in which the lysine positive charges in this domain were eliminated or reversed. Using a fluorescence resonance energy transfer assay, we analyzed the rates and mechanism of fatty acid transfer from wild type and mutant proteins to acceptor membranes. Most of the alpha-helical domain mutants showed slower absolute fatty acid transfer rates to zwitterionic membranes, with substitution of one of the lysines of the alpha(2) helix, Lys(27), resulting in a particularly dramatic decrease in the fatty acid transfer rate. Sensitivity to negatively charged phospholipid membranes was also reduced, with charge reversal mutants in the alpha(2) helix the most affected. The results support the hypothesis that the portal region undergoes a conformational change during protein-membrane interaction, which leads to release of the bound fatty acid to the membrane and that the alpha(2) segment is of particular importance in the establishment of charge-charge interactions between IFABP and membranes. Cross-linking experiments with a phospholipid-photoactivable reagent underscored the importance of charge-charge interactions, showing that the physical interaction between wild-type intestinal fatty acid-binding protein and phospholipid membranes is enhanced by electrostatic interactions. Protein-membrane interactions were also found to be enhanced by the presence of ligand, suggesting different collisional complex structures for holo- and apo-IFABP.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Rutgers State Univ, Dept Biochem & Microbiol, New Brunswick, NJ 08901 USA; Natl Univ La Plata, Fac Ciencias Med, CONICET, INIBIOLP, RA-1900 La Plata, Argentina	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata	Storch, J (corresponding author), Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA.	storch@aesop.rutgers.edu; bcorsico@atlas.med.unlp.edu.ar	Falomir Lockhart, Lisandro Jorge/V-7730-2019	Falomir Lockhart, Lisandro Jorge/0000-0003-4815-5768; Storch, Judith/0000-0001-5482-1777	FIC NIH HHS [TW01100-01] Funding Source: Medline; NIDDK NIH HHS [DK 38389, R01 DK038389] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389, R29DK038389] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P110; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; Clerico EM, 2000, BBA-PROTEIN STRUCT M, V1476, P203, DOI 10.1016/S0167-4838(99)00247-2; Corsico B, 2005, J LIPID RES, V46, P1765, DOI 10.1194/jlr.M500140-JLR200; Corsico B, 2004, BIOCHEMISTRY-US, V43, P3600, DOI 10.1021/bi0357356; Corsico B, 2001, J BIOL CHEM, V276, P16978, DOI 10.1074/jbc.M011533200; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; Di Pietro SM, 2003, BIOCHEMISTRY-US, V42, P8192, DOI 10.1021/bi034213n; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; FRIEDEN C, 1995, BIOCHEMISTRY-US, V34, P2724, DOI 10.1021/bi00008a040; Garner J, 1998, J BIOL CHEM, V273, P5167, DOI 10.1074/jbc.273.9.5167; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; Herr FM, 1996, BIOCHEMISTRY-US, V35, P1296, DOI 10.1021/bi952204b; HERR FM, 1995, BIOCHEMISTRY-US, V34, P11840, DOI 10.1021/bi00037a023; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; Huang C, 1974, Methods Enzymol, V32, P485; Kajander T, 2000, STRUCTURE, V8, P1203, DOI 10.1016/S0969-2126(00)00520-7; KIM HK, 1992, J BIOL CHEM, V267, P77; Kim K, 1996, BIOCHEMISTRY-US, V35, P7553, DOI 10.1021/bi9529115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LiCata VJ, 1998, PROTEINS, V33, P577, DOI 10.1002/(SICI)1097-0134(19981201)33:4<577::AID-PROT10>3.0.CO;2-2; Liou HL, 2002, J BIOL CHEM, V277, P1806, DOI 10.1074/jbc.M107987200; Liou HL, 2001, BIOCHEMISTRY-US, V40, P6475, DOI 10.1021/bi0101042; Massey JB, 1997, BIOPHYS J, V72, P1732, DOI 10.1016/S0006-3495(97)78819-2; RICHARDS FM, 1985, METHOD ENZYMOL, V115, P440; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; RICHARDS FM, 1971, J MOL BIOL, V6, P151; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; ROSEMAN MA, 1980, BIOCHEMISTRY-US, V19, P439, DOI 10.1021/bi00544a006; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; Schlattner U, 2004, J BIOL CHEM, V279, P24334, DOI 10.1074/jbc.M314158200; STORCH J, 1990, HEPATOLOGY, V12, P1447, DOI 10.1002/hep.1840120632; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P8708; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Thumser AEA, 2000, J LIPID RES, V41, P647; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; WEBER T, 1994, J BIOL CHEM, V269, P18353; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001; Wu F, 2001, BIOCHEMISTRY-US, V40, P1976, DOI 10.1021/bi002252i; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9	50	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13979	13989		10.1074/jbc.M511943200	http://dx.doi.org/10.1074/jbc.M511943200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551626	Green Published, hybrid			2022-12-25	WOS:000237512300020
J	Hattori, T; Eberspaecher, H; Lu, JF; Zhang, R; Nishida, T; Kahyo, T; Yasuda, H; de Crombrugghe, B				Hattori, Takako; Eberspaecher, Heidi; Lu, Jingfang; Zhang, Ren; Nishida, Tamotsu; Kahyo, Tomoaki; Yasuda, Hideyo; de Crombrugghe, Benoit			Interactions between PIAS proteins and SOX9 result in an increase in the cellular concentrations of SOX9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROCYTE DIFFERENTIATION PATHWAY; PRO-ALPHA-1(II) COLLAGEN GENE; ANDROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; SUMO-1 MODIFICATION; CARTILAGE FORMATION; LONG FORM; EXPRESSION; INHIBITOR; LIGASES	We have identified PIAS1 (protein inhibitor of activated STAT-1), -3, -x alpha, and -x beta as SOX9-associated polypeptides using the Gal4-based yeast two-hybrid system and a cDNA library derived from a chondrocytic cell line. These PIAS proteins were shown to interact directly with SOX9 in two-hybrid, co-immunoprecipitation, and electrophoretic mobility shift assays. SOX9 was sumoylated in cotransfection experiments with COS-7 cells using PIAS and SUMO-1 (small ubiquitin-like modifier-1) expression vectors. SOX9 was also sumoylated in vitro by PIAS proteins in the presence of SUMO-1, the SUMO-activating enzyme, and the SUMO-conjugating enzyme. In COS-7 cells, PIAS proteins stimulated the SOX9-dependent transcriptional activity of a Col2a1 promoter-enhancer reporter. This increase in reporter activity was paralleled by an increase in the cellular levels of SOX9. Cotransfection with a SUMO-expressing vector further enhanced the transcriptional activity of this SOX9-dependent Col2a1 reporter in COS-7 cells, and this additional activation was inhibited in the presence of either SUMO-1 mutants or PIAS RING domain mutants or by coexpression of a desumoylation enzyme. Immunofluorescence microscopy of SOX9-transfected COS-7cells showed that the subnuclear distribution of SOX9 became more diffuse in the presence of PIAS1 and SUMO-1. Our results suggest that, by controlling the cellular concentrations of SOX9, PIAS proteins and sumoylation may be part of a major regulatory system of SOX9 functions.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Tokyo Univ Pharm & Life Sci, Div Mol Biol, Sch Life Sci, Hachioji, Tokyo 1920392, Japan; Nippon Flour Mills Co Ltd, Div Biosci, Cent Lab, Atsugi, Kanagawa 2430041, Japan	University of Texas System; UTMD Anderson Cancer Center; Tokyo University of Pharmacy & Life Sciences	de Crombrugghe, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	bdecromb@mdanderson.org						Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Akiyama H, 2005, MATRIX BIOL, V23, P499, DOI 10.1016/j.matbio.2004.10.002; Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Huang WD, 2002, J BIOL CHEM, V277, P50668, DOI 10.1074/jbc.M206544200; Hwang ES, 2004, MOL ENDOCRINOL, V18, P2672, DOI 10.1210/me.2004-0168; Janne OA, 2000, BIOCHEM SOC T, V28, P401, DOI 10.1042/0300-5127:0280401; Jimenez-Lara AM, 2002, FEBS LETT, V526, P142, DOI 10.1016/S0014-5793(02)03154-X; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kawakami Y, 2005, P NATL ACAD SCI USA, V102, P2414, DOI 10.1073/pnas.0407510102; Koopman P, 1999, CELL MOL LIFE SCI, V55, P839; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1996, ANN NY ACAD SCI, V785, P284, DOI 10.1111/j.1749-6632.1996.tb56285.x; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Roth W, 2004, J IMMUNOL, V173, P6189, DOI 10.4049/jimmunol.173.10.6189; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Zhang P, 2003, J BIOL CHEM, V278, P117, DOI 10.1074/jbc.M208049200; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhou RJ, 2002, NUCLEIC ACIDS RES, V30, P3245, DOI 10.1093/nar/gkf443; Zuber M, 1995, BIOL CELL, V85, P77, DOI 10.1016/0248-4900(96)89129-5	36	60	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14417	14428		10.1074/jbc.M511330200	http://dx.doi.org/10.1074/jbc.M511330200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16554309	hybrid			2022-12-25	WOS:000237512300069
J	Zhao, Y; Yin, P; Bach, LA; Duan, CM				Zhao, Yang; Yin, Ping; Bach, Leon A.; Duan, Cunming			Several acidic amino acids in the N-domain of insulin-like growth factor-binding protein-5 are important for its transactivation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR; FACTOR-I; FUNCTIONAL DISSECTION; NUCLEAR-LOCALIZATION; FACTOR (IGF)-I; CELL-DEATH; IGF; IGFBP-5; PHOSPHORYLATION; PROTEASE	Insulin-like growth factor-binding protein ( IGFBP)-5 is a secreted protein that binds to IGFs and modulates IGF actions. IGFBP-5 is also found in the nuclei of cultured cells and has transactivation activity. Here we report the nuclear localization of endogenous IGFBP-5 in mouse embryonic skeletal cells. Chromatin immunoprecipitation experiments indicated that IGFBP-5 interacts with the nuclear histone-DNA complex. Using a series of deletion mutants, the transactivation domain of IGFBP-5 was mapped to its N-terminal region. Intriguingly, the transactivation activity of IGFBP-5 is masked by negative regulatory elements located in the L- and C-domains. Among the other IGFBPs, the N-domains of IGFBP-2 and -3 also had strong transactivation activity, whereas those of IGFBP-1 and -6 had no activity. The IGFBP-4 N-domain had modest activity. Sequence analysis revealed several amino acids in the IGFBP-5 N-domain that are not present in IGFBP-1. The activities of mutants in which these residues were changed to the corresponding IGFBP-1 sequence were determined. Mutations that changed acidic residues to neutral residues ( e. g. E8A, D11S, E12A, E30S/P31A, E43L, and E52A) or a polar to a basic residue ( e. g. Q56R) significantly reduced transactivation activity. The E8A/D11S/E12A triple mutant and E52A/Q56R double mutants showed further reduced activity. The combinatory mutants had essentially no transactivation activity. Taken together, our results indicate that there are several conserved residues in the IGFBP-5 N-terminal region that are critical for transactivation and that IGFBP-2 and -3 also have strong transactivation activity in their N-domains.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Monash Univ, Alfred Hosp, Dept Med, Melbourne, Vic 3004, Australia; Monash Univ, Alfred Hosp, Dept Endocrinol & Diabet, Melbourne, Vic 3004, Australia	University of Michigan System; University of Michigan; Florey Institute of Neuroscience & Mental Health; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Nat Sci Bldg,Room 3065B,830 N Univ St, Ann Arbor, MI 48109 USA.	cduan@umich.edu		Bach, Leon/0000-0002-9062-1518	NHLBI NIH HHS [2R01HL60679] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060679] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abedi M, 2001, BMC Mol Biol, V2, P10, DOI 10.1186/1471-2199-2-10; Abrass CK, 1997, AM J PHYSIOL-RENAL, V273, pF899, DOI 10.1152/ajprenal.1997.273.6.F899; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; Bach LA, 2005, TRENDS ENDOCRIN MET, V16, P228, DOI 10.1016/j.tem.2005.05.005; Berfield AK, 2000, KIDNEY INT, V57, P1991, DOI 10.1046/j.1523-1755.2000.00049.x; Besnard V, 2001, BBA-MOL CELL RES, V1538, P47, DOI 10.1016/S0167-4889(00)00136-1; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Cobb LJ, 2004, J CELL SCI, V117, P1737, DOI 10.1242/jcs.01028; Duan CM, 1996, J BIOL CHEM, V271, P4280; Duan CM, 1999, J BIOL CHEM, V274, P37147, DOI 10.1074/jbc.274.52.37147; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; Hsieh JC, 2004, BIOCHEM BIOPH RES CO, V324, P801, DOI 10.1016/j.bbrc.2004.09.139; Hsieh T, 2003, J BIOL CHEM, V278, P42886, DOI 10.1074/jbc.M303835200; Imai Y, 1997, J CLIN INVEST, V100, P2596, DOI 10.1172/JCI119803; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; Kabuta T, 2002, J BIOL CHEM, V277, P6846, DOI 10.1074/jbc.M107058200; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; McCaig C, 2002, J CELL SCI, V115, P4293, DOI 10.1242/jcs.00097; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; Perks CM, 2002, BIOCHEM BIOPH RES CO, V294, P995, DOI 10.1016/S0006-291X(02)00570-3; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; RADULESCU RT, 1994, TRENDS BIOCHEM SCI, V19, P278, DOI 10.1016/0968-0004(94)90004-3; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Schedlich LJ, 2004, BIOCHEM BIOPH RES CO, V314, P83, DOI 10.1016/j.bbrc.2003.12.049; Schedlich LJ, 2003, ENDOCRINOLOGY, V144, P1984, DOI 10.1210/en.2002-220798; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Scholtz B, 1996, DEV BIOL, V173, P420, DOI 10.1006/dbio.1996.0037; Sherman MA, 2002, J IMMUNOL, V169, P3811, DOI 10.4049/jimmunol.169.7.3811; Siwanowicz I, 2005, STRUCTURE, V13, P155, DOI 10.1016/j.str.2004.11.009; Sprenger-Haussels M, 2000, PLANT J, V22, P1, DOI 10.1046/j.1365-313x.2000.00687.x; Suzuki K, 2002, J EXP MED, V196, P27, DOI 10.1084/jem.20011682; Tonner E, 2002, DEVELOPMENT, V129, P4547; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Wiesner C, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf079; Wraight CJ, 1998, J INVEST DERMATOL, V111, P239, DOI 10.1046/j.1523-1747.1998.00258.x; Xu QJ, 2004, CIRC RES, V94, pE46, DOI 10.1161/01.RES.0000124761.62846.DF; Yin P, 2004, J BIOL CHEM, V279, P32660, DOI 10.1074/jbc.M401378200; Zeslawski W, 2001, EMBO J, V20, P3638, DOI 10.1093/emboj/20.14.3638	51	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14184	14191		10.1074/jbc.M506941200	http://dx.doi.org/10.1074/jbc.M506941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543235	hybrid			2022-12-25	WOS:000237512300042
J	Fath, DM; Kong, XG; Liang, DM; Lin, Z; Chou, A; Jiang, YB; Fang, J; Caro, J; Sang, NL				Fath, DM; Kong, XG; Liang, DM; Lin, Z; Chou, A; Jiang, YB; Fang, J; Caro, J; Sang, NL			Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; SUBEROYLANILIDE HYDROXAMIC ACID; TRANSCRIPTIONAL ACTIVITY; FACTOR 1-ALPHA; INDUCED ANGIOGENESIS; TUMOR ANGIOGENESIS; DNA-DAMAGE; PROTEASOMAL DEGRADATION; STRUCTURAL BASIS; IN-VITRO	Hypoxia- inducible factors (HIFs) are heterodimeric transcription factors regulating the oxygen supply, glucose metabolism, and angiogenesis. HIF function requires the recruitment of p300/CREB-binding protein, two coactivators with histone acetyltransferase activity, by the C-terminal transactivation domain of HIF-alpha (HIF-alpha CAD). Histone deacetylase inhibitors (HDAIs) induce differentiation or apoptosis and repress tumor growth and angiogenesis, hence being explored intensively as anti-cancer agents. Using combined pharmacological, biochemical, and genetic approaches, here we show that HDAIs repress the transactivation potential of HIF-alpha CAD. This repression is independent of the function of tumor suppressors von Hippel-Lindau or p53 or the degradation of HIF-alpha. We also demonstrate the sufficiency of low concentrations of HDAIs in repression of HIF target genes in tumor cells. We further show that HDAIs induce hyperacetylation of p300 and repress the HIF-1 alpha p300 complex in vivo. In vitro acetylation analysis reveals that the p300CH1 region, but not HIF-alpha CAD, is susceptible to acetylation. Taken together, our data demonstrate that a deacetylase activity is indispensable for the transactivation potential of HIF-CAD and support a model that acetylation regulates HIF function by targeting HIF-alpha p300 complex, not by direct acetylating HIF-alpha. The demonstration that HDAIs repress both HIF-1 alpha and HIF-2 alpha transactivation potential independently of von Hippel-Lindau tumor suppressor and p53 function indicates that HDAIs may have biological effects in a broad range of tissues in addition to tumors.	Cardeza Fdn, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Sang, NL (corresponding author), Cardeza Fdn, 1015 Walnut St,Curtis Bldg,Rm 711, Philadelphia, PA 19107 USA.	nianli.sang@jefferson.edu			NCI NIH HHS [R25CA048010, K01 CA098809, R01-CA89212, K01-CA098809, R01 CA089212] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA098809, R25CA048010, R01CA089212] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 2005, CANCER CELL, V7, P121, DOI 10.1016/j.ccr.2005.01.017; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arnesen T, 2005, FEBS LETT, V579, P6428, DOI 10.1016/j.febslet.2005.10.036; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Heinl-Green A, 2005, EUR HEART J, V26, P1327, DOI 10.1093/eurheartj/ehi223; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee YM, 2003, BIOCHEM BIOPH RES CO, V300, P241, DOI 10.1016/S0006-291X(02)02787-0; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luttun A, 2004, CURR OPIN HEMATOL, V11, P262, DOI 10.1097/01.moh.0000126936.58889.95; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Michaelis M, 2004, MOL PHARMACOL, V65, P520, DOI 10.1124/mol.65.3.520; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; O'Connor OA, 2006, J CLIN ONCOL, V24, P166, DOI 10.1200/JCO.2005.01.9679; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Powis G, 2004, MOL CANCER THER, V3, P647; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Qian DZ, 2004, CANCER RES, V64, P6626, DOI 10.1158/0008-5472.CAN-04-0540; Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132; Ravi R, 2000, GENE DEV, V14, P34; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sasakawa Y, 2003, BIOCHEM PHARMACOL, V66, P897, DOI 10.1016/S0006-2952(03)00411-8; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SEMENZA GL, 2000, PHYSL, V19, P176; Simone C, 2004, ONCOGENE, V23, P2177, DOI 10.1038/sj.onc.1207327; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Vincent KA, 2000, CIRCULATION, V102, P2255; Williams RJ, 2001, EXPERT OPIN INV DRUG, V10, P1571, DOI 10.1517/13543784.10.8.1571; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yu XD, 2002, J NATL CANCER I, V94, P504; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zgouras D, 2003, BIOCHEM BIOPH RES CO, V300, P832, DOI 10.1016/S0006-291X(02)02916-9	71	93	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13612	13619		10.1074/jbc.M600456200	http://dx.doi.org/10.1074/jbc.M600456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543236	Green Accepted, hybrid			2022-12-25	WOS:000237336600071
J	Weber, C; de Queiroz, FM; Downie, BR; Suckow, A; Stuhmer, W; Pardo, LA				Weber, C; de Queiroz, FM; Downie, BR; Suckow, A; Stuhmer, W; Pardo, LA			Silencing the activity and proliferative properties of the human EagI potassium channel by RNA interference	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; GENE-EXPRESSION; K+ CHANNELS; ACTIVATION; ETHER; CELLS; DROSOPHILA; BLOCK; INHIBITION; IMIPRAMINE	EagI potassium channels are natively expressed in the mammalian brain as well as in many cancer cell lines and tumor tissues. The role of EagI in malignant transformation has been suggested by several experiments, but the lack of specific EagI inhibitors has made it difficult to examine the influence of the channel on oncogenesis and its potential as a therapeutic target. We have used short interfering RNA to test the effects of EagI reduction on the behavior of tumor cells in vitro. By generating and optimizing an EagI-specific short interfering RNA system, we were able to study the effects of EagI depletion on several cancer cell lines that endogenously express this protein. We show here that our short interfering RNA sequences act specifically on EagI, reproducibly induce a significant decrease in the proliferation of tumor cell lines, and do not trigger any observable nonspecific responses.	Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, D-37075 Gottingen, Germany	Max Planck Society	Pardo, LA (corresponding author), Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, Hermann Rein Str 3, D-37075 Gottingen, Germany.	Pardo@em.mpg.de	Pardo, Luis/C-5066-2013; Stuehmer, Walter/A-2176-2009	Pardo, Luis/0000-0003-1375-4349; Stuehmer, Walter/0000-0002-0642-7764; Downie, Bryan/0000-0001-8278-722X				[Anonymous], 2003, NAT CELL BIOL, V5, P489, DOI 10.1038/ncb0603-490; Bantounas I, 2004, J MOL ENDOCRINOL, V33, P545, DOI 10.1677/jme.1.01582; Bauer CK, 2001, J MEMBRANE BIOL, V182, P1; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; Choi I, 2005, J BIOTECHNOL, V120, P251, DOI 10.1016/j.jbiotec.2005.06.014; Daude N, 2003, J CELL SCI, V116, P2775, DOI 10.1242/jcs.00494; Eckstein F, 2005, TRENDS BIOCHEM SCI, V30, P445, DOI 10.1016/j.tibs.2005.06.008; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Garcia-Ferreiro RE, 2004, J GEN PHYSIOL, V124, P301, DOI 10.1085/jgp.200409041; Gavrilova-Ruch O, 2002, J MEMBRANE BIOL, V188, P137, DOI 10.1007/s00232-001-0181-3; Gurney Alison M., 2005, Journal of Pharmacological and Toxicological Methods, V51, P253, DOI 10.1016/j.vascn.2004.08.012; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Huesken D, 2005, NAT BIOTECHNOL, V23, P995, DOI 10.1038/nbt1118; Huppi K, 2005, MOL CELL, V17, P1, DOI 10.1016/j.molcel.2004.12.017; Izquierdo M, 2005, CANCER GENE THER, V12, P217, DOI 10.1038/sj.cgt.7700791; KAPLAN WD, 1969, GENETICS, V61, P399; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MINKS MA, 1979, J BIOL CHEM, V254, P180; Napp J, 2005, J BIOL CHEM, V280, P29506, DOI 10.1074/jbc.M504228200; Ouadid-Ahidouch H, 2001, RECEPTOR CHANNEL, V7, P345; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 2004, PHYSIOLOGY, V19, P285, DOI 10.1152/physiol.00011.2004; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Peyrl A, 2003, PROTEOMICS, V3, P1781, DOI 10.1002/pmic.200300460; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Saganich MJ, 2001, J NEUROSCI, V21, P4609, DOI 10.1523/JNEUROSCI.21-13-04609.2001; Schonherr R, 2000, EMBO J, V19, P3263, DOI 10.1093/emboj/19.13.3263; Sellappan S, 2004, CANCER RES, V64, P3479, DOI 10.1158/0008-5472.CAN-3299-2; Sledz CA, 2004, BIOCHEM SOC T, V32, P952, DOI 10.1042/BST0320952; Stansfeld CE, 1996, P NATL ACAD SCI USA, V93, P9910, DOI 10.1073/pnas.93.18.9910; Terlau H, 1996, PFLUG ARCH EUR J PHY, V432, P301, DOI 10.1007/s004240050137; Tulac S, 2004, MOL HUM REPROD, V10, P705, DOI 10.1093/molehr/gah105; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zhou ZF, 1999, J CARDIOVASC ELECTR, V10, P836, DOI 10.1111/j.1540-8167.1999.tb00264.x; Ziechner U, 2006, FEBS J, V273, P1074, DOI 10.1111/j.1742-4658.2006.05134.x	37	95	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13030	13037		10.1074/jbc.M600883200	http://dx.doi.org/10.1074/jbc.M600883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537547	hybrid			2022-12-25	WOS:000237336600006
J	Imai, K; Okamoto, T				Imai, K; Okamoto, T			Transcriptional repression of human immunodeficiency virus type 1 by AP-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; RNA-POLYMERASE-II; NF-KAPPA-B; HISTONE DEACETYLASE; GENE-EXPRESSION; MEDIATED TRANSCRIPTION; BINDING PROTEINS; HIV-1 LTR; TATA BOX; T-CELLS	Elucidation of the mechanism of transcriptional silencing of human immunodeficiency virus type 1 (HIV-1) provirus in latently infected cells is crucial to understand the pathophysiology of HIV-1 infection and to develop novel therapies. Here we demonstrate that AP-4 is responsible for the transcriptional repression of HIV-1. We found that AP-4 site within the viral long terminal repeat (LTR) is well conserved in the majority of HIV-1 subtypes and that AP-4 represses HIV-1 gene expression by recruiting histone deacetylase ( HDAC) 1 as well as by masking TATA-binding protein to TATA box. AP-4-mediated transcriptional repression was inhibited by an HDAC inhibitor, tricostatin A, and could be exerted even at distant locations from the TATA box. In addition, AP-4 interacted with HDAC1 both in vivo and in vitro. Moreover, chromatin immuno-precipitation assays have revealed that AP-4 and HDAC1 are present in the HIV-1 LTR promoter in latently infected ACH2 and U1 cells, and they are dissociated from the promoter concomitantly with the association of acetylated histone H3, TBP, and RNA polymerase II upon TNF-alpha stimulation of HIV-1 replication. Furthermore, when AP-4 is knocked down by siRNA, HIV-1 production was greatly augmented in cells transfected with a full-length HIV-1 clone. These results suggest that AP-4 may be responsible for transcriptional quiescence of latent HIV-1 provirus and give a molecular basis to the reported efficacy of combination therapy of conventional anti-HIV drugs with an HDAC inhibitor in accelerating the clearance of HIV-1 from individuals infected with the virus.	Nagoya City Univ, Dept Mol & Cellular Biol, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Dept Mol & Cellular Biol, Grad Sch Med Sci, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.	tokamoto@med.nagoya-cu.ac.jp						Andriamanalijaona R, 2003, ARTHRITIS RHEUM, V48, P1569, DOI 10.1002/art.11020; Aranburu A, 2001, BIOCHEM J, V354, P431, DOI 10.1042/0264-6021:3540431; Asamitsu K, 2003, J BIOL CHEM, V278, P26879, DOI 10.1074/jbc.M211831200; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; CANNON P, 1994, J VIROL, V68, P1993, DOI 10.1128/JVI.68.3.1993-1997.1994; Chitikila C, 2002, MOL CELL, V10, P871, DOI 10.1016/S1097-2765(02)00683-4; Chun TW, 2001, P NATL ACAD SCI USA, V98, P253, DOI 10.1073/pnas.98.1.253; Coull JJ, 2000, J VIROL, V74, P6790, DOI 10.1128/JVI.74.15.6790-6799.2000; Courey AJ, 2001, GENE DEV, V15, P2786; Cui Y, 1998, GENE, V224, P97, DOI 10.1016/S0378-1119(98)00512-5; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; Dreikhausen U, 2005, MOL CELL BIOL, V25, P7473, DOI 10.1128/MCB.25.17.7473-7483.2005; Estable MC, 1996, J VIROL, V70, P4053, DOI 10.1128/JVI.70.6.4053-4062.1996; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; Glahder JA, 2003, J GEN VIROL, V84, P3429, DOI 10.1099/vir.0.19250-0; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; Guo S, 2000, NATURE, V408, P366, DOI 10.1038/35042590; He GC, 2002, MOL CELL BIOL, V22, P2965, DOI 10.1128/MCB.22.9.2965-2973.2002; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; Imai K, 2005, J BIOL CHEM, V280, P26701, DOI 10.1074/jbc.M503313200; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KAUFMAN PD, 1991, P NATL ACAD SCI USA, V88, P2613, DOI 10.1073/pnas.88.7.2613; KUIKEN C, 2002, HIV SEQUENCE COMPEND, P370; Kumar PP, 2005, MOL CELL BIOL, V25, P1620, DOI 10.1128/MCB.25.5.1620-1633.2005; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lehrman G, 2005, LANCET, V366, P549, DOI 10.1016/S0140-6736(05)67098-5; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Marban C, 2005, NUCLEIC ACIDS RES, V33, P2318, DOI 10.1093/nar/gki529; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; OLSEN HS, 1992, J VIROL, V66, P5594, DOI 10.1128/JVI.66.9.5594-5597.1992; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; Persaud D, 2003, J VIROL, V77, P1659, DOI 10.1128/JVI.77.3.1659-1665.2003; Pomerantz RJ, 2004, ARCH IMMUNOL THER EX, V52, P297; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; SAKAGUCHI M, 1991, J VIROL, V65, P5448, DOI 10.1128/JVI.65.10.5448-5456.1991; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853; Takada N, 2002, J VIROL, V76, P8019, DOI 10.1128/JVI.76.16.8019-8030.2002; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; van Opijnen T, 2004, J VIROL, V78, P6883, DOI 10.1128/JVI.78.13.6883-6890.2004; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	54	118	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12495	12505		10.1074/jbc.M511773200	http://dx.doi.org/10.1074/jbc.M511773200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16540471	hybrid			2022-12-25	WOS:000237134700037
J	Wang, YF; Tan, CG; Fagan, RJ; Klein, PS				Wang, YF; Tan, CG; Fagan, RJ; Klein, PS			Phosphorylation of frizzled-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR CELL POLARITY; WNT PATHWAY; DISHEVELLED PHOSPHORYLATION; RECEPTOR ENDOCYTOSIS; KINASE; BETA-ARRESTIN-2; TRANSDUCTION; MECHANISMS; FAMILY	Wnts are secreted proteins important to many biological processes. frizzled genes encode a family of Wnt receptors that signal to the intracellular compartment through the cytosolic protein Disheveled. Limited information is available concerning the regulation of Frizzleds at a biochemical level. We report here that Xenopus Frizzled-3 is phosphorylated in a Disheveled-dependent manner that appears to require the DEP domain of Disheveled. Phosphorylation of serine 576 causes a decrease in electrophoretic mobility and accounts for a significant fraction of receptor phosphorylation, although additional residues in the C-terminal tail are also phosphorylated. In addition, mutations that interfere with Frizzled-3 function also interfere with phosphorylation, but these inactive mutants can be phosphorylated when an active form of Frizzled-3 is co-expressed. Mutation of C-terminal serines including serine 576 significantly enhances Frizzled-3-mediated induction of neural crest markers, suggesting that C-terminal phosphorylation plays a role in down-regulating Frizzled signaling.	Univ Penn, Sch Med, Cell & Mol Biol Grad Program, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Klein, PS (corresponding author), 364 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	pklein@mail.med.upenn.edu		Tan, Change/0000-0001-8291-3337	NIMH NIH HHS [R01MH58324] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058324] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Boutros M, 2000, SCIENCE, V288, P1825, DOI 10.1126/science.288.5472.1825; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Chen W, 2004, SCIENCE, V306, P2257, DOI 10.1126/science.1104135; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Deardorff MA, 2001, DEVELOPMENT, V128, P3655; Djiane A, 2005, CELL, V121, P621, DOI 10.1016/j.cell.2005.03.014; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Huang HC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-234; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; Kinoshita N, 2003, GENE DEV, V17, P1663, DOI 10.1101/gad.1101303; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rasmussen JT, 2001, P NATL ACAD SCI USA, V98, P3861, DOI 10.1073/pnas.071586298; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Shi DL, 1998, MECH DEVELOP, V70, P35, DOI 10.1016/S0925-4773(97)00166-4; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Tada M, 2000, DEVELOPMENT, V127, P2227; Tan C, 2001, DEVELOPMENT, V128, P3665; Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092-8674(02)00715-8; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Wang HY, 2004, CELL MOL LIFE SCI, V61, P69, DOI 10.1007/s00018-003-3165-x; Wang YS, 2002, J NEUROSCI, V22, P8563; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Yamamoto A, 2005, CELL, V120, P223, DOI 10.1016/j.cell.2004.11.051	39	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11603	11609		10.1074/jbc.M600713200	http://dx.doi.org/10.1074/jbc.M600713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513654	hybrid			2022-12-25	WOS:000236988100023
J	Goldsmith, KC; Liu, X; Dam, V; Morgan, BT; Shabbout, M; Cnaan, A; Letai, A; Korsmeyer, SJ; Hogarty, MD				Goldsmith, K. C.; Liu, X.; Dam, V.; Morgan, B. T.; Shabbout, M.; Cnaan, A.; Letai, A.; Korsmeyer, S. J.; Hogarty, M. D.			BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma	ONCOGENE			English	Article						apoptosis; neuroblastoma; Bcl-2 homologues; programmed cell death; MYCN	HUMAN NEURO-BLASTOMA; CELL-LINES; CANCER-CELLS; IN-VIVO; P53; PROTEINS; DOMAINS; TUMOR; RESISTANCE; MUTATIONS	The major impediment to cure for many malignancies is the development of therapy resistance with resultant tumor progression. Genetic alterations leading to subversion of inherent apoptosis pathways are common themes in therapy resistance. Bcl-2 family proteins play a critical role in regulating mitochondrial apoptosis that governs chemotherapeutic effects, and defective engagement of these pathways contributes to treatment failure. We have studied the efficacy of BH3 peptidomimetics consisting of the minimal death, or BH3, domains of the proapoptotic BH3-only proteins Bid and Bad to induce apoptosis using neuroblastoma (NB) as a model system. We demonstrate that BH3 peptides, modified with an arginine homopolymer for membrane transduction (called r8-BidBH3 and r8-BadBH3, respectively), potently induce apoptosis in NB cells, including those with MYCN amplification. Cell death is caspase 9 dependent, consistent with a requirement for the intrinsic mitochondrial pathway. Substitutions at highly conserved residues within the r8-BidBH3 peptide abolish apoptotic efficacy supporting activity through specific BH domain interactions. Concomitant exposure to r8-BadBH3 and r8-BidBH3 at sublethal monotherapy doses revealed potent synergy consistent with a competitive displacement model, whereby BH3 peptides displace sequestered BH3 proteins to induce cell death. Further, BH3 peptides demonstrate antitumor efficacy in a xenograft model of NB in the absence of additional genotoxic or trophic stressors. These data provide proof of principle that targeted re-engagement of apoptosis pathways may be of therapeutic utility, and BH3-like compounds are attractive lead agents to re-establish therapy-induced apoptosis in refractory malignancies.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Hogarty, MD (corresponding author), Childrens Hosp Philadelphia, Div Oncol, 9 N ARC,Suite 902C,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	hogartym@email.chop.edu			NATIONAL CANCER INSTITUTE [P01CA097323] Funding Source: NIH RePORTER; NCI NIH HHS [CA97323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cooperman J, 2004, STEM CELLS, V22, P1111, DOI 10.1634/stemcells.22-6-1111; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Dive C, 1992, Semin Cancer Biol, V3, P417; FEDER MK, 1983, J NATL CANCER I, V70, P1051; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Keshelava N, 2001, CANCER RES, V61, P6185; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Moreau C, 2003, J BIOL CHEM, V278, P19426, DOI 10.1074/jbc.M209472200; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SCHLESINGER HR, 1976, CANCER RES, V36, P3094; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Tajiri T, 2003, CLIN CANCER RES, V9, P3345; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Tweddle DA, 2001, CANCER RES, V61, P8; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	39	47	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4525	4533		10.1038/sj.onc.1209489	http://dx.doi.org/10.1038/sj.onc.1209489			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16568093				2022-12-25	WOS:000239457500003
J	Zheng, Z; Cantor, A; Bepler, G				Zheng, Z.; Cantor, A.; Bepler, G.			A global genome damage score predictive of lung cancer patients outcome	ONCOGENE			English	Article						lung cancer; chromosome aberrations; prognosis; survival	PROGNOSTIC-SIGNIFICANCE; DNA; HETEROZYGOSITY; CARCINOMAS; MECHANISMS; NEOPLASIA; REGIONS; GENE; 18Q	Genome damage is a hallmark of human cancer. Efforts at assessing the impact of genome damage on tumor phenotype and patients outcome have focused on measurements of the relative DNA content in tumor cells compared to normal cells and the assessment of allelic loss at single or multiple selected loci that are thought to harbor genes important in cancer biology. We adapted a global, high-resolution genotyping method for determination of global and unbiased allelic loss. We generated a score, termed global genome damage score (GGDS), that is a continuous variable from zero to one and a measure of the extent of damaged DNA in individual tumors. In 71 patients with completely resected non-small-cell lung cancer, the GGDS ranged from 0.0006 to 0.5530 with a median value of 0.0401 indicating that between 0.06 and 55.3% of the genome has allelic loss. Patients with high scores (> 0.04) had a significantly worse outcome than those with low scores (median overall survival time 35.5 vs > 120.0 months, P = 0.006 log-rank test; median disease free survival 28.3 vs > 120.0 months, P = 0.003 log-rank test). This suggests that the clinical behavior of lung tumors with low GGDS is relatively benign whereas tumors with high GGDS are aggressive resulting in early death of patients.	H Lee Moffit Canc Ctr & Res Inst, Thorac Oncol Program, Tampa, FL 33612 USA		Bepler, G (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Thorac Oncol Program, MRC-4W,12902 Magnolia Dr, Tampa, FL 33612 USA.	beplerg@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [U01CA101222, R01CA102726] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102726, U01 CA101222] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; AUER G, 1984, CANCER RES, V44, P394; BARLOGIE B, 1982, CANCER GENET CYTOGEN, V6, P17, DOI 10.1016/0165-4608(82)90017-6; BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; Bepler G, 2002, J CLIN ONCOL, V20, P1353, DOI 10.1200/JCO.20.5.1353; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Contal C, 1999, COMPUT STAT DATA AN, V30, P253, DOI 10.1016/S0167-9473(98)00096-6; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FONG KM, 1995, CANCER RES, V55, P220; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Mandrekar J, 2003, SUGI, V28, P261; Mitsudomi T, 1996, CLIN CANCER RES, V2, P1185; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; ROYLE NJ, 1988, GENOMICS, V3, P352, DOI 10.1016/0888-7543(88)90127-9; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOLM M, 1985, CANCER-AM CANCER SOC, V56, P1396, DOI 10.1002/1097-0142(19850915)56:6<1396::AID-CNCR2820560630>3.0.CO;2-L; WOLLEY RC, 1982, J NATL CANCER I, V69, P15; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	22	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4491	4494		10.1038/sj.onc.1209476	http://dx.doi.org/10.1038/sj.onc.1209476			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16518406				2022-12-25	WOS:000239326000012
J	Arjunan, P; Sax, M; Brunskill, A; Chandrasekhar, K; Nemeria, N; Zhang, S; Jordan, F; Furey, W				Arjunan, Palaniappa; Sax, Martin; Brunskill, Andrew; Chandrasekhar, Krishnamoorthy; Nemeria, Natalia; Zhang, Sheng; Jordan, Frank; Furey, William			A thiamin-bound, pre-decarboxylation reaction intermediate analogue in the pyruvate dehydrogenase E1 subunit induces large scale disorder-to-order transformations in the enzyme and reveals novel structural features in the covalently bound adduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MULTIENZYME COMPLEXES; ANGSTROM RESOLUTION; DIPHOSPHATE BINDING; ACTIVE-SITES; CATALYSIS; CRYSTALLOGRAPHY; TRANSKETOLASE	The crystal structure of the E1 component from the Escherichia coli pyruvate dehydrogenase multienzyme complex (PDHc) has been determined with phosphonolactylthiamin diphosphate (PLThDP) in its active site. PLThDP serves as a structural and electrostatic analogue of the natural intermediate alpha-lactylthiamin diphosphate (LThDP), in which the carboxylate from the natural substrate pyruvate is replaced by a phosphonate group. This represents the first example of an experimentally determined, three-dimensional structure of a thiamin diphosphate (ThDP)-dependent enzyme containing a covalently bound, pre-decarboxylation reaction intermediate analogue and should serve as a model for the corresponding intermediates in other ThDP-dependent decarboxylases. Regarding the PDHc-specific reaction, the presence of PLThDP induces large scale conformational changes in the enzyme. In conjunction with the E1-PLThDP and E1-ThDP structures, analysis of a H407AE1-PLThDP variant structure shows that an interaction between His-407 and PLThDP is essential for stabilization of two loop regions in the active site that are otherwise disordered in the absence of intermediate analogue. This ordering completes formation of the active site and creates a new ordered surface likely involved in interactions with the lipoyl domains of E2s within the PDHc complex. The tetrahedral intermediate analogue is tightly held in the active site through direct hydrogen bonds to residues His-407, Tyr-599, and His-640 and reveals a new, enzyme-induced, strain-related feature that appears to aid in the decarboxylation process. This feature is almost certainly present in all ThDP- dependent decarboxylases; thus its inclusion in our understanding of general thiamin catalysis is important.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Vet Affairs Med Ctr, Biocrystallog Lab, Pittsburgh, PA 15240 USA; Rutgers State Univ, Dept Chem, Newark, NJ 07102 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Rutgers State University Newark; Rutgers State University New Brunswick	Furey, W (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, 1340W BSTWR, Pittsburgh, PA 15261 USA.	fureyw@pitt.edu			NIGMS NIH HHS [GM-62330, GM-61791] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061791, R01GM062330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; Arjunan P, 2005, ACTA CRYSTALLOGR A, V61, pC202, DOI 10.1107/S0108767305091415; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chabriere E, 1999, NAT STRUCT BIOL, V6, P182; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; Fiedler E, 2002, P NATL ACAD SCI USA, V99, P591, DOI 10.1073/pnas.022510999; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; FUREY W, 2004, THIAMINE CATALYTIC M, P407; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; Jones DD, 2001, J MOL BIOL, V305, P49, DOI 10.1006/jmbi.2000.4257; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan F, 2005, BIOORG CHEM, V33, P190, DOI 10.1016/j.bioorg.2005.02.001; Jordan F, 2003, NAT PROD REP, V20, P184, DOI 10.1039/b111348h; Jordan F, 2003, J AM CHEM SOC, V125, P12732, DOI 10.1021/ja0346126; KLUGER R, 1987, CHEM REV, V87, P863, DOI 10.1021/cr00081a001; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li J, 2004, J BIOL CHEM, V279, P32968, DOI 10.1074/jbc.M403611200; MULLER YA, 1993, STRUCTURE, V1, P95, DOI 10.1016/0969-2126(93)90025-C; Nakai T, 2004, J MOL BIOL, V337, P1011, DOI 10.1016/j.jmb.2004.02.011; Nemeria N, 2004, BIOCHEMISTRY-US, V43, P6565, DOI 10.1021/bi049549r; Nemeria N, 2002, BIOCHEMISTRY-US, V41, P15459, DOI 10.1021/bi0205909; Nemeria N, 2001, J BIOL CHEM, V276, P45969, DOI 10.1074/jbc.M104116200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLETCHER J, 1977, J AM CHEM SOC, V99, P1396, DOI 10.1021/ja00447a019; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; TURANO A, 1982, J AM CHEM SOC, V104, P3089, DOI 10.1021/ja00375a024; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; Wynn RM, 2004, STRUCTURE, V12, P2185, DOI 10.1016/j.str.2004.09.013; Zhang S, 2004, J BIOL CHEM, V279, P54312, DOI 10.1074/jbc.M409278200	34	84	85	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15296	15303		10.1074/jbc.M600656200	http://dx.doi.org/10.1074/jbc.M600656200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16531404	hybrid			2022-12-25	WOS:000237922200033
J	Chaurasia, P; Aguirre-Ghiso, JA; Liang, OD; Gardsvoll, H; Ploug, M; Ossowski, L				Chaurasia, Pratima; Aguirre-Ghiso, Julio A.; Liang, Olin D.; Gardsvoll, Henrik; Ploug, Michael; Ossowski, Liliana			A region in urokinase plasminogen receptor domain III controlling a functional association with alpha 5 beta 1 integrin and tumor growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR RECEPTOR; INTEGRIN FUNCTION; CELL-ADHESION; MONOCLONAL-ANTIBODY; BETA(3) INTEGRINS; CRYSTAL-STRUCTURE; HUMAN CARCINOMA; LIGAND-BINDING; IN-VIVO; FIBRONECTIN	Highly expressed urokinase plasminogen activator receptor (uPAR) can interact with alpha 5 beta 1 integrin leading to persistent ERK activation and tumorigenicity. Disrupting this interaction reduces ERK activity, forcing cancer cells into dormancy. We identified a site in uPAR domain III that is indispensable for these effects. A 9-mer peptide derived from a sequence in domain III ( residues 240-248) binds purified alpha 5 beta 1 integrin. Substituting a single amino acid ( S245A) in this peptide, or in full-length soluble uPAR, impairs binding of the purified integrin. In the recently solved crystal structure of uPAR the Ser-245 is confined to the large external surface of the receptor, a location that is well separated from the central urokinase plasminogen binding cavity. The impact of this site on alpha 5 beta 1 integrin-dependent cell functions was examined by comparing cells induced to express uPAR(wt) or the uPAR(S245A) mutant. Transfecting uPARwt into cells with low endogenous levels of uPAR, inactive integrin, lowERK activity, and a dormant phenotype in vivo restores these functions and reinstates growth in vivo. In contrast, transfection of the same cells with uPAR(S245A) elicits only very small changes. Incubation of highly malignant cells with the wild-type, but not the S245A mutant peptide, disrupts the uPAR integrin interaction leading to down-regulation of ERK activity. The relevance of this binding site, and of the lateral uPAR-alpha 5 beta 1 integrin interaction, to ERK pathway activation and tumor growth implicates it as a possible specific target for cancer therapy.	Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA; Univ Giessen, Fachbereich Human Med, Inst Biochem, D-35392 Giessen, Germany; Copenhagen Univ Hosp, Finsen Lab, DK-2100 Copenhagen, Denmark	Icahn School of Medicine at Mount Sinai; Justus Liebig University Giessen; University of Copenhagen	Ossowski, L (corresponding author), Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	Liliana.Ossowski@mssm.edu		Aguirre-Ghiso, Julio/0000-0002-6694-6507; Ploug, Michael/0000-0003-2215-4265	NCI NIH HHS [CA 40578] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; Behrendt N, 2004, BIOL CHEM, V385, P103, DOI 10.1515/BC.2004.031; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Butta N, 2003, BLOOD, V102, P2491, DOI 10.1182/blood-2003-01-0213; Calzada MJ, 2002, J BIOL CHEM, V277, P39899, DOI 10.1074/jbc.M205886200; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Degryse B, 2005, J BIOL CHEM, V280, P24792, DOI 10.1074/jbc.M413954200; Gardsvoll H, 1999, J BIOL CHEM, V274, P37995, DOI 10.1074/jbc.274.53.37995; Gardsvoll H, 2004, PROTEIN EXPRES PURIF, V34, P284, DOI 10.1016/j.pep.2003.12.002; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hansen LV, 2004, BIOCHEM J, V380, P845, DOI 10.1042/BJ20031478; Huai Q, 2006, SCIENCE, V311, P656, DOI 10.1126/science.1121143; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Kugler MC, 2003, CURR PHARM DESIGN, V9, P1565, DOI 10.2174/1381612033454658; Liang OD, 2003, J BIOCHEM, V134, P661, DOI 10.1093/jb/mvg190; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; NISHIDA T, 1988, INVEST OPHTH VIS SCI, V29, P1820; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Ploug M, 1998, J BIOL CHEM, V273, P13933, DOI 10.1074/jbc.273.22.13933; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Pluskota E, 2003, BLOOD, V101, P1582, DOI 10.1182/blood-2002-06-1842; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xue W, 1997, CANCER RES, V57, P1682; Zhang F, 2003, J CELL BIOL, V163, P177, DOI 10.1083/jcb.200304065	45	103	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14852	14863		10.1074/jbc.M512311200	http://dx.doi.org/10.1074/jbc.M512311200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16547007	hybrid			2022-12-25	WOS:000237671300039
J	Callebaut, I; Malivert, L; Fischer, A; Mornon, JP; Revy, P; de Villartay, JP				Callebaut, Isabelle; Malivert, Laurent; Fischer, Alain; Mornon, Jean-Paul; Revy, Patrick; de Villartay, Jean-Pierre			Cernunnos interacts with the XRCC4 center dot DNA-ligase IV complex and is homologous to the yeast nonhomologous end-joining factor Nej1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-LIGASE-IV; HYDROPHOBIC CLUSTER-ANALYSIS; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; CRYSTAL-STRUCTURE; PROTEIN-SEQUENCE; REPAIR PROTEIN; MATING-TYPE; IMMUNODEFICIENCY	DNA double strand breaks are considered as the most harmful DNA lesions and are repaired by either homologous recombination or nonhomologous end joining (NHEJ). A new NHEJ factor, Cernunnos, has been identified, the defect of which leads to a severe immunodeficiency condition associated with microcephaly and other developmental defects in humans. This presentation is reminiscent to that of DNA-ligase IV deficiency and suggests a possible interplay between Cernunnos and the XRCC4 center dot DNA-ligase IV complex. We show here that Cernunnos physically interacts with the XRCC4 center dot DNA-ligase IV complex. Moreover, a combination of sensitive methods of sequence analysis revealed that Cernunnos can be associated with the XRCC4 family of proteins and that it corresponds to the genuine homolog of the yeast Nej1 protein. Altogether these results shed new lights on the last step, the DNA religation, of the NHEJ pathway.	Univ Paris 06, IMPMC, Dept Biol Struct, CNRS UMR 7590, F-75252 Paris 05, France; Univ Paris 07, IMPMC, Dept Biol Struct, CNRS UMR 7590, F-75252 Paris 05, France; Hop Necker Enfants Malad, INSERM, U768, Unite Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France; Univ Paris 05, Fac Med Rene Descartes, F-75005 Paris, France; Hop Necker Enfants Malad, AP HP, Unite Immunol & Hematol, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Callebaut, I (corresponding author), Univ Paris 06, IMPMC, Dept Biol Struct, CNRS UMR 7590, Case 115,4 Pl Jussieu, F-75252 Paris 05, France.	IsabelleCallebaut@impmc.jussieu.fr; devillar@necker.fr	Revy, Patrick/H-8137-2017; de Villartay, jean pierre/H-9353-2017	de Villartay, jean pierre/0000-0001-5987-0463; Revy, Patrick/0000-0003-0758-8022; Malivert, Laurent/0000-0002-0944-6573				Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Astrom SU, 1999, NATURE, V397, P310, DOI 10.1038/16833; Ben-Omran TI, 2005, AM J MED GENET A, V137A, P283, DOI 10.1002/ajmg.a.30869; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Clikeman JA, 2001, GENETICS, V157, P579; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; Frank-Vaillant M, 2001, GENE DEV, V15, P3005, DOI 10.1101/gad.206801; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; George RA, 2005, NUCLEIC ACIDS RES, V33, pW160, DOI 10.1093/nar/gki381; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Kegel A, 2001, CURR BIOL, V11, P1611, DOI 10.1016/S0960-9822(01)00488-2; Lee KJ, 2000, J BIOL CHEM, V275, P34787, DOI 10.1074/jbc.M004011200; Lee SE, 1999, CURR BIOL, V9, P767, DOI 10.1016/S0960-9822(99)80339-X; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Modesti M, 2003, J MOL BIOL, V334, P215, DOI 10.1016/j.jmb.2003.09.031; Noordzij JG, 2000, BLOOD, V96, P203, DOI 10.1182/blood.V96.1.203.013k33_203_209; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; Revy P, 2005, ADV IMMUNOL, V87, P237, DOI 10.1016/S0065-2776(05)87007-5; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Valencia M, 2001, NATURE, V414, P666, DOI 10.1038/414666a; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003	29	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13857	13860		10.1074/jbc.C500473200	http://dx.doi.org/10.1074/jbc.C500473200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16571728	hybrid			2022-12-25	WOS:000237512300003
J	Douillette, A; Bibeau-Poirier, A; Gravel, SP; Clement, JF; Chenard, V; Moreau, P; Servant, MJ				Douillette, A; Bibeau-Poirier, A; Gravel, SP; Clement, JF; Chenard, V; Moreau, P; Servant, MJ			The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the I kappa B kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; MONOCYTE CHEMOATTRACTANT PROTEIN-1; HERITABLE HYPERLIPIDEMIC RABBIT; EGF RECEPTOR TRANSACTIVATION; CELL-ADHESION MOLECULE-1; MYOCARDIAL-INFARCTION; TRANSCRIPTION FACTORS; GENE-EXPRESSION; IKK-ALPHA; P38 MAPK	The vasoactive hormone angiotensin II ( Ang II) probably triggers inflammatory cardiovascular diseases by activating transcription factors such as NF-kappa B. We describe here a novel mode of NF-kappa B activation in cultured vascular smooth muscle cells exposed to Ang II. Ang II treatment resulted in an increase in the phosphotransferase activity of the IKK complex, which was mediated through the AT1 receptor subtype. The typical phosphorylation and proteasome-dependent degradation of the NF-kappa B inhibitor I kappa B alpha were not observed. Rather, Ang II treatment of vascular smooth muscle cells led to the phosphorylation of p65 on serine 536, a signal detected in both the cytoplasm and the nuclear compartments. The use of pharmacological inhibitors that inhibit the activation of MEK by Ang II revealed that phosphorylation of p65 on serine 536 did not require the MEK-ERK-RSK signaling pathway. On the other hand, specifically targeting the IKK beta subunit of the IKK complex by overexpression of a dominant negative version of IKK beta( IKK beta K44A) or silencing RNA technology demonstrated that the IKK beta subunit of the IKK complex was responsible for the detected phosphoserine 536 signal in Ang II-treated cells. Characterization of the signaling pathway leading to activation of the IKK complex by Ang II revealed that neither epidermal growth factor receptor transactivation nor the phosphatidylinositol 3-kinase-AKT signaling cascade were involved. Collectively, our data demonstrate that the proinflammatory activity of Ang II is independent of the classical pathway leading to I kappa B alpha phosphorylation and degradation but clearly depends on the recruitment of an IKK complex signaling cascade leading to phosphorylation of p65 on serine 536.	Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Servant, MJ (corresponding author), POB 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	marc.servant@umontreal.ca		Chenard, Valerie/0000-0002-2073-1279; Gravel, Simon-Pierre/0000-0001-8411-8054; Moreau, Pierre/0000-0002-3604-721X				ABERG G, 1990, J CARDIOVASC PHAR S5, V15, P65; Alderman M H, 1995, Curr Opin Nephrol Hypertens, V4, P201, DOI 10.1097/00041552-199503000-00015; ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Brasier AR, 2002, ARTERIOSCL THROM VAS, V22, P1257, DOI 10.1161/01.ATV.0000021412.56621.A2; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; CHOBANIAN AV, 1992, HYPERTENSION, V20, P473, DOI 10.1161/01.HYP.20.4.473; CHOBANIAN AV, 1990, HYPERTENSION, V15, P327, DOI 10.1161/01.HYP.15.3.327; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Eguchi S, 2000, REGUL PEPTIDES, V91, P13, DOI 10.1016/S0167-0115(00)00126-9; Funakoshi Y, 1999, HYPERTENSION, V34, P118, DOI 10.1161/01.HYP.34.1.118; Funakoshi Y, 2001, HYPERTENSION, V38, P100, DOI 10.1161/01.HYP.38.1.100; Furukawa Y, 1996, CIRCULATION, V93, P333, DOI 10.1161/01.CIR.93.2.333; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Gravel SP, 2005, J BIOL CHEM, V280, P7477, DOI 10.1074/jbc.M410392200; Griendling KK, 1997, HYPERTENSION, V29, P366, DOI 10.1161/01.HYP.29.1.366; Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Jiang BB, 2004, J BIOL CHEM, V279, P20363, DOI 10.1074/jbc.M314172200; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kon V, 2004, CURR OPIN NEPHROL HY, V13, P291, DOI 10.1097/00041552-200405000-00005; Kranzhofer R, 1999, ARTERIOSCL THROM VAS, V19, P1623, DOI 10.1161/01.ATV.19.7.1623; Kwon H, 1998, J BIOL CHEM, V273, P7431, DOI 10.1074/jbc.273.13.7431; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lemarie CA, 2003, CIRC RES, V93, P207, DOI 10.1161/01.RES.0000086942.13523.88; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Maas R, 2003, ATHEROSCLEROSIS SUPP, V4, P5, DOI 10.1016/S1567-5688(03)00028-X; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; MEADE TW, 1993, NEW ENGL J MED, V329, P616, DOI 10.1056/NEJM199308263290905; Meloche S, 2000, MOL CELL BIOCHEM, V212, P99, DOI 10.1023/A:1007140606333; Ortego M, 1999, ATHEROSCLEROSIS, V147, P253, DOI 10.1016/S0021-9150(99)00193-8; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PRATT RE, 1993, CELLULAR MOL BIOL RE, P471; Pueyo ME, 2000, ARTERIOSCL THROM VAS, V20, P645, DOI 10.1161/01.ATV.20.3.645; Ruiz-Ortega M, 2000, CIRC RES, V86, P1266, DOI 10.1161/01.RES.86.12.1266; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873; Schmidt-Ott KM, 2000, REGUL PEPTIDES, V93, P65, DOI 10.1016/S0167-0115(00)00178-6; Shah BH, 2006, J CELL PHYSIOL, V206, P47, DOI 10.1002/jcp.20423; SHCELLIGN P, 1991, J HYPERTENS, V9, P3; Skurk T, 2004, ARTERIOSCL THROM VAS, V24, P1199, DOI 10.1161/01.ATV.0000131266.38312.2e; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Suzuki Y, 2003, INT J BIOCHEM CELL B, V35, P881, DOI 10.1016/S1357-2725(02)00271-6; Tanaka H, 2005, J BIOL CHEM, V280, P40965, DOI 10.1074/jbc.M506235200; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Voisin L, 2002, AM J PHYSIOL-CELL PH, V283, pC446, DOI 10.1152/ajpcell.00261.2001; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wassmann S, 2004, CIRCULATION, V110, P3062, DOI 10.1161/01.CIR.0000137970.47771.AF; Witherow DS, 2004, P NATL ACAD SCI USA, V101, P8603, DOI 10.1073/pnas.0402851101; Wolf G, 2002, KIDNEY INT, V61, P1986, DOI 10.1046/j.1523-1755.2002.00365.x; Wu L, 2004, MOL ENDOCRINOL, V18, P666, DOI 10.1210/me.2003-0053; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zhang LP, 2005, ARTERIOSCL THROM VAS, V25, P1148, DOI 10.1161/01.ATV.0000164624.00099.e7; Zhang LP, 2005, CIRC RES, V97, P975, DOI 10.1161/01.RES.0000190589.52286.41; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	63	64	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13275	13284		10.1074/jbc.M512815200	http://dx.doi.org/10.1074/jbc.M512815200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16513650	hybrid			2022-12-25	WOS:000237336600033
J	Sidyelyeva, G; Baker, NE; Fricker, LD				Sidyelyeva, G; Baker, NE; Fricker, LD			Characterization of the molecular basis of the Drosophila mutations in carboxypeptidase D - Effect on enzyme activity and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-VIRUS-PARTICLES; D DOMAIN-II; METALLOCARBOXYPEPTIDASE D; CRYSTAL-STRUCTURE; INTRACELLULAR TRAFFICKING; 3-DIMENSIONAL STRUCTURE; ATT-20 CELLS; PROTEIN; FURIN; LOCALIZATION	Carboxypeptidase D ( CPD) functions in the processing of proteins and peptides in the secretory pathway. Drosophila CPD is encoded by the silver gene ( svr), which is differentially spliced to produce long transmembrane protein forms with three metallocarboxypeptidase ( CP)- like domains and short soluble forms with a single CP domain. Many svr mutants have been reported, but the precise molecular defects have not been previously determined. In the present study, three mutant lines were characterized. svr(PG33) mutants do not survive past the early larval stage. These mutants have a P- element insertion within exon 1B upstream of the initiation ATG, which greatly reduces mRNA levels of all forms of CPD. Both svr(1) and svr(poi]) mutants are viable, with a silvery body color and pointed wings. The wing shape is generally similar between these two mutants, although svrpoi mutants have smaller wings. The svr(1) gene has a three- nucleotide deletion in exon 6, removing a leucine in a region of the protein predicted to function as a folding domain for the second CP- like domain. svr(poi) has a 1072- bp duplication of the gene that introduces a stop codon into the open reading frame, causing the truncation of the protein in the middle of the second CP- like domain. Both deletions eliminate enzyme activity of the second CP- like domain and appear to cause the misfolding of the protein. This greatly reduces the levels of the long forms of CPD protein but do not affect the levels of the short forms. Taken together, these findings suggest that lethal and viable svr alleles differ in which protein forms are affected. Flies that retain the short form are viable, whereas flies that are missing all forms of CPD do not survive past the early larval stages.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Fricker, LD (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	fricker@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061230] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-51271] Funding Source: Medline; NIGMS NIH HHS [GM-61230] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aloy P, 2001, J BIOL CHEM, V276, P16177, DOI 10.1074/jbc.M011457200; AUL DS, 2004, HDB PROTEOLYTIC ENZY, P812; AVILES FX, 2004, HDB PROTEOLYTIC ENZY, P851; Bourbon HM, 2002, MECH DEVELOP, V110, P71, DOI 10.1016/S0925-4773(01)00566-4; COLL M, 1991, EMBO J, V10, P1; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Cui YZ, 2001, GENE DEV, V15, P2797; Degnin C, 2004, MOL BIOL CELL, V15, P5012, DOI 10.1091/mbc.E04-08-0673; Eng FJ, 1998, J BIOL CHEM, V273, P8382, DOI 10.1074/jbc.273.14.8382; Fan XM, 1999, DNA CELL BIOL, V18, P121, DOI 10.1089/104454999315501; Fricker L. D., 2002, ENZYMES, V23, P421; FRICKER LD, 2004, HDB PROTEOLYTIC ENZY, P844; Fricker LD, 2004, HDB PROTEOLYTIC ENZY, V8, P840; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; Gomis-Ruth FX, 1999, EMBO J, V18, P5817, DOI 10.1093/emboj/18.21.5817; Harris A, 2000, MOL CELL NEUROSCI, V16, P578, DOI 10.1006/mcne.2000.0900; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; Henrich S, 2005, J MOL BIOL, V345, P211, DOI 10.1016/j.jmb.2004.10.050; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Ishikawa T, 1998, GENE, V215, P361, DOI 10.1016/S0378-1119(98)00270-4; Jiang N, 2000, DEV BIOL, V226, P118, DOI 10.1006/dbio.2000.9832; Kalinina E, 2002, J CELL BIOCHEM, V85, P101, DOI 10.1002/jcb.10112; Keshishian H, 2004, TRENDS NEUROSCI, V27, P143, DOI 10.1016/j.tins.2004.01.004; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; Layne MD, 2001, MOL CELL BIOL, V21, P5256, DOI 10.1128/MCB.21.15.5256-5261.2001; Lei YH, 1999, DNA CELL BIOL, V18, P175, DOI 10.1089/104454999315565; LINDSLEY DL, 1968, GENETIC VARIATIONS D, P468; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Marques G, 2003, DEVELOPMENT, V130, P5457, DOI 10.1242/dev.00772; McCabe BD, 2003, NEURON, V39, P241, DOI 10.1016/S0896-6273(03)00426-4; Nakayama T, 2000, CELL MOL LIFE SCI, V57, P943, DOI 10.1007/PL00000736; Novikova EG, 1999, J BIOL CHEM, V274, P28887, DOI 10.1074/jbc.274.41.28887; PERRIMON N, 1989, GENETICS, V121, P333; Ray RP, 2001, DEVELOPMENT, V128, P3913; Ray RP, 2001, CELL, V104, P801, DOI 10.1016/S0092-8674(01)00275-6; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; SETTLE SH, 1995, P NATL ACAD SCI USA, V92, P9470, DOI 10.1073/pnas.92.21.9470; Sidyelyeva G, 2002, J BIOL CHEM, V277, P49613, DOI 10.1074/jbc.M209652200; Siekhaus DE, 1999, J NEUROSCI, V19, P6942, DOI 10.1523/JNEUROSCI.19-16-06942.1999; SKIDGEL RA, 2004, HDB PROTEOLYTIC ENZY, P837; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; Springman EB, 2004, HDB PROTEOLYTIC ENZY, P828; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; Than ME, 2005, ACTA CRYSTALLOGR D, V61, P505, DOI 10.1107/S0907444905002556; Varlamov O, 1999, J BIOL CHEM, V274, P14759, DOI 10.1074/jbc.274.21.14759; Varlamov O, 1998, J CELL SCI, V111, P877; Varlamov O, 1999, J BIOL CHEM, V274, P14040, DOI 10.1074/jbc.274.20.14040; Walter MF, 1996, ARCH INSECT BIOCHEM, V31, P219, DOI 10.1002/(SICI)1520-6327(1996)31:2&lt;219::AID-ARCH9&gt;3.0.CO;2-U; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; Xin XN, 1998, DNA CELL BIOL, V17, P897, DOI 10.1089/dna.1998.17.897; Yu K, 2000, DEVELOPMENT, V127, P2143	55	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13844	13852		10.1074/jbc.M513499200	http://dx.doi.org/10.1074/jbc.M513499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16556608	hybrid			2022-12-25	WOS:000237336600095
J	Singh, A; Severance, S; Kaur, N; Wiltsie, W; Kosman, DJ				Singh, A; Severance, S; Kaur, N; Wiltsie, W; Kosman, DJ			Assembly, activation, and trafficking of the Fet3p center dot Ftr1p high affinity iron permease complex in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICOPPER OXIDASE FET3P; RESONANCE ENERGY-TRANSFER; PROTEIN-COUPLED RECEPTOR; FERROXIDASE ACTIVITY; PLASMA-MEMBRANE; QUALITY-CONTROL; COPPER UPTAKE; YEAST; TRANSPORT; GENE	The high affinity iron uptake complex in the yeast plasma membrane ( PM) consists of the ferroxidase, Fet3p, and the ferric iron permease, Ftr1p. We used a combination of yeast two- hybrid analysis, confocal fluorescence microscopy, and fluorescence resonance energy transfer ( FRET) quantification to delineate the motifs in the two proteins required for assembly and maturation into an uptake-competent complex. The cytoplasmic, carboxyl- terminal domain of each protein contains a four- residue motif adjacent to the cytoplasm-PM interface that supports an interaction between the proteins. This interaction has been quantified by two- hybrid analysis and is required for assembly and trafficking of the complex to the PM and for the similar to 13% maximum FRET efficiency determined. In contrast, the Fet3p transmembrane domain ( TM) can be exchanged with the TM domain from the vacuolar ferroxidase, Fet5p, with no loss of assembly and trafficking. A carboxyl- terminal interaction between the vacuolar proteins, Fet5p and Fth1p, also was quantified. As a measure of the specificity of interaction, no interaction between heterologous ferroxidase permease pairs was observed. Also, whereas FRET was quantified between fluorescent fusions of the copper permease ( monomers), Ctr1p, none was observed between Fet3p and Ctr1p. The results are consistent with a ( minimal) heterodimer model of the Fet3p center dot Ftr1p complex that supports the trafficking of iron from Fet3p to Ftr1p for iron permeation across the yeast PM.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Kosman, DJ (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	camkos@buffalo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053820] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53820] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aller SG, 2004, J BIOL CHEM, V279, P53435, DOI 10.1074/jbc.M409421200; Askwith C, 1997, J BIOL CHEM, V272, P401; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; di Patti MCB, 2000, FEBS LETT, V472, P283, DOI 10.1016/S0014-5793(00)01435-6; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; Floyd DH, 2003, J BIOL CHEM, V278, P35354, DOI 10.1074/jbc.M305607200; Frieden E, 1974, Adv Exp Med Biol, V48, P235; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Kosman DJ, 2003, MOL MICROBIOL, V47, P1185, DOI 10.1046/j.1365-2958.2003.03368.x; Kosman DJ, 2002, ADV PROTEIN CHEM, V60, P221; Levine T, 2004, TRENDS CELL BIOL, V14, P483, DOI 10.1016/j.tcb.2004.07.017; Miller JH., 1972, EXPT MOL GENETICS; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Overton MC, 2002, METHODS, V27, P324, DOI 10.1016/S1046-2023(02)00090-7; Pichler H, 2001, EUR J BIOCHEM, V268, P2351, DOI 10.1046/j.1432-1327.2001.02116.x; Quintanar L, 2004, J AM CHEM SOC, V126, P6579, DOI 10.1021/ja049220t; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Sato M, 2004, MOL BIOL CELL, V15, P1417, DOI 10.1091/mbc.E03-10-0765; Severance S, 2004, BIOCHEM J, V380, P487, DOI 10.1042/BJ20031921; Shi XL, 2003, J BIOL CHEM, V278, P50309, DOI 10.1074/jbc.M307019200; SIKORSKI RS, 1989, GENETICS, V122, P19; Spizzo T, 1997, MOL GEN GENET, V256, P547; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Taylor AB, 2005, P NATL ACAD SCI USA, V102, P15459, DOI 10.1073/pnas.0506227102; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang TP, 2003, J BIOL INORG CHEM, V8, P611, DOI 10.1007/s00775-003-0456-5; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; [No title captured], DOI DOI 10.1002/0470862106.IA055	38	59	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13355	13364		10.1074/jbc.M512042200	http://dx.doi.org/10.1074/jbc.M512042200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16522632	hybrid			2022-12-25	WOS:000237336600041
J	Tremblay, MR; Carbonetto, S				Tremblay, MR; Carbonetto, S			An extracellular pathway for dystroglycan function in acetylcholine receptor aggregation and laminin deposition in skeletal myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; ALPHA-DYSTROGLYCAN; BETA-DYSTROGLYCAN; NEUROMUSCULAR-JUNCTIONS; POSTSYNAPTIC PROTEINS; AGRIN; MUSCLE; RAPSYN; EXPRESSION; MEMBRANE	The dystroglycan ( DG) complex is involved in agrin- induced acetylcholine receptor clustering downstream of muscle- specific kinase where it regulates the stability of acetylcholine receptor aggregates as well as assembly of the synaptic basement membrane. We have previously proposed that this entails coordinate extracellular and intracellular interactions of its two subunits, alpha- and beta- DG. To assess the contribution of the extracellular and intracellular portions of DG, we have used adenoviruses to express full- length and deletion mutants of beta- DG in myotubes derived from wild- type embryonic stem cells or from cells null for DG. We show that alpha- DG is properly glycosylated and targeted to the myotube surface in the absence of beta- DG. Extracellular interactions of DG modulate the size and the microcluster density of agrin- induced acetylcholine receptor aggregates and are responsible for targeting laminin to these clusters. Thus, the association of alpha- and beta- DG in skeletal muscle may coordinate independent roles in signaling. We discuss how DG may regulate synapses through extracellular signaling functions of its alpha subunit.	McGill Univ, Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; McGill Univ, Montreal Gen Hosp, Res Inst, Dept Biol, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University	Carbonetto, S (corresponding author), McGill Univ, Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, 1650 Cedar, Montreal, PQ H3G 1A4, Canada.	Sal.carbonetto@mcgill.ca						APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; BALDWIN TJ, 1988, DEVELOPMENT, V104, P557; Bartoli M, 2001, J BIOL CHEM, V276, P24911, DOI 10.1074/jbc.M103258200; Borges LS, 2001, J CELL BIOL, V153, P1, DOI 10.1083/jcb.153.1.1; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Cartaud A, 2004, J CELL BIOL, V165, P505, DOI 10.1083/jcb.200307164; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; Cluchague N, 2004, FEBS LETT, V572, P216, DOI 10.1016/j.febslet.2004.07.032; COHEN MW, 1995, DEV BIOL, V167, P458, DOI 10.1006/dbio.1995.1041; COHEN MW, 1995, J CELL BIOL, V129, P1093, DOI 10.1083/jcb.129.4.1093; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Esapa CT, 2003, FEBS LETT, V555, P209, DOI 10.1016/S0014-5793(03)01230-4; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Francis MM, 2005, NEURON, V46, P581, DOI 10.1016/j.neuron.2005.04.010; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; Fuhrer C, 1999, J NEUROSCI, V19, P6405; Gally C, 2004, NATURE, V431, P578, DOI 10.1038/nature02893; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heathcote RD, 2000, DEV BIOL, V227, P595, DOI 10.1006/dbio.2000.9906; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Henry MD, 2001, HUM PATHOL, V32, P791, DOI 10.1053/hupa.2001.26468; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Holt KH, 2000, FEBS LETT, V468, P79, DOI 10.1016/S0014-5793(00)01195-9; Holzfeind PJ, 2002, HUM MOL GENET, V11, P2673, DOI 10.1093/hmg/11.21.2673; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Jacobson C, 1998, J NEUROSCI, V18, P6340; Kahl J, 2003, J NEUROSCI, V23, P392, DOI 10.1523/JNEUROSCI.23-02-00392.2003; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; Knox S, 2002, J BIOL CHEM, V277, P14657, DOI 10.1074/jbc.M111826200; Leschziner A, 2000, J NEUROCHEM, V74, P70, DOI 10.1046/j.1471-4159.2000.0740070.x; Levedakou EN, 2005, MOL CELL NEUROSCI, V28, P757, DOI 10.1016/j.mcn.2004.12.007; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; Marangi PA, 2002, J CELL BIOL, V157, P883, DOI 10.1083/jcb.200202110; Marchand S, 2002, J NEUROSCI, V22, P8891; Martin PT, 2003, GLYCOBIOLOGY, V13, p55R, DOI 10.1093/glycob/cwg076; MARTIN PT, 1995, SCIENCE, V269, P413, DOI 10.1126/science.7618109; McDearmon EL, 2003, J BIOL CHEM, V278, P44868, DOI 10.1074/jbc.M307026200; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Montanaro F, 2003, NEURON, V37, P193, DOI 10.1016/S0896-6273(03)00032-1; Montanaro F, 1998, J NEUROSCI, V18, P1250; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Moransard M, 2003, J BIOL CHEM, V278, P7350, DOI 10.1074/jbc.M210865200; Moukhles H, 2000, J COMP NEUROL, V420, P182, DOI 10.1002/(SICI)1096-9861(20000501)420:2<182::AID-CNE3>3.0.CO;2-2; Muschler J, 2002, CANCER RES, V62, P7102; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; Palmai-Pallag T, 2005, FEBS J, V272, P2901, DOI 10.1111/j.1742-4658.2005.04711.x; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; Pereboev AV, 2001, BBA-GEN SUBJECTS, V1527, P54, DOI 10.1016/S0304-4165(01)00147-7; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; Rimer M, 1998, MOL CELL NEUROSCI, V12, P1, DOI 10.1006/mcne.1998.0695; SALPETER MM, 1983, J CELL BIOL, V96, P1781, DOI 10.1083/jcb.96.6.1781; Shiao T, 2004, HUM MOL GENET, V13, P1873, DOI 10.1093/hmg/ddh204; Smirnov SP, 2005, J BIOL CHEM, V280, P41449, DOI 10.1074/jbc.M508939200; Smirnov SP, 2002, J BIOL CHEM, V277, P18928, DOI 10.1074/jbc.M201880200; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; Spence HJ, 2004, EMBO REP, V5, P484, DOI 10.1038/sj.embor.7400140; Sugiyama JE, 1997, J CELL BIOL, V139, P181, DOI 10.1083/jcb.139.1.181; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; VATER R, 1995, J NEUROPATH EXP NEUR, V54, P557, DOI 10.1097/00005072-199507000-00010; VOGEL Z, 1983, J NEUROSCI, V3, P1058; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1992, J NEUROBIOL, V23, P592, DOI 10.1002/neu.480230512; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Xu RF, 1997, J NEUROSCI, V17, P8194; Xu RF, 1999, J CELL PHYSIOL, V181, P107, DOI 10.1002/(SICI)1097-4652(199910)181:1<107::AID-JCP11>3.3.CO;2-0; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Yang X, 2001, NEURON, V30, P399, DOI 10.1016/S0896-6273(01)00287-2; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6	89	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13365	13373		10.1074/jbc.M600912200	http://dx.doi.org/10.1074/jbc.M600912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531403	hybrid			2022-12-25	WOS:000237336600042
J	Cajo, GC; Horne, BE; Kelley, WL; Schwager, F; Georgopoulos, C; Genevaux, P				Cajo, GC; Horne, BE; Kelley, WL; Schwager, F; Georgopoulos, C; Genevaux, P			The role of the DIF motif of the DnaJ (Hsp40) co-chaperone in the regulation of the DnaK (Hsp70) chaperone cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; FINGER-LIKE DOMAIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; YEAST HSP40; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE EXCHANGE; ATPASE ACTIVITY; RICH REGION	To perform effectively as a molecular chaperone, DnaK (Hsp70) necessitates the assistance of its DnaJ (Hsp40) co-chaperone partner, which efficiently stimulates its intrinsically weak ATPase activity and facilitates its interaction with polypeptide substrates. In this study, we address the function of the conserved glycine- and phenyalanine-rich (G/F-rich) region of the Escherichia coli DnaJ in the DnaK chaperone cycle. We show that the G/F-rich region is critical for DnaJ co-chaperone functions in vivo and that despite a significant degree of sequence conservation among the G/F-rich regions of Hsp40 homologs from bacteria, yeast, or humans, functional complementation in the context of the E. coli DnaJ is limited. Furthermore, we found that the deletion of the whole G/F-rich region is mirrored by mutations in the conserved Asp-Ile/Val-Phe (DIF) motif contained in this region. Further genetic and biochemical analyses revealed that this amino acid triplet plays a critical role in regulation of the DnaK chaperone cycle, possibly by modulating a crucial step subsequent to DnaK-mediated ATP hydrolysis.	Univ Geneva, Ctr Med, Dept Microbiol & Med Mol, CH-1211 Geneva 4, Switzerland; Tulane Univ, Dept Biochem, Hlth Sci Ctr, New Orleans, LA 70112 USA	University of Geneva; Tulane University	Genevaux, P (corresponding author), Univ Geneva, Ctr Med, Dept Microbiol & Med Mol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	pierre.genevaux@medecine.unige.ch	Genevaux, Pierre/A-4851-2015	GENEVAUX, Pierre/0000-0001-7539-3126				ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; Aron R, 2005, GENETICS, V169, P1873, DOI 10.1534/genetics.104.037242; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Brehmer D, 2004, J BIOL CHEM, V279, P27957, DOI 10.1074/jbc.M403558200; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Deloche O, 1997, J BIOL CHEM, V272, P28539, DOI 10.1074/jbc.272.45.28539; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Genevaux P, 2002, GENETICS, V162, P1045; Genevaux P, 2001, J BIOL CHEM, V276, P7906, DOI 10.1074/jbc.M003855200; Genevaux P, 2001, J BACTERIOL, V183, P5747, DOI 10.1128/JB.183.19.5747-5750.2001; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hennessy F, 2005, PROTEIN SCI, V14, P1697, DOI 10.1110/ps.051406805; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Kelley WL, 1997, MOL MICROBIOL, V25, P913, DOI 10.1111/j.1365-2958.1997.mmi527.x; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; Li JZ, 2003, STRUCTURE, V11, P1475, DOI 10.1016/j.str.2003.10.012; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Linke K, 2003, J BIOL CHEM, V278, P44457, DOI 10.1074/jbc.M307491200; Lopez N, 2003, MOL BIOL CELL, V14, P1172, DOI 10.1091/mbc.E02-09-0593; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; MISSIAKAS D, 1993, J BACTERIOL, V175, P2613, DOI 10.1128/JB.175.9.2613-2624.1993; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Shi YY, 2005, J BIOL CHEM, V280, P22761, DOI 10.1074/jbc.M503643200; Shomura Y, 2005, MOL CELL, V17, P367, DOI 10.1016/j.molcel.2004.12.023; Sondheimer N, 2001, EMBO J, V20, P2435, DOI 10.1093/emboj/20.10.2435; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; Wu YK, 2005, J MOL BIOL, V346, P1005, DOI 10.1016/j.jmb.2004.12.040; Yan W, 1999, MOL CELL BIOL, V19, P7751; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	42	47	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12436	12444		10.1074/jbc.M511192200	http://dx.doi.org/10.1074/jbc.M511192200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16533811	Green Published, hybrid			2022-12-25	WOS:000237134700030
J	Heyduk, E; Kuznedelov, K; Severinov, K; Heyduk, T				Heyduk, E; Kuznedelov, K; Severinov, K; Heyduk, T			A consensus adenine at position-11 of the nontemplate strand of bacterial promoter is important for nucleation of promoter melting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; LAMBDA-PR PROMOTER; SIGMA-FACTOR MUTATIONS; OPEN COMPLEX-FORMATION; CONFORMATIONAL-CHANGES; CORE ENZYME; DNA; BINDING; RECOGNITION; KINETICS	Numerous studies have suggested an important role of adenine at position -11 of the nontemplate strand of bacterial promoters for sequence-specific recognition of the -10 promoter element in single-stranded form. In this work, we attempted to identify a specific step in transcription initiation reaction that is most critically dependent on specific recognition of -11A. Mutating -11A in the context of a model promoter resulted in a profound decrease of the rate of heparin-resistant promoter complex formation and in a modest increase of the rate of heparin-resistant complex dissociation. The identity of nontemplate base at position -11 became relatively unimportant when the duplex in the vicinity of this position was destabilized by base pair mismatches. For promoters with a nonnative thymine at nontemplate position -11, we observed a remarkable correlation between the rate of heparin-resistant complex formation (or transcription activity) and the free energy of duplex stability in the vicinity of this residue, indicating that the replacement of -11A with a T affected a step in the reaction that involves local melting of DNA duplex. These data show that a promoter melting defect caused by a loss of RNA polymerase contact with -11A can be rescued by artificially induced local destabilization of the DNA duplex. These results are consistent with and support the idea that specific recognition of adenine at the nontemplate -11-position is important only for the initial nucleation of melting, which probably involves the flipping of this adenine out from the DNA duplex.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Saint Louis University; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Heyduk, T (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	heydukt@slu.edu	Severinov, Konstantin/C-8545-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R01GM064530] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 64530, R01 GM 50514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altan-Bonet G., 2003, PHYS REV LETT, V90, P1; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Callaci S, 1998, J BIOL CHEM, V273, P32995, DOI 10.1074/jbc.273.49.32995; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; Chen YF, 1997, J MOL BIOL, V267, P47, DOI 10.1006/jmbi.1996.0853; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Huang XJ, 1997, NUCLEIC ACIDS RES, V25, P2603, DOI 10.1093/nar/25.13.2603; JUANG YL, 1995, BIOCHEMISTRY-US, V34, P8465, DOI 10.1021/bi00026a030; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; Lee HJ, 2004, J BIOL CHEM, V279, P16899, DOI 10.1074/jbc.C400054200; Li XY, 1998, J BIOL CHEM, V273, P23558, DOI 10.1074/jbc.273.36.23558; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Matlock DL, 2000, BIOCHEMISTRY-US, V39, P12274, DOI 10.1021/bi001433h; Niedziela-Majka A, 2005, J BIOL CHEM, V280, P38219, DOI 10.1074/jbc.M507984200; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; Roberts CW, 1996, CELL, V86, P495; ROE JH, 1985, BIOCHEMISTRY-US, V24, P4721, DOI 10.1021/bi00339a002; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; Rowe-Magnus DA, 1998, P NATL ACAD SCI USA, V95, P5305, DOI 10.1073/pnas.95.9.5305; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Stivers JT, 2003, CHEM REV, V103, P2729, DOI 10.1021/cr010219b; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; Tsujikawa L, 2002, BIOCHEMISTRY-US, V41, P15334, DOI 10.1021/bi026539m; Young BA, 2004, SCIENCE, V303, P1382, DOI 10.1126/science.1092462	34	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12362	12369		10.1074/jbc.M601364200	http://dx.doi.org/10.1074/jbc.M601364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531399	hybrid			2022-12-25	WOS:000237134700021
J	Kaye, SL; Sansom, MSP; Biggin, PC				Kaye, SL; Sansom, MSP; Biggin, PC			Molecular dynamics simulations of the ligand-binding domain of an N-methyl-D aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICLE MESH EWALD; GLUTAMATE-RECEPTOR; CRYSTAL-STRUCTURES; PROTEIN-STRUCTURE; MECHANISMS; ACTIVATION; COMPLEX; SUBUNITS; CLOSURE; GLUR5	The mechanism of partial agonism at N-methyl-D-aspartate receptors is an unresolved issue, especially with respect to the role of protein dynamics. We have performed multiple molecular dynamics simulations (7 x 20 ns) to examine the behavior of the ligand-binding core of the NR1 subunit with a series of ligands. Our results show that water plays an important role in stabilizing different conformations of the core and how a closed cleft conformation of the protein might be stabilized in the absence of ligands. In the case of ligand-bound simulations with both full and partial agonists, we observed that ligands within the binding cleft may undergo distinct conformational changes, without grossly influencing the degree of cleft closure within the ligand-binding domain. In agreement with recently published crystallographic data, we also observe similar changes in backbone torsions corresponding to the hinge region between the two lobes for the partial agonist, D-cycloserine. This observation rationalizes the classification of D-cycloserine as a partial agonist and should provide a basis with which to predict partial agonism in this class of receptor by analyzing the behavior of these torsions with other potential ligands.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Biggin, PC (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	philip.biggin@bioch.ox.ac.uk	Sansom, Mark S.P./C-5157-2009	Sansom, Mark S.P./0000-0001-6360-7959; Biggin, Philip/0000-0001-5100-8836	Biotechnology and Biological Sciences Research Council [B19456, BEP17032, BBS/B/16011] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Arinaminpathy Y, 2006, MOL PHARMACOL, V69, P5, DOI 10.1124/mol.105.016691; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dingledine R, 1999, PHARMACOL REV, V51, P7; Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; Gouaux E, 2004, J PHYSIOL-LONDON, V554, P249, DOI 10.1113/jphysiol.2003.054320; Hashimoto K, 2003, ARCH GEN PSYCHIAT, V60, P572, DOI 10.1001/archpsyc.60.6.572; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hogner A, 2002, J MOL BIOL, V322, P93, DOI 10.1016/S0022-2836(02)00650-2; Inanobe A, 2005, NEURON, V47, P71, DOI 10.1016/j.neuron.2005.05.022; Laruelle M, 2003, ANN NY ACAD SCI, V1003, P138, DOI 10.1196/annals.1300.063; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Madden DR, 2005, J BIOL CHEM, V280, P23637, DOI 10.1074/jbc.M414523200; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Mayer ML, 2005, NEURON, V45, P539, DOI 10.1016/j.neuron.2005.01.031; Mayer ML, 2005, CURR OPIN NEUROBIOL, V15, P282, DOI 10.1016/j.conb.2005.05.004; Mueller HT, 2004, MOL BRAIN RES, V121, P60, DOI 10.1016/j.molbrainres.2003.11.004; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; Nanao MH, 2005, P NATL ACAD SCI USA, V102, P1708, DOI 10.1073/pnas.0409573102; Naur P, 2005, FEBS LETT, V579, P1154, DOI 10.1016/j.febslet.2005.01.012; Pang A, 2005, PROTEINS, V61, P809, DOI 10.1002/prot.20672; Pang A, 2003, FEBS LETT, V550, P168, DOI 10.1016/S0014-5793(03)00866-4; Roccatano D, 2001, J MOL BIOL, V310, P1039, DOI 10.1006/jmbi.2001.4808; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Tsai GC, 2002, ANNU REV PHARMACOL, V42, P165, DOI 10.1146/annurev.pharmtox.42.082701.160735	34	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12736	12742		10.1074/jbc.M512728200	http://dx.doi.org/10.1074/jbc.M512728200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513640	hybrid			2022-12-25	WOS:000237134700066
J	Zhang, YJ; Tu, YZ; Gkretsi, V; Wu, CY				Zhang, YJ; Tu, YZ; Gkretsi, V; Wu, CY			Migfilin interacts with vasodilator-stimulated phosphoprotein (VASP) and regulates VASP localization to cell-matrix adhesions and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BASED MOTILITY; ENA/VASP PROTEINS; LISTERIA-MONOCYTOGENES; AXON GUIDANCE; SHAPE MODULATION; TYROSINE KINASE; FOCAL ADHESIONS; CYTOSKELETON; FAMILY; RECEPTOR	Cell migration is a complex process that is coordinately regulated by cell-matrix adhesion and actin cytoskeleton. We report here that migfilin, a recently identified component of cell-matrix adhesions, is a biphasic regulator of cell migration. Loss of migfilin impairs cell migration. Surprisingly, overexpression of migfilin also reduces cell migration. Molecularly, we have identified vasodilator-stimulated phosphoprotein (VASP) as a new migfilin-binding protein. The interaction is mediated by the VASP EVH1 domain and a single (LPPPPP)-P-104 site located within the migfilin proline-rich domain. Migfilin and VASP form a complex in both suspended and adhered cells, and in the latter, they co-localize in cell-matrix adhesions. Functionally, migfilin facilitates VASP localization to cell-matrix adhesions. Using two different approaches (VASP-binding defective migfilin mutants and small interfering RNA-mediated VASP knockdown), we show that the interaction with VASP is crucially involved in migfilin-mediated regulation of cell migration. Our results identify migfilin as an important regulator of cell migration and provide new information on the mechanism by which migfilin regulates this process.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, CY (corresponding author), 707B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	carywu@pitt.edu	Gkretsi, Vasiliki/Q-2158-2019	Gkretsi, Vasiliki/0000-0002-3671-4078	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54639] Funding Source: Medline; NIGMS NIH HHS [GM65188] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Cossart P, 2001, CURR OPIN IMMUNOL, V13, P96, DOI 10.1016/S0952-7915(00)00188-6; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Garvalov BK, 2003, J CELL BIOL, V161, P33, DOI 10.1083/jcb.200211015; Geese M, 2002, MOL BIOL CELL, V13, P2383, DOI 10.1091/mbc.E02-01-0058; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Gitai Z, 2003, NEURON, V37, P53, DOI 10.1016/S0896-6273(02)01149-2; Gkretsi V, 2005, J CELL SCI, V118, P697, DOI 10.1242/jcs.01638; Goh KL, 2002, CURR BIOL, V12, P565, DOI 10.1016/S0960-9822(02)00725-X; Gouin E, 2005, CURR OPIN MICROBIOL, V8, P35, DOI 10.1016/j.mib.2004.12.013; Han YH, 2002, J BIOL CHEM, V277, P49877, DOI 10.1074/jbc.M209107200; Howe AK, 2002, J BIOL CHEM, V277, P38121, DOI 10.1074/jbc.M205379200; HUMPHRIES MJ, 1998, CURRENT PROTOCOLS CE; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Krause M, 2004, DEV CELL, V7, P571, DOI 10.1016/j.devcel.2004.07.024; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lebrand C, 2004, NEURON, V42, P37, DOI 10.1016/S0896-6273(04)00108-4; Menzies AS, 2004, J NEUROSCI, V24, P8029, DOI 10.1523/JNEUROSCI.1057-04.2004; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Renfranz PJ, 2002, CURR OPIN CELL BIOL, V14, P88, DOI 10.1016/S0955-0674(01)00299-X; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rogalski TM, 2000, J CELL BIOL, V150, P253, DOI 10.1083/jcb.150.1.253; Samarin S, 2003, J CELL BIOL, V163, P131, DOI 10.1083/jcb.200303191; Sechi AS, 2004, FRONT BIOSCI, V9, P1294, DOI 10.2741/1324; Skoble J, 2001, J CELL BIOL, V155, P89, DOI 10.1083/jcb.200106061; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Takafuta T, 2003, J BIOL CHEM, V278, P12175, DOI 10.1074/jbc.M209339200; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; Withee J, 2004, GENETICS, V167, P1165, DOI 10.1534/genetics.103.025676; Wu CY, 2005, TRENDS CELL BIOL, V15, P460, DOI 10.1016/j.tcb.2005.07.002; Wu CY, 2005, J CELL SCI, V118, P659, DOI 10.1242/jcs.01639; Yu TW, 2002, NAT NEUROSCI, V5, P1147, DOI 10.1038/nn956; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	48	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12397	12407		10.1074/jbc.M512107200	http://dx.doi.org/10.1074/jbc.M512107200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531412	hybrid			2022-12-25	WOS:000237134700025
J	Tilki, D; Irmak, S; Oliveira-Ferrer, L; Hauschild, J; Miethe, K; Atakaya, H; Hammerer, P; Friedrich, MG; Schuch, G; Galalae, R; Stief, CG; Kilic, E; Huland, H; Ergun, S				Tilki, D.; Irmak, S.; Oliveira-Ferrer, L.; Hauschild, J.; Miethe, K.; Atakaya, H.; Hammerer, P.; Friedrich, M. G.; Schuch, G.; Galalae, R.; Stief, C. G.; Kilic, E.; Huland, H.; Ergun, S.			CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer	ONCOGENE			English	Article						CEACAM1; prostate cancer; angiogenesis; Ang1; siRNA; vascular destabilization	ENDOTHELIAL GROWTH-FACTOR; BILIARY GLYCOPROTEIN; C-CAM; COLORECTAL CARCINOMAS; CD66A BGP; CEACAM1; EXPRESSION; ANTIGEN; FAMILY; MECHANISMS	We demonstrate here that epithelial carcinoembryonic antigen (CEA)-related cell adhesion molecule-1 (CEACAM1) downregulation in prostate intraepithelial neoplasia (PIN) is inversely correlated with its upregulation in adjacent blood vessels. CEACAM1 silencing in prostate cancer cell line DU-145 via small interfering ribonucleic acid (siRNA) increased but its overexpression suppressed the expression of angiogenic/lymphangiogenic factors such as vascular endothelial growth factor (VEGF)-A, -C and -D, and angiogenic inhibitor collagen 18/endostatin. Furthermore, CEACAM1 overexpression in DU-145 cells increased but CEACAM1 silencing reduced angiopoietin-1 expression. Inverse relation was found for angiopoietin-2. Supernatant of CEACAM1-overexpressing DU-145 suppressed but that of CEACAM1-silenced increased the VEGF-induced endothelial tubes. Electron microscopically the majority of PIN-associated blood vessels was structurally destabilized exhibiting endothelial fenestration, trans- and inter-endothelial gaps. In some PIN areas, invasion of single tumor cells into the destabilized blood vessels was observed. These data show that disappearance of epithelial CEACAM1 in PIN is accompanied by its upregulation in adjacent vasculature which apparently correlates with vascular destabilization and increased vascularization of prostate cancer. Strategies to either conserve the epithelial CEACAM1 or to target endothelial CEACAM1 might be useful for an anti-angiogenic therapy of prostate cancer.	Univ Hamburg Hosp, Ctr Expt Med, Inst Anat, D-20246 Hamburg, Germany; Univ Hamburg Hosp, Ctr Surg, Urol Clin, D-20246 Hamburg, Germany; Univ Hamburg Hosp, Ctr Theoret Med, Inst Pathol, D-20246 Hamburg, Germany; Univ Hamburg Hosp, Dept Haematol & Oncol, Ctr Internal Med, D-20246 Hamburg, Germany; Univ Hosp Kiel, Dept Radiat Oncol, Kiel, Germany; Univ Hosp, Dept Urol, Munich, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Kiel; Schleswig Holstein University Hospital; University of Munich	Ergun, S (corresponding author), Univ Hamburg Hosp, Ctr Expt Med, Inst Anat, Martinistr 52, D-20246 Hamburg, Germany.	erguen@uke.uni-hamburg.de						Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Bamberger AM, 1998, AM J PATHOL, V152, P1401; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; Brummer J, 2001, AM J PATHOL, V159, P537, DOI 10.1016/S0002-9440(10)61725-7; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chalajour F, 2004, EXP CELL RES, V298, P455, DOI 10.1016/j.yexcr.2004.04.034; Ebrahimnejad A, 2000, EXP CELL RES, V260, P365, DOI 10.1006/excr.2000.5026; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ergun S, 1996, CELL TISSUE RES, V286, P93, DOI 10.1007/s004410050678; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HIXSON DC, 1985, CANCER RES, V45, P3742; Hong YK, 2004, NAT GENET, V36, P683, DOI 10.1038/ng1383; Huss WJ, 2001, CANCER RES, V61, P2736; Iijima H, 2004, J EXP MED, V199, P471, DOI 10.1084/jem.20030437; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Kilic N, 2005, J BIOL CHEM, V280, P2361, DOI 10.1074/jbc.M409407200; KILIC N, 2001, METASTASIS RES PROTO; KUROKI M, 1991, BIOCHEM BIOPH RES CO, V176, P578, DOI 10.1016/S0006-291X(05)80223-2; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; Lin SH, 1999, SEMIN ONCOL, V26, P227; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Mazzucchelli R, 2000, PROSTATE, V45, P72; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580; Oliveira-Ferrer L, 2004, CANCER RES, V64, P8932, DOI 10.1158/0008-5472.CAN-04-0505; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; ROBERTS WG, 1995, J CELL SCI, V108, P2369; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; Saaristo A, 2002, FASEB J, V16, P1041, DOI 10.1096/fj.01-1042com; Singer BB, 2000, CANCER RES, V60, P1236; Volpert O, 2002, J BIOL CHEM, V277, P35696, DOI 10.1074/jbc.M205319200; Wagener C, 2000, EXP CELL RES, V261, P19, DOI 10.1006/excr.2000.5038	39	53	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2006	25	36					4965	4974		10.1038/sj.onc.1209514	http://dx.doi.org/10.1038/sj.onc.1209514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568082				2022-12-25	WOS:000239921300002
J	Arnesen, T; Gromyko, D; Pendino, F; Ryningen, A; Varhaug, J; Lillehaug, J				Arnesen, T.; Gromyko, D.; Pendino, F.; Ryningen, A.; Varhaug, J. E.; Lillehaug, J. R.			Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex	ONCOGENE			English	Article						apoptosis; NATH; hARD1; protein N-acetylation; siRNA; daunorubicin	TERMINAL ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; ARD1 GENE; IDENTIFICATION; ACETYLATION; YEAST; DESTABILIZATION; HIF-1-ALPHA; EXPRESSION; HYPOXIA	Protein N-epsilon-acetylation is recognized as an important modi. cation influencing many biological processes, and protein deacetylase inhibitors leading to N-epsilon-hyperacetylation of histones are being clinically tested for their potential as anticancer drugs. In contrast to N-epsilon-acetyltransferases, the N-alpha-acetyltransferases transferring acetyl groups to the alpha-amino groups of protein N-termini have only been briefly described in mammalians. Human arrest defective 1(hARD1), the only described human enzyme in this class, complexes with N-acetyltransferase human (NATH) and cotranslationally transfers acetyl groups to the N-termini of nascent polypeptides. Here, we demonstrate that knockdown of NATH and/or hARD1 triggers apoptosis in human cell lines. Knockdown of hARD1 also sensitized cells to daunorubicin-induced apoptosis, potentially pointing at the NATH-hARD1 acetyltransferase complex as a novel target for chemotherapy. Our results argue for an essential role of the NATH-hARD1 complex in cell survival and underscore the importance of protein N-alpha-acetylation in mammalian cells.	Univ Bergen, Dept Mol Biol, Bergen High Technol Ctr, N-5020 Bergen, Norway; Univ Bergen, Dept Surg Sci, N-5020 Bergen, Norway; Haukeland Univ Hosp, Dept Med, N-5021 Bergen, Norway	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital	Arnesen, T (corresponding author), Univ Bergen, Dept Mol Biol, Bergen High Technol Ctr, Thormohlensgate 55, N-5020 Bergen, Norway.	thomas.arnesen@mbi.uib.no	Arnesen, Thomas/Q-8117-2019; PENDINO, Frederic/G-6630-2017; Arnesen, Thomas/J-7139-2017	Arnesen, Thomas/0000-0002-3005-147X; Arnesen, Thomas/0000-0002-3005-147X				Arnesen T, 2005, FEBS LETT, V579, P6428, DOI 10.1016/j.febslet.2005.10.036; Arnesen T, 2005, THYROID, V15, P1131, DOI 10.1089/thy.2005.15.1131; Arnesen T, 2005, BIOCHEM J, V386, P433, DOI 10.1042/BJ20041071; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; Di Gennaro E, 2004, AMINO ACIDS, V26, P435, DOI 10.1007/s00726-004-0087-3; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Fluge O, 2002, ONCOGENE, V21, P5056, DOI 10.1038/sj.onc.1205687; Gautschi M, 2003, MOL CELL BIOL, V23, P7403, DOI 10.1128/MCB.23.20.7403-7414.2003; Harborth J, 2001, J CELL SCI, V114, P4557; Ingram AK, 2000, MOL BIOCHEM PARASIT, V111, P309, DOI 10.1016/S0166-6851(00)00322-4; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; Morley SJ, 2005, CELL DEATH DIFFER, V12, P571, DOI 10.1038/sj.cdd.4401591; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Polevoda B, 2003, BIOCHEM BIOPH RES CO, V308, P1, DOI 10.1016/S0006-291X(03)01316-0; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Ryningen A, 2005, LEUKEMIA RES, V29, P185, DOI 10.1016/j.leukres.2004.06.008; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; Sowter HM, 2001, CANCER RES, V61, P6669; Sugiura N, 2003, J BIOL CHEM, V278, P40113, DOI 10.1074/jbc.M301218200; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713; WHITEWAY M, 1985, CELL, V43, P483, DOI 10.1016/0092-8674(85)90178-3	27	80	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4350	4360		10.1038/sj.onc.1209469	http://dx.doi.org/10.1038/sj.onc.1209469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518407				2022-12-25	WOS:000239240100010
J	Chang, AJ; Song, DH; Wolfe, MM				Chang, Albert J.; Song, Diane H.; Wolfe, M. Michael			Attenuation of peroxisome proliferator-activated receptor gamma(PPAR gamma) mediates gastrin-stimulated colorectal cancer cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN COLON-CANCER; MULTIPLE SIGNALING PATHWAYS; ADENOMA-CARCINOMA SEQUENCE; CCK-B/GASTRIN RECEPTOR; PPAR-GAMMA LIGAND; PROTEIN-KINASE; GENE-EXPRESSION; CYCLOOXYGENASE-2 EXPRESSION; TRANSCRIPTIONAL ACTIVITY	Peroxisome proliferators-activated receptor gamma(PPAR gamma) has been shown to suppress cell proliferation and tumorigenesis, whereas the gastrointestinal regulatory peptide gastrin stimulates the growth of neoplastic cells. The present studies were directed to determine whether changes in PPAR gamma expression might mediate the effects of gastrin on the proliferation of colorectal cancer (CRC). Initially, using growth assays, we determined that the human CRC cell line DLD-1 expressed both functional PPAR gamma and gastrin receptors. Amidated gastrin (G-17) attenuated the growth suppressing effects of PPAR gamma by decreasing PPAR gamma activity and total protein expression, in part through an increase in the rate of proteasomal degradation. G-17-induced degradation of PPAR gamma appeared to be mediated through phosphorylation of PPAR gamma at serine 84 by a process involving the biphasic phosphorylation of ERK1/2 and activation of the epidermal growth factor receptor (EGFR). These results were confirmed through the use of EGFR antagonist AG1478 and MEK1 inhibitor PD98059. Furthermore, mutation of PPAR gamma at serine 84 reduced the effects of G-17, as evident by inability of G-17 to attenuate PPAR gamma promoter activity, degrade PPAR gamma, or inhibit the growth suppressing effects of PPAR gamma. The results of these studies demonstrate that the trophic properties of gastrin in CRC may be mediated in part by transactivation of the EGFR and phosphorylation of ERK1/2, leading to degradation of PPAR alpha protein and a decrease in PPAR alpha activation.	Boston Med Ctr, Sect Gastroenterol, Boston, MA 02118 USA; Boston Univ, Sch Med, Sect Gastroenterol, Boston, MA 02118 USA	Boston Medical Center; Boston University	Wolfe, MM (corresponding author), Boston Med Ctr, Sect Gastroenterol, 650 Albany St,Rm 504, Boston, MA 02118 USA.	michael.wolfe@bmc.org			NATIONAL CANCER INSTITUTE [R01CA118992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK067812] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 118992] Funding Source: Medline; NIDDK NIH HHS [F32 DK 67812] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Ahmed S, 2004, FEBS LETT, V556, P199, DOI 10.1016/S0014-5793(03)01408-X; Artru P, 1998, GASTROEN CLIN BIOL, V22, P607; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Camp HS, 1997, J BIOL CHEM, V272, P10811; Caplin ME, 1999, REGUL PEPTIDES, V84, P81, DOI 10.1016/S0167-0115(99)00071-3; Chen AP, 2005, AM J PHYSIOL-GASTR L, V288, pG447, DOI 10.1152/ajpgi.00209.2004; Chen F, 2003, J CELL BIOCHEM, V90, P732, DOI 10.1002/jcb.10668; Chen GG, 2002, LIFE SCI, V70, P2631, DOI 10.1016/S0024-3205(02)01510-2; CICCOTOSTO GD, 1995, GASTROENTEROLOGY, V109, P1142, DOI 10.1016/0016-5085(95)90572-3; Colucci R, 2005, BRIT J PHARMACOL, V144, P338, DOI 10.1038/sj.bjp.0706053; Darmoul D, 2004, J BIOL CHEM, V279, P20927, DOI 10.1074/jbc.M401430200; Dockray G, 2005, PFLUG ARCH EUR J PHY, V449, P344, DOI 10.1007/s00424-004-1347-5; Dockray GJ, 2001, ANNU REV PHYSIOL, V63, P119, DOI 10.1146/annurev.physiol.63.1.119; Dockray GJ, 1999, J PHYSIOL-LONDON, V518, P315, DOI 10.1111/j.1469-7793.1999.0315p.x; Edkins JS, 1905, P R SOC LOND B-CONTA, V76, P376, DOI 10.1098/rspb.1905.0029; Edkins JS, 1906, J PHYSIOL-LONDON, V34, P133; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Floyd ZE, 2002, J BIOL CHEM, V277, P4062, DOI 10.1074/jbc.M108473200; Gelman L, 2005, CURR OPIN CELL BIOL, V17, P216, DOI 10.1016/j.ceb.2005.02.002; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Grommes C, 2004, LANCET ONCOL, V5, P419, DOI 10.1016/S1470-2045(04)01509-8; Guo YS, 2002, J BIOL CHEM, V277, P48755, DOI 10.1074/jbc.M209016200; Gupta RA, 2001, J BIOL CHEM, V276, P29681, DOI 10.1074/jbc.M103779200; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Higashiyama S, 2004, PROTEIN PEPTIDE LETT, V11, P443, DOI 10.2174/0929866043406562; Horner-Glister E, 2005, J MOL ENDOCRINOL, V35, P421, DOI 10.1677/jme.1.01784; Hosokawa M, 2004, BBA-GEN SUBJECTS, V1675, P113, DOI 10.1016/j.bbagen.2004.08.012; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; IMDAHL A, 1995, J CANCER RES CLIN, V121, P661, DOI 10.1007/BF01218524; IMDAHL A, 1989, J CANCER RES CLIN, V115, P388, DOI 10.1007/BF00400968; Jung TI, 2005, GYNECOL ONCOL, V97, P365, DOI 10.1016/j.ygyno.2005.01.019; Kato M, 2004, J CANCER RES CLIN, V130, P73, DOI 10.1007/s00432-003-0510-2; KUSYK CJ, 1986, AM J PHYSIOL, V251, P597; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MATSUSHIMA Y, 1994, JPN J CANCER RES, V85, P819, DOI 10.1111/j.1349-7006.1994.tb02953.x; MIHAS AA, 1995, RES COMMUN MOL PATH, V90, P301; Miyazaki Y, 1999, GASTROENTEROLOGY, V116, P78, DOI 10.1016/S0016-5085(99)70231-3; Moore TC, 2004, REGUL PEPTIDES, V120, P195, DOI 10.1016/j.regpep.2004.03.012; Nahle Z, 2004, CURR OPIN CLIN NUTR, V7, P397, DOI 10.1097/01.mco.0000134360.30911.bb; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Reubi JC, 1997, CANCER RES, V57, P1377; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Shah BH, 2005, MOL PHARMACOL, V67, P184, DOI 10.1124/mol.104.003533; Shimada T, 2002, GUT, V50, P658, DOI 10.1136/gut.50.5.658; Shipley JM, 2003, MOL PHARMACOL, V64, P355, DOI 10.1124/mol.64.2.355; Sinclair NF, 2004, AM J PHYSIOL-GASTR L, V286, pG992, DOI 10.1152/ajpgi.00206.2002; Slice LW, 2003, J CELL PHYSIOL, V196, P454, DOI 10.1002/jcp.10304; Smith AM, 2000, GUT, V47, P820, DOI 10.1136/gut.47.6.820; Song DH, 2003, AM J PHYSIOL-GASTR L, V285, pG217, DOI 10.1152/ajpgi.00516.2002; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG1363, DOI 10.1152/ajpgi.1999.276.6.G1363; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG415, DOI 10.1152/ajpgi.1999.276.2.G415; Takhar AS, 2004, SURG-J R COLL SURG E, V2, P251, DOI 10.1016/S1479-666X(04)80093-3; Terashita Y, 2002, JPN J CLIN ONCOL, V32, P238, DOI 10.1093/jjco/hyf056; Thorburn CM, 1998, GASTROENTEROLOGY, V115, P275, DOI 10.1016/S0016-5085(98)70193-3; Todisco A, 2001, AM J PHYSIOL-GASTR L, V280, pG298, DOI 10.1152/ajpgi.2001.280.2.G298; Tsutsui S, 1997, BIOCHEM BIOPH RES CO, V235, P520, DOI 10.1006/bbrc.1997.6824; UPP JR, 1989, CANCER RES, V49, P488; Varro A, 2002, GUT, V50, P827, DOI 10.1136/gut.50.6.827; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; WATSON S, 1989, BRIT J CANCER, V59, P554, DOI 10.1038/bjc.1989.112; Watson SA, 2000, INT J CANCER, V87, P20, DOI 10.1002/1097-0215(20000701)87:1<20::AID-IJC4>3.0.CO;2-C; Watson SA, 2002, BRIT J CANCER, V87, P567, DOI 10.1038/sj.bjc.6600509; Yang CH, 2001, INT J BIOCHEM CELL B, V33, P1071, DOI 10.1016/S1357-2725(01)00077-2; Yoshizumi T, 2004, INT J ONCOL, V25, P631; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	72	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14700	14710		10.1074/jbc.M602623200	http://dx.doi.org/10.1074/jbc.M602623200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16574647	hybrid			2022-12-25	WOS:000237671300023
J	Vlasova, II; Tyurin, VA; Kapralov, AA; Kurnikov, IV; Osipov, AN; Potapovich, MV; Stoyanovsky, DA; Kagan, VE				Vlasova, Irina I.; Tyurin, Vladimir A.; Kapralov, Alexandr A.; Kurnikov, Igor V.; Osipov, Anatoly N.; Potapovich, Maxim V.; Stoyanovsky, Detcho A.; Kagan, Valerian E.			Nitric oxide inhibits peroxidase activity of cytochrome c(center dot) cardiolipin complex and blocks cardiolipin oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; HYDROGEN-PEROXIDE; ORGANIC-MOLECULES; MEMBRANE; STRESS; PEROXYNITRITE; MECHANISM; STATE; EPR; NO	The increased production of NO during the early stages of apoptosis indicates its potential involvement in the regulation of programmed cell death through yet to be identified mechanisms. Recently, an important role for catalytically competent peroxidase form of pentacoordinate cytochrome c (cyt c) in a complex with a mitochondriaspecific phospholipid, cardiolipin (CL), has been demonstrated during execution of the apoptotic program. Because the cyt c(.)CL complex acts as CL oxygenase and selectively oxidizes CL in apoptotic cells in a reaction dependent on the generation of protein-derived (tyrosyl) radicals, we hypothesized that binding and nitrosylation of cyt c regulates CL oxidation. Here we demonstrate by low temperature electron paramagnetic resonance spectroscopy that CL facilitated interactions of ferro-and ferri-states of cyt c with NO and NO-, respectively, to yield a mixture of penta- and hexa-coordinate nitrosylated cyt c. In the nitrosylated cyt c(.)CL complex, NO chemically reacted with H2O2-activated peroxidase intermediates resulting in their reduction. A dose-dependent quenching of H2O2-induced protein-derived radicals by NO donors was shown using direct electron paramagnetic resonance measurements as well as immuno-spin trapping with antibodies against protein 5,5-dimethyl-1-pyrrolineN-oxide-nitrone adducts. In the presence of NO donors, H2O2-induced oligomeric forms of cyt c positively stained for 3-nitrotyrosine confirming the reactivity of NO toward tyrosyl radicals of cyt c. Interaction of NO with the cyt c(.)CL complex inhibited its peroxidase activity with three different substrates: CL, etoposide, and 3,3'-diaminobenzidine. Given the importance of CL oxidation in apoptosis, mass spectrometry analysis was utilized to assess the effects of NO on oxidation of 1,1'2,2'-tertalinoleoyl cardiolipin. NO effectively inhibited 1,1'2,2'-tertalinoleoyl cardiolipin oxidation catalyzed by the peroxidase activity of cyt c. Thus, NO can act as a regulator of peroxidase activity of cyt c(.)CL complexes.	Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kagan, VE (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Rad & Antioxidant Hlth, 100 Technol Dr,CLMCL, Pittsburgh, PA 15260 USA.	vkagan@eoh.pitt.edu		Stoyanovsky, Detcho/0000-0001-5591-4780; Kagan, Valerian E./0000-0002-7245-1885; Tyurin, Vladimir/0000-0002-3474-1697; Kapralov, Oleksandr/0000-0002-3006-916X	NHLBI NIH HHS [HL 70755] Funding Source: Medline; NIAID NIH HHS [U19 AI 068021] Funding Source: Medline; NIEHS NIH HHS [ES 09648-01A2] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009648] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; ASCENZI P, 1994, J INORG BIOCHEM, V53, P273, DOI 10.1016/0162-0134(94)85114-X; BABBS CF, 1991, AM J PHYSIOL, V260, pH123, DOI 10.1152/ajpheart.1991.260.1.H123; Batthyany C, 2005, BIOCHEMISTRY-US, V44, P8038, DOI 10.1021/bi0474620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; Brunori M, 2004, BBA-BIOENERGETICS, V1655, P365, DOI 10.1016/j.bbabio.2003.06.008; Castro L, 2004, ARCH BIOCHEM BIOPHYS, V421, P99, DOI 10.1016/j.abb.2003.08.033; Chamulitrat W, 2001, ANTIOXID REDOX SIGN, V3, P177, DOI 10.1089/152308601300185151; Chen YR, 2004, FREE RADICAL BIO MED, V37, P1591, DOI 10.1016/j.freeradbiomed.2004.07.013; Chen YR, 2004, J BIOL CHEM, V279, P18054, DOI 10.1074/jbc.M307706200; Chen YR, 2002, J BIOL CHEM, V277, P29781, DOI 10.1074/jbc.M200709200; Clark SR, 2002, J IMMUNOL, V169, P5889, DOI 10.4049/jimmunol.169.10.5889; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Diederix REM, 2002, BIOCHEMISTRY-US, V41, P13067, DOI 10.1021/bi0260841; Estevam ML, 2004, J BIOL CHEM, V279, P39214, DOI 10.1074/jbc.M402093200; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Glover RE, 1999, NITRIC OXIDE-BIOL CH, V3, P439, DOI 10.1006/niox.1999.0256; Goldenthal MJ, 2004, MOL CELL BIOCHEM, V262, P1, DOI 10.1023/B:MCBI.0000038228.85494.3b; GOLDMAN R, 1997, ENV NUTR INTERACT, V1, P97; GORBUNOV NV, 1995, BIOCHEMISTRY-US, V34, P6689, DOI 10.1021/bi00020a014; Haynes V, 2004, J BIOENERG BIOMEMBR, V36, P341, DOI 10.1023/B:JOBB.0000041765.27145.08; Herold S, 2001, J BIOL INORG CHEM, V6, P543, DOI 10.1007/s007750100231; Hoang L, 2002, P NATL ACAD SCI USA, V99, P12173, DOI 10.1073/pnas.152439199; Ischiropoulos H, 1996, FREE RADICAL BIO MED, V20, P373, DOI 10.1016/0891-5849(95)02098-5; Jang B, 2006, BIOCHIMIE, V88, P53, DOI 10.1016/j.biochi.2005.06.016; Jantschko W, 2005, BIOCHEM PHARMACOL, V69, P1149, DOI 10.1016/j.bcp.2005.02.006; Kagan V E, 1998, Methods Mol Biol, V108, P71; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kagan VE, 1999, MOL PHARMACOL, V56, P494, DOI 10.1124/mol.56.3.494; Kagan VE, 2004, FREE RADICAL BIO MED, V37, P1963, DOI 10.1016/j.freeradbiomed.2004.08.016; Kagan VE, 2001, ANTIOXID REDOX SIGN, V3, P189, DOI 10.1089/152308601300185160; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; KON H, 1968, J BIOL CHEM, V243, P4350; Kumar R, 2005, BIOCHEMISTRY-US, V44, P3024, DOI 10.1021/bi0478998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence A, 2003, J BIOL CHEM, V278, P29410, DOI 10.1074/jbc.M300054200; Maity H, 2004, J MOL BIOL, V343, P223, DOI 10.1016/j.jmb.2004.08.005; Mannick JB, 2004, FREE RADICAL RES, V38, P1, DOI 10.1080/10715760310001629065; Nantes IL, 2001, J BIOL CHEM, V276, P153, DOI 10.1074/jbc.M006338200; Oellerich S, 2002, J PHYS CHEM B, V106, P6566, DOI 10.1021/jp013841g; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P112, DOI 10.1016/0003-9861(91)90171-E; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P118, DOI 10.1016/0003-9861(91)90172-F; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Ramirez DC, 2003, FREE RADICAL BIO MED, V34, P830, DOI 10.1016/S0891-5849(02)01437-5; RAMIREZ DC, 2005, CURR PROTOCOLS TOXIC; RITOV VB, 1938, TOXICOL SCI S1, V78, P114; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Schonhoff CM, 2003, J BIOL CHEM, V278, P18265, DOI 10.1074/jbc.M212459200; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Shvedova AA, 1999, BIOCHEM PHARMACOL, V57, P989, DOI 10.1016/S0006-2952(99)00007-6; Silkstone GG, 2005, J AM CHEM SOC, V127, P92, DOI 10.1021/ja045719b; SMITH PAS, 1960, J AM CHEM SOC, V82, P5731, DOI 10.1021/ja01506a043; Stoyanovsky DA, 2004, J MED CHEM, V47, P210, DOI 10.1021/jm030192j; Tyurina YY, 2004, ANTIOXID REDOX SIGN, V6, P209, DOI 10.1089/152308604322899288; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; Wink David A., 1999, P245; YOSHIMURA T, 1988, ARCH BIOCHEM BIOPHYS, V264, P450, DOI 10.1016/0003-9861(88)90310-4; Zucchi MR, 2003, BIOCHEM J, V370, P671, DOI 10.1042/BJ20021521	63	77	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14554	14562		10.1074/jbc.M509507200	http://dx.doi.org/10.1074/jbc.M509507200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16543234	hybrid			2022-12-25	WOS:000237671300006
J	Bossen, C; Ingold, K; Tardivel, A; Bodmer, JL; Gaide, O; Hertig, S; Ambrose, C; Tschopp, J; Schneider, P				Bossen, Claudia; Ingold, Karine; Tardivel, Aubry; Bodmer, Jean-Luc; Gaide, Olivier; Hertig, Sylvie; Ambrose, Christine; Tschopp, Juerg; Schneider, Pascal			Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CELL-DEATH; T-CELL; FAS LIGAND; BINDING; TWEAK; IDENTIFICATION; ACTIVATION; APRIL; BAFF	Ligands of the tumor necrosis factor superfamily (TNFSF) (4-1BBL, APRIL, BAFF, CD27L, CD30L, CD40L, EDA1, EDA2, FasL, GITRL, LIGHT, lymphotoxin alpha, lymphotoxin alpha beta, OX40L, RANKL, TL1A, TNF, TWEAK, and TRAIL) bind members of the TNF receptor superfamily (TNFRSF). A comprehensive survey of ligand-receptor interactions was performed using a flow cytometry-based assay. All ligands engaged between one and five receptors, whereas most receptors only bound one to three ligands. The receptors DR6, RELT, TROY, NGFR, and mouse TNFRH3 did not interact with any of the known TNFSF ligands, suggesting that they either bind other types of ligands, function in a ligand-independent manner, or bind ligands that remain to be identified. The study revealed that ligand-receptor pairs are either cross-reactive between human and mouse (e.g. Tweak/Fn14, RANK/RANKL), strictly species-specific (GITR/GITRL), or partially species-specific (e.g. OX40/OX40L, CD40/CD40L). Interestingly, the receptor binding patterns of lymphotoxin alpha and alpha beta are redundant in the human but not in the mouse system. Ligand oligomerization allowed detection of weak interactions, such as that of human TNF with mouse TNFR2. In addition, mouse APRIL exists as two different splice variants differing by a single amino acid. Although human APRIL does not interact with BAFF-R, the shorter variant of mouse APRIL exhibits weak but detectable binding to mouse BAFF-R.	Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; Biogenldec, Cambridge, MA 02142 USA	University of Lausanne	Schneider, P (corresponding author), Univ Lausanne, Dept Biochem, Boveresses 155, CH-1066 Epalinges, Switzerland.	pascal.schneider@unil.ch		Schneider, Pascal/0000-0003-0677-9409				Ameloot P, 2001, J BIOL CHEM, V276, P37426, DOI 10.1074/jbc.M102020200; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Bischof D, 2006, BLOOD, V107, P3235, DOI 10.1182/blood-2005-01-0256; Bodmer JL, 2000, J BIOL CHEM, V275, P20632, DOI 10.1074/jbc.M909721199; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Brandt SM, 2004, PLOS BIOL, V2, P2067, DOI 10.1371/journal.pbio.0020418; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Brunetti CR, 2003, P NATL ACAD SCI USA, V100, P4831, DOI 10.1073/pnas.0737244100; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Compaan DM, 2005, J BIOL CHEM, V280, P39553, DOI 10.1074/jbc.M507629200; Feldmann M, 2005, J AUTOIMMUN, V25, P26, DOI 10.1016/j.jaut.2005.09.006; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Hurle B, 1998, GENOMICS, V52, P79, DOI 10.1006/geno.1998.5407; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Kalled SL, 2005, IMMUNOL REV, V204, P43, DOI 10.1111/j.0105-2896.2005.00219.x; Kanda H, 2002, J BIOL CHEM, V277, P28372, DOI 10.1074/jbc.C200324200; Kaptein A, 2000, FEBS LETT, V485, P135, DOI 10.1016/S0014-5793(00)02219-5; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Legler DF, 2004, FASEB J, V18, P73, DOI 10.1096/fj.03-1338fje; Liu YF, 2003, NATURE, V423, P49, DOI 10.1038/nature01543; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Nykjaer A, 2005, CURR OPIN NEUROBIOL, V15, P49, DOI 10.1016/j.conb.2005.01.004; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Pelletier M, 2003, J BIOL CHEM, V278, P33127, DOI 10.1074/jbc.M305754200; Pispa J, 2003, DEV BIOL, V262, P195, DOI 10.1016/S0012-1606(03)00325-7; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; POWELL EE, 1994, MAMM GENOME, V5, P726, DOI 10.1007/BF00426081; Pradet-Balade B, 2002, EMBO J, V21, P5711, DOI 10.1093/emboj/cdf565; RANGES GE, 1989, J IMMUNOL, V142, P1203; Schneider P, 2000, METHOD ENZYMOL, V322, P325; Schneider P, 1997, J BIOL CHEM, V272, P18827, DOI 10.1074/jbc.272.30.18827; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Schneider P, 2003, J BIOL CHEM, V278, P5444, DOI 10.1074/jbc.M210783200; Schneider P, 2001, J EXP MED, V194, P1691, DOI 10.1084/jem.194.11.1691; Schneider P, 2005, CURR OPIN IMMUNOL, V17, P282, DOI 10.1016/j.coi.2005.04.005; Sedy JR, 2005, NAT IMMUNOL, V6, P90, DOI 10.1038/ni1144; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; SHERBLOM AP, 1988, J BIOL CHEM, V263, P5418; Shrivastava P, 2004, MOL CELL BIOL, V24, P6763, DOI 10.1128/MCB.24.15.6763-6772.2004; Tamada K, 2006, CANCER IMMUNOL IMMUN, V55, P355, DOI 10.1007/s00262-005-0081-y; Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105-2896.2005.00327.x; Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wroblewski VJ, 2003, DRUG METAB DISPOS, V31, P502, DOI 10.1124/dmd.31.4.502; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523	58	325	355	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13964	13971		10.1074/jbc.M601553200	http://dx.doi.org/10.1074/jbc.M601553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16547002	hybrid, Green Published			2022-12-25	WOS:000237512300018
J	Kassavetis, GA; Driscoll, R; Geiduschek, EP				Kassavetis, George A.; Driscoll, Robert; Geiduschek, E. Peter			Mapping the principal interaction site of the Brf1 and Bdp1 subunits of Saccharomyces cerevisiae TFIIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; INITIATION-FACTOR-TFIIIB; TATA-BINDING PROTEIN; U6 SNRNA GENE; SANT DOMAIN; COMPLEX; PROMOTER; RECRUITMENT; BOX	The Brf1 subunit of the central RNA polymerase (pol) III transcription initiation factor TFIIIB is bipartite; its N-terminal TFIIB-related half is principally responsible for recruiting pol III to the promoter and for promoter opening near the transcriptional start site, whereas its pol III-specific C-terminal half contributes most of the affinities that hold the three subunits of TFIIIB together. Here, the principal attachment site of Brf1 for the Bdp1 subunit of TFIIIB has been mapped by a combination of structure-informed, site-directed mutagenesis and photochemical protein-DNA cross-linking. A 66-amino acid segment of Brf1 is shown to serve as a two-sided adhesive surface, with the side chains projecting away from its extended interface with TATA-binding protein anchoring Bdp1 binding. An extensive collection of N-terminal, C-terminal, and internal deletion proteins has been used to demarcate the interacting Bdp1 domain to a 66-amino acid segment that includes the SANT domain of this subunit and is phylogenetically the most conserved region of Bdp1.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Genet Mol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kassavetis, GA (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gak@biomail.ucsd.edu						Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Bachman N, 2005, GENE DEV, V19, P955, DOI 10.1101/gad.1299105; Bartholomew B, 1995, METHOD ENZYMOL, V262, P476; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; Boyer LA, 2004, NAT REV MOL CELL BIO, V5, P158, DOI 10.1038/nrm1314; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; Colbert T, 1998, MOL CELL BIOL, V18, P1682, DOI 10.1128/MCB.18.3.1682; Ding ZH, 2004, J BIOL CHEM, V279, P28009, DOI 10.1074/jbc.M403793200; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; Hedges SB, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-2; Huang Y, 2001, NUCLEIC ACIDS RES, V29, P2675, DOI 10.1093/nar/29.13.2675; Huet J, 1997, J BIOL CHEM, V272, P18341, DOI 10.1074/jbc.272.29.18341; Ishiguro A, 2002, MOL CELL BIOL, V22, P3264, DOI 10.1128/MCB.22.10.3264-3275.2002; Juo ZS, 2003, NATURE, V422, P534, DOI 10.1038/nature01534; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; Kassavetis GA, 2005, P NATL ACAD SCI USA, V102, P15406, DOI 10.1073/pnas.0507653102; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; Kassavetis GA, 2001, EMBO J, V20, P2823, DOI 10.1093/emboj/20.11.2823; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Kumar A, 1997, MOL CELL BIOL, V17, P1868, DOI 10.1128/MCB.17.4.1868; Mital R, 1996, MOL CELL BIOL, V16, P7031; Mo XM, 2005, GENE DEV, V19, P2447, DOI 10.1101/gad.355405; Padovan ACB, 2005, J MOL EVOL, V60, P726, DOI 10.1007/s00239-004-0164-y; Roberts S, 1996, J BIOL CHEM, V271, P14903, DOI 10.1074/jbc.271.25.14903; Saxena A, 2005, MOL CELL BIOL, V25, P9406, DOI 10.1128/MCB.25.21.9406-9418.2005; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Schroder O, 2003, EMBO J, V22, P5115, DOI 10.1093/emboj/cdg476; Shah SMA, 1999, J BIOL CHEM, V274, P28736, DOI 10.1074/jbc.274.40.28736; Shivaswamy S, 2004, MOL CELL BIOL, V24, P3596, DOI 10.1128/MCB.24.9.3596-3606.2004; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WHITE RJ, 2002, RNA POLYMERASE 3 TRA; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; Yieh L, 2002, J BIOL CHEM, V277, P25920, DOI 10.1074/jbc.M202729200	41	19	19	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14321	14329		10.1074/jbc.M601702200	http://dx.doi.org/10.1074/jbc.M601702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551611	hybrid			2022-12-25	WOS:000237512300058
J	Martinez-Yamout, MA; Venkitakrishnan, RP; Preece, NE; Kroon, G; Wright, PE; Dyson, HJ				Martinez-Yamout, Maria A.; Venkitakrishnan, Rani P.; Preece, Nicholas E.; Kroon, Gerard; Wright, Peter E.; Dyson, H. Jane			Localization of Sites of Interaction between p23 and Hsp90 in Solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI HSP90; N-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONE; ATPASE ACTIVITY; BINDING; DIMERIZATION; RECEPTOR; CONFORMATION	The co-chaperone p23 forms a complex with the chaperone Hsp90 that mediates the folding pathway leading to the production of functional steroid receptors. Solution NMR spectroscopy has been used to characterize sites of interaction between Hsp90 and p23. Titration of p23 with Hsp90 results in the selective broadening of certain cross-peaks in the N-15-H-1 heteronuclear single quantum correlation (HSQC) spectrum. The interaction sites on p23 and Hsp90 have been localized by dissection of Hsp90 into single-domain and two-domain constructs. The N-terminal (N) domain of Hsp90 does not affect the NMR spectrum of p23 either in the presence or absence of the ATP analogue ATP gamma S. Similarly, the HSQC spectrum of N-15-labeled N domain is unperturbed by the addition of p23. A subset of cross-peaks in the HSQC spectrum of p23 is shifted upon addition of the middle (M) domain of Hsp90, and the same shifts are observed upon the addition of the two-domain construct containing the N and M domains (NM). The addition of the co-chaperone Aha1, which is known to bind to the M domain of Hsp90, displaces p23 from Hsp90. The resonances that shift upon addition of the M and NM Hsp90 constructs correspond to those that were broadened at the lowest ratios of full-length Hsp90 to p23 and define an Hsp90 binding site that includes much of the C-terminal sequence of p23 together with a contiguous beta-hairpin from the N terminus. We conclude that p23 forms a specific complex with Hsp90 primarily through binding to its middle domain.	[Martinez-Yamout, Maria A.; Venkitakrishnan, Rani P.; Preece, Nicholas E.; Kroon, Gerard; Wright, Peter E.; Dyson, H. Jane] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Dyson, HJ (corresponding author), Scripps Res Inst, Dept Mol Biol MB2, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dyson@scripps.edu	Dyson, Jane/D-4160-2011	Dyson, Jane/0000-0001-6855-3398; Wright, Peter/0000-0002-1368-0223	National Institutes of Health [GM57374]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057374] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Grant GM57374 from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Dehner A, 2003, CHEMBIOCHEM, V4, P870, DOI 10.1002/cbic.200300658; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Harris SF, 2004, STRUCTURE, V12, P1087, DOI 10.1016/j.str.2004.03.020; Harst A, 2005, BIOCHEM J, V387, P789, DOI 10.1042/BJ20041283; Huai Q, 2005, STRUCTURE, V13, P579, DOI 10.1016/j.str.2004.12.018; Jez JM, 2003, CHEM BIOL, V10, P361, DOI 10.1016/S1074-5521(03)00075-9; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; McLaughlin SH, 2006, J MOL BIOL, V356, P746, DOI 10.1016/j.jmb.2005.11.085; McLaughlin SH, 2004, J MOL BIOL, V344, P813, DOI 10.1016/j.jmb.2004.09.055; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Meyer P, 2004, EMBO J, V23, P1402, DOI 10.1038/sj.emboj.7600141; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Obradovic Z, 2003, PROTEINS, V53, P566, DOI 10.1002/prot.10532; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RAO RV, 2005, CELL DEATH DIFFER; Richter K, 2004, J MOL BIOL, V342, P1403, DOI 10.1016/j.jmb.2004.07.064; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Siligardi G, 2004, J BIOL CHEM, V279, P51989, DOI 10.1074/jbc.M410562200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Sullivan WP, 2002, J BIOL CHEM, V277, P45942, DOI 10.1074/jbc.M207754200; Terasawa K, 2005, J BIOCHEM, V137, P443, DOI 10.1093/jb/mvi056; Weaver AJ, 2000, J BIOL CHEM, V275, P23045, DOI 10.1074/jbc.M003410200; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Weikl T, 1999, J MOL BIOL, V293, P685, DOI 10.1006/jmbi.1999.3172; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X	40	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14457	14464		10.1074/jbc.M601759200	http://dx.doi.org/10.1074/jbc.M601759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16565516	hybrid			2022-12-25	WOS:000207179300004
J	Wang, GK; Hu, LM; Fuller, GN; Zhang, W				Wang, George K.; Hu, Limei; Fuller, Gregory N.; Zhang, Wei			An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha 5 is essential for IGFBP2-induced cell mobility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; GLIOBLASTOMA-MULTIFORME; KINASE PATHWAY; OVARIAN-CANCER; HUMAN GLIOMAS; EXPRESSION; MIGRATION; ADHESION; TISSUE; PROLIFERATION	In the study we report here, we tested the hypothesis that insulin-like growth factor-binding protein 2 (IGFBP2) promotes cell mobility through its interaction with integrin alpha 5. Our previous microarray studies showed that IGFBP2 activates the expression of integrin alpha 5. In addition, IGFBP2 has an Arg-Gly-Asp (RGD) domain, which is a known integrin binding motif. We first confirmed our microarray results by showing that the expression of integrin alpha 5 is indeed up-regulated at the protein level in IGFBP2-overexpressing SNB19 glioma cells. Using co-immunoprecipitation, we confirmed that IGFBP2 does interact with integrin alpha 5. To confirm that IGFBP2 interacts directly with integrin alpha 5 through the RGD domain, we created an RGD 3 RGE mutant (D306E) IGFBP2 and stably overexpressed the mutant IGFBP2 in the same cell line. Co-immunoprecipitation then showed that D306E-IGFBP2 had no detectable binding with integrin alpha 5. We further observed that IGFBP2-overexpressing cells have extensive cell surface lamellipodia, whereas D306E-IGFBP2-overexpressing cells show abundant cell surface focal adhesions. Consistent with this, phenotype analysis then showed that IGFBP2-overexpressing cells have elevated migration rates compared with vector control; in contrast, the migration rates of the D306E-IGFBP2-overexpressing cells were not elevated and were comparable with that of vector control. Decreased expression of integrin alpha 5 by small interference RNA in IGFBP2-overexpressing cells also reduced cell mobility. Therefore, we have concluded that one mechanism by which IGFBP2 activates IGFBP2-induced cell mobility is through its interaction with integrin alpha 5 and this interaction is specifically mediated through the RGD domain on IGFBP2.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Zhang, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	wzhang@mdanderson.org		Fuller, Gregory/0000-0001-9447-2647	NCI NIH HHS [CA98503, CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098503, R56CA098503, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baron-Hay S, 2004, CLIN CANCER RES, V10, P1796, DOI 10.1158/1078-0432.CCR-0672-2; Chatterjee S, 2004, INT J UROL, V11, P876, DOI 10.1111/j.1442-2042.2004.00898.x; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Davidson B, 2003, GYNECOL ONCOL, V90, P248, DOI 10.1016/S0090-8258(03)00321-4; DEGIROLAMI U, 1999, ROBBINS PATHOLOGIC B, P1293; Elmlinger MW, 2001, ENDOCRINOLOGY, V142, P1652, DOI 10.1210/en.142.4.1652; Flyvbjerg A, 1997, J CLIN ENDOCR METAB, V82, P2308, DOI 10.1210/jc.82.7.2308; Fuller GN, 1999, CANCER RES, V59, P4228; GINGRAS MC, 1995, J NEUROIMMUNOL, V57, P143, DOI 10.1016/0165-5728(94)00178-Q; Gleeson LM, 2001, J CLIN ENDOCR METAB, V86, P2484, DOI 10.1210/jc.86.6.2484; GREEN BN, 1994, ENDOCRINOLOGY, V134, P954, DOI 10.1210/en.134.2.954; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; Kiyama S, 2003, CANCER RES, V63, P3575; Lee EJ, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-7; LEE WH, 1993, NEUROSCIENCE, V53, P251, DOI 10.1016/0306-4522(93)90303-W; Mahesparan R, 2003, ACTA NEUROPATHOL, V105, P49, DOI 10.1007/s00401-002-0610-0; Moore MG, 2003, INT J CANCER, V105, P14, DOI 10.1002/ijc.11015; Nemeth JA, 2003, CLIN EXP METASTAS, V20, P413, DOI 10.1023/A:1025461507027; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Richardsen E, 2003, VIRCHOWS ARCH, V442, P329, DOI 10.1007/s00428-003-0786-2; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sallinen SL, 2000, CANCER RES, V60, P6617; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Wang H, 2003, CANCER RES, V63, P4315; Wang HM, 2002, BRAIN PATHOL, V12, P95; Yang CQ, 2003, CANCER RES, V63, P8312; Zhang W, 2002, BRAIN PATHOL, V12, P87; Zheng DQ, 1999, CANCER RES, V59, P1655	30	98	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14085	14091		10.1074/jbc.M513686200	http://dx.doi.org/10.1074/jbc.M513686200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16569642	hybrid			2022-12-25	WOS:000237512300031
J	Cruciat, CM; Hassler, C; Niehrs, C				Cruciat, CM; Hassler, C; Niehrs, C			The MRH protein Erlectin is a member of the endoplasmic reticulum synexpression group and functions in N-glycan recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTORS; ER-ASSOCIATED DEGRADATION; POLYCYSTIC LIVER-DISEASE; GLUCOSIDASE-II; MISFOLDED GLYCOPROTEINS; GENE-EXPRESSION; QUALITY-CONTROL; SUBCELLULAR-LOCALIZATION; HETERODIMERIC STRUCTURE; IDENTIFIES YOS9P	Kremen1 and 2 (Krm1/2) are coreceptors for Dickkopf1 (Dkk1), an antagonist of Wnt/beta-catenin signaling, and play a role in head induction during early Xenopus development. In a proteomic approach we identified Erlectin, a novel protein that interacts with Krm2. Erlectin (XTP3-B) is member of a protein family containing mannose 6-phosphate receptor homology (MRH-, or PRKCSH-) domains implicated in N-glycan binding. Like other members of the MRH family, Erlectin is a luminal resident protein of the endoplasmic reticulum. It contains two MRH domains, of which one is essential for Krm2 binding, and this interaction is abolished by Krm2 deglycosylation. The overexpression of Erlectin inhibits transport of Krm2 to the cell surface. Analysis of its embryonic expression pattern in Xenopus reveals that Erlectin is member of the endoplasmic reticulum synexpression group. Erlectin morpholino antisense injection leads to head and axial defects during organogenesis stages in Xenopus embryos. The results indicate that Erlectin functions in N-glycan recognition in the endoplasmic reticulum, suggesting that it may regulate glycoprotein traffic.	German Canc Res Ctr, Dept Mol Embryol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Niehrs, C (corresponding author), German Canc Res Ctr, Dept Mol Embryol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	niehrs@dkfz-heidelberg.de						Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Baldessari D, 2005, MECH DEVELOP, V122, P441, DOI 10.1016/j.mod.2004.11.007; Bhamidipati A, 2005, MOL CELL, V19, P741, DOI 10.1016/j.molcel.2005.07.027; BLITZ IL, 1995, DEVELOPMENT, V121, P993; Bosnar MH, 2004, EXP CELL RES, V298, P275, DOI 10.1016/j.yexcr.2004.04.018; Bourguignon C, 1998, DEVELOPMENT, V125, P4889; BRADLEY LC, 1993, MECH DEVELOP, V40, P73, DOI 10.1016/0925-4773(93)90089-G; Buschhorn BA, 2004, FEBS LETT, V577, P422, DOI 10.1016/j.febslet.2004.10.039; Culi J, 2003, CELL, V112, P343, DOI 10.1016/S0092-8674(02)01279-5; D'Alessio C, 1999, J BIOL CHEM, V274, P25899, DOI 10.1074/jbc.274.36.25899; Davidson G, 2002, DEVELOPMENT, V129, P5587, DOI 10.1242/dev.00154; Drenth JPH, 2004, GASTROENTEROLOGY, V126, P1819, DOI 10.1053/j.gastro.2004.02.023; Drenth JPH, 2003, NAT GENET, V33, P345, DOI 10.1038/ng1104; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Gawantka V, 1998, MECH DEVELOP, V77, P95, DOI 10.1016/S0925-4773(98)00115-4; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; GONT LK, 1993, DEVELOPMENT, V119, P991; Heasman J, 2000, DEV BIOL, V222, P124, DOI 10.1006/dbio.2000.9720; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hsieh JC, 2003, CELL, V112, P355, DOI 10.1016/S0092-8674(03)00045-X; Kim W, 2005, MOL CELL, V19, P753, DOI 10.1016/j.molcel.2005.08.010; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Lee JR, 2001, CELL, V107, P161, DOI 10.1016/S0092-8674(01)00526-8; Litovchick L, 2002, J BIOL CHEM, V277, P34413, DOI 10.1074/jbc.M203986200; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Munro S, 2001, CURR BIOL, V11, pR499, DOI 10.1016/S0960-9822(01)00302-5; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; Osborne AR, 2005, ANNU REV CELL DEV BI, V21, P529, DOI 10.1146/annurev.cellbio.21.012704.133214; Pelissier A, 2003, CURR BIOL, V13, P1848, DOI 10.1016/j.cub.2003.10.023; Pelletier MF, 2000, GLYCOBIOLOGY, V10, P815, DOI 10.1093/glycob/10.8.815; Pollet N, 2005, MECH DEVELOP, V122, P365, DOI 10.1016/j.mod.2004.11.009; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Raas-Rothschild A, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015222; Raas-Rothschild A, 2000, J CLIN INVEST, V105, P673, DOI 10.1172/JCI5826; Schirle M, 2003, MOL CELL PROTEOMICS, V2, P1297, DOI 10.1074/mcp.M300087-MCP200; Scholpp S, 2004, CURR BIOL, V14, P1834, DOI 10.1016/j.cub.2004.09.084; Sen J, 2000, DEVELOPMENT, V127, P5541; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; Starr CJ, 2004, P NATL ACAD SCI USA, V101, P2572, DOI 10.1073/pnas.0308474100; Szathmary R, 2005, MOL CELL, V19, P765, DOI 10.1016/j.molcel.2005.08.015; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; Treml K, 2000, GLYCOBIOLOGY, V10, P493, DOI 10.1093/glycob/10.5.493; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Weissman JT, 2001, TRAFFIC, V2, P465, DOI 10.1034/j.1600-0854.2001.20704.x; Wilkinson BM, 2006, J BIOL CHEM, V281, P6325, DOI 10.1074/jbc.M510455200; Wilson JM, 2000, MOL BIOL CELL, V11, P2657, DOI 10.1091/mbc.11.8.2657; Yamamoto A, 2005, CELL, V120, P223, DOI 10.1016/j.cell.2004.11.051	54	26	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12986	12993		10.1074/jbc.M511872200	http://dx.doi.org/10.1074/jbc.M511872200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531414	hybrid			2022-12-25	WOS:000237134700094
J	Mao, JN; Qiao, XY; Luo, HY; Wu, JP				Mao, JN; Qiao, XY; Luo, HY; Wu, JP			Transgenic Drak2 overexpression in mice leads to increased T cell apoptosis and compromised memory T cell development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SERINE/THREONINE KINASE; DAP KINASE; DEATH; BETA; AUTOIMMUNITY; ACTIVATION; BINDING; SIGNAL	Drak2 is a death-associated protein family serine-threonine kinase. Its expression and roles in the immune system were investigated in this study. According to in situ hybridization, Drak2 expression was ubiquitous at the mid-gestation stage in embryos, followed by more focal expression in various organs in the perinatal period and adulthood, notably in the thymus, spleen, lymph nodes, cerebellum, suprachiasmatic nuclei, pituitary, olfactory lobes, adrenal medulla, stomach, skin, and testes. Drak2 transgenic (Tg) mice were generated using the human beta-actin promoter. These Tg mice showed normal T cell versus B cell and CD4 versus CD8 populations in the spleen, but their spleen weight cellularity was lower in comparison with wild type mice. After TCR activation, the proliferation response in Drak2 Tg T cells was normal, although their interleukin (IL)-2 and IL-4 but not interferon-gamma production was augmented. Activated Drak2 Tg T cells demonstrated significantly enhanced apoptosis in the presence of exogenous IL-2. At the molecular level, Drak2 Tg T cells manifested a lower increase of anti-apoptotic factors during activation; such a change probably rendered the cells vulnerable to subsequent IL-2 insults. The compromised apoptosis in Drak2 Tg T cells was associated with reduced numbers of T cells with the memory cell phenotype ( CD62L(lo)) and repressed secondary T cell responses in delayed type hypersensitivity. Our study demonstrates that Drak2 expresses in the T cell compartment but is not T cell- specific; it plays critical roles in T cell apoptosis and memory T cell development.	CHUM, Immunol Lab, Res Ctr, Notre Dame Hosp, Montreal, PQ H2L 4M1, Canada; CHUM, Serv Nephrol, Notre Dame Hosp, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Luo, HY (corresponding author), CHUM, Immunol Lab, Res Ctr, Notre Dame Hosp, Pavill DeSeve,Rm Y-5616,1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.	hongyu.luo@umontreal.ca	mao, jianning/A-4254-2011					DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Friedrich ML, 2005, INT IMMUNOL, V17, P1379, DOI 10.1093/intimm/dxh315; Henshall DC, 2003, J NEUROCHEM, V86, P1260, DOI 10.1046/j.1471-4159.2003.01934.x; HULI J, 1989, J IMMUNOL, V142, P800; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Kawai T, 1999, ONCOGENE, V18, P3471, DOI 10.1038/sj.onc.1202701; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kuo JC, 2003, J CELL SCI, V116, P4777, DOI 10.1242/jcs.00794; Laemle LK, 1998, PHYSIOL BEHAV, V64, P165, DOI 10.1016/S0031-9384(98)00045-6; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Luo HY, 2001, J IMMUNOL, V167, P1362, DOI 10.4049/jimmunol.167.3.1362; Luo HY, 2004, J CLIN INVEST, V114, P1762, DOI 10.1172/JCI200421846; Marcinkiewicz M, 2002, J NEUROPATH EXP NEUR, V61, P815, DOI 10.1093/jnen/61.9.915; Matsumoto M, 2001, J BIOCHEM, V130, P217, DOI 10.1093/oxfordjournals.jbchem.a002975; McGargill MA, 2004, IMMUNITY, V21, P781, DOI 10.1016/j.immuni.2004.10.008; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Shani G, 2001, EMBO J, V20, P1099, DOI 10.1093/emboj/20.5.1099; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771	23	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12587	12595		10.1074/jbc.M600497200	http://dx.doi.org/10.1074/jbc.M600497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517594	hybrid			2022-12-25	WOS:000237134700048
J	Ponthier, JL; Schluepen, C; Chen, WG; Lerscho, RA; Gee, SL; Hou, VC; Lo, AJ; Short, SA; Chasis, JA; Winkelmann, JC; Conboy, JG				Ponthier, JL; Schluepen, C; Chen, WG; Lerscho, RA; Gee, SL; Hou, VC; Lo, AJ; Short, SA; Chasis, JA; Winkelmann, JC; Conboy, JG			Fox-2 splicing factor binds to a conserved intron motif to promote inclusion of protein 4.1R alternative exon 16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; FUNCTIONAL-CHARACTERIZATION; EXPRESSION; SPECTRIN; INTERACTS; ISOFORMS; HOMOLOGS; COMPLEX; FAMILY; REGULATOR	Activation of protein 4.1R exon 16 (E16) inclusion during erythropoiesis represents a physiologically important splicing switch that increases 4.1R affinity for spectrin and actin. Previous studies showed that negative regulation of E16 splicing is mediated by the binding of heterogeneous nuclear ribonucleoprotein ( hnRNP) A/B proteins to silencer elements in the exon and that down-regulation of hnRNP A/B proteins in erythroblasts leads to activation of E16 inclusion. This article demonstrates that positive regulation of E16 splicing can be mediated by Fox-2 or Fox-1, two closely related splicing factors that possess identical RNA recognition motifs. SELEX experiments with human Fox-1 revealed highly selective binding to the hexamer UGCAUG. Both Fox-1 and Fox-2 were able to bind the conserved UGCAUG elements in the proximal intron downstream of E16, and both could activate E16 splicing in HeLa cell co-transfection assays in a UGCAUG-dependent manner. Conversely, knockdown of Fox- 2 expression, achieved with two different siRNA sequences resulted in decreased E16 splicing. Moreover, immunoblot experiments demonstrate mouse erythroblasts express Fox-2. These findings suggest that Fox- 2 is a physiological activator of E16 splicing in differentiating erythroid cells in vivo. Recent experiments show that UGCAUG is present in the proximal intron sequence of many tissue-specific alternative exons, and we propose that the Fox family of splicing enhancers plays an important role in alternative splicing switches during differentiation in metazoan organisms.	Lawrence Berkeley Natl Lab, Life Sci Div, Berkeley, CA 94720 USA; Univ Cincinnati, Coll Med, Div Hematol Oncol, Dept Internal Med,Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University System of Ohio; University of Cincinnati	Conboy, JG (corresponding author), Lawrence Berkeley Natl Lab, Life Sci Div, 1 Cyclotron Rd,Mail Stop 74-157, Berkeley, CA 94720 USA.	jgconboy@lbl.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045182, R56HL045182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45182, R01 HL045182] Funding Source: Medline; NIDDK NIH HHS [DK32094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auweter SD, 2006, EMBO J, V25, P163, DOI 10.1038/sj.emboj.7600918; Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; Baraniak AP, 2006, MOL CELL BIOL, V26, P1209, DOI 10.1128/MCB.26.4.1209-1222.2006; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Brett D, 2002, NAT GENET, V30, P29, DOI 10.1038/ng803; Brudno M, 2001, NUCLEIC ACIDS RES, V29, P2338, DOI 10.1093/nar/29.11.2338; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; Deguillien M, 2001, BLOOD, V98, P3809, DOI 10.1182/blood.V98.13.3809; DISCHER D, 1993, J BIOL CHEM, V268, P7186; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Forch P, 2002, EMBO J, V21, P6882, DOI 10.1093/emboj/cdf668; Gee SL, 2000, BLOOD, V95, P692, DOI 10.1182/blood.V95.2.692; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Guo NH, 2000, J BIOL CHEM, V275, P33641, DOI 10.1074/jbc.M005597200; Hedjran F, 1997, P NATL ACAD SCI USA, V94, P12343, DOI 10.1073/pnas.94.23.12343; HORNE WC, 1993, BLOOD, V82, P2558; Hou VC, 2001, CURR OPIN HEMATOL, V8, P74, DOI 10.1097/00062752-200103000-00003; Hou VC, 2002, EMBO J, V21, P6195, DOI 10.1093/emboj/cdf625; HUANG JP, 1993, J BIOL CHEM, V268, P3758; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; Jin Y, 2003, EMBO J, V22, P905, DOI 10.1093/emboj/cdg089; Kawamoto S, 1996, J BIOL CHEM, V271, P17613; Kontrogianni-Konstantopoulos A, 2000, MOL BIOL CELL, V11, P3805, DOI 10.1091/mbc.11.11.3805; KOURY MJ, 1984, J CELL PHYSIOL, V121, P526, DOI 10.1002/jcp.1041210311; Lee G, 2003, BLOOD, V101, P1790, DOI 10.1182/blood-2002-08-2529; Lieberman AP, 2001, BIOCHEM BIOPH RES CO, V282, P499, DOI 10.1006/bbrc.2001.4617; Lim LP, 1998, MOL CELL BIOL, V18, P3900, DOI 10.1128/MCB.18.7.3900; Minovitsky S, 2005, NUCLEIC ACIDS RES, V33, P714, DOI 10.1093/nar/gki210; Modafferi EF, 1997, MOL CELL BIOL, V17, P6537, DOI 10.1128/MCB.17.11.6537; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Nakahata S, 2005, NUCLEIC ACIDS RES, V33, P2078, DOI 10.1093/nar/gki338; Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Ramez M, 2003, KIDNEY INT, V63, P1321, DOI 10.1046/j.1523-1755.2003.00870.x; Roberts GC, 2002, CURR OPIN CHEM BIOL, V6, P375, DOI 10.1016/S1367-5931(02)00320-4; Schischmanoff PO, 1997, J BIOL CHEM, V272, P10254, DOI 10.1074/jbc.272.15.10254; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; Shibata H, 2000, HUM MOL GENET, V9, P1303, DOI 10.1093/hmg/9.9.1303; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Underwood JG, 2005, MOL CELL BIOL, V25, P10005, DOI 10.1128/MCB.25.22.10005-10016.2005; Wang JW, 1997, J BIOL CHEM, V272, P22227, DOI 10.1074/jbc.272.35.22227; Winkelmann JC, 2000, BLOOD, V96, p592A; Yang G, 2005, BLOOD, V105, P2146, DOI 10.1182/blood-2004-05-1757; Yeo GW, 2005, P NATL ACAD SCI USA, V102, P2850, DOI 10.1073/pnas.0409742102	51	87	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12468	12474		10.1074/jbc.M511556200	http://dx.doi.org/10.1074/jbc.M511556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16537540	Green Submitted, hybrid			2022-12-25	WOS:000237134700034
J	Swiatek, W; Kang, H; Garcia, BA; Shabanowitz, J; Coombs, GS; Hunt, DF; Virshup, DM				Swiatek, W; Kang, H; Garcia, BA; Shabanowitz, J; Coombs, GS; Hunt, DF; Virshup, DM			Negative regulation of LRP6 function by casein kinase I epsilon phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; WNT SIGNALING PATHWAY; SLEEP PHASE SYNDROME; BETA-CATENIN; MASS-SPECTROMETRY; ACTIVATION; MECHANISM; MUTATION; DENSITY; CKI	Wnt signaling acts in part through the low density lipoprotein receptor-related transmembrane proteins LRP5 and LRP6 to regulate embryonic development and stem cell proliferation. Up-regulated signaling is associated with many forms of cancer. Casein kinase I epsilon (CKI epsilon) is a known component of the Wnt-beta-catenin signaling pathway. We find that CKI epsilon binds to LRP5 and LRP6 in vitro and in vivo and identify three CKI epsilon-specific phosphorylation sites in LRP6. Two of the identified phosphorylation sites, Ser(1420) and Ser(1430), influence Wnt signaling in vivo, since LRP6 with mutation of these sites is a more potent activator of both beta-catenin accumulation and Lef-1 reporter activity. Whereas Wnt3a regulates CKI epsilon kinase activity, LRP6 does not, placing CKI epsilon upstream of LRP6. Mutation of LRP6 Ser(1420) and Ser(1430) to alanine strengthens its interaction with axin, suggesting a mechanism by which CKI epsilon may negatively regulate Wnt signaling. The role of CKI epsilon is therefore more complex than was previously appreciated. Generation of active CKI epsilon may induce a negative feedback loop by phosphorylation of sites on LRP5/6 that modulate axin binding and hence beta-catenin degradation.	Univ Utah, Huntsman Canc Inst, Dept Pediat, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22901 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Virginia; University of Virginia	Virshup, DM (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Pediat, Salt Lake City, UT 84112 USA.	david.virshup@hci.utah.edu	Virshup, David M/C-1449-2009; Hunt, Donald F/I-6936-2012	Virshup, David M/0000-0001-6976-850X; Hunt, Donald F/0000-0003-2815-6368; Coombs, Gary/0000-0002-0711-185X	NATIONAL CANCER INSTITUTE [P30CA042014, P01CA073992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA73992, P30 CA42014] Funding Source: Medline; NIGMS NIH HHS [R01 GM37537] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946-4955.2005; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brennan K, 2004, ONCOGENE, V23, P4873, DOI 10.1038/sj.onc.1207642; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; Endo Y, 2005, J BIOL CHEM, V280, P777, DOI 10.1074/jbc.M406391200; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hodgkin J, 1998, INT J DEV BIOL, V42, P501; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu F, 2002, J BIOL CHEM, V277, P45393, DOI 10.1074/jbc.M204499200; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; Matsubayashi H, 2004, MOL CELL BIOL, V24, P2012, DOI 10.1128/MCB.24.5.2012-2024.2004; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Swiatek W, 2004, J BIOL CHEM, V279, P13011, DOI 10.1074/jbc.M304682200; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8; Xu Y, 2005, NATURE, V434, P640, DOI 10.1038/nature03453; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	46	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12233	12241		10.1074/jbc.M510580200	http://dx.doi.org/10.1074/jbc.M510580200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513652	hybrid			2022-12-25	WOS:000237134700006
J	Daikoku, T; Kudoh, A; Sugaya, Y; Iwahori, S; Shirata, N; Isomura, H; Tsurumi, T				Daikoku, T; Kudoh, A; Sugaya, Y; Iwahori, S; Shirata, N; Isomura, H; Tsurumi, T			Postreplicative mismatch repair factors are recruited to Epstein-Barr virus replication compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; BMRF1 GENE-PRODUCTS; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; LYTIC REPLICATION; ESCHERICHIA-COLI; BINDING PROTEIN; HOMEOLOGOUS RECOMBINATION; RECOGNITION COMPLEX	The mismatch repair (MMR) system, highly conserved throughout evolution, corrects nucleotide mispairing that arise during cellular DNA replication. We report here that proliferating cell nuclear antigen (PCNA), the clamp loader complex (RF-C), and a series of MMR proteins like MSH-2, MSH-6, MLH1, and hPSM2 can be assembled to Epstein-Barr virus replication compartments, the sites of viral DNA synthesis. Levels of the DNA-bound form of PCNA increased with progression of viral productive replication. Bromodeoxyuridine-labeled chromatin immunodepletion analyses confirmed that PCNA is loaded onto newly synthesized viral DNA as well as BALF2 and BMRF1 viral proteins during lytic replication. Furthermore, the anti-PCNA, - MSH2, - MSH3, or - MSH6 antibodies could immunoprecipitate BMRF1 replication protein probably via the viral DNA genome. PCNA loading might trigger transfer of a series of host MMR proteins to the sites of viral DNA synthesis. The MMR factors might function for the repair of mismatches that arise during viral replication or act to inhibit recombination between moderately divergent ( homologous) sequences.	Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Tsurumi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ttsurumi@aichi-cc.jp	Iwahori, Satoko/L-1948-2019					ABBOTTS J, 1987, NUCLEIC ACIDS RES, V15, P1185, DOI 10.1093/nar/15.3.1185; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Bell P, 2000, J VIROL, V74, P11800, DOI 10.1128/JVI.74.24.11800-11810.2000; BISHOP DK, 1987, NATURE, V328, P362, DOI 10.1038/328362a0; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; Cejka P, 2003, EMBO J, V22, P2245, DOI 10.1093/emboj/cdg216; Chambers SR, 1996, MOL CELL BIOL, V16, P6110; Chen MR, 2000, J VIROL, V74, P3093, DOI 10.1128/JVI.74.7.3093-3104.2000; Chen WL, 1999, GENETICS, V151, P1299; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Daikoku T, 2005, J VIROL, V79, P3409, DOI 10.1128/JVI.79.6.3409-3418.2005; Daikoku T, 2004, J BIOL CHEM, V279, P54817, DOI 10.1074/jbc.M405911200; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; FIXMAN ED, 1995, J VIROL, V69, P2998, DOI 10.1128/JVI.69.5.2998-3006.1995; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Fujita M, 2002, J BIOL CHEM, V277, P10354, DOI 10.1074/jbc.M111398200; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Harland J, 2003, J NEUROVIROL, V9, P477, DOI 10.1080/13550280390218788; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; Jiricny J, 2000, NAT GENET, V24, P6, DOI 10.1038/71698; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kudoh A, 2003, J VIROL, V77, P851, DOI 10.1128/JVI.77.2.851-861.2003; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Lau PJ, 2003, J BIOL CHEM, V278, P14, DOI 10.1074/jbc.C200627200; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nicholson A, 2000, GENETICS, V154, P133; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Peterson-Roth E, 2005, MOL CELL BIOL, V25, P3596, DOI 10.1128/MCB.25.9.3596-3607.2005; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; SU SS, 1988, J BIOL CHEM, V263, P6829; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; TAKAGI S, 1991, VIROLOGY, V185, P309, DOI 10.1016/0042-6822(91)90778-A; Taylor TJ, 2004, J VIROL, V78, P5856, DOI 10.1128/JVI.78.11.5856-5866.2004; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1999, MOL CELL BIOL, V19, P2000; TSURUMI T, 1993, J VIROL, V67, P1681, DOI 10.1128/JVI.67.3.1681-1687.1993; TSURUMI T, 1993, J VIROL, V67, P4651, DOI 10.1128/JVI.67.8.4651-4658.1993; TSURUMI T, 1991, VIROLOGY, V182, P376, DOI 10.1016/0042-6822(91)90685-5; Tsurumi T, 1998, J GEN VIROL, V79, P1257, DOI 10.1099/0022-1317-79-5-1257; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; Wang HX, 2002, J BIOL CHEM, V277, P26143, DOI 10.1074/jbc.M200358200; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; Xie YL, 1999, GENETICS, V151, P499; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Zhang G, 1999, P NATL ACAD SCI USA, V96, P1869, DOI 10.1073/pnas.96.5.1869; ZIMMERMANN J, 1995, J VIROL, V69, P3147, DOI 10.1128/JVI.69.5.3147-3155.1995	62	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11422	11430		10.1074/jbc.M510314200	http://dx.doi.org/10.1074/jbc.M510314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16510450	hybrid			2022-12-25	WOS:000236822200085
J	Watanabe, J; Nishiyama, H; Matsui, Y; Ito, M; Kawanishi, H; Kamoto, T; Ogawa, O				Watanabe, J; Nishiyama, H; Matsui, Y; Ito, M; Kawanishi, H; Kamoto, T; Ogawa, O			Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines	ONCOGENE			English	Article						urogenital cancer; cisplatin; dicoumarol; p53; JNK	SUSTAINED ACTIVATION; CARCINOMA-CELLS; BLADDER-CANCER; JNK; OXIDOREDUCTASE-1; PHOSPHORYLATION; INDUCTION; PATHWAYS; JNK/P38; ROS	3-3'-Methylene-bis [4-hydroxycoumarin] (dicoumarol), an inhibitor of NADPH: quinone oxidoreductase 1, has been reported to possess potential antineoplastic effects and the ability to abrogate p53 protein. In the present study, we investigated the cytotoxic effects of dicoumarol in combination with cisplatin ( CDDP), using four bladder (RT112, 253J, J82 and UMUC3) and two prostate (LNCap and PC3) cancer cell lines. Single treatment with 100 mu M dicoumarol suppressed cell proliferation but did not induce apoptosis at 24 h in all cell lines examined. On the other hand, pretreatment with dicoumarol enhanced cytotoxicity of CDDP in three cell lines with wild type of p53(RT112, 253J and LNCap), but not in three other cell lines with mutant p53 or in RT112 stable transfectants with a dominant-negative mutant of p53. In RT112 and LNCap, CDDP induced p53 and p21 expression, while pretreatment of dicoumarol suppressed induction of p53/p21 and resulted in sequential activation of c-Jun N-terminal kinase (JNK) in a time-dependent manner. Furthermore, inhibition of JNK, using SP600125, completely suppressed activity of caspases and poly-(ADP-ribose) polymerase cleavage, leading to suppression of enhancement of CDDP-mediated apoptosis by dicoumarol. These results suggested that dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways.	Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ogawa, O (corresponding author), Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	ogawao@kuhp.kyoto-u.ac.jp						Anwar A, 2003, J BIOL CHEM, V278, P10368, DOI 10.1074/jbc.M211981200; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Brozovic A, 2004, INT J CANCER, V112, P974, DOI 10.1002/ijc.20522; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Danson S, 2004, CANCER TREAT REV, V30, P437, DOI 10.1016/j.ctrv.2004.01.002; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Goktas S, 1999, SEMIN ONCOL, V26, P162; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Lewis A, 2004, CLIN CANCER RES, V10, P4550, DOI 10.1158/1078-0432.CCR-03-0667; Madari H, 2003, CANCER RES, V63, P1214; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Martinez LA, 2002, CARCINOGENESIS, V23, P1289, DOI 10.1093/carcin/23.8.1289; Nishiyama H, 2004, EUR UROL, V45, P176, DOI 10.1016/j.eururo.2003.09.011; Siegel D, 2004, MOL PHARMACOL, V65, P1238, DOI 10.1124/mol.65.5.1238; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Vasilevskaya IA, 2004, MOL PHARMACOL, V65, P235, DOI 10.1124/mol.65.1.235; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watanabe J, 2004, UROLOGY, V63, P989, DOI 10.1016/j.urology.2003.11.031; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361	25	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2500	2508		10.1038/sj.onc.1209162	http://dx.doi.org/10.1038/sj.onc.1209162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16518417				2022-12-25	WOS:000236948000008
J	Kukekov, NV; Xu, ZH; Greene, LA				Kukekov, Nickolay V.; Xu, Zhiheng; Greene, Lloyd A.			Direct interaction of the molecular scaffolds POSH and JIP is required for apoptotic activation of JNKs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BAX-DEPENDENT APOPTOSIS; BINDING PROTEINS RAC1; C-JUN; NEURONAL APOPTOSIS; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; PATHWAY; STRESS; FAMILY; DEATH	A sequential pathway ( the JNK pathway) that includes activation of Rac1/Cdc42, mixed lineage kinases, MAP kinase kinases 4 and 7, and JNKs plays a required role in many paradigms of apoptotic cell death. However, the means by which this pathway is assembled and directed toward apoptotic death has been unclear. Here, we report that propagation of the apoptotic JNK pathway requires the cooperative interaction of two molecular scaffolds, POSH and JIPs. POSH ( plenty of SH3s) is a multidomain GTP-Rac1-interacting protein that binds and promotes activation of mixed lineage kinases. JIPs are reported to bind MAP kinase kinases 4/7 and JNKs. We find that POSH and JIPs directly associate with one another to form a multiprotein complex, PJAC ( POSH-JIP apoptotic complex), that includes all of the known kinase components of the pathway. Our observations indicate that this complex is required for JNK activation and cell death in response to apoptotic stimuli.	Columbia Univ, Dept Pathol, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Ctr Neurobiol & Behav, Coll Phys & Surg, New York, NY 10032 USA; Chinese Acad Sci, Key Lab Mol & Dev Biol, Inst Genet & Dev Biol, Beijing 100101, Peoples R China	Columbia University; Columbia University; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS	Greene, LA (corresponding author), Columbia Univ, Dept Pathol, Coll Phys & Surg, New York, NY 10032 USA.	lag3@columbia.edu		Xu, Zhiheng/0000-0002-4809-2851				COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Morris EJ, 1996, J CELL BIOL, V134, P757, DOI 10.1083/jcb.134.3.757; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Park DS, 1998, J NEUROSCI, V18, P830; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Rideout HJ, 2001, NEUROSCIENCE, V107, P339, DOI 10.1016/S0306-4522(01)00322-0; Stefanis L, 1999, J NEUROSCI, V19, P6235; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Xu ZH, 2005, MOL CELL BIOL, V25, P9949, DOI 10.1128/MCB.25.22.9949-9959.2005; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhang QG, 2005, J NEUROCHEM, V95, P784, DOI 10.1111/j.1471-4159.2005.03435.x	22	55	62	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15517	15524		10.1074/jbc.M601056200	http://dx.doi.org/10.1074/jbc.M601056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16571722	hybrid			2022-12-25	WOS:000237922200058
J	Morohashi, Y; Kan, T; Tominari, Y; Fuwa, H; Okamura, Y; Watanabe, N; Sato, C; Natsugari, H; Fukuyama, T; Iwatsubo, T; Tomita, T				Morohashi, Yuichi; Kan, Toshiyuki; Tominari, Yusuke; Fuwa, Haruhiko; Okamura, Yumiko; Watanabe, Naoto; Sato, Chihiro; Natsugari, Hideaki; Fukuyama, Tohru; Iwatsubo, Takeshi; Tomita, Taisuke			C-terminal fragment of presenilin is the molecular target of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDE PEPTIDASE; AMYLOID-BETA PROTEIN; ACTIVE-SITE; INTRAMEMBRANE CLEAVAGE; COMPLEX; BINDING; ENDOPROTEOLYSIS; STABILIZATION; NICASTRIN; A-BETA-42	gamma-Secretase is a multimeric membrane protein complex composed of presenilin (PS), nicastrin, Aph-1 and, Pen-2 that is responsible for the intramembrane proteolysis of various type I transmembrane proteins, including amyloid beta-precursor protein and Notch. The direct labeling of PS polypeptides by transition-state analogue gamma-secretase inhibitors suggested that PS represents the catalytic center of gamma-secretase. Here we show that one of the major gamma-secretase inhibitors of dipeptidic type, N-[N-( 3,5- difluorophenacetyl)-L-alanyl]-S- phenylglycine t-butyl ester (DAPT), targets the C-terminal fragment of PS, especially the transmembrane domain 7 or more C-terminal region, by designing and synthesizing DAP-BpB (N-[N-(3,5- difluorophenacetyl)-L-alanyl]-(S)-phenylglycine4-(4-(8-biotinamido) octylamino)benzoyl)benzyl) methylamide), a photoactivable DAPT derivative. We also found that DAP-BpB selectively binds to the high molecular weight gamma-secretase complex in an activity-dependent manner. Photolabeling of PS by DAP-BpB is completely blocked by DAPT or its structural relatives (e.g. Compound E) as well as by arylsulfonamides. In contrast, transition-state analogue inhibitor L-685,458 or alpha-helical peptidic inhibitor attenuated the photolabeling of PS1 only at higher concentrations. These data illustrate the DAPT binding site as a novel functional domain within the PS C-terminal fragment that is distinct from the catalytic site or the substrate binding site.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Synth Nat Prod Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Rat Med Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	iwatsubo@mol.f.u-tokyo.ac.jp; taisuke@mol.f.u-tokyo.ac.jp	Tomita, Taisuke/L-5427-2015; Fuwa, Haruhiko/D-1773-2010	Tomita, Taisuke/0000-0002-0075-5943; Fuwa, Haruhiko/0000-0001-5343-9023; Sato, Chihiro/0000-0002-7639-8727; Kan, Toshiyuki/0000-0002-9709-6365				Barten DM, 2005, J PHARMACOL EXP THER, V312, P635, DOI 10.1124/jpet.104.075408; Beher D, 2003, BIOCHEMISTRY-US, V42, P8133, DOI 10.1021/bi034045z; Das C, 2003, J AM CHEM SOC, V125, P11794, DOI 10.1021/ja037131v; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fraering PC, 2005, J BIOL CHEM, V280, P41987, DOI 10.1074/jbc.M501368200; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Fuwa H, 2004, TETRAHEDRON LETT, V45, P2323, DOI 10.1016/j.tetlet.2004.01.087; Hayashi I, 2004, J BIOL CHEM, V279, P38040, DOI 10.1074/jbc.M405597200; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; Kaether C, 2004, EMBO J, V23, P4738, DOI 10.1038/sj.emboj.7600478; Kan T, 2004, BIOORG MED CHEM LETT, V14, P1983, DOI 10.1016/j.bmcl.2004.01.067; Kan T, 2003, CHEM COMMUN, P2244, DOI 10.1039/b306970b; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kornilova AY, 2005, P NATL ACAD SCI USA, V102, P3230, DOI 10.1073/pnas.0407640102; Kornilova AY, 2003, J BIOL CHEM, V278, P16470, DOI 10.1074/jbc.C300019200; Lai MT, 2003, J BIOL CHEM, V278, P22475, DOI 10.1074/jbc.M300974200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; Oh YS, 2005, AM J PHYSIOL-CELL PH, V289, pC576, DOI 10.1152/ajpcell.00636.2004; Qi-Takahara Y, 2005, J NEUROSCI, V25, P436, DOI 10.1523/JNEUROSCI.1575-04.2005; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Schmidt B, 2003, CHEMBIOCHEM, V4, P366, DOI 10.1002/cbic.200200532; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 2004, DRUG NEWS PERSPECT, V17, P321, DOI 10.1358/dnp.2004.17.5.829036; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Wang J, 2006, J NEUROCHEM, V96, P218, DOI 10.1111/j.1471-4159.2005.03548.x; Wang J, 2004, NEUROBIOL DIS, V15, P654, DOI 10.1016/j.nbd.2003.12.008; Watanabe N, 2005, J BIOL CHEM, V280, P41967, DOI 10.1074/jbc.M509066200; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wrigley JDJ, 2004, J NEUROCHEM, V90, P1312, DOI 10.1111/j.1471-4159.2004.02596.x; Ye J, 2000, P NATL ACAD SCI USA, V97, P5123, DOI 10.1073/pnas.97.10.5123; Yu G, 2000, J BIOL CHEM, V275, P27348; Zhao GJ, 2004, J BIOL CHEM, V279, P50647, DOI 10.1074/jbc.C400473200	51	165	173	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14670	14676		10.1074/jbc.M513012200	http://dx.doi.org/10.1074/jbc.M513012200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16569643	hybrid			2022-12-25	WOS:000237671300019
J	Nieto-Miguel, T; Gajate, C; Mollinedo, F				Nieto-Miguel, Teresa; Gajate, Consuelo; Mollinedo, Faustino			Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; LIPID RAFTS; PHOSPHATIDYLCHOLINE SYNTHESIS; ENDOPLASMIC-RETICULUM; ET-18-OCH3 EDELFOSINE; CANCER-CELLS; C-JUN; PHOSPHOLIPID 1-O-OCTADECYL-2-O-METHYL-RAC-GLYCERO-3-PHOSPHOCHOLINE; KINASE ACTIVATION; INDUCED APOPTOSIS	Synthetic alkyl-lysophospholipids represent a family of promising anticancer drugs that induce apoptosis in a variety of tumor cells. Here we have found a differential subcellular distribution of the alkyl-lysophospholipid edelfosine in leukemic and solid tumor cells that leads to distinct anticancer responses. Edelfosine induced rapid apoptosis in human leukemic cells, including acute T-cell leukemia Jurkat and Peer cells, but promoted a late apoptotic response, preceded by G(2)/M arrest, in human solid tumor cells such as cervix epitheloid carcinoma HeLa cells and lung carcinoma A549 cells. c-Jun amino-terminal kinase (JNK) and caspase-3 were accordingly activated at earlier times in edelfosine-treated Jurkat cells as compared with drug-treated HeLa cells. Both leukemic and solid tumor cells took up this alkyl-lysophospholipid and expressed the two putative edelfosine targets, namely cell surface Fas death receptor (also known as APO-1 or CD95) and endoplasmic reticulum CTP: phosphocholine cytidylyltransferase. However, edelfosine was mainly located to plasma membrane lipid rafts in Jurkat and Peer leukemic cells and to endoplasmic reticulum in solid tumor HeLa and A549 cells. Edelfosine induced translocation of Fas, Fas-associated death domain-containing protein, and JNK into membrane rafts in Jurkat cells, but not in HeLa cells. In contrast, edelfosine inhibited phosphatidylcholine biosynthesis in both HeLa and A549 cells, but not in Jurkat or Peer leukemic cells, before the triggering of apoptosis. These data indicate that edelfosine targets two different subcellular structures in a cell type-dependent manner, namely cell surface lipid rafts in leukemic cells and endoplasmic reticulum in solid tumor cells.	Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, E-37007 Salamanca, Spain; Hosp Univ Salamanca, Unidad Invest, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca	Mollinedo, F (corresponding author), Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	fmollin@usal.es	2006, Secribsal/A-1263-2012; Nieto Miguel, Teresa/L-1496-2016	Nieto Miguel, Teresa/0000-0002-8374-5379; Gajate, Consuelo/0000-0003-0604-6459				Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FRA AM, 1994, J BIOL CHEM, V269, P30745; Gabel BR, 2004, INFECT IMMUN, V72, P7367, DOI 10.1128/IAI.72.12.7367-7373.2004; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Gajate C, 2000, CANCER RES, V60, P2651; Gajate C, 2002, J BIOL CHEM, V277, P41580, DOI 10.1074/jbc.M204644200; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2000, INT J CANCER, V86, P208, DOI 10.1002/(SICI)1097-0215(20000415)86:2<208::AID-IJC10>3.0.CO;2-E; Gajate C, 2002, CURR DRUG METAB, V3, P491, DOI 10.2174/1389200023337225; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOFFMAN DR, 1992, BIOCHIM BIOPHYS ACTA, V1127, P74, DOI 10.1016/0005-2760(92)90203-8; Hofmann TG, 2001, INT J CANCER, V93, P185, DOI 10.1002/ijc.1316; HOULIHAN WJ, 1995, MED RES REV, V15, P157, DOI 10.1002/med.2610150302; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; Jendrossek V., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P343, DOI 10.2174/1568011033482341; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; Kiss Z, 1997, FEBS LETT, V412, P313, DOI 10.1016/S0014-5793(97)00817-X; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; MAGISTRELLI A, 1995, DRUG METAB DISPOS, V23, P113; Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129; Mollinedo F, 1997, CANCER RES, V57, P1320; Mollinedo F, 2004, CURR MED CHEM, V11, P3163, DOI 10.2174/0929867043363703; MOLLINEDO F, 2004, FAS SIGNALING, P1; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; POWIS G, 1992, CANCER RES, V52, P2835; Quesada E, 2004, J MED CHEM, V47, P5333, DOI 10.1021/jm049808a; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; Ruiter GA, 1999, CANCER RES, V59, P2457; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Van der Luit AH, 2003, BIOCHEM J, V374, P747, DOI 10.1042/BJ20030179; van der Luit AH, 2002, J BIOL CHEM, V277, P39541, DOI 10.1074/jbc.M203176200; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zaremberg V, 2005, J BIOL CHEM, V280, P38047, DOI 10.1074/jbc.M502849200; ZHOU X, 1995, EUR J BIOCHEM, V232, P881, DOI 10.1111/j.1432-1033.1995.881zz.x	57	51	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14833	14840		10.1074/jbc.M511251200	http://dx.doi.org/10.1074/jbc.M511251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16540473	hybrid			2022-12-25	WOS:000237671300037
J	Gorska, MM; Cen, O; Liang, QL; Stafford, SJ; Alam, R				Gorska, Magdalena M.; Cen, Osman; Liang, Qiaoling; Stafford, Susan J.; Alam, Rafeul			Differential Regulation of Interleukin 5-stimulated Signaling Pathways by Dynamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Through the yeast two-hybrid screen we have identified dynamin-2 as a molecule that interacts with the alpha subunit of the interleukin (IL) 5 receptor. Dynamin-2 is a GTPase that is critical for endocytosis. We have shown that dynamin-2 interacts with the IL-5 receptor-associated tyrosine kinases, Lyn and JAK2, in eosinophils. Tyrosine phosphorylation of dynamin is markedly enhanced upon IL-5 stimulation. The inhibition of tyrosine kinases results in complete abolition of ligand-induced receptor endocytosis. Inhibition of dynamin by a dominant-negative mutant or by small interfering RNA results in enhancement of IL-5-stimulated ERK1/2 signaling and cell proliferation. In contrast, the absence of a functional dynamin does not affect STAT5 or AKT phosphorylation or cell survival. Thus, we have identified specific functions for dynamin in the IL-5 signaling pathway and demonstrated its role in receptor endocytosis and termination of the ERK1/2 signaling pathway.	[Gorska, Magdalena M.; Liang, Qiaoling; Alam, Rafeul] Natl Jewish Med & Res Ctr, Dept Med, Div Allergy & Immunol, Denver, CO 80206 USA; [Cen, Osman; Stafford, Susan J.] Univ Texas Med Branch, Dept Med, Div Allergy & Immunol, Galveston, TX 77555 USA	National Jewish Health; University of Texas System; University of Texas Medical Branch Galveston	Alam, R (corresponding author), 1400 Jackson St, Denver, CO 80206 USA.	alamr@njc.org		Cen, Osman/0000-0002-0224-6739	National Institutes of Health [RO1 AI50179, AI059719AI68088]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050179, R01AI059719, R01AI068088] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health Grants RO1 AI50179, AI059719, and AI68088. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Adachi T, 2000, J IMMUNOL, V165, P2198, DOI 10.4049/jimmunol.165.4.2198; Adachi T, 1998, AM J PHYSIOL-CELL PH, V275, pC623, DOI 10.1152/ajpcell.1998.275.3.C623; Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Bhattacharya R, 2005, FASEB J, V19, P1692, DOI 10.1096/fj.05-3889fje; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; Buttner C, 2003, EUR RESPIR J, V21, P799, DOI 10.1183/09031936.03.00027302; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Cen O, 2003, J BIOL CHEM, V278, P8837, DOI 10.1074/jbc.M208261200; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Crotzer VL, 2004, J EXP MED, V199, P981, DOI 10.1084/jem.20031105; Dijkers PF, 1999, ONCOGENE, V18, P3334, DOI 10.1038/sj.onc.1202678; Elhamdani A, 2000, J NEUROSCI, V20, P2495; Farr CD, 2004, J NEUROCHEM, V91, P438, DOI 10.1111/j.1471-4159.2004.02735.x; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gomez TS, 2005, NAT IMMUNOL, V6, P261, DOI 10.1038/ni1168; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Jans DA, 1997, FEBS LETT, V410, P368, DOI 10.1016/S0014-5793(97)00622-4; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Martinez-Moczygemba M, 2001, J CLIN INVEST, V108, P1797, DOI 10.1172/JCI200113877; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Paling NRD, 2002, BIOCHEM J, V368, P885, DOI 10.1042/BJ20021054; PAZDRAK K, 1995, J IMMUNOL, V155, P397; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Shinkai K, 2002, NATURE, V420, P825, DOI 10.1038/nature01202; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Sun TX, 2002, AM J PHYSIOL-RENAL, V282, pF998, DOI 10.1152/ajprenal.00257.2001; Tse SML, 2003, J BIOL CHEM, V278, P3331, DOI 10.1074/jbc.M207966200; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vila-Coro AJ, 1999, J IMMUNOL, V163, P3037; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Wan KF, 2001, J BIOL CHEM, V276, P37802; YEN JJY, 1995, J IMMUNOL, V154, P2144; Yoo JY, 2005, BIOCHEM BIOPH RES CO, V328, P424, DOI 10.1016/j.bbrc.2004.12.179; Yu AX, 2000, J IMMUNOL, V165, P2556, DOI 10.4049/jimmunol.165.5.2556	51	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14429	14439		10.1074/jbc.M512718200	http://dx.doi.org/10.1074/jbc.M512718200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16556602	hybrid			2022-12-25	WOS:000207179300001
J	Koteiche, HA; Mchaourab, HS				Koteiche, Hanane A.; Mchaourab, Hassane S.			Mechanism of a hereditary cataract phenotype - Mutations in alpha A-crystallin activate substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DESMIN-RELATED MYOPATHY; CHAPERONE-LIKE FUNCTION; B-CRYSTALLIN; T4 LYSOZYME; LENS CRYSTALLINS; SUBUNIT INTERACTIONS; MISSENSE MUTATION; BETA-CRYSTALLIN; EXCITED-STATES	We present a novel hypothesis for the molecular mechanism of autosomal dominant cataract linked to two mutations in the alpha A-crystallin gene of the ocular lens. alpha A-crystallin is a molecular chaperone that plays a critical role in the suppression of protein aggregation and hence in the long termmaintenance of lens optical properties. Using a steady state binding assay in which the chaperone-substrate complex is directly detected, we demonstrate that the mutations result in a substantial increase in the level of binding to non-native states of the model substrate T4 lysozyme. The structural basis of the enhanced binding is investigated through equivalent substitutions in the homologous heat shock protein 27. The mutations shift the oligomeric equilibrium toward a dissociated multimeric form previously shown to be the binding-competent state. In the context of a recent thermodynamic model of chaperone function that proposes the coupling of small heat shock protein activation to the substrate folding equilibrium (Shashidharamurthy, R., Koteiche, H. A., Dong, J., and McHaourab, H.S. (2005) J. Biol. Chem. 280, 5281-5289), the enhanced binding by the alpha A-crystallin mutants is predicted to shift the substrate folding equilibrium toward non-native intermediates, i.e. the mutants promote substrate unfolding. Given the high concentration of alpha A-crystallin in the lens, the molecular basis of pathogenesis implied by our results is a gain of function that leads to the binding of undamaged proteins and subsequent precipitation of the saturated alpha-crystallin complexes in the developing lens of affected individuals.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Mchaourab, HS (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, 221 Garland Ave,741 Light Hall, Nashville, TN 37232 USA.	Hassane.mchaourab@vanderbilt.edu			PHS HHS [R01-12018, R01-12683] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ajaz MS, 1997, J BIOL CHEM, V272, P11250; Andley UP, 2002, J BIOL CHEM, V277, P10178, DOI 10.1074/jbc.M109211200; Aquilina JA, 2004, J BIOL CHEM, V279, P28675, DOI 10.1074/jbc.M403348200; Bassnett S, 1997, INVEST OPHTH VIS SCI, V38, P1678; Benedek GB, 1997, INVEST OPHTH VIS SCI, V38, P1911; Bera S, 2002, BIOCHEMISTRY-US, V41, P297, DOI 10.1021/bi011010v; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; Berengian AR, 1999, J BIOL CHEM, V274, P6305, DOI 10.1074/jbc.274.10.6305; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Cobb BA, 2000, BIOCHEMISTRY-US, V39, P15791, DOI 10.1021/bi001453j; David LL, 1996, J BIOL CHEM, V271, P4273; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; Giese KC, 2004, J BIOL CHEM, V279, P32674, DOI 10.1074/jbc.M404455200; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2005, NAT STRUCT MOL BIOL, V12, P842, DOI 10.1038/nsmb993; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim YH, 2002, BIOCHEMISTRY-US, V41, P14076, DOI 10.1021/bi026288h; Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200; Koteiche HA, 2002, FEBS LETT, V519, P16, DOI 10.1016/S0014-5793(02)02688-1; KOTEICHE HA, 2003, INVEST OPHTHALMOL VI, V44; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; Lampi KJ, 2002, INVEST OPHTH VIS SCI, V43, P216; Lampi KJ, 2001, EXP EYE RES, V72, P279, DOI 10.1006/exer.2000.0950; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Ma ZX, 1998, EXP EYE RES, V67, P21, DOI 10.1006/exer.1998.0482; Mackay DS, 2003, EUR J HUM GENET, V11, P784, DOI 10.1038/sj.ejhg.5201046; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P14627, DOI 10.1021/bi971700s; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932; Sathish HA, 2004, J BIOL CHEM, V279, P16425, DOI 10.1074/jbc.M313402200; Sathish HA, 2003, J BIOL CHEM, V278, P44214, DOI 10.1074/jbc.M307578200; Shashidharamurthy R, 2005, J BIOL CHEM, V280, P5281, DOI 10.1074/jbc.M407236200; Shroff NP, 2000, BIOCHEMISTRY-US, V39, P1420, DOI 10.1021/bi991656b; Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403	52	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14273	14279		10.1074/jbc.M512938200	http://dx.doi.org/10.1074/jbc.M512938200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16531622	hybrid			2022-12-25	WOS:000237512300052
J	Lim, CM; Cater, MA; Mercer, JFB; La Fontaine, S				Lim, Chris M.; Cater, Michael A.; Mercer, Julian F. B.; La Fontaine, Sharon			Copper-dependent interaction of dynactin subunit p62 with the N terminus of ATP7B but not ATP7A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSONS-DISEASE PROTEIN; METAL-BINDING SITES; P-TYPE ATPASE; POLARIZED HEPATIC CELLS; MENKES PROTEIN; CYTOPLASMIC DYNEIN; INTRACELLULAR TRAFFICKING; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; TRANSPORTING ATPASE	The P-type ATPase affected in Wilson disease, ATP7B, is a key liver protein required to regulate and maintain copper homeostasis. When hepatocytes are exposed to elevated copper levels, ATP7B traffics from the trans-Golgi network toward the biliary canalicular membrane to excrete excess copper into bile. The N-terminal region of ATP7B contains six metal-binding sites (MBS), each with the copper-binding motif MXCXXC. These sites are required for the activity and copper-regulated intracellular redistribution of ATP7B. Two proteins are known to interact with the ATP7B N-terminal region: the copper chaperone ATOX1 that delivers copper to ATP7B, and COMMD1 (MURR1) that is potentially involved in vesicular copper sequestration. To identify additional proteins that interact with ATP7B and hence are involved in copper homeostasis, a yeast two-hybrid approach was employed to screen a human liver cDNA library. The dynactin subunit p62 (dynactin 4; DCTN4) was identified as an interacting partner, and this interaction was confirmed by co-immunoprecipitation from mammalian cells. The dynactin complex binds cargo, such as vesicles and organelles, to cytoplasmic dynein for retrograde microtubule-mediated trafficking and could feasibly be involved in the copper-regulated trafficking of ATP7B. The ATP7B/p62 interaction required copper, the metal-binding CXXC motifs, and the region between MBS 4 and MBS 6 of ATP7B. The p62 subunit did not interact with the related copper ATPase, ATP7A. We propose that the ATP7B interaction with p62 is a key component of the copper-induced trafficking pathway that delivers ATP7B to subapical vesicles of hepatocytes for the removal of excess copper into bile.	Deakin Univ, Sch Life & Environm Sci, Ctr Cellular & Mol Biol, Burwood, Vic 3125, Australia	Deakin University	La Fontaine, S (corresponding author), Deakin Univ, Sch Life & Environm Sci, Ctr Cellular & Mol Biol, 221 Burwood Hwy, Burwood, Vic 3125, Australia.	sharonl@deakin.edu.au	La Fontaine, Sharon/G-7113-2018; Mercer, Julian/R-8583-2019	La Fontaine, Sharon/0000-0002-9948-074X; 				Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bastaki M, 2002, MOL BIOL CELL, V13, P225, DOI 10.1091/mbc.01-07-0376; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; Burke D., 2000, METHODS YEAST GENETI, P171; Cater MA, 2006, GASTROENTEROLOGY, V130, P493, DOI 10.1053/j.gastro.2005.10.054; Cater MA, 2004, BIOCHEM J, V380, P805, DOI 10.1042/BJ20031804; *CLONT, 2000, PUBL; Cobine PA, 2000, BIOCHEMISTRY-US, V39, P6857, DOI 10.1021/bi000015+; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Eckley DM, 1999, J CELL BIOL, V147, P307, DOI 10.1083/jcb.147.2.307; EILERS U, 1989, J CELL BIOL, V108, P13, DOI 10.1083/jcb.108.1.13; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Forbes JR, 2000, HUM MOL GENET, V9, P1927, DOI 10.1093/hmg/9.13.1927; Garces JA, 1999, CURR BIOL, V9, P1497, DOI 10.1016/S0960-9822(00)80122-0; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gitlin JD, 2003, GASTROENTEROLOGY, V125, P1868, DOI 10.1053/j.gastro.2003.05.010; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; Greenough M, 2004, AM J PHYSIOL-CELL PH, V287, pC1463, DOI 10.1152/ajpcell.00179.2004; Guo Y, 2005, AM J PHYSIOL-GASTR L, V289, pG904, DOI 10.1152/ajpgi.00262.2005; Hamza I, 2003, P NATL ACAD SCI USA, V100, P1215, DOI 10.1073/pnas.0336230100; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARADA M, 1993, HEPATOLOGY, V17, P111, DOI 10.1016/0270-9139(93)90200-7; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Huster D, 2003, J BIOL CHEM, V278, P32212, DOI 10.1074/jbc.M305408200; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 2000, J BIOL CHEM, V275, P4834, DOI 10.1074/jbc.275.7.4834; Ke BX, 2006, AM J PHYSIOL-REG I, V290, pR1460, DOI 10.1152/ajpregu.00806.2005; Kim BE, 2002, J BIOL CHEM, V277, P44079, DOI 10.1074/jbc.M208737200; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; La Fontaine S, 1998, J BIOL CHEM, V273, P31375; La Fontaine S, 2001, HUM MOL GENET, V10, P361, DOI 10.1093/hmg/10.4.361; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Lee IH, 2001, MOL BIOL CELL, V12, P2195, DOI 10.1091/mbc.12.7.2195; Lindenbaum P, 2002, LIBRARY, V3, P32, DOI 10.1093/library/3.1.32; Linder MC, 1996, AM J CLIN NUTR, V63, P797; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Mercer JFB, 2003, BIOMETALS, V16, P175, DOI 10.1023/A:1020719016675; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; MURATA Y, 1995, BIOCHEM BIOPH RES CO, V209, P349, DOI 10.1006/bbrc.1995.1510; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Scriver C. R., 2001, METABOLIC MOL BASES, V2, P3105; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Strausak D, 2003, J BIOL CHEM, V278, P20821, DOI 10.1074/jbc.M212437200; TAO TY, 1993, J BIOL CHEM, V278, P415; Vallee RB, 2003, NATURE, V421, P701, DOI 10.1038/421701a; van de Sluis B, 2002, HUM MOL GENET, V11, P165, DOI 10.1093/hmg/11.2.165; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; Welte MA, 2004, CURR BIOL, V14, pR525, DOI 10.1016/j.cub.2004.06.045	64	48	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14006	14014		10.1074/jbc.M512745200	http://dx.doi.org/10.1074/jbc.M512745200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16554302	hybrid, Green Published			2022-12-25	WOS:000237512300023
J	Chen, C; Saxena, AK; Simcoke, WN; Garboczi, DN; Pedersen, PL; Ko, YH				Chen, C; Saxena, AK; Simcoke, WN; Garboczi, DN; Pedersen, PL; Ko, YH			Mitochondrial ATP synthase - Crystal structure of the catalytic F-1 unit in a vanadate-induced transition-like state and implications for mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; MYOSIN MOTOR DOMAIN; ADENOSINE-TRIPHOSPHATASE; LIVER MITOCHONDRIA; CHEMICAL MECHANISM; P-I; COMPLEX; PROTEIN; ADP; PURIFICATION	ATP synthesis from ADP, P-i, and Mg2+ takes place in mitochondria on the catalytic F-1 unit (alpha 3 beta 3 gamma delta epsilon) of the ATP synthase complex ( F0F1), a remarkable nanomachine that interconverts electrochemical and mechanical energy, producing the high energy terminal bond of ATP. In currently available structural models of F1, the P- loop ( amino acid residues (156)GGAGVGKT(163)) contributes to substrate binding at the beta subunit catalytic sites. Here, we report the first transition state- like structure of F-1 ( ADP center dot V-i center dot Mg center dot F-1) from rat liver that was crystallized with the phosphate ( Pi) analog vanadate ( VO43- or V-i). Compared with earlier " ground state" structures, this new F1 structure reveals that the active site region has undergone significant remodeling. P- loop residue alanine 158 is located much closer to Vi than it is to Pi in a previous structural model. No significant movements of P- loop residues of the alpha subunit were observed at its analogous but noncatalytic sites. Under physiological conditions, such active site remodeling involving the small hydrophobic alanine residue may promote ATP synthesis by lowering the local dielectric constant, thus facilitating the dehydration of ADP and Pi. This new crystallographic study provides strong support for the catalytic mechanism of ATP synthesis deduced from earlier biochemical studies of liver F-1 conducted in the presence of V-i.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; NIAID, Immunogenet Lab, Struct Biol Sect, NIH, Rockville, MD 20852 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	ppederse@jhmi.edu			NCI NIH HHS [CA010951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA010951, R01CA010951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison WS, 2000, J BIOENERG BIOMEMBR, V32, P531, DOI 10.1023/A:1005677310791; AMZEL LM, 1978, J BIOL CHEM, V253, P2067; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BRAIG K, 2000, STRUCTURE, V15, P567; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchanan SK, 1996, BIOCHEM J, V318, P343, DOI 10.1042/bj3180343; CATTERAL.WA, 1973, J BIOL CHEM, V248, P7427; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; Chen C, 2004, J BIOL CHEM, V279, P31761, DOI 10.1074/jbc.M401353200; COLLINSON IR, 1994, J MOL BIOL, V242, P408; CREMO CR, 1989, J BIOL CHEM, V264, P6608; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Golden TR, 1998, BIOCHEMISTRY-US, V37, P13871, DOI 10.1021/bi981120a; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Ko YH, 1999, J BIOL CHEM, V274, P28853, DOI 10.1074/jbc.274.41.28853; Ko YH, 1997, J BIOL CHEM, V272, P18875, DOI 10.1074/jbc.272.30.18875; Ko YH, 2000, J BIOL CHEM, V275, P32931, DOI 10.1074/jbc.M004453200; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEDERSEN PL, 1981, J BIOL CHEM, V256, P1362; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P423, DOI 10.1023/A:1005652605340; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; PUYOU AG, 1986, EUR J BIOCHEM, V159, P133, DOI 10.1111/j.1432-1033.1986.tb09843.x; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; TENNER JJ, 1997, CELL, V89, P251; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127	38	45	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13777	13783		10.1074/jbc.M513369200	http://dx.doi.org/10.1074/jbc.M513369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531409	hybrid			2022-12-25	WOS:000237336600088
J	Kang, HJ; Kim, HJ; Rih, JK; Mattson, TL; Kim, KW; Cho, CH; Isaacs, JS; Bae, I				Kang, HJ; Kim, HJ; Rih, JK; Mattson, TL; Kim, KW; Cho, CH; Isaacs, JS; Bae, I			BRCA1 plays a role in the hypoxic response by regulating HIF-1 alpha stability and by modulating vascular endothelial growth factor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; TRANSCRIPTIONAL COACTIVATORS; TUMOR ANGIOGENESIS; GENE-EXPRESSION; OVARIAN-CANCER; BREAST; ACTIVATION; PROTEIN; INHIBITION; MUTATIONS	A recent study of breast cancer patients with and without BRCA1 gene mutations found significantly lower levels of VEGF in serum from patients with BRCA1 mutations (Tarnowski, B., Chudecka-Glaz, A., Gorski, B., and Rzepka-Gorska, I. (2004) Breast Cancer Res. Treat. 88, 287-288). Here, we describe a possible mechanistic explanation for this correlation. Because hypoxia in tumors stimulates VEGF expression and secretion we hypothesized that altered BRCA1 protein levels in breast tumors could affect hypoxia-stimulated VEGF promoter activity. This possibility was tested in cells transfected with various combinations of expression plasmids for BRCA1, BRCA1 specific inhibitory RNAs (BRCA1-siRNAs), HIF-1 alpha, and a VEGF promoter-reporter and then incubated in normoxia (21%, O-2) or hypoxia (0.1%, O-2). As predicted, increased BRCA1 levels enhanced both hypoxia-stimulated VEGF promoter activity and the amounts of VEGF mRNA, as determined by semiquantitative RT-PCR and quantitative real time PCR. Using the ChIP assay, we discovered that BRCA1 could be recruited to the endogenous human VEGF promoter along with HIF-1 alpha following hypoxia. An interaction between BRCA1 and HIF-1 alpha was found in human breast cancer cells. We also found that hypoxia-stimulated VEGF promoter activity and secretion was reduced in cells containing reduced amounts of endogenous BRCA1 protein (obtained by transfecting with BRCA1 siRNAs). A mechanistic explanation for these effects is provided by our finding a reduced half-life and reduced accumulation of HIF-1 alpha in hypoxic cells transfected with BRCA1-siRNAs and that proteasome inhibitors blocked these effects of BRCA1-siRNAs. Thus, our results suggest that normal amounts of BRCA1 function in hypoxia to regulate HIF-1 alpha stability, probably by interacting with HIF-1 alpha.	Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Seoul Natl Univ, Pharmaceut Sci Res Inst, Div Pharmaceut Biosci, Coll Pharm, Seoul 135725, South Korea; Keimyung Univ, Sch Med, Dept Obstet & Gynecol, Taegu 700712, South Korea; Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA	Georgetown University; Seoul National University (SNU); Keimyung University; Medical University of South Carolina	Bae, I (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd,NW, Washington, DC 20057 USA.	ib42@georgetown.edu			PHS HHS [E014440-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abeliovich D, 1997, AM J HUM GENET, V60, P505; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; [Anonymous], 2003, NAT CELL BIOL, V5, P489, DOI 10.1038/ncb0603-490; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bachelder RE, 2001, CANCER RES, V61, P5736; Bae I, 2004, CANCER RES, V64, P7893, DOI 10.1158/0008-5472.CAN-04-1119; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Beischlag TV, 2004, J BIOL CHEM, V279, P54620, DOI 10.1074/jbc.M410456200; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; DACHS GU, 2003, METH MOLEC MED, V90, P371; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fodor FH, 1998, AM J HUM GENET, V63, P45, DOI 10.1086/301903; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hesling C, 2004, J INVEST DERMATOL, V122, P369, DOI 10.1046/j.0022-202X.2004.22212.x; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kranz A, 1999, INT J CANCER, V84, P293, DOI 10.1002/(SICI)1097-0215(19990621)84:3<293::AID-IJC16>3.0.CO;2-T; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lynch BJ, 1998, HUM PATHOL, V29, P1140, DOI 10.1016/S0046-8177(98)90427-0; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tarnowski B, 2004, BREAST CANCER RES TR, V88, P287, DOI 10.1007/s10549-004-0779-0; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; VAUPEL P, 1991, CANCER RES, V51, P3316; Vujaskovic Z, 2003, INT J HYPERTHER, V19, P498, DOI 10.1080/0265673031000121517; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu JW, 2005, ENDOCRINOLOGY, V146, P2031, DOI 10.1210/en.2004-0409; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yoo YG, 2004, J BIOL CHEM, V279, P53365, DOI 10.1074/jbc.M408554200; Yoshiji H, 1997, CANCER RES, V57, P3924; Yoshiji H, 1996, CANCER RES, V56, P2013; Yudoh K, 2005, ARTHRITIS RES THER, V7, pR904, DOI 10.1186/ar1765	55	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13047	13056		10.1074/jbc.M513033200	http://dx.doi.org/10.1074/jbc.M513033200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543242	hybrid, Green Published			2022-12-25	WOS:000237336600008
J	Cox, JM; Abbott, SN; Chitteni-Pattu, S; Inman, RB; Cox, MM				Cox, JM; Abbott, SN; Chitteni-Pattu, S; Inman, RB; Cox, MM			Complementation of one RecA protein point mutation by another - Evidence for trans catalysis of ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; CRYSTAL-STRUCTURE; REPLICATION FORKS; BRANCH MIGRATION; BINDING-PROTEIN; IN-VIVO; HELICASE; MECHANISM; RUVB; COMPLEXES	The RecA residues Lys248 and Glu96 are closely opposed across the RecA subunit-subunit interface in some recent models of the RecA nucleoprotein filament. The K248R and E96D single mutant proteins of the Escherichia coli RecA protein each bind to DNA and form nucleoprotein filaments but do not hydrolyze ATP or dATP. A mixture of K248R and E96D single mutant proteins restores dATP hydrolysis to 25% of the wild type rate, with maximum restoration seen when the proteins are present in a 1: 1 ratio. The K248R/E96D double mutant RecA protein also hydrolyzes ATP and dATP at rates up to 10-fold higher than either single mutant, although at a reduced rate compared with the wild type protein. Thus, the K248R mutation partially complements the inactive E96D mutation and vice versa. The complementation is not sufficient to allow DNA strand exchange. The K248R and E96D mutations originate from opposite sides of the subunit-subunit interface. The functional complementation suggests that Lys248 plays a significant role in ATP hydrolysis in trans across the subunit-subunit interface in the RecA nucleoprotein filament. This could be part of a mechanism for the long range coordination of hydrolytic cycles between subunits within the RecA filament.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NIGMS NIH HHS [GM52725] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Campbell MJ, 1999, J MOL BIOL, V286, P437, DOI 10.1006/jmbi.1998.2457; Campbell MJ, 1999, J MOL BIOL, V286, P417, DOI 10.1006/jmbi.1998.2456; Conway AB, 2004, NAT STRUCT MOL BIOL, V11, P791, DOI 10.1038/nsmb795; Cox JM, 2005, PLOS BIOL, V3, P231, DOI 10.1371/journal.pbio.0030052; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Crampton DJ, 2004, P NATL ACAD SCI USA, V101, P4373, DOI 10.1073/pnas.0400968101; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; Hishida T, 2004, P NATL ACAD SCI USA, V101, P9573, DOI 10.1073/pnas.0403584101; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; Leipe DD, 2000, GENOME RES, V10, P5; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; NGUYEN TT, 1993, J BIOL CHEM, V268, P3107; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Robu ME, 2004, J BIOL CHEM, V279, P10973, DOI 10.1074/jbc.M312184200; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Schlacher K, 2005, MOL CELL, V17, P561, DOI 10.1016/j.molcel.2005.01.006; Schnos M, 2000, MOL BIOTECHNOL, V16, P77, DOI 10.1385/MB:16:1:77; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; Wu Y, 2004, MOL CELL, V15, P423, DOI 10.1016/j.molcel.2004.07.014; Yamada K, 2001, P NATL ACAD SCI USA, V98, P1442, DOI 10.1073/pnas.031470598; Ye JQ, 2004, BBA-BIOENERGETICS, V1659, P1, DOI 10.1016/j.bbabio.2004.06.003	36	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12968	12975		10.1074/jbc.M513736200	http://dx.doi.org/10.1074/jbc.M513736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527806	hybrid			2022-12-25	WOS:000237134700092
J	Duan, HO; Simpson-Haidaris, PJ				Duan, HO; Simpson-Haidaris, PJ			Cell type-specific differential induction of the human gamma-fibrinogen promoter by interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; LUNG EPITHELIAL-CELLS; B MESSENGER-RNA; GENE-EXPRESSION; CARCINOMA-CELLS; STAT3; PROTEIN; DEXAMETHASONE; TRANSCRIPTION; ACTIVATION	During an acute phase response, interleukin-6 (IL-6) and glucocorticoids up-regulate expression of the three fibrinogen (FBG) genes (fga, fgb, and fgg) in liver and lung epithelium; however, little constitutive lung expression occurs. Recently, we showed that the magnitude of Stat3 binding to three IL-6 motifs on the human gamma FBG promoter correlates negatively with their functional activity in hepatocytes, although these cis-elements are critical for promoter activity. We determined the role of IL-6-receptor-gp130-Stat3 signaling in IL-6 activation of the gamma FBG promoter in liver and lung epithelial cells. Although IL-6 induced gamma FBG promoter activity similar to 30-fold in HepG2 cells, it was increased only 2-fold in lung A549 cells. Equivalent production of gp130 was demonstrated in both cell types by Western blotting; however, lower production of both IL-6-receptor and Stat3 explains, in part, reduced activity of the gamma FBG promoter in lung cells. Dexamethasone potentiated IL-6 induction of the gamma FBG promoter 2.3-fold in both HepG2 and A549 cells for a combined increase in promoter activity of 70-fold or 4.5-fold, respectively. Dexamethasone potentiation is likely due to the induction of IL-6-receptor expression as well as prolonged intensity and duration of Stat3 activation. By circumventing IL-6-receptor-gp130-coupled signaling with ectopic expression of the granulocyte colony-stimulating factor receptor (GCSFR)-gp130(133) chimeric receptor, overexpression of Stat3 induced gamma FBG promoter activity similar to 30-fold in A549 cells. Together, the data suggest tissue-specific differences in IL-6-receptor-gp130-coupled signaling, thereby limiting the extent of Stat3 activation and gamma FBG expression during lung inflammation.	Univ Rochester, Sch Med & Dent, Dept Med, Div Hematol Oncol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Simpson-Haidaris, PJ (corresponding author), Univ Rochester, Sch Med & Dent, Dept Med, Div Hematol Oncol, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.	pj_simpsonhaidaris@urmc.rochester.edu		, PJ/0000-0003-2778-2500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL50616, P01-HL30616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Asselta R, 1998, THROMB HAEMOSTASIS, V79, P1144, DOI 10.1055/s-0037-1615031; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BINI A, 2000, ENCY REFERENCE VASCU, P107; Bode JG, 2001, J IMMUNOL, V167, P1469, DOI 10.4049/jimmunol.167.3.1469; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; DAUER DJ, 2005, ONCOGENE, V28, P28; Dentener MA, 2000, AM J RESP CELL MOL, V23, P146, DOI 10.1165/ajrcmb.23.2.3855; DONALDSON DJ, 1989, J CELL SCI, V94, P101; Duan HO, 2003, J BIOL CHEM, V278, P41270, DOI 10.1074/jbc.M304210200; GRAY AJ, 1993, J CELL SCI, V104, P409; Guadiz G, 1997, AM J RESP CELL MOL, V17, P60, DOI 10.1165/ajrcmb.17.1.2730; Guadiz G, 1997, BLOOD, V90, P2644, DOI 10.1182/blood.V90.7.2644.2644_2644_2653; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HUBER P, 1990, J BIOL CHEM, V265, P5695; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; Lawrence SO, 2004, THROMB HAEMOSTASIS, V92, P234, DOI 10.1160/TH04-01-0024; Lee SY, 1996, THROMB HAEMOSTASIS, V75, P466; Lerner L, 2003, GENE DEV, V17, P2564, DOI 10.1101/gad.1135003; MOLMENTI EP, 1993, J CLIN INVEST, V92, P2022, DOI 10.1172/JCI116797; Nguyen MDT, 2000, AM J RESP CELL MOL, V22, P209, DOI 10.1165/ajrcmb.22.2.3746; Odrljin TM, 1996, BBA-PROTEIN STRUCT M, V1298, P69, DOI 10.1016/S0167-4838(96)00090-8; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; PARROTT JA, 1993, ENDOCRINOLOGY, V133, P1645, DOI 10.1210/en.133.4.1645; PHELPS DS, 1991, AM J PHYSIOL, V260, pL146, DOI 10.1152/ajplung.1991.260.2.L146; Ramin SM, 2004, AM J OBSTET GYNECOL, V190, P952, DOI 10.1016/j.ajog.2004.01.015; Rubenstein NM, 2003, J BIOL CHEM, V278, P10353, DOI 10.1074/jbc.M213121200; Rybarczyk BJ, 2003, BLOOD, V102, P4035, DOI 10.1182/blood-2003-03-0822; Rybarczyk BJ, 2000, CANCER RES, V60, P2033; Severgnini M, 2004, AM J PHYSIOL-LUNG C, V286, pL1282, DOI 10.1152/ajplung.00349.2003; Shi RJ, 1998, INFECT IMMUN, V66, P1070, DOI 10.1128/IAI.66.3.1070-1075.1998; Simpson-Haidaris PJ, 1998, INFECT IMMUN, V66, P4431; SimpsonHaidaris PJ, 1995, GENE, V167, P273, DOI 10.1016/0378-1119(95)00679-6; SIMPSONHAIDARIS PJ, 1990, BLOOD COAGUL FIBRIN, V1, P433; SIMPSONHAIDARIS PJ, 1997, BLOOD, V89, P873; Sloboda DM, 2005, CURR PHARM DESIGN, V11, P1459, DOI 10.2174/1381612053507873; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; Solito E, 1998, CYTOKINE, V10, P514, DOI 10.1006/cyto.1997.0325; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yan C, 2002, J BIOL CHEM, V277, P10967, DOI 10.1074/jbc.M109986200; YANG FM, 1995, LAB INVEST, V73, P433; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	50	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12451	12457		10.1074/jbc.M600294200	http://dx.doi.org/10.1074/jbc.M600294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524883	hybrid			2022-12-25	WOS:000237134700032
J	Koo, BH; Longpre, JM; Somerville, RPT; Alexander, JP; Leduc, R; Apteo, SS				Koo, BH; Longpre, JM; Somerville, RPT; Alexander, JP; Leduc, R; Apteo, SS			Cell-surface processing of pro-ADAMTS9 by furin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAMTS FAMILY; INTRACELLULAR MATURATION; CAENORHABDITIS-ELEGANS; PROPROTEIN CONVERTASES; EXTRACELLULAR-MATRIX; PRECURSOR PROTEINS; SECRETORY PATHWAY; PLASMA-MEMBRANE; METALLOPROTEASE; ACTIVATION	Processing of polypeptide precursors by proprotein convertases (PCs) such as furin typically occurs within the trans-Golgi network. Here, we show in a variety of cell types that the propeptide of ADAMTS9 is not excised intracellularly. Pulse-chase analysis in HEK293F cells indicated that the intact zymogen was secreted to the cell surface and was subsequently processed there before release into the medium. The processing occurred via a furin-dependent mechanism as shown using PC inhibitors, lack of processing in furin-deficient cells, and rescue by furin in these cells. Moreover, down-regulation of furin by small interference RNA reduced ADAMTS9 processing in HEK293F cells. PC5A could also process pro-ADAMTS9, but similarly to furin, processed forms were absent intracellularly. Cell-surface, furin-dependent processing of pro-ADAMTS9 creates a precedent for extracellular maturation of endogenously produced secreted proproteins. It also indicates the existence of a variety of mechanisms for processing of ADAMTS proteases.	Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Orthopaed Res Ctr, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada; Triple Point Biol, Portland, OR 97116 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Sherbrooke	Apteo, SS (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.	aptes@ccf.org		Apte, Suneel/0000-0001-8441-1226	NIAMS NIH HHS [AR49930] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR049930, R01AR049930] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; Arner EC, 2002, CURR OPIN PHARMACOL, V2, P322, DOI 10.1016/S1471-4892(02)00148-0; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; Cao Y, 2002, J BIOL CHEM, V277, P26403, DOI 10.1074/jbc.M110814200; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Dagoneau N, 2004, AM J HUM GENET, V75, P801, DOI 10.1086/425231; Demircan K, 2005, ARTHRITIS RHEUM-US, V52, P1451, DOI 10.1002/art.21010; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; Dufour EK, 1998, FEBS LETT, V426, P41, DOI 10.1016/S0014-5793(98)00307-X; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Huxley-Jones J, 2005, INT J BIOCHEM CELL B, V37, P1838, DOI 10.1016/j.biocel.2005.03.009; Jungers KA, 2005, GENE EXPR PATTERNS, V5, P609, DOI 10.1016/j.modgep.2005.03.004; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; LEDUC R, 1992, J BIOL CHEM, V267, P14304; Leonard JD, 2005, BIOCHEM J, V387, P797, DOI 10.1042/BJ20041727; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Llamazares M, 2003, J BIOL CHEM, V278, P13382, DOI 10.1074/jbc.M211900200; Longpre JM, 2004, J BIOL CHEM, V279, P33237, DOI 10.1074/jbc.M313151200; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Mayer G, 2004, J HISTOCHEM CYTOCHEM, V52, P567, DOI 10.1177/002215540405200502; Mayer G, 2003, J CELL SCI, V116, P1763, DOI 10.1242/jcs.00394; MILEWICZ DM, 1995, J CLIN INVEST, V95, P2373, DOI 10.1172/JCI117930; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Rao C, 2003, DEVELOPMENT, V130, P4665, DOI 10.1242/dev.00668; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Somerville RPT, 2004, J BIOL CHEM, V279, P51208, DOI 10.1074/jbc.M409036200; Somerville RPT, 2004, J BIOL CHEM, V279, P35159, DOI 10.1074/jbc.M402380200; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Tsuji A, 2003, BBA-PROTEINS PROTEOM, V1645, P95, DOI 10.1016/S1570-9639(02)00532-0; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zheng M, 1997, DEV BIOL, V181, P268, DOI 10.1006/dbio.1996.8402; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	47	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12485	12494		10.1074/jbc.M511083200	http://dx.doi.org/10.1074/jbc.M511083200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16537537	hybrid			2022-12-25	WOS:000237134700036
J	Jacquard, C; Trioulier, Y; Cosker, F; Escartin, C; Bizat, N; Hantraye, P; Cancela, JM; Bonvento, G; Brouillet, E				Jacquard, Carine; Trioulier, Yael; Cosker, Francois; Escartin, Carole; Bizat, Nicolas; Hantraye, Philippe; Cancela, Jose Manuel; Bonvento, Gilles; Brouillet, Emmanuel			Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation	FASEB JOURNAL			English	Article						3-nitropropionic acid; calpain; striatum; Huntington's disease	D-ASPARTATE RECEPTOR; HUNTINGTONS-DISEASE; SUCCINATE-DEHYDROGENASE; 3-NITROPROPIONIC ACID; COMPLEX-II; PERMEABILITY TRANSITION; STRIATAL DEGENERATION; CALCIUM ACCUMULATION; NEURONAL DEATH; IN-VIVO	According to the "indirect" excitotoxicity hypothesis, mitochondrial defects increase Ca2+ entry into neurons by rendering NMDA-R hypersensitive to glutamate. We tested this hypothesis by investigating in the rat striatum and cultured striatal cells how partial mitochondrial complex II inhibition produced by 3-nitropropionic acid (3NP) modifies the toxicity of the NMDA-R agonist quinolinate (QA). We showed that nontoxic 3NP treatment, leading to partial inhibition of complex II activity, greatly exacerbated striatal degeneration produced by slightly toxic QA treatment through an "all-or-nothing" process. The potentiation of QA-induced cell death by 3NP was associated with increased calpain activity and massive calpain-mediated cleavage of several postsynaptic proteins, suggesting major neuronal Ca2+ deregulation in the striatum. However, Ca2+ anomalies probably do not result from NMDA-R hypersensitivity. Indeed, brain imaging experiments using [F-18] fluorodeoxyglucose indirectly showed that 3NP did not increase QA-induced ionic perturbations at the striatal glutamatergic synapses in vivo. Consistent with this, the exacerbation of QA toxicity by 3NP was not related to an increase in the QA-induced entry of Ca-45(2+) into striatal neurons. The present results demonstrate that the potentiation of NMDA-R-mediated excitotoxicity by mitochondrial defects involves primarily intracellular Ca2+ deregulation, in the absence of NMDA-R hypersensitivity.	CEA, CNRS, URA 2210, Serv Hosp Frederic Joliot,DRM,DSV, F-91401 Orsay, France; CNRS, Lab Neurobiol Cellulaire & Mol, UPR 9040, Gif Sur Yvette, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Brouillet, E (corresponding author), CEA, CNRS, URA 2210, Serv Hosp Frederic Joliot,DRM,DSV, 4 Pl Gen Leclerc, F-91401 Orsay, France.	brouille@shfj.cea.fr	Brouillet, Emmanuel/B-4784-2014; Bonvento, Gilles/F-6023-2013; Escartin, Carole/A-1952-2010	Brouillet, Emmanuel/0000-0001-6322-7403; Bonvento, Gilles/0000-0002-2886-4228; Escartin, Carole/0000-0003-3613-4118; Cancela, Jose-Manuel/0000-0002-6234-1500; Jacquard, Carine/0000-0003-0972-8455				ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; Alexi T, 1998, EXP NEUROL, V153, P74, DOI 10.1006/exnr.1998.6842; ALSTON TA, 1977, P NATL ACAD SCI USA, V74, P3767, DOI 10.1073/pnas.74.9.3767; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Beal M F, 1992, Curr Opin Neurobiol, V2, P657, DOI 10.1016/0959-4388(92)90035-J; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; BEAL MF, 1992, FASEB J, V6, P3338, DOI 10.1096/fasebj.6.15.1464368; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bezprozvanny I, 2004, BIOCHEM BIOPH RES CO, V322, P1310, DOI 10.1016/j.bbrc.2004.08.035; Bizat N, 2003, J NEUROSCI, V23, P5020; Blum D, 2003, J NEUROSCI, V23, P5361; Bonvento G, 2002, TRENDS NEUROSCI, V25, P359, DOI 10.1016/S0166-2236(02)02168-9; Bordelon YM, 1998, NEUROSCIENCE, V83, P459, DOI 10.1016/S0306-4522(97)00421-1; Brouillet E, 1998, J NEUROCHEM, V70, P794; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Brustovetsky N, 2000, J NEUROSCI, V20, P103, DOI 10.1523/JNEUROSCI.20-01-00103.2000; Calabresi P, 2001, J NEUROSCI, V21, P5110, DOI 10.1523/JNEUROSCI.21-14-05110.2001; Cepeda C, 2001, J NEUROSCI RES, V66, P525, DOI 10.1002/jnr.1244; Choo YS, 2004, HUM MOL GENET, V13, P1407, DOI 10.1093/hmg/ddh162; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; COLES CJ, 1979, J BIOL CHEM, V254, P5161; Dautry W, 2000, J CEREBR BLOOD F MET, V20, P789, DOI 10.1097/00004647-200005000-00005; EIMERL S, 1994, J NEUROCHEM, V62, P1223; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Galas MC, 2004, NEUROBIOL DIS, V15, P152, DOI 10.1016/j.nbd.2003.09.013; Greene JG, 1998, NEUROSCIENCE, V84, P503, DOI 10.1016/S0306-4522(97)00389-8; GREENE JG, 1995, J NEUROCHEM, V64, P430; Greene JG, 1996, PROG NEUROBIOL, V48, P613, DOI 10.1016/0301-0082(96)00006-8; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Laforet GA, 2001, J NEUROSCI, V21, P9112, DOI 10.1523/JNEUROSCI.21-23-09112.2001; LUST WD, 1981, ANAL BIOCHEM, V110, P258, DOI 10.1016/0003-2697(81)90144-5; Maciel EN, 2004, J NEUROCHEM, V90, P1025, DOI 10.1111/j.1471-4159.2004.02565.x; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; Nasr P, 2003, NEUROCHEM INT, V43, P89, DOI 10.1016/S0197-0186(02)00229-2; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; RIDDLE D, 1992, J NEUROSCI, V12, P3509; Saulle E, 2004, MOL CELL NEUROSCI, V25, P9, DOI 10.1016/j.mcn.2003.09.013; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; SIMPSON JR, 1993, EXP NEUROL, V121, P57, DOI 10.1006/exnr.1993.1071; Song C, 2003, J BIOL CHEM, V278, P33364, DOI 10.1074/jbc.M304240200; Sun Y, 2001, J BIOL CHEM, V276, P24713, DOI 10.1074/jbc.M103501200; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Ward MW, 2005, J NEUROCHEM, V92, P1081, DOI 10.1111/j.1471-4159.2004.02928.x; WELLISZ T, 1993, J LONG-TERM EFF MED, V3, P223; White RJ, 1996, J NEUROSCI, V16, P5688; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3	60	51	53	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					1021	+		10.1096/fj.05-5085fje	http://dx.doi.org/10.1096/fj.05-5085fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571773				2022-12-25	WOS:000240157700042
J	Zhang, HY; Sawashita, J; Fu, XY; Korenaga, T; Yan, JM; Mori, M; Higuchi, K				Zhang, Huanyu; Sawashita, Jinko; Fu, Xiaoying; Korenaga, Tatsumi; Yan, Jingmin; Mori, Masayuki; Higuchi, Keiichi			Transmissibility of mouse AApoAII amyloid fibrils: inactivation by physical and chemical methods	FASEB JOURNAL			English	Article						amyloidosis; disruption; organic compounds	PRION PROTEIN; CONFORMATIONAL TRANSITIONS; NORDIHYDROGUAIARETIC ACID; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; BETA PROTEIN; IN-VITRO; APOLIPOPROTEIN; TETRACYCLINES; AGGREGATION	AApoAII amyloid fibrils have exhibited prion-like transmissibility in mouse senile amyloidosis. We have demonstrated that AApoAII is extremely active and can induce amyloidosis following doses less than 1 pg. We tested physical and chemical methods to disrupt AApoAII fibrils in vitro as determined by thioflavin T binding and electron microscopy (EM) as well as inactivating the transmissibility of AApoAII fibrils in vivo. Complete disruption of AApoAII fibrils was achieved by treatment with formic acid, 6 M guanidine hydrochloride, and autoclaving in an alkaline solution. Injection of these disrupted AApoAII fibrils did not induce amyloidosis in mice. Disaggregation with 6 M urea, autoclaving, and alkaline solution was incomplete, and injection of these AApoAII fibrils induced mild amyloidosis. Treatment with formalin, delipidation, freeze-thaw, and RNase did not have any major effect. A distinct correlation was obtained between the amounts of amyloid fibrils and the transmissibility of amyloid fibrils, thereby indicating the essential role of fibril conformation for transmission of amyloidosis. We also studied the inactivation of AApoAII fibrils by several organic compounds in vitro and in vivo. AApoAII amyloidosis provides a valuable system for studying factors that may prevent transmission of amyloid disease as well as potential novel therapies.	Shinshu Univ, Grad Sch Med, Dept Aging Biol, Inst Aging & Adaptat, Matsumoto, Nagano 3908621, Japan	Shinshu University	Higuchi, K (corresponding author), Shinshu Univ, Grad Sch Med, Dept Aging Biol, Inst Aging & Adaptat, Asahi 3-1-1, Matsumoto, Nagano 3908621, Japan.	khiguchi@sch.md.shinshu-u.ac.jp		Sawashita, Jinko/0000-0001-8016-6649				BAKER HF, 1994, MOL NEUROBIOL, V8, P25, DOI 10.1007/BF02778005; Ban T, 2003, J BIOL CHEM, V278, P16462, DOI 10.1074/jbc.C300049200; Benson MD, 2001, GENOMICS, V72, P272, DOI 10.1006/geno.2000.6499; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Bitan G, 2005, AMYLOID, V12, P88, DOI 10.1080/13506120500106958; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Botelho MG, 2003, J BIOL CHEM, V278, P34259, DOI 10.1074/jbc.M303189200; BROWN P, 1982, J INFECT DIS, V145, P683, DOI 10.1093/infdis/145.2.683; BROWN P, 1984, NEW ENGL J MED, V310, P727; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cardoso I, 2003, FASEB J, V17, P803, DOI 10.1096/fj.02-0764com; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Chiba T, 1999, AM J PATHOL, V155, P1319, DOI 10.1016/S0002-9440(10)65234-0; Cui D, 2002, PATHOL INT, V52, P40, DOI 10.1046/j.1440-1827.2002.01309.x; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Fichet G, 2004, LANCET, V364, P521, DOI 10.1016/S0140-6736(04)16810-4; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; Forloni G, 2002, P NATL ACAD SCI USA, V99, P10849, DOI 10.1073/pnas.162195499; Forloni G, 2001, FEBS LETT, V487, P404, DOI 10.1016/S0014-5793(00)02380-2; Fu XY, 2004, FEBS LETT, V563, P179, DOI 10.1016/S0014-5793(04)00295-9; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; HIGUCHI K, 1993, FEBS LETT, V317, P207, DOI 10.1016/0014-5793(93)81277-7; HIGUCHI K, 1995, LAB INVEST, V72, P75; Higuchi K, 1998, LAB INVEST, V78, P1535; HIGUCHI K, 1986, J BIOL CHEM, V261, P2834; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KLUNK WE, 1990, J NEUROCHEM, V54, P2050, DOI 10.1111/j.1471-4159.1990.tb04910.x; Lundmark K, 2002, P NATL ACAD SCI USA, V99, P6979, DOI 10.1073/pnas.092205999; May BCH, 2003, P NATL ACAD SCI USA, V100, P3416, DOI 10.1073/pnas.2627988100; McDonnell G, 2003, CLIN INFECT DIS, V36, P1152, DOI 10.1086/374668; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; Moss MA, 2004, MOL PHARMACOL, V66, P592; Naiki H, 1998, BIOCHEMISTRY-US, V37, P17882, DOI 10.1021/bi980550y; Ono K, 2003, J NEUROCHEM, V87, P172, DOI 10.1046/j.1471-4159.2003.01976.x; Ono K, 2002, J NEUROCHEM, V81, P434, DOI 10.1046/j.1471-4159.2002.00904.x; PRAS M, 1969, J EXP MED, V130, P777, DOI 10.1084/jem.130.4.777; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Sigurdsson EM, 2002, TRENDS MOL MED, V8, P411, DOI 10.1016/S1471-4914(02)02403-6; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Southwick PC, 1996, J NEUROCHEM, V66, P259; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Tomiyama T, 1996, J BIOL CHEM, V271, P6839, DOI 10.1074/jbc.271.12.6839; Vanderstichele H, 2000, AMYLOID, V7, P245, DOI 10.3109/13506120009146438; Westermark P, 2002, AMYLOID, V9, P197; Westermark P, 1998, AM J PATHOL, V152, P1125; Wickner RB, 1999, J BIOL CHEM, V274, P555, DOI 10.1074/jbc.274.2.555; Xing YM, 2002, J BIOL CHEM, V277, P33164, DOI 10.1074/jbc.M111570200; Xing YM, 2001, LAB INVEST, V81, P493, DOI 10.1038/labinvest.3780257; YONEZU T, 1986, FEBS LETT, V203, P149, DOI 10.1016/0014-5793(86)80732-3; Zerovnik E, 2002, EUR J BIOCHEM, V269, P3362, DOI 10.1046/j.1432-1033.2002.03024.x; Zobeley E, 1999, MOL MED, V5, P240, DOI 10.1007/BF03402121	55	22	22	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					1012	+		10.1096/fj.05-4890fje	http://dx.doi.org/10.1096/fj.05-4890fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16549653				2022-12-25	WOS:000240157700039
J	Thrash, BR; Menges, CW; Pierce, RH; McCance, DJ				Thrash, BR; Menges, CW; Pierce, RH; McCance, DJ			AKT1 provides an essential survival signal required for differentiation and stratification of primary human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; NF-KAPPA-B; EPITHELIAL-CELL DIFFERENTIATION; TERMINAL DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; EPIDERMAL-KERATINOCYTES; MICE LACKING; ACTIVATION; GROWTH; SKIN	Keratinocyte differentiation and stratification are complex processes involving multiple signaling pathways, which convert a basal proliferative cell into an inviable rigid squame. Loss of attachment to the basement membrane triggers keratinocyte differentiation, while in other epithelial cells, detachment from the extracellular matrix leads to rapid programmed cell death or anoikis. The potential role of AKT in providing a survival signal necessary for stratification and differentiation of primary human keratinocytes was investigated. AKT activity increased during keratinocyte differentiation and was attributed to the specific activation of AKT1 and AKT2. Targeted reduction of AKT1 expression, but not AKT2, by RNA interference resulted in an abnormal epidermis in organotypic skin cultures with a thin parabasal region and a pronounced but disorganized cornified layer. This abnormal stratification was due to significant cell death in the suprabasal layers and was alleviated by caspase inhibition. Normal expression patterns of both early and late markers of keratinocyte differentiation were also disrupted, producing a poorly developed stratum corneum.	Univ Rochester, Sch Med & Dent, James P Wilmont Canc Ctr, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	McCance, DJ (corresponding author), Univ Rochester, Sch Med & Dent, James P Wilmont Canc Ctr, 601 Elmwood Ave,Box 672, Rochester, NY 14642 USA.	dennis_mccance@urmc.rochester.edu		Pierce, MD, Robert Hamilton/0000-0002-2677-144X	NIAID NIH HHS [R01 AI 30798] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030798] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alibardi L, 2004, J HISTOCHEM CYTOCHEM, V52, P1561, DOI 10.1369/jhc.4A6300.2004; Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Calera MR, 1998, BIOCHEM BIOPH RES CO, V251, P835, DOI 10.1006/bbrc.1998.9566; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gandarillas A, 1999, EXP DERMATOL, V8, P71, DOI 10.1111/j.1600-0625.1999.tb00350.x; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kaneko S, 2002, J BIOL CHEM, V277, P23230, DOI 10.1074/jbc.M201733200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Mack JA, 2005, J BIOL CHEM, V280, P29904, DOI 10.1074/jbc.M505262200; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sayama K, 2002, J BIOL CHEM, V277, P40390, DOI 10.1074/jbc.M112423200; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Umeda J, 2003, FASEB J, V17, P610, DOI 10.1096/fj.02-0597com; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6	46	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12155	12162		10.1074/jbc.M512116200	http://dx.doi.org/10.1074/jbc.M512116200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16517604	hybrid			2022-12-25	WOS:000236988100085
J	Velazquez, F; Fernandez, S; de Lorenzo, V				Velazquez, F; Fernandez, S; de Lorenzo, V			The upstream-activating sequences of the sigma(54) promoter Pu of Pseudomonas putida filter transcription readthrough from upstream genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-INDEPENDENT TERMINATORS; COLI RNA-POLYMERASE; ENHANCER-BINDING PROTEIN; TOL PLASMID PWW0; ESCHERICHIA-COLI; PROKARYOTIC ENHANCER; PROMOTER PU; CONDITIONAL PHENOTYPES; NUCLEAR-ORGANIZATION; CATABOLIC OPERONS	Although the m-xylene-responsive sigma(54) promoter Pu of Pseudomonas putida mt-2, borne by the TOL plasmid pWWO, is one of the strongest known promoters in vivo, its base-line level in the absence of its aromatic inducer is below the limit of any detection procedure. This is unusual because regulatory networks ( such as the one to which Pu belongs) can hardly escape the noise caused by intrinsic fluctuations in background transcription, including that transmitted from upstream promoters. This study provides genetic evidence that the upstream-activating sequences (UAS), which serve as the binding sites for the pWW0-encoded XylR protein ( the m-xylene-responsive sigma(54)-dependent activator of Pu), isolate expression of the upper TOL genes from any adventitious transcriptional flow originating further upstream. An in vivo test system was developed in which different segments of the Pu promoter were examined for the inhibition of incoming transcription products from an upstream promoter in P. putida and Escherichia coli. Minimal transcription filter ability was located within a 105-bp fragment encompassing the UAS of Pu. Although S1 nuclease assays showed that the UAS prevented the buildup of downstream transcripts, the mechanism seems to diverge from a typical termination system. This was shown by the fact that the UAS did not halt transcription in vitro and that the filter effect could not be relieved by the anti-termination system of lambda phage. Because the Pu promoter lies adjacent to the edge of a transposon in pWW0, the preset transcriptional filter in the UAS may isolate the upper TOL operon from undue expression after random insertion of the mobile genetic element in a new replicon.	CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; CSIC, Inst Neurobiol Ramon & Cajal, Madrid 28002, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC)	de Lorenzo, V (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus UAM Cantoblanco, E-28049 Madrid, Spain.	vdlorenzo@cnb.uam.es		de Lorenzo, Victor/0000-0002-6041-2731				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; ADHYA S, 1974, P NATL ACAD SCI USA, V71, P2534, DOI 10.1073/pnas.71.6.2534; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Babu MM, 2004, CURR OPIN STRUC BIOL, V14, P283, DOI 10.1016/j.sbi.2004.05.004; Barrick JE, 2004, P NATL ACAD SCI USA, V101, P6421, DOI 10.1073/pnas.0308014101; Bertoni G, 1998, EMBO J, V17, P5120, DOI 10.1093/emboj/17.17.5120; Capelson M, 2004, BIOL CELL, V96, P617, DOI 10.1016/j.biolcel.2004.06.004; Carmona M, 1999, J BIOL CHEM, V274, P33790, DOI 10.1074/jbc.274.47.33790; Carmona M, 2005, J BACTERIOL, V187, P125, DOI 10.1128/JB.187.1.125-134.2005; Carpousis AJ, 2002, BIOCHEM SOC T, V30, P150, DOI 10.1042/bst0300150; Cases I, 2005, NAT REV MICROBIOL, V3, P105, DOI 10.1038/nrmicro1084; Cases I, 2003, ENVIRON MICROBIOL, V5, P1281, DOI 10.1111/j.1462-2920.2003.00528.x; Cases I, 1996, MOL MICROBIOL, V19, P7, DOI 10.1046/j.1365-2958.1996.345873.x; Cebolla A, 1996, APPL ENVIRON MICROB, V62, P214, DOI 10.1128/AEM.62.1.214-220.1996; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; DAS A, 1984, CELL, V38, P165, DOI 10.1016/0092-8674(84)90537-3; Delgado A, 1992, Microb Releases, V1, P23; deLorenzo V, 1996, MOL MICROBIOL, V19, P1177; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; DEVITO J, 1994, P NATL ACAD SCI USA, V91, P8660, DOI 10.1073/pnas.91.18.8660; Devos D, 2002, ENVIRON MICROBIOL, V4, P29, DOI 10.1046/j.1462-2920.2002.00265.x; DING QQ, 1995, MOL MICROBIOL, V16, P649, DOI 10.1111/j.1365-2958.1995.tb02427.x; DOMINGUEZCUEVAS P, 2006, J BIOL CHEM; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; Dworkin J, 1998, GENE DEV, V12, P894, DOI 10.1101/gad.12.6.894; ELLEDGE SJ, 1989, P NATL ACAD SCI USA, V86, P3689, DOI 10.1073/pnas.86.10.3689; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; Fraile S, 2001, J BACTERIOL, V183, P5571, DOI 10.1128/JB.183.19.5571-5579.2001; Garmendia J, 2000, MOL MICROBIOL, V38, P401, DOI 10.1046/j.1365-2958.2000.02139.x; Garmendia J, 2000, MICROBIOL-SGM, V146, P2555, DOI 10.1099/00221287-146-10-2555; Gerasimova TI, 2001, ANNU REV GENET, V35, P193, DOI 10.1146/annurev.genet.35.102401.090349; Geyer PK, 2002, CELL MOL LIFE SCI, V59, P2112, DOI 10.1007/s000180200011; Greated A, 2002, ENVIRON MICROBIOL, V4, P856, DOI 10.1046/j.1462-2920.2002.00305.x; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; HARAYAMA S, 1989, J BACTERIOL, V171, P5048, DOI 10.1128/jb.171.9.5048-5055.1989; Hooshangi S, 2005, P NATL ACAD SCI USA, V102, P3581, DOI 10.1073/pnas.0408507102; INGHAM CJ, 1995, NUCLEIC ACIDS RES, V23, P370, DOI 10.1093/nar/23.3.370; Jurado P, 2003, J BACTERIOL, V185, P3379, DOI 10.1128/JB.185.11.3379-3383.2003; KESSLER B, 1994, J BACTERIOL, V176, P3171, DOI 10.1128/jb.176.11.3171-3176.1994; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lai J, 2003, CURR OPIN NEUROBIOL, V13, P291, DOI 10.1016/S0959-4388(03)00074-6; Macchi R, 2003, J BIOL CHEM, V278, P27695, DOI 10.1074/jbc.M303031200; MACIAN F, 1994, GENE, V145, P17, DOI 10.1016/0378-1119(94)90317-4; MEIKLEJOHN AL, 1985, CELL, V43, P769, DOI 10.1016/0092-8674(85)90250-8; Moller S, 1998, APPL ENVIRON MICROB, V64, P721; Pedraza JM, 2005, SCIENCE, V307, P1965, DOI 10.1126/science.1109090; PerezMartin J, 1996, GENE, V172, P81, DOI 10.1016/0378-1119(96)00193-X; PerezMartin J, 1996, J MOL BIOL, V258, P562, DOI 10.1006/jmbi.1996.0269; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P7277, DOI 10.1073/pnas.92.16.7277; RAMOS JL, 1991, APPL ENVIRON MICROB, V57, P260, DOI 10.1128/AEM.57.1.260-266.1991; Ramos JL, 1997, ANNU REV MICROBIOL, V51, P341, DOI 10.1146/annurev.micro.51.1.341; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Rappas M, 2005, SCIENCE, V307, P1972, DOI 10.1126/science.1105932; Rauhut R, 1999, FEMS MICROBIOL REV, V23, P353, DOI 10.1016/S0168-6445(99)00012-1; Regenhardt D, 2002, ENVIRON MICROBIOL, V4, P912, DOI 10.1046/j.1462-2920.2002.00368.x; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RUIZ R, 2004, TRANSCRIPTIONAL REGU, P509; Rutberg B, 1997, MOL MICROBIOL, V23, P413, DOI 10.1046/j.1365-2958.1997.d01-1867.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Storz G, 2004, CURR OPIN MICROBIOL, V7, P140, DOI 10.1016/j.mib.2004.02.015; TAKIFF HE, 1989, J BACTERIOL, V171, P2581, DOI 10.1128/jb.171.5.2581-2590.1989; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Valls M, 2003, NUCLEIC ACIDS RES, V31, P6926, DOI 10.1093/nar/gkg912; Velazquez F, 2005, MOL MICROBIOL, V57, P1557, DOI 10.1111/j.1365-2958.2005.04787.x; Vilar JMG, 2005, CURR OPIN GENET DEV, V15, P136, DOI 10.1016/j.gde.2005.02.005; Wikstrom P, 2001, J MOL BIOL, V314, P971, DOI 10.1006/jmbi.2000.5212; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; WILSON KS, 1994, J MOL BIOL, V244, P36, DOI 10.1006/jmbi.1994.1702; Xia Y, 2004, ANNU REV BIOCHEM, V73, P1051, DOI 10.1146/annurev.biochem.73.011303.073950; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611; ZHENG CH, 1994, P NATL ACAD SCI USA, V91, P7543, DOI 10.1073/pnas.91.16.7543; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	80	4	5	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11940	11948		10.1074/jbc.M511782200	http://dx.doi.org/10.1074/jbc.M511782200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16510445	hybrid			2022-12-25	WOS:000236988100063
J	Choi, J; Sullards, MC; Olzmann, JA; Rees, HD; Weintraub, ST; Bostwick, DE; Gearing, M; Levey, AI; Chin, LS; Li, L				Choi, J; Sullards, MC; Olzmann, JA; Rees, HD; Weintraub, ST; Bostwick, DE; Gearing, M; Levey, AI; Chin, LS; Li, L			Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE OXIDATION; MODIFIED PROTEINS; NEURODEGENERATIVE DISORDERS; CRYSTAL-STRUCTURE; STRESS; MUTATIONS; L166P; IDENTIFICATION; CARBONYLATION; DYSFUNCTION	Mutations in DJ-1 cause an autosomal recessive, early onset familial form of Parkinson disease (PD). However, little is presently known about the role of DJ-1 in the more common sporadic form of PD and in other age-related neurodegenerative diseases, such as Alzheimer disease (AD). Here we report that DJ-1 is oxidatively damaged in the brains of patients with idiopathic PD and AD. By using a combination of two-dimensional gel electrophoresis and mass spectrometry, we have identified 10 different DJ-1 isoforms, of which the acidic isoforms (pI 5.5 and 5.7) of DJ-1 monomer and the basic isoforms (pI 8.0 and 8.4) of SDS-resistant DJ-1 dimer are selectively accumulated in PD and AD frontal cortex tissues compared with age-matched controls. Quantitative Western blot analysis shows that the total level of DJ-1 protein is significantly increased in PD and AD brains. Mass spectrometry analyses reveal that DJ-1 is not only susceptible to cysteine oxidation but also to previously unsuspected methionine oxidation. Furthermore, we show that DJ-1 protein is irreversibly oxidized by carbonylation as well as by methionine oxidation to methionine sulfone in PD and AD. Our study provides new insights into the oxidative modifications of DJ-1 and indicates association of oxidative damage to DJ-1 with sporadic PD and AD.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Georgia Inst Technol, Sch Chem & Biochem, Parker H Petit Inst Bioengn & Biosci, Bioanalyt Mass Spectrometry Facil, Atlanta, GA 30322 USA; Georgia Inst Technol, Sch Biol, Atlanta, GA 30322 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Emory University; Emory University; University System of Georgia; Georgia Institute of Technology; University System of Georgia; Georgia Institute of Technology; University of Texas System; University of Texas Health San Antonio	Li, L (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	lianli@pharm.emory.edu	Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X; Li, Lian/0000-0003-4700-1134; Olzmann, James/0000-0001-7751-8316; Chin, Lih-Shen/0000-0002-0817-0368	NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS054597, R01NS047199, R01NS050650, R01NS047575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG025688, R01AG021489] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA054174, CA54174] Funding Source: Medline; NIA NIH HHS [R01 AG021489, P50 AG025688, AG021489, AG025688] Funding Source: Medline; NINDS NIH HHS [R01 NS047575, NS047575, R01 NS047199, F31 NS054597, NS047199, F31 NS054597-01, NS050650, R01 NS050650, F31 NS054597-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abou-Sleiman PM, 2003, ANN NEUROL, V54, P283, DOI 10.1002/ana.10675; Bandopadhyay R, 2004, BRAIN, V127, P420, DOI 10.1093/brain/awh054; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Beardsley RL, 2002, ANAL CHEM, V74, P1884, DOI 10.1021/ac015613o; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Butterfield DA, 2003, AMINO ACIDS, V25, P419, DOI 10.1007/s00726-003-0027-7; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0; Chen LN, 2005, J BIOL CHEM, V280, P21418, DOI 10.1074/jbc.M413955200; Choi J, 2005, J BIOL CHEM, V280, P11648, DOI 10.1074/jbc.M414327200; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; Cordato DJ, 2004, J CLIN NEUROSCI, V11, P119, DOI 10.1016/j.jocn.2003.10.009; Dalle-Donne I, 2003, TRENDS MOL MED, V9, P169, DOI 10.1016/S1471-4914(03)00031-5; Dalle-Donne I, 2002, FREE RADICAL BIO MED, V32, P927, DOI 10.1016/S0891-5849(02)00799-2; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Goldberg MS, 2005, NEURON, V45, P489, DOI 10.1016/j.neuron.2005.01.041; Gorner K, 2004, J BIOL CHEM, V279, P6943, DOI 10.1074/jbc.M309204200; Gracy RW, 1999, MUTAT RES-FUND MOL M, V428, P17, DOI 10.1016/S1383-5742(99)00027-7; Hedrich K, 2004, ANN NEUROL, V55, P145, DOI 10.1002/ana.10816; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; Huai Q, 2003, FEBS LETT, V549, P171, DOI 10.1016/S0014-5793(03)00764-6; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jenner P, 2001, TRENDS NEUROSCI, V24, P245, DOI 10.1016/S0166-2236(00)01789-6; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; Kinumi T, 2004, BIOCHEM BIOPH RES CO, V317, P722, DOI 10.1016/j.bbrc.2004.03.110; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; Martinat C, 2004, PLOS BIOL, V2, P1754, DOI 10.1371/journal.pbio.0020327; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Moore DJ, 2005, HUM MOL GENET, V14, P71, DOI 10.1093/hmg/ddi007; Neumann M, 2004, ACTA NEUROPATHOL, V107, P489, DOI 10.1007/s00401-004-0834-2; Nishikawa K, 2003, BIOCHEM BIOPH RES CO, V304, P176, DOI 10.1016/S0006-291X(03)00555-2; Nystrom T, 2005, EMBO J, V24, P1311, DOI 10.1038/sj.emboj.7600599; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Pardo LM, 2005, MUTAT RES-FUND MOL M, V592, P89, DOI 10.1016/j.mrfmmm.2005.06.006; Rizzu P, 2004, ANN NEUROL, V55, P113, DOI 10.1002/ana.10782; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Stadtman ER, 2005, BBA-PROTEINS PROTEOM, V1703, P135, DOI 10.1016/j.bbapap.2004.08.010; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664	52	367	381	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10816	10824		10.1074/jbc.M509079200	http://dx.doi.org/10.1074/jbc.M509079200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16517609	Green Accepted, hybrid			2022-12-25	WOS:000236822200021
J	De Marco, N; Buono, M; Troise, F; Diez-Roux, G				De Marco, Nadia; Buono, Mario; Troise, Fulvia; Diez-Roux, Graciana			Optineurin increases cell survival and translocates to the nucleus in a Rab8-dependent manner upon an apoptotic stimulus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN-ANGLE GLAUCOMA; OPTIC-NERVE DAMAGE; GOLGI-COMPLEX; MYOSIN-VI; RAB PROTEINS; FIBROBLASTS; HUNTINGTIN; DEATH; TRANSCRIPTION; LOCALIZATION	In glaucoma the retinal ganglion cells of the retina die through the induction of apoptosis leading to excavation of the optic nerve and blindness. Mutations in the optineurin (optic neuropathy inducing) protein were found associated with an adult form of glaucoma. To date, the role of optineurin in the neurodegeneration process that occurs during glaucoma is still unknown. We now report that in response to an apoptotic stimulus, optineurin changes subcellular localization and translocates from the Golgi to the nucleus. This translocation is dependent on the GTPase activity of Rab8, an interactor of optineurin. Furthermore, we demonstrate that the overexpression of optineurin protects cells from H2O2-induced cell death and blocks cytochrome c release from the mitochondria. A mutated form of optineurin, E50K, identified in normal tension glaucoma patients loses its ability to translocate to the nucleus and when overexpressed compromises the mitochondrial membrane integrity resulting in cells that are less fit to survive under stress conditions. The correlation between optineurin function and cell survival will be key to begin to understand retinal ganglion cell biology and signaling and to design general "survival" strategies to treat a disease of such a complex etiology as glaucoma.	Telethon Inst Genet & Med, I-80131 Naples, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM)	Diez-Roux, G (corresponding author), Telethon Inst Genet & Med, Via Pietro Castellino 111, I-80131 Naples, Italy.	diezroux@tigem.it			Telethon [TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; Coleman AL, 1999, LANCET, V354, P1803, DOI 10.1016/S0140-6736(99)04240-3; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Gao YS, 1998, J BIOL CHEM, V273, P33825, DOI 10.1074/jbc.273.50.33825; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hattula K, 2000, CURR BIOL, V10, P1603, DOI 10.1016/S0960-9822(00)00864-2; Li YG, 1998, MOL CELL BIOL, V18, P1601, DOI 10.1128/MCB.18.3.1601; Libby RT, 2005, ANNU REV GENOM HUM G, V6, P15, DOI 10.1146/annurev.genom.6.080604.162209; Maag RS, 2003, CURR OPIN CELL BIOL, V15, P456, DOI 10.1016/S0955-0674(03)00075-9; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Moreland RJ, 2000, NUCLEIC ACIDS RES, V28, P1986, DOI 10.1093/nar/28.9.1986; Morrison JC, 2005, PROG RETIN EYE RES, V24, P217, DOI 10.1016/j.preteyeres.2004.08.003; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; QUIGLEY HA, 1979, OPHTHALMOLOGY, V86, P1803; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; QUIGLEY HA, 1993, NEW ENGL J MED, V328, P1097, DOI 10.1056/NEJM199304153281507; Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901; Sahlender DA, 2005, J CELL BIOL, V169, P285, DOI 10.1083/jcb.200501162; Sarfarazi Mansoor, 2003, Ophthalmol Clin North Am, V16, P529; Schwamborn K, 2000, J BIOL CHEM, V275, P22780, DOI 10.1074/jbc.M001500200; SHEFFIELD VC, 2001, METABOLIC MOL BASED, P6023; Stroissnigg H, 2002, EXP CELL RES, V278, P133, DOI 10.1006/excr.2002.5567; van Loo G, 2002, CELL DEATH DIFFER, V9, P1207, DOI 10.1038/sj.cdd.4401101; Warner CL, 2003, EMBO J, V22, P569, DOI 10.1093/emboj/cdg055; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	32	98	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16147	16156		10.1074/jbc.M601467200	http://dx.doi.org/10.1074/jbc.M601467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16569640	hybrid			2022-12-25	WOS:000237996000068
J	Jubb, AM; Chalasani, S; Frantz, GD; Smits, R; Grabsch, HI; Kavi, V; Maughan, NJ; Hillan, KJ; Quirke, P; Koeppen, H				Jubb, AM; Chalasani, S; Frantz, GD; Smits, R; Grabsch, HI; Kavi, V; Maughan, NJ; Hillan, KJ; Quirke, P; Koeppen, H			Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia	ONCOGENE			English	Article						small intestinal cancer; colorectal cancer; colorectal adenomas; Wnt signalling; achaete-scute like 2	CANCER CELLS; COLON-CANCER; EXPRESSION; TRANSCRIPTION; METHYLATION; SURVIVIN; PROTEINS; FEATURES; TISSUE; CYCLE	Achaete-scute like (ASCL)2 is a basic helix-loop-helix transcription factor essential for the maintenance of proliferating trophoblasts during placental development. Using oligonucleotide microarrays we identified ascl2 as a gene significantly upregulated in colorectal adenocarcinomas (n=36 cancers, n=16 normals; 15-fold, P < 0.0001). This finding was confirmed by quantitative reverse transcriptase (RT)-PCR on large intestinal cancers (n=29 cancers, n=16 normals; 10-fold, P < 0.0001). In situ hybridization for ascl2 demonstrated expression at the base of small and large intestinal crypts (n=304), but in no other normal tissues excepting placenta. By in situ hybridization, 52-71% of colorectal adenomas (n=187), 50-73% of large (n=327) and 33-64% of small intestinal adenocarcinomas (n=124) were positive for ascl2 expression. Upregulation of murine ascl2 was also observed using oligonucleotide microarrays, quantitative RT-PCR and in situ hybridization on apc(min/+) and apc(1638N/+) smad4(-/+) tumours. Tumour cell lines stably transfected with LEF1(DN) or APC2, or transiently transfected with short-interfering RNA (siRNA) against beta-catenin showed a significant downregulation of ascl2. Colocalization of ascl2 with nuclear beta-catenin was observed in 73 small intestinal adenocarcinomas (P < 0.0008) and apc(min/+) tumours. Preliminary in vitro data suggest ascl2 may promote progression through the G2/M cell cycle checkpoint. In summary, ascl2 is a putative regulator of proliferation that is overexpressed in intestinal neoplasia.	Univ Leeds, Acad Unit Pathol, Leeds Inst Mol Med, St James Hosp, Leeds LS9 7TF, W Yorkshire, England; Erasmus Univ, Med Ctr, Rotterdam, Netherlands; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Saint James's University Hospital; University of Leeds; Erasmus University Rotterdam; Erasmus MC; Roche Holding; Genentech	Jubb, AM (corresponding author), Univ Leeds, Acad Unit Pathol, Leeds Inst Mol Med, St James Hosp, Level 4,IMMECR JIF Bldg, Leeds LS9 7TF, W Yorkshire, England.	adrianjubb@gmail.com	Quirke, Philip/AAI-1362-2019	Quirke, Philip/0000-0002-3597-5444				Alders M, 1997, HUM MOL GENET, V6, P859, DOI 10.1093/hmg/6.6.859; Banerjea A, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-21; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; Jubb AM, 2003, J PATHOL, V200, P577, DOI 10.1002/path.1371; Leow CC, 2004, CANCER RES, V64, P6050, DOI 10.1158/0008-5472.CAN-04-0290; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Miyamoto T, 2002, J ASSIST REPROD GEN, V19, P240, DOI 10.1023/A:1015362903486; Morison IM, 2005, TRENDS GENET, V21, P457, DOI 10.1016/j.tig.2005.06.008; Myohanen SK, 1998, CANCER RES, V58, P591; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Westerman Ba, 2002, CLIN CANCER RES, V8, P1082; Westerman BA, 2001, PLACENTA, V22, P511, DOI 10.1053/plac.2001.0695; Yang SY, 2002, ARTERIOSCL THROM VAS, V22, P1797, DOI 10.1161/01.ATV.0000038995.31179.24; Zhang T, 2001, CANCER RES, V61, P8664; Zheng SC, 2000, CARCINOGENESIS, V21, P2057, DOI 10.1093/carcin/21.11.2057	25	100	110	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2006	25	24					3445	3457		10.1038/sj.onc.1209382	http://dx.doi.org/10.1038/sj.onc.1209382			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16568095				2022-12-25	WOS:000238448100009
J	Koc, A; Mathews, CK; Wheeler, LJ; Gross, MK; Merrill, GF				Koc, Ahmet; Mathews, Christopher K.; Wheeler, Linda J.; Gross, Michael K.; Merrill, Gary F.			Thioredoxin is required for deoxyribonucleotide pool maintenance during S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; DNA PRECURSOR ASYMMETRIES; CELL-CYCLE; RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; HYDROGEN DONOR; REPLICATION FIDELITY; SYNTHESIS GENES; BUDDING YEAST; GLUTATHIONE	Thioredoxin was initially identified by its ability to serve as an electron donor for ribonucleotide reductase in vitro. Whether it serves a similar function in vivo is unclear. In Saccharomyces cerevisiae, it was previously shown that Delta trx1 Delta trx2 mutants lacking the two genes for cytosolic thioredoxin have a slower growth rate because of a longer S phase, but the basis for S phase elongation was not identified. The hypothesis that S phase protraction was due to inefficient dNTP synthesis was investigated by measuring dNTP levels in asynchronous and synchronized wild-type and Delta trx1 Delta trx2 yeast. In contrast to wild-type cells, Delta trx1 Delta trx2 cells were unable to accumulate or maintain high levels of dNTPs when alpha-factor- or cdc15-arrested cells were allowed to reenter the cell cycle. At 80 min after release, when the fraction of cells in S phase was maximal, the dNTP pools in Delta trx1 Delta trx2 cells were 60% that of wild-type cells. The data suggest that, in the absence of thioredoxin, cells cannot support the high rate of dNTP synthesis required for efficient DNA synthesis during S phase. The results constitute in vivo evidence for thioredoxin being a physiologically relevant electron donor for ribonucleotide reductase during DNA precursor synthesis.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Merrill, GF (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 ALS Bldg, Corvallis, OR 97331 USA.	merrillg@onid.orst.edu	KOÇ, AHMET/ABI-3322-2020	KOÇ, AHMET/0000-0003-3484-2137	NCI NIH HHS [CA82633] Funding Source: Medline; NIEHS NIH HHS [P30 ES00210] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Carmel-Harel O, 2001, MOL MICROBIOL, V39, P595, DOI 10.1046/j.1365-2958.2001.02255.x; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Draculic T, 2000, MOL MICROBIOL, V36, P1167, DOI 10.1046/j.1365-2958.2000.01948.x; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1979, BIOCHEMISTRY-US, V18, P5591, DOI 10.1021/bi00592a011; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; Koc A, 2004, J BIOL CHEM, V279, P223, DOI 10.1074/jbc.M303952200; Koc A, 2003, J BIOL CHEM, V278, P9345, DOI 10.1074/jbc.M213013200; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; MULLER EGD, 1994, J BIOL CHEM, V269, P24466; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; Rose MD., 1990, METHODS YEAST GENETI; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; SLATER ML, 1977, P NATL ACAD SCI USA, V74, P3850, DOI 10.1073/pnas.74.9.3850; Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Wheeler LJ, 2005, DNA REPAIR, V4, P1450, DOI 10.1016/j.dnarep.2005.09.003; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yao RJ, 2003, P NATL ACAD SCI USA, V100, P6628, DOI 10.1073/pnas.1131932100; Zhang Z, 2006, P NATL ACAD SCI USA, V103, P1422, DOI 10.1073/pnas.0510516103	28	52	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15058	15063		10.1074/jbc.M601968200	http://dx.doi.org/10.1074/jbc.M601968200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574642	Green Published, hybrid			2022-12-25	WOS:000237922200007
J	Singh, RR; Gururaj, AE; Vadlamudi, RK; Kumar, R				Singh, Rajesh R.; Gururaj, Anupama E.; Vadlamudi, Ratna K.; Kumar, Rakesh			9-cis-retinoic acid up-regulates expression of transcriptional coregulator PELP1, a novel coactivator of the retinoid X receptor alpha pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; HUMAN-BREAST; CANCER; ACTIVATION; APOPTOSIS; CLONING	Retinoid X receptor alpha(RXR alpha), functioning as either a homodimer or a heterodimer with peroxisome proliferator receptors, is known to be involved in manifesting antiproliferative effects in cells. Consequently, studies of RXR alpha functions and its coregulators have been in the focus for therapeutic approaches against cancer. Here we have discovered that 9-cis-retinoic acid (9-cis-RA), a RXR alpha-specific ligand, up-regulated the expression of transcriptional coregulatory protein PELP1 (proline-, glutamic acid-, and leucine-rich protein 1). PELP1 functioned as a coactivator of RXR alpha, increasing its transactivation function in response to 9-cis-RA as evident by the retinoid X receptor response element-luciferase assays. PELP1 was found to be a binding partner of RXR alpha, and the binding interactions were confirmed both in vitro and in vivo. An electrophoretic mobility shift assay showed greater formation and stability of RXR alpha homodimers on consensus oligonucleotides in PELP1-overexpressing clones in comparison to the pcDNA clones. The presence of PELP1 in these oligonucleotide-bound RXR alpha homodimers was proved by the supershift of the complex when incubated with PELP1-specific antibody. PELP1-overexpressing stable MCF-7 cells exhibited a significantly higher extent of 9-cis-RA-induced apoptosis than the control pcDNA clones. Silencing of PELP1 expression in parental MCF-7 cells and PELP1-overexpressing clones using PELP1-specific RNA-mediated interference compromised the susceptibility to 9-cis-RA-induced apoptosis. PELP1 could also function as a coactivator of the RXR alpha-peroxisome proliferator-activated receptor(PPAR gamma) heterodimer as evident by the peroxisome proliferator activated receptor response element-luciferase assay in response to both 9-cis-RA and PPAR gamma-specific ligands. This was reinforced by the higher propensity of PELP1-overexpressing clones to undergo differentiation in response to PPAR gamma-specific ligands. This study has revealed a novel facet of PELP1 functions and identified it to be an important potentiator of the antiproliferative effects of 9-cis-RA and PPAR gamma-specific ligands.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Obstet & Gynecol, San Antonio, TX 78229 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803	NATIONAL CANCER INSTITUTE [R01CA065746, U01CA065746, R01CA098823] Funding Source: NIH RePORTER; NCI NIH HHS [CA 65746, CA 98823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Balasenthil S, 2003, J BIOL CHEM, V278, P22119, DOI 10.1074/jbc.M212822200; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Choi YB, 2004, J BIOL CHEM, V279, P50930, DOI 10.1074/jbc.M406831200; Freshney R.I., 1987, CULTURE ANIMAL CELLS, P117; IJpenberg A, 2004, EMBO J, V23, P2083, DOI 10.1038/sj.emboj.7600209; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Lazar MA, 2005, BIOCHIMIE, V87, P9, DOI 10.1016/j.biochi.2004.10.021; Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Manavathi B, 2005, CANCER RES, V65, P5571, DOI 10.1158/0008-5472.CAN-04-4664; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mishra SK, 2004, GENE, V330, P115, DOI 10.1016/j.gene.2004.01.011; NAIR SS, 2000, CANCER RES, V64, P6416; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Shulman AI, 2004, CELL, V116, P417, DOI 10.1016/S0092-8674(04)00119-9; Simeone AM, 2004, CELL MOL LIFE SCI, V61, P1475, DOI 10.1007/s00018-004-4002-6; Simoni D, 2001, CURR PHARM DESIGN, V7, P1823, DOI 10.2174/1381612013397168; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stallcup MR, 2001, ONCOGENE, V20, P3014, DOI 10.1038/sj.onc.1204325; Tanaka T, 2004, MOL CELL BIOL, V24, P3972, DOI 10.1128/MCB.24.9.3972-3982.2004; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X	31	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15394	15404		10.1074/jbc.M601593200	http://dx.doi.org/10.1074/jbc.M601593200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574651	hybrid			2022-12-25	WOS:000237922200045
J	Ward, EM; Stambach, NS; Drickamer, K; Taylor, ME				Ward, Eliot M.; Stambach, Nicola S.; Drickamer, Kurt; Taylor, Maureen E.			Polymorphisms in human Langerin affect stability and sugar binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; BIRBECK GRANULES; MANNOSE-BINDING; DC-SIGN; DENDRITIC CELLS; PROTEIN; RECEPTOR; GENE; IDENTIFICATION; RECOGNITION	Langerhans cells are specialized skin dendritic cells that take up and degrade antigens for presentation to the immune system. Langerin, a cell surface C-type lectin of Langerhans cells, can be internalized and accumulates in Birbeck granules, subdomains of the endosomal recycling compartment that are specific to Langerhans cells. Langerin binds and mediates uptake and degradation of glycoconjugates containing mannose and related sugars. Analysis of the human genome has identified three single nucleotide polymorphisms that result in amino acid changes in the carbohydrate-recognition domain of langerin. The effects of the amino acid changes on the activity of langerin were examined by expressing each of the polymorphic forms. Expression of full-length versions of the four common langerin haplotypes in fibroblasts revealed that all of these forms can mediate endocytosis of neoglycoprotein ligands. However, sugar binding assays and differential scanning calorimetry performed on fragments from the extracellular domain showed that two of the amino acid changes reduce the affinity of the carbohydrate-recognition domain for mannose and decrease the stability of the extracellular domain. In addition, analysis of sugar binding by langerin containing the rare W264R mutation, previously identified in an individual lacking Birbeck granules, shows that this mutation abolishes sugar binding activity. These findings suggest that certain langerin haplotypes may differ in their binding to pathogens and thus might be associated with susceptibility to infection.	Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England; Univ Oxford, Glycobiol Inst, Dept Biochem, Oxford OX1 3QU, England	Imperial College London; University of Oxford	Taylor, ME (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, Biochem Bldg, London SW7 2AZ, England.	maureen.taylor@imperial.ac.uk		Taylor, Maureen/0000-0001-8300-4987	Wellcome Trust [062435, 075565, 041845] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; Feinberg H, 2005, J BIOL CHEM, V280, P1327, DOI 10.1074/jbc.M409925200; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GREENWOOD FC, 1963, BIOCHEM J, V89, P123; Hirs C. H. W., 1967, METHOD ENZYMOL, V11, P325; Hunger RE, 2004, J CLIN INVEST, V113, P701, DOI 10.1172/JCI200419655; IOBST ST, 1994, J BIOL CHEM, V269, P15505; Kissenpfennig A, 2005, MOL CELL BIOL, V25, P88, DOI 10.1128/MCB.25.1.88-99.2005; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Levitzki A., 1997, PROTEIN FUNCTION PRA, P101; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; Mc Dermott R, 2002, MOL BIOL CELL, V13, P317, DOI 10.1091/mbc.01-06-0300; MELLOW TE, 1988, J BIOL CHEM, V263, P5468; Stambach NS, 2003, GLYCOBIOLOGY, V13, P401, DOI 10.1093/glycob/cwg045; Takahara K, 2004, INT IMMUNOL, V16, P819, DOI 10.1093/intimm/dxh084; Takahara K, 2002, INT IMMUNOL, V14, P433, DOI 10.1093/intimm/14.5.433; Turner MW, 2003, MOL IMMUNOL, V40, P423, DOI 10.1016/S0161-5890(03)00155-X; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; Valladeau J, 1999, EUR J IMMUNOL, V29, P2695, DOI 10.1002/(SICI)1521-4141(199909)29:09<2695::AID-IMMU2695>3.0.CO;2-Q; Verdijk P, 2005, J INVEST DERMATOL, V124, P714, DOI 10.1111/j.0022-202X.2005.23645.x; Wallis R, 2004, J BIOL CHEM, V279, P14065, DOI 10.1074/jbc.M400171200; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400	26	29	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15450	15456		10.1074/jbc.M511502200	http://dx.doi.org/10.1074/jbc.M511502200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16567809	hybrid			2022-12-25	WOS:000237922200051
J	Czirjak, G; Enyedi, P				Czirjak, Gabor; Enyedi, Peter			Targeting of calcineurin to an NFAT-like docking site is required for the calcium-dependent activation of the background K(+)channel, TRESK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; POTASSIUM CHANNELS; ESCHERICHIA-COLI; INHIBITORS; ANESTHETICS; ENZYME	The two-pore domain K+ channel, TRESK (TWIK-related spinal cord K+ channel) is activated in response to the calcium signal by the calcium/calmodulin-dependent protein phosphatase, calcineurin. In the present study we report that calcineurin also interacts with TRESK via an NFAT-like docking site, in addition to its enzymatic action. In its intracellular loop, mouse TRESK possesses the amino acid sequence, PQIVID, which is similar to the calcineurin binding consensus motif, PXIXIT (where X denotes any amino acids), necessary for NFAT (nuclear factor of activated T cells) activation and nuclear translocation. Mutations of the PQIVID sequence of TRESK to PQIVIA, PQIVAD, or PQAVAD increasingly deteriorated the calcium-dependent activation in the listed order and correspondingly reduced the benzocaine sensitivity (a property discriminating activated channels from resting ones), when it was measured after the calcium signal in Xenopus oocytes. Microinjection of VIVIT peptide, designed to inhibit the NFAT-calcineurin interaction specifically, also eliminated TRESK activation. The intracellular loop of TRESK, expressed as a GST fusion protein, bound constitutively active calcineurin in vitro. PQAVAD mutation as well as addition of VIVIT peptide to the reaction abrogated this calcineurin binding. Wild type calcineurin was recruited to GST-TRESK-loop in the presence of calcium and calmodulin. These results indicate that the PQIVID sequence is a docking site for calcineurin, and its occupancy is required for the calcium-dependent regulation of TRESK. Immunosuppressive compounds, developed to target the NFAT binding site of calcineurin, are also expected to interfere with TRESK regulation, in addition to their desired effect on NFAT.	Semmelweis Univ, Dept Physiol, H-1444 Budapest, Hungary	Semmelweis University	Enyedi, P (corresponding author), Semmelweis Univ, Dept Physiol, POB 259, H-1444 Budapest, Hungary.	enyedi@puskin.sote.hu		Czirjak, Gabor/0000-0002-5485-2327				Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Boustany LM, 2002, GENE DEV, V16, P608, DOI 10.1101/gad.967602; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; Czirjak B, 2004, J BIOL CHEM, V279, P18550, DOI 10.1074/jbc.M312229200; Czirjak G, 2000, MOL ENDOCRINOL, V14, P863, DOI 10.1210/me.14.6.863; Czirjak G, 2001, AM J PHYSIOL-CELL PH, V281, pC700, DOI 10.1152/ajpcell.2001.281.2.C700; Dodge KL, 2003, BIOCHEM BIOPH RES CO, V311, P1111, DOI 10.1016/j.bbrc.2003.09.040; Farazi TA, 2000, BIOCHEMISTRY-US, V39, P15807, DOI 10.1021/bi002074t; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Kang D, 2004, J BIOL CHEM, V279, P28063, DOI 10.1074/jbc.M402940200; KANG D, 2006, IN PRESS AM J PHYSL; Keshavaprasad B, 2005, ANESTH ANALG, V101, P1042, DOI 10.1213/01.ane.0000168447.87557.5a; Kim D, 2005, CURR PHARM DESIGN, V11, P2717, DOI 10.2174/1381612054546824; Kim SJ, 2003, J BIOL CHEM, V278, P15550, DOI 10.1074/jbc.M210210200; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Li HM, 2004, J MOL BIOL, V342, P1659, DOI 10.1016/j.jmb.2004.07.068; Liu CH, 2004, ANESTH ANALG, V99, P1715, DOI 10.1213/01.ANE.0000136849.07384.44; Liu JO, 2003, BIOCHEM BIOPH RES CO, V311, P1103, DOI 10.1016/j.bbrc.2003.10.020; Martinez-Martinez S, 2004, CURR MED CHEM, V11, P997, DOI 10.2174/0929867043455576; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; Roehrl MHA, 2004, BIOCHEMISTRY-US, V43, P16067, DOI 10.1021/bi048232o; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; Sano Y, 2003, J BIOL CHEM, V278, P27406, DOI 10.1074/jbc.M206810200; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; Talley EM, 2003, NEUROSCIENTIST, V9, P46, DOI 10.1177/1073858402239590; YOSHIDA S, 1992, J PHYSIOL-LONDON, V458, P307, DOI 10.1113/jphysiol.1992.sp019419	27	81	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14677	14682		10.1074/jbc.M602495200	http://dx.doi.org/10.1074/jbc.M602495200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16569637	hybrid, Green Published			2022-12-25	WOS:000237671300020
J	Li, H; Xie, B; Zhou, YJ; Rahmeh, A; Trusa, S; Zhang, SF; Gao, Y; Lee, EYC; Lee, MYWT				Li, Hao; Xie, Bin; Zhou, Yajing; Rahmeh, Amal; Trusa, Sandra; Zhang, Sufang; Gao, Yan; Lee, Ernest Y. C.; Lee, Marietta Y. W. T.			Functional roles of p12, the fourth subunit of human DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; PCNA-BINDING; SCHIZOSACCHAROMYCES-POMBE; 3RD SUBUNIT; REPLICATION; IDENTIFICATION; RECONSTITUTION; CHROMATOGRAPHY; DOMAINS; PROTEIN	Mammalian DNA polymerase delta(pol delta), a key enzyme of chromosomal DNA replication, consists of four subunits as follows: the catalytic subunit; p125, which is tightly associated with the p50 subunit; p68, a proliferating cell nuclear antigen ( PCNA)- binding protein; and a fourth subunit, p12. In this study, the functional roles of the p12 subunit of pol delta were studied. The inter-subunit interactions of the p12 subunit were determined by yeast two-hybrid assays and by pulldown assays. These assays revealed that p12 interacts with p125 as well as p50. This dual interaction of p12 suggests that it may serve to stabilize the p125-p50 interaction. p12 was shown to be a novel PCNA-binding protein. This was confirmed by identification of a PCNA-binding motif at its N terminus by binding assays and by site-directed mutagenesis. The activities and reaction products of recombinant pol delta containing a p12 mutant defective in PCNA binding, as well as purified recombinant pol delta and its subassemblies, were analyzed. Our results indicate that p12 contributes to PCNA-dependent pol delta activity, i.e. the p12-PCNA interaction is functional. Our data indicate that both p12 and p68 are required for optimal pol delta activity. This supports the hypothesis that the interaction between pol delta and PCNA is a divalent one that involves p12 and p68. We propose a model in which pol delta interacts with PCNA via at least two of its subunits, and one in which p12 could play a role in stabilizing the overall pol delta- PCNA complex as well as pol delta itself.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Lee, MYWT (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	Marietta_Lee@nymc.edu		Rahmeh, Amal/0000-0003-0985-7978; Zhang, Sufang/0000-0003-3883-023X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18512] Funding Source: Medline; NIGMS NIH HHS [GM 31973] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bambara RA, 1995, METHOD ENZYMOL, V262, P270; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bermudez VP, 2002, J BIOL CHEM, V277, P36853, DOI 10.1074/jbc.M202897200; Bruning JB, 2004, STRUCTURE, V12, P2209, DOI 10.1016/j.str.2004.09.018; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Dell'Era P, 2005, ONCOGENE, V24, P1117, DOI 10.1038/sj.onc.1208359; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; Johansson E, 2004, J BIOL CHEM, V279, P22204, DOI 10.1074/jbc.M402652200; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Lu XQ, 2002, J BIOL CHEM, V277, P24340, DOI 10.1074/jbc.M200065200; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; Naryzhny SN, 2005, J BIOL CHEM, V280, P13888, DOI 10.1074/jbc.M500304200; Podust VN, 2002, J BIOL CHEM, V277, P3894, DOI 10.1074/jbc.M109684200; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Reynolds N, 1998, CURR GENET, V34, P250, DOI 10.1007/s002940050394; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Sakurai S, 2005, EMBO J, V24, P683, DOI 10.1038/sj.emboj.7600519; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; TAN CK, 1986, J BIOL CHEM, V261, P2310; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; Xie B, 2002, BIOCHEMISTRY-US, V41, P13133, DOI 10.1021/bi0262707; Xu H, 2001, BIOCHEMISTRY-US, V40, P4512, DOI 10.1021/bi010103+; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	36	66	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14748	14755		10.1074/jbc.M600322200	http://dx.doi.org/10.1074/jbc.M600322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16510448	hybrid			2022-12-25	WOS:000237671300028
J	Gonzalez, CF; Proudfoot, M; Brown, G; Korniyenko, Y; Mori, H; Savchenko, AV; Yakunin, AF				Gonzalez, Claudio F.; Proudfoot, Michael; Brown, Greg; Korniyenko, Yurij; Mori, Hirotada; Savchenko, Alexei V.; Yakunin, Alexander F.			Molecular Basis of Formaldehyde Detoxification CHARACTERIZATION OF TWO S-FORMYLGLUTATHIONE HYDROLASES FROM ESCHERICHIA COLI, FrmB AND YeiG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-FORMYLGLUTATHIONE HYDROLASE; HUMAN ESTERASE-D; ESCHERICHIA-COLI; GLYOXALASE-I; METHYLGLYOXAL; DEHYDROGENASE; PURIFICATION; PATHWAY; ENZYME; IDENTIFICATION	The Escherichia coli genes frmB (yaiM) and yeiG encode two uncharacterized proteins that share 54% sequence identity and contain a serine esterase motif. We demonstrated that purified FrmB and YeiG have high carboxylesterase activity against the model substrates, p-nitrophenyl esters of fatty acids (C2-C6) and alpha-naphthyl acetate. However, both proteins had the highest hydrolytic activity toward S-formylglutathione, an intermediate of the glutathione-dependent pathway of formaldehyde detoxification. With this substrate, both proteins had similar affinity (K-m = 0.41-0.43 mM), but FrmB was almost 5 times more active. Alanine replacement mutagenesis of YeiG demonstrated that Ser(145), Asp(233), and His(256) are absolutely required for activity, indicating that these residues represent a serine hydrolase catalytic triad in this protein and in other S-formylglutathione hydrolases. This was confirmed by inspecting the crystal structure of the Saccharomyces cerevisiae S-formylglutathione hydrolase YJG8 (Protein Data Bank code 1pv1), which has 45% sequence identity to YeiG. The structure revealed a canonical alpha/beta-hydrolase fold and a classical serine hydrolase catalytic triad (Ser(161), His(276), Asp(241)). In E. coli cells, the expression of frmB was stimulated 45-75 times by the addition of formaldehyde to the growth medium, whereas YeiG was found to be a constitutive enzyme. The simultaneous deletion of both frmB and yeiG genes was required to increase the sensitivity of the growth of E. coli cells to formaldehyde, suggesting that both FrmB and YeiG contribute to the detoxification of formaldehyde. Thus, FrmB and YeiG are S-formylglutathione hydrolases with a Ser-His-Asp catalytic triad involved in the detoxification of formaldehyde in E. coli.	[Gonzalez, Claudio F.; Proudfoot, Michael; Brown, Greg; Korniyenko, Yurij; Savchenko, Alexei V.; Yakunin, Alexander F.] Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; [Mori, Hirotada] Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	University of Toronto; Nara Institute of Science & Technology	Yakunin, AF (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	a.iakounine@utoronto.ca	Yakunin, Alexander/J-1519-2014; Mori, Hirotada/B-4934-2011	Yakunin, Alexander/0000-0003-0813-6490	Ontario Genomics Institute; National Institutes of Health [GM62414-01]; CREST (Japan Science and Technology); Inamori Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER	Ontario Genomics Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CREST (Japan Science and Technology)(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); Inamori Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Genome Canada through the Ontario Genomics Institute, National Institutes of Health Grant GM62414-01, CREST (Japan Science and Technology), and the Inamori Foundation (to H. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Aas PA, 2003, NATURE, V421, P859, DOI 10.1038/nature01363; Berge R K, 1981, Methods Enzymol, V71 Pt C, P234; BOLT HM, 1987, J CANCER RES CLIN, V113, P305, DOI 10.1007/BF00397713; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BYSTRYKH LV, 1993, J GEN MICROBIOL, V139, P1979, DOI 10.1099/00221287-139-9-1979; CHAW YFM, 1980, BIOCHEMISTRY-US, V19, P5525, DOI 10.1021/bi00565a010; COOPER RA, 1984, ANNU REV MICROBIOL, V38, P49, DOI 10.1146/annurev.mi.38.100184.000405; COWELL JK, 1986, HUM GENET, V74, P298; CYGLER M, 1993, PROTEIN SCI, V2, P366; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Degrassi G, 1999, APPL ENVIRON MICROB, V65, P3470; Fall R, 1996, TRENDS PLANT SCI, V1, P296, DOI 10.1016/S1360-1385(96)88175-0; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; Ferguson GP, 1998, ARCH MICROBIOL, V170, P209, DOI 10.1007/s002030050635; FREEDBERG WB, 1971, J BACTERIOL, V108, P137, DOI 10.1128/JB.108.1.137-144.1971; GOLD AM, 1965, BIOCHEMISTRY-US, V4, P897, DOI 10.1021/bi00881a016; Gutheil WG, 1997, BIOCHEM BIOPH RES CO, V238, P693, DOI 10.1016/S0006-291X(00)90000-7; Hanson AD, 2000, TRENDS PLANT SCI, V5, P206, DOI 10.1016/S1360-1385(00)01599-5; Harms N, 1996, J BACTERIOL, V178, P6296, DOI 10.1128/jb.178.21.6296-6299.1996; HECK HD, 1990, CRIT REV TOXICOL, V20, P397; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; Herring CD, 2004, J BACTERIOL, V186, P6714, DOI 10.1128/JB.186.20.6714-6720.2004; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Holmquist M, 2000, CURR PROTEIN PEPT SC, V1, P209, DOI 10.2174/1389203003381405; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; Irizarry K., 2001, Pharmacogenomics Journal, V1, P193, DOI 10.1038/sj.tpj.6500042; ITO K, 1994, J BACTERIOL, V176, P2483, DOI 10.1128/JB.176.9.2483-2491.1994; Jensen DE, 1998, BIOCHEM J, V331, P659, DOI 10.1042/bj3310659; Kalapos MP, 1999, TOXICOL LETT, V110, P145, DOI 10.1016/S0378-4274(99)00160-5; KITAGAWA M, 2006, DNA RES IN PRESS; Kordic S, 2002, ARCH BIOCHEM BIOPHYS, V399, P232, DOI 10.1006/abbi.2002.2772; Kuznetsova E, 2005, FEMS MICROBIOL REV, V29, P263, DOI 10.1016/j.femsre.2004.12.006; LEE EYHP, 1986, P NATL ACAD SCI USA, V83, P6337, DOI 10.1073/pnas.83.17.6337; LEE WH, 1986, P NATL ACAD SCI USA, V83, P6790, DOI 10.1073/pnas.83.18.6790; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; MA TH, 1988, MUTAT RES, V196, P37, DOI 10.1016/0165-1110(88)90027-9; MISRA K, 1995, BIOCHEM J, V305, P999, DOI 10.1042/bj3050999; Misra K, 1996, MOL CELL BIOCHEM, V156, P117, DOI 10.1007/BF00426333; MOULIS JM, 1991, BIOCHEMISTRY-US, V30, P5743, DOI 10.1021/bi00237a016; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Polgar L, 2005, CELL MOL LIFE SCI, V62, P2161, DOI 10.1007/s00018-005-5160-x; Powers J C, 1993, Agents Actions Suppl, V42, P3; PRECIOUS E, 1988, BIOCHEM PHARMACOL, V37, P707, DOI 10.1016/0006-2952(88)90145-1; Ramasamy R, 2006, CELL, V124, P258, DOI 10.1016/j.cell.2006.01.002; RICHARD JP, 1993, BIOCHEM SOC T, V21, P549, DOI 10.1042/bst0210549; RITVO ER, 1988, ARCH GEN PSYCHIAT, V45, P600; SAKAI Y, 1995, FEMS MICROBIOL LETT, V127, P229; Sanghani PC, 2002, BIOCHEMISTRY-US, V41, P15189, DOI 10.1021/bi026705q; Schapiro JM, 2003, P NATL ACAD SCI USA, V100, P8496, DOI 10.1073/pnas.1033133100; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; Spitsyn V. A., 2001, Genetika, V37, P698; Stover NA, 2005, MOL BIOL EVOL, V22, P1539, DOI 10.1093/molbev/msi151; THORNALLEY PJ, 1995, CRIT REV ONCOL HEMAT, V20, P99, DOI 10.1016/1040-8428(94)00149-N; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; UOTILA L, 1974, J BIOL CHEM, V249, P7664; UOTILA L, 1979, ARCH BIOCHEM BIOPHYS, V196, P33, DOI 10.1016/0003-9861(79)90548-4; Uotila L., 1981, METH ENZYMOL, V77, P424, DOI [10.1016/S0076-6879(81)77058-7, DOI 10.1016/S0076-6879(81)77058-7]; VORDERWULBECKE T, 1992, ENZYME MICROB TECH, V14, P631, DOI 10.1016/0141-0229(92)90038-P; Yao DC, 2006, CELL, V124, P275, DOI 10.1016/j.cell.2005.11.024; Yuasa I, 2004, HUM BIOL, V76, P479, DOI 10.1353/hub.2004.0051; Zhang RG, 2001, STRUCTURE, V9, P1095, DOI 10.1016/S0969-2126(01)00675-X	63	97	102	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14514	14522		10.1074/jbc.M600996200	http://dx.doi.org/10.1074/jbc.M600996200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16567800	hybrid			2022-12-25	WOS:000207179300010
J	Grubisha, O; Rafty, LA; Takanishi, CL; Xu, X; Tong, L; Perraud, AL; Scharenberg, AM; Denu, JM				Grubisha, Olivera; Rafty, Louise A.; Takanishi, Christina L.; Xu, Xiaojie; Tong, Lei; Perraud, Anne-Laure; Scharenberg, Andrew M.; Denu, John M.			Metabolite of SIR2 reaction modulates TRPM2 ion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNEL; SECRETING CELL-LINE; ACETYL-ADP-RIBOSE; HYDROGEN-PEROXIDE; PROTEIN DEACETYLASES; OXIDATIVE STRESS; NAD(+)-DEPENDENT DEACETYLASES; HISTONE/PROTEIN DEACETYLASES; HISTONE DEACETYLATION; TRANSCRIPTION FACTORS	The transient receptor potential melastatin-related channel 2 (TRPM2) is a nonselective cation channel, whose prolonged activation by oxidative and nitrative agents leads to cell death. Here, we show that the drug puromycin selectively targets TRPM2-expressing cells, leading to cell death. Our data suggest that the silent information regulator 2 (Sir2 or sirtuin) family of enzymes mediates this susceptibility to cell death. Sirtuins are protein deacetylases that regulate gene expression, apoptosis, metabolism, and aging. These NAD(+)- dependent enzymes catalyze a reaction in which the acetyl group from substrate is transferred to the ADP-ribose portion of NAD(+) to form deacetylated product, nicotinamide, and the metabolite OAADPr, whose functions remain elusive. Using cell-based assays and RNA interference, we show that puromycin-induced cell death is greatly diminished by nicotinamide ( a potent sirtuin inhibitor), and by decreased expression of sirtuins SIRT2 and SIRT3. Furthermore, we demonstrate using channel current recordings and binding assays that OAADPr directly binds to the cytoplasmic domain of TRPM2 and activates the TRPM2 channel. ADP-ribose binds TRPM2 with similarly affinity, whereas NAD(+) displays almost negligible binding. These studies provide the first evidence for the potential role of sirtuin-generated OAADPr in TRPM2 channel gating.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Washington, Dept Pediat & Immunol, Seattle, WA 98195 USA; Childrens Hosp & Med Ctr, Seattle, WA 98195 USA	University of Wisconsin System; University of Wisconsin Madison; Oregon Health & Science University; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Denu, JM (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	jmdenu@wisc.edu		Grubisha, Olivera/0000-0003-1067-1230	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065386, R01GM064091] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65386, GM64091] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellizzi D, 2005, GENOMICS, V85, P258, DOI 10.1016/j.ygeno.2004.11.003; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1; Diefenbach J, 2005, CELL MOL LIFE SCI, V62, P721, DOI 10.1007/s00018-004-4503-3; Ercan-Fang N, 2002, AM J PHYSIOL-ENDOC M, V283, pE29, DOI 10.1152/ajpendo.00425.2001; Fonfria E, 2004, BRIT J PHARMACOL, V143, P186, DOI 10.1038/sj.bjp.0705914; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Grubisha O, 2005, FEBS J, V272, P4607, DOI 10.1111/j.1742-4658.2005.04862.x; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; Herson PS, 1999, J BIOL CHEM, V274, P833, DOI 10.1074/jbc.274.2.833; Herson PS, 1999, J PHYSIOL-LONDON, V514, P47, DOI 10.1111/j.1469-7793.1999.047af.x; Herson PS, 1997, J PHYSIOL-LONDON, V505, P65, DOI 10.1111/j.1469-7793.1997.065bc.x; Herson PS, 1997, J PHYSIOL-LONDON, V501, P59, DOI 10.1111/j.1469-7793.1997.059bo.x; Inamura K, 2003, J MEMBRANE BIOL, V191, P201, DOI 10.1007/s00232-002-1057-x; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; Jackson MD, 2003, J BIOL CHEM, V278, P50985, DOI 10.1074/jbc.M306552200; Kobayashi Y, 2005, INT J MOL MED, V16, P237; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Kuhn FJP, 2004, J BIOL CHEM, V279, P46431, DOI 10.1074/jbc.M407263200; Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Liou GG, 2005, CELL, V121, P515, DOI 10.1016/j.cell.2005.03.035; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Perraud AL, 2005, J BIOL CHEM, V280, P6138, DOI 10.1074/jbc.M411446200; Perraud AL, 2003, CELL CALCIUM, V33, P519, DOI 10.1016/S0143-4160(03)00057-5; Perraud AL, 2003, J BIOL CHEM, V278, P1794, DOI 10.1074/jbc.M205601200; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Qian F, 2002, DIABETES, V51, pS183, DOI 10.2337/diabetes.51.2007.S183; Rafty LA, 2002, J BIOL CHEM, V277, P47114, DOI 10.1074/jbc.M208997200; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rose G, 2003, EXP GERONTOL, V38, P1065, DOI 10.1016/S0531-5565(03)00209-2; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P9249, DOI 10.1021/bi034959l; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Schmidt MT, 2004, J BIOL CHEM, V279, P40122, DOI 10.1074/jbc.M407484200; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Shen BW, 2003, J MOL BIOL, V332, P385, DOI 10.1016/S0022-2836(03)00954-9; Shi T, 2005, J BIOL CHEM, V280, P13560, DOI 10.1074/jbc.M414670200; Smith MA, 2003, J PHYSIOL-LONDON, V547, P417, DOI 10.1113/jphysiol.2002.034561; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang W, 2003, J BIOL CHEM, V278, P16222, DOI 10.1074/jbc.M300298200	61	124	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14057	14065		10.1074/jbc.M513741200	http://dx.doi.org/10.1074/jbc.M513741200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16565078	hybrid, Green Accepted			2022-12-25	WOS:000237512300028
J	Jeong, W; Park, SJ; Chang, TS; Lee, DY; Rhee, SG				Jeong, Woojin; Park, Sung Jun; Chang, Tong-Shin; Lee, Duck-Yeon; Rhee, Sue Goo			Molecular mechanism of the reduction of cysteine sulfinic acid of peroxiredoxin to cysteine by mammalian sulfiredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; HYDROGEN-PEROXIDE; 2-CYS PEROXIREDOXIN; ACTIVE-SITE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; PROTEIN; INACTIVATION; OXIDATION; CATALYSIS	Among many proteins with cysteine sulfinic acid (Cys-SO2H) residues, the sulfinic forms of certain peroxiredoxins (Prxs) are selectively reduced by sulfiredoxin (Srx) in the presence of ATP. All Srx enzymes contain a conserved cysteine residue. To elucidate the mechanism of the Srx-catalyzed reaction, we generated various mutants of Srx and examined their interaction with PrxI, their ATPase activity, and their ability to reduce sulfinic PrxI. Our results suggest that three surface-exposed amino acid residues, corresponding to Arg(50), Asp(57), and Asp(79) of rat Srx, are critical for substrate recognition. The presence of the sulfinic form (but not the reduced form) of PrxI induces the conserved cysteine of Srx to take the gamma-phosphate of ATP and then immediately transfers the phosphate to the sulfinic moiety of PrxI to generate a sulfinic acid phosphoryl ester (Prx-Cys-S(=O)OPO32-). This ester is reductively cleaved by a thiol molecule (RSH) such as GSH, thioredoxin, and dithiothreitol to produce a disulfide-S-monoxide (Prx-Cys-S(=O)-S-R). The disulfide-S-monoxide is further reduced through the oxidation of three thiol equivalents to complete the catalytic cycle and regenerate Prx-Cys-SH.	Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	Ewha Womans University; Ewha Womans University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), Ewha Womans Univ, Ctr Cell Signaling Res, Sci Bldg C,Rm 211,11 Daehyun Dong, Seoul 120750, South Korea.	rheesg@ewha.ac.kr						Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Bozonet SM, 2005, J BIOL CHEM, V280, P23319, DOI 10.1074/jbc.M502757200; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; CASHEL M, 1969, J CHROMATOGR, V40, P103, DOI 10.1016/S0021-9673(01)96624-5; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chang TS, 2004, J BIOL CHEM, V279, P50994, DOI 10.1074/jbc.M409482200; Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; ISHII T, 1993, J BIOL CHEM, V268, P18633; Jeong W, 2004, J BIOL CHEM, V279, P3142, DOI 10.1074/jbc.M307932200; Jonsson TJ, 2005, BIOCHEMISTRY-US, V44, P8634, DOI 10.1021/bi050131i; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; Mallis RJ, 2002, BIOL CHEM, V383, P649, DOI 10.1515/BC.2002.067; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; Vivancos AP, 2005, P NATL ACAD SCI USA, V102, P8875, DOI 10.1073/pnas.0503251102; Wang QP, 2004, BIOCHEMISTRY-US, V43, P4294, DOI 10.1021/bi035986e; Woo HA, 2005, J BIOL CHEM, V280, P3125, DOI 10.1074/jbc.C400496200; Woo HA, 2003, J BIOL CHEM, V278, P47361, DOI 10.1074/jbc.C300428200; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	34	117	123	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14400	14407		10.1074/jbc.M511082200	http://dx.doi.org/10.1074/jbc.M511082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16565085	hybrid			2022-12-25	WOS:000237512300067
J	Jin, ZH; May, WS; Gao, FQ; Flagg, T; Deng, XM				Jin, Zhaohui; May, W. Stratford; Gao, Fengqin; Flagg, Tammy; Deng, Xingming			Bcl2 Suppresses DNA Repair by Enhancing c-Myc Transcriptional Activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Bcl2 and c-Myc are two major oncogenic proteins that can functionally promote DNA damage, genetic instability, and tumorigenesis. However, the mechanism(s) remains unclear. Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is the most potent carcinogen contained in cigarette smoke that induces cellular DNA damage. Here we found that Bcl2 potently suppresses the repair of NNK-induced abasic sites of DNA lesions in association with increased c-Myc transcriptional activity. The Bcl2 BH4 domain (amino acids 6-31) was found to bind directly to c-Myc MBII domain (amino acids 106-143), and this interaction is required for Bcl2 to enhance c-Myc transcriptional activity and inhibit DNA repair. In addition to mitochondria, Bcl2 is also expressed in the nucleus, where it co-localizes with c-Myc. Expression of nuclear-targeted Bcl2 enhances c-Myc transcriptional activity with suppression of DNA repair but fails to prolong cell survival. Depletion of c-Myc expression from cells overexpressing Bcl2 significantly accelerates the repair of NNK-induced DNA damage, indicating that c-Myc may be essential for the Bcl2 effect on DNA repair. It is known that apurinic/apyrimidinic endonuclease (APE1) plays a crucial role in the repair of abasic sites of DNA lesions. That overexpression of Bcl2 results in up-regulation of c-Myc and down-regulation of APE1 suggests APE1 may function as the downstream target of Bcl2/c-Myc in the DNA repair machinery. Thus, Bcl2, in addition to its survival function, may also suppress DNA repair in a novel mechanism involving c-Myc and APE1, which may lead to an accumulation of DNA damage in living cells, genetic instability, and tumorigenesis.	[Deng, Xingming] Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu	Jin, Zhaohui/AAQ-2893-2021; Jin, Zhaohui/AAI-5562-2020	Jin, Zhaohui/0000-0001-7844-5833	NCI; National Institutes of Health [R01 CA112183]; Flight Attendant Medical Research Institute Clinical Innovator Award; NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute Clinical Innovator Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI, National Institutes of Health Grant R01 CA112183 and by a Flight Attendant Medical Research Institute Clinical Innovator Award (to X. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Boiteux S, 2004, DNA REPAIR, V3, P1, DOI 10.1016/j.dnarep.2003.10.002; Brunnemann KD, 1996, CRIT REV TOXICOL, V26, P121, DOI 10.3109/10408449609017926; Carmella SG, 1997, CARCINOGENESIS, V18, P587, DOI 10.1093/carcin/18.3.587; CASTONGUAY A, 1985, ENVIRON HEALTH PERSP, V62, P197, DOI 10.2307/3430113; CHEBONNELLASSER.C, 1996, ONCOGENE, V13, P1489; Cheng NL, 2004, ONCOGENE, V23, P3770, DOI 10.1038/sj.onc.1207478; CHUNG FL, 1992, CARCINOGENESIS, V13, P1269, DOI 10.1093/carcin/13.7.1269; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; Cloutier JF, 2001, J MOL BIOL, V313, P539, DOI 10.1006/jmbi.2001.4997; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; DOBRZANSKI KD, 1992, CARCINOGENESIS, V13, P1447; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hecht S S, 1991, IARC Sci Publ, P54; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; HOFFMANN D, 1991, CRIT REV TOXICOL, V21, P305, DOI 10.3109/10408449109017917; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; JORQUERA R, 1994, CARCINOGENESIS, V15, P389, DOI 10.1093/carcin/15.2.389; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kuo ML, 1999, MOL PHARMACOL, V55, P894; Li Q, 1999, MOL CELL BIOL, V19, P5339; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; LIU L, 1990, CANCER RES, V50, P1810; Liu YF, 1997, CANCER RES, V57, P1650; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; Mai S, 1996, ONCOGENE, V12, P277; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MOISSAC D, 1999, J BIOL CHEM, V274, P29505; Mol C. D., 2000, MUTAT RES; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Nakamura J, 1999, CANCER RES, V59, P2522; Papadimitriou JC, 1996, CANC DETECT PREV, V2, P529; Raffoul JJ, 2004, J BIOL CHEM, V279, P18425, DOI 10.1074/jbc.M313983200; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; ROYDS JA, 1992, J PATHOL, V166, P225, DOI 10.1002/path.1711660304; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Schandl CA, 1999, J HISTOCHEM CYTOCHEM, V47, P151, DOI 10.1177/002215549904700204; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; Schuller HM, 2002, NAT REV CANCER, V2, P455, DOI 10.1038/nrc824; Sipowicz MA, 1997, CANCER LETT, V117, P87, DOI 10.1016/S0304-3835(97)00208-5; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; STRASSER A, 1993, ONCOGENE, V8, P1; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; WASEEM NH, 1990, J CELL SCI, V96, P121; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	62	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14446	14456		10.1074/jbc.M511914200	http://dx.doi.org/10.1074/jbc.M511914200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16554306	hybrid			2022-12-25	WOS:000207179300003
J	Hernandez-Pigeon, H; Jean, C; Charruyer, A; Haure, MJ; Titeux, M; Tonasso, L; Quillet-Mary, A; Baudouin, C; Charveron, M; Laurent, G				Hernandez-Pigeon, H; Jean, C; Charruyer, A; Haure, MJ; Titeux, M; Tonasso, L; Quillet-Mary, A; Baudouin, C; Charveron, M; Laurent, G			Human keratinocytes acquire cellular cytotoxicity under UV-B irradiation - Implication of granzyme B and perforin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; SKIN-CANCER; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; INDUCED APOPTOSIS; SERINE PROTEASES; OXIDATIVE STRESS; LEUKEMIC-CELLS	Ultraviolet ( UV) radiation from the sun is widely considered as a major cause of human skin photoaging and skin cancer. Granzyme B ( GrB) and perforin ( PFN) are two proteins contained in granules and implicated in one of the mechanisms by which cytotoxic lymphocytes and natural killer cells exert their cytotoxicity against virus- infected, alloreactive, or transformed cells. The distribution of GrB and PFN in the skin has received little attention. However, Berthou and co- workers ( Berthou, C., Michel, L., Soulie, A., Jean-Louis, F., Flageul, B., Dubertret, L., Sigaux, F., Zhang, Y., and Sasportes, M. ( 1997) J. Immunol. 159, 5293 - 5300) described that, whereas freshly isolated epidermal cells did not express GrB or PFN, keratinocyte growth to confluence was associated with GrB and PFN mRNA and protein synthesis. In this work, we have investigated the possible role of UV- B on GrB and PFN expression in keratinocytes. We found that UV- B induces GrB and PFN expression in these cells through redox-, epidermal growth factor receptor-, and mitogen- activated protein kinase- dependent signaling. Furthermore, under UV irradiation, keratinocytes acquire a significant cytotoxicity, which is GrB and PFN dependent, toward a variety of cellular targets including transformed T- lymphocytes, melanocytes, and keratinocytes. This phenomenon may have important functional consequences in the regulation of skin inflammatory response and in the emergence of cancer skin.	CHU Purpan, Hematol Serv, F-31059 Toulouse, France; Inst Rech Pierre Fabre, CERPER, Lab Biol Cellulaire Cutanee, Toulouse, France	CHU de Toulouse; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	Hernandez-Pigeon, H (corresponding author), CHU Purpan, INSERM, U563, CPTP, Bat B,Pavillon Lefebvre,Pl Dr Baylac,BP 3028, F-31024 Toulouse 3, France.	helene.hernandez@toulouse.inserm.fr	QUILLET-MARY, Anne/H-4690-2013; jean, christine/P-2920-2014; Titeux, Matthias/K-8411-2017	jean, christine/0000-0002-6936-289X; Titeux, Matthias/0000-0001-7386-2769				ANANTHASWAMY HN, 1992, PROG CLIN BIOL RES, V376, P61; Andre ND, 2004, J CLIN LAB ANAL, V18, P27, DOI 10.1002/jcla.20006; Ashida M, 2003, EXP DERMATOL, V12, P445, DOI 10.1034/j.1600-0625.2003.00101.x; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Berthou C, 1997, J IMMUNOL, V159, P5293; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; BRANDER C, 1993, EUR J IMMUNOL, V23, P3217, DOI 10.1002/eji.1830231226; Bruno AP, 2000, BLOOD, V96, P1914, DOI 10.1182/blood.V96.5.1914.h8001914_1914_1920; Butler MP, 2005, J BIOL CHEM, V280, P27759, DOI 10.1074/jbc.M500756200; Buzza MS, 2005, J BIOL CHEM, V280, P23549, DOI 10.1074/jbc.M412001200; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; COHENKNAFO E, 1995, J CLIN PATHOL, V48, P826, DOI 10.1136/jcp.48.9.826; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; El-Abaseri TB, 2005, CANCER RES, V65, P3958, DOI 10.1158/0008-5472.CAN-04-2204; GoihmanYahr M, 1996, CLIN DERMATOL, V14, P153, DOI 10.1016/0738-081X(95)00150-E; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Guilloton F, 2005, LEUKEMIA, V19, P2206, DOI 10.1038/sj.leu.2403952; Hart PH, 2001, CLIN EXP PHARMACOL P, V28, P1, DOI 10.1046/j.1440-1681.2001.03392.x; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hirst CE, 2001, MOL HUM REPROD, V7, P1133, DOI 10.1093/molehr/7.12.1133; Horiuchi K, 2003, J RHEUMATOL, V30, P1799; HUDIG D, 1991, J IMMUNOL, V147, P1360; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; LEONARD M, 1993, BLOOD, V82, P1071; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; LICHTENHELD MG, 1989, J IMMUNOL, V143, P4267; MUNKER R, 1987, BLOOD, V70, P1730; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; OSTERGAARD HL, 1987, NATURE, V330, P71, DOI 10.1038/330071a0; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROBERTSON MJ, 1995, LEUKEMIA LYMPHOMA, V17, P51, DOI 10.3109/10428199509051703; Ronday HK, 2001, RHEUMATOLOGY, V40, P55, DOI 10.1093/rheumatology/40.1.55; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sander CS, 2004, INT J DERMATOL, V43, P326, DOI 10.1111/j.1365-4632.2004.02222.x; Sasson R, 2003, BIOCHEM PHARMACOL, V66, P1393, DOI 10.1016/S0006-2952(03)00489-1; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Simon T, 2003, AM J TRANSPLANT, V3, P1121, DOI 10.1034/j.1600-6143.2003.00187.x; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Tchernitchko D, 2002, BIOCHEM J, V363, P449, DOI 10.1042/0264-6021:3630449; Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911; van den Broek MF, 2000, EXP PHYSIOL, V85, P681; WATT FM, 1987, ARCH DERMATOL RES, V279, P335, DOI 10.1007/BF00431227; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; YOUN BS, 1991, J EXP MED, V173, P813, DOI 10.1084/jem.173.4.813; YOUNG AR, 1990, SEMIN DERMATOL, V9, P25	54	65	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13525	13532		10.1074/jbc.M512694200	http://dx.doi.org/10.1074/jbc.M512694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16524880	hybrid			2022-12-25	WOS:000237336600060
J	Kim, KY; Cheon, HG				Kim, KY; Cheon, HG			Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; NITRIC-OXIDE; POTASSIUM CHANNELS; LIGANDS; GROWTH; PHOSPHORYLATION; MODULATION; APOPTOSIS; MIGRATION; PROTEIN	Recent evidence shows that peroxisome proliferator- activated receptor gamma ( PPAR gamma) ligands induce the antiangiogenic effect in endothelial cells and tumors. In the present study, we elucidated the involvement of maxi- K channel activation in the antiangiogenic effect of rosiglitazone, a well known PPAR gamma ligand in human umbilical vein endothelial cells. We found that the antiangiogenic effects of rosiglitazone were reversed by either bisphenol A diaglycidyl ether, a PPAR gamma antagonist, or iberiotoxin, a maxi- K channel blocker. Knockdown of maxi- K channel expression also reversed the antiangiogenic effects. Iberiotoxin reversed the rosiglitazone- induced hyperpolarization while having no effect on the endogenous PPAR gamma activation, suggesting that rosiglitazone activates maxi- K channel via PPAR gamma. In the rosiglita-zone-induced antiangiogenic process, endothelial nitric- oxide synthase- Ser(1179) phosphorylation and NO production were significantly elevated, and treatment with the NOS inhibitor N-G-monomethyl-(L)- arginine acetate abolished the antiangiogenic and apoptotic effects of rosiglitazone, indicating NO as a key mediator of the rosiglitazone actions. In conclusion, rosiglitazone significantly inhibited VEGF(165)- induced angiogenesis by a proapoptotic mechanism via PPAR gamma- mediated NO production, followed by maxi- K channel opening.	Korea Res Inst Chem Technol, Div Med Sci, Taejon 305600, South Korea	Korea Research Institute of Chemical Technology (KRICT)	Cheon, HG (corresponding author), Korea Res Inst Chem Technol, Div Med Sci, POB 107, Taejon 305600, South Korea.	hgcheon@krict.re.kr						Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Brakemeier S, 2003, KIDNEY INT, V64, P199, DOI 10.1046/j.1523-1755.2003.00051.x; Calnek DS, 2003, ARTERIOSCL THROM VAS, V23, P52, DOI 10.1161/01.ATV.0000044461.01844.C9; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Cho DH, 2004, J BIOL CHEM, V279, P2499, DOI 10.1074/jbc.M309451200; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Frieden M, 2002, J PHYSIOL-LONDON, V540, P73, DOI 10.1113/jphysiol.2002.017053; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; Goetze S, 2002, HYPERTENSION, V40, P748, DOI 10.1161/01.HYP.0000035522.63647.D3; Haburcak M, 1997, CELL CALCIUM, V21, P291, DOI 10.1016/S0143-4160(97)90117-2; Hsueh WA, 2001, ARTERIOSCL THROM VAS, V21, P1891, DOI 10.1161/hq1201.100261; Huang HH, 2004, MOL CANCER RES, V2, P541; Kalvelyte A, 2003, BIOCHEM PHARMACOL, V66, P1661, DOI 10.1016/S0006-2952(03)00540-9; Kim KY, 2004, EUR J PHARMACOL, V497, P267, DOI 10.1016/j.ejphar.2004.06.058; Kraft R, 2003, PFLUG ARCH EUR J PHY, V446, P248, DOI 10.1007/s00424-003-1012-4; Krick S, 2001, AM J PHYSIOL-CELL PH, V280, pC970, DOI 10.1152/ajpcell.2001.280.4.C970; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Loviscach M, 2000, DIABETOLOGIA, V43, P304, DOI 10.1007/s001250050048; Margeli A., 2003, Angiogenesis, V6, P165, DOI 10.1023/B:AGEN.0000021377.13669.c0; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709, DOI 10.1001/archopht.119.5.709; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Poolos NP, 1999, J NEUROSCI, V19, P5205; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Wolfram CR, 2004, THROMB HAEMOSTASIS, V92, P1099, DOI 10.1160/TH04-03-0196; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Zhang XF, 2003, NEUROSCIENCE, V122, P1003, DOI 10.1016/j.neuroscience.2003.08.035	36	29	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13503	13512		10.1074/jbc.M510357200	http://dx.doi.org/10.1074/jbc.M510357200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16527820	hybrid			2022-12-25	WOS:000237336600058
J	Kobayashi, T; Solaro, RJ				Kobayashi, T; Solaro, RJ			Increased Ca2+ affinity of cardiac thin filaments reconstituted with cardiomyopathy-related mutant cardiac troponin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; ENERGY-TRANSFER SPECTROSCOPY; PROTEIN-KINASE-C; SKELETAL-MUSCLE; RESTRICTIVE CARDIOMYOPATHY; REGULATORY DOMAIN; INHIBITORY REGION; CALCIUM-BINDING; ACTIN-TROPOMYOSIN; ATPASE ACTIVITY	To understand the molecular mechanisms whereby cardiomyopathy-related cardiac troponin I ( cTnI) mutations affect myofilament activity, we have investigated the Ca2+ binding properties of various assemblies of the regulatory components that contain one of the cardiomyopahty- related mutant cTnI. Acto- S1 ATPase activities in reconstituted systems were also determined. We investigated R145G and R145W mutations from the inhibitory region and D190H and R192H mutations from the second actin- tropomyosin-binding site. Each of the four mutations sensitized the acto- S1 ATPase to Ca2+. Whereas the mutations from the inhibitory region increased the basal level of ATPase activity, those from the second actin- tropomyosin- binding site did not. The effects on the Ca2+ binding properties of the troponin ternary complex and the troponin-tropomyosin complex with one of four mutations were either desensitization or no effect compared with those with wild- type cTnI. All of the mutations, however, affected the Ca2+ sensitivities of the reconstituted thin filaments in the same direction as the acto- S1 ATPase activity. Also the thin filaments with one of the mutant cTnIs bound Ca2+ with less cooperativity compared with those with wild- type cTnI. These data indicate that the mutations found in the inhibitory region and those from the second actin-tropomyosin site shift the equilibrium of the states of the thin filaments differently. Moreover, the increased Ca2+ bound to myofilaments containing the mutant cTnIs may be an important factor in triggered arrhythmias associated with the cardiomyopathy.	Univ Illinois, Dept Physiol & Biophys, Coll Med, Chicago, IL 60612 USA; Univ Illinois, Cardiovasc Res Ctr, Coll Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kobayashi, T (corresponding author), Univ Illinois, Dept Physiol & Biophys, Coll Med, 835 S Wolcott Ave,M-C 901, Chicago, IL 60612 USA.	tkoba@uic.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022231, P01HL062426] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL 22231, P01 HL 62426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERS DM, 1994, METHOD CELL BIOL, V40, P3; Burton D, 2002, BIOCHEM J, V362, P443, DOI 10.1042/0264-6021:3620443; Craig R, 2001, J MOL BIOL, V311, P1027, DOI 10.1006/jmbi.2001.4897; Deng Y, 2001, BIOCHEMISTRY-US, V40, P14593, DOI 10.1021/bi0115232; Digel J, 2001, ARCH BIOCHEM BIOPHYS, V387, P243, DOI 10.1006/abbi.2000.2259; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; Dong WJ, 1997, BIOPHYS J, V72, P850, DOI 10.1016/S0006-3495(97)78719-8; Dvoretsky A, 2002, J BIOL CHEM, V277, P38565, DOI 10.1074/jbc.M205306200; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; Foster DB, 2003, CIRC RES, V93, P917, DOI 10.1161/01.RES.0000099889.35340.6F; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; Gomes AV, 2005, J BIOL CHEM, V280, P30909, DOI 10.1074/jbc.M500287200; Gong HY, 2005, P NATL ACAD SCI USA, V102, P656, DOI 10.1073/pnas.0407225102; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GRABAREK Z, 1983, J BIOL CHEM, V258, P4098; GRAND RJA, 1982, BIOCHEM J, V203, P61, DOI 10.1042/bj2030061; GUTH K, 1987, J BIOL CHEM, V262, P13627; Hai H, 2002, J BIOCHEM, V131, P407, DOI 10.1093/oxfordjournals.jbchem.a003116; HOFMANN PA, 1987, AM J PHYSIOL, V253, pC90; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; James J, 2000, CIRC RES, V87, P805, DOI 10.1161/01.RES.87.9.805; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; Kimura C, 2002, J BIOCHEM, V132, P93, DOI 10.1093/oxfordjournals.jbchem.a003204; Kobayashi T, 2005, ANNU REV PHYSIOL, V67, P39, DOI 10.1146/annurev.physiol.67.040403.114025; Kobayashi T, 2005, J MOL CELL CARDIOL, V38, P213, DOI 10.1016/j.yjmcc.2004.10.014; Kobayashi T, 2004, BIOCHEMISTRY-US, V43, P5996, DOI 10.1021/bi036073n; Kobayashi T, 2001, BBA-PROTEIN STRUCT M, V1549, P148, DOI 10.1016/S0167-4838(01)00254-0; Kobayashi T, 2000, BIOCHEMISTRY-US, V39, P86, DOI 10.1021/bi991903b; Kobayashi T, 1999, BIOCHEMISTRY-US, V38, P5386, DOI 10.1021/bi981320m; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Kruger M, 2005, J PHYSIOL-LONDON, V564, P347, DOI 10.1113/jphysiol.2004.079095; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; Li MX, 2003, BIOCHEMISTRY-US, V42, P14460, DOI 10.1021/bi035408y; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Luo Y, 1999, BIOCHEMISTRY-US, V38, P6678, DOI 10.1021/bi9824341; Luo Y, 2000, J MOL BIOL, V296, P899, DOI 10.1006/jmbi.1999.3495; Martyn DA, 2001, BIOPHYS J, V80, P360, DOI 10.1016/S0006-3495(01)76020-1; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; Maytum R, 2003, J BIOL CHEM, V278, P6696, DOI 10.1074/jbc.M210690200; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; McKay RT, 1999, BIOCHEMISTRY-US, V38, P5478; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MIKI M, 1990, EUR J BIOCHEM, V187, P155, DOI 10.1111/j.1432-1033.1990.tb15289.x; Miki M, 1998, J BIOCHEM-TOKYO, V123, P324; Mogensen J, 2003, J CLIN INVEST, V111, P209, DOI 10.1172/JCI200316336; Murakami K, 2005, J MOL BIOL, V352, P178, DOI 10.1016/j.jmb.2005.06.067; PAN BS, 1987, J BIOL CHEM, V262, P7839; Patchell VB, 2005, J BIOL CHEM, V280, P14469, DOI 10.1074/jbc.M414202200; Pirani A, 2005, J MOL BIOL, V346, P761, DOI 10.1016/j.jmb.2004.12.013; Putkey JA, 1997, BIOCHEMISTRY-US, V36, P970, DOI 10.1021/bi9617466; Ramos CHI, 1999, J BIOL CHEM, V274, P18189, DOI 10.1074/jbc.274.26.18189; Rarick HM, 1997, J BIOL CHEM, V272, P26887, DOI 10.1074/jbc.272.43.26887; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; Sumandea MP, 2003, J BIOL CHEM, V278, P35135, DOI 10.1074/jbc.M306325200; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; Szczesna D, 1999, J BIOL CHEM, V274, P29536, DOI 10.1074/jbc.274.41.29536; Takahashi-Yanaga F, 2001, J MOL CELL CARDIOL, V33, P2095, DOI 10.1006/jmcc.2001.1473; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; ter Keurs HEDJ, 2006, PROG BIOPHYS MOL BIO, V90, P151, DOI 10.1016/j.pbiomolbio.2005.07.002; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; Westfall MV, 2002, CIRC RES, V91, P525, DOI 10.1161/01.RES.0000034710.46739.C0; WNUK W, 1984, J BIOL CHEM, V259, P9017; Yumoto F, 2005, BIOCHEM BIOPH RES CO, V338, P1519, DOI 10.1016/j.bbrc.2005.10.116; Zhou X, 2000, BIOCHEMISTRY-US, V39, P1128, DOI 10.1021/bi992327m	73	102	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13471	13477		10.1074/jbc.M509561200	http://dx.doi.org/10.1074/jbc.M509561200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531415	hybrid			2022-12-25	WOS:000237336600054
J	Ono, K; Okajima, T; Tani, M; Kuroda, S; Sun, D; Davidson, VL; Tanizawa, K				Ono, K; Okajima, T; Tani, M; Kuroda, S; Sun, D; Davidson, VL; Tanizawa, K			Involvement of a putative [Fe-S]-cluster-binding protein in the biogenesis of quinohemoprotein amine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN TRYPTOPHYLQUINONE BIOGENESIS; QUINONE COFACTOR BIOGENESIS; PARACOCCUS-DENITRIFICANS; METHYLAMINE DEHYDROGENASE; PSEUDOMONAS-PUTIDA; REDOX COFACTOR; ACTIVE-SITE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; LYSYL OXIDASE	Quinohemoprotein amine dehydrogenase (QHNDH) of Paracoccus denitrificans contains a peptidyl quinone cofactor, cysteine tryptophylquinone, as well as intrapeptidyl thioether cross-links between Cys and Asp/Glu residues within the smallest gamma-subunit of the alpha beta gamma heterotrimeric protein. A putative [Fe-S]-cluster-binding protein (ORF2 protein) encoded between the structural genes for the alpha- and gamma-subunitsof QHNDH in the n-butylamine-utilizing operon likely belongs to a Radical SAM (S-Ado Met) superfamily that includes many proteins involved in vitamin biosynthesis and enzyme activation. In this study the role of ORF2 protein in the biogenesis of QHNDH has been explored. Although the wild-type strain of Paracoccus denitrificans produced an active, mature enzyme upon induction with n-butylamine, a mutant strain in which the ORF2 gene had been mostly deleted, neither grew in the n-butylamine medium nor showed QHNDH activity. When the mutant strain was transformed with an expression plasmid for the ORF2 protein, n butylamine-dependent bacterial growth and QHNDH activity were restored. Site-specific mutations in the putative [Fe-S]-cluster or SAM binding motifs in the ORF2 protein failed to support bacterial growth. The alpha- and beta subunits were both detected in the periplasm of the mutant strain, whereas the gamma-subunit polypeptide was accumulated in the cytoplasm and stained negatively for redox-cycling quinone staining. Matrix-assisted laser desorption ionization time-of-flight mass spectrometric analysis revealed that the gamma-subunit isolated from the mutant strain had not undergone post-translational modification. These results unequivocally show that the putative [ Fe-S]-cluster- and SAM-binding ORF2 protein is necessary for the posttranslational processing of gamma-subunit, most likely participating in the formation of the intrapeptidyl thioether cross-links.	Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan; Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	Osaka University; University of Mississippi; University of Mississippi Medical Center	Okajima, T (corresponding author), Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan.	tokajima@sanken.osaka-u.ac.jp; tanizawa@sanken.osaka-u.ac.jp		Okajima, Toshihide/0000-0003-1733-9580; Davidson, Victor/0000-0002-1966-7302	NIGMS NIH HHS [GM-41574] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041574, R01GM041574] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi O, 1998, BIOSCI BIOTECH BIOCH, V62, P469, DOI 10.1271/bbb.62.469; ALEFOUNDER PR, 1981, BIOCHEM BIOPH RES CO, V98, P778, DOI 10.1016/0006-291X(81)91179-7; Bollinger JA, 2005, BIOCHEMISTRY-US, V44, P11708, DOI 10.1021/bi0504310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buis JM, 2005, ARCH BIOCHEM BIOPHYS, V433, P288, DOI 10.1016/j.abb.2004.09.028; Chen LY, 1998, J MOL BIOL, V276, P131, DOI 10.1006/jmbi.1997.1511; Cianciotto NP, 2005, MOL MICROBIOL, V56, P1408, DOI 10.1111/j.1365-2958.2005.04650.x; Datta S, 2003, ACTA CRYSTALLOGR D, V59, P1551, DOI 10.1107/S090744490301429X; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; Davidson VL, 2004, ARCH BIOCHEM BIOPHYS, V428, P32, DOI 10.1016/j.abb.2004.03.022; Fang QH, 2004, J BIOL CHEM, V279, P14570, DOI 10.1074/jbc.M313855200; Fujieda N, 2002, BIOCHEMISTRY-US, V41, P13736, DOI 10.1021/bi026387v; HARMS N, 1985, J BACTERIOL, V164, P1064, DOI 10.1128/JB.164.3.1064-1070.1985; HARMS N, 1991, J BIOENERG BIOMEMBR, V23, P187, DOI 10.1007/BF00762217; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; Jones LH, 2005, J BIOL CHEM, V280, P17392, DOI 10.1074/jbc.M500943200; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marsh ENG, 2004, BIOORG CHEM, V32, P326, DOI 10.1016/j.bioorg.2004.06.001; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; PAZ MA, 1991, J BIOL CHEM, V266, P689; Pearson AR, 2004, BIOCHEMISTRY-US, V43, P5494, DOI 10.1021/bi049863l; Pearson AR, 2003, BIOCHEMISTRY-US, V42, P3224, DOI 10.1021/bi027073a; Satoh A, 2003, BBA-PROTEINS PROTEOM, V1647, P272, DOI 10.1016/S1570-9639(03)00069-4; Satoh A, 2002, J BIOL CHEM, V277, P2830, DOI 10.1074/jbc.M109090200; Simon R., 1983, MOL GENETICS BACTERI, V1st ed., P98; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Takagi K, 1999, BIOCHEMISTRY-US, V38, P6935, DOI 10.1021/bi9828268; Takagi K, 2001, EUR J BIOCHEM, V268, P470, DOI 10.1046/j.1432-1033.2001.01912.x; Torrents E, 2001, J BIOL CHEM, V276, P33488, DOI 10.1074/jbc.M103743200; Vandenberghe I, 2001, J BIOL CHEM, V276, P42923, DOI 10.1074/jbc.M107164200; VANDERPALEN CJNM, 1995, EUR J BIOCHEM, V230, P860; vanderPalen CJNM, 1997, ANTON LEEUW INT J G, V72, P219, DOI 10.1023/A:1000441925796; VANSPANNING RJM, 1994, EUR J BIOCHEM, V226, P201; VANSPANNING RJM, 1991, J BACTERIOL, V173, P6962, DOI 10.1128/jb.173.21.6962-6970.1991; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; Wang YT, 2005, J AM CHEM SOC, V127, P8258, DOI 10.1021/ja051734k; Wang YT, 2003, BIOCHEMISTRY-US, V42, P7318, DOI 10.1021/bi034243q; Whittaker MM, 2003, J BIOL CHEM, V278, P22090, DOI 10.1074/jbc.M300112200	41	28	28	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13672	13684		10.1074/jbc.M600029200	http://dx.doi.org/10.1074/jbc.M600029200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16546999	hybrid			2022-12-25	WOS:000237336600078
J	Sanders, RJ; Ofman, R; Duran, M; Kemp, S; Wanders, RJA				Sanders, RJ; Ofman, R; Duran, M; Kemp, S; Wanders, RJA			omega-oxidation of very long-chain fatty acids in human liver microsomes - Implications for X-linked adrenoleukodystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROMES P450; RAT-LIVER; ACETYLSALICYLIC-ACID; MONOCARBOXYLIC ACIDS; SELECTIVE INHIBITORS; DICARBOXYLIC-ACIDS; SKIN FIBROBLASTS; BETA-OXIDATION; METABOLISM; EXPRESSION	X-linked adrenoleukodystrophy ( X-ALD) is a severe neurodegenerative disorder biochemically characterized by elevated levels of very long-chain fatty acids ( VLCFA). Excess levels of VLCFAs are thought to play an important role in the pathogenesis of X-ALD. Therefore, therapeutic approaches for X-ALD are focused on the reduction or normalization of VLCFAs. In this study, we investigated an alternative oxidation route for VLCFAs, namely omega-oxidation. The results described in this study show that VLCFAs are substrates for the omega-oxidation system in human liver microsomes. Moreover, VLCFAs were not only converted into omega-hydroxy fatty acids, but they were also further oxidized to dicarboxylic acids via cytochrome P450-mediated reactions. High sensitivity toward the specific P450 inhibitor 17-octadecynoic acid suggested that omega-hydroxylation of VLCFAs is catalyzed by P450 enzymes belonging to the CYP4A/F subfamilies. Studies with individually expressed human recombinant P450 enzymes revealed that two P450 enzymes, i.e. CYP4F2 and CYP4F3B, participate in the omega-hydroxylation of VLCFAs. Both enzymes belong to the cytochrome P450 4F subfamily and have a high affinity for VLCFAs. In summary, this study demonstrates that VLCFAs are substrates for the human omega-oxidation system, and for this reason, stimulation of the in vivo VLCFA omega-oxidation pathway may provide an alternative mode of treatment to reduce the levels of VLCFAs in patients with X-ALD.	Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Wanders, RJA (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, Meibergdreef 9,Rm F0-224, NL-1105 AZ Amsterdam, Netherlands.	r.j.wanders@amc.uva.nl	Kemp, Stephan/A-3935-2008	Kemp, Stephan/0000-0003-2023-064X				Adas F, 1999, J LIPID RES, V40, P1990; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; BALDWIN SJ, 1995, XENOBIOTICA, V25, P261, DOI 10.3109/00498259509061850; BJORKHEM I, 1978, J LIPID RES, V19, P585; CHEN LP, 1993, ARCH BIOCHEM BIOPHYS, V300, P18, DOI 10.1006/abbi.1993.1003; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Christmas P, 2001, J BIOL CHEM, V276, P38166; Collins XH, 2005, J BIOL CHEM, V280, P33157, DOI 10.1074/jbc.M504055200; Dickins M, 2004, CURR TOP MED CHEM, V4, P1745, DOI 10.2174/1568026043387115; Eagling VA, 1998, BRIT J CLIN PHARMACO, V45, P107, DOI 10.1046/j.1365-2125.1998.00679.x; Ferdinandusse S, 2004, J LIPID RES, V45, P1104, DOI 10.1194/jlr.M300512-JLR200; IGARASHI M, 1976, J NEUROCHEM, V26, P851, DOI 10.1111/j.1471-4159.1976.tb04462.x; JAKOBS C, 1981, CLIN CHIM ACTA, V111, P169, DOI 10.1016/0009-8981(81)90184-4; Kawashima H, 1997, ARCH BIOCHEM BIOPHYS, V347, P148, DOI 10.1006/abbi.1997.0342; Kelson TL, 1997, BBA-GEN SUBJECTS, V1335, P99, DOI 10.1016/S0304-4165(96)00126-2; Kemp S, 2004, CLIN CHEM, V50, P1824, DOI 10.1373/clinchem.2004.038539; KIKUTA Y, 1994, FEBS LETT, V348, P70, DOI 10.1016/0014-5793(94)00587-7; Kikuta Y, 2002, PROSTAG OTH LIPID M, V68-9, P345, DOI 10.1016/S0090-6980(02)00039-4; KOLVRAA S, 1986, BIOCHIM BIOPHYS ACTA, V876, P515, DOI 10.1016/0005-2760(86)90039-1; Korman SH, 2000, J INHERIT METAB DIS, V23, P425, DOI 10.1023/A:1005624523611; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; Kroetz DL, 2005, ANNU REV PHARMACOL, V45, P413, DOI 10.1146/annurev.pharmtox.45.120403.100045; KUNDU RK, 1993, J LIPID RES, V34, P1187; KUNDU RK, 1991, J CLIN INVEST, V88, P1865, DOI 10.1172/JCI115508; Lewis DFV, 2004, PHARMACOGENOMICS, V5, P305, DOI 10.1517/phgs.5.3.305.29827; MITZ MA, 1961, BIOCHIM BIOPHYS ACTA, V46, P45, DOI 10.1016/0006-3002(61)90644-8; Moser H., 2001, METABOLIC MOL BASES, VII, P3257; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NEWTON DJ, 1995, DRUG METAB DISPOS, V23, P154; Nguyen X, 1999, AM J PHYSIOL-REG I, V276, pR1691; Nishimura M, 2003, YAKUGAKU ZASSHI, V123, P369; Okita RT, 2001, CURR DRUG METAB, V2, P265; ROBBINS KC, 1968, ARCH BIOCHEM BIOPHYS, V123, P531, DOI 10.1016/0003-9861(68)90174-4; ROCCHICCIOLI F, 1986, PEDIATR RES, V20, P62, DOI 10.1203/00006450-198601000-00018; Sanders RJ, 2005, J LIPID RES, V46, P1001, DOI 10.1194/jlr.M400510-JLR200; SINGH I, 1984, PEDIATR RES, V18, P286, DOI 10.1203/00006450-198403000-00016; Valianpour F, 2003, MOL GENET METAB, V79, P189, DOI 10.1016/S1096-7192(03)00098-2; WAKABAYASHI K, 1963, BIOCHIM BIOPHYS ACTA, V70, P132, DOI 10.1016/0006-3002(63)90733-9; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Wanders RJA, 2004, MOL GENET METAB, V83, P16, DOI 10.1016/j.ymgme.2004.08.016; Wen X, 2002, DRUG METAB DISPOS, V30, P631, DOI 10.1124/dmd.30.6.631; Xu FY, 2004, J PHARMACOL EXP THER, V308, P887, DOI 10.1124/jpet.103.059626; Zhang XL, 2000, ARCH BIOCHEM BIOPHYS, V378, P364, DOI 10.1006/abbi.2000.1836	43	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13180	13187		10.1074/jbc.M513481200	http://dx.doi.org/10.1074/jbc.M513481200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547005	Green Submitted, hybrid			2022-12-25	WOS:000237336600023
J	Yoo, MH; Xu, XM; Carlson, BA; Gladyshev, VN; Hatfield, DL				Yoo, MH; Xu, XM; Carlson, BA; Gladyshev, VN; Hatfield, DL			Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOPROTEIN THIOREDOXIN REDUCTASE; HUMAN CANCER; SELENIUM; SELENOCYSTEINE; INHIBITION; EXPRESSION; GROWTH; P53; INDUCTION; MECHANISM	Dietary selenium has potent cancer prevention activity. Both low molecular weight selenocompounds and selenoproteins are implicated in this effect. Thioredoxin reductase 1 (TR1) is one of the major antioxidant and redox regulators in mammals that supports p53 function and other tumor suppressor activities. However, this selenium-containing oxidoreductase is also overexpressed in many malignant cells and has been proposed as a target for cancer therapy. To further assess the role of TR1 in the malignancy process, we used RNA interference technology to decrease its expression in mouse lung carcinoma (LLC1) cells. Stable transfection of LLC1 cells with a small interfering RNA construct that specifically targets TR1 removal manifested a reversal in the morphology and anchorage-independent growth properties of these cancer cells that made them similar to those of normal cells. The expression of at least two cancer-related protein mRNAs, Hgf and Opn1, were reduced dramatically in the TR1 knockdown cells. Mice injected with the TR1 knockdown showed a dramatic reduction in tumor progression and metastasis compared with those mice injected with the corresponding control vector. In addition, tumors that arose from injected TR1 knockdown cells lost the targeting construct, suggesting that TR1 is essential for tumor growth in mice. These observations provide direct evidence that the reduction of TR1 levels in malignant cells is antitumorigenic and suggest that the enzyme is a prime target for cancer therapy.	NIH, Mol Bil Selenium Sect, Lab Canc Prevent, Canc Res Ctr, Bethesda, MD 20892 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	National Institutes of Health (NIH) - USA; University of Nebraska System; University of Nebraska Lincoln	Hatfield, DL (corresponding author), NIH, Mol Bil Selenium Sect, Lab Canc Prevent, Canc Res Ctr, Bldg 37,Rm 6032, Bethesda, MD 20892 USA.	hatfield@mail.nih.gov	Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013	Gladyshev, Vadim/0000-0002-0372-7016	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [CA080946] Funding Source: Medline; NIGMS NIH HHS [GM065204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080946, Z01BC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM065204, R01GM065204] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Behne D, 2001, ANNU REV NUTR, V21, P453, DOI 10.1146/annurev.nutr.21.1.453; Biaglow JE, 2005, CANCER BIOL THER, V4, P6; Carlson BA, 2005, J BIOL CHEM, V280, P5542, DOI 10.1074/jbc.M411725200; Carlson BA, 2004, J BIOL CHEM, V279, P8011, DOI 10.1074/jbc.M310470200; Cenas N, 2006, J BIOL CHEM, V281, P5593, DOI 10.1074/jbc.M511972200; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Diwadkar-Navsariwala V, 2004, J NUTR, V134, P2899, DOI 10.1093/jn/134.11.2899; Engman L, 2003, ANTI-CANCER DRUG, V14, P153, DOI 10.1097/00001813-200302000-00009; Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200; Gan L, 2005, J CELL BIOCHEM, V96, P653, DOI 10.1002/jcb.20585; Gromer S, 2005, CELL MOL LIFE SCI, V62, P2414, DOI 10.1007/s00018-005-5143-y; IRONS R, 2006, IN PRESS J NUTR; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Lincoln DT, 2003, ANTICANCER RES, V23, P2425; Liu HJ, 2005, CIRC RES, V97, P967, DOI 10.1161/01.RES.0000188210.72062.10; Merrill GF, 1999, CANCER RES, V59, P3175; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; Mukherjee A, 2005, BRIT J CANCER, V92, P350, DOI 10.1038/sj.bjc.6602338; NGUYEN P, 2006, IN PRESS CANC LETT; Novoselov SV, 2005, ONCOGENE, V24, P8003, DOI 10.1038/sj.onc.1208940; Rayman MP, 2005, P NUTR SOC, V64, P527, DOI 10.1079/PNS2005467; Ren Y, 2005, CLIN CANCER RES, V11, P6190, DOI 10.1158/1078-0432.CCR-04-2553; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Seemann S, 2005, ONCOGENE, V24, P3853, DOI 10.1038/sj.onc.1208549; Shi CJ, 2003, BIOCHEM BIOPH RES CO, V309, P578, DOI 10.1016/j.bbrc.2003.08.032; Smart DDK, 2004, CANCER RES, V64, P6716, DOI 10.1158/0008-5472.CAN-03-3990; Witte AB, 2005, FREE RADICAL BIO MED, V39, P696, DOI 10.1016/j.freeradbiomed.2005.04.025; Xu XM, 2005, J BIOL CHEM, V280, P41568, DOI 10.1074/jbc.M506696200; ZHAO F, 2006, IN PRESS CANC LETT; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	34	232	236	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13005	13008		10.1074/jbc.C600012200	http://dx.doi.org/10.1074/jbc.C600012200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16565519	hybrid, Green Submitted			2022-12-25	WOS:000237336600002
J	Kurihara, R; Tohyama, Y; Matsusaka, S; Naruse, H; Kinoshita, E; Tsujioka, T; Katsumata, Y; Yamamura, H				Kurihara, R; Tohyama, Y; Matsusaka, S; Naruse, H; Kinoshita, E; Tsujioka, T; Katsumata, Y; Yamamura, H			Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIGRATION; RHO; ACTIVATION; EXPRESSION; KINASE; HL-60; CB2; 2-ARACHIDONOYLGLYCEROL; PHOSPHORYLATION; DIFFERENTIATION	The possible role of the peripheral cannabinoid receptor (CB2) in neutrophil migration was investigated by using human promyelocytic HL60 cells differentiated into neutrophil-like cells and human neutrophils isolated from whole blood. Cell surface expression of CB2 on HL60 cells, on neutrophil-like HL60 cells, and on human neutrophils was confirmed by flow cytometry. Upon stimulation with either of the CB2 ligands JWH015 and 2-arachidonoylglycerol (2-AG), neutrophil-like HL60 cells rapidly extended and retracted one or more pseudopods containing F-actin in different directions instead of developing front/rear polarity typically exhibited by migrating leukocytes. Activity of the Rho-GTPase RhoA decreased in response to CB2 stimulation, whereas Rac1, Rac2, and Cdc42 activity increased. Moreover, treatment of cells with RhoA-dependent protein kinase (p160-ROCK) inhibitor Y27632 yielded cytoskeletal organization similar to that of CB2-stimulated cells. In human neutrophils, neither JWH015 nor 2-AG induced motility or morphologic alterations. However, pretreatment of neutrophils with these ligands disrupted N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)-induced front/rear polarization and migration and also substantially suppressed fMLP-induced RhoA activity. These results suggest that CB2 might play a role in regulating excessive inflammatory response by controlling RhoA activation, thereby suppressing neutrophil migration.	Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Proteom, Kobe, Hyogo 6500017, Japan; Nagoya Univ, Grad Sch Med, Dept Legal Med & Bioeth, Nagoya, Aichi 4668550, Japan; Kawasaki Med Sch, Dept Lab Med & Clin Pathol, Kurashiki, Okayama 7010192, Japan	Kobe University; Nagoya University; Kawasaki Medical School	Tohyama, Y (corresponding author), Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Proteom, Kobe, Hyogo 6500017, Japan.	ytohyama@med.kobe-u.ac.jp						Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Berdyshev EV, 2000, CHEM PHYS LIPIDS, V108, P169, DOI 10.1016/S0009-3084(00)00195-X; Bokoch GM, 2005, TRENDS CELL BIOL, V15, P163, DOI 10.1016/j.tcb.2005.01.002; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Croxford JL, 2005, J NEUROIMMUNOL, V166, P3, DOI 10.1016/j.jneuroim.2005.04.023; Derocq JM, 2000, J BIOL CHEM, V275, P15621, DOI 10.1074/jbc.275.21.15621; Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425; Deusch E, 2003, J NEUROIMMUNOL, V141, P99, DOI 10.1016/S0165-5728(03)00259-5; Dong XM, 2005, CURR BIOL, V15, P1874, DOI 10.1016/j.cub.2005.09.014; Eddy RJ, 2002, MOL BIOL CELL, V13, P4470, DOI 10.1091/mbc.E02-04-0241; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Hogg N, 2003, J CELL SCI, V116, P4695, DOI 10.1242/jcs.00876; Jorda MA, 2004, BLOOD, V104, P526, DOI 10.1182/blood-2003-12-4257; Jorda MA, 2002, BLOOD, V99, P2786; Joseph J, 2004, CANCER IMMUNOL IMMUN, V53, P723, DOI 10.1007/s00262-004-0509-9; Kaminski NE, 1998, J NEUROIMMUNOL, V83, P124, DOI 10.1016/S0165-5728(97)00228-2; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Matsusaka S, 2005, BIOCHEM BIOPH RES CO, V328, P1163, DOI 10.1016/j.bbrc.2005.01.076; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Miah SMS, 2004, GENES CELLS, V9, P993, DOI 10.1111/j.1365-2443.2004.00784.x; Miura Y, 2000, BLOOD, V96, P1733, DOI 10.1182/blood.V96.5.1733.h8001733_1733_1739; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Niggli V, 2003, J CELL SCI, V116, P813, DOI 10.1242/jcs.00306; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sacerdote P, 2000, J NEUROIMMUNOL, V109, P155, DOI 10.1016/S0165-5728(00)00307-6; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Sugiura T, 2004, J PHARMACOL SCI, V96, P367, DOI 10.1254/jphs.FMJ04003X3; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Valk PJM, 1997, J VIROL, V71, P6796, DOI 10.1128/JVI.71.9.6796-6804.1997; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Xu JS, 2005, P NATL ACAD SCI USA, V102, P6884, DOI 10.1073/pnas.0502106102; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5	42	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12908	12918		10.1074/jbc.M510871200	http://dx.doi.org/10.1074/jbc.M510871200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513651	hybrid			2022-12-25	WOS:000237134700086
J	Kwon, JE; La, M; Oh, KH; Oh, YM; Kim, GR; Seol, JH; Baek, SH; Chiba, T; Tanaka, K; Bang, OS; Joe, CO; Chung, CH				Kwon, JE; La, M; Oh, KH; Oh, YM; Kim, GR; Seol, JH; Baek, SH; Chiba, T; Tanaka, K; Bang, OS; Joe, CO; Chung, CH			BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; E3 LIGASE; CELL-CYCLE; C-ELEGANS; TGF-BETA; GENE; COMPLEX; P53; DEGRADATION; FAMILY	Daxx is a multifunctional protein that regulates a variety of cellular processes, including transcription, cell cycle, and apoptosis. SPOP is a BTB (Bric-a-brac/Tramtrack/Broad complex) protein that constitutes Cul3-based ubiquitin ligases. Here we show that SPOP serves as an adaptor of Daxx for the ubiquitination by Cul3-based ubiquitin ligase and subsequent degradation by the proteasome. Expression of SPOP with Cul3 markedly reduced Daxx level, and this degradation was blocked by SPOP-specific short hairpin RNAs. Inhibition of the proteasome by MG132 caused the prevention of Daxx degradation in parallel with the accumulation of ubiquitinated Daxx. Expression of SPOP with Cul3 reversed Daxx-mediated repression of ETS1- and p53-dependent transcription, and short hairpin RNA-mediated knock down of SPOP blocked the recovery of their transcriptional activation. Furthermore, Daxx degradation led to the cleavage of poly(ADP-ribose) polymerase and the increase in the number of terminal deoxynucleotidyltransferase-mediated dUTP-fluorescein nick end-labeling-positive apoptotic cells. These results suggest that SPOP/Cul3-ubiquitin ligase plays an essential role in the control of Daxx level and, thus, in the regulation of Daxx-mediated cellular processes, including transcriptional regulation and apoptosis.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Seoul Natl Univ, Sch Biol Sci, NRL Prot Biochem, Seoul 151742, South Korea; Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Tokyo Metropolitan Institute of Medical Science	Joe, CO (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	cojoe@kaist.ac.kr; chchung@snu.ac.kr	Joe, Cheol O/C-1917-2011					Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; Buttice G, 1996, ONCOGENE, V13, P2297; Cermak L, 2002, J BIOL CHEM, V277, P7955, DOI 10.1074/jbc.M108048200; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen LY, 2003, MOL CELL BIOL, V23, P7108, DOI 10.1128/MCB.23.20.7108-7121.2003; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; La M, 2004, BIOCHEM BIOPH RES CO, V320, P760, DOI 10.1016/j.bbrc.2004.06.022; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Michaelson JS, 2000, APOPTOSIS, V5, P217, DOI 10.1023/A:1009696227420; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; MIYASHITA T, 1995, CELL, V80, P293; Nagai Y, 1997, FEBS LETT, V418, P23, DOI 10.1016/S0014-5793(97)01340-9; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Ou CY, 2002, GENE DEV, V16, P2403, DOI 10.1101/gad.1011402; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2003, CURR BIOL, V13, P911, DOI 10.1016/S0960-9822(03)00336-1; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Srayko M, 2000, GENE DEV, V14, P1072; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Wu SY, 2002, NEOPLASIA, V4, P486, DOI 10.1038/sj.neo.7900264; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhao LY, 2004, J BIOL CHEM, V279, P50566, DOI 10.1074/jbc.M406743200; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	47	150	161	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12664	12672		10.1074/jbc.M600204200	http://dx.doi.org/10.1074/jbc.M600204200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524876	hybrid			2022-12-25	WOS:000237134700057
J	Sun, W; Singh, S; Zhang, RG; Turnbull, JL; Christendat, D				Sun, W; Singh, S; Zhang, RG; Turnbull, JL; Christendat, D			Crystal structure of prephenate dehydrogenase from Aquifex aeolicus - Insights into the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORISMATE MUTASE; ESCHERICHIA-COLI; AUXIN TRANSPORT; PROTEIN; BIOSYNTHESIS; FLAVONOIDS; TYROSINE; BINDING; GENE; EXPRESSION	The enzyme prephenate dehydrogenase catalyzes the oxidative decarboxylation of prephenate to 4-hydroxyphenylpyruvate for the biosynthesis of tyrosine. Prephenate dehydrogenases exist as either monofunctional or bifunctional enzymes. The bifunctional enzymes are diverse, since the prephenate dehydrogenase domain is associated with other enzymes, such as chorismate mutase and 3-phosphoskimate 1-carboxyvinyltransferase. We report the first crystal structure of a monofunctional prephenate dehydrogenase enzyme from the hyper-thermophile Aquifex aeolicus in complex with NAD(+). This protein consists of two structural domains, a modified nucleotide-binding domain and a novel helical prephenate binding domain. The active site of prephenate dehydrogenase is formed at the domain interface and is shared between the subunits of the dimer. We infer from the structure that access to the active site is regulated via a gated mechanism, which is modulated by an ionic network involving a conserved arginine, Arg(250). In addition, the crystal structure reveals for the first time the positions of a number of key catalytic residues and the identity of other active site residues that may participate in the reaction mechanism; these residues include Ser(126) and Lys(246) and the catalytic histidine, His(147). Analysis of the structure further reveals that two secondary structure elements, beta 3 and beta 7, are missing in the prephenate dehydrogenase domain of the bifunctional chorismate mutase-prephenate dehydrogenase enzymes. This observation suggests that the two functional domains of chorismate mutase- prephenate dehydrogenase are interdependent and explains why these domains cannot be separated.	Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada; Midwest Ctr Struct Genom & Struct Biol, Argonne Natl Lab, Argonne, IL 60440 USA; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H4B 1R6, Canada	University of Toronto; United States Department of Energy (DOE); Argonne National Laboratory; Concordia University - Canada	Christendat, D (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.	dinesh.christendat@utoronto.ca	Singh, Sasha/H-3612-2012	Singh, Sasha/0000-0003-0929-3164				Barycki JJ, 1999, BIOCHEMISTRY-US, V38, P5786, DOI 10.1021/bi9829027; Bonner CA, 2004, BIOCHEM J, V382, P279, DOI 10.1042/BJ20031809; Brown DE, 2001, PLANT PHYSIOL, V126, P524, DOI 10.1104/pp.126.2.524; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buer CS, 2004, PLANT CELL, V16, P1191, DOI 10.1105/tpc.020313; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; Chen SQ, 2003, EUR J BIOCHEM, V270, P757, DOI 10.1046/j.1432-1033.2003.03438.x; Christendat D, 2000, J BIOL CHEM, V275, P24608, DOI 10.1074/jbc.C000238200; Christendat D, 1998, BIOCHEMISTRY-US, V37, P15703, DOI 10.1021/bi981412b; Christendat D, 1999, BIOCHEMISTRY-US, V38, P4782, DOI 10.1021/bi982673o; COTTON RGH, 1965, BIOCHIM BIOPHYS ACTA, V100, P76, DOI 10.1016/0304-4165(65)90429-0; Dill GM, 2005, PEST MANAG SCI, V61, P219, DOI 10.1002/ps.1008; Frick S, 1999, PLANT J, V17, P329, DOI 10.1046/j.1365-313X.1999.00379.x; Guyon V, 2004, PLANT J, V39, P643, DOI 10.1111/j.1365-313X.2004.02162.x; HERMES JD, 1984, BIOCHEMISTRY-US, V23, P6263, DOI 10.1021/bi00320a057; HEYDE E, 1979, BIOCHEMISTRY-US, V18, P2766, DOI 10.1021/bi00580a012; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaneko M, 2003, J IND MICROBIOL BIOT, V30, P456, DOI 10.1007/s10295-003-0061-1; Kobayashi H, 2004, MOL MICROBIOL, V51, P335, DOI 10.1046/j.1365-2958.2003.03841.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; Liu JS, 1997, NAT STRUCT BIOL, V4, P896, DOI 10.1038/nsb1197-896; Lokanath NK, 2005, J MOL BIOL, V352, P905, DOI 10.1016/j.jmb.2005.07.068; Matak-Vinkovic D, 2001, BIOCHEMISTRY-US, V40, P14493, DOI 10.1021/bi011020w; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; Memelink J, 2004, NAT BIOTECHNOL, V22, P1526, DOI 10.1038/nbt1204-1526; Mobley EM, 1999, GENE, V240, P115, DOI 10.1016/S0378-1119(99)00423-0; MOLLER BL, 1979, J BIOL CHEM, V254, P8575; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NOCEK B, 2005, J MOL BIOL; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rescigno A, 1998, BIOCHEM PHARMACOL, V56, P1089, DOI 10.1016/S0006-2952(98)00170-1; Roberts CW, 2002, J INFECT DIS, V185, pS25, DOI 10.1086/338004; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Song J, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-13; Taylor LP, 2005, CURR OPIN PLANT BIOL, V8, P317, DOI 10.1016/j.pbi.2005.03.005; Taylor LP, 1997, ANNU REV PLANT PHYS, V48, P461, DOI 10.1146/annurev.arplant.48.1.461; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TURNBULL J, 1991, BIOCHEMISTRY-US, V30, P7777, DOI 10.1021/bi00245a016; XIA TH, 1992, J GEN MICROBIOL, V138, P1309, DOI 10.1099/00221287-138-7-1309; Xie G, 2000, COMP BIOCHEM PHYS C, V125, P65, DOI 10.1016/S0742-8413(99)00090-0	45	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12919	12928		10.1074/jbc.M511986200	http://dx.doi.org/10.1074/jbc.M511986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513644	hybrid			2022-12-25	WOS:000237134700087
J	Huang, Y; Niwa, J; Sobue, G; Breitwieser, GE				Huang, Y; Niwa, J; Sobue, G; Breitwieser, GE			Calcium-sensing receptor ubiquitination and degradation mediated by the E3 ubiquitin ligase dorfin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CA2+ RECEPTOR; N-LINKED GLYCOSYLATION; EXTRACELLULAR DOMAIN; UBIQUITYLATED INCLUSIONS; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; CELL-SURFACE; LEWY BODIES; PROTEIN; DIMERIZATION	Calcium-sensing receptors ( CaR) contribute to regulation of systemic calcium homeostasis by activation of G(q)- and G(i)-linked signaling pathways in the parathyroids, kidney, and intestine. Little is known about the mechanisms regulating CaR synthesis and degradation. Screening of a human kidney yeast two-hybrid library identified the E3 ubiquitin ligase dorfin as a binding partner for the intracellular carboxyl terminus of CaR. Interaction between CaR and dorfin was confirmed by coimmunoprecipitation from HEK293 cells. Ubiquitination of CaR was observed in the presence of the proteasomal inhibitor MG132; mutation of all putative intracellular loop and carboxyl-terminal lysine residues abolished ubiquitination of CaR. Coexpression with dorfin decreased the amount of total CaR protein and increased CaR ubiquitination, whereas a dominant negative fragment of dorfin had opposite effects. The AAA-ATPase p97/valosin-containing protein associates with both CaR and dorfin in HEK293 cells. Treatment with tunicamycin, ininhibitor of N-linked glycosylation, induced the appearance of the unglycosylated 115-kDa CaR form, which was further increased by exposure to MG132, or upon transfection with a dorfin dominant negative construct, suggesting that dorfin-mediated proteasomal degradation of immature CaR occurs from the endoplasmic reticulum. Because endogenous CaR in Madin-Darby canine kidney cells is also subject to degradation from the endoplasmic reticulum, dorfin-mediated ubiquitination may contribute to a general mechanism for CaR quality control during biosynthesis.	Geisinger Med Clin, Weis Ctr Res, Danville, PA 17822 USA; Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA; Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4668500, Japan	Geisinger Medical Center; Syracuse University; Nagoya University	Breitwieser, GE (corresponding author), Geisinger Med Clin, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.	gebreitwieser@geisinger.edu		Breitwieser, Gerda/0000-0001-9081-0362	NIGMS NIH HHS [R01 GM077563, R01 GM077563-02, GM58578] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058578, R01GM077563] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arthur JM, 2000, BIOCHEM BIOPH RES CO, V275, P538, DOI 10.1006/bbrc.2000.3226; Arthur JM, 1997, AM J PHYSIOL-RENAL, V273, pF129, DOI 10.1152/ajprenal.1997.273.1.F129; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; Cook LB, 2003, MOL ENDOCRINOL, V17, P1777, DOI 10.1210/me.2003-0073; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Gama L, 1999, BIOTECHNIQUES, V26, P814, DOI 10.2144/99265bm03; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hishikawa N, 2003, AM J PATHOL, V163, P609, DOI 10.1016/S0002-9440(10)63688-7; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Ishigaki S, 2004, J BIOL CHEM, V279, P51376, DOI 10.1074/jbc.M406683200; Ito T, 2003, J BIOL CHEM, V278, P29106, DOI 10.1074/jbc.M302763200; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Martin NP, 2003, J BIOL CHEM, V278, P45954, DOI 10.1074/jbc.M308285200; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; PEACE SHS, 1997, J ENDOCRINOL, V154, P371; Penela P, 1998, J BIOL CHEM, V273, P35238, DOI 10.1074/jbc.273.52.35238; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Saliba RS, 2002, J CELL SCI, V115, P2907; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhang ML, 2005, J BIOL CHEM, V280, P11140, DOI 10.1074/jbc.M412242200	43	61	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11610	11617		10.1074/jbc.M513552200	http://dx.doi.org/10.1074/jbc.M513552200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513638	hybrid			2022-12-25	WOS:000236988100024
J	Taha, TA; Kitatani, K; El-Alwani, M; Bielawski, J; Hannun, YA; Obeid, LM				Taha, TA; Kitatani, K; El-Alwani, M; Bielawski, J; Hannun, YA; Obeid, LM			Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis	FASEB JOURNAL			English	Article						ceramide; Bax; mitochondria	CANCER-THERAPY; SPHINGOSINE-1-PHOSPHATE PHOSPHOHYDROLASE; SIGNAL-TRANSDUCTION; INHIBITS APOPTOSIS; MOLECULAR-CLONING; CYTOCHROME-C; CA2+ SIGNALS; CERAMIDE; MEMBRANE; GROWTH	Activation of sphingosine kinase-1 (SK1) by overexpression or agonist stimulation promotes cell proliferation, survival, and anti-apoptosis. Studies on the function of endogenous SK1 are lacking. Endogenous SK1 has been shown to be down-regulated under stress, and knockdown of the enzyme reduces the percentage of viable MCF-7 breast cancer cells (Taha, T. A. et al. 2004. J. Biol. Chem. 279, 20546- 20554). In this study, we examined the mechanisms by which SK1 loss affects the growth of cells. Knockdown of the enzyme by small interfering RNA caused cell cycle arrest and induced apoptosis. Cell death involved effector caspase activation, cytochrome c release and Bax oligomerization in the mitochondrial membrane, thus placing SK1 knockdown upstream of the mitochondrial pathway of apoptosis. SK1 knockdown also induced significant increases in ceramide levels in whole cells and in mitochondria enriched fractions of cells. Inhibition of de novo sphingolipid biosynthesis with myriocin significantly attenuated Bax oligomerization and downstream caspase activation after SK1 loss. These studies for the first time implicate endogenous SK1 as an important survival enzyme in MCF-7 cells and link the biological consequences of knocking down the enzyme to its biochemical role as a regulator of sphingolipid metabolism.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29401 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135; obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA097132] Funding Source: Medline; NIA NIH HHS [AG16583] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; Birbes H, 2005, BIOCHEM J, V386, P445, DOI 10.1042/BJ20041627; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brindley DN, 2002, BBA-MOL CELL BIOL L, V1582, P33, DOI 10.1016/S1388-1981(02)00135-X; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; El-Assaad W, 1998, BIOCHEM J, V336, P735, DOI 10.1042/bj3360735; ENDO K, 1991, CANCER RES, V51, P1613; Eto M, 2003, PROSTATE, V57, P66, DOI 10.1002/pros.10275; French KJ, 2003, CANCER RES, V63, P5962; Furuya S, 1998, J NEUROCHEM, V71, P366; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hannun YA, 1997, ADV EXP MED BIOL, V400, P305; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hong GY, 1999, FEBS LETT, V460, P513, DOI 10.1016/S0014-5793(99)01400-3; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Ibrahim FBM, 2004, J BIOL CHEM, V279, P44802, DOI 10.1074/jbc.M403977200; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; Jung EM, 1998, J INVEST DERMATOL, V110, P318, DOI 10.1046/j.1523-1747.1998.00137.x; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; KHAN WA, 1990, BIOCHEM BIOPH RES CO, V172, P683, DOI 10.1016/0006-291X(90)90728-6; Kleuser B, 1998, CANCER RES, V58, P1817; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kroesen BJ, 2003, J BIOL CHEM, V278, P14723, DOI 10.1074/jbc.M210756200; Kurinna SM, 2004, CANCER RES, V64, P7852, DOI 10.1158/0008-5472.CAN-04-1552; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Lee TK, 1998, TAIWAN J MATH, V2, P457, DOI 10.11650/twjm/1500407017; LIMAYE VS, 2005, BLOOD; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Nava VE, 2000, CANCER RES, V60, P4468; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Novgorodov SA, 2005, J BIOL CHEM, V280, P16096, DOI 10.1074/jbc.M411707200; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; OKOSHI H, 1991, CANCER RES, V51, P6019; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; PARK YS, 1994, CANCER RES, V54, P2213; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Tafani M, 2002, J BIOL CHEM, V277, P49569, DOI 10.1074/jbc.M208915200; Taha TA, 2005, J BIOL CHEM, V280, P17196, DOI 10.1074/jbc.M413744200; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Uchida Y, 2003, J INVEST DERMATOL, V120, P662, DOI 10.1046/j.1523-1747.2003.12098.x; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Young KW, 2000, EUR J PHARMACOL, V402, P55, DOI 10.1016/S0014-2999(00)00509-4; Zhu XF, 2003, CANCER LETT, V193, P149, DOI 10.1016/S0304-3835(03)00050-8	75	121	133	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					482	+		10.1096/fj.05-4412fje	http://dx.doi.org/10.1096/fj.05-4412fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16507765				2022-12-25	WOS:000234405500015
J	Keren-Paz, A; Bercovich, Z; Porat, Z; Erez, O; Brener, O; Kahana, C				Keren-Paz, A.; Bercovich, Z.; Porat, Z.; Erez, O.; Brener, O.; Kahana, C.			Overexpression of antizyme-inhibitor in NIH3T3 fibroblasts provides growth advantage through neutralization of antizyme functions	ONCOGENE			English	Article						antizyme inhibitor; antizyme; ornithine decarboxylase; polyamines; cell growth; cellular transformation	ORNITHINE-DECARBOXYLASE ACTIVITY; TISSUE-CULTURE CELLS; POLYAMINE TRANSPORT; GENE-EXPRESSION; TRANSGENIC MICE; REQUIRES INTERACTION; RETICULOCYTE LYSATE; NEGATIVE REGULATION; HOMOLOGOUS PROTEIN; PROSTATE-CANCER	Antizyme inhibitor (AzI) is a homolog of ornithine decarboxylase (ODC), a key enzyme of polyamine synthesis. Antizyme inhibitor retains no enzymatic activity, but exhibits high affinity to antizyme (Az), a negative regulator of polyamine homeostasis. As polyamines are involved in maintaining cellular proliferation, and since AzI may negate Az functions, we have investigated the role of AzI in regulating cell growth. We show here that overexpression of AzI in NIH3T3 cells increased growth rate, enabled growth in low serum, and permitted anchorage-independent growth in soft agar, while reduction of AzI levels by AzI siRNA reduced cellular proliferation. Moreover, AzI overproducing cells gave rise to tumors when injected into nude mice. AzI overexpression resulted in elevation of ODC activity and of polyamine uptake. These effects of AzI are a result of its ability to neutralize Az, as overexpression of an AzI mutant with reduced Az binding failed to alter cellular polyamine metabolism and growth properties. We also demonstrate upregulation of AzI in Ras transformed cells, suggesting its relevance to some naturally occurring transformations. Finally, increased uptake activity rendered AzI overproducing and Ras-transformed cells more sensitive to toxic polyamine analogs. Our results therefore imply that AzI has a central and meaningful role in modulation of polyamine homeostasis, and in regulating cellular proliferation and transformation properties.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Vet Resources, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Kahana, C (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	chaim.kahana@weizmann.ac.il	Porat, Ziv/K-1672-2012	Porat, Ziv/0000-0003-3059-181X				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bercovich Z, 2004, J BIOL CHEM, V279, P54097, DOI 10.1074/jbc.M410234200; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BEY P, 1978, J MED CHEM, V21, P50, DOI 10.1021/jm00199a009; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BRUMMELKAMP TR, 2002, SCIENCE, V21, P21; Choi KS, 2005, BIOCHEM BIOPH RES CO, V328, P206, DOI 10.1016/j.bbrc.2004.11.172; CLIFFORD A, 1995, CANCER RES, V55, P1680; DON S, 1975, CANCER RES, V35, P3618; Feith DJ, 2001, CANCER RES, V61, P6073; Fong LYY, 2003, CANCER RES, V63, P3945; FUJITA K, 1982, BIOCHEM J, V204, P647, DOI 10.1042/bj2040647; Gandre S, 2002, EUR J BIOCHEM, V269, P1316, DOI 10.1046/j.1432-1033.2002.02774.x; GAZDAR AF, 1976, NATURE, V262, P696, DOI 10.1038/262696a0; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; GILMOUR SK, 1985, J BIOL CHEM, V260, P6439; HADDOX MK, 1980, CANCER RES, V40, P604; HE Y, 1994, BIOCHEM BIOPH RES CO, V203, P608, DOI 10.1006/bbrc.1994.2226; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Janne J, 1983, Spec Top Endocrinol Metab, V5, P227; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATZ A, 1989, EMBO J, V8, P1163, DOI 10.1002/j.1460-2075.1989.tb03487.x; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KITANI T, 1989, BIOCHIM BIOPHYS ACTA, V991, P44, DOI 10.1016/0304-4165(89)90026-3; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MEGOSH L, 1995, CANCER RES, V55, P4205; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; Mitchell JLA, 2002, BIOCHEM J, V366, P663, DOI 10.1042/BJ20011612; Moinard C, 2005, CLIN NUTR, V24, P184, DOI 10.1016/j.clnu.2004.11.001; MOSHIER JA, 1993, CANCER RES, V53, P2618; MURAKAMI Y, 1989, BIOCHEM J, V259, P839, DOI 10.1042/bj2590839; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Nilsson J, 2000, BIOCHEM J, V346, P699, DOI 10.1042/0264-6021:3460699; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1995, J CELL BIOCHEM, P132; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Sakata K, 2000, BIOCHEM J, V347, P297, DOI 10.1042/0264-6021:3470297; Sakata K, 1997, BIOCHEM BIOPH RES CO, V238, P415, DOI 10.1006/bbrc.1997.7266; Schaner ME, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-26; Seiler N, 1970, Methods Biochem Anal, V18, P259, DOI 10.1002/9780470110362.ch5; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shantz LM, 1998, CANCER RES, V58, P2748; Shantz LM, 2004, BIOCHEM J, V377, P257, DOI 10.1042/BJ20030778; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; TONIN PN, 1989, ONCOGENE, V4, P1117; Valasinas A, 2003, BIOORGAN MED CHEM, V11, P4121, DOI 10.1016/S0968-0896(03)00453-X; van Duin M, 2005, GENE CHROMOSOME CANC, V44, P438, DOI 10.1002/gcc.20259; YUSPA SH, 1976, NATURE, V262, P402, DOI 10.1038/262402a0	61	55	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5163	5172		10.1038/sj.onc.1209521	http://dx.doi.org/10.1038/sj.onc.1209521			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16568078				2022-12-25	WOS:000240063700009
J	Nguyen-Khac, F; Della Valle, V; Lopez, RG; Ravet, E; Mauchauffe, M; Friedman, AD; Huang, LE; Fichelson, S; Ghysdael, J; Bernard, OA				Nguyen-Khac, F.; Della Valle, V.; Lopez, R. G.; Ravet, E.; Mauchauffe, M.; Friedman, A. D.; Huang, L. E.; Fichelson, S.; Ghysdael, J.; Bernard, O. A.			Functional analyses of the TEL-ARNT fusion protein underscores a role for oxygen tension in hematopoietic cellular differentiation	ONCOGENE			English	Article						TEL/ETV6; ARNT; transcription factor; leukemia; differentiation block	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; ACUTE MYELOID-LEUKEMIA; ENDOTHELIAL-CELLS; TUMOR-SUPPRESSOR; FACTOR 1-ALPHA; TRANSCRIPTION; GROWTH; TRANSLOCATION; METABOLISM; ACTIVATION	The transcription factor hypoxia inducible factor 1 (HIF1), an HIF1 alpha-aryl hydrocarbon receptor nuclear translocator ( ARNT) dimeric factor, is essential to the cellular response to hypoxia. We described a t(1;12)(q21;p13) chromosomal translocation in human acute myeloblastic leukemia that involves the translocated Ets leukemia (TEL/ETV6) and the ARNT genes and results in the expression of a TEL-ARNT fusion protein. Functional studies show that TEL-ARNT interacts with HIF1 alpha and the complex binds to consensus hypoxia response element. In low oxygen tension conditions, the HIF1 alpha/TEL-ARNT complex does not activate transcription but exerts a dominant-negative effect on normal HIF1 activity. Differentiation of normal human CD34+ progenitors cells along all the erythrocytic, megakaryocytic and granulocytic pathways was accelerated in low versus high oxygen tension conditions. Murine 32Dcl3 myeloid cells also show accelerated granulocytic differentiation in low oxygen tension in response to granulocyte colony-stimulating factor. Interestingly, stable expression of the TEL-ARNT in 32Dcl3 subclones resulted in impaired HIF1-mediated transcriptional response and inhibition of differentiation enhancement in hypoxic conditions. Taken together, our results underscore the role of oxygen tension in the modulation of normal hematopoietic differentiation, whose targeting can participate in human malignancies.	Grp Hosp Pitie Salpetriere, Serv Hematol Biol, F-75013 Paris, France; Univ Paris 05, INSERM, Hop Necker Enfants Malad, IRNEM, Paris, France; CNRS, Inst Curie, UMR 146, F-91405 Orsay, France; CNRS, Inst Cochin Genet Mol, Dept Hematol, INSERM,U567,UMR 8104, Paris, France; INSERM, U674, Paris, France; Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD USA; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nguyen-Khac, F (corresponding author), Grp Hosp Pitie Salpetriere, Serv Hematol Biol, Pavillon Laveran 47-83 Bd Hop, F-75013 Paris, France.	florence.nguyen@psl.aphp.fr	GHYSDAEL, Jacques/F-3377-2013; Bernard, Olivier A./E-5721-2016	Bernard, Olivier/0000-0002-0463-9747; Nguyen-Khac, Florence/0000-0003-3107-6668; Huang, Eric/0000-0002-6444-1708				Acker T, 2005, CANCER CELL, V8, P131, DOI 10.1016/j.ccr.2005.07.003; Adelman DM, 1999, GENE DEV, V13, P2478, DOI 10.1101/gad.13.19.2478; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kline DD, 2002, P NATL ACAD SCI USA, V99, P821, DOI 10.1073/pnas.022634199; Kojima H, 2002, P NATL ACAD SCI USA, V99, P2170, DOI 10.1073/pnas.052706699; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Kroon ME, 2001, J CELL SCI, V114, P825; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Li J, 2002, J CELL SCI, V115, P1951; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu W, 2006, BLOOD, V107, P698, DOI 10.1182/blood-2005-03-1278; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Ramirez-Bergeron DL, 2004, DEVELOPMENT, V131, P4623, DOI 10.1242/dev.01310; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Semenza GL, 2000, GENE DEV, V14, P1983; Speck NA, 2001, CURR OPIN HEMATOL, V8, P192, DOI 10.1097/00062752-200107000-00002; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2	45	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4840	4847		10.1038/sj.onc.1209503	http://dx.doi.org/10.1038/sj.onc.1209503			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547490				2022-12-25	WOS:000239687100002
J	Cayrol, C; Clerc, P; Bertrand, C; Gigoux, V; Portolan, G; Fourmy, D; Dufresne, M; Seva, C				Cayrol, C.; Clerc, P.; Bertrand, C.; Gigoux, V.; Portolan, G.; Fourmy, D.; Dufresne, M.; Seva, C.			Cholecystokinin-2 receptor modulates cell adhesion through beta 1-integrin in human pancreatic cancer cells	ONCOGENE			English	Article						gastrin; integrin; pancreatic cancer; cell adhesion	GROWTH-FACTOR ACTION; TYROSINE PHOSPHORYLATION; CYCLOOXYGENASE-2 EXPRESSION; MOLECULAR-MECHANISMS; SIGNALING PATHWAY; MURINE PANCREAS; MESSENGER-RNA; GASTRIN; INTEGRIN; ACTIVATION	Several lines of evidence suggest that gastrin and the CCK-2 receptor (CCK2R) could contribute to pancreatic carcinogenesis by modulating processes such as proliferation, cell adhesion or migration. In the current study, we used a 'cancer gene array' and identified beta 1-integrin subunit as a new gastrin-regulated gene in human pancreatic cancer cells. We also demonstrated that Src family kinases and the phosphatidylinositol-3-kinase (PI-3-kinase) pathway play a crucial role in the expression of beta 1-integrin induced by gastrin. Our results also showed that gastrin modulates cell-substrate adhesion via beta 1-integrin. Indeed, using blocking anti-beta 1-integrin monoclonal antibodies, we completely reversed the increase in cell substrate adhesion induced by gastrin. In addition, we observed that in response to gastrin, beta 1-integrin is tyrosine phosphorylated by Src family kinases and associates with paxillin, a scaffold protein involved in focal adhesion and integrin signalling. This mechanism might be involved in gastrin-induced cell adhesion. Moreover, we showed in vivo that targeted CCK2R expression in the pancreas of Elas-CCK2 mice leads to the overexpression of beta 1-integrin. This process may contribute to pancreatic tumour development observed in these transgenic animals.	INSERM, U531, IFR31, Inst Louis Bugnard, F-31432 Toulouse 4, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Seva, C (corresponding author), INSERM, U531, IFR31, Inst Louis Bugnard, F-31432 Toulouse 4, France.	sevac@toulouse.inserm.fr	Gigoux, Véronique/AAE-6090-2020; Dufresne, Marlène/M-6332-2014; SEVA, Catherine/O-9166-2014; Fourmy, Daniel/AAE-3703-2019	Gigoux, Véronique/0000-0003-1408-5335; SEVA, Catherine/0000-0002-4265-7372; Fourmy, Daniel/0000-0001-9910-4827				Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; Bierkamp C, 2004, AM J PATHOL, V165, P2135, DOI 10.1016/S0002-9440(10)63263-4; Bierkamp C, 2002, ONCOGENE, V21, P7656, DOI 10.1038/sj.onc.1205999; Butler B, 2005, J BIOL CHEM, V280, P14556, DOI 10.1074/jbc.M411765200; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; Caplin M, 2000, BRIT J SURG, V87, P1035, DOI 10.1046/j.1365-2168.2000.01488.x; CHAO JT, 2005, AM J PHYSL CELL PHYS; Chiu SJ, 2002, J BIOMED SCI, V9, P261, DOI 10.1159/000059427; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; Colucci R, 2005, BRIT J PHARMACOL, V144, P338, DOI 10.1038/sj.bjp.0706053; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Daulhac L, 1999, FEBS LETT, V445, P251, DOI 10.1016/S0014-5793(99)00129-5; de Weerth A, 1999, HEPATO-GASTROENTEROL, V46, P472; Eliceiri BP, 2000, CANCER J, V6, pS245; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Ferrand A, 2005, J BIOL CHEM, V280, P10710, DOI 10.1074/jbc.M413309200; Ferrand A, 2004, EXP CELL RES, V301, P128, DOI 10.1016/j.yexcr.2004.07.037; Fontana MG, 1999, EUR SURG RES, V31, P406, DOI 10.1159/000008719; Fukui H, 1998, GASTROENTEROLOGY, V115, P1483, DOI 10.1016/S0016-5085(98)70027-7; Funahashi H, 2003, PANCREAS, V27, P190, DOI 10.1097/00006676-200308000-00013; Gao CL, 2005, J BIOL CHEM, V280, P15422, DOI 10.1074/jbc.M414457200; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Grippo PJ, 2003, CANCER RES, V63, P2016; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Guo YS, 2002, J BIOL CHEM, V277, P48755, DOI 10.1074/jbc.M209016200; Halatsch ME, 1997, CANCER LETT, V118, P7, DOI 10.1016/S0304-3835(97)00217-6; Hocker M, 2004, ANN NY ACAD SCI, V1014, P97, DOI 10.1196/annals.1294.010; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Kaufmann R, 1997, NEUROPEPTIDES, V31, P573, DOI 10.1016/S0143-4179(97)90003-2; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; Lohr M, 1996, PANCREAS, V12, P248; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Prasad NB, 2005, CANCER RES, V65, P1619, DOI 10.1158/0008-5472.CAN-04-1413; Ross RS, 2004, CARDIOVASC RES, V63, P381, DOI 10.1016/j.cardiores.2004.04.027; Shimoyama S, 1995, INT J PANCREATOL, V18, P227; Sinclair NF, 2004, AM J PHYSIOL-GASTR L, V286, pG992, DOI 10.1152/ajpgi.00206.2002; Slice LW, 2003, J CELL PHYSIOL, V196, P454, DOI 10.1002/jcp.10304; Smith JP, 1999, CANCER LETT, V135, P107; Smith JP, 1998, INT J MOL MED, V2, P309; SMITH JP, 1995, AM J PHYSIOL-REG I, V268, pR135, DOI 10.1152/ajpregu.1995.268.1.R135; Smith JP, 1996, AM J PHYSIOL-REG I, V270, pR1078, DOI 10.1152/ajpregu.1996.270.5.R1078; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG1363, DOI 10.1152/ajpgi.1999.276.6.G1363; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG415, DOI 10.1152/ajpgi.1999.276.2.G415; TANIGUCHI T, 1994, ONCOGENE, V9, P861; Taniguchi T, 1996, ONCOGENE, V12, P1357; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; Turner CE, 2000, J CELL SCI, V113, P4139; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wagner M, 1998, GASTROENTEROLOGY, V115, P1254, DOI 10.1016/S0016-5085(98)70098-8; Wang JY, 1995, AM J PHYSIOL-CELL PH, V269, pC1474, DOI 10.1152/ajpcell.1995.269.6.C1474; Wroblewski LE, 2002, BIOCHEM J, V365, P873, DOI 10.1042/BJ20020068; Zhukova E, 2001, J CELL PHYSIOL, V189, P291, DOI 10.1002/jcp.10018	55	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4421	4428		10.1038/sj.onc.1209484	http://dx.doi.org/10.1038/sj.onc.1209484			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547500				2022-12-25	WOS:000239326000005
J	Levy, O; Granot, Y				Levy, Oren; Granot, Yossef			Arginine-vasopressin activates the JAK-STAT pathway in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; ANGIOTENSIN-II; SERINE PHOSPHORYLATION; SIGNAL TRANSDUCERS; JAK/STAT PATHWAY; PHORBOL ESTERS; MAP KINASE; STIMULATION; GROWTH	JAK (Janus-activated kinase)-STAT ( signal transducers and activators of transcription) signaling is a major signal transduction pathway in mammalian cells. Different growth factors and cytokines were reported as activators of the JAK-STAT pathway in various cell types. Interestingly, arginine-vasopressin (AVP) was never reported as an inducer of the JAK-STAT pathway. In the present study, we show for the first time that AVP stimulation of vascular smooth muscle cells (VSMCs) induces STAT3 tyrosine and serine phosphorylation, followed by nuclear translocation of the phosphorylated STAT3. In addition, we found that AVP induced JAK2 tyrosine phosphorylation. Taken together, these results demonstrate that AVP activates the JAK-STAT pathway in VSMCs. Furthermore, our results indicate that AVP-induced STAT3 tyrosine phosphorylation requires both JAK2 and c-Src tyrosine kinases. The present study also implicates that extracellular signal-regulated kinase (ERK1/2), which are serine/threonine kinases, are the mediators of STAT3 serine phosphorylation upon AVP stimulation. We further suggest that AVP-induced STAT3 serine phosphorylation negatively modulates AVP-induced STAT3 tyrosine phosphorylation. Finally, our results implicate a novel role for the JAK-STAT pathway, mediating AVP-induced VSMC hypertrophy.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University	Levy, O (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, POB 653, IL-84105 Beer Sheva, Israel.	levyor@bgu.ac.il; ygranot@bgu.ac.il	Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X				Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Bhanoori M, 2003, ONCOGENE, V22, P117, DOI 10.1038/sj.onc.1206065; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byron KL, 2002, J BIOL CHEM, V277, P7298, DOI 10.1074/jbc.M104726200; CARAMELO C, 1989, AM J PHYSIOL, V256, pF875, DOI 10.1152/ajprenal.1989.256.5.F875; CHEN CC, 1993, FEBS LETT, V332, P169, DOI 10.1016/0014-5793(93)80506-P; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Decker T, 1997, IMMUNOBIOLOGY, V198, P99, DOI 10.1016/S0171-2985(97)80031-9; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; KRIBBEN A, 1993, AM J PHYSIOL, V265, pC939, DOI 10.1152/ajpcell.1993.265.4.C939; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Madamanchi NR, 2001, J BIOL CHEM, V276, P18915, DOI 10.1074/jbc.M008802200; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Nemenoff R.A, 1998, FRONT BIOSCI-LANDMRK, V3, P194; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; STAUBLE B, 1993, BIOCHEM MOL BIOL INT, V29, P203; TAKEDA K, 1988, AM J PHYSIOL, V254, pF254, DOI 10.1152/ajprenal.1988.254.2.F254; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016	37	15	21	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15597	15604		10.1074/jbc.M502750200	http://dx.doi.org/10.1074/jbc.M502750200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16567810	hybrid			2022-12-25	WOS:000237996000003
J	Chandrasekar, B; Mummidi, S; Mahimainathan, L; Patel, DN; Bailey, SR; Imam, SZ; Greene, WC; Valente, AJ				Chandrasekar, Bysani; Mummidi, Srinivas; Mahimainathan, Lenin; Patel, Devang N.; Bailey, Steven R.; Imam, Syed Z.; Greene, Warner C.; Valente, Anthony J.			Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappa B- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; MATRIX METALLOPROTEINASES; SIGNALING PATHWAY; STATIN THERAPY; INVASIVENESS; CHOLESTEROL; EVENTS; MMP-9; ATHEROSCLEROSIS; ACTIVATION	The proliferation and migration of arterial smooth muscle cells (SMCs) are key events in the vascular restenosis that frequently follows angioplasty. Furthermore, SMC migration and neointimal hyperplasia are promoted by degradation of the extracellular matrix by matrix metalloproteinases ( MMPs). Because we demonstrated previously that the proinflammatory and proatherogenic cytokine interleukin-18 (IL-18) stimulates SMC proliferation ( Chandrasekar, B., Mummidi, S., Valente, A. J., Patel, D. N., Bailey, S. R., Freeman, G. L., Hatano, M., Tokuhisa, T., and Jensen, L. E. ( 2005) J. Biol. Chem. 280, 26263 - 26277), we investigated whether IL-18 induces SMC migration in an MMP-dependent manner and whether the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin can inhibit this response. IL-18 treatment increased both mRNA and protein expression of MMP9 in human coronary artery SMCs. Gel shift, enzyme-linked immunosorbent, and chromatin immunoprecipitation assays revealed a strong induction of IL-18-mediated AP-1 (c-Fos, c-Jun, and Fra-1) and NF-kappa B (p50 and p65) activation and stimulation of MMP9 promoter-dependent reporter gene activity in an AP-1- and NF-kappa B-dependent manner. Ectopic expression of p65, c-Fos, c-Jun, and Fra-1 induced MMP9 promoter activity. Specific antisense or small interfering RNA reagents for these transcription factors reduced IL-18-mediated MMP9 transcription. Furthermore, IL-18 stimulated SMC migration in an MMP9-dependent manner. Atorvastatin effectively suppressed IL-18-mediated AP-1 and NF-kappa B-activation, MMP9 expression, and SMC migration. Together, our results indicate for the first time that the proatherogenic cytokine IL-18 induces human coronary artery SMC migration in an MMP9-dependent manner. Atorvastatin inhibits IL-18-mediated aortic SMC migration and has therapeutic potential for attenuating the progression of atherosclerosis and restenosis.	S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, Dept Immunol & Microbiol, San Francisco, CA 94158 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; University of California System; University of California San Francisco; The J David Gladstone Institutes	Chandrasekar, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med Cardiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	chandraseka@uthscsa.edu	Mummidi, Srinivas/H-3335-2017; Mummidi, Srinivas/C-1004-2008	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380; /0000-0001-5077-3552	NHLBI NIH HHS [HL68020] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068020] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnaud C, 2005, TRENDS CARDIOVAS MED, V15, P202, DOI 10.1016/j.tcm.2005.07.002; Auge N, 2004, CIRCULATION, V110, P571, DOI 10.1161/01.CIR.0000136995.83451.1D; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Chandrasekar B, 2006, BIOCHEM BIOPH RES CO, V339, P956, DOI 10.1016/j.bbrc.2005.11.100; Chandrasekar B, 2005, J BIOL CHEM, V280, P26263, DOI 10.1074/jbc.M502586200; Chandrasekar B, 2005, J BIOL CHEM, V280, P4553, DOI 10.1074/jbc.M411787200; Chandrasekar B, 2004, J BIOL CHEM, V279, P20221, DOI 10.1074/jbc.M313980200; Chandrasekar B, 2004, J BIOL CHEM, V279, P3188, DOI 10.1074/jbc.M311660200; Cho A, 2002, CIRC RES, V91, P845, DOI 10.1161/01.RES.0000040420.17366.2E; Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20; Dinarello CA, 2000, EUR CYTOKINE NETW, V11, P483; Elhage R, 2003, CARDIOVASC RES, V59, P234, DOI 10.1016/S0008-6363(03)00343-2; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Gerdes N, 2002, J EXP MED, V195, P245, DOI 10.1084/jem.20011022; Hellwig-Burgel T, 2005, J INTERF CYTOK RES, V25, P297, DOI 10.1089/jir.2005.25.297; Ikeda U, 2003, CLIN CARDIOL, V26, P55, DOI 10.1002/clc.4960260203; Kim HS, 2005, INVEST OPHTH VIS SCI, V46, P840, DOI 10.1167/iovs.04-0929; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Lefer AM, 2001, CARDIOVASC RES, V49, P281, DOI 10.1016/S0008-6363(00)00247-9; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Mallat Z, 2002, HEART, V88, P467, DOI 10.1136/heart.88.5.467; Mallat Z, 2001, CIRCULATION, V104, P1598, DOI 10.1161/hc3901.096721; Mandler RN, 2001, BRAIN, V124, P493, DOI 10.1093/brain/124.3.493; Newby AC, 2000, J PATHOL, V190, P300, DOI 10.1002/(SICI)1096-9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I; Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000; Nold M, 2003, N-S ARCH PHARMACOL, V367, P68, DOI 10.1007/s00210-002-0648-5; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sakata K, 2000, INT J ONCOL, V17, P673; Sanceau J, 2003, J BIOL CHEM, V278, P36537, DOI 10.1074/jbc.M304300200; SATO H, 1993, ONCOGENE, V8, P395; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Sever PS, 2005, DIABETES CARE, V28, P1151, DOI 10.2337/diacare.28.5.1151; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Sumi D, 2001, ATHEROSCLEROSIS, V155, P347, DOI 10.1016/S0021-9150(00)00597-9; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; Weber C, 1997, J AM COLL CARDIOL, V30, P1212, DOI 10.1016/S0735-1097(97)00324-0; Wei LH, 2005, ONCOGENE, V24, P390, DOI 10.1038/sj.onc.1208192; Whitman SC, 2002, CIRC RES, V90, pE34, DOI 10.1161/hh0202.105292; Yamagami H, 2005, ARTERIOSCL THROM VAS, V25, P1458, DOI 10.1161/01.ATV.0000168417.52486.56; Zhang B, 2004, LEUKEMIA RES, V28, P91, DOI 10.1016/S0145-2126(03)00121-8	42	168	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15099	15109		10.1074/jbc.M600200200	http://dx.doi.org/10.1074/jbc.M600200200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16554298	hybrid			2022-12-25	WOS:000237922200012
J	Stempien-Otero, A; Plawman, A; Meznarich, J; Dyamenahalli, T; Otsuka, G; Dichek, DA				Stempien-Otero, April; Plawman, Abigail; Meznarich, Jessica; Dyamenahalli, Teja; Otsuka, Goro; Dichek, David A.			Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; IDIOPATHIC DILATED CARDIOMYOPATHY; MATRIX-METALLOPROTEINASE ACTIVITY; MYOCARDIAL-INFARCTION; TRANSGENIC MICE; HUMAN HEART; PHARMACOLOGICAL INHIBITION; TRANSCRIPTION FACTORS; TARGETED DELETION; ENDOTHELIAL-CELLS	Human hearts with end-stage failure and fibrosis have macrophage accumulation and elevated plasminogen activator activity. However, the mechanisms that link macrophage accumulation and plasminogen activator activity with cardiac fibrosis are unclear. We previously reported that mice with macrophage-targeted overexpression of urokinase plasminogen activator (SR-uPA(+/0) mice) develop cardiac macrophage accumulation by 5 weeks of age and cardiac fibrosis by 15 weeks. We used (SR-uPA(+/o) mice) to investigate mechanisms through which macrophage-expressed uPA causes cardiac macrophage accumulation and fibrosis. We hypothesized that: 1) macrophage accumulation and cardiac fibrosis in (SR-uPA +/o mice) are dependent on localization of uPA by the uPA receptor (uPAR); 2) activation of plasminogen by uPA and subsequent activation of transforming growth factor-beta 1 (TGF-beta 1) and matrix metalloproteinase (MMP)-2 and -9 by plasmin are critical pathways through which uPA-expressing macrophages accumulate in the heart and cause fibrosis; and 3) uPA-induced cardiac fibrosis can be attenuated by treatment with verapamil. To test these hypotheses, we bred the SR-uPA(+/o) transgene into mice deficient in either uPAR or plasminogen and measured cardiac macrophage accumulation and fibrosis. We also measured cardiac TGF-beta 1 protein ( total and active), Smad2 phosphorylation, and MMP activity after the onset of macrophage accumulation but before the onset of cardiac fibrosis. Finally, we treated mice with verapamil. Our studies revealed that plasminogen is necessary for uPA-induced cardiac fibrosis and macrophage accumulation but uPAR is not. We did not detect plasmin-mediated activation of TGF- beta 1, MMP-2, or MMP-9 in hearts of SR-uPA(+/o) mice. However, verapamil treatment significantly attenuated both cardiac fibrosis and macrophage accumulation.	Univ Washington, Sch Med, Med Ctr, Dept Med,Div Cardiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Stempien-Otero, A (corresponding author), Univ Washington, Sch Med, Med Ctr, Dept Med,Div Cardiol, Box 357710, Seattle, WA 98195 USA.	april@u.washington.edu		Dichek, David/0000-0002-5224-2736	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080597, K08HL070941] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70941, HL080597] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azzawi M, 2005, HISTOPATHOLOGY, V46, P314, DOI 10.1111/j.1365-2559.2005.02075.x; BACHMANN F, 2001, HEMOSTASIS THROMBOSI, P289; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Brown DM, 2004, AM J PHYSIOL-LUNG C, V286, pL344, DOI 10.1152/ajplung.00139.2003; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; CHAPMAN HA, 1984, J CLIN INVEST, V73, P806, DOI 10.1172/JCI111275; Cohn RD, 2001, J CLIN INVEST, V107, pR1, DOI 10.1172/JCI11642; Coker ML, 1998, AM J PHYSIOL-HEART C, V274, pH1516, DOI 10.1152/ajpheart.1998.274.5.H1516; Cozen AE, 2004, CIRCULATION, V109, P2129, DOI 10.1161/01.CIR.0000127369.24127.03; Creemers E, 2000, AM J PATHOL, V156, P1865, DOI 10.1016/S0002-9440(10)65060-2; DONG R, 1992, J CLIN INVEST, V90, P2022, DOI 10.1172/JCI116082; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; East E, 2005, AM J PATHOL, V167, P545, DOI 10.1016/S0002-9440(10)62996-3; EGHBALI M, 1991, CIRC RES, V69, P483, DOI 10.1161/01.RES.69.2.483; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Falkenberg M, 2002, P NATL ACAD SCI USA, V99, P10665, DOI 10.1073/pnas.162236599; Gaertner R, 2005, J MOL CELL CARDIOL, V38, P193, DOI 10.1016/j.yjmcc.2004.10.017; Gu JM, 2005, J CELL PHYSIOL, V204, P73, DOI 10.1002/jcp.20262; GunjaSmith Z, 1996, AM J PATHOL, V148, P1639; Hein S, 2003, CIRCULATION, V107, P984, DOI 10.1161/01.CIR.0000051865.66123.B7; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Heymans S, 2005, AM J PATHOL, V166, P15, DOI 10.1016/S0002-9440(10)62228-6; HUME DA, 1983, J CELL PHYSIOL, V117, P189, DOI 10.1002/jcp.1041170209; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; Kamkin A, 2005, BASIC RES CARDIOL, V100, P337, DOI 10.1007/s00395-005-0529-4; KESKIOJA J, 1992, EXP CELL RES, V202, P471, DOI 10.1016/0014-4827(92)90101-D; Kim HE, 2000, J CLIN INVEST, V106, P857, DOI 10.1172/JCI8040; KOBAYASHI A, 1987, J AM COLL CARDIOL, V10, P1128, DOI 10.1016/S0735-1097(87)80356-X; Kuhl U, 1995, EUR HEART J, V16, P100, DOI 10.1093/eurheartj/16.suppl_O.100; Lee S, 2006, J MOL CELL CARDIOL, V40, P148, DOI 10.1016/j.yjmcc.2005.09.015; LI Q, 1993, J CLIN INVEST, V91, P1499, DOI 10.1172/JCI116355; Lijnen PJ, 2000, MOL GENET METAB, V71, P418, DOI 10.1006/mgme.2000.3032; Lindahl GE, 2002, J BIOL CHEM, V277, P6153, DOI 10.1074/jbc.M108966200; List K, 2000, BIOCHEMISTRY-US, V39, P508, DOI 10.1021/bi991701f; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Matrat M, 1998, J TOXICOL ENV HEAL A, V55, P359; Matsumura S, 2005, J CLIN INVEST, V115, P599, DOI 10.1172/JCI200522304; Moriwaki H, 2004, CIRC RES, V95, P637, DOI 10.1161/01.RES.0000141427.61023.f4; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Pogwizd SM, 1998, CIRCULATION, V98, P2404, DOI 10.1161/01.CIR.98.22.2404; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; Romero-Gallo J, 2005, ONCOGENE, V24, P3028, DOI 10.1038/sj.onc.1208475; Rosenkranz S, 2002, AM J PHYSIOL-HEART C, V283, pH1253, DOI 10.1152/ajpheart.00578.2001; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SCHULTHEISS HP, 1988, J EXP MED, V168, P2105, DOI 10.1084/jem.168.6.2105; Schulze PC, 2004, CIRC RES, V95, P552, DOI 10.1161/01.RES.0000143420.87587.9e; Thomas CV, 1998, CIRCULATION, V97, P1708, DOI 10.1161/01.CIR.97.17.1708; Tyagi SC, 1996, J MOL CELL CARDIOL, V28, P1415, DOI 10.1006/jmcc.1996.0132; Tyagi SC, 1996, J CELL PHYSIOL, V167, P137, DOI 10.1002/(SICI)1097-4652(199604)167:1<137::AID-JCP16>3.0.CO;2-8; Ustach CV, 2005, MOL CELL BIOL, V25, P6279, DOI 10.1128/MCB.25.14.6279-6288.2005; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; Wang B, 2005, AM J PHYSIOL-HEART C, V289, pH108, DOI 10.1152/ajpheart.00001.2005; WANG DL, 1995, CIRC RES, V77, P294, DOI 10.1161/01.RES.77.2.294; Weber KT, 2004, HYPERTENSION, V43, P716, DOI 10.1161/01.HYP.0000118586.38323.5b; WEBER KT, 1993, CARDIOVASC RES, V27, P341, DOI 10.1093/cvr/27.3.341; Weisberg AD, 2005, ARTERIOSCL THROM VAS, V25, P365, DOI 10.1161/01.ATV.0000152356.85791.52; Wheeler MT, 2004, J CLIN INVEST, V113, P668, DOI 10.1172/JCI200420410; Wheeler MT, 2004, AM J PATHOL, V164, P1063, DOI 10.1016/S0002-9440(10)63193-8; WUNSCH M, 1991, J MOL CELL CARDIOL, V23, P1051, DOI 10.1016/0022-2828(91)91640-D; Yamaguchi M, 1997, TRANSPLANTATION, V63, P759, DOI 10.1097/00007890-199703150-00024; Zhang GQ, 2003, J AM SOC NEPHROL, V14, P1234, DOI 10.1097/01.ASN.0000064701.70231.3F	64	36	36	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15345	15351		10.1074/jbc.M512818200	http://dx.doi.org/10.1074/jbc.M512818200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16554301	hybrid			2022-12-25	WOS:000237922200039
J	Chang, TH; Guo, RT; Ko, TP; Wang, AHJ; Liang, PH				Chang, Tao-Hsin; Guo, Rey-Ting; Ko, Tzu-Ping; Wang, Andrew H. -J.; Liang, Po-Huang			Crystal structure of type-III geranylgeranyl pyrophosphate synthase from Saccharomyces cerevisiae and the mechanism of product chain length determination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; ELONGATION; SUBSTRATE; CATALYSIS; MARITIMA; DENSITY; PATHWAY; ENZYME; MODE	Geranylgeranyl pyrophosphate synthase ( GGPPs) catalyzes a condensation reaction of farnesyl pyrophosphate with isopentenyl pyrophosphate to generate C-20 geranylgeranyl pyrophosphate, which is a precursor for carotenoids, chlorophylls, geranylgeranylated proteins, and archaeal ether-linked lipid. For short-chain trans-prenyltransferases that synthesize C-10-C-25 products, bulky amino acid residues generally occupy the fourth or fifth position upstream from the first DDXXD motif to block further elongation of the final products. However, the short-chain type-III GGPPs in eukaryotes lack any large amino acid at these positions. In this study, the first structure of type-III GGPPs from Saccharomyces cerevisiae has been determined to 1.98 (A) over circle resolution. The structure is composed entirely of 15 alpha-helices joined by connecting loops and is arranged with alpha-helices around a large central cavity. Distinct from other known structures of trans-prenyltransferases, the N-terminal 17 amino acids ( 9-amino acid helix A and the following loop) of this GGPPs protrude from the helix core into the other subunit and contribute to the tight dimer formation. Deletion of the first 9 or 17 amino acids caused the dissociation of dimer into monomer, and the Delta( 1 - 17) mutant showed abolished enzyme activity. In each subunit, an elongated hydrophobic crevice surrounded by D, F, G, H, and I alpha-helices contains two DDXXD motifs at the top for substrate binding with one Mg2+ coordinated by Asp(75), Asp(79), and four water molecules. It is sealed at the bottom with three large residues of Tyr(107), Phe(108), and His(139). Compared with the major product C-30 synthesized by mutant H139A, the products generated by mutant Y107A and F108A are predominantly C-40 and C-30, respectively, suggesting the most important role of Tyr(107) in determining the product chain length.	Acad Sinica, Inst Biol Chem, Taiwan Int Grad Program, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan	Wang, AHJ (corresponding author), Acad Sinica, Inst Biol Chem, Taiwan Int Grad Program, 128 Acad Rd, Taipei 115, Taiwan.	ahjwang@gate.sinica.edu.tw; phliang@gate.sinica.edu.tw	Liang, Po-Huang/H-6610-2015	Liang, Po-Huang/0000-0003-1207-5256; Chang, Tao-Hsin/0000-0001-7242-2585; Guo, Rey-Ting/0000-0003-2942-7246				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang SY, 2004, PROTEIN SCI, V13, P971, DOI 10.1110/ps.03519904; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; Guerrero SA, 2001, APPL MICROBIOL BIOT, V56, P718, DOI 10.1007/s002530100690; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo RT, 2005, J BIOL CHEM, V280, P20762, DOI 10.1074/jbc.M502121200; Guo RT, 2004, J BIOL CHEM, V279, P4903, DOI 10.1074/jbc.M310161200; Guo RT, 2004, BIOCHEMISTRY-US, V43, P7678, DOI 10.1021/bi036336d; Hemmi H, 2003, EUR J BIOCHEM, V270, P2186, DOI 10.1046/j.1432-1033.2003.03583.x; Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200; JIANG Y, 1995, J BIOL CHEM, V270, P21793, DOI 10.1074/jbc.270.37.21793; Kellogg BA, 1997, CURR OPIN CHEM BIOL, V1, P570, DOI 10.1016/S1367-5931(97)80054-3; Ko TP, 2001, J BIOL CHEM, V276, P47474, DOI 10.1074/jbc.M106747200; Kuo TH, 2002, BBA-PROTEINS PROTEOM, V1599, P125, DOI 10.1016/S1570-9639(02)00410-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; Long SB, 1998, BIOCHEMISTRY-US, V37, P9612, DOI 10.1021/bi980708e; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogura K, 1998, CHEM REV, V98, P1263, DOI 10.1021/cr9600464; Ogura K, 1997, Subcell Biochem, V28, P57; Ohnuma S, 1996, J BIOL CHEM, V271, P30748, DOI 10.1074/jbc.271.48.30748; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan JJ, 2000, BIOCHEMISTRY-US, V39, P10936, DOI 10.1021/bi000992l; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Sun HY, 2005, J BACTERIOL, V187, P8137, DOI 10.1128/JB.187.23.8137-8148.2005; Szkopinska A, 2005, ACTA BIOCHIM POL, V52, P45; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; Wang K, 1999, TRENDS BIOCHEM SCI, V24, P445, DOI 10.1016/S0968-0004(99)01464-4	34	79	81	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14991	15000		10.1074/jbc.M512886200	http://dx.doi.org/10.1074/jbc.M512886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16554305	hybrid, Green Published			2022-12-25	WOS:000237671300052
J	Lauer, JM; Dalal, S; Marz, KE; Nonet, ML; Hanson, PI				Lauer, Joshua M.; Dalal, Seema; Marz, Karla E.; Nonet, Michael L.; Hanson, Phyllis I.			SNARE complex zero layer residues are not critical for N-ethylmaleimide-sensitive factor-mediated disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; CRYSTAL-STRUCTURE; ALPHA-SNAP; NEUROTRANSMITTER RELEASE; FUSION COMPLEX; MEMBRANE; SYNTAXIN; EXOCYTOSIS; PROTEIN; TRANSMISSION	Membrane-anchored SNAREs assemble into SNARE complexes that bring membranes together to promote fusion. SNARE complexes are parallel four-helix bundles stabilized in part by hydrophobic interactions within their core. At the center of SNARE complexes is a distinctive zero layer that consists of one arginine and three glutamines. This zero layer is thought to play a special role in the biology of the SNARE complex. One proposal is that the polar residues of the zero layer enable N-ethylmaleimide-sensitive factor (NSF)-mediated SNARE complex disassembly. Here, we studied the effects of manipulating the zero layer of the well studied synaptic SNARE complex in vitro and in vivo. Using a fluorescence-based assay to follow SNARE complex disassembly in real time, we found that the maximal rate at which NSF disassembles complexes was unaffected by mutations in the zero layer, including single replacement of the syntaxin glutamine with arginine as well as multiple replacement of all four layer residues with non-polar amino acids. To determine whether syntaxin with arginine instead of glutamine in its zero layer can support SNARE function in vivo, we introduced it as a transgene into a Caenorhabditis elegans syntaxin-null strain. Mutant syntaxin rescued viability and locomotory defects similarly to wild-type syntaxin, demonstrating that SNARE complexes with two glutamines and two arginines in the zero layer can support neurotransmission. These findings show that residues of the zero layer do not play an essential role in NSF-mediated disassembly.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hanson, PI (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid,Campus Box 8228, St Louis, MO 63110 USA.	phanson@cellbiology.wustl.edu	Hanson, Phyllis/E-9420-2012					Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chen YA, 2001, J BIOL CHEM, V276, P26680, DOI 10.1074/jbc.M103522200; Dilcher M, 2001, J BIOL CHEM, V276, P34537, DOI 10.1074/jbc.M101551200; Dybbs M, 2005, PLOS GENET, V1, P6, DOI 10.1371/journal.pgen.0010002; Ernst JA, 2003, J BIOL CHEM, V278, P8630, DOI 10.1074/jbc.M211889200; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fergestad T, 2001, J NEUROSCI, V21, P9142, DOI 10.1523/JNEUROSCI.21-23-09142.2001; Graf CT, 2005, MOL BIOL CELL, V16, P2263, DOI 10.1091/mbc.E04-09-0830; Graham ME, 2001, J CELL SCI, V114, P4397; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hohl TM, 1998, MOL CELL, V2, P539, DOI 10.1016/S1097-2765(00)80153-7; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Lackner MR, 1999, NEURON, V24, P335, DOI 10.1016/S0896-6273(00)80848-X; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Martinez-Arca S, 2004, TRAFFIC, V5, P371, DOI 10.1111/j.1398-9219.2004.00180.x; Marz KE, 2003, J BIOL CHEM, V278, P27000, DOI 10.1074/jbc.M302003200; May AP, 2001, J BIOL CHEM, V276, P21991, DOI 10.1074/jbc.R100013200; Mello C, 1995, METHOD CELL BIOL, V48, P451; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; Miller KG, 1999, NEURON, V24, P323, DOI 10.1016/S0896-6273(00)80847-8; Nonet ML, 1998, J NEUROSCI, V18, P70; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; NONET ML, 1999, FR MOLEC B, V23, P265; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Saifee O, 1998, MOL BIOL CELL, V9, P1235, DOI 10.1091/mbc.9.6.1235; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Swanton E, 2000, J CELL SCI, V113, P1783; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; van Swinderen B, 1999, P NATL ACAD SCI USA, V96, P2479, DOI 10.1073/pnas.96.5.2479; Wang Y, 2001, J BIOL CHEM, V276, P28598, DOI 10.1074/jbc.M101644200; Wang ZW, 2001, NEURON, V32, P867, DOI 10.1016/S0896-6273(01)00522-0; Wei SH, 2000, EMBO J, V19, P1279, DOI 10.1093/emboj/19.6.1279; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Yizhar O, 2004, P NATL ACAD SCI USA, V101, P2578, DOI 10.1073/pnas.0308700100	51	16	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14823	14832		10.1074/jbc.M512706200	http://dx.doi.org/10.1074/jbc.M512706200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16522630	hybrid			2022-12-25	WOS:000237671300036
J	Silvaggi, NR; Zhang, CC; Lu, ZB; Dai, JY; Dunaway-Mariano, D; Allen, KN				Silvaggi, Nicholas R.; Zhang, Chunchun; Lu, Zhibing; Dai, Jianying; Dunaway-Mariano, Debra; Allen, Karen N.			The X-ray crystal structures of human alpha-phosphomannomutase 1 reveal the structural basis of congenital disorder of glycosylation type 1a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PHOSPHOGLUCOMUTASE; MUTATIONS; PHOSPHATASE; PMM2; 1A; DIVERSIFICATION; GLYCOFORMS; EVOLUTION; INSIGHT; IA	Congential disorder of glycosylation type 1a (CDG-1a) is a congenital disease characterized by severe defects in nervous system development. It is caused by mutations in alpha-phosphomannomutase (of which there are two isozymes, alpha-PMM1 and alpha-PPM2). Here we report the x-ray crystal structures of human alpha-PMM1 in the open conformation, with and without the bound substrate, alpha-D-mannose 1-phosphate. alpha-PMM1, like most haloalkanoic acid dehalogenase superfamily (HADSF) members, consists of two domains, the cap and core, which open to bind substrate and then close to provide a solvent-exclusive environment for catalysis. The substrate phosphate group is observed at a positively charged site of the cap domain, rather than at the core domain phosphoryl-transfer site defined by the Asp19 nucleophile and Mg2+ cofactor. This suggests that substrate binds first to the cap and then is swept into the active site upon cap closure. The orientation of the acid/base residue Asp(21) suggests that alpha-phosphomannomutase (alpha-PMM) uses a different method of protecting the aspartylphosphate from hydrolysis than the HADSF member beta-phosphoglucomutase. It is hypothesized that the electrostatic repulsion of positive charges at the interface of the cap and core domains stabilizes alpha-PMM1 in the open conformation and that the negatively charged substrate binds to the cap, thereby facilitating its closure over the core domain. The two isozymes, alpha-PMM1 and alpha-PMM2, are shown to have a conserved active-site structure and to display similar kinetic properties. Analysis of the known mutation sites in the context of the structures reveals the genotype- phenotype relationship underlying CDG-1a.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87103 USA	Boston University; University of New Mexico	Allen, KN (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA.	allen@med-xtal.bu.edu	Allen, Karen N./J-7045-2019	Allen, Karen N./0000-0001-7296-0551	NHLBI NIH HHS [HL 07291] Funding Source: Medline; NIGMS NIH HHS [GM 61099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061099] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen KN, 2004, TRENDS BIOCHEM SCI, V29, P495, DOI 10.1016/j.tibs.2004.07.008; Alton G, 1998, GLYCOBIOLOGY, V8, P285, DOI 10.1093/glycob/8.3.285; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bjursell C, 2000, HUM MUTAT, V16, P395, DOI 10.1002/1098-1004(200011)16:5<395::AID-HUMU3>3.0.CO;2-T; BROOKS SA, 1994, BIOCHEM SOC T, V22, pS95, DOI 10.1042/bst022095s; DAI JB, 1992, J BIOL CHEM, V267, P6322; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Echols N, 2003, NUCLEIC ACIDS RES, V31, P478, DOI 10.1093/nar/gkg104; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Grunewald S, 2002, PEDIATR RES, V52, P618, DOI 10.1203/01.PDR.0000031921.02259.35; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; Lu ZB, 2005, BIOCHEMISTRY-US, V44, P8684, DOI 10.1021/bi050009j; Matthijs G, 1998, AM J HUM GENET, V62, P542, DOI 10.1086/301763; Matthijs G, 1997, NAT GENET, V16, P88, DOI 10.1038/ng0597-88; Matthijs G, 2000, HUM MUTAT, V16, P386, DOI 10.1002/1098-1004(200011)16:5<386::AID-HUMU2>3.0.CO;2-Y; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Naught LE, 2001, ARCH BIOCHEM BIOPHYS, V396, P111, DOI 10.1006/abbi.2001.2618; Neumann LM, 2003, EUR J PEDIATR, V162, P710, DOI 10.1007/s00431-003-1278-8; Noelle V, 2005, EUR J PEDIATR, V164, P223, DOI 10.1007/s00431-004-1611-x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peisach E, 2004, BIOCHEMISTRY-US, V43, P12770, DOI 10.1021/bi0490688; Pirard M, 1999, FEBS LETT, V452, P319, DOI 10.1016/S0014-5793(99)00673-0; Pirard M, 1999, BIOCHEM J, V339, P201, DOI 10.1042/0264-6021:3390201; Pirard M, 1997, FEBS LETT, V411, P251, DOI 10.1016/S0014-5793(97)00704-7; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; RADEMACHER TW, 1994, P NATL ACAD SCI USA, V91, P6123, DOI 10.1073/pnas.91.13.6123; RUDD PM, 1994, IMMUNOLOGY, V83, P99; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Tremblay LW, 2006, BIOCHEMISTRY-US, V45, P1183, DOI 10.1021/bi051842j; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1; VARIKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI DOI 10.1093/GLYCOB/3.2.97; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Weeks CM, 2002, Z KRISTALLOGR, V217, P686, DOI 10.1524/zkri.217.12.686.20659; WOODS RJ, 1994, NAT STRUCT BIOL, V1, P499, DOI 10.1038/nsb0894-499; Zhang GF, 2005, BIOCHEMISTRY-US, V44, P9404, DOI 10.1021/bi050558p	39	58	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14918	14926		10.1074/jbc.M601505200	http://dx.doi.org/10.1074/jbc.M601505200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16540464	hybrid			2022-12-25	WOS:000237671300045
J	Rothnie, A; Callaghan, R; Deeley, RG; Cole, SPC				Rothnie, Alice; Callaghan, Richard; Deeley, Roger G.; Cole, Susan P. C.			Role of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; CANCER CELL-LINE; NUCLEOTIDE-BINDING; P-GLYCOPROTEIN; LEUKOTRIENE C-4; MRP1 ABCC1; CONFORMATIONAL-CHANGES; VINCRISTINE TRANSPORT; SUBSTRATE-SPECIFICITY; GLUTATHIONE TRANSPORT	Multidrug resistance protein 1 (MRP1/ABCC1) is an ATP-dependent efflux pump that can confer resistance to multiple anticancer drugs and transport conjugated organic anions. Unusually, transport of several MRP1 substrates requires glutathione (GSH). For example, estrone sulfate transport by MRP1 is stimulated by GSH, vincristine is co-transported with GSH, or GSH can be transported alone. In the present study, radioligand binding assays were developed to investigate the mechanistic details of GSH-stimulated transport of estrone sulfate by MRP1. We have established that estrone sulfate binding to MRP1 requires GSH, or its non-reducing analogue S-methyl GSH (S-mGSH), and further that the affinity (K-d) of MRP1 for estrone sulfate is 2.5-fold higher in the presence of S-mGSH than GSH itself. Association kinetics show that GSH binds to MRP1 first, and we propose that GSH binding induces a conformational change, which makes the estrone sulfate binding site accessible. Binding of non-hydrolyzable ATP analogues to MRP1 decreases the affinity for estrone sulfate. However, GSH (or S-mGSH) is still required for estrone sulfate binding, and the affinity for GSH is unchanged. Estrone sulfate affinity remains low following hydrolysis of ATP. The affinity for GSH also appears to decrease in the post-hydrolytic state. Our results indicate ATP binding is sufficient for reconfiguration of the estrone sulfate binding site to lower affinity and argue for the presence of a modulatory GSH binding site not associated with transport of this tripeptide. A model for the mechanism of GSH-stimulated estrone sulfate transport is proposed.	Queens Univ, Inst Canc Res, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England	Queens University - Canada; University of Oxford	Cole, SPC (corresponding author), Queens Univ, Inst Canc Res, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada.	SusanPC.Cole@Queensu.ca	Callaghan, Richard/B-7032-2012; Callaghan, Richard/ABG-1638-2020; Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017; Rothnie, Alice/F-1358-2011	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; Cole, Susan P.C./0000-0001-6571-6884; Rothnie, Alice/0000-0002-4259-7015				Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Basso C, 2003, J GEN PHYSIOL, V122, P333, DOI 10.1085/jgp.200308798; Berger AL, 2005, P NATL ACAD SCI USA, V102, P455, DOI 10.1073/pnas.0408575102; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLE SPC, 1992, BRIT J CANCER, V65, P498, DOI 10.1038/bjc.1992.103; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Haimeur A, 2004, MOL PHARMACOL, V65, P1375, DOI 10.1124/mol.65.6.1375; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Jedlitschky G, 1996, CANCER RES, V56, P988; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012; Leslie EM, 2003, J PHARMACOL EXP THER, V304, P643, DOI 10.1124/jpet.102.044073; Leslie EM, 2003, DRUG METAB DISPOS, V31, P11, DOI 10.1124/dmd.31.1.11; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Lorico A, 1997, CANCER RES, V57, P5238; Manciu L, 2003, J BIOL CHEM, V278, P3347, DOI 10.1074/jbc.M207963200; Mao QC, 2002, J BIOL CHEM, V277, P28690, DOI 10.1074/jbc.M202182200; Martin C, 2001, BIOCHEMISTRY-US, V40, P15733, DOI 10.1021/bi011211z; Merino V., 2004, Current Drug Delivery, V1, P203, DOI 10.2174/1567201043334650; Mueller CFH, 2005, CIRC RES, V97, P637, DOI 10.1161/01.RES.0000183734.21112.b7; Payen L, 2005, MOL PHARMACOL, V67, P1944, DOI 10.1124/mol.104.007708; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Peklak-Scott C, 2005, BIOCHEMISTRY-US, V44, P4426, DOI 10.1021/bi047810y; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Rappa G, 1997, CANCER RES, V57, P5232; Ren XQ, 2005, J BIOL CHEM, V280, P6231, DOI 10.1074/jbc.M409498200; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Rothman A, 1997, BIOCHEMISTRY-US, V36, P14572, DOI 10.1021/bi971800y; Salerno M, 2001, EUR J PHARMACOL, V421, P1, DOI 10.1016/S0014-2999(01)00992-X; SENDA M, 1983, ARCH BIOCHEM BIOPHYS, V220, P398, DOI 10.1016/0003-9861(83)90429-0; Situ D, 2004, J BIOL CHEM, V279, P38871, DOI 10.1074/jbc.M403832200; Tabas LB, 2002, ANAL BIOCHEM, V310, P61, DOI 10.1016/S0003-2697(02)00282-8; TANFORD C, 1983, P NATL ACAD SCI-BIOL, V80, P3701, DOI 10.1073/pnas.80.12.3701; Trompier D, 2004, CANCER RES, V64, P4950, DOI 10.1158/0008-5472.CAN-04-0143; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; Wijnholds J, 1998, J EXP MED, V188, P797, DOI 10.1084/jem.188.5.797; Yang RY, 2005, BBA-BIOMEMBRANES, V1668, P248, DOI 10.1016/j.bbamem.2004.12.013	53	43	46	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13906	13914		10.1074/jbc.M600869200	http://dx.doi.org/10.1074/jbc.M600869200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16565074	hybrid			2022-12-25	WOS:000237512300011
J	Novitskaya, V; Bocharova, OV; Bronstein, I; Baskakov, IV				Novitskaya, V; Bocharova, OV; Bronstein, I; Baskakov, IV			Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO CONVERSION; ALPHA-SYNUCLEIN; NEURITE OUTGROWTH; COMMON MECHANISM; NEUROTOXICITY; DISEASE; OLIGOMERS; APOPTOSIS; SCRAPIE; RECEPTOR	A growing body of evidence indicates that small, soluble oligomeric species generated from a variety of proteins and peptides rather than mature amyloid fibrils are inherently highly cytotoxic. Here, we show for the first time that mature amyloid fibrils produced from full- length recombinant mammalian prion protein ( rPrP) were highly toxic to cultured cells and primary hippocampal and cerebella neurons. Fibrils induced apoptotic cell death in a time- and dose- dependent manner. The toxic effect of fibrils was comparable with that exhibited by soluble small beta- oligomers generated from the same protein. Fibrils prepared from insulin were not toxic, suggesting that the toxic effect was not solely due to the highly polymeric nature of the fibrillar form. The cell death caused by rPrP fibrils or beta- oligomers was substantially reduced when expression of endogenous PrPC was down- regulated by small interfering RNAs. In opposition to the beta- oligomer and amyloid fibrils of rPrP, the monomeric alpha- helical form of rPrP stimulated neurite outgrowth and survival of neurons. These studies illustrated that both soluble beta- oligomer and amyloid fibrils of the prion protein are intrinsically toxic and confirmed that endogenously expressed PrPC is required for mediating the toxicity of abnormally folded external PrP aggregates.	Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; MRC National Institute for Medical Research	Baskakov, IV (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA.	Baskakov@umbi.umd.edu	Bocharova, Olga V./J-8284-2018	Bocharova, Olga V./0000-0002-5056-1506	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045585, R21NS046291] Funding Source: NIH RePORTER; NINDS NIH HHS [NS046291, NS045585] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON M, 2006, IN PRESS J MOL BIOL; Appel TR, 1999, BIOL CHEM, V380, P1295, DOI 10.1515/BC.1999.165; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2004, J BIOL CHEM, V279, P7671, DOI 10.1074/jbc.M310594200; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bocharova OV, 2005, BIOCHEMISTRY-US, V44, P6776, DOI 10.1021/bi050251q; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Chen SZ, 2003, MOL CELL NEUROSCI, V22, P227, DOI 10.1016/S1044-7431(02)00014-3; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Chiesa R, 2005, P NATL ACAD SCI USA, V102, P238, DOI 10.1073/pnas.0406173102; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; DOBSON M, 2002, TRENDS BIOCHEM SCI, V24, P329; Ettaiche M, 2000, J BIOL CHEM, V275, P36487, DOI 10.1074/jbc.C000579200; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Gatti R, 1998, J HISTOCHEM CYTOCHEM, V46, P895, DOI 10.1177/002215549804600804; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Giese A, 1998, BRAIN PATHOL, V8, P449; Gu YP, 2002, J BIOL CHEM, V277, P2275, DOI 10.1074/jbc.M104345200; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hug H, 1999, BIOCHEMISTRY-US, V38, P13906, DOI 10.1021/bi9913395; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Kanaani J, 2005, J NEUROCHEM, V95, P1373, DOI 10.1111/j.1471-4159.2005.03469.x; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kaylor J, 2005, J MOL BIOL, V353, P357, DOI 10.1016/j.jmb.2005.08.046; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Krebs MRH, 2004, P NATL ACAD SCI USA, V101, P14420, DOI 10.1073/pnas.0405933101; Krishnan R, 2005, NATURE, V435, P765, DOI 10.1038/nature03679; Li AM, 2005, J BIOL CHEM, V280, P17430, DOI 10.1074/jbc.C500058200; MAAR T, 1995, INT J DEV NEUROSCI, V13, P491, DOI 10.1016/0736-5748(95)00068-R; Malisauskas M, 2005, J BIOL CHEM, V280, P6269, DOI 10.1074/jbc.M407273200; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mange A, 2002, FEBS LETT, V514, P159, DOI 10.1016/S0014-5793(02)02338-4; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Ronn LCB, 2000, J NEUROSCI METH, V100, P25, DOI 10.1016/S0165-0270(00)00228-4; Roucou X, 2005, CELL DEATH DIFFER, V12, P783, DOI 10.1038/sj.cdd.4401629; Roucou X, 2005, J MOL MED, V83, P3, DOI 10.1007/s00109-004-0605-5; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Santuccione A, 2005, J CELL BIOL, V169, P341, DOI 10.1083/jcb.200409127; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Souillac PO, 2002, J BIOL CHEM, V277, P12666, DOI 10.1074/jbc.M109229200; Sousa MM, 2001, AM J PATHOL, V159, P1993; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Thellung S, 2002, NEUROBIOL DIS, V9, P69, DOI 10.1006/nbdi.2001.0461; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Zhu M, 2004, J BIOL CHEM, V279, P24452, DOI 10.1074/jbc.M400004200; Zou WQ, 2004, P NATL ACAD SCI USA, V101, P1380, DOI 10.1073/pnas.0307825100	74	201	205	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13828	13836		10.1074/jbc.M511174200	http://dx.doi.org/10.1074/jbc.M511174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16554307	hybrid			2022-12-25	WOS:000237336600093
J	Aranovich, A; Gdalevsky, GY; Cohen-, R; Fishov, I; Parola, AH				Aranovich, A; Gdalevsky, GY; Cohen-, R; Fishov, I; Parola, AH			Membrane-catalyzed nucleotide exchange on DnaA - Effect of surface molecular crowding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAA; CHROMOSOMAL REPLICATION; FUNCTIONAL INTERACTION; IN-VITRO; PROTEIN; INITIATOR; DOMAINS; BINDING; PHOSPHOLIPIDS; ADSORPTION	DnaA is the initiator protein for chromosomal replication in bacteria; its activity plays a central role in the timing of the primary initiations within the Escherichia coli cell cycle. A controlled, reversible conversion between the active ATP-DnaA and the inactive ADP forms modulates this activity. In a DNA-dependent manner, bound ATP is hydrolyzed to ADP. Acidic phospholipids with unsaturated fatty acids are capable of reactivating ADP-DnaA by promoting the release of the tightly bound ADP. The nucleotide dissociation kinetics, measured in the present study with the fluorescent derivative 3'-O-(N-methylantraniloyl)-5'-adenosine triphosphate, was dependent on the density of DnaA on the membrane in a cooperative manner: it increased 5-fold with decreased protein density. At all surface densities the nucleotide was completely released, presumably due to protein exchange on the membrane. Distinct temperature dependences and the effect of the crowding agent Ficoll suggest that two functional states of DnaA exist at high and low membrane occupancy, ascribed to local macromolecular crowding on the membrane surface. These novel phenomena are thought to play a major role in the mechanism regulating the initiation of chromosomal replication in bacteria.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Fishov, I (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, POB 653, IL-84105 Beer Sheva, Israel.	fishov@bgu.ac.il	FISHOV, ITZHAK/F-2264-2012	Fishov, Itzhak/0000-0002-2125-0012; Parola, Abraham H./0000-0002-3953-5454				AMES BN, 1960, J BIOL CHEM, V235, P769; Arnold RS, 1997, BIOCHEMISTRY-US, V36, P6149, DOI 10.1021/bi970023z; Boeneman K, 2005, CURR OPIN MICROBIOL, V8, P143, DOI 10.1016/j.mib.2005.02.006; Boye E, 2000, EMBO REP, V1, P479, DOI 10.1093/embo-reports/kvd116; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camara JE, 2005, EMBO REP, V6, P736, DOI 10.1038/sj.embor.7400467; CARTY CE, 1981, J BACTERIOL, V145, P472, DOI 10.1128/JB.145.1.472-478.1981; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; Crooke E, 2001, BIOCHIMIE, V83, P19, DOI 10.1016/S0300-9084(00)01224-4; CROOKE E, 1992, J BIOL CHEM, V267, P16779; Dauty E, 2004, J MOL RECOGNIT, V17, P441, DOI 10.1002/jmr.709; Dowhan W, 2004, BBA-BIOMEMBRANES, V1666, P19, DOI 10.1016/j.bbamem.2004.04.010; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Felczak MM, 2005, J BIOL CHEM, V280, P24627, DOI 10.1074/jbc.M503684200; Fishov I, 1999, MOL MICROBIOL, V32, P1166, DOI 10.1046/j.1365-2958.1999.01425.x; Galletto R, 2000, BIOCHEMISTRY-US, V39, P12959, DOI 10.1021/bi0012484; Garner J, 1998, J BIOL CHEM, V273, P5167, DOI 10.1074/jbc.273.9.5167; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; Hall D, 2003, BBA-PROTEINS PROTEOM, V1649, P127, DOI 10.1016/S1570-9639(03)00167-5; HANSEN FG, 1991, RES MICROBIOL, V142, P161, DOI 10.1016/0923-2508(91)90025-6; Hase M, 1998, J BIOL CHEM, V273, P28651, DOI 10.1074/jbc.273.44.28651; HELMSTETTER CE, 1996, ESCHERICHIA COLI SAL, P1627; Ishida T, 2004, J BIOL CHEM, V279, P45546, DOI 10.1074/jbc.M402762200; Kadner R. J., 1996, ESCHERICHIA COLI SAL, P58; Katayama T, 1999, BIOCHIMIE, V81, P835, DOI 10.1016/S0300-9084(99)00213-8; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Kim PD, 2003, J BACTERIOL, V185, P1817, DOI 10.1128/JB.185.6.1817-1824.2003; Kitagawa R, 1996, MOL MICROBIOL, V19, P1137, DOI 10.1046/j.1365-2958.1996.453983.x; Kitchen JL, 1999, BIOCHEMISTRY-US, V38, P6213, DOI 10.1021/bi982733q; Koppelman CM, 2001, J BACTERIOL, V183, P6144, DOI 10.1128/JB.183.20.6144-6147.2001; KUNG HF, 1972, P NATL ACAD SCI USA, V69, P925, DOI 10.1073/pnas.69.4.925; Kurokawa K, 1999, EMBO J, V18, P6642, DOI 10.1093/emboj/18.23.6642; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P276; Lee DG, 2000, CURR OPIN CELL BIOL, V12, P280, DOI 10.1016/S0955-0674(00)00089-2; Li ZY, 2005, J BIOL CHEM, V280, P9796, DOI 10.1074/jbc.M413923200; Li ZY, 1999, PROTEIN EXPRES PURIF, V17, P41, DOI 10.1006/prep.1999.1094; LIDE DR, 1990, HDB CHEM PHYS, pD264; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; Mileykovskaya E, 2003, J BIOL CHEM, V278, P22193, DOI 10.1074/jbc.M302603200; Mileykovskaya E, 2000, J BACTERIOL, V182, P1172, DOI 10.1128/JB.182.4.1172-1175.2000; Minton AP, 2000, BIOPHYS CHEM, V86, P239, DOI 10.1016/S0301-4622(00)00151-4; Minton AP, 2001, BIOPHYS J, V80, P1641, DOI 10.1016/S0006-3495(01)76136-X; Minton AP, 1999, BIOPHYS J, V76, P176, DOI 10.1016/S0006-3495(99)77187-0; Mizushima T, 1996, J BIOL CHEM, V271, P3633; Morigen, 2005, J BACTERIOL, V187, P3913, DOI 10.1128/JB.187.12.3913-3920.2005; MOZHAROV AD, 1985, FEBS LETT, V186, P103, DOI 10.1016/0014-5793(85)81348-X; Newman G, 2000, J BACTERIOL, V182, P2604, DOI 10.1128/JB.182.9.2604-2610.2000; Norris V, 2001, BIOCHIMIE, V83, P91, DOI 10.1016/S0300-9084(00)01203-7; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Su'etsugu M, 2005, J BIOL CHEM, V280, P6528, DOI 10.1074/jbc.M412060200; THOMAS DD, 1978, P NATL ACAD SCI USA, V75, P5746, DOI 10.1073/pnas.75.12.5746; Vanounou S, 2003, MOL MICROBIOL, V49, P1067, DOI 10.1046/j.1365-2958.2003.03614.x; Vanounou S, 2002, PHOTOCHEM PHOTOBIOL, V76, P1, DOI 10.1562/0031-8655(2002)076<0001:CODWDO>2.0.CO;2; Walz AC, 2002, BIOCHEM J, V365, P471, DOI 10.1042/BJ20011853; Wenner JR, 1999, BIOPHYS J, V77, P3234, DOI 10.1016/S0006-3495(99)77154-7; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; Yamaguchi Y, 1999, BIOCHEM J, V340, P433, DOI 10.1042/0264-6021:3400433	63	20	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12526	12534		10.1074/jbc.M510266200	http://dx.doi.org/10.1074/jbc.M510266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517983	hybrid			2022-12-25	WOS:000237134700041
J	Chapman-Smith, A; Whitelaw, ML				Chapman-Smith, A; Whitelaw, ML			Novel DNA binding by a basic helix-loop-helix protein - The role of the dioxin receptor PAS domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOACTIVE YELLOW PROTEIN; AH-RECEPTOR; CRYSTAL-STRUCTURE; NUCLEAR TRANSLOCATOR; TRANSCRIPTION; DIMERIZATION; IDENTIFICATION; RECOGNITION; SPECIFICITY; REGION	Central issues surrounding the basic helix-loop-helix ( bHLH) superfamily of dimeric transcription factors concern how specificity of partner selection and DNA binding are achieved. bHLH proteins bind DNA through the basic sequence that is contiguous with a helix-loop-helix dimerization domain. For the two subgroups within the family, dimerization is further regulated by an adjacent Per-Arnt-Sim homology ( PAS) or leucine zipper (LZ) domain. We provide evidence that for the bHLH(.)PAS transcription factors Dioxin Receptor (DR) and Arnt, the DR PAS A domain has a unique interaction with the bHLH region that underpins both dimerization strength and affinity for an atypical E-box DNA sequence. A PAS swap heterodimer, where the DR bHLH domain was fused to Arnt PAS A and the Arnt bHLH fused to DR PAS A, gave strong DNA binding, but dimerization was only effective with the native arrangement, suggesting the PAS A domain is critical for each process via distinct mechanisms. LZ domains, which regulate heterodimerization for the bHLH(.)LZ family members Myc and Max, could not replace the PAS domains for either dimerization or DNA binding in the DR/Arnt heterodimer. In vitro footprinting revealed that the PAS domains influence the conformation of target DNA in a manner consistent with DNA bending. These results provide the first insights for understanding mechanisms of selective dimerization and DNA interaction that distinguish bHLH(.)PAS proteins from the broader bHLH superfamily.	Univ Adelaide, Sch Mol & Biomed Sci Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Australian Res Council, Special Ctr Mol Genet Dev, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Chapman-Smith, A (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci Biochem, Adelaide, SA 5005, Australia.	anne.chapmansmith@adelaide.edu.au						ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Chapman-Smith A, 2004, J BIOL CHEM, V279, P5353, DOI 10.1074/jbc.M310041200; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; DAMARE ARF, 1994, EMBO J, V13, P180; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DONG QP, 1994, EMBO J, V13, P200, DOI 10.1002/j.1460-2075.1994.tb06249.x; Dove SL, 1998, GENE DEV, V12, P745, DOI 10.1101/gad.12.5.745; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; ELFERINK CJ, 1990, J BIOL CHEM, V265, P5718; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Fieber W, 2001, J MOL BIOL, V307, P1395, DOI 10.1006/jmbi.2001.4537; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; Joung JK, 2000, P NATL ACAD SCI USA, V97, P7382, DOI 10.1073/pnas.110149297; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Kholod N, 2001, BIOTECHNIQUES, V31, P322, DOI 10.2144/01312st03; Khorasanizadeh S, 2001, TRENDS BIOCHEM SCI, V26, P384, DOI 10.1016/S0968-0004(01)01800-X; Kumar R, 2005, J STEROID BIOCHEM, V94, P383, DOI 10.1016/j.jsbmb.2004.12.046; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MASON GGF, 1994, J BIOL CHEM, V269, P4438; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; NumayamaTsuruta K, 1997, EUR J BIOCHEM, V246, P486, DOI 10.1111/j.1432-1033.1997.00486.x; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; Rishi V, 2004, J BIOL CHEM, V279, P11863, DOI 10.1074/jbc.M308000200; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; WATSON AJ, 1992, J BIOL CHEM, V267, P6874; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019; Yildiz O, 2005, MOL CELL, V17, P69, DOI 10.1016/j.molcel.2004.11.022; Yindeeyoungyeon W, 2000, BIOTECHNIQUES, V29, P1034, DOI 10.2144/00295st05; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	45	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12535	12545		10.1074/jbc.M512145200	http://dx.doi.org/10.1074/jbc.M512145200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520375	hybrid			2022-12-25	WOS:000237134700042
J	Pirner, HM; Stolz, J				Pirner, HM; Stolz, J			Biotin sensing in Saccharomyces cerevisiae is mediated by a conserved DNA element and requires the activity of biotin-protein ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA-CARBOXYLASE; PLASMA-MEMBRANE; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; YEAST; BINDING; BIOSYNTHESIS; TRANSPORTER; IDENTIFICATION; GLUCOKINASE	Biotin is a water-soluble vitamin that functions as a prosthetic group in carboxylation reactions. In addition to its role as a cofactor, biotin has multiple roles in gene regulation. We analyzed biotin effects on gene expression in the yeast Saccharomyces cerevisiae and demonstrated by microarray, Northern, and Western analyses that all yeast genes encoding proteins involved in biotin metabolism are up-regulated following biotin depletion. Many of these genes contain a palindromic promoter element that is necessary and sufficient for mediating the biotin response and functions as an upstream-activating sequence. Mutants lacking the plasma membrane biotin transporter Vht1p display constitutively high expression levels of biotin-responsive genes. However, they react normally to biotin precursors that do not require Vht1p for uptake. The biotin-like effect of precursors with regard to gene expression requires their intracellular conversion to biotin. This demonstrates that Vht1p does not act as a sensor for biotin and that intracellular biotin is crucial for gene expression. Mutants with defects in biotin-protein ligase, similar to vht1 Delta mutants, also display aberrantly high expression of biotin-responsive genes. Like vht1 Delta cells, they have reduced levels of protein biotinylation, but unlike vht1 Delta mutants, they possess normal levels of free intracellular biotin. This indicates that free intracellular biotin is irrelevant for gene regulation and identifies biotin-protein ligase as an important element of the biotin-sensing pathway in yeast.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany	University of Regensburg	Stolz, J (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ Str 31, D-93040 Regensburg, Germany.	juergen.stolz@biologie.uni-regensburg.de						Boles E, 2004, TOP CURR GENET, V9, P121; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; CHAUHAN J, 1991, J BIOL CHEM, V266, P10035; Che P, 2003, PLANT PHYSIOL, V131, P1479, DOI 10.1104/pp.013243; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; CRONAN JE, 1995, FEMS MICROBIOL LETT, V130, P221, DOI 10.1016/0378-1097(95)00210-V; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; DAKSHINAMURTI K, 1968, CAN J BIOCHEM CELL B, V46, P75, DOI 10.1139/o68-012; Donaton MCV, 2003, MOL MICROBIOL, V50, P911, DOI 10.1046/j.1365-2958.2003.03732.x; DUVAL M, 1994, BIOCHEM J, V299, P141, DOI 10.1042/bj2990141; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guillen-Navarro K, 2005, FEMS MICROBIOL LETT, V246, P159, DOI 10.1016/j.femsle.2005.04.020; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; HASSLACHER M, 1993, J BIOL CHEM, V268, P10946; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; Hoja U, 2004, J BIOL CHEM, V279, P21779, DOI 10.1074/jbc.M401071200; Hoja U, 1998, EUR J BIOCHEM, V254, P520, DOI 10.1046/j.1432-1327.1998.2540520.x; Holsbeeks I, 2004, TRENDS BIOCHEM SCI, V29, P556, DOI 10.1016/j.tibs.2004.08.010; Hoppen J, 2005, YEAST, V22, P601, DOI 10.1002/yea.1209; Hymes J, 1996, CLIN CHIM ACTA, V255, P1, DOI 10.1016/0009-8981(96)06396-6; Jesch SA, 2005, J BIOL CHEM, V280, P9106, DOI 10.1074/jbc.M411770200; Kaiser C., 1994, METHODS YEAST GENETI; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kim HS, 2004, J BIOL CHEM, V279, P42445, DOI 10.1074/jbc.M407137200; Koser S.A., 1968, VITAMIN REQUIREMENTS; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Melcher K, 2000, GENE, V247, P53, DOI 10.1016/S0378-1119(00)00124-4; MISHINA M, 1980, EUR J BIOCHEM, V111, P79; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; OHSUGI M, 1985, J NUTR SCI VITAMINOL, V31, P563, DOI 10.3177/jnsv.31.563; OTSUKA A, 1978, NATURE, V276, P689, DOI 10.1038/276689a0; Pacheco-Alvarez D, 2005, MOL GENET METAB, V85, P301, DOI 10.1016/j.ymgme.2005.04.001; Pacheco-Alvarez D, 2004, J BIOL CHEM, V279, P52312, DOI 10.1074/jbc.M407056200; Phalip V, 1999, GENE, V232, P43, DOI 10.1016/S0378-1119(99)00117-1; Polyak SW, 1999, J BIOL CHEM, V274, P32847, DOI 10.1074/jbc.274.46.32847; Rodionov DA, 2002, GENOME RES, V12, P1507, DOI 10.1101/gr.314502; Rodriguez-Melendez R, 2003, J NUTR BIOCHEM, V14, P680, DOI 10.1016/j.jnutbio.2003.07.001; Rodriguez-Melendez R, 2003, J NUTR, V133, P1259; ROGERS TO, 1969, J BACTERIOL, V100, P565, DOI 10.1128/JB.100.2.565-572.1969; ROGERS TO, 1969, J BACTERIOL, V100, P557, DOI 10.1128/JB.100.2.557-564.1969; Santiago TC, 2003, J BIOL CHEM, V278, P38723, DOI 10.1074/jbc.M303008200; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULLER HJ, 1995, FEBS LETT, V370, P149, DOI 10.1016/0014-5793(95)00818-T; Shakoury-Elizeh M, 2004, MOL BIOL CELL, V15, P1233, DOI 10.1091/mbc.E03-09-0642; Solorzano-Vargas RS, 2002, P NATL ACAD SCI USA, V99, P5325, DOI 10.1073/pnas.082097699; Stolz J, 1999, J BIOL CHEM, V274, P18741, DOI 10.1074/jbc.274.26.18741; Stolz J, 2003, J BIOL CHEM, V278, P18990, DOI 10.1074/jbc.M300949200; Stolz J, 2003, YEAST, V20, P221, DOI 10.1002/yea.959; STUCKA R, 1991, MOL GEN GENET, V229, P307, DOI 10.1007/BF00272171; SUMRADA RA, 1982, J BIOL CHEM, V257, P9119; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WICKERHAM LJ, 1948, J BACTERIOL, V56, P363, DOI 10.1128/JB.56.3.363-371.1948; Wu H, 2005, APPL ENVIRON MICROB, V71, P6845, DOI 10.1128/AEM.71.11.6845-6855.2005; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; ZHANG SG, 1994, ARCH BIOCHEM BIOPHYS, V309, P29, DOI 10.1006/abbi.1994.1079	58	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12381	12389		10.1074/jbc.M511075200	http://dx.doi.org/10.1074/jbc.M511075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531611	hybrid			2022-12-25	WOS:000237134700023
J	Roy, BB; Hu, J; Guo, XF; Russell, RS; Guo, F; Kleiman, L; Liang, C				Roy, BB; Hu, J; Guo, XF; Russell, RS; Guo, F; Kleiman, L; Liang, C			Association of RNA helicase a with human immunodeficiency virus type 1 particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE TRANSPORT ELEMENT; CELLULAR COFACTOR; MALELESS PROTEIN; HIV-1 GAG; APOBEC3G; REGION; DIMERIZATION; REPLICATION; DELETION; COMPLEX	RNA helicase A (RHA) belongs to the DEAH family of proteins that are capable of unwinding double-stranded RNA structure. In addition to its involvement in the metabolism of cellular RNA, RHA has been shown to stimulate RNA transcription from the long terminal repeat promoter of human immunodeficiency virus type 1 (HIV-1) as well as to enhance Rev/Rev response element-mediated gene expression. In this study, we provide evidence that RHA associates with HIV-1 Gag in an RNA-dependent manner. This interaction results in specific incorporation of RHA into HIV-1 particles. Knockdown of endogenous RHA in virus producer cells leads to generation of HIV-1 particles that are less infectious in part as a result of restricted reverse transcription. Therefore, RHA represents the first example of cellular RNA helicases that participate in HIV-1 particle production and promote viral reverse transcription.	Jewish Gen Hosp, Lady Davis Inst Med Res, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B4, Canada	Lady Davis Institute; McGill University; McGill University	Liang, C (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, McGill AIDS Ctr, Rm 326,3755 Cote Ste, Montreal, PQ H3T 1E2, Canada.	chen.liang@mcgill.ca	Russell, Rod/AAU-3109-2021					Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Cen Shan, 2004, Retrovirology, V1, P33, DOI 10.1186/1742-4690-1-33; Cocude C, 2003, J GEN VIROL, V84, P3215, DOI 10.1099/vir.0.19300-0; Fang JH, 2004, VIROLOGY, V330, P471, DOI 10.1016/j.virol.2004.09.039; Fujii R, 2001, J BIOL CHEM, V276, P5445, DOI 10.1074/jbc.M006892200; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Guo XF, 2005, VIROLOGY, V335, P232, DOI 10.1016/j.virol.2005.03.004; Guo XF, 2004, J VIROL, V78, P551, DOI 10.1128/JVI.78.2.551-560.2004; Hartmuth K, 2002, P NATL ACAD SCI USA, V99, P16719, DOI 10.1073/pnas.262483899; Huang Y, 2001, J VIROL, V75, P4947, DOI 10.1128/JVI.75.10.4947-4951.2001; Khan MA, 2005, J VIROL, V79, P5870, DOI 10.1128/JVI.79.9.5870-5874.2005; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Krishnan Vyjayanthi, 2004, Retrovirology, V1, P42, DOI 10.1186/1742-4690-1-42; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; Kwong AD, 2005, NAT REV DRUG DISCOV, V4, P845, DOI 10.1038/nrd1853; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee CG, 1997, EMBO J, V16, P2671, DOI 10.1093/emboj/16.10.2671; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; LEE CG, 1992, J BIOL CHEM, V267, P4398; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Liang C, 2002, AIDS RES HUM RETROV, V18, P1117, DOI 10.1089/088922202320567851; Luo K, 2004, J VIROL, V78, P11841, DOI 10.1128/JVI.78.21.11841-11852.2004; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Paillart JC, 2004, NAT REV MICROBIOL, V2, P461, DOI 10.1038/nrmicro903; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rong LW, 2003, VIROLOGY, V314, P221, DOI 10.1016/S0042-6822(03)00405-7; Russell RS, 2003, J VIROL, V77, P12986, DOI 10.1128/JVI.77.24.12986-12995.2003; Russell RS, 2003, J VIROL, V77, P84, DOI 10.1128/JVI.77.1.84-96.2003; SHENG NJ, 1994, J VIROL, V68, P6207, DOI 10.1128/JVI.68.10.6207-6214.1994; Smith WA, 2004, J BIOL CHEM, V279, P22795, DOI 10.1074/jbc.C300512200; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 2000, J BIOL CHEM, V275, P32694, DOI 10.1074/jbc.M003933200; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tetsuka T, 2004, EUR J BIOCHEM, V271, P3741, DOI 10.1111/j.1432-1033.2004.04314.x; Walstrom KM, 2005, MECH DEVELOP, V122, P707, DOI 10.1016/j.mod.2004.12.002; Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000; Yang JP, 2001, J BIOL CHEM, V276, P30694, DOI 10.1074/jbc.M102809200; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; Zennou W, 2004, J VIROL, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004; Zhang SS, 1997, J BIOL CHEM, V272, P11487; Zhang SS, 2004, ACTA BIOCH BIOPH SIN, V36, P177, DOI 10.1093/abbs/36.3.177	48	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12625	12635		10.1074/jbc.M510596200	http://dx.doi.org/10.1074/jbc.M510596200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527808	hybrid			2022-12-25	WOS:000237134700053
J	Papp, E; Szaraz, P; Korcsmaros, T; Csermely, P				Papp, Eszter; Szaraz, Peter; Korcsmaros, Tamas; Csermely, Peter			Changes of endoplasmic reticulum chaperone complexes, redox state, and impaired protein disulfide reductase activity in misfolding alpha 1-antitrypsin transgenic mice	FASEB JOURNAL			English	Article						glucose regulated proteins; heat shock proteins; oxidative stress; protein aggregation; redox imbalance	OXIDATIVE STRESS; MUTANT ALPHA(1)-ANTITRYPSIN-Z; PIZ ALPHA-1-ANTITRYPSIN; RAT-LIVER; ACCUMULATION; DEGRADATION; PROTEASOME; ISOMERASE; GLUTATHIONE; DEFICIENCY	alpha 1-antitrypsin (AAT) deficiency is characterized by the accumulation of the misfolded mutant, Z form of alpha 1-antitrypsin (PiZ) inside the lumen of the hepatic endoplasmic reticulum (ER). Both human patients and PiZ transgenic mice have similar symptoms of hepatic failure culminating in cirrhosis and hepatocellular carcinoma. The involvement of molecular chaperones, as well as the relevance of oxidative stress in this disease is not characterized well yet. Here, we show that, in the PiZ transgenic mice, the 58-kDa protein disulfide isomerase (PDI), the most important oxidoreductase and chaperone of the endoplasmic reticulum, is in a complex with PiZ, which is accompanied by a decrease of protein disulfide reductase activity of the ER. PiZ transgenic mice have a shift toward a more reduced ER environment and an elevation of cytoplasmic chaperones and antioxidant enzymes. Our data suggest that lower availability of PDI and a decreased protein disulfide reductase activity of the ER along with a cytoplasmic stress may contribute to the toxic effects of PiZ aggregation.	Semmelweis Univ, Dept Med Chem, H-1444 Budapest 8, Hungary	Semmelweis University	Csermely, P (corresponding author), Semmelweis Univ, Dept Med Chem, POB 260, H-1444 Budapest 8, Hungary.	Csermely@puskin.sote.hu	Korcsmaros, Tamas/C-3526-2015; Csermely, Peter/J-2067-2017	Korcsmaros, Tamas/0000-0003-1717-996X; Csermely, Peter/0000-0001-9234-0659				Ahner A, 2004, TRENDS CELL BIOL, V14, P474, DOI 10.1016/j.tcb.2004.07.013; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Barrett MJ, 2004, J NEUROSCI RES, V78, P420, DOI 10.1002/jnr.20249; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabral CM, 2002, MOL BIOL CELL, V13, P2639, DOI 10.1091/mbc.E02-02-0068; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; Conconi M, 1998, BIOCHEM J, V333, P407, DOI 10.1042/bj3330407; CRESTEIL D, 1990, FEBS LETT, V267, P277, DOI 10.1016/0014-5793(90)80944-E; Demasi M, 2003, FEBS LETT, V542, P89, DOI 10.1016/S0014-5793(03)00353-3; DYCAICO MJ, 1988, SCIENCE, V242, P1409, DOI 10.1126/science.3264419; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Frand AR, 2000, MOL BIOL CELL, V11, P2833, DOI 10.1091/mbc.11.9.2833; GELLER SA, 1994, HEPATOLOGY, V19, P389; Gillece P, 1999, J CELL BIOL, V147, P1443, DOI 10.1083/jcb.147.7.1443; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020; HAGERTY DT, 1995, J IMMUNOL, V155, P2993; HENNE V, 1986, FEBS LETT, V202, P267, DOI 10.1016/0014-5793(86)80699-8; Heuck AP, 1997, J BIOCHEM BIOPH METH, V34, P213, DOI 10.1016/S0165-022X(97)00014-6; Hidvegi T, 2005, J BIOL CHEM, V280, P39002, DOI 10.1074/jbc.M508652200; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Kern JC, 2005, FRONT BIOSCI-LANDMRK, V10, P1727, DOI 10.2741/1656; Lawless MW, 2004, J IMMUNOL, V172, P5722, DOI 10.4049/jimmunol.172.9.5722; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Lomas DA, 2004, THORAX, V59, P529, DOI 10.1136/thx.2003.006528; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Nardai G, 2005, BIOCHEM BIOPH RES CO, V334, P787, DOI 10.1016/j.bbrc.2005.06.172; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Papp E, 2003, BIOFACTORS, V17, P249, DOI 10.1002/biof.5520170124; Perlmutter DH, 2002, J CLIN INVEST, V110, P1579, DOI 10.1172/JCI200216787; PERLMUTTER DH, 1989, J CLIN INVEST, V84, P1555, DOI 10.1172/JCI114332; Petropoulos I, 2000, J GERONTOL A-BIOL, V55, pB220, DOI 10.1093/gerona/55.5.B220; Rudnick DA, 2004, HEPATOLOGY, V39, P1048, DOI 10.1002/hep.20118; Schmidt BZ, 2005, AM J PHYSIOL-GASTR L, V289, pG444, DOI 10.1152/ajpgi.00237.2004; Sideraki V, 2000, BIOCHEMISTRY-US, V39, P1180, DOI 10.1021/bi992246q; SITIA R, 2004, SCI STKE, V239, pPE27; Smith JD, 2004, BIOTECHNOL BIOENG, V85, P340, DOI 10.1002/bit.10853; Sreedhar AS, 2004, FEBS LETT, V562, P11; Sreekumar PG, 2005, BIOCHEM BIOPH RES CO, V334, P245, DOI 10.1016/j.bbrc.2005.06.081; Teckman JH, 2002, AM J PHYSIOL-GASTR L, V283, pG1156, DOI 10.1152/ajpgi.00041.2002; Teckman JH, 2001, J BIOL CHEM, V276, P44865, DOI 10.1074/jbc.M103703200; TECKMAN JH, 2003, AM J PHYSIOL-GASTR L, V286, pG815; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Varsanyi M, 2004, J BIOL CHEM, V279, P3370, DOI 10.1074/jbc.M307783200; Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100	48	30	30	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					1018	+		10.1096/fj.05-5065fje	http://dx.doi.org/10.1096/fj.05-5065fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571774				2022-12-25	WOS:000240157700041
J	Shiau, CW; Huang, JW; Wang, DS; Weng, JR; Yang, CC; Lin, CH; Li, CL; Chen, CS				Shiau, CW; Huang, JW; Wang, DS; Weng, JR; Yang, CC; Lin, CH; Li, CL; Chen, CS			alpha-tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-E-SUCCINATE; SIGNAL-REGULATED KINASE; MOLECULAR-BASIS; IN-VIVO; ACTIVATION; DORMANCY; PATHWAY; AGENT	Although the antitumor effect of alpha-tocopheryl succinate ( vitamin E succinate) has been well demonstrated, its underlying mechanism remains elusive. This study provides evidence that inhibition of Bcl-xL/Bcl- 2 function represents a major pathway whereby alpha-tocopheryl succinate mediates apoptosis induction in prostate cancer cells. In vitro data indicate that alpha-tocopheryl succinate was able to disrupt the binding of Bak BH3 peptide to Bcl-xL and Bcl-2 with IC50 of 26 mu M, in line with its potency in antiproliferation. Treatment of PC-3 cells with this agent led to reduced association of Bcl-2 and Bcl-xL with Bak, leading to caspase-dependent apoptosis. Moreover, overexpression of Bcl-xL protected LNCaP cells from the apoptosis induction. This mechanistic finding provided a basis to develop potent Bcl-xL/Bcl- 2 inhibitors. Docking of alpha-tocopheryl succinate into the Bak peptide-binding site indicates that it adopted a unique hairpin-shaped conformation for protein interactions. We rationalized that the hemisuccinate and the two proximal isopranyl units of the side chain played a crucial role in ligand anchoring and protein-ligand complex stabilization, respectively. However, exposure of the distal isopranyl unit to a polar environment might diminish the binding affinity of alpha-tocopheryl succinate. This premise was corroborated by a structure-activity analysis of a series of derivatives with truncated side chains and/or altered carboxyl terminus. This computer model predicted that the removal of the distal isopranyl unit from the side chain would improve binding affinity, leading to two agents with significantly higher potency in inhibiting Bak peptide binding and in suppressing prostate cancer cell proliferation.	Ohio State Univ, Coll Pharm, Div Med Chem, Columbus, OH 43210 USA; China Med Univ & Hosp, Dept Biol Sci & Technol, Taichung 404, Taiwan	University System of Ohio; Ohio State University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Chen, CS (corresponding author), Ohio State Univ, Coll Pharm, Div Med Chem, 336 Pk Hall,500 W 12th Ave, Columbus, OH 43210 USA.	chen.844@osu.edu	Li, Chenglong/E-7182-2010; Weng, Jing-Ru/L-1743-2013	Li, Chenglong/0000-0003-3174-8719; 	NATIONAL CANCER INSTITUTE [R01CA112250] Funding Source: NIH RePORTER; NCI NIH HHS [CA-112250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bang OS, 2001, BIOCHEM BIOPH RES CO, V288, P789, DOI 10.1006/bbrc.2001.5839; Barnett KT, 2002, J SURG RES, V106, P292, DOI 10.1006/jsre.2002.6466; Dalen H, 2003, BRIT J CANCER, V88, P153, DOI 10.1038/sj.bjc.6600683; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Kogure K, 2003, CANCER LETT, V192, P19, DOI 10.1016/S0304-3835(02)00683-3; Li XY, 2001, CANCER RES, V61, P1699; Lugovskoy AA, 2002, J AM CHEM SOC, V124, P1234, DOI 10.1021/ja011239y; Malafa MP, 2002, ANN SURG ONCOL, V9, P1023, DOI 10.1245/ASO.2002.03.580; Malafa MP, 2000, J SURG RES, V93, P163, DOI 10.1006/jsre.2000.5948; Manion MK, 2004, J BIOL CHEM, V279, P2159, DOI 10.1074/jbc.M306021200; Neuzil H, 2002, BIOCHEM BIOPH RES CO, V293, P1309, DOI 10.1016/S0006-291X(02)00358-3; Neuzil J, 1999, FEBS LETT, V445, P295, DOI 10.1016/S0014-5793(99)00141-6; Neuzil J, 2001, BRIT J CANCER, V84, P87, DOI 10.1054/bjoc.2000.1559; Prasad KN, 2003, J AM COLL NUTR, V22, P108, DOI 10.1080/07315724.2003.10719283; PRASAD KN, 1982, CANCER RES, V42, P550; Qian M, 1997, ONCOGENE, V15, P223, DOI 10.1038/sj.onc.1201181; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677; Turley JM, 1997, CANCER RES, V57, P2668; Weber T, 2003, BIOCHEMISTRY-US, V42, P4277, DOI 10.1021/bi020527j; Weber T, 2002, CLIN CANCER RES, V8, P863; Yang CC, 2003, J BIOL CHEM, V278, P25872, DOI 10.1074/jbc.M301744200; You HH, 2002, MOL CARCINOGEN, V33, P228, DOI 10.1002/mc.10040; Yu WP, 2001, CANCER RES, V61, P6569	25	97	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11819	11825		10.1074/jbc.M511015200	http://dx.doi.org/10.1074/jbc.M511015200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16520381	hybrid			2022-12-25	WOS:000236988100048
J	Mangan, JK; Tantravahi, RV; Rane, SG; Reddy, EP				Mangan, JK; Tantravahi, RV; Rane, SG; Reddy, EP			Granulocyte colony-stimulating factor-induced upregulation of Jak3 transcription during granulocytic differentiation is mediated by the cooperative action of Sp1 and Stat3	ONCOGENE			English	Article						granulopoiesis; Jaks; STATs; transcription; cytokines; promoter analysis	MICE LACKING JAK3; PROGENITOR-CELL LINE; MYELOID CELLS; DNA-BINDING; IN-VIVO; PROMOTER; GENE; ACTIVATION; EXPRESSION; PROLIFERATION	We previously demonstrated that Jak3 is a primary response gene for G-CSF and ectopic overexpression of Jak3 can accelerate granulocytic differentiation of normal mouse bone marrow cells induced by G-CSF and GMCSF. To gain insight into the regulation of G-CSF-induced transcription of Jak3, we constructed deletion and linker scanning mutants of the Jak3 promoter sequences and performed luciferase reporter assays in the murine myeloid cell line 32Dcl3, with and without G-CSF stimulation. These experiments showed that mutation of a -67 to -85 element, which contained a putative Sp1 binding site, or mutation of a -44 to -53 GAS element resulted in a marked reduction of Jak3 promoter activity. Electrophoretic mobility shift assays revealed that Sp1 and Stat3 present in nuclear lysates of 32Dcl3 cells stimulated with G-CSF can bind to the -67 to -85 element and -44 to -53 GAS element, respectively. In addition, cotransfection of a constitutively active mutant of Stat3 along with a Jak3 promoter/luciferase reporter resulted in enhanced Jak3 promoter activity. Together, these results demonstrate that activation of Jak3 transcription during G-CSF-induced granulocytic differentiation is mediated by the combined action of Sp1 and Stat3, a mechanism also shown to be important in IL-6-induced monocytic differentiation.	Temple Univ, Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Inst Canc Res & Mol Biol, Sch Med, 3307 N Broad St,AHP Room 154, Philadelphia, PA 19140 USA.	reddy@temple.edu	Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA068239, R24CA088261, R01CA079086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009225] Funding Source: NIH RePORTER; NCI NIH HHS [CA79086, R24 CA88261, CA68239] Funding Source: Medline; NIEHS NIH HHS [ES09225] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aringer M, 2003, J IMMUNOL, V170, P6057, DOI 10.4049/jimmunol.170.12.6057; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Chakraborty A, 1998, LEUKEMIA LYMPHOMA, V30, P433, DOI 10.3109/10428199809057555; CHEN HM, 1993, J BIOL CHEM, V268, P8230; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grossman WJ, 1999, BLOOD, V94, P932, DOI 10.1182/blood.V94.3.932.415k30_932_939; Hauses M, 1998, J BIOL CHEM, V273, P31844, DOI 10.1074/jbc.273.48.31844; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kao WY, 1997, J CELL BIOCHEM, V65, P231, DOI 10.1002/(SICI)1097-4644(199705)65:2<231::AID-JCB8>3.0.CO;2-V; Khanna-Gupta A, 2000, BLOOD, V95, P3734; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kumar A, 2001, GENE, V270, P221, DOI 10.1016/S0378-1119(01)00473-5; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Mangan JK, 2004, BLOOD, V103, P4093, DOI 10.1182/blood-2003-06-2165; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Rane SG, 2002, BLOOD, V100, P2753, DOI 10.1182/blood.V100.8.2753; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; ROVERA G, 1987, ONCOGENE, V1, P29; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sjin RMTT, 1999, J BIOL CHEM, V274, P28697, DOI 10.1074/jbc.274.40.28697; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Tomita K, 2001, J BIOL CHEM, V276, P25378, DOI 10.1074/jbc.M011363200; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yu B, 2003, NUCLEIC ACIDS RES, V31, P5368, DOI 10.1093/nar/gkg706; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	45	7	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2489	2499		10.1038/sj.onc.1209280	http://dx.doi.org/10.1038/sj.onc.1209280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16518416				2022-12-25	WOS:000236948000007
J	Liu, L; Gao, Y; Qiu, H; Miller, WT; Poli, V; Reich, NC				Liu, L.; Gao, Y.; Qiu, H.; Miller, W. T.; Poli, V.; Reich, N. C.			Identification of STAT3 as a specific substrate of breast tumor kinase	ONCOGENE			English	Article						tyrosine phosphorylation; transcription factor; signal transduction	NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; GASTROINTESTINAL-TRACT; THERAPEUTIC TARGET; BRK; PROTEINS; ACTIVATION; EXPRESSION; RECEPTOR; BINDING	Breast tumor kinase (Brk) is a non-receptor tyrosine kinase distantly related to the Src family kinase. It is expressed in more than 60% of breast tumors, but the biological role of this kinase remains to be determined. Only a limited number of substates have been identified for Brk, and the link of Brk to tumorigenesis remains largely unknown. In this study, we provide evidence that the signal transducer and activator of transcription 3, STAT3, is a physiological target of Brk. Activation of STAT3 previously has been linked to oncogenesis, and results in this study demonstrate that STAT3 is tyrosine phosphorylated and transcriptionally activated in cells expressing endogenous Brk. Signal transducer and activator of transcription 3 is specifically targeted since other STAT members are not responsive to Brk expression. Signal transducer and activator of transcription 3 activation requires the catalytic activity of Brk, and expression of both STAT3 and Brk stimulate cellular proliferation. In addition, we have identified a negative regulator of Brk, the suppressor of cytokine signaling, SOCS3. The SOCS3 protein is known to block signaling mediated by cytokine receptors, and here we find that SOCS3 is able to repress the activity of the Brk nonreceptor tyrosine kinase.	SUNY Stony Brook, Dept Microbiol & Mol Genet, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Turin, Dept Genet Biol & Biochem, Turin, Italy	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Turin	Reich, NC (corresponding author), SUNY Stony Brook, Dept Microbiol & Mol Genet, Nicolls Rd,Life Sci Rm 168, Stony Brook, NY 11794 USA.	nreich@notes.cc.sunysb.edu	Poli, Valeria/A-9215-2012	Poli, Valeria/0000-0002-3739-3966	NCI NIH HHS [R01CA50773] Funding Source: Medline; PHS HHS [PPGCA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Banninger G, 2004, J BIOL CHEM, V279, P39199, DOI 10.1074/jbc.M400815200; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Coppo P, 2003, ONCOGENE, V22, P4102, DOI 10.1038/sj.onc.1206607; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 1999, CELL MOL LIFE SCI, V55, P1505, DOI 10.1007/s000180050390; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Haegebarth A, 2004, J BIOL CHEM, V279, P54398, DOI 10.1074/jbc.M409579200; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; HENNIPMAN A, 1989, CANCER RES, V49, P516; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kang KN, 2002, BBA-GENE STRUCT EXPR, V1574, P365, DOI 10.1016/S0167-4781(02)00234-8; Kim HI, 2005, J BIOL CHEM, V280, P28973, DOI 10.1074/jbc.M504568200; Krebs DL, 2000, J CELL SCI, V113, P2813; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Llor X, 1999, CLIN CANCER RES, V5, P1767; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; Mitchell PJ, 1997, ONCOGENE, V15, P1497, DOI 10.1038/sj.onc.1201292; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Qiu HQ, 2005, ONCOGENE, V24, P5656, DOI 10.1038/sj.onc.1208721; Qiu HQ, 2004, ONCOGENE, V23, P2216, DOI 10.1038/sj.onc.1207339; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Serfas MS, 2003, ONCOL RES, V13, P409; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; VANDENBRULE FA, 1992, INT J CANCER, V52, P653, DOI 10.1002/ijc.2910520426; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	55	68	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4904	4912		10.1038/sj.onc.1209501	http://dx.doi.org/10.1038/sj.onc.1209501			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16568091				2022-12-25	WOS:000239687100008
J	Elling, CE; Frimurer, TM; Gerlach, LO; Jorgensen, R; Holst, B; Schwartz, TW				Elling, Christian E.; Frimurer, Thomas M.; Gerlach, Lars-Ole; Jorgensen, Rasmus; Holst, Birgitte; Schwartz, Thue W.			Metal ion site engineering indicates a global toggle switch model for seven-transmembrane receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; TRANSMEMBRANE DOMAINS III; TACHYKININ NK-1 RECEPTOR; BINDING SITES; BETA(2)-ADRENERGIC RECEPTOR; CONFORMATIONAL-CHANGES; RHODOPSIN ACTIVATION; GHRELIN RECEPTOR; OPIOID RECEPTOR	Much evidence indicates that, during activation of seven-transmembrane (7TM) receptors, the intracellular segments of the transmembrane helices (TMs) move apart with large amplitude, rigid body movements of especially TM-VI and TM-VII. In this study, AspIII:08 (Asp(113)), the anchor point for monoamine binding in TM-III, was used as the starting point to engineer activating metal ion sites between the extracellular segments of the beta(2)-adrenergicreceptor. Cu(II) and Zn(II) alone and in complex with aromatic chelators acted as potent (EC50 decreased to 0.5 mu M) and efficacious agonists in sites constructed between positions III:08 (AsporHis), VI:16 (preferentiallyCys), and/or VII:06 (preferentially Cys). In molecular models built over the backbone conformation of the inactive rhodopsin structure, the heavy atoms that coordinate the metal ion were located too far away from each other to form high affinity metal ion sites in both the bidentate and potential tridentate settings. This indicates that the residues involved in the main ligand-binding pocket will have to move closer to each other during receptor activation. On the basis of the distance constraints from these activating metalionsites, we propose a global toggle switch mechanism for 7TM receptor activation in which inward movement of the extracellular segments of especially TM-VI and, to some extent, TM-VII is coupled to the well established outward movement of the intracellular segments of these helices. We suggest that the pivots for these vertical seesaw movements are the highly conserved proline bends of the involved helices.	Univ Copenhagen, Panum Inst, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; 7TM Pharma AS, DK-2970 Horsholm, Denmark	University of Copenhagen	Schwartz, TW (corresponding author), Univ Copenhagen, Panum Inst, Mol Pharmacol Lab, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	schwartz@molpharm.dk		Frimruer, Thomas/0000-0002-9682-8245; Holst, Birgitte/0000-0001-7432-097X; Schwartz, Thue W./0000-0002-0261-6904				Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Buck E, 2005, P NATL ACAD SCI USA, V102, P2719, DOI 10.1073/pnas.0500016102; DEL CR, 2004, MOL PHARM, V66, P356; Dinner AR, 1999, PROTEIN ENG, V12, P909, DOI 10.1093/protein/12.11.909; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Elling CE, 2000, BIOCHEMISTRY-US, V39, P667, DOI 10.1021/bi991777b; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; Erlanson DA, 2004, ANNU REV BIOPH BIOM, V33, P199, DOI 10.1146/annurev.biophys.33.110502.140409; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Fowler CB, 2004, BIOCHEMISTRY-US, V43, P8700, DOI 10.1021/bi036067r; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Han SJ, 2005, J BIOL CHEM, V280, P34849, DOI 10.1074/jbc.M506711200; Hendlich M, 2003, J MOL BIOL, V326, P607, DOI 10.1016/S0022-2836(02)01408-0; Holst B, 2003, MOL ENDOCRINOL, V17, P2201, DOI 10.1210/me.2003-0069; Holst B, 2004, J BIOL CHEM, V279, P53806, DOI 10.1074/jbc.M407676200; Holst B, 2000, MOL PHARMACOL, V58, P263, DOI 10.1124/mol.58.2.263; Holst B, 2002, J BIOL CHEM, V277, P47662, DOI 10.1074/jbc.M202103200; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Klabunde T, 2002, CHEMBIOCHEM, V3, P929, DOI 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO;2-5; Kobilka B, 2004, MOL PHARMACOL, V65, P1060, DOI 10.1124/mol.65.5.1060; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Lefkowitz RJ, 2004, TRENDS PHARMACOL SCI, V25, P413, DOI 10.1016/j.tips.2004.06.006; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; LI ZQ, 1987, P NATL ACAD SCI USA, V84, P6611, DOI 10.1073/pnas.84.19.6611; Liapakis G, 2004, MOL PHARMACOL, V65, P1181, DOI 10.1124/mol.65.5.1181; Lu ZL, 2000, J BIOL CHEM, V275, P5682, DOI 10.1074/jbc.275.8.5682; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Patel AB, 2005, J MOL BIOL, V347, P803, DOI 10.1016/j.jmb.2005.01.069; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; Russ AP, 2005, DRUG DISCOV TODAY, V10, P1607, DOI 10.1016/S1359-6446(05)03666-4; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Schwartz TW, 1996, TRENDS PHARMACOL SCI, V17, P213, DOI 10.1016/0165-6147(96)10017-1; SCHWARTZ TW, 2002, TXB RECEPTOR PHARM, P811; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Thirstrup K, 1996, J BIOL CHEM, V271, P7875, DOI 10.1074/jbc.271.14.7875	53	85	88	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	2006	281	25					17337	17346		10.1074/jbc.M512510200	http://dx.doi.org/10.1074/jbc.M512510200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	053SV	16567806	hybrid			2022-12-25	WOS:000238326300060
J	Velasco, G; Grkovic, S; Ansieau, S				Velasco, Guillaume; Grkovic, Steve; Ansieau, Stephane			New insights into BS69 functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE METHYLTRANSFERASE ACTIVITY; ADENOVIRUS E1A-ASSOCIATED PROTEIN; INTERACTION DOMAIN; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; COMPLEX; EXPRESSION; TRANSCRIPTION; INHIBITOR; RECEPTOR	The BS69 protein has been commonly described as a co-repressor associated with various transcription factors. However, this hypothesis relied predominately on overexpression of tagged proteins due to the lack of a reliable BS69 antibody. We present for the first time a complete sequence of BS69 and valuable tools to characterize the endogenous protein. We show that the full-length BS69 protein, as well as minor alternatively spliced isoforms, is ubiquitously expressed, nuclear, and associates with chromatin and mitotic chromosomes. Accordingly, BS69 interacts with a set of chromatin remodeling factors, including ATP-dependent helicases, histone deacetylases, and histone methyltransferases, as well as the E2F6 transcription factor. These data strengthen a role for BS69 in gene repression and link BS69 to chromatin remodeling.	Univ Lyon 1, Ctr Leon Berard, INSERM, U59O, F-69008 Lyon, France; Univ Lyon 1, Ctr Leon Berard, INSERM, U412, F-69008 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard	Ansieau, S (corresponding author), Univ Lyon 1, Ctr Leon Berard, INSERM, U59O, 28 Rue Laennec, F-69008 Lyon, France.	ANSIEAU@lyon.fnclcc.fr	Velasco, Guillaume/AAM-2447-2020; Ansieau, Stephane/I-6195-2016	ANSIEAU, Stephane/0000-0003-0989-2108				Ansieau S, 2003, PATHOL BIOL, V51, P397, DOI 10.1016/S0369-8114(03)00019-1; Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; Ballif BA, 2004, MOL CELL PROTEOMICS, V3, P1093, DOI 10.1074/mcp.M400085-MCP200; Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Hamer KM, 2002, HYBRIDOMA HYBRIDOM, V21, P245, DOI 10.1089/153685902760213859; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Kozu T, 2005, GENE CHROMOSOME CANC, V43, P45, DOI 10.1002/gcc.20165; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Kurozumi K, 1998, GENES CELLS, V3, P257, DOI 10.1046/j.1365-2443.1998.00186.x; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Ladendorff NE, 2001, ONCOGENE, V20, P125, DOI 10.1038/sj.onc.1204048; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Miyagishi M, 2004, J GENE MED, V6, P715, DOI 10.1002/jgm.556; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Slater LM, 2003, J MOL BIOL, V330, P571, DOI 10.1016/S0022-2836(03)00470-4; Stec I, 2000, FEBS LETT, V473, P1, DOI 10.1016/S0014-5793(00)01449-6; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wei G, 2003, ANTICANCER RES, V23, P2173	28	29	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16546	16550		10.1074/jbc.M600573200	http://dx.doi.org/10.1074/jbc.M600573200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16565076	hybrid			2022-12-25	WOS:000238165700045
J	Nabhan, JF; Ribeiro, P				Nabhan, Joseph F.; Ribeiro, Paula			The 19 S proteasomal subunit POH1 contributes to the regulation of c-Jun ubiquitination, stability, and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							26 S PROTEASOME; GENE; DEGRADATION; PROTEINS; NUCLEAR; AP-1; EXPRESSION; RPN11; DEUBIQUITINATION; TRANSCRIPTION	The AP1 ( activator protein 1) transcription factor, c-Jun, is an important regulator of cell proliferation, differentiation, survival, and death. Its activity is regulated both at the level of transcription and post-translationally through phosphorylation, sumoylation, and targeted degradation. The degradation of c-Jun by the ubiquitin proteasome pathway has been well established. Here, we report that POH1, a subunit of the 19 S proteasome lid with a recently described deubiq-uitinase activity, is a regulator of c-Jun. Ectopic expression of POH1 in HEK293 cells decreased the level of c-Jun ubiquitination, leading to significant accumulation of the protein and a corresponding increase in AP1-mediated gene expression. The stabilization also correlated with a redistribution of c-Jun in the nucleus. These effects were reduced by mutation of a cysteine residue in the Mpr1 pad1 N-terminal plus motif of POH1 (Cys-120) and appeared to be selective for c-Jun, because POH1 had no effect on other proteasomal substrates. Our results identify a novel mechanism of c-Jun regulation in mammalian cells.	McGill Univ, Inst Parasitol, Ste Anne De Bellevue, PQ H9X 3V9, Canada	McGill University	Ribeiro, P (corresponding author), McGill Univ, Inst Parasitol, 21111 Lakeshore Rd,MacDonald Campus, Ste Anne De Bellevue, PQ H9X 3V9, Canada.	paula.ribeiro@mcgill.ca						Afjehi-Sadat L, 2004, AMINO ACIDS, V27, P129, DOI 10.1007/s00726-004-0125-1; Ambroggio XI, 2004, PLOS BIOL, V2, P113, DOI 10.1371/journal.pbio.0020002; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Arce JD, 2004, J BIOL CHEM, V279, P45408, DOI 10.1074/jbc.M401818200; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Glickman MH, 2004, PLOS BIOL, V2, P25, DOI 10.1371/journal.pbio.0020013; Guterman A, 2004, CURR PROTEIN PEPT SC, V5, P201, DOI 10.2174/1389203043379756; Hendil KB, 2004, CURR PROTEIN PEPT SC, V5, P135, DOI 10.2174/1389203043379747; Krasko A, 2001, ENVIRON TOXICOL CHEM, V20, P198, DOI 10.1002/etc.5620200123; Lafarga M, 2002, MOL BIOL CELL, V13, P2771, DOI 10.1091/mbc.E02-03-0122; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lundgren J, 2003, MOL CELL BIOL, V23, P5320, DOI 10.1128/MCB.23.15.5320-5330.2003; Marchenko ND, 2002, J BIOL CHEM, V277, P18967, DOI 10.1074/jbc.M201197200; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; Mekhail K, 2005, J CELL BIOL, V170, P733, DOI 10.1083/jcb.200506030; Nabhan JF, 2002, MOL BIOCHEM PARASIT, V121, P161, DOI 10.1016/S0166-6851(02)00012-9; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Ohta T, 2004, ONCOGENE, V23, P2079, DOI 10.1038/sj.onc.1207371; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Penney M, 1998, J BIOL CHEM, V273, P23938, DOI 10.1074/jbc.273.37.23938; Prasad JC, 2003, BIOINFORMATICS, V19, P1682, DOI 10.1093/bioinformatics/btg211; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; Rinaldi T, 2004, BIOCHEM J, V381, P275, DOI 10.1042/BJ20040008; Rockel TD, 2002, J STRUCT BIOL, V140, P189; Schwartz AL, 1999, ANNU REV MED, V50, P57; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SHIMANUKI M, 1995, J CELL SCI, V108, P569; Takeuchi J, 1999, MOL CELL BIOL, V19, P6575; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	41	34	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16099	16107		10.1074/jbc.M512086200	http://dx.doi.org/10.1074/jbc.M512086200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16569633	hybrid			2022-12-25	WOS:000237996000063
J	Parra-Lopez, C; Calvo-Calle, JM; Cameron, TO; Vargas, LE; Salazar, LM; Patarroyo, ME; Nardin, E; Stern, LJ				Parra-Lopez, Carlos; Calvo-Calle, J. Mauricio; Cameron, Thomas O.; Vargas, Luis E.; Salazar, Luz Mary; Patarroyo, Manuel E.; Nardin, Elizabeth; Stern, Lawrence J.			Major histocompatibility complex and T cell interactions of a universal T cell epitope from Plasmodium falciparum circumsporozoite protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; MALARIA VACCINE; PEPTIDE-BINDING; HLA-DR4 DRA-ASTERISK-0101; CRYSTAL-STRUCTURE; IMMUNE-RESPONSES; CD4(+); HLA; ANTIGEN; IDENTIFICATION	A20-residue sequence from the C-terminal region of the circumsporozoite protein of the malaria parasite Plasmodium falciparum is considered a universal helper T cell epitope because it is immunogenic in individuals of many major histocompatibility complex (MHC) haplotypes. Subunit vaccines containing T* and the major B cell epitope of the circumsporozoite protein induce high antibody titers to the malaria parasite and significant T cell responses in humans. In this study we have evaluated the specificity of the T* sequence with regard to its binding to the human class II MHC protein DR4 (HLA- DRB1* 0401), its interactions with antigen receptors on T cells, and the effect of natural variants of this sequence on its immunogenicity. Computational approaches identified multiple potential DR4- binding epitopes within T*, and experimental binding studies confirmed the following two tight binding epitopes: one located toward the N terminus (the T*-1 epitope) and one at the C terminus (the T*-5 epitope). Immunization of a human DR4 volunteer with a peptide- based vaccine containing the T* sequence elicited CD4(+) T cells that recognize each of these epitopes. Here we present an analysis of the immunodominant N-terminal epitope T*-1. T*-1 residues important for interaction with DR4 and with antigen receptors on T*- specific T cells were mapped. MHC tetramers carrying DR4/T*-1 MHC-peptide complexes stained and efficiently stimulated these cells in vitro. T*-1 overlaps a region of the protein that has been described as highly polymorphic; however, the particular T*-1 residues required for anchoring to DR4 were highly conserved in Plasmodium sequences described to date.	Univ Massachusetts, Sch Med, Dept Pathol & Biochem, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol, Worcester, MA 01655 USA; Fundac Inst Inmunol Colombia, Grp Func Inmunol, Bogota, Colombia; Univ Nacl Colombia, Fac Ciencias, Bogota, Colombia; NYU, Sch Med, Dept Mol Parasitol, New York, NY 10010 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Universidad Nacional de Colombia; New York University; New York University	Stern, LJ (corresponding author), Dept Pathol, 55 Lake Ave N, Worcester, MA 01655 USA.	lawrence.stern@umassmed.edu	Patarroyo, Manuel-Elkin/S-1422-2017	Patarroyo, Manuel-Elkin/0000-0002-1119-6040; PARRA LOPEZ, CARLOS ALBERTO/0000-0002-6084-8981	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038996, U19AI057319] Funding Source: NIH RePORTER; NIAID NIH HHS [U19 AI 57319, R01 AI 025035, R01 AI 38996] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Anderson MW, 2005, BIOCHEMISTRY-US, V44, P5617, DOI 10.1021/bi048675s; Blake N, 2000, J IMMUNOL, V165, P7078, DOI 10.4049/jimmunol.165.12.7078; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Calvo-Calle JM, 2005, J IMMUNOL, V175, P7575, DOI 10.4049/jimmunol.175.11.7575; CalvoCalle JM, 1997, J IMMUNOL, V159, P1362; Cameron TO, 2002, IMMUNOGENETICS, V54, P611, DOI 10.1007/s00251-002-0508-y; Cameron TO, 2002, J IMMUNOL METHODS, V268, P51, DOI 10.1016/S0022-1759(02)00200-4; Carvalho LH, 2002, NAT MED, V8, P166, DOI 10.1038/nm0202-166; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1992, MOL BIOCHEM PARASIT, V54, P1, DOI 10.1016/0166-6851(92)90089-3; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Cochran JR, 2000, CHEM BIOL, V7, P683, DOI 10.1016/S1074-5521(00)00019-3; DELACRUZ VF, 1988, J IMMUNOL, V141, P2456; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; Doolan DL, 2003, P NATL ACAD SCI USA, V100, P9952, DOI 10.1073/pnas.1633254100; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; Geluk A, 2000, J IMMUNOL, V165, P6463, DOI 10.4049/jimmunol.165.11.6463; Godkin AJ, 2002, J IMMUNOL, V169, P2210, DOI 10.4049/jimmunol.169.4.2210; GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; Harrison LC, 1997, J EXP MED, V185, P1013, DOI 10.1084/jem.185.6.1013; Hennecke J, 2002, J EXP MED, V195, P571, DOI 10.1084/jem.20011194; HERRINGTON D, 1991, AM J TROP MED HYG, V45, P539, DOI 10.4269/ajtmh.1991.45.539; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Kim SK, 2000, J IMMUNOL, V165, P7285, DOI 10.4049/jimmunol.165.12.7285; Klein MR, 2001, J INFECT DIS, V183, P928, DOI 10.1086/319267; Klenerman P, 2002, NAT REV IMMUNOL, V2, P263, DOI 10.1038/nri777; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074; Lazarski CA, 2005, IMMUNITY, V23, P29, DOI 10.1016/j.immuni.2005.05.009; Maile R, 2005, J IMMUNOL, V174, P619, DOI 10.4049/jimmunol.174.2.619; Meyer AL, 2000, P NATL ACAD SCI USA, V97, P11433, DOI 10.1073/pnas.190335897; MORENO A, 1993, J IMMUNOL, V151, P489; MORENO A, 1991, INT IMMUNOL, V3, P997, DOI 10.1093/intimm/3.10.997; Nardin EH, 2001, J IMMUNOL, V166, P481, DOI 10.4049/jimmunol.166.1.481; NARDIN EH, 1989, SCIENCE, V246, P1603, DOI 10.1126/science.2480642; Nepom GT, 2002, ARTHRITIS RHEUM, V46, P5, DOI 10.1002/1529-0131(200201)46:1<5::AID-ART10063>3.0.CO;2-S; Novak EJ, 1999, J CLIN INVEST, V104, pR63, DOI 10.1172/JCI8476; Novak EJ, 2001, J IMMUNOL, V166, P6665, DOI 10.4049/jimmunol.166.11.6665; Oliveira GA, 2005, INFECT IMMUN, V73, P3587, DOI 10.1128/IAI.73.6.3587-3597.2005; Precopio ML, 2003, J IMMUNOL, V170, P2590, DOI 10.4049/jimmunol.170.5.2590; Prezzi C, 2001, EUR J IMMUNOL, V31, P894, DOI 10.1002/1521-4141(200103)31:3<894::AID-IMMU894>3.0.CO;2-I; Ravkov EV, 2003, J IMMUNOL, V170, P2461, DOI 10.4049/jimmunol.170.5.2461; Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009; RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y; ROCHE PA, 1990, J IMMUNOL, V144, P1849; Schuler-Thurner B, 2000, J IMMUNOL, V165, P3492, DOI 10.4049/jimmunol.165.6.3492; Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Southwood S, 1998, J IMMUNOL, V160, P3363; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Stone JD, 2005, P NATL ACAD SCI USA, V102, P3744, DOI 10.1073/pnas.0407019102; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555, DOI 10.1038/9858; Sun PF, 2003, J IMMUNOL, V171, P6961, DOI 10.4049/jimmunol.171.12.6961; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; TAYLORROBINSON AW, 1993, PARASITE IMMUNOL, V15, P301, DOI 10.1111/j.1365-3024.1993.tb00614.x; Trollmo C, 2001, J IMMUNOL, V166, P5286, DOI 10.4049/jimmunol.166.8.5286; Valmori D, 2001, CANCER RES, V61, P509; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279; Xu HJ, 2002, J EXP MED, V195, P881, DOI 10.1084/jem.20011174; Zavala-Ruiz Z, 2004, CHEM BIOL, V11, P1395, DOI 10.1016/j.chembiol.2004.08.007; Zavala-Ruiz Z, 2004, P NATL ACAD SCI USA, V101, P13279, DOI 10.1073/pnas.0403371101; ZEVERING Y, 1994, EUR J IMMUNOL, V24, P1418, DOI 10.1002/eji.1830240627	66	27	29	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14907	14917		10.1074/jbc.M511571200	http://dx.doi.org/10.1074/jbc.M511571200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16565072	hybrid			2022-12-25	WOS:000237671300044
J	Ahn, JW; Verma, R; Kim, M; Lee, JY; Kim, YK; Bang, JW; Reiter, WD; Pai, HS				Ahn, JW; Verma, R; Kim, M; Lee, JY; Kim, YK; Bang, JW; Reiter, WD; Pai, HS			Depletion of UDP-D-apiose/UDP-D-xylose synthases results in rhamnogalacturonan-II deficiency, cell wall thickening, and cell death in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; PECTIC POLYSACCHARIDE; GENE-EXPRESSION; MUTANT; BORON; DIFFERENTIATION; PROLIFERATION; PROTOPLASTS; ACTIVATION; PROTEASOME	(D)- Apiose serves as the binding site for borate cross- linking of rhamnogalacturonan II ( RG- II) in the plant cell wall, and biosynthesis of (D)- apiose involves UDP- (D)- apiose/ UDP- (D)- xylose synthase catalyzing the conversion of UDP- (D)- glucuronate to a mixture of UDP- (D)- apiose and UDP- (D)- xylose. In this study we have analyzed the cellular effects of depletion of UDP- D- apiose/ UDP- (D)- xylose synthases in plants by using virus- induced gene silencing ( VIGS) of NbAXS1 in Nicotiana benthamiana. The recombinant NbAXS1 protein exhibited UDP- (D)-apiose/ UDP- (D)- xylose synthase activity in vitro. The NbAXS1 gene was expressed in all major plant organs, and an NbAXS1- green fluorescent protein fusion protein was mostly localized in the cytosol. VIGS of NbAXS1 resulted in growth arrest and leaf yellowing. Microscopic studies of the leaf cells of the NbAXS1 VIGS lines revealed cell death symptoms including cell lysis and disintegration of cellular organelles and compartments. The cell death was accompanied by excessive formation of reactive oxygen species and by induction of various protease genes. Furthermore, abnormal wall structure of the affected cells was evident including excessive cell wall thickening and wall gaps. The mutant cell walls contained significantly reduced levels of D- apiose as well as 2- O- methyl- (L)- fucose and 2- O- methyl- (D)- xylose, which serve as markers for the RG- II side chains B and A, respectively. These results suggest that VIGS of NbAXS1 caused a severe deficiency in the major side chains of RG- II and that the growth defect and cell death was likely caused by structural alterations in RG- II due to a (D)- apiose deficiency.	Yonsei Univ, Dept Biol, Seoul 120749, South Korea; Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, Taejon 305333, South Korea; Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA; Korea Res Inst Biosci & Biotechnol, BioNanotechnol Ctr, Taejon 305333, South Korea; Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea	Yonsei University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Connecticut; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University	Pai, HS (corresponding author), Yonsei Univ, Dept Biol, Seoul 120749, South Korea.	hspai@yonsei.ac.kr						Abel S, 1998, METH MOL B, V82, P209; Ahn JW, 2004, PLANT J, V38, P969, DOI 10.1111/j.1365-313X.2004.02102.x; Beers EP, 2000, PLANT MOL BIOL, V44, P399, DOI 10.1023/A:1026556928624; Bethke PC, 2001, PLANT J, V25, P19, DOI 10.1046/j.1365-313x.2001.00930.x; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; Demura T, 2002, P NATL ACAD SCI USA, V99, P15794, DOI 10.1073/pnas.232590499; Dormann P, 1998, PLANT J, V13, P641, DOI 10.1046/j.1365-313X.1998.00067.x; Ellis C, 2002, PLANT CELL, V14, P1557, DOI 10.1105/tpc.002022; Golovchenko VV, 2002, PHYTOCHEMISTRY, V60, P89, DOI 10.1016/S0031-9422(02)00040-7; HAHLBROCK K, 1976, EUR J BIOCHEM, V61, P199, DOI 10.1111/j.1432-1033.1976.tb10012.x; Heath MC, 2000, PLANT MOL BIOL, V44, P321, DOI 10.1023/A:1026592509060; Ishii T, 2001, PLANT PHYSIOL, V126, P1698, DOI 10.1104/pp.126.4.1698; Iwai H, 2002, P NATL ACAD SCI USA, V99, P16319, DOI 10.1073/pnas.252530499; Kim M, 2003, J BIOL CHEM, V278, P19406, DOI 10.1074/jbc.M210539200; Kobayashi M, 1996, PLANT PHYSIOL, V110, P1017, DOI 10.1104/pp.110.3.1017; Lee HS, 1996, PLANT J, V9, P613, DOI 10.1046/j.1365-313X.1996.9050613.x; Lee SS, 2003, PLANT J, V33, P825, DOI 10.1046/j.1365-313X.2003.01672.x; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; Matoh T, 2000, PLANT CELL PHYSIOL, V41, P363, DOI 10.1093/pcp/41.3.363; Molhoj M, 2003, PLANT J, V35, P693, DOI 10.1046/j.1365-313X.2003.01841.x; Noguchi K, 2003, J PLANT NUTR SOIL SC, V166, P175, DOI 10.1002/jpln.200390025; O'Neill MA, 2004, ANNU REV PLANT BIOL, V55, P109, DOI 10.1146/annurev.arplant.55.031903.141750; O'Neill MA, 2001, SCIENCE, V294, P846, DOI 10.1126/science.1062319; Park JA, 2005, PLANT J, V42, P153, DOI 10.1111/j.1365-313X.2005.02361.x; Pellerin P, 1996, CARBOHYD RES, V290, P183, DOI 10.1016/0008-6215(96)00139-5; Perez S, 2003, BIOCHIMIE, V85, P109, DOI 10.1016/S0300-9084(03)00053-1; Pontier D, 1998, MOL PLANT MICROBE IN, V11, P544, DOI 10.1094/MPMI.1998.11.6.544; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Ratcliff F, 2001, PLANT J, V25, P237, DOI 10.1046/j.0960-7412.2000.00942.x; REITER WD, 1993, SCIENCE, V261, P1032, DOI 10.1126/science.261.5124.1032; STEVENSON TT, 1988, CARBOHYD RES, V182, P207, DOI 10.1016/0008-6215(88)84004-7; Takano J, 2002, NATURE, V420, P337, DOI 10.1038/nature01139; Vanzin GF, 2002, P NATL ACAD SCI USA, V99, P3340, DOI 10.1073/pnas.052450699; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Willats WGT, 2001, PLANT MOL BIOL, V47, P9, DOI 10.1023/A:1010662911148; Ye ZH, 1996, PLANT MOL BIOL, V30, P1233, DOI 10.1007/BF00019555; Zhang H, 2001, ANAL BIOCHEM, V298, P170, DOI 10.1006/abio.2001.5348	37	80	86	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13708	13716		10.1074/jbc.M512403200	http://dx.doi.org/10.1074/jbc.M512403200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16549428	hybrid			2022-12-25	WOS:000237336600081
J	Jensen, PJ; Gitlin, JD; Carayannopoulos, MO				Jensen, PJ; Gitlin, JD; Carayannopoulos, MO			GLUT1 deficiency links nutrient availability and apoptosis during embryonic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE TRANSPORTERS; ZEBRAFISH; SURVIVAL; MODEL; PHOSPHORYLATION; EMBRYOGENESIS; GLUCOKINASE; GLYCOLYSIS; SIGNALS; SYSTEM	GLUT1 is essential for human brain development and function, as evidenced by the severe epileptic encephalopathy observed in children with GLUT1 deficiency syndrome resulting from inherited loss- of- function mutations in the gene encoding this facilitative glucose transporter. To further elucidate the pathophysiology of this disorder, the zebrafish orthologue of human GLUT1 was identified, and expression of this gene was abrogated during early embryonic development, resulting in a phenotype of aberrant brain organogenesis consistent with the observed expression of Glut1 in the embryonic tectum and specifically rescued by human GLUT1 mRNA. Affected embryos displayed impaired glucose uptake concomitant with increased neural cell apoptosis and subsequent ventricle enlargement, trigeminal ganglion cell loss, and abnormal hindbrain architecture. Strikingly, inhibiting expression of the zebrafish orthologue of the proapoptotic protein Bad resulted in complete rescue of this phenotype, and this occurred even in the absence of restoration of apparent glucose uptake. Taken together, these studies describe a tractable system for elucidating the cellular and molecular mechanisms of Glut1 deficiency and provide compelling in vivo genetic evidence directly linking nutrient availability and activation of mitochondria- dependent apoptotic mechanisms during embryonic brain development.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL)	Carayannopoulos, MO (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, McDonnell Pediat Res Bldg,660 S Euclid Ave,Campus, St Louis, MO 63110 USA.	carayannopoulos@kids.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R37DK044464, R01DK044464] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01459] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-06, DK44464, P30 DK056341-05S2, P30 DK056341] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdelilah S, 1996, DEVELOPMENT, V123, P217; Ackermann GE, 2003, FRONT BIOSCI-LANDMRK, V8, pD1227, DOI 10.2741/1092; Bernhardt RR, 1999, J NEUROBIOL, V38, P137, DOI 10.1002/(SICI)1097-4695(199901)38:1<137::AID-NEU11>3.0.CO;2-P; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dooley K, 2000, CURR OPIN GENET DEV, V10, P252, DOI 10.1016/S0959-437X(00)00074-5; Driever W, 1996, DEVELOPMENT, V123, P37; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; KELLER K, 1989, J BIOL CHEM, V264, P18884; Kim WH, 2005, DIABETES, V54, P2602, DOI 10.2337/diabetes.54.9.2602; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Nusslein-Volhard C, 2002, ZEBRAFISH; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Scholpp S, 2001, GENESIS, V30, P129, DOI 10.1002/gene.1047; Taylor MR, 2004, P NATL ACAD SCI USA, V101, P4584, DOI 10.1073/pnas.0307074101; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Virgintino D, 2000, DEV BRAIN RES, V123, P95, DOI 10.1016/S0165-3806(00)00086-9; Wang D, 2005, ANN NEUROL, V57, P111, DOI 10.1002/ana.20331; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE, V4th Edn; WILSON SW, 1990, DEVELOPMENT, V108, P121; Wood IS, 2003, BRIT J NUTR, V89, P3, DOI 10.1079/BJN2002763	25	64	66	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13382	13387		10.1074/jbc.M601881200	http://dx.doi.org/10.1074/jbc.M601881200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543226	hybrid			2022-12-25	WOS:000237336600044
J	du Plessis, DJF; Nouwen, N; Driessen, AJM				du Plessis, DJF; Nouwen, N; Driessen, AJM			Subunit a of cytochrome o oxidase requires both YidC and SecYEG for membrane insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; BO(3) UBIQUINOL OXIDASE; COLI INNER MEMBRANE; ESCHERICHIA-COLI; PROTEIN INSERTION; PREPROTEIN TRANSLOCASE; CYTOPLASMIC MEMBRANE; NASCENT FTSQ; SECA; BIOGENESIS	The Escherichia coli YidC protein belongs to the Oxa1 family of membrane proteins that facilitate the insertion of membrane proteins. Depletion of YidC in E. coli leads to a specific defect in the functional assembly of major energy transducing complexes such as the F1F0 ATPase and cytochrome bo(3) oxidase. Here we report on the in vitro reconstitution of the membrane insertion of the CyoA subunit of cytochrome bo(3) oxidase. Efficient insertion of in vitro synthesized pre-CyoA into proteoliposomes requires YidC, SecYEG, and SecA and occurs independently of the proton motive force. These data demonstrate that pre-CyoA is a substrate of a novel pathway that involves both SecYEG and YidC.	Univ Groningen, Groningen Biomol Sci & Biotechnol, Dept Mol Microbiol, Inst Mat Sci Ctr Plus, NL-9751 NN Haren, Netherlands	University of Groningen	Driessen, AJM (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol, Dept Mol Microbiol, Inst Mat Sci Ctr Plus, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Abramson J, 2000, ACTA CRYSTALLOGR D, V56, P1076, DOI 10.1107/S0907444900007605; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; Angelini S, 2005, EMBO REP, V6, P476, DOI 10.1038/sj.embor.7400385; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; Dalbey RE, 2004, BBA-MOL CELL RES, V1694, P37, DOI 10.1016/j.bbamcr.2004.03.009; Froderberg L, 2004, J BIOL CHEM, V279, P31026, DOI 10.1074/jbc.M403229200; Houben ENG, 2004, EMBO REP, V5, P970, DOI 10.1038/sj.embor.7400261; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Koch HG, 2000, J CELL BIOL, V150, P689, DOI 10.1083/jcb.150.3.689; Koch HG, 2002, J BIOL CHEM, V277, P5715, DOI 10.1074/jbc.C100683200; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Ma JX, 1997, BIOCHEMISTRY-US, V36, P11298, DOI 10.1021/bi9709710; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; Mori H, 2001, P NATL ACAD SCI USA, V98, P5128, DOI 10.1073/pnas.081617398; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Shimohata N, 2005, J BACTERIOL, V187, P3997, DOI 10.1128/JB.187.12.3997-4004.2005; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; van der Does C, 2003, METHOD ENZYMOL, V372, P86; van der Laan M, 2005, CURR OPIN MICROBIOL, V8, P182, DOI 10.1016/j.mib.2005.02.004; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2004, J BIOL CHEM, V279, P1659, DOI 10.1074/jbc.M306527200; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; Yi L, 2005, MOL MEMBR BIOL, V22, P101, DOI 10.1080/09687860500041718	31	70	70	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12248	12252		10.1074/jbc.M600048200	http://dx.doi.org/10.1074/jbc.M600048200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513637	hybrid, Green Published			2022-12-25	WOS:000237134700008
J	Gomes, B; Savignac, M; Cabral, MD; Paulet, P; Moreau, M; Leclerc, C; Feil, R; Hofmann, F; Guery, JC; Dietrich, G; Pelletier, L				Gomes, B; Savignac, M; Cabral, MD; Paulet, P; Moreau, M; Leclerc, C; Feil, R; Hofmann, F; Guery, JC; Dietrich, G; Pelletier, L			The cGMP/protein kinase G pathway contributes to dihydropyridine-sensitive calcium response and cytokine production in TH2 lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; SIGNALING PATHWAY; IL-4 PRODUCTION; NITRIC-OXIDE; PROTEIN; CHANNELS; CGMP; ACTIVATION; PHOSPHODIESTERASE-4; DIFFERENTIATION	Th2 lymphocytes differ from other CD4(+) T lymphocytes not only by their effector tasks but also by their T cell receptor (TCR)-dependent signaling pathways. We previously showed that dihydropyridine receptors ( DHPR) involved in TCR-induced calcium inflow were selectively expressed in Th2 cells. In this report, we studied whether cGMP-dependent protein kinase G (PKG) activation was implicated in the regulation of DHPR-dependent calcium response and cytokine production in Th2 lymphocytes. The contribution of cGMP in Th2 signaling was supported by the following results: 1) TCR activation elicited cGMP production, which triggered calcium increase responsible for nuclear factor of activated T cell translocation and Il4 gene expression; 2) guanylate cyclase activation by nitric oxide donors increased intracellular cGMP concentration and induced calcium inflow and IL-4 production; 3) reciprocally, guanylate cyclase inhibition reduced calcium response and Th2 cytokine production associated with TCR activation. In addition, DHPR blockade abolished cGMP-induced [Ca2+](i) increase, indicating that TCR-induced DHP-sensitive calcium inflow is dependent on cGMP in Th2 cells. Th2 lymphocytes from PKG1-deficient mice displayed impaired calcium signaling and IL-4 production, as did wild-type Th2 cells treated with PKG inhibitors. Altogether, our data indicate that, in Th2 cells, cGMP is produced upon TCR engagement and activates PKG, which controls DHP-sensitive calcium inflow and Th2 cytokine production.	INSERM, Ctr Physiopathol Toulouse Purpan, U563, F-31024 Toulouse 3, France; Univ Toulouse 3, CNRS, UMR 5547, F-31062 Toulouse 4, France; Tech Univ Munich, Inst Pharmakol & Toxikol, G-80802 Munich, Germany	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Technical University of Munich	Pelletier, L (corresponding author), CHU Purpan, INSERM, U563, Dept Genet, Pl Dr Baylac,Pavill Lefebvre,BP 3028, F-31024 Toulouse 3, France.	Lucette.Pelletier@toulouse.inserm.fr	Feil, Robert/B-8918-2014; Savignac, Magali/K-1757-2014; GUERY, Jean-Charles/G-1452-2013; Pelletier, Lucette/L-2956-2014; Dietrich, Gilles/AAC-2119-2020; Leclerc, Catherine/O-6514-2015	Feil, Robert/0000-0002-7335-4841; GUERY, Jean-Charles/0000-0003-4499-3270; Dietrich, Gilles/0000-0002-2232-1716; 				Abrahamsen H, 2004, J IMMUNOL, V173, P4847, DOI 10.4049/jimmunol.173.8.4847; Akha AAS, 1996, J BIOL CHEM, V271, P7297, DOI 10.1074/jbc.271.13.7297; Barry ELR, 1998, J MEMBRANE BIOL, V161, P55, DOI 10.1007/s002329900314; Bielekova B, 2000, J IMMUNOL, V164, P1117, DOI 10.4049/jimmunol.164.2.1117; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bosc LVG, 2004, J BIOL CHEM, V279, P10702, DOI 10.1074/jbc.M312920200; Boswell-Smith V, 2006, BRIT J PHARMACOL, V147, pS252, DOI 10.1038/sj.bjp.0706495; Essayan DM, 2001, J ALLERGY CLIN IMMUN, V108, P671, DOI 10.1067/mai.2001.119555; Fanger CM, 2000, J IMMUNOL, V164, P1153, DOI 10.4049/jimmunol.164.3.1153; Faroudi M, 2003, P NATL ACAD SCI USA, V100, P14145, DOI 10.1073/pnas.2334336100; Fischer TA, 2001, J BIOL CHEM, V276, P5967, DOI 10.1074/jbc.M009781200; Gomes B, 2004, CRIT REV IMMUNOL, V24, P425, DOI 10.1615/CritRevImmunol.v24.i6.30; Grafton G, 2003, BIOCHEM PHARMACOL, V66, P2001, DOI 10.1016/j.bcp.2003.07.005; Guo LY, 2004, IMMUNITY, V20, P193, DOI 10.1016/S1074-7613(04)00025-1; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; Kotturi MF, 2003, J BIOL CHEM, V278, P46949, DOI 10.1074/jbc.M309268200; KUBO M, 1994, J BIOL CHEM, V269, P19441; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; KUBO RT, 1989, J IMMUNOL, V142, P2736; Madrenas J, 2003, IMMUNITY, V18, P459, DOI 10.1016/S1074-7613(03)00089-X; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Mowen KA, 2004, IMMUNOL REV, V202, P203, DOI 10.1111/j.0105-2896.2004.00209.x; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; Poggi A, 1998, J BIOL CHEM, V273, P7205, DOI 10.1074/jbc.273.13.7205; Rosenthal R, 2002, ADV EXP MED BIOL, V514, P225; Savignac M, 2004, J IMMUNOL, V172, P5206, DOI 10.4049/jimmunol.172.9.5206; Savignac M, 2001, FASEB J, V15, P1577, DOI 10.1096/fj.00-0733fje; SCHMIDT J, 1995, IMMUNOPHARMACOLOGY, V30, P191, DOI 10.1016/0162-3109(95)00022-L; Singh RAK, 1999, J IMMUNOL, V163, P6393; SloanLancaster J, 1997, J IMMUNOL, V159, P1160; Sommers CL, 2002, SCIENCE, V296, P2040, DOI 10.1126/science.1069066; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; Stokes L, 2004, J BIOL CHEM, V279, P19566, DOI 10.1074/jbc.M401481200; TAMURA T, 1993, J IMMUNOL, V151, P6051; TAMURA T, 1995, J IMMUNOL, V155, P4692; Tamura T, 2001, J IMMUNOL, V167, P1962, DOI 10.4049/jimmunol.167.4.1962; Tanaka Y, 2003, IMMUNITY, V18, P403, DOI 10.1016/S1074-7613(03)00054-2; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Urban J, 2000, J IMMUNOL, V164, P4250, DOI 10.4049/jimmunol.164.8.4250; Wang YG, 2000, CARDIOVASC RES, V48, P310, DOI 10.1016/S0008-6363(00)00178-4; Wegener JW, 2002, CIRC RES, V90, P18, DOI 10.1161/hh0102.103222; White RA, 2003, FASEB J, V17, P482, DOI 10.1096/fj.02-0622fje; Winslow MM, 2003, CURR OPIN IMMUNOL, V15, P299, DOI 10.1016/S0952-7915(03)00050-5; Yamashita M, 2005, J BIOL CHEM, V280, P29409, DOI 10.1074/jbc.M502333200; Zocchi MR, 1998, J IMMUNOL, V161, P2938; ZWILLER J, 1985, J BIOL CHEM, V260, P1350	47	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12421	12427		10.1074/jbc.M510653200	http://dx.doi.org/10.1074/jbc.M510653200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16533816	hybrid			2022-12-25	WOS:000237134700028
J	Matsuura, B; Dong, MQ; Naik, S; Miller, LJ; Onji, M				Matsuura, B; Dong, MQ; Naik, S; Miller, LJ; Onji, M			Differential contributions of motilin receptor extracellular domains for peptide and non-peptidyl agonist binding and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE SECRETAGOGUE; LIGAND-BINDING; ERYTHROMYCIN; GHRELIN	The family of G protein-coupled receptors that includes receptors for motilin, ghrelin, and growth hormone secretagogue has substantial potential importance as drug targets. Understanding of the molecular basis of hormone binding and receptor activation should provide insights that are helpful in the development of such drugs. We previously examined the unique second extracellular loop domain of the motilin receptor, identifying key epitopes in perimembranous locations at each end of this long loop (Matsuura, B., Dong, M., and Miller, L. J. (2002) J. Biol. Chem. 277, 9834-9839). Here, we have extended that work, examining the other predicted extracellular domains of the motilin receptor by using sequential deletions of segments ranging from one to six amino acid residues and site-directed alanine replacement mutagenesis approaches. Each construct was transiently expressed in COS cells, and characterized for motilin- and erythromycin-stimulated intracellular calcium responses and motilin radioligand binding. Only those receptor segments that included key Cys residues in positions 25, 30, and 111 or perimembranous regions at the ends of the amino terminus and the first and third extracellular loops disrupted motilin biological activity. Each of these Cys deletions also disrupted action of erythromycin. Alanine replacements for each of the potentially important amino acid residues in the perimembranous segments revealed that residues Gly(36), Pro(103), Leu(109), and Phe(332) were responsible for the selective negative impact on motilin biological activity, while responding normally to erythromycin. These results support the presence of functionally important disulfide bonds in the motilin receptor ectodomain and demonstrate that the structural determinants for binding and biological activity of peptide and non-peptidyl agonist ligands are distinct, with a broad extracellular perimembranous base contributing to normal motilin binding.	Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA; Ehime Univ, Sch Med, Dept Internal Med 3, Tohon, Ehime 7910295, Japan	Mayo Clinic; Mayo Clinic Phoenix; Ehime University	Miller, LJ (corresponding author), Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu; onjimori@m.ehime-u.ac.jp		Naik, Shruthi/0000-0002-8593-9193				Coulie B, 2001, J BIOL CHEM, V276, P35518, DOI 10.1074/jbc.M104489200; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hosoda H, 2000, J BIOL CHEM, V275, P21995, DOI 10.1074/jbc.M002784200; Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; JANSSENS J, 1990, NEW ENGL J MED, V322, P1028, DOI 10.1056/NEJM199004123221502; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Matsuura B, 2005, J PHARMACOL EXP THER, V313, P1101, DOI 10.1124/jpet.104.081562; Matsuura B, 2002, J BIOL CHEM, V277, P9834, DOI 10.1074/jbc.M111051200; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PEETERS TL, 1993, GASTROENTEROLOGY, V105, P1886, DOI 10.1016/0016-5085(93)91089-Z; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533	15	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12390	12396		10.1074/jbc.M511921200	http://dx.doi.org/10.1074/jbc.M511921200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531413	hybrid			2022-12-25	WOS:000237134700024
J	Valerio, A; Ghisi, V; Dossena, M; Tonello, C; Giordano, A; Frontini, A; Ferrario, M; Pizzi, M; Spano, P; Carruba, MO; Nisoli, E				Valerio, A; Ghisi, V; Dossena, M; Tonello, C; Giordano, A; Frontini, A; Ferrario, M; Pizzi, M; Spano, P; Carruba, MO; Nisoli, E			Leptin increases axonal growth cone size in developing mouse cortical neurons by convergent signals inactivating glycogen synthase kinase-3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECEPTOR MESSENGER-RNA; LONG-TERM POTENTIATION; BODY-MASS INDEX; NEUROENDOCRINE FUNCTION; LYSOPHOSPHATIDIC ACID; SYNAPTIC PLASTICITY; HIPPOCAMPAL-NEURONS; GAP-43 NEUROMODULIN; ENTORHINAL CORTEX	We examined the effects of the adipose hormone leptin on the development of mouse cortical neurons. Treatment of neonatal and adult mice with intraperitoneal leptin ( 5 mg/kg) induced extracellular signal-regulated kinase (ERK) 1/2 phosphorylation in pyriform and entorhinal cortex neurons. Stimulation of cultured embryonic cortical neurons with leptin evoked Janus kinase 2 and ERK1/2 phosphorylation and activated the downstream effector 90-kDa ribosomal protein S6 kinase. Moreover, leptin elicited the phosphorylation of the phosphatidylinositol 3-kinase effector Akt and evoked Ser-9 phosphorylation of glycogen synthase kinase-3 beta (GSK3 beta), an event inactivating this kinase. Leptin-mediated GSK3 beta phosphorylation was prevented by the MEK/ERK inhibitor PD98059, the phosphatidylinositol 3-kinase inhibitor LY294002, or the protein kinase C inhibitor GF109203X. Exposure of cortical neurons to leptin also induced Ser-41 phosphorylation of the neuronal growth-associated protein GAP-43, an effect prevented by LY294002 and GF109203X but not by PD98059. Ser-41-GAP-43 phosphorylation is usually high in expanding axonal growth cones. Neurons exposed to 100 ng/ml leptin for 72 h displayed reduced rate of growth cone collapse, a shift of growth cone size distribution toward higher values, and a 4-fold increase in mean growth cone surface area compared with control cultures. The leptin-induced growth cone spreading was hampered in cortical neurons from Lepr(db/db) mice lacking functional leptin receptors; it was associated with localized Ser-9-GSK3 beta phosphorylation and mimicked by the GSK3 beta inhibitor SB216763. At concentrations preventing GSK3 beta phosphorylation, PD98059, LY294002, or GF109203X reversed the leptin-induced growth cone surface enlargement. We concluded that the leptin-mediated regulation of growth cone morphogenesis in cortical neurons relies on upstream regulators of GSK3 beta activity.	Univ Milan, Dept Pharmacol, Sch Med, I-20129 Milan, Italy; Univ Milan, Ctr Study & Res Obes, I-20129 Milan, Italy; Univ Milan, Dept Preclin Sci, I-20157 Milan, Italy; Univ Brescia, Div Pharmacol, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Marche Polytech Univ, Sch Med, Inst Normal Human Morphol, I-60020 Ancona, Italy; Ist Auxol Italiano, I-20149 Milan, Italy	University of Milan; University of Milan; University of Milan; University of Brescia; Marche Polytechnic University; IRCCS Istituto Auxologico Italiano	Nisoli, E (corresponding author), Univ Milan, Dept Pharmacol, Sch Med, Via VanVitelli 32, I-20129 Milan, Italy.	enzo.nisoli@unimi.it	Valerio, Alessandra/B-3413-2009; Frontini, A/AAB-8767-2021; Nisoli, Enzo/D-6526-2014; Spano, Pier Franco F/J-9944-2016; Dossena, Marta/I-2125-2012; Pizzi, Marina/C-1452-2011; Spano, Pier Franco A/E-7621-2010; Pizzi, Marina/K-2064-2016	Valerio, Alessandra/0000-0001-5844-2256; Nisoli, Enzo/0000-0002-6670-1630; Spano, Pier Franco F/0000-0002-9906-0964; Dossena, Marta/0000-0003-1717-8350; Frontini, Andrea/0000-0002-7381-4107; Carruba, Michele/0000-0003-4589-387X; Pizzi, Marina/0000-0002-4857-5204; Giordano, Antonio/0000-0003-1401-5855				Ahima RS, 1999, ENDOCRINOLOGY, V140, P2755, DOI 10.1210/en.140.6.2755; Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; AIGNER L, 1995, J CELL BIOL, V128, P647, DOI 10.1083/jcb.128.4.647; Bates SH, 2003, TRENDS ENDOCRIN MET, V14, P447, DOI 10.1016/j.tem.2003.10.003; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bhat RV, 2004, J NEUROCHEM, V89, P1313, DOI 10.1111/j.1471-4159.2004.02422.x; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Burguera B, 2000, NEUROENDOCRINOLOGY, V71, P187, DOI 10.1159/000054536; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Dent EW, 1998, J NEUROBIOL, V35, P287, DOI 10.1002/(SICI)1097-4695(19980605)35:3<287::AID-NEU6>3.0.CO;2-V; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eiras S, 2004, J CELL PHYSIOL, V201, P214, DOI 10.1002/jcp.20046; Elias MF, 2003, INT J OBESITY, V27, P260, DOI 10.1038/sj.ijo.802225; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; Goold RG, 2004, BIOCHEM SOC T, V32, P809, DOI 10.1042/BST0320809; Gustafson D, 2004, NEUROLOGY, V63, P1876, DOI 10.1212/01.WNL.0000141850.47773.5F; Gustafson D, 2003, ARCH INTERN MED, V163, P1524, DOI 10.1001/archinte.163.13.1524; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; He Q, 1997, J NEUROSCI, V17, P3515; Hebert AE, 2002, LEARN MEMORY, V9, P156, DOI 10.1101/lm.48502; Henson MC, 2000, BIOL REPROD, V63, P1219, DOI 10.1095/biolreprod63.5.1219; Hoggard N, 1997, P NATL ACAD SCI USA, V94, P11073, DOI 10.1073/pnas.94.20.11073; Huang XF, 1996, NEUROREPORT, V7, P2635, DOI 10.1097/00001756-199611040-00045; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Killiany RJ, 2002, NEUROLOGY, V58, P1188, DOI 10.1212/WNL.58.8.1188; Li XL, 2002, NEUROSCIENCE, V113, P607, DOI 10.1016/S0306-4522(02)00162-8; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; Matsuda J, 1999, ENDOCRINOLOGY, V140, P5233, DOI 10.1210/en.140.11.5233; MEIRI KF, 1991, J CELL BIOL, V112, P991, DOI 10.1083/jcb.112.5.991; Munzberg H, 2003, ENDOCRINOLOGY, V144, P2121, DOI 10.1210/en.2002-221037; Nordin S, 1998, ANN NY ACAD SCI, V855, P686, DOI 10.1111/j.1749-6632.1998.tb10646.x; Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301-0082(97)00043-9; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Rosengren A, 2005, ARCH INTERN MED, V165, P321, DOI 10.1001/archinte.165.3.321; Segal RA, 2003, ANNU REV NEUROSCI, V26, P299, DOI 10.1146/annurev.neuro.26.041002.131421; Shanley LJ, 2002, J PHYSIOL-LONDON, V545, P933, DOI 10.1113/jphysiol.2002.029488; Shanley LJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0001.2001; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Sweeney G, 2002, CELL SIGNAL, V14, P655, DOI 10.1016/S0898-6568(02)00006-2; Takekoshi K, 2001, ENDOCRINOLOGY, V142, P4861, DOI 10.1210/en.142.11.4861; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Udagawa J, 2000, BRAIN RES, V868, P251, DOI 10.1016/S0006-8993(00)02334-9; Valerio A, 2002, MOL CELL NEUROSCI, V21, P602, DOI 10.1006/mcne.2002.1208; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wurmbach E, 2001, J BIOL CHEM, V276, P47195, DOI 10.1074/jbc.M108716200; Yamashita H, 2001, ENDOCRINOLOGY, V142, P2888, DOI 10.1210/en.142.7.2888	55	73	78	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12950	12958		10.1074/jbc.M508691200	http://dx.doi.org/10.1074/jbc.M508691200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522636	hybrid			2022-12-25	WOS:000237134700090
J	Giesemann, T; Jank, T; Gerhard, R; Maier, E; Just, I; Benz, R; Aktories, K				Giesemann, T; Jank, T; Gerhard, R; Maier, E; Just, I; Benz, R; Aktories, K			Cholesterol-dependent pore formation of Clostridium difficile toxin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID BILAYER-MEMBRANES; BOTULINUM C2 TOXIN; DIPHTHERIA-TOXIN; PROTEIN TOXINS; LOW PH; ESCHERICHIA-COLI; BACTERIAL TOXINS; RETROGRADE TRANSPORT; CELLULAR UPTAKE; RHO-PROTEINS	The large clostridial cytotoxins toxin A and toxin B from Clostridium difficile are major virulence factors known to cause antibiotic-associated diarrhea and pseudomembranous colitis. Both toxins mono-glucosylate and thereby inactivate small GTPases of the Rho family. Recently, it was reported that toxin B, but not toxin A, induces pore formation in membranes of target cells under acidic conditions. Here, we reassessed data on pore formation of toxin A in cells derived from human colon carcinoma. Treatment of Rb-86(+)-loaded cells with native or recombinant toxin A resulted in an increased efflux of radioactive cations induced by an acidic pulse. The efficacy of pore formation was dependent on membrane cholesterol, since cholesterol depletion of membranes with methyl-beta-cyclodextrin inhibited Rb-86(+) efflux, and cholesterol repletion reconstituted pore-forming activity of toxin A. Similar results were obtained with toxin B. Consistently, methyl-beta-cyclodextrin treatment delayed intoxication of cells in a concentration-dependent manner. In black lipid membranes, toxin A induced ion-permeable pores only in cholesterol containing bilayers and at low pH. In contrast, release of glycosylphosphatidylinositol-anchored structures by phosphatidylinositol specific phospholipase C treatment did not reduce cell sensitivity toward toxins A and B. These data indicate that in colonic cells toxin A induces pore formation in an acidic environment (e.g. endosomes) similar to that reported for toxin B and suggest that pore formation by clostridial glucosylating toxins depends on the presence of cholesterol.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Hannover Med Sch, Inst Toxikol, D-30625 Hannover, Germany; Biozentrum, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany	University of Freiburg; Hannover Medical School; University of Wurzburg	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Albert Str 25, D-79104 Freiburg, Germany.	Klaus.Aktories@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022; Jank, Thomas/R-9627-2017	Aktories, Klaus/0000-0002-5397-0436; Benz, Roland/0000-0002-9510-9265				Aktories K, 2005, CURR TOP MICROBIOL, V291, P113; Andersen C, 2002, J BIOL CHEM, V277, P41318, DOI 10.1074/jbc.M206804200; BARROSO LA, 1994, MICROB PATHOGENESIS, V16, P297, DOI 10.1006/mpat.1994.1030; Barth H, 2005, REV PHYSIOL BIOCH P, V152, P165, DOI 10.1007/s10254-004-0029-1; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; Barth H, 2004, MICROBIOL MOL BIOL R, V68, P373, DOI 10.1128/MMBR.68.3.373-402.2004; Barth H, 2001, J BIOL CHEM, V276, P10670, DOI 10.1074/jbc.M009445200; BARTLETT JG, 1978, GASTROENTEROLOGY, V75, P778; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1980, J MEMBRANE BIOL, V56, P19, DOI 10.1007/BF01869348; BENZ R, 1994, J BIOL CHEM, V269, P27231; Benz R., 2001, MICROBIAL TRANSPORT, P227; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BOQUET P, 1982, P NATL ACAD SCI-BIOL, V79, P7614, DOI 10.1073/pnas.79.24.7614; Burger S, 2003, BIOCHEM BIOPH RES CO, V307, P584, DOI 10.1016/S0006-291X(03)01234-8; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DOVE CH, 1990, INFECT IMMUN, V58, P480, DOI 10.1128/IAI.58.2.480-488.1990; ERIKSEN S, 1994, EMBO J, V13, P4433, DOI 10.1002/j.1460-2075.1994.tb06765.x; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; FIORENTINI C, 1991, TOXICON, V29, P543, DOI 10.1016/0041-0101(91)90050-2; FLORIN I, 1983, BIOCHIM BIOPHYS ACTA, V763, P383, DOI 10.1016/0167-4889(83)90100-3; Gerhard R, 2005, MICROB PATHOGENESIS, V38, P77, DOI 10.1016/j.micpath.2004.12.002; Gerhard R, 2005, J BIOL CHEM, V280, P1499, DOI 10.1074/jbc.M406014200; Giddings KS, 2003, P NATL ACAD SCI USA, V100, P11315, DOI 10.1073/pnas.2033520100; Hayakawa E, 1998, BIOPHYS J, V74, P892, DOI 10.1016/S0006-3495(98)74012-3; HENRIQUES B, 1987, MICROB PATHOGENESIS, V2, P455, DOI 10.1016/0882-4010(87)90052-0; Hofmann F, 1997, J BIOL CHEM, V272, P11074; Just I, 2005, REV PHYSIOL BIOCH P, V152, P23, DOI 10.1007/s10254-004-0033-5; Just I, 2000, CURR TOP MICROBIOL, V250, P55; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Just I., 1997, BACTERIAL TOXINS TOO, P159; Kelly CP, 1998, ANNU REV MED, V49, P375; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KRIVAN HC, 1986, INFECT IMMUN, V53, P573, DOI 10.1128/IAI.53.3.573-581.1986; Lencer WI, 2004, INT J MED MICROBIOL, V293, P491, DOI 10.1078/1438-4221-00293; Lord JM, 1999, CELL MICROBIOL, V1, P85, DOI 10.1046/j.1462-5822.1999.00015.x; Lord JM, 1998, J CELL BIOL, V140, P733; Mylonakis E, 2001, ARCH INTERN MED, V161, P525, DOI 10.1001/archinte.161.4.525; NETZER A, 1993, RENAL PHYSIOL BIOCH, V16, P299; Palmer M, 2004, FEMS MICROBIOL LETT, V238, P281, DOI 10.1016/j.femsle.2004.07.059; Pfeifer G, 2003, J BIOL CHEM, V278, P44535, DOI 10.1074/jbc.M307540200; Qa'Dan M, 2000, INFECT IMMUN, V68, P2470, DOI 10.1128/IAI.68.5.2470-2474.2000; Reinert DJ, 2005, J MOL BIOL, V351, P973, DOI 10.1016/j.jmb.2005.06.071; Rupnik M, 2005, MICROBIOL-SGM, V151, P199, DOI 10.1099/mic.0.27474-0; Sandvig K, 2004, INT J MED MICROBIOL, V293, P483, DOI 10.1078/1438-4221-00294; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; Sandvig K, 2005, GENE THER, V12, P865, DOI 10.1038/sj.gt.3302525; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SCHMID A, 1994, J BIOL CHEM, V269, P16706; Teneberg S, 1996, GLYCOBIOLOGY, V6, P599, DOI 10.1093/glycob/6.6.599; Thelestam M, 2000, CURR TOP MICROBIOL, V250, P85; VONEICHELSTREIBER C, 1992, J BACTERIOL, V174, P6707, DOI 10.1128/JB.174.20.6707-6710.1992; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; Voth DE, 2005, CLIN MICROBIOL REV, V18, P247, DOI 10.1128/CMR.18.2.247-263.2005; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	61	65	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10808	10815		10.1074/jbc.M512720200	http://dx.doi.org/10.1074/jbc.M512720200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16513641	hybrid			2022-12-25	WOS:000236822200020
J	Alahyan, M; Webb, MR; Marston, SB; El-Mezgueldi, M				Alahyan, Mustapha; Webb, Martin R.; Marston, Steven B.; El-Mezgueldi, Mohammed			The mechanism of smooth muscle caldesmon-tropomyosin inhibition of the elementary steps of the actomyosin ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; MYOSIN SUBFRAGMENT-1; HEAVY-MEROMYOSIN; THIN-FILAMENTS; ACTIN-TROPOMYOSIN; BINDING PROTEIN; TROPONIN TROPOMYOSIN; PHOSPHATE RELEASE; FLUORESCENT-PROBE; F-ACTIN	Caldesmon is a component of smooth muscle thin filaments that inhibits the actomyosin ATPase via its interaction with actin-tropomyosin. We have performed a comprehensive transient kinetic characterization of the actomyosin ATPase in the presence of smooth muscle caldesmon and tropomyosin. At physiological ratios of caldesmon to actin (1 caldesmon/7 actin monomers) actomyosin ATPase is inhibited by about 75%. Inhibitory caldesmon concentrations had little effect upon the rate of S1 binding to actin, actin-S1 dissociation by ATP, and dissociation of ADP from actin-S1(.)ADP; however the rate of phosphate release from the actin-S1(.)ADP(.)P(i) complex was decreased by more than 80%. In addition the transient of phosphate release displayed a lag of up to 200 ms. The presence of a lag phase indicates that a step on the pathway prior to phosphate release has become rate-limiting. Premixing the actin-tropomyosin filaments with myosin heads resulted in the disappearance of the lag phase. We conclude that caldesmon inhibition of the rate of phosphate release is caused by the thin filament being switched by caldesmon to an inactive state. The active and inactive states correspond to the open and closed states observed in skeletal muscle thin filaments with no evidence for the existence of a third, blocked state. Taken together these data suggest that at physiological concentrations, caldesmon controls the isomerization of the weak binding complex to the strong binding complex, and this causes the inhibition of the rate of phosphate release. This inhibition is sufficient to account for the inhibition of the steady state actomyosin ATPase by caldesmon and tropomyosin.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Myocardial Syst Biol Grp, London SW3 6LY, England; Natl Inst Med Res, MRC, London NW7 1AA, England	Imperial College London; MRC National Institute for Medical Research	El-Mezgueldi, M (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mem16@le.ac.uk		Webb, Martin/0000-0002-0134-9621	MRC [MC_U117512742] Funding Source: UKRI; Medical Research Council [MC_U117512742] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ansari S, 2003, J MUSCLE RES CELL M, V24, P513, DOI 10.1023/B:JURE.0000009812.74980.13; ANSARI SN, 2004, NATL HEART LUNG I, P256; BARANY M, 1993, ARCH BIOCHEM BIOPHYS, V305, P202, DOI 10.1006/abbi.1993.1412; BARANY M, 1996, BIOCH SMOOTH MUSCLE, P321; BARTEGI A, 1990, J BIOL CHEM, V265, P2231; BRENNER B, 1991, P NATL ACAD SCI USA, V88, P5739, DOI 10.1073/pnas.88.13.5739; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; CHACKO S, 1994, J BIOL CHEM, V269, P15803; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; Chalovich JM, 1998, ACTA PHYSIOL SCAND, V164, P427; CORRIE JET, 1991, J CHEM SOC P1, P2975; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; Earley JJ, 1998, CIRC RES, V83, P661, DOI 10.1161/01.RES.83.6.661; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; El-Mezgueldi M, 1998, BIOCHEM J, V332, P395, DOI 10.1042/bj3320395; Elmezgueldi M, 2005, BIOPHYS J, V88, p133A; ELMEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; ELMEZGUELDI M, 2001, WILEY ENCY MOL MED, V5, P428; Fersht A., 1985, ENZYME STRUCTURE MEC; Fredricksen S, 2003, BIOCHEMISTRY-US, V42, P6136, DOI 10.1021/bi0274017; GEEVES MA, 1989, BIOCHEMISTRY-US, V28, P5864, DOI 10.1021/bi00440a024; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; GEEVES MA, 1995, BIOPHYS J, V68, pS196; GEEVES MA, 1986, BIOCHEMISTRY-US, V25, P8454, DOI 10.1021/bi00374a020; He ZH, 1998, BIOPHYS J, V75, P3031, DOI 10.1016/S0006-3495(98)77744-6; Heeley DH, 2002, P NATL ACAD SCI USA, V99, P16731, DOI 10.1073/pnas.252236399; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; Hodgkinson JL, 1997, BIOPHYS J, V72, P2398, DOI 10.1016/S0006-3495(97)78885-4; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JOHNSON KA, 2004, INTRO KINETIC ANAL E; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Malmquist U, 1996, PFLUG ARCH EUR J PHY, V432, P241, DOI 10.1007/s004240050130; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Marston S, 1998, ACTA PHYSIOL SCAND, V164, P401, DOI 10.1111/j.1365-201X.1998.tb10696.x; MARSTON S, 1990, BIOCHEM J, V272, P305, DOI 10.1042/bj2720305; MARSTON SB, 1994, J BIOL CHEM, V269, P32104; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; MCKILLOP DFA, 1991, BIOCHEM J, V279, P711, DOI 10.1042/bj2790711; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; PATE E, 1989, PFLUG ARCH EUR J PHY, V414, P73, DOI 10.1007/BF00585629; Pavlov D, 2003, J BIOL CHEM, V278, P5517, DOI 10.1074/jbc.M210889200; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; ROSENFELD SS, 1987, J BIOL CHEM, V262, P9994; ROSENFELD SS, 1987, J BIOL CHEM, V262, P9984; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; Sen A, 2001, BIOCHEMISTRY-US, V40, P5757, DOI 10.1021/bi002724t; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; VELAZ L, 1990, J BIOL CHEM, V265, P2929; Webb Martin R., 2003, P131; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Yan B, 2003, BIOCHEMISTRY-US, V42, P4208, DOI 10.1021/bi0273009	68	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 14	2006	281	28					19433	19448		10.1074/jbc.M507602200	http://dx.doi.org/10.1074/jbc.M507602200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	061BU	16540476	hybrid			2022-12-25	WOS:000238847000059
J	Reddy, VB; Iuga, AO; Kounga, K; Lerner, EA				Reddy, Vemuri B.; Iuga, Aurel O.; Kounga, Kounga; Lerner, Ethan A.			Functional analysis of recombinant mutants of maxadilan with a PAC1 receptor-expressing melanophore cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; LUTZOMYIA-LONGIPALPIS; VASODILATORY PEPTIDE; I RECEPTOR; CLONING	Maxadilan, a 61-amino-acid vasodilatory peptide, was initially isolated from the salivary glands of the sand fly Lutzomyia longipalpis. Although its primary sequence has no homology to that of pituitary adenylate cyclase-activating peptide, maxadilan is an agonist for the PAC1 receptor. A total of 58 substitution and deletion mutants was engineered in an effort to determine which residues were important for receptor activation. The mutants were characterized functionally using an assay based on pigment granule translocation in PAC1-expressing Xenopus laevis melanophores. Substitution of charged residues and proline 43 could alter ( but not eliminate) the agonist activity of the mutants. In contrast, we found that several multiple substitution mutants of the predicted beta-strand threonine residues became antagonists at the PAC1 receptor. The results suggest that these threonine residues are cooperatively involved in PAC1 activation.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Lerner, EA (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	ethan.lerner@cbrc2.mgh.harvard.edu	Iuga, Aurel/AAU-4341-2021	Iuga, Aurel/0000-0002-8796-1933	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI061420] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI 61420-02] Funding Source: Medline; NIAMS NIH HHS [R01 AR 2005] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Lanzaro GC, 1999, INSECT MOL BIOL, V8, P267, DOI 10.1046/j.1365-2583.1999.820267.x; LERNER EA, 1992, J BIOL CHEM, V267, P1062; LERNER EA, 1991, J BIOL CHEM, V266, P11234; Milleron RS, 2004, AM J TROP MED HYG, V70, P286, DOI 10.4269/ajtmh.2004.70.286; Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966; Moro O, 1999, J BIOL CHEM, V274, P23103, DOI 10.1074/jbc.274.33.23103; Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226; Pereira P, 2002, PIGM CELL RES, V15, P461, DOI 10.1034/j.1600-0749.2002.02077.x; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Qureshi AA, 1996, AM J TROP MED HYG, V54, P665, DOI 10.4269/ajtmh.1996.54.665; Vaudry D, 2000, PHARMACOL REV, V52, P269	11	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16197	16201		10.1074/jbc.M509429200	http://dx.doi.org/10.1074/jbc.M509429200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16569645	hybrid			2022-12-25	WOS:000238165700004
J	Frey, RS; Gao, XP; Javaid, K; Siddiqui, SS; Rahman, A; Malik, AB				Frey, Randall S.; Gao, Xiaopei; Javaid, Kamran; Siddiqui, Shahid S.; Rahman, Arshad; Malik, Asrar B.			Phosphatidylinositol 3-kinase gamma signaling through protein kinase C zeta induces NADPH oxidase-mediated oxidant generation and NF-kappa B activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; G-BETA-GAMMA; PHOSPHOINOSITIDE 3-KINASE GAMMA; NEUTROPHIL RESPIRATORY BURST; DEPENDENT ACTIVATION; GENE-TRANSCRIPTION; MEMBRANE; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION	We addressed the role of class 1B phosphatidylinositol 3-kinase (PI3K) isoform PI3K gamma in mediating NADPH oxidase activation and reactive oxidant species (ROS) generation in endothelial cells (ECs) and of PI3K gamma-mediated oxidant signaling in the mechanism of NF-kappa B activation and intercellular adhesion molecule (ICAM)-1 expression. We used lung microvascular ECs isolated from mice with targeted deletion of the p110 gamma catalytic subunit of PI3K gamma. Tumor necrosis factor (TNF)alpha challenge of wild type ECs caused p110 gamma translocation to the plasma membrane and phosphatidylinositol 1,4,5- trisphosphate production coupled to ROS production; however, this response was blocked in p110 gamma (-)/(-) ECs. ROS production was the result of TNF alpha activation of Ser phosphorylation of NADPH oxidase subunit p47(phox) and its translocation to EC membranes. NADPH oxidase activation failed to occur in p110 gamma(-/-) ECs. Additionally, the TNF alpha- activated NF-kappa B binding to the ICAM-1 promoter, ICAM- 1 protein expression, and PMN adhesion to ECs required functional PI3K gamma. TNF alpha challenge of p110 gamma(-/-) ECs failed to induce phosphorylation of PDK1 and activation of the atypical PKC isoform, PKC xi. Thus, PI3K gamma lies upstream of PKC xi in the endothelium, and its activation is crucial in signaling NADPH oxidase-dependent oxidant production and subsequent NF-kappa B activation and ICAM-1 expression.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Ctr Lung & Vasc Biol, Chicago, IL 60612 USA; Univ Rochester, Sch Med, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Rochester; University of Rochester	Frey, RS (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,E403, Chicago, IL 60612 USA.	RFrey@uic.edu		Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678, R01HL067424] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07239, HL60678, HL67424] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cadwallader KA, 2002, J IMMUNOL, V169, P3336, DOI 10.4049/jimmunol.169.6.3336; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chen RY, 2002, J HISTOCHEM CYTOCHEM, V50, P697, DOI 10.1177/002215540205000511; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Fan J, 2002, J BIOL CHEM, V277, P3404, DOI 10.1074/jbc.M110054200; Fan J, 2003, J CLIN INVEST, V112, P1234, DOI 10.1172/JCI200318696; Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; Gillham H, 1999, J CELL BIOL, V146, P869, DOI 10.1083/jcb.146.4.869; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Hannigan M, 2002, P NATL ACAD SCI USA, V99, P3603, DOI 10.1073/pnas.052010699; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Ho LKF, 1997, BIOCHEM BIOPH RES CO, V235, P130, DOI 10.1006/bbrc.1997.6747; Javaid K, 2003, CIRC RES, V92, P1089, DOI 10.1161/01.RES.0000072971.88704.CB; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Krymskaya VP, 2001, AM J PHYSIOL-LUNG C, V280, pL1009, DOI 10.1152/ajplung.2001.280.5.L1009; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LO SK, 1993, AM J PHYSIOL, V264, P406; Martin K, 2003, PROTEOMICS, V3, P1244, DOI 10.1002/pmic.200300445; Milne SB, 2005, J LIPID RES, V46, P1796, DOI 10.1194/jlr.D500010-JLR200; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Puri KD, 2005, BLOOD, V106, P150, DOI 10.1182/blood-2005-01-0023; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Rahman A, 1999, MOL PHARMACOL, V55, P575; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Strassheim D, 2004, J IMMUNOL, V172, P5727, DOI 10.4049/jimmunol.172.9.5727; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wang YJ, 2004, J IMMUNOL, V173, P6820, DOI 10.4049/jimmunol.173.11.6820; Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yang KY, 2003, CELL SIGNAL, V15, P225, DOI 10.1016/S0898-6568(02)00063-3; Yum HK, 2001, J IMMUNOL, V167, P6601, DOI 10.4049/jimmunol.167.11.6601	52	117	121	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16128	16138		10.1074/jbc.M508810200	http://dx.doi.org/10.1074/jbc.M508810200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16527821	hybrid			2022-12-25	WOS:000237996000066
J	Aritake, K; Kado, Y; Inoue, T; Miyano, M; Urade, Y				Aritake, Kosuke; Kado, Yuji; Inoue, Tsuyoshi; Miyano, Masashi; Urade, Yoshihiro			Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIALLERGIC DRUG HQL-79; ALLERGIC INFLAMMATION; PHORBOL ESTER; CELLS; PROTEIN; ACTIVATION; EXPRESSION; D-2; RECEPTORS; INDUCTION	We determined the crystal structure of human hematopoietic prostaglandin (PG) D synthase (H-PGDS) as the quaternary complex with glutathione (GSH), Mg2+, and an inhibitor, HQL-79, having anti-inflammatory activities in vivo, at a 1.45-angstrom resolution. In the quaternary complex, HQL-79 was found to reside within the catalytic cleft between Trp(104) and GSH. HQL-79 was stabilized by interaction of a phenyl ring of its diphenyl group with Trp104 and by its piperidine group with GSH and Arg(14) through water molecules, which form a network with hydrogen bonding and salt bridges linked to Mg2+. HQL-79 inhibited human H-PGDS competitively against the substrate PGH(2) and non-competitively against GSH with K-i of 5 and 3 mu(M), respectively. Surface plasmon resonance analysis revealed that HQL-79 bound to H-PGDS with an affinity that was 12-fold higher in the presence of GSH and Mg2+ (K-d, 0.8 mu(M)) than in their absence. Mutational studies revealed that Arg14 was important for the Mg2+-mediated increase in the binding affinity of H-PGDS for HQL-79, and that Trp(104), Lys(112), and Lys(198) were important for maintaining the HQL-binding pocket. HQL-79 selectively inhibited PGD(2) production by H-PGDS-expressing human megakaryocytes and rat mastocytoma cells with an IC50 value of about 100 mu(M) but only marginally affected the production of other prostanoids, suggesting the tight functional engagement between H-PGDS and cyclooxygenase. Orally administered HQL-79 (30 mg/kg body weight) inhibited antigen-induced production of PGD(2), without affecting the production of PGE(2) and PGF(2 alpha), and ameliorated airway inflammation in wild-type and human H-PGDS-overexpressing mice. Knowledge about this structure of quaternary complex is useful for understanding the inhibitory mechanism of HQL-79 and should accelerate the structure-based development of novel anti-inflammatory drugs that inhibit PGD2 production specifically.	Osaka Biosci Inst, Dept Mol Behav Biol, Suita, Osaka 5650874, Japan; Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan; RIKEN, SPring 8 Ctr, Struct Biophys Lab, Sayo, Hyogo 6795148, Japan	Osaka University; Japan Synchrotron Radiation Research Institute; RIKEN	Urade, Y (corresponding author), Osaka Biosci Inst, Dept Mol Behav Biol, 6-2-4 Furuedai, Suita, Osaka 5650874, Japan.	uradey@obi.or.jp	Miyano, Masashi/R-2785-2016	Miyano, Masashi/0000-0003-2253-6175				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726; Fujimori K, 2005, J BIOL CHEM, V280, P18452, DOI 10.1074/jbc.M411755200; Guyton AG, 1991, TXB MED PHYSL, P38; Halter F, 2001, GUT, V49, P443, DOI 10.1136/gut.49.3.443; Harizi H, 2003, J IMMUNOL, V170, P139, DOI 10.4049/jimmunol.170.1.139; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Inoue I, 1996, P NATL ACAD SCI USA, V93, P13316, DOI 10.1073/pnas.93.23.13316; Inoue T, 2004, J BIOCHEM, V135, P279, DOI 10.1093/jb/mvh033; Inoue T, 2003, NAT STRUCT BIOL, V10, P291, DOI 10.1038/nsb907; Inui T, 2003, J BIOL CHEM, V278, P2845, DOI 10.1074/jbc.M209934200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanaoka Y, 2000, EUR J BIOCHEM, V267, P3315, DOI 10.1046/j.1432-1327.2000.01362.x; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Kanaoka Y, 2003, PROSTAG LEUKOTR ESS, V69, P163, DOI 10.1016/S0952-3278(03)00077-2; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Lazarus M, 2002, ARCH BIOCHEM BIOPHYS, V397, P336, DOI 10.1006/abbi.2001.2614; LEWIS RA, 1982, J IMMUNOL, V129, P1627; Li LX, 2003, J BIOL CHEM, V278, P4725, DOI 10.1074/jbc.C200635200; Mahmud I, 1997, J BIOL CHEM, V272, P28263, DOI 10.1074/jbc.272.45.28263; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Matsushita N, 1998, JPN J PHARMACOL, V78, P1, DOI 10.1254/jjp.78.1; Matsushita N, 1998, JPN J PHARMACOL, V78, P11, DOI 10.1254/jjp.78.11; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Mohri I, 2006, J NEUROSCI, V26, P4383, DOI 10.1523/JNEUROSCI.4531-05.2006; Nantel F, 2004, PROSTAG OTH LIPID M, V73, P87, DOI 10.1016/j.prostaglandins.2003.12.002; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; OKANO M, 2006, IN PRESS AM J RHINOL; Okinaga T, 2002, ACTA NEUROPATHOL, V104, P377, DOI 10.1007/s00401-002-0567-z; Pinzar E, 2000, P NATL ACAD SCI USA, V97, P4903, DOI 10.1073/pnas.090093997; Pinzar E, 2000, J BIOL CHEM, V275, P31239, DOI 10.1074/jbc.M000750200; Psaty BM, 2005, NEW ENGL J MED, V352, P1133, DOI 10.1056/NEJMe058042; Shichijo M, 2003, J PHARMACOL EXP THER, V307, P518, DOI 10.1124/jpet.103.055442; Spik I, 2005, J IMMUNOL, V174, P3703, DOI 10.4049/jimmunol.174.6.3703; Steiner T, 2001, J MOL BIOL, V305, P535, DOI 10.1006/jmbi.2000.4301; Suzuki T, 1997, BIOCHEM BIOPH RES CO, V241, P288, DOI 10.1006/bbrc.1997.7803; Takeuchi K, 2001, J PHARMACOL EXP THER, V297, P1160; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Taniike M, 2002, J NEUROSCI, V22, P4885, DOI 10.1523/JNEUROSCI.22-12-04885.2002; Ueda N, 1997, BBA-LIPID LIPID MET, V1344, P103, DOI 10.1016/S0005-2760(96)00131-2; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Urade Y, 2000, VITAM HORM, V58, P89, DOI 10.1016/S0083-6729(00)58022-4; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; 2003, NAT STRUCT BIOL, V10, P233	46	88	98	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15277	15286		10.1074/jbc.M506431200	http://dx.doi.org/10.1074/jbc.M506431200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16547010	hybrid			2022-12-25	WOS:000237922200031
J	Andrew, AJ; Dutkiewicz, R; Knieszner, H; Craig, EA; Marszalek, J				Andrew, Amy J.; Dutkiewicz, Rafal; Knieszner, Helena; Craig, Elizabeth A.; Marszalek, Jaroslaw			Characterization of the interaction between the J-protein Jac1p and the scaffold for Fe-S cluster biogenesis, Isu1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CHAPERONE SYSTEM; SUBSTRATE-SPECIFICITY; SHUTTLE VECTORS; DNAK CHAPERONE; HSP70 SSQ1; ISCU; MITOCHONDRIA	Jac1p is a conserved, specialized J-protein that functions with Hsp70 in Fe-S cluster biogenesis in mitochondria of the yeast Saccharomyces cerevisiae. Although Jac1p as well as its specialized Hsp70 partner, Ssq1p, binds directly to the Fe-S cluster scaffold protein Isu, the Jac1p-Isu1p interaction is not well understood. Here we report that a C-terminal fragment of Jac1p lacking its J-domain is sufficient for interaction with Isu1p, and amino acid alterations in this domain affect interaction with Isu1p but not Ssq1p. In vivo, such JAC1 mutations had no obvious phenotypic effect. However, when present in combination with a mutation in SSQ1 that causes an alteration in the substrate binding cleft, growth was significantly compromised. Wild type Jac1p and Isu1p cooperatively stimulate the ATPase activity of Ssq1p. Jac1p mutant protein is only slightly compromised in this regard. Our in vivo and in vitro results indicate that independent interaction of Jac1p and the Isu client protein with Hsp70 is sufficient for robust growth under standard laboratory conditions. However, our results also support the idea that Isu protein can be "targeted" to Ssq1p after forming a complex with Jac1p. We propose that Isu protein targeting may be particularly important when environmental conditions place high demands on Fe-S cluster biogenesis or in organisms lacking specialized Hsp70s for Fe-S cluster biogenesis.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Grad Program Biomol Chem, Madison, WI 53706 USA; Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Fahrenheit Universities; University of Gdansk	Craig, EA (corresponding author), Univ Wisconsin, Dept Biochem, 441E Biochem Addict,433 Babcock Dr, Madison, WI 53706 USA.	ecraig@wisc.edu	Dutkiewicz, Rafal/ABE-6979-2020; Marszalek, Jaroslaw/F-5824-2011; Dutkiewicz, Rafal/F-5956-2011	Dutkiewicz, Rafal/0000-0003-4150-0450; Marszalek, Jaroslaw/0000-0002-6978-1189	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870, T32GM008349] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 27870, 5T32 GM 08349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cupp-Vickery JR, 2000, J MOL BIOL, V304, P835, DOI 10.1006/jmbi.2000.4252; Dutkiewicz R, 2006, J BIOL CHEM, V281, P7801, DOI 10.1074/jbc.M513301200; Dutkiewicz R, 2004, J BIOL CHEM, V279, P29167, DOI 10.1074/jbc.M402947200; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Erbse A, 2004, BIOCHEM SOC T, V32, P617, DOI 10.1042/BST0320617; HALL BG, 2004, PHYLOGENETIC TREES M, P9; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; Knieszner H, 2005, J BIOL CHEM, V280, P28966, DOI 10.1074/jbc.M503031200; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; PTASHNE M, 2002, GENES SIGNALS; Ramelot TA, 2004, J MOL BIOL, V344, P567, DOI 10.1016/j.jmb.2004.08.038; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SHERMAN F, 1986, LAB COURSE MANUAL ME, P177; SIKORSKI RS, 1989, GENETICS, V122, P19; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Skerra A, 2000, METHOD ENZYMOL, V326, P271; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0	33	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14580	14587		10.1074/jbc.M600842200	http://dx.doi.org/10.1074/jbc.M600842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551614	hybrid			2022-12-25	WOS:000237671300009
J	Gong, PF; Cederbaum, AI				Gong, Pengfei; Cederbaum, Arthur I.			Transcription factor Nrf2 protects HepG2 cells against CYP2E1 plus arachidonic acid-dependent toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME OXYGENASE-1 GENE; OXIDATIVE STRESS; CYTOCHROME-P450 2E1; LIPID-PEROXIDATION; RESPONSIVE ELEMENT; SUBUNIT GENE; G2 CELLS; FISH-OIL; EXPRESSION; LIVER	Nrf2 is a transcription factor that regulates important antioxidant and phase II detoxification genes. Arachidonic acid (AA) causes CYP2E1-dependent toxicity in HepG2 cells. The ability of Nrf2 to protect against CYP2E1-dependent AA toxicity and its possible mechanism were evaluated. AA activates Nrf2 in CYP2E1-expressing HepG2 cells (E47 cells), increasing Nrf2 protein and mRNA levels, Nrf2 nuclear translocation, and Nrf2-ARE binding activity. These increases in Nrf2 are associated with elevated expression of Nrf2-regulated antioxidant genes. Overexpression of Nrf2 by transient transfection of plasmid Nrf2 confers resistance of E47 cells against AA toxicity. Blocking Nrf2 with small interfering RNA (siRNA)-Nrf2 potentiates the CYP2E1-dependent AA toxicity. This enhanced toxicity is accompanied by decreases of cellular GSH levels and increases in production of reactive oxygen species and lipid peroxidation. There is also a potentiation of mitochondrial damage in the presence of siRNA-Nrf2. The protective effects of Nrf2 against CYP2E1-dependent toxicity can be blocked by L-buthionine(S,R)-sulfoximine, a specific inhibitor of glutamate-cysteine ligase, which is a rate-limiting enzyme in the synthesis of GSH and is regulated by Nrf2. Elevation of GSH by supplementing with glutathione ethyl ester can partially reverse the enhanced AA toxicity by siRNA-Nrf2. Moreover, in contrast to AA, L-buthionine(S,R)- sulfoximine toxicity is not prevented by plasmid Nrf2 probably because protective GSH cannot be synthesized. Together, these results suggest that Nrf2, through up-regulation of glutamate-cysteine ligase and increase of GSH levels, protects against CYP2E1-dependent AA toxicity.	CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol, Box 1603,1 Gustave L Levy Pl, New York, NY 10029 USA.	arthur.cederbaum@mssm.edu						Alam J, 2000, J BIOL CHEM, V275, P27694; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; Cederbaum AI, 2001, FREE RADICAL BIO MED, V31, P1539, DOI 10.1016/S0891-5849(01)00743-2; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; CHOW SC, 1990, J BIOL CHEM, V265, P902; FRAGA CG, 1987, FREE RADICAL BIO MED, V3, P119, DOI 10.1016/S0891-5849(87)80006-0; FRENCH SW, 1992, CRIT REV CL LAB SCI, V29, P83, DOI 10.3109/10408369209114597; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Gong PF, 2006, HEPATOLOGY, V43, P144, DOI 10.1002/hep.21004; Gong PF, 2000, IND HEALTH, V38, P224, DOI 10.2486/indhealth.38.224; Gong PF, 2004, FREE RADICAL BIO MED, V36, P307, DOI 10.1016/j.freeradbiomed.2003.10.017; Gong PF, 2003, J BIOL CHEM, V278, P29693, DOI 10.1074/jbc.M304728200; Gong PF, 2002, ARCH BIOCHEM BIOPHYS, V405, P265, DOI 10.1016/S0003-9861(02)00404-6; Gonzalez FJ, 2005, MUTAT RES-FUND MOL M, V569, P101, DOI 10.1016/j.mrfmmm.2004.04.021; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; Kurose I, 1997, HEPATOLOGY, V25, P368; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Lee SST, 1996, J BIOL CHEM, V271, P12063, DOI 10.1074/jbc.271.20.12063; Mari R, 2000, J BIOL CHEM, V275, P15563; MORIMOTO M, 1994, P SOC EXP BIOL MED, V207, P197, DOI 10.3181/00379727-207-43807; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Novak RF, 2000, ARCH PHARM RES, V23, P267, DOI 10.1007/BF02975435; Primiano T, 1997, Adv Pharmacol, V38, P293; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Talalay P, 2003, ADV ENZYME REGUL, V43, P121, DOI 10.1016/S0065-2571(02)00038-9; TSUKAMOTO H, 1990, HEPATOLOGY, V12, P599, DOI 10.1002/hep.1840120325; Wu DF, 2000, MOL CELL BIOCHEM, V204, P157, DOI 10.1023/A:1007064706101; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082	38	26	27	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14573	14579		10.1074/jbc.M600613200	http://dx.doi.org/10.1074/jbc.M600613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551616	hybrid			2022-12-25	WOS:000237671300008
J	Udayakumar, TS; Belakavadi, M; Choi, KH; Pandey, PK; Fondell, JD				Udayakumar, T. S.; Belakavadi, Madesh; Choi, Kyoung-Han; Pandey, Pradeep K.; Fondell, Joseph D.			Regulation of Aurora-A kinase gene expression via GABP recruitment of TRAP220/MED1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING PROTEIN; RNA-POLYMERASE-II; THYROID-HORMONE; TRANSCRIPTIONAL REGULATION; COACTIVATOR COMPLEX; TRAP/MEDIATOR-SUBUNIT; NUCLEAR RECEPTORS; MEDIATOR; YEAST; E2F	The TRAP/Mediator coactivator complex serves as a functional interface between DNA-bound transactivators and the RNA polymerase II-associated basal transcription apparatus. TRAP220/MED1 is a variably associated subunit of the complex that plays a specialized role in selectively targeting TRAP/Mediator to specific genes. Ablation of the Trap220/Med1 gene in mice impairs embryonic cell growth, yet the underlying mechanism is unknown. In this report, we identified distinct cell growth regulatory genes whose expression is affected by the loss of TRAP220/MED1 by RNA interference. Among the down-regulated genes revealed by cDNA microarray analyses, we identified Aurora-A, a centrosome kinase that plays a critical role in regulating M phase events and is frequently amplified in several types of cancer. In general, we found that TRAP220/MED1 expression is required for high basal levels of Aurora-A gene expression and that ectopic overexpression of TRAP220/MED1 coactivates transcription from the Aurora-A gene promoter. Furthermore, chromatin immunoprecipitation assays show that TRAP220/MED1-containing TRAP/Mediator complexes directly bind to the Aurora-A promoter in vivo. Finally, we present evidence suggesting that TRAP/Mediator is recruited to the Aurora-A gene via direct interactions between TRAP220/MED1 and the Ets-related transcription factor GABP. Taken together, these findings suggest that TRAP220/MED1 plays a novel coregulatory role in facilitating the recruitment of TRAP/Mediator to specific target genes involved in growth and cell cycle progression.	UMDNJ, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Fondell, JD (corresponding author), UMDNJ, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA.	fondeljd@umdnj.edu	Wang, Qianben/E-4267-2011		NIDDK NIH HHS [DK 54030-06] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054030] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; Frade R, 2000, CANCER RES, V60, P6585; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Ko JK, 2005, AM J PHYSIOL-CELL PH, V288, pC1273, DOI 10.1152/ajpcell.00517.2004; Landles C, 2003, MOL ENDOCRINOL, V17, P2418, DOI 10.1210/me.2003-0097; Lau JF, 2003, MOL CELL BIOL, V23, P620, DOI 10.1128/MCB.23.2.620-628.2003; Lewis BA, 2003, J CELL SCI, V116, P3667, DOI 10.1242/jcs.00734; Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Malik S, 2004, MOL CELL BIOL, V24, P8244, DOI 10.1128/MCB.24.18.8244-8254.2004; Martin J, 1999, MOL CELL BIOL, V19, P5548; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Pandey PK, 2005, MOL CELL BIOL, V25, P10695, DOI 10.1128/MCB.25.24.10695-10710.2005; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Rosmarin  AG, 2004, BLOOD CELL MOL DIS, V32, P143, DOI 10.1016/j.bcmd.2003.09.005; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sato S, 2004, MOL CELL, V14, P685, DOI 10.1016/j.molcel.2004.05.006; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Taatjes DJ, 2004, MOL CELL, V14, P675, DOI 10.1016/j.molcel.2004.05.014; Taatjes DJ, 2004, NAT REV MOL CELL BIO, V5, P403, DOI 10.1038/nrm1369; Tanaka M, 2002, J BIOL CHEM, V277, P10719, DOI 10.1074/jbc.M108252200; Tommasi S, 1997, J BIOL CHEM, V272, P30483, DOI 10.1074/jbc.272.48.30483; Wada O, 2004, ONCOGENE, V23, P6000, DOI 10.1038/sj.onc.1207786; Wang QB, 2002, J BIOL CHEM, V277, P42852, DOI 10.1074/jbc.M206061200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang JC, 1999, MOL ENDOCRINOL, V13, P1130, DOI 10.1210/me.13.7.1130; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	45	31	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14691	14699		10.1074/jbc.M600163200	http://dx.doi.org/10.1074/jbc.M600163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16574658	hybrid			2022-12-25	WOS:000237671300022
J	Chen, H; Wei, P; Huang, CK; Tan, L; Liu, Y; Lai, LH				Chen, Hao; Wei, Ping; Huang, Changkang; Tan, Lei; Liu, Ying; Lai, Luhua			Only one protomer is active in the dimer of SARS 3C-like proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE RESPIRATORY SYNDROME; MOLECULAR-DYNAMICS SIMULATIONS; CORONAVIRUS MAIN PROTEINASE; CRYSTAL-STRUCTURES; PROTEASE; DESIGN; DIMERIZATION; INHIBITORS; MECHANISM; REVEALS	The severe acute respiratory syndrome coronavirus 3C-like protease has been proposed to be a key target for structurally based drug design against SARS. The enzyme exists as a mixture of dimer and monomer, and only the dimer was considered to be active. In this report, we have investigated, using molecular dynamics simulation and mutational studies, the problems as to why only the dimer is active and whether both of the two protomers in the dimer are active. The molecular dynamics simulations show that the monomers are always inactive, that the two protomers in the dimer are asymmetric, and that only one protomer is active at a time. The enzyme activity of the hybrid severe acute respiratory syndrome coronavirus 3C-like protease of the wild-type protein and the inactive mutant proves that the dimerization is important for enzyme activity and only one active protomer in the dimer is enough for the catalysis. Our simulations also show that the right conformation for catalysis in one protomer can be induced upon dimer formation. These results suggest that the enzyme may follow the association, activation, catalysis, and dissociation mechanism for activity control.	Peking Univ, Coll Chem, State Key Lab Struct Chem Unstable & Stable Speci, Beijing 100871, Peoples R China; Peking Univ, Ctr Theoret Biol, Beijing 100871, Peoples R China	Chinese Academy of Sciences; Peking University; Peking University	Lai, LH (corresponding author), Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China.	lhlai@pku.edu.cn						Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chen S, 2005, J BIOL CHEM, V280, P164, DOI 10.1074/jbc.M408211200; Chou CY, 2004, BIOCHEMISTRY-US, V43, P14958, DOI 10.1021/bi0490237; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200; Hsu WC, 2005, J BIOL CHEM, V280, P22741, DOI 10.1074/jbc.M502556200; Huang CK, 2004, BIOCHEMISTRY-US, V43, P4568, DOI 10.1021/bi036022q; Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kuang WF, 2005, BIOCHEM BIOPH RES CO, V331, P1554, DOI 10.1016/j.bbrc.2005.04.072; Lee TW, 2005, J MOL BIOL, V353, P1137, DOI 10.1016/j.jmb.2005.09.004; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061; NOSE S, 1984, MOL PHYS, V52, P255, DOI 10.1080/00268978400101201; Pang YP, 2004, PROTEINS, V57, P747, DOI 10.1002/prot.20249; PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693; Shi JH, 2004, J BIOL CHEM, V279, P24765, DOI 10.1074/jbc.M311744200; Tan JZ, 2005, J MOL BIOL, V354, P25, DOI 10.1016/j.jmb.2005.09.012; Wei P, 2006, BIOCHEM BIOPH RES CO, V339, P865, DOI 10.1016/j.bbrc.2005.11.102; Xiong B, 2003, ACTA PHARMACOL SIN, V24, P497; Xu T, 2005, ACTA CRYSTALLOGR F, V61, P964, DOI 10.1107/S1744309105033257; Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324; Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100	30	78	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13894	13898		10.1074/jbc.M510745200	http://dx.doi.org/10.1074/jbc.M510745200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16565086	hybrid, Green Published			2022-12-25	WOS:000237512300009
J	Shen, X; Jun, S; O'Neal, LE; Sonoda, E; Bemark, M; Sale, JE; Li, L				Shen, Xi; Jun, Sohee; O'Neal, Lindsey E.; Sonoda, Eiichiro; Bemark, Mats; Sale, Julian E.; Li, Lei			REV3 and REV1 play major roles in recombination-independent repair of DNA interstrand cross-links mediated by monoubiquitinated proliferating cell nuclear antigen (PCNA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; POLYMERASE-ZETA; MULTIPLE ROLES; PROTEIN; BYPASS; DAMAGE; ETA; TOLERANCE; UBIQUITIN; PATHWAYS	DNA interstrand cross-links (ICLs) are the most cytotoxic lesions to eukaryotic genome and are repaired by both homologous recombination-dependent and -independent mechanisms. To better understand the role of lesion bypass polymerases in ICL repair, we investigated recombination-independent repair of ICLs in REV3 and REV1 deletion mutants constructed in avian DT40 cells and mouse embryonic fibroblast cells. Our results showed that Rev3 plays a major role in recombination-independent ICL repair, which may account for the extreme sensitivity of REV3 mutants to cross-linking agents. This result raised the possibility that the NER gap synthesis, when encountering an adducted base present in the ICL repair intermediate, can lead to recruitment of Rev3, analogous to the recruitment of polymerase eta during replicative synthesis. Indeed, the monoubiquitination-defective proliferating Cell Nuclear Antigen (PCNA) mutant exhibits impaired recombination-independent ICL repair as well as drastically reduced mutation rate, indicating that the PCNA switch is utilized to enable lesion bypass during DNA repair synthesis. Analyses of a REV1 deletion mutant also revealed a significant reduction in recombination-independent ICL repair, suggesting that Rev1 cooperates with Rev3 in recombination-independent ICL repair. Moreover, deletion of REV3 or REV1 significantly altered the spectrum of mutations resulting from ICL repair, further confirming their involvement in mutagenic repair of ICLs.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Kyoto 6068501, Japan; Univ Gothenburg, SE-41346 Gothenburg, Sweden; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Kyoto University; University of Gothenburg; MRC Laboratory Molecular Biology	Li, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.	leili@mdanderson.org	Bemark, Mats/B-2578-2019	Bemark, Mats/0000-0001-7416-9819; Sale, Julian/0000-0002-5031-3780	Medical Research Council [MC_U105178808] Funding Source: Medline; NCI NIH HHS [CA97175, P30 CA16672, CA91029] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091029, P01CA097175, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; MRC [MC_U105178808] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Garg P, 2005, P NATL ACAD SCI USA, V102, P18361, DOI 10.1073/pnas.0505949102; Greenberg RB, 2001, J BIOL CHEM, V276, P31551, DOI 10.1074/jbc.M103588200; Guo CX, 2003, EMBO J, V22, P6621, DOI 10.1093/emboj/cdg626; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; LEMONTT JF, 1971, GENETICS, V68, P21; Murakumo Y, 2006, GENES CELLS, V11, P193, DOI 10.1111/j.1365-2443.2006.00938.x; Murakumo Y, 2001, J BIOL CHEM, V276, P35644, DOI 10.1074/jbc.M102051200; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Nojima K, 2005, CANCER RES, V65, P11704, DOI 10.1158/0008-5472.CAN-05-1214; Okada T, 2005, MOL CELL BIOL, V25, P6103, DOI 10.1128/MCB.25.14.6103-6111.2005; Ross AL, 2005, NUCLEIC ACIDS RES, V33, P1280, DOI 10.1093/nar/gki279; Saffran WA, 2004, J BIOL CHEM, V279, P36462, DOI 10.1074/jbc.M402323200; Sarkar S, 2006, EMBO J, V25, P1285, DOI 10.1038/sj.emboj.7600993; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SLADEK FM, 1989, P NATL ACAD SCI USA, V86, P3982, DOI 10.1073/pnas.86.11.3982; Sonoda E, 2003, EMBO J, V22, P3188, DOI 10.1093/emboj/cdg308; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; Zander L, 2004, DNA REPAIR, V3, P743, DOI 10.1016/j.dnarep.2004.03.031; Zhang YB, 2002, NUCLEIC ACIDS RES, V30, P1630, DOI 10.1093/nar/30.7.1630; Zhang YB, 2002, DNA REPAIR, V1, P559, DOI 10.1016/S1568-7864(02)00055-1; Zheng HY, 2003, MOL CELL BIOL, V23, P754, DOI 10.1128/MCB.23.2.754-761.2003	25	81	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13869	13872		10.1074/jbc.C600071200	http://dx.doi.org/10.1074/jbc.C600071200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16571727	hybrid			2022-12-25	WOS:000237512300006
J	El-Mahdy, MA; Zhu, QZ; Wang, QE; Wani, G; Praetorius-Ibba, M; Wani, AA				El-Mahdy, MA; Zhu, QZ; Wang, QE; Wani, G; Praetorius-Ibba, M; Wani, AA			Cullin 4A-mediated proteolysis of DDB2 protein at DNA damage sites regulates in vivo lesion recognition by XPC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-E; GROUP-E CELLS; CYCLOBUTANE PYRIMIDINE DIMERS; GLOBAL GENOMIC REPAIR; GROUP-C PROTEIN; E GENE-PRODUCT; BINDING-PROTEIN; ESCHERICHIA-COLI; COP9 SIGNALOSOME	Xeroderma pigmentosum ( XP) complementation group E gene product, damaged DNA- binding protein 2 ( DDB2), is a subunit of the DDB heterodimeric protein complex with high specificity for binding to a variety of DNA helix- distorting lesions. DDB is believed to play a role in the initial step of damage recognition in mammalian nucleotide excision repair ( NER) of ultraviolet light ( UV)- induced photolesions. It has been shown that DDB2 is rapidly degraded after cellular UV irradiation. However, the relevance of DDB2 degradation to its functionality in NER is still unknown. Here, we have provided evidence that Cullin 4A ( CUL- 4A), a key component of CUL4A- based ubiquitin ligase, mediates DDB2 degradation at the damage sites and regulates the recruitment of XPC and the repair of cyclobutane pyrimidine dimers. We have shown that CUL- 4A can be identified in a UV- responsive protein complex containing both DDB subunits. CUL- 4A was visualized in localized UV- irradiated sites together with DDB2 and XPC. Degradation of DDB2 could be blocked by silencing CUL- 4A using small interference RNA or by treating cells with proteasome inhibitor MG132. This blockage resulted in prolonged retention of DDB2 at the subnuclear DNA damage foci within micropore irradiated cells. Knock down of CUL- 4A also decreased recruitment of the damage recognition factor, XPC, to the damaged foci and concomitantly reduced the removal of cyclobutane pyrimidine dimers from the entire genome. These results suggest that CUL- 4A mediates the proteolytic degradation of DDB2 and that this degradation event, initiated at the lesion sites, regulates damage recognition by XPC during the early steps of NER.	Ohio State Univ, Dept Radiol, Columbus, OH 43240 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43240 USA; Ohio State Univ, James Canc Hosp, Columbus, OH 43240 USA; Ohio State Univ, Solove Res Inst, Columbus, OH 43240 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Wani, AA (corresponding author), Ohio State Univ, Dept Radiol, 2001 Polaris Pkwy, Columbus, OH 43240 USA.	wani.2@osu.edu	Zhu, Qianzheng/A-4902-2013		NCI NIH HHS [CA93413] Funding Source: Medline; NIEHS NIH HHS [ES12991, R01 ES012991, ES2388] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002388, R01ES012991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Araujo SJ, 2000, GENE DEV, V14, P349; Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Fitch ME, 2003, J BIOL CHEM, V278, P46906, DOI 10.1074/jbc.M307254200; Fitch ME, 2003, DNA REPAIR, V2, P819, DOI 10.1016/S1568-7864(03)00066-1; Ford JM, 1997, CURR TOP MICROBIOL, V221, P47; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; KEENEY S, 1993, J BIOL CHEM, V268, P21293; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Kulaksiz G, 2005, MOL CELL BIOL, V25, P9784, DOI 10.1128/MCB.25.22.9784-9792.2005; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; Matsuda N, 2005, DNA REPAIR, V4, P537, DOI 10.1016/j.dnarep.2004.12.012; Moser J, 2005, DNA REPAIR, V4, P571, DOI 10.1016/j.dnarep.2005.01.001; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Rapic-Otrin V, 2003, HUM MOL GENET, V12, P1507, DOI 10.1093/hmg/ddg174; Rapic-Otrin V, 2002, NUCLEIC ACIDS RES, V30, P2588, DOI 10.1093/nar/30.11.2588; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 2005, CELL, V121, P387, DOI 10.1016/j.cell.2005.02.035; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; TREIBER DK, 1992, NUCLEIC ACIDS RES, V20, P5805, DOI 10.1093/nar/20.21.5805; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Venkatachalam S, 1997, ONCOGENE, V14, P801, DOI 10.1038/sj.onc.1200890; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wakasugi M, 2001, J BIOL CHEM, V276, P15434, DOI 10.1074/jbc.M011177200; Wang QE, 2005, NUCLEIC ACIDS RES, V33, P4023, DOI 10.1093/nar/gki684; Wang QE, 2005, MOL CARCINOGEN, V42, P53, DOI 10.1002/mc.20065; Wang QE, 2004, CARCINOGENESIS, V25, P1033, DOI 10.1093/carcin/bgh085; Wang QE, 2003, DNA REPAIR, V2, P483, DOI 10.1016/S1568-7864(03)00002-8; WANI AA, 1987, PHOTOCHEM PHOTOBIOL, V46, P477, DOI 10.1111/j.1751-1097.1987.tb04798.x; Wittschieben BO, 2005, J BIOL CHEM, V280, P39982, DOI 10.1074/jbc.M507854200; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029	52	118	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13404	13411		10.1074/jbc.M511834200	http://dx.doi.org/10.1074/jbc.M511834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16527807	hybrid			2022-12-25	WOS:000237336600047
J	Iijima, J; Zhao, Y; Isaji, T; Kameyama, A; Nakaya, S; Wang, X; Ihara, H; Cheng, X; Nakagawa, T; Miyoshi, E; Kondo, A; Narimatsu, H; Taniguchi, N; Gu, JG				Iijima, J; Zhao, Y; Isaji, T; Kameyama, A; Nakaya, S; Wang, X; Ihara, H; Cheng, X; Nakagawa, T; Miyoshi, E; Kondo, A; Narimatsu, H; Taniguchi, N; Gu, JG			Cell-cell interaction-dependent regulation of N-acetylglucosaminyltransferase III and the bisected N-glycans in GE11 epithelial cells - Involvement of E-cadherin-mediated cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PROTEIN GLYCOSYLATION; FACTOR RECEPTOR; OLIGOSACCHARIDES; ACTIVATION; EXPRESSION; SUPPRESSION; SURFACE; OVEREXPRESSION	Changes in oligosaccharide structures are associated with numerous physiological and pathological events. In this study, the effects of cell-cell interactions on N-linked oligosaccharides (N-glycans) were investigated in GE11 epithelial cells. N-glycans were purified from whole cell lysates by hydrazinolysis and then detected by high performance liquid chromatography and mass spectrometry. Interestingly, the population of the bisecting GlcNAc-containing N-glycans, the formation of which is catalyzed by N-acetylglucosaminyltransferase III (GnT-III), was substantially increased in cells cultured under dense conditions compared with those cultured under sparse conditions. The expression levels and activities of GnT-III but not other glycosyltransferases, such as GnT-V and alpha 1,6-fucosyltransferase, were also consistently increased in these cells. However, this was not observed in mouse embryonic fibroblasts or MDA-MB231 cells, in which E-cadherin is deficient. In contrast, perturbation of E-cadherin-mediated adhesion by treatment with EDTA or a neutralizing anti-E-cadherin antibody abolished the up-regulation of expression of GnT-III. Furthermore, we observed the significant increase in GnT-III activity under dense growth conditions after restoration of the expression of E-cadherin in MDA-MB231 cells. Our data together indicate that a E-cadherin-dependent pathway plays a critical role in regulation of GnT-III expression. Given the importance of GnT-III and the dynamic regulation of cell-cell interaction during tissue development and homeostasis, the changes in GnT-III expression presumably contribute to intracellular signaling transduction during such processes.	Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Glycotherapeut, Suita, Osaka 5650871, Japan; Tohoku Pharmaceut Univ, Div Regulatory Glycobiol, Sendai, Miyagi 9818558, Japan; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058568, Japan	Osaka University; Osaka University; Tohoku Medical & Pharmaceutical University; National Institute of Advanced Industrial Science & Technology (AIST)	Taniguchi, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Biochem, 2-2 Yamadaoka,B1, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp; jgu@tohoku-pharm.ac.jp	Kameyama, Akihiko/A-9641-2008; Gu, Jianguo/ABC-9257-2020; Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016; Isaji, Tomoya/ABC-9285-2021	Kameyama, Akihiko/0000-0002-8229-4449; Taniguchi, Naoyuki/0000-0001-5889-5968; Ihara, Hideyuki/0000-0003-0490-6355				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Asada M, 1997, CANCER RES, V57, P1073; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Cooper CA, 2001, PROTEOMICS, V1, P340, DOI 10.1002/1615-9861(200102)1:2<340::AID-PROT340>3.0.CO;2-B; Dennis JW, 2002, BBA-GEN SUBJECTS, V1573, P414, DOI 10.1016/S0304-4165(02)00411-7; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; DWEK RA, 1995, BIOCHEM SOC T, V23, P1; FEIGE JJ, 1987, J CELL PHYSIOL, V133, P461, DOI 10.1002/jcp.1041330306; Fukuda M, 2002, BBA-GEN SUBJECTS, V1573, P394, DOI 10.1016/S0304-4165(02)00409-9; Gimond C, 1999, J CELL BIOL, V147, P1325, DOI 10.1083/jcb.147.6.1325; Granovsky M, 2000, NAT MED, V6, P306; Gu JG, 2004, GLYCOBIOLOGY, V14, P177, DOI 10.1093/glycob/cwh016; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; Gu JG, 2004, GLYCOCONJUGATE J, V21, P9, DOI 10.1023/B:GLYC.0000043741.47559.30; Guo HB, 2003, J BIOL CHEM, V278, P52412, DOI 10.1074/jbc.M308837200; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Ihara H, 2002, EUR J BIOCHEM, V269, P193, DOI 10.1046/j.0014-2956.2001.02640.x; Ihara Y, 1997, J BIOL CHEM, V272, P9629; Inamori K, 2004, J BIOL CHEM, V279, P2337, DOI 10.1074/jbc.C300480200; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Kang RJ, 2000, ARCH BIOCHEM BIOPHYS, V374, P52, DOI 10.1006/abbi.1999.1577; Kannagi R, 2001, ADV EXP MED BIOL, V491, P267; Kikuchi N, 2005, BIOINFORMATICS, V21, P1717, DOI 10.1093/bioinformatics/bti152; Kitada T, 2001, J BIOL CHEM, V276, P475, DOI 10.1074/jbc.M006689200; Kobata A, 2000, GLYCOCONJUGATE J, V17, P443, DOI 10.1023/A:1011006122704; LARSSON O, 1993, J CELL SCI, V106, P299; Locascio A, 2001, CURR OPIN GENET DEV, V11, P464, DOI 10.1016/S0959-437X(00)00218-5; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Lowe JB, 2002, BIOCHEM SOC SYMP, V69, P33; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Naven TJP, 1996, RAPID COMMUN MASS SP, V10, P1361, DOI 10.1002/(SICI)1097-0231(199608)10:11<1361::AID-RCM642>3.0.CO;2-A; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; POCHEC E, 2003, BIOCHIM BIOPHYS ACTA, V7, P1; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; SCHACHTER H, 1983, CAN J BIOCHEM CELL B, V61, P1049, DOI 10.1139/o83-134; Shigeta M, 2003, J CELL BIOL, V163, P165, DOI 10.1083/jcb.200301075; SHIRAYOSHI Y, 1983, CELL, V35, P631, DOI 10.1016/0092-8674(83)90095-8; Stanley P, 2002, BBA-GEN SUBJECTS, V1573, P363, DOI 10.1016/S0304-4165(02)00404-X; Sultan AS, 1997, J BIOL CHEM, V272, P2866, DOI 10.1074/jbc.272.5.2866; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Twal WO, 2001, J CELL SCI, V114, P4587; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Yagi T, 2000, GENE DEV, V14, P1169; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754; Zhang WT, 2006, J CELL SCI, V119, P283, DOI 10.1242/jcs.02738	53	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13038	13046		10.1074/jbc.M601961200	http://dx.doi.org/10.1074/jbc.M601961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537539	hybrid			2022-12-25	WOS:000237336600007
J	Wilson, AJ; Byun, DS; Popova, N; Murray, LB; L'Italien, K; Sowa, Y; Arango, D; Velcich, A; Augenlicht, LH; Mariadason, JM				Wilson, AJ; Byun, DS; Popova, N; Murray, LB; L'Italien, K; Sowa, Y; Arango, D; Velcich, A; Augenlicht, LH; Mariadason, JM			Histone deacetylase 3 (HDAC3) and other class IHDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; BUTYRATE-INDUCED DIFFERENTIATION; MEMBRANE GLYCOPROTEIN SYNTHESIS; TRANSCRIPTIONAL REPRESSION; SURFACE MEMBRANE; CARCINOMA-CELLS; GENE PROMOTER; CACO-2 CELLS; SP1 SITES; CLASS-I	Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in clinical trials. Whereas a role for HDAC1 and -2 in mediating components of the HDAC inhibitor response has been reported, the role of HDAC3 is unknown. Here we demonstrate increased protein expression of HDAC3 in human colon tumors and in duodenal adenomas from Apc1638(N/+) mice. HDAC3 was also maximally expressed in proliferating crypt cells in normal intestine. Silencing of HDAC3 expression in colon cancer cell lines resulted in growth inhibition, a decrease in cell survival, and increasedapoptosis. SimilareffectswereobservedforHDAC2and, toa lesser extent, for HDAC1. HDAC3 silencing also selectively induced expression of alkaline phosphatase, amarker of colon cell maturation. Concurrent with its effect on cell growth, overexpression of HDAC3 and other Class I HDACs inhibited basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas silencing of HDAC3 stimulated p21 promoter activity and expression. However, the magnitude of the effects elicited by silencing of individual Class I HDACs was significantly less than that induced by HDAC inhibitors. These findings identify HDAC3 as a gene deregulated in human colon cancer and as a novel regulator of colon cell maturation and p21 expression. These findings also demonstrate that multiple Class I HDACs are involved in repressing p21 and suggest that the growthinhibitory and apoptotic effects induced byHDACinhibitors are probably mediated through the inhibition of multiple HDACs.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kyoto 6028566, Japan; Valle Hebron Hosp Res Inst, Program Funct Genom, Mol Biol & Biochem Res Ctr, Barcelona 08035, Spain	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Kyoto Prefectural University of Medicine; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)	Mariadason, JM (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	jmariada@aecom.yu.edu	Arango, Diego/M-5667-2016; Arango, Diego/AFW-0125-2022; Mariadason, John/N-2003-2013	Arango, Diego/0000-0003-2953-3284; Arango, Diego/0000-0003-2953-3284; Mariadason, John/0000-0001-9123-7684	NATIONAL CANCER INSTITUTE [U01CA088104, R01CA100823] Funding Source: NIH RePORTER; NCI NIH HHS [CA88104-04, CA100823-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Cho YS, 2005, GENOMICS, V86, P606, DOI 10.1016/j.ygeno.2005.07.007; Codina A, 2005, P NATL ACAD SCI USA, V102, P6009, DOI 10.1073/pnas.0500299102; FERRARIS RP, 1992, AM J PHYSIOL, V262, pG1047, DOI 10.1152/ajpgi.1992.262.6.G1047; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guenther MG, 2000, GENE DEV, V14, P1048; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HEERDT BG, 1994, CANCER RES, V54, P3288; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Huang WF, 2006, BIOCHEM BIOPH RES CO, V339, P165, DOI 10.1016/j.bbrc.2005.11.010; Jepsen K, 2002, J CELL SCI, V115, P689; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Litvak DA, 1998, SURGERY, V124, P161, DOI 10.1067/msy.1998.90365; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Mariadason JM, 2003, CANCER RES, V63, P8791; Mariadason JM, 1997, AM J PHYSIOL-GASTR L, V272, pG705, DOI 10.1152/ajpgi.1997.272.4.G705; Mariadason JM, 2001, CANCER RES, V61, P3465; Mariadason JM, 2001, GASTROENTEROLOGY, V120, P889, DOI 10.1053/gast.2001.22472; Mariadason JM, 2000, J CELL PHYSIOL, V183, P347, DOI 10.1002/(SICI)1097-4652(200006)183:3<347::AID-JCP7>3.0.CO;2-W; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Mei SP, 2004, INT J ONCOL, V25, P1509; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Tou LQ, 2004, MOL CELL BIOL, V24, P3132, DOI 10.1128/MCB.24.8.3132-3139.2004; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; WEISER MM, 1973, J BIOL CHEM, V248, P2542; WEISER MM, 1973, J BIOL CHEM, V248, P2536; Yang WC, 2001, CANCER RES, V61, P565; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	44	434	460	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13548	13558		10.1074/jbc.M510023200	http://dx.doi.org/10.1074/jbc.M510023200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533812	hybrid			2022-12-25	WOS:000237336600063
J	Choi, JY; Guengerich, FP				Choi, JY; Guengerich, FP			Kinetic evidence for inefficient and error-prone bypass across bulky N-2-guanine DNA adducts by human DNA polymerase iota	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; STEADY-STATE KINETICS; REPLICATION FIDELITY; NUCLEOTIDE INSERTION; KLENOW FRAGMENT; BASE-PAIR; Y-FAMILY; POL-IOTA; TEMPLATE; EXTENSION	DNA polymerase (pol) iota has been proposed to be involved in translesion synthesis past minor groove DNA adducts via Hoogsteen base pairing. The N2 position of G, located in minor groove side of duplex DNA, is a major site for DNA modification by various carcinogens. Oligonucleotides with varying adduct size at G N2 were analyzed for bypass ability and fidelity with human pol iota. Pol iota effectively bypassed N-2-methyl (Me) G and N-2-ethyl(Et)G, partially bypassed N-2-isobutyl(Ib)G and N-2-benzylG, and was blocked at N-2-CH2(2-naphthyl)G (N-2-NaphG), N-2-CH2(9-anthracenyl)G (N-2-AnthG), and N-2-CH2(6-benzo[a]pyrenyl)G. Steady-state kinetic analysis showed decreases of k(cat)/K-m for dCTP insertion opposite N-2-G adducts according to size, with a maximal decrease opposite N-2-AnthG (61-fold). dTTP misinsertion frequency opposite template G was increased 3-11-fold opposite adducts (highest with N2-NaphG), indicating the additive effect of bulk (or possibly hydrophobicity) on T misincorporation. N-2-IbG, N-2-NaphG, and N-2-AnthG also decreased the pre-steady-state kinetic burst rate compared with unmodified G. High kinetic thio effects (Sp-2'-deoxycytidine 5'-O-(1-thiotriphosphate)) opposite N-2-EtG and N-2-AnthG (but not G) suggest that the chemistry step is largely interfered with by adducts. Severe inhibition of polymerization opposite N-2, N-2-diMeG compared with N-2-EtG by pol eta but not by pol iota is consistent with Hoogsteen base pairing by pol iota. Thus, polymerization by pol iota is severely inhibited by a bulky group at G N2 despite an advantageous mode of Hoogsteen base pairing; pol iota may play a limited role in translesion synthesis on bulky N-2-G adducts in cells.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Aves, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NIEHS NIH HHS [R01 ES10375, P30 ES00267] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R01ES010375] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Bergoglio V, 2002, J CELL SCI, V115, P4413, DOI 10.1242/jcs.00162; Bi XH, 2005, J BIOL CHEM, V280, P22343, DOI 10.1074/jbc.M501562200; BORER PN, 1975, HDB BIOCH MOL BIOL; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; Choi JY, 2005, J MOL BIOL, V352, P72, DOI 10.1016/j.jmb.2005.06.079; Choi JY, 2004, J BIOL CHEM, V279, P19217, DOI 10.1074/jbc.M313759200; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; EARLE CE, 1984, CHEM CARCINOGENS, V1; EARLE CE, 1984, CHEM CARCINOGENS, V2; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; Fang JL, 1997, CARCINOGENESIS, V18, P627, DOI 10.1093/carcin/18.4.627; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Forgacs E, 1997, J BIOL CHEM, V272, P8525, DOI 10.1074/jbc.272.13.8525; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Furge LL, 1998, BIOCHEMISTRY-US, V37, P3567, DOI 10.1021/bi9722094; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; Furge LL, 1999, BIOCHEMISTRY-US, V38, P4818, DOI 10.1021/bi982163u; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Guengerich FP, 2006, CHEM REV, V106, P420, DOI 10.1021/cr0404693; HARRIS CM, 1991, J AM CHEM SOC, V113, P4328, DOI 10.1021/ja00011a044; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kannouche P, 2002, EMBO J, V21, P6246, DOI 10.1093/emboj/cdf618; Kim D, 2005, ANNU REV PHARMACOL, V45, P27, DOI 10.1146/annurev.pharmtox.45.120403.100010; KORNBERG A, 1992, DNA REPUBLICATION; Matsuda T, 1999, BIOCHEMISTRY-US, V38, P929, DOI 10.1021/bi982134j; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Nair DT, 2005, STRUCTURE, V13, P1569, DOI 10.1016/j.str.2005.08.010; Nair DT, 2005, SCIENCE, V309, P2219, DOI 10.1126/science.1116336; Nair DT, 2004, NATURE, V430, P377, DOI 10.1038/nature02692; Ogi T, 2005, J CELL SCI, V118, P129, DOI 10.1242/jcs.01603; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; RIEDBERG E, 2006, DNA REPAI MUTAGENESI; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1999, BIOCHEMISTRY-US, V38, P715, DOI 10.1021/bi981854n; Terashima I, 2001, BIOCHEMISTRY-US, V40, P4106, DOI 10.1021/bi002719p; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005; Wang M, 2004, CANCER RES, V64, P1924, DOI 10.1158/0008-5472.CAN-03-3080; Washington MT, 2004, MOL CELL BIOL, V24, P5687, DOI 10.1128/MCB.24.13.5687-5693.2004; Washington MT, 2004, MOL CELL BIOL, V24, P936, DOI 10.1128/MCB.24.2.936-943.2004; Wolfle WT, 2005, MOL CELL BIOL, V25, P8748, DOI 10.1128/MCB.25.19.8748-8754.2005; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1027, DOI 10.1021/bi011495n; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1039, DOI 10.1021/bi011496f; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yang J, 2004, CANCER RES, V64, P5597, DOI 10.1158/0008-5472.CAN-04-0603; Yasui M, 2001, NUCLEIC ACIDS RES, V29, P1994, DOI 10.1093/nar/29.9.1994; Zang H, 2005, CHEM RES TOXICOL, V18, P389, DOI 10.1021/tx049683c; Zang H, 2005, J BIOL CHEM, V280, P1165, DOI 10.1074/jbc.M405996200; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	60	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12315	12324		10.1074/jbc.M600112200	http://dx.doi.org/10.1074/jbc.M600112200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527824	hybrid			2022-12-25	WOS:000237134700016
J	Hiromasa, Y; Hu, LY; Roche, TE				Hiromasa, Y; Hu, LY; Roche, TE			Ligand-induced effects on pyruvate dehydrogenase kinase isoform 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER LIPOYL DOMAIN; ACETYL-COENZYME-A; DIHYDROLIPOYL ACETYLTRANSFERASE; TRANSACETYLASE COMPONENT; TRYPTOPHAN FLUORESCENCE; PHOSPHATASE ISOFORM-1; ACTIVATED FUNCTION; COMPLEX; BINDING; PROTEIN	Tryptophan fluorescence was used to analyze binding of ligands to human pyruvate dehydrogenase isoform 2 (PDHK2) and to demonstrate effects of ligand binding on distal structure of PDHK2 that is required for binding to the inner lipoyl domain (L2) of the dihydrolipoyl acetyltransferase. Ligand-altered binding of PDHK2 to L2 and effects of specific ligands on PDHK2 oligomeric state were characterized by analytical ultracentrifugation. ATP, ADP, and pyruvate markedly quenched the tryptophan fluorescence of PDHK2 and gave maximum quenching L-0.5 estimates: similar to 53%/3 mu M for ATP; similar to 49%/15 mu M for ADP; and similar to 71%/similar to 590 mu M for pyruvate. The conversion of Trp-383 to phenylalanine completely removed ATP- and ADP-induced quenching and >= 80% of the absolute decrease in fluorescence due to pyruvate. The W383F-PDHK2 mutant retained high catalytic activity. Pyruvate, added after ADP, quenched Trp fluorescence with an L-0.5 of 3.4 mu M pyruvate, >= 150-fold lower concentration than needed with pyruvate alone. ADP-enhanced binding of pyruvate was maintained with W383F-PDHK2. Binding of PDHK2 dimer to L2 is enhanced when L2 are housed in oligomeric structures, including the glutathione S-transferase (GST)-L2 dimer, and further strengthened by reduction of the lipoyl groups (GST-L2(red)) (Hiromasa and Roche (2003) J. Biol. Chem. 278, 33681 - 33693). Binding of PDHK2 to GST-L2(red) was modestly hindered by 200 mu M level of ATP or ADP or 5.0 mM pyruvate; a marked change to nearly complete prevention of binding was observed with ATP or ADP plus pyruvate at only 100 mu M levels, and these conditions caused PDHK2 dimer to associate to a tetramer. These changes should make major contributions to synergistic inhibition of PDHK2 activity by ADP and pyruvate. Ligand-induced changes that interfere with PDHK2 binding to GST-L2(red) may involve release of an interdomain cross arm between PDHK2 subunits in which Trp-383 plays a critical anchoring role.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Roche, TE (corresponding author), Kansas State Univ, Dept Biochem, Willard Hall, Manhattan, KS 66506 USA.	bchter@ksu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK018320, R01DK018320] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18320] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aicher TD, 1999, J MED CHEM, V42, P2741, DOI 10.1021/jm9902584; Baker JC, 2000, J BIOL CHEM, V275, P15773, DOI 10.1074/jbc.M909488199; Bao HY, 2004, BIOCHEMISTRY-US, V43, P13442, DOI 10.1021/bi0494875; Bao HY, 2004, BIOCHEMISTRY-US, V43, P13432, DOI 10.1021/bi049488x; Bowker-Kinley M, 1999, BIOCHEM J, V344, P47, DOI 10.1042/0264-6021:3440047; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Callis PR, 2004, J PHYS CHEM B, V108, P4248, DOI 10.1021/jp0310551; Callis PR, 2003, CHEM PHYS LETT, V369, P409, DOI 10.1016/S0009-2614(02)02046-8; CATE RL, 1978, J BIOL CHEM, V253, P496; CATE RL, 1979, J BIOL CHEM, V254, P1659; Chen GL, 1996, J BIOL CHEM, V271, P28064, DOI 10.1074/jbc.271.45.28064; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; Correia JJ, 2000, METHOD ENZYMOL, V321, P81; Correia JJ, 2001, BIOCHEMISTRY-US, V40, P1473, DOI 10.1021/bi0019343; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Hiromasa Y, 2004, J BIOL CHEM, V279, P6921, DOI 10.1074/jbc.M308172200; Hiromasa Y, 2003, J BIOL CHEM, V278, P33681, DOI 10.1074/jbc.M212733200; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; Kato M, 2005, EMBO J, V24, P1763, DOI 10.1038/sj.emboj.7600663; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; Klyuyeva A, 2005, BIOCHEMISTRY-US, V44, P13573, DOI 10.1021/bi0505868; Knoechel TR, 2006, BIOCHEMISTRY-US, V45, P402, DOI 10.1021/bi051402s; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; LIU TC, 1995, J BIOL CHEM, V270, P15545, DOI 10.1074/jbc.270.26.15545; LOEWENTHAL R, 1991, BIOCHEMISTRY-US, V30, P6775, DOI 10.1021/bi00241a021; ONO K, 1993, J BIOL CHEM, V268, P26135; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PETTIT FH, 1975, BIOCHEM BIOPH RES CO, V65, P575, DOI 10.1016/S0006-291X(75)80185-9; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Popov KM, 1997, FEBS LETT, V419, P197, DOI 10.1016/S0014-5793(97)01453-1; PRATT ML, 1979, BIOCHEM BIOPH RES CO, V91, P289, DOI 10.1016/0006-291X(79)90616-8; PRATT ML, 1979, J BIOL CHEM, V254, P7191; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1985, J BIOL CHEM, V260, P146; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; ROCHE TE, 1989, ANN NY ACAD SCI, V573, P168, DOI 10.1111/j.1749-6632.1989.tb14994.x; Roche TE, 2003, EUR J BIOCHEM, V270, P1050, DOI 10.1046/j.1432-1033.2003.03468.x; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Stafford WF, 2000, METHOD ENZYMOL, V323, P302; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; Steussy CN, 2001, J BIOL CHEM, V276, P37443, DOI 10.1074/jbc.M104285200; Tuganova A, 2005, BIOCHEM J, V387, P147, DOI 10.1042/BJ20040805; Tuganova A, 2002, BIOCHEM J, V366, P129, DOI 10.1042/BJ20020301; Turkan A, 2004, BIOCHEMISTRY-US, V43, P15073, DOI 10.1021/bi048901y; Turkan A, 2002, J BIOL CHEM, V277, P14976, DOI 10.1074/jbc.M108434200; Vivian JT, 2001, BIOPHYS J, V80, P2093, DOI 10.1016/S0006-3495(01)76183-8; Wynn RM, 2000, J BIOL CHEM, V275, P30512, DOI 10.1074/jbc.M005075200; Yang DQ, 1998, J BIOL CHEM, V273, P14130, DOI 10.1074/jbc.273.23.14130	56	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12568	12579		10.1074/jbc.M513514200	http://dx.doi.org/10.1074/jbc.M513514200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517984	hybrid			2022-12-25	WOS:000237134700046
J	Bilsland, LG; Dick, JRT; Pryce, G; Petrosino, S; Di Marzo, V; Baker, D; Greensmith, L				Bilsland, Lynsey G.; Dick, James R. T.; Pryce, Gareth; Petrosino, Stefania; Di Marzo, Vincenzo; Baker, David; Greensmith, Linda			Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice	FASEB JOURNAL			English	Article						motoneuron; WIN55,212-2; endocannabinoids; neurodegeneration; transgenic mice	AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MOUSE MODEL; MOTOR-NEURON DEGENERATION; RECEPTOR KNOCKOUT MICE; RAT MICROGLIAL CELLS; MULTIPLE-SCLEROSIS; PROLONGS SURVIVAL; FAMILIAL ALS; SPINAL-CORD; TNF-ALPHA	Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the selective loss of motoneurons in the spinal cord, brain stem, and motor cortex. However, despite intensive research, an effective treatment for this disease remains elusive. In this study we show that treatment of postsymptomatic, 90-day-old SOD1(G93A) mice with a synthetic cannabinoid, WIN55,212-2, significantly delays disease progression. Furthermore, genetic ablation of the Faah enzyme, which results in raised levels of the endocannabinoid anandamide, prevented the appearance of disease signs in 90-day-old SOD1(G93A) mice. Surprisingly, elevation of cannabinoid levels with either WIN55,212-2 or Faah ablation had no effect on life span. Ablation of the CB(1) receptor, in contrast, had no effect on disease onset in SOD1(G93A) mice but significantly extended life span. Together these results show that cannabinoids have significant neuroprotective effects in this model of ALS and suggest that these beneficial effects may be mediated by non-CB(1) receptor mechanisms.	UCL, Sobell Dept Motor Neurosci & Movement Disorders, Inst Neurol, London WC1N 3BG, England; UCL, Dept Neuroinflammat, Inst Neurol, London WC1N 3BG, England; CNR, Ist Chim Biomol, Endocannabinoid Res Grp, I-80125 Naples, Italy	University of London; University College London; University of London; University College London; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR)	Greensmith, L (corresponding author), UCL, Sobell Dept Motor Neurosci & Movement Disorders, Inst Neurol, Queen Sq, London WC1N 3BG, England.	l.greensmith@ion.ucl.ac.uk	Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abood ME, 2001, NEUROSCI LETT, V309, P197, DOI 10.1016/S0304-3940(01)02065-1; Alexianu ME, 2001, NEUROLOGY, V57, P1282, DOI 10.1212/WNL.57.7.1282; Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cadas H, 1996, J NEUROSCI, V16, P3934; Canton T, 2001, J PHARMACOL EXP THER, V299, P314; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; CUDKOWICZ M, 2004, CONSORTIUM NEALS S2, V5; Culling CFA, 1963, HDB HISTOPATHOLOGICA, V2nd, P362; Di Marzo V, 2000, J NEUROCHEM, V75, P2434, DOI 10.1046/j.1471-4159.2000.0752434.x; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Drachman DB, 2002, ANN NEUROL, V52, P771, DOI 10.1002/ana.10374; Facchinetti F, 2003, GLIA, V41, P161, DOI 10.1002/glia.10177; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hajos N, 2001, NEUROSCIENCE, V106, P1, DOI 10.1016/S0306-4522(01)00287-1; Hall ED, 1998, GLIA, V23, P249, DOI 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hampson AJ, 1998, J NEUROCHEM, V70, P671; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HH, 2002, J NEUROCHEM, V82, P154, DOI 10.1046/j.1471-4159.2002.00961.x; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Kieran D, 2004, NAT MED, V10, P402, DOI 10.1038/nm1021; Kieran D, 2004, NEUROSCIENCE, V125, P427, DOI 10.1016/j.neuroscience.2004.01.046; Klegeris A, 2003, BRIT J PHARMACOL, V139, P775, DOI 10.1038/sj.bjp.0705304; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Maihofner C, 2003, EUR J NEUROSCI, V18, P1527, DOI 10.1046/j.1460-9568.2003.02879.x; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Marsicano G, 2002, J NEUROCHEM, V80, P448, DOI 10.1046/j.0022-3042.2001.00716.x; Massa F, 2004, J CLIN INVEST, V113, P1202, DOI 10.1172/JCI200419465; McGeer PL, 2002, MUSCLE NERVE, V26, P459, DOI 10.1002/mus.10191; Molina-Holgado F, 2003, J NEUROSCI, V23, P6470; MolinaHolgado F, 1997, NEUROREPORT, V8, P1929, DOI 10.1097/00001756-199705260-00027; Nagayama T, 1999, J NEUROSCI, V19, P2987; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pompl PN, 2003, FASEB J, V17, P725, DOI 10.1096/fj.02-0876fje; Pryce G, 2003, BRAIN, V126, P2191, DOI 10.1093/brain/awg224; Puffenbarger RA, 2000, GLIA, V29, P58, DOI 10.1002/(SICI)1098-1136(20000101)29:1<58::AID-GLIA6>3.3.CO;2-N; Raman C, 2004, AMYOTROPH LATERAL SC, V5, P33, DOI 10.1080/14660820310016813; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sharp PS, 2005, NEUROSCIENCE, V130, P897, DOI 10.1016/j.neuroscience.2004.09.069; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; Sugiura T, 2000, BIOCHEM BIOPH RES CO, V271, P654, DOI 10.1006/bbrc.2000.2686; Tikka TM, 2002, BRAIN, V125, P722, DOI 10.1093/brain/awf068; Van Damme P, 2003, NEUROSCI LETT, V343, P81, DOI 10.1016/S0304-3940(03)00314-8; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; WEYDT P, 2003, 2003 ABSTRACT VIEWER; Witting A, 2004, J NEUROCHEM, V89, P1555, DOI 10.1111/j.1471-4159.2004.02544.x; Yasojima K, 2001, NEUROLOGY, V57, P952, DOI 10.1212/WNL.57.6.952; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	53	104	109	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					1003	+		10.1096/fj.05-4743fje	http://dx.doi.org/10.1096/fj.05-4743fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571781				2022-12-25	WOS:000240157700036
J	Servillo, L; Balestrieri, C; Giovane, A; Pari, P; Palma, D; Giannattasio, G; Triggiani, M; Balestrieri, ML				Servillo, Luigi; Balestrieri, Ciro; Giovane, Alfonso; Pari, Paola; Palma, Davide; Giannattasio, Giorgio; Triggiani, Massimo; Balestrieri, Maria Luisa			Lysophospholipid transacetylase in the regulation of PAF levels in human monocytes and macrophages	FASEB JOURNAL			English	Article						PAF; inflammation	PLATELET-ACTIVATING-FACTOR; FACTOR (PAF)-DEPENDENT TRANSACETYLASE; COLONY-STIMULATING FACTOR; FACTOR-ACETYLHYDROLASE; ENDOTHELIAL-CELLS; PROTEIN-KINASE; ALVEOLAR MACROPHAGES; OXIDATIVE STRESS; ACYL ANALOGS; BIOSYNTHESIS	The transacetylase (TA), reported to be identical to platelet-activating factor (PAF) acetylhydrolase (II), is a multifunctional enzyme with three catalytic activities: lysophospholipid transacetylase (TAL), sphingosine transacetylase (TAS), and acetylhydrolase (AH). We report that TAL activity participates in the control of PAF levels in monocytes and macrophages and that its regulation differs in these two types of cells. In monocytes, LPS or granulocyte-macrophage colony-stimulating factor (GM-CSF) specifically increased the TAL activity. Western blot analysis and enzyme assays on immunoprecipitates revealed that the increased activity can be ascribed to PAF-AH (II) and that both translocation from cytosol to membranes and p38/ ERKs-mediated phosphorylation regulate the enzyme activation. Instead, in macrophages differentiated in vitro from monocytes by incubation with FCS, an increase of both TAL and AH activities was observed. Moreover, activation of ERKs and p38 MAP kinase was not required for the up-regulation of PAF-AH (II) in differentiated macrophages. The differences observed in macrophages as compared to monocytes can be explained by 1) p38/ ERKs-independent phosphorylation of PAF-AH (II) and 2) appearance of plasma PAF-AH in the course of macrophage differentiation.	Univ Naples 2, Dept Biochem & Biophys, I-80138 Naples, Italy; Univ Naples Federico II, Div Allergy & Clin Immunol, Naples, Italy	Universita della Campania Vanvitelli; University of Naples Federico II	Balestrieri, C (corresponding author), Univ Naples 2, Dept Biochem & Biophys, Via Le Crecchio 7, I-80138 Naples, Italy.	mluisa.balestrieri@unina2.it	Triggiani, Massimo/K-8271-2016	Triggiani, Massimo/0000-0001-7318-2093; Balestrieri, Maria Luisa/0000-0001-6001-1789; Giovane, Alfonso/0000-0002-2508-2597				AKOH CC, 1990, LIPIDS, V25, P613, DOI 10.1007/BF02536011; ALBERT DH, 1983, J BIOL CHEM, V258, P97; Arai H, 2002, PROSTAG OTH LIPID M, V68-9, P83, DOI 10.1016/S0090-6980(02)00023-0; Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559; Bae KA, 2000, J BIOL CHEM, V275, P26704; Baker PRS, 2002, BBA-MOL CELL RES, V1592, P175, DOI 10.1016/S0167-4889(02)00314-2; Balestrieri ML, 2004, FREE RADICAL BIO MED, V36, P1058, DOI 10.1016/j.freeradbiomed.2004.01.014; Balestrieri ML, 2003, J LIPID RES, V44, P380, DOI 10.1194/jlr.M200292-JLR200; Balestrieri ML, 2000, FEBS LETT, V479, P63, DOI 10.1016/S0014-5793(00)01870-6; Balestrieri ML, 1997, J BIOL CHEM, V272, P17431, DOI 10.1074/jbc.272.28.17431; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bussolati B, 1997, IMMUNOLOGY, V90, P440, DOI 10.1111/j.1365-2567.1997.00440.x; CAMUSSI G, 1983, INT ARCH ALLER A IMM, V70, P245, DOI 10.1159/000233331; Dupuis F, 1996, BBA-MOL CELL RES, V1311, P27, DOI 10.1016/0167-4889(95)00193-X; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; Gaposchkin DP, 1999, J LIPID RES, V40, P495; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; HENSON PM, 1989, AM J RESP CELL MOL, V1, P263, DOI 10.1165/ajrcmb/1.4.263; Jacob SS, 2002, MOL CELL BIOCHEM, V233, P9, DOI 10.1023/A:1015593232347; Karasawa K, 2003, PROG LIPID RES, V42, P93, DOI 10.1016/S0163-7827(02)00049-8; Karasawa K, 1999, J BIOL CHEM, V274, P8655, DOI 10.1074/jbc.274.13.8655; Koch A, 2004, AM J RESP CELL MOL, V30, P342, DOI 10.1165/rcmb.2003-0122OC; Lee TC, 2001, ARCH BIOCHEM BIOPHYS, V387, P41, DOI 10.1006/abbi.2000.2226; LEE TC, 1992, J BIOL CHEM, V267, P19992; LEE TC, 1987, PLATELET ACTIVATING; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; MCMANUS LM, 1993, LAB INVEST, V69, P639; Meja KK, 2000, BRIT J PHARMACOL, V131, P1143, DOI 10.1038/sj.bjp.0703684; Min JH, 2001, BIOCHEMISTRY-US, V40, P4539, DOI 10.1021/bi002600g; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; NAKAGAWA Y, 1992, BIOCHIM BIOPHYS ACTA, V1126, P277, DOI 10.1016/0005-2760(92)90241-M; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Nixon AB, 1999, J BIOL CHEM, V274, P5469, DOI 10.1074/jbc.274.9.5469; Pearson LL, 2001, INT IMMUNOL, V13, P273, DOI 10.1093/intimm/13.3.273; Shindou H, 2005, J IMMUNOL, V175, P1177, DOI 10.4049/jimmunol.175.2.1177; Sodhi A, 2002, J INTERF CYTOK RES, V22, P517, DOI 10.1089/10799900252981990; Tjoelker LW, 2000, BBA-MOL CELL BIOL L, V1488, P102, DOI 10.1016/S1388-1981(00)00114-1; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; Triggiani M, 2000, J IMMUNOL, V164, P4908, DOI 10.4049/jimmunol.164.9.4908; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Winkler JD, 1997, BBA-LIPID LIPID MET, V1346, P173, DOI 10.1016/S0005-2760(97)00032-5; Wittmann M, 2002, J IMMUNOL, V168, P3793, DOI 10.4049/jimmunol.168.8.3793; Wu XQ, 2004, J BIOL CHEM, V279, P36158, DOI 10.1074/jbc.M402454200	46	9	9	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					1015	+		10.1096/fj.05-5059fje	http://dx.doi.org/10.1096/fj.05-5059fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571775				2022-12-25	WOS:000240157700040
J	Bauer, R; Humphries, M; Fassler, R; Winklmeier, A; Craig, SE; Bosserhoff, AK				Bauer, R; Humphries, M; Fassler, R; Winklmeier, A; Craig, SE; Bosserhoff, AK			Regulation of integrin activity by MIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA INHIBITORY-ACTIVITY; MALIGNANT-MELANOMA; ALPHA-4 INTEGRIN; ADHESION; PROTEIN; CELLS; METASTASIS; MIGRATION; CLEAVAGE; INVASION	MIA ( melanoma inhibitory activity) has been identified as a small protein secreted from malignant melanoma cells, which interacts with extracellular matrix proteins including fibronectin. Here, we show that MIA negatively regulates the activity of the mitogen-activated protein kinase pathway in malignant melanoma. Using far Western blotting and co-immunoprecipitation we searched for MIA-binding cell surface proteins. We found that MIA interacts with integrin alpha 4 beta 1 and alpha 5 beta 1, leading to down-regulation of integrin activity and reduction of mitogen-activated protein kinase signaling. These findings also suggest that MIA may play a role in tumor progression and the spread of malignant melanomas via mediating detachment of cells from extracellular matrix molecules by modulating integrin activity. Inhibiting MIA functions in vivo may therefore provide a novel therapeutic strategy for metastatic melanoma disease.	Univ Regensburg, Sch Med, Inst Pathol, D-93053 Regensburg, Germany; Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Regensburg; University of Manchester; Max Planck Society	Bosserhoff, AK (corresponding author), Univ Regensburg, Sch Med, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022	Humphries, Martin/0000-0002-4331-6967; Bosserhoff, Anja/0000-0001-8147-394X				Barazi HO, 2002, J BIOL CHEM, V277, P42859, DOI 10.1074/jbc.M206849200; Bergeron E, 2003, BIOCHEM J, V373, P475, DOI 10.1042/BJ20021630; Bi XN, 2001, J COMP NEUROL, V435, P184, DOI 10.1002/cne.1201; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 2003, LAB INVEST, V83, P1583, DOI 10.1097/01.LAB.0000097191.12477.5D; Bosserhoff AK, 1997, CANCER RES, V57, P3149; Bosserhoff AK, 2001, MELANOMA RES, V11, P417, DOI 10.1097/00008390-200108000-00013; Chun D, 2001, NEUROSCIENCE, V105, P815, DOI 10.1016/S0306-4522(01)00173-7; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, INT ARCH ALLERGY IMM, V106, P323, DOI 10.1159/000236862; Guba M, 2000, BRIT J CANCER, V83, P1216, DOI 10.1054/bjoc.2000.1424; Hartstein ME, 1997, OPHTHAL PLAST RECONS, V13, P227, DOI 10.1097/00002341-199712000-00001; Humphries JD, 2005, J BIOL CHEM, V280, P10234, DOI 10.1074/jbc.M411102200; Hyduk SJ, 2002, J IMMUNOL, V168, P696, DOI 10.4049/jimmunol.168.2.696; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Juliano RL, 2004, BIOCHEM SOC T, V32, P443, DOI 10.1042/BST0320443; Kuphal S, 2005, CANCER METAST REV, V24, P195, DOI 10.1007/s10555-005-1572-1; Lougheed JC, 2001, P NATL ACAD SCI USA, V98, P5515, DOI 10.1073/pnas.091601698; MORETTI S, 1993, MELANOMA RES, V3, P235; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; NARUMIYA S, 1994, INT IMMUNOL, V6, P139, DOI 10.1093/intimm/6.1.139; Nikkola J, 2004, MELANOMA RES, V14, P29, DOI 10.1097/01.cmr.0000114662.02608.a5; Roebroek AJM, 2004, J BIOL CHEM, V279, P53442, DOI 10.1074/jbc.M407152200; Stoll R, 2003, PROTEIN SCI, V12, P510, DOI 10.1110/ps.0222603; Stoll R, 2001, EMBO J, V20, P340, DOI 10.1093/emboj/20.3.340; Stoll R, 2000, J BIOMOL NMR, V17, P87, DOI 10.1023/A:1008306918293; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786	28	47	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11669	11677		10.1074/jbc.M511367200	http://dx.doi.org/10.1074/jbc.M511367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16517605	hybrid			2022-12-25	WOS:000236988100030
J	Foster, KSJ; McCrary, WJ; Ross, JS; Wright, CF				Foster, K. S. J.; McCrary, W. J.; Ross, J. S.; Wright, C. F.			Members of the hSWI/SNF chromatin remodeling complex associate with. and are phosphorylated by protein kinase B/Akt	ONCOGENE			English	Article						hSWI/SNF; INI1; BAF155; Akt	RHABDOID TUMOR-CELLS; BAF COMPLEX; ENDOTHELIAL-CELLS; SWI/SNF COMPLEX; CYCLE ARREST; BRG1; GENES; INI1; AKT; TRANSCRIPTION	In an adenosine triphosphate (ATP)-dependent process, the hSWI/SNF chromatin remodeling complex functions to alter chromatin structure, thereby regulating transcription factor access to DNA. In addition to interactions with transcription factors and recognition of acetylated histone residues, the chromatin remodeling activity of hSWI/SNF has also been shown to respond to a variety of cell signaling pathways. Our results demonstrate a novel interaction between the serine/threonine kinase Akt and members of the hSWI/SNF chromatin remodeling complex. Activation of Akt in HeLa cells resulted in its association with hSWI/SNF subunits: INI1, BAF155 and BAF170, as well as actin. BAF155 became preferentially recognized by an antibody that detects phosphorylated Akt substrates upon activation of Akt, suggesting that BAF155 may be an in vivo target for phosphorylation by Akt. Gtutathione-S-transferase (GST) pulldown experiments demonstrated that INI1 and BAF155 were both capable of directly interacting with Akt. Finally, in vitro kinase assays provided additional evidence that BAF155 and potentially INI1 are substrates for Akt phosphorylation. These data provide the first evidence that Akt signaling may modulate function of the hSWI/SNF complex.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Coll Med, Charleston, SC 29425 USA; Fayetteville State Univ, Dept Nat Sci, Fayetteville, NC USA	Medical University of South Carolina; Medical University of South Carolina; University of North Carolina; Fayetteville State University	Wright, CF (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 165 Ashley Ave,Suite 309,POB 250908, Charleston, SC 29425 USA.	wrightcf@musc.edu		Wright, Cynthia/0000-0003-0442-1665	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007769] Funding Source: NIH RePORTER; NHLBI NIH HHS [T35 HL007769-14] Funding Source: Medline; NIDDK NIH HHS [T32 DK007431-21] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Chai JJ, 2005, CANCER RES, V65, P10192, DOI 10.1158/0008-5472.CAN-05-1896; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Cui KR, 2004, MOL CELL BIOL, V24, P4476, DOI 10.1128/MCB.24.10.4476-4486.2004; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; FRANKE TF, 1999, NEURAL NOTES, V5, P3; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; Liu H, 2002, MOL CELL BIOL, V22, P6471, DOI 10.1128/MCB.22.18.6471-6479.2002; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Pattenden SG, 2002, EMBO J, V21, P1978, DOI 10.1093/emboj/21.8.1978; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Rando OJ, 2002, P NATL ACAD SCI USA, V99, P2824, DOI 10.1073/pnas.032662899; Reincke BS, 2003, J CELL PHYSIOL, V194, P303, DOI 10.1002/jcp.10201; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wu DY, 2002, J BIOL CHEM, V277, P27706, DOI 10.1074/jbc.M200955200; Xu WP, 2003, CANCER RES, V63, P7777; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	45	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4605	4612		10.1038/sj.onc.1209496	http://dx.doi.org/10.1038/sj.onc.1209496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16568092				2022-12-25	WOS:000239457500010
J	Joliot, V; Cormier, F; Medyouf, H; Alcalde, H; Ghysdael, J				Joliot, V.; Cormier, F.; Medyouf, H.; Alcalde, H.; Ghysdael, J.			Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis	ONCOGENE			English	Article						STAT5; p53; leukemia; lymphoma; B lymphocytes; oncogenic cooperation	IN-VIVO; SIGNAL TRANSDUCER; POLYCYTHEMIA-VERA; T-CELLS; MICE; TRANSCRIPTION; PROTEINS; LEUKEMIA; LEUKEMOGENESIS; PHOSPHATASE	Signal transducers and activator of transcription 5 (STAT5) A and B are transcriptional regulators that play a central role in cytokine signaling in the hematopoietic lineage and which are frequently activated in a persistent manner in human leukemia/lymphoma, as assessed by their constitutive tyrosine phosphorylation and DNA-binding activity. To study the intrinsic oncogenic properties of persistent STAT5 activation, we generated transgenic mice in which a constitutively activated point mutant of STAT5A, STAT5A(S711F), was expressed at physiological level in their lymphoid compartment. In this model, persistent STAT5 activation is weakly oncogenic, leading to the late emergence of clonal B-cell lymphoma/leukemia at a low incidence. In contrast, STAT5(S711F) was found to cooperate with the loss of function of the p53 tumor suppressor gene to both accelerate disease onset and to skew the large tumor spectrum that normally characterize p53-deficient mice to strongly favor B-cell lymphoma/leukemia. The emergence of STAT5A(S711F)-induced B-cell tumors is associated with the activation of STAT5 tyrosine phosphorylation and DNA-binding activity, indicating that activation of STAT5 oncogenic properties in transgenic STAT5A (TgSTAT5A) (S711F) mice involves the deregulation of STAT5 phosphorylation dynamics.	Ctr Univ Orsay, CNRS, Inst Curie, UMR 146, F-91405 Orsay, France; Univ Paris 07, UFR Biochim, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Ghysdael, J (corresponding author), Ctr Univ Orsay, CNRS, Inst Curie, UMR 146, Bat 110, F-91405 Orsay, France.	acques.ghysdael@curie.u-psud.fr	GHYSDAEL, Jacques/F-3377-2013	Medyouf, Hind/0000-0003-4652-9455; Cormier, Francoise/0000-0002-6904-5122				Abraham N, 2005, ONCOGENE, V24, P5252, DOI 10.1038/sj.onc.1208726; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Burchill MA, 2003, J IMMUNOL, V171, P5853, DOI 10.4049/jimmunol.171.11.5853; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carron C, 2000, BLOOD, V95, P3891; Chen Y, 2003, J BIOL CHEM, V278, P16520, DOI 10.1074/jbc.M210572200; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Fleming HE, 2004, J IMMUNOL, V173, P2542, DOI 10.4049/jimmunol.173.4.2542; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Goetz CA, 2005, J IMMUNOL, V174, P7753, DOI 10.4049/jimmunol.174.12.7753; Goetz CA, 2004, J IMMUNOL, V172, P4770, DOI 10.4049/jimmunol.172.8.4770; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kang JS, 2004, J IMMUNOL, V173, P2307, DOI 10.4049/jimmunol.173.4.2307; Kelly J, 2003, J IMMUNOL, V170, P210, DOI 10.4049/jimmunol.170.1.210; Kelly JA, 2003, J EXP MED, V198, P79, DOI 10.1084/jem.20021548; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lebigot I, 2003, BLOOD, V102, P4555, DOI 10.1182/blood-2003-06-2077; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Reddy J, 2005, ONCOGENE, V24, P732, DOI 10.1038/sj.onc.1208032; Sambroock J., 1989, MOL CLONING LAB MANU; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; Sommer VH, 2004, LEUKEMIA, V18, P1288, DOI 10.1038/sj.leu.2403385; Sternberg DW, 2004, J CLIN ONCOL, V22, P361, DOI 10.1200/JCO.2004.10.124; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WeberNordt RM, 1996, BLOOD, V88, P809	51	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4573	4584		10.1038/sj.onc.1209480	http://dx.doi.org/10.1038/sj.onc.1209480			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16532027				2022-12-25	WOS:000239457500007
J	Viswanathan, K; Tomiya, N; Park, J; Singh, S; Lee, YC; Palter, K; Betenbaugh, MJ				Viswanathan, Karthik; Tomiya, Noboru; Park, Jung; Singh, Sundeep; Lee, Yuan C.; Palter, Karen; Betenbaugh, Michael J.			Expression of a functional Drosophila melanogaster CMP-sialic acid synthetase - Differential localization of the drosophila and human enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLNEURAMINIC ACID; CELL-ADHESION MOLECULE; PHOSPHATE SYNTHASE GENE; PROTEIN GLYCOSYLATION; BIOSYNTHETIC ABILITY; RECOMBINANT PROTEINS; INSECT CELLS; CLONING; SIGNAL; SEQUENCE	CMP-N-acetylneuraminic acid is a critical metabolite in the generation of glycoconjugates that play a role in development and other physiological processes. Whereas pathways for its generation are firmly established in vertebrates, the presence and function of the relevant synthetic enzyme in insects and other protostomes is unknown. In this study, we characterize the first functional CMP-sialic acid synthase (DmCSAS) from any protostome lineage expressed from a D. melanogaster cDNA clone. Homologous genes were subsequently identified in other insect species. The gene is developmentally regulated, with expression first appearing at 12 - 24 h of embryogenesis, low expression through larval and pupal stages, and greatly enriched expression in the adult head, suggesting a possible role in the central nervous system. Activity of the enzyme was verified by an increase in in vitro and in vivo CMP-N-acetylneuraminic acid levels when expressed in a heterologous host. Unlike all known vertebrate CMP-sialic acid synthetase (CSAS) proteins that localize to the nucleus, the D. melanogaster CSAS protein was targeted to the Golgi compartment when expressed in both heterologous mammalian and insect cell lines. Replacement of the N-terminal leader sequence of DmCSAS with the human CSAS N-terminal sequence resulted in the redirection of the chimeric CSAS protein to the nucleus but with a concomitant loss of enzymatic activity. The localization of CSAS orthologs to different intracellular organelles represents, to our knowledge, the first example of differential protein targeting of orthologs in eukaryotes and reveals how the sialylation pathway diverged during the evolution of protostomes and deuterostomes.	Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Temple Univ, Dept Biol, Philadelphia, PA 19122 USA	Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Betenbaugh, MJ (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, MD221,3400 N Charles St, Baltimore, MD 21218 USA.	beten@jhu.edu	Betenbaugh, Michael J./A-3252-2010	Betenbaugh, Michael J./0000-0002-6336-4659				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Aoki K, 2003, J BIOL CHEM, V278, P22887, DOI 10.1074/jbc.M302620200; Aumiller JJ, 2003, GLYCOBIOLOGY, V13, P497, DOI 10.1093/glycob/cwg051; Aumiller JJ, 2002, PROTEIN EXPRES PURIF, V26, P438, DOI 10.1016/S1046-5928(02)00550-8; Chen H, 2002, GLYCOBIOLOGY, V12, P65, DOI 10.1093/glycob/12.2.65; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P196; CUNNINGHAM BA, 1983, P NATL ACAD SCI-BIOL, V80, P3116, DOI 10.1073/pnas.80.10.3116; DAMICO P, 1995, TISSUE CELL, V27, P23, DOI 10.1016/S0040-8166(95)80005-0; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Effertz K, 1999, J BIOL CHEM, V274, P28771, DOI 10.1074/jbc.274.40.28771; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fukuda M, 1996, CANCER RES, V56, P2237; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; KEAN E L, 1991, Glycobiology, V1, P441, DOI 10.1093/glycob/1.5.441; Kean EL, 2004, BBA-GEN SUBJECTS, V1673, P56, DOI 10.1016/j.bbagen.2004.04.006; Kim K, 2002, GLYCOBIOLOGY, V12, P73, DOI 10.1093/glycob/12.2.73; Kiss JZ, 2001, REV NEUROSCIENCE, V12, P297; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; Krapp S, 2003, J MOL BIOL, V334, P625, DOI 10.1016/j.jmb.2003.09.080; Lawrence SM, 2000, J BIOL CHEM, V275, P17869, DOI 10.1074/jbc.M000217200; Lawrence SM, 2001, GLYCOCONJUGATE J, V18, P205, DOI 10.1023/A:1012452705349; Malykh YN, 1999, GLYCOCONJUGATE J, V16, P731, DOI 10.1023/A:1007115627708; Marchal I, 2001, BIOL CHEM, V382, P151, DOI 10.1515/BC.2001.023; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; Mosimann SC, 2001, J BIOL CHEM, V276, P8190, DOI 10.1074/jbc.M007235200; Munster AK, 2002, J BIOL CHEM, V277, P19688, DOI 10.1074/jbc.M201093200; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nielsen H, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P122; Palomares LA, 2003, BIOTECHNOL PROGR, V19, P185, DOI 10.1021/bp025598o; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; Potvin B, 1995, J BIOL CHEM, V270, P30415, DOI 10.1074/jbc.270.51.30415; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; Segawa H, 2002, EUR J BIOCHEM, V269, P128, DOI 10.1046/j.0014-2956.2001.02632.x; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; Stroud RM, 1999, CURR OPIN STRUC BIOL, V9, P754, DOI 10.1016/S0959-440X(99)00040-8; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; Tomiya N, 2001, ANAL BIOCHEM, V293, P129, DOI 10.1006/abio.2001.5091; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vimr ER, 2004, MICROBIOL MOL BIOL R, V68, P132, DOI 10.1128/MMBR.68.1.132-153.2004; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; WARREN L, 1963, COMP BIOCHEM PHYSIOL, V10, P153, DOI 10.1016/0010-406X(63)90238-X; Watanabe S, 2002, J BIOL CHEM, V277, P5090, DOI 10.1074/jbc.M110548200; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; [No title captured]	51	31	31	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15929	15940		10.1074/jbc.M512186200	http://dx.doi.org/10.1074/jbc.M512186200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16537535	hybrid			2022-12-25	WOS:000237996000044
J	Huddleson, JP; Ahmad, N; Lingrel, JB				Huddleson, Justin P.; Ahmad, Nisar; Lingrel, Jerry B.			Up-regulation of the KLF2 transcription factor by fluid shear stress requires nucleolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR-2; MESSENGER-RNA; BINDING-PROTEIN; GENE-EXPRESSION; DNA; IDENTIFICATION; CELLS; INHIBITION; FLOW; LKLF	We have previously characterized the regulation of the KLF2 transcription factor gene by describing an induction complex that binds to and regulates its promoter. In the present study, by using DNA affinity chromatography and mass spectrometry, we have identified nucleolin as an additional protein that binds to a palindromic response region in the KLF2 promoter. The presence of nucleolin on the KLF2 promoter in macrophages was verified by electrophoretic mobility shift assays. Interestingly, in mouse and human endothelial cell lines, electrophoretic mobility shift assays and chromatin immunoprecipitation analyses indicated that nucleolin binds the KLF2 promoter only upon application of fluid shear stress. Pretreatment of the endothelial cells with LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3K), blocked the shear stress-induced binding of nucleolin to the promoter, demonstrating its PI3K-dependent regulation. Additionally, nucleolin exhibited dynamic flow-specific, PI3K-dependent alterations in size. Anti-nucleolin antibodies interacted with a 110-kDa form in static endothelial cells and with several catalytic forms that changed in abundance after the application of shear stress. Immunoprecipitation experiments demonstrated that fluid flow induced the interaction of nucleolin with the p85 regulatory subunit of PI3K. Finally, introduction of small interfering RNAs targeting the nucleolin genetic sequence selectively reduced nucleolin expression and was sufficient to block the induction of KLF2 by shear stress. These data support a general role for nucleolin in gene regulation and identify it as a novel factor involved in regulation of KLF2 expression.	Univ Cincinnati, Coll Med, Ctr Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Ctr Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jerry.lingrel@uc.edu			NHLBI NIH HHS [R01 HL57281] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad N, 2005, BIOCHEMISTRY-US, V44, P6276, DOI 10.1021/bi050018s; ASAKURA T, 1990, CIRC RES, V66, P1045, DOI 10.1161/01.RES.66.4.1045; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Barel M, 2001, J IMMUNOL, V166, P3167, DOI 10.4049/jimmunol.166.5.3167; Basu P, 2005, BLOOD, V106, P2566, DOI 10.1182/blood-2005-02-0674; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Bicknell K, 2005, BIOCHEM BIOPH RES CO, V332, P817, DOI 10.1016/j.bbrc.2005.05.022; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Chen CY, 2000, GENE DEV, V14, P1236; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Dekker RJ, 2005, AM J PATHOL, V167, P609, DOI 10.1016/S0002-9440(10)63002-7; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; ERARD M, 1990, EUR J BIOCHEM, V191, P19, DOI 10.1111/j.1432-1033.1990.tb19088.x; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Gilchrist JSC, 2002, J CELL BIOCHEM, V85, P268, DOI 10.1002/jcb.10121; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Harms G, 2001, BIOCHEM J, V360, P531, DOI 10.1042/0264-6021:3600531; Huddleson JP, 2005, J BIOL CHEM, V280, P23371, DOI 10.1074/jbc.M413839200; Huddleson JP, 2004, BIOL CHEM, V385, P723, DOI 10.1515/BC.2004.088; Ito T, 2003, MOL CELL BIOCHEM, V247, P75, DOI 10.1023/A:1024184116764; Kito S, 2003, BIOCHEM BIOPH RES CO, V300, P950, DOI 10.1016/S0006-291X(02)02942-X; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; Kumar A, 2005, MOL CELL BIOL, V25, P5893, DOI 10.1128/MCB.25.14.5893-5903.2005; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Lin CT, 1997, NUCLEIC ACIDS RES, V25, P3009, DOI 10.1093/nar/25.15.3009; Lin ZY, 2005, CIRC RES, V96, pE48, DOI 10.1161/01.RES.0000159707.05637.a1; Morimoto H, 2002, J HISTOCHEM CYTOCHEM, V50, P1187, DOI 10.1177/002215540205000905; Parmar KM, 2005, J BIOL CHEM, V280, P26714, DOI 10.1074/jbc.C500144200; Pearson CE, 1996, J CELL BIOCHEM, V63, P1; Schrick JJ, 1999, GENE, V236, P185, DOI 10.1016/S0378-1119(99)00235-8; Sen-Banerjee S, 2005, CIRCULATION, V112, P720, DOI 10.1161/CIRCULATIONAHA.104.525774; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Sohn SJ, 2005, MOL CELL BIOL, V25, P8553, DOI 10.1128/MCB.25.19.8553-8566.2005; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Tricot O, 2000, CIRCULATION, V101, P2450, DOI 10.1161/01.CIR.101.21.2450; Tuteja N, 1997, BIOCHEM BIOPH RES CO, V236, P636, DOI 10.1006/bbrc.1997.7021; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; Wadkins RM, 2000, CURR MED CHEM, V7, P1; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Wani MA, 1999, GENOMICS, V60, P78, DOI 10.1006/geno.1999.5888; Wasserman SM, 2002, PHYSIOL GENOMICS, V12, P13, DOI 10.1152/physiolgenomics.00102.2002; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; Wu JH, 2005, BIOCHEMISTRY-US, V44, P11098, DOI 10.1021/bi050166i; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Wu JH, 2005, J IMMUNOL, V175, P3060, DOI 10.4049/jimmunol.175.5.3060; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007	55	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15121	15128		10.1074/jbc.M513406200	http://dx.doi.org/10.1074/jbc.M513406200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16571724	hybrid			2022-12-25	WOS:000237922200014
J	Shigi, N; Sakaguchi, Y; Suzuki, T; Watanabe, K				Shigi, Naoki; Sakaguchi, Yuriko; Suzuki, Tsutomu; Watanabe, Kimitsuna			Identification of two tRNA thiolation genes required for cell growth at extremely high temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; THERMUS-THERMOPHILUS HB8; PSI-C LOOP; ESCHERICHIA-COLI; CYSTEINE DESULFURASE; CRYSTAL-STRUCTURE; POSTTRANSCRIPTIONAL MODIFICATION; PSEUDOURIDINE SYNTHASE; THIAMIN BIOSYNTHESIS; NUCLEOSIDES PRESENT	Thermostability of tRNA in thermophilic bacteria is effected by post-transcriptional modifications, such as 2-thioribothymidine (s2T) at position 54. Using a proteomics approach, we identified two genes (ttuA and ttuB; tRNA-two-thiouridine) that are essential for the synthesis of s(2)T in Thermus thermophilus. Mutation of either gene completely abolishes thio-modification of s2T, and these mutants exhibit a temperature-sensitive phenotype. These results suggest that bacterial growth at higher temperatures is achieved through the thermal stabilization of tRNA by a 2-thiolation modification. TtuA (TTC0106) is possibly an ATPase possessing a P-loop motif. TtuB (TTC0105) is a putative thio-carrier protein that exhibits significant sequence homology with ThiS of the thiamine synthesis pathway. Both TtuA and TtuB are required for in vitro s2T formation in the presence of cysteine and ATP. The addition of cysteine desulfurases such as IscS (TTC0087) or SufS (TTC1373) enhances the sulfur transfer reaction in vitro.	Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan; Univ Tokyo, Dept Chem & Biotechnol, Grad Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Watanabe, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, 2-42 Aomi, Tokyo 1350064, Japan.	kwatanab@jbirc.aist.go.jp	Suzuki, Tsutomu/J-1776-2015; Shigi, Naoki/L-7135-2018	Suzuki, Tsutomu/0000-0002-9731-1731; Shigi, Naoki/0000-0003-4452-8264				Bishop AC, 2002, J BIOL CHEM, V277, P25090, DOI 10.1074/jbc.M203208200; BORK P, 1994, PROTEINS, V20, P347, DOI 10.1002/prot.340200407; De Bie LGS, 2003, J BACTERIOL, V185, P3238, DOI 10.1128/JB.185.10.3238-3243.2003; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; Droogmans L, 2003, NUCLEIC ACIDS RES, V31, P2148, DOI 10.1093/nar/gkg314; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; Hori H, 2002, GENES CELLS, V7, P259, DOI 10.1046/j.1365-2443.2002.00520.x; HORIE N, 1985, BIOCHEMISTRY-US, V24, P5711, DOI 10.1021/bi00342a004; Hoseki J, 1999, J BIOCHEM-TOKYO, V126, P951, DOI 10.1093/oxfordjournals.jbchem.a022539; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; Ikeuchi Y, 2005, MOL CELL, V19, P235, DOI 10.1016/j.molcel.2005.06.007; Jager G, 2004, J BACTERIOL, V186, P750, DOI 10.1128/JB.186.3.750-757.2004; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; Kaya Y, 2003, RNA, V9, P711, DOI 10.1261/rna.5230603; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; KOYAMA Y, 1986, J BACTERIOL, V166, P338, DOI 10.1128/jb.166.1.338-340.1986; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Legge GB, 2004, J MOL BIOL, V343, P1081, DOI 10.1016/j.jmb.2004.08.087; Leipuviene R, 2004, J BACTERIOL, V186, P758, DOI 10.1128/JB.186.3.758-766.2004; Leon S, 2003, BIOCHEM J, V371, P823, DOI 10.1042/BJ20021946; Loiseau L, 2005, J BIOL CHEM, V280, P26760, DOI 10.1074/jbc.M504067200; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; Mueller EG, 1999, PROTEIN SCI, V8, P2424; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; NURSE K, 1995, RNA, V1, P102; Ortenberg R, 2003, ANTIOXID REDOX SIGN, V5, P403, DOI 10.1089/152308603768295140; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; Park JH, 2003, BIOCHEMISTRY-US, V42, P12430, DOI 10.1021/bi034902z; Pines J, 2005, NAT CELL BIOL, V7, P731, DOI 10.1038/ncb0805-731; Rizzi M, 2002, CURR OPIN STRUC BIOL, V12, P709, DOI 10.1016/S0959-440X(02)00385-8; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; Settembre E, 2003, CURR OPIN STRUC BIOL, V13, P739, DOI 10.1016/j.sbi.2003.10.006; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shigi N, 2006, J BIOL CHEM, V281, P2104, DOI 10.1074/jbc.M510771200; Shigi N, 2002, J BIOL CHEM, V277, P39128, DOI 10.1074/jbc.M207323200; Soma A, 2003, MOL CELL, V12, P689, DOI 10.1016/S1097-2765(03)00346-0; Stefankova P, 2005, GEN PHYSIOL BIOPHYS, V24, P3; TAKADA T, 1993, APPL ENVIRON MICROB, V59, P2737, DOI 10.1128/AEM.59.8.2737-2739.1993; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Urbonavicius J, 2005, NUCLEIC ACIDS RES, V33, P3955, DOI 10.1093/nar/gki703; WATANABE K, 1976, BIOCHEM BIOPH RES CO, V72, P1137, DOI 10.1016/S0006-291X(76)80250-1; WATANABE K, 1984, J BIOCHEM-TOKYO, V96, P1625, DOI 10.1093/oxfordjournals.jbchem.a134993; WATANABE K, 1974, FEBS LETT, V43, P59, DOI 10.1016/0014-5793(74)81105-1; WATANABE K, 1979, BIOCHEM BIOPH RES CO, V91, P671, DOI 10.1016/0006-291X(79)91574-2; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yokoyama S, 1987, Adv Biophys, V23, P115, DOI 10.1016/0065-227X(87)90006-2	53	52	56	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14296	14306		10.1074/jbc.M511675200	http://dx.doi.org/10.1074/jbc.M511675200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16547008	hybrid			2022-12-25	WOS:000237512300055
J	Azuma, M; Toyama, R; Laver, E; Dawid, IB				Azuma, M; Toyama, R; Laver, E; Dawid, IB			Perturbation of rRNA synthesis in the bap28 mutation leads to apoptosis mediated by p53 in the zebrafish central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DYSKERATOSIS-CONGENITA; EMBRYONIC-DEVELOPMENT; XENOPUS-LAEVIS; PRE-RIBOSOMES; DANIO-RERIO; PROTEIN; GENES; BIOGENESIS; YEAST	Zebrafish is a powerful vertebrate model system for using forward genetics to elucidate mechanisms of early development. We have used chemical mutagenesis to screen for mutants that show defects in the CNS. Here we describe the isolation of the bap28 mutation that leads to abnormalities in the brain starting at mid-somitogenesis stages. Mutant embryos display excess apoptosis primarily in the central nervous system ( CNS) and die by days 6 - 7 after fertilization. The mutation was positionally cloned and shown to affect a gene that encodes a large protein with high similarity to the uncharacterized human protein BAP28 and lower similarity to yeast Utp10. Utp10 is a component of a nucleolar U3 small nucleolar RNA-containing RNP complex that is required for transcription of ribosomal DNA and for processing of 18 S rRNA. We show that zebrafish Bap28 likewise is required for rRNA transcription and processing, with a major effect on 18 S rRNA maturation. We suggest that bap28 is required for cell survival in the CNS through its role in rRNA synthesis and processing. Inhibition of p53 protein expression in bap28 mutants led to embryos with morphologically normal appearance, suggesting that p53 is involved in triggering apoptosis in the bap28 mutant CNS. The bap28 mutation provides a genetic approach to study the role of ribosome biogenesis in the development of a vertebrate embryo.	NICHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dawid, IB (corresponding author), NICHD, Mol Genet Lab, NIH, 9000 Rockville Pike Bldg,6B Rm 413, Bethesda, MD 20892 USA.	idawid@nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008809, ZIAHD001002] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008809, Z01HD001002] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abdelilah S, 1996, DEVELOPMENT, V123, P217; Adams CC, 2002, RNA, V8, P150, DOI 10.1017/S1355838202010026; ALLENDE ML, 1994, DEV BIOL, V166, P509, DOI 10.1006/dbio.1994.1334; Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Ando H, 1998, NEUROSCI LETT, V244, P81, DOI 10.1016/S0304-3940(98)00132-3; Brittis PA, 2002, CELL, V110, P223, DOI 10.1016/S0092-8674(02)00813-9; BROWN DD, 1968, SCIENCE, V160, P272, DOI 10.1126/science.160.3825.272; BROWN DD, 1964, P NATL ACAD SCI USA, V51, P139, DOI 10.1073/pnas.51.1.139; Cole LK, 2001, DEV BIOL, V240, P123, DOI 10.1006/dbio.2001.0432; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; DAWID IB, 1988, SCIENCE, V240, P1443, DOI 10.1126/science.3287620; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Gallagher JEG, 2004, GENE DEV, V18, P2506, DOI 10.1101/gad.1226604; Gerbi SA, 2003, CURR OPIN CELL BIOL, V15, P318, DOI 10.1016/S0955-0674(03)00049-8; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Granneman S, 2004, EXP CELL RES, V296, P43, DOI 10.1016/j.yexcr.2004.03.016; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Kawahara A, 2001, CURR BIOL, V11, P1353, DOI 10.1016/S0960-9822(01)00398-0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KIRKLAND DJ, 1983, MUTAT RES, V116, P73, DOI 10.1016/0165-1218(83)90098-8; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; Korzh V, 1998, DEV DYNAM, V213, P92, DOI 10.1002/(SICI)1097-0177(199809)213:1<92::AID-AJA9>3.0.CO;2-T; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Lekven AC, 2000, PHYSIOL GENOMICS, V2, P37, DOI 10.1152/physiolgenomics.2000.2.2.37; Matsuda N, 2004, DEVELOPMENT, V131, P1913, DOI 10.1242/dev.01085; MILLER OL, 1969, SCIENCE, V164, P955, DOI 10.1126/science.164.3882.955; Nechiporuk A, 1999, GENOME RES, V9, P1231, DOI 10.1101/gr.9.12.1231; Oeffinger M, 2004, GENE DEV, V18, P196, DOI 10.1101/gad.285604; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Postlethwait JH, 1997, TRENDS GENET, V13, P183, DOI 10.1016/S0168-9525(97)01129-3; Roman BL, 2002, DEVELOPMENT, V129, P3009; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Steward O, 2002, CELL, V110, P537, DOI 10.1016/S0092-8674(02)00934-0; Strahle U, 1996, INT J DEV BIOL, V40, P929; TRAPMAN J, 1976, BIOCHIM BIOPHYS ACTA, V442, P275, DOI 10.1016/0005-2787(76)90302-6; TRAPMAN J, 1976, BIOCHIM BIOPHYS ACTA, V442, P265, DOI 10.1016/0005-2787(76)90301-4; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker C, 1999, METHOD CELL BIOL, V60, P43; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381	51	68	70	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13309	13316		10.1074/jbc.M601892200	http://dx.doi.org/10.1074/jbc.M601892200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531401	hybrid			2022-12-25	WOS:000237336600036
J	Wendholt, D; Spilker, C; Schmitt, A; Dolnik, A; Smalla, KH; Proepper, C; Bockmann, J; Sobue, K; Gundelfinger, ED; Kreutz, MR; Boeckers, TM				Wendholt, D; Spilker, C; Schmitt, A; Dolnik, A; Smalla, KH; Proepper, C; Bockmann, J; Sobue, K; Gundelfinger, ED; Kreutz, MR; Boeckers, TM			ProSAP-interacting protein 1 (ProSAPiP1), a novel protein of the postsynaptic density that links the spine-associated rap-gap (SPAR) to the scaffolding protein ProSAP2/Shank3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHANK FAMILY; PDZ DOMAINS; SYNAPTIC PROTEINS; BINDING-PROTEIN; RECEPTOR; EXPRESSION; BRAIN; GENE; LOCALIZATION; PSD-ZIP70	ProSAPs/ Shanks are a family of proteins that have a major scaffolding function for components of the postsynaptic density ( PSD) of excitatory brain synapses. Members of the family harbor a variety of domains for protein- protein interactions, one of which is a unique PDZ domain that differs significantly from those of other proteins. We have identified a novel binding partner for this PDZ domain, termed ProSAPiP1, that is highly enriched in the PSD and shares significant sequence homology with the PSD protein PSDZip70. Both molecules code for a Fez1 domain that can be found in a total of four related proteins. ProSAPiP1 is widely expressed in rat brain and co- localizes with ProSAP2/ Shank3 in excitatory spines and synapses. ProSAP2/ Shank3 co- immunoprecipitates with ProSAPiP1 but not with PSD- Zip70. Both proteins, however, bind and recruit SPAR to synapses with a central coiled- coil region that harbors a leucine zipper motif. This region is also responsible for homo- and heteromultimerization of ProSAPiP1 and PSD- Zip70. Thus, ProSAPiP1 and PSD- Zip70 are founders of a novel family of scaffolding proteins, the " Fezzins," which adds further complexity to the organization of the PSD protein network.	Univ Ulm, Inst Anat & Cell Biol, D-89081 Ulm, Germany; AG Mol Mechanisms Plast, Leibniz Inst Neurobiol, Dept Neurochem Mol Biol, D-39118 Magdeburg, Germany; Osaka Univ, Sch Med, Dept Neurosci, Suita, Osaka 565, Japan	Ulm University; Leibniz Institut fur Neurobiologie (LIN); Osaka University	Kreutz, MR (corresponding author), Univ Ulm, Inst Anat & Cell Biol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	michael.kreutz@ifn-magdeburg.de; tobias.boeckers@uni-ulm.de	Smalla, Dr. Karl-Heinz/C-3950-2012	Smalla, Dr. Karl-Heinz/0000-0002-0269-0311; Spilker, Christina/0000-0002-7996-7673; Dolnik, Anna/0000-0003-4166-2900				Baron MK, 2006, SCIENCE, V311, P531, DOI 10.1126/science.1118995; Bockers TM, 2001, J BIOL CHEM, V276, P40104, DOI 10.1074/jbc.M102454200; Boeckers TM, 1999, BIOCHEM BIOPH RES CO, V264, P247, DOI 10.1006/bbrc.1999.1489; Boeckers TM, 2005, J NEUROCHEM, V92, P519, DOI 10.1111/j.1471-4159.2004.02910.x; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P6707, DOI 10.1038/sj.onc.1204866; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Harris BZ, 2001, J CELL SCI, V114, P3219; Helmuth M, 2001, ANAL BIOCHEM, V293, P149, DOI 10.1006/abio.2001.5107; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Konno D, 2002, J CELL SCI, V115, P4695, DOI 10.1242/jcs.00127; Kreienkamp HJ, 2000, J BIOL CHEM, V275, P32387, DOI 10.1074/jbc.C000490200; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; Laube G, 2002, MOL CELL NEUROSCI, V19, P459, DOI 10.1006/mcne.2001.1078; Li KW, 2004, J BIOL CHEM, V279, P987, DOI 10.1074/jbc.M303116200; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Maruoka H, 2005, J NEUROSCI, V25, P1421, DOI 10.1523/JNEUROSCI.3920-04.2005; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Olson PA, 2005, J NEUROSCI, V25, P1050, DOI 10.1523/JNEUROSCI.3327-04.2005; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; Perez AS, 1998, NEUROSCI LETT, V258, P121, DOI 10.1016/S0304-3940(98)00846-5; Roussignol G, 2005, J NEUROSCI, V25, P3560, DOI 10.1523/JNEUROSCI.4354-04.2005; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Seidenbecher CI, 1998, J BIOL CHEM, V273, P21324, DOI 10.1074/jbc.273.33.21324; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Tadokoro S, 1999, P NATL ACAD SCI USA, V96, P13801, DOI 10.1073/pnas.96.24.13801; Tobaben S, 2000, J BIOL CHEM, V275, P36204, DOI 10.1074/jbc.M006448200; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Woolfson DN, 2005, ADV PROTEIN CHEM, V70, P79, DOI 10.1016/S0065-3233(04)70004-2; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463; Zhang H, 2005, J NEUROSCI, V25, P1037, DOI 10.1523/JNEUROSCI.4554-04.2005; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	43	43	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13805	13816		10.1074/jbc.M601101200	http://dx.doi.org/10.1074/jbc.M601101200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16522626	hybrid			2022-12-25	WOS:000237336600091
J	Douchin, V; Bohn, C; Bouloc, P				Douchin, V; Bohn, C; Bouloc, P			Down-regulation of porins by a small RNA bypasses the essentiality of the regulated intramembrane proteolysis protease RseP in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACYTOPLASMIC-STRESS-RESPONSE; OUTER-MEMBRANE PROTEINS; ANTI-SIGMA FACTOR; NONCODING RNAS; COMPARATIVE GENOMICS; ANTISENSE RNA; PDZ DOMAIN; GENE; IDENTIFICATION; INHIBITION	Adaptation to extracytoplasmic stress in Escherichia coli depends on the activation of sigma(E), normally sequestered by the membrane protein RseA. sigma(E) is released in response to stress through the successive RseA cleavage by DegS and the RIP protease RseP. sigma(E) and proteases that free it from RseA are essential. We isolated a multicopy suppressor that alleviated RseP and DegS requirement. The suppressor encodes a novel small RNA, RseX. Its activity required the RNA-binding protein Hfq. We used the property that small RNAs are often involved in RNA-RNA interactions to capture RseX putative partners; ompA and ompC mRNA, which encode two major outer membrane proteins, were identified. RseX activity was shown to confer an Hfq-dependent coordinate OmpA and OmpC down-regulation. Because RseP is shown to be no longer essential in a strain lacking OmpA and OmpC, we conclude that RseP, which is required for normal sigma(E) activation, prevents toxicity due to the presence of two specific outer membrane proteins that are down-regulated by RseX.	Univ Paris Sud, Inst Genet & Microbiol, Signalisat & Reseaux Regulat Bacteriens, CNRS,UMR 8621,IFR115,Ctr Sci Orsay, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Bouloc, P (corresponding author), Univ Paris Sud, Inst Genet & Microbiol, Signalisat & Reseaux Regulat Bacteriens, CNRS,UMR 8621,IFR115,Ctr Sci Orsay, Batiment 400, F-91405 Orsay, France.	bouloc@infobiogen.fr	Bouloc, Philippe/ABA-5732-2021	Bouloc, Philippe/0000-0003-4601-3387; Bohn, Chantal/0000-0003-1569-9072				ABA T, 2006, MOL SYST BIOL   0221, DOI DOI 10.1038/MSB.4100050; Ades SE, 1999, GENE DEV, V13, P2449, DOI 10.1101/gad.13.18.2449; Ades SE, 2004, CURR OPIN MICROBIOL, V7, P157, DOI 10.1016/j.mib.2004.02.010; Alba BM, 2004, MOL MICROBIOL, V52, P613, DOI 10.1111/j.1365-2958.2003.03982.x; Alba BM, 2002, GENE DEV, V16, P2156, DOI 10.1101/gad.1008902; Alba BM, 2001, MOL MICROBIOL, V40, P1323, DOI 10.1046/j.1365-2958.2001.02475.x; ANDERSEN J, 1987, NUCLEIC ACIDS RES, V15, P2089, DOI 10.1093/nar/15.5.2089; Antal M, 2005, J BIOL CHEM, V280, P7901, DOI 10.1074/jbc.M413071200; Argaman L, 2001, CURR BIOL, V11, P941, DOI 10.1016/S0960-9822(01)00270-6; Beck BJ, 1997, J BACTERIOL, V179, P6504, DOI 10.1128/jb.179.21.6862-6864.1997; Bensing BA, 1996, P NATL ACAD SCI USA, V93, P7794, DOI 10.1073/pnas.93.15.7794; Bohn C, 2004, MOL MICROBIOL, V52, P427, DOI 10.1111/j.1365-2958.2004.03985.x; Bohn C, 1998, J BACTERIOL, V180, P6072, DOI 10.1128/JB.180.22.6072-6075.1998; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Campbell EA, 2003, MOL CELL, V11, P1067, DOI 10.1016/S1097-2765(03)00148-5; Chen S, 2004, J BACTERIOL, V186, P6689, DOI 10.1128/JB.186.20.6689-6697.2004; Chen S, 2002, BIOSYSTEMS, V65, P157, DOI 10.1016/S0303-2647(02)00013-8; Collier J, 2004, J BIOL CHEM, V279, P54193, DOI 10.1074/jbc.M314012200; Dartigalongue C, 2001, EMBO J, V20, P5908, DOI 10.1093/emboj/20.21.5908; Dartigalongue C, 2001, J BIOL CHEM, V276, P20866, DOI 10.1074/jbc.M100464200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DeLasPenas A, 1997, MOL MICROBIOL, V24, P373, DOI 10.1046/j.1365-2958.1997.3611718.x; Delihas N, 2001, J MOL BIOL, V313, P1, DOI 10.1006/jmbi.2001.5029; Doerrler WT, 2005, J BIOL CHEM, V280, P27679, DOI 10.1074/jbc.M504796200; FERNANDEZMORA M, 1995, GENE, V158, P67, DOI 10.1016/0378-1119(95)00171-2; Flynn JM, 2004, GENE DEV, V18, P2292, DOI 10.1101/gad.1240104; Folichon M, 2003, NUCLEIC ACIDS RES, V31, P7302, DOI 10.1093/nar/gkg915; Gottesman S, 2004, ANNU REV MICROBIOL, V58, P303, DOI 10.1146/annurev.micro.58.030603.123841; Grigorova IL, 2004, GENE DEV, V18, P2686, DOI 10.1101/gad.1238604; Guillier M, 2006, MOL MICROBIOL, V59, P231, DOI 10.1111/j.1365-2958.2005.04929.x; Kanehara K, 2001, GENE, V281, P71, DOI 10.1016/S0378-1119(01)00823-X; Kanehara K, 2002, GENE DEV, V16, P2147, DOI 10.1101/gad.1002302; Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101; MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; MIZUNO T, 1984, P NATL ACAD SCI-BIOL, V81, P1966, DOI 10.1073/pnas.81.7.1966; Morita T, 2005, GENE DEV, V19, P2176, DOI 10.1101/gad.1330405; Rasmussen AA, 2005, MOL MICROBIOL, V58, P1421, DOI 10.1111/j.1365-2958.2005.04911.x; Repoila F, 2003, MOL MICROBIOL, V48, P855, DOI 10.1046/j.1365-2958.2003.03454.x; Rezuchova B, 2003, FEMS MICROBIOL LETT, V225, P1, DOI 10.1016/S0378-1097(03)00480-4; Rhodius VA, 2006, PLOS BIOL, V4, P43, DOI 10.1371/journal.pbio.0040002; Rivas E, 2001, CURR BIOL, V11, P1369, DOI 10.1016/S0960-9822(01)00401-8; ROUVIERE PE, 1995, EMBO J, V14, P1032, DOI 10.1002/j.1460-2075.1995.tb07084.x; Sambrook J, 2001, MOL CLONING LAB MANU; Udekwu KI, 2005, GENE DEV, V19, P2355, DOI 10.1101/gad.354405; Valentin-Hansen P, 2004, MOL MICROBIOL, V51, P1525, DOI 10.1111/j.1365-2958.2003.03935.x; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Wassarman KM, 2001, GENE DEV, V15, P1637, DOI 10.1101/gad.901001; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Werner J, 2005, MOL MICROBIOL, V57, P1450, DOI 10.1111/j.1365-2958.2005.04775.x; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	56	89	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12253	12259		10.1074/jbc.M600819200	http://dx.doi.org/10.1074/jbc.M600819200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513633	hybrid			2022-12-25	WOS:000237134700009
J	Bindels, S; Mestdagt, M; Vandewalle, C; Jacobs, N; Volders, L; Noel, A; van Roy, F; Berx, G; Foidart, JM; Gilles, C				Bindels, S.; Mestdagt, M.; Vandewalle, C.; Jacobs, N.; Volders, L.; Noel, A.; van Roy, F.; Berx, G.; Foidart, J-M; Gilles, C.			Regulation of vimentin by SIP1 in human epithelial breast tumor cells	ONCOGENE			English	Article						vimentin; SIP1; cell migration	SMAD-INTERACTING PROTEIN-1; REPRESSES E-CADHERIN; INTERMEDIATE-FILAMENTS; BETA-CATENIN; MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTORS; SNAIL; EXPRESSION; GENE; INVASION	The expression of Smad interacting protein-1 (SIP1; ZEB2) and the de novo expression of vimentin are frequently involved in epithelial-to-mesenchymal transitions (EMTs) under both normal and pathological conditions. In the present study, we investigated the potential role of SIP1 in the regulation of vimentin during the EMT associated with breast tumor cell migration and invasion. Examining several breast tumor cell lines displaying various degrees of invasiveness, we found SIP1 and vimentin expression only in invasive cell lines. Also, using a model of cell migration with human mammary MCF10A cells, we showed that SIP1 is induced specifically in vimentin-positive migratory cells. Furthermore, transfection of SIP1 cDNA in MCF10A cells increased their vimentin expression both at the mRNA and protein levels and enhanced their migratory abilities in Boyden Chamber assays. Inversely, inhibition of SIP1 expression by RNAi strategies in BT-549 cells and MCF10A cells decreased vimentin expression. We also showed that SIP1 transfection did not activate the TOP-FLASH reporter system, suggesting that the beta-catenin/TCF pathway is not implicated in the regulation of vimentin by SIP1. Our results therefore implicate SIP1 in the regulation of vimentin observed in the EMT associated with breast tumor cell migration, a pathway that may contribute to the metastatic progression of breast cancer.	Univ Liege, CHU Sart Tilman, Lab Tumor & Dev Biol, Ctr Biomed Integrated Genoproteom, B-4000 Liege, Belgium; Univ Ghent VIB, Dept Mol Biomed Res, B-9000 Ghent, Belgium; Univ Liege, CHU Sart Tilman, Lab Anatomopathol, Ctr Biomed Integrated Genoproteom, B-4000 Liege, Belgium	University of Liege; Flanders Institute for Biotechnology (VIB); Ghent University; University of Liege	Gilles, C (corresponding author), Univ Liege, CHU Sart Tilman, Lab Tumor & Dev Biol, Ctr Biomed Integrated Genoproteom, Tour Pathol B23, B-4000 Liege, Belgium.	cgilles@ulg.ac.be	van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039; Noel, Agnes/0000-0002-7670-6179; Jacobs, Nathalie/0000-0002-9895-8465; Berx, Geert/0000-0001-5770-2458				Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Come C, 2004, J MAMMARY GLAND BIOL, V9, P183, DOI 10.1023/B:JOMG.0000037161.91969.de; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Duband JL, 1995, ACTA ANAT, V154, P63; Eckes B, 1998, J CELL SCI, V111, P1897; Eckes B, 2000, J CELL SCI, V113, P2455; Eisaki A, 2000, BIOCHEM BIOPH RES CO, V271, P151, DOI 10.1006/bbrc.2000.2545; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gilles C, 1999, J CELL SCI, V112, P4615; Gilles C, 2003, CANCER RES, V63, P2658; Gilles C, 1996, BREAST JOURNAL, VOL 2, NO 1, JANUARY/FEBRUARY 1996, P83; GILLES C, 2004, RISE FALL EPITHELIAL, pCH2; Goldman RD, 1999, FASEB J, V13, pS261, DOI 10.1096/fasebj.13.9002.S261; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; GUARINO M, 1995, HISTOL HISTOPATHOL, V10, P171; Hajra KM, 2002, CANCER RES, V62, P1613; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Helfand BT, 2004, J CELL SCI, V117, P133, DOI 10.1242/jcs.00936; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Hendrix MJC, 1996, CANCER METAST REV, V15, P507, DOI 10.1007/BF00054016; Homan SM, 1998, J CELL SCI, V111, P2717; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kreis S, 2005, EXP CELL RES, V305, P110, DOI 10.1016/j.yexcr.2004.12.023; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Million K, 2001, AM J RESP CELL MOL, V25, P744, DOI 10.1165/ajrcmb.25.6.4549; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; NAWROCKI RB, 2001, INT J CANCER, V93, P644; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; RAMAEKERS FCS, 1983, P NATL ACAD SCI-BIOL, V80, P2618, DOI 10.1073/pnas.80.9.2618; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Singh S, 2003, CANCER RES, V63, P2306; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tsuruta D, 2003, J CELL SCI, V116, P4977, DOI 10.1242/jcs.00823; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P173, DOI 10.1016/S1357-2725(03)00243-7; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; van Grunsven LA, 2003, J BIOL CHEM, V278, P26135, DOI 10.1074/jbc.M300597200; van Grunsven LA, 2000, MECH DEVELOP, V94, P189, DOI 10.1016/S0925-4773(00)00318-X; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wu AL, 1999, MOL CELL, V4, P619, DOI 10.1016/S1097-2765(00)80212-9; Yokoyama K, 2003, INT J ONCOL, V22, P891	61	149	153	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4975	4985		10.1038/sj.onc.1209511	http://dx.doi.org/10.1038/sj.onc.1209511			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568083	Green Submitted			2022-12-25	WOS:000239921300003
J	Patel, HV; Vyas, KA; Savtchenko, R; Roseman, S				Patel, Himatkumar V.; Vyas, Kavita A.; Savtchenko, Regina; Roseman, Saul			The monomer/dimer transition of enzyme I of the Escherichia coli phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR-TRANSPORT; SALMONELLA-TYPHIMURIUM; BACTERIAL PHOSPHOENOLPYRUVATE; CONFORMATIONAL STABILITY; FLUORESCENCE ANISOTROPY; PHOSPHORYL TRANSFER; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; PROTEIN; HPR	Enzyme I (EI) is the first protein in the phosphotransfer sequence of the bacterial phosphoenolpyruvate: glycose phosphotransferase system. This system catalyzes sugar phosphorylation/transport and is stringently regulated. Since EI homodimer accepts the phosphoryl group from phosphoenolpyruvate ( PEP), whereas the monomer does not, EI may be a major factor in controlling sugar uptake. Previous work from this and other laboratories (e.g. Dimitrova, M. N., Szczepanowski, R. H., Ruvinov, S. B., Peterkofsky, A., and Ginsburg A. (2002) Biochem. 41, 906 - 913), indicate that Ka is sensitive to several parameters. We report here a systematic study of Ka determined by sedimentation equilibrium, which showed that it varied by 1000-fold, responding to virtually every parameter tested, including temperature, phosphorylation, pH (6.5 versus 7.5), ionic strength, and especially the ligands Mg2+ and PEP. This variability may be required for a regulatory protein. Further insight was gained by analyzing EI by sedimentation velocity, by near UV CD spectroscopy, and with a nonphosphorylatable active site mutant, EI-H189Q, which behaved virtually identically to EI. The singular properties of EI are explained by a model consistent with the results reported here and in the accompanying paper (Patel, H. V., Vyas, K. A., Mattoo, R. L., Southworth, M., Perler, F. B., Comb, D., and Roseman, S. (2006) J. Biol. Chem. 281, 17579 17587). We suggest that EI and EI-H189Q each comprise a multiplicity of conformers and progressively fewer conformers as they dimerize and bind Mg2+ and finally PEP. Mg2+ alone induces small or no detectable changes in structure, but large conformational changes ensue with Mg2+/PEP. This effect is explained by a "swiveling mechanism" (similar to that suggested for pyruvate phosphate dikinase (Herzberg, O., Chen, C. C., Kapadia, G., McGuire, M., Carroll, L. J., Noh, S. J., and Dunaway-Mariano, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2652 - 2657)), which brings the C-terminal domain with the two bound ligands close to the active site His(189).	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charle St, Baltimore, MD 21218 USA.	roseman@jhu.edu	Vyas, Kavita/GRJ-4578-2022		NIGMS NIH HHS [GM 38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038759, R37GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON B, 1971, J BIOL CHEM, V246, P7023; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; CHAUVIN F, 1994, J BIOL CHEM, V269, P20263; CHAUVIN F, 1994, J BIOL CHEM, V269, P20270; Chauvin F, 1996, RES MICROBIOL, V147, P471, DOI 10.1016/0923-2508(96)84001-0; Chauvin F, 1996, P NATL ACAD SCI USA, V93, P7028, DOI 10.1073/pnas.93.14.7028; Dam J, 2004, METHOD ENZYMOL, V384, P185; Dimitrova MN, 2003, PROTEIN SCI, V12, P2047, DOI 10.1110/ps.0352103; Dimitrova MN, 2002, BIOCHEMISTRY-US, V41, P906, DOI 10.1021/bi011801x; Ginsburg A, 2002, ARCH BIOCHEM BIOPHYS, V397, P273, DOI 10.1006/abbi.2001.2603; HAN MK, 1990, J BIOL CHEM, V265, P1985; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KEPES A, 1962, BACTERIA, V1, P179; KUKURUZINSKA MA, 1984, J BIOL CHEM, V259, P1679; KUKURUZINSKA MA, 1982, J BIOL CHEM, V257, P4470; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; LICALSI C, 1991, J BIOL CHEM, V266, P19519; LIU KDF, 1983, P NATL ACAD SCI-BIOL, V80, P7142, DOI 10.1073/pnas.80.23.7142; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Meadow ND, 2005, BIOCHEMISTRY-US, V44, P12790, DOI 10.1021/bi0502846; Oberholzer AE, 2005, J MOL BIOL, V346, P521, DOI 10.1016/j.jmb.2004.11.077; Patel HV, 2006, J BIOL CHEM, V281, P17579, DOI 10.1074/jbc.M508966200; Patel HV, 2004, P NATL ACAD SCI USA, V101, P17486, DOI 10.1073/pnas.0407865101; Pelton JG, 1996, J BIOL CHEM, V271, P33446, DOI 10.1074/jbc.271.52.33446; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; ROSEMAN S, 1990, J BIOL CHEM, V265, P2993; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SIMONI RD, 1967, P NATL ACAD SCI USA, V58, P1963, DOI 10.1073/pnas.58.5.1963; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; Zhu PP, 1999, BIOCHEMISTRY-US, V38, P15470, DOI 10.1021/bi991680p	37	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17570	17578		10.1074/jbc.M508965200	http://dx.doi.org/10.1074/jbc.M508965200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16547355	hybrid			2022-12-25	WOS:000238490300006
J	Laize, V; Viegas, CSB; Price, PA; Cancela, ML				Laize, Vincent; Viegas, Carla S. B.; Price, Paul A.; Cancela, M. Leonor			Identification of an osteocalcin isoform in fish with a large acidic prodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; GAMMA-CARBOXYGLUTAMIC ACID; MATRIX GLA PROTEIN; BIOLOGICAL IMPLICATIONS; MINERALIZED TISSUE; GENOME DUPLICATION; DEFICIENT MICE; BONE; EVOLUTION; BIOMINERALIZATION	Osteocalcin is a small, secreted bone protein whose gene consists of four exons. In the course of analyzing the structure of fish osteocalcin genes, we recently found that the spotted green pufferfish has two possible exon 2 structures, one of 15 bp and the other of 324 bp. Subsequent analysis of the pufferfish cDNA showed that only the transcript with a large exon 2 exists. Exon 2 codes for the osteocalcin propeptide, and exon 2 of pufferfish osteocalcin is similar to 3.4-fold larger than exon 2 previously found in other vertebrate species. We have termed this new pufferfish osteocalcin isoform OC2. Additional studies showed that the OC2 isoform is restricted to a unique fish taxonomic group, the Osteichthyes; OC2 is the only osteocalcin isoform found so far in six Osteichthyes species, whereas both OC1 and OC2 isoforms coexist in zebrafish and rainbow trout. The larger size of the OC2 propeptide is due to an acidic region that is likely to be highly phosphorylated and has no counterpart in the OC1 propeptide. We propose 1) that OC1 and OC2 are encoded by distinct genes that originated from a duplication event that probably occurred in the teleost fish lineage soon after divergence from tetrapods and 2) that the novel OC2 propeptide could be, if secreted, a phosphoprotein that participates in the regulation of biomineralization through its large acidic and phosphorylated propeptide.	Univ Algarve, Ctr Ciencias Mar, P-8005139 Faro, Portugal; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	Universidade do Algarve; University of California System; University of California San Diego	Laize, V (corresponding author), Univ Algarve, Ctr Ciencias Mar, P-8005139 Faro, Portugal.	vlaize@ualg.pt	Viegas, Carla CSB/N-6695-2014; Cancela, M. Leonor/F-4665-2012; Viegas, Carla/N-6314-2019; Laizé, Vincent/B-4463-2008	Viegas, Carla CSB/0000-0002-5765-3665; Cancela, M. Leonor/0000-0003-3114-6662; Viegas, Carla/0000-0002-5765-3665; Laizé, Vincent/0000-0001-9565-9198				Amores A, 2004, GENOME RES, V14, P1, DOI 10.1101/gr.1717804; Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756-3282(98)00092-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Christensen B, 2005, BIOCHEM J, V390, P285, DOI 10.1042/BJ20050341; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; ENGELKE JA, 1991, BIOCHIM BIOPHYS ACTA, V1078, P31, DOI 10.1016/0167-4838(91)90088-H; Frazao C, 2005, BIOCHEMISTRY-US, V44, P1234, DOI 10.1021/bi048336z; GORSKI JP, 1992, CALCIFIED TISSUE INT, V50, P391, DOI 10.1007/BF00296767; GUNDBERG CM, 1992, J BONE MINER RES, V7, P73; HAUSCHKA PV, 1989, ANAT REC, V224, P180, DOI 10.1002/ar.1092240208; HAUSCHKA PV, 1982, BIOCHEMISTRY-US, V21, P2538, DOI 10.1021/bi00539a038; He G, 2005, J BIOL CHEM, V280, P33109, DOI 10.1074/jbc.M500159200; HOSODA K, 1993, J BONE MINER RES, V8, P553; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; Huq NL, 2005, ARCH ORAL BIOL, V50, P599, DOI 10.1016/j.archoralbio.2004.12.009; Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Laize V, 2005, J BIOL CHEM, V280, P26659, DOI 10.1074/jbc.M500257200; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nishimoto SK, 2003, J BIOL CHEM, V278, P11843, DOI 10.1074/jbc.M211449200; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; POSER JW, 1979, J BIOL CHEM, V254, P431; PRICE PA, 1985, J BIOL CHEM, V260, P4971; Sommer B, 1996, BONE, V19, P371, DOI 10.1016/S8756-3282(96)00218-9; Stothard P, 2000, BIOTECHNIQUES, V28, P1102, DOI 10.2144/00286ir01; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Woods IG, 2005, GENOME RES, V15, P1307, DOI 10.1101/gr.4134305	31	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15037	15043		10.1074/jbc.M600373200	http://dx.doi.org/10.1074/jbc.M600373200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16565091	Green Published, hybrid			2022-12-25	WOS:000237922200004
J	Peelman, F; Iserentant, H; De Smet, AS; Vandekerckhove, J; Zabeau, L; Tavernier, J				Peelman, Frank; Iserentant, Hannes; De Smet, Anne-Sophie; Vandekerckhove, JoeL; Zabeau, Lennart; Tavernier, Jan			Mapping of binding site III in the leptin receptor and modeling of a hexameric leptin center dot leptin receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAIN; STIMULATING FACTOR-RECEPTOR; MULTIPLE SEQUENCE ALIGNMENT; INHIBITORY FACTOR LIF; EXTRACELLULAR DOMAIN; OB-R; RECOMBINANT HUMAN; CRYSTAL-STRUCTURE; OBESE GENE; CYTOKINE	The leptin.leptin receptor ( LR) system shows strong similarities to the long chain cytokine interleukin-6 ( IL-6) and granulocyte colony-stimulating factor ( G-CSF) cytokine.cytokine receptor systems. The IL-6 family cytokines interact with their receptors through three different binding sites ( I-III). We demonstrated previously that leptin has similar binding sites I-III and mapped the interactions between binding site II and cytokine receptor homology domain II ( CRH2) ( Peelman, F., Van Beneden, K., Zabeau, L., Iserentant, H., Ulrichts, P., Defeau, D., Verhee, A., Catteeuw, D., Elewaut, D., and Tavernier, J. ( 2004) J. Biol. Chem. 279, 41038 41046). In this study, we built homology models for the CRH1 and Ig-like domains of the LR. The Ig-like domain shows a large conserved surface patch in the beta-sheet formed by beta-strands 3, 6, and 7. Mutations in this patch almost completely abolished the leptin-induced STAT3-dependent reporter activity. We propose that a conserved cluster of residues Leu(370), Ala(407), Tyr(409), His(417), and His(418) forms the center of binding site III of the LR. We built a hexameric leptin.LR complex model based on the hexameric IL-6 complex. In this model, a conserved hydrophobic protuberance of Val(36), Thr(37), Phe(41), and Phe(43) in the A-B loop of leptin fits perfectly in the CRH2 domain, corresponding to the IL-6 alpha-receptor, and forms the center of binding site I. The 2: 4 hexameric leptin.LR complex offers a rational explanation for mutagenesis studies and residue conservation.	State Univ Ghent VIB, Dept Med Prot Res, B-9000 Ghent, Belgium; Univ Ghent, Fac Med & Hlth Sci, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	Tavernier, J (corresponding author), State Univ Ghent VIB, Dept Med Prot Res, Baertsoenkaai 3, B-9000 Ghent, Belgium.	jan.tavernier@ugent.be	Tavernier, Jan/AAG-3636-2019					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; Bairoch A, 2005, NUCLEIC ACIDS RES, V33, pD154, DOI 10.1093/nar/gki070; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bitard J, 2003, J BIOL CHEM, V278, P16253, DOI 10.1074/jbc.M207193200; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Couturier C, 2003, J BIOL CHEM, V278, P26604, DOI 10.1074/jbc.M302002200; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Fong TM, 1998, MOL PHARMACOL, V53, P234, DOI 10.1124/mol.53.2.234; Fruhbeck G, 2001, P NUTR SOC, V60, P301, DOI 10.1079/PNS200196; Haniu M, 1998, J BIOL CHEM, V273, P28691, DOI 10.1074/jbc.273.44.28691; He W, 2005, FEBS LETT, V579, P4317, DOI 10.1016/j.febslet.2005.06.061; He W, 2002, FEBS LETT, V514, P214, DOI 10.1016/S0014-5793(02)02367-0; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043; Iida M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/bbrc.1996.1070; Iserentant H, 2005, J CELL SCI, V118, P2519, DOI 10.1242/jcs.02386; Ishibashi M, 2001, PROTEIN EXPRES PURIF, V21, P317, DOI 10.1006/prep.2000.1381; La Cava A, 2004, NAT REV IMMUNOL, V4, P371, DOI 10.1038/nri1350; Layton JE, 2001, J BIOL CHEM, V276, P36779, DOI 10.1074/jbc.M104787200; MADEJ T, 1995, FEBS LETT, V373, P13, DOI 10.1016/0014-5793(95)00977-H; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Nakashima K, 1997, FEBS LETT, V403, P79, DOI 10.1016/S0014-5793(97)00013-6; Niv-Spector L, 2005, BIOCHEM J, V391, P221, DOI 10.1042/BJ20050457; Niv-Spector L, 2005, BIOCHEM J, V390, P475, DOI 10.1042/BJ20050233; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Peelman F, 2004, J BIOL CHEM, V279, P41038, DOI 10.1074/jbc.M404962200; Peelman F, 2004, PROG LIPID RES, V43, P283, DOI 10.1016/j.plipres.2004.03.001; Plun-Favreau H, 2003, J BIOL CHEM, V278, P27169, DOI 10.1074/jbc.M303168200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sandowski Y, 2002, J BIOL CHEM, V277, P46304, DOI 10.1074/jbc.M207556200; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498; Zabeau L, 2005, J BIOL CHEM, V280, P22632, DOI 10.1074/jbc.M413308200; Zabeau L, 2004, MOL ENDOCRINOL, V18, P150, DOI 10.1210/me.2003-0078; Zabeau L, 2003, FEBS LETT, V546, P45, DOI 10.1016/S0014-5793(03)00440-X; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	44	63	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15496	15504		10.1074/jbc.M512622200	http://dx.doi.org/10.1074/jbc.M512622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16540470	hybrid			2022-12-25	WOS:000237922200056
J	Han, BW; Bingman, CA; Mahnke, DK; Bannen, RM; Bednarek, SY; Sabina, RL; Phillips, GN				Han, Byung Woo; Bingman, Craig A.; Mahnke, Donna K.; Bannen, Ryan M.; Bednarek, Sebastian Y.; Sabina, Richard L.; Phillips, George N., Jr.			Membrane association, mechanism of action, and structure of Arabidopsis embryonic factor 1 (FAC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-DEAMINASE ISOFORMS; AMINO-ACID-COMPOSITION; PLANT-CELL CULTURE; ADENOSINE-DEAMINASE; METABOLIC-REGULATION; ADENYLATE DEAMINASE; PURINE NUCLEOTIDES; SUBUNIT STRUCTURE; MOLECULAR-WEIGHT; TRANSITION-STATE	Embryonic factor 1 (FAC1) is one of the earliest expressed plant genes and encodes an AMP deaminase ( AMPD), which is also an identified herbicide target. This report identifies an N-terminal transmembrane domain in Arabidopsis FAC1, explores subcellular fractionation, and presents a 3.3-angstrom globular catalytic domain x-ray crystal structure with a bound herbicide-based transition state inhibitor that provides the first glimpse of a complete AMPD active site. FAC1 contains an (alpha/beta)(8)-barrel characterized by loops in place of strands 5 and 6 that places it in a small subset of the amidohydrolase superfamily with imperfect folds. Unlike tetrameric animal orthologs, FAC1 is a dimer and each subunit contains an exposed Walker A motif that may be involved in the dramatic combined Km (25 - 80-fold lower) and V-max (5-6-fold higher) activation by ATP. Normal mode analysis predicts a hinge motion that flattens basic surfaces on each monomer that flank the dimer interface, which suggests a reversible association between the FAC1 globular catalytic domain and intracellular membranes, with N-terminal transmembrane and disordered linker regions serving as the anchor and attachment to the globular catalytic domain, respectively.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Ctr Eukaryot Struct Genom, Madison, WI 53706 USA	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Phillips, GN (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	phillips@biochem.wisc.edu		Bannen, Ryan/0000-0002-6001-3060	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074901, P50GM064598] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007359] Funding Source: NIH RePORTER; NIGMS NIH HHS [1U54 GM 074901-01, P50 GM 64598] Funding Source: Medline; NLM NIH HHS [5T15 LM 007359] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Athwal GS, 1998, PLANT PHYSIOL, V118, P1041, DOI 10.1104/pp.118.3.1041; BarPeled M, 1997, PLANT PHYSIOL, V114, P315, DOI 10.1104/pp.114.1.315; BAUSCHJURKEN MT, 1992, J BIOL CHEM, V267, P22407; Bazin R.J., 2003, UK Patent, Patent No. [GB2373504, 2373504]; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSH BD, 1993, PHYTOCHEMISTRY, V32, P737, DOI 10.1016/S0031-9422(00)95163-X; BUTTERS JA, 1985, PHYSIOL PLANT PATHOL, V27, P65, DOI 10.1016/0048-4059(85)90057-8; Camoni L, 2001, J BIOL CHEM, V276, P31709, DOI 10.1074/jbc.M104194200; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Dancer JE, 1997, PLANT PHYSIOL, V114, P119, DOI 10.1104/pp.114.1.119; FRIEDEN C, 1980, BIOCHEMISTRY-US, V19, P5303, DOI 10.1021/bi00564a024; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Haas AL, 2003, PROTEIN EXPRES PURIF, V27, P293, DOI 10.1016/S1046-5928(02)00636-8; Haberer G, 2002, PLANT PHYSIOL, V128, P354, DOI 10.1104/pp.010773; Han BW, 2005, ACTA CRYSTALLOGR F, V61, P740, DOI 10.1107/S1744309105019792; Hinsen K, 1999, PROTEINS, V34, P369, DOI 10.1002/(SICI)1097-0134(19990215)34:3<369::AID-PROT9>3.0.CO;2-F; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ISAAC BG, 1991, J ANTIBIOT, V44, P729, DOI 10.7164/antibiotics.44.729; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; LEFLOCH F, 1983, Z PFLANZENPHYSIOL, V113, P61, DOI 10.1016/S0044-328X(83)80019-1; LEFLOCH F, 1983, PHYSIOL VEG, V21, P15; LEFLOCH F, 1982, PLANT SCI LETT, V27, P309, DOI 10.1016/0304-4211(82)90133-X; MADEJ T, 1995, PROTEINS, V23, P356, DOI 10.1002/prot.340230309; Mahnke-Zizelman DK, 2001, BIOCHEM BIOPH RES CO, V285, P489, DOI 10.1006/bbrc.2001.5180; Mahnke-Zizelman DK, 1998, J BIOL CHEM, V273, P35118, DOI 10.1074/jbc.273.52.35118; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAMURA H, 1974, J AM CHEM SOC, V96, P4327, DOI 10.1021/ja00820a049; ODRISCOLL D, 1976, BIOCHEM SOC T, V4, P928, DOI 10.1042/bst0040928; OGASAWARA N, 1982, BIOCHIM BIOPHYS ACTA, V714, P298; OGASAWARA N, 1977, BIOCHEM BIOPH RES CO, V79, P671, DOI 10.1016/0006-291X(77)91164-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rancour DM, 2004, J BIOL CHEM, V279, P54264, DOI 10.1074/jbc.M405498200; Rancour DM, 2002, PLANT PHYSIOL, V130, P1241, DOI 10.1104/pp.011742; Sabina RL, 2000, PHARMACOL THERAPEUT, V87, P279, DOI 10.1016/S0163-7258(00)00040-1; Seibert CM, 2005, BIOCHEMISTRY-US, V44, P6383, DOI 10.1021/bi047326v; STANKIEWICZ A, 1979, COMP BIOCHEM PHYS B, V62, P363, DOI 10.1016/0305-0491(79)90104-4; STANKIEWICZ A, 1981, INT J BIOCHEM, V13, P1177, DOI 10.1016/0020-711X(81)90211-1; SWAIN JL, 1982, AM J PHYSIOL, V242, P818; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; TURNER DH, 1961, BIOCHEM J, V79, P143, DOI 10.1042/bj0790143; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VALENTINE WN, 1985, P NATL ACAD SCI USA, V82, P6682, DOI 10.1073/pnas.82.19.6682; Wang ZM, 1998, BIOCHEMISTRY-US, V37, P8314, DOI 10.1021/bi980324o; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; Xu J, 2005, PLANT J, V42, P743, DOI 10.1111/j.1365-313X.2005.02411.x; YABUKI N, 1992, PHYTOCHEMISTRY, V31, P1905, DOI 10.1016/0031-9422(92)80332-9; YABUKI N, 1991, BIOCHIM BIOPHYS ACTA, V1073, P474, DOI 10.1016/0304-4165(91)90218-6; YOSHINO M, 1980, Z PFLANZENPHYSIOL, V99, P331, DOI 10.1016/S0044-328X(80)80147-4	52	22	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14939	14947		10.1074/jbc.M513009200	http://dx.doi.org/10.1074/jbc.M513009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16543243	hybrid			2022-12-25	WOS:000237671300047
J	Jean-Louis, S; Akare, S; Ali, MA; Mash, EA; Meuillet, E; Martinez, JD				Jean-Louis, Samira; Akare, Sandeep; Ali, M. Ahad; Mash, Eugene A., Jr.; Meuillet, Emmanuelle; Martinez, Jesse D.			Deoxycholic acid induces intracellular signaling through membrane perturbations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; LIGAND-INDEPENDENT ACTIVATION; SECONDARY BILE-ACIDS; COLON-CANCER CELLS; URSODEOXYCHOLIC ACID; INDUCED APOPTOSIS; BINDING-PROTEIN; LIPID RAFTS; CHOLESTEROL	Secondary bile acids have long been postulated to be tumor promoters in the colon; however, their mechanism of action remains unclear. In this study, we examined the actions of bile acids at the cell membrane and found that they can perturb membrane structure by alteration of membrane microdomains. Depletion of membrane cholesterol by treating with methyl-beta-cyclodextrin suppressed deoxycholic acid (DCA)-induced apoptosis, and staining for cholesterol with filipin showed that DCA caused a marked rearrangement of this lipid in the membrane. Likewise, DCA was found to affect membrane distribution of caveolin-1, amarker protein that is enriched in caveolae membrane microdomains. Additionally, fluorescence anisotropy revealed that DCA causes a decrease in membrane fluidity consistent with the increase in membrane cholesterol content observed after 4 h of DCA treatment of HCT116 cells. Significantly, by using radiolabeled bile acids, we found that bile acids are able to interact with and localize to microdomains differently depending on their physicochemical properties. DCA was also found to induce tyrosine phosphorylation and activate the receptor tyrosine kinase epidermal growth factor receptor in a ligand-independent manner. In contrast, ursodeoxycholic acid did not exhibit any of these effects even though it interacted significantly with the microdomains. Collectively, these data suggest that bile acid-induced signaling is initiated through alterations of the plasma membrane structure and the redistribution of cholesterol.	Univ Arizona, Dept Cellular Biol & Anat, Tucson, AZ 85724 USA; Univ Arizona, Ctr Canc, Tucson, AZ 85724 USA; Univ Arizona, Canc Biol Interdisciplinary Program, Tucson, AZ USA; Univ Arizona, Synth Chem Shared Serv, Tucson, AZ USA; Univ Arizona, Dept Nutrit Sci, Tucson, AZ USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Dept Cellular Biol & Anat, POB 245024,1501 N Campbell Ave, Tucson, AZ 85724 USA.	jmartinez@azcc.arizona.edu			NCI NIH HHS [CA 72008-08S1, CA 72008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akare S, 2005, BBA-MOL CELL BIOL L, V1735, P59, DOI 10.1016/j.bbalip.2005.04.006; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BAYERDORFFER E, 1995, GUT, V36, P268, DOI 10.1136/gut.36.2.268; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boord JB, 2002, ARTERIOSCL THROM VAS, V22, P1686, DOI 10.1161/01.ATV.0000033090.81345.E6; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BREUER N, 1985, KLIN WOCHENSCHR, V63, P97, DOI 10.1007/BF01734247; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cai CX, 2004, BIOCHEM BIOPH RES CO, V320, P868, DOI 10.1016/j.bbrc.2004.06.030; Carey Martin C., 1994, P719; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Chiou TJ, 2000, TOXICOLOGY, V154, P75, DOI 10.1016/S0300-483X(00)00321-8; COHEN BI, 1981, CANCER RES, V41, P3759; COLEMAN R, 1979, BIOCHEM J, V178, P201, DOI 10.1042/bj1780201; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; EARNEST DL, 1994, CANCER RES, V54, P5071; FITZER CJ, 1987, CARCINOGENESIS, V8, P217, DOI 10.1093/carcin/8.2.217; FREIFELDER D, 1982, PHYSICAL BIOCH, P537; GUILLEM JG, 1987, ARCH SURG-CHICAGO, V122, P1475; Herget T, 2000, J BIOL CHEM, V275, P30344, DOI 10.1074/jbc.M000714200; Hirano F, 1996, CARCINOGENESIS, V17, P427, DOI 10.1093/carcin/17.3.427; HOFFMAN AF, 1994, BIOL PATHOPHYSIOLOGY, P677; HOOVER RL, 1983, J CELL BIOL, V97, P73, DOI 10.1083/jcb.97.1.73; HUANG XP, 1992, INT J CANCER, V52, P444, DOI 10.1002/ijc.2910520319; Ikegami T, 1998, CANCER LETT, V134, P129, DOI 10.1016/S0304-3835(98)00248-1; Ikonen E, 2004, BIOCHEM SOC T, V32, P121, DOI 10.1042/BST0320121; Im E, 2004, J NUTR, V134, P483, DOI 10.1093/jn/134.2.483; JOHNSON SM, 1977, BIOCHEM BIOPH RES CO, V76, P869, DOI 10.1016/0006-291X(77)91581-9; KAMMER GM, 1983, J IMMUNOL, V130, P38; KORPELA JT, 1988, SCAND J GASTROENTERO, V23, P277, DOI 10.3109/00365528809093865; KRUTH HS, 1984, AM J PATHOL, V114, P201; KullakUblick GA, 1996, HEPATOLOGY, V23, P1053; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu PS, 2000, J BIOL CHEM, V275, P31648, DOI 10.1074/jbc.M004599200; LUCIANO L, 1989, CELL TISSUE RES, V258, P339; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Martinez JD, 1998, NUTR CANCER, V31, P111, DOI 10.1080/01635589809514689; Merchant NB, 2005, SURGERY, V138, P415, DOI 10.1016/j.surg.2005.06.030; MILKIEWICZ PM, 1999, P FALK WORKSH LOND U, P1; MILLS CO, 1991, BIOCHIM BIOPHYS ACTA, V1115, P151, DOI 10.1016/0304-4165(91)90024-B; Mills CO, 1997, BBA-GEN SUBJECTS, V1336, P485, DOI 10.1016/S0304-4165(97)00063-9; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Morgan Winston A., 1997, Biochemical Society Transactions, V25, p75S; MORVAY K, 1989, DIS COLON RECTUM, V32, P860, DOI 10.1007/BF02554556; Moschetta A, 2001, J HEPATOL, V34, P492, DOI 10.1016/S0168-8278(00)00046-5; NARISAWA T, 1978, Gastroenterologia Japonica, V13, P206; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P10315, DOI 10.1021/bi025943i; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; Powell AA, 2001, BIOCHEM J, V356, P481, DOI 10.1042/0264-6021:3560481; Qiao DH, 2000, J BIOL CHEM, V275, P15090, DOI 10.1074/jbc.M908890199; Qiao DH, 2001, CARCINOGENESIS, V22, P957, DOI 10.1093/carcin/22.6.957; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Rao YP, 2002, HEPATOLOGY, V35, P307, DOI 10.1053/jhep.2002.31104; REDDY BS, 1977, CANCER RES, V37, P3238; Rizzo Giovanni, 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P289, DOI 10.2174/1568008054863781; Rodrigues CMP, 1998, MOL MED, V4, P165, DOI 10.1007/BF03401914; ROGERS AE, 1975, CANCER RES, V35, P3427; SAGAWA H, 1993, AM J PHYSIOL, V264, pG835, DOI 10.1152/ajpgi.1993.264.5.G835; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; SHINITZKY M, 1974, J BIOL CHEM, V249, P2652; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stravitz RT, 1996, AM J PHYSIOL-GASTR L, V271, pG293, DOI 10.1152/ajpgi.1996.271.2.G293; Tabas I, 2002, J CLIN INVEST, V110, P583, DOI 10.1172/JCI200216381; VANMUNSTER IP, 1993, EUR J CLIN INVEST, V23, P773; Veyron P, 1996, TRANSPLANTATION, V62, P1039, DOI 10.1097/00007890-199610270-00001; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; VYVODA OS, 1977, BIOCHIM BIOPHYS ACTA, V465, P68, DOI 10.1016/0005-2736(77)90356-X; Wang LF, 2005, HEPATOLOGY, V41, P1241, DOI 10.1002/hep.20697; Xu GR, 2002, J BIOL CHEM, V277, P50491, DOI 10.1074/jbc.M209176200; Yu CJ, 2005, J LIPID RES, V46, P1678, DOI 10.1194/jlr.M500060-JLR200	74	97	100	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14948	14960		10.1074/jbc.M506710200	http://dx.doi.org/10.1074/jbc.M506710200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16547009	hybrid			2022-12-25	WOS:000237671300048
J	Waters, L; Yue, BG; Veverka, V; Renshaw, P; Bramham, J; Matsuda, S; Frenkiel, T; Kelly, G; Muskett, F; Carr, M; Heery, DM				Waters, Lorna; Yue, Baigong; Veverka, Vaclav; Renshaw, Philip; Bramham, Janice; Matsuda, Sachiko; Frenkiel, Thomas; Kelly, Geoffrey; Muskett, Frederick; Carr, Mark; Heery, David M.			Structural diversity in p160/CREB-binding protein coactivator complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LXXLL MOTIF; TRANSCRIPTIONAL ACTIVATION; BINDING-PROTEIN; RECEPTOR; DOMAIN; ALPHA; NMR; CBP; CBP/P300; SRC1	Ligand-induced transcription by nuclear receptors involves the recruitment of p160 coactivators such as steroid receptor coactivator 1 (SRC1), in complex with histone acetyltransferases such as CREB-binding protein (CBP) and p300. Here we describe the solution structure of a complex formed by the SRC1 interaction domain (SID) of CBP and the activation domain (AD1) of SRC1, both of which contain four helical regions (C alpha 1, C alpha 2, C alpha 3, and C alpha 3' in CBP and S alpha 1, S alpha 2', S alpha 2, and S alpha 3 in SRC1). A tight four-helix bundle is formed between S alpha 1, C alpha 1, C alpha 2, and C alpha 3 that is capped by S alpha 3. In contrast to the structure of the AD1 domain of the related p160 protein ACTR in complex with CBP SID, the sequences forming S alpha 2' and S alpha 2 in SRC1 AD1 are not involved in the interface between the two domains but rather serve to position S alpha 3. Thus, although the CBP SID domain adopts a similar fold in complex with different p160 proteins, the topologies of the AD1 domains are strikingly different, a feature that is likely to contribute to functional specificity of these coactivator complexes.	Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; MRC, Biomed NMR Ctr, Natl Inst Med Res, London NW7 1AA, England	University of Nottingham; University of Leicester; MRC National Institute for Medical Research	Heery, DM (corresponding author), Univ Nottingham, Sch Pharm, Univ Pk, Nottingham NG7 2RD, England.	david.heery@nottingham.ac.uk	Veverka, Vaclav/G-9174-2014; Veverka, Vaclav/P-5251-2019	Veverka, Vaclav/0000-0003-3782-5279; Veverka, Vaclav/0000-0003-3782-5279; Heery, David/0000-0002-5035-2392; Carr, Mark/0000-0002-3939-0996	MRC [MC_U117533887] Funding Source: UKRI; Medical Research Council [MC_U117533887] Funding Source: Medline; Wellcome Trust [063632, 054401/Z/98/B, 066047] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Carr MD, 2003, J BIOL CHEM, V278, P43736, DOI 10.1074/jbc.M307235200; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Coulthard VH, 2003, J BIOL CHEM, V278, P10942, DOI 10.1074/jbc.M212950200; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demarest SJ, 2004, PROTEIN SCI, V13, P203, DOI 10.1110/ps.03366504; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; FEENEY J, 1991, J MAGN RESON, V91, P607, DOI 10.1016/0022-2364(91)90388-A; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kindle KB, 2005, MOL CELL BIOL, V25, P988, DOI 10.1128/MCB.25.3.988-1002.2005; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kung AL, 2000, GENE DEV, V14, P272; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200; Lucey MJ, 2005, NUCLEIC ACIDS RES, V33, P6393, DOI 10.1093/nar/gki940; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; Matsuda S, 2004, J BIOL CHEM, V279, P14055, DOI 10.1074/jbc.M310188200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Plevin MJ, 2005, TRENDS BIOCHEM SCI, V30, P66, DOI 10.1016/j.tibs.2004.12.001; Qin BY, 2005, STRUCTURE, V13, P1269, DOI 10.1016/j.str.2005.06.011; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sheppard HM, 2003, J MOL ENDOCRINOL, V30, P411, DOI 10.1677/jme.0.0300411; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Zhang H, 2004, GENE DEV, V18, P1753, DOI 10.1101/gad.1194704; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	53	61	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14787	14795		10.1074/jbc.M600237200	http://dx.doi.org/10.1074/jbc.M600237200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16540468	hybrid			2022-12-25	WOS:000237671300032
J	Zhang, YN; Baig, E; Williams, DB				Zhang, Yinan; Baig, Ehtesham; Williams, David B.			Functions of ERp57 in the folding and assembly of major histocompatibility complex class I molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; THIOL-DEPENDENT REDUCTASE; PEPTIDE-LOADING COMPLEX; ENDOPLASMIC-RETICULUM; BOND FORMATION; MONOCLONAL-ANTIBODIES; OXIDOREDUCTASE ERP57; TRANSLATION SYSTEM; BINDING SITE; B' DOMAIN	ERp57 is a thiol oxidoreductase of the endoplasmic reticulum that appears to be recruited to substrates indirectly through its association with the molecular chaperones calnexin and calreticulin. However, its functions in living cells have been difficult to demonstrate. During the biogenesis of class I histocompatibility molecules, ERp57 has been detected in association with free class I heavy chains and, at a later stage, with a large complex termed the peptide loading complex. This implicates ERp57 in heavy chain disulfide formation, isomerization, or reduction as well as in the loading of peptides onto class I molecules. In this study, we show that ERp57 does indeed participate in oxidative folding of the heavy chain. Depletion of ERp57 byRNAinterference delayed heavy chain disulfide bond formation, slowed folding of the heavy chain alpha(3) domain, and caused slight delays in the transport of class I molecules from the endoplasmic reticulum to the Golgi apparatus. In contrast, heavy chain-beta(2)-microglobulin association kinetics were normal, suggesting that the interaction between heavy chain and-beta 2-microglobulin does not depend on an oxidized alpha(3) domain. Likewise, the peptide loading complex assembled properly, and peptide loading appeared normal upon depletion of ERp57. These studies demonstrate that ERp57 is involved in disulfide formation in vivo but do not support a role for ERp57 in peptide loading of class I molecules. Interestingly, depletion of another thiol oxidoreductase, ERp72, had no detectable effect on class I biogenesis, consistent with a specialized role for ERp57 in this process.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Williams, DB (corresponding author), Univ Toronto, Dept Biochem, 100 Coll St,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	david.williams@utoronto.ca	Zhang, Yinan/N-6432-2014	Zhang, Yinan/0000-0002-3471-6598				Alanen HI, 2003, ANTIOXID REDOX SIGN, V5, P367, DOI 10.1089/152308603768295096; Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Garbi N, 2006, NAT IMMUNOL, V7, P93, DOI 10.1038/ni1288; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Howarth M, 2004, P NATL ACAD SCI USA, V101, P11737, DOI 10.1073/pnas.0306294101; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Koivunen P, 1996, BIOCHEM J, V316, P599, DOI 10.1042/bj3160599; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Lehner PJ, 2004, CURR OPIN IMMUNOL, V16, P82, DOI 10.1016/j.coi.2003.11.012; Lindquist JA, 2001, FASEB J, V15, P1448, DOI 10.1096/fj.00-0720fje; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; MIYAZAKI JI, 1986, P NATL ACAD SCI USA, V83, P757, DOI 10.1073/pnas.83.3.757; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Momburg F, 2002, MOL IMMUNOL, V39, P217, DOI 10.1016/S0161-5890(02)00103-7; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; Paquet ME, 2004, J IMMUNOL, V172, P7548, DOI 10.4049/jimmunol.172.12.7548; Paquet ME, 2002, INT IMMUNOL, V14, P347, DOI 10.1093/intimm/14.4.347; Paulsson K, 2003, BBA-MOL CELL RES, V1641, P1, DOI 10.1016/S0167-4889(03)00048-X; Peaper DR, 2005, EMBO J, V24, P3613, DOI 10.1038/sj.emboj.7600814; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Silvennoinen L, 2004, J BIOL CHEM, V279, P13607, DOI 10.1074/jbc.M313054200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; SOLA T, 2006, J BIOL CHEM, V281, P6219; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Suh WK, 1999, J IMMUNOL, V162, P1530; WANG H, 1994, J BIOL CHEM, V269, P22276; WARBURTON RJ, 1994, HUM IMMUNOL, V39, P261, DOI 10.1016/0198-8859(94)90269-0; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	52	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14622	14631		10.1074/jbc.M512073200	http://dx.doi.org/10.1074/jbc.M512073200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16567808	hybrid			2022-12-25	WOS:000237671300014
J	Sturm, A; Schierhorn, A; Lindenstrauss, U; Lilie, H; Bruser, T				Sturm, Alexander; Schierhorn, Angelika; Lindenstrauss, Ute; Lilie, Hauke; Brueser, Thomas			YcdB from Escherichia coli reveals a novel class of Tat-dependently translocated hemoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYE-DECOLORIZING PEROXIDASE; CANDIDUM DEC 1; CYTOCHROME-C; HETEROLOGOUS EXPRESSION; PROTEIN TRANSLOCATION; PATHWAY; CATABOLISM; TRANSPORT; SEQUENCE; EXPORT	The Tat (twin-arginine translocation) system of Escherichia coli serves to translocate folded proteins across the cytoplasmic membrane. The reasons established so far for the Tat dependence are cytoplasmic cofactor assembly and/or heterodimerization of the respective proteins. We were interested in the reasons for the Tat dependence of novel Tat substrates and focused on two uncharacterized proteins, YcdO and YcdB. Both proteins contain predicted Tat signal sequences. However, we found that only YcdB was indeed Tat-dependently translocated, whereas YcdO was equally well translocated in a Tat-deficient strain. YcdB is a dimeric protein and contains a heme cofactor that was identified to be a high-spin Fe-III-protoporphyrin IX complex. In contrast to all other periplasmic hemoproteins analyzed so far, heme was assembled into YcdB in the cytoplasm, suggesting that heme assembly could take place prior to translocation. The function of YcdB in the periplasm may be related to a detoxification reaction under specific conditions because YcdB had peroxidase activity at acidic pH, which coincides well with the known acid-induced expression of the gene. The data demonstrate the existence of a class of heme-containing Tat substrates, the first member of which is YcdB.	Univ Halle Wittenberg, Inst Microbiol, D-06120 Halle, Germany; Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle, Germany; Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Max Planck Society	Bruser, T (corresponding author), Univ Halle Wittenberg, Inst Microbiol, Kurt Mothes Str 3, D-06120 Halle, Germany.	t.brueser@mikrobiologie.uni-halle.de		Sturm, Alexander/0000-0002-3818-0428; Bruser, Thomas/0000-0002-5889-8306				Alder NN, 2003, CELL, V112, P231, DOI 10.1016/S0092-8674(03)00032-1; Berks BC, 2005, CURR OPIN MICROBIOL, V8, P174, DOI 10.1016/j.mib.2005.02.010; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berthelmann F, 2004, FEBS LETT, V569, P82, DOI 10.1016/j.febslet.2004.05.054; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bruser T, 1998, FEMS MICROBIOL LETT, V164, P329; Bruser T, 2003, EUR J BIOCHEM, V270, P1211, DOI 10.1046/j.1432-1033.2003.03481.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Choe YK, 2005, J COMPUT CHEM, V26, P1600, DOI 10.1002/jcc.20302; Demirev PA, 2002, ANAL CHEM, V74, P3262, DOI 10.1021/ac025621k; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hinsley AP, 2001, FEBS LETT, V497, P45, DOI 10.1016/S0014-5793(01)02428-0; Jongbloed JDH, 2004, MOL MICROBIOL, V54, P1319, DOI 10.1111/j.1365-2958.2004.04341.x; Kim SJ, 1999, APPL ENVIRON MICROB, V65, P1029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maurer LM, 2005, J BACTERIOL, V187, P304, DOI 10.1128/JB.187.1.304-319.2005; McHugh JP, 2003, J BIOL CHEM, V278, P29478, DOI 10.1074/jbc.M303381200; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Sanders C, 2001, MOL MICROBIOL, V41, P241, DOI 10.1046/j.1365-2958.2001.02514.x; Sato T, 2004, ACTA CRYSTALLOGR D, V60, P149, DOI 10.1107/S0907444903025472; Stancik LM, 2002, J BACTERIOL, V184, P4246, DOI 10.1128/JB.184.15.4246-4258.2002; Sugano Y, 2004, BIOCHEM BIOPH RES CO, V322, P126, DOI 10.1016/j.bbrc.2004.07.090; Sugano Y, 2000, APPL ENVIRON MICROB, V66, P1754, DOI 10.1128/AEM.66.4.1754-1758.2000; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; ThroneHolst M, 1997, FEBS LETT, V410, P351, DOI 10.1016/S0014-5793(97)00656-X; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; WOOD PM, 1984, BIOCHIM BIOPHYS ACTA, V768, P293, DOI 10.1016/0304-4173(84)90020-X; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472	30	89	99	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13972	13978		10.1074/jbc.M511891200	http://dx.doi.org/10.1074/jbc.M511891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551627	hybrid			2022-12-25	WOS:000237512300019
J	Gopalan, SM; Wilczynska, KM; Konik, BS; Bryan, L; Kordula, T				Gopalan, SM; Wilczynska, KM; Konik, BS; Bryan, L; Kordula, T			Nuclear factor-1-X regulates astrocyte-specific expression of the alpha 1-antichymotrypsin and glial fibrillary acidic protein genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; FACTOR-I; TRANSCRIPTION FACTOR; DNA-BINDING; CHROMATIN-STRUCTURE; ALZHEIMERS-DISEASE; MESSENGER-RNA; JC VIRUS; BRAIN; INHIBITOR	Discrete tissue-specific changes in chromatin structure of the distal serpin subcluster on human chromosome 14q32.1 allow a single gene encoding alpha 1-antichymotrypsin (ACT) to be expressed in astrocytes and glioma cells. This astrocyte-specific regulation involves activatory protein-1 (AP-1) because overexpression of dominant-negative c-jun(TAM67) abolishes ACT expression in glioma cells. Here we identify a new regulatory element, located within the -13-kb enhancer of the ACT gene, that binds nuclear factor-1 (NFI) and is indispensable for the full basal transcriptional activity of the ACT gene. Furthermore, down-regulation of NFI expression by siRNA abolishes basal ACT expression in glioma cells. However, NFI does not mediate astrocyte-specific expression by itself, but likely cooperates with AP-1. A detailed analysis of the 14-kb long 5'-flanking region of the ACT gene indicated the presence of adjacent NFI and AP-1 elements that colocalized with DNase I-hypersensitive sites found in astrocytes and glioma cells. Interestingly, knock-down of NFI expression also specifically abrogates the expression of glial acidic fibrillary protein (GFAP), which is an astrocyte-specific marker protein. Mutations introduced into putative NFI and AP-1 elements within the 5'-flanking region of the GFAP gene also diminished basal expression of the reporter. In addition, we found, using isoform-specific siRNAs, that NFI-X regulates the astrocyte-specific expression of ACT and GFAP. We propose that NFI-X cooperates with AP-1 by an unknown mechanism in astrocytes, which results in the expression of a subset of astrocyte-specific genes.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA	Virginia Commonwealth University	Kordula, T (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.	tkordula@vcu.edu	Paugh, Barbara/B-3625-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044118] Funding Source: NIH RePORTER; NINDS NIH HHS [NS044118] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baumeister H, 1999, MOL BRAIN RES, V72, P65, DOI 10.1016/S0169-328X(99)00210-7; Bedford FK, 1998, J NEUROSCI, V18, P6186; Behrens M, 2000, EUR J NEUROSCI, V12, P1372, DOI 10.1046/j.1460-9568.2000.00032.x; Belikov S, 2004, J BIOL CHEM, V279, P49857, DOI 10.1074/jbc.M409713200; Belikov S, 2004, MOL CELL BIOL, V24, P3036, DOI 10.1128/MCB.24.7.3036-3047.2004; BESNARD F, 1991, J BIOL CHEM, V266, P18877; Bisgrove DA, 2000, J BIOL CHEM, V275, P30668, DOI 10.1074/jbc.M003828200; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; Gopalan S, 2005, J NEUROCHEM, V94, P763, DOI 10.1111/j.1471-4159.2005.03204.x; Gopalan SM, 2006, J BIOL CHEM, V281, P1956, DOI 10.1074/jbc.M510935200; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; Kordula T, 2000, J NEUROSCI, V20, P7510; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Monaco MCG, 2001, J VIROL, V75, P9687, DOI 10.1128/JVI.75.20.9687-9695.2001; Mukhopadhyay SS, 2001, MOL CELL BIOL, V21, P6859, DOI 10.1128/MCB.21.20.6859-6869.2001; Murtagh J, 2003, J MAMMARY GLAND BIOL, V8, P241, DOI 10.1023/A:1025909109843; Namciu SJ, 2004, MAMM GENOME, V15, P162, DOI 10.1007/s00335-003-2311-y; OH YJ, 1993, GLIA, V8, P77, DOI 10.1002/glia.440080203; PASTERNACK JM, 1989, AM J PATHOL, V135, P827; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Rollini P, 1999, P NATL ACAD SCI USA, V96, P10308, DOI 10.1073/pnas.96.18.10308; Rollini P, 1997, GENOMICS, V46, P409, DOI 10.1006/geno.1997.5077; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SELMAJ K, 1991, J NEUROCHEM, V57, P823, DOI 10.1111/j.1471-4159.1991.tb08225.x; Shu TZ, 2003, J NEUROSCI, V23, P203; Steele-Perkins G, 2005, MOL CELL BIOL, V25, P685, DOI 10.1128/MCB.25.2.685-698.2005; Steele-Perkins G, 2003, MOL CELL BIOL, V23, P1075, DOI 10.1128/MCB.23.3.1075-1084.2003; Sumner C, 1996, J NEUROVIROL, V2, P87, DOI 10.3109/13550289609146542; Wang W, 2004, J BIOL CHEM, V279, P53491, DOI 10.1074/jbc.M410370200	44	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13126	13133		10.1074/jbc.M601194200	http://dx.doi.org/10.1074/jbc.M601194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16565071	hybrid			2022-12-25	WOS:000237336600017
J	Kessels, MM; Qualmann, B				Kessels, MM; Qualmann, B			Syndapin oligomers interconnect the machineries for endocytic vesicle formation and actin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-WASP; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; BINDING-PROTEIN; ARP2/3 COMPLEX; DYNAMIN; CYTOSKELETON; FILAMENT; FAMILY; BAR	Syndapins were proposed to interconnect the machineries for vesicle formation and actin polymerization, as they interact with dynamin and the Arp2/3 complex activator N-WASP ( neural Wiskott-Aldrich syndrome protein). Syndapins, however, have only one Src homology 3 domain mediating both interactions. Here we show that syndapins self-associate via direct syndapin/syndapin interactions, providing a molecular mechanism for the coordinating role of syndapin. Cross-link studies with overexpressed and endogenous syndapins suggest that predominantly dimers form in vivo. Our analyses show that the N-terminal Fes/Cip4 homology domain but not the central coiled-coil domain is sufficient for oligomerization. Additionally, a second interface located further C-terminally mediated interactions with the N terminus. The Src homology 3 domain and the NPF region are not involved and thus available for further interactions interconnecting different syndapin binding partners. Our analyses showed that self-association is crucial for syndapin function. Both syndapin-mediated cytoskeletal rearrangements and endocytosis were disrupted by a self-association-deficient mutant. Consistent with a role of syndapins in linking actin polymerization bursts with endocytic vesicle formation, syndapin-containing complexes had a size of 300 - 500 kDa in gel filtration analysis and contained both dynamin and N-WASP. The existence of an interconnection of the GTPase dynamin with N-WASP via syndapin oligomers was demonstrated both by coimmunoprecipitations and by reconstitution at membranes in intact cells. The interconnection was disrupted by coexpression of syndapin mutants incapable of self-association. Syndapin oligomers may thus act as multivalent organizers spatially and temporally coordinating vesicle fission with local actin polymerization.	Leibniz Inst Neurobiol, Res Grp Cell Biol, D-39118 Magdeburg, Germany; Leibniz Inst Neurobiol, Res Grp Membrane Trafficking & Cytoskeleton, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany	Leibniz Institut fur Neurobiologie (LIN); Leibniz Institut fur Neurobiologie (LIN)	Qualmann, B (corresponding author), Leibniz Inst Neurobiol, Res Grp Cell Biol, Brenneckestr 6, D-39118 Magdeburg, Germany.	qualmann@ifn-magdeburg.de						Benesch S, 2005, J CELL SCI, V118, P3103, DOI 10.1242/jcs.02444; Braun A, 2005, MOL BIOL CELL, V16, P3642, DOI 10.1091/mbc.E05-01-0076; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; da Costa SR, 2003, MOL BIOL CELL, V14, P4397, DOI 10.1091/mbc.E03-05-0315; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Innocenti M, 2005, NAT CELL BIOL, V7, P969, DOI 10.1038/ncb1304; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Kamioka Y, 2004, J BIOL CHEM, V279, P40091, DOI 10.1074/jbc.M404899200; Kessels MM, 2004, J CELL SCI, V117, P3077, DOI 10.1242/jcs.01290; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 2004, EUR J CELL BIOL, V83, P13, DOI 10.1078/0171-9335-00356; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Modregger J, 2000, J CELL SCI, V113, P4511; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Nikki M, 2002, BIOCHEMISTRY-US, V41, P6320, DOI 10.1021/bi015991n; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 2004, J NEUROSCI, V24, P2481, DOI 10.1523/JNEUROSCI.5479-03.2004; Qualmann B, 2002, INT REV CYTOL, V220, P93; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Salazar MA, 2003, J BIOL CHEM, V278, P49031, DOI 10.1074/jbc.M308104200; Sever S, 2000, TRAFFIC, V1, P385, DOI 10.1034/j.1600-0854.2000.010503.x; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Takenawa T, 2001, J CELL SCI, V114, P1801; Taunton J, 2001, CURR OPIN CELL BIOL, V13, P85, DOI 10.1016/S0955-0674(00)00178-2; Valentijn K, 1999, BIOCHEM BIOPH RES CO, V266, P652, DOI 10.1006/bbrc.1999.1883; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774	41	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13285	13299		10.1074/jbc.M510226200	http://dx.doi.org/10.1074/jbc.M510226200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16540475	hybrid			2022-12-25	WOS:000237336600034
J	Pan, YH; Liao, CC; Kuo, CC; Duan, KJ; Liang, PH; Yuan, HS; Hu, ST; Chak, KF				Pan, YH; Liao, CC; Kuo, CC; Duan, KJ; Liang, PH; Yuan, HS; Hu, ST; Chak, KF			The critical roles of polyamines in regulating ColE7 production and restricting ColE7 uptake of the colicin-producing Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOPEPTIDE-BINDING-PROTEIN; OUTER-MEMBRANE PERMEABILITY; ARGININE DECARBOXYLASE; SYNTHESIZE PUTRESCINE; ION CHANNELS; DNASE DOMAIN; ACIDIC PH; SPERMIDINE; CELLS; OMPF	The ColE7 operon is an SOS response regulon, which encodes bacteriocin ColE7 to kill susceptible Escherichia coli and its related enterobacteria under conditions of stress. We have observed for the first time that polyamines confer limited resistance against ColE7 on E. coli cells. Thus, this study aims to investigate the role of polyamines in modulating the protective effect of the E. coli cells against colicin. In the experiments, we surprisingly found that endogenous polyamines are also essential for ColE7 production, and the rate of polyamine synthesis is directly related to the SOS response. Our experimental results further indicated that exogenous polyamines suppress the expression of TolA, BtuB, OmpF, and OmpC proteins that are responsible for ColE7 uptake. Moreover, two-dimensional gel electrophoresis revealed that the production of two periplasmic proteins, PotD and OppA, is increased in E. coli cells under ColE7 exposure. Based on these observations, we propose that endogenous polyamines may play a dual role in the ColE7 system. Polyamines may participate in initiating the expression of the SOS response of the ColE7 operon and simultaneously down-regulate proteins that are essential for colicin uptake, thus conferring a survival advantage on colicin-producing E. coli under stress conditions in the natural environment.	Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11221, Taiwan; Tatung Univ, Inst Bioengn, Taipei 10452, Taiwan; Acad Sinica, Inst Biol Chem & Mol Biol, Taipei 1529, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Tatung University; Academia Sinica - Taiwan	Chak, KF (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan.	kfchak@ym.edu.tw	Liang, Po-Huang/H-6610-2015; Pan, Yi-Hsuan/ABG-6271-2020; Yuan, Hanna S./AAA-4005-2021	Liang, Po-Huang/0000-0003-1207-5256; Pan, Yi-Hsuan/0000-0001-5156-9887; Yuan, Hanna S./0000-0001-9671-6967				ANDREWS JC, 1986, J BACTERIOL, V165, P428, DOI 10.1128/jb.165.2.428-433.1986; Bachrach U, 2001, NEWS PHYSIOL SCI, V16, P106, DOI 10.1152/physiologyonline.2001.16.3.106; Bolter B, 2001, EMBO J, V20, P935, DOI 10.1093/emboj/20.5.935; Bredin J, 2003, BIOCHEM J, V376, P245, DOI 10.1042/BJ20030814; BUCH JK, 1985, J BACTERIOL, V163, P522, DOI 10.1128/JB.163.2.522-527.1985; CARPER SW, 1991, J BIOL CHEM, V266, P12439; CHAK KF, 1991, J GEN MICROBIOL, V137, P91, DOI 10.1099/00221287-137-1-91; Chak KF, 1998, PROTEINS, V32, P17, DOI 10.1002/(SICI)1097-0134(19980701)32:1<17::AID-PROT4>3.0.CO;2-B; Chen FC, 2003, BIOCHEM BIOPH RES CO, V312, P708, DOI 10.1016/j.bbrc.2003.10.155; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; de Zamaroczy M, 2001, MOL CELL, V8, P159, DOI 10.1016/S1097-2765(01)00276-3; delaVega AL, 1996, J BACTERIOL, V178, P3715, DOI 10.1128/jb.178.13.3715-3721.1996; Gibson KE, 1999, J BACTERIOL, V181, P563, DOI 10.1128/JB.181.2.563-571.1999; GOODELL EW, 1987, J BACTERIOL, V169, P3861, DOI 10.1128/jb.169.8.3861-3865.1987; GUYER CA, 1986, J BACTERIOL, V168, P775, DOI 10.1128/jb.168.2.775-779.1986; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; Igarashi K, 1997, J BIOL CHEM, V272, P4058, DOI 10.1074/jbc.272.7.4058; Igarashi K, 2001, RES MICROBIOL, V152, P271, DOI 10.1016/S0923-2508(01)01198-6; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Iyer R, 1997, J BIOL CHEM, V272, P18595, DOI 10.1074/jbc.272.30.18595; Iyer R, 2000, J MOL BIOL, V297, P933, DOI 10.1006/jmbi.2000.3599; James R, 2002, BIOCHIMIE, V84, P381, DOI 10.1016/S0300-9084(02)01450-5; James R, 1996, MICROBIOL-SGM, V142, P1569, DOI 10.1099/13500872-142-7-1569; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; Ko TP, 1999, STRUCT FOLD DES, V7, P91, DOI 10.1016/S0969-2126(99)80012-4; Ku WY, 2002, NUCLEIC ACIDS RES, V30, P1670, DOI 10.1093/nar/30.7.1670; Kurisu G, 2003, NAT STRUCT BIOL, V10, P948, DOI 10.1038/nsb997; KUZMINOV A, 1995, J THEOR BIOL, V177, P29, DOI 10.1006/jtbi.1995.0222; Lazdunski C, 2000, INT J MED MICROBIOL, V290, P337; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; Lazzaroni JC, 2002, BIOCHIMIE, V84, P391, DOI 10.1016/S0300-9084(02)01419-0; Liao CC, 2001, BIOCHEM BIOPH RES CO, V284, P556, DOI 10.1006/bbrc.2001.5016; Limsuwun K, 2000, J BACTERIOL, V182, P5373, DOI 10.1128/JB.182.19.5373-5380.2000; Liu NZ, 1997, BBA-BIOMEMBRANES, V1326, P201, DOI 10.1016/S0005-2736(97)00024-2; Liu XQ, 2001, MICROBIOL-SGM, V147, P2981, DOI 10.1099/00221287-147-11-2981; Lu FM, 1996, MOL GEN GENET, V251, P407, DOI 10.1007/BF02172368; MORGAN DML, 1998, POLAMINE PROTOCOLS, P119; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; Oh TJ, 1999, BIOCHEM BIOPH RES CO, V264, P584, DOI 10.1006/bbrc.1999.1553; Oh TJ, 1999, CELL BIOL TOXICOL, V15, P291, DOI 10.1023/A:1007663701589; PANAGIOTIDIS CA, 1987, P NATL ACAD SCI USA, V84, P4423, DOI 10.1073/pnas.84.13.4423; PARK JT, 1993, J BACTERIOL, V175, P7, DOI 10.1128/JB.175.1.7-11.1993; Pasquali C, 1997, ELECTROPHORESIS, V18, P2573, DOI 10.1002/elps.1150181413; Riley MA, 2002, ANNU REV MICROBIOL, V56, P117, DOI 10.1146/annurev.micro.56.012302.161024; Riley MA, 1999, TRENDS MICROBIOL, V7, P129, DOI 10.1016/S0966-842X(99)01459-6; Samartzidou H, 1999, J BACTERIOL, V181, P791, DOI 10.1128/JB.181.3.791-798.1999; Samartzidou H, 2003, J BACTERIOL, V185, P13, DOI 10.1128/JB.185.1.13-19.2003; SOONG BW, 1994, MOL GEN GENET, V243, P477; TABOR CW, 1978, J BIOL CHEM, V253, P3671; TABOR H, 1980, J BACTERIOL, V144, P952, DOI 10.1128/JB.144.3.952-956.1980; TABOR H, 1981, J BACTERIOL, V147, P702, DOI 10.1128/JB.147.2.702-704.1981; Tkachenko A, 2001, ARCH MICROBIOL, V176, P155, DOI 10.1007/s002030100301; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yoshida M, 2004, J BIOL CHEM, V279, P46008, DOI 10.1074/jbc.M404393200; Yoshida M, 2001, J BIOL CHEM, V276, P16289, DOI 10.1074/jbc.M011059200; Yoshida M, 1999, J BIOL CHEM, V274, P22723, DOI 10.1074/jbc.274.32.22723; Yu SL, 2000, J BACTERIOL, V182, P5962, DOI 10.1128/JB.182.21.5962-5968.2000; Zakharov SD, 2004, FRONT BIOSCI-LANDMRK, V9, P1311, DOI 10.2741/1334	62	21	22	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13083	13091		10.1074/jbc.M511365200	http://dx.doi.org/10.1074/jbc.M511365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16549429	hybrid, Green Submitted			2022-12-25	WOS:000237336600012
J	Reddy, MA; Li, SL; Sahar, S; Kim, YS; Xu, ZG; Lanting, L; Natarajan, R				Reddy, MA; Li, SL; Sahar, S; Kim, YS; Xu, ZG; Lanting, L; Natarajan, R			Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; C-SRC; TYROSINE PHOSPHORYLATION; ADVANCED GLYCOSYLATION; SIGNAL TRANSDUCERS; POTENTIAL ROLE; RAGE; EXPRESSION	The receptor for advanced glycation end products (RAGE) and its ligands have been implicated in the activation of oxidant stress and inflammatory pathways in vascular smooth muscle cells (VSMCs) leading to the initiation and augmentation of atherosclerosis. Here we report that non-receptor Src tyrosine kinase and the membrane protein caveolin-1 (Cav-1) play a key role in the activation of RAGE by S100B in VSMCs. S100B increased the activation of Src kinase and tyrosine phosphorylation of caveolin-1 in VSMCs. A RAGE-specific antibody blocked both these effects. An inhibitor of Src kinase, PP2, significantly blocked S100B-induced activation of Src kinase, mitogen-activated protein kinases, transcription factors NF-B and STAT3, superoxide production, tyrosine phosphorylation of Cav-1, VSMC migration, and expression of the pro-inflammatory genes monocyte chemotactic protein-1 and interleukin-6. Cholesterol depletion also inhibited S100B-induced effects indicating the requirement for intact caveolae in RAGE-specific signaling. Nucleofection of either a Src dominant negative mutant, or a Cav-1 mutant lacking the scaffolding domain, or Cav-1 short hairpin RNA significantly reduced S100B- induced inflammatory gene expression in VSMCs. Furthermore, VSMCs derived from insulin-resistant and diabetic db/db mice displayed increased RAGE expression, Src activation, and migration compared with those from control db/(+) mice. The RAGE antibody blocked enhanced migration in db/db cells. These studies demonstrate for the first time that, in VSMCs, Src kinase and Cav-1 play important roles in RAGE- mediated inflammatory gene expression and migration, key events associated with diabetic vascular complications.	Beckman Res Inst, Dept Diabet, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Natarajan, R (corresponding author), Beckman Res Inst, Dept Diabet, Duarte, CA 91010 USA.	RNatarajan@coh.org		Reddy, Marpadga A/0000-0001-9259-7243	NHLBI NIH HHS [P01-HL55798] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aronson D, 2002, MED HYPOTHESES, V59, P297, DOI 10.1016/S0306-9877(02)00172-X; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Bucciarelli LG, 2002, CIRCULATION, V106, P2827, DOI 10.1161/01.CIR.0000039325.03698.36; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Dwarakanath RS, 2004, J MOL CELL CARDIOL, V36, P585, DOI 10.1016/j.yjmcc.2004.02.007; Fan CG, 2004, J CLIN INVEST, V113, P746, DOI 10.1172/JCI200417337; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Funakoshi-Tago M, 2005, J BIOCHEM, V137, P189, DOI 10.1093/jb/mvi018; Hatley ME, 2003, J BIOL CHEM, V278, P25369, DOI 10.1074/jbc.M301175200; Hattori Y, 2002, HYPERTENSION, V39, P22, DOI 10.1161/hy1201.097300; Higashi T, 1997, DIABETES, V46, P463, DOI 10.2337/diabetes.46.3.463; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Huang JS, 2001, J CELL BIOCHEM, V81, P102, DOI 10.1002/1097-4644(20010401)81:1<102::AID-JCB1027>3.0.CO;2-Y; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Kim W, 2005, ANN NY ACAD SCI, V1043, P553, DOI 10.1196/annals.1338.063; Kislinger T, 2001, ARTERIOSCL THROM VAS, V21, P905, DOI 10.1161/01.ATV.21.6.905; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li SL, 2005, J LIPID RES, V46, P220, DOI 10.1194/jlr.M400328-JLR200; Li SW, 1996, J BIOL CHEM, V271, P3863; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lu HF, 2004, ENDOCRINOLOGY, V145, P4934, DOI 10.1210/en.2004-0737; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mizutani K, 2000, BIOCHEM BIOPH RES CO, V274, P61, DOI 10.1006/bbrc.2000.3097; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Naka Y, 2004, ARTERIOSCL THROM VAS, V24, P1342, DOI 10.1161/01.ATV.0000133191.71196.90; NATARAJAN R, 1992, BIOCHEM BIOPH RES CO, V187, P552, DOI 10.1016/S0006-291X(05)81529-3; Natarajan R, 1996, J CELL PHYSIOL, V169, P391, DOI 10.1002/(SICI)1097-4652(199611)169:2<391::AID-JCP19>3.3.CO;2-Q; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Ramasamy R, 2005, GLYCOBIOLOGY, V15, p16R, DOI 10.1093/glycob/cwi053; Reddy MA, 2003, HYPERTENSION, V41, P1294, DOI 10.1161/01.HYP.0000069011.18333.08; Reddy MA, 2002, AM J PHYSIOL-RENAL, V283, pF985, DOI 10.1152/ajprenal.00181.2002; Reddy MA, 2002, J BIOL CHEM, V277, P9920, DOI 10.1074/jbc.M111305200; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; Sahar S, 2005, CIRC RES, V96, P1064, DOI 10.1161/01.RES.0000168210.10358.f4; Sakaguchi T, 2003, J CLIN INVEST, V111, P959, DOI 10.1172/JCI200317115; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seki Y, 2000, CIRC RES, V87, P12, DOI 10.1161/01.RES.87.1.12; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaw SS, 2003, DIABETES, V52, P2381, DOI 10.2337/diabetes.52.9.2381; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Srivastava AK, 2002, INT J MOL MED, V9, P85; STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; VLASSARA H, 1994, LAB INVEST, V70, P138; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wang Ruojiao, 2001, Journal of Nippon Medical School, V68, P472, DOI 10.1272/jnms.68.472; Williams TM, 2004, ANN MED, V36, P584, DOI 10.1080/07853890410018899; Yan SF, 2003, CIRC RES, V93, P1159, DOI 10.1161/01.RES.0000103862.26506.3D; Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855	58	129	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13685	13693		10.1074/jbc.M511425200	http://dx.doi.org/10.1074/jbc.M511425200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551628	hybrid			2022-12-25	WOS:000237336600079
J	Tsui, J; Malenka, RC				Tsui, J; Malenka, RC			Substrate localization creates specificity in calcium/calmodulin-dependent protein kinase II signaling at synapses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; RECEPTOR GLUR1 SUBUNIT; D-ASPARTATE RECEPTOR; BIDIRECTIONAL SYNAPTIC PLASTICITY; CULTURED HIPPOCAMPAL-NEURONS; AMPA RECEPTOR; NMDA RECEPTOR; POSTSYNAPTIC DENSITY; DENDRITIC SPINES; PHOSPHORYLATION SITE	Calcium/ calmodulin- dependent protein kinase II ( CaMKII), a major component of the postsynaptic density ( PSD) of excitatory synapses, plays a key role in the regulation of synaptic function in the mammalian brain. Although many postsynaptic substrates for CaMKII have been characterized in vitro, relatively little is known about their phosphorylation in vivo. By tagging synaptic proteins with a peptide substrate specific for CaMKII and expressing them in cultured neurons, we have visualized substrate phosphorylation by CaMKII at intact synapses. All substrates tested were strongly phosphorylated by CaMKII in HEK293 cells. However, activity- dependent phosphorylation of substrates at synapses was highly selective in that the glutamate receptor subunits NR2B and GluR1 were poorly phosphorylated whereas PSD- 95 and Stargazin, proteins implicated in the scaffolding and trafficking of AMPA receptors, were robustly phosphorylated. Phosphatase activity limited phosphorylation of Stargazin but not NR2B and GluR1. These results suggest that the unique molecular architecture of the PSD results in highly selective substrate discrimination by CaMKII.	Stanford Univ, Dept Psychiat & Behav Sci, Stanford Med Ctr, Nancy Pritzker Lab, Palo Alto, CA 94304 USA	Stanford University	Malenka, RC (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, Stanford Med Ctr, Nancy Pritzker Lab, 1201 Welch Rd, Palo Alto, CA 94304 USA.	malenka@stanford.edu			NIMH NIH HHS [MH 063394] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH063394, R01MH063394] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Barria A, 2005, NEURON, V48, P289, DOI 10.1016/j.neuron.2005.08.034; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Chang BH, 1998, P NATL ACAD SCI USA, V95, P10890, DOI 10.1073/pnas.95.18.10890; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; El-Hussein AE, 2000, SCIENCE, V290, P1364; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Holtmaat AJGD, 2005, NEURON, V45, P279, DOI 10.1016/j.neuron.2005.01.003; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; Inagaki N, 2000, J BIOL CHEM, V275, P27165; Kasai H, 2003, TRENDS NEUROSCI, V26, P360, DOI 10.1016/S0166-2236(03)00162-0; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu CS, 2003, NEURON, V40, P1185, DOI 10.1016/S0896-6273(03)00786-4; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; Matsuzaki M, 2001, NAT NEUROSCI, V4, P1086, DOI 10.1038/nn736; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Montgomery JM, 2004, CELL MOL LIFE SCI, V61, P911, DOI 10.1007/s00018-003-3364-5; Niethammer M, 1996, J NEUROSCI, V16, P2157; Ninan I, 2004, NEURON, V42, P129, DOI 10.1016/S0896-6273(04)00143-6; Noguchi J, 2005, NEURON, V46, P609, DOI 10.1016/j.neuron.2005.03.015; OH MC, 2005, NAT NEUROSCI; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; Petersen JD, 2003, J NEUROSCI, V23, P11270; Pratt KG, 2003, NEURON, V39, P269, DOI 10.1016/S0896-6273(03)00422-7; Prybylowski K, 2005, NEURON, V47, P845, DOI 10.1016/j.neuron.2005.08.016; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Sobczyk A, 2005, J NEUROSCI, V25, P6037, DOI 10.1523/JNEUROSCI.1221-05.2005; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1997, J NEUROCHEM, V68, P2119; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Takumi Y, 1999, NAT NEUROSCI, V2, P618, DOI 10.1038/10172; Tomita S, 2005, NATURE, V435, P1052, DOI 10.1038/nature03624; Tomita S, 2005, NEURON, V45, P269, DOI 10.1016/j.neuron.2005.01.009; Tsui J, 2005, J BIOL CHEM, V280, P9210, DOI 10.1074/jbc.M407653200; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Yasuda R, 2003, NAT NEUROSCI, V6, P948, DOI 10.1038/nn1112; Yoshimura Y, 2002, BIOCHEM BIOPH RES CO, V290, P948, DOI 10.1006/bbrc.2001.6320; Yoshimura Y, 2000, MOL BRAIN RES, V81, P118, DOI 10.1016/S0169-328X(00)00170-4; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805	63	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13794	13804		10.1074/jbc.M600966200	http://dx.doi.org/10.1074/jbc.M600966200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551613	hybrid			2022-12-25	WOS:000237336600090
J	Abildayeva, K; Jansen, PJ; Hirsch-Reinshagen, V; Bloks, VW; Bakker, AHF; Ramaekers, FCS; de Vente, J; Groen, AK; Wellington, CL; Kuipers, F; Mulder, M				Abildayeva, K; Jansen, PJ; Hirsch-Reinshagen, V; Bloks, VW; Bakker, AHF; Ramaekers, FCS; de Vente, J; Groen, AK; Wellington, CL; Kuipers, F; Mulder, M			24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; BRAIN CHOLESTEROL; A-I; ADIPOSE-TISSUE; GLIAL-CELLS; MACROPHAGE CHOLESTEROL; GENE-EXPRESSION; ALPHA GENE; LXR-ALPHA	Both apolipoprotein E (apoE) and 24(S)-hydroxycholesterol are involved in the pathogenesis of Alzheimer disease (AD). It has been hypothesized that apoE affects AD development via isoform-specific effects on lipid trafficking between astrocytes and neurons. However, the regulation of the cholesterol supply of neurons via apoE-containing high density lipoproteins remains to be clarified. We show for the first time that the brain-specific metabolite of cholesterol produced by neurons, i.e. 24(S)-hydroxycholesterol, induces apoE transcription, protein synthesis, and secretion in a dose- and time-dependent manner in cells of astrocytic but not of neuronal origin. Moreover, 24(S)-hydroxycholesterol primes astrocytoma, but not neuroblastoma cells, to mediate cholesterol efflux to apoE. Similar results were obtained using the synthetic liver X receptor (LXR) agonist GW683965A, suggesting involvement of an LXR-controlled signaling pathway. A 10-20-fold higher basal LXR alpha and -beta expression level in astrocytoma compared with neuroblastoma cells may underlie these differential effects. Furthermore, apoE-mediated cholesterol efflux from astrocytoma cells may be controlled by the ATP binding cassette transporters ABCA1 and ABCG1, since their expression was also up-regulated by both compounds. In contrast, ABCG4 seems not to be involved, because its expression was induced only in neuronal cells. The expression of sterol regulatory element-binding protein (SREBP-2), low density lipoprotein receptor, 3-hydroxy-3-methylglutaryl-CoA reductase, and SREBP-1c was transiently up-regulated by GW683965A in astrocytes but down-regulated by 24(S)-hydroxycholesterol, suggesting that cholesterol efflux and synthesis are regulated independently. In conclusion, evidence is provided that 24(S)-hydroxycholesterol induces apoE-mediated efflux of cholesterol in astrocytes via an LXR-controlled pathway, which may be relevant for chronic and acute neurological diseases.	Univ Maastricht, Dept Mol Cell Biol, European Grad Sch Neurosci EURON, Inst Brain & Behav, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Dept Psychiat & Neuropsychol, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Dept Mol Genet, NL-6200 MD Maastricht, Netherlands; Univ British Columbia, Dept Pathol & Lab Med, British Columbia Child & Family Res Inst, Vancouver, BC V4Z 5H5, Canada; Acad Med Ctr, Dept Med Biochem, NL-1105 BK Amsterdam, Netherlands; Univ Groningen, Med Ctr, Dept Pediat, NL-9713 GZ Groningen, Netherlands	Maastricht University; Maastricht University; Maastricht University; Child & Family Research Institute; University of British Columbia; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen	Mulder, M (corresponding author), Univ Maastricht, Dept Mol Cell Biol, European Grad Sch Neurosci EURON, Inst Brain & Behav, POB 616,Box 17, NL-6200 MD Maastricht, Netherlands.	M.Mulder@MOLCELB.unimaas.nl	Bloks, Vincent/A-7609-2012	Bloks, Vincent/0000-0001-6493-7482; Kuipers, Folkert/0000-0003-2518-737X				Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Argmann CA, 2005, J BIOL CHEM, V280, P22212, DOI 10.1074/jbc.M502761200; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b; Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178; Bogdanovica N, 2001, NEUROSCI LETT, V314, P45, DOI 10.1016/S0304-3940(01)02277-7; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Deumens R, 2004, NEUROSCIENCE, V125, P591, DOI 10.1016/j.neuroscience.2004.02.010; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Dijkstra S, 1999, NEUROSCIENCE, V92, P1331, DOI 10.1016/S0306-4522(99)00060-3; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; Groen AK, 2004, ANN MED, V36, P135, DOI 10.1080/07853890310020635; Harr SD, 1996, J NEUROCHEM, V66, P2429; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Hummasti S, 2004, J LIPID RES, V45, P616, DOI 10.1194/jlr.M300312-JLR200; Jiang XC, 2003, J BIOL CHEM, V278, P49072, DOI 10.1074/jbc.M304274200; Joseph SB, 2003, CURR OPIN PHARMACOL, V3, P192, DOI 10.1016/S1471-4892(03)00009-2; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Kockx M, 2004, J BIOL CHEM, V279, P25966, DOI 10.1074/jbc.M401177200; Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200; Kolsch H, 2002, MOL PSYCHIATR, V7, P899, DOI 10.1038/sj.mp.4001109; KRAUSE BR, 1984, J LIPID RES, V25, P97; LaDu MJ, 2000, ANN NY ACAD SCI, V903, P167, DOI 10.1111/j.1749-6632.2000.tb06365.x; Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; MOCKEL B, 1994, J NEUROCHEM, V62, P788; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; Oldfield S, 2002, BBA-MOL CELL RES, V1591, P175, DOI 10.1016/S0167-4889(02)00269-0; Oram JF, 2001, J LIPID RES, V42, P1173; Panin LE, 2000, BIOCHEMISTRY-MOSCOW+, V65, P1419, DOI 10.1023/A:1002861008363; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Pfrieger FW, 2003, CELL MOL LIFE SCI, V60, P1158, DOI 10.1007/s00018-003-3018-7; Pfrieger FW, 2003, BIOESSAYS, V25, P72, DOI 10.1002/bies.10195; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Rebeck GW, 2004, J MOL NEUROSCI, V23, P219, DOI 10.1385/JMN:23:3:219; Reiss AB, 2004, NEUROBIOL AGING, V25, P977, DOI 10.1016/j.neurobiolaging.2003.11.009; Reiss Allison B, 2005, Am J Alzheimers Dis Other Demen, V20, P91, DOI 10.1177/153331750502000208; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Slezak M, 2003, TRENDS NEUROSCI, V26, P531, DOI 10.1016/j.tins.2003.08.005; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Steffensen KR, 2003, BIOCHEM BIOPH RES CO, V310, P589, DOI 10.1016/j.bbrc.2003.08.139; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Ulven SM, 2004, J LIPID RES, V45, P2052, DOI 10.1194/jlr.M400119-JLR200; Vance JE, 2005, SEMIN CELL DEV BIOL, V16, P193, DOI 10.1016/j.semcdb.2005.01.005; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Walczak R, 2002, J LIPID RES, V43, P177; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Whitney KD, 2001, J BIOL CHEM, V276, P43509, DOI 10.1074/jbc.M106155200; Wolozin B, 2004, CNS DRUG REV, V10, P127; Wood WG, 1999, LIPIDS, V34, P225, DOI 10.1007/s11745-999-0357-9; Yu LQ, 2003, J BIOL CHEM, V278, P15565, DOI 10.1074/jbc.M301311200	66	181	191	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12799	12808		10.1074/jbc.M601019200	http://dx.doi.org/10.1074/jbc.M601019200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524875	Green Published, hybrid			2022-12-25	WOS:000237134700074
J	Baltin, J; Leist, S; Odronitz, F; Wollscheid, HP; Baack, M; Kapitza, T; Schaarschmidt, D; Knippers, R				Baltin, J; Leist, S; Odronitz, F; Wollscheid, HP; Baack, M; Kapitza, T; Schaarschmidt, D; Knippers, R			DNA replication in protein extracts from human cells requires ORC and mcm proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; IN-VITRO REPLICATION; EUKARYOTIC CELLS; XENOPUS EGGS; FREE SYSTEM; HELA-CELLS; INITIATION; BINDING; SEQUENCE; INVITRO	We used protein extracts from proliferating human HeLa cells to support plasmid DNA replication in vitro. An extract with soluble nuclear proteins contains the major replicative chain elongation functions, whereas a high salt extract from isolated nuclei contains the proteins for initiation. Among the initiator proteins active in vitro are the origin recognition complex (ORC) and Mcm proteins. Recombinant Orc1 protein stimulates in vitro replication presumably in place of endogenous Orc1 that is known to be present in suboptimal amounts in HeLa cell nuclei. Partially purified endogenous ORC, but not recombinant ORC, is able to rescue immunodepleted nuclear extracts. Plasmid replication in the in vitro replication system is slow and of limited efficiency but robust enough to serve as a basis to investigate the formation of functional pre-replication complexes under biochemically defined conditions.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Schaarschmidt, D (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	daniel.schaarschmidt@uni-konstanz.de						ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BERBERICH S, 1995, J MOL BIOL, V245, P92, DOI 10.1006/jmbi.1994.0010; Biamonti G, 2003, CHROMOSOME RES, V11, P403, DOI 10.1023/A:1024910307162; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DePamphilis ML, 2005, CELL CYCLE, V4, P70, DOI 10.4161/cc.4.1.1333; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; Giordano-Coltart J, 2005, P NATL ACAD SCI USA, V102, P69, DOI 10.1073/pnas.0408690102; Gruss C, 1999, METH MOL B, V119, P291; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; Jenke ACW, 2004, P NATL ACAD SCI USA, V101, P11322, DOI 10.1073/pnas.0401355101; Kneissl M, 2003, J MOL BIOL, V327, P111, DOI 10.1016/S0022-2836(03)00079-2; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFFAK M, 1989, MOL CELL BIOL, V9, P586, DOI 10.1128/MCB.9.2.586; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Mizushima T, 2000, GENE DEV, V14, P1631; Natale DA, 2000, EMBO J, V19, P2728, DOI 10.1093/emboj/19.11.2728; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Pasero P, 1997, GENE DEV, V11, P1504, DOI 10.1101/gad.11.12.1504; PEARSON CE, 1994, SOMAT CELL MOLEC GEN, V20, P147, DOI 10.1007/BF02254755; PEARSON CE, 1991, BIOCHIM BIOPHYS ACTA, V1090, P156, DOI 10.1016/0167-4781(91)90096-5; Piechaczek C, 1999, NUCLEIC ACIDS RES, V27, P426, DOI 10.1093/nar/27.2.426; Price GB, 2003, J BIOL CHEM, V278, P19649, DOI 10.1074/jbc.M207002200; Remus D, 2004, EMBO J, V23, P897, DOI 10.1038/sj.emboj.7600077; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; Schaarschmidt D, 2004, EMBO J, V23, P191, DOI 10.1038/sj.emboj.7600029; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; Wu JR, 1997, METHODS, V13, P313, DOI 10.1006/meth.1997.0530; ZANNISHADJOPOULOS M, 1994, GENE, V151, P273, DOI 10.1016/0378-1119(94)90670-X; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	46	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12428	12435		10.1074/jbc.M510758200	http://dx.doi.org/10.1074/jbc.M510758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16537544	hybrid			2022-12-25	WOS:000237134700029
J	Smyth, JT; Lemonnier, L; Vazquez, G; Bird, GS; Putney, JW				Smyth, JT; Lemonnier, L; Vazquez, G; Bird, GS; Putney, JW			Dissociation of regulated trafficking of TRPC3 channels to the plasma membrane from their activation by phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-PERMEABLE CATION CHANNEL; INOSITOL TRISPHOSPHATE RECEPTOR; PROTEIN-COUPLED RECEPTOR; CAPACITATIVE CA2+ ENTRY; TRANSIENT RECEPTOR; FUNCTIONAL EXPRESSION; SIGNALING MECHANISM; STORE DEPLETION; B-LYMPHOCYTES; KINASE-C	Regulated translocation of canonical transient receptor potential ( TRPC) proteins to the plasma membrane has been proposed as a mechanism of their activation. By using total internal reflection fluorescence microscopy (TIRFM), we monitored green fluorescent protein-labeled TRPC3 (TRPC3-GFP) movement to the plasma membrane in HEK293 cells stably expressing this fusion protein. We observed no increase in TRPC3-GFP TIRFM in response to the muscarinic receptor agonist methacholine or the synthetic diacylglycerol, 1-oleoyl-2-acetyl-sn-glycerol, despite activation of TRPC3 by these agents. We did, however, observe a TIRFM response to epidermal growth factor (EGF). This TIRFM response to EGF was accompanied by increased Ba2+ entry and TRPC3 currents. However, 1-oleoyl-2-acetyl-sn-glycerol-induced TRPC3 activity was not increased. TIRFM also increased in response to Gd3+, a competitive inhibitor of TRPC3 channels. This may be indicative of constitutive trafficking of TRPC3, with Gd3+ acting to "trap" cycling TRPC3 molecules in the plasma membrane. Consistent with this interpretation, TRPC3-expressing cells exhibited large variance in membrane capacitance, and this variance was decreased by both Gd3+ and EGF. These results indicate the following: (i) trafficking of TRPC3 may play a role in regulating the concentration of channels in the plasma membrane but is not involved in activation through the phospholipase C pathway; (ii) TRPC3 undergoes constitutive cyclical trafficking in the plasma membrane, and the mechanism by which growth factors increase the number of plasma membrane channels may involve stabilizing them in the plasma membrane.	NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019; Lemonnier, Loic/L-7289-2018; Bird, Gary/AAI-8186-2021	Putney, James W/0000-0002-3379-4789; Lemonnier, Loic/0000-0001-6200-5382; Bird, Gary/0000-0003-1389-8748	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Cayouette S, 2004, J BIOL CHEM, V279, P7241, DOI 10.1074/jbc.M312042200; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; KREYE VAW, 1986, PFLUG ARCH EUR J PHY, V406, P308, DOI 10.1007/BF00640919; KWAN CY, 1990, J BIOL CHEM, V265, P678; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; MONTELL C, 2001, SCI STKE, V90, P1; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Newton AC, 2002, METHOD ENZYMOL, V345, P499; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Ordaz B, 2005, J BIOL CHEM, V280, P30788, DOI 10.1074/jbc.M504745200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Royle SJ, 2003, BIOESSAYS, V25, P39, DOI 10.1002/bies.10200; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; UVELIUS B, 1974, BLOOD VESSELS, V11, P245; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vazquez G, 2004, J BIOL CHEM, V279, P40521, DOI 10.1074/jbc.M405280200; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2003, J BIOL CHEM, V278, P29031, DOI 10.1074/jbc.M302751200; von Gersdorff H, 1999, ANNU REV PHYSIOL, V61, P725, DOI 10.1146/annurev.physiol.61.1.725; Wissenbach U, 2004, BIOL CELL, V96, P47, DOI 10.1016/j.biolcel.2003.12.003; Yildirim E, 2005, P NATL ACAD SCI USA, V102, P3307, DOI 10.1073/pnas.0409908102; Zeng FN, 2004, J PHYSIOL-LONDON, V559, P739, DOI 10.1113/jphysiol.2004.065391; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	44	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11712	11720		10.1074/jbc.M510541200	http://dx.doi.org/10.1074/jbc.M510541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16522635	hybrid			2022-12-25	WOS:000236988100035
J	Cuevas, BD; Winter-Vann, AM; Johnson, NL; Johnson, GL				Cuevas, B. D.; Winter-Vann, A. M.; Johnson, N. L.; Johnson, G. L.			MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer	ONCOGENE			English	Article						breast cancer; metastasis; kinase; proteinase; MAPK; knockout	UROKINASE PLASMINOGEN-ACTIVATOR; HUMAN-BREAST-CANCER; DEFICIENT MICE; GROWTH-FACTOR; REDUCED METASTASIS; GENE DISRUPTION; ERK/MAP KINASE; MESSENGER-RNA; IN-VITRO; EXPRESSION	Mammary tumor cells are required to degrade the surrounding matrix and disseminate in order to metastasize, and both of these processes are controlled by a tumor cell-signaling network that remains poorly defined. MEKK1 is a MAPKKK that regulates both the extracellular signal regulated kinase (ERK1/2) and the c-Jun amino terminal kinase (JNK) signaling pathways. MEKK1 signaling regulates migration through control of cell adhesion and is required for inducible expression of urokinase-type plasminogen activator (uPA). MEKK1-deficient mice with mammary gland-targeted expression of the polyoma middle T antigen (PyMT) transgene develop primary mammary tumors at a rate and frequency similar to wild-type littermates, indicating that MEKK1 deficiency does not affect PyMT-mediated transformation. However, MEKK1-/- mice display significantly delayed tumor cell dissemination and lung metastasis. Delayed MEKK1-dependent tumor dissemination is associated with markedly reduced tumor uPA expression, gelatinase activity, and prolonged tumor basement membrane integrity. siRNA-mediated MEKK1 knockdown inhibits uPA activity, cell migration and invasion in MDA-MB-231 human breast cancer cells. Thus MEKK1 controls tumor progression by regulating both the migration and proteolysis aspects of tumor cell invasiveness. To our knowledge, this is the first example of a MAPKKK that regulates metastasis through control of tumor invasiveness.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cuevas, BD (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, 1108 Mary Ellen Jones Bldg,Campus Box 7365, Chapel Hill, NC 27599 USA.	bruce_cuevas@med.unc.edu; glj@med.unc.edu	, Pathology Services Core/CEZ-2246-2022		NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed F, 2002, CANCER RES, V62, P7166; Almholt K, 2005, INT J CANCER, V113, P525, DOI 10.1002/ijc.20631; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Balduyck M, 2000, CLIN EXP METASTAS, V18, P171, DOI 10.1023/A:1006762425323; Bianco FJ, 1998, CLIN CANCER RES, V4, P3011; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Christensen L, 1996, INT J CANCER, V66, P441; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Cuevas BD, 2005, ONCOGENE, V24, P801, DOI 10.1038/sj.onc.1208239; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DAVIES B, 1993, CANCER RES, V53, P5365; Duffy MJ, 2004, ANN CLIN BIOCHEM, V41, P370, DOI 10.1258/0004563041731529; Duffy MJ, 2004, CLIN BIOCHEM, V37, P541, DOI 10.1016/j.clinbiochem.2004.05.013; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ELYAZIDI I, 1995, ANTICANCER RES, V15, P783; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FIDLER IJ, 1991, ACTA ONCOL, V30, P669, DOI 10.3109/02841869109092438; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Frederiks WM, 2004, J HISTOCHEM CYTOCHEM, V52, P711, DOI 10.1369/jhc.4R6251.2004; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gelder MEV, 2004, CANCER RES, V64, P4563, DOI 10.1158/0008-5472.CAN-03-3848; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hamasaki T, 1998, UROL RES, V26, P371, DOI 10.1007/s002400050071; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Itoh T, 1998, CANCER RES, V58, P1048; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Manders P, 2004, CANCER-AM CANCER SOC, V101, P486, DOI 10.1002/cncr.20374; Nielsen BS, 1996, LAB INVEST, V74, P168; Nielsen BS, 2001, LAB INVEST, V81, P1485, DOI 10.1038/labinvest.3780363; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Schweinitz A, 2004, J BIOL CHEM, V279, P33613, DOI 10.1074/jbc.M314151200; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Sieuwerts AM, 1999, BREAST CANCER RES TR, V55, P9, DOI 10.1023/A:1006190729866; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Tanaka Y, 2004, GYNECOL ONCOL, V94, P725, DOI 10.1016/j.ygyno.2004.06.012; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Witowsky J, 2003, J BIOL CHEM, V278, P5941, DOI 10.1074/jbc.M212363200; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	49	47	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4998	5010		10.1038/sj.onc.1209507	http://dx.doi.org/10.1038/sj.onc.1209507			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568086				2022-12-25	WOS:000239921300005
J	Silva, FP; Hamamoto, R; Furukawa, Y; Nakamura, Y				Silva, F. P.; Hamamoto, R.; Furukawa, Y.; Nakamura, Y.			TIPUH1 encodes a novel KRAB zinc-finger protein highly expressed in human hepatocellular carcinomas	ONCOGENE			English	Article						TIPUH1; hepatocellular carcinoma; TIF1 beta; hnRNPU; nucleolin	MECHANISMS; CANCER; GENE; CARCINOGENESIS; INVOLVEMENT; FAMILY	To achieve a better understanding of mechanisms that underlie hepatocarcinogenesis and to identify novel target molecules for diagnosis and therapy of hepatocellular carcinoma (HCC), we previously analysed gene-expression profiles of 20 HCC tissues on a cDNA microarray. Among the genes upregulated in the tumor tissues compared with their nontumor counterparts, we focused on a novel gene termed transcription-involved protein upregulated in HCC (TIPUH1) that putatively encoded a 500-amino-acid protein containing 12 zinc-finger domains and a Kruppel-associated box domain. Multiple-tissue northern blot analysis revealed it's testis- and placenta-specific expression in normal tissues. Colony-formation assay in soft agar showed that TIPUH1 conferred anchorage-independent growth to NIH3T3 cells, suggesting its oncogenic activity. Conversely, specific siRNA for TIPUH1 knocked down its expression in HCC cells, which resulted in their growth inhibition. We identified four TIPUH1-interacting proteins including TIF1 beta, a transcription-intermediary protein, and three involved in pre-mRNA processing (hnRNPU, hnRNPF, and Nucleolin), suggesting that overexpressed TIPUH1 may play a role in hepatocarcinogenesis by regulating transcription and/or RNA processing of growth control genes. These data may contribute to a better understanding of liver neoplasia, and to the development of novel strategy for treatment of HCCs.	Univ Tokyo, Inst Med Sci, Human Genome Ctr, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Human Genome Ctr, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Hamamoto, Ryuji/AAF-9600-2019; Silva, Fabio Pittella/B-2621-2013	Hamamoto, Ryuji/0000-0002-2632-1334; Silva, Fabio Pittella/0000-0002-9644-7098				Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Grisham JW, 2002, MOLECULAR BASIS OF HUMAN CANCER, P269; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Howell M, 2004, J BIOL CHEM, V279, P26300, DOI 10.1074/jbc.M401070200; Kim GJ, 2003, CANCER GENET CYTOGEN, V142, P129, DOI 10.1016/S0165-4608(02)00834-8; Looman C, 2002, MOL BIOL EVOL, V19, P2118, DOI 10.1093/oxfordjournals.molbev.a004037; Mark C, 1999, DNA CELL BIOL, V18, P381, DOI 10.1089/104454999315277; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Oguri T, 1998, GENE, V222, P61, DOI 10.1016/S0378-1119(98)00464-8; Okabe H, 2001, CANCER RES, V61, P2129; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Raidl M, 2004, J HEPATOL, V40, P660, DOI 10.1016/j.jhep.2003.12.020; Reed R, 2001, NAT CELL BIOL, V3, pE201, DOI 10.1038/ncb0901-e201; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Shimokawa T, 2003, CANCER RES, V63, P6116; Silva FP, 2005, NEOPLASIA, V7, P348, DOI 10.1593/neo.04544; TANAKA S, 1993, CANCER RES, V53, P2884; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Wilkens L, 2001, J PATHOL, V193, P476, DOI 10.1002/path.825; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	25	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5063	5070		10.1038/sj.onc.1209517	http://dx.doi.org/10.1038/sj.onc.1209517			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568080				2022-12-25	WOS:000239921300012
J	Salazar, M; Rojo, AI; Velasco, D; de Sagarra, RM; Cuadrado, A				Salazar, Maria; Rojo, Ana I.; Velasco, Diego; de Sagarra, Rosa Maria; Cuadrado, Antonio			Glycogen synthase kinase-3 beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; SUBSTRATE ADAPTER PROTEIN; OXIDATIVE STRESS; HEME OXYGENASE-1; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL-3 KINASE/AKT; PROTEASOMAL DEGRADATION; INDUCIBLE EXPRESSION; NEGATIVE REGULATION; HEAT-SHOCK	The transcription factor Nrf2 ( nuclear factor E2-related factor 2) regulates the expression of antioxidant phase II genes and contributes to preserve redox homeostasis and cell viability in response to oxidant insults. Nrf2 should be coordinated with the canonical cell survival pathway represented by phosphatidylinositol 3-kinase (PI3K) and the Ser/Thr kinase Akt but so far the mechanistic connections remain undefined. Here we identify glycogen synthase kinase-3 beta (GSK-3 beta), which is inhibited by Akt-mediated phosphorylation, as the link between both processes. Using heme oxygenase-1 (HO-1) as a model phase II gene, we found that both PI3K and Akt increased mRNA and protein levels of this enzyme. Pharmacological inhibitors (LiCl and PDZD-8) and genetic variants of GSK-3 beta ( constitutively active and dominant negative mutants) indicated that PI3K/Akt activates and GSK-3 beta inhibits the antioxidant response elements of the ho1 promoter and pointed Nrf2 as directly involved in this process. Indeed, GSK-3 beta phosphorylated Nrf2 in vitro and in vivo. Immunocytochemistry and subcellular fractionation analyses demonstrated that the effect of GSK-3 beta-mediated phosphorylation of Nrf2 is to exclude this transcription factor from the nucleus. Nrf2 up-regulated the expression of HO-1, glutathione peroxidase, glutathione S-transferase A1, NAD(P)H: quinone oxidoreductase and glutamate-cysteine ligase and protected against hydrogen peroxide-induced glutathione depletion and cell death, whereas co-expression of active GSK-3 beta attenuated both phase II gene expression and oxidant protection. These results contribute to clarify the cross-talk between the survival signal elicited by PI3K/Akt and the antioxidant phase II cell response, and introduce GSK-3 beta as the key mediator of this regulation mechanism.	Univ Autonoma Madrid, Dept Bioquim, Fac Med, Madrid 28029, Spain; Univ Autonoma Madrid, Inst Invest Biomed, Fac Med, Madrid 28029, Spain	Autonomous University of Madrid; Autonomous University of Madrid	Cuadrado, A (corresponding author), Univ Autonoma Madrid, Dept Bioquim, Fac Med, Arzobispo Morcillo 4, Madrid 28029, Spain.	antonio.cuadrado@uam.es	Roa, Maria Salazar/I-1168-2015; Rojo, Ana I/AAA-5203-2019	Roa, Maria Salazar/0000-0001-6784-9541; Rojo, Ana I/0000-0002-0312-5867; Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dennery PA, 2006, FREE RADICAL BIO MED, V40, P1, DOI 10.1016/j.freeradbiomed.2005.09.003; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Kang KW, 2005, ANTIOXID REDOX SIGN, V7, P1664, DOI 10.1089/ars.2005.7.1664; Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005; KIM HP, 2005, ANN REV PHARM TOXICO; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Koh SH, 2004, NEUROTOXICOLOGY, V25, P793, DOI 10.1016/j.neuro.2004.02.001; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; LEGRAND C, 1992, J BIOTECHNOL, V25, P231, DOI 10.1016/0168-1656(92)90158-6; Li WG, 2005, J BIOL CHEM, V280, P28430, DOI 10.1074/jbc.M410601200; Maines MD, 2005, BIOCHEM BIOPH RES CO, V338, P568, DOI 10.1016/j.bbrc.2005.08.121; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Martin D, 2001, J NEUROCHEM, V78, P1000, DOI 10.1046/j.1471-4159.2001.00472.x; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moreira PI, 2005, ANN NY ACAD SCI, V1043, P545, DOI 10.1196/annals.1333.062; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; Salinas M, 2003, J BIOL CHEM, V278, P13898, DOI 10.1074/jbc.M209164200; Sasaki C, 2001, NEUROL RES, V23, P588, DOI 10.1179/016164101101199054; Schafer M, 2004, BRAIN RES, V1005, P84, DOI 10.1016/j.brainres.2004.01.037; Sebastia J, 2003, CYTOM PART A, V51A, P16, DOI 10.1002/cyto.a.10003; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Zhang DD, 2005, J BIOL CHEM, V280, P30091, DOI 10.1074/jbc.M501279200; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zielonka J, 2005, FREE RADICAL BIO MED, V39, P853, DOI 10.1016/j.freeradbiomed.2005.05.001; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	58	377	383	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14841	14851		10.1074/jbc.M513737200	http://dx.doi.org/10.1074/jbc.M513737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551619	hybrid			2022-12-25	WOS:000237671300038
J	Vizeacoumar, FJ; Vreden, WN; Aitchison, JD; Rachubinski, RA				Vizeacoumar, Franco J.; Vreden, Wanda N.; Aitchison, John D.; Rachubinski, Richard A.			Pex19p binds Pex30p and Pex32p at regions required for their peroxisomal localization but separate from their peroxisomal targeting signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; RAT-LIVER PEROXISOMES; NUCLEAR-PORE COMPLEX; ENDOPLASMIC-RETICULUM; ASCORBATE PEROXIDASE; POTENTIAL ROLE; YEAST; BIOGENESIS; MULTIPLE; TOPOGENESIS	The assembly of proteins in the peroxisomal membrane is amultistep process requiring their recognition in the cytosol, targeting to and insertion into the peroxisomal membrane, and stabilization within the lipid bilayer. The peroxin Pex19p has been proposed to be either the receptor that recognizes and targets newly synthesized peroxisomal membrane proteins (PMP) to the peroxisome or a chaperone required for stabilization of PMPs at the peroxisomal membrane. Differentiating between these two roles for Pex19p could be achieved by determining whether the peroxisomal targeting signal (PTS) and the region of Pex19p binding of a PMP are the same or different. We addressed the role for Pex19p in the assembly of two PMPs, Pex30p and Pex32p, of the yeast Saccharomyces cerevisiae. Pex30p and Pex32p control peroxisome size and number but are dispensable for peroxisome formation. Systematic truncations from the carboxyl terminus, together with in-frame deletions of specific regions, have identified PTSs essential for targeting Pex30p and Pex32p to peroxisomes. Both Pex30p and Pex32p interact with Pex19p in regions that do not overlap with their PTSs. However, Pex19p is required for localizing Pex30p and Pex32p to peroxisomes, because mutations that disrupt the interaction of Pex19p with Pex30p and Pex32p lead to their mislocalization to a compartment other than peroxisomes. Mutants of Pex30p and Pex32p that localize to peroxisomes but produce cells exhibiting the peroxisomal phenotypes of cells lacking these proteins demonstrate that the regions in these proteins that control peroxisomal targeting and cell biological activity are separable. Together, our data show that the interaction of Pex19p with Pex30p and Pex32p is required for their roles in peroxisome biogenesis and are consistent with a chaperone role for Pex19p in stabilizing or maintaining membrane proteins in peroxisomes.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Inst Syst Biol, Seattle, WA 98103 USA	University of Alberta; Institute for Systems Biology (ISB)	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, Med Sci Bldg 5-14, Edmonton, AB T6G 2H7, Canada.	rick.rachubinski@ualberta.ca	Vizeacoumar, Franco/GLS-7161-2022		NIGMS NIH HHS [GM 067228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BODNAR AG, 1991, BIOCHEM CELL BIOL, V69, P499, DOI 10.1139/o91-074; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; DIESTELKOTTER P, 1993, J CELL BIOL, V123, P1717, DOI 10.1083/jcb.123.6.1717; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; Eitzen GA, 1996, J BIOL CHEM, V271, P20300, DOI 10.1074/jbc.271.34.20300; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Fransen M, 2004, J BIOL CHEM, V279, P12615, DOI 10.1074/jbc.M304941200; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gotte K, 1998, MOL CELL BIOL, V18, P616; Heiland I, 2005, FEBS J, V272, P2362, DOI 10.1111/j.1742-4658.2005.04690.x; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Hoepfner D, 2005, CELL, V122, P85, DOI 10.1016/j.cell.2005.04.025; Honsho M, 2002, J BIOL CHEM, V277, P44513, DOI 10.1074/jbc.M206139200; Honsho M, 2001, J BIOL CHEM, V276, P9375, DOI 10.1074/jbc.M003304200; Imanaka T, 1996, J BIOL CHEM, V271, P3706; Iouk T, 2002, J CELL BIOL, V159, P807, DOI 10.1083/jcb.200205068; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Kammerer S, 1997, GENOMICS, V45, P200, DOI 10.1006/geno.1997.4914; Kragt A, 2005, J BIOL CHEM, V280, P34350, DOI 10.1074/jbc.M505432200; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Millband DN, 2002, TRENDS CELL BIOL, V12, P205, DOI 10.1016/S0962-8924(02)02276-6; Mullen RT, 1999, PLANT CELL, V11, P2167, DOI 10.1105/tpc.11.11.2167; Mullen RT, 2000, J BIOL CHEM, V275, P16337, DOI 10.1074/jbc.M001266200; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Rottensteiner H, 2004, MOL BIOL CELL, V15, P3406, DOI 10.1091/mbc.E04-03-0188; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Schliebs W, 2004, CURR BIOL, V14, pR397, DOI 10.1016/j.cub.2004.05.017; Scholz O, 2000, EUR J BIOCHEM, V267, P1565, DOI 10.1046/j.1432-1327.2000.01170.x; Shibata H, 2004, J BIOL CHEM, V279, P38486, DOI 10.1074/jbc.M402204200; Smith JJ, 2002, J CELL BIOL, V158, P259, DOI 10.1083/jcb.200204059; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; SUZUKI Y, 1987, J BIOCHEM-TOKYO, V101, P491, DOI 10.1093/oxfordjournals.jbchem.a121935; Tam YYC, 2005, J BIOL CHEM, V280, P34933, DOI 10.1074/jbc.M506208200; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; Titorenko VI, 2001, NAT REV MOL CELL BIO, V2, P357, DOI 10.1038/35073063; Vizeacoumar FJ, 2004, MOL BIOL CELL, V15, P665, DOI 10.1091/mbc.E03-09-0681; Wang XD, 2004, MOL BIOL CELL, V15, P1702, DOI 10.1091/mbc.E03-11-0810; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200	51	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14805	14812		10.1074/jbc.M601808200	http://dx.doi.org/10.1074/jbc.M601808200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551610	hybrid			2022-12-25	WOS:000237671300034
J	Lim, NS; Kozlov, G; Chang, TC; Groover, O; Siddiqui, N; Volpon, L; De Crescenzo, G; Shyu, AB; Gehring, K				Lim, Nadia S.; Kozlov, Guennadi; Chang, Tsung-Cheng; Groover, Olivia; Siddiqui, Nadeem; Volpon, Laurent; De Crescenzo, Gregory; Shyu, Ann-Bin; Gehring, Kalle			Comparative peptide binding studies of the PABC domains from the ubiquitin-protein isopeptide ligase HYD and poly(A)-binding protein - Implications for HYD function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERPLASTIC DISCS PROTEIN; TUMOR-SUPPRESSOR GENE; DNA-DAMAGE RESPONSE; C-TERMINAL DOMAIN; CELL-PROLIFERATION; GERM-CELLS; RAT TESTIS; FAMILY; IDENTIFICATION; RECOGNITION	The PABC domain is a peptide-binding domain that is specifically found in poly(A)-binding protein (PABP) and a HECT ubiquitin-protein isopeptide ligase (E3) known as HYD ( hyperplastic discs), EDD (E3 isolated by differential display), or Rat100. The PABC domain of PABP recruits various regulatory proteins and translation factors to poly(A) mRNAs through binding of a conserved 12-amino acid peptide motif, PAM2 (PABP-interacting motif 2). In contrast, little is known about the specificity or function of the domain from HYD. Here, we used isothermal calorimetry and surface plasmon resonance titrations to show that the PABC domain of HYD binds PAM2 peptides with micromolar affinity. NMR chemical shift perturbations were used to map the peptide-binding site in the PABC domain of HYD. The structural features of binding are very similar to those of the interactions with the domain of PABP, which explains the overlapping peptide specificity and binding affinity. We identified the anti-proliferative Tob proteins as potential binding partners of HYD. This was confirmed by glutathione S-transferase pulldown and immunoprecipitation experiments demonstrating the interaction with full-length Tob2. Altogether, our results point to a role of the PABC domain as a protein-protein interaction domain that brings together the processes of translation, ubiquitin-mediated protein degradation, and cell cycle control.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Ecole Polytech Montreal, Dept Genie Chim, Montreal, PQ H3T 1J4, Canada	McGill University; University of Texas System; Universite de Montreal; Polytechnique Montreal	Gehring, K (corresponding author), McGill Univ, Dept Biochem, 3655 Mromenade Sir William Oslor, Montreal, PQ H3G 1Y6, Canada.	kalle.gehring@mcgill.ca	Gehring, Kalle/I-4403-2013; Chang, Tsung-Cheng/C-2761-2008; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Chang, Tsung-Cheng/0000-0003-4706-0468; Gehring, Kalle/0000-0001-6500-1184	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht M, 2004, BIOCHEM BIOPH RES CO, V316, P129, DOI 10.1016/j.bbrc.2004.02.024; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; Clancy JL, 2003, ONCOGENE, V22, P5070, DOI 10.1038/sj.onc.1206775; Deo RC, 2001, P NATL ACAD SCI USA, V98, P4414, DOI 10.1073/pnas.071552198; Eblen ST, 2003, J BIOL CHEM, V278, P14926, DOI 10.1074/jbc.M300485200; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Khaleghpour K, 2001, MOL CELL, V7, P205, DOI 10.1016/S1097-2765(01)00168-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; Kozlov G, 2004, EMBO J, V23, P272, DOI 10.1038/sj.emboj.7600048; Kozlov Guennadi, 2002, Journal of Biological Chemistry, V277, P22822, DOI 10.1074/jbc.M201230200; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Okochi K, 2005, GENES CELLS, V10, P151, DOI 10.1111/j.1365-2443.2005.00826.x; Oughtred R, 2002, ENDOCRINOLOGY, V143, P3740, DOI 10.1210/en.2002-220262; RABURN DJ, 1995, ENDOCRINOLOGY, V136, P5769, DOI 10.1210/en.136.12.5769; Ralser M, 2005, J MOL BIOL, V346, P203, DOI 10.1016/j.jmb.2004.11.024; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Roy G, 2002, MOL CELL BIOL, V22, P3769, DOI 10.1128/MCB.22.11.3769-3782.2002; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; Siddiqui N, 2003, PROTEIN SCI, V12, P1925, DOI 10.1110/ps.0390103; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tasaki T, 2005, MOL CELL BIOL, V25, P7120, DOI 10.1128/MCB.25.16.7120-7136.2005; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200; YOSHIDA M, 2006, IN PRESS EMBO J	36	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14376	14382		10.1074/jbc.M600307200	http://dx.doi.org/10.1074/jbc.M600307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16554297	hybrid			2022-12-25	WOS:000237512300064
J	Chen, YR; Chen, CL; Yeh, A; Liu, XP; Zweier, JL				Chen, YR; Chen, CL; Yeh, A; Liu, XP; Zweier, JL			Direct and indirect roles of cytochrome b in the mediation of superoxide generation and NO catabolism by mitochondrial succinate-cytochrome c reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; FREE-RADICAL GENERATION; OXYGEN-FREE RADICALS; NITRIC-OXIDE; ELECTRON-TRANSFER; BC(1) COMPLEX; NADH DEHYDROGENASE; HYDROGEN-PEROXIDE; REACTIVE OXYGEN; UBIQUINOL	Mitochondrial superoxide (O-2(center dot)) production is an important mediator of oxidative cellular injury. Succinate-cytochrome c reductase (SCR) of the electron transport chain has been implicated as an essential part of the mediation of O-2(center dot) generation and an alternative target of nitric oxide (NO) in the regulation of mitochondrial respiration. The Q cycle mechanism plays a central role in controlling both events. In the present work, O-2(center dot) generation by SCR was measured with the EPR spin-trapping technique using DEPMPO (5-diethoxylphosphoryl-5-methyl-1-pyrroline N-oxide) as the spin trap. In the presence of succinate, O-2(center dot) generation from SCR was detected as the spin adduct DEPMPO/(OOH)-O-center dot. Inhibitors of the Q(o) site only marginally reduced (20-30%) this O-2(center dot) production, suggesting a secondary role of Qo. in the mediation of O-2(center dot) generation. Addition of cyanide significantly decreased (similar to 70%) O-2(center dot) production, indicating the involvement of the heme component. UV-visible spectral analysis revealed that oxidation of ferrocytochrome b was accompanied by cytochrome c(1) reduction, and the reaction was mediated by the formation of an O-2(center dot) intermediate, indicating a direct role for cytochrome b in O-2(center dot) generation. In the presence of NO, DEPMPO/(OOH)-O-center dot production was progressively diminished, implying that NO interacted with SCR or trapped the O-2(center dot). The consumption of NO by SCR was investigated by electrochemical detection using an NO electrode. In the presence of succinate, SCR-mediated NO consumption was observed and inhibited by the addition of superoxide dismutase, suggesting the involvement of O-2(center dot). Under the conditions of argon saturation, the NO consumption rate was not enhanced by succinate, suggesting a direct role for O-2(center dot) in the mediation of NO consumption. In the presence of succinate, oxidation of the ferrocytochrome b moiety of SCR was accelerated by the addition of NO, and was inhibited by argon saturation, indicating an indirect role for cytochrome b in the mediation of NO consumption.	Ohio State Univ, Davis Heart & Lung Res Inst, Coll Med, Div Cardiovasc Med,Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	Ohio State University; Ohio State University	Chen, YR (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst, Coll Med, Div Cardiovasc Med,Dept Internal Med, 473 W 12th Ave, Columbus, OH 43210 USA.	yeong-renn.chen@osumc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083237, R29HL038324, P01HL065608, R01HL063744, R01HL038324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES011031] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38324, HL65608, HL63744, R01 HL083237, HL083237] Funding Source: Medline; NIEHS NIH HHS [ES11031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; BUTLER J, 1982, J BIOL CHEM, V257, P747; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cadenas E, 2000, FREE RADICAL RES, V33, P747, DOI 10.1080/10715760000301271; Chen YR, 2005, ARCH BIOCHEM BIOPHYS, V439, P200, DOI 10.1016/j.abb.2005.05.014; Chen YR, 2004, FREE RADICAL BIO MED, V37, P1591, DOI 10.1016/j.freeradbiomed.2004.07.013; Chen YR, 2004, J BIOL CHEM, V279, P18054, DOI 10.1074/jbc.M307706200; Chen YR, 2005, J BIOL CHEM, V280, P37339, DOI 10.1074/jbc.M503936200; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; GENG Y, 1992, CIRC RES, V71, P1268, DOI 10.1161/01.RES.71.5.1268; Gong X, 2005, J BIOL CHEM, V280, P9251, DOI 10.1074/jbc.M409994200; GWAK SH, 1986, BIOCHEMISTRY-US, V25, P7675, DOI 10.1021/bi00371a059; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Lee CI, 2000, J BIOL CHEM, V275, P9369, DOI 10.1074/jbc.275.13.9369; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Liu XP, 2004, AM J PHYSIOL-HEART C, V287, pH2421, DOI 10.1152/ajpheart.00487.2004; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; Pearce LL, 1999, J BIOL CHEM, V274, P35763, DOI 10.1074/jbc.274.50.35763; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Poderoso JJ, 1999, FREE RADICAL BIO MED, V26, P925, DOI 10.1016/S0891-5849(98)00277-9; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Ramachandran A, 2002, FREE RADICAL BIO MED, V33, P1465, DOI 10.1016/S0891-5849(02)01142-5; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Villamena FA, 2004, ANTIOXID REDOX SIGN, V6, P619, DOI 10.1089/152308604773934387; Welter R, 1996, ARCH BIOCHEM BIOPHYS, V331, P9, DOI 10.1006/abbi.1996.0276; YU L, 1982, J BIOL CHEM, V257, P2016; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zhao X, 2005, CIRCULATION, V111, P2966, DOI 10.1161/CIRCULATIONAHA.104.527226; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	47	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13159	13168		10.1074/jbc.M513627200	http://dx.doi.org/10.1074/jbc.M513627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531408	hybrid			2022-12-25	WOS:000237336600021
J	Woods, A; Beier, F				Woods, A; Beier, F			RhoA/ROCK signaling regulates chondrogenesis in a context-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTROPHIC CHONDROCYTE DIFFERENTIATION; FOCAL ADHESION KINASE; II COLLAGEN GENE; CARTILAGE FORMATION; SOX9 EXPRESSION; RETINOIC ACID; N-CADHERIN; CELL-SHAPE; RHO-KINASE; IN-VITRO	The development of the cartilage template that precedes endochondral bone formation requires the condensation of mesenchymal cells and their subsequent differentiation to the chondrocytic lineage. We have previously shown that inhibition of the RhoA/ROCK signaling pathway or actin dynamics enhances Sox9 mRNA expression, increases glycosaminoglycan production, and transforms cell shape to a spherical, chondrocyte-like morphology. However, we demonstrate here that in three-dimensional micromass cultures of mesenchymal cells, increased expression of Sox9 in response to these manipulations is not sufficient to induce the expression of established Sox9 target genes. This is illustrated by a decrease in the transcript levels of collagen II and aggrecan as well as reduced activity of a Sox9-responsive reporter gene in response to ROCK inhibition and cytochalasin D. We also demonstrate a decrease in mRNA levels of the transcriptional co-activators L-Sox5 and Sox6 upon ROCK inhibition and cytochalasin D. The decrease in Sox9 activity is likely partially due to reduced L-Sox5 and Sox6 levels but also to a delay in Sox9 phosphorylation following ROCK inhibition. In contrast, inhibition of the RhoA/ROCK pathway and cytochalasin D treatment in monolayer culture results in the enhancement of a number of markers of chondrogenesis such as Sox9 activity and collagen II and aggrecan transcripts levels. These data demonstrate that the effects of RhoA/ROCK signaling and actin polymerization inhibitors on chondrogenic gene expression are dependent on the cellular context.	Univ Western Ontario, CIHR Grp Skeletal Dev & Remodelling, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Beier, F (corresponding author), Univ Western Ontario, CIHR Grp Skeletal Dev & Remodelling, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.	fbeier@uwo.ca	Beier, Frank/T-4734-2019; Beier, Frank/G-4595-2013	Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537				Aigner T, 2003, MATRIX BIOL, V22, P363, DOI 10.1016/S0945-053X(03)00049-0; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BROWN PD, 1988, J CELL BIOL, V106, P171, DOI 10.1083/jcb.106.1.171; Clancy RM, 1997, J CLIN INVEST, V100, P1789, DOI 10.1172/JCI119706; Colnot C, 2004, DEV BIOL, V269, P55, DOI 10.1016/j.ydbio.2004.01.011; Delise AM, 2002, DEV DYNAM, V225, P195, DOI 10.1002/dvdy.10151; Di Nino DL, 2001, DEV BIOL, V240, P433, DOI 10.1006/dbio.2001.0471; DOEGE KJ, 1999, GUIDEBOOK EXTRACELLU, P359; Healy C, 1999, DEV DYNAM, V215, P69, DOI 10.1002/(SICI)1097-0177(199905)215:1<69::AID-DVDY8>3.3.CO;2-E; Horton W. A., 1993, EXTRACELLULAR MATRIX, P73; Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149-4158.2000; Huang ZM, 2004, J BONE MINER RES, V19, P245, DOI 10.1359/jbmr.2004.19.2.245; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kobayashi K, 2004, J NEUROSCI, V24, P3480, DOI 10.1523/JNEUROSCI.0295-04.2004; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; Mammoto A, 2004, J BIOL CHEM, V279, P26323, DOI 10.1074/jbc.M402725200; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; Nishiyama T, 2004, J BIOL CHEM, V279, P47311, DOI 10.1074/jbc.M403546200; NOBES CD, 1995, J CELL SCI, V108, P225; Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; SEIFERT R, 1994, CELL TISSUE RES, V277, P549; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Shakibaei M, 1997, CELL BIOL INT, V21, P75, DOI 10.1006/cbir.1996.0119; Shum L, 2002, ARTHRITIS RES, V4, P94, DOI 10.1186/ar396; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Takahashi I, 2003, EUR J CELL BIOL, V82, P182, DOI 10.1078/0171-9335-00307; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Wang GY, 2004, J BIOL CHEM, V279, P13205, DOI 10.1074/jbc.M311427200; Weston AD, 2003, J CELL SCI, V116, P2885, DOI 10.1242/jcs.00525; Weston AD, 2002, J CELL BIOL, V158, P39, DOI 10.1083/jcb.200112029; Woods A, 2005, J BIOL CHEM, V280, P11626, DOI 10.1074/jbc.M409158200; ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115; Zhao ZY, 2004, DEV BIOL, V275, P183, DOI 10.1016/j.ydbio.2004.08.002	42	146	151	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13134	13140		10.1074/jbc.M509433200	http://dx.doi.org/10.1074/jbc.M509433200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16565087	hybrid			2022-12-25	WOS:000237336600018
J	Tosha, T; Uchida, T; Brash, AR; Kitagawa, T				Tosha, T; Uchida, T; Brash, AR; Kitagawa, T			On the relationship of coral allene oxide synthase to catalase - A single active site mutation that induces catalase activity in coral allene oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; CYTOCHROME-C PEROXIDASE; MAGNETIC CIRCULAR-DICHROISM; LIPOXYGENASE FUSION PROTEIN; BOVINE LIVER CATALASE; HORSERADISH-PEROXIDASE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; HYDROGEN-PEROXIDE; DISTAL HISTIDINE	A heme domain of coral allene oxide synthase (cAOS) catalyzes the formation of allene oxide from fatty acid hydroperoxide. Although cAOS has a similar heme active site to that of catalase, cAOS is completely lacking in catalase activity. A close look at the hydrogen-bonding possibilities around the distal His in cAOS suggested that the imidazole ring is rotated by 180 degrees relative to that of catalase because of the hydrogen bond between Thr-66 and the distal His-67. This could contribute to the functional differences between cAOS and catalase, and to examine this possibility, we mutated Thr-66 in cAOS to Val, the corresponding residue in catalase. In contrast to the complete absence of catalase activity in wild type (WT) cAOS, T66V had a modest catalase activity. On the other hand, the mutation suppressed the native enzymatic activity of the formation of allene oxide to 14% of that of WT cAOS. In the resonance Raman spectrum, whereas WT cAOS has only a 6-coordinate/high spin heme, T66V has a 5-coordinate/ high spin heme as a minor species. Because catalase adopts a 5-coordinate/ high spin structure, probably the 5-coordinate/ high spin portion of T66V showed the catalase activity. Furthermore, in accord with the fact that the CN affinity of catalase is higher than that of WTc AOS, the CN affinity of T66V was 8-fold higher than that of WT cAOS, indicating that the mutation could mimic the heme active site in catalase. We, therefore, propose that the hydrogen bond between Thr-66 and distal His-67 could modulate the orientation of distal His, thereby regulating the enzymatic activity in cAOS.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Vanderbilt University	Kitagawa, T (corresponding author), Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan.	teizo@ims.ac.jp	Tosha, Takehiko/AAR-2404-2020; Uchida, Takeshi/A-6455-2017	Tosha, Takehiko/0000-0002-8971-0759; Uchida, Takeshi/0000-0001-9270-8329				ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; Abraham BD, 2001, BIOCHEMISTRY-US, V40, P2251, DOI 10.1021/bi002121h; Bateman L, 2001, J AM CHEM SOC, V123, P9260, DOI 10.1021/ja0158612; BIELSKI BHJ, 1977, J PHYS CHEM-US, V81, P1048, DOI 10.1021/j100526a005; Boutaud O, 1999, J BIOL CHEM, V274, P33764, DOI 10.1074/jbc.274.47.33764; BRANCACCIO A, 1994, J BIOL CHEM, V269, P13843; BRASH AR, 1995, J LIPID MEDIAT CELL, V12, P275, DOI 10.1016/0929-7855(95)00033-M; Bravo J, 1999, PROTEINS, V34, P155, DOI 10.1002/(SICI)1097-0134(19990201)34:2<155::AID-PROT1>3.0.CO;2-P; BROWETT WR, 1979, BIOCHIM BIOPHYS ACTA, V577, P291, DOI 10.1016/0005-2795(79)90033-3; Carpena X, 2003, PROTEINS, V50, P423, DOI 10.1002/prot.10284; Chang MS, 1996, BIOCHEMISTRY-US, V35, P464, DOI 10.1021/bi952081v; CHUANG WJ, 1988, J INORG BIOCHEM, V34, P201, DOI 10.1016/0162-0134(88)85030-X; DESBOIS A, 1979, BIOCHEMISTRY-US, V18, P1510, DOI 10.1021/bi00575a019; Dou Y, 1996, BIOCHEMISTRY-US, V35, P7107, DOI 10.1021/bi9600299; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; Hernandez-Ruiz J, 2001, BIOCHEM J, V354, P107, DOI 10.1042/0264-6021:3540107; Howes BD, 1997, BIOCHEMISTRY-US, V36, P1532, DOI 10.1021/bi962502o; HU SZ, 1993, J AM CHEM SOC, V115, P12446, DOI 10.1021/ja00079a028; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; Kato S, 2004, J BIOL CHEM, V279, P52376, DOI 10.1074/jbc.M403532200; Kirkman HN, 1999, J BIOL CHEM, V274, P13908, DOI 10.1074/jbc.274.20.13908; Koljak R, 1997, SCIENCE, V277, P1994, DOI 10.1126/science.277.5334.1994; Maj M, 1996, BBA-PROTEIN STRUCT M, V1298, P241, DOI 10.1016/S0167-4838(96)00134-3; Mate MJ, 1999, J MOL BIOL, V286, P135, DOI 10.1006/jmbi.1998.2453; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0; Nelson D R, 1998, Methods Mol Biol, V107, P15; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; Obinger C, 1997, ARCH BIOCHEM BIOPHYS, V342, P58, DOI 10.1006/abbi.1997.9988; Oldham ML, 2005, P NATL ACAD SCI USA, V102, P297, DOI 10.1073/pnas.0406352102; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; Putnam CD, 2000, J MOL BIOL, V296, P295, DOI 10.1006/jmbi.1999.3458; SHARMA KD, 1989, J BIOL CHEM, V264, P12772; Silkstone GG, 2005, J AM CHEM SOC, V127, P92, DOI 10.1021/ja045719b; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Switala J, 2002, ARCH BIOCHEM BIOPHYS, V401, P145, DOI 10.1016/S0003-9861(02)00049-8; Wu FY, 2003, BIOCHEMISTRY-US, V42, P6871, DOI 10.1021/bi027427y	47	19	21	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12610	12617		10.1074/jbc.M600061200	http://dx.doi.org/10.1074/jbc.M600061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513636	hybrid			2022-12-25	WOS:000237134700051
J	Vizeacoumar, FJ; Vreden, WN; Fagarasanu, M; Eitzen, GA; Aitchison, JD; Rachubinski, RA				Vizeacoumar, FJ; Vreden, WN; Fagarasanu, M; Eitzen, GA; Aitchison, JD; Rachubinski, RA			The dynamin-like protein Vps1p of the yeast Saccharomyces cerevisiae associates with peroxisomes in a Pex19p-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; NUCLEAR-PORE COMPLEX; REGULATING ACTIN DYNAMICS; YARROWIA-LIPOLYTICA; BUDDING YEAST; ENLARGED PEROXISOMES; TARGETING SIGNALS; HUMAN PEX19P; NUMBER; SIZE	Dynamins and dynamin-like proteins play important roles in organelle division. In Saccharomyces cerevisiae, the dynamin-like protein Vps1p ( vacuolar protein sorting protein 1) is involved in peroxisome fission, as cells deleted for the VPS1 gene contain reduced numbers of enlarged peroxisomes. What relationship Vps1p has with peroxisomes remains unclear. Here we show that Vps1p interacts with Pex19p, a peroxin that acts as a shuttling receptor for peroxisomal membrane proteins or as a chaperone assisting the assembly/stabilization of proteins at the peroxisome membrane. Vps1p contains two putative Pex19p recognition sequences at amino acids 509-523 and 633-647. Deletion of the first (but not the second) sequence results in reduced numbers of enlarged peroxisomes in cells, as in vps1 Delta cells. Deletion of either sequence has no effect on vacuolar morphology or vacuolar protein sorting, suggesting that the peroxisome and vacuole biogenic functions of Vps1p are separate and separable. Substitution of proline for valine at position 516 of Vps1p abrogates Pex19p binding and gives the peroxisome phenotype of vps1 Delta cells. Microscopic analysis showed that overexpression of Pex19p or redirection of Pex19p to the nucleus does not affect the normal cellular distribution of Vps1p in the cytosol and in punctate structures that are not peroxisomes, suggesting that Pex19p does not function in targeting Vps1p to peroxisomes. Subcellular fractionation showed that a fraction of Vps1p is associated with peroxisomes and that deletion or mutation of the first Pex19p recognition sequence abrogates this association. Our results are consistent with Pex19p acting as a chaperone to stabilize the association of Vps1p with peroxisomes and not as a receptor involved in targeting Vps1p to peroxisomes.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Inst Syst Biol, Seattle, WA 98103 USA	University of Alberta; Institute for Systems Biology (ISB)	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, Med Sci Bldg 5-14, Edmonton, AB T6G 2H7, Canada.	rick.rachubinski@ualberta.ca	Eitzen, Gary/D-3682-2009; Vizeacoumar, Franco/GLS-7161-2022		NIGMS NIH HHS [GM067228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FJ, 1944, CURRENT PROTOCOLS MO; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; Chang CC, 1999, J CELL SCI, V112, P1579; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; EITZEN GA, 1995, J BIOL CHEM, V270, P1429, DOI 10.1074/jbc.270.3.1429; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gotte K, 1998, MOL CELL BIOL, V18, P616; Gourlay CW, 2003, J CELL SCI, V116, P2551, DOI 10.1242/jcs.00454; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Howard JP, 2002, J CELL BIOL, V157, P315, DOI 10.1083/jcb.200110027; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Iouk T, 2002, J CELL BIOL, V159, P807, DOI 10.1083/jcb.200205068; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Koch A, 2004, J CELL SCI, V117, P3995, DOI 10.1242/jcs.01268; Li XL, 2003, J BIOL CHEM, V278, P17012, DOI 10.1074/jbc.M212031200; Li XL, 2002, MOL CELL BIOL, V22, P8226, DOI 10.1128/MCB.22.23.8226-8240.2002; Li XL, 2002, J CELL BIOL, V156, P643, DOI 10.1083/jcb.200112028; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Marelli M, 2004, J CELL BIOL, V167, P1099, DOI 10.1083/jcb.200404119; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Millband DN, 2002, TRENDS CELL BIOL, V12, P205, DOI 10.1016/S0962-8924(02)02276-6; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Osteryoung KW, 2003, SCIENCE, V302, P1698, DOI 10.1126/science.1082192; Osteryoung KW, 2001, CURR OPIN MICROBIOL, V4, P639, DOI 10.1016/S1369-5274(01)00263-6; Peters C, 2004, CELL, V119, P667, DOI 10.1016/j.cell.2004.11.023; POLLTHE BT, 1988, AM J HUM GENET, V42, P422; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Rottensteiner H, 2004, MOL BIOL CELL, V15, P3406, DOI 10.1091/mbc.E04-03-0188; Rottensteiner H, 2003, MOL BIOL CELL, V14, P4316, DOI 10.1091/mbc.E03-03-0153; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; SAKAI Y, 1995, J BACTERIOL, V177, P6773, DOI 10.1128/jb.177.23.6773-6781.1995; Scholz O, 2000, EUR J BIOCHEM, V267, P1565, DOI 10.1046/j.1432-1327.2000.01170.x; Seeley ES, 2002, MOL BIOL CELL, V13, P782, DOI 10.1091/mbc.01-10-0512; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shibata H, 2004, J BIOL CHEM, V279, P38486, DOI 10.1074/jbc.M402204200; Smith JJ, 2000, J BIOL CHEM, V275, P20168, DOI 10.1074/jbc.M909285199; Smith JJ, 2002, J CELL BIOL, V158, P259, DOI 10.1083/jcb.200204059; Snyder WB, 2000, J CELL BIOL, V149, P1171, DOI 10.1083/jcb.149.6.1171; Tam YYC, 2003, MOL BIOL CELL, V14, P4089, DOI 10.1091/mbc.E03-03-0150; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; van Roermund CWT, 2000, J CELL BIOL, V150, P489, DOI 10.1083/jcb.150.3.489; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Vizeacoumar FJ, 2004, MOL BIOL CELL, V15, P665, DOI 10.1091/mbc.E03-09-0681; Vizeacoumar FJ, 2003, J CELL BIOL, V161, P321, DOI 10.1083/jcb.200210130; Warren DT, 2002, J CELL SCI, V115, P1703; Yu XW, 2004, J CELL SCI, V117, P3839, DOI 10.1242/jcs.01239	57	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12817	12823		10.1074/jbc.M600365200	http://dx.doi.org/10.1074/jbc.M600365200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520372	hybrid			2022-12-25	WOS:000237134700076
J	Kang, BN; Tirumurugaan, KG; Deshpande, DA; Amrani, Y; Panettieri, RA; Walseth, TF; Kannano, MS				Kang, Bit-Na; Tirumurugaan, K. G.; Deshpande, Deepak A.; Amrani, Yassine; Panettieri, Reynold A.; Walseth, Timothy F.; Kannano, Mathur S.			Transcriptional regulation of CD38 expression by tumor necrosis factor-alpha in human airway smooth muscle cells: role of NF-kappa B and sensitivity to glucocorticoids	FASEB JOURNAL			English	Article						cytokines; transcription factors; smooth muscle; airway; glucocorticoid	RIBOSE HYDROLASE ACTIVITIES; NUCLEAR EXPORT SIGNAL; GENE-EXPRESSION; DNA-BINDING; AP-1 ACTIVITY; C-JUN; RECEPTOR; INHIBITION; CYTOKINES; PATHWAY	The transmembrane glycoprotein CD38 catalyzes the synthesis of the calcium mobilizing molecule cyclic ADP-ribose from NAD. In human airway smooth muscle (HASM) cells, the expression and function of CD38 are augmented by the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), leading to increased intracellular calcium response to agonists. A glucocorticoid response element in the CD38 gene has been computationally described, providing evidence for transcriptional regulation of its expression. In the present study, we investigated the effects of dexamethasone, a glucocorticoid, on CD38 expression and ADP-ribosyl cyclase activity in HASM cells stimulated with TNF-alpha. In HASM cells, TNF-alpha augmented CD38 expression and ADP-ribosyl cyclase activity, which were attenuated by dexamethasone. TNF-alpha increased NF-kappa B expression and its activation, and dexamethasone partially reversed these effects. TNF-alpha increased the expression of I kappa B alpha, and dexamethasone increased it further. An inhibitor of NF-kappa B activation or transfection of cells with I kappa B mutants decreased TNF-alpha-induced CD38 expression. The results indicate that TNF-alpha-induced CD38 expression involves NF-kappa B expression and its activation and dexamethasone inhibits CD38 expression through NF-kappa B-dependent and -independent mechanisms.	Univ Minnesota, Coll Vet Med, Dept Vet & Biomed Sci, St Paul, MN 55108 USA; Univ Minnesota, Dept Pharmacol, St Paul, MN 55108 USA; Univ Minnesota, Dept Pediat, St Paul, MN 55108 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania	Kannano, MS (corresponding author), Univ Minnesota, Coll Vet Med, Dept Vet & Biomed Sci, 1971 Commonwealth Ave, St Paul, MN 55108 USA.	kanna001@umn.edu	Amrani, Yassine/Q-6323-2019; Amrani, Yassine/A-1826-2013; panettieri, reynold/AAG-9485-2019; Walseth, Timothy F/F-9518-2010	Amrani, Yassine/0000-0002-7042-6926; Walseth, Timothy F/0000-0003-2558-7859	NHLBI NIH HHS [R01 HL055301, HL55301, HL057498, R01 HL057498] Funding Source: Medline; NIDA NIH HHS [DA11806, P50 DA011806] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057498, R01HL055301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ammit AJ, 2002, AM J RESP CELL MOL, V26, P465, DOI 10.1165/ajrcmb.26.4.4681; Amrani Y, 2000, Respir Res, V1, P49, DOI 10.1186/rr12; Amrani Y, 2001, MOL PHARMACOL, V60, P646; Amrani Y, 1999, J IMMUNOL, V163, P2128; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Barata H, 2004, ENDOCRINOLOGY, V145, P881, DOI 10.1210/en.2003-0774; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Chikanza IC, 2003, J ENDOCRINOL, V179, P301, DOI 10.1677/joe.0.1790301; Deshpande DA, 2005, AM J PHYSIOL-LUNG C, V288, pL773, DOI 10.1152/ajplung.00217.2004; Deshpande DA, 2005, AM J RESP CELL MOL, V32, P149, DOI 10.1165/rcmb.2004-0243OC; Deshpande DA, 2004, AM J RESP CELL MOL, V31, P36, DOI 10.1165/rcmb.2003-0313OC; Deshpande DA, 2003, FASEB J, V17, P452, DOI 10.1096/fj.02-0450fje; Dogan S, 2002, BIOL REPROD, V66, P596, DOI 10.1095/biolreprod66.3.596; dos Santos CC, 2004, PHYSIOL GENOMICS, V19, P331, DOI 10.1152/physiolgenomics.00153.2004; Doucas V, 2000, P NATL ACAD SCI USA, V97, P11893, DOI 10.1073/pnas.220413297; Ferrero E, 2000, CHEM IMMUNOL, V75, P1; Hakonarson H, 2001, AM J RESP CELL MOL, V25, P761, DOI 10.1165/ajrcmb.25.6.4628; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Jiang X, 2004, J BIOL CHEM, V279, P38480, DOI 10.1074/jbc.M403948200; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Mehta K, 2000, CHEM IMMUNOL, V75, P20; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Riffo-Vasquez Y, 2000, INT J BIOCHEM CELL B, V32, P833, DOI 10.1016/S1357-2725(00)00029-7; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SCHEINMAN RI, 1995, SCIENCE, V270, P286; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Shore SA, 2002, CLIN EXP PHARMACOL P, V29, P859, DOI 10.1046/j.1440-1681.2002.03756.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Tliba O, 2004, MOL PHARMACOL, V66, P322, DOI 10.1124/mol.104.001040; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; White TA, 2000, BBA-MOL CELL RES, V1498, P64, DOI 10.1016/S0167-4889(00)00077-X; Wyszomierski SL, 1999, MOL ENDOCRINOL, V13, P330, DOI 10.1210/me.13.2.330; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	47	51	54	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2006	20	7					1000	+		10.1096/fj.05-4585fje	http://dx.doi.org/10.1096/fj.05-4585fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571778				2022-12-25	WOS:000240157700035
J	Cheng, T; Hitomi, K; van Vlijmen-Willems, IMJJ; de Jongh, GJ; Yamamoto, K; Nishi, K; Watts, C; Reinheckel, T; Schalkwijk, J; Zeeuwen, PLJM				Cheng, Tsing; Hitomi, Kiyotaka; van Vlijmen-Willems, Ivonne M. J. J.; de Jongh, Gys J.; Yamamoto, Kanae; Nishi, Koji; Watts, Colin; Reinheckel, Thomas; Schalkwijk, Joost; Zeeuwen, Patrick L. J. M.			Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site - A novel clue for the role of cystatin M/E in epidermal cornification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASE-INHIBITOR; HAIR FOLLICLE MORPHOGENESIS; ASPARAGINYL ENDOPEPTIDASE; PROTEASE INHIBITORS; CORNIFIED ENVELOPE; MAMMALIAN LEGUMAIN; DEFICIENT MICE; CROSS-LINKING; TRANSGLUTAMINASE; DIFFERENTIATION	Cystatin M/E is a high affinity inhibitor of the asparaginyl endopeptidase legumain, and we have previously reported that both proteins are likely to be involved in the regulation of stratum corneum formation in skin. Although cystatin M/E contains a predicted binding site for papain-like cysteine proteases, no high affinity binding for any member of this family has been demonstrated so far. We report that human cathepsin V (CTSV) and human cathepsin L (CTSL) are strongly inhibited by human cystatin M/E. Kinetic studies show that K-i values of cystatin M/E for the interaction with CTSV and CTSL are 0.47 and 1.78 nM, respectively. On the basis of the analogous sites in cystatin C, we used site-directed mutagenesis to identify the binding sites of these proteases in cystatin M/E. We found that the W135A mutant was rendered inactive against CTSV and CTSL but retained legumain-inhibiting activity. Conversely, the N64A mutant lost legumain-inhibiting activity but remained active against the papain-like cysteine proteases. We conclude that legumain and papain-like cysteine proteases are inhibited by two distinct non-overlapping sites. Using immunohistochemistry on normal human skin, we found that cystatin M/E co-localizes with CTSV and CTSL. In addition, we show that CTSL is the elusive enzyme that processes and activates epidermal transglutaminase 3. The identification of CTSV and CTSL as novel targets for cystatin M/E, their (co)-expression in the stratum granulosum of human skin, and the activity of CTSL toward transglutaminase 3 strongly imply an important role for these enzymes in the differentiation process of human epidermis.	Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Dermatol, NL-6500 HB Nijmegen, Netherlands; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan; Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany	Radboud University Nijmegen; Nagoya University; University of Dundee; University of Freiburg	Schalkwijk, J (corresponding author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Dermatol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	j.schalkwijk@derma.umcn.nl	Schalkwijk, Joost/R-7509-2019; Schalkwijk, Joost/N-1774-2013; Reinheckel, Thomas/AAL-9761-2021; van Vlijmen-Willems, Ivonne MJJ/P-5336-2015; Zeeuwen, Patrick/N-1779-2013	Schalkwijk, Joost/0000-0002-1308-1319; Reinheckel, Thomas/0000-0001-9866-9105; van Vlijmen-Willems, Ivonne MJJ/0000-0002-3522-2573; Zeeuwen, Patrick/0000-0002-6878-2438; Watts, Colin/0000-0001-6183-2087; Cheng, Tsing/0000-0001-5191-3289				Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Adachi W, 1998, INVEST OPHTH VIS SCI, V39, P1789; Ahvazi B, 2002, EMBO J, V21, P2055, DOI 10.1093/emboj/21.9.2055; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Alvarez-Fernandez M, 2005, J BIOL CHEM, V280, P18221, DOI 10.1074/jbc.M411914200; BARRETT AJ, 2004, HDB PROTEOLYTIC ENZY, P1097; Benavides F, 2002, AM J PATHOL, V161, P693, DOI 10.1016/S0002-9440(10)64225-3; BIETH JG, 1980, CLIN RES PROC, V16, P183; BOBEK LA, 1992, CRIT REV ORAL BIOL M, V3, P307, DOI 10.1177/10454411920030040101; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; CALKINS CC, 1995, BIOL CHEM H-S, V376, P71; Candi E, 1999, J BIOL CHEM, V274, P7226, DOI 10.1074/jbc.274.11.7226; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Egberts F, 2004, J CELL SCI, V117, P2295, DOI 10.1242/jcs.01075; El Ghalbzouri A, 2002, CELL TISSUE RES, V310, P189, DOI 10.1007/s00441-002-0621-0; Hagemann S, 2004, EUR J CELL BIOL, V83, P775, DOI 10.1078/0171-9335-00404; Hitomi K, 2000, BIOSCI BIOTECH BIOCH, V64, P2128, DOI 10.1271/bbb.64.2128; Hitomi K, 1999, J BIOCHEM-TOKYO, V125, P1048, DOI 10.1093/oxfordjournals.jbchem.a022385; Hitomi K, 2003, BIOSCI BIOTECH BIOCH, V67, P2492, DOI 10.1271/bbb.67.2492; Hitomi K, 2003, J DERMATOL SCI, V32, P95, DOI 10.1016/S0923-1811(03)00091-4; Ishidoh K, 1998, BIOCHEM BIOPH RES CO, V252, P202, DOI 10.1006/bbrc.1998.9613; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; KIM HC, 1990, J BIOL CHEM, V265, P21971; Maehr R, 2005, J IMMUNOL, V174, P7066, DOI 10.4049/jimmunol.174.11.7066; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; Ni J, 1997, J BIOL CHEM, V272, P10853; PALSDOTTIR A, 1988, LANCET, V2, P603; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Santamaria I, 1998, CANCER RES, V58, P1624; Shirahama-Noda K, 2003, J BIOL CHEM, V278, P33194, DOI 10.1074/jbc.M302742200; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; TAKAHASHI M, 1994, FEBS LETT, V340, P173, DOI 10.1016/0014-5793(94)80131-2; Takahashi M, 1996, ARCH BIOCHEM BIOPHYS, V329, P123, DOI 10.1006/abbi.1996.0199; Tarcsa E, 1997, J BIOL CHEM, V272, P27893, DOI 10.1074/jbc.272.44.27893; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; Turk B, 2002, CURR PHARM DESIGN, V8, P1623, DOI 10.2174/1381612023394124; Turk B, 1997, BIOL CHEM, V378, P141; Watkinson A, 1999, ARCH DERMATOL RES, V291, P260, DOI 10.1007/s004030050406; Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388; Zeeuwen PLJM, 2004, HUM MOL GENET, V13, P1069, DOI 10.1093/hmg/ddh115; Zeeuwen PLJM, 2003, J INVEST DERMATOL, V121, P65, DOI 10.1046/j.1523-1747.2003.12312.x; Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x; Zeeuwen PLJM, 2002, HUM MOL GENET, V11, P2867, DOI 10.1093/hmg/11.23.2867; Zeeuwen PLJM, 2001, J INVEST DERMATOL, V116, P693, DOI 10.1046/j.1523-1747.2001.01309.x	48	88	91	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					15893	15899		10.1074/jbc.M600694200	http://dx.doi.org/10.1074/jbc.M600694200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16565075	hybrid			2022-12-25	WOS:000237996000039
J	Gobeil, F; Zhu, T; Brault, S; Geha, A; Vazquez-Tello, A; Fortier, A; Barbaz, D; Checchin, D; Hou, X; Nader, M; Bkaily, G; Gratton, JP; Heveker, N; Ribeiro-da-Silva, A; Peri, K; Bard, H; Chorvatova, A; D'Orleans-Juste, P; Goetzl, EJ; Chemtob, S				Gobeil, Fernand, Jr.; Zhu, Tang; Brault, Sonia; Geha, Antoinette; Vazquez-Tello, Alejandro; Fortier, Audrey; Barbaz, David; Checchin, Daniella; Hou, Xin; Nader, Moni; Bkaily, Ghassan; Gratton, Jean-Philippe; Heveker, Nikolaus; Ribeiro-da-Silva, Alfredo; Peri, Krishna; Bard, Harry; Chorvatova, Alzbeta; D'Orleans-Juste, Pedro; Goetzl, Edward J.; Chemtob, Sylvain			Nitric oxide signaling via nuclearized endothelial nitric-oxide synthase modulates expression of the immediate early genes iNOS and mPGES-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; SMOOTH-MUSCLE; CYCLIC-GMP; CALCIUM; LOCALIZATION; ACTIVATION; TRANSLOCATION; CALMODULIN; CAVEOLIN-1; RECEPTORS	Stimulation of freshly isolated rat hepatocytes with lysophosphatidic acid (LPA) resulted in LPA(1) receptor-mediated and nitricoxide-dependent up-regulation of the immediate early genes iNOS (inducible nitric-oxide synthase (NOS)) and mPGES-1 (microsomal prostaglandin E synthase-1). Because LPA is a ligand for both cell surface and intracellular receptor sites and a potent endothelial NOS (eNOS) activator, we hypothesized that NO derived from activated nuclearizede NOS might participate in gene regulation. Herein we show, by confocal microscopy performed on porcine cerebral endothelial cells expressing native LPA(1)-receptor and eNOS and on HTC4 rat hepatoma cells co-transfected with recombinant human LPA(1)-receptor and fused eNOS-GFP cDNA, a dynamic eNOS translocation from peripheral to nuclear regions upon stimulation with LPA. Nuclear localization of eNOS and its downstream effector, soluble guanylate cyclase, were demonstrated in situ in rat liver specimens by immunogold labeling using specific antibodies. Stimulation of this nuclear fraction with LPA and the NO donor sodium nitroprusside resulted, respectively, in increased production of nitrite (and eNOS phosphorylation) and cGMP; these separate responses were also correspondingly blocked by NOS inhibitor L-NAME and soluble guanylate cyclase inhibitor ODQ. In addition, sodium nitroprusside evoked a sequential increase in nuclear Ca2+ transients, activation of p42 MAPK, NF-kappa B binding to DNA consensus sequence, and dependent iNOS RNA. This study describes a hitherto unrecognized molecular mechanism by which nuclear eNOS through ensuing NO modulates nuclear calcium homeostasis involved in gene transcription-associated events. Moreover, our findings strongly support the concept of the nucleus as an autonomous signaling compartment.	Univ Sherbrooke, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada; Hop St Justine, Res Ctr, Dept Pediat, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Res Ctr, Dept Ophthalmol, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Res Ctr, Dept Pharmacol, Montreal, PQ H3T 1C5, Canada; Univ Sherbrooke, Dept Anat & Cell Biol, Sherbrooke, PQ J1H 5N4, Canada; Inst Rech Clin Montreal, Montreal, PQ N2W 1R7, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Theratechnol, Montreal, PQ H4S 2A4, Canada; Univ Calif San Francisco, Dept Med & Microbiol Immunol, San Francisco, CA 94143 USA	University of Sherbrooke; Universite de Montreal; Universite de Montreal; Universite de Montreal; University of Sherbrooke; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; University of California System; University of California San Francisco	Gobeil, F (corresponding author), Univ Sherbrooke, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada.	Fernand.Gobeil@USherbrooke.ca; sylvain.chemtob@umontreal.ca	Ribeiro-da-Silva, Alfredo/K-4783-2012; Heveker, Nikolaus/G-5306-2012	Ribeiro-da-Silva, Alfredo/0000-0002-4125-0255; Marcek Chorvatova, Alzbeta/0000-0002-8798-0624; Gratton, Jean-Philippe/0000-0001-9877-8520; Nader, Moni/0000-0003-2138-5213				Abramson SB, 2001, BEST PRACT RES CL RH, V15, P831, DOI 10.1053/berh.2001.0196; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; Beauchamp MH, 2004, FREE RADICAL BIO MED, V37, P1885, DOI 10.1016/j.freeradbiomed.2004.09.008; Bkaily G, 1997, MOL CELL BIOCHEM, V172, P171, DOI 10.1023/A:1006840228104; Bkaily G, 2001, RECEPTORS STRUCTURE, P209; BOSSER R, 1993, J BIOL CHEM, V268, P15477; Callsen D, 1998, J IMMUNOL, V161, P4852; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Connelly L, 2005, J BIOL CHEM, V280, P10040, DOI 10.1074/jbc.M411991200; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; EARP HS, 1977, P NATL ACAD SCI USA, V74, P946, DOI 10.1073/pnas.74.3.946; Elzaouk L, 2004, BBA-GEN SUBJECTS, V1670, P56, DOI 10.1016/j.bbagen.2003.10.015; Erwin PA, 2006, J BIOL CHEM, V281, P151, DOI 10.1074/jbc.M510421200; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Forstermann U, 1998, FASEB J, V12, P773; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; Gilchrist M, 2004, BLOOD, V104, P462, DOI 10.1182/blood-2003-08-2990; Giordano A, 2002, FEBS LETT, V514, P135, DOI 10.1016/S0014-5793(02)02245-7; Gobeil F, 2003, CAN J PHYSIOL PHARM, V81, P196, DOI 10.1139/Y02-163; Gobeil F, 2003, J BIOL CHEM, V278, P38875, DOI 10.1074/jbc.M212481200; Gobeil F, 2002, CIRC RES, V90, P682, DOI 10.1161/01.RES.0000013303.17964.7A; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Govers R, 2002, J HISTOCHEM CYTOCHEM, V50, P779, DOI 10.1177/002215540205000604; Guihard G, 1996, BIOCHEM J, V318, P849, DOI 10.1042/bj3180849; Hanafy K A, 2001, Med Sci Monit, V7, P801; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Heinrich UR, 2000, BRAIN RES, V885, P6, DOI 10.1016/S0006-8993(00)02833-X; Jagnandan D, 2005, AM J PHYSIOL-CELL PH, V289, pC1024, DOI 10.1152/ajpcell.00162.2005; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Kou RQ, 2002, BIOCHEMISTRY-US, V41, P4982, DOI 10.1021/bi016017r; Leite MF, 2003, P NATL ACAD SCI USA, V100, P2975, DOI 10.1073/pnas.0536590100; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; Marrache AM, 2002, J IMMUNOL, V169, P6474, DOI 10.4049/jimmunol.169.11.6474; MONCADA S, 1991, PHARMACOL REV, V43, P109; Perez-Sala D, 2001, AM J PHYSIOL-RENAL, V280, pF466, DOI 10.1152/ajprenal.2001.280.3.F466; Pritchard MT, 2005, J LEUKOCYTE BIOL, V78, P630, DOI 10.1189/jlb.0404220; Re R, 1999, HYPERTENSION, V34, P534, DOI 10.1161/01.HYP.34.4.534; Rooney TA, 1996, J BIOL CHEM, V271, P19817, DOI 10.1074/jbc.271.33.19817; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Subbaramaiah K, 2004, J BIOL CHEM, V279, P12647, DOI 10.1074/jbc.M312972200; Zimmermann K, 2002, P NATL ACAD SCI USA, V99, P17167, DOI 10.1073/pnas.252345399	46	66	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16058	16067		10.1074/jbc.M602219200	http://dx.doi.org/10.1074/jbc.M602219200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16574649	hybrid			2022-12-25	WOS:000237996000058
J	Tan, CB; Dlugosz, PJ; Peng, J; Zhang, Z; Lapolla, SM; Plafker, SM; Andrews, DW; Lin, JL				Tan, Chibing; Dlugosz, Paulina J.; Peng, Jun; Zhang, Zhi; Lapolla, Suzanne M.; Plafker, Scott M.; Andrews, David W.; Lin, Jialing			Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BH3-ONLY PROTEINS; CELL-DEATH; FAMILY-MEMBERS; CONFORMATIONAL-CHANGE; BH3 DOMAINS; PROAPOPTOTIC ACTIVITY; SMAC/DIABLO RELEASE; OUTER-MEMBRANE; X-L	Interactions among Bcl-2 family proteins mediated by Bcl-2 homology (BH) regions transform apoptosis signals into actions. The interactions between BH3 region-only proteins and multi-BH region proteins such as Bax and Bcl-2 have been proposed to be the dominant interactions required for initiating apoptosis. Experimental evidence also suggests that both homo- and hetero-interactions are mediated primarily by the BH3 regions in all Bcl-2 family proteins and contribute to commitment to or inhibition of apoptosis. We found that a peptide containing the BH3 helix of Bax was not sufficient to activate recombinant Bax to permeabilize mitochondria. However, an extended peptide containing the BH3 helix and additional downstream sequences activated Bax to permeabilize mitochondria and liposomes. Bcl-2 inhibited the membrane-permeabilizing activity of peptide-activated Bax. This activity of Bcl-2 was inhibited by the extended but not the BH3-only peptide despite both peptides binding to Bcl-2 with similar affinity. Further, membrane-bound Bax activation intermediates directly activated soluble Bax further permeabilizing the membrane. Bcl-2 inhibited Bax auto-activation. We therefore propose that Bax auto-activation amplifies the initial death signal produced by BH3-only proteins and that Bcl-2 functions as an inhibitor of Bax auto-activation.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73190 USA; McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; McMaster University	Lin, JL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd,BMSB 935,POB 26901, Oklahoma City, OK 73190 USA.	jialing-lin@ouhsc.edu		Andrews, David/0000-0002-9266-7157	NIGMS NIH HHS [GM 062964, R01 GM062964, R01 GM062964-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062964] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Cartron PF, 2005, J BIOL CHEM, V280, P10587, DOI 10.1074/jbc.M409714200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cuconati A, 2002, J VIROL, V76, P4547, DOI 10.1128/JVI.76.9.4547-4558.2002; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Heuck AP, 2003, J BIOL CHEM, V278, P31218, DOI 10.1074/jbc.M303151200; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kim KM, 2001, BIOCHEMISTRY-US, V40, P4911, DOI 10.1021/bi002368e; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; Kim PK, 2004, MOL CELL, V14, P523, DOI 10.1016/S1097-2765(04)00263-1; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P303; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Lucken-Ardjomande S, 2005, J CELL SCI, V118, P473, DOI 10.1242/jcs.01654; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Moreau C, 2003, J BIOL CHEM, V278, P19426, DOI 10.1074/jbc.M209472200; Oh KJ, 2005, J BIOL CHEM, V280, P753, DOI 10.1074/jbc.M405428200; OLTVAI ZN, 1993, CELL, V74, P619; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Polster BM, 2003, CELL DEATH DIFFER, V10, P365, DOI 10.1038/sj.cdd.4401158; Polster BM, 2001, J BIOL CHEM, V276, P37887; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rehm M, 2003, J CELL BIOL, V162, P1031, DOI 10.1083/jcb.200303123; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; TANAKA S, 1993, J BIOL CHEM, V268, P10920; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Zhang Z, 2004, J BIOL CHEM, V279, P43920, DOI 10.1074/jbc.M406412200; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	63	117	136	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14764	14775		10.1074/jbc.M602374200	http://dx.doi.org/10.1074/jbc.M602374200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16571718	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000237671300030
J	Perrier, C; Sprenger, N; Corthesy, B				Perrier, Clementine; Sprenger, Norbert; Corthesy, Blaise			Glycans on secretory component participate in innate protection against mucosal pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; ENTEROPATHOGENIC ESCHERICHIA-COLI; CLOSTRIDIUM-DIFFICILE TOXIN; IGA MONOCLONAL-ANTIBODIES; HUMAN GASTRIC EPITHELIUM; IN-VITRO; HELICOBACTER-PYLORI; SIALIC-ACID; STREPTOCOCCUS-PNEUMONIAE; DIMERIC IGA	In mucosal secretions, secretory component (SC) is found either free or bound to polymeric IgA within the secretory IgA complex. SC displays numerous and various glycans, which are potential ligands for bacterial compounds. We first established that human SC (hSC) purified from colostrum (hSCcol) or produced in Chinese hamster ovary cells (hSCrec) exhibits the same lectin reactivity. Both forms bind to Clostridium difficile toxin A and functionally protect polarized Caco-2 cell monolayers from the cytopathic effect of the toxin. The interaction is mediated by glycans present on hSC and involves galactose and sialic acid residues. hSCcol and hSCrec were also shown to bind enteropathogenic Escherichia coli adhesin intimin and to inhibit its infectivity on HEp-2 cells in a glycan-dependent manner as well. SC remained operative in the context of the whole secretory IgA molecule and can therefore enhance its Fab-mediated neutralizing properties. On the contrary, hSC did not interact with three different strains of rotavirus (RF, RRV, and SA11). Accordingly, infection of target MA104 cells with these rotavirus strains was not reduced in the presence of either form of hSC tested. Although not a universal mechanism, these findings identify hSC as a microbial scavenger contributing to the antipathogenic arsenal that protects the body epithelial surfaces.	CHU Vaudois, R&D Lab, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland; Nestle Res Ctr, Dept Nutr, CH-1000 Lausanne 26, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Nestle SA	Corthesy, B (corresponding author), CHU Vaudois, R&D Lab, Div Immunol & Allergy, Rue Bugnon,BH 19-650, CH-1011 Lausanne, Switzerland.	blaise.corthesy@chuv.ch	Perrier, Clementine/A-3925-2011					BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Brandtzaeg P, 2004, TRENDS IMMUNOL, V25, P570, DOI 10.1016/j.it.2004.09.005; Brock SC, 2002, INFECT IMMUN, V70, P5091, DOI 10.1128/IAI.70.9.5091-5095.2002; Burns JW, 1996, SCIENCE, V272, P104, DOI 10.1126/science.272.5258.104; Ciarlet M, 1999, J GEN VIROL, V80, P943, DOI 10.1099/0022-1317-80-4-943; Cleary J, 2004, MICROBIOL-SGM, V150, P527, DOI 10.1099/mic.0.26740-0; CLEVELAND MG, 1991, J IMMUNOL, V147, P181; CORTHIER G, 1991, INFECT IMMUN, V59, P1192, DOI 10.1128/IAI.59.3.1192-1195.1991; Cottet S, 2002, J BIOL CHEM, V277, P33978, DOI 10.1074/jbc.M201726200; COYNE RS, 1994, J BIOL CHEM, V269, P31620; Crottet P, 1998, J IMMUNOL, V161, P5445; Crottet P, 1999, J BIOL CHEM, V274, P31445, DOI 10.1074/jbc.274.44.31445; Crottet P, 1999, J BIOL CHEM, V274, P31456, DOI 10.1074/jbc.274.44.31456; Dai DW, 2000, J PEDIATR GASTR NUTR, V30, pS23, DOI 10.1097/00005176-200003002-00005; Dallas SD, 1998, J MED MICROBIOL, V47, P879, DOI 10.1099/00222615-47-10-879; Delorme C, 2001, J VIROL, V75, P2276, DOI 10.1128/JVI.75.5.2276-2287.2001; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; Favre LI, 2003, J CHROMATOGR B, V786, P143, DOI 10.1016/S1570-0232(02)00723-7; Frankel G, 2001, TRENDS MICROBIOL, V9, P214, DOI 10.1016/S0966-842X(01)02016-9; Giammarioli AM, 1996, VIROLOGY, V225, P97, DOI 10.1006/viro.1996.0578; GIUGLIANO LG, 1995, J MED MICROBIOL, V42, P3, DOI 10.1099/00222615-42-1-3; Gomez HF, 2003, J INFECT DIS, V187, P87, DOI 10.1086/345875; Hamburger AE, 2004, STRUCTURE, V12, P1925, DOI 10.1016/j.str.2004.09.006; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; Hughes GJ, 1999, BBA-PROTEIN STRUCT M, V1434, P86, DOI 10.1016/S0167-4838(99)00168-5; Jepson MA, 2003, CELL MICROBIOL, V5, P773, DOI 10.1046/j.1462-5822.2003.00315.x; Jones RML, 1998, BBA-PROTEIN STRUCT M, V1429, P265, DOI 10.1016/S0167-4838(98)00239-8; Kaetzel CS, 2005, IMMUNOL REV, V206, P83, DOI 10.1111/j.0105-2896.2005.00278.x; Kaetzel CS, 2001, CURR BIOL, V11, pR35, DOI 10.1016/S0960-9822(00)00041-5; Kanamaru Y, 1999, BIOSCI BIOTECH BIOCH, V63, P246, DOI 10.1271/bbb.63.246; Kelly G, 1999, NAT STRUCT BIOL, V6, P313; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kiefel MJ, 2003, METHOD ENZYMOL, V363, P395; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; Kvistgaard AS, 2004, J DAIRY SCI, V87, P4088, DOI 10.3168/jds.S0022-0302(04)73551-1; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; Lopez S, 2004, TRENDS MICROBIOL, V12, P271, DOI 10.1016/j.tim.2004.04.003; Lu L, 2003, J BIOL CHEM, V278, P48178, DOI 10.1074/jbc.M306906200; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Mantis NJ, 2004, J IMMUNOL, V172, P6838, DOI 10.4049/jimmunol.172.11.6838; Marchetti M, 1996, ANTIVIR RES, V29, P221, DOI 10.1016/0166-3542(95)00840-3; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; Ochoa TJ, 2003, INFECT IMMUN, V71, P5149, DOI 10.1128/IAI.71.9.5149-5155.2003; Phalipon A, 2003, TRENDS IMMUNOL, V24, P55, DOI 10.1016/S1471-4906(02)00031-5; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; Rey J, 2004, J IMMUNOL, V172, P3026, DOI 10.4049/jimmunol.172.5.3026; RINDISBACHER L, 1995, J BIOL CHEM, V270, P14220, DOI 10.1074/jbc.270.23.14220; Royle L, 2003, J BIOL CHEM, V278, P20140, DOI 10.1074/jbc.M301436200; Schroten H, 1998, INFECT IMMUN, V66, P3971, DOI 10.1128/IAI.66.8.3971-3973.1998; Stubbe H, 2000, J IMMUNOL, V164, P1952, DOI 10.4049/jimmunol.164.4.1952; Superti F, 2001, BBA-GEN SUBJECTS, V1528, P107, DOI 10.1016/S0304-4165(01)00178-7; WALLACE CJA, 1987, EUR J BIOCHEM, V170, P293, DOI 10.1111/j.1432-1033.1987.tb13698.x; WOLD AE, 1990, INFECT IMMUN, V58, P3073, DOI 10.1128/IAI.58.9.3073-3077.1990; Woof JM, 2005, IMMUNOL REV, V206, P64, DOI 10.1111/j.0105-2896.2005.00290.x; Yu L, 2000, NATURE, V405, P1073, DOI 10.1038/35016618; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4	58	78	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14280	14287		10.1074/jbc.M512958200	http://dx.doi.org/10.1074/jbc.M512958200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543244	hybrid			2022-12-25	WOS:000237512300053
J	Sobko, AA; Kotova, EA; Antonenko, YN; Zakharov, SD; Cramer, WA				Sobko, Alexander A.; Kotova, Elena A.; Antonenko, Yuri N.; Zakharov, Stanislav D.; Cramer, William A.			Lipid dependence of the channel properties of a colicin E1-lipid toroidal pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROBING ALAMETHICIN CHANNELS; TRANSMEMBRANE ALPHA-HELICES; WATER-SOLUBLE POLYMERS; ION-CHANNEL; BILAYER THICKNESS; SURFACE-CHARGE; SPONTANEOUS CURVATURE; GRAMICIDIN CHANNELS; MEMBRANE CURVATURE; FORMING COLICINS	Colicin E1 belongs to a group of bacteriocins whose cytotoxicity toward Escherichia coli is exerted through formation of ion channels that depolarize the cytoplasmic membrane. The lipid dependence of colicin single-channel conductance demonstrated intimate involvement of lipid in the structure of this channel. The colicin formed "small" conductance 60-picosiemens (pS) channels, with properties similar to those previously characterized, in 1,2-dieicosenoyl-sn-glycero3- phosphocholine (C20) or thinner membranes, whereas it formed a novel "large" conductance 600-pS state in thicker 1,2-dierucoyl-sn-glycero-3-phosphocholine (C22) bilayers. Both channel states were anion-selective and voltage-gated and displayed a requirement for acidic pH. Lipids having negative spontaneous curvature inhibited the formation of both channels but increased the ratio of open 600 pS to 60 pS conductance states. Different diameters of small and large channels, 12 and 16 angstrom, were determined from the dependence of single-channel conductance on the size of nonelectrolyte solute probes. Colicin-induced lipid "flip-flop" and the decrease in anion selectivity of the channel in the presence of negatively charged lipids implied a significant contribution of lipid to the structure of the channel, most readily described as toroidal organization of lipid and protein to form the channel pore.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Phys Chem Biol, Moscow 119992, Russia; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Russian Acad Sci, Inst Basic Problems Biol, Pushchino 142290, Moscow Region, Russia	Lomonosov Moscow State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Russian Academy of Sciences	Antonenko, YN (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Phys Chem Biol, Moscow 119992, Russia.	antonen@genebee.msu.ru	Kotova, Elena/A-6214-2012; Antonenko, Yuri N/K-1323-2013		FOGARTY INTERNATIONAL CENTER [R03TW001235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018457] Funding Source: NIH RePORTER; FIC NIH HHS [TW01235] Funding Source: Medline; NIGMS NIH HHS [GM-18457] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguilella VM, 2001, EUR BIOPHYS J BIOPHY, V30, P233, DOI 10.1007/s002490100145; Alcaraz A, 2004, BIOPHYS J, V87, P943, DOI 10.1529/biophysj.104/043414; Alvis SJ, 2003, BIOPHYS J, V85, P3828, DOI 10.1016/S0006-3495(03)74797-3; Andersen O S, 1999, Methods Enzymol, V294, P208; APELL HJ, 1979, BIOCHIM BIOPHYS ACTA, V552, P369, DOI 10.1016/0005-2736(79)90181-0; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; BENZ R, 1975, BIOCHIM BIOPHYS ACTA, V394, P323, DOI 10.1016/0005-2736(75)90287-4; Betanzos M, 2002, NAT STRUCT BIOL, V9, P704, DOI 10.1038/nsb828; Bezrukov SM, 2000, CURR OPIN COLLOID IN, V5, P237, DOI 10.1016/S1359-0294(00)00061-3; BEZRUKOV SM, 1993, BIOPHYS J, V64, P16, DOI 10.1016/S0006-3495(93)81336-5; BISHOP LJ, 1986, J MEMBRANE BIOL, V92, P237, DOI 10.1007/BF01869392; BISHOP LJ, 1985, J BACTERIOL, V164, P237, DOI 10.1128/JB.164.1.237-244.1985; BRAUN V, 1994, ARCH MICROBIOL, V161, P199, DOI 10.1007/s002030050042; Bredin J, 2002, BIOCHEM J, V363, P521, DOI 10.1042/0264-6021:3630521; Breukink E, 2003, J BIOL CHEM, V278, P19898, DOI 10.1074/jbc.M301463200; BRUGGEMANN EP, 1986, P NATL ACAD SCI USA, V83, P4273, DOI 10.1073/pnas.83.12.4273; BULLOCK JO, 1983, J BIOL CHEM, V258, P9908; BULLOCK JO, 1992, J MEMBRANE BIOL, V125, P255; Chen Z, 1997, BIOPHYS J, V73, P267, DOI 10.1016/S0006-3495(97)78067-6; Chernyshev A, 2003, BIOPHYS J, V84, P238, DOI 10.1016/S0006-3495(03)74845-0; CLEVELAND MV, 1983, P NATL ACAD SCI-BIOL, V80, P3706, DOI 10.1073/pnas.80.12.3706; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; DANKERT JR, 1982, J BIOL CHEM, V257, P3857; Epand RF, 2002, BIOCHEM J, V367, P849, DOI 10.1042/BJ20020986; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Epand RM, 1998, BBA-REV BIOMEMBRANES, V1376, P353, DOI 10.1016/S0304-4157(98)00015-X; Garavaglia M, 2004, CELL PHYSIOL BIOCHEM, V14, P231, DOI 10.1159/000080332; Garcia-Saez AJ, 2005, BIOPHYS J, V88, P3976, DOI 10.1529/biophysj.104.058008; Gilbert RJC, 2005, STRUCTURE, V13, P1097, DOI 10.1016/j.str.2005.04.019; GOULD JM, 1977, J BIOL CHEM, V252, P5491; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Haque ME, 2004, BIOCHEMISTRY-US, V43, P3507, DOI 10.1021/bi035794j; Harroun TA, 1999, BIOPHYS J, V76, P3176, DOI 10.1016/S0006-3495(99)77469-2; Hsu STD, 2004, NAT STRUCT MOL BIOL, V11, P963, DOI 10.1038/nsmb830; Hung WC, 2000, BBA-BIOMEMBRANES, V1467, P198, DOI 10.1016/S0005-2736(00)00221-2; Jakes KS, 1999, Q REV BIOPHYS, V32, P189, DOI 10.1017/S0033583599003492; James R, 2002, BIOCHIMIE, V84, P381, DOI 10.1016/S0300-9084(02)01450-5; Kienker PK, 2000, J GEN PHYSIOL, V116, P587, DOI 10.1085/jgp.116.4.587; Killian JA, 1998, BBA-REV BIOMEMBRANES, V1376, P401, DOI 10.1016/S0304-4157(98)00017-3; Krasilnikov OV, 1998, J MEMBRANE BIOL, V161, P83; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; Krasilnikov OV, 1998, BIOFIZIKA+, V43, P299; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lakey JH, 2001, CURR TOP MICROBIOL, V257, P131; Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012; Lee MT, 2005, BIOPHYS J, V89, P4006, DOI 10.1529/biophysj.105.068080; LEVINTHAL F, 1991, PROTEINS, V11, P254, DOI 10.1002/prot.340110404; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; Lindeberg M, 2000, J MOL BIOL, V295, P679, DOI 10.1006/jmbi.1999.3396; LIU Q R, 1986, Proteins Structure Function and Genetics, V1, P218, DOI 10.1002/prot.340010304; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; Malev VV, 2002, BIOPHYS J, V82, P1985, DOI 10.1016/S0006-3495(02)75547-1; Martinac B, 2002, P NATL ACAD SCI USA, V99, P4308, DOI 10.1073/pnas.072632899; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; Menestrina G, 2003, FEBS LETT, V552, P54, DOI 10.1016/S0014-5793(03)00850-0; Merzlyak PG, 1999, BIOPHYS J, V77, P3023, DOI 10.1016/S0006-3495(99)77133-X; Mobashery N, 1997, FEBS LETT, V412, P15, DOI 10.1016/S0014-5793(97)00709-6; Muller P, 2000, CHEM PHYS LIPIDS, V106, P89, DOI 10.1016/S0009-3084(00)00134-1; Musse AA, 2006, J BIOL CHEM, V281, P885, DOI 10.1074/jbc.M511140200; OHNOIWASHITA Y, 1982, J BIOL CHEM, V257, P6446; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; Park JB, 2003, J GEN PHYSIOL, V121, P375, DOI 10.1085/jgp.200208746; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; PETERSON AA, 1987, J MEMBRANE BIOL, V99, P197, DOI 10.1007/BF01995700; Phale PS, 2001, BIOCHEMISTRY-US, V40, P6319, DOI 10.1021/bi010046k; Powl AM, 2003, BIOCHEMISTRY-US, V42, P14306, DOI 10.1021/bi034995k; RAYMOND L, 1985, J MEMBRANE BIOL, V84, P173, DOI 10.1007/BF01872215; ROPELE M, 1989, BIOCHIM BIOPHYS ACTA, V985, P9, DOI 10.1016/0005-2736(89)90096-5; Rostovtseva TK, 1998, BIOPHYS J, V75, P1783, DOI 10.1016/S0006-3495(98)77620-9; SCHEIN SJ, 1978, NATURE, V276, P159, DOI 10.1038/276159a0; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SHIRABE K, 1989, J BIOL CHEM, V264, P1951; SLATIN SL, 1988, INT J BIOCHEM, V20, P737, DOI 10.1016/0020-711X(88)90058-4; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; Sobko AA, 2004, FEBS LETT, V576, P205, DOI 10.1016/j.febslet.2004.09.016; Sparr E, 2005, J BIOL CHEM, V280, P39324, DOI 10.1074/jbc.M502810200; Starostin AV, 1999, BIOCHEMISTRY-US, V38, P6144, DOI 10.1021/bi9826355; SUNSHINE C, 1992, BIOCHIM BIOPHYS ACTA, V1108, P240, DOI 10.1016/0005-2736(92)90031-G; Terrones O, 2004, J BIOL CHEM, V279, P30081, DOI 10.1074/jbc.M313420200; Tillman TS, 2003, CELL BIOCHEM BIOPHYS, V38, P161, DOI 10.1385/CBB:38:2:161; Uhrikova D, 2003, BBA-BIOMEMBRANES, V1611, P31, DOI 10.1016/S0005-2736(02)00705-8; Valcarcel CA, 2001, BIOPHYS J, V80, P2761, DOI 10.1016/S0006-3495(01)76244-3; Valiyaveetil FI, 2002, BIOCHEMISTRY-US, V41, P10771, DOI 10.1021/bi026215y; VANDENBRINKVAND.KJ, 2004, BIOCHIM BIOPHYS ACTA, V1666, P275; VODYANOY I, 1992, BIOPHYS J, V62, P10, DOI 10.1016/S0006-3495(92)81762-9; VODYANOY I, 1993, BIOPHYS J, V65, P2097, DOI 10.1016/S0006-3495(93)81245-1; WHITE SH, 1978, BIOPHYS J, V23, P337, DOI 10.1016/S0006-3495(78)85453-8; Wiggins P, 2004, P NATL ACAD SCI USA, V101, P4071, DOI 10.1073/pnas.0307804101; Williamson IM, 2002, BIOPHYS J, V83, P2026, DOI 10.1016/S0006-3495(02)73964-7; Wimley WC, 2000, BIOCHEMISTRY-US, V39, P4432, DOI 10.1021/bi992746j; Yan L, 2003, FEBS LETT, V555, P545, DOI 10.1016/s0014-5793(03)01346-2; Yuan CB, 2004, BIOPHYS J, V86, P3620, DOI 10.1529/biophysj.103.029678; Zakharov SD, 2002, P NATL ACAD SCI USA, V99, P8654, DOI 10.1073/pnas.122613099; Zakharov SD, 1998, P NATL ACAD SCI USA, V95, P4282, DOI 10.1073/pnas.95.8.4282; Zakharov SD, 2004, BBA-BIOMEMBRANES, V1666, P239, DOI 10.1016/j.bbamem.2004.07.001; Zakharov SD, 2002, BBA-BIOMEMBRANES, V1565, P333, DOI 10.1016/S0005-2736(02)00579-5; Zemel A, 2003, BIOPHYS J, V84, P2242, DOI 10.1016/S0006-3495(03)75030-9; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215	99	61	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14408	14416		10.1074/jbc.M513634200	http://dx.doi.org/10.1074/jbc.M513634200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16556601	hybrid			2022-12-25	WOS:000237512300068
J	Vandermoere, F; El Yazidi-Belkoura, I; Slomianny, C; Demont, Y; Bidaux, G; Adriaenssens, E; Lemoine, J; Hondermarck, H				Vandermoere, Franck; El Yazidi-Belkoura, Ikram; Slomianny, Christian; Demont, Yohann; Bidaux, Gabriel; Adriaenssens, Eric; Lemoine, Jerome; Hondermarck, Hubert			The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; NERVE GROWTH-FACTOR; MEMBRANE-FUSION; KINASE-B; SUBSTRATE; BRCA1; PHOSPHORYLATION; ACTIVATION; PROTEASOME; REVEALS	The serine/threonine kinase Akt is a key mediator of cell survival and growth, but its precise mechanism of action, and more specifically, the nature of its signaling partners largely remain to be elucidated. We show, using a proteomics-based approach, that the valosin-containing protein (VCP), a member of the AAA ( ATPases associated with a variety of cellular activities) family, is a target of Akt signaling. SDS-PAGE of Akt co-immunoprecipitated proteins obtained from MCF-7 breast cancer cells revealed the increase of a 97-kDa band under Akt activation. Mass spectrometry analysis allowed the identification of VCP, and we have shown a serine/threonine phosphorylation on an Akt consensus site upon activation by growth factors. Site-directed mutagenesis identified Ser-351, Ser-745, and Ser-747 as Akt phosphorylation sites on VCP. Confocal microscopy indicated a co-localization between Akt and VCP upon Akt stimulation. Interestingly, small interfering RNA against VCP induced an inhibition of the growth factor-induced activation of NF-kappa B and a potent pro-apoptotic effect. Together, these data identify VCP as an essential target of Akt signaling.	Univ Sci & Technol Lille, INSERM ERI 8, F-59655 Villeneuve Dascq, France; Univ Sci & Technol Lille, INSERM EMI 0228, F-59655 Villeneuve Dascq, France; Univ Sci & Technol Lille, UMR 8576, CNRS, IFR 118, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Hondermarck, H (corresponding author), Univ Sci & Technol Lille, INSERM ERI 8, Batiment SN3, F-59655 Villeneuve Dascq, France.	hubert.hondermarck@univ-lille1.fr	lemoine, jerome/C-4272-2014; Slomianny, Christian/L-8285-2018; El Yazidi-Belkoura, Ikram/AAE-8805-2022; Bidaux, Gabriel/F-1294-2016	lemoine, jerome/0000-0002-5497-6880; EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509; VANDERMOERE, Franck/0000-0001-5724-7037; Bidaux, Gabriel/0000-0002-6162-3223				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; El Yazidi-Belkoura I, 2003, J BIOL CHEM, V278, P16952, DOI 10.1074/jbc.M300631200; Hondermarck H, 2003, MOL CELL PROTEOMICS, V2, P281, DOI 10.1074/mcp.R300003-MCP200; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Klein JB, 2005, J BIOL CHEM, V280, P31870, DOI 10.1074/jbc.M501802200; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vandermoere F, 2005, ONCOGENE, V24, P5482, DOI 10.1038/sj.onc.1208713; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Villafuerte BC, 2004, J BIOL CHEM, V279, P36650, DOI 10.1074/jbc.M404349200; Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014; Welm BE, 2002, J CELL BIOL, V157, P703, DOI 10.1083/jcb.200107119; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168	28	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14307	14313		10.1074/jbc.M510003200	http://dx.doi.org/10.1074/jbc.M510003200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551632	Green Published, hybrid			2022-12-25	WOS:000237512300056
J	Caruano-Yzermans, AL; Bartnikas, TB; Gitlin, JD				Caruano-Yzermans, AL; Bartnikas, TB; Gitlin, JD			Mechanisms of the copper-dependent turnover of the copper chaperone for superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAFFICKING PROTEINS; MESSENGER-RNA; CCS; DEFICIENT; METALLOCHAPERONE; METABOLISM; ACTIVATION; TRANSPORT; INSIGHTS; DISEASE	The copper chaperone for superoxide dismutase (CCS) is an intracellular metallochaperone required for incorporation of copper into the essential antioxidant enzyme copper/zinc superoxide dismutase (SOD1). Nutritional studies have revealed that the abundance of CCS is inversely proportional to the dietary and tissue copper content. To determine the mechanisms of copper-dependent regulation of CCS, copper incorporation into SOD1 and SOD1 enzymatic activity as well as CCS abundance and half-life were determined after metabolic labeling of CCS-/- fibroblasts transfected with wild-type or mutant CCS. Wild-type CCS restored SOD1 activity in CCS-/- fibroblasts, and the abundance of this chaperone in these cells was inversely proportional to the copper content of the media, indicating that copper-dependent regulation of CCS is entirely post-translational. Although mutational studies demonstrated no role for CCS Domain I in this copper-dependent regulation, similar analysis of the CXC motif in Domain III revealed a critical role for these cysteine residues in mediating copper-dependent turnover of CCS. Further mutational studies revealed that this CXC-dependent copper-mediated turnover of CCS is independent of the mechanisms of delivery of copper to SOD1 including CCS-SOD1 interaction. Taken together these data demonstrate a mechanism determining the abundance of CCS that is competitive with the process of copper delivery to SOD1, revealing a unique post- translational component of intracellular copper homeostasis.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL)	Gitlin, JD (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, McDonnell Pediat Res Bldg,660 S Euclid Ave, St Louis, MO 63110 USA.	gitlin@kids.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R01DK061763] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 61763, P30 DK056341-06, P30 DK056341-05S2, P30 DK056341] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; Bertinato J, 2004, J NUTR BIOCHEM, V15, P316, DOI 10.1016/j.jnutbio.2004.02.004; Bertinato J, 2003, J BIOL CHEM, V278, P35071, DOI 10.1074/jbc.M302242200; Bertinato J, 2003, J NUTR, V133, P28, DOI 10.1093/jn/133.1.28; Brown NM, 2004, P NATL ACAD SCI USA, V101, P5518, DOI 10.1073/pnas.0401175101; Carroll MC, 2004, P NATL ACAD SCI USA, V101, P5964, DOI 10.1073/pnas.0308298101; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Hellman NE, 2002, J BIOL CHEM, V277, P46632, DOI 10.1074/jbc.M206246200; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Lee J, 2002, J BIOL CHEM, V277, P40253, DOI 10.1074/jbc.M208002200; Luk E, 2003, J BIOL INORG CHEM, V8, P803, DOI 10.1007/s00775-003-0482-3; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; Narayanan VS, 2001, J NUTR, V131, P1427, DOI 10.1093/jn/131.5.1427; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Prohaska JR, 2004, J NUTR, V134, P1003, DOI 10.1093/jn/134.5.1003; Prohaska JR, 2003, ARCH BIOCHEM BIOPHYS, V417, P227, DOI 10.1016/S0003-9861(03)00364-3; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Tao TY, 2003, HEPATOLOGY, V37, P1241, DOI 10.1053/jhep.2003.50281; Thiele DJ, 2003, J NUTR, V133, p1579S, DOI 10.1093/jn/133.5.1579S; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197	31	67	68	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13581	13587		10.1074/jbc.M601580200	http://dx.doi.org/10.1074/jbc.M601580200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531609	hybrid			2022-12-25	WOS:000237336600067
J	Kim, YS; Kang, KR; Wolff, EC; Bell, JK; McPhie, P; Park, MH				Kim, YS; Kang, KR; Wolff, EC; Bell, JK; McPhie, P; Park, MH			Deoxyhypusine hydroxylase is an Fe(II)-dependent, heat-repeat enzyme - Identification of amino acid residues critical for Fe(II) binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 5A; CELL VIABILITY; POSTTRANSLATIONAL MODIFICATION; SACCHAROMYCES-CEREVISIAE; RAT TESTIS; IN-VIVO; HYPUSINE; PROTEIN; SYNTHASE; INHIBITION	Deoxyhypusine hydroxylase ( DOHH) catalyzes the final step in the post-translational synthesis of hypusine ( N-epsilon-( 4-amino-2-hydroxybutyl) lysine) in eIF5A. DOHH is a HEAT-repeat protein with eight tandem helical hairpins in a symmetrical dyad. It contains two potential iron coordination sites ( one on each dyad) composed of two strictly conserved His-Glu motifs. The purified human recombinant DOHH was a mixture of active holoenzyme containing 2 mol of iron/mol of DOHH and inactive metal-free apoenzyme. The two species could be distinguished by their different mobilities upon native gel electrophoresis. The DOHH apoenzyme exhibited markedly reduced levels of iron and activity. DOHH activity could be restored only by the addition of Fe2+ to the apoenzyme but not by other metals including Cd2+, Co2+, Cr2+, Cu2+, Mg2+, Mn2+, Ni2+, and Zn2+. The role of the strictly conserved His-Glu residues was evaluated by site-directed mutagenesis. Substitution of any single amino acid in the four His-Glu motifs with alanine abolished the enzyme activity. Of these eight alanine substitutions, six, including H56A, H89A, E90A, H207A, H240A, and E241A, caused a severe reduction in the iron content. Our results provide strong evidence that Fe( II) is the active-site-bound metal critical for DOHH catalysis and that the strictly conserved His-Glu motifs are essential for iron binding and catalysis. Furthermore, the iron to DOHH stoichiometry and dependence of iron binding on each of the four conserved His-Glu motifs suggest a binuclear iron mediated reaction mechanism, distinct from that of other Fe( II)-dependent protein hydroxylases, such as prolyl 4-hydroxylase or lysyl hydroxylases.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Park, MH (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.	mhpark@nih.gov	Bell, Jessica/I-3893-2013	Bell, Jessica/0000-0003-1455-3274	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK024964, Z01DK024942] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 DE999999] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Andrus L, 1998, BIOCHEM PHARMACOL, V55, P1807, DOI 10.1016/S0006-2952(98)00053-7; Aravind L, 2001, GENOME BIOL, V2; BARTIG D, 1990, SYST APPL MICROBIOL, V13, P112, DOI 10.1016/S0723-2020(11)80156-6; Bevec D, 1996, SCIENCE, V271, P1858, DOI 10.1126/science.271.5257.1858; Bevec D, 1997, BIOL SIGNAL, V6, P124; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; Caraglia M, 2003, J BIOCHEM, V133, P757, DOI 10.1093/jb/mvg097; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P13869, DOI 10.1073/pnas.1835918100; Chen KY, 1997, BIOL SIGNAL, V6, P105; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Clement PMJ, 2002, INT J CANCER, V100, P491, DOI 10.1002/ijc.10515; Csonga R, 1996, FEBS LETT, V380, P209, DOI 10.1016/0014-5793(96)00020-8; GERNER EW, 1986, BIOCHEM J, V239, P379, DOI 10.1042/bj2390379; GLICK BR, 1975, P NATL ACAD SCI USA, V72, P4257, DOI 10.1073/pnas.72.11.4257; Hanauske-Abel HM, 2003, CURR MED CHEM, V10, P1005, DOI 10.2174/0929867033457601; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; Hanawa-Suetsugu K, 2004, P NATL ACAD SCI USA, V101, P9595, DOI 10.1073/pnas.0308667101; Hausinger RP, 2004, CRIT REV BIOCHEM MOL, V39, P21, DOI 10.1080/10409230490440541; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Liu YP, 1997, BIOL SIGNAL, V6, P166; Nishimura K, 2005, BIOCHEM J, V385, P779, DOI 10.1042/BJ20041477; Park JH, 2006, P NATL ACAD SCI USA, V103, P51, DOI 10.1073/pnas.0509348102; Park JH, 2003, J BIOL CHEM, V278, P32683, DOI 10.1074/jbc.M304247200; Park MH, 2006, J BIOCHEM, V139, P161, DOI 10.1093/jb/mvj034; PARK MH, 1984, J BIOL CHEM, V259, P2123; Park MH, 1998, J BIOL CHEM, V273, P1677, DOI 10.1074/jbc.273.3.1677; Phizicky EM, 2002, METHOD ENZYMOL, V350, P546; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Spradling AC, 1999, GENETICS, V153, P135; Sugimoto A, 2004, DIFFERENTIATION, V72, P81, DOI 10.1111/j.1432-0436.2004.07202004.x; Thompson GM, 2003, FEBS LETT, V555, P464, DOI 10.1016/S0014-5793(03)01305-X; Tshuva EY, 2004, CHEM REV, V104, P987, DOI 10.1021/cr020622y; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Wei PP, 2005, J AM CHEM SOC, V127, P16098, DOI 10.1021/ja053661a; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660	44	46	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13217	13225		10.1074/jbc.M601081200	http://dx.doi.org/10.1074/jbc.M601081200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533814	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000237336600027
J	Chen, YH; Beischlag, TV; Kim, JH; Perdew, GH; Stallcup, MR				Chen, YH; Beischlag, TV; Kim, JH; Perdew, GH; Stallcup, MR			Role of GAC63 in transcriptional activation mediated by the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; NUCLEAR TRANSLOCATOR; AH RECEPTOR; COACTIVATOR; RECRUITMENT; PROTEIN; DIOXIN; BINDING; FAMILY; CANCER	The aryl hydrocarbon receptor (AHR), a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH-PAS) gene family, binds a variety of polycyclic aromatic hydrocarbons and mediates their toxic effects. GAC63 has been shown to act as a coactivator in nuclear receptor-mediated gene transcription. In this report, we demonstrate that GAC63 interacts with AHR through its bHLH-PAS domain. Overexpression of GAC63 greatly enhanced AHR-regulated reporter gene activity in a ligand-dependent manner in transient transfection assays. Upon ligand treatment, endogenous GAC63 was recruited to the xeno-biotic response element of the mouse CYP1A1 gene, an AHR-responsive gene. Reduction of the endogenous GAC63 level by small interfering RNA inhibited transcriptional activation by AHR. These findings reveal a new function of GAC63 in AHR-mediated gene transcription.	Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA	University of Southern California; University of Southern California; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Stallcup, MR (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, MCA-51A,1333 San Pablo St, Los Angeles, CA 90089 USA.	stallcup@usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES004869, R01ES004869] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43093, R01 DK043093] Funding Source: Medline; NIEHS NIH HHS [R01 ES004869, ES04869] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexander DL, 1998, J CELL SCI, V111, P3311; Beischlag TV, 2004, J BIOL CHEM, V279, P54620, DOI 10.1074/jbc.M410456200; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Carlson DB, 2002, J BIOCHEM MOL TOXIC, V16, P317, DOI 10.1002/jbt.10051; Chen YH, 2005, MOL CELL BIOL, V25, P5965, DOI 10.1128/MCB.25.14.5965-5972.2005; Denison MS, 2002, CHEM-BIOL INTERACT, V141, P3, DOI 10.1016/S0009-2797(02)00063-7; GIERTHY JF, 1993, CANCER RES, V53, P3149; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hankinson O, 2005, ARCH BIOCHEM BIOPHYS, V433, P379, DOI 10.1016/j.abb.2004.09.031; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Jana NR, 1999, BIOCHEM BIOPH RES CO, V256, P462, DOI 10.1006/bbrc.1999.0367; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Kim JH, 2004, J BIOL CHEM, V279, P49842, DOI 10.1074/jbc.M408535200; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kuil CW, 1998, J BIOL CHEM, V273, P8829, DOI 10.1074/jbc.273.15.8829; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Rivera SP, 2005, TOXICOLOGY, V207, P401, DOI 10.1016/j.tox.2004.10.009; Saarikoski Sirkku T, 2005, Toxicol Appl Pharmacol, V207, P62, DOI 10.1016/j.taap.2004.12.027; Safe S, 1998, TOXICOL LETT, V103, P343; Sim DLC, 2002, INT J BIOCHEM CELL B, V34, P487, DOI 10.1016/S1357-2725(01)00156-X; Sim DLC, 1999, GENOMICS, V59, P224, DOI 10.1006/geno.1999.5856; SPINK DC, 1990, P NATL ACAD SCI USA, V87, P6917, DOI 10.1073/pnas.87.17.6917; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; ZACHAREWSKI T, 1991, BIOCHEM PHARMACOL, V41, P1931, DOI 10.1016/0006-2952(91)90133-P	28	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12242	12247		10.1074/jbc.M512537200	http://dx.doi.org/10.1074/jbc.M512537200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513642	hybrid, Green Accepted			2022-12-25	WOS:000237134700007
J	Rahman, NS; Godderz, LJ; Stray, SJ; Capra, JD; Rodgers, KK				Rahman, NS; Godderz, LJ; Stray, SJ; Capra, JD; Rodgers, KK			DNA cleavage of a cryptic recombination signal sequence by RAG1 and RAG2 - Implications for partial V-H gene replacement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIABLE REGION GENES; CODING END SEQUENCE; V(D)J RECOMBINATION; RECEPTOR REVISION; IMMUNE DIVERSIFICATION; STRUCTURE REQUIREMENTS; B-LYMPHOCYTES; PROTEIN RAG1; TRANSPOSITION; IDENTIFICATION	Antibody and T cell receptor genes are assembled from gene segments by V(D)J recombination to produce an almost infinitely diverse repertoire of antigen specificities. Recombination is initiated by cleavage of conserved recombination signal sequences (RSS) by RAG1 and RAG2 during lymphocyte development. Recent evidence demonstrates that recombination can occur at noncanonical RSS sites within Ig genes or at other loci, outside the context of normal lymphocyte receptor gene rearrangement. We have characterized the ability of the RAG proteins to bind and cleave a cryptic RSS (cRSS) located within an Ig V-H gene segment. The RAG proteins bound with sequence specificity to either the consensus RSS or the cRSS. The RAG proteins nick the cRSS on both the top and bottom strands, thereby bypassing the formation of the DNA hairpin intermediate observed in RAG cleavage of canonical RSS substrates. We propose that the RAG proteins may utilize an alternative mechanism for double-stranded DNA cleavage, depending on the substrate sequence. These results have implications for further diversification of the antigen receptor repertoire as well as the role of the RAG proteins in genomic instability.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Oklahoma Med Res Fdn, Mol Immunogenet Res Program, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	Rodgers, KK (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 S L Young Blvd, Oklahoma City, OK 73190 USA.	karla-rodgers@ouhsc.edu		Rodgers, Karla/0000-0002-7338-0281	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012127, R37AI012127] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-12127] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Akamatsu Y, 1998, MOL CELL BIOL, V18, P4670, DOI 10.1128/MCB.18.8.4670; Arbuckle JL, 2001, J BIOL CHEM, V276, P37093, DOI 10.1074/jbc.M105988200; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bellan C, 2002, DIAGN MOL PATHOL, V11, P2, DOI 10.1097/00019606-200203000-00002; Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; Casellas R, 2001, SCIENCE, V291, P1541, DOI 10.1126/science.1056600; Cowell LG, 2003, J EXP MED, V197, P207, DOI 10.1084/jem.20020250; Cuomo CA, 1996, MOL CELL BIOL, V16, P5683; Darlow JM, 2005, IMMUNOLOGY, V114, P155, DOI 10.1111/j.1365-2567.2004.02084.x; De P, 2004, IMMUNOL REV, V200, P70, DOI 10.1111/j.0105-2896.2004.00154.x; De P, 2004, MOL CELL BIOL, V24, P6850, DOI 10.1128/mcb.24.15.6850-6860.2004; de Villartay JP, 2003, NAT REV IMMUNOL, V3, P962, DOI 10.1038/nri1247; Eastman QM, 1997, NUCLEIC ACIDS RES, V25, P4370, DOI 10.1093/nar/25.21.4370; Ezekiel UR, 1997, MOL CELL BIOL, V17, P4191, DOI 10.1128/MCB.17.7.4191; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; GERSTEIN RM, 1993, GENE DEV, V7, P1459, DOI 10.1101/gad.7.7b.1459; Godderz LJ, 2003, NUCLEIC ACIDS RES, V31, P2014, DOI 10.1093/nar/gkg281; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; Hillion S, 2005, ANN NY ACAD SCI, V1050, P10, DOI 10.1196/annals.1313.002; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Itoh K, 2000, J EXP MED, V192, P1151, DOI 10.1084/jem.192.8.1151; Jankovic M, 2004, ANNU REV IMMUNOL, V22, P485, DOI 10.1146/annurev.immunol.22.012703.104707; Kolar GR, 2004, SCAND J IMMUNOL, V60, P108, DOI 10.1111/j.0300-9475.2004.01467.x; Kouskoff V, 2001, LIFE SCI, V69, P1105, DOI 10.1016/S0024-3205(01)01219-X; Lee AI, 2003, PLOS BIOL, V1, P56, DOI 10.1371/journal.pbio.0000001; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lenze D, 2003, J CLIN PATHOL-MOL PA, V56, P249, DOI 10.1136/mp.56.5.249; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; Montalbano A, 2003, J IMMUNOL, V171, P5296, DOI 10.4049/jimmunol.171.10.5296; Neiditch MB, 2002, MOL CELL, V9, P871, DOI 10.1016/S1097-2765(02)00494-X; Nemazee D, 2003, CURR OPIN IMMUNOL, V15, P182, DOI 10.1016/S0952-7915(03)00008-6; Peak MM, 2003, J BIOL CHEM, V278, P18235, DOI 10.1074/jbc.M302041200; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; Raghavan SC, 2005, MOL CELL BIOL, V25, P5904, DOI 10.1128/MCB.25.14.5904-5919.2005; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; Santagata S, 1998, J BIOL CHEM, V273, P16325, DOI 10.1074/jbc.273.26.16325; Santagata S, 1999, MOL CELL, V4, P935, DOI 10.1016/S1097-2765(00)80223-3; Shih IH, 2002, EMBO J, V21, P6625, DOI 10.1093/emboj/cdf630; Shockett PE, 1999, MOL CELL BIOL, V19, P4159; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; Swanson PC, 2002, MOL CELL BIOL, V22, P1340, DOI 10.1128/MCB.22.5.1340-1351.2002; Swanson PC, 1998, IMMUNITY, V9, P115, DOI 10.1016/S1074-7613(00)80593-2; Weinstock DM, 2006, MOL CELL BIOL, V26, P131, DOI 10.1128/MCB.26.1.131-139.2006; Wilson PC, 2000, J EXP MED, V191, P1881, DOI 10.1084/jem.191.11.1881; Yu KF, 1999, MOL CELL BIOL, V19, P8094; Yu KF, 2000, MOL CELL BIOL, V20, P7914, DOI 10.1128/MCB.20.21.7914-7921.2000; Zhang ZX, 2004, IMMUNOL REV, V197, P231, DOI 10.1111/j.0105-2896.2004.0107.x; Zhang ZX, 2003, IMMUNITY, V19, P21, DOI 10.1016/S1074-7613(03)00170-5	54	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12370	12380		10.1074/jbc.M507906200	http://dx.doi.org/10.1074/jbc.M507906200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531612	hybrid			2022-12-25	WOS:000237134700022
J	Sarkar, M; Leventis, PA; Silvescu, CI; Reinhold, VN; Schachter, H; Boulianne, GL				Sarkar, M; Leventis, PA; Silvescu, CI; Reinhold, VN; Schachter, H; Boulianne, GL			Null mutations in Drosophila N-acetylglucosaminyltransferase I produce defects in locomotion and a reduced life span	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; INSECT CELLS; CAENORHABDITIS-ELEGANS; ALPHA-MANNOSIDASE; GLYCOPROTEIN-SYNTHESIS; PROTEIN GLYCOSYLATION; MUSCULAR-DYSTROPHY; GLYCANS; MELANOGASTER; COMPLEX	UDP-GlcNAc:alpha 3-D-mannoside beta 1,2-N-acetylglucosaminyltransferase I (encoded by Mgat1) controls the synthesis of hybrid, complex, and paucimannose N-glycans. Mice make hybrid and complex N-glycans but little or no paucimannose N-glycans. In contrast, Drosophila melanogaster and Caenorhabditis elegans make paucimannose N-glycans but little or no hybrid or complex N-glycans. To determine the functional requirement for beta 1,2-N-acetylglucosaminyltransferase I in Drosophila, we generated null mutations by imprecise excision of a nearby transposable element. Extracts from Mgat1(1)/Mgat1(1) null mutants showed no beta 1,2-N-acetylglucosaminyltransferase I enzyme activity. Moreover, mass spectrometric analysis of these extracts showed dramatic changes in N-glycans compatible with lack of beta 1,2-N-acetylglucosaminyltransferase I activity. Interestingly, Mgat1(1)/Mgat1(1) null mutants are viable but exhibit pronounced defects in adult locomotory activity when compared with Mgat1(1)/CyO-GFP heterozygotes or wild type flies. In addition, in null mutants males are sterile and have a severely reduced mean and maximum life span. Microscopic examination of mutant adult fly brains showed the presence of fused beta lobes. The removal of both maternal and zygotic Mgat1 also gave rise to embryos that no longer express the horseradish peroxidase antigen within the central nervous system. Taken together, the data indicate that beta 1,2-N-acetylglucosaminyltransferase I-dependent N-glycans are required for locomotory activity, life span, and brain development in Drosophila.	Hosp Sick Children, Program Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University System Of New Hampshire; University of New Hampshire; University of Toronto; University of Toronto	Schachter, H (corresponding author), Hosp Sick Children, Program Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	harry@sickkids.ca						ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P150, DOI 10.1007/BF00731359; Apweiler R, 1999, BBA-GEN SUBJECTS, V1473, P4, DOI 10.1016/S0304-4165(99)00165-8; Ashline D, 2005, ANAL CHEM, V77, P6250, DOI 10.1021/ac050724z; ATIENZASAMOLS SB, 1980, DEV BIOL, V79, P19, DOI 10.1016/0012-1606(80)90070-6; Boquet I, 2000, J NEUROBIOL, V42, P33; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Chen W, 2003, GLYCOBIOLOGY, V13, P43, DOI 10.1093/glycob/cwg003; Chiba A, 1997, J BIOL CHEM, V272, P2156; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DESAI CJ, 1994, J NEUROSCI, V14, P7272; Drysdale RA, 2005, NUCLEIC ACIDS RES, V33, pD390, DOI 10.1093/nar/gki046; Endo T, 2003, BIOL PHARM BULL, V26, P1641, DOI 10.1248/bpb.26.1641; Endo T, 1999, BBA-GEN SUBJECTS, V1473, P237, DOI 10.1016/S0304-4165(99)00182-8; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Finnie JW, 2001, J COMP PATHOL, V125, P318, DOI 10.1053/jcpa.2001.0510; Grunewald S, 2002, PEDIATR RES, V52, P618, DOI 10.1203/01.PDR.0000031921.02259.35; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Haslam SM, 2003, BIOCHIMIE, V85, P25, DOI 10.1016/S0300-9084(03)00041-5; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Ichimiya T, 2004, J BIOL CHEM, V279, P42638, DOI 10.1074/jbc.M404900200; Iliadi KG, 2002, BEHAV GENET, V32, P173, DOI 10.1023/A:1016017028041; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; Ioffe E, 1997, GLYCOBIOLOGY, V7, P913, DOI 10.1093/glycob/7.7.913; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; Kawar Z, 2001, J BIOL CHEM, V276, P16335, DOI 10.1074/jbc.M100119200; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; LAINE RA, 1994, GLYCOBIOLOGY, V4, P759, DOI 10.1093/glycob/4.6.759; LEONARD R, 2005, J BIOL CHEM, V281, P4567; Leventis PA, 2001, TRAFFIC, V2, P839; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Marchal I, 2001, BIOL CHEM, V382, P151, DOI 10.1515/BC.2001.023; Marek KW, 1999, GLYCOBIOLOGY, V9, P1263; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; Moremen KW, 2002, BBA-GEN SUBJECTS, V1573, P225, DOI 10.1016/S0304-4165(02)00388-4; Parekh RB, 1997, CURR OPIN BIOTECH, V8, P718, DOI 10.1016/S0958-1669(97)80126-7; Paschinger K, 2004, J BIOL CHEM, V279, P49588, DOI 10.1074/jbc.M408978200; Paschinger K, 2005, GLYCOBIOLOGY, V15, P463, DOI 10.1093/glycob/cwi028; Pittet M, 2006, GLYCOBIOLOGY, V16, P155, DOI 10.1093/glycob/cwj043; Rabouille C, 1999, J CELL SCI, V112, P3319; Rendic D, 2006, J BIOL CHEM, V281, P3343, DOI 10.1074/jbc.M508334200; Routtenberg A, 2005, TRENDS NEUROSCI, V28, P12, DOI 10.1016/j.tins.2004.11.006; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; Schachter H, 2000, GLYCOCONJUGATE J, V17, P465; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; Schachter H, 2005, GLYCOBIOLOGY, V15, P1191; Schachter H, 2005, P NATL ACAD SCI USA, V102, P15721, DOI 10.1073/pnas.0507659102; Schachter H, 2003, GLYCOCONJUGATE J, V20, P291, DOI 10.1023/B:GLYC.0000033626.65127.e4; SCHACHTER H, 2005, NEUROGLYCOBIOLOGY, P157; Selleck SB, 2001, SEMIN CELL DEV BIOL, V12, P127, DOI 10.1006/scdb.2000.0242; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; STANLEY P, 2000, MOL CELLULAR GLYCOBI, V30, P169; Staudacher E, 1998, GLYCOCONJUGATE J, V15, P355, DOI 10.1023/A:1006969701231; SURANI MAH, 1979, CELL, V18, P217; Tan J, 1996, AM J HUM GENET, V59, P810; Tsitilou SG, 2003, BIOCHEM BIOPH RES CO, V312, P1372, DOI 10.1016/j.bbrc.2003.11.059; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Varki Ajit, 1995, Seminars in Developmental Biology, V6, P127, DOI 10.1016/S1044-5781(06)80022-8; VITALE A, 1984, J CELL BIOL, V99, P133, DOI 10.1083/jcb.99.1.133; Wagner R, 1996, GLYCOBIOLOGY, V6, P165, DOI 10.1093/glycob/6.2.165; Wagner R, 1996, J VIROL, V70, P4103, DOI 10.1128/JVI.70.6.4103-4109.1996; Wang Y, 2001, GLYCOBIOLOGY, V11, P1051, DOI 10.1093/glycob/11.12.1051; Watanabe S, 2002, J BIOL CHEM, V277, P5090, DOI 10.1074/jbc.M110548200; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931; Zhang WL, 2003, CLIN BIOCHEM, V36, P339, DOI 10.1016/S0009-9120(03)00036-5; Zhu SX, 2004, BIOCHEM J, V382, P995, DOI 10.1042/BJ20040793	71	72	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12776	12785		10.1074/jbc.M512769200	http://dx.doi.org/10.1074/jbc.M512769200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522637	hybrid			2022-12-25	WOS:000237134700071
J	Takahashi, Y; Dominici, M; Swift, J; Nagy, C; Ihle, JN				Takahashi, Y; Dominici, M; Swift, J; Nagy, C; Ihle, JN			Trophoblast stem cells rescue placental defect in SOCS3-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE	Stem cells have important clinical and experimental potentials. Trophoblast stem ( TS) cells possess the ability to differentiate into trophoblast subtypes in vitro and contribute to the trophoblast lineage in vivo. Suppressor of cytokine signaling 3 ( SOCS3) is a negative regulator of cytokine signaling. Targeted disruption of SOCS3 revealed embryonic lethality on E12.5; it was caused by placental defect with enhanced leukemia inhibitory factor receptor signaling. A complementation of the wild-type ( WT) placenta by using tetraploid rescue technique showed that the embryonic lethality in SOCS3-deficient embryo was due to the placental defect. Here we demonstrate that TS cells supplementation rescues placental defect in SOCS3-deficient embryos. In the rescued placenta, TS cells were integrated into the placental structure, and a substantial structural improvement was observed in the labyrinthine layer that was disrupted in the SOCS3-deficient placenta. Importantly, by supplying TS cells, living SOCS3-deficient embryos were detected at term. These results indicate a functional contribution of TS cells in the placenta and their potential application.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol,Chuo, Kobe, Hyogo 6500017, Japan; St Jude Childrens Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Hosp, Cryopreservat Unit, Memphis, TN 38105 USA; St Jude Childrens Hosp, Transgen Core Unit, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Memphis, TN 38063 USA	Kobe University; Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Takahashi, Y (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol,Chuo, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	takahash@med.kobe-u.ac.jp	Dominici, Massimo/K-8014-2016	Dominici, Massimo/0000-0002-4007-1503				Dominici M, 2004, P NATL ACAD SCI USA, V101, P11761, DOI 10.1073/pnas.0404626101; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Ihle JN, 2000, CELL, V102, P131, DOI 10.1016/S0092-8674(00)00017-9; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072	9	17	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11444	11445		10.1074/jbc.C600015200	http://dx.doi.org/10.1074/jbc.C600015200			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16517610	hybrid, Green Published			2022-12-25	WOS:000236988100003
J	Wang, TH; Chan, YH; Chen, CW; Kung, WH; Lee, YS; Wang, ST; Chang, TC; Wang, HS				Wang, T-H; Chan, Y-H; Chen, C-W; Kung, W-H; Lee, Y-S; Wang, S-T; Chang, T-C; Wang, H-S			Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways	ONCOGENE			English	Article						paclitaxel; Taxol; JNK; interleukin 6 (IL-6)	NF-KAPPA-B; GENE-EXPRESSION; PROTEIN-KINASE; NUCLEAR-FACTOR; APOPTOSIS; ACTIVATION; RESISTANCE; INHIBITION; IL-6; LIPOPOLYSACCHARIDE	Paclitaxel (Taxol) is an antineoplastic agent that specifically targets microtubules and arrests cells at the G2/M phase of the cell cycle. In addition to mitotic arrest, the activation of c-Jun N-terminal kinase (JNK) signaling pathway has been demonstrated to be involved in the process leading to apoptosis. In an attempt to explore what genes are transcriptionally regulated by the activated JNK signaling pathway upon paclitaxel treatment, we used cDNA microarrays to analyse the changes of gene expression in human ovarian cancer cells that were treated with paclitaxel and/or the JNK inhibitor SP600125. Among 20 genes that were specifically regulated by the paclitaxel-activated JNK pathway, interleukin (IL)-6 was shown to elicit function through the JAK-STAT signaling pathway in an autocrine and/or paracrine fashion. Subsequently, we identified that 87.5% of eight tested ovarian cancer lines secreted detectable levels of IL-6, which could be further upregulated 2-3.2 fold by 1 mu M paclitaxel. Dissection on regulatory pathways for IL-6 indicated that (i) when ovarian cancer cells were treated with paclitaxel at low but clinically achievable concentrations (exemplified by 1 mu M in this study), the JNK signaling pathway was the major stimulator of IL-6 gene regulation and (ii) at suprapharmacologically high concentrations (exemplified by 50 mu M), paclitaxel exerted lipopolysaccharide-like effects, most likely through the Toll-like receptor 4 signaling pathway. Collectively, these results suggest that paclitaxel upregulates functional IL-6 expression in human ovarian cancer cells through multiple signaling pathways.	Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Tao Yuan 333, Taiwan; Chang Gung Mem Hosp, Dept Obstet & Gynecol, Lin Kou Med Ctr, Tao Yuan, Taiwan; Chang Gung Mem Hosp, GMRCL, Tao Yuan, Taiwan; Min Chuan Univ, Dept Biotechnol, Tao Yuan, Taiwan; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Northwestern University; Feinberg School of Medicine	Wang, HS (corresponding author), Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, 5 Fuhsing St, Tao Yuan 333, Taiwan.	hswang@cgmh.org.tw						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAFFET G, 1991, MOL BIOL MED, V8, P141; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Brichory FM, 2001, P NATL ACAD SCI USA, V98, P9824, DOI 10.1073/pnas.171320598; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Cui XQ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-210; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Dey S, 2003, CLIN CANCER RES, V9, P1557; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Duan ZF, 1999, CLIN CANCER RES, V5, P3445; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Flynn V, 2003, INT J ONCOL, V23, P317; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Hefler LA, 2003, CANCER RES, V63, P3066; Huang Y, 2002, MOL PHARMACOL, V61, P105, DOI 10.1124/mol.61.1.105; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; Lee LF, 1996, CANCER RES, V56, P1303; Lee YS, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-132; LI BY, 1992, CANCER RES, V52, P2248; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Nakshatri H, 2004, ONCOGENE, V23, P7330, DOI 10.1038/sj.onc.1207995; Penson RT, 2000, INT J GYNECOL CANCER, V10, P33, DOI 10.1046/j.1525-1438.2000.00003.x; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Pusztai L, 2004, CYTOKINE, V25, P94, DOI 10.1016/j.cyto.2003.10.004; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Sriuranpong V, 2003, CANCER RES, V63, P2948; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Taxman DJ, 2003, CANCER RES, V63, P5095; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Uzzo RG, 2002, CLIN CANCER RES, V8, P3579; Villunger A, 1996, INT J CANCER, V65, P498, DOI 10.1002/(SICI)1097-0215(19960208)65:4<498::AID-IJC18>3.0.CO;2-6; Vivat-Hannah V, 2001, CANCER RES, V61, P8703; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XX, 2004, DRUG CHEM TOXICOL, V27, P243, DOI 10.1081/DCT-120037505; WATSON JM, 1990, CANCER RES, V50, P6959; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174/1568009033333754	56	55	63	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4857	4866		10.1038/sj.onc.1209498	http://dx.doi.org/10.1038/sj.onc.1209498			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547493				2022-12-25	WOS:000239687100004
J	Yu, X; Siegel, R; Roeder, RG				Yu, Xin; Siegel, Rachael; Roeder, Robert G.			Interaction of the B cell-specific transcriptional coactivator OCA-B and galectin-1 and a possible role in regulating BCR-mediated B cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; BOB.1/OBF.1-DEFICIENT MICE; PRE-B; PROTEIN; EXPRESSION; APOPTOSIS; ASSOCIATION; RECEPTORS; ANTIGEN; GENE	OCA-B is a B cell-specific transcriptional coactivator for OCT factors during the activation of immunoglobulin genes. In addition, OCA-B is crucial for B cell activation and germinal center formation. However, the molecular mechanisms for OCA-B function in these processes are not clear. Our previous studies documented two OCA-B isoforms and suggested a novel mechanism for the function of the myristoylated, membrane-bound form of OCA-B/p35 as a signaling molecule. Here, we report the identification of galectin-1, and related galectins, as a novel OCA-B-interacting protein. The interaction of OCA-B and galectin-1 can be detected both in vivo and in vitro. The galectin-1 binding domain in OCA-B has been localized to the N terminus of OCA-B. In B cells lacking OCA-B expression, increased galectin-1 expression, secretion, and cell surface association are observed. Consistent with these observations, and a reported inhibitory interaction of galectin-1 with CD45, the phosphatase activity of CD45 is reduced modestly, but significantly, in OCA-B-deficient B cells. Finally, galectin-1 is shown to negatively regulate B cell proliferation and tyrosine phosphorylation upon BCR stimulation. Together, these results raise the possibility that OCA-B may regulate BCR signaling through an association with galectin-1.	Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Rockefeller University	Roeder, RG (corresponding author), 1230 York Ave, New York, NY 10021 USA.	roeder@mail.rockefeller.edu			NATIONAL CANCER INSTITUTE [R01CA113872] Funding Source: NIH RePORTER; NCI NIH HHS [CA 113872, CA 09673-28A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acosta-Rodriguez EV, 2004, J IMMUNOL, V172, P493, DOI 10.4049/jimmunol.172.1.493; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Brunner C, 2003, J BIOL CHEM, V278, P45231, DOI 10.1074/jbc.M302539200; Brunner C, 2003, J EXP MED, V197, P1205, DOI 10.1084/jem.20022014; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Casellas R, 2002, CELL, V110, P575, DOI 10.1016/S0092-8674(02)00911-X; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; Choi JY, 1998, J CELL SCI, V111, P3035; Delbrouck C, 2002, LAB INVEST, V82, P147, DOI 10.1038/labinvest.3780407; Elola MT, 2005, J BIOMED SCI, V12, P13, DOI 10.1007/s11373-004-8169-5; Fouillit M, 2000, GLYCOBIOLOGY, V10, P413, DOI 10.1093/glycob/10.4.413; Gauthier L, 2002, P NATL ACAD SCI USA, V99, P13014, DOI 10.1073/pnas.202323999; Hess J, 2001, MOL CELL BIOL, V21, P1531, DOI 10.1128/MCB.21.5.1531-1539.2001; Hoffmann R, 2002, GENOME RES, V12, P98, DOI 10.1101/gr.201501; Hoyer KK, 2004, AM J PATHOL, V164, P893, DOI 10.1016/S0002-9440(10)63177-X; Jankovic M, 2003, INT IMMUNOL, V15, P1099, DOI 10.1093/intimm/dxg109; Kim U, 2003, P NATL ACAD SCI USA, V100, P8868, DOI 10.1073/pnas.1033108100; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; Kim U, 2000, J IMMUNOL, V165, P6825, DOI 10.4049/jimmunol.165.12.6825; Knoepfel L, 1996, BIOL CHEM H-S, V377, P139, DOI 10.1515/bchm3.1996.377.2.139; La M, 2003, AM J PATHOL, V163, P1505, DOI 10.1016/S0002-9440(10)63507-9; Laumen H, 2004, NUCLEIC ACIDS RES, V32, P1577, DOI 10.1093/nar/gkh327; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Luo Y, 1998, MOL CELL BIOL, V18, P3803, DOI 10.1128/MCB.18.7.3803; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Luo Y, 1999, COLD SPRING HARB SYM, V64, P119, DOI 10.1101/sqb.1999.64.119; Manie SN, 1996, BLOOD, V87, P1855; Moiseeva EP, 1999, J VASC RES, V36, P47, DOI 10.1159/000025625; Moiseeva EP, 2003, BIOCHEM BIOPH RES CO, V310, P1010, DOI 10.1016/j.bbrc.2003.09.112; Murphy JJ, 1997, BIOCHEM SOC T, V25, pS248, DOI 10.1042/bst025248s; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Park JW, 2001, NUCLEIC ACIDS RES, V29, P3595, DOI 10.1093/nar/29.17.3595; Paz FL, 2001, EUR J IMMUNOL, V31, P777; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; PFISTERER P, 1995, J BIOL CHEM, V270, P29870, DOI 10.1074/jbc.270.50.29870; Qin XF, 1998, EMBO J, V17, P5066, DOI 10.1093/emboj/17.17.5066; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Samardzic T, 2002, MOL CELL BIOL, V22, P8320, DOI 10.1128/MCB.22.23.8320-8331.2002; Samardzic T, 2002, EUR J IMMUNOL, V32, P2481, DOI 10.1002/1521-4141(200209)32:9<2481::AID-IMMU2481>3.0.CO;2-C; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; Seelenmeyer C, 2005, J CELL BIOL, V171, P373, DOI 10.1083/jcb.200506026; Sotomayor C E, 2000, Dev Immunol, V7, P117, DOI 10.1155/2000/36321; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Teitell MA, 2003, TRENDS IMMUNOL, V24, P546, DOI 10.1016/j.it.2003.08.002; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Wang JL, 2004, BBA-GEN SUBJECTS, V1673, P75, DOI 10.1016/j.bbagen.2004.03.013; Wells V, 1999, EUR J CANCER, V35, P978, DOI 10.1016/S0959-8049(99)00020-9; Yang RY, 2003, CELL MOL LIFE SCI, V60, P267, DOI 10.1007/s000180300022; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2001, IMMUNITY, V14, P157, DOI 10.1016/S1074-7613(09)00090-9; Zuniga E, 2001, J LEUKOCYTE BIOL, V70, P73	54	26	28	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15505	15516		10.1074/jbc.M509041200	http://dx.doi.org/10.1074/jbc.M509041200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16565088	hybrid			2022-12-25	WOS:000237922200057
J	Meloni, G; Zovo, K; Kazantseva, J; Palumaa, P; Vasak, M				Meloni, Gabriele; Zovo, Kairit; Kazantseva, Jekaterina; Palumaa, Peep; Vasak, Milan			Organization and assembly of metal-thiolate clusters in epithelium-specific metallothionein-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-INHIBITORY FACTOR; NMR-SPECTROSCOPY; CD-113 NMR; MOUSE; DIFFERENTIATION; EXPRESSION; INDUCTION; FEATURES; FAMILY; ZINC	Mammalian metallothionein-4 (MT-4) was found to be specifically expressed in stratified squamous epithelia where it plays an essential but poorly defined role in regulating zinc or copper metabolism. Here we report on the organization, stability, and the pathway of metal-thiolate cluster assembly in MT-4 reconstituted with Cd2+ and Co2+ ions. Both the Cd-113 NMR studies of (Cd7MT)-Cd-113-4 and the spectroscopic characterization of Co7MT-4 showed that, similar to the classical MT-1 and MT-2 proteins, metal ions are organized in two independent Cd(4)Cys(11) and Cd(3)Cys(9) clusters with each metal ion tetrahedrally coordinated by terminal and bridging cysteine ligands. Moreover, we have demonstrated that the cluster formation in Cd7MT-4 is cooperative and sequential, with the Cd4Cys11 cluster being formed first, and that a distinct single-metal nucleation intermediate Cd1MT-4 is required in the cluster formation process. Conversely, the absorption and circular dichroism features of metal-thiolate clusters in Cd7MT-4 indicate that marked differences in the cluster geometry exist when compared with those in Cd7MT-1/2. The biological implication of our studies as to the role of MT-4 in zinc metabolism of stratified epithelia is discussed.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Tallinn Univ Technol, Dept Gene Technol, EE-12618 Tallinn, Estonia	University of Zurich; Tallinn University of Technology	Vasak, M (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	mvasak@bioc.unizh.ch	Kazantseva, Jekaterina/M-1037-2016; Kazantseva, Jekaterina/AAA-2882-2021; Palumaa, Peep/B-4668-2019; Palumaa, Peep/AAF-7617-2020	Kazantseva, Jekaterina/0000-0001-6108-5499; Palumaa, Peep/0000-0002-3505-3466; Palumaa, Peep/0000-0002-3505-3466; Meloni, Gabriele/0000-0003-4976-1401; Zovo, Kairit/0000-0001-5834-5157				Bernhard W. R., 1992, METALLOTHIONEINS, P128; BERTINI I, 1983, MET IONS BIOL SYST, V15, P101; Binz PA, 1999, METALLOTHIONEIN IV, P7; BRAUN W, 1992, P NATL ACAD SCI USA, V89, P10124, DOI 10.1073/pnas.89.21.10124; Cai B, 2005, PROTEIN J, V24, P327, DOI 10.1007/s10930-005-7588-0; Faller P, 1999, BIOCHEMISTRY-US, V38, P10158, DOI 10.1021/bi990489c; Hasler DW, 2000, BIOCHEMISTRY-US, V39, P14567, DOI 10.1021/bi001569f; HENEHAN CJ, 1993, PROTEIN SCI, V2, P1756, DOI 10.1002/pro.5560021019; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; KAEGI JH, 1961, J BIOL CHEM, V236, P2435; KAGI JHR, 1993, ADV LIF SCI, P29; Liang LC, 1996, MOL REPROD DEV, V43, P25, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;25::AID-MRD4&gt;3.0.CO;2-W; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S; MASTERS BA, 1994, J NEUROSCI, V14, P5844; Miles AT, 2000, CRIT REV BIOCHEM MOL, V35, P35, DOI 10.1080/10409230091169168; OTVOS JD, 1985, BIOCHEMISTRY-US, V24, P6735, DOI 10.1021/bi00345a001; Oz GL, 1998, BIOCHEM CELL BIOL, V76, P223, DOI 10.1139/bcb-76-2-3-223; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Palumaa P, 2004, BIOCHEM J, V382, P307, DOI 10.1042/BJ20040360; PEDERSEN AO, 1980, EUR J BIOCHEM, V106, P291; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Romero-Isart N, 2002, J INORG BIOCHEM, V88, P388, DOI 10.1016/S0162-0134(01)00347-6; Romero-Isart N, 2002, J BIOL CHEM, V277, P37023, DOI 10.1074/jbc.M205730200; Schlake T, 2001, MECH DEVELOP, V109, P419, DOI 10.1016/S0925-4773(01)00538-X; Sogawa CA, 2001, ACTA MED OKAYAMA, V55, P1; STLLMAN MJ, 1992, METALLOTHIONEINS, P55; Theocharis SE, 2004, HISTOPATHOLOGY, V45, P103, DOI 10.1111/j.1365-2559.2004.01922.x; Tio L, 2004, J BIOL CHEM, V279, P24403, DOI 10.1074/jbc.M401346200; VALLEE BL, 1995, NEUROCHEM INT, V27, P23, DOI 10.1016/0197-0186(94)00165-Q; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; VASAK M, 1991, METHOD ENZYMOL, V205, P452; VASAK M, 1981, BIOCHEMISTRY-US, V20, P6659, DOI 10.1021/bi00526a021; VASAK M, 1980, J AM CHEM SOC, V102, P3953, DOI 10.1021/ja00531a048; VASAK M, 1981, BIOCHEMISTRY-US, V20, P2852, DOI 10.1021/bi00513a022; Vasak M, 1998, BIODEGRADATION, V9, P501, DOI 10.1023/A:1008346231847; VASAK M, 1983, MET IONS BIOL SYST, V15, P213; Vasßk M., 2005, ENCY INORGANIC CHEM, P3208; WANG YJ, 1994, EUR J BIOCHEM, V225, P449, DOI 10.1111/j.1432-1033.1994.00449.x; WILLNER H, 1987, BIOCHEMISTRY-US, V26, P6287, DOI 10.1021/bi00393a049; Zangger K, 1999, PROTEIN SCI, V8, P2630, DOI 10.1110/ps.8.12.2630	41	48	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14588	14595		10.1074/jbc.M601724200	http://dx.doi.org/10.1074/jbc.M601724200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16556599	hybrid			2022-12-25	WOS:000237671300010
J	Yoshikawa, K; Kita, Y; Kishimoto, K; Shimizu, T				Yoshikawa, Keisuke; Kita, Yoshihiro; Kishimoto, Koji; Shimizu, Takao			Profiling of eicosanoid production in the rat hippocampus during kainic acid-induced seizure - Dual phase regulation and differential involvement of COX-1 and COX-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); CYCLOOXYGENASE-2 EXPRESSION; PROSTAGLANDIN E-2; MESSENGER-RNA; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; EPITHELIAL-CELLS; NERVOUS-SYSTEM; BINDING-SITES; KAPPA-B; KAINATE	Kainic acid (KA)-induced seizure in rat involves eicosanoid production in the brain, but their production mechanism and biological functions are poorly understood. We profiled the eicosanoid production during KA-induced seizure by a comprehensive lipidomics analysis using liquid chromatography-tandem mass spectrometry. Systemic KA administration caused production of large amounts of prostaglandin (PG) F-2 alpha and PGD2 in the hippocampus, with smaller amounts of other PGs and hydroxyeicosatetraenoic acids. The production was biphasic, which consisted of an initial burst in the first 30 min and a sustained late phase production. The initial phase was specific to the hippocampus and was blocked by intracerebroven-tricular administration of KA receptor antagonists. A selective cyclooxygenase (COX)-2 inhibitor, NS398, completely inhibited the initial phase productions, except for PGD2 and thromboxane B-2, whose productions were also dependent on COX-1. These results suggest that KA signals directly stimulate the arachidonic acid cascade in the initial phase and that COX-1 and COX-2, both constitutively expressed at low levels, differentially contribute to PG productions. In the late phase, a sustained PG production in hippocampus appears due to the increased COX-2 levels even with a limited arachidonic acid supply. The present study demonstrates a dual phase regulatory mechanism of eicosanoid production during KA-induced seizure, providing a biochemical basis for understanding the biosynthesis and roles of eicosanoids in the brain.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	tshimizu@m.u-tokyo.ac.jp	Shimizu, Takao/AAV-7052-2021; Yoshikawa, Keisuke/AAA-4185-2019	Yoshikawa, Keisuke/0000-0002-6348-6138				Baik EJ, 1999, BRAIN RES, V843, P118, DOI 10.1016/S0006-8993(99)01797-7; BARAN H, 1994, BRAIN RES, V646, P201, DOI 10.1016/0006-8993(94)90078-7; BARAN H, 1987, BRAIN RES, V404, P107, DOI 10.1016/0006-8993(87)91360-6; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Brock TG, 1999, J BIOL CHEM, V274, P11660, DOI 10.1074/jbc.274.17.11660; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Chang MS, 2005, CELL SIGNAL, V17, P299, DOI 10.1016/j.cellsig.2004.07.008; Chen BC, 2004, J BIOL CHEM, V279, P20889, DOI 10.1074/jbc.M311279200; Chen C, 2005, PROSTAG OTH LIPID M, V77, P65, DOI 10.1016/j.prostaglandins.2005.07.001; CHEN J, 1995, NEUROREPORT, V6, P245; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Ciceri P, 2002, J PHARMACOL EXP THER, V302, P846, DOI 10.1124/jpet.302.3.846; ENSOR CM, 1994, BBA-PROTEIN STRUCT M, V1208, P151, DOI 10.1016/0167-4838(94)90172-4; ENSOR CM, 1995, J LIPID MEDIAT CELL, V12, P313, DOI 10.1016/0929-7855(95)00040-W; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Gobbo OL, 2004, NEUROSCIENCE, V125, P317, DOI 10.1016/j.neuroscience.2004.01.045; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; Jeon SH, 2000, EXP MOL MED, V32, P227, DOI 10.1038/emm.2000.37; Kawaguchi K, 2005, BRAIN RES, V1050, P130, DOI 10.1016/j.brainres.2005.05.038; Kim EJ, 2001, BRAIN RES, V908, P1, DOI 10.1016/S0006-8993(01)02432-5; Kim SW, 2004, BRAIN RES, V1007, P188, DOI 10.1016/j.brainres.2004.02.009; Kita Y, 2005, ANAL BIOCHEM, V342, P134, DOI 10.1016/j.ab.2005.03.048; Kita Y, 2005, BIOCHEM BIOPH RES CO, V330, P898, DOI 10.1016/j.bbrc.2005.03.055; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lee JK, 2002, MOL CELLS, V14, P339; LISTON TE, 1985, P NATL ACAD SCI USA, V82, P6030, DOI 10.1073/pnas.82.18.6030; Manev H, 2000, EXP GERONTOL, V35, P1201, DOI 10.1016/S0531-5565(00)00152-2; Matsuoka Y, 1999, BRAIN RES, V836, P213, DOI 10.1016/S0006-8993(99)01633-9; Moepps Barbara, 2003, EMBO Reports, V4, P237, DOI 10.1038/sj.embor.embor777; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; More JCA, 2004, NEUROPHARMACOLOGY, V47, P46, DOI 10.1016/j.neuropharm.2004.03.005; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Naraba H, 1998, J IMMUNOL, V160, P2974; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Park SA, 2003, EXP MOL MED, V35, P365, DOI 10.1038/emm.2003.48; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Scher JU, 2005, CLIN IMMUNOL, V114, P100, DOI 10.1016/j.clim.2004.09.008; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; Tai HH, 2002, PROSTAG OTH LIPID M, V68-9, P483, DOI 10.1016/S0090-6980(02)00050-3; TREMBLAY E, 1985, BRAIN RES, V343, P378, DOI 10.1016/0006-8993(85)90761-9; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545	46	59	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14663	14669		10.1074/jbc.M511089200	http://dx.doi.org/10.1074/jbc.M511089200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16569634	hybrid			2022-12-25	WOS:000237671300018
J	Cabrera, JR; Sanchez-Pulido, L; Rojas, AM; Valencia, A; Manes, S; Naranjo, JR; Mellstrom, B				Cabrera, J. Ruben; Sanchez-Pulido, Luis; Rojas, Ana M.; Valencia, Alfonso; Manes, Santos; Naranjo, Jose R.; Mellstrom, Britt			Gas1 is related to the glial cell-derived neurotrophic factor family receptors alpha and regulates Ret signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARREST-SPECIFIC GENE-1; C-RET; GDNF FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-STRUCTURE; TYROSINE KINASE; LIPID RAFTS; DIFFERENTIATION; EXPRESSION; ACTIVATION	The growth arrest-specific gene 1 (Gas1) protein has been proposed to function during development as an inhibitor of growth and a mediator of cell death and is also re-expressed in adult neurons during excitotoxic insult. Here we have demonstrated that the Gas1 protein shows high structural similarity to the glial cell-derived neurotrophic factor (GDNF) family receptors alpha, which mediate GDNF responses through the receptor tyrosine kinase Ret. We found that Gas1 binds Ret in a ligand-independent manner and sequesters Ret in lipid rafts. Signaling downstream of Ret is thus modified through a mechanism that involves the adaptor protein Shc as well as ERK, eventually blocking Akt activation. Consequently, when Gas1 is induced, Ret-mediated GDNF-dependent survival effects are compromised.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, E-28049 Madrid, Spain; CSIC, Ctr Nacl Biotecnol, Prot Design Grp, E-28049 Madrid, Spain; CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Mellstrom, B (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Darwin 3, E-28049 Madrid, Spain.	bmellstr@cnb.uam.es	IBIS, BIOINFORMATICA/O-1882-2015; Rojas, Ana M./I-2882-2019; Rojas, Ana M/D-5777-2011; Rojas, Ana M/C-3022-2008; NARANJO, Jose R/K-1950-2014; Valencia, Alfonso/I-3127-2015; Cabrera, Jorge Rubén/H-6310-2015; Manes, Santos/E-4725-2011	Rojas, Ana M./0000-0003-0750-9099; Rojas, Ana M/0000-0003-0750-9099; NARANJO, Jose R/0000-0002-0270-3469; Valencia, Alfonso/0000-0002-8937-6789; Cabrera, Jorge Rubén/0000-0003-4481-0198; Manes, Santos/0000-0001-8023-957X; Sanchez Pulido, Luis/0000-0002-2300-8502				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bielke W, 1997, CELL DEATH DIFFER, V4, P114, DOI 10.1038/sj.cdd.4400220; Cheung Eric C C, 2004, Sci STKE, V2004, pPE45; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Feng DF, 1996, METHOD ENZYMOL, V266, P368; Fu M, 2004, J CELL BIOL, V166, P673, DOI 10.1083/jcb.200401077; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Gomez-Villafuertes R, 2005, J NEUROSCI, V25, P10822, DOI 10.1523/JNEUROSCI.3912-05.2005; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lee CS, 2001, DEV BIOL, V236, P17, DOI 10.1006/dbio.2001.0280; Lee CS, 2001, P NATL ACAD SCI USA, V98, P11347, DOI 10.1073/pnas.201418298; Lee KKH, 2001, DEV BIOL, V234, P188, DOI 10.1006/dbio.2001.0249; Leppanen VM, 2004, EMBO J, V23, P1452, DOI 10.1038/sj.emboj.7600174; Li ZH, 2005, J NEUROCHEM, V95, P361, DOI 10.1111/j.1471-4159.2005.03372.x; Liu Y, 2001, DEV BIOL, V236, P30, DOI 10.1006/dbio.2000.0146; Mellstrom B, 2002, MOL CELL NEUROSCI, V19, P417, DOI 10.1006/mcne.2001.1092; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Park J, 1997, J MOL BIOL, V273, P349, DOI 10.1006/jmbi.1997.1288; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Rost B, 1996, METHOD ENZYMOL, V266, P525; Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stebel M, 2000, FEBS LETT, V481, P152, DOI 10.1016/S0014-5793(00)02004-4; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200	47	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14330	14339		10.1074/jbc.M509572200	http://dx.doi.org/10.1074/jbc.M509572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551639	hybrid, Green Published			2022-12-25	WOS:000237512300059
J	Chen, ZH; Akin, BL; Stokes, DL; Jones, LR				Chen, Zhenhui; Akin, Brandy L.; Stokes, David L.; Jones, Larry R.			Cross-linking of C-terminal residues of phospholamban to the Ca2+ pump of cardiac sarcoplasmic reticulum to probe spatial and functional interactions within the transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR SOLUTION STRUCTURE; CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; CYTOPLASMIC DOMAIN; ATPASE INTERACTION; PROTEIN-STRUCTURE; CA2+-ATPASE; THAPSIGARGIN; INHIBITION; PHOSPHORYLATION	Interactions between the transmembrane domains of phospholamban (PLB) and the cardiac Ca2+ pump (SERCA2a) have been investigated by chemical cross-linking. Specifically, C-terminal, transmembrane residues 45-52 of PLB were individually mutated to Cys, then cross-linked to V89C in the M2 helix of SERCA2a with the thiol-specific cross-linking reagents Cu2+-phenanthroline, dibromobimane, and bismaleimidohexane. V49C-, M50C-, and L52C-PLB all crosslinked strongly to V89C-SERCA2a, coupling to 70-100% of SERCA2a molecules. Residues 45-48 and 51 of PLB also cross-linked to V89C of SERCA2a, but more weakly. Evidence for the mechanism of PLB regulation of SERCA2a was provided by the conformational dependence of cross-linking. In particular, the required absence of Ca2+ for cross-linking implicated the E2 conformation of SERCA2a, and its enhancement by ATP confirmed E2(.)ATP as the conformation with the highest affinity for PLB. In contrast, E2 phosphorylated with inorganic phosphate (E2P) and E2 inhibited by thapsigargin ( E2(.)TG) both failed to cross-link to PLB. These results with transmembrane PLB residues are completely consistent with cytoplasmic PLB residues studied previously, suggesting that the dissociation of PLB from the Ca2+ pump is complete, not partial, when the pump binds Ca2+ (E1(.)Ca(2)) or adopts the E2P or E2(.)TG conformations. V49C of PLB cross-linked to 100% of SERCA2a molecules, suggesting that this residue might have functional importance for regulation. Indeed, we found that mutation of Val(49) to smaller side-chained residues V49A or V49G augmented PLB inhibition, whereas mutation to the larger hydrophobic residue, V49L, prevented PLB inhibition. A model for the interaction of PLB with SERCA2a is presented, showing that Val49 fits into a constriction at the lumenal end of the M2 helix of SERCA, possibly controlling access of PLB to its binding site on SERCA.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; New York Struct Biol Ctr, New York, NY 10027 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; New York University	Jones, LR (corresponding author), 1800 N Capitol Ave, Indianapolis, IN 46202 USA.	lrjones@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049428, R37HL049428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056960] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49428] Funding Source: Medline; NIGMS NIH HHS [GM56960] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andronesi OC, 2005, J AM CHEM SOC, V127, P12965, DOI 10.1021/ja0530164; Asahi M, 2000, J BIOL CHEM, V275, P15034, DOI 10.1074/jbc.275.20.15034; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; Autry JM, 1998, ANN NY ACAD SCI, V853, P92, DOI 10.1111/j.1749-6632.1998.tb08259.x; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; Chen ZH, 2005, J BIOL CHEM, V280, P10530, DOI 10.1074/jbc.M414007200; Chen ZH, 2003, J BIOL CHEM, V278, P48348, DOI 10.1074/jbc.M309545200; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Haghighi K, 2004, BIOCHEM BIOPH RES CO, V322, P1214, DOI 10.1016/j.bbrc.2004.07.164; Haghighi K, 2001, J BIOL CHEM, V276, P24145, DOI 10.1074/jbc.M102403200; Hughes E, 2005, BIOCHEMISTRY-US, V44, P4055, DOI 10.1021/bi0482351; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; INESI G, 1994, J MEMBRANE BIOL, V141, P1; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; Jones LR, 2002, J BIOL CHEM, V277, P28319, DOI 10.1074/jbc.M204085200; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Kirby TL, 2004, BIOCHEMISTRY-US, V43, P5842, DOI 10.1021/bi035749b; Lamberth S, 2000, HELV CHIM ACTA, V83, P2141, DOI 10.1002/1522-2675(20000906)83:9<2141::AID-HLCA2141>3.0.CO;2-W; Li JH, 2004, BIOCHEMISTRY-US, V43, P3870, DOI 10.1021/bi036183u; LICHTNER R, 1979, BIOCHEM J, V181, P759, DOI 10.1042/bj1810759; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; Mueller B, 2004, BIOCHEMISTRY-US, V43, P8754, DOI 10.1021/bi049732k; NAPIER RM, 1987, BIOCHIM BIOPHYS ACTA, V903, P374, DOI 10.1016/0005-2736(87)90228-8; Oxenoid K, 2005, P NATL ACAD SCI USA, V102, P10870, DOI 10.1073/pnas.0504920102; Picard M, 2006, J BIOL CHEM, V281, P3360, DOI 10.1074/jbc.M511385200; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2003, P NATL ACAD SCI USA, V100, P467, DOI 10.1073/pnas.0237326100; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Young HS, 2004, J MEMBRANE BIOL, V198, P55, DOI 10.1007/s00232-004-0666-y; Zamoon J, 2003, BIOPHYS J, V85, P2589, DOI 10.1016/S0006-3495(03)74681-5	47	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14163	14172		10.1074/jbc.M601338200	http://dx.doi.org/10.1074/jbc.M601338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16554295	hybrid			2022-12-25	WOS:000237512300040
J	Prieto-Sanchez, RM; Berenjeno, IM; Bustelo, XR				Prieto-Sanchez, R. M.; Berenjeno, I. M.; Bustelo, X. R.			Involvement of the Rho/Rac family member RhoG in caveolar endocytosis	ONCOGENE			English	Article						rhoG; caveolin; endocytosis; cholera toxin; vesicle trafficking	LIPID RAFTS; ACTIVATES RAC1; GOLGI-COMPLEX; CHOLERA-TOXIN; DISTINCT; PATHWAY; CDC42; PHAGOCYTOSIS; INTERNALIZATION; TRANSDUCTION	We show here that the GTPase RhoG is involved in caveolar trafficking. Wild-type RhoG moves sequentially to the plasma membrane, intracellular vesicles, and the Golgi apparatus along markers of this endocytic pathway. Such translocation is associated with changes in RhoG GDP/GTP levels and is highly dependent on lipid raft integrity and on the function of the GTPase dynamin2. In addition, the constitutively active RhoG(Q61L) mutant is preferentially located in endocytic vesicles that can be decorated with markers of the caveola-derived endocytic pathway. RhoG(Q61L,) but not the analogous Rac1 mutant protein, affects caveola internalization and the subsequent delivery of endocytic vesicles to the Golgi apparatus. The expression of RhoG/Rac1 chimeric proteins and RhoG(Q61L) effector mutants in cells induces alterations in the internalization of caveolae and severe changes in vesicle structure, respectively. However, the knockdown of endogenous rhoG transcripts using small interfering RNAs does not affect significantly the trafficking of caveola-derived vesicles, suggesting that RhoG function is dispensable for this endocytic process or, alternatively, that its function is compensated by other molecules. Taken together, these observations assign a novel function to RhoG and suggest that caveolar trafficking, as previously shown for other endocytic routes, is modulated by GTPases of the Ras superfamily.	Univ Salamanca, CSIC, IBMCC, E-37007 Salamanca, Spain; Univ Salamanca, CSIC, Red Temat Cooperat Ctr Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, IBMCC, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072	NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER; NCI NIH HHS [5-R01-CA73735-08, R01 CA073735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Felberbaum-Corti M, 2003, NAT CELL BIOL, V5, P382, DOI 10.1038/ncb0503-382; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Greenberg S, 1999, J LEUKOCYTE BIOL, V66, P712, DOI 10.1002/jlb.66.5.712; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; LI GP, 1993, J BIOL CHEM, V268, P24475; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; May V, 2002, J NEUROSCI, V22, P6980; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Pelkmans L, 2005, NATURE, V436, P128, DOI 10.1038/nature03866; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Prieto-Sanchez RM, 2003, J BIOL CHEM, V278, P37916, DOI 10.1074/jbc.M301437200; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Torgersen ML, 2001, J CELL SCI, V114, P3737; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	35	32	34	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2961	2973		10.1038/sj.onc.1209333	http://dx.doi.org/10.1038/sj.onc.1209333			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16568096	Green Accepted, Green Submitted			2022-12-25	WOS:000237950800001
J	Jia, HY; Bagherzadeh, A; Hartzoulakis, B; Jarvis, A; Loehr, M; Shaikh, S; Aqil, R; Cheng, LL; Tickner, M; Esposito, D; Harris, R; Driscoll, PC; Selwood, DL; Zachary, IC				Jia, HY; Bagherzadeh, A; Hartzoulakis, B; Jarvis, A; Loehr, M; Shaikh, S; Aqil, R; Cheng, LL; Tickner, M; Esposito, D; Harris, R; Driscoll, PC; Selwood, DL; Zachary, IC			Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor Exon 8 for NP-1 binding and role of NP-1 in KDR signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTACYCLIN PRODUCTION; CELL PROLIFERATION; CRYSTAL-STRUCTURE; VEGF RECEPTOR-1; TUMOR-CELLS; ORF VIRUS; DOMAIN; PROTEIN; ACTIVATION; SYSTEM	Neuropilin- 1 ( NP- 1) is a receptor for vascular endothelial growth factor- A(165)( VEGF- A(165)) in endothelial cells. To define the role of NP- 1 in the biological functions of VEGF, we developed a specific peptide antagonist of VEGF binding to NP- 1 based on the NP- 1 binding site located in the exon 7- and 8- encoded VEGF- A165 domain. The bicyclic peptide, EG3287, potently ( K-i 1.2 mu M) and effectively (> 95% inhibition at 100 mu M) inhibited VEGF- A(165) binding to porcine aortic endothelial cells expressing NP- 1 ( PAE/ NP- 1) and breast carcinoma cells expressing only NP- 1 receptors for VEGF- A, but had no effect on binding to PAE/ KDR or PAE/ Flt- 1. Molecular dynamics calculations, a nuclear magnetic resonance structure of EG3287, and determination of stability in media, indicated that it constitutes a stable subdomain very similar to the corresponding region of native VEGF- A(165). The C terminus encoded by exon 8 and the three- dimensional structure were both critical for EG3287 inhibition of NP- 1 binding, whereas modifications at the N terminus had little effect. Although EG3287 had no direct effect on VEGF- A(165) binding to KDR receptors, it inhibited cross- linking of VEGF- A(165) to KDR in human umbilical vein endothelial cells co- expressing NP- 1, and inhibited stimulation of KDR and PLC- gamma tyrosine phosphorylation, activation of ERKs1/ 2 and prostanoid production. These findings characterize the first specific antagonist of VEGF- A(165) binding to NP- 1 and demonstrate that NP- 1 is essential for optimum KDR activation and intracellular signaling. The results also identify a key role for the C- terminal exon 8 domain in VEGF- A(165) binding to NP-1.	UCL, BHF Labs, Dept Med, Ctr Cardiovasc Biol & Med, London WC1E 6JJ, England; UCL, Ark Therapeut Ltd, Rayne Inst, London WC1E 6JJ, England; UCL, Wolfson Inst Biomed Res, London WC1E GBT, England; NCE Discovery Ltd, Cambridge CB4 0PA, England; UCL, Dept Biochem & Mol Biol, Bloomsbury Ctr Struct Biol, London WC1E 6BT, England	University of London; University College London; University of London; King's College London; University College London; University of London; University College London; University of London; Birkbeck University London; University College London	Zachary, IC (corresponding author), UCL, BHF Labs, Dept Med, Ctr Cardiovasc Biol & Med, 5 Univ St, London WC1E 6JJ, England.	i.zachary@ucl.ac.uk	Selwood, David/C-1571-2008; Driscoll, Paul C/B-8007-2010	Driscoll, Paul C/0000-0002-4124-6950; Harris, Richard/0000-0001-7459-1745; Selwood, David/0000-0002-6817-5064	Medical Research Council [MC_U117533887, MC_U117574559] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [MC_U117533887] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Bates DO, 2002, CANCER RES, V62, P4123; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Cheng LL, 2004, J BIOL CHEM, V279, P30654, DOI 10.1074/jbc.M402488200; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Fujisawa H, 1997, CELL TISSUE RES, V290, P465, DOI 10.1007/s004410050954; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Inai Y, 2003, BIOPOLYMERS, V70, P310, DOI 10.1002/bip.10390; Jia HY, 2004, J BIOL CHEM, V279, P36148, DOI 10.1074/jbc.M401538200; Joukov V, 1996, EMBO J, V15, P290; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Murga M, 2005, BLOOD, V105, P1992, DOI 10.1182/blood-2004-07-2598; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PAGEL MD, 1994, PROTEINS, V18, P205, DOI 10.1002/prot.340180302; Peggion E, 2003, BIOPOLYMERS, V68, P437, DOI 10.1002/bip.10294; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; SELWOOD D, 2003, Patent No. 03082918; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Song JX, 1997, BIOCHEMISTRY-US, V36, P3760, DOI 10.1021/bi962720h; Stams T, 1996, P NATL ACAD SCI USA, V93, P13589, DOI 10.1073/pnas.93.24.13589; Stauffer ME, 2002, J BIOMOL NMR, V23, P57, DOI 10.1023/A:1015346504499; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Takashima S, 2002, P NATL ACAD SCI USA, V99, P3657, DOI 10.1073/pnas.022017899; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TISCHER E, 1991, J BIOL CHEM, V266, P11947; von Wronski MA, 2006, J BIOL CHEM, V281, P5702, DOI 10.1074/jbc.M511941200; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Zachary I, 2003, BIOCHEM SOC T, V31, P1171; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	61	110	121	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13493	13502		10.1074/jbc.M512121200	http://dx.doi.org/10.1074/jbc.M512121200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16513643	hybrid			2022-12-25	WOS:000237336600057
J	Navarro, FJ; Machin, F; Martin, Y; Siverio, JM				Navarro, FJ; Machin, F; Martin, Y; Siverio, JM			Down-regulation of eukaryotic nitrate transporter by nitrogen-dependent ubiquitinylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST HANSENULA-POLYMORPHA; PEST-LIKE SEQUENCE; AMINO-ACID PERMEASE; SACCHAROMYCES-CEREVISIAE; NICOTIANA-PLUMBAGINIFOLIA; CONSTITUTIVE EXPRESSION; NITRITE REDUCTASE; URACIL PERMEASE; ASSIMILATION; UBIQUITINATION	In the yeast Hansenula polymorpha, the YNT1 gene encodes the high affinity nitrate transporter, which is repressed by reduced nitrogen sources such as ammonium or glutamine. Ynt1 protein is degraded in response to glutamine in the growth medium. Ynt1 disappears independently of YNT1 glutamine repression as shown in strains where YNT1 repression is abolished. Ynt1-green fluorescent protein chimera and a mutant defective in vacuolar proteinase A ( Delta pep4) showed that Ynt1 is degraded in the vacuole in response to glutamine. The central hydrophilic domain of Ynt1 contains PEST-like sequences whose deletion blocked Ynt1 down-regulation. Site-directed mutagenesis showed that Lys-253 and Lys-270, located in this sequence, were involved in internalization and subsequent vacuolar degradation of Ynt1. Ynt1-ubiquitin conjugates were induced by glutamine and not nitrate. We conclude that glutamine triggers Ynt1 down-regulation via ubiquitinylation of lysines in the central hydrophilic domain, and proteolysis in the vacuole.	Univ La Laguna, Dept Bioquim & Biol Mol, Inst Univ Enfermedades Trop, E-38206 San Cristobal la Laguna, Tenerife, Spain	Universidad de la Laguna	Siverio, JM (corresponding author), Univ La Laguna, Dept Bioquim & Biol Mol, Inst Univ Enfermedades Trop, Av Astrofis Fco Sanchez S-N, E-38206 San Cristobal la Laguna, Tenerife, Spain.	jsiverio@ull.es	Machín, Félix/K-6569-2017	Machín, Félix/0000-0003-4559-7798; NAVARRO, FRANCISCO J./0000-0002-9332-0737				Campbell WH, 1999, ANNU REV PLANT PHYS, V50, P277, DOI 10.1146/annurev.arplant.50.1.277; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; CRAWFORD NM, 1993, ANNU REV GENET, V27, P115, DOI 10.1146/annurev.ge.27.120193.000555; Daniel-Vedele F, 1998, CURR OPIN PLANT BIOL, V1, P235, DOI 10.1016/S1369-5266(98)80110-6; Dupre S, 2004, BBA-MOL CELL RES, V1695, P89, DOI 10.1016/j.bbamcr.2004.09.024; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; Forde BG, 2000, BBA-BIOMEMBRANES, V1465, P219, DOI 10.1016/S0005-2736(00)00140-1; Fraisier V, 2000, PLANT J, V23, P489, DOI 10.1046/j.1365-313x.2000.00813.x; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GODECKE S, 1994, GENE, V139, P35, DOI 10.1016/0378-1119(94)90520-7; GONZALEZ C, 1992, J GEN MICROBIOL, V138, P1445, DOI 10.1099/00221287-138-7-1445; Hein C, 1997, MOL MICROBIOL, V24, P607, DOI 10.1046/j.1365-2958.1997.3771735.x; Horak J, 2003, BBA-BIOMEMBRANES, V1614, P139, DOI 10.1016/S0005-2736(03)00195-0; Kaiser WM, 2001, J EXP BOT, V52, P1981, DOI 10.1093/jexbot/52.363.1981; Lin JT, 1998, ADV MICROB PHYSIOL, V39, P1; Liu KH, 2003, EMBO J, V22, P1005, DOI 10.1093/emboj/cdg118; Machin F, 2004, YEAST, V21, P265, DOI 10.1002/yea.1075; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; Marzluf GA, 1997, MICROBIOL MOL BIOL R, V61, P17, DOI 10.1128/.61.1.17-32.1997; Medintz I, 2000, BIOCHEMISTRY-US, V39, P4518, DOI 10.1021/bi992455a; Montanini B, 2006, BIOCHEM J, V394, P125, DOI 10.1042/BJ20051199; Navarro FJ, 2003, FEMS YEAST RES, V4, P149, DOI 10.1016/S1567-1356(03)00163-6; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Perdomo G, 2002, PLANT MOL BIOL, V50, P405, DOI 10.1023/A:1019814505677; Perez MD, 1997, BIOCHEM J, V321, P397, DOI 10.1042/bj3210397; Read ND, 2003, FUNGAL GENET BIOL, V39, P199, DOI 10.1016/S1087-1845(03)00045-8; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; Sengupta S, 1997, FEBS LETT, V416, P51, DOI 10.1016/S0014-5793(97)01166-6; Siverio JM, 2002, FEMS MICROBIOL REV, V26, P277, DOI 10.1016/S0168-6445(02)00100-6; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Springael JY, 1999, J CELL SCI, V112, P1375; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Torralba S, 2002, FUNGAL GENET BIOL, V37, P221, DOI 10.1016/S1087-1845(02)00513-3; Unkles SE, 2001, EMBO J, V20, P6246, DOI 10.1093/emboj/20.22.6246; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; VINCENTZ M, 1991, EMBO J, V10, P1027, DOI 10.1002/j.1460-2075.1991.tb08041.x; VOLLAND C, 1992, J BIOL CHEM, V267, P23767	41	24	26	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13268	13274		10.1074/jbc.M601253200	http://dx.doi.org/10.1074/jbc.M601253200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543229	hybrid			2022-12-25	WOS:000237336600032
J	Tsai, HJ; Huang, WH; Li, TK; Tsai, YL; Wu, KJ; Tseng, SF; Teng, SC				Tsai, HJ; Huang, WH; Li, TK; Tsai, YL; Wu, KJ; Tseng, SF; Teng, SC			Involvement of topoisomerase III in telomere-telomere recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE TELOMERES; SGS1 DNA HELICASE; HUMAN-CELLS; LACKING TELOMERASE; HOLLIDAY JUNCTIONS; RECQ HELICASES; YEAST; REPLICATION; MAINTENANCE; PATHWAYS	Telomere maintenance is required for chromosome stability, and telomeres are typically replicated by the action of telomerase. In both mammalian tumor and yeast cells that lack telomerase, telomeres are maintained by an alternative ( ALT) recombination mechanism. In yeast, Sgs1p and its associated type IA topoisomerase, Top3p, may work coordinately in removing Holliday junction intermediates from a crossover- producing recombination pathway. Previous studies have also indicated that Sgs1 helicase acts in a telomere recombination pathway. Here we show that topoisomerase III is involved in telomere- telomere recombination. The recovery of telomere recombination- dependent survivors in a telomerase- minus yeast strain was dependent on Top3p catalytic activity. Moreover, the RIF1 and RIF2 genes are required for the establishment of TOP3/ SGS1- dependent telomere-telomere recombination. In human Saos- 2 ALT cells, human topoisomerase III alpha( hTOP3 alpha) also contributes to telomere recombination. Strikingly, the telomerase activity is clearly enhanced in surviving si- hTOP3 alpha Saos- 2 ALT cells. Altogether, the present results suggest a potential role for hTOP3 alpha in dissociating telomeric structures in telomerase- deficient cells, providing therapeutic implications in human tumors.	Natl Taiwan Univ, Coll Med, Dept Microbiol, Taipei 10018, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan; Natl Taiwan Univ Hosp, Inst Internal Med, Taipei 10018, Taiwan	National Taiwan University; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University Hospital	Teng, SC (corresponding author), Natl Taiwan Univ, Coll Med, Dept Microbiol, 1,Sec 1,Jen Ai Rd, Taipei 10018, Taiwan.	scteng@ha.mc.ntu.edu.tw	Wu, Kou-Juey/P-4654-2015	LI, TSAI-KUN/0000-0003-0393-2340; Tsai, Hung-Ji/0000-0003-4192-9310; TENG, SHU-CHUN/0000-0002-6492-2560				Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Bennett RJ, 2001, P NATL ACAD SCI USA, V98, P11108, DOI 10.1073/pnas.201387098; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Fourel G, 2002, BIOESSAYS, V24, P828, DOI 10.1002/bies.10139; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Jiang WQ, 2005, MOL CELL BIOL, V25, P2708, DOI 10.1128/MCB.25.7.2708-2721.2005; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; KIM RA, 1995, P NATL ACAD SCI USA, V92, P2667, DOI 10.1073/pnas.92.7.2667; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; Le S, 1999, GENETICS, V152, P143; Levy DL, 2004, MOL CELL BIOL, V24, P10857, DOI 10.1128/MCB.24.24.10857-10867.2004; Liberi G, 2005, GENE DEV, V19, P339, DOI 10.1101/gad.322605; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Liti G, 2003, MOL CELL, V11, P1373, DOI 10.1016/S1097-2765(03)00177-1; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Meeker AK, 2002, CANCER RES, V62, P6405; Myung K, 2002, P NATL ACAD SCI USA, V99, P4500, DOI 10.1073/pnas.062702199; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(05)00094-8; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Tsai YL, 2002, MOL CELL BIOL, V22, P5679, DOI 10.1128/MCB.22.16.5679-5687.2002; Vega LR, 2003, NAT REV MOL CELL BIO, V4, P948, DOI 10.1038/nrm1256; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wilson TM, 2000, J BIOL CHEM, V275, P1533, DOI 10.1074/jbc.275.3.1533; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Wu L, 2002, MUTAT RES-FUND MOL M, V509, P35, DOI 10.1016/S0027-5107(02)00225-7; Yeager TR, 1999, CANCER RES, V59, P4175; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	47	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13717	13723		10.1074/jbc.M600649200	http://dx.doi.org/10.1074/jbc.M600649200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16546998	hybrid			2022-12-25	WOS:000237336600082
J	Yahata, Y; Shirakata, Y; Tokumaru, S; Yang, LJ; Dai, XJ; Tohyama, M; Tsuda, T; Sayama, K; Iwai, M; Horiuchi, M; Hashimoto, K				Yahata, Y; Shirakata, Y; Tokumaru, S; Yang, LJ; Dai, XJ; Tohyama, M; Tsuda, T; Sayama, K; Iwai, M; Horiuchi, M; Hashimoto, K			A novel function of angiotensin II in skin wound healing - Induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated egf receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC FIBROBLASTS; CELL-PROLIFERATION; HAIR FOLLICLE; FACTOR-ALPHA; HB-EGF; MYOCYTES; METALLOPROTEINASE; MICE; HYPERTROPHY; EPIREGULIN	The role of angiotensin II ( Ang II) in the control of systemic blood pressure and volume homeostasis is well known and has been extensively studied. Recently, Ang II was suggested to also have a function in skin wound healing. In the present study, the in vivo function of Ang II in skin wound healing was investigated using Ang II type 1 receptor ( AT1R) knock-out mice. Wound healing in these mice was found to be markedly delayed. Keratinocytes and fibroblasts play important roles in wound healing, and thus the effect of Ang II on the migration of these cells was examined. Ang II stimulated keratinocyte and fibroblast migration in a dose-dependent manner. It has been reported that G protein-coupled receptor ( GPCR) activation induces epidermal growth factor ( EGF) receptor ( EGFR) transactivation through the shedding of heparin-binding EGF-like growth factor ( HB-EGF). As AT1R is a GPCR, it was hypothesized that Ang II-induced keratinocyte and fibroblast migration is mediated by EGFR transactivation. Ang II induced EGFR phosphorylation, which was inhibited by an AT1R antagonist, HB-EGF neutralizing antibody, and an HB-EGF antagonist in both keratinocytes and in fibroblasts. Moreover, Ang II-induced migration of keratinocytes and fibroblasts was also prevented by these inhibitors. Taken together, these findings clearly demonstrate, for the first time, that Ang II plays an important role in skin wound healing and that it functions by accelerating keratinocyte and fibroblast migration in a process mediated by HB-EGF shedding.	Ehime Univ, Sch Med, Dept Dermatol, Toon, Ehime 7910295, Japan; Ehime Univ, Sch Med, Div Med Biochem & Cardiovasc Biol, Toon, Ehime 7910295, Japan	Ehime University; Ehime University	Shirakata, Y (corresponding author), Ehime Univ, Sch Med, Dept Dermatol, Shitsukawa, Toon, Ehime 7910295, Japan.	shirakat@m.ehime-u.ac.jp						Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BOOZ GW, 1995, CARDIOVASC RES, V30, P537, DOI 10.1016/S0008-6363(96)88507-5; CAMPBELLBOSWELL M, 1981, EXP MOL PATHOL, V35, P265, DOI 10.1016/0014-4800(81)90066-6; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; Fischer TA, 1997, AM J PHYSIOL-HEART C, V272, pH958, DOI 10.1152/ajpheart.1997.272.2.H958; HAHN AWA, 1993, J CARDIOVASC PHARM, V22, pS37, DOI 10.1097/00005344-199322005-00007; Hansen LA, 1997, AM J PATHOL, V150, P1959; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; Hashimoto K, 2000, J DERMATOL SCI, V24, pS46, DOI 10.1016/S0923-1811(00)00141-9; KIM NN, 1995, AM J PHYSIOL-ENDOC M, V269, pE426, DOI 10.1152/ajpendo.1995.269.3.E426; KIMURA B, 1992, BIOCHEM BIOPH RES CO, V187, P1083, DOI 10.1016/0006-291X(92)91308-D; KO Y, 1993, AM J HYPERTENS, V6, P496, DOI 10.1093/ajh/6.6.496; LAURENT GJ, 1987, AM J PHYSIOL, V252, pC1, DOI 10.1152/ajpcell.1987.252.1.C1; Lindblad William, 1998, Wound Repair and Regeneration, V6, P186, DOI 10.1046/j.1524-475X.1998.60304.x; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; Matsusaka T, 1999, J CLIN INVEST, V103, P1451, DOI 10.1172/JCI5056; Mifune M, 2005, J BIOL CHEM, V280, P26592, DOI 10.1074/jbc.M502906200; Min LJ, 2004, ENDOCRINOLOGY, V145, P253, DOI 10.1210/en.2003-0673; Ohkubo N, 1997, CIRCULATION, V96, P3954; Okuyama N, 1999, ANN PLAS SURG, V42, P313, DOI 10.1097/00000637-199903000-00014; OWENS GK, 1985, CIRC RES, V56, P525, DOI 10.1161/01.RES.56.4.525; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Rodgers K, 2001, WOUND REPAIR REGEN, V9, P238, DOI 10.1046/j.1524-475x.2001.00238.x; Rodgers Kathleen E., 1997, Journal of Burn Care and Rehabilitation, V18, P381, DOI 10.1097/00004630-199709000-00002; SCHELLING P, 1979, J CELL PHYSIOL, V98, P503, DOI 10.1002/jcp.1040980309; SCHORB W, 1995, J MOL CELL CARDIOL, V27, P1151, DOI 10.1016/0022-2828(95)90051-9; Shirakata Y, 2005, J CELL SCI, V118, P2363, DOI 10.1242/jcs.02346; Shirakata Y, 2004, J DERMATOL SCI, V36, P41, DOI 10.1016/j.jdermsci.2004.07.002; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; Shirasawa S, 2004, P NATL ACAD SCI USA, V101, P13921, DOI 10.1073/pnas.0404217101; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; SUGAYA T, 1995, J BIOL CHEM, V270, P18719, DOI 10.1074/jbc.270.32.18719; SUN Y, 1994, J LAB CLIN MED, V123, P372; Takeda H, 2004, AM J PATHOL, V165, P1653, DOI 10.1016/S0002-9440(10)63422-0; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Tsuzuki S, 1996, HYPERTENSION, V28, P916, DOI 10.1161/01.HYP.28.5.916; Uchiyama-Tanaka Y, 2001, KIDNEY INT, V60, P2153, DOI 10.1046/j.1523-1755.2001.00067.x; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156	47	105	120	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13209	13216		10.1074/jbc.M509771200	http://dx.doi.org/10.1074/jbc.M509771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543233	hybrid			2022-12-25	WOS:000237336600026
J	Miedel, MT; Weixel, KM; Bruns, JR; Traub, LM; Weisz, OA				Miedel, MT; Weixel, KM; Bruns, JR; Traub, LM; Weisz, OA			Posttranslational cleavage and adaptor protein complex-dependent trafficking of mucolipin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; CATION CHANNEL; MUTATIONS; IV; IDENTIFICATION; TRANSPORT; TRP-ML1; SIGNALS; PH	Mucolipin-1 (ML1) is a member of the transient receptor potential ion channel superfamily that is thought to function in the biogenesis of lysosomes. Mutations in ML1 result in mucolipidosis type IV, a lysosomal storage disease characterized by the intracellular accumulation of enlarged vacuolar structures containing phospholipids, sphingolipids, and mucopolysaccharides. Little is known about how ML1 trafficking or activity is regulated. Here we have examined the processing and trafficking of ML1 in a variety of cell types. We find that a significant fraction of ML1 undergoes cell type-independent cleavage within the first extracellular loop of the protein during a late step in its biosynthetic delivery. To determine the trafficking route of ML1, we systematically examined the effect of ablating adaptor protein complexes on the localization of this protein. Whereas ML1 trafficking was not apparently affected in fibroblasts from mocha mice that lack functional adaptor protein complex (AP)-3, small interfering RNA-mediated knockdown revealed a requirement for AP-1 in Golgi export of ML1. Knockdown of functional AP-2 had no effect on ML1 localization. Interestingly, cleavage of ML1 was not compromised in AP-1-deficient cells, suggesting that proteolysis occurs in a prelysosomal compartment, possibly the trans-Golgi network. Our results suggest that posttranslational processing of ML1 is more complex than previously described and that this protein is delivered to lysosomes primarily via an AP-1-dependent route that does not involve passage via the cell surface.	Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weisz, OA (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Dept Med, 3550 Terrace Sr, Pittsburgh, PA 15261 USA.	weisz@pitt.edu		Traub, Linton/0000-0002-1303-0298; Miedel, Mark/0000-0002-0132-6032	NIDDK NIH HHS [T32-DK61296, R01-DK54407] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061296, R01DK054407] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bach G, 2005, PFLUG ARCH EUR J PHY, V451, P313, DOI 10.1007/s00424-004-1361-7; Bargal R, 2000, NAT GENET, V26, P118, DOI 10.1038/79095; Bargal R, 1997, J INHERIT METAB DIS, V20, P625, DOI 10.1023/A:1005362123443; Bargal R, 2002, NEUROPEDIATRICS, V33, P199, DOI 10.1055/s-2002-34496; Bassi MT, 2000, AM J HUM GENET, V67, P1110, DOI 10.1016/S0002-9297(07)62941-3; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Cantiello HF, 2005, PFLUG ARCH EUR J PHY, V451, P304, DOI 10.1007/s00424-005-1448-9; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Di Palma F, 2002, P NATL ACAD SCI USA, V99, P14994, DOI 10.1073/pnas.222425399; Fares H, 2001, NAT GENET, V28, P64, DOI 10.1038/ng0501-64; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; Huang CL, 2004, J AM SOC NEPHROL, V15, P1690, DOI 10.1097/01.ASN.0000129115.69395.65; Janvier K, 2005, MOL BIOL CELL, V16, P4231, DOI 10.1091/mbc.E05-03-0213; Kiselyov K, 2005, J BIOL CHEM, V280, P43218, DOI 10.1074/jbc.M508210200; LaPlante JM, 2002, FEBS LETT, V532, P183, DOI 10.1016/S0014-5793(02)03670-0; LaPlante JM, 2004, BIOCHEM BIOPH RES CO, V322, P1384, DOI 10.1016/j.bbrc.2004.08.045; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; Manzoni M, 2004, FEBS LETT, V567, P219, DOI 10.1016/j.febslet.2004.04.080; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Piper RC, 2004, TRENDS CELL BIOL, V14, P471, DOI 10.1016/j.tcb.2004.07.010; Raychowdhury MK, 2004, HUM MOL GENET, V13, P617, DOI 10.1093/hmg/ddh067; Soyombo AA, 2006, J BIOL CHEM, V281, P7294, DOI 10.1074/jbc.M508211200; Sun M, 2000, HUM MOL GENET, V9, P2471, DOI 10.1093/hmg/9.17.2471; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; Treusch S, 2004, P NATL ACAD SCI USA, V101, P4483, DOI 10.1073/pnas.0400709101; Vergarajauregui S, 2006, TRAFFIC, V7, P337, DOI 10.1111/j.1600-0854.2006.00387.x; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Yang W, 2000, J CELL SCI, V113, P4077	32	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12751	12759		10.1074/jbc.M511104200	http://dx.doi.org/10.1074/jbc.M511104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517607	hybrid			2022-12-25	WOS:000237134700068
J	Chaudhry, UI; Katz, SC; Kingham, TP; Pillarisetty, VG; Raab, JR; Shah, AB; DeMatteo, RP				Chaudhry, Umer I.; Katz, Steven C.; Kingham, T. Peter; Pillarisetty, Venu G.; Raab, Jesse R.; Shah, Alaap B.; DeMatteo, Ronald P.			In vivo overexpression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells	FASEB JOURNAL			English	Article						antigen presentation/processing; cell proliferation; cytotoxicity	IFN-GAMMA-PRODUCTION; TOLL-LIKE RECEPTORS; HUMAN NK CELLS; CROSS-PRESENTATION; T-CELLS; INTERFERON-GAMMA; APOPTOTIC CELLS; ANTIGEN; CD8(+); ALPHA	Natural killer dendritic cells ( NKDC) are a unique class of murine immune cells that possess the characteristics of both natural killer ( NK) cells and dendritic cells ( DC). Because NKDC are able to secrete IFN-gamma, directly lyse tumor cells, and present antigen to naive T cells, they have immunotherapeutic potential. The relative paucity of NKDC, however, impedes their detailed study. We have found that in vivo, overexpression of the hematopoietic cytokine Flt3 ligand ( Flt3L) expands NKDC in various organs from 2-18 fold. Flt3L expanded splenic NKDC retain the ability to lyse tumor cells and become considerably more potent at activating naive allogeneic and antigen-specific T cells. Compared to normal splenic NKDC, Flt3L-expanded splenic NKDC have a more mature phenotype, a slightly increased ability to capture and process antigen, and a similar cytokine profile. In vivo, we found that Flt3L-expanded splenic NKDC are more effective than normal splenic NKDC in stimulating antigen-specific CD8 T cells. Additionally, we show that NKDC are able to cross-present antigen in vivo. The ability to expand NKDC in vivo using Flt3L will facilitate further analysis of their unique biology. Moreover, Flt3L-expanded NKDC may have enhanced immunotherapeutic potential, given their increased ability to stimulate T cells.	Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	DeMatteo, RP (corresponding author), Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, Box 203,1275 York Ave, New York, NY 10021 USA.	dematter@mskcc.org	Pillarisetty, Venu/AAF-4425-2020	Pillarisetty, Venu/0000-0002-1162-9643; Raab, Jesse/0000-0001-6387-8994; Chaudhry, Umer/0000-0002-9080-9131; Kingham, T Peter/0000-0002-3359-3186	NIDDK NIH HHS [R01 DK068346, DK-068346] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068346] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Belz GT, 2002, CRIT REV IMMUNOL, V22, P439; CARBONE FR, 1992, INT IMMUNOL, V4, P861, DOI 10.1093/intimm/4.8.861; Chakravarty PK, 1999, CANCER RES, V59, P6028; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Esche C, 1998, CANCER RES, V58, P380; Eto M, 2002, J IMMUNOL, V169, P2390, DOI 10.4049/jimmunol.169.5.2390; Frucht DM, 2001, TRENDS IMMUNOL, V22, P556, DOI 10.1016/S1471-4906(01)02005-1; Fukao T, 2000, J IMMUNOL, V164, P64, DOI 10.4049/jimmunol.164.1.64; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Granucci F, 2004, J EXP MED, V200, P287, DOI 10.1084/jem.20040370; Hanada K, 1996, J LEUKOCYTE BIOL, V60, P181, DOI 10.1002/jlb.60.2.181; Hanna J, 2004, J CLIN INVEST, V114, P1612, DOI 10.1172/JCI200422787; Heath WR, 2004, IMMUNOL REV, V199, P9, DOI 10.1111/j.0105-2896.2004.00142.x; Heath WR, 2001, NAT REV IMMUNOL, V1, P126, DOI 10.1038/35100512; Hochrein H, 2001, J IMMUNOL, V166, P5448, DOI 10.4049/jimmunol.166.9.5448; Homann D, 2002, IMMUNITY, V16, P403, DOI 10.1016/S1074-7613(02)00290-X; Iyoda T, 2002, J EXP MED, V195, P1289, DOI 10.1084/jem.20020161; Josien R, 1997, J EXP MED, V186, P467, DOI 10.1084/jem.186.3.467; Kaisho T, 2003, CURR MOL MED, V3, P759, DOI 10.2174/1566524033479366; Kaisho T, 2001, ACTA ODONTOL SCAND, V59, P124, DOI 10.1080/000163501750266701; Kamath AT, 2005, J IMMUNOL, V174, P767, DOI 10.4049/jimmunol.174.2.767; Lian ZX, 2003, J IMMUNOL, V170, P2323, DOI 10.4049/jimmunol.170.5.2323; Lynch DH, 1997, NAT MED, V3, P625, DOI 10.1038/nm0697-625; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Marquez C, 1998, BLOOD, V91, P2760, DOI 10.1182/blood.V91.8.2760.2760_2760_2771; Melief CJM, 2003, EUR J IMMUNOL, V33, P2645, DOI 10.1002/eji.200324341; Miller G, 2003, J IMMUNOL, V170, P3554, DOI 10.4049/jimmunol.170.7.3554; Miller G, 2002, J IMMUNOL, V169, P2875, DOI 10.4049/jimmunol.169.6.2875; Miller JS, 1999, BLOOD, V93, P96, DOI 10.1182/blood.V93.1.96.401k13_96_106; Munder M, 1998, J EXP MED, V187, P2103, DOI 10.1084/jem.187.12.2103; Ohteki T, 1999, J EXP MED, V189, P1981, DOI 10.1084/jem.189.12.1981; Peron JM, 1998, J IMMUNOL, V161, P6164; Pillarisetty VG, 2005, J IMMUNOL, V174, P2612, DOI 10.4049/jimmunol.174.5.2612; Pillarisetty VG, 2003, HEPATOLOGY, V37, P641, DOI 10.1053/jhep.2003.50074; Pillarisetty VG, 2004, J IMMUNOL, V172, P1009, DOI 10.4049/jimmunol.172.2.1009; Pooley JL, 2001, J IMMUNOL, V166, P5327, DOI 10.4049/jimmunol.166.9.5327; Puddu P, 1997, J IMMUNOL, V159, P3490; Schindler H, 2001, J IMMUNOL, V166, P3075, DOI 10.4049/jimmunol.166.5.3075; Schleicher U, 2005, BLOOD, V105, P1319, DOI 10.1182/blood-2004-05-1749; Shaw SG, 1998, J IMMUNOL, V161, P2817; Shen HQ, 2003, J IMMUNOL, V171, P3401, DOI 10.4049/jimmunol.171.7.3401; Shurin MR, 1997, CELL IMMUNOL, V179, P174, DOI 10.1006/cimm.1997.1152; Sivori S, 2004, P NATL ACAD SCI USA, V101, P10116, DOI 10.1073/pnas.0403744101; Stober D, 2001, J IMMUNOL, V167, P957, DOI 10.4049/jimmunol.167.2.957; Trinite B, 2000, J IMMUNOL, V165, P4202, DOI 10.4049/jimmunol.165.8.4202; Viney JL, 1998, J IMMUNOL, V160, P5815; Wilson JL, 1999, J IMMUNOL, V163, P6365; Wilson NS, 2005, ADV IMMUNOL, V86, P241, DOI 10.1016/S0065-2776(04)86007-3	51	31	32	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					982	+		10.1096/fj.05-5411fje	http://dx.doi.org/10.1096/fj.05-5411fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571772				2022-12-25	WOS:000240157700029
J	Eltit, JM; Garcia, AA; Hidalgo, J; Liberona, JL; Chiong, M; Lavandero, S; Maldonado, E; Jaimovich, E				Eltit, JM; Garcia, AA; Hidalgo, J; Liberona, JL; Chiong, M; Lavandero, S; Maldonado, E; Jaimovich, E			Membrane electrical activity elicits inositol 1,4,5-trisphosphate-dependent slow Ca2+ signals through a G beta gamma/phosphatidylinositol 3-kinase gamma pathway in skeletal myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; MUSCLE DIHYDROPYRIDINE RECEPTOR; PLECKSTRIN HOMOLOGY DOMAIN; ELEMENT-BINDING PROTEIN; II-III LOOP; PHOSPHOINOSITIDE 3-KINASE-GAMMA; PHOSPHOLIPASE-C; RYANODINE RECEPTOR; CALCIUM CHANNELS; IP3 RECEPTORS	Tetanic electrical stimulation of myotubes evokes a ryanodine receptor-related fast calcium signal, during the stimulation, followed by a phospholipase C/inositol 1,4,5-trisphosphate-dependent slow calcium signal few seconds after stimulus end. L-type calcium channels (Cav 1.1, dihydropyridine receptors) acting as voltage sensors activate an unknown signaling pathway involved in phospholipase C activation. We demonstrated that both G protein and phosphatidylinositol 3- kinase were activated by electrical stimulation, and both the inositol 1,4,5-trisphosphate rise and slow calcium signal induced by electrical stimulation were blocked by pertussis toxin, by a G beta gamma scavenger peptide, and by phosphatidylinositol 3- kinase inhibitors. Immunofluorescence using anti-phosphatidylinositol 3- kinase gamma antibodies showed a clear location in striations within the cytoplasm, consistent with a position near the I band region of the sarcomere. The time course of phosphatidylinositol 3- kinase activation, monitored in single living cells using a pleckstrin homology domain fused to green fluorescent protein, was compatible with sequential phospholipase C gamma 1 activation as confirmed by phosphorylation assays for the enzyme. Co-transfection of a dominant negative form of phosphatidylinositol 3- kinase gamma inhibited the phosphatidylinositol 3- kinase activity as well as the slow calcium signal. We conclude that G beta gamma/phosphatidylinositol 3- kinase gamma signaling pathway is involved in phospholipase C activation and the generation of the slow calcium signal induced by tetanic stimulation. We postulate that membrane potential fluctuations in skeletal muscle cells can activate a pertussis toxin-sensitive G protein, phosphatidylinositol 3- kinase, phospholipase C pathway toward modulation of long term, activity-dependent plastic changes.	Univ Chile, Fac Med, Inst Ciencias Biomed, Ctr Estudios Mol Celula, Santiago 7, Chile; Univ Chile, Fac Ciencias Quim & Farmaceut, Inst Ciencias Biomed, Ctr Estudios Mol Celula, Santiago 7, Chile	Universidad de Chile; Universidad de Chile	Jaimovich, E (corresponding author), Univ Chile, Fac Med, Inst Ciencias Biomed, Ctr Estudios Mol Celula, Independecia 1027, Santiago 7, Chile.	ejaimovi@med.uchile.cl	Chiong, M./ABH-5784-2020; Jaimovich, Enrique/AAY-7632-2020; Lavandero, Sergio/B-6001-2013; Chiong, Mario/I-1043-2013	Chiong, M./0000-0002-5174-6545; Lavandero, Sergio/0000-0003-4258-1483; Chiong, Mario/0000-0002-5174-6545	FIC NIH HHS [R03TW07053-01] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Anis Y, 1999, J BIOL CHEM, V274, P7431, DOI 10.1074/jbc.274.11.7431; Araya R, 2003, J GEN PHYSIOL, V121, P3, DOI 10.1085/jgp.20028671; Bell DC, 2001, J NEUROPHYSIOL, V85, P816, DOI 10.1152/jn.2001.85.2.816; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cardenas C, 2005, J CELL SCI, V118, P3131, DOI 10.1242/jcs.02446; Cardenas C, 2004, J BIOL CHEM, V279, P39122, DOI 10.1074/jbc.M401044200; Carrasco MA, 2003, AM J PHYSIOL-CELL PH, V284, pC1438, DOI 10.1152/ajpcell.00117.2002; CARRASCO MA, 1994, ARCH BIOCHEM BIOPHYS, V310, P76, DOI 10.1006/abbi.1994.1142; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; COHEN-ARMON M, 1993, J BIOL CHEM, V268, P9824; Dirksen RT, 1999, J GEN PHYSIOL, V114, P393, DOI 10.1085/jgp.114.3.393; Eltit JM, 2004, BIOPHYS J, V86, P3042, DOI 10.1016/S0006-3495(04)74353-2; FOSSET M, 1983, J BIOL CHEM, V258, P6086; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hartzell C, 2005, ANNU REV PHYSIOL, V67, P719, DOI 10.1146/annurev.physiol.67.032003.154341; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jaimovich E, 2000, AM J PHYSIOL-CELL PH, V278, pC998, DOI 10.1152/ajpcell.2000.278.5.C998; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Le Blanc C, 2004, CIRC RES, V95, P300, DOI 10.1161/01.RES.0000138017.76125.8b; LERCHE H, 1995, PFLUG ARCH EUR J PHY, V429, P738, DOI 10.1007/BF00373997; MILTING H, 1994, FEBS LETT, V345, P211, DOI 10.1016/0014-5793(94)00440-4; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Patrucco E, 2004, CELL, V118, P375, DOI 10.1016/j.cell.2004.07.017; Powell JA, 2003, J NEUROSCI, V23, P8185; Powell JA, 2001, J CELL SCI, V114, P3673; Proenza C, 2002, J BIOL CHEM, V277, P6530, DOI 10.1074/jbc.M106471200; Protasi F, 2002, BIOPHYS J, V83, P3230, DOI 10.1016/S0006-3495(02)75325-3; Quignard JF, 2001, J BIOL CHEM, V276, P32545, DOI 10.1074/jbc.M102582200; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Shah AS, 2001, CIRCULATION, V103, P1311; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TOUTANT M, 1990, EMBO J, V9, P363, DOI 10.1002/j.1460-2075.1990.tb08119.x; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vecchione C, 2005, J EXP MED, V201, P1217, DOI 10.1084/jem.20040995; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9	47	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12143	12154		10.1074/jbc.M511218200	http://dx.doi.org/10.1074/jbc.M511218200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513646	hybrid			2022-12-25	WOS:000236988100084
J	Babic, I; Cherry, E; Fujita, DJ				Babic, I.; Cherry, E.; Fujita, D. J.			SUMO modification of Sam68 enhances its ability to repress cyclin D1 expression and inhibits its ability to induce apoptosis	ONCOGENE			English	Article						SUMO; Sam68; apoptosis; cyclin D1	NUCLEAR RIBONUCLEOPROTEIN-K; BINDING PROTEIN SAM68; FUNCTIONAL INTERACTION; RNA; PHOSPHORYLATION; PROGRESSION; SUMOYLATION; ACTIVATION; PIAS; SRC	Sam68 (Src associated in mitosis; 68 kDa) is an RNA-binding protein and substrate of Src family kinases. It is thought to play a role in cell cycle progression. Overexpression of Sam68 in fibroblasts was reported to have two separable functions dependent on its ability to bind RNA-cell cycle arrest or the induction of apoptosis. Post-translational modification with SUMO (small ubi-quitinlike modi. er) is common to many transcription factors and can regulate protein localization, stability and function. Here we show Sam68 to be modified by SUMO, and demonstrate that the SUMO E3 ligase (PIAS1) (protein inhibitor of activated STAT1) can enhance Sam68 sumoylation. Lysine 96, the first lysine in the amino-terminal region of Sam68, was found to be the major SUMO acceptor site. Mutation of the SUMO acceptor lysine to arginine enhanced the ability of Sam68 to induce apoptosis but inhibited its ability to act as a transcriptional inhibitor of cyclin D1 expression. A SUMO-1 Sam68 fusion protein, on the other hand, inhibited the ability of Sam68 to induce apoptosis but was a strong repressor of cyclin D1 expression. Thus, SUMO may be an important regulator of Sam68 function in cell cycle progression.	Univ Calgary, So Alberta Canc Res Inst, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	Fujita, DJ (corresponding author), Univ Calgary, So Alberta Canc Res Inst, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.	dfujita@ucalgary.ca						Babic I, 2004, ONCOGENE, V23, P3781, DOI 10.1038/sj.onc.1207484; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100; Hong W, 2002, MOL CANCER RES, V1, P48; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Li QH, 2002, FEBS LETT, V525, P145, DOI 10.1016/S0014-5793(02)03103-4; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Lukong KE, 2005, J BIOL CHEM, V280, P38639, DOI 10.1074/jbc.M505802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Vassileva MT, 2004, MOL CELL BIOL, V24, P3623, DOI 10.1128/MCB.24.9.3623-3632.2004; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yang HP, 2002, ONCOGENE, V21, P7187, DOI 10.1038/sj.onc.1205759; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	48	56	62	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4955	4964		10.1038/sj.onc.1209504	http://dx.doi.org/10.1038/sj.onc.1209504			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568089				2022-12-25	WOS:000239921300001
J	Cotroneo, MS; Merry, GM; Haag, JD; Lan, H; Shepel, LA; Gould, MN				Cotroneo, M. S.; Merry, G. M.; Haag, J. D.; Lan, H.; Shepel, L. A.; Gould, M. N.			The Mcs7 quantitative trait locus is associated with an increased susceptibility to mammary cancer in congenic rats and an allele-specific imbalance	ONCOGENE			English	Article						breast cancer; animal models; loss of heterozygosity (LOH); genotype/phenotype correlation	BREAST-CANCER; TUMOR SUSCEPTIBILITY; MULTIPLE LOCI; GENE; HETEROZYGOSITY; CARCINOMAS; CARCINOGENESIS; CHROMOSOME-10; NEUROBLASTOMA; SCHWANNOMAS	Identification of high-penetrance breast cancer genes such as Brca1 has been accomplished by analysing familial cases. However, these genes occur at low frequency and do not account for the majority of genetic risk. Identification of low-penetrance alleles that occur commonly in populations may benefit from unbiased genome-wide screening. One such approach uses linkage studies in rodent models to identify homologous human candidates. The Wistar Kyoto (WKy) rat is resistant to mammary carcinomas induced with 7,12-dimethybenz[a]anthracene (DMBA), whereas the Wistar Furth (WF) strain is susceptible. Previous genome-wide linkage studies in crosses of these strains identified three WKy resistance quantitative trait loci, Mcs5, Mcs6 and Mcs8, and one predicted to increase susceptibility, Mcs7. The Mcs7 region on rat chromosome 10 (RNO10) is orthologous to human 17q, a common site of genetic aberrations in breast cancer. Here, we establish the independent phenotype conferred by Mcs7 using congenic rats carrying the WKy Mcs7 locus on a WF background. Tumor multiplicity was significantly higher (similar to 50%) in DMBA-treated congenics homozygous and heterozygous for the WKy allele at the Mcs7 locus, compared to controls. We also investigated allelic imbalance (AI) in mammary carcinomas from (WKy x WF)F1 rats and Mcs7 heterozygous congenics. Of the four known WKy Mcs loci tested, only Mcs7 displayed AI. The pattern of AI in carcinomas from both F1 and Mcs7 congenic rats was similar, suggesting a WF allelic loss. Together, these data suggest that one or more breast cancer-related genes are located within the dominantly acting WKy allele at the Mcs7 locus.	Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cotroneo, MS (corresponding author), Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	cotroneo@oncology.wisc.edu	Gould, Michael N/C-7414-2014		NATIONAL CANCER INSTITUTE [R01CA077494] Funding Source: NIH RePORTER; NCI NIH HHS [CA77494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CALLAHAN R, 1993, J CELL BIOCHEM, P167; Chen KS, 1996, CARCINOGENESIS, V17, P1561, DOI 10.1093/carcin/17.8.1561; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Easton D F, 1999, Breast Cancer Res, V1, P14, DOI 10.1186/bcr6; Haag JD, 2003, CANCER RES, V63, P5808; Haag JD, 1996, MOL CARCINOGEN, V17, P134, DOI 10.1002/(SICI)1098-2744(199611)17:3<134::AID-MC5>3.3.CO;2-N; Haag JD, 1999, MOL CARCINOGEN, V24, P47, DOI 10.1002/(SICI)1098-2744(199901)24:1<47::AID-MC7>3.0.CO;2-B; Hino O, 2001, MUTAT RES-FUND MOL M, V477, P155, DOI 10.1016/S0027-5107(01)00116-6; Kindler-Rohrborn A, 1999, CANCER RES, V59, P1109; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Koelsch BU, 2002, CARCINOGENESIS, V23, P1033, DOI 10.1093/carcin/23.6.1033; Lan H, 1999, MAMM GENOME, V10, P687, DOI 10.1007/s003359901071; Lan H, 2001, GENETICS, V157, P331; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Lastowska M, 2004, GENE CHROMOSOME CANC, V40, P158, DOI 10.1002/gcc.20031; Lastowska M, 2002, GENE CHROMOSOME CANC, V34, P428, DOI 10.1002/gcc.10089; Lesueur F, 2005, HUM MOL GENET, V14, P2349, DOI 10.1093/hmg/ddi237; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Newton MA, 2000, BIOMETRICS, V56, P1088, DOI 10.1111/j.0006-341X.2000.01088.x; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; NORLANDER C, 2005, CANCER GENET CYTOGEN, V156, P158; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Peto R, 2000, NEW ENGL J MED, V343, P1495; Phelan CM, 1998, CANCER RES, V58, P1004; Ponder BAJ, 2005, BREAST CANCER RES, V7, pS14, DOI 10.1186/bcr1083; Samuelson DJ, 2005, CANCER RES, V65, P9637, DOI 10.1158/0008-5472.CAN-05-1498; Samuelson DJ, 2003, CARCINOGENESIS, V24, P1455, DOI 10.1093/carcin/bgg112; Shepel LA, 1998, GENETICS, V149, P289; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Toyota M, 1996, MOL CARCINOGEN, V15, P176, DOI 10.1002/(SICI)1098-2744(199603)15:3<176::AID-MC3>3.0.CO;2-G; Yu MS, 2000, MOL CARCINOGEN, V27, P76, DOI 10.1002/(SICI)1098-2744(200002)27:2<76::AID-MC3>3.0.CO;2-7	32	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5011	5017		10.1038/sj.onc.1209506	http://dx.doi.org/10.1038/sj.onc.1209506			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568087				2022-12-25	WOS:000239921300006
J	Hagerstrand, D; Hesselager, G; Achterberg, S; Bolin, UW; Kowanetz, M; Kastemar, M; Heldin, CH; Isaksson, A; Nister, M; Ostman, A				Hagerstrand, D.; Hesselager, G.; Achterberg, S.; Bolin, U. Wickenberg; Kowanetz, M.; Kastemar, M.; Heldin, C-H; Isaksson, A.; Nister, M.; Ostman, A.			Characterization of an imatinib-sensitive subset of high-grade human glioma cultures	ONCOGENE			English	Article						PDGF receptor; imatinib; CXCL12; glioblastoma multiforme; microarray	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE; BRAIN-TUMORS; CELL-GROWTH; PDGF RECEPTORS; MESSENGER-RNA; PHASE-II; B-CHAIN; GLIOBLASTOMA; EXPRESSION	High-grade gliomas, including glioblastomas, are malignant brain tumors for which improved treatment is urgently needed. Genetic studies have demonstrated the existence of biologically distinct subsets. Preliminary studies have indicated that platelet-derived growth factor (PDGF) receptor signaling contributes to the growth of some of these tumors. In this study, human high-grade glioma primary cultures were analysed for sensitivity to treatment with the PDGF receptor inhibitor imatinib/Glivec/Gleevec/STI571. Six out of 15 cultures displayed more than 40% growth inhibition after imatinib treatment, whereas seven cultures showed less than 20% growth inhibition. In the sensitive cultures, apoptosis contributed to growth inhibition. Platelet-derived growth factor receptor status correlated with imatinib sensitivity. Supervised analyses of gene expression profiles and real-time PCR analyses identified expression of the chemokine CXCL12/SDF-1 (stromal cell-derived factor 1) as a predictor of imatinib sensitivity. Exogenous addition of CXCL12 to imatinib-insensitive cultures conferred some imatinib sensitivity. Finally, coregulation of CXCL12 and PDGF alpha-receptor was observed in glioblastoma biopsies. We have thus defined the characteristics of a novel imatinib-sensitive subset of glioma cultures, and provided evidence for a functional relationship between imatinib sensitivity and chemokine signaling. These findings will assist in the design and evaluation of clinical trials exploring therapeutic effects of imatinib on malignant brain tumors.	Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, S-17176 Stockholm, Sweden; Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, Uppsala, Sweden; Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden	Karolinska Institutet; Uppsala University; Ludwig Institute for Cancer Research; Uppsala University	Ostman, A (corresponding author), Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Inst, R8-03, S-17176 Stockholm, Sweden.	arne.ostman@ki.se	Hägerstrand, Daniel/AAH-3009-2019; Hägerstrand, Daniel C/D-1584-2014	Hägerstrand, Daniel/0000-0001-7270-0776; Hägerstrand, Daniel C/0000-0001-7270-0776; Isaksson, Anders/0000-0001-6576-7825	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Backlund LM, 2003, CLIN CANCER RES, V9, P4151; Cabioglu N, 2005, CANCER RES, V65, P6493, DOI 10.1158/0008-5472.CAN-04-1303; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Dresemann G, 2005, ANN ONCOL, V16, P1702, DOI 10.1093/annonc/mdi317; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Haas-Kogan DA, 2005, JNCI-J NATL CANCER I, V97, P880, DOI 10.1093/jnci/dji161; Heimberger AB, 2002, CLIN CANCER RES, V8, P3496; HERMANSON M, 1992, CANCER RES, V52, P3213; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; Johnson BE, 2005, CANCER RES, V65, P7525, DOI 10.1158/0008-5472.CAN-05-1257; Kilic T, 2000, CANCER RES, V60, P5143; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; KOVALENKO M, 1994, CANCER RES, V54, P6106; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Nutt CL, 2003, CANCER RES, V63, P1602; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002; Pietras K, 2003, CANCER CELL, V3, P439, DOI 10.1016/S1535-6108(03)00089-8; Pietras K, 2001, CANCER RES, V61, P2929; PONTEN J, 1978, MED BIOL, V56, P184; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Reardon DA, 2005, J CLIN ONCOL, V23, P9359, DOI 10.1200/JCO.2005.03.2185; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; Sihto H, 2005, J CLIN ONCOL, V23, P49, DOI 10.1200/JCO.2005.02.093; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sjoblom T, 2001, CANCER RES, V61, P5778; STRAWN LM, 1994, J BIOL CHEM, V269, P21215; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uhrbom L, 1998, CANCER RES, V58, P5275; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311	44	70	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4913	4922		10.1038/sj.onc.1209497	http://dx.doi.org/10.1038/sj.onc.1209497			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547494	Bronze			2022-12-25	WOS:000239687100009
J	Wang, L; Tam, JP; Liu, DX				Wang, L.; Tam, J. P.; Liu, D. X.			Biochemical and functional characterization of Epstein-Barr virus-encoded BARF1 protein: interaction with human hTid1 protein facilitates its maturation and secretion	ONCOGENE			English	Article						Epstein-Barr virus; BARF1; human hTid1; interaction; maturation and secretion	HUMAN DNAJ PROTEIN; DROSOPHILA TUMOR-SUPPRESSOR; MALIGNANT-TRANSFORMATION; NASOPHARYNGEAL CARCINOMA; HUMAN HOMOLOG; CELL-LINE; GENE; EXPRESSION; HSP70; ABSENCE	EBV BARF1 gene encodes a secretory protein with transforming and mitogenic activities. In this report, the post-translational modification, folding, maturation and secretion of BARF1 are systematically studied by site-directed mutagenesis and overexpression of the protein in mammalian cells using the vaccinia/T7 system. The protein was shown to be post-translationally modified by N-linked glycosylation on the asparagine 95 residue. This modi. cation was confirmed to be essential for the maturation and secretion of the protein. Analysis of the four cysteine residues by site-directed mutagenesis demonstrated that cysteine 146 and 201 were essential for proper folding and secretion of the protein. To search for human proteins involved in the maturation process of the protein, a yeast two-hybrid screening was carried out using the BARF1 sequence from amino acids 21 - 221 (BARF1 Delta) as bait, leading to the identification of human hTid1 protein as a potential interacting protein. This interaction was subsequently confirmed by coimmunoprecipitation and dual immunofluorescent labeling of cells coexpressing BARF1 and hTid1, and the interaction domain in hTid1 was mapped to amino acids 149 - 320. Interestingly, coexpression of BARF1 with hTid1 demonstrated that hTid1 could promote secretion of BARF1, suggesting that hTid1 may act as a chaperone to facilitate the folding, processing and maturation of BARF1.	Inst Mol & Cell Biol, Singapore 138673, Singapore; Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Liu, DX (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	dxliu@imcb.a-star.edu.sg	Tam, James P/A-2176-2011; Liu, Ding Xiang/A-2226-2011	Tam, James P/0000-0003-4433-198X; 				BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Cohen JI, 1999, J VIROL, V73, P7627, DOI 10.1128/JVI.73.9.7627-7632.1999; Danve C, 2001, VIROLOGY, V288, P223, DOI 10.1006/viro.2001.1072; de Turenne-Tessier M, 2005, VIRUS RES, V109, P9, DOI 10.1016/j.virusres.2004.10.003; Decaussin G, 2000, CANCER RES, V60, P5584; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; KIEFF E, 1996, FIELDS VIROLOGY, V3, P2343; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; Liu DX, 1997, J VIROL, V71, P1814, DOI 10.1128/JVI.71.3.1814-1820.1997; Mayer MP, 2005, REV PHYSIOL BIOCH P, V153, P1, DOI 10.1007/s10254-004-0025-5; Nishikawa J, 1999, J VIROL, V73, P1286, DOI 10.1128/JVI.73.2.1286-1292.1999; Sall A, 2004, ONCOGENE, V23, P4938, DOI 10.1038/sj.onc.1207607; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Schaaf CP, 2004, FASEB J, V18, P267, DOI 10.1096/fj.04-1558fje; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Seto E, 2005, J MED VIROL, V76, P82, DOI 10.1002/jmv.20327; Sheng W, 2003, J VIROL, V77, P3859, DOI 10.1128/JVI.77.6.3859-3865.2003; Sheng W, 2001, ONCOGENE, V20, P1176, DOI 10.1038/sj.onc.1204217; Strockbine LD, 1998, J VIROL, V72, P4015, DOI 10.1128/JVI.72.5.4015-4021.1998; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Wang CC, 2004, DEV CELL, V7, P359, DOI 10.1016/j.devcel.2004.08.002; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988	28	16	17	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4320	4331		10.1038/sj.onc.1209458	http://dx.doi.org/10.1038/sj.onc.1209458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518412				2022-12-25	WOS:000239240100007
J	Kaiserova, K; Srivastava, S; Hoetker, JD; Awe, SO; Tang, XL; Cai, J; Bhatnagar, A				Kaiserova, Karin; Srivastava, Sanjay; Hoetker, Joseph D.; Awe, Sunday O.; Tang, Xian-Liang; Cai, Jian; Bhatnagar, Aruni			Redox activation of aldose reductase in the ischemic heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; TYROSINE-PHOSPHATASE 1B; PROTEIN-SULFENIC ACIDS; UNACTIVATED FORMS; OXIDATIVE STRESS; LATE-PHASE; KINASE-C; SITE; INVOLVEMENT; INHIBITION	Aldose reductase (AR) reduces cytotoxic aldehydes and glutathione conjugates of aldehydes derived from lipid peroxidation. Its inhibition has been shown to increase oxidative injury and abolish the late phase of ischemic preconditioning. However, the mechanisms by which ischemia regulates AR activity remain unclear. Herein, we report that rat hearts subjected to ischemia, in situ or ex vivo, display a 2-4-fold increase in AR activity. The AR activity was not further enhanced by reperfusion. Activation increased V-max of the enzyme without affecting the K-m and decreased the sensitivity of the enzyme to inhibition by sorbinil. Enzyme activation could be prevented by pretreating the hearts with the radical scavenging thiol, N-(2-mercaptoproprionyl) glycine or the superoxide dismutase mimetic, Tiron, or by treating homogenates with dithiothreitol. In vitro, the recombinant enzyme was activated upon treatment with H2O2 and the activated, but not the native enzyme, formed a covalent adduct with the sulfenic acid-specific reagent dimedone. The enzyme activity in the ischemic, but not the non-ischemic heart homogenates was inhibited by dimedone. Separation of proteins from hearts subjected to coronary occlusion by two-dimensional electrophoresis and subsequent matrix-assisted laser desorption ionization time-of-flight/mass spectrometry analysis revealed the formation of sulfenic acids at Cys-298 and Cys-303. These data indicate that reactive oxygen species formed in the ischemic heart activate AR by modifying its cysteine residues to sulfenic acids.	Univ Louisville, Inst Mol Cardiol, Louisville, KY 40202 USA; Univ Louisville, Dept Physiol & Biophys, Louisville, KY 40292 USA; Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA	University of Louisville; University of Louisville; University of Louisville	Bhatnagar, A (corresponding author), Univ Louisville, Inst Mol Cardiol, Louisville, KY 40202 USA.	aruni@louisville.edu	Srivastava, Sanjay/D-3921-2012; Bhatnagar, Aruni/H-7791-2013; Tang, Xian-Liang/L-5703-2015		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065618, R01HL059378, R01HL055477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011860] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65618, HL55477, HL59378] Funding Source: Medline; NIEHS NIH HHS [ES11860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BHATNAGAR A, 1990, BIOCHEM PHARMACOL, V39, P1115, DOI 10.1016/0006-2952(90)90292-S; BHATNAGAR A, 1995, J CARDIOVASC PHARM, V26, P343, DOI 10.1097/00005344-199509000-00001; BHATNAGAR A, 1994, BBA-PROTEIN STRUCT M, V1205, P207, DOI 10.1016/0167-4838(94)90235-6; BHATNAGAR A, 1989, MOL PHARMACOL, V36, P825; Bolli R, 2000, CIRC RES, V87, P972, DOI 10.1161/01.RES.87.11.972; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; Chandra A, 1997, BBA-PROTEIN STRUCT M, V1341, P217, DOI 10.1016/S0167-4838(97)00084-8; Chandra A, 1997, BIOCHEMISTRY-US, V36, P15801, DOI 10.1021/bi9714722; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; DAS B, 1985, DIABETES, V34, P1145, DOI 10.2337/diabetes.34.11.1145; Dixit BL, 2000, J BIOL CHEM, V275, P21587, DOI 10.1074/jbc.M909235199; DOWNEY JM, 1990, ANNU REV PHYSIOL, V52, P487, DOI 10.1146/annurev.ph.52.030190.002415; Grimshaw CE, 1996, ARCH BIOCHEM BIOPHYS, V327, P89, DOI 10.1006/abbi.1996.0096; GRIMSHAW CE, 1990, ARCH BIOCHEM BIOPHYS, V278, P273, DOI 10.1016/0003-9861(90)90259-2; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hwang YC, 2001, FASEB J, V15, P243, DOI 10.1096/fj.01-0368fje; Iwata T, 1999, J BIOL CHEM, V274, P7993, DOI 10.1074/jbc.274.12.7993; Kaiserova K, 2005, CIRCULATION, V112, pU337; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Keightley JA, 2004, MOL CELL PROTEOMICS, V3, P167, DOI 10.1074/mcp.M300119-MCP200; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LIU SQ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P329, DOI 10.1016/0167-4838(92)90256-D; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; MALONE JI, 1980, DIABETES, V29, P861, DOI 10.2337/diabetes.29.11.861; NEELY JR, 1984, CIRC RES, V55, P816, DOI 10.1161/01.RES.55.6.816; O'Connor T, 1999, BIOCHEM J, V343, P487, DOI 10.1042/0264-6021:3430487; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; Ramana KV, 2000, BIOCHEMISTRY-US, V39, P12172, DOI 10.1021/bi000796e; Ramana KV, 2005, DIABETES, V54, P818, DOI 10.2337/diabetes.54.3.818; Ramana KV, 2004, FASEB J, V18, P1209, DOI 10.1096/fj.04-1650com; Ramana KV, 2004, DIABETES, V53, P2910, DOI 10.2337/diabetes.53.11.2910; Ramana KV, 2003, FASEB J, V17, P417, DOI 10.1096/fj.02-0722com; Ramana KV, 2002, J BIOL CHEM, V277, P32063, DOI 10.1074/jbc.M202126200; Ramasamy R, 1997, DIABETES, V46, P292, DOI 10.2337/diabetes.46.2.292; Rittner HL, 1999, J CLIN INVEST, V103, P1007, DOI 10.1172/JCI4711; Ruef J, 2000, ARTERIOSCL THROM VAS, V20, P1745, DOI 10.1161/01.ATV.20.7.1745; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Saurin AT, 2004, P NATL ACAD SCI USA, V101, P17982, DOI 10.1073/pnas.0404762101; Shinmura K, 2002, CIRC RES, V91, P240, DOI 10.1161/01.RES.0000029970.97247.57; Spycher SE, 1997, FASEB J, V11, P181, DOI 10.1096/fasebj.11.2.9039961; Srivastava S, 1999, BIOCHEMISTRY-US, V38, P42, DOI 10.1021/bi981794l; Srivastava S, 2004, J BIOL CHEM, V279, P53395, DOI 10.1074/jbc.M403416200; Srivastava S, 2001, BIOCHEM J, V358, P111, DOI 10.1042/0264-6021:3580111; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; SRIVASTAVA SK, 1986, BIOCHIM BIOPHYS ACTA, V870, P302, DOI 10.1016/0167-4838(86)90234-7; Srivastava SK, 2005, ENDOCR REV, V26, P380, DOI 10.1210/er.2004-0028; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P7222, DOI 10.1073/pnas.82.21.7222; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Varma T, 2003, FEBS LETT, V534, P175, DOI 10.1016/S0014-5793(02)03834-6; Vivancos AP, 2005, P NATL ACAD SCI USA, V102, P8875, DOI 10.1073/pnas.0503251102; Vogt AM, 2002, J BIOL CHEM, V277, P24411, DOI 10.1074/jbc.M201138200; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; Yang JC, 2000, CIRCULATION, V102, P3046	56	69	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15110	15120		10.1074/jbc.M600837200	http://dx.doi.org/10.1074/jbc.M600837200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16567803	hybrid			2022-12-25	WOS:000237922200013
J	Yan, HX; Yang, W; Zhang, R; Chen, L; Tang, L; Zhai, B; Liu, SQ; Cao, HF; Man, XB; Wu, HP; Wu, MC; Wang, HY				Yan, He-Xin; Yang, Wen; Zhang, Rui; Chen, Lei; Tang, Liang; Zhai, Bo; Liu, Shu-Qin; Cao, Hui-Fang; Man, Xiao-Bo; Wu, Hong-Ping; Wu, Meng-Chao; Wang, Hong-Yang			Protein-tyrosine phosphatase PCP-2 inhibits beta-catenin signaling and increases E-cadherin-dependent cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTP-MU; IN-VIVO; ASSOCIATION; MELANOMA; KINASES; FAMILY; CANCER; PHOSPHORYLATION; ACTIVATION; EXPRESSION	beta-Catenin is a key molecule involved in both cell adhesion and Wnt signaling pathway. However, the exact relationship between these two roles has not been clearly elucidated. Tyrosine phosphorylation of beta-catenin was shown to decrease its binding to E-cadherin, leading to decreased cell adhesion and increased beta-catenin signaling. We have previously shown that receptor-like protein-tyrosine phosphatase PCP-2 localizes to the adherens junctions and directly binds and dephosphorylates beta-catenin, suggesting that PCP-2 might regulate the balance between signaling and adhesive beta-catenin. Here we demonstrate that PCP-2 can inhibit both the wild-type and constitutively active forms of beta-catenin in activating target genes such as c-myc. The phosphatase activity of PCP-2 is required for this effect since loss of catalytic activity attenuates its inhibitory effect on beta-catenin activation. Expression of PCP-2 in SW480 colon cancer cells can lead to stabilization of cytosolic pools of beta-catenin perhaps, by virtue of their physical interaction. PCP-2 expression also leads to increased membrane-bound E-cadherin and greater stabilization of adherens junctions by dephosphorylation of beta-catenin, which could further sequester cytosolic beta-catenin and thus inhibit beta-catenin mediated nuclear signaling. Furthermore, SW480 cells stably expressing PCP-2 have a reduced ability to proliferate and migrate. Thus, PCP-2 may play an important role in the maintenance of epithelial integrity, and a loss of its regulatory function may be an alternative mechanism for activating beta-catenin signaling.	Second Mil Med Univ, Eastern Hepatobil Surg Inst, Int Cooperat Lab Signal Transduct, Shanghai 200438, Peoples R China; Shanghai Jiao Tong Univ, Natl Lab Oncogene & Related Genes, Inst Canc, Shanghai 200032, Peoples R China	Naval Medical University; Shanghai Jiao Tong University	Wang, HY (corresponding author), Second Mil Med Univ, Eastern Hepatobil Surg Inst, Int Cooperat Lab Signal Transduct, 225 Changhai Rd, Shanghai 200438, Peoples R China.	hywangk@vip.sina.com	Wang, Hongyang/B-1340-2010					Aerne B, 2004, DEVELOPMENT, V131, P3391, DOI 10.1242/dev.01222; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Besco J, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-14; Bonvini P, 2001, CANCER RES, V61, P1671; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Kulas DT, 1996, J BIOL CHEM, V271, P755, DOI 10.1074/jbc.271.2.755; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Majeti R, 2001, CHEM REV, V101, P2441, DOI 10.1021/cr000085m; McArdle L, 2001, J INVEST DERMATOL, V117, P1255, DOI 10.1046/j.0022-202x.2001.01534.x; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nam JS, 2002, CLIN CANCER RES, V8, P2430; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wang HY, 1996, ONCOGENE, V12, P2555; Yan HX, 2002, BIOCHEMISTRY-US, V41, P15854, DOI 10.1021/bi026095u; Zondag GCM, 1997, BIOCHIMIE, V79, P477, DOI 10.1016/S0300-9084(97)82739-3	33	45	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15423	15433		10.1074/jbc.M602607200	http://dx.doi.org/10.1074/jbc.M602607200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574648	hybrid			2022-12-25	WOS:000237922200048
J	Edlich, F; Weiwad, M; Wildemann, D; Jarczowski, F; Kilka, S; Moutty, MC; Jahreis, G; Lucke, C; Schmidt, W; Striggow, F; Fischer, G				Edlich, Frank; Weiwad, Matthias; Wildemann, Dirk; Jarczowski, Franziska; Kilka, Susann; Moutty, Marie-Christine; Jahreis, Guenther; Luecke, Christian; Schmidt, Werner; Striggow, Frank; Fischer, Gunter			The specific FKBP38 inhibitor N-(N ',N '-dimethylcarboxamidomethyl) cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; DELAYED NEURONAL DEATH; FK506 BINDING-PROTEIN; CIS-TRANS ISOMERASE; IMMUNOSUPPRESSANT FK506; CYCLOSPORINE-A; CELL-DEATH; NEUROIMMUNOPHILIN LIGANDS; IMMUNOPHILIN LIGANDS; DOPAMINERGIC-NEURONS	FK506 and FK506-derived inhibitors of the FK506-binding protein ( FKBP)-type peptidylprolyl cis/trans-isomerases ( PPIase) display potent neuroprotective and neuroregenerative properties in various neurodegeneration models, showing the importance of neuroimmunophilins as targets for the treatment of acute and chronic neurodegenerative diseases. However, the PPIase activity targeted by active site-directed ligands remainsed unknown so far. Here we show that neurotrophic FKBP ligands, such as GPI1046 and N-[methyl( ethoxycarbonyl)] cycloheximide, inhibit the calmodulin/Ca2+ ( CaM/Ca2+)-regulated FKBP38 with up to 80-fold higher affinity than FKBP12. In contrast, the non-neurotrophic rapamycin inhibits FKBP38 center dot CaM/Ca2+ 500-fold less affine than other neuroimmunophillins. In the context of the high expression of FKBP38 in neuroblastoma cells, these data suggest that FKBP38 center dot CaM/Ca2+ inhibition can mediate neurotrophic properties of FKBP ligands. The FKBP38-specific cycloheximide derivative, N-( N', N'-dimethylcarboxamidomethyl) cycloheximide ( DM-CHX) was synthesized and used in a rat model of transient focal cerebral ischemia. Accordingly, DM-CHX caused neuronal protection as well as neural stem cell proliferation and neuronal differentiation at a dosage of 27.2 mu g/kg. These effects were still dominant, if DM-CHX was applied 2 - 6 h post-insult. In parallel, sustained motor behavior deficits of diseased animals were improved by drug administration, revealing a potential therapeutic relevance. Thus, our results demonstrate that FKBP38 inhibition by DM-CHX regulates neuronal cell death and proliferation, providing a promising strategy for the treatment of acute and/or chronic neurodegenerative diseases.	Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Germany; KeyNeurotek AG, D-39120 Magdeburg, Germany	Max Planck Society	Fischer, G (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle, Germany.	fischer@enzyme-halle.mpg.de						Alemdar AY, 2001, EXP NEUROL, V172, P416, DOI 10.1006/exnr.2001.7801; BEHRENS MI, 1995, NEUROREPORT, V6, P545, DOI 10.1097/00001756-199502000-00034; Bochelen D, 1999, J PHARMACOL EXP THER, V288, P653; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; Brecht S, 2003, NEUROSCIENCE, V120, P1037, DOI 10.1016/S0306-4522(03)00404-4; Burnett AL, 2004, J UROLOGY, V171, P495, DOI 10.1097/01.ju.0000089775.88825.ec; Christner C., 2001, Mini-Reviews in Medicinal Chemistry, V1, P377, DOI 10.2174/1389557013406675; COOPER TG, 1976, J BIOL CHEM, V251, P7278; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Costantini LC, 1998, NEUROBIOL DIS, V5, P97, DOI 10.1006/nbdi.1998.0185; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DREYER EB, 1995, NEUROREPORT, V6, P942, DOI 10.1097/00001756-199504190-00029; Edlich F, 2005, EMBO J, V24, P2688, DOI 10.1038/sj.emboj.7600739; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FUNAUCHI M, 1994, NEUROSCI RES, V19, P269, DOI 10.1016/0168-0102(94)90039-6; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; Gold BG, 1998, NEUROREPORT, V9, P553, DOI 10.1097/00001756-199802160-00031; Gold BG, 1999, J PHARMACOL EXP THER, V289, P1202; Gold BG, 1997, MOL NEUROBIOL, V15, P285, DOI 10.1007/BF02740664; GOTO K, 1990, BRAIN RES, V534, P299, DOI 10.1016/0006-8993(90)90144-Z; Graziani F, 1999, J BIOMOL SCREEN, V4, P3, DOI 10.1177/108705719900400102; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; Hamilton GS, 1997, BIOORG MED CHEM LETT, V7, P1785, DOI 10.1016/S0960-894X(97)00304-1; Hamilton GS, 1997, CURR PHARM DESIGN, V3, P405; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; Hodgkiss JP, 1995, BRAIN RES, V705, P241, DOI 10.1016/0006-8993(95)01168-4; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Kuzmic P, 1999, ANAL BIOCHEM, V267, P17, DOI 10.1006/abio.1998.2670; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; Metz GA, 2002, NEUROSCIENCE, V111, P325, DOI 10.1016/S0306-4522(02)00013-1; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Mogi M, 2000, NEUROSCI LETT, V289, P165, DOI 10.1016/S0304-3940(00)01275-1; MORRIS I, 1966, NATURE, V211, P1190, DOI 10.1038/2111190b0; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V5th Edn, DOI 10.1016/c2009-0-63235-9; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Poulter MO, 2004, NEUROSCIENCE, V128, P1, DOI 10.1016/j.neuroscience.2004.06.016; RATAN RR, 1994, J NEUROCHEM, V62, P376; SERGHINI R, 1994, NEUROREPORT, V6, P29, DOI 10.1097/00001756-199412300-00009; SHARKEY J, 1995, J NEUROSCI METH, V60, P125, DOI 10.1016/0165-0270(95)00003-D; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Steiner JP, 1996, MOL MED, V2, P325, DOI 10.1007/BF03401630; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; TASCA RJ, 1970, NATURE, V225, P1022, DOI 10.1038/2251022a0; TORTOSA A, 1994, J NEUROL SCI, V121, P10, DOI 10.1016/0022-510X(94)90149-X; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086	57	79	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14961	14970		10.1074/jbc.M600452200	http://dx.doi.org/10.1074/jbc.M600452200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16547004	hybrid			2022-12-25	WOS:000237671300049
J	De Jong, AS; Visch, HJ; De Mattia, F; van Dommelen, MM; Swarts, HG; Luyten, T; Callewaert, G; Melchers, WJ; Willems, PH; van Kuppeveld, FJ				De Jong, Arjan S.; Visch, Henk-Jan; De Mattia, Fabrizio; van Dommelen, Michiel M.; Swarts, Herman G.; Luyten, Tomas; Callewaert, Geert; Melchers, Willem J.; Willems, Peter H.; van Kuppeveld, Frank J.			The coxsackievirus 2B protein increases efflux of ions from the endoplasmic reticulum and Golgi, thereby inhibiting protein trafficking through the Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PERMEABILIZATION; POLIOVIRUS INFECTION; CHANNEL ACTIVITY; QUALITY-CONTROL; AMPHIPATHIC HELIX; LIVING CELLS; 3A PROTEIN; CALCIUM; REPLICATION; HOMEOSTASIS	Coxsackievirus infection leads to a rapid reduction of the filling state of the endoplasmic reticulum ( ER) and Golgi Ca2+ stores. The coxsackievirus 2B protein, a small membrane protein that localizes to the Golgi and to a lesser extent to the ER, has been proposed to play an important role in this effect by forming membrane-integral pores, thereby increasing the efflux of Ca2+ from the stores. Here, evidence is presented that supports this idea and that excludes the possibility that 2B reduces the uptake of Ca2+ into the stores. Measurement of intra-organelle-free Ca2+ in permeabilized cells revealed that the ability of 2B to reduce the Ca2+ filling state of the stores was preserved at steady ATP. Biochemical analysis in a cell-free system further showed that 2B had no adverse effect on the activity of the sarco/endoplasmic reticulum calcium ATPase, the Ca2+-ATPase that transports Ca2+ from the cytosol into the stores. To investigate whether 2B specifically affects Ca2+ homeostasis or other ion gradients, we measured the lumenal Golgi pH. Expression of 2B resulted in an increased Golgi pH, indicative for the efflux of H+ from the Golgi lumen. Together, these data support a model that 2B increases the efflux of ions from the ER and Golgi by forming membrane-integral pores. We have demonstrated that a major consequence of this activity is the inhibition of protein trafficking through the Golgi complex.	Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Biochem, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Catholic Univ Louvain, Dept Physiol, B-3000 Louvain, Belgium	Radboud University Nijmegen; Radboud University Nijmegen; Universite Catholique Louvain	van Kuppeveld, FJ (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Nijmegen Ctr Mol Life Sci, POB 9101, NL-6500 HB Nijmegen, Netherlands.	f.vankuppeveld@ncmls.ru.nl	Jong, A.S./L-4416-2015; Melchers, Willem/C-8819-2015; Willems, P.H.G.M./L-4759-2015	Melchers, Willem/0000-0002-5446-2230; Willems, P.H.G.M./0000-0002-0915-1599; van Kuppeveld, Frank/0000-0001-5800-749X				Agirre A, 2002, J BIOL CHEM, V277, P40434, DOI 10.1074/jbc.M205393200; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; Arvan P, 2002, TRAFFIC, V3, P771, DOI 10.1034/j.1600-0854.2002.31102.x; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BIENZ K, 1994, ARCH VIROL, P147; Burgoyne RD, 2003, BBA-MOL CELL RES, V1641, P137, DOI 10.1016/S0167-4889(03)00089-2; Campanella M, 2004, J BIOL CHEM, V279, P18440, DOI 10.1074/jbc.M309494200; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; de Jong AS, 2004, J BIOL CHEM, V279, P19924, DOI 10.1074/jbc.M314094200; de Jong AS, 2003, J BIOL CHEM, V278, P1012, DOI 10.1074/jbc.M207745200; de Jong AS, 2002, J GEN VIROL, V83, P783, DOI 10.1099/0022-1317-83-4-783; Deitz SB, 2000, P NATL ACAD SCI USA, V97, P13790, DOI 10.1073/pnas.250483097; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Dodd DA, 2001, J VIROL, V75, P8158, DOI 10.1128/JVI.75.17.8158-8165.2001; Doedens JR, 1997, J VIROL, V71, P9054, DOI 10.1128/JVI.71.12.9054-9064.1997; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; Henkel JR, 2000, J CELL BIOL, V148, P495, DOI 10.1083/jcb.148.3.495; INCE C, 1985, PFLUG ARCH EUR J PHY, V403, P240, DOI 10.1007/BF00583594; JOHNSON KL, 1991, J VIROL, V65, P4341, DOI 10.1128/JVI.65.8.4341-4349.1991; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Papp S, 2003, J CELL BIOL, V160, P475, DOI 10.1083/jcb.200207136; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; Sandoval IV, 1997, J VIROL, V71, P4679, DOI 10.1128/JVI.71.6.4679-4693.1997; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; Schoonderwoert VTG, 2001, J MEMBRANE BIOL, V182, P159, DOI 10.1007/s00232-001-0040-2; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; SWARTS HGP, 1995, J BIOL CHEM, V270, P7890, DOI 10.1074/jbc.270.14.7890; Toomre D, 1999, J CELL SCI, V112, P21; van Kuppeveld FJM, 2002, J VIROL, V76, P9446, DOI 10.1128/JVI.76.18.9446-9456.2002; VanKuppeveld FJM, 1997, VIROLOGY, V227, P111, DOI 10.1006/viro.1996.8320; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; VANKUPPEVELD FJM, 1995, J VIROL, V69, P7782, DOI 10.1128/JVI.69.12.7782-7790.1995; vanKuppeveld FJM, 1996, J VIROL, V70, P3876, DOI 10.1128/JVI.70.6.3876-3886.1996; Visch HJ, 2004, J BIOL CHEM, V279, P40328, DOI 10.1074/jbc.M408068200; Wessels E, 2005, J VIROL, V79, P5163, DOI 10.1128/JVI.79.8.5163-5173.2005; Zuber C, 2000, MOL BIOL CELL, V11, P4227, DOI 10.1091/mbc.11.12.4227	48	79	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14144	14150		10.1074/jbc.M511766200	http://dx.doi.org/10.1074/jbc.M511766200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16540472	hybrid			2022-12-25	WOS:000237512300038
J	Gui, PC; Wu, X; Ling, SZ; Stotz, SC; Winkfein, RJ; Wilson, E; Davis, GE; Braun, AP; Zamponi, GW; Davis, MJ				Gui, Peichun; Wu, Xin; Ling, Shizhang; Stotz, Stephanie C.; Winkfein, Robert J.; Wilson, Emily; Davis, George E.; Braun, Andrew P.; Zamponi, Gerald W.; Davis, Michael J.			Integrin receptor activation triggers converging regulation of Cav1.2 calcium channels by c-Src and protein kinase A pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ALPHA(1C) CA(V)1.2 SUBUNIT; GATED POTASSIUM CHANNELS; CA2+ CHANNEL; SMOOTH-MUSCLE; ALPHA(V)BETA(3) INTEGRIN; ADHESION MOLECULES; CARBOXYL-TERMINUS; ION CHANNELS; N-TERMINUS	L-type, voltage-gated Ca2+ channels (CaL) play critical roles in brain and muscle cell excitability. Here we show that currents through heterologously expressed neuronal and smooth muscle CaL channel isoforms are acutely potentiated following alpha 5 beta 1 integrin activation. Only the alpha(1C) pore-forming channel subunit is critical for this process. Truncation and site-directed mutagenesis strategies reveal that regulation of Cav1.2 by alpha 5 beta 1 integrin requires phosphorylation of alpha(1C) C-terminal residues Ser(1901) and Tyr(2122). These sites are known to be phosphorylated by protein kinase A(PKA) and c-Src, respectively, and are conserved between rat neuronal (Cav1.2c) and smooth muscle (Cav1.2b) isoforms. Kinase assays are consistent with phosphorylation of these two residues by PKA and c-Src. Following alpha 5 beta 1 integrin activation, native CaL channels in rat arteriolar smooth muscle exhibit potentiation that is completely blocked by combined PKA and Src inhibition. Our results demonstrate that integrin-ECM interactions are a common mechanism for the acute regulation of CaL channels in brain and muscle. These findings are consistent with the growing recognition of the importance of integrin-channel interactions in cellular responses to injury and the acute control of synaptic and blood vessel function.	Univ Missouri, Sch Med, Dept Med Pharmacol & Physiol, Columbia, MO 65212 USA; Texas A&M Univ, Coll Med, Dept Syst Biol & Translat Med, College Stn, TX 77840 USA; Univ Calgary, Sch Med, Smooth Muscle Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Sch Med, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada	University of Missouri System; University of Missouri Columbia; Texas A&M University System; Texas A&M University College Station; University of Calgary; University of Calgary	Davis, MJ (corresponding author), 1 Hosp Dr,M451, Columbia, MO 65212 USA.	davismj@health.missouri.edu	Ling, Shizhang/J-6114-2014	Ling, Shizhang/0000-0002-6856-3577; Zamponi, Gerald W./0000-0002-0644-9066; wu, xin/0000-0002-5005-6358	NCRR NIH HHS [RR-017353] Funding Source: Medline; NHLBI NIH HHS [HL-72989] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR017353] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072989] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altier C, 2002, J BIOL CHEM, V277, P33598, DOI 10.1074/jbc.M202476200; Artym VV, 2002, J GEN PHYSIOL, V120, P29, DOI 10.1085/jgp.20028607; Bahr BA, 1997, J NEUROSCI, V17, P1320; Bence-Hanulec KK, 2000, NEURON, V27, P121, DOI 10.1016/S0896-6273(00)00014-3; Bloch W, 2001, J CELL BIOL, V154, P753, DOI 10.1083/jcb.200103011; Burkin DJ, 1998, J CELL BIOL, V143, P1067, DOI 10.1083/jcb.143.4.1067; Callaghan B, 2004, CIRC RES, V94, P626, DOI 10.1161/01.RES.0000118248.17466.B7; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chun D, 2001, NEUROSCIENCE, V105, P815, DOI 10.1016/S0306-4522(01)00173-7; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Davis MJ, 2002, CELL BIOCHEM BIOPHYS, V36, P41, DOI 10.1385/CBB:36:1:41; Davis MJ, 2001, AM J PHYSIOL-HEART C, V281, pH1835, DOI 10.1152/ajpheart.2001.281.5.H1835; Dubuis E, 2006, CARDIOVASC RES, V69, P391, DOI 10.1016/j.cardiores.2005.11.006; Gall CM, 2003, NEUROSCIENCE, V118, P925, DOI 10.1016/S0306-4522(02)00990-9; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; Gao TY, 2001, J BIOL CHEM, V276, P21089, DOI 10.1074/jbc.M008000200; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; Gualandris A, 1996, J NEUROSCI, V16, P2220; HELL JW, 1993, J BIOL CHEM, V268, P19451; Hernandez RV, 2001, BIOL BULL, V201, P236, DOI 10.2307/1543341; Hescheler Juergen, 2002, Basic Research in Cardiology, V97; Hofmann G, 2001, J BIOL CHEM, V276, P4923, DOI 10.1074/jbc.M005682200; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hu XQ, 1998, J BIOL CHEM, V273, P5337, DOI 10.1074/jbc.273.9.5337; Intengan HD, 2000, HYPERTENSION, V36, P312, DOI 10.1161/01.HYP.36.3.312; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; Jin XC, 2002, GASTROENTEROLOGY, V123, P827, DOI 10.1053/gast.2002.35388; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kawasaki J, 2004, J BIOL CHEM, V279, P12959, DOI 10.1074/jbc.M313791200; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Kramar EA, 2002, NEUROSCIENCE, V110, P29, DOI 10.1016/S0306-4522(01)00540-1; Kramar EA, 2003, J BIOL CHEM, V278, P10722, DOI 10.1074/jbc.M210225200; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; Levite M, 2000, J EXP MED, V191, P1167, DOI 10.1084/jem.191.7.1167; Lin B, 2003, J NEUROPHYSIOL, V89, P2874, DOI 10.1152/jn.00783.2002; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Martinez-Lemus LA, 2003, J VASC RES, V40, P211, DOI 10.1159/000071886; McDonough SI, 2002, J GEN PHYSIOL, V119, P313, DOI 10.1085/jgp.20028560; McHugh D, 2000, P NATL ACAD SCI USA, V97, P12334, DOI 10.1073/pnas.210384297; Meiners S, 2003, MOL NEUROBIOL, V27, P177, DOI 10.1385/MN:27:2:177; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; Milner R, 2002, J NEUROSCI RES, V69, P286, DOI 10.1002/jnr.10321; Mitterdorfer J, 1996, BIOCHEMISTRY-US, V35, P9400, DOI 10.1021/bi960683o; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Murchison D, 1998, J NEUROPHYSIOL, V80, P350, DOI 10.1152/jn.1998.80.1.350; Nishimura SL, 1998, BRAIN RES, V791, P271, DOI 10.1016/S0006-8993(98)00118-8; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Rueckschloss U, 2004, J PHYSIOL-LONDON, V560, P403, DOI 10.1113/jphysiol.2004.062604; Rueckschloss U, 2001, J PHYSIOL-LONDON, V537, P363, DOI 10.1111/j.1469-7793.2001.00363.x; Ruiz-Velasco V, 1998, CIRC RES, V82, P557, DOI 10.1161/01.RES.82.5.557; Sadeghi A, 2002, AM J PHYSIOL-CELL PH, V282, pC1502, DOI 10.1152/ajpcell.00435.2001; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; Staubli U, 1998, J NEUROSCI, V18, P3460; Vasilyev DV, 2003, J PHYSIOL-LONDON, V547, P859, DOI 10.1113/jphysiol.2002.036889; Waitkus-Edwards KR, 2002, CIRC RES, V90, P473, DOI 10.1161/hh0402.105899; Wang YG, 2000, J PHYSIOL-LONDON, V526, P57, DOI 10.1111/j.1469-7793.2000.t01-1-00057.x; Wang YG, 2000, J PHYSIOL-LONDON, V527, P3, DOI 10.1111/j.1469-7793.2000.t01-2-00003.x; WEI XY, 1994, J BIOL CHEM, V269, P1635; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Wijetunge S, 1996, FEBS LETT, V399, P63, DOI 10.1016/S0014-5793(96)01177-5; WIJETUNGE S, 1995, BRIT J PHARMACOL, V115, P534, DOI 10.1111/j.1476-5381.1995.tb16367.x; Wildering WC, 2002, J NEUROSCI, V22, P2419, DOI 10.1523/JNEUROSCI.22-07-02419.2002; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Wu X, 2001, J BIOL CHEM, V276, P30285, DOI 10.1074/jbc.M102436200; Zhong JM, 1999, AM J PHYSIOL-CELL PH, V277, pC840	76	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14015	14025		10.1074/jbc.M600433200	http://dx.doi.org/10.1074/jbc.M600433200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16554304	hybrid			2022-12-25	WOS:000237512300024
J	Shibata, M; Lu, T; Furuya, T; Degterev, A; Mizushima, N; Yoshimori, T; MacDonald, M; Yankner, B; Yuan, JY				Shibata, Mamoru; Lu, Tao; Furuya, Tsuyoshi; Degterev, Alexei; Mizushima, Noboru; Yoshimori, Tamotsu; MacDonald, Marcy; Yankner, Bruce; Yuan, Junying			Regulation of Intracellular Accumulation of Mutant Huntingtin by Beclin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Intracellular accumulation of mutant Huntingtin with expanded polyglutamine provides a context-dependent cytotoxicity critical for the pathogenesis of Huntington disease (Everett, C. M., and Wood, N. W. (2004) Brain 127, 2385-2405). Here we demonstrate that the accumulation of mutant Huntingtin is highly sensitive to the expression of beclin 1, a gene essential for autophagy. Moreover, we show that the accumulated mutant Huntingtin recruits Beclin 1 and impairs the Beclin 1-mediated long lived protein turnover. Thus, sequestration of Beclin 1 in the vulnerable neuronal population of Huntington disease patients might further reduce Beclin 1 function and autophagic degradation of mutant Huntingtin. Finally, we demonstrate that the expression of beclin 1 decreases in an age-dependent fashion in human brains. Because beclin 1 gene is haploid insufficient in regulating autophagosome function (Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E. L., Mizushima, N., Ohsumi, Y., Cattoretti, G., and Levine, B. (2003) J. Clin. Invest. 112, 1809-1820; Yue, Z., Jin, S., Yang, C., Levine, A. J., and Heintz, N. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 15077 15082), we propose that the age-dependent decrease of beclin 1 expression may lead to a reduction of autophagic activity during aging, which in turn promotes the accumulation of mutant Htt and the progression of the disease.	[Shibata, Mamoru; Furuya, Tsuyoshi; Degterev, Alexei; Yuan, Junying] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Shibata, Mamoru; Furuya, Tsuyoshi; Degterev, Alexei; Yuan, Junying] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Lu, Tao; Yankner, Bruce] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Lu, Tao; Yankner, Bruce] Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; [MacDonald, Marcy] Massachusetts Gen Hosp East, Ctr Human Genet Res, Charlestown, MA 02129 USA; [MacDonald, Marcy] Massachusetts Gen Hosp East, Mol Neurogenet Unit, Charlestown, MA 02129 USA; [Mizushima, Noboru] Tokyo Metropolitan Inst Med Sci, Dept Bioregulat & Metab, Bunkyo Ku, Tokyo 1138613, Japan; [Yoshimori, Tamotsu] Natl Inst Genet, Dept Cell Genet, Mishima, Shizuoka 4118540, Japan	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Tokyo Metropolitan Institute of Medical Science; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	jyuan@hms.harvard.edu	Mizushima, Noboru/C-3635-2009; Shibata, Mamoru/L-8537-2013	Mizushima, Noboru/0000-0002-6258-6444; Shibata, Mamoru/0000-0002-2416-4259	HighQ Foundation; NIA, National Institutes of Health [R37-12859, NS32765, NS16367]; Huntington's Disease Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016367, R01NS032765, P50NS016367] Funding Source: NIH RePORTER	HighQ Foundation; NIA, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Huntington's Disease Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the HighQ Foundation, by NIA, National Institutes of Health Grant R37-12859 (to J. Y.), by National Institutes of Health Grants NS32765 and NS16367, and by the Huntington's Disease Center Without Walls (to M. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Cuervo AM, 2004, MOL CELL BIOCHEM, V263, P55, DOI 10.1023/B:MCBI.0000041848.57020.57; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Donati A, 2001, J GERONTOL A-BIOL, V56, pB375, DOI 10.1093/gerona/56.9.B375; Everett CM, 2004, BRAIN, V127, P2385, DOI 10.1093/brain/awh278; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; MacDonald Marcy E, 2003, Sci STKE, V2003, ppe48; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	40	357	373	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14474	14485		10.1074/jbc.M600364200	http://dx.doi.org/10.1074/jbc.M600364200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16522639	Green Published, hybrid			2022-12-25	WOS:000207179300006
J	Ghosh, S; Johnson, JJ; Sen, R; Mukhopadhyay, S; Liu, YY; Zhang, F; Wei, Y; Chapman, HA; Stack, MS				Ghosh, S; Johnson, JJ; Sen, R; Mukhopadhyay, S; Liu, YY; Zhang, F; Wei, Y; Chapman, HA; Stack, MS			Functional relevance of urinary-type plasminogen activator receptor-alpha 3 beta 1 integrin association in proteinase regulatory pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMA; UROKINASE RECEPTOR; EXTRACELLULAR-MATRIX; ORAL KERATINOCYTES; BASEMENT-MEMBRANE; BINDING-SITES; TUMOR-GROWTH; EXPRESSION; METASTASIS; INVASION	Squamous cell carcinoma of the oral cavity is characterized by persistent, disorganized expression of integrin alpha 3 beta 1 and enhanced production of urinary-type plasminogen activator (uPA) and its receptor ( uPAR) relative to normal oral mucosa. Because multivalent aggregation of alpha 3 beta 1 integrin up-regulates uPA and induces a dramatic co-clustering of uPAR, we explored the hypothesis that lateral ligation of alpha 3 beta 1 integrin by uPAR contributes to uPA regulation in oral mucosal cells. To investigate mechanisms by which uPAR/alpha 3 beta 1 binding enhances uPA expression, integrin-dependent signal activation was assessed. Both Src and ERK1/2 were phosphorylated in response to integrin aggregation, and blocking Src kinase activity completely abrogated ERK1/2 activation and uPA induction, whereas inhibition of epidermal growth factor receptor tyrosine kinase activity did not alter uPA expression. Proteinase up-regulation occurred at the transcriptional level and mutation of the AP1 (-1967) site in the uPA promoter blocked the uPAR/integrin-mediated transcriptional activation. Because uPAR is redistributed to clustered alpha 3 beta 1 integrins, the requirement for uPAR/alpha 3 beta 1 interaction in uPA regulation was assessed. Clustering of alpha 3 beta 1 in the presence of a peptide (alpha 325) that disrupts uPAR/alpha 3 beta 1 integrin binding prevented uPA induction. Depletion of cell surface uPAR using small interfering RNA also blocked uPA induction following integrin alpha 3 beta 1 clustering. These results were confirmed using a genetic strategy in which alpha 3 null epithelial cells reconstituted with wild type alpha 3 integrin, but not a mutant alpha 3 unable to bind uPAR, induced uPA expression upon integrin clustering, confirming the critical role of uPAR in integrin-regulated proteinase expression. Disruption of uPAR/alpha 3 beta 1 binding using peptide alpha 325 or small interfering RNA blocked filopodia formation and matrix invasion, indicating that this interaction stimulates invasive behavior. Together these data support a model wherein matrix-induced clustering of alpha 3 beta 1 integrin promotes uPAR/alpha 3 beta 1 interaction, thereby potentiating cellular signal transduction pathways culminating in activation of uPA expression and enhanced uPA-dependent invasive behavior.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of California System; University of California San Francisco	Stack, MS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Super St,Lurie Bldg 3-111, Chicago, IL 60611 USA.	mss130@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA085870] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA85870] Funding Source: Medline; NHLBI NIH HHS [R01HL44712] Funding Source: Medline; NIDCR NIH HHS [P01DE12328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BECKER J, 1991, VIRCHOWS ARCH A, V419, P237, DOI 10.1007/BF01626354; Berndt A, 1997, INVAS METAST, V17, P251; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Chodniewicz D, 2004, EXP CELL RES, V301, P31, DOI 10.1016/j.yexcr.2004.08.006; Degryse B, 2005, J BIOL CHEM, V280, P24792, DOI 10.1074/jbc.M413954200; Ellerbroek SM, 1998, INT J CANCER, V78, P331, DOI 10.1002/(SICI)1097-0215(19981029)78:3<331::AID-IJC13>3.0.CO;2-9; Geuijen CAW, 2002, MOL BIOL CELL, V13, P3845, DOI 10.1091/mbc.02-01-0601; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; Ghosh S, 2002, CANCER-AM CANCER SOC, V95, P2524, DOI 10.1002/cncr.10997; Haas KM, 2001, J HISTOCHEM CYTOCHEM, V49, P1261; Hicks WL, 1997, HEAD NECK-J SCI SPEC, V19, P400; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Jones JCR, 2000, MICROSC RES TECHNIQ, V51, P211, DOI 10.1002/1097-0029(20001101)51:3<211::AID-JEMT1>3.0.CO;2-P; Kosmehl H, 1999, BRIT J CANCER, V81, P1071, DOI 10.1038/sj.bjc.6690809; Kugler MC, 2003, CURR PHARM DESIGN, V9, P1565, DOI 10.2174/1381612033454658; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; LENGYEL E, 1995, BBA-MOL CELL RES, V1268, P65, DOI 10.1016/0167-4889(95)00050-3; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Munshi HG, 2002, J BIOL CHEM, V277, P38159, DOI 10.1074/jbc.M202384200; Myohanen H, 2004, CELL MOL LIFE SCI, V61, P2840, DOI 10.1007/s00018-004-4230-9; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Oda D, 1996, EXP CELL RES, V226, P164, DOI 10.1006/excr.1996.0215; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; Shinohara M, 1999, AM J CLIN PATHOL, V111, P75; Shiratsuchi T, 2002, J CELL PHYSIOL, V193, P340, DOI 10.1002/jcp.10181; Smith PC, 2004, J PERIODONTAL RES, V39, P380, DOI 10.1111/j.1600-0765.2004.00753.x; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; Wang H, 2004, J CELL BIOL, V164, P935, DOI 10.1083/jcb.200309112; Wang ZM, 1999, J CELL SCI, V112, P2925; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xue W, 1997, CANCER RES, V57, P1682; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zhang F, 2003, J CELL BIOL, V163, P177, DOI 10.1083/jcb.200304065	48	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13021	13029		10.1074/jbc.M508526200	http://dx.doi.org/10.1074/jbc.M508526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16510444	hybrid			2022-12-25	WOS:000237336600005
J	Leroyer, SN; Tordjman, J; Chauvet, G; Quette, J; Chapron, C; Forest, C; Antoine, B				Leroyer, SN; Tordjman, J; Chauvet, G; Quette, J; Chapron, C; Forest, C; Antoine, B			Rosiglitazone controls fatty acid cycling in human adipose tissue by means of glyceroneogenesis and glycerol phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE ACTIVITY; INSULIN-RESISTANCE; DIABETES-MELLITUS; IN-VIVO; METABOLISM; ADIPOCYTES; TRIGLYCERIDE; OBESITY; GENE	Control of fatty acid homeostasis is crucial to prevent insulin resistance. During fasting, the plasma fatty acid level depends on triglyceride lipolysis and fatty acid re-esterification within fat cells. In rodents, Rosiglitazone (R) controls fatty acid homeostasis by stimulating two pathways in the adipocytes, glyceroneogenesis and glycerol phosphorylation, that provide the glycerol 3-phosphate necessary for fatty acid re-esterification. Here, we analyzed the functionality of both pathways for controlling fatty acid release in subcutaneous adipose tissue samples from lean and overweight women before and after Rosiglitazone (R) ex vivo treatment. In controls, pyruvate, used as a substrate of glyceroneogenesis, could contribute to the re-esterification of up to 65% of the fatty acids released after basal lipolysis, whereas glycerol phosphorylation accounted for only 14 +/- 9%. However, the efficiency of glyceroneogenesis diminished as body mass index (BMI) of women increased. After Rosiglitazone treatment, increase of either pyruvate- or glycerol-dependent fatty acid re-esterification was strictly correlated to that of phosphoenolpyruvate carboxykinase and glycerol kinase, the key enzymes of each pathway, but depended on BMI of the women. Whereas the Rosiglitazone (R) responsiveness of glyceroneogenesis was rather constant according to the BMI of the women, glycerol phosphorylation was mostly enhanced in lean women (BMI < 27). Overall, these data indicate that, whereas glyceroneogenesis is more utilized than glycerol phosphorylation for fatty acid re-esterification in human subcutaneous adipose tissue in the physiological situation, both are solicited in response to Rosiglitazone (R) but with lower efficiency when BMI is increased.	Univ Paris 06, INSERM UMR S 530 747, F-75006 Paris, France; CHU Cochin, Grp Hosp Univ Ouest, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	Antoine, B (corresponding author), Ctr Univ St Antoine, INSERM, U 680, 27 Rue Chaligny, F-75012 Paris, France.	benedicte.antoine@univ-paris5.fr	Chapron, Charles/O-8567-2017	Forest, Claude/0000-0003-3401-8148				Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Beale EG, 2002, FASEB J, V16, P1695, DOI 10.1096/fj.02-0407rev; BLIGH EG, 1959, CAN J BIOCH PHYSL, V371, P1991; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Bogacka I, 2004, DIABETES CARE, V27, P1660, DOI 10.2337/diacare.27.7.1660; Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796; CHAKRABARTY K, 1984, INT J OBESITY, V8, P609; CHANG HC, 1966, J BIOL CHEM, V241, P2413; Chen JL, 2005, J BIOL CHEM, V280, P25396, DOI 10.1074/jbc.M413948200; DUFF DA, 1982, BIOCHEM J, V206, P147, DOI 10.1042/bj2060147; Duplus E, 2003, BIOCHIMIE, V85, P1257, DOI 10.1016/j.biochi.2003.10.016; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; HAMMOND VA, 1987, METABOLISM, V36, P308, DOI 10.1016/0026-0495(87)90199-5; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; JENSEN MD, 1991, J CLIN INVEST, V87, P187, DOI 10.1172/JCI114969; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Mayerson AB, 2002, DIABETES, V51, P797, DOI 10.2337/diabetes.51.3.797; Miyazaki Y, 2001, DIABETOLOGIA, V44, P2210, DOI 10.1007/s001250100031; NEWSHOLME EA, 1967, BIOCHIM BIOPHYS ACTA, V132, P338, DOI 10.1016/0005-2744(67)90153-2; Patsouris D, 2004, J CLIN INVEST, V114, P94, DOI 10.1172/JC1200420468; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; PERSICO PA, 1975, AM J PHYSIOL, V228, P1868, DOI 10.1152/ajplegacy.1975.228.6.1868; RANDLE PJ, 1963, LANCET, V1, P785; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; RESHEF L, 1969, J BIOL CHEM, V244, P1994; RESHEF L, 1969, J BIOL CHEM, V244, P5577; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; Tan GD, 2005, DIABETOLOGIA, V48, P83, DOI 10.1007/s00125-004-1619-9; Tan GD, 2003, NAT MED, V9, P811, DOI 10.1038/nm0703-811; Tordjman J, 2003, J BIOL CHEM, V278, P18785, DOI 10.1074/jbc.M206999200; VAUGHAN M, 1962, J BIOL CHEM, V237, P3354; WATFORD M, 1980, CAN J BIOCHEM CELL B, V58, P440, DOI 10.1139/o80-058	37	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13141	13149		10.1074/jbc.M512943200	http://dx.doi.org/10.1074/jbc.M512943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16524879	hybrid			2022-12-25	WOS:000237336600019
J	Matos, P; Jordan, P				Matos, P; Jordan, P			Rac1, but not Rac1B, stimulates RelB-mediated gene transcription in colorectal cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRCP-UBIQUITIN LIGASE; IKK-ALPHA; CYCLIN D1; INDEPENDENT PATHWAYS; DEPENDENT PATHWAY; NF-KAPPA-B2 P100; SPLICE VARIANT; NADPH OXIDASE; RHO-GTPASES	Increased NF- kappa B- mediated transcription has been extensively linked to tumorigenesis and can be stimulated by deregulated Rac1 signaling. For example, the overexpression of Rac1b, a highly activated splicing variant of Rac1 with increased expression in colorectal tumors, stimulates NF- kappa B- mediated G(1)/ S progression and cell survival, and was shown to promote cell transformation and epithelial-mesenchymal transition. Here we show evidence of further complexity between Rac1b and Rac1 signaling toward NF- kappa B in colorectal cells. Consistent with data from other cell types we demonstrate that both Rac1 and Rac1b stimulate transcriptional activation from reporter genes driven by NF- kappa B motifs or the cyclin D1 promoter in an I kappa B alpha- and reactive oxygen species- dependent manner. However, we found that in colorectal cells Rac1, but not Rac1b, induces nuclear translocation of RelB and p52, activates transcription from a RelB- specific reporter, and can be isolated in a complex with endogenous RelB and its inhibitor NF- kappa B2/ p100. In addition, Rac1 colocalizes at the plasmamembrane with RelB, p100, and cullin-1, a core subunit of the E3 ubiquitin ligase that marks p100 for proteolytic processing to p52. Interestingly, this Rac1- specific pathway is not mediated via the production of reactive oxygen species. These data provide evidence that both Rac1 and Rac1b activate the canonical RelA- I kappa B alpha pathway, whereas Rac1 further stimulates NF- kappa B by inducing the RelB- NF- kappa B2/ p100 pathway. The RelB pathway was reported to down- regulate canonical NF- kappa B activation during the inflammatory response, suggesting that increased levels of Rac1b in colorectal tumors may promote tumorigenesis by stimulating canonical NF- kappa B signaling while circumventing a negative feedback from the RelB pathway.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Human Genet, P-1649016 Lisbon, Portugal	Instituto Nacional de Saude Dr. Ricardo Jorge	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Human Genet, P-1649016 Lisbon, Portugal.	peter.jordan@insa.min-saude.pt	Matos, Paulo/F-5245-2012; Matos, Paulo/P-3012-2019; Jordan, Peter/G-9335-2012	Matos, Paulo/0000-0002-9379-9696; Matos, Paulo/0000-0002-9379-9696; Jordan, Peter/0000-0002-1425-9211				Amir RE, 2004, ONCOGENE, V23, P2540, DOI 10.1038/sj.onc.1207366; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Boyer L, 2004, MOL BIOL CELL, V15, P1124, DOI 10.1091/mbc.E03-05-0301; Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Fiegen D, 2004, J BIOL CHEM, V279, P4743, DOI 10.1074/jbc.M310281200; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marienfeld R, 2003, J BIOL CHEM, V278, P19852, DOI 10.1074/jbc.M301945200; Marinari B, 2002, EUR J IMMUNOL, V32, P447, DOI 10.1002/1521-4141(200202)32:2<447::AID-IMMU447>3.0.CO;2-5; Matos P, 2005, EXP CELL RES, V305, P292, DOI 10.1016/j.yexcr.2004.12.029; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Senadheera D, 2001, INT J MOL MED, V8, P127; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	55	39	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13724	13732		10.1074/jbc.M513243200	http://dx.doi.org/10.1074/jbc.M513243200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551621	hybrid			2022-12-25	WOS:000237336600083
J	Rosenkilde, MM; Benned-Jensen, T; Andersen, H; Holst, PJ; Kledal, TN; Luttichau, HR; Larsen, JK; Christensen, JP; Schwartz, TW				Rosenkilde, MM; Benned-Jensen, T; Andersen, H; Holst, PJ; Kledal, TN; Luttichau, HR; Larsen, JK; Christensen, JP; Schwartz, TW			Molecular pharmacological phenotyping of EBI2 - An orphan seven-transmembrane receptor with constitutive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; NF-KAPPA-B; GHRELIN RECEPTOR; CELL-SURVIVAL; CHEMOKINE; EXPRESSION; CLONING; LIGAND; IDENTIFICATION	Epstein-Barr virus ( EBV)-induced receptor 2 ( EBI2) is an orphan seven-transmembrane ( 7TM) receptor originally identified as the most up-regulated gene (> 200-fold) in EBV-infected cells. Here we show that EBI2 signals with constitutive activity through G alpha(i) as determined by a receptor-mediated inhibition of forskolin-induced cAMP production and an induction of the serum response element-driven transcriptional activity in a pertussis toxin-sensitive manner. G alpha(s) and G alpha(q) were not activated constitutively as determined by the lack of cAMP production, the lack of inositol phosphate turnover, and the lack of activities of the transcription factors: cAMP response element-binding protein and nuclear factor-kappa B. Immunohistochemistry and confocal microscopy of FLAG- and green fluorescent protein-tagged EBI2 revealed cell-surface expression. A putative N-terminal truncated version of EBI2, Delta 4-EBI2, showed similar expression and signaling through G alpha(i) as full-length EBI2. By using a P-32-labeled EBI2 probe we found a very high expression in lymphoid tissue ( spleen and lymph node) and peripheral blood mononuclear cells and a high expression in lung tissue. Real-time PCR of EBV-infected cells showed high expression of EBI2 during latent and lytic infection, in contrast to the EBV-encoded 7TM receptor BILF1, which was induced during lytic infection. EBI2 clustered with the orphan GPR18 by alignment analysis as well as by close proximity in the chromosomal region 13q32.3. Based on the constitutive signaling and cellular expression pattern of EBI2, it is suggested that it may function in conjunction with BILF1 in the reprogramming of the cell during EBV infection.	Univ Copenhagen, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark; Panum Inst, Inst Med Microbiol & Immunol, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark; Univ Copenhagen Hosp, Finser Ctr, Finsen Lab, DK-2200 Copenhagen N, Denmark; Univ Copenhagen Hosp, Dept Infect Dis, DK-2200 Copenhagen N, Denmark; Univ Copenhagen Hosp, Clin Res Unit, DK-2650 Hvidovre, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen	Rosenkilde, MM (corresponding author), Univ Copenhagen, Dept Pharmacol, Mol Pharmacol Lab, Bldg 18-6,Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	rosenkilde@molpharm.dk	Christensen, Jan Pravsgaard/I-4782-2017	Christensen, Jan Pravsgaard/0000-0002-4299-9479; Rosenkilde, Mette Marie/0000-0001-9600-3254; Holst, Peter Johannes/0000-0002-1279-304X; Schwartz, Thue W./0000-0002-0261-6904; Luttichau, Hans Rudolf/0000-0002-5428-4075				AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beisser PS, 2005, J VIROL, V79, P441, DOI 10.1128/JVI.79.1.441-449.2005; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BIRKENBACH M, 1989, J VIROL, V63, P4079, DOI 10.1128/JVI.63.9.4079-4084.1989; Cahir-McFarland ED, 2004, J VIROL, V78, P4108, DOI 10.1128/JVI.78.8.4108-4119.2004; Cannon M, 2003, J VIROL, V77, P57, DOI 10.1128/JVI.77.1.57-67.2003; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Couty JP, 2005, TRENDS PHARMACOL SCI, V26, P405, DOI 10.1016/j.tips.2005.06.004; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Goltz M, 2002, VIROLOGY, V294, P383, DOI 10.1006/viro.2002.1390; Gruijthuijsen YK, 2002, J VIROL, V76, P1328, DOI 10.1128/JVI.76.3.1328-1338.2002; Hill Stephen J., 2001, Current Opinion in Pharmacology, V1, P526, DOI 10.1016/S1471-4892(01)00091-1; Holst B, 2003, MOL ENDOCRINOL, V17, P2201, DOI 10.1210/me.2003-0069; Holst B, 2004, J BIOL CHEM, V279, P53806, DOI 10.1074/jbc.M407676200; Holst B, 2004, TRENDS PHARMACOL SCI, V25, P113, DOI 10.1016/j.tips.2004.01.010; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; Joost P, 2002, GENOME BIOL, V3; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; Lapinsh M, 2002, PROTEIN SCI, V11, P795, DOI 10.1110/ps.2500102; Lindow M, 2003, TRENDS PHARMACOL SCI, V24, P126, DOI 10.1016/S0165-6147(03)00033-6; Liu CQ, 2004, J VIROL, V78, P2460, DOI 10.1128/JVI.78.5.2460-2471.2004; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Melchjorsen J, 2002, J VIROL, V76, P2780, DOI 10.1128/JVI.76.6.2780-2788.2002; Melchjorsen J, 2003, J LEUKOCYTE BIOL, V74, P331, DOI 10.1189/jlb.1102577; Montaner S, 2001, CANCER RES, V61, P2641; Moorman NJ, 2003, VIROLOGY, V307, P179, DOI 10.1016/S0042-6822(02)00023-5; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; Nakayama T, 2002, J VIROL, V76, P3072, DOI 10.1128/JVI.76.6.3072-3077.2002; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nijenhuis WAJ, 2001, MOL ENDOCRINOL, V15, P164, DOI 10.1210/me.15.1.164; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Ponimaskin EG, 2002, J BIOL CHEM, V277, P20812, DOI 10.1074/jbc.M112216200; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Rosenkilde MM, 2006, CURR DRUG TARGETS, V7, P103, DOI 10.2174/138945006775270259; Rosenkilde MM, 2005, NEUROPHARMACOLOGY, V48, P1, DOI 10.1016/j.neuropharm.2004.09.017; Rosenkilde MM, 2004, J BIOL CHEM, V279, P32524, DOI 10.1074/jbc.M313392200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2005, MOL PHARMACOL, V68, P11, DOI 10.1124/mol.105.011239; ROSENKILDE MM, 2004, HDB CELL SIGNALING, P779; Sabroe I, 1998, J IMMUNOL, V161, P6139; SCHWARTZ TW, 2003, TXB RECEPTOR PHARM, P65; Seifert R, 2001, RECEPTOR CHANNEL, V7, P357; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	53	83	86	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13199	13208		10.1074/jbc.M602245200	http://dx.doi.org/10.1074/jbc.M602245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16540462	hybrid			2022-12-25	WOS:000237336600025
J	Anand, AR; Ganju, RK				Anand, AR; Ganju, RK			HIV-1 gp120-mediated apoptosis of T cells is regulated by the membrane tyrosine phosphatase CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FAS-LIGAND; PHOSPHATIDYLINOSITOL 3-KINASE; CD95-MEDIATED APOPTOSIS; INHIBITS APOPTOSIS; KINASE ACTIVATION; ANTIGEN RECEPTOR; UP-REGULATION; PROTEIN; DEATH	The molecular mechanism of the human immunodeficiency virus type 1 (HIV-1) gp120-induced apoptosis of bystander T cells is not well defined. Here, we demonstrate that CD45, a key component of the T cell receptor pathway, plays a crucial role in apoptosis induced by HIV-1 gp120. We observed that HIV-1 gp120-induced apoptosis was significantly reduced in a CD45-deficient cell line and that reconstitution of CD45 in these cells restored gp120-induced apoptosis. However, expression of a chimeric protein containing only the intracellular phosphatase domain was not able to restore the apoptotic function in the CD45-negative clone, indicating an important role for the extracellular domain of CD45 in this function. The role of CD45 in gp120-induced apoptosis was further confirmed in T cell lines and peripheral blood mononuclear cells using a selective CD45 inhibitor as well as CD45-specific small interfering RNA. We also observed that gp120 treatment induced CD45 association with the HIV coreceptor CXCR4. Further elucidation of downstream signaling events revealed that CD45 modulates HIV-1 gp120-induced apoptosis by regulating Fas ligand induction and activation of the phosphoinositide 3-kinase/Akt pathway. These results suggest a novel CD45-mediated mechanism for the HIV envelope-induced apoptosis of T cells.	Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Ctr Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center	Ganju, RK (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Ctr Med, Harvard Inst Med Bldg,Rm 343,4 Blackfan Circle, Boston, MA 02115 USA.	rganju@bidmc.harvard.edu			NIAID NIH HHS [AI49140] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049140] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Accornero P, 1998, FEBS LETT, V436, P461, DOI 10.1016/S0014-5793(98)01127-2; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Ameisen J C, 1995, Curr Top Microbiol Immunol, V200, P195; Badley AD, 2000, BLOOD, V96, P2951, DOI 10.1182/blood.V96.9.2951.h8002951_2951_2964; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; Berndt C, 1998, P NATL ACAD SCI USA, V95, P12556, DOI 10.1073/pnas.95.21.12556; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Cicala C, 2002, P NATL ACAD SCI USA, V99, P9380, DOI 10.1073/pnas.142287999; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Descamps G, 2004, J IMMUNOL, V173, P4953, DOI 10.4049/jimmunol.173.8.4953; DISOMMA MM, 1995, FEBS LETT, V363, P101, DOI 10.1016/0014-5793(95)00292-H; Dockrell DH, 1999, AIDS RES HUM RETROV, V15, P1509, DOI 10.1089/088922299309793; Eischen CM, 1997, J IMMUNOL, V159, P1135; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Fernandez M, 2004, J MOL ENDOCRINOL, V33, P155, DOI 10.1677/jme.0.0330155; Fernandis AZ, 2003, J BIOL CHEM, V278, P9536, DOI 10.1074/jbc.M211803200; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Fortin M, 2002, J IMMUNOL, V168, P6084, DOI 10.4049/jimmunol.168.12.6084; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; Francois F, 2003, J VIROL, V77, P2539, DOI 10.1128/JVI.77.4.2539-2549.2003; Giovannetti A, 2000, AIDS RES HUM RETROV, V16, P211, DOI 10.1089/088922200309304; Gougeon ML, 2003, NAT REV IMMUNOL, V3, P392, DOI 10.1038/nri1087; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; Guntermann C, 1998, BIOCHEM BIOPH RES CO, V252, P69, DOI 10.1006/bbrc.1998.9595; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; Hosaka N, 1998, J INFECT DIS, V178, P1030, DOI 10.1086/515700; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; Klaus SJ, 1996, J IMMUNOL, V156, P2743; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; Kozieradzki I, 1997, J IMMUNOL, V158, P3130; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; Nguyen JT, 2001, J IMMUNOL, V167, P5697, DOI 10.4049/jimmunol.167.10.5697; Oliveira DM, 2003, GENESIS, V36, P203, DOI 10.1002/gene.10212; PANTALEO G, 1995, NAT MED, V1, P118, DOI 10.1038/nm0295-118; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; Roggero R, 2001, J VIROL, V75, P7637, DOI 10.1128/JVI.75.16.7637-7650.2001; SCHRAVEN B, 1995, FEBS LETT, V368, P491, DOI 10.1016/0014-5793(95)00720-T; Shenoi H, 1999, J IMMUNOL, V162, P7120; Shimamura H, 2003, J AM SOC NEPHROL, V14, P1427, DOI 10.1097/01.ASN.0000066140.99610.32; Sloand EM, 1997, BLOOD, V89, P1357, DOI 10.1182/blood.V89.4.1357; STAQUIER J, 1996, BLOOD, V87, P4959; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Urbanek RA, 2001, J MED CHEM, V44, P1777, DOI 10.1021/jm000447i; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wu MX, 1996, J IMMUNOL, V157, P707	62	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12289	12299		10.1074/jbc.M511786200	http://dx.doi.org/10.1074/jbc.M511786200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524887	hybrid			2022-12-25	WOS:000237134700013
J	Bluschke, B; Volkmer-Engert, R; Schneider, E				Bluschke, B; Volkmer-Engert, R; Schneider, E			Topography of the surface of the signal-transducing protein EIIA(Glc) that interacts with the MalK subunits of the maltose ATP-binding cassette transporter (MalFGK(2)) of Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; PHOSPHORYL TRANSFER COMPLEX; ESCHERICHIA-COLI; INDUCER EXCLUSION; GLUCOSE-TRANSPORTER; SUGAR-TRANSPORT; IIA(GLC); DOMAIN; IIA(GLUCOSE); SEQUENCE	The signal-transducing protein EIIA(Glc), a component of the phosphoenolpyruvate-glucose phosphotransferase system, plays a key role in carbon regulation in enteric bacteria, such as Escherichia coli and Salmonella typhimurium. The phosphorylation state of EIIAGlc governs transport and metabolism of a number of carbohydrates. When glucose as preferred carbon source is transported, EIIAGlc becomes predominantly unphosphorylated and allosterically inhibits several permeases, including the maltose ATP-binding cassette transport system (MalFGK2) in a process termed "inducer exclusion." We have mapped the binding surface of EIIAGlc that interacts with the MalK subunits by using synthetic cellulose-bound peptide arrays like pep scan- and substitutional analyses. Three regions constituting two binding sites were identified encompassing residues 69-79 (I), 87-91 (II), and 118-127 (III). Region III is MalK-specific, whereas residues from regions I and II partly overlap but are not identical to the binding interfaces for interaction with glycerol kinase and lactose permease. These results were fully verified by studying the inhibitory effect of purified EIIAGlc variants carrying mutations at positions representative of each of the three regions on the ATPase activity of the purified maltose transport complex reconstituted into proteoliposomes. Moreover, a synthetic peptide encompassing residues 69-91 was demonstrated to partially inhibit ATPase activity. We also show for the first time that the N-terminal domain of EIIAGlc is essential for inducer exclusion.	Humboldt Univ, Inst Biol Bakterienphysiol, D-10115 Berlin, Germany; Charite Univ Med Berlin, Inst Med Immunol, D-10098 Berlin, Germany	Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schneider, E (corresponding author), Humboldt Univ, Inst Biol Bakterienphysiol, Chausseestr 117, D-10115 Berlin, Germany.	erwin.schneider@rz.hu-berlin.de	Müller, Bettina/H-3276-2018	Müller, Bettina/0000-0002-0030-7710; Volkmer, Rudolf/0000-0003-4710-1143				BENTRUP KHZ, 1994, MICROBIOL-UK, V140, P945, DOI 10.1099/00221287-140-4-945; Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; Boisguerin P, 2004, CHEM BIOL, V11, P449, DOI 10.1016/j.chembiol.2004.03.010; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; DEAN DA, 1990, J BIOL CHEM, V265, P21005; Feese MD, 1997, BIOCHEMISTRY-US, V36, P16087, DOI 10.1021/bi971999e; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; KUHNAU S, 1991, J BACTERIOL, V173, P2180; Landmesser H, 2002, BBA-BIOMEMBRANES, V1565, P64, DOI 10.1016/S0005-2736(02)00506-0; LEGELER JW, 1996, HDB BIOL PHYS; MEADOW ND, 1986, J BIOL CHEM, V261, P3504; MISKO TP, 1987, J BIOL CHEM, V262, P16261; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; REINEKE U, 2003, CURR OPIN BIOTECH, V12, P59; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; Samanta S, 2003, J BIOL CHEM, V278, P35265, DOI 10.1074/jbc.M301171200; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; SCHNEIDER E, 2003, ABC PROTEINS BACTERI, P157; Sondej M, 2000, BIOCHEMISTRY-US, V39, P2931, DOI 10.1021/bi9919596; Stein A, 2002, EUR J BIOCHEM, V269, P4074, DOI 10.1046/j.1432-1033.2002.03099.x; Takahashi H, 1998, MOL GEN GENET, V259, P317, DOI 10.1007/s004380050818; VOLKMERENGERT R, 1994, LETT PEPT SCI, V1, P243; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; Wang GS, 2003, PROTEIN SCI, V12, P1087, DOI 10.1110/ps.0301503; Wang GS, 2000, J BIOL CHEM, V275, P39811, DOI 10.1074/jbc.C000709200; Weiser AA, 2005, ANAL BIOCHEM, V342, P300, DOI 10.1016/j.ab.2005.04.033; Wenschuh H, 2000, PRACT APPROACH SER, V233, P95; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; ZENG GQ, 1992, RES MICROBIOL, V143, P251, DOI 10.1016/0923-2508(92)90017-I	33	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12833	12840		10.1074/jbc.M512646200	http://dx.doi.org/10.1074/jbc.M512646200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527815	hybrid			2022-12-25	WOS:000237134700078
J	Raghevendran, V; Patil, KR; Olsson, L; Nielsen, J				Raghevendran, V; Patil, KR; Olsson, L; Nielsen, J			Hap4 is not essential for activation of respiration at low specific growth rates in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; CHEMOSTAT CULTURES; METABOLIC NETWORK; YEAST; OXYGEN; IDENTIFICATION; REPRESSION; NUCLEAR; COMPLEX	In Saccharomyces cerevisiae, the heme-activated protein complex Hap2/3/4/5 plays a major role in the transcription of genes involved in respiration. Thus, overexpression of HAP4 has been shown to result in a 10% increase in the respiratory capacity. Here the physiology of a HAP4-deleted S. cerevisiae strain was investigated, and we found that the hap4 Delta S. cerevisiae exhibited poor growth on ethanol, although the growth rate on glucose was indifferent from the wild type in aerobic as well as anaerobic cultures. Moreover, it exhibited a large (75%) reduction in the critical glucose uptake rate at which fermentative metabolism is onset, indicating a substantial reduction in respiratory capacity. We also performed whole genome transcription analysis for the hap4 Delta and the wild type, grown in carbon-limited chemostat cultures operated at a dilution rate of 0.05 h(-1). Although both strains exhibited respiratory metabolism, there was significant change in expression of many genes in the hap4 Delta strain. These genes are involved in several different parts of the metabolism, including oxidative stress response, peroxisomal functions, and energy generation. This study strongly indicates that Hap4 activation only occurs at intermediate specific growth rates, below which the transcription of genes responsible for respiration is dependent on the Hap2/3/5 complex and above which the Hap4 protein augments the transcription. Furthermore, statistical analysis of the transcription data and integration of the data with a genome scale metabolic network provided new insight and evidence for the role of Hap4 in transcriptional regulation of mitochondrial respiration.	Tech Univ Denmark, BioCentrum, Ctr Microbial Biotechnol, DK-2800 Lyngby, Denmark	Technical University of Denmark	Nielsen, J (corresponding author), Tech Univ Denmark, BioCentrum, Ctr Microbial Biotechnol, Bldg 223, DK-2800 Lyngby, Denmark.	jn@biocentrum.dtu.dk	Raghavendran, Vijay/G-6425-2015; Patil, Kiran R/B-9709-2009; Nielsen, Jens/Q-1347-2017	Raghavendran, Vijay/0000-0002-2021-2786; Patil, Kiran R/0000-0002-6166-8640; /0000-0002-0827-5442; Nielsen, Jens/0000-0002-9955-6003				Bakker BM, 2000, J BACTERIOL, V182, P4730, DOI 10.1128/JB.182.17.4730-4737.2000; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; Berkey CD, 2004, EUKARYOT CELL, V3, P311, DOI 10.1128/EC.3.2.311-317.2004; Brons JF, 2002, YEAST, V19, P923, DOI 10.1002/yea.886; Buschlen S, 2003, COMP FUNCT GENOM, V4, P37, DOI 10.1002/cfg.254; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; dos Santos MM, 2004, METAB ENG, V6, P352, DOI 10.1016/j.ymben.2004.06.002; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; Forster J, 2003, GENOME RES, V13, P244, DOI 10.1101/gr.234503; Gombert AK, 2001, J BACTERIOL, V183, P1441, DOI 10.1128/JB.183.4.1441-1451.2001; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; HESHEY JWB, 1996, TRANSLATIONAL CONTRO; Kaniak A, 2004, EUKARYOT CELL, V3, P221, DOI 10.1128/EC.3.1.221-231.2004; KAPPELI O, 1986, ADV MICROB PHYSIOL, V28, P181; Kwast KE, 1998, J EXP BIOL, V201, P1177; Lascaris R, 2004, MICROBIOL-SGM, V150, P929, DOI 10.1099/mic.0.26742-0; LEI F, 2001, THESIS TU DENMARK LY; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Liu WD, 2002, EUR J BIOCHEM, V269, P3560, DOI 10.1046/j.1432-1033.2002.03047.x; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; Machado CR, 1997, J MOL BIOL, V273, P114, DOI 10.1006/jmbi.1997.1302; Overkamp KM, 2000, J BACTERIOL, V182, P2823, DOI 10.1128/JB.182.10.2823-2830.2000; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Patil KR, 2005, P NATL ACAD SCI USA, V102, P2685, DOI 10.1073/pnas.0406811102; Pinkham JL, 1997, CURR GENET, V31, P281, DOI 10.1007/s002940050207; Poyton RO, 1999, RESP PHYSIOL, V115, P119, DOI 10.1016/S0034-5687(99)00028-6; Rao AU, 2005, P NATL ACAD SCI USA, V102, P4270, DOI 10.1073/pnas.0500877102; Seino A, 2005, BBA-GENE STRUCT EXPR, V1681, P166, DOI 10.1016/j.bbaexp.2004.11.009; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Stebbins JL, 2004, EUKARYOT CELL, V3, P339, DOI 10.1128/EC.3.2.339-347.2004; Tai SL, 2005, J BIOL CHEM, V280, P437, DOI 10.1074/jbc.M410573200; van Maris AJA, 2001, FEMS YEAST RES, V1, P139, DOI 10.1016/S1567-1356(01)00022-8; VERDUYN C, 1990, J GEN MICROBIOL, V136, P405, DOI 10.1099/00221287-136-3-405; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; Westergaard SL, 2004, FEMS YEAST RES, V5, P193, DOI 10.1016/j.femsyr.2004.06.013; ZITOMER RS, 1992, MICROBIOL REV, V56, P1; ZOLLNER A, 1994, CURR GENET, V25, P291, DOI 10.1007/BF00351480	38	27	27	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12308	12314		10.1074/jbc.M512972200	http://dx.doi.org/10.1074/jbc.M512972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522629	hybrid			2022-12-25	WOS:000237134700015
J	Wada, K; Nakajima, A; Katayama, K; Kudo, C; Shibuya, A; Kubota, N; Terauchi, Y; Tachibana, M; Miyoshi, H; Kamisaki, Y; Mayumi, T; Kadowaki, T; Blumberg, RS				Wada, K; Nakajima, A; Katayama, K; Kudo, C; Shibuya, A; Kubota, N; Terauchi, Y; Tachibana, M; Miyoshi, H; Kamisaki, Y; Mayumi, T; Kadowaki, T; Blumberg, RS			Peroxisome proliferator-activated receptor gamma-mediated regulation of neural stem cell proliferation and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; INSULIN-RESISTANCE; PROGENITOR CELLS; GROWTH-FACTOR; CYCLE CONTROL; LIGANDS; KINASE; CANCER; MICE; MECHANISMS	Peroxisome proliferator-activated receptor gamma ( PPAR gamma) plays an important role in insulin sensitivity, tissue homeostasis, and regulating cellular functions. We found high-level expression of PPAR gamma in embryo mouse brain and neural stem cells (NSCs), in contrast to extremely low levels in adult mouse brain. Here, we show that PPAR gamma mediates the proliferation and differentiation of murine NSCs via up-regulation of the epidermal growth factor receptor and activation of the ERK pathway. Cell growth rates of NSCs prepared from heterozygous PPAR gamma-deficient mouse brains, PPAR gamma-RNA-silenced NSCs, and PPAR gamma dominant-negative NSCs were significantly decreased compared with those of wild-type NSCs. Physiological concentrations of PPAR gamma agonists, rosiglitazone and pioglitazone, stimulated NSC growth, whereas antagonists caused cell death in a concentration-dependent manner via activation of the caspase cascade. The stimulation of cell growth by PPAR gamma was associated with a rapid activation of the ERK pathway by phosphorylation and up-regulation of epidermal growth factor receptor and cyclin B protein levels. In contrast, activation of PPAR gamma by agonists inhibited the differentiation of NSCs into neurons. The inhibition of differentiation was associated with an activation of STAT3. These data indicate that PPAR gamma regulates the development of the central nervous system during early embryogenesis via control of NSC proliferation.	Osaka Univ, Grad Sch Dent, Dept Pharmacol, Suita, Osaka 5650871, Japan; Brigham & Womens Hosp, Dept Med, Div Gastroenterol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Yokohama City Univ, Sch Med, Dept Internal Med 3, Yokohama, Kanagawa 2360004, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Suita, Osaka 5650871, Japan; Univ Tokyo, Bunkyo Ku, Dept Metab Dis, Grad Sch Med, Tokyo 1130033, Japan; Tsukuba Inst, RIKEN, BioResource Ctr, Subteam Manipulat Cell Fate, Ibaraki 3050074, Japan	Osaka University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yokohama City University; Osaka University; University of Tokyo; RIKEN	Wada, K (corresponding author), Osaka Univ, Grad Sch Dent, Dept Pharmacol, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	kwada@dent.osaka-u.ac.jp	Mayumi, Toshihiko/AAC-7418-2019; Terauchi, Yasuo/AAO-4347-2020; Kubota, Naoto/N-7892-2015; Miyoshi, Hiroyuki/G-9808-2013	Tachibana, Masashi/0000-0002-0376-508X	NIDDK NIH HHS [DK44319, DK53056, DK51362] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044319, R01DK044319, R01DK053056, R01DK051362] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; Chang TH, 2000, CANCER RES, V60, P1129; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GRANA X, 1995, ONCOGENE, V11, P211; Gritti A, 1996, J NEUROSCI, V16, P1091; Han SW, 2001, CLIN CANCER RES, V7, P98; HANAOKATAHARA S, 2002, EXP HEMATOL, V30, P11; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Katayama K, 2003, GASTROENTEROLOGY, V124, P1315, DOI 10.1016/S0016-5085(03)00262-2; Katayama K, 2004, FEBS LETT, V560, P178, DOI 10.1016/S0014-5793(04)00100-0; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kudo C, 2004, J NEUROCHEM, V88, P1416, DOI 10.1046/j.1471-4159.2003.02270.x; LEBRASSEUR NK, 2006, AM J PHYSL ENDOCRINO; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Reh TA, 2002, NAT NEUROSCI, V5, P392, DOI 10.1038/nn0502-392; Rokos CL, 1997, J BIOL CHEM, V272, P13452, DOI 10.1074/jbc.272.20.13452; Saha AK, 2004, BIOCHEM BIOPH RES CO, V314, P580, DOI 10.1016/j.bbrc.2003.12.120; Shiojiri T, 2002, EUR J PHARMACOL, V448, P231, DOI 10.1016/S0014-2999(02)01946-5; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Torii MA, 1999, DEVELOPMENT, V126, P443; Toyota M, 2002, LIFE SCI, V70, P1565, DOI 10.1016/S0024-3205(01)01524-7; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Zander T, 2002, J NEUROCHEM, V81, P1052, DOI 10.1046/j.1471-4159.2002.00899.x	38	140	149	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12673	12681		10.1074/jbc.M513786200	http://dx.doi.org/10.1074/jbc.M513786200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524877	hybrid			2022-12-25	WOS:000237134700058
J	Peeters, E; Willaert, R; Maes, D; Charlier, D				Peeters, E; Willaert, R; Maes, D; Charlier, D			Ss-LrpB from Sulfolobus solfataricus condenses about 100 base pairs of its own operator DNA into globular nucleoprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCANNING FORCE MICROSCOPY; REGULATORY PROTEIN; TRANSCRIPTIONAL REGULATOR; ESCHERICHIA-COLI; BINDING PROTEIN; EXPRESSION; FAMILY; FORMS	Ss-LrpB from the hyperthermoacidophilic crenarchaeote Sulfolobus solfataricus P2 is a member of the Lrp-like family of Bacterial/ Archaeal transcription regulators that binds its own control region at three regularly spaced and partially conserved 15-bp-long imperfect palindromes. We have used atomic force microscopy to analyze the architecture of Ss-LrpB . DNA complexes with a different stoichiometry formed with the wild type operator and with an operator mutant. Binding of dimeric Ss-LrpB to all three target sites is accompanied by the formation of globular complexes, in which the protein induces strong DNA deformations. Furthermore, DNA contour length foreshortening of these complexes indicates DNA wrapping, with about 100 bp being condensed. The average bending angle is 260 degrees. The establishment of protein-protein contacts between Ss-LrpB dimers in these globular complexes will contribute to the cooperativity of the binding. The profound remodeling of the control region is expected to have a strong impact on gene expression and might constitute the key element in the autoregulatory process.	Vrije Univ Brussel, Erfelijkheidsleer Microbiol, B-1050 Brussels, Belgium; Vrije Univ Brussel, Lab Ultrastruct, B-1050 Brussels, Belgium; Vlaams Interuniv Inst Biotechnol, B-1050 Brussels, Belgium	Vrije Universiteit Brussel; Vrije Universiteit Brussel	Charlier, D (corresponding author), Vrije Univ Brussel, Erfelijkheidsleer Microbiol, Pleinlaan 2, B-1050 Brussels, Belgium.	dcharlie@vub.ac.be		Peeters, Eveline/0000-0001-7423-8714; Maes, Dominique/0000-0002-9179-3186; Willaert, Ronnie/0000-0002-5400-7019; Charlier, Daniel/0000-0002-6844-376X				Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Beerens N, 2005, J BIOL CHEM, V280, P4722, DOI 10.1074/jbc.M409147200; Beloin C, 2003, J BIOL CHEM, V278, P5333, DOI 10.1074/jbc.M207489200; Brinkman AB, 2003, MOL MICROBIOL, V48, P287, DOI 10.1046/j.1365-2958.2003.03442.x; Brinkman AB, 2002, J BIOL CHEM, V277, P29537, DOI 10.1074/jbc.M203528200; Dame RT, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni073; Dame RT, 2005, NUCLEIC ACIDS RES, V33, P2767, DOI 10.1093/nar/gki577; Dame RT, 2003, J MICROSC-OXFORD, V212, P244, DOI 10.1111/j.1365-2818.2003.01243.x; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; Enoru-Eta J, 2002, MOL MICROBIOL, V45, P1541, DOI 10.1046/j.1365-2958.2002.03136.x; Geiduschek EP, 2005, MOL MICROBIOL, V56, P1397, DOI 10.1111/j.1365-2958.2005.04627.x; Heddle JG, 2004, J MOL BIOL, V337, P597, DOI 10.1016/j.jmb.2004.01.049; Jafri S, 2002, J BACTERIOL, V184, P5293, DOI 10.1128/JB.184.19.5293-5300.2002; Jafri S, 1999, J MOL BIOL, V288, P811, DOI 10.1006/jmbi.1999.2715; Koike H, 2004, P NATL ACAD SCI USA, V101, P2840, DOI 10.1073/pnas.0400109101; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; Leonard PM, 2001, EMBO J, V20, P990, DOI 10.1093/emboj/20.5.990; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; Napoli A, 1999, J BACTERIOL, V181, P1474, DOI 10.1128/JB.181.5.1474-1480.1999; Napoli A, 2001, J BIOL CHEM, V276, P10745, DOI 10.1074/jbc.M010611200; NEWMAN EB, 1995, ANNU REV MICROBIOL, V49, P747, DOI 10.1146/annurev.mi.49.100195.003531; Ouhammouch M, 2001, EMBO J, V20, P146, DOI 10.1093/emboj/20.1.146; Peeters E, 2004, MOL MICROBIOL, V54, P321, DOI 10.1111/j.1365-2958.2004.04274.x; Ratcliff GC, 2001, J AM CHEM SOC, V123, P5632, DOI 10.1021/ja005750n; Rivetti C, 1996, J MOL BIOL, V264, P919, DOI 10.1006/jmbi.1996.0687; Rivetti C, 1999, EMBO J, V18, P4464, DOI 10.1093/emboj/18.16.4464; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Xue Y, 2002, BIOCHEMISTRY-US, V41, P2901, DOI 10.1021/bi0157161; Yang Y, 2003, METHODS, V29, P175, DOI 10.1016/S1046-2023(02)00308-0; ZILLIG W, 1980, ARCH MICROBIOL, V125, P259, DOI 10.1007/BF00446886	32	20	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11721	11728		10.1074/jbc.M600383200	http://dx.doi.org/10.1074/jbc.M600383200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16522627	hybrid			2022-12-25	WOS:000236988100036
J	Sastry, SK; Rajfur, Z; Liu, BP; Cote, JF; Tremblay, ML; Burridge, K				Sastry, SK; Rajfur, Z; Liu, BP; Cote, JF; Tremblay, ML; Burridge, K			PTP-PEST couples membrane protrusion and tail retraction via VAV2 and p190RhoGAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; RHO-GTPASES; RAC ACTIVATION; CELL-ADHESION; C-SRC; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; PROTEIN; SUBSTRATE; MIGRATION	Cell motility is regulated by a balance between forward protrusion and tail retraction. These phenomena are controlled by a spatial asymmetry in signals at the front and the back of the cell. We show here that the protein-tyrosine phosphatase, PTP-PEST, is required for the coupling of protrusion and retraction during cell migration. PTP-PEST null fibroblasts, which are blocked in migration, exhibit exaggerated protrusions at the leading edge and long, unretracted tails in the rear. This altered morphology is accompanied by changes in the activity of Rho GTPases, Rac1 and RhoA, which mediate protrusion and retraction, respectively. PTP-PEST null cells exhibit enhanced Rac1 activity and decreased RhoA activity. We further show that PTP-PEST directly targets the upstream regulators of Rac1 and RhoA, VAV2 and p190RhoGAP. Moreover, we demonstrate that the activities of VAV2 and p190RhoGAP are regulated by PTP-PEST. Finally, we present evidence indicating the VAV2 can be regulated by integrin-mediated adhesion. These data suggest that PTP-PEST couples protrusion and retraction by acting on VAV2 and p190RhoGAP to reciprocally modulate the activity of Rac1 and RhoA.	Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA; Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; McGill Univ, Dept Biochem, Montreal, PQ H2W 1R7, Canada; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of Texas System; University of Texas Medical Branch Galveston; Yale University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Sastry, SK (corresponding author), Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	sasastry@utmb.edu	Sastry, Sarita/A-1291-2013; Rajfur, Zenon/H-2506-2013	Rajfur, Zenon/0000-0003-1265-6480	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Brahmbhatt AA, 2003, J BIOL CHEM, V278, P13016, DOI 10.1074/jbc.M211873200; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Cote JF, 2005, NAT CELL BIOL, V7, P797, DOI 10.1038/ncb1280; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gardiner EM, 2002, CURR BIOL, V12, P2029, DOI 10.1016/S0960-9822(02)01334-9; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; HART M, 1995, METHOD ENZYMOL, V255, P129; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jamieson JS, 2005, J CELL SCI, V118, P5835, DOI 10.1242/jcs.02693; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Lyons PD, 2001, J BIOL CHEM, V276, P24422, DOI 10.1074/jbc.M011080200; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sastry SK, 2002, J CELL SCI, V115, P4305, DOI 10.1242/jcs.00105; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200	66	53	56	1	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11627	11636		10.1074/jbc.M600897200	http://dx.doi.org/10.1074/jbc.M600897200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513648	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000236988100026
J	Tomikawa, J; Fukatsu, K; Tanaka, S; Shiota, K				Tomikawa, J; Fukatsu, K; Tanaka, S; Shiota, K			DNA methylation-dependent epigenetic regulation of dimethylarginine dimethylaminohydrolase 2 gene in trophoblast cell lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MESSENGER-RNA; MOUSE EMBRYO; EXPRESSION; DEMETHYLATION; STEM; UNDERMETHYLATION; EMBRYOGENESIS; TRANSCRIPTION; LOCALIZATION	Trophoblast cell lineage is established through the first cellular differentiation in mammalian embryogenesis, and its developmental potential is restricted to the extraembryonic tissues contributing solely to the placenta. Several lines of evidence suggest a relative lack of importance of DNA methylation in gene regulation in the extraembryonic tissues when compared with embryonic ones. Here we analyzed the dynamics of epigenetic status in the upstream region of mouse Ddah2 gene, which was found to be specifically repressed in a stem cell population of trophoblast cell lineage. We found a tissue-dependent differentially methylated region in the regulatory region of the Ddah2 gene. This region was hypermethylated in trophoblast stem cells and was hypomethylated in differentiated cells both in vivo and in vitro. This change was well correlated with Ddah2 expression. In addition, in vitro methylation confined to the differentially methylated region was sufficient to repress promoter activity in the reporter assay. Furthermore, a repressive pattern of histone modifications was formed around the differentially methylated region in undifferentiated trophoblast stem cells with repressed Ddah2. Our data suggest that DNA methylation-mediated chromatin remodeling is involved in the regulation of the Ddah2 gene expression and thus is important even in trophoblast cell lineage.	Univ Tokyo, Lab Cellular Biochem Anim Resource Sci Vet Med Sc, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Tanaka, S (corresponding author), Univ Tokyo, Lab Cellular Biochem Anim Resource Sci Vet Med Sc, Bunkyo Ku, Tokyo 1138657, Japan.	asatoshi@mail.ecc.u-tokyo.ac.jp		Tanaka, Satoshi/0000-0002-4745-550X; Tomikawa, Junko/0000-0002-6149-1400				Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Chan Y, 2004, J BIOL CHEM, V279, P35087, DOI 10.1074/jbc.M405063200; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; COLOSI P, 1987, MOL ENDOCRINOL, V1, P767, DOI 10.1210/mend-1-11-767; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Fish JE, 2005, J BIOL CHEM, V280, P24824, DOI 10.1074/jbc.M502115200; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Gagioti S, 2000, BIOL REPROD, V62, P260, DOI 10.1095/biolreprod62.2.260; GRUENBAUM Y, 1981, FEBS LETT, V124, P67, DOI 10.1016/0014-5793(81)80055-5; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hattori N, 2004, J BIOL CHEM, V279, P17063, DOI 10.1074/jbc.M309002200; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; Jones LC, 2003, BIOCHEM BIOPH RES CO, V310, P836, DOI 10.1016/j.bbrc.2003.09.097; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; MacAllister RJ, 1996, BRIT J PHARMACOL, V119, P1533, DOI 10.1111/j.1476-5381.1996.tb16069.x; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; Nishino K, 2004, J BIOL CHEM, V279, P22306, DOI 10.1074/jbc.M309513200; Ohgane J, 2002, BIOCHEM BIOPH RES CO, V290, P701, DOI 10.1006/bbrc.2001.6258; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; ROSSANT J, 1986, DEV BIOL, V117, P567, DOI 10.1016/0012-1606(86)90325-8; Sado T, 2000, DEV BIOL, V225, P294, DOI 10.1006/dbio.2000.9823; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shiota K, 2002, GENES CELLS, V7, P961, DOI 10.1046/j.1365-2443.2002.00574.x; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tanaka M, 1999, MECH DEVELOP, V87, P129, DOI 10.1016/S0925-4773(99)00158-6; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Tran CTL, 2000, GENOMICS, V68, P101, DOI 10.1006/geno.2000.6262; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400	36	47	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					12163	12169		10.1074/jbc.M513782200	http://dx.doi.org/10.1074/jbc.M513782200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16520373	hybrid			2022-12-25	WOS:000236988100086
J	Rodriguez, JA; Lens, SMA; Span, SW; Vader, G; Medema, RH; Kruyt, FAE; Giaccone, G				Rodriguez, J. A.; Lens, S. M. A.; Span, S. W.; Vader, G.; Medema, R. H.; Kruyt, F. A. E.; Giaccone, G.			Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown	ONCOGENE			English	Article						Survivin; Borealin; INCENP; Aurora B; nuclear envelope breakdown; nuclear transport	B KINASE-ACTIVITY; AURORA-B; EXPORT SIGNALS; SURVIVIN; INCENP; SPINDLE; CANCER; EXPRESSION; CENTROMERE; PHOSPHORYLATION	As mitosis progresses, the chromosomal passenger proteins (CPPs) Survivin, Aurora B, INCENP and Borealin dynamically colocalize to mitotic structures. Chromosomal passenger proteins are already expressed during G2, whereas the nuclear envelope is only disassembled at the end of prophase. However, the mechanisms that modulate their nucleocytoplasmic localization before nuclear envelope breakdown (NEB) are poorly characterized. Using epitope-tagged proteins, we show that Aurora B, like Survivin, undergoes CRM1-mediated nucleocytoplasmic shuttling, although both proteins lack identifiable 'classical' nuclear transport signals. On the other hand, INCENP resides more stably in the nucleus and contains multiple nuclear localization signals. Finally, Borealin was detected in the nucleolus and the cytoplasm, but its cytoplasmic localization is not directly regulated by CRM1. Coexpression experiments indicate that the nuclear localization of Aurora B, but not of Survivin, is modulated by INCENP and that Survivin prevents the nucleolar accumulation of Borealin. Our data reveal that, in contrast to their closely related localization during mitosis, the nucleocytoplasmic localization of the CPPs before NEB is largely unrelated. Furthermore, the specific effect of INCENP and Survivin on the localization of Aurora B and Borealin, respectively, suggests that different complexes of CPPs may exist not only during mitosis, as recently reported, but also before NEB.	Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Netherlands Cancer Institute	Rodriguez, JA (corresponding author), Vrije Univ Amsterdam, Dept Med Oncol, Med Ctr, Acad Hosp, KRIGO BR232,Postbus 7057, NL-1007 MB Amsterdam, Netherlands.	ja.rodriguez@vumc.nl	Giaccone, Giuseppe/E-8297-2017; Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011; Rodriguez, Jose Antonio/AAA-1125-2019	Giaccone, Giuseppe/0000-0002-5023-7562; Rodriguez, Jose Antonio/0000-0002-2823-3733; Vader, Gerben/0000-0001-5729-0991; Kruyt, Frank/0000-0002-2445-9380; Medema, Rene/0000-0002-6754-0381				Adams RR, 2001, CHROMOSOMA, V110, P65, DOI 10.1007/s004120100130; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Altura RA, 2003, BRIT J CANCER, V89, P1743, DOI 10.1038/sj.bjc.6601334; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Arnaoutov A, 2005, NAT CELL BIOL, V7, P626, DOI 10.1038/ncb1263; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Burke B, 2002, NAT REV MOL CELL BIO, V3, P487, DOI 10.1038/nrm860; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Krysan K, 2004, FASEB J, V18, P205, DOI 10.1096/fj.03-0369fje; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Mahotka C, 1999, CANCER RES, V59, P6097; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rodriguez JA, 2002, EXP CELL RES, V275, P44, DOI 10.1006/excr.2002.5492; Rodriguez JA, 2004, ONCOGENE, V23, P1809, DOI 10.1038/sj.onc.1207302; Saffery R, 1999, MAMM GENOME, V10, P415, DOI 10.1007/s003359901014; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Song JX, 2005, IMMUNITY, V22, P621, DOI 10.1016/j.immuni.2005.03.012; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tonini G, 2005, BRIT J CANCER, V92, P2225, DOI 10.1038/sj.bjc.6602632; Vader G, 2006, EMBO REP, V7, P85, DOI 10.1038/sj.embor.7400562; Vischioni B, 2004, ANN ONCOL, V15, P1654, DOI 10.1093/annonc/mdh436; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200	43	28	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4867	4879		10.1038/sj.onc.1209499	http://dx.doi.org/10.1038/sj.onc.1209499			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547492				2022-12-25	WOS:000239687100005
J	Jin, A; Kurosu, T; Tsuji, K; Mizuchi, D; Arai, A; Fujita, H; Hattori, M; Minato, N; Miura, O				Jin, A.; Kurosu, T.; Tsuji, K.; Mizuchi, D.; Arai, A.; Fujita, H.; Hattori, M.; Minato, N.; Miura, O.			BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion	ONCOGENE			English	Article						BCR/ABL; IL-3; Rap1; B-Raf; Akt; adhesion	CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC-CELL ADHESION; KINASE-ACTIVITY; BCR-ABL; ERYTHROPOIETIN RECEPTOR; PROGENITOR CELLS; EXCHANGE FACTOR; CYCLIC-AMP; PROTEINS	The Ras family small GTPase Rap1 is activated by hematopoietic cytokines, such as interleukin (IL)-3, to induce beta 1 integrin-mediated cell adhesion or by the BCR/ABL fusion tyrosine kinase to stimulate the MEK/Erk signaling pathway. Here, we demonstrate that the abrogation of Rap1 activation by SPA-1, a Rap1-specific GAP, inhibits activation of B-Raf, MEK, Erk, and Akt in a murine hematopoietic cell line, Ton.B210, stimulated with IL-3 or inducibly expressing BCR/ABL. Furthermore, Rap1 inactivation had an inhibitory effects on proliferation and survival of Ton.B210 cells, which were more remarkable when cells were stimulated by BCR/ABL than by IL-3. Induction of BCR/ABL expression increased adhesion of Ton.B210 cells to fibronectin in a manner at least partly dependent on its kinase activity, and Rap1 inhibition by SPA-1 partially inhibited BCR/ABL-induced adhesion of cells. Thus, IL-3- or BCR/ABL-induced activation of Rap1 may play important roles in regulation of cell proliferation and survival through activation of the B-Raf/MEK/Erk and Akt signaling pathways and in induction of integrin-mediated cell adhesion. Furthermore, as compared with IL-3, BCR/ABL is more dependent on Rap1-mediated signaling to induce cell proliferation and survival and, thus, Rap1 may represent an attractive target for novel therapies for leukemias caused by BCR/ABL.	Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, Tokyo 1138519, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Immunol & Cell Biol, Kyoto, Japan	Tokyo Medical & Dental University (TMDU); Kyoto University	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	miura.hema@tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054; Fujita, Harumi/0000-0003-2133-845X				Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Barnes DJ, 2005, ONCOGENE, V24, P6432, DOI 10.1038/sj.onc.1208796; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bhatia R, 2001, BRIT J HAEMATOL, V115, P845, DOI 10.1046/j.1365-2141.2001.03192.x; Bondzi C, 2000, ONCOGENE, V19, P5030, DOI 10.1038/sj.onc.1203862; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Christian SL, 2003, J BIOL CHEM, V278, P41756, DOI 10.1074/jbc.M303180200; Clarkson B, 2003, LEUKEMIA, V17, P1211, DOI 10.1038/sj.leu.2402912; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Hattori M, 2003, J BIOCHEM, V134, P479, DOI 10.1093/jb/mvg180; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klein S, 2005, NAT REV CANCER, V5, P573, DOI 10.1038/nrc1651; Klejman A, 2002, ONCOGENE, V21, P5868, DOI 10.1038/sj.onc.1205724; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Kometani K, 2004, TRENDS MOL MED, V10, P401, DOI 10.1016/j.molmed.2004.06.004; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200; Marley SB, 2004, BRIT J HAEMATOL, V125, P500, DOI 10.1111/j.1365-2141.2004.04933.x; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; Mizuchi D, 2005, BIOCHEM BIOPH RES CO, V326, P645, DOI 10.1016/j.bbrc.2004.11.086; Papin C, 1996, ONCOGENE, V12, P2213; PIZON V, 1988, ONCOGENE, V3, P201; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stork PJS, 2005, BLOOD, V106, P2952, DOI 10.1182/blood-2005-03-1062; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wertheim JA, 2003, BLOOD, V102, P2220, DOI 10.1182/blood-2003-01-0062; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122	47	45	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4332	4340		10.1038/sj.onc.1209459	http://dx.doi.org/10.1038/sj.onc.1209459			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518411				2022-12-25	WOS:000239240100008
J	Yeh, HH; Lai, WW; Chen, HHW; Liu, HS; Su, WC				Yeh, H-H; Lai, W-W; Chen, H. H. W.; Liu, H-S; Su, W-C			Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion	ONCOGENE			English	Article						malignant pleural effusion; lung cancer; IL-6; Stat3; VEGF	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; CANCER CELL-LINES; TUMOR ANGIOGENESIS; MOLECULAR TARGETS; CARCINOMA CELLS; FACTOR RECEPTOR; INTERLEUKIN-6; EXPRESSION; CYTOKINES	Malignant pleural effusion (MPE) is a poor prognostic sign for patients with non-small-cell lung cancer (NSCLC). The generation of MPE is largely regulated by vascular endothelial growth factor (VEGF), and upregulation of VEGF by Stat3 has been observed in several types of tumor cells. In this study, we demonstrate constitutively activated Stat3 in several human lung cancer cell lines and in tumor cells infiltrated in the pleurae of patients with adenocarcinoma cell lung cancer (ADCLC) and MPE. The observations suggest that activated Stat3 plays a role in the pathogenesis of ADCLC. In PC14PE6/AS2 cells, a Stat3-positive human ADCLC cell line, autocrine IL-6 activated Stat3 via JAKs, not via Src kinase. PC14PE6/AS2 cells express higher VEGF mRNA and protein than do Stat3-negative PC14PE6/AS2/dnStat3 cells. In an animal model, PC14P6/AS2/dnStat3 cells produced no MPE and less lung metastasis than did PC14P6/AS2 cells. PC14PE6/AS2 cells also expressed higher VEGF protein, microvessel density , and vascular permeability in tumors than did PC14P6/AS2/dnStat3 cells. Therefore, we hypothesize that autocrine IL-6 activation of Stat3 in ADCLC may be involved in the formation of malignant pleural effusion by upregulating VEGF. Higher levels of IL-6 and VEGF were also found in the pleural fluids of patients with ADCLC than in patients with congestive heart failure. The autocrine IL-6/Stat3/VEGF signaling pathway may also be activated in patients with ADCLC and MPE. These findings provide novel targets for the management of MPE.	Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med,Div Hematol Oncol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg, Tainan 704, Taiwan; Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Radiotherapy, Tainan 704, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital	Su, WC (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med,Div Hematol Oncol, 138 Sheng Li Rd, Tainan 704, Taiwan.	sunnysu@mail.ncku.edu.tw	, 賴吾為/T-8615-2019	, 賴吾為/0000-0001-9174-8310; Liu, Hsiao-Sheng/0000-0003-0576-7203; Su, Wu-Chou/0000-0003-2953-4105				Alexandrakis MG, 2000, ONCOL REP, V7, P1327; ANDERSON CB, 1974, CANCER-AM CANCER SOC, V33, P916, DOI 10.1002/1097-0142(197404)33:4<916::AID-CNCR2820330405>3.0.CO;2-U; Bihl M, 1998, AM J RESP CELL MOL, V19, P606, DOI 10.1165/ajrcmb.19.4.3247; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Hoheisel G, 1998, RESPIRATION, V65, P183, DOI 10.1159/000029256; Hung TL, 2003, CLIN CANCER RES, V9, P2605; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; MEMON A, 1981, Current Problems in Cancer, V5, P1, DOI 10.1016/S0147-0272(81)80012-8; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; Naito T, 1997, ANTICANCER RES, V17, P4743; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Okamoto M, 1997, CANCER RES, V57, P141; Seki Y, 2004, INT J ONCOL, V24, P931; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Sugiura S, 1997, CLIN CANCER RES, V3, P47; Takayama K, 2000, CANCER RES, V60, P2169; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yamaguchi T, 2000, JPN J CLIN ONCOL, V30, P53, DOI 10.1093/jjco/hyd014; Yano S, 2000, AM J PATHOL, V157, P1893, DOI 10.1016/S0002-9440(10)64828-6; Yano S, 2000, CLIN CANCER RES, V6, P957; YOKOYAMA A, 1992, CHEST, V102, P1055, DOI 10.1378/chest.102.4.1055; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364	36	183	188	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4300	4309		10.1038/sj.onc.1209464	http://dx.doi.org/10.1038/sj.onc.1209464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518408				2022-12-25	WOS:000239240100005
J	Gronholm, M; Muranen, T; Toby, GG; Utermark, T; Hanemann, CO; Golemis, EA; Carpen, O				Gronholm, M.; Muranen, T.; Toby, G. G.; Utermark, T.; Hanemann, C. O.; Golemis, E. A.; Carpen, O.			A functional association between merlin and HEI10, a cell cycle regulator	ONCOGENE			English	Article						NF2; ERM; HEI10	TUMOR-SUPPRESSOR PROTEIN; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; P21-ACTIVATED KINASE; SCHWANN-CELLS; ERM PROTEINS; NF2 GENE; EZRIN; GROWTH; CYTOSKELETON	Merlin and ezrin are homologous proteins with opposite effects on neoplastic growth. Merlin is a tumor suppressor inactivated in the neurofibromatosis 2 disease, whereas upregulated ezrin expression is associated with increased malignancy. Merlin's tumor suppressor mechanism is not known, although participation in cell cycle regulation has been suggested. To characterize merlin's biological activities, we screened for molecules that would interact with merlin but not ezrin. We identified the cyclin B-binding protein and cell cycle regulator HEI10 as a novel merlin-binding partner. The interaction is mediated by the alpha-helical domain in merlin and the coiled-coil domain in HEI10 and requires conformational opening of merlin. The two proteins show partial subcellular colocalization, which depends on cell cycle stage and cell adhesion. Comparison of Schwann cells and schwannoma cultures demonstrated that the distribution of HEI10 depends on merlin expression. In transfected cells, a constitutively open merlin construct affected HEI10 protein integrity. These results link merlin to the cell cycle control machinery and may help to understand its tumor suppressor function.	Univ Helsinki, Program Neurosci, Biomed Helsinki, Dept Pathol, Helsinki 00014, Finland; Helsinki Univ Hosp, Helsinki 00014, Finland; Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA USA; Univ Ulm, Dept Neurol, D-7900 Ulm, Germany; Peninsula Med Sch, Clin Neurobiol, Inst Clin & Biomed Sci, Plymouth, Devon, England; Turku Univ, Dept Pathol, Turku, Finland; Turku Univ Hosp, FIN-20520 Turku, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Fox Chase Cancer Center; Ulm University; University of Plymouth; University of Turku; University of Turku	Gronholm, M (corresponding author), Univ Helsinki, Program Neurosci, Biomed Helsinki, Dept Pathol, Haartmanink 8,PB 63, Helsinki 00014, Finland.	mikaela.gronholm@helsinki.fi	Gronholm, Mikaela/B-4225-2010; Muranen, Taru/AAM-9349-2021; Hanemann, C Oliver/AAV-6257-2020	Hanemann, C Oliver/0000-0002-1951-1025; Muranen, Taru/0000-0003-4158-9002; Golemis, Erica/0000-0003-3618-3673; Gronholm, Mikaela/0000-0002-2378-8924				Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chambers DN, 2005, BIOCHEMISTRY-US, V44, P3926, DOI 10.1021/bi0480382; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Geiger KD, 2000, AM J PATHOL, V157, P1785, DOI 10.1016/S0002-9440(10)64816-X; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 2003, J BIOL CHEM, V278, P41167, DOI 10.1074/jbc.M306149200; Gronholm M, 1999, J CELL SCI, V112, P895; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hanemann CO, 1998, GLIA, V23, P89, DOI 10.1002/(SICI)1098-1136(199806)23:2<89::AID-GLIA1>3.0.CO;2-Z; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Huynh DP, 1996, ONCOGENE, V13, P73; Ilmonen S, 2005, MODERN PATHOL, V18, DOI 10.1038/modpathol.3800429; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; Mine N, 2001, JPN J CANCER RES, V92, P135, DOI 10.1111/j.1349-7006.2001.tb01075.x; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Pineau P, 2003, INT J CANCER, V106, P216, DOI 10.1002/ijc.11214; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; Sainio M, 1997, J CELL SCI, V110, P2249; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Smith AP, 2004, CANCER BIOL THER, V3, P104, DOI 10.4161/cbt.3.1.661; Toby GG, 2003, MOL CELL BIOL, V23, P2109, DOI 10.1128/MCB.23.6.2109-2122.2003; Tynninen O, 2004, NEUROPATH APPL NEURO, V30, P472, DOI 10.1111/j.1365-2990.2004.00562.x; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	38	24	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4389	4398		10.1038/sj.onc.1209475	http://dx.doi.org/10.1038/sj.onc.1209475			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16532029				2022-12-25	WOS:000239326000002
J	Castellani, L; Salvati, E; Alema, S; Falcone, G				Castellani, Loriana; Salvati, Erica; Alema, Stefano; Falcone, Germana			Fine regulation of RhoA and rock is required for skeletal muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; INHIBITS MYOGENIC DIFFERENTIATION; ACTIVATED PROTEIN-KINASE; BINDING PROTEIN; GTPASES; RAC1; EXPRESSION; MYOD; RAS; DOWNSTREAM	The RhoA GTPase controls a variety of cell functions such as cell motility, cell growth, and gene expression. Previous studies suggested that RhoA mediates signaling inputs that promote skeletal myogenic differentiation. We show here that levels and activity of RhoA protein are down-regulated in both primary avian myoblasts and mouse satellite cells undergoing differentiation, suggesting that a fine regulation of this GTPase is required. In addition, ectopic expression of activated RhoA in primary quail myocytes, but not in mouse myocytes, inhibits accumulation of muscle-specific proteins and cell fusion. By disrupting RhoA signaling with specific inhibitors, we have shown that this GTPase, although required for cell identity in proliferating myoblasts, is not essential for commitment to terminal differentiation and muscle gene expression. Ectopic expression of an activated form of its downstream effector, Rock, impairs differentiation of both avian and mouse myoblasts. Conversely, Rock inhibition with specific inhibitors and small interfering RNA-mediated gene silencing leads to accelerated progression in the lineage and enhanced cell fusion, underscoring a negative regulatory function of Rock in myogenesis. Finally, we have reported that Rock acts independently from RhoA in preventing myoblast exit from the cell cycle and commitment to differentiation and may receive signaling inputs from Raf-1 kinase.	CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy; Univ Cassino, Dipartimento Sci Motorie & Salute, I-03043 Cassino, FR, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Cassino	Falcone, G (corresponding author), CNR, Ist Biol Cellulare, Via Ramarini 32, I-00016 Monterotondo, Italy.	alema@ibc.cnr.it; gfalcone@ibc.cnr.it	Falcone, Germana/A-3735-2016	Falcone, Germana/0000-0002-3508-7623; Castellani, Loriana/0000-0002-8519-3504; Alema, Stefano/0000-0002-9869-6354; Salvati, Erica/0000-0002-3373-7442				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Betuing S, 1998, J BIOL CHEM, V273, P15804, DOI 10.1074/jbc.273.25.15804; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Charrasse S, 2003, J MUSCLE RES CELL M, V24, P309; Charrasse S, 2006, MOL BIOL CELL, V17, P749, DOI 10.1091/mbc.E05-04-0284; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Dhawan J, 2004, J CELL SCI, V117, P3735, DOI 10.1242/jcs.01197; Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3; Ehrenreiter K, 2005, J CELL BIOL, V168, P955, DOI 10.1083/jcb.200409162; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; Falcone G, 2003, ONCOGENE, V22, P8302, DOI 10.1038/sj.onc.1206915; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; Grossi M, 2005, P NATL ACAD SCI USA, V102, P11313, DOI 10.1073/pnas.0505011102; Heller H, 2001, J BIOL CHEM, V276, P37307, DOI 10.1074/jbc.M103195200; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Nishiyama T, 2004, J BIOL CHEM, V279, P47311, DOI 10.1074/jbc.M403546200; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Russo S, 1997, ONCOGENE, V14, P63, DOI 10.1038/sj.onc.1200805; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vartiainen M, 2000, MOL CELL BIOL, V20, P1772, DOI 10.1128/MCB.20.5.1772-1783.2000; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Winter B, 2000, J CELL SCI, V113, P4211	43	64	66	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15249	15257		10.1074/jbc.M601390200	http://dx.doi.org/10.1074/jbc.M601390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574652	hybrid			2022-12-25	WOS:000237922200028
J	Hirashima, M; Satoh, S; Tanaka, R; Tanaka, A				Hirashima, Masumi; Satoh, Soichirou; Tanaka, Ryouichi; Tanaka, Ayumi			Pigment shuffling in antenna systems achieved by expressing prokaryotic chlorophyllide a oxygenase in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; PHOTOSYSTEM-II; PROTEIN COMPLEXES; BINDING-PROTEINS; IN-VITRO; EVOLUTION; SPINACH; CAO; OVEREXPRESSION; PHOTOSYNTHESIS	The organization of pigment molecules in photosystems is strictly determined. The peripheral antennae have both chlorophyll a and b, but the core antennae consist of only chlorophyll a in green plants. Furthermore, according to the recent model obtained from the crystal structure of light-harvesting chlorophyll a/b-protein complexes II (LHCII), individual chlorophyll-binding sites are occupied by either chlorophyll a or chlorophyll b. In this study, we succeeded in altering these pigment organizations by introducing a prokaryotic chlorophyll b synthesis gene (chlorophyllide a oxygenase (CAO)) into Arabidopsis. In these transgenic plants (Prochlirothrix hollandica CAO plants), similar to 40% of chlorophyll a of the core antenna complexes was replaced by chlorophyll b in both photosystems. Chlorophyll a/b ratios of LHCII also decreased from 1.3 to 0.8 in PhCAO plants. Surprisingly, these transgenic plants were capable of photosynthetic growth similar to wild type under low light conditions. These results indicate that chlorophyll organizations are not solely determined by the binding affinities, but they are also controlled by CAO. These data also suggest that strict organizations of chlorophyll molecules are not essential for photosynthesis under low light conditions.	Hokkaido Univ, Inst Low Temp Sci, Kita Ku, Sapporo, Hokkaido 0600819, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan	Hokkaido University; Japan Science & Technology Agency (JST)	Tanaka, A (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Kita Ku, N19 W8, Sapporo, Hokkaido 0600819, Japan.	ayumi@pop.lowtem.hokudai.ac.jp	Tanaka, Ayumi/D-9003-2012; Tanaka, Ryouichi/A-4030-2012	Tanaka, Ryouichi/0000-0002-5858-5326; Satoh, Soichirou/0000-0002-7622-1868				ANDERSON JM, 1978, FEBS LETT, V92, P227, DOI 10.1016/0014-5793(78)80760-1; APT KE, 1995, J MOL BIOL, V248, P79, DOI 10.1006/jmbi.1995.0203; Bailey S, 2001, PLANTA, V213, P794, DOI 10.1007/s004250100556; Barber J, 2000, BBA-BIOENERGETICS, V1459, P239, DOI 10.1016/S0005-2728(00)00158-4; BURKE JJ, 1978, ARCH BIOCHEM BIOPHYS, V187, P252, DOI 10.1016/0003-9861(78)90031-0; Caffarri S, 2004, BIOCHEMISTRY-US, V43, P9467, DOI 10.1021/bi036265i; Depege N, 2003, SCIENCE, V299, P1572, DOI 10.1126/science.1081397; Durnford DG, 1996, MOL GEN GENET, V253, P377, DOI 10.1007/s004380050334; Falbel TG, 1996, PLANT PHYSIOL, V112, P821, DOI 10.1104/pp.112.2.821; Fromme P, 2001, BBA-BIOENERGETICS, V1507, P5, DOI 10.1016/S0005-2728(01)00195-5; Gallie DR, 2002, NUCLEIC ACIDS RES, V30, P3401, DOI 10.1093/nar/gkf457; Garczarek L, 1998, PHOTOSYNTH RES, V56, P131, DOI 10.1023/A:1006049832657; Green BR, 1996, ANNU REV PLANT PHYS, V47, P685, DOI 10.1146/annurev.arplant.47.1.685; GROSSMAN AR, 1993, MICROBIOL REV, V57, P725, DOI 10.1128/MMBR.57.3.725-749.1993; Haldrup A, 2001, TRENDS PLANT SCI, V6, P301, DOI 10.1016/S1360-1385(01)01953-7; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; Hobe S, 2003, J BIOL CHEM, V278, P5912, DOI 10.1074/jbc.M211145200; Hofmann E, 1996, SCIENCE, V272, P1788, DOI 10.1126/science.272.5269.1788; Hoober JK, 2001, FEBS LETT, V489, P1, DOI 10.1016/S0014-5793(00)02410-8; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; Jin ES, 2003, PLANT PHYSIOL, V132, P352, DOI 10.1104/pp.102.019620; KATOH T, 1993, METHOD ENZYMOL, V214, P402; KLEIN RR, 1988, PLANT PHYSIOL, V88, P1246, DOI 10.1104/pp.88.4.1246; KROL M, 1995, PLANT PHYSIOL, V107, P873, DOI 10.1104/pp.107.3.873; KUWABARA T, 1982, PLANT CELL PHYSIOL, V23, P533, DOI 10.1093/oxfordjournals.pcp.a076378; LaRoche J, 1996, P NATL ACAD SCI USA, V93, P15244; LEECH RM, 1973, PLANT PHYSIOL, V52, P240, DOI 10.1104/pp.52.3.240; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; MAYFIELD SP, 1984, PLANTA, V161, P481, DOI 10.1007/BF00407079; Mimuro M, 2004, FEBS LETT, V556, P95, DOI 10.1016/S0014-5793(03)01383-8; Miyagawa Y, 2001, NAT BIOTECHNOL, V19, P965, DOI 10.1038/nbt1001-965; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; MULLET JE, 1980, PLANT PHYSIOL, V65, P814, DOI 10.1104/pp.65.5.814; Nagata N, 2004, PLANTA, V218, P1019, DOI 10.1007/s00425-003-1181-6; Oster U, 2000, PLANT J, V21, P305, DOI 10.1046/j.1365-313x.2000.00672.x; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; PREISS S, 1995, PLANT PHYSIOL, V107, P709, DOI 10.1104/pp.107.3.709; Satoh S, 2002, FEBS LETT, V528, P235, DOI 10.1016/S0014-5793(02)03320-3; Satoh S, 2001, J BIOL CHEM, V276, P4293, DOI 10.1074/jbc.M008238200; Steglich C, 2003, FEBS LETT, V553, P79, DOI 10.1016/S0014-5793(03)00971-2; SUKENIK A, 1987, NATURE, V327, P704, DOI 10.1038/327704a0; Tanaka A, 1997, PLANT CELL PHYSIOL, V38, P17, DOI 10.1093/oxfordjournals.pcp.a029080; Tanaka A, 1998, P NATL ACAD SCI USA, V95, P12719, DOI 10.1073/pnas.95.21.12719; TANAKA A, 1987, PLANT CELL PHYSIOL, V28, P1537; Tanaka R, 2003, PLANT CELL PHYSIOL, V44, P1266, DOI 10.1093/pcp/pcg172; Tanaka R, 2001, PLANT J, V26, P365, DOI 10.1046/j.1365-313X.2001.2641034.x; TANAKA Y, 1992, PLANT PHYSIOL BIOCH, V30, P123; Ting CS, 2002, TRENDS MICROBIOL, V10, P134, DOI 10.1016/S0966-842X(02)02319-3; Tomitani A, 1999, NATURE, V400, P159, DOI 10.1038/22101; Xu H, 2001, P NATL ACAD SCI USA, V98, P14168, DOI 10.1073/pnas.251530298; Yamasato A, 2005, PLANT CELL, V17, P1585, DOI 10.1105/tpc.105.031518	52	68	74	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15385	15393		10.1074/jbc.M602903200	http://dx.doi.org/10.1074/jbc.M602903200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574646	hybrid			2022-12-25	WOS:000237922200044
J	Novitskaya, V; Makarava, N; Bellon, A; Bocharova, OV; Bronstein, IB; Williamson, RA; Baskakov, IV				Novitskaya, Vera; Makarava, Natallia; Bellon, Anne; Bocharova, Olga V.; Bronstein, Igor B.; Williamson, R. Anthony; Baskakov, Ilia V.			Probing the conformation of the prion protein within a single amyloid fibril using a novel immunoconformational assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; MOLECULAR CLASSIFICATION; PHYSICAL-PROPERTIES; N-TERMINUS; IN-VITRO; STRAIN; PRPSC; BSE; ANTIBODIES; FEATURES	The coexistence of multiple strains or subtypes of the disease-related isoform of prion protein ( PrP) in natural isolates, together with the observed conformational heterogeneity of PrP amyloid fibrils generated in vitro, indicates the importance of probing the conformation of single particles within heterogeneous samples. Using an array of PrP-specific antibodies, we report the development of a novel immunoconformational assay. Uniquely, application of this new technology allows the conformation of multimeric PrP within a single fibril or particle to be probed without pretreatment of the sample with proteinase K. Using amyloid fibrils prepared from full-length recombinant PrP, we demonstrated the utility of this assay to define ( i) PrP regions that are surface-exposed or buried, ( ii) the susceptibility of defined PrP regions to GdnHCl-induced denaturation, and ( iii) the conformational heterogeneity of PrP fibrils as measured for either the entire fibrillar population or for individual fibrils. Specifically, PrP regions 159 - 174 and 224 230 were shown to be buried and were the most resistant to denaturation. The 132 - 156 segment of PrP was found to be cryptic under native conditions and solvent-exposed under partially denaturing conditions, whereas the region 95 - 105 was solvent-accessible regardless of the solvent conditions. Remarkably, a subfraction of fibrils showed immunoreactivity to PrPSc-specific antibodies designated as IgGs 89 - 112 and 136 - 158. The immunoreactivity of the conformational epitopes was reduced upon exposure to partially denaturing conditions. Unexpectedly, PrPSc-specific antibodies revealed conformational polymorphisms even within individual fibrils. Our studies provide valuable new insight into fibrillar substructure and offer a new tool for probing the conformation of single PrP fibrils.	Univ Maryland, Ctr Med Biotechnol, Inst Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Compton Lab, Inst Anim Hlth, Compton RG20 7NN, England	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Scripps Research Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Baskakov, IV (corresponding author), Univ Maryland, Ctr Med Biotechnol, Inst Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA.	Baskakov@umbi.umd.edu	Bocharova, Olga V./J-8284-2018	Bocharova, Olga V./0000-0002-5056-1506	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045585] Funding Source: NIH RePORTER; NIA NIH HHS [AG004243] Funding Source: Medline; NINDS NIH HHS [NS045585] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson M, 2006, J MOL BIOL, V358, P580, DOI 10.1016/j.jmb.2006.02.007; Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Bellon A, 2003, J GEN VIROL, V84, P1921, DOI 10.1099/vir.0.18996-0; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; Bocharova OV, 2005, PROTEIN SCI, V14, P1222, DOI 10.1110/ps.041186605; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Chan JCC, 2005, BIOCHEMISTRY-US, V44, P10669, DOI 10.1021/bi050724t; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Khalili-Shirazi A, 2005, J GEN VIROL, V86, P2635, DOI 10.1099/vir.0.80375-0; Korth C, 2003, P NATL ACAD SCI USA, V100, P4784, DOI 10.1073/pnas.2627989100; Kuczius T, 1999, MOL MED, V5, P406, DOI 10.1007/BF03402129; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Leclerc E, 2001, EMBO J, V20, P1547, DOI 10.1093/emboj/20.7.1547; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Legname G, 2005, P NATL ACAD SCI USA, V102, P2168, DOI 10.1073/pnas.0409079102; Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102; Manuelidis L, 1997, SCIENCE, V277, P94, DOI 10.1126/science.277.5322.94; May BCH, 2004, TRENDS BIOCHEM SCI, V29, P162, DOI 10.1016/j.tibs.2004.02.008; Moroncini G, 2004, P NATL ACAD SCI USA, V101, P10404, DOI 10.1073/pnas.0403522101; Notari S, 2004, J BIOL CHEM, V279, P16797, DOI 10.1074/jbc.M313220200; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Polymenidou M, 2005, LANCET NEUROL, V4, P805, DOI 10.1016/S1474-4422(05)70225-8; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Ritter C, 2005, NATURE, V435, P844, DOI 10.1038/nature03793; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Safar JG, 2002, NAT BIOTECHNOL, V20, P1147, DOI 10.1038/nbt748; Schoch G, 2006, PLOS MED, V3, P236, DOI 10.1371/journal.pmed.0030014; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Tomzig A, 2004, J BIOL CHEM, V279, P33847, DOI 10.1074/jbc.M403730200; Tremblay P, 2004, J VIROL, V78, P2088, DOI 10.1128/JVI.78.4.2088-2099.2004; Yull HM, 2006, AM J PATHOL, V168, P151, DOI 10.2353/ajpath.2006.050766	40	59	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15536	15545		10.1074/jbc.M601349200	http://dx.doi.org/10.1074/jbc.M601349200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16569635	hybrid			2022-12-25	WOS:000237922200060
J	Zimmerman, TL; Thevananther, S; Ghose, R; Burns, AR; Karpen, SJ				Zimmerman, Tracy L.; Thevananther, Sundararajah; Ghose, Romi; Burns, Alan R.; Karpen, Saul J.			Nuclear export of retinoid X receptor alpha in response to interleukin-1 beta-mediated cell signaling - Roles for JNK and Ser(260)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACUTE-PHASE RESPONSE; VITAMIN-D-RECEPTOR; ANION TRANSPORTERS; ACID RECEPTORS; BILE-ACIDS; PHOSPHORYLATION; LIVER; EXPRESSION; CYTOKINES	As the obligate heterodimer partner to class II nuclear receptors, the retinoid X receptor alpha( RXR alpha) plays a vital physiological role in the regulation of multiple hepatic functions, including bile formation, intermediary metabolism, and endobiotic/xenobiotic detoxification. Many RXR alpha-regulated genes are themselves suppressed in inflamed liver via unknown mechanisms, which constitute a substantial component of the negative hepatic acute phase response. In this study we show that RXR alpha, generally considered a stable nuclear resident protein, undergoes rapid nuclear export in response to signals initiated by the pro-inflammatory cytokine interleukin-1 beta( IL-1 beta), a central activator of the acute phase response. Within 30 min of exposure to IL-1 beta, nuclear levels of RXR alpha are markedly suppressed in human liver-derived HepG2 cells, temporally coinciding with its appearance in the cytoplasm. The nuclear residence of RXR alpha is maintained by inhibiting c-jun N-terminal kinase ( JNK, curcumin or SP600125) or CRM-1-mediated nuclear export ( Leptomycin B). Pretreatment with the proteasome inhibitor MG132 blocks IL-1 beta-mediated reductions in nuclear RXR alpha levels while increasing accumulation in the cytoplasm. Mutational studies identify one residue, serine 260, a JNK phosphoacceptor site whose phosphorylation status had an unknown role in RXR alpha function, as critical for IL-1 beta-mediated nuclear export of transfected human RXR alpha-green fluorescent fusion constructs. These findings indicate that inflammation-mediated cell signaling leads to rapid and profound reductions in nuclear RXR alpha levels, via a multistep, JNK-dependent mechanism involving Ser260, nuclear export, and proteasomal degradation. Thus, inflammation-meditated cell signaling targets RXR alpha for nuclear export and degradation; a potential mechanism that explains the broad suppression of RXR alpha-dependent gene expression in the inflamed liver.	Baylor Coll Med, TX Childrens Liver Ctr, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine	Karpen, SJ (corresponding author), Baylor Coll Med, TX Childrens Liver Ctr, Dept Pediat, 1 Baylor Pl, Houston, TX 77030 USA.	skarpen@bcm.tmc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338, R01DK056239] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46773] Funding Source: Medline; NIDDK NIH HHS [R01 DK056239, R01 DK056239-05, DK56239, DK56338] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Beigneux AP, 2000, J BIOL CHEM, V275, P16390, DOI 10.1074/jbc.M000953200; Bruck N, 2005, CELL SIGNAL, V17, P1229, DOI 10.1016/j.cellsig.2004.12.006; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Denson LA, 2000, J BIOL CHEM, V275, P8835, DOI 10.1074/jbc.275.12.8835; Feingold KR, 1996, J LIPID RES, V37, P223; Geier A, 2003, HEPATOLOGY, V38, P345, DOI 10.1053/jhep.2003.50317; Ghose Romi, 2004, Nucl Recept, V2, P4, DOI 10.1186/1478-1336-2-4; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hartmann G, 2002, J PHARMACOL EXP THER, V303, P273, DOI 10.1124/jpet.102.039404; Itoh M, 2002, MOL ENDOCRINOL, V16, P2382, DOI 10.1210/me.2002-0144; Karpen SJ, 2002, J HEPATOL, V36, P832, DOI 10.1016/S0168-8278(02)00129-0; Karpen SJ, 1996, J BIOL CHEM, V271, P15211, DOI 10.1074/jbc.271.25.15211; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; LEFEBVRE P, 1995, J BIOL CHEM, V270, P10806, DOI 10.1074/jbc.270.18.10806; Li D, 2002, J BIOL CHEM, V277, P31416, DOI 10.1074/jbc.M204818200; MATKOVITS T, 1995, MOL ENDOCRINOL, V9, P232, DOI 10.1210/me.9.2.232; Matsushima-Nishiwaki R, 2001, CANCER RES, V61, P7675; Morgan ET, 1997, DRUG METAB REV, V29, P1129, DOI 10.3109/03602539709002246; Moseley Richard H, 2004, Clin Liver Dis, V8, P83; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; Poulos JE, 1997, AM J PHYSIOL-GASTR L, V273, pG804, DOI 10.1152/ajpgi.1997.273.4.G804; Prufer K, 2002, MOL ENDOCRINOL, V16, P1738, DOI 10.1210/me.2001-0345; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Srinivas H, 2005, MOL CELL BIOL, V25, P1054, DOI 10.1128/MCB.25.3.1054-1069.2005; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Trauner M, 1998, J CLIN INVEST, V101, P2092, DOI 10.1172/JCI1680; Wan YJY, 2000, MOL CELL BIOL, V20, P4436, DOI 10.1128/MCB.20.12.4436-4444.2000; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	34	81	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15434	15440		10.1074/jbc.M508277200	http://dx.doi.org/10.1074/jbc.M508277200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16551633	hybrid			2022-12-25	WOS:000237922200049
J	Nomata, J; Mizoguchi, T; Tamiaki, H; Fujita, Y				Nomata, Jiro; Mizoguchi, Tadashi; Tamiaki, Hitoshi; Fujita, Yuichi			A second nitrogenase-like enzyme for bacteriochlorophyll biosynthesis - Reconstitution of chlorophyllide a reductase with purified X-protein (BchX) and YZ-protein (BchY-BchZ) from Rhodobacter capsulatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOCHLOROPHYLLIDE REDUCTASE; C-20 METHYLTRANSFERASE; ARABIDOPSIS-THALIANA; GENETIC-ANALYSIS; PHOTOSYNTHESIS; EVOLUTION; PIGMENTS; ENCODES; PATHWAY; MUTANT	In most photosynthetic organisms, the chlorin ring structure of chlorophyll a is formed by the reduction of the porphyrin D-ring by the dark-operative nitrogenase-like enzyme, protochlorophyllide reductase ( DPOR). Subsequently, the chlorin B-ring is reduced in bacteriochlorophyll biosynthesis to form a bacteriochlorin ring structure. Phenotypic analysis of mutants lacking one of three genes, bchX, bchY, or bchZ, which show significant sequence similarity to the structural genes of nitrogenase, suggests that a second nitrogenase-like enzyme is involved in the chlorin B-ring reduction. However, there is no biochemical evidence for this. Here, we report the reconstitution of chlorophyllide a reductase ( COR) with purified proteins. Two Rhodobacter capsulatus strains that overexpressed Strep-tagged BchX and BchY were isolated. Strep-tagged BchX was purified as a single polypeptide, and BchZ was co-purified with Strep-tagged BchY. When BchX and BchY-BchZ components were incubated with chlorophyllide a, ATP, and dithionite under anaerobic conditions, chlorophyllide a was converted to a new pigment with a Qy band of longer wavelength at 734 nm ( P734) in 80% acetone. The formation of P734 was dependent on ATP and dithionite. High performance liquid chromatography and mass spectroscopic analysis indicated that P734 is 3-vinyl bacteriochlorophyllide a, which is formed by the B-ring reduction of chlorophyllide a. These results demonstrate that the B-ring of chlorin is reduced by a second nitrogenase-like enzyme and that the sequential actions of two nitrogenase-like enzymes, DPOR and COR, convert porphyrin to bacteriochlorin. The evolutionary implications of nitrogenase-like enzymes to determine the ring structure of ( bacterio) chlorophyll pigments are discussed.	Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; Ritsumeikan Univ, Dept Biosci & Biotechnol, Kusatsu 5258577, Japan	Nagoya University; Ritsumeikan University	Fujita, Y (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan.	fujita@agr.nagoya-u.ac.jp	Fujita, Yuichi/G-8908-2013; Nomata, Jiro/D-1813-2015	Nomata, Jiro/0000-0001-9849-2426				[Anonymous], 2002, PHOTOSYNTHETICA; Beale SI, 2005, TRENDS PLANT SCI, V10, P309, DOI 10.1016/j.tplants.2005.05.005; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; BURKE DH, 1993, P NATL ACAD SCI USA, V90, P7134, DOI 10.1073/pnas.90.15.7134; BURKE DH, 1993, J BACTERIOL, V175, P2407, DOI 10.1128/JB.175.8.2407-2413.1993; Fujita Y, 2000, J BIOL CHEM, V275, P23583, DOI 10.1074/jbc.M002904200; Fujita Y., 2003, PORPHYRIN HDB CHLORO, P109, DOI DOI 10.1016/B978-0-08-092387-1.50010-2; Goodwin PJ, 1998, BIOCHEMISTRY-US, V37, P10420, DOI 10.1021/bi980435n; GRIFFITHS TW, 1991, CHLOROPHYLLS, P433; Harada J, 2005, FEBS LETT, V579, P1983, DOI 10.1016/j.febslet.2005.01.087; Heyes DJ, 2005, TRENDS BIOCHEM SCI, V30, P642, DOI 10.1016/j.tibs.2005.09.001; Igarashi RY, 2003, CRIT REV BIOCHEM MOL, V38, P351, DOI 10.1080/10409230390242380; Kadish K, 2003, PORPHYRIN HDB, P49; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Maresca JA, 2004, J BACTERIOL, V186, P2558, DOI 10.1128/JB.186.9.2558-2566.2004; Masuda T, 2004, PHOTOSYNTH RES, V81, P1, DOI 10.1023/B:PRES.0000028392.80354.7c; MCGLYNN P, 1993, MOL GEN GENET, V236, P227, DOI 10.1007/BF00277117; Nagata N, 2005, PLANT CELL, V17, P233, DOI 10.1105/tpc.104.027276; Nakanishi H, 2005, PLANT CELL PHYSIOL, V46, P467, DOI 10.1093/pcp/pci053; Naylor GW, 1999, PHOTOSYNTH RES, V62, P121, DOI 10.1023/A:1006350405674; Nomata J, 2005, BBA-BIOENERGETICS, V1708, P229, DOI 10.1016/j.bbabio.2005.02.002; PUDEK MR, 1975, BIOCHEMISTRY-US, V14, P3132, DOI 10.1021/bi00685a015; Raymond J, 2004, MOL BIOL EVOL, V21, P541, DOI 10.1093/molbev/msh047; RUDIGER W, 2003, PORPHYRIN HDB, V13, P71; Rzeznicka K, 2005, P NATL ACAD SCI USA, V102, P5886, DOI 10.1073/pnas.0501784102; SEEFELDT LC, 1994, ANAL BIOCHEM, V221, P379, DOI 10.1006/abio.1994.1429; SENGE MO, 1994, ANOXYGENIC PHOTOSYNT, P137; Shepherd M, 2004, BIOCHEM J, V382, P1009, DOI 10.1042/BJ20040661; Shepherd M, 2003, BIOCHEM J, V371, P351, DOI 10.1042/BJ20021394; STRUCK A, 1992, BIOCHIM BIOPHYS ACTA, V1101, P321, DOI 10.1016/0167-4838(92)90559-V; Suzuki JY, 1997, ANNU REV GENET, V31, P61, DOI 10.1146/annurev.genet.31.1.61; TAYLOR DP, 1983, J BACTERIOL, V154, P580, DOI 10.1128/JB.154.2.580-590.1983; Tottey S, 2003, P NATL ACAD SCI USA, V100, P16119, DOI 10.1073/pnas.2136793100; WEAVER PF, 1975, ARCH MICROBIOL, V105, P207, DOI 10.1007/BF00447139; Willows R.D., 2003, PORPHYRIN HDB CHLORO, V13, P1, DOI [10.1016/B978-0-08-092387-1.50007-2, DOI 10.1016/B978-0-08-092387-1.50007-2]; YAKUNIN AF, 1983, BIOCHIM BIOPHYS ACTA, V725, P298, DOI 10.1016/0005-2728(83)90203-7; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558	38	81	89	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					15021	15028		10.1074/jbc.M601750200	http://dx.doi.org/10.1074/jbc.M601750200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16571720	hybrid			2022-12-25	WOS:000237671300055
J	Detmers, FJM; De Groot, BL; Muller, EM; Hinton, A; Konings, IBM; Sze, M; Flitsch, SL; Grubmuller, H; Deen, PMT				Detmers, Frank J. M.; De Groot, Bert L.; Mueller, E. Matthias; Hinton, Andrew; Konings, Irene B. M.; Sze, Mozes; Flitsch, Sabine L.; Grubmueller, Helmut; Deen, Peter M. T.			Quaternary ammonium compounds as water channel blockers - Specificity, potency, and site of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; MOLECULAR-DYNAMICS; POTASSIUM CHANNEL; AQUAPORIN CHIP; EXPRESSION; MEMBRANE; MICE; GENE; SELECTIVITY; PERMEATION	Excessive water uptake through Aquaporins (AQP) can be life-threatening and reversible AQP inhibitors are needed. Here, we determined the specificity, potency, and binding site of tetraethylammonium (TEA) to block Aquaporin water permeability. Using oocytes, externally applied TEA blocked AQP1/AQP2/AQP4 with IC50 values of 1.4, 6.2, and 9.8 mu M, respectively. Related tetraammonium compounds yielded some ( propyl) or no ( methyl, butyl, or pentyl) inhibition. TEA inhibition was lost upon a Tyr to Phe amino acid switch in the external water pore of AQP1/AQP2/AQP4, whereas the water permeability of AQP3 and AQP5, which lack a corresponding Tyr, was not blocked by TEA. Consistent with experimental data, multi-nanosecond molecular dynamics simulations showed one stable binding site for TEA, but not tetramethyl (TMA), in AQP1, resulting in a nearly 50% water permeability inhibition, which was reduced in AQP1-Y186F due to effects on the TEA inhibitory binding region. Moreover, in the simulation TEA interacted with charged residues in the C (Asp128) and E (Asp185) loop, and the A(Tyr37-Asn42-Thr44) loop of the neighboring monomer, but not directly with Tyr186. The loss of TEA inhibition in oocytes expressing properly folded AQP1-N42A or -T44A is in line with the computationally predicted binding mode. Our data reveal that the molecular interaction of TEA with AQP1 differs and is about 1000-fold more effective on AQPs than on potassium channels. Moreover, the observed experimental and simulated similarities open the way for rational design and virtual screening for AQP-specific inhibitors, with quaternary ammonium compounds in general, and TEA in particular as a lead compound.	RUNMC Nijmegen, Dept Physiol 286, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Max Planck Inst Biophys Chem, Theoret & Computat Biophys Dept, D-37077 Gottingen, Germany; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	Radboud University Nijmegen; Max Planck Society; University of Edinburgh	Deen, PMT (corresponding author), RUNMC Nijmegen, Dept Physiol 286, Nijmegen Ctr Mol Life Sci, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.deen@ncmls.ru.nl	Deen, P.M.T./H-8023-2014; Deen, Peter MT/B-9854-2013; Flitsch, Sabine/AAJ-6812-2020	Deen, P.M.T./0000-0002-7868-4655; Deen, Peter MT/0000-0002-7868-4655; Flitsch, Sabine/0000-0003-3974-646X				*ACC INC, 2000, INS MOD ENV REL 2000; BASH PA, 1987, SCIENCE, V236, P564, DOI 10.1126/science.3576184; BERENDSEN HJ, 2004, INTERMOLECULAR FORCE; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Blaustein RO, 2004, NATURE, V427, P499, DOI 10.1038/427499a; Brooks HL, 2000, MOL PHARMACOL, V57, P1021; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Deen PMT, 2000, EUR J CELL BIOL, V79, P523, DOI 10.1078/0171-9335-00075; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Deen PMT, 1997, PFLUG ARCH EUR J PHY, V433, P780, DOI 10.1007/s004240050345; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ewing TJA, 1997, J COMPUT CHEM, V18, P1175, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1175::AID-JCC6>3.0.CO;2-O; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; Hendriks G, 2004, J BIOL CHEM, V279, P2975, DOI 10.1074/jbc.M310767200; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; Knoers NVAM, 2001, PEDIATR NEPHROL, V16, P1146, DOI 10.1007/s004670100051; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; Lee MD, 1996, J BIOL CHEM, V271, P8599, DOI 10.1074/jbc.271.15.8599; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lu MQ, 1996, P NATL ACAD SCI USA, V93, P10908, DOI 10.1073/pnas.93.20.10908; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marr N, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000027355.41663.14; Marr N, 2001, PFLUG ARCH EUR J PHY, V442, P73, DOI 10.1007/s004240000498; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Mulders SM, 1998, PFLUG ARCH EUR J PHY, V436, P599, DOI 10.1007/s004240050677; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Niemietz CM, 2002, FEBS LETT, V531, P443, DOI 10.1016/S0014-5793(02)03581-0; PEARLMAN RS, 1998, CONCORD USERS MANUAL; Pedersen RS, 2003, KIDNEY INT, V63, P1417, DOI 10.1046/j.1523-1755.2003.00858.x; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Song YL, 2002, J PHYSIOL-LONDON, V541, P561, DOI 10.1113/jphysiol.2001.020180; Sougrat R, 2002, J INVEST DERMATOL, V118, P678, DOI 10.1046/j.1523-1747.2002.01710.x; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Tajkhorshid E, 2002, SCIENCE, V296, P525, DOI 10.1126/science.1067778; van Balkom BWM, 2003, J BIOL CHEM, V278, P1101, DOI 10.1074/jbc.M207339200; van Os CH, 2000, PFLUG ARCH EUR J PHY, V440, P513, DOI 10.1007/s004240000317; VANBUUREN AR, 1993, J PHYS CHEM-US, V97, P9206, DOI 10.1021/j100138a023; VANGUNSTEREN WF, 1987, GROMOS MANUAL BIOMOS; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WIDMER A, 1997, WITNOTP COMPUTER PRO; Yool Andrea J, 2002, BMC Physiol, V2, P4, DOI 10.1186/1472-6793-2-4; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	59	104	110	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14207	14214		10.1074/jbc.M513072200	http://dx.doi.org/10.1074/jbc.M513072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551622	Green Published, hybrid, Green Submitted			2022-12-25	WOS:000237512300044
J	Schon, S; Prante, C; Bahr, C; Kuhn, J; Kleesiek, K; Gotting, C				Schoen, Sylvia; Prante, Christian; Bahr, Claudia; Kuhn, Joachim; Kleesiek, Knut; Goetting, Christian			Cloning and recombinant expression of active full-length xylosyltransferase I (XT-I) and characterization of subcellular localization of XT-I and XT-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-D-XYLOSE; BETA-D-XYLOSYLTRANSFERASE; MEMBRANE-SPANNING DOMAIN; GOLGI LOCALIZATION; GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; MOLECULAR-CLONING; CYTOPLASMIC TAIL; KIN RECOGNITION; BREFELDIN-A; STEM REGION	Xylosyltransferase I (XT-I) catalyzes the transfer of xylose from UDP-xylose to serine residues in proteoglycan core proteins. This is the first and apparently rate-limiting step in the biosynthesis of the tetrasaccharide linkage region in glycosaminoglycan-containing proteoglycans. The XYLT-II gene codes for a highly homologous protein, but its physiological function is not yet known. Here we present for the first time the construction of a vector encoding the full-length GFP-tagged human XT-I and the recombinant expression of the active enzyme in mammalian cells. We expressed XT-I-GFP and various GFP-tagged XT-I and XT-II mutants with C-terminal truncations and deletions in HEK-293 and SaOS-2 cells in order to investigate the intracellular localization of XT-I and XT-II. Immunofluorescence analysis showed a distinct perinuclear pattern of XT-I-GFP and XT-II-GFP similar to that of alpha-mannosidase II, which is a known enzyme of the Golgi cisternae. Furthermore, a co-localization of native human XT-I and alpha-mannosidase II could also be demonstrated in untransfected cells. Using brefeldin A, we could also show that both xylosyltransferases are resident in the early cisternae of the Golgi apparatus. For its complete Golgi retention, XT-I requires the N-terminal 214 amino acids. Unlike XT-I, for XT-II, the first 45 amino acids are sufficient to target and retain the GFP reporter in the Golgi compartment. Here we show evidence that the stem regions were indispensable for Golgi localization of XT-I and XT-II.	Ruhr Univ Bochum, Inst Labs & Transfus Med, Herz & Diabet Zentrum Nordrhein Westfalen, Univ Klin, D-32545 Bad Oeynhausen, Germany	Ruhr University Bochum	Gotting, C (corresponding author), Ruhr Univ Bochum, Inst Labs & Transfus Med, Herz & Diabet Zentrum Nordrhein Westfalen, Univ Klin, Georgstr 11, D-32545 Bad Oeynhausen, Germany.	cgoetting@hdz-nrw.de						Andersson AM, 1998, J VIROL, V72, P9585, DOI 10.1128/JVI.72.12.9585-9596.1998; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DAHDAL RY, 1993, J BIOL CHEM, V268, P26310; de Graffenried CL, 2004, J BIOL CHEM, V279, P40035, DOI 10.1074/jbc.M405709200; DRIOUICH A, 1993, PLANT PHYSIOL, V101, P1363, DOI 10.1104/pp.101.4.1363; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; Gleeson PA, 1998, HISTOCHEM CELL BIOL, V109, P517, DOI 10.1007/s004180050252; Gotting C, 2004, J BIOL CHEM, V279, P42566, DOI 10.1074/jbc.M401340200; Gotting C, 1999, J INVEST DERMATOL, V112, P919, DOI 10.1046/j.1523-1747.1999.00590.x; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Gotting C, 2002, CLIN CHIM ACTA, V317, P199, DOI 10.1016/S0009-8981(01)00793-8; Gotting C, 2000, ACTA DERM-VENEREOL, V80, P60; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; HORWITZ AL, 1968, J CELL BIOL, V38, P358, DOI 10.1083/jcb.38.2.358; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KAHNERT H, 1991, EUR J CLIN CHEM CLIN, V29, P624; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; KLEESIEK K, 1987, J CLIN CHEM CLIN BIO, V25, P473; Kuhn J, 2003, BIOCHEM BIOPH RES CO, V312, P537, DOI 10.1016/j.bbrc.2003.10.157; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; LOHMANDER LS, 1989, J BIOL CHEM, V264, P18775; Milland J, 2002, J BIOL CHEM, V277, P10374, DOI 10.1074/jbc.M111799200; Muller S, 2006, BIOCHEM J, V394, P163, DOI 10.1042/BJ20051606; Muller S, 2005, BIOCHEM J, V386, P227, DOI 10.1042/BJ20041206; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; PAULSON JC, 1987, BIOCHEM SOC T, V15, P618, DOI 10.1042/bst0150618; Prydz K, 2000, J CELL SCI, V113, P193; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; RODEN L, 1980, BIOCH GLYCOPROTEINS, P269; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; Sasai K, 2001, J BIOL CHEM, V276, P759, DOI 10.1074/jbc.M004972200; SCHACHTER H, 1994, MOL GLYCOBIOLOGY, P88; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; SCHWARTZ NB, 1985, FED PROC, V44, P369; Weilke C, 1997, CLIN CHEM, V43, P45; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; Wilson IBH, 2004, CELL MOL LIFE SCI, V61, P794, DOI 10.1007/s00018-003-3278-2	45	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14224	14231		10.1074/jbc.M510690200	http://dx.doi.org/10.1074/jbc.M510690200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16569644	hybrid			2022-12-25	WOS:000237512300046
J	Seo, BB; Nakamaru-Ogiso, E; Flotte, TR; Matsuno-Yagi, A; Yagi, T				Seo, Byoung Boo; Nakamaru-Ogiso, Eiko; Flotte, Terence R.; Matsuno-Yagi, Akemi; Yagi, Takao			In vivo complementation of complex I by the yeast Ndi1 enzyme - Possible application for treatment of Parkinson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-QUINONE OXIDOREDUCTASE; ADENOASSOCIATED VIRAL VECTORS; INSENSITIVE INTERNAL NADH; SACCHAROMYCES-CEREVISIAE MITOCHONDRIA; UBIQUINONE OXIDOREDUCTASE; OXIDATIVE-PHOSPHORYLATION; RESPIRATORY-CHAIN; MAMMALIAN-CELLS; GENE-THERAPY; DEFECTS	Recent studies suggest that dysfunction of the NADH-quinone oxidoreductase (complex I) is associated with a number of human diseases, including neurodegenerative disorders such as Parkinson disease. We have shown previously that the single subunit rote-none-insensitive NADH-quinone oxidoreductase (NdI1) of Saccharomyces cerevisiae mitochondria can restore NADH oxidation in complex I-deficient mammalian cells. The Ndi1 enzyme is insensitive to complex I inhibitors such as rotenone and 1-methyl-4-phenylpyridinium ion, known as a metabolite of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). To test the possible use of the NDI1 gene as a therapeutic agent in vivo, we chose amouse model of Parkinson disease. The NDI1-recombinant adeno-associated virus particles (rAAV-NDI1) were injected unilaterally into the substantia nigra of mice. The animals were then subjected to treatment with MPTP. The degree of neurodegeneration in the nigrostriatal system was assessed immunohistochemically through the analysis of tyrosine hydroxylase and glial fibrillary acidic protein. It was evident that the substantia nigra neurons on the side used for injection of rAAV-NDI1 retained a high level of tyrosine hydroxylase-positive cells, and the ipsilateral striatum exhibited significantly less denervation than the contralateral striatum. Furthermore, striatal concentrations of dopamine and its metabolites in the hemisphere that received rAAV-NDI1 were substantially higher than those of the untreated hemisphere, reaching more than 50% of the normal levels. These results indicate that the expressed NdI1 protein elicits resistance to MPTP-induced neuronal injury. The present study is the first successful demonstration of complementation of complex I by the NdI1 enzyme in animals.	Scripps Res Inst, Div Biochem, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Florida, Genet Inst, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA	Scripps Research Institute; State University System of Florida; University of Florida	Matsuno-Yagi, A (corresponding author), Scripps Res Inst, Div Biochem, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ayagi@scripps.edu; yagi@scripps.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048441] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL59412] Funding Source: Medline; NIDDK NIH HHS [R01DK053244] Funding Source: Medline; NINDS NIH HHS [R01NS048441] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Alam M, 2002, BEHAV BRAIN RES, V136, P317, DOI 10.1016/S0166-4328(02)00180-8; Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900; Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Burger C, 2005, HUM GENE THER, V16, P781, DOI 10.1089/hum.2005.16.781; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Champy P, 2004, J NEUROCHEM, V88, P63, DOI 10.1046/j.1471-4159.2003.02138.x; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; de Grey ADNJ, 2000, TRENDS BIOTECHNOL, V18, P394, DOI 10.1016/S0167-7799(00)01476-1; DEVRIES S, 1992, EUR J BIOCHEM, V203, P587; Greenamyre JT, 2001, IUBMB LIFE, V52, P135, DOI 10.1080/15216540152845939; Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354; Hinchliffe P, 2005, SCIENCE, V309, P771, DOI 10.1126/science.1113988; Janssen RJRJ, 2004, EXPERT REV MOL DIAGN, V4, P143, DOI 10.1586/14737159.4.2.143; Kitajima-Ihara T, 1998, FEBS LETT, V421, P37, DOI 10.1016/S0014-5793(97)01533-0; Lau YS, 2003, METH MOLEC MED, V79, P103; Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851; MARRES CAM, 1991, EUR J BIOCHEM, V195, P857, DOI 10.1111/j.1432-1033.1991.tb15775.x; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Muramatsu SI, 2002, HUM GENE THER, V13, P345, DOI 10.1089/10430340252792486; NAGLEY P, 1988, P NATL ACAD SCI USA, V85, P2091, DOI 10.1073/pnas.85.7.2091; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Seo BB, 2000, J BIOL CHEM, V275, P37774, DOI 10.1074/jbc.M007033200; Seo BB, 1999, BBA-BIOENERGETICS, V1412, P56, DOI 10.1016/S0005-2728(99)00051-1; Seo BB, 2004, HUM GENE THER, V15, P887, DOI 10.1089/1043034041839217; Seo BB, 2002, MOL THER, V6, P336, DOI 10.1006/mthe.2002.0674; SINGER TP, 1990, FEBS LETT, V274, P1, DOI 10.1016/0014-5793(90)81315-F; SONSALLA PK, 1986, EUR J PHARMACOL, V129, P339, DOI 10.1016/0014-2999(86)90444-9; Sugama S, 2003, BRAIN RES, V964, P288, DOI 10.1016/S0006-8993(02)04085-4; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; WAGNER J, 1982, J NEUROCHEM, V38, P1241, DOI 10.1111/j.1471-4159.1982.tb07897.x; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Zolotukhin S, 2002, METHODS, V28, P158, DOI 10.1016/S1046-2023(02)00220-7; Zullo SJ, 2001, SEMIN NEUROL, V21, P327, DOI 10.1055/s-2001-17949	37	68	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14250	14255		10.1074/jbc.M600922200	http://dx.doi.org/10.1074/jbc.M600922200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543240	hybrid			2022-12-25	WOS:000237512300049
J	Terao, Y; Yamaguchi, M; Hamada, S; Kawabata, S				Terao, Yutaka; Yamaguchi, Masaya; Hamada, Shigeyuki; Kawabata, Shigetada			Multifunctional glyceraldehyde-3-phosphate dehydrogenase of Streptococcus pyogenes is essential for evasion from neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; FIBRONECTIN-BINDING PROTEIN; HUMAN PHARYNGEAL CELL; COMPLEMENT FACTOR-H; C5A PEPTIDASE GENE; EPITHELIAL-CELLS; VIRULENCE DETERMINANT; ESCHERICHIA-COLI; PLASMIN RECEPTOR; GENOME SEQUENCE	Streptococcus pyogenes is an important pathogen that causes pharyngitis, sepsis, and rheumatic fever. Cell-associated streptococcal C5a peptidase (ScpA) protects S. pyogenes from phagocytosis and has been suggested to interrupt host defenses by enzymatically cleaving complement C5a, a major factor in the accumulation of neutrophils at sites of infection. How S. pyogenes recognizes and binds to C5a, however, is unclear. We detected a C5a-binding protein in 8 M urea extracts of S. pyogenes by ligand blotting using biotinylated C5a. Searching of genome databases showed that the C5a-binding protein is identical to the streptococcal plasmin receptor (Plr), also known as streptococcal surface dehydrogenase (SDH) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In the present study we identified a novel function of this multifunctional protein. Western blotting and immunofluorescence microscopy with anti-Plr/SDH/GAPDH showed that Plr/SDH/GAPDH is located on the bacterial surface and released into the culturesupernatant. Next, weexaminedwhetherthestreptococcalPlr/ SDH/ GAPDH inhibits the biological effects of C5a on human neutrophils. We found that soluble Plr/ SDH/ GAPDH inhibits C5a- activated chemotaxis andH2O2 production. Furthermore, our results suggested thatsolublePlr/ SDH/ GAPDHcapturesC5a, inhibitingitschemotactic function. Also, cell- associated Plr/ SDH/ GAPDH and ScpA were both necessary for the cleavage of C5a on the bacterial surface. Together, these results indicate that the multifunctional protein Plr/ SDH/ GAPDH has additional functions	Osaka Univ, Dept Oral & Mol Microbiol, Suita, Osaka 5650871, Japan; Nihon Univ, Dept Life Sci, Adv Res Inst Sci & Humanities, Chiyoda Ku, Tokyo 1028251, Japan	Osaka University; Nihon University	Kawabata, S (corresponding author), Osaka Univ, Dept Oral & Mol Microbiol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kawabata@dent.osaka-u.ac.jp	Yamaguchi, Masaya/I-8156-2019	Yamaguchi, Masaya/0000-0001-6218-7112; Terao, Yutaka/0000-0002-4450-5583				Anderson ET, 2002, EUR J BIOCHEM, V269, P4839, DOI 10.1046/j.1432-1033.2002.03183.x; Betschel SD, 1998, INFECT IMMUN, V66, P1671, DOI 10.1128/IAI.66.4.1671-1679.1998; Braunwald E, 1996, NEW ENGL J MED, V334, P51, DOI 10.1056/NEJM199601043340113; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; CHEN CC, 1990, J BIOL CHEM, V265, P3161; CHEN CC, 1989, INFECT IMMUN, V57, P1740, DOI 10.1128/IAI.57.6.1740-1745.1989; Courtney HS, 1999, MOL MICROBIOL, V32, P89, DOI 10.1046/j.1365-2958.1999.01328.x; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; DeMaster E, 2002, INFECT IMMUN, V70, P350, DOI 10.1128/IAI.70.1.350-359.2002; Edwards RJ, 2005, J INFECT DIS, V192, P783, DOI 10.1086/432485; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; Frevert CW, 1998, J IMMUNOL METHODS, V213, P41, DOI 10.1016/S0022-1759(98)00016-7; HAMADA S, 1991, INFECT IMMUN, V59, P4161, DOI 10.1128/IAI.59.11.4161-4167.1991; Herwald H, 2004, CELL, V116, P367, DOI 10.1016/S0092-8674(04)00057-1; Hidalgo-Grass C, 2004, LANCET, V363, P696, DOI 10.1016/S0140-6736(04)15643-2; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; Huber-Lang MS, 2003, J IMMUNOL, V170, P6115, DOI 10.4049/jimmunol.170.12.6115; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; Jaffe J, 1996, MOL MICROBIOL, V21, P373, DOI 10.1046/j.1365-2958.1996.6331356.x; Ji YD, 1996, INFECT IMMUN, V64, P503, DOI 10.1128/IAI.64.2.503-510.1996; Ji YD, 1997, INFECT IMMUN, V65, P2080, DOI 10.1128/IAI.65.6.2080-2087.1997; Jin H, 2005, J MOL BIOL, V350, P27, DOI 10.1016/j.jmb.2005.04.063; Kacani L, 2001, J IMMUNOL, V166, P3410, DOI 10.4049/jimmunol.166.5.3410; KAJITA T, 1990, AM J PATHOL, V137, P467; Kawabata S, 2001, INFECT IMMUN, V69, P924, DOI 10.1128/IAI.69.2.924-930.2001; Kawabata S, 1999, INFECT IMMUN, V67, P5863, DOI 10.1128/IAI.67.11.5863-5868.1999; Kotarsky H, 2001, MOL MICROBIOL, V41, P817, DOI 10.1046/j.1365-2958.2001.02496.x; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; Monsinjon T, 2003, FASEB J, V17, P1003, DOI 10.1096/fj.02-0737com; Nakagawa I, 2003, GENOME RES, V13, P1042, DOI 10.1101/gr.1096703; Okamoto S, 2004, INFECT IMMUN, V72, P6068, DOI 10.1128/IAI.72.10.6068-6075.2004; Pancholi V, 1997, J EXP MED, V186, P1633, DOI 10.1084/jem.186.10.1633; PANCHOLI V, 1993, P NATL ACAD SCI USA, V90, P8154, DOI 10.1073/pnas.90.17.8154; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Pandiripally V, 2003, INFECT IMMUN, V71, P7119, DOI 10.1128/IAI.71.12.7119-7128.2003; Pandiripally V, 2002, INFECT IMMUN, V70, P6206, DOI 10.1128/IAI.70.11.6206-6214.2002; Podbielski A, 1996, MED MICROBIOL IMMUN, V185, P171, DOI 10.1007/s004300050028; PODBIELSKI A, 1995, INFECT IMMUN, V63, P9, DOI 10.1128/IAI.63.1.9-20.1995; Rocha CL, 1999, INFECT IMMUN, V67, P2720, DOI 10.1128/IAI.67.6.2720-2728.1999; SOLOMKIN JS, 1981, SURGERY, V90, P319; Stafslien DK, 2000, J BACTERIOL, V182, P3254, DOI 10.1128/JB.182.11.3254-3258.2000; Stinson MW, 1998, INFECT IMMUN, V66, P259, DOI 10.1128/IAI.66.1.259-265.1998; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; TAO L, 1992, GENE, V120, P105, DOI 10.1016/0378-1119(92)90016-I; Terao Y, 2005, J INFECT DIS, V192, P2081, DOI 10.1086/498162; Terao Y, 2002, J BIOL CHEM, V277, P47428, DOI 10.1074/jbc.M209133200; Terao Y, 2001, MOL MICROBIOL, V42, P75, DOI 10.1046/j.1365-2958.2001.02579.x; Terao Y, 2002, INFECT IMMUN, V70, P993; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269; WEXLER DE, 1985, P NATL ACAD SCI USA, V82, P8144, DOI 10.1073/pnas.82.23.8144; WEXLER DE, 1985, INFECT IMMUN, V50, P757, DOI 10.1128/IAI.50.3.757-764.1985; Winram SB, 1998, MICROBIOL-SGM, V144, P2025, DOI 10.1099/00221287-144-8-2025; Winram SB, 1996, MICROBIOL-SGM, V142, P2311, DOI 10.1099/13500872-142-8-2311	58	115	121	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14215	14223		10.1074/jbc.M513408200	http://dx.doi.org/10.1074/jbc.M513408200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16565520	hybrid			2022-12-25	WOS:000237512300045
J	Zhang, XL; Zhang, SW; Yamane, H; Wahl, R; Ali, A; Lofgren, JA; Kendall, RL				Zhang, Xiaoling; Zhang, Shiwen; Yamane, Harvey; Wahl, Robert; Ali, Arisha; Lofgren, Julie A.; Kendall, Richard L.			Kinetic mechanism of AKT/PKB enzyme family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; ADENOSINE 5'-DIPHOSPHATE PHOSPHORYLATION; MOLECULAR-CLONING; CATALYTIC SUBUNIT; 3-KINASE/AKT PATHWAY; INSULIN-RESISTANCE; AKT PROTOONCOGENE; CRYSTAL-STRUCTURE; MAMMALIAN TARGET; ACTIVATION	AKT/PKB is a phosphoinositide-dependent serine/threonine protein kinase that plays a critical role in the signal transduction of receptors. It also serves as an oncogene in the tumorigenesis of cancer cells when aberrantly activated by genetic lesions of the PTEN tumor suppressor, phosphatidylinositol 3-kinase, and receptor tyrosine kinase overexpression. Here we have characterized and compared kinetic mechanisms of the three AKT isoforms. Initial velocity studies revealed that all AKT isozymes follow the sequential kinetic mechanism by which an enzyme-substrate ternary complex forms before the product release. The empirically derived kinetic parameters are apparently different among the isoforms. AKT2 showed the highest K-m value for ATP, and AKT3 showed the highest k(cat) value. The patterns of product inhibition of AKT1, AKT2, and AKT3 by ADP were all consistent with an ordered substrate addition mechanism with ATP binding to the enzymes prior to the peptide substrate. Further analysis of steady state kinetics of AKT1 in the presence of dead-end inhibitors supported the finding and suggested that the AKT family of kinases catalyzes reactions via an Ordered Bi Bi sequential mechanism with ATP binding to the enzyme prior to peptide substrate and ADP being released after the phosphopeptide product. These results suggest that ATP is an initiating factor for the catalysis of AKT enzymes and may play a role in the regulation AKT enzyme activity in cells.	Amgen Inc, Dept Oncol Res, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Prot Sci, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Mol Pharmacol, Thousand Oaks, CA 91320 USA	Amgen; Amgen; Amgen	Zhang, XL (corresponding author), Amgen Inc, Dept Oncol Res, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	xzhang@amgen.com						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dragoi AM, 2005, EMBO J, V24, P779, DOI 10.1038/sj.emboj.7600539; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; QAMAR R, 1993, BIOCHEMISTRY-US, V32, P6802, DOI 10.1021/bi00077a035; QAMAR R, 1992, BIOCHEMISTRY-US, V31, P9986, DOI 10.1021/bi00156a018; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Segel I.H, 1993, ENZYME KINETICS; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	55	30	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13949	13956		10.1074/jbc.M601384200	http://dx.doi.org/10.1074/jbc.M601384200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16540465	hybrid			2022-12-25	WOS:000237512300016
J	Dresios, J; Chan, YL; Wool, IG				Dresios, J; Chan, YL; Wool, IG			Determination of the amino acids in yeast ribosomal protein YS11 essential for the recognition of nucleotides in 18 S ribosomal RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ANGSTROM-RESOLUTION; NEAMINE RESISTANCE; NEW-MODEL; MUTATION; L25; SUBUNIT; IDENTIFICATION; LOCALIZATION	The nucleotides in domain I of 18 S rRNA that are important for the binding of the essential yeast ribosomal protein YS11 are mainly in a kink- turn motif and the terminal loop of helix 11 ( H11). In the atomic structure of the Thermus thermophilus 30 S subunit, 16 amino acids in S17, the homolog of YS11, are within hydrogen bonding distance of nucleotides in 16 S rRNA. The homologous or analogous 16 amino acids in YS11 were replaced with alanine; nine of the substitutions slowed the growth of yeast cells. The most severe effects were caused by mutations R103A, N106A, K133A, T134A, and K151A. The T. thermophilus analogs of Arg(103), Asn(106), Thr(134), and Lys(151) contact nucleotides in the kink- turn motif of 16 S rRNA, whereas Lys(133) contacts nucleotides in the terminal loop of H11. These contacts are predominantly with backbone phosphate and sugar oxygens in regions that deviate from A- form geometry, suggesting that YS11 recognizes the shape of its rRNA- binding site rather than reading the sequence of nucleotides. The effect of the mutations on the binding of YS11 to a domain I fragment of 18 S rRNA accorded, in general, with their effect on growth. Mutations of seven YS11 amino acids ( Ser(77), Met(80), Arg(88), Tyr(97), Pro(130), Ser(132), and Arg(136)) whose homologs or analogs in S17 are within hydrogen bonding distance of nucleotides in 16 S rRNA did not affect binding. Apparently, proximities alone do not define either the amino acids or the nucleotides that are important for recognition.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Wool, IG (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 929 E 57th St, Chicago, IL 60637 USA.	irawool@uchicago.edu			NIGMS NIH HHS [GM33702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allers J, 2001, J MOL BIOL, V311, P75, DOI 10.1006/jmbi.2001.4857; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; BOLLEN A, 1975, J MOL BIOL, V99, P795, DOI 10.1016/S0022-2836(75)80185-9; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; Dresios J, 2005, J MOL BIOL, V345, P681, DOI 10.1016/j.jmb.2004.10.027; Dresios J, 2002, J MOL BIOL, V316, P475, DOI 10.1006/jmbi.2001.5374; ELBARADI TTAL, 1987, BIOCHIMIE, V69, P939, DOI 10.1016/0300-9084(87)90227-6; ELBARADI TTAL, 1985, EMBO J, V4, P2101, DOI 10.1002/j.1460-2075.1985.tb03898.x; FOLLEY LS, 1994, GENETICS, V137, P369; HELD WA, 1974, J BIOL CHEM, V249, P3103; HERZOG A, 1979, MOL GEN GENET, V171, P15, DOI 10.1007/BF00274010; Jakovljevic J, 2004, MOL CELL, V14, P331, DOI 10.1016/S1097-2765(04)00215-1; Klein DJ, 2001, EMBO J, V20, P4214, DOI 10.1093/emboj/20.15.4214; KOOI EA, 1994, J MOL BIOL, V240, P243, DOI 10.1006/jmbi.1994.1438; Lescoute A, 2005, NUCLEIC ACIDS RES, V33, P2395, DOI 10.1093/nar/gki535; Mueller F, 1997, J MOL BIOL, V271, P566, DOI 10.1006/jmbi.1997.1212; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; POWERS T, 1995, RNA, V1, P194; Ramakrishnan V, 1998, TRENDS BIOCHEM SCI, V23, P208, DOI 10.1016/S0968-0004(98)01214-6; RUTGERS CA, 1990, BIOCHIM BIOPHYS ACTA, V1050, P74, DOI 10.1016/0167-4781(90)90144-Q; RUTGERS CA, 1991, J MOL BIOL, V218, P375, DOI 10.1016/0022-2836(91)90719-M; SCHAAP PJ, 1991, J MOL BIOL, V221, P225; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1988, J MOL BIOL, V200, P291, DOI 10.1016/0022-2836(88)90241-0; TRAUB P, 1968, J MOL BIOL, V34, P575, DOI 10.1016/0022-2836(68)90182-4; Urlaub H, 1997, J PROTEIN CHEM, V16, P375, DOI 10.1023/A:1026380504377; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; YAGUCHI M, 1976, J MOL BIOL, V104, P617, DOI 10.1016/0022-2836(76)90124-8	31	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13478	13484		10.1074/jbc.M513036200	http://dx.doi.org/10.1074/jbc.M513036200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16540469	hybrid			2022-12-25	WOS:000237336600055
J	Chen, YY; Sankala, M; Ojala, JRM; Sun, Y; Tuuttila, A; Isenman, DE; Tryggvason, K; Pikkarainen, T				Chen, YY; Sankala, M; Ojala, JRM; Sun, Y; Tuuttila, A; Isenman, DE; Tryggvason, K; Pikkarainen, T			A phage display screen and binding studies with acetylated low density lipoprotein provide evidence for the importance of the scavenger receptor cysteine-rich (SRCR) domain in the ligand-binding function of MARCO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; SPLENIC MARGINAL ZONE; LIPOTEICHOIC ACID; COLLAGENOUS STRUCTURE; CRYSTAL-STRUCTURE; HOST-DEFENSE; IN-VIVO; BACTERIA; PEPTIDE; LIPOPOLYSACCHARIDE	MARCO is a class A scavenger receptor capable of binding both Gram-negative and -positive bacteria. Using the surface plasmon resonance technique, we show here that a recombinant, soluble form of MARCO, sMARCO, binds the major Gram-negative and -positive bacterial surface components, lipopolysaccharide and lipoteichoic acid. Yet, the interaction of these two polyanions with sMARCO is of much lower affinity than that of polyinosinic acid, a polyanionic inhibitor of bacterial binding to MARCO. To further elucidate the ligand-binding functions of MARCO, we performed a phage display screen with sMARCO. The screening resulted in the enrichment of only a handful of phage clones. Contrary to expectations, no polyanionic peptides, but only those with a predominantly hydrophobic nature, were enriched. One peptide, VRWGSFAAWL, was displayed on two-thirds of the phages recovered after four rounds of screening. The VRWGSFAAWL phage-sMARCO interaction had significantly slower dissociation kinetics than that between sMARCO and lipopolysaccharide or lipoteichoic acid. Further work with this phage, and the second most enriched phage, displaying the peptide RLNWAWWLSY, demonstrated that both peptides bind to the SRCR domain of MARCO, and that they probably bind to the same site. Data base searches suggested that the VRWGSFAAWL peptide represents complement component C4, but we could not convincingly confirm this suggestion. A study with chimeric scavenger receptors indicated that even minor sequence changes in the MARCO scavenger receptor cysteine-rich (SRCR) domain can have profound effects on the binding of the prototypic scavenger receptor ligand, acetylated low density lipoprotein. As shown by differential binding of glutathione S-transferase-VRWGSFAAWL, these differences were very likely due to conformational changes. These findings led to experiments that demonstrated a crucial role of the SRCR domain for acetylated low density lipoprotein binding in MARCO. Thus, our results strengthen the notion that the SRCR domain is the major ligand-binding domain in MARCO. Furthermore, they suggest that the domain may contain multiple ligand-binding sites.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden; Univ Toronto, Dept Biochem, Toronto, ON M55 1A8, Canada	Karolinska Institutet; University of Toronto	Pikkarainen, T (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden.	timo.pikkarainen@ki.se		Ojala, Juha/0000-0003-2018-6124				Andrew CD, 2001, PROTEINS, V45, P449, DOI 10.1002/prot.1161; Arredouani M, 2004, J EXP MED, V200, P267, DOI 10.1084/jem.20040731; ASHKENAS J, 1993, J LIPID RES, V34, P983; Aurell CA, 1998, BIOCHEM BIOPH RES CO, V253, P119, DOI 10.1006/bbrc.1998.9773; Bin LH, 2003, J IMMUNOL, V171, P924, DOI 10.4049/jimmunol.171.2.924; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; Cardo-Vila M, 2003, MOL CELL, V11, P1151, DOI 10.1016/S1097-2765(03)00138-2; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; El-Mousawi M, 2003, J BIOL CHEM, V278, P46681, DOI 10.1074/jbc.M308681200; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Greenberg JW, 1996, INFECT IMMUN, V64, P3318, DOI 10.1128/IAI.64.8.3318-3325.1996; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; Ito S, 1999, ARCH HISTOL CYTOL, V62, P83, DOI 10.1679/aohc.62.83; Karlsson MCI, 2003, J EXP MED, V198, P333, DOI 10.1084/jem.20030684; Koivunen E, 1999, METH MOL B, V129, P3; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Koolpe M, 2002, J BIOL CHEM, V277, P46974, DOI 10.1074/jbc.M208495200; LABISCHINSKI H, 1991, EUR J BIOCHEM, V202, P1269, DOI 10.1111/j.1432-1033.1991.tb16499.x; Lei HT, 2002, J BIOL CHEM, V277, P43137, DOI 10.1074/jbc.M203103200; Murai KK, 2003, MOL CELL NEUROSCI, V24, P1000, DOI 10.1016/j.mcn.2003.08.006; Palecanda A, 1999, J EXP MED, V189, P1497, DOI 10.1084/jem.189.9.1497; PEARSON AM, 1993, J BIOL CHEM, V268, P3546; Peiser L, 2002, CURR OPIN IMMUNOL, V14, P123, DOI 10.1016/S0952-7915(01)00307-7; Pikkarainen T, 1999, J BIOL CHEM, V274, P10975, DOI 10.1074/jbc.274.16.10975; Pillutla RC, 2002, J BIOL CHEM, V277, P22590, DOI 10.1074/jbc.M202119200; Resnick D, 1996, J BIOL CHEM, V271, P26924, DOI 10.1074/jbc.271.43.26924; RISCO C, 1991, J HISTOCHEM CYTOCHEM, V39, P607, DOI 10.1177/39.5.2016511; Sankala M, 2002, J BIOL CHEM, V277, P33378, DOI 10.1074/jbc.M204494200; Santos NC, 2003, CHEMBIOCHEM, V4, P96, DOI 10.1002/cbic.200390020; Sarraj MA, 2005, DEV DYNAM, V234, P1026, DOI 10.1002/dvdy.20594; Stefanidakis M, 2003, J BIOL CHEM, V278, P34674, DOI 10.1074/jbc.M302288200; van den Elsen JMH, 2002, J MOL BIOL, V322, P1103, DOI 10.1016/S0022-2836(02)00854-9; van der Laan LJW, 1999, J IMMUNOL, V162, P939; vanderLaan LJW, 1997, IMMUNOL LETT, V57, P203, DOI 10.1016/S0165-2478(97)00077-1; Wellinghausen N, 1996, J IMMUNOL, V157, P3139	37	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12767	12775		10.1074/jbc.M513628200	http://dx.doi.org/10.1074/jbc.M513628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524885	hybrid			2022-12-25	WOS:000237134700070
J	Niebisch, A; Kabus, A; Schultz, C; Weil, B; Bott, M				Niebisch, A; Kabus, A; Schultz, C; Weil, B; Bott, M			Corynebacterial protein kinase G controls 2-oxoglutarate dehydrogenase activity via the phosphorylation status of the OdhI protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOGLUTARATE DEHYDROGENASE; GLUTAMATE-PRODUCING BACTERIUM; MYCOBACTERIUM-TUBERCULOSIS; PYRUVATE-DEHYDROGENASE; MOLECULAR ANALYSIS; BREVIBACTERIUM-LACTOFERMENTUM; FHA DOMAINS; IN-VIVO; GLUTAMICUM; GROWTH	A novel regulatory mechanism for control of the ubiquitous 2-oxoglutarate dehydrogenase complex (ODH), a key enzyme of the tricarboxylic acid cycle, was discovered in the actinomycete Corynebacterium glutamicum, a close relative of important human pathogens like Corynebacterium diphtheriae and Mycobacterium tuberculosis. Based on the finding that a C. glutamicum mutant lacking serine/threonine protein kinase G (PknG) was impaired in glutamine utilization, proteome comparisons led to the identification of OdhI as a putative substrate of PknG. OdhI is a 15-kDa protein with a forkhead-associated domain and a homolog of mycobacterial GarA. By using purified proteins, PknG was shown to phosphorylate OdhI at threonine 14. The glutamine utilization defect of the Delta pknG mutant could be abolished by the additional deletion of odhI, whereas transformation of a Delta odhI mutant with a plasmid encoding OdhI-T14A caused a defect in glutamine utilization. Affinity purification of OdhI-T14A led to the specific copurification of OdhA, the E1 subunit of ODH. Because ODH is essential for glutamine utilization, we assumed that unphosphorylated OdhI inhibits ODH activity. In fact, OdhI was shown to strongly inhibit ODH activity with a K-i value of 2.4 nM. The regulatory mechanism described offers a molecular clue for the reduced ODH activity that is essential for the industrial production of 1.5 million tons/year of glutamate with C. glutamicum. Moreover, because this signaling cascade is likely to operate also in mycobacteria, our results suggest that the attenuated pathogenicity of mycobacteria lacking PknG might be caused by a disturbed tricarboxylic acid cycle.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Bott, M (corresponding author), Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany.	m.bott@fz-juelich.de	Bott, Michael/E-8004-2011	Bott, Michael/0000-0002-4701-8254				Alderwick LJ, 2005, J BIOL CHEM, V280, P32362, DOI 10.1074/jbc.M506339200; Av-Gay Y, 2000, TRENDS MICROBIOL, V8, P238, DOI 10.1016/S0966-842X(00)01734-0; Belanger AE, 1999, J BACTERIOL, V181, P6670, DOI 10.1128/JB.181.21.6670-6678.1999; Cowley S, 2004, MOL MICROBIOL, V52, P1691, DOI 10.1111/j.1365-2958.2004.04085.x; CREMER J, 1990, MOL GEN GENET, V220, P478, DOI 10.1007/BF00391757; Eggeling L., 2005, HDB CORYNEBACTERIUM, DOI 10.1201/9781420039696; EIKMANNS BJ, 1991, GENE, V102, P93, DOI 10.1016/0378-1119(91)90545-M; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; Kawahara Y, 1997, BIOSCI BIOTECH BIOCH, V61, P1109, DOI 10.1271/bbb.61.1109; KEILHAUER C, 1993, J BACTERIOL, V175, P5595, DOI 10.1128/JB.175.17.5595-5603.1993; Kennelly PJ, 2002, FEMS MICROBIOL LETT, V206, P1, DOI 10.1016/S0378-1097(01)00479-7; Kinoshita S., 1957, J GEN APPL MICROBIOL, V3, P193, DOI [10.2323/jgam.3.193, DOI 10.2323/JGAM.3.193]; KORNFELD S, 1977, J BIOL CHEM, V252, P2940; Koul A, 2001, MICROBIOL-SGM, V147, P2307, DOI 10.1099/00221287-147-8-2307; KRAMER R, 1990, EUR J BIOCHEM, V194, P929, DOI 10.1111/j.1432-1033.1990.tb19488.x; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; Molle V, 2004, FEMS MICROBIOL LETT, V234, P215, DOI 10.1016/j.femsle.2004.03.033; Molle V, 2003, BIOCHEMISTRY-US, V42, P15300, DOI 10.1021/bi035150b; Munoz-Elias EJ, 2005, NAT MED, V11, P638, DOI 10.1038/nm1252; Nguyen L, 2005, J BACTERIOL, V187, P5852, DOI 10.1128/JB.187.16.5852-5856.2005; Niebisch A, 2001, ARCH MICROBIOL, V175, P282, DOI 10.1007/s002030100262; Pallen M, 2002, TRENDS MICROBIOL, V10, P556, DOI 10.1016/S0966-842X(02)02476-9; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Schaffer S, 2001, ELECTROPHORESIS, V22, P4404, DOI 10.1002/1522-2683(200112)22:20<4404::AID-ELPS4404>3.0.CO;2-2; Schreiner ME, 2005, J BACTERIOL, V187, P6005, DOI 10.1128/JB.187.17.6005-6018.2005; Schwinde JW, 2001, MICROBIOL-SGM, V147, P2223, DOI 10.1099/00221287-147-8-2223; Segel I.H., 1975, ENZYME KINETICS BEHA, P161; SHIIO I, 1982, AGR BIOL CHEM TOKYO, V46, P493, DOI 10.1080/00021369.1982.10865088; SHIIO I, 1980, AGR BIOL CHEM TOKYO, V44, P1897, DOI 10.1080/00021369.1980.10864219; Shirai T, 2005, METAB ENG, V7, P59, DOI 10.1016/j.ymben.2004.10.001; SIEWE RM, 1995, ARCH MICROBIOL, V164, P98; SZEDLACSEK SE, 1988, BIOCHEM J, V254, P311, DOI 10.1042/bj2540311; Tian J, 2005, P NATL ACAD SCI USA, V102, P10670, DOI 10.1073/pnas.0501605102; Tian J, 2005, MOL MICROBIOL, V57, P859, DOI 10.1111/j.1365-2958.2005.04741.x; Usuda Y, 1996, MICROBIOL-UK, V142, P3347, DOI 10.1099/13500872-142-12-3347; Uy D, 2005, BIOPROC BIOSYST ENG, V27, P153, DOI 10.1007/s00449-004-0393-x; Villarino A, 2005, J MOL BIOL, V350, P953, DOI 10.1016/j.jmb.2005.05.049; Walburger A, 2004, SCIENCE, V304, P1800, DOI 10.1126/science.1099384; Weinstein EA, 2005, P NATL ACAD SCI USA, V102, P4548, DOI 10.1073/pnas.0500469102; Wittmann C, 2004, ANAL BIOCHEM, V327, P135, DOI 10.1016/j.ab.2004.01.002	41	149	172	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12300	12307		10.1074/jbc.M512515200	http://dx.doi.org/10.1074/jbc.M512515200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522631	hybrid			2022-12-25	WOS:000237134700014
J	Yagasaki, Y; Numakawa, T; Kumamaru, E; Hayashi, T; Su, TP; Kunugi, H				Yagasaki, Y; Numakawa, T; Kumamaru, E; Hayashi, T; Su, TP; Kunugi, H			Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C ACTIVITY; POSTMORTEM BRAIN; BINDING-SITES; MESSENGER-RNA; ELECTROCONVULSIVE SEIZURE; CA2+ OSCILLATIONS; MAP KINASE; EXPRESSION; PROTEIN; BDNF	Up-regulation of BDNF (brain-derived neurotrophic factor) has been suggested to contribute to the action of antidepressants. However, it is unclear whether chronic treatment with antidepressants may influence acute BDNF signaling in central nervous system neurons. Because BDNF has been shown by us to reinforce excitatory glutamatergic transmission in cultured cortical neurons via the phospholipase-gamma (PLC-gamma)/inositol 1,4,5-trisphosphate (IP3)/Ca2+ pathway (Numakawa, T., Yamagishi, S., Adachi, N., Matsumoto, T., Yokomaku, D., Yamada, M., and Hatanaka, H. (2002) J. Biol. Chem. 277, 6520-6529), we examined in this study the possible effects of pretreatment with antidepressants on the BDNF signaling through the PLC-gamma)/IP3/Ca2+ pathway. Furthermore, because the PLC-gamma IP3/Ca2+ pathway is regulated by sigma-1 receptors (Hayashi, T., and Su, T. P. ( 2001) Proc. Natl. Acad. Sci. U. S. A. 98, 491-496), we examined whether the BDNF signaling is modulated by sigma-1 receptors (Sig-1R). We found that the BDNF-stimulated PLC-gamma activation and the ensued increase in intracellular Ca2+ ([Ca2+](i)) were potentiated by pretreatment with imipramine or fluvoxamine, so was the BDNF-induced glutamate release. Furthermore, enhancement of the interaction between PLC-gamma and TrkB ( receptor for BDNF) after imipramine pretreatment was observed. Interestingly, BD1047, a potent Sig-1R antagonist, blocked the imipraminedependent potentiation on the BDNF-induced PLC-gamma activation and glutamate release. In contrast, overexpression of Sig-1R per se, without antidepressant pretreatment, enhances BDNF-induced PLC-gamma activation and glutamate release. These results suggest that antidepressant pretreatment selectively enhance the BDNF signaling on the PLC-gamma/IP3/Ca2+ pathway via Sig-1R, and that Sig-1R plays an important role in BDNF signaling leading to glutamate release.	NCNP, Dept Mental Disorder Res, Natl Inst Neurosci, Tokyo 1878502, Japan; DPS, Cellular Pathobiol Unit, Cellular Neurobiol Res Branch, Intramural Res Program,Dept Hlth & Human Serv,NID, Baltimore, MD 21224 USA	National Center for Neurology & Psychiatry - Japan	Numakawa, T (corresponding author), NCNP, Dept Mental Disorder Res, Natl Inst Neurosci, Tokyo 1878502, Japan.	numakawa@ncnp.go.jp	Kunugi, Hiroshi/ABC-5260-2021; Hayashi, Teruo/A-9690-2008	Kunugi, Hiroshi/0000-0002-7209-3790				Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Chen B, 2001, BIOL PSYCHIAT, V50, P260, DOI 10.1016/S0006-3223(01)01083-6; Conti AC, 2002, J NEUROSCI, V22, P3262, DOI 10.1523/JNEUROSCI.22-08-03262.2002; COWBURN RF, 1994, BRAIN RES, V633, P297, DOI 10.1016/0006-8993(94)91552-0; Dijkhuizen PA, 2005, J NEUROBIOL, V62, P278, DOI 10.1002/neu.20100; Dowlatshahi D, 1999, J NEUROCHEM, V73, P1121, DOI 10.1046/j.1471-4159.1999.0731121.x; Duman RS, 2002, MOL PSYCHIATR, V7, pS29, DOI 10.1038/sj.mp.4001016; Duman RS, 1997, ARCH GEN PSYCHIAT, V54, P597; Dwivedi Y, 2005, NEUROPSYCHOPHARMACOL, V30, P473, DOI 10.1038/sj.npp.1300605; Dwivedi Y, 2002, NEUROPHARMACOLOGY, V43, P1269, DOI 10.1016/S0028-3908(02)00253-8; Dwivedi Y, 2001, J NEUROCHEM, V77, P916, DOI 10.1046/j.1471-4159.2001.00300.x; Dwivedi Y, 2003, ARCH GEN PSYCHIAT, V60, P804, DOI 10.1001/archpsyc.60.8.804; Fitzgerald LR, 1996, J NEUROCHEM, V66, P429; FUKUDA H, 1994, NEUROCHEM INT, V25, P567, DOI 10.1016/0197-0186(94)90155-4; Hayashi T, 2003, J PHARMACOL EXP THER, V306, P718, DOI 10.1124/jpet.103.051284; Hayashi T, 2003, J PHARMACOL EXP THER, V306, P726, DOI 10.1124/jpet.103.051292; Hayashi T, 2001, P NATL ACAD SCI USA, V98, P491, DOI 10.1073/pnas.021413698; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Jensen JB, 2000, EUR NEUROPSYCHOPHARM, V10, P105, DOI 10.1016/S0924-977X(99)00064-4; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Karege F, 2005, BIOL PSYCHIAT, V57, P1068, DOI 10.1016/j.biopsych.2005.01.008; KAWAMURA M, 2003, RRD NEUROCHEMISTRY, V6, P105; Kouchi Z, 2004, J BIOL CHEM, V279, P10408, DOI 10.1074/jbc.M313801200; Lu B, 2003, LEARN MEMORY, V10, P86, DOI 10.1101/lm.54603; MATSUMOTO RR, 1995, EUR J PHARMACOL, V280, P301, DOI 10.1016/0014-2999(95)00208-3; Morin-Surun MP, 1999, P NATL ACAD SCI USA, V96, P8196, DOI 10.1073/pnas.96.14.8196; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Numakawa T, 2004, HUM MOL GENET, V13, P2699, DOI 10.1093/hmg/ddh280; Numakawa T, 1999, BRAIN RES, V842, P431, DOI 10.1016/S0006-8993(99)01867-3; Numakawa T, 2003, J BIOL CHEM, V278, P41259, DOI 10.1074/jbc.M304409200; Numakawa T, 2002, J BIOL CHEM, V277, P6520, DOI 10.1074/jbc.M109139200; Numakawa T, 2002, J BIOL CHEM, V277, P28861, DOI 10.1074/jbc.M202927200; Numakawa T, 2001, J NEUROSCI RES, V66, P96, DOI 10.1002/jnr.1201; Pandey GN, 1999, AM J PSYCHIAT, V156, P1895; Pilc A, 1995, NEUROREPORT, V7, P85, DOI 10.1097/00001756-199512290-00020; Reddy DS, 1998, NEUROREPORT, V9, P3069, DOI 10.1097/00001756-199809140-00028; Russo-Neustadt AA, 2000, NEUROSCIENCE, V101, P305, DOI 10.1016/S0306-4522(00)00349-3; Saarelainen T, 2003, J NEUROSCI, V23, P349; Shirayama Y, 2002, J NEUROSCI, V22, P3251, DOI 10.1523/JNEUROSCI.22-08-03251.2002; Shirayama Y, 1997, EUR J PHARMACOL, V331, P319, DOI 10.1016/S0014-2999(97)01051-0; Siuciak JA, 1997, PHARMACOL BIOCHEM BE, V56, P131, DOI 10.1016/S0091-3057(96)00169-4; Skolnick P, 1999, EUR J PHARMACOL, V375, P31, DOI 10.1016/S0014-2999(99)00330-1; SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995; Su TP, 2003, CURR MED CHEM, V10, P2073, DOI 10.2174/0929867033456783; SU TP, 1982, J PHARMACOL EXP THER, V223, P284; Takebayashi M, 2004, PHARMACOPSYCHIATRY, V37, pS208, DOI 10.1055/s-2004-832679; Takei N, 1998, J BIOL CHEM, V273, P27620, DOI 10.1074/jbc.273.42.27620; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Urani A, 2001, J PHARMACOL EXP THER, V298, P1269; WAHL MI, 1992, J BIOL CHEM, V267, P10447; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298	53	98	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12941	12949		10.1074/jbc.M508157200	http://dx.doi.org/10.1074/jbc.M508157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522641	hybrid			2022-12-25	WOS:000237134700089
J	Boughan, PK; Argent, RH; Body-Malapel, M; Park, JH; Ewings, KE; Bowie, AG; Ong, SJ; Cook, SJ; Sorensen, OE; Manzo, BA; Inohara, N; Klein, NJ; Nunez, G; Atherton, JC; Bajaj-Elliott, M				Boughan, PK; Argent, RH; Body-Malapel, M; Park, JH; Ewings, KE; Bowie, AG; Ong, SJ; Cook, SJ; Sorensen, OE; Manzo, BA; Inohara, N; Klein, NJ; Nunez, G; Atherton, JC; Bajaj-Elliott, M			Nucleotide-binding oligomerization domain-1 and epidermal growth factor receptor - Critical regulators of beta-defensins during helicobacter pylori infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GASTRIC EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASES; HUMAN BETA-DEFENSIN-2; INNATE IMMUNITY; INTERLEUKIN-8 SECRETION; ANTIMICROBIAL RESPONSE; GENE-EXPRESSION; INCREASED RISK; UP-REGULATION	Host-pathogen interactions that allow Helicobacter pylori to survive and persist in the stomach of susceptible individuals remain unclear. Human beta-defensins ( hBDs), epithelial-derived antimicrobial peptides are critical components of host-defense at mucosal surfaces. The role of H. pylori-mediated NF-kappa B and epidermal growth factor receptor ( EGFR) activation on beta-defensin expression was investigated. Transient transfection studies utilizing beta-defensin promoter constructs were conducted in gastric cells with contribution of individual signaling events evaluated by the addition of specific inhibitors, small interference nucleotide-binding oligomerization domain 1( NOD1) RNA or plasmids encoding Vaccinia virus proteins that interrupt interleukin-1 and Toll-like receptor signaling. The role of individual MAPK pathways was further delineated in HEK-293 cells expressing conditional MAPK mutants. We found hBD2 expression exclusively dependent on the presence of the bacterial cag pathogenicity island, with NOD1 a critical host sensor. Impairment of murine beta-defensin 4( an orthologue of hBD2) expression in NOD1-deficient mice 7-days post-infection further confirmed the role of this cytoplasmic pattern-recognition receptor in eliciting host innate immunity. In contrast to hBD2, hBD3 expression was NOD1-independent but EGFR and ERK pathway-dependent. Importantly, Toll-like receptor signaling was not implicated in H. pylori-mediated hBD2 and hBD3 gene expression. The divergent signaling events governing hBD2 and hBD3 expression suggest temporal functional variation, such that hBD2 may contribute to antimicrobial barrier function during the inflammatory phase with hBD3 playing a greater role during the repair, wound healing phase of infection.	Inst Child Hlth, Infect Dis & Microbiol Unit, London WC1N 1EH, England; Univ Nottingham, Queens Med Ctr, Inst Infect Immun & Inflammat, Nottingham NG7 2UH, England; Univ Nottingham, Queens Med Ctr, Wolfson Digest Dis Ctr, Nottingham NG7 2UH, England; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Babraham Inst, Lab Mol Signaling, Cambridge CB2 4AT, England; Lund Univ, Biomed Ctr B14, Dept Clin Sci, Sect Clin & Expt Infect Med, SE-22184 Lund, Sweden; Barts & London Queen Marys Sch Med & Dent, Inst Cell & Mol Biol, Res Ctr Gastroenterol, London E1 2AD, England	University of London; University College London; University of Nottingham; University of Nottingham; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Trinity College Dublin; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Lund University; University of London; Queen Mary University London	Bajaj-Elliott, M (corresponding author), Inst Child Hlth, Infect Dis & Microbiol Unit, 30 Guilford St, London WC1N 1EH, England.	M.Bajaj-Elliott@ich.ucl.ac.uk	Body-Malapel, Mathilde/K-9981-2018; Nuñez, Gabriel/A-7160-2014	Body-Malapel, Mathilde/0000-0003-3392-4229; /0000-0001-6180-0042; Bajaj-Elliott, Mona/0000-0002-5234-576X; Klein, Nigel/0000-0003-3925-9258; Bowie, Andrew/0000-0001-5316-4373	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061707] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C199] Funding Source: Medline; NIDDK NIH HHS [R01-DK61707] Funding Source: Medline; Wellcome Trust [065883] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Atherton JC, 1998, BRIT MED BULL, V54, P105; Atherton JC, 1997, GUT, V40, P701, DOI 10.1136/gut.40.6.701; Bajaj-Elliott M, 2002, GUT, V51, P356, DOI 10.1136/gut.51.3.356; Bebb JR, 2003, INFECT IMMUN, V71, P3623, DOI 10.1128/IAI.71.6.3623-3627.2003; Bhattacharyya A, 2002, BIOCHEM J, V368, P121, DOI 10.1042/BJ20020555; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI [10.1172/JCI200420925, 10.1172/JCI20925]; Blaser MJ, 1996, SCI AM, V274, P104, DOI 10.1038/scientificamerican0296-104; Blaser MJ, 2001, J CLIN INVEST, V107, P767, DOI 10.1172/JCI12672; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Covacci A, 2000, J EXP MED, V191, P587, DOI 10.1084/jem.191.4.587; Crabtree JE, 1999, J CLIN PATHOL, V52, P653, DOI 10.1136/jcp.52.9.653; CRABTREE JE, 1995, J CLIN PATHOL, V48, P967, DOI 10.1136/jcp.48.10.967; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Finlay BB, 2004, NAT REV MICROBIOL, V2, P497, DOI 10.1038/nrmicro908; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; George JT, 2003, MOL IMMUNOL, V40, P451, DOI 10.1016/S0161-5890(03)00158-5; Gewirtz AT, 2004, J INFECT DIS, V189, P1914, DOI 10.1086/386289; Hamanaka Y, 2001, GUT, V49, P481, DOI 10.1136/gut.49.4.481; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harte MT, 2003, J EXP MED, V197, P343, DOI 10.1084/jem.20021652; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hertz CJ, 2003, J IMMUNOL, V171, P6820, DOI 10.4049/jimmunol.171.12.6820; Israel DA, 2001, ALIMENT PHARM THER, V15, P1271, DOI 10.1046/j.1365-2036.2001.01052.x; Jang BC, 2004, BIOCHEM BIOPH RES CO, V320, P1026, DOI 10.1016/j.bbrc.2004.06.049; Karin M, 2004, ANN RHEUM DIS, V63, P62, DOI 10.1136/ard.2004.028274; Keates S, 2005, GUT, V54, P1363, DOI 10.1136/gut.2005.066977; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200; Kim SY, 2006, CELL MICROBIOL, V8, P97, DOI 10.1111/j.1462-5822.2005.00603.x; Leahy DJ, 2004, ADV PROTEIN CHEM, V68, P1; Levenstein S, 1999, CAN J GASTROENTEROL, V13, P753, DOI 10.1155/1999/521393; Liu LD, 2003, J IMMUNOL, V170, P575, DOI 10.4049/jimmunol.170.1.575; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Meyer-ter-Vehn T, 2000, J BIOL CHEM, V275, P16064, DOI 10.1074/jbc.M000959200; Mitsuno Y, 2001, GUT, V49, P18, DOI 10.1136/gut.49.1.18; Naumann M, 2001, INT J MED MICROBIOL, V291, P299, DOI 10.1078/1438-4221-00133; Naumann M, 2004, TRENDS MICROBIOL, V12, P29, DOI 10.1016/j.tim.2003.11.005; Nozawa Y, 2002, BIOCHEM PHARMACOL, V64, P21, DOI 10.1016/S0006-2952(02)01030-4; O'Neil DA, 2000, INFECT IMMUN, V68, P5412, DOI 10.1128/IAI.68.9.5412-5415.2000; Ozato K, 2002, BIOTECHNIQUES, P66; Philpott DJ, 2004, MOL IMMUNOL, V41, P1099, DOI 10.1016/j.molimm.2004.06.012; Rittig MG, 2003, CELL MICROBIOL, V5, P887, DOI 10.1046/j.1462-5822.2003.00328.x; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Semple CAM, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-32; Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200; Sorensen OE, 2005, J IMMUNOL, V174, P4870, DOI 10.4049/jimmunol.174.8.4870; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Su B, 2003, INFECT IMMUN, V71, P3496, DOI 10.1128/IAI.71.6.3496-3502.2003; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Todd DE, 2004, ONCOGENE, V23, P3284, DOI 10.1038/sj.onc.1207467; Torok AM, 2005, INFECT IMMUN, V73, P1523, DOI 10.1128/IAI.73.3.1523-1531.2005; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Vora P, 2004, J IMMUNOL, V173, P5398, DOI 10.4049/jimmunol.173.9.5398; Wada A, 1999, BIOCHEM BIOPH RES CO, V263, P770, DOI 10.1006/bbrc.1999.1452; Wada A, 2001, CELL MICROBIOL, V3, P115, DOI 10.1046/j.1462-5822.2001.00096.x; Wallasch C, 2002, BIOCHEM BIOPH RES CO, V295, P695, DOI 10.1016/S0006-291X(02)00740-4; Wang XR, 2003, FASEB J, V17, P1727, DOI 10.1096/fj.02-0616fje; Wehkamp J, 2004, INFECT IMMUN, V72, P5750, DOI 10.1128/IAI.72.10.5750-5758.2004; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Zilbauer M, 2005, INFECT IMMUN, V73, P7281, DOI 10.1128/IAI.73.11.7281-7289.2005	70	141	150	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11637	11648		10.1074/jbc.M510275200	http://dx.doi.org/10.1074/jbc.M510275200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513653	hybrid			2022-12-25	WOS:000236988100027
J	Kay, JG; Murray, RZ; Pagan, JK; Stow, JL				Kay, JG; Murray, RZ; Pagan, JK; Stow, JL			Cytokine secretion via cholesterol-rich lipid raft-associated SNAREs at the phagocytic cup	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; PLASMA-MEMBRANE; CELLULAR CHOLESTEROL; PHAGOSOME FORMATION; VESICLE FUSION; PC12 CELLS; MACROPHAGES; PROTEINS; EXOCYTOSIS	Lipopolysaccharide-activated macrophages rapidly synthesize and secrete tumor necrosis factor alpha(TNF alpha) to prime the immune system. Surface delivery of membrane carrying newly synthesized TNF alpha is controlled and limited by the level of soluble N-ethylmaleimide-sensitive factor attachment protein receptor ( SNARE) proteins syntaxin 4 and SNAP-23. Many functions in immune cells are coordinated from lipid rafts in the plasma membrane, and we investigated a possible role for lipid rafts in TNF alpha trafficking and secretion. TNF alpha surface delivery and secretion were found to be cholesterol-dependent. Upon macrophage activation, syntaxin 4 was recruited to cholesterol-dependent lipid rafts, whereas its regulatory protein, Munc18c, was excluded from the rafts. Syntaxin 4 in activated macrophages localized to discrete cholesterol-dependent puncta on the plasma membrane, particularly on filopodia. Imaging the early stages of TNF alpha surface distribution revealed these puncta to be the initial points of TNF alpha delivery. During the early stages of phagocytosis, syntaxin 4 was recruited to the phagocytic cup in a cholesterol-dependent manner. Insertion of VAMP3-positive recycling endosome membrane is required for efficient ingestion of a pathogen. Without this recruitment of syntaxin 4, it is not incorporated into the plasma membrane, and phagocytosis is greatly reduced. Thus, relocation of syntaxin 4 into lipid rafts in macrophages is a critical and rate-limiting step in initiating an effective immune response.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland	Stow, JL (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	j.stow@imb.uq.edu.au	Pagan, Julia/O-1929-2016; Stow, Jennifer L/I-4723-2013; Murray, Rachael/J-1370-2012	Pagan, Julia/0000-0002-7079-6388; Stow, Jennifer L/0000-0002-5409-9101; Murray, Rachael/0000-0002-4935-7794; Kay, Jason/0000-0001-8944-6612				Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Christian AE, 1997, J LIPID RES, V38, P2264; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Cuschieri J, 2004, SURGERY, V136, P169, DOI 10.1016/j.surg.2004.04.009; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Foster LJ, 2000, AM J PHYSIOL-CELL PH, V279, pC877, DOI 10.1152/ajpcell.2000.279.4.C877; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; Gaus K, 2005, J CELL BIOL, V171, P121, DOI 10.1083/jcb.200505047; Gaus K, 2005, J LIPID RES, V46, P1526, DOI 10.1194/jlr.M500103-JLR200; Gaus K, 2003, P NATL ACAD SCI USA, V100, P15554, DOI 10.1073/pnas.2534386100; Gil C, 2005, BIOCHEM BIOPH RES CO, V329, P117, DOI 10.1016/j.bbrc.2005.01.111; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grusovin J, 2000, BIOCHEM J, V350, P741, DOI 10.1042/0264-6021:3500741; Hackam DJ, 1996, J IMMUNOL, V156, P4377; Hailstones D, 1998, J LIPID RES, V39, P369; Harder T, 2004, TRAFFIC, V5, P265, DOI 10.1111/j.1600-0854.2003.00163.x; Hong WJ, 2005, BBA-MOL CELL RES, V1744, P120, DOI 10.1016/j.bbamcr.2005.03.014; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Joukhadar C, 2001, THROMB HAEMOSTASIS, V85, P47, DOI 10.1055/s-0037-1612902; Kiener PA, 2001, INT IMMUNOPHARMACOL, V1, P105, DOI 10.1016/S0162-3109(00)00272-1; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Laude AJ, 2004, MOL MEMBR BIOL, V21, P193, DOI 10.1080/09687680410001700517; Li N, 2003, PROTEOMICS, V3, P536, DOI 10.1002/pmic.200390067; Loike JD, 2004, ARTERIOSCL THROM VAS, V24, P2051, DOI 10.1161/01.ATV.0000143858.15909.29; Matsumoto M, 2004, J IMMUNOL, V172, P7377, DOI 10.4049/jimmunol.172.12.7377; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Murray RZ, 2005, J BIOL CHEM, V280, P10478, DOI 10.1074/jbc.M414420200; Murray RZ, 2005, SCIENCE, V310, P1492, DOI 10.1126/science.1120225; Pagan JK, 2003, CURR BIOL, V13, P156, DOI 10.1016/S0960-9822(03)00006-X; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Parton RG, 2004, TRENDS CELL BIOL, V14, P141, DOI 10.1016/j.tcb.2004.02.001; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; Poloso NJ, 2004, J IMMUNOL, V173, P4539, DOI 10.4049/jimmunol.173.7.4539; Pombo I, 2003, FEBS LETT, V550, P144, DOI 10.1016/S0014-5793(03)00864-0; Predescu SA, 2005, J BIOL CHEM, V280, P37130, DOI 10.1074/jbc.M505659200; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; Ravasi T, 2002, J IMMUNOL, V168, P44, DOI 10.4049/jimmunol.168.1.44; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Salaun C, 2004, TRAFFIC, V5, P255, DOI 10.1111/j.1600-0854.2004.0162.x; Salaun C, 2005, J BIOL CHEM, V280, P19449, DOI 10.1074/jbc.M501923200; Shurety W, 2001, LAB INVEST, V81, P107, DOI 10.1038/labinvest.3780216; Shurety W, 2000, J INTERF CYTOK RES, V20, P427, DOI 10.1089/107999000312379; Stoddart A, 2002, IMMUNITY, V17, P451, DOI 10.1016/S1074-7613(02)00416-8; Sun DX, 2003, CELL IMMUNOL, V223, P52, DOI 10.1016/S0008-8749(03)00148-5; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tuluc F, 2003, INT IMMUNOPHARMACOL, V3, P1775, DOI 10.1016/j.intimp.2003.08.002; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; von Tresckow B, 2004, J IMMUNOL, V172, P4324, DOI 10.4049/jimmunol.172.7.4324; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	66	87	89	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11949	11954		10.1074/jbc.M600857200	http://dx.doi.org/10.1074/jbc.M600857200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513632	hybrid			2022-12-25	WOS:000236988100064
J	San Filippo, J; Chi, P; Sehorn, MG; Etchin, J; Krejci, L; Sung, P				San Filippo, J; Chi, P; Sehorn, MG; Etchin, J; Krejci, L; Sung, P			Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; HOMOLOGOUS RECOMBINATION; COMPLEX-FORMATION; PROTEIN; BINDING; REPAIR; DEFICIENCY; YEAST; DSS1	BRCA2 likely exerts its tumor suppressor function by enhancing the efficiency of the homology-directed repair of injured chromosomes. To help define the DNA repair role of BRCA2, we expressed and purified a polypeptide, BRC3/4-DBD, that harbors its BRC3 and BRC4 repeats and DNA binding domain. BRC3/4-DBD interacted with hRad51 and bound DNA with a distinct preference for single-stranded ( ss) DNA. Importantly we demonstrated by biochemical means and electron microscopy that BRC3/4-DBD nucleates hRad51 onto ssDNA and acts as a recombination mediator in enabling hRad51 to utilize replication protein A-coated ssDNA as recombination substrate. These functions of BRC3/4-DBD required both the BRC repeats and the BRCA2 DNA binding domain. The results thus clarify the role of BRCA2 in Rad51-dependent DNA recombination and repair, and the experimental strategies described herein should be valuable for systematically deciphering this BRCA2 function.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,C130 Sterling Hall Med, New Haven, CT 06520 USA.	Patrick.Sung@yale.edu	Chi, Peter/AAI-1580-2019; Huang, Wenchi/F-3981-2010; Krejci, Lumir/B-7842-2009	Chi, Peter/0000-0001-9229-8729; Huang, Wenchi/0000-0001-5556-1460; Krejci, Lumir/0000-0002-4732-1405	NATIONAL CANCER INSTITUTE [R01CA110415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA110415, R01CA110415] Funding Source: Medline; NIEHS NIH HHS [R01 ES007061] Funding Source: Medline; Wellcome Trust [076476, GR076476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chi P, 2006, DNA REPAIR, V5, P381, DOI 10.1016/j.dnarep.2005.11.005; D'Andrea AD, 2003, GENE DEV, V17, P1933, DOI 10.1101/gad.1128303; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; KIM JS, 1993, PROTEIN SCI, V2, P348; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Li J, 2006, ONCOGENE, V25, P1186, DOI 10.1038/sj.onc.1209153; Lo T, 2003, DNA REPAIR, V2, P1015, DOI 10.1016/S1568-7864(03)00097-1; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Morrison C, 1999, MOL CELL BIOL, V19, P6891; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; Yonetani Y, 2005, NUCLEIC ACIDS RES, V33, P4544, DOI 10.1093/nar/gki766; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398; Yuan SSF, 1999, CANCER RES, V59, P3547	32	95	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11649	11657		10.1074/jbc.M601249200	http://dx.doi.org/10.1074/jbc.M601249200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513631	Green Accepted, hybrid			2022-12-25	WOS:000236988100028
J	Wilson, SJ; Smyth, EM				Wilson, SJ; Smyth, EM			Internalization and recycling of the human prostacyclin receptor is modulated through its isoprenylation-dependent interaction with the delta subunit of cGMP phosphodiesterase 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARRESTIN-INDEPENDENT INTERNALIZATION; SMOOTH-MUSCLE-CELLS; ROD PHOSPHODIESTERASE; THROMBOXANE A(2); BINDING-PROTEIN; HUMAN PLATELETS; PDE-DELTA; DESENSITIZATION; PHOSPHORYLATION; RAB13	Prostacyclin, the major cyclooxygenase-derived product of arachidonic acid formed in the vasculature, mediates its potent anti-thrombotic and anti-proliferative effects through its G protein-coupled receptor (GPCR) termed the IP. Unlike many GPCRs, agonist-induced internalization of the IP occurs in an arrestin/ GPCR kinase-independent manner. However, deletion of the IP COOH-terminal region prevented internalization suggesting that protein interactions at this region are involved in IP regulation. Using the COOH-terminal region of IP as bait we identified the delta subunit of cGMP phosphodiesterase 6 (PDE6 delta) as a novel hIP-interacting protein in two independent yeast two-hybrid screens. Interaction of IP and PDE6 delta was confirmed by co-immunoprecipitation in HEK293 cells, and in HEPG2 cells, which endogenously express neither IP nor PDE6 delta. IP isoprenylation was critical for this interaction, as PDE6 delta was unable to associate with an isoprenylation-deficient mutant IP (IPSSLC). PDE6 delta overexpression altered the temporal pattern of agonist-induced internalization of IP, but not IPSSLC, in HEPG2 cells, increasing initial internalization but facilitating the return of IP to the cell surface despite the continued presence of agonist. Depletion of PDE6 delta using short interfering RNA abolished cicaprost-induced IP internalization in human aortic smooth muscle cells. Recycling of IP, but not IPSSLC, upon agonist removal was facilitated by overexpression of PDE6 delta. Thus PDE6 delta interacts specifically with IP to modulate receptor trafficking.	Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Smyth, EM (corresponding author), Univ Penn, Inst Translat Med & Therapeut, 808 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	emer@spirit.gcrc.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL066233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l; Cook TA, 2001, J BIOL CHEM, V276, P5248, DOI 10.1074/jbc.M004690200; Fisch A, 1997, CIRCULATION, V96, P756; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Giebing G, 2005, CIRC RES, V97, P707, DOI 10.1161/01.RES.0000184670.58688.9F; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; Giovanazzi S, 1997, BIOCHEM J, V325, P71, DOI 10.1042/bj3250071; Hamelin E, 2005, J BIOL CHEM, V280, P36195, DOI 10.1074/jbc.M503438200; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Hanzal-Bayer M, 2005, J MOL BIOL, V350, P1074, DOI 10.1016/j.jmb.2005.05.036; Hayes JS, 1999, J BIOL CHEM, V274, P23707, DOI 10.1074/jbc.274.34.23707; Kobayashi T, 2004, J CLIN INVEST, V114, P784, DOI 10.1172/JCI200421446; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Kothapalli D, 2005, PROSTAG OTH LIPID M, V78, P3, DOI 10.1016/j.prostaglandins.2005.04.003; Kothapalli D, 2003, MOL PHARMACOL, V64, P249, DOI 10.1124/mol.64.2.249; Lawler OA, 2001, J BIOL CHEM, V276, P33596, DOI 10.1074/jbc.M104434200; Li N, 1998, GENOMICS, V49, P76, DOI 10.1006/geno.1998.5210; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Marzesco AM, 1998, J BIOL CHEM, V273, P22340, DOI 10.1074/jbc.273.35.22340; Marzesco AM, 2001, METHOD ENZYMOL, V329, P197; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Miggin SM, 2002, EUR J BIOCHEM, V269, P1714, DOI 10.1046/j.1432-1327.2002.02817.x; Morimoto S, 2005, J BIOL CHEM, V280, P2220, DOI 10.1074/jbc.M406906200; Munro S, 2005, BIOCHEM SOC T, V33, P601, DOI 10.1042/BST0330601; Nancy V, 2002, J BIOL CHEM, V277, P15076, DOI 10.1074/jbc.M109983200; Nilius SM, 2000, FEBS LETT, V484, P211, DOI 10.1016/S0014-5793(00)02156-6; Norton AW, 2005, J BIOL CHEM, V280, P1248, DOI 10.1074/jbc.M410475200; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258; Smyth EM, 2000, J BIOL CHEM, V275, P32037, DOI 10.1074/jbc.M003873200; Sobolewski A, 2004, AM J PHYSIOL-LUNG C, V287, pL352, DOI 10.1152/ajplung.00270.2003; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; Wilson SJ, 2004, J BIOL CHEM, V279, P53036, DOI 10.1074/jbc.M405002200; Wong DR, 2005, CURR OPIN PHARMACOL, V5, P204, DOI 10.1016/j.coph.2005.02.001	37	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11780	11786		10.1074/jbc.M513110200	http://dx.doi.org/10.1074/jbc.M513110200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16527812	hybrid			2022-12-25	WOS:000236988100043
J	Sprangers, M; Feldhahn, N; Herzog, S; Hansmann, ML; Reppel, M; Hescheler, J; Jumaa, H; Siebert, R; Muschen, M				Sprangers, M.; Feldhahn, N.; Herzog, S.; Hansmann, M-L; Reppel, M.; Hescheler, J.; Jumaa, H.; Siebert, R.; Mueschen, M.			The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells	ONCOGENE			English	Article						pre-B cell receptor; SRC kinases; linker molecules; leukemia; tyrosine phosphorylation	ACUTE LYMPHOBLASTIC-LEUKEMIA; BRUTONS TYROSINE KINASE; ANTIGEN-RECEPTOR; LINKER PROTEIN; TUMOR-SUPPRESSOR; ACTIVATION; EXPRESSION; SLP-65; BLNK; REQUIREMENT	SLP65 represents a critical component in (pre-)B cell receptor signal transduction but is compromised in a subset of pre-B cell-derived acute lymphoblastic leukemia. Based on these findings, we investigated (i.) whether SLP65-deficiency also occurs in mature B cell-derived lymphoma and (ii.) whether SLP65-deficient B cell lymphoma cells use an alternative B cell receptor signaling pathway in the absence of SLP65. Indeed, expression of SLP65 protein was also missing in a fraction of B cell lymphoma cases. While SLP65 is essential for B cell receptor-induced Ca2+ mobilization in normal B cells, B cell receptor engagement in SLP65-deficient as compared to SLP65-reconstituted B cell lymphoma cells resulted in an accelerated yet shortlived Ca2+-signal. B cell receptor engagement of SLP65-deficient lymphoma cells involves SRC kinase activation, which is critical for B cell receptor-dependent Ca2+-mobilisation in the absence but not in the presence of SLP65. As shown by RNA interference, the SRC kinase LYN is required for B cell receptor-induced Ca2+ release in SLP65-deficient B cell lymphoma cells but dispensable after SLP65-reconstitution. B cell receptor engagement in SLP65-deficient B cell lymphoma cells also resulted in tyrosine-phosphorylation of the proliferation- and survival-related MAPK1 and STAT5 molecules, which was sensitive to silencing of the SRC kinase LYN. Inhibition of SRC kinase activity resulted in growth arrest and cell death specifically in SLP65-deficient lymphoma cells. These findings indicate that LYN can short-circuit conventional B cell receptor signaling in SLP65-deficient B cell lymphoma cells and thereby promote activation of survival and proliferation-related molecules.	Univ Dusseldorf, Lab Mol Stem Cell Biol, D-40225 Dusseldorf, Germany; Max Planck Inst Immunobiol, D-7800 Freiburg, Germany; Univ Frankfurt, Dept Pathol, D-6000 Frankfurt, Germany; Univ Cologne, Inst Neurophysiol, D-5000 Cologne 41, Germany; Univ Hosp Schleswig Holstein, Inst Human Genet, Kiel, Germany	Heinrich Heine University Dusseldorf; Max Planck Society; Goethe University Frankfurt; University of Cologne; University of Kiel; Schleswig Holstein University Hospital	Muschen, M (corresponding author), Univ Dusseldorf, Lab Mol Stem Cell Biol, Moorenstr 5, D-40225 Dusseldorf, Germany.	markus.mueschen@uni-duesseldorf.de	Siebert, Reiner/A-8049-2010	Herzog, Sebastian/0000-0001-7167-3489				Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Cooperman J, 2004, STEM CELLS, V22, P1111, DOI 10.1634/stemcells.22-6-1111; Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; Flemming A, 2003, NAT IMMUNOL, V4, P38, DOI 10.1038/ni862; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Hayashi K, 2003, IMMUNITY, V18, P825, DOI 10.1016/S1074-7613(03)00142-0; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Imai C, 2004, LEUKEMIA, V18, P922, DOI 10.1038/sj.leu.2403349; Ishiai M, 1999, J IMMUNOL, V163, P1746; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Karras JG, 1996, J IMMUNOL, V157, P39; Kersseboom R, 2003, J EXP MED, V198, P91, DOI 10.1084/jem.20030615; Klein F, 2004, J EXP MED, V199, P673, DOI 10.1084/jem.20031637; Li FJ, 2005, BLOOD, V105, P3295, DOI 10.1182/blood-2004-10-4083; Middendorp S, 2003, J IMMUNOL, V171, P5988, DOI 10.4049/jimmunol.171.11.5988; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Prakash O, 2005, BLOOD, V105, P3987, DOI 10.1182/blood-2004-07-2781; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Reppel M, 2005, J BIOL CHEM, V280, P36019, DOI 10.1074/jbc.M504750200; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791	23	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2006	25	36					5056	5062		10.1038/sj.onc.1209510	http://dx.doi.org/10.1038/sj.onc.1209510			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568084				2022-12-25	WOS:000239921300011
J	Shi, J; Kahle, A; Hershey, JWB; Honchak, BM; Warneke, JA; Leong, SPL; Nelson, MA				Shi, J.; Kahle, A.; Hershey, J. W. B.; Honchak, B. M.; Warneke, J. A.; Leong, S. P. L.; Nelson, M. A.			Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells	ONCOGENE			English	Article						eukaryotic initiation factor 3f; tumorigenesis; translation initiation; apoptosis; melanoma; pancreatic cancer	PREINITIATION COMPLEX; PROTEIN-SYNTHESIS; FACTOR EIF3; SUBUNITS; DEGRADATION; BINDING; DEATH; ACTIVATION; INDUCTION; INTERACTS	The eukaryotic initiation factor 3f (eIF3f) is the p47 subunit of the multi-subunit eIF3 complex. eIF3 plays an important role in translation initiation. In the present study, we investigate the biological function of eIF3f in translation and apoptosis in tumor cells. We demonstrated for the first time that eIF3f is downregulated in most human tumors using a cancer pro. ling array and confirmed by real-time reverse transcription PCR in melanoma and pancreatic cancer. Overexpression of eIF3f inhibits cell proliferation and induces apoptosis in melanoma and pancreatic cancer cells. Silencing of eIF3f protects melanoma cells from apoptosis. We further investigated the biological function of eIF3f. In vitro translation studies indicate that eIF3f is a negative regulator of translation and that the region between amino acids 170 and 248 of eIF3f is required for its translation regulatory function. Ectopic expression of eIF3f inhibits translation and overall cellular protein synthesis. Ribosome pro. le and ribosomal RNA (rRNA) fragmentation assays revealed that eIF3f reduces ribosomes, which may be associated with rRNA degradation. We propose that eIF3f may play a role in ribosome degradation during apoptosis. These data provide critical insights into the cellular function of eIF3f and in linking translation initiation and apoptosis.	Univ Arizona, Dept Pathol, Tucson, AZ 85724 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; No Arizona Univ, Flagstaff, AZ 86011 USA; Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Calif San Francisco, Dept Surg, Mt Zion Med Ctr, San Francisco, CA 94143 USA	University of Arizona; University of California System; University of California Davis; Northern Arizona University; Arizona Center Cancer Care; University of Arizona; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	Nelson, MA (corresponding author), Univ Arizona, Dept Pathol, AHSC Rm 5226,1501 N Campbell Ave, Tucson, AZ 85724 USA.	mnelson@azcc.arizona.edu		Shi, Jiaqi/0000-0003-4893-1587	NCI NIH HHS [CA 09213, CA70145, CA95060] Funding Source: Medline; NIEHS NIH HHS [ES066694] Funding Source: Medline; NIGMS NIH HHS [GM22135] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070145, P50CA095060, T32CA009213, R29CA070145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Ariza ME, 1999, J BIOL CHEM, V274, P28505, DOI 10.1074/jbc.274.40.28505; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Castelli J, 1998, BIOMED PHARMACOTHER, V52, P386, DOI 10.1016/S0753-3322(99)80006-7; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; Fraser CS, 2004, J BIOL CHEM, V279, P8946, DOI 10.1074/jbc.M312745200; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Joseph P, 2002, CANCER RES, V62, P703; King KL, 2000, CELL DEATH DIFFER, V7, P994, DOI 10.1038/sj.cdd.4400731; Majumdar R, 2003, J BIOL CHEM, V278, P6580, DOI 10.1074/jbc.M210357200; Martinand C, 1998, EUR J BIOCHEM, V254, P248, DOI 10.1046/j.1432-1327.1998.2540248.x; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; Mikolajczyk M, 2004, BIOCHEM J, V384, P461, DOI 10.1042/BJ20040848; Miura Y, 2002, BLOOD, V100, P2650, DOI 10.1182/blood-2002-01-0176; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Nadano D, 2000, J BIOL CHEM, V275, P13967, DOI 10.1074/jbc.275.18.13967; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; Shi JQ, 2003, J BIOL CHEM, V278, P5062, DOI 10.1074/jbc.M206427200; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SONENBERG N, 2000, TRANSLATIONAL CONTRO, P33; Tang DM, 1998, J BIOL CHEM, V273, P16601, DOI 10.1074/jbc.273.26.16601; Thompson FH, 1996, CANCER GENET CYTOGEN, V87, P55, DOI 10.1016/0165-4608(95)00248-0; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Xiang Y, 2003, CANCER RES, V63, P6795	33	87	94	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4923	4936		10.1038/sj.onc.1209495	http://dx.doi.org/10.1038/sj.onc.1209495			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16532022				2022-12-25	WOS:000239687100010
J	Herbert, AP; Uhrin, D; Lyon, M; Pangburn, MK; Barlow, PN				Herbert, Andrew P.; Uhrin, Dusan; Lyon, Malcolm; Pangburn, Michael K.; Barlow, Paul N.			Disease-associated sequence variations congregate in a polyanion recognition patch on human factor H revealed in three-dimensional structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC-UREMIC SYNDROME; COMPLEMENT FACTOR-H; GROWTH FACTOR/SCATTER FACTOR; DECAY-ACCELERATING FACTOR; HEPARIN-BINDING DOMAIN; CONTROL PROTEIN MODULE; MACULAR DEGENERATION; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; C3B INACTIVATOR	Mutations and polymorphisms in the regulator of complement activation, factor H, have been linked to atypical hemolytic uremic syndrome (aHUS), membranoproliferative glomerulonephritis, and age-related macular degeneration. Many aHUS patients carry mutations in the two C-terminal modules of factor H, which normally confer upon this abundant 155-kDa plasma glycoprotein its ability to selectively bind self-surfaces and prevent them from inappropriately triggering the complement cascade via the alternative pathway. In the current study, the three-dimensional solution structure of the C-terminal module pair of factor H has been determined. A binding site for a fully sulfated heparin-derived tetrasaccharide has been delineated using chemical shift mapping and the C3d/C3b-binding site inferred from sequence comparisons and computational docking. The resultant information allows assessment of the likely consequences of aHUS-associated amino acid substitutions in this critical region of factor H. It is striking that, excepting those likely to perturb the three-dimensional structure, aHUS-associated missense mutations congregate in the polyanion-binding site delineated in this study, thus potentially disrupting a vital mechanism for control of complement on self-surfaces in the microvasculature of the kidney. It is intriguing that a single nucleotide polymorphism predisposing to age-related macular degeneration occupies another region of factor H that harbors a polyanion-binding site.	Univ Edinburgh, Dept Chem, Edinburgh Biomol NMR Unit, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ Texas Hlth Ctr, Tyler, TX 75708 USA; Univ Manchester, Christie Hosp NHS Trust, Canc Res UK Dept Med Oncol, Manchester M20 4BX, Lancs, England	University of Edinburgh; Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Barlow, PN (corresponding author), Univ Edinburgh, Dept Chem, Edinburgh Biomol NMR Unit, W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	Paul.Barlow@ed.ac.uk	Barlow, Paul N/G-2853-2011; Herbert, Andy P/F-6693-2010; Herbert, Andrew P/C-4755-2008	Herbert, Andy P/0000-0002-4549-6965; Herbert, Andrew P/0000-0002-4549-6965; Lyon, Malcolm/0000-0001-9575-6879	Medical Research Council [G0001089] Funding Source: Medline; NIDDK NIH HHS [DK 35081] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035081, R37DK035081] Funding Source: NIH RePORTER; MRC [G0001089] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720; BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buddles MRH, 2000, AM J HUM GENET, V66, P1721, DOI 10.1086/302877; Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297; Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911; Delehedde M, 2002, J BIOL CHEM, V277, P12456, DOI 10.1074/jbc.M111345200; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Esparza-Gordillo J, 2005, HUM MOL GENET, V14, P703, DOI 10.1093/hmg/ddi066; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FREMEAUXBACCHI V, 2005, J MED GENET, V22, P22; Ganesh VK, 2004, P NATL ACAD SCI USA, V101, P8924, DOI 10.1073/pnas.0400744101; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Habeck Michael, 2004, Methods Mol Biol, V278, P379; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Hellwage J, 2002, J IMMUNOL, V169, P6935, DOI 10.4049/jimmunol.169.12.6935; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; JACKSON P, 1994, METHOD ENZYMOL, V230, P250; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; KRAULIS PJ, 1994, J MOL BIOL, V243, P696, DOI 10.1016/0022-2836(94)90042-6; KUHN S, 1995, J IMMUNOL, V155, P5663; LAMBRIS JD, 1988, J BIOL CHEM, V263, P12147; Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101; Lyon M, 2004, J BIOL CHEM, V279, P43560, DOI 10.1074/jbc.M408510200; Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; Neuhaus TJ, 1997, ARCH DIS CHILD, V76, P518, DOI 10.1136/adc.76.6.518; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; Nilges M, 1997, FOLD DES, V2, pS53, DOI 10.1016/S1359-0278(97)00064-3; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Olie KH, 2004, PEDIATR NEPHROL, V19, P1173, DOI 10.1007/s00467-004-1565-2; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; Pangburn MK, 2002, J IMMUNOL, V169, P4702, DOI 10.4049/jimmunol.169.9.4702; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201; Perkins SJ, 2002, J MOL BIOL, V316, P217, DOI 10.1006/jmbi.2001.5337; RENAUD C, 1995, PEDIATR NEPHROL, V9, P24, DOI 10.1007/BF00858960; Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285; Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4; Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19; Soares DC, 2005, PROTEIN ENG DES SEL, V18, P379, DOI 10.1093/protein/gzi039; Tarr PI, 2005, LANCET, V365, P1073, DOI 10.1016/S0140-6736(05)71144-2; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1111/j.1523-1755.1998.00824.x; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; WHALEY K, 1976, SCIENCE, V193, P1011, DOI 10.1126/science.948757; Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426	62	83	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16512	16520		10.1074/jbc.M513611200	http://dx.doi.org/10.1074/jbc.M513611200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16533809	hybrid			2022-12-25	WOS:000238165700041
J	Han, P; Sonati, P; Rubin, C; Michaeli, T				Han, Ping; Sonati, Pushpalatha; Rubin, Charles; Michaeli, Tamar			PDE7A1, a cAMP-specific phosphodiesterase, inhibits cAMP-dependent protein kinase by a direct interaction with C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE INHIBITOR; CATALYTIC SUBUNIT; ANCHORING PROTEINS; REGULATORY SUBUNIT; GENE; COMPARTMENTALIZATION; IDENTIFICATION; REASSOCIATION; DETERMINANTS; LOCALIZATION	The N-terminal regulatory region of the high affinity cAMP-specific phosphodiesterase, PDE7A1, contains two copies of the cAMP-dependent kinase (PKA) pseudosubstrate site RRGAI. In beta TC3 insulinoma cells, PDE7A1 co-localizes with PKA II in the Golgi-centrosome region. The roles PDE7A1 and its regulatory region play in cAMP signaling were examined by studying interactions with PKA subunits. PDE7A1 associates with the dissociated C subunit of PKA ( C), but does not bind tetrameric PKA holoenzyme. High affinity binding of C by PDE7A1 inhibits kinase activity in vitro (IC50 = 0.5 nM). The domain containing PKA pseudosubstrate sites at the N terminus of PDE7A1 mediates complex formation with C. The PDE7A1 N-terminal repeat region inhibits C activity in CHO-K1 cells and also suppresses C dependent, cAMP-independent, physiological responses in yeast. Thus, PDE7A1 possesses a non-catalytic activity that can contribute to the termination of cAMP signals via direct inhibition of C. This study identifies a novel inhibitor of PKA and a non-catalytic affect of a cyclic nucleotide phosphodiesterase.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Michaeli, T (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA.	michaeli@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058871, P60DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-58871, DK20541] Funding Source: Medline; NIGMS NIH HHS [GM-22792] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALHANATY E, 1985, CURR TOP CELL REGUL, V27, P267; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; Asirvatham AL, 2004, J IMMUNOL, V173, P4806, DOI 10.4049/jimmunol.173.8.4806; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baillie GS, 2005, FEBS LETT, V579, P3264, DOI 10.1016/j.febslet.2005.03.089; Baillie GS, 2005, CURR OPIN CELL BIOL, V17, P129, DOI 10.1016/j.ceb.2005.01.003; BUECHLER YJ, 1993, J BIOL CHEM, V268, P16495; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CHAU V, 1980, BIOCHEMISTRY-US, V19, P924, DOI 10.1021/bi00546a016; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; DAMBRA R, 1990, ENDOCRINOLOGY, V126, P2815, DOI 10.1210/endo-126-6-2815; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GROVE JR, 1989, J BIOL CHEM, V264, P19506; Han P, 1997, J BIOL CHEM, V272, P16152, DOI 10.1074/jbc.272.26.16152; Han P, 1998, GENOMICS, V48, P275, DOI 10.1006/geno.1997.5168; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; Houslay MD, 1997, BIOCHEM SOC T, V25, P374, DOI 10.1042/bst0250374; HUBBARD EJA, 1992, GENETICS, V130, P71; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; OGREID D, 1983, BIOCHEMISTRY-US, V22, P1686; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; Richter W, 2002, PROTEIN EXPRES PURIF, V25, P138, DOI 10.1006/prep.2002.1620; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Sasaki T, 2000, BIOCHEM BIOPH RES CO, V271, P575, DOI 10.1006/bbrc.2000.2661; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; Wang HC, 2005, J BIOL CHEM, V280, P30949, DOI 10.1074/jbc.M504398200; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; WEISS A, 1988, MOL ENDOCRINOL, V2, P412, DOI 10.1210/mend-2-5-412; WEN W, 1994, J BIOL CHEM, V269, P8423; WEN W, 1994, J BIOL CHEM, V269, P32214; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Yang GC, 2003, J IMMUNOL, V171, P6414, DOI 10.4049/jimmunol.171.12.6414; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zhu XY, 2000, CURR GENET, V38, P60, DOI 10.1007/s002940000133; ZOLLER MJ, 1991, GENE, V99, P171, DOI 10.1016/0378-1119(91)90124-T	62	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15050	15057		10.1074/jbc.M601333200	http://dx.doi.org/10.1074/jbc.M601333200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16556600	hybrid			2022-12-25	WOS:000237922200006
J	Schafer, E; Seelert, H; Reifschneider, NH; Krause, F; Dencher, NA; Vonck, J				Schaefer, Eva; Seelert, Holger; Reifschneider, Nicole H.; Krause, Frank; Dencher, Norbert A.; Vonck, Janet			Architecture of active mammalian respiratory chain supercomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; OXIDATIVE-PHOSPHORYLATION COMPLEXES; MITOCHONDRIAL ELECTRON-TRANSPORT; BLUE NATIVE ELECTROPHORESIS; C-OXIDASE; YEAST MITOCHONDRIA; PROTEIN COMPLEXES; ANGSTROM; RESPIRASOMES; LOCALIZATION	In the inner mitochondrial membrane, the respiratory chain complexes generate an electrochemical proton gradient, which is utilized to synthesize most of the cellular ATP. According to an increasing number of biochemical studies, these complexes are assembled into supercomplexes. However, little is known about the architecture of the proposed multicomplex assemblies. Here, we report the electron microscopic characterization of the two respiratory chain supercomplexes I1III2 and I1III2IV1 in bovine heart mitochondria, which are also two major supercomplexes in human mitochondria. After purification and demonstration of enzymatic activity, their structures in projection were determined by single particle image analysis. A difference map between the supercomplexes I1III2 and I1III2IV1 closely fits the x-ray structure of monomeric complex IV and shows its location in the assembly. By comparing different views of supercomplex I1III2IV1, the location and mutual arrangement of complex I and the complex III dimer are discussed. Detailed knowledge of the architecture of the active supercomplexes is a prerequisite for a deeper understanding of energy conversion by mitochondria in mammals.	Max Planck Inst Biophys, Dept Biol Struct, D-60438 Frankfurt, Germany; Tech Univ Darmstadt, Dept Chem Phys Biochem, D-64287 Darmstadt, Germany	Max Planck Society; Technical University of Darmstadt	Vonck, J (corresponding author), Max Planck Inst Biophys, Dept Biol Struct, Max von Laue Str 3, D-60438 Frankfurt, Germany.	janet.vonck@mpibp-frankfurt.mpg.de	Dencher, Norbert/G-6640-2014	Vonck, Janet/0000-0001-5659-8863				Acin-Perez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8; ANGERMULLER S, 1981, HISTOCHEMISTRY, V71, P33, DOI 10.1007/BF00592568; Bianchi C, 2004, J BIOL CHEM, V279, P36562, DOI 10.1074/jbc.M405135200; BOSTINA M, 2004, THESIS J WOLFGANG GO; CHANCE B, 1955, NATURE, V176, P250, DOI 10.1038/176250a0; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102; Eubel H, 2004, PLANT PHYSIOL, V134, P1450, DOI 10.1104/pp.103.038018; Eubel H, 2003, PLANT PHYSIOL, V133, P274, DOI 10.1104/pp.103.024620; Gabaldon T, 2005, J MOL BIOL, V348, P857, DOI 10.1016/j.jmb.2005.02.067; Gong X, 2005, J BIOL CHEM, V280, P9251, DOI 10.1074/jbc.M409994200; GrandierVazeille X, 1996, ANAL BIOCHEM, V242, P248, DOI 10.1006/abio.1996.0460; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Krause F, 2005, BIOCHEM BIOPH RES CO, V329, P583, DOI 10.1016/j.bbrc.2005.02.010; Krause F, 2004, J BIOL CHEM, V279, P48369, DOI 10.1074/jbc.M406085200; Krause F, 2004, J BIOL CHEM, V279, P26453, DOI 10.1074/jbc.M402756200; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Poetsch A, 2000, BBA-BIOMEMBRANES, V1466, P339, DOI 10.1016/S0005-2736(00)00191-7; Rexroth S, 2003, ELECTROPHORESIS, V24, P2814, DOI 10.1002/elps.200305543; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2004, J BIOL CHEM, V279, P36349, DOI 10.1074/jbc.M404033200; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Schagger H, 2001, J BIOL CHEM, V276, P37861; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	36	202	212	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15370	15375		10.1074/jbc.M513525200	http://dx.doi.org/10.1074/jbc.M513525200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16551638	hybrid			2022-12-25	WOS:000237922200042
J	Ding, B; Liu, CJ; Huang, Y; Hickey, RP; Yu, J; Kong, WH; Lengyel, P				Ding, Bo; Liu, Chuan-Ju; Huang, Yan; Hickey, Reed P.; Yu, Jin; Kong, Weihua; Lengyel, Peter			p204 is required for the differentiation of P19 murine embryonal carcinoma cells to beating cardiac myocytes - Its expression is activated by the cardiac GATA4, NKX2.5, and TBX5 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-INDUCIBLE GENE; NF-KAPPA-B; TRANSCRIPTION FACTORS; CARDIOMYOCYTE DIFFERENTIATION; COMBINATORIAL INTERACTIONS; MYOBLAST DIFFERENTIATION; RETINOBLASTOMA PROTEIN; MUSCLE DIFFERENTIATION; DIMETHYL-SULFOXIDE; HEART DEVELOPMENT	Among 10 adult mouse tissues tested, the p204 protein levels were highest in heart and skeletal muscle. We described previously that the MyoD-inducible p204 protein is required for the differentiation of cultured murine C2C12 skeletal muscle myoblasts to myotubes. Here we report that p204 was also required for the differentiation of cultured P19 murine embryonal carcinoma stem cells to beating cardiac myocytes. As shown by others, this process can be triggered by dimethyl sulfoxide ( DMSO). We established that DMSO induced the formation of 204RNA and p204. Ectopic p204 could partially substitute for DMSO in inducing differentiation, whereas ectopic 204 antisense RNA inhibited the differentiation. Experiments with reporter constructs, including regulatory regions from the Ifi204 gene ( encoding p204) in P19 cells and in cultured newborn rat cardiac myocytes, as well as chromatin coimmunoprecipitations with transcription factors, revealed that p204 expression was synergistically transactivated by the cardiac Gata4, Nkx2.5, and Tbx5 transcription factors. Furthermore, ectopic p204 triggered the expression of Gata4 and Nkx2.5 in P19 cells. p204 contains a nuclear export signal and was partially translocated to the cytoplasm during the differentiation. p204 from which the nuclear export signal was deleted was not translocated, and it did not induce differentiation. The various mechanisms by which p204 promoted the differentiation are reported in the accompanying article.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; NYU, Sch Med, Dept Orthoped Surg & Cell Biol, New York, NY 10003 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University; New York University; Yale University	Lengyel, P (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.	peter.lengyel@yale.edu	Liu, Chuan-ju/AAT-8165-2021	liu, chuanju/0000-0002-7181-8032	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012320, R21AI012320, R01AI012320] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 12320] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agulnik SI, 1996, GENETICS, V144, P249; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Asefa B, 2004, BLOOD CELL MOL DIS, V32, P155, DOI 10.1016/j.bcmd.2003.10.002; BRIGGS JA, 1992, J CELL BIOCHEM, V49, P82, DOI 10.1002/jcb.240490114; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; Deschamps S, 2003, GENOMICS, V82, P34, DOI 10.1016/S0888-7543(03)00092-2; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Ding B, 2006, J BIOL CHEM, V281, P14893, DOI 10.1074/jbc.M511748200; Ding Y, 2004, ONCOGENE, V23, P4556, DOI 10.1038/sj.onc.1207592; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Durocher D, 1998, DEV GENET, V22, P250, DOI 10.1002/(SICI)1520-6408(1998)22:3<250::AID-DVG7>3.0.CO;2-5; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Ghosh TK, 2001, HUM MOL GENET, V10, P1983, DOI 10.1093/hmg/10.18.1983; Giordano FJ, 1997, CIRCULATION, V96, P400; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Horak CE, 2002, P NATL ACAD SCI USA, V99, P2924, DOI 10.1073/pnas.052706999; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; KELLEY C, 1993, DEVELOPMENT, V118, P817; Kemp DM, 2002, BIOCHEM PHARMACOL, V64, P689, DOI 10.1016/S0006-2952(02)01212-1; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Liberatore CM, 2000, DEV BIOL, V223, P169, DOI 10.1006/dbio.2000.9748; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2005, J BIOL CHEM, V280, P2788, DOI 10.1074/jbc.M412604200; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Ludlow LEA, 2005, EXP CELL RES, V308, P1, DOI 10.1016/j.yexcr.2005.03.032; Ma XY, 2003, J BIOL CHEM, V278, P23008, DOI 10.1074/jbc.M302105200; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Min W, 1996, MOL CELL BIOL, V16, P359; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MORLEY P, 1993, J CELL PHYSIOL, V156, P219, DOI 10.1002/jcp.1041560202; Nemer G, 2001, ANN MED, V33, P604, DOI 10.3109/07853890109002106; OPDENAKKER G, 1989, VIROLOGY, V171, P568, DOI 10.1016/0042-6822(89)90626-0; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V70, P99; Rozzo SJ, 2001, IMMUNITY, V15, P435, DOI 10.1016/S1074-7613(01)00196-0; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; SEN GC, 1997, TRANSCRIPTIONAL REGU; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Teunissen BEJ, 2003, GENE, V322, P123, DOI 10.1016/j.gene.2003.08.011; TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415; van der Heyden MAG, 2003, CARDIOVASC RES, V58, P292, DOI 10.1016/S0008-6363(02)00771-X; Ventura C, 2000, CIRC RES, V87, P189, DOI 10.1161/01.RES.87.3.189; Wang H, 2000, J BIOL CHEM, V275, P27377; Wang H, 1999, GENOMICS, V60, P281, DOI 10.1006/geno.1999.5923; Xin H, 2003, J CELL BIOCHEM, V88, P191, DOI 10.1002/jcb.10372	76	26	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14882	14892		10.1074/jbc.M511747200	http://dx.doi.org/10.1074/jbc.M511747200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16556595	hybrid			2022-12-25	WOS:000237671300042
J	Ding, B; Liu, CJ; Huang, Y; Yu, J; Kong, WH; Lengyel, P				Ding, Bo; Liu, Chuan-Ju; Huang, Yan; Yu, Jin; Kong, Weihua; Lengyel, Peter			p204 protein overcomes the inhibition of the differentiation of P19 murine embryonal carcinoma cells to beating cardiac myocytes by id proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; GATA TRANSCRIPTION FACTORS; INDUCIBLE 204 GENE; NF-KAPPA-B; DNA-BINDING; RETINOBLASTOMA PROTEIN; MYOBLAST DIFFERENTIATION; MUSCLE DIFFERENTIATION; MEDIATED DEGRADATION; NEGATIVE REGULATOR	We reported in the accompanying article (Ding, B., Liu, C., Huang, Y., Hickey, R. P., Yu, J., Kong, W., and Lengyel, P. (2006) J. Biol. Chem. 281, 14882 - 14892) that (i) the p204 protein is required for the differentiation of murine P19 embryonal carcinoma stem cells to beating cardiac myocytes, and (ii) the expression of p204 in the differentiating P19 cells is synergistically transactivated by the cardiac transcription factors Gata4, Nkx2.5, and Tbx5. Here we report that endogenous or ectopic inhibitor of differentiation (Id) proteins inhibited the differentiation of P19 cells to myocytes. This was in consequence of the binding of Id1, Id2, or Id3 protein to the Gata4 and Nkx2.5 proteins and the resulting inhibitions (i) of the binding of these transcription factors to each other and to DNA and (ii) of their synergistic transactivation of the expression of various genes, including atrial natriuretic factor and Ifi204 (encoding p204). p204 overcame this inhibition by Id proteins in consequence of (i) binding and sequestering Id proteins, (ii) accelerating their ubiquitination and degradation by proteasomes, and (iii) decreasing the level of Id proteins in the nucleus by increasing their translocation from the nucleus to the cytoplasm. Points (ii) and (iii) depended on the presence of the nuclear export signal in p204. In the course of the differentiation, Gata4, Nkx2.5, and p204 were components of a positive feedback loop. This loop arose in consequence of it that p204 overcame the inhibition of the synergistic activity of Gata4 and Nkx2.5 by the Id proteins.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; NYU, Sch Med, Dept Orthoped Surg & Cell Biol, New York, NY 10003 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University; New York University; Yale University	Lengyel, P (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.	peter.lengyel@yale.edu	Liu, Chuan-ju/AAT-8165-2021	liu, chuanju/0000-0002-7181-8032	NIAID NIH HHS [AI 12320] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012320, R01AI012320, R21AI012320] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benezra R, 2001, ONCOGENE, V20, P8288, DOI 10.1038/sj.onc.1205161; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Berse M, 2004, J MOL BIOL, V343, P361, DOI 10.1016/j.jmb.2004.08.043; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Brewer AC, 2005, STEM CELLS DEV, V14, P425, DOI 10.1089/scd.2005.14.425; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; De Andrea M, 2002, J INTERF CYTOK RES, V22, P1113, DOI 10.1089/10799900260442539; Deschamps S, 2003, GENOMICS, V82, P34, DOI 10.1016/S0888-7543(03)00092-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding B, 2006, J BIOL CHEM, V281, P14882, DOI 10.1074/jbc.M511747200; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fajerman I, 2004, BIOCHEM BIOPH RES CO, V314, P505, DOI 10.1016/j.bbrc.2003.12.116; Fraidenraich D, 2004, SCIENCE, V306, P247, DOI 10.1126/science.1102612; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Frosst P, 2002, J CELL BIOL, V156, P617, DOI 10.1083/jcb.200106046; GARIGLIO M, 1992, VIROLOGY, V187, P115, DOI 10.1016/0042-6822(92)90300-E; Ghosh TK, 2001, HUM MOL GENET, V10, P1983, DOI 10.1093/hmg/10.18.1983; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jamali M, 2001, J BIOL CHEM, V276, P42252, DOI 10.1074/jbc.M107814200; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kaplun L, 2003, J BIOL CHEM, V278, P48727, DOI 10.1074/jbc.M308671200; Kurooka H, 2005, J BIOL CHEM, V280, P4313, DOI 10.1074/jbc.M412614200; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2005, J BIOL CHEM, V280, P2788, DOI 10.1074/jbc.M412604200; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Ludlow LEA, 2005, EXP CELL RES, V308, P1, DOI 10.1016/j.yexcr.2005.03.032; Ma XY, 2003, J BIOL CHEM, V278, P23008, DOI 10.1074/jbc.M302105200; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Min W, 1996, MOL CELL BIOL, V16, P359; Moldes M, 1999, BIOCHEM J, V344, P873, DOI 10.1042/0264-6021:3440873; Molkentin JD, 2000, DEV BIOL, V217, P301, DOI 10.1006/dbio.1999.9544; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Nemer G, 2001, ANN MED, V33, P604, DOI 10.3109/07853890109002106; NISHIMOTO T, 1980, SOMAT CELL GENET, V6, P465, DOI 10.1007/BF01539150; NISHITANI H, 1992, BIOCHEM BIOPH RES CO, V184, P1015, DOI 10.1016/0006-291X(92)90692-E; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V70, P99; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Searcy RD, 1998, DEVELOPMENT, V125, P4461; Severs NJ, 2000, BIOESSAYS, V22, P188, DOI 10.1002/(SICI)1521-1878(200002)22:2<188::AID-BIES10>3.0.CO;2-T; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; van der Heyden MAG, 2003, CARDIOVASC RES, V58, P292, DOI 10.1016/S0008-6363(02)00771-X; Wang H, 2000, J BIOL CHEM, V275, P27377; Wojcik C, 2003, INT J BIOCHEM CELL B, V35, P579, DOI 10.1016/S1357-2725(02)00380-1; Xin H, 2003, J CELL BIOCHEM, V88, P191, DOI 10.1002/jcb.10372; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zaffran S, 2004, CIRC RES, V95, P261, DOI 10.1161/01.RES.0000136815.73623.BE	68	29	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14893	14906		10.1074/jbc.M511748200	http://dx.doi.org/10.1074/jbc.M511748200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16556596	hybrid			2022-12-25	WOS:000237671300043
J	Zhou, J; Zhai, YG; Mu, Y; Gong, HB; Uppal, H; Toma, D; Ren, SR; Evans, RM; Xie, W				Zhou, Jie; Zhai, Yonggong; Mu, Ying; Gong, Haibiao; Uppal, Hirdesh; Toma, David; Ren, Songrong; Evans, Ronald M.; Xie, Wen			A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; CHAIN FATTY-ACIDS; PPAR-GAMMA; NUCLEAR RECEPTORS; XENOBIOTIC RESPONSE; GENE-EXPRESSION; MOUSE-LIVER; DIFFERENTIATION; METABOLISM; PXR	The pregnane X receptor ( PXR) was isolated as a xenosensor regulating xenobiotic responses. In this study, we show that PXR plays an endobiotic role by impacting lipid homeostasis. Expression of an activated PXR in the livers of transgenic mice resulted in an increased hepatic deposit of triglycerides. This PXR-mediated lipid accumulation was independent of the activation of the lipogenic transcriptional factor SREBP-1c ( sterol regulatory element-binding protein 1c) and its primary lipogenic target enzymes, including fatty-acid synthase ( FAS) and acetyl-CoA carboxylase 1 ( ACC-1). Instead, the lipid accumulation in transgenic mice was associated with an increased expression of the free fatty acid transporter CD36 and several accessory lipogenic enzymes, such as stearoyl-CoA desaturase-1 ( SCD-1) and long chain free fatty acid elongase. Studies using transgenic and knock-out mice showed that PXR is both necessary and sufficient for Cd36 activation. Promoter analyses revealed a DR-3-type of PXR-response element in the mouse Cd36 promoter, establishing Cd36 as a direct transcriptional target of PXR. The hepatic lipid accumulation and Cd36 induction were also seen in the hPXR "humanized" mice treated with the hPXR agonist rifampicin. The activation of PXR was also associated with an inhibition of pro-beta-oxidative genes, such as peroxisome proliferator-activated receptor alpha( PPAR alpha) and thiolase, and an up-regulation of PPAR gamma, a positive regulator of CD36. The cross-regulation of CD36 by PXR and PPAR gamma suggests that this fatty acid transporter may function as a common target of orphan nuclear receptors in their regulation of lipid homeostasis.	Univ Pittsburgh, Ctr Pharmacognet, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15213 USA; Salk Inst Biol Studies, Gene Express Lab, Howard Hughes Med Inst, La Jolla, CA 92122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Howard Hughes Medical Institute; Salk Institute	Xie, W (corresponding author), Univ Pittsburgh, Ctr Pharmacognet, Pittsburgh, PA 15213 USA.	wex6@pitt.edu	Xie, Wen/M-1768-2016; Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NATIONAL CANCER INSTITUTE [P30CA014195, R01CA107011] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [F05AT002029] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL105278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK057978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337, R01ES012479] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCCIH NIH HHS [AT 002029] Funding Source: Medline; NCI NIH HHS [R01 CA107011, CA 107011, P30 CA014195] Funding Source: Medline; NHLBI NIH HHS [R01 HL105278] Funding Source: Medline; NIDDK NIH HHS [R37 DK057978] Funding Source: Medline; NIEHS NIH HHS [R01 ES012479, P42 ES010337, ES 012479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barish GD, 2004, CELL, V119, P149, DOI 10.1016/j.cell.2004.10.003; Barish GD, 2004, TRENDS ENDOCRIN MET, V15, P158, DOI 10.1016/j.tem.2004.03.003; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bonen A, 2004, P NUTR SOC, V63, P245, DOI 10.1079/PNS2004331; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; Gong HB, 2006, MOL ENDOCRINOL, V20, P279, DOI 10.1210/me.2005-0205; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kodama S, 2004, MOL CELL BIOL, V24, P7931, DOI 10.1128/MCB.24.18.7931-7940.2004; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lamb DC, 1998, FEBS LETT, V425, P263, DOI 10.1016/S0014-5793(98)00247-6; Lee RG, 2005, J LIPID RES, V46, P1205, DOI 10.1194/jlr.M500018-JLR200; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Matsuzaka T, 2002, J LIPID RES, V43, P911; MORERE P, 1975, SEM HOP PARIS, V51, P2095; Mu Y, 2005, MOL PHARMACOL, V68, P403, DOI 10.1124/mol.105.013292; NAGAYOSHI A, 1995, J BIOCHEM-TOKYO, V117, P787, DOI 10.1093/oxfordjournals.jbchem.a124777; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Saini SPS, 2004, MOL PHARMACOL, V65, P292, DOI 10.1124/mol.65.2.292; Saini SPS, 2005, HEPATOLOGY, V41, P497, DOI 10.1002/hep.20570; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Sonoda J, 2003, CURR DRUG METAB, V4, P59, DOI 10.2174/1389200033336739; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Strom SC, 1999, SEMIN LIVER DIS, V19, P39, DOI 10.1055/s-2007-1007096; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Uppal H, 2005, HEPATOLOGY, V41, P168, DOI 10.1002/hep.20512; VANNIEUWENHOVEN FA, 1995, BIOCHEM BIOPH RES CO, V207, P747, DOI 10.1006/bbrc.1995.1250; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2004, DRUG DISCOV TODAY, V9, P442, DOI 10.1016/S1359-6446(04)03061-2; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885; Zhou J, 2005, CURR DRUG METAB, V6, P289, DOI 10.2174/1389200054633853; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	57	270	289	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					15013	15020		10.1074/jbc.M511116200	http://dx.doi.org/10.1074/jbc.M511116200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16556603	Green Accepted, hybrid			2022-12-25	WOS:000237671300054
J	Bellodi, C; Kindle, K; Bernassola, F; Dinsdale, D; Cossarizza, A; Melino, G; Heery, D; Salomoni, P				Bellodi, Cristian; Kindle, Karin; Bernassola, Francesca; Dinsdale, David; Cossarizza, Andrea; Melino, Gerry; Heery, David; Salomoni, Paolo			Cytoplasmic Function of Mutant Promyelocytic Leukemia (PML) and PML-Retinoic Acid Receptor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAR-ALPHA; HISTONE DEACETYLASE; FUSION PROTEINS; EXPRESSION; ISOFORMS; GENE; DEGRADATION; DISEASE; APL	The promyelocytic leukemia (PML) tumor suppressor of acute promyelocytic leukemia (APL) regulates major apoptotic and growth-suppressive pathways. In APL, PML is involved in a chromosomal translocation generating the PML-retinoic acid receptor-alpha (RAR alpha) fusion protein. Two missense mutations in the remaining PML alleles have been identified, which give rise to a truncated cytoplasmic PML protein (Mut PML). APL patients carrying these mutations display resistance to retinoic acid (RA) and very poor prognosis. Here we show that Mut PML associates with the cytoplasmic regions we refer to as PML-cytoplasmic bodies (PML-CBs). Mut PML interacts with PML-RAR alpha in PML-CB and potentiates PML-RAR alpha-mediated inhibition of RA-dependent transcription. Remarkably, Mut PML stabilizes PML-RAR alpha and inhibits differentiation induced by pharmacological doses of RA. A mutant form of PML-RAR alpha that accumulates in the cytoplasm inhibits RA-dependent transcription and differentiation, thus suggesting that cytoplasmic localization of PML-RAR alpha may contribute to transformation. Finally, we show that the bcr3 PML-RAR alpha form is predominantly cytoplasmic and accumulates in PML-CBs. Taken together, these findings reveal novel insights into the molecular mechanisms contributing to APL.	[Bellodi, Cristian; Dinsdale, David; Melino, Gerry; Salomoni, Paolo] Med Res Council Toxicol Unit, Leicester LE1 9HN, Leics, England; [Kindle, Karin; Heery, David] Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England; [Bernassola, Francesca] Univ Roma Tor Vergata, Dept Expt Med, IDI IRCCS Biochem Lab, I-00133 Rome, Italy; [Bellodi, Cristian; Cossarizza, Andrea] Univ Modena & Reggio Emilia, Dept Biomed Sci, I-41100 Modena, Italy	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Nottingham; University of Rome Tor Vergata; Universita di Modena e Reggio Emilia	Salomoni, P (corresponding author), Med Res Council Toxicol Unit, Leicester LE1 9HN, Leics, England.	ps90@le.ac.uk	Bellodi, Cristian/J-8157-2013; Bellodi, Cristian/N-2341-2015	Heery, David/0000-0002-5035-2392; Bellodi, Cristian/0000-0001-8047-5329; Garrie, Karin/0000-0003-2204-9975; Cossarizza, Andrea/0000-0002-5381-1558	Medical Research Council; MRC [MC_U132670601, MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670601, MC_U132670600] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Medical Research Council. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Chen GQ, 1997, BLOOD, V89, P3345; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DINSDALE D, 1992, HISTOCHEM J, V24, P144, DOI 10.1007/BF01047464; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gurrieri C, 2004, BLOOD, V103, P2358, DOI 10.1182/blood-2003-07-2200; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hofmann H, 2002, J VIROL, V76, P5769, DOI 10.1128/JVI.76.11.5769-5783.2002; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Khan MM, 2004, J BIOL CHEM, V279, P11814, DOI 10.1074/jbc.M312121200; Khelifi AF, 2005, CELL DEATH DIFFER, V12, P724, DOI 10.1038/sj.cdd.4401559; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zhu J, 2005, CANCER CELL, V7, P143, DOI 10.1016/j.ccr.2005.01.005; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	31	29	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14465	14473		10.1074/jbc.M600457200	http://dx.doi.org/10.1074/jbc.M600457200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16540467	hybrid			2022-12-25	WOS:000207179300005
J	Burdick, MM; Chu, JT; Godar, S; Sackstein, R				Burdick, Monica M.; Chu, Julia T.; Godar, Samuel; Sackstein, Robert			HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER METASTASIS; FLOW CONDITIONS; CANCER CELLS; TUMOR-CELLS; LEUKOCYTE ADHESION; DEPENDENT ADHESION; ENDOTHELIAL-CELLS; CD44S EXPRESSION; P-SELECTIN; GROWTH	Engagement of vascular E-selectin and leukocyte L-selectin with relevant counter-receptors expressed on tumor cells contributes to the hematogenous spread of colon carcinoma. We recently demonstrated that the LS174T colon carcinoma cell line expresses the CD44 glycoform known as hematopoietic cell E-/L-selectin ligand (HCELL), which functions as a high affinity E- and L-selectin ligand on these cells. To define the contribution of HCELL to selectin-mediated adhesion on intact tumor cells, we measured the binding of LS174T cells transduced with CD44 short interfering RNA (siRNA) or with vector alone to 6-h interleukin-1 beta-stimulated human umbilical vein endothelial cells (HUVEC) and to human peripheral blood mononuclear cells (PBMC) under physiological flow conditions. LS174T cell attachment to HUVEC was entirely E-selectin-dependent, and PBMC tethering to tumor cell monolayers was completely L-selectin-dependent. At physiological shear stress, CD44 siRNA transduction led to an similar to 50% decrease in the number of LS174T cells binding to stimulated HUVEC relative to vector alone-transduced cells. CD44 siRNA-transduced cells also rolled significantly faster than vector-transduced cells on HUVEC, indicating prominent HCELL participation in stabilizing tumor cell-endothelial adhesive interactions against fluid shear. Furthermore, HCELL was identified as the principal L-selectin ligand on LS174T cells, as PBMC binding to CD44 siRNA-transduced tumor cells was reduced similar to 80% relative to vector-transduced cells. These data indicate that expression of HCELL confers robust and predominant tumor cell binding to E- and L-selectin, highlighting a central role for HCELL in promoting shear-resistant adhesive interactions essential for hematogenous cancer dissemination.	Harvard Univ, Sch Med, Harvard Skin Dis Res Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Sackstein, R (corresponding author), Harvard Univ, Inst Med, 77 Ave Louis Pasteur,Rm 671, Boston, MA 02115 USA.	rsackstein@rics.bwh.harvard.edu		Burdick, Monica/0000-0003-3168-0072	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073714, R01HL060528] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL073714, R01 HL60528] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Borsig L, 2004, NEWS PHYSIOL SCI, V19, P16, DOI 10.1152/nips.01450.2003; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; Bresalier RS, 1998, INT J CANCER, V76, P556; Brodt P, 1997, INT J CANCER, V71, P612, DOI 10.1002/(SICI)1097-0215(19970516)71:4<612::AID-IJC17>3.0.CO;2-D; Burdick MM, 2003, AM J PHYSIOL-CELL PH, V284, pC977, DOI 10.1152/ajpcell.00423.2002; Catterall JB, 1999, CLIN EXP METASTAS, V17, P583, DOI 10.1023/A:1006756518500; Choi SH, 2000, INT J CANCER, V85, P523, DOI 10.1002/(SICI)1097-0215(20000215)85:4<523::AID-IJC13>3.0.CO;2-6; Dimitroff CJ, 2000, P NATL ACAD SCI USA, V97, P13841, DOI 10.1073/pnas.250484797; Dimitroff CJ, 2004, CANCER RES, V64, P5261, DOI 10.1158/0008-5472.CAN-04-0691; Dimitroff CJ, 2001, J BIOL CHEM, V276, P47623, DOI 10.1074/jbc.M105997200; Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fuhlbrigge RC, 2002, J IMMUNOL, V168, P5645, DOI 10.4049/jimmunol.168.11.5645; Fujisaki T, 1999, CANCER RES, V59, P4427; GIAVAZZI R, 1993, J CLIN INVEST, V92, P3038, DOI 10.1172/JCI116928; Goetz DJ, 1996, ANN BIOMED ENG, V24, P87, DOI 10.1007/BF02770998; Hanley WD, 2005, CANCER RES, V65, P5812, DOI 10.1158/0008-5472.CAN-04-4557; Hanley WD, 2006, FASEB J, V20, P337, DOI 10.1096/fj.05-4574fje; Harada N, 2001, INT J CANCER, V91, P67, DOI 10.1002/1097-0215(20010101)91:1<67::AID-IJC1011>3.0.CO;2-D; IZUMI Y, 1995, EXP CELL RES, V216, P215, DOI 10.1006/excr.1995.1027; Jadhav S, 2001, J IMMUNOL, V167, P5986, DOI 10.4049/jimmunol.167.10.5986; Jones DA, 1996, BIOMATERIALS, V17, P337, DOI 10.1016/0142-9612(96)85572-4; Khatib AM, 2002, CANCER RES, V62, P5393; Khatib AM, 1999, CANCER RES, V59, P1356; Klopocki AG, 1998, EUR J BIOCHEM, V253, P309, DOI 10.1046/j.1432-1327.1998.2530309.x; Laskowska A, 2001, EUR J CELL BIOL, V80, P784, DOI 10.1078/0171-9335-00211; LAWRENCE MB, 1994, IMMUNITY, V1, P137, DOI 10.1016/1074-7613(94)90107-4; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; Milinkovic M, 2004, BLOOD, V103, P740, DOI 10.1182/blood-2003-05-1500; OXLEY SM, 1994, BLOOD, V84, P3299; Pereira PA, 2001, ANTICANCER RES, V21, P2713; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Sackstein R, 2005, CURR OPIN HEMATOL, V12, P444, DOI 10.1097/01.moh.0000177827.78280.79; SAWADA R, 1994, J BIOL CHEM, V269, P1425; Slattery MJ, 2003, INT J CANCER, V106, P713, DOI 10.1002/ijc.11297; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Sy MS, 1996, CURR TOP MICROBIOL, V213, P129	39	78	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13899	13905		10.1074/jbc.M513617200	http://dx.doi.org/10.1074/jbc.M513617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16565092	hybrid			2022-12-25	WOS:000237512300010
J	Gao, L; Yin, HY; Milne, GL; Porter, NA; Morrow, JD				Gao, Ling; Yin, Huiyong; Milne, Ginger L.; Porter, Ned A.; Morrow, Jason D.			Formation of F-ring isoprostane-like compounds (F-3-isoprostanes) in vivo from eicosapentaenoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRIC QUANTIFICATION; POLYUNSATURATED FATTY-ACIDS; PROSTAGLANDIN F-2 ALPHA; LIPID-PEROXIDATION; OXIDANT STRESS; DOCOSAHEXAENOIC ACID; BIOACTIVE PRODUCTS; ANTI-INFLAMMATION; FISH-OIL; IDENTIFICATION	Eicosapentaenoic acid (EPA, C20: 5, omega-3) is the most abundant polyunsaturated fatty acid (PUFA) in fish oil. Recent studies suggest that the beneficial effects of fish oil are due, in part, to the generation of various free radical-generated non-enzymatic bioactive oxidation products from omega-3 PUFAs, although the specific molecular species responsible for these effects have not been identified. Our research group has previously reported that pro-inflammatory prostaglandin F-2-like compounds, termed F-2-isoprostanes (IsoPs), are produced in vivo by the free radical-catalyzed peroxidation of arachidonic acid and represent one of the major products resulting from the oxidation of this PUFA. Based on these observations, we questioned whether F-2-IsoP-like compounds (F-3-IsoPs) are formed from the oxidation of EPA in vivo. Oxidation of EPA in vitro yielded a series of compounds that were structurally established to be F-3-IsoPs using a number of chemical and mass spectrometric approaches. The amounts formed were extremely large (up to 8.7 + 1.0 mu g/mg EPA) and greater than levels of F-2-IsoPs generated from arachidonic acid. We then examined the formation of F-3-IsoPs in vivo in mice. Levels of F-3-IsoPs in tissues such as heart are virtually undetectable at baseline, but supplementation of animals with EPA markedly increases quantities up to 27.4 + 5.6 ng/g of heart. Interestingly, EPA supplementation also markedly reduced levels of pro-inflammatory arachidonate-derived F-2-IsoPs by up to 64% ( p < 0.05). Our studies provide the first evidence that identify F-3-IsoPs as novel oxidation products of EPA that are generated in vivo. Further understanding of the biological consequences of F-3-IsoP formation may provide valuable insights into the cardioprotective mechanism of EPA.	Vanderbilt Univ, Div Clin Pharmacol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Morrow, JD (corresponding author), Vanderbilt Univ, Div Clin Pharmacol, Dept Med, 221 Kirkland Hall, Nashville, TN 37232 USA.	jason.morrow@vanderbilt.edu	Milne, Ginger/D-7648-2014	Milne, Ginger/0000-0003-3890-151X	NCI NIH HHS [CA77839] Funding Source: Medline; NCRR NIH HHS [RR00096] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIEHS NIH HHS [ES31125] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arita K, 2003, FREE RADICAL BIO MED, V35, P189, DOI 10.1016/S0891-5849(03)00310-1; BALAPURE AK, 1989, BIOCHEM PHARMACOL, V38, P2375, DOI 10.1016/0006-2952(89)90478-4; Calder PC, 2001, LIPIDS, V36, P1007, DOI 10.1007/s11745-001-0812-7; Cracowski JL, 2000, EUR J PHARMACOL, V397, P161, DOI 10.1016/S0014-2999(00)00217-X; Cracowski JL, 2001, J VASC RES, V38, P93, DOI 10.1159/000051036; Das UN, 1999, PROSTAG LEUKOTR ESS, V61, P157, DOI 10.1054/plef.1999.0085; Habib A, 2004, CHEM PHYS LIPIDS, V128, P69, DOI 10.1016/j.chemphyslip.2003.10.004; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Kerwin JL, 1996, J MASS SPECTROM, V31, P184, DOI 10.1002/(SICI)1096-9888(199602)31:2<184::AID-JMS283>3.0.CO;2-2; Kerwin JL, 1996, ANAL BIOCHEM, V237, P56, DOI 10.1006/abio.1996.0200; KISERUD CE, 1995, THROMB RES, V80, P75, DOI 10.1016/0049-3848(95)00152-H; Kokura S, 2002, CANCER LETT, V185, P139, DOI 10.1016/S0304-3835(02)00262-8; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; Kromer BM, 1996, BRIT J PHARMACOL, V119, P1276, DOI 10.1111/j.1476-5381.1996.tb16033.x; KULKARNI PS, 1985, INVEST OPHTH VIS SCI, V26, P1178; MORRISON WR, 1964, J LIPID RES, V5, P600; Morrow Jason D, 2002, Methods Mol Biol, V186, P57; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Morrow JD, 1996, J BIOL CHEM, V271, P23185, DOI 10.1074/jbc.271.38.23185; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Morrow JD, 2000, DRUG METAB REV, V32, P377, DOI 10.1081/DMR-100102340; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; NouroozZadeh J, 1997, BIOCHEM BIOPH RES CO, V236, P467, DOI 10.1006/bbrc.1997.6869; Pratico D, 1996, J BIOL CHEM, V271, P14916, DOI 10.1074/jbc.271.25.14916; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Ruxton Carrie, 2004, Nurs Stand, V18, P38; Serhan CN, 2003, CHEM IMMUNOL, V83, P115; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Sethi S, 2002, REDOX REP, V7, P369, DOI 10.1179/135100002125001144; Sethi S, 1996, J LAB CLIN MED, V128, P27, DOI 10.1016/S0022-2143(96)90111-0; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; Uauy R, 1999, EUR J CLIN NUTR, V53, pS66, DOI 10.1038/sj.ejcn.1600745; Vallve JC, 2002, ATHEROSCLEROSIS, V164, P45, DOI 10.1016/S0021-9150(02)00046-1; Waugh RJ, 1997, FREE RADICAL BIO MED, V23, P943, DOI 10.1016/S0891-5849(97)00133-0; Yang PY, 2004, J LIPID RES, V45, P1030, DOI 10.1194/jlr.M300455-JLR200; Yin HY, 2004, J BIOL CHEM, V279, P3766, DOI 10.1074/jbc.M307137200	41	100	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14092	14099		10.1074/jbc.M601035200	http://dx.doi.org/10.1074/jbc.M601035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16569632	hybrid			2022-12-25	WOS:000237512300032
J	Sayan, BS; Sayan, AE; Knight, RA; Melino, G; Cohen, GM				Sayan, BS; Sayan, AE; Knight, RA; Melino, G; Cohen, GM			p53 is cleaved by caspases generating fragments localizing to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; APOPTOSIS; ACTIVATION; DEGRADATION; DISRUPTION; MUTATIONS; COMPLEX; CANCER; DEATH	The p53 tumor suppressor protein exerts most of its anti- tumorigenic activity by transcriptionally activating several pro-apoptotic genes. Accumulating evidence also suggests a transcription-independent function of p53 during apoptosis. It has recently been shown that, when activated, a fraction of p53 translocates to mitochondria, causing cytochrome c release. We now demonstrate a caspase-dependent cleavage of p53 resulting in the generation of four fragments, two of which lack a nuclear localization signal and consequently localize to cytosol. Moreover, these two fragments translocate to mitochondria and induce mitochondrial membrane depolarization in the absence of transcriptional activity. This novel feature of p53 supports the model whereby cytosolic p53 exerts major functions in apoptosis and also suggests the presence of a positive feedback loop in which activated caspases cleave p53 to augment mitochondrial membrane depolarization.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Melino, G (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,Lancaster Rd,POB 138, Leicester LE1 9HN, Leics, England.	gm89@leicester.ac.uk	SAYAN, A. EMRE/H-7330-2012; Cohen, Gerald M/A-1687-2008	SAYAN, A. EMRE/0000-0002-5291-1485; 	Medical Research Council [MC_U132670600] Funding Source: Medline; MRC [MC_U132670600] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ADDISON C, 1990, ONCOGENE, V5, P423; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Kakudo Y, 2005, CANCER RES, V65, P2108, DOI 10.1158/0008-5472.CAN-04-2935; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	24	77	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13566	13573		10.1074/jbc.M512467200	http://dx.doi.org/10.1074/jbc.M512467200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16531411	hybrid			2022-12-25	WOS:000237336600065
J	Squires, LN; Jakubowski, JA; Stuart, JN; Rubakhin, SS; Hatcher, NG; Kim, WS; Chen, K; Shih, JC; Seif, I; Sweedler, JV				Squires, LN; Jakubowski, JA; Stuart, JN; Rubakhin, SS; Hatcher, NG; Kim, WS; Chen, K; Shih, JC; Seif, I; Sweedler, JV			Serotonin catabolism and the formation and fate of 5-hydroxyindole thiazolidine carboxylic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED FLUORESCENCE DETECTION; CAPILLARY-ELECTROPHORESIS; BRAIN-SEROTONIN; 5-HYDROXYTRYPTAMINE; MITOCHONDRIA; METABOLISM; BEHAVIOR; NEURONS; DRUGS; RAT	Serotonin ( 5- HT) functions as a neurotransmitter and neuromodulator in both the central and enteric nervous systems of mammals. The dynamic degradation of 5- HT metabolites in 5- HT- containing nervous system tissues is monitored by capillary electrophoresis with wavelength-resolved laser- induced native fluorescence detection in an effort to investigate known and novel 5- HT catabolic pathways. Tissue samples from wild type mice, genetically altered mice, Long Evans rats, and cultured differentiated rat pheochromocytoma PC- 12 cells, are analyzed before and after incubation with excess 5- HT. From these experiments, several new compounds are detected. One metabolite, identified as 5- hydroxyindole thiazoladine carboxylic acid ( 5- HITCA), has been selected for further study. In 5- HT-incubated central and enteric nervous system tissue samples and differentiated PC- 12 cells, 5- HITCA forms at levels equivalent to 5- hydroxyindole acetic acid, via a condensation reaction between L- cysteine and 5- hydroxyindole acetaldehyde. In the enteric nervous system, 5- HITCA is detected without the addition of 5- HT. The levels of L- cysteine and homocysteine in rat brain mitochondria are measured between 80 and 140 mu M and 1.9 and 3.4 mu M, respectively, demonstrating that 5- HITCA can be formed using available, free L- cysteine in these tissues. The lack of significant accumulation of 5- HITCA in the central and enteric nervous systems, along with data showing the degradation of 5- HITCA into 5- hydroxyindole acetaldehyde, suggests that an equilibrium coupled to the enzyme, aldehyde dehydrogenase type 2, prevents the accumulation of 5- HITCA. Even so, the formation of 5- HITCA represents a catabolic pathway of 5- HT that can affect the levels of 5- HT- derived compounds in the body.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; Univ So Calif, Keck Sch Med, Pharmaceut Sci Ctr, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Southern California; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Sweedler, JV (corresponding author), Univ Illinois, Dept Chem, 600 S Mathews Ave,63-5, Urbana, IL 61801 USA.	jsweedle@uiuc.edu	Sweedler, Jonathan V/A-9405-2009; Squires, Leah/B-9798-2017; Rubakhin, Stanislav S/E-6685-2017	Sweedler, Jonathan V/0000-0003-3107-9922; Squires, Leah/0000-0002-9546-0792; Rubakhin, Stanislav S/0000-0003-0437-1493	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R33DK070285] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA018310] Funding Source: NIH RePORTER; NIDA NIH HHS [P30 DA018310, DA018310] Funding Source: Medline; NIDDK NIH HHS [DK70285, R33 DK070285] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almeida A, 1997, BRAIN RES, V764, P167, DOI 10.1016/S0006-8993(97)00453-8; Buhot HC, 2000, ANN MED, V32, P210, DOI 10.3109/07853890008998828; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; DHASMANA KM, 1993, LIFE SCI, V53, P1651; Fuller RR, 1998, NEURON, V20, P173, DOI 10.1016/S0896-6273(00)80446-8; Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256; Gershon MD, 1999, ALIMENT PHARM THER, V13, P15; GERSHON MD, 1966, J PHYSIOL-LONDON, V186, P451, DOI 10.1113/jphysiol.1966.sp008046; GREENE LA, 1981, ADVANCES CELLULAR NE, P373; Jin CY, 2006, TETRAHEDRON LETT, V47, P943, DOI 10.1016/j.tetlet.2005.11.153; Keung WM, 1998, P NATL ACAD SCI USA, V95, P2198, DOI 10.1073/pnas.95.5.2198; Kim DY, 2000, AM J GASTROENTEROL, V95, P2698, DOI 10.1016/S0002-9270(00)01970-5; Kim WS, 2002, ANAL CHEM, V74, P5614, DOI 10.1021/ac025917q; Murphy DL, 1998, J CLIN PSYCHIAT, V59, P4; ORLICZSZCZESNA G, 1989, Z MIKROSK ANAT FORSC, V103, P504; OSBORNE NN, 1988, NEURONAL SEROTONIN; Park YN, 1999, ANAL CHEM, V71, P4997, DOI 10.1021/ac990659r; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; SINGH S, 1992, J MED CHEM, V35, P2667, DOI 10.1021/jm00092a018; Stone TW, 2002, NAT REV DRUG DISCOV, V1, P609, DOI 10.1038/nrd870; Stuart JN, 2003, J NEUROCHEM, V84, P1358, DOI 10.1046/j.1471-4159.2003.01617.x; Stuart JN, 2003, ANAL BIOANAL CHEM, V375, P28, DOI 10.1007/s00216-002-1609-z; SUSILO R, 1989, J NEUROCHEM, V52, P1793, DOI 10.1111/j.1471-4159.1989.tb07259.x; SUSILO R, 1988, J NEUROCHEM, V50, P1817, DOI 10.1111/j.1471-4159.1988.tb02483.x; UNDENFRIEND S, 1956, J BIOL CHEM, V217, P335; Verge KM, 2002, J AM SOC MASS SPECTR, V13, P901, DOI 10.1016/S1044-0305(02)00386-0; Walther DJ, 2003, CELL, V115, P851, DOI 10.1016/S0092-8674(03)01014-6; Xiang ZM, 2000, J NEUROSCI METH, V98, P145, DOI 10.1016/S0165-0270(00)00197-7; Zhang X, 2002, ANAL BIOANAL CHEM, V373, P332, DOI 10.1007/s00216-002-1288-9; Zhang X, 2001, FRESEN J ANAL CHEM, V369, P206, DOI 10.1007/s002160000654	32	24	26	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13463	13470		10.1074/jbc.M602210200	http://dx.doi.org/10.1074/jbc.M602210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537538	hybrid			2022-12-25	WOS:000237336600053
J	Ignatova, Z; Gierasch, LM				Ignatova, Z; Gierasch, LM			Extended polyglutamine tracts cause aggregation and structural perturbation of an adjacent beta barrel protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEIN; AMYLOID-LIKE FIBRILS; HUNTINGTONS-DISEASE; NEURODEGENERATIVE DISEASES; GLUTAMINE-REPEAT; RETINOIC ACID; MUTANT HUNTINGTIN; CLAM PROTEIN; INTRANUCLEAR INCLUSIONS; EXPANDED GLUTAMINE	Formation of fibrillar intranuclear inclusions and related neuropathologies of the CAG-repeat disorders are linked to the expansion of a polyglutamine tract. Despite considerable effort, the etiology of these devastating diseases remains unclear. Although polypeptides with glutamine tracts recapitulate many of the observed characteristics of the gene products with CAG repeats, such as in vitro and in vivo aggregation and toxicity in model organisms, extended polyglutamine segments have also been reported to structurally perturb proteins into which they are inserted. Additionally, the sequence context of a polyglutamine tract has recently been shown to modulate its propensity to aggregate. These findings raise the possibility that indirect influences of the repeat tract on adjacent protein domains are contributory to pathologies. Destabilization of an adjacent domain may lead to loss of function, as well as favoring non-native structures in the neighboring domain causing them to be prone to intermolecular association and consequent aggregation. To explore these phenomena, we have used chimeras of a well studied globular protein and exon 1 of huntingtin. We find that expansion of the polyglutamine segment beyond the pathological threshold (> 35 glutamines) results in structural perturbation of the neighboring protein whether the huntingtin exon is N- or C- terminal. Elongation of the polyglutamine region also substantially increases the propensity of the chimera to aggregate, both in vitro and in vivo, and in vitro aggregation kinetics of a chimera with a 53-glutamine repeat follow a nucleation polymerization mechanism with amonomeric nucleus.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Gierasch, LM (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, 913 Lederle Grad Res Tower B,710 N Pleasant St, Amherst, MA 01003 USA.	gierasch@biochem.umass.edu	Gierasch, Lila M/D-1494-2009	Ignatova, Zoya/0000-0002-9478-8825	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027616] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM027616] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; Armen RS, 2005, P NATL ACAD SCI USA, V102, P13433, DOI 10.1073/pnas.0502068102; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bevivino AE, 2001, P NATL ACAD SCI USA, V98, P11955, DOI 10.1073/pnas.211305198; Bhattacharyya A, 2006, J MOL BIOL, V355, P524, DOI 10.1016/j.jmb.2005.10.053; Bhattacharyya AM, 2005, P NATL ACAD SCI USA, V102, P15400, DOI 10.1073/pnas.0501651102; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Chen YW, 1999, P NATL ACAD SCI USA, V96, P1257, DOI 10.1073/pnas.96.4.1257; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chow MKM, 2004, J BIOL CHEM, V279, P47643, DOI 10.1074/jbc.M405799200; Chow MKM, 2004, J MOL BIOL, V335, P333, DOI 10.1016/j.jmb.2003.08.064; Clark PL, 1996, PROTEIN SCI, V5, P1108; Clark PL, 1997, NAT STRUCT BIOL, V4, P883, DOI 10.1038/nsb1197-883; Clark PL, 1998, FOLD DES, V3, P401, DOI 10.1016/S1359-0278(98)00053-4; Clerico EM, 2000, BBA-PROTEIN STRUCT M, V1476, P203, DOI 10.1016/S0167-4838(99)00247-2; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; de Chiara C, 2005, J MOL BIOL, V354, P883, DOI 10.1016/j.jmb.2005.09.083; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Eyles SJ, 2000, J MOL BIOL, V301, P737, DOI 10.1006/jmbi.2000.4002; Ferrone F, 1999, METHOD ENZYMOL, V309, P256; Griffin BA, 2000, METHOD ENZYMOL, V327, P565; Gunasekaran K, 2004, PROTEINS, V54, P179, DOI 10.1002/prot.10520; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Holmberg CI, 2004, EMBO J, V23, P4307, DOI 10.1038/sj.emboj.7600426; Ignatova Z, 2005, BIOCHEMISTRY-US, V44, P7266, DOI 10.1021/bi047404e; Ignatova Z, 2004, P NATL ACAD SCI USA, V101, P523, DOI 10.1073/pnas.0304533101; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Khare SD, 2005, PLOS COMPUT BIOL, V1, P230, DOI 10.1371/journal.pcbi.0010030; KLEYWEGT GJ, 1994, STRUCTURE, V2, P1241, DOI 10.1016/S0969-2126(94)00125-1; Krishnan VV, 2000, BIOCHEMISTRY-US, V39, P9119, DOI 10.1021/bi000296l; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; Masino L, 2002, FEBS LETT, V513, P267, DOI 10.1016/S0014-5793(02)02335-9; Morley JF, 2002, P NATL ACAD SCI USA, V99, P10417, DOI 10.1073/pnas.152161099; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Nozaki K, 2001, NEUROREPORT, V12, P3357, DOI 10.1097/00001756-200110290-00042; Nucifora FC, 2003, J BIOL CHEM, V278, P13047, DOI 10.1074/jbc.M211224200; OBERG K, 1994, BIOCHEMISTRY-US, V33, P2628, DOI 10.1021/bi00175a035; Park Y, 2005, MOL CELLS, V19, P23; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5596, DOI 10.1073/pnas.042681599; Radley TL, 2003, J MOL BIOL, V332, P529, DOI 10.1016/S0022-2836(03)00925-2; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Ross CA, 2003, P NATL ACAD SCI USA, V100, P1, DOI 10.1073/pnas.0237018100; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Sharma D, 2005, PROTEINS, V61, P398, DOI 10.1002/prot.20602; Simeoni S, 2000, HUM MOL GENET, V9, P133, DOI 10.1093/hmg/9.1.133; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; Tanaka M, 2002, BIOCHEMISTRY-US, V41, P10277, DOI 10.1021/bi0258905; Tanaka M, 2001, J BIOL CHEM, V276, P45470, DOI 10.1074/jbc.M107502200; Thakur AK, 2002, P NATL ACAD SCI USA, V99, P17014, DOI 10.1073/pnas.252523899; THOMPSON JR, 1995, J MOL BIOL, V252, P433, DOI 10.1006/jmbi.1995.0509; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Wang WF, 2005, NEUROBIOL DIS, V20, P500, DOI 10.1016/j.nbd.2005.03.026; Wang ZL, 2005, APPL RADIAT ISOTOPES, V63, P311, DOI 10.1016/j.apradiso.2005.03.017; WETZEL R, 2006, GENETIC INSTABILITIE; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	62	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12959	12967		10.1074/jbc.M511523200	http://dx.doi.org/10.1074/jbc.M511523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524881	hybrid			2022-12-25	WOS:000237134700091
J	Taniura, H; Sanada, N; Kuramoto, N; Yoneda, Y				Taniura, H; Sanada, N; Kuramoto, N; Yoneda, Y			A metabotropic glutamate receptor family gene in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; PROTEIN; CLONING	Metabotropic glutamate receptors (mGluRs) are a class of G-protein-coupled receptors that possess a seven transmembrane region involved in the modulation of excitatory synaptic transmission in the nervous system. mGluR orthologs have been identified in Drosophila, Caenorhabditis elegans, and higher organisms. Drosophila possesses two mGluR genes, DmGluRA and DmXR. We screened the Dictyostelium genome data base using the ligand binding domain of rat mGluR1 as bait, and identified a new receptor, Ddm-GluPR, belonging to the mGluR family. Similar to Drosophila DmXR, the residues of mGluRs involved in the binding of the alpha-carboxylic and alpha-amino groups of glutamate were well conserved in DdmGluPR, but the residues interacting with the gamma-carboxylic group of glutamate were not. The phylogenetic analysis suggests that DdmGluPR diverged after the mGluR family-GABA(B) receptors split but before mGluR family divergence. DdmGluPR mRNA was expressed in vegetative cells and throughout starvation-induced development, but the level of the expression was relatively high until 4 h after starvation. DdmGluPR was localized to the plasma membrane of axenically grown Ax-2 cells expressed as a green fluorescent protein fusion protein. DdmGluPR-null cells grew faster at high cell density and reached higher densities than wild-type cells. DdmGluPR-null cells exhibited delayed aggregates formation upon starvation and impaired chemotaxis toward cAMP. Although expressions of cAR1 and aca, cAMP-signaling components, were rapidly induced and peaked at 2-4 h in wild-type cells, DdmGluPR-null cells displayed sustained and peaked at 8 h of the expressions of these genes. Our findings suggest the involvement of DdmGluPR in the early development of Dictyostelium discoideum.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University	Taniura, H (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Mol Pharmacol Lab, Kanazawa, Ishikawa 9201192, Japan.	hideo@p.kanazawa-u.ac.jp	Yoneda, Yukio/ABI-1864-2020	Yoneda, Yukio/0000-0002-4624-177X				Bogdanik L, 2004, J NEUROSCI, V24, P9105, DOI 10.1523/JNEUROSCI.2724-04.2004; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Deery WJ, 1999, J BIOL CHEM, V274, P34476, DOI 10.1074/jbc.274.48.34476; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Kimmel AR, 1991, CURR OPIN GENET DEV, V1, P383, DOI 10.1016/S0959-437X(05)80304-1; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Levi S, 2000, PLASMID, V44, P231, DOI 10.1006/plas.2000.1487; MATSUNAMI H, 1997, CELL, V90, P773; Mitri C, 2004, J BIOL CHEM, V279, P9313, DOI 10.1074/jbc.M310878200; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Parmentier ML, 1996, J NEUROSCI, V16, P6687; Pin JP, 2002, CNS NEUROL DISORD-DR, V1, P297, DOI 10.2174/1568007023339328; RATHI A, 1992, MECH DEVELOP, V36, P173, DOI 10.1016/0925-4773(92)90068-U	17	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12336	12343		10.1074/jbc.M512723200	http://dx.doi.org/10.1074/jbc.M512723200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527814	hybrid			2022-12-25	WOS:000237134700018
J	Weniger, MA; Melzner, I; Menz, CK; Wegener, S; Bucur, AJ; Dorsch, K; Mattfeldt, T; Barth, TFE; Moller, P				Weniger, MA; Melzner, I; Menz, CK; Wegener, S; Bucur, AJ; Dorsch, K; Mattfeldt, T; Barth, TFE; Moller, P			Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation	ONCOGENE			English	Article						SOCS-1; Hodgkin lymphoma; primary mediastinal B-cell lymphoma; STAT5	B-CELL LYMPHOMA; EPIGENETIC ACTIVATION; SHP1 HYPERMETHYLATION; NEGATIVE REGULATOR; METHYLATION; REL; DEGRADATION; PROTEINS; GAINS; 2P	The suppressors of cytokine signaling ( SOCS) are critically involved in the regulation of cellular proliferation, survival, and apoptosis via cytokine-induced JAK/STAT signaling. SOCS-1 silencing by aberrant DNA methylation contributes to oncogenesis in various B-cell neoplasias and carcinomas. Recently, we showed an alternative loss of SOCS-1 function due to deleterious SOCS-1 mutations in a major subset of primary mediastinal B-cell lymphoma ( PMBL) and in the PMBL line MedB-1, and a biallelic SOCS-1 deletion in PMBL line Karpas1106P. For both cell lines our previous data demonstrated retarded JAK2 degradation and sustained phospho-JAK2 action leading to enhanced DNA binding of phospho-STAT5. Here, we analysed SOCS-1 in laser-microdissected Hodgkin and Reed-Sternberg ( HRS) cells of classical Hodgkin lymphoma ( cHL). We detected SOCS-1 mutations in HRS cells of eight of 19 cHL samples and in three of five Hodgkin lymphoma ( HL)derived cell lines by sequencing analysis. Moreover, we found a significant association between mutated SOCS-1 of isolated HRS cells and nuclear phospho-STAT5 accumulation in HRS cells of cHL tumor tissue ( P < 0.01). Collectively, these findings support the concept that PMBL and cHL share many overlapping features, and that defective tumor suppressor gene SOCS-1 triggers an oncogenic pathway operative in both lymphomas.	Univ Ulm, Dept Pathol, D-89081 Ulm, Germany	Ulm University	Moller, P (corresponding author), Univ Ulm, Dept Pathol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	peter.moeller@medizin.uni-ulm.de						Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Barth TFE, 2002, LANCET ONCOL, V3, P229, DOI 10.1016/S1470-2045(02)00714-3; Chen CY, 2003, GENE CHROMOSOME CANC, V37, P300, DOI 10.1002/gcc.10222; Chim CS, 2004, BLOOD, V103, P4630, DOI 10.1182/blood-2003-06-2007; Chim CS, 2004, LEUKEMIA, V18, P356, DOI 10.1038/sj.leu.2403216; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Guiter C, 2004, BLOOD, V104, P543, DOI 10.1182/blood-2003-10-3545; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2003, INT J CANCER, V103, P489, DOI 10.1002/ijc.10845; Komazaki T, 2004, JPN J CLIN ONCOL, V34, P191, DOI 10.1093/jjco/hyh035; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Melzner I, 2006, INT J CANCER, V118, P1941, DOI 10.1002/ijc.21485; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; Ritz O, 2005, J PATHOL, V205, P336, DOI 10.1002/path.1688; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Skinnider BF, 2002, BLOOD, V99, P618, DOI 10.1182/blood.V99.2.618; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	25	200	206	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2679	2684		10.1038/sj.onc.1209151	http://dx.doi.org/10.1038/sj.onc.1209151			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16532038				2022-12-25	WOS:000237099400012
J	Shaya, D; Tocilj, A; Li, YG; Myette, J; Venkataraman, G; Sasisekharan, R; Cygler, M				Shaya, David; Tocilj, Ante; Li, Yunge; Myette, James; Venkataraman, Ganesh; Sasisekharan, Ram; Cygler, Miroslaw			Crystal structure of heparinase II from Pedobacter heparinus and its complex with a disaccharide product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN AC LYASE; FLAVOBACTERIUM-HEPARINUM; HEPARAN-SULFATE; SUBSTRATE-SPECIFICITY; ENZYMATIC-ACTIVITY; ESCHERICHIA-COLI; SITE; PURIFICATION; EXPRESSION; CLONING	Heparinase II depolymerizes heparin and heparan sulfate glycosaminoglycans, yielding unsaturated oligosaccharide products through an elimination degradation mechanism. This enzyme cleaves the oligosaccharide chain on the nonreducing end of either glucuronic or iduronic acid, sharing this characteristic with a chondroitin ABC lyase. We have determined the first structure of a heparin-degrading lyase, that of heparinase II from Pedobacter heparinus ( formerly Flavobacterium heparinum), in a ligand-free state at 2.15 (A) over circle resolution and in complex with a disaccharide product of heparin degradation at 2.30 (A) over circle resolution. The protein is composed of three domains: an N-terminal alpha-helical domain, a central two-layered beta-sheet domain, and a C-terminal domain forming a two-layered beta-sheet. Heparinase II shows overall structural similarities to the polysaccharide lyase family 8 ( PL8) enzymes chondroitin AC lyase and hyaluronate lyase. In contrast to PL8 enzymes, however, heparinase II forms stable dimers, with the two active sites formed independently within each monomer. The structure of the N- terminal domain of heparinase II is also similar to that of alginate lyases from the PL5 family. A Zn2+ ion is bound within the central domain and plays an essential structural role in the stabilization of a loop forming one wall of the substrate-binding site. The disaccharide binds in a long, deep canyon formed at the top of the N- terminal domain and by loops extending from the central domain. Based on structural comparison with the lyases from the PL5 and PL8 families having bound substrates or products, the disaccharide found in heparinase II occupies the "+1" and "+2" subsites. The structure of the enzyme-product complex, combined with data from previously characterized mutations, allows us to propose a putative chemical mechanism of heparin and heparan-sulfate degradation.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Momenta Pharmaceut Inc, Cambridge, MA 02142 USA; MIT, Biol Engn Div, Ctr Biomed Engn, Cambridge, MA 02139 USA	National Research Council Canada; McGill University; Massachusetts Institute of Technology (MIT)	Cygler, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	mirek@bri.nrc.ca			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM057073, R01GM057073] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 057073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; Hashimoto W, 2003, J BIOL CHEM, V278, P7663, DOI 10.1074/jbc.M208100200; Huang WJ, 2003, J MOL BIOL, V328, P623, DOI 10.1016/S0022-2836(03)00345-0; Huang WJ, 1999, J MOL BIOL, V294, P1257, DOI 10.1006/jmbi.1999.3292; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINHARDT RJ, 1986, APPL BIOCHEM BIOTECH, V12, P135; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; Lunin VV, 2004, J MOL BIOL, V337, P367, DOI 10.1016/j.jmb.2003.12.071; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mayans O, 1997, STRUCTURE, V5, P677, DOI 10.1016/S0969-2126(97)00222-0; Menozzi FD, 2002, MOL MICROBIOL, V43, P1379, DOI 10.1046/j.1365-2958.2002.02841.x; Michel G, 2004, J BIOL CHEM, V279, P32882, DOI 10.1074/jbc.M403421200; MOFFAT CF, 1991, EUR J BIOCHEM, V202, P531, DOI 10.1111/j.1432-1033.1991.tb16405.x; MOFFAT CF, 1991, EUR J BIOCHEM, V197, P449, DOI 10.1111/j.1432-1033.1991.tb15931.x; Muraki M, 2002, PROTEIN PEPTIDE LETT, V9, P195, DOI 10.2174/0929866023408751; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myette JR, 2002, BIOCHEMISTRY-US, V41, P7424, DOI 10.1021/bi012147o; NADER HB, 1990, J BIOL CHEM, V265, P16807; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; Quiocho FA, 1997, STRUCTURE, V5, P997, DOI 10.1016/S0969-2126(97)00253-0; REINHOLD BB, 1995, J BIOL CHEM, V270, P13197, DOI 10.1074/jbc.270.22.13197; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P12232, DOI 10.1073/pnas.95.21.12232; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; Sharon N, 2002, J AGR FOOD CHEM, V50, P6586, DOI 10.1021/jf020190s; Shaya D, 2004, ACTA CRYSTALLOGR D, V60, P1644, DOI 10.1107/S0907444904016695; Shriver Z, 1998, J BIOL CHEM, V273, P10160, DOI 10.1074/jbc.273.17.10160; Shriver Z, 1998, J BIOL CHEM, V273, P22904, DOI 10.1074/jbc.273.36.22904; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Steyn PL, 1998, INT J SYST BACTERIOL, V48, P165, DOI 10.1099/00207713-48-1-165; Su HS, 2001, MICROBIOL-UK, V147, P581, DOI 10.1099/00221287-147-3-581; Su HS, 1996, APPL ENVIRON MICROB, V62, P2723, DOI 10.1128/AEM.62.8.2723-2734.1996; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Yoon HJ, 1999, J MOL BIOL, V290, P505, DOI 10.1006/jmbi.1999.2883; Yoon HJ, 2001, J MOL BIOL, V307, P9, DOI 10.1006/jmbi.2000.4509	57	68	73	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15525	15535		10.1074/jbc.M512055200	http://dx.doi.org/10.1074/jbc.M512055200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16565082	hybrid			2022-12-25	WOS:000237922200059
J	Yi, AK; Yoon, H; Park, JE; Kim, BS; Kim, HJ; Martinez-Hernandez, A				Yi, Ae-Kyung; Yoon, Hyunsook; Park, Jeoung-Eun; Kim, Beom-Sue; Kim, Hae Jong; Martinez-Hernandez, Antonio			CpG DNA-mediated induction of acute liver injury in D-galactosamine-sensitized mice - The mitochondrial apoptotic pathway-dependent death of hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTORS; ACTIVATED PROTEIN-KINASES; CYTOCHROME-C RELEASE; BACTERIAL-DNA; TNF-ALPHA; ENDOTOXIC-SHOCK; CELL ACTIVATION; HEPATIC-INJURY; SEPTIC SHOCK	Unmethylated CpG motifs present in bacterial DNA ( CpG DNA) induce innate inflammatory responses, including rapid induction of proinflammatory cytokines. Although innate inflammatory responses induced by CpG DNA and other pathogen-associated molecular patterns are essential for the eradication of infectious microorganisms, excessive activation of innate immunity is detrimental to the host. In this study, we demonstrate that CpG DNA, but not control non-CpG DNA, induces a fulminant liver failure with subsequent shock-mediated death by promoting massive apoptotic death of hepatocytes in D-galactosamine ( D-GalN)-sensitized mice. Inhibition of mitochondrial membrane permeability transition pore opening or caspase 9 activity in vivo protects D-GalN-sensitized mice from the CpG DNA-mediated liver injury and death. CpG DNA enhanced production of proinflammatory cytokines in D-GalN-sensitized mice via a TLR9/MyD88-dependent pathway. In addition, CpG DNA failed to induce massive hepatocyte apoptosis and subsequent fulminant liver failure and death in D-GalN-sensitized mice that lack TLR9, MyD88, tumor necrosis factor (TNF)-alpha, or TNF receptor I but not interleukin-6 or -12p40. Taken together, our results provide direct evidence that CpG DNA induces a severe acute liver injury and shock-mediated death through the mitochondrial apoptotic pathway-dependent death of hepatocytes caused by an enhanced production of TNF-alpha through a TLR9/MyD88 signaling pathway in D-GalN-sensitized mice.	Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN 38103 USA; Lebonheur Childrens Hosp & Med Ctr, Childrens Fdn Res Ctr, Memphis, TN 38103 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; Vet Adm Med Ctr, Pathol & Lab Med Serv, Memphis, TN 38104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Yi, AK (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pediat, 50 N Dunlap St,WPT Rm 315, Memphis, TN 38103 USA.	ayi@utmem.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047379] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 053137] Funding Source: Medline; NIAMS NIH HHS [AR 47379] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Bang R, 2003, J PHARMACOL EXP THER, V305, P31, DOI 10.1124/jpet.102.043539; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bohlinger I, 1996, AM J PATHOL, V149, P1381; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Cowdery J, 1996, J IMMUNOL, V156, P4570; Crouser ED, 2004, MITOCHONDRION, V4, P729, DOI 10.1016/j.mito.2004.07.023; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; Ding WX, 2004, J CELL MOL MED, V8, P445, DOI 10.1111/j.1582-4934.2004.tb00469.x; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Henry SP, 1997, ANTI-CANCER DRUG DES, V12, P1; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Josephs MD, 2000, AM J PHYSIOL-REG I, V278, pR1196, DOI 10.1152/ajpregu.2000.278.5.R1196; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Kim WH, 2003, AM J PHYSIOL-GASTR L, V285, pG761, DOI 10.1152/ajpgi.00224.2003; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kobayashi Y, 2004, PEDIATR INT, V46, P685, DOI 10.1111/j.1442-200x.2004.01980.x; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; LEIST M, 1995, J IMMUNOL, V154, P1307; LEIST M, 1994, J IMMUNOL, V153, P1778; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu DY, 2004, J BIOL CHEM, V279, P48434, DOI 10.1074/jbc.M407190200; Liu SB, 2002, INFECT IMMUN, V70, P3433, DOI 10.1128/IAI.70.7.3433-3442.2002; Louis H, 1997, GASTROENTEROLOGY, V112, P935, DOI 10.1053/gast.1997.v112.pm9041256; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Malagarie-Cazenave S, 2004, J BIOL CHEM, V279, P18648, DOI 10.1074/jbc.M314294200; Michie HR, 1996, WORLD J SURG, V20, P460, DOI 10.1007/s002689900072; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; Morikawa A, 1996, INFECT IMMUN, V64, P734, DOI 10.1128/IAI.64.3.734-738.1996; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Nagaki M, 1999, J HEPATOL, V31, P815, DOI 10.1016/S0168-8278(99)80282-7; Nowak M, 2000, AM J PHYSIOL-REG I, V278, pR1202, DOI 10.1152/ajpregu.2000.278.5.R1202; Oku H, 2002, EUR J PHARMACOL, V446, P167, DOI 10.1016/S0014-2999(02)01757-0; Osawa Y, 2001, LIVER, V21, P309, DOI 10.1034/j.1600-0676.2001.210503.x; Razin A, 1981, Prog Nucleic Acid Res Mol Biol, V25, P33, DOI 10.1016/S0079-6603(08)60482-1; Rutz M, 2004, EUR J IMMUNOL, V34, P2541, DOI 10.1002/eji.200425218; Soriano ME, 2004, J BIOL CHEM, V279, P36803, DOI 10.1074/jbc.M405297200; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takenaka K, 1998, DIGEST DIS SCI, V43, P887, DOI 10.1023/A:1018898905478; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; Wang XD, 2001, GENE DEV, V15, P2922; Xu HM, 2003, J BIOL CHEM, V278, P36334, DOI 10.1074/jbc.M305698200; Yeo SJ, 2003, J BIOL CHEM, V278, P40590, DOI 10.1074/jbc.M306280200; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 1998, J IMMUNOL, V160, P4755; Yi AK, 1996, J IMMUNOL, V156, P558; Yi AK, 2002, J IMMUNOL, V168, P4711, DOI 10.4049/jimmunol.168.9.4711; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200	62	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					15001	15012		10.1074/jbc.M601337200	http://dx.doi.org/10.1074/jbc.M601337200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16554296	hybrid			2022-12-25	WOS:000237671300053
J	Kuehner, JN; Brow, DA				Kuehner, Jason N.; Brow, David A.			Quantitative analysis of in vivo initiator selection by yeast RNA polymerase II supports a scanning model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							START SITE SELECTION; TRANSCRIPTION INITIATION; SACCHAROMYCES-CEREVISIAE; MOLECULAR-GENETICS; PROMOTER ELEMENT; BINDING-PROTEIN; DNA CONTACTS; SEQUENCE; TFIIB; TATA	Initiation of transcription by RNA polymerase II ( RNAP II) on Saccharomyces cerevisiae messenger RNA ( mRNA) genes typically occurs at multiple sites 40-120 bp downstream of the TATA box. The mechanism that accommodates this extended and variable promoter architecture is unknown, but one model suggests that RNAP II forms an open promoter complex near the TATA box and then scans the template DNA strand for start sites. Unlike most protein-coding genes, small nuclear RNA gene transcription starts predominantly at a single position. We identify a highly efficient initiator element as the primary start site determinant for the yeast U4 small nuclear RNA gene, SNR14. Consistent with the scanning model, transcription of an SNR14 allele with tandemly duplicated start sites initiates primarily from the upstream site, yet the downstream site is recognized with equivalent efficiency by the diminished population of RNAP II molecules that encounter it. A quantitative in vivo assay revealed that SNR14 initiator efficiency is nearly perfect (similar to 90%), which explains the precision of U4 RNA 5' end formation. Initiator efficiency was reduced by cis-acting mutations at -8, -7, -1, and +1 and trans-acting substitutions in the TFIIB B-finger. These results expand our understanding of RNAP II initiation preferences and provide new support for the scanning model.	Univ Wisconsin, Sch Med & Pub Hlth, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Brow, DA (corresponding author), Univ Wisconsin, Sch Med & Pub Hlth, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	dabrow@wisc.edu		Kuehner, Jason/0000-0001-9432-8506	NIGMS NIH HHS [GM44665] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044665] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartlett MS, 2004, J BIOL CHEM, V279, P5894, DOI 10.1074/jbc.M311429200; Beinoraviciute-Kellner R, 2005, FEBS LETT, V579, P4535, DOI 10.1016/j.febslet.2005.07.009; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Chen BS, 2004, BIOCHEMISTRY-US, V43, P12741, DOI 10.1021/bi048993r; Chen BS, 2004, MOL CELL BIOL, V24, P3983, DOI 10.1128/MCB.24.9.3983-3991.2004; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Faitar SL, 2001, MOL CELL BIOL, V21, P4427, DOI 10.1128/MCB.21.14.4427-4440.2001; Fourel G, 2002, J BIOL CHEM, V277, P41736, DOI 10.1074/jbc.M202578200; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; FURTERGRAVES EM, 1990, MOL GEN GENET, V223, P407, DOI 10.1007/BF00264447; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; Ghazy MA, 2004, MOL CELL BIOL, V24, P10975, DOI 10.1128/MCB.24.24.10975-10985.2004; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HEALY AM, 1990, CURR GENET, V18, P105, DOI 10.1007/BF00312597; HEALY AM, 1987, MOL CELL BIOL, V7, P3785, DOI 10.1128/MCB.7.10.3785; HEKMATPANAH DS, 1991, MOL CELL BIOL, V11, P5781, DOI 10.1128/MCB.11.11.5781; HULL MW, 1991, METHOD CELL BIOL, V35, P383; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; Kwan S, 2000, RNA, V6, P1859, DOI 10.1017/S1355838200991325; Lascaris RF, 2000, NUCLEIC ACIDS RES, V28, P1390, DOI 10.1093/nar/28.6.1390; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; MAICAS E, 1990, NUCLEIC ACIDS RES, V18, P3387, DOI 10.1093/nar/18.11.3387; Martin MP, 2001, MOL CELL BIOL, V21, P6429, DOI 10.1128/MCB.21.19.6429-6439.2001; MOSCH HU, 1992, EMBO J, V11, P4583, DOI 10.1002/j.1460-2075.1992.tb05560.x; Mukherjee S, 2004, NAT GENET, V36, P1331, DOI 10.1038/ng1473; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Ohishi-Shofuda T, 1999, BIOCHEM BIOPH RES CO, V255, P157, DOI 10.1006/bbrc.1999.0157; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; Qu LH, 1999, MOL CELL BIOL, V19, P1144; RATHJEN J, 1990, NUCLEIC ACIDS RES, V18, P3219, DOI 10.1093/nar/18.11.3219; Renfrow MB, 2004, J BIOL CHEM, V279, P2825, DOI 10.1074/jbc.M311433200; SAKURAI H, 1994, MOL CELL BIOL, V14, P6819, DOI 10.1128/MCB.14.10.6819; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; Shuman S, 1997, P NATL ACAD SCI USA, V94, P12758, DOI 10.1073/pnas.94.24.12758; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; SUN ZW, 1995, P NATL ACAD SCI USA, V92, P3127, DOI 10.1073/pnas.92.8.3127; WISE JA, 1991, METHOD ENZYMOL, V194, P405; Zhang ZH, 2005, NUCLEIC ACIDS RES, V33, P2838, DOI 10.1093/nar/gki583	55	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14119	14128		10.1074/jbc.M601937200	http://dx.doi.org/10.1074/jbc.M601937200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16571719	hybrid			2022-12-25	WOS:000237512300035
J	Sakurai, N; Utsumi, T				Sakurai, Nagisa; Utsumi, Toshihiko			Posttranslational N-myristoylation is required for the anti-apoptotic activity of human tGelsolin, the C-terminal caspase cleavage product of human gelsolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-REGULATORY PROTEIN; PREVENTS APOPTOSIS; MITOCHONDRIA; ASSOCIATION; INHIBITION; ENZYMOLOGY; ACYLATION; FRAGMENT; MOTILITY; BIOLOGY	Protein N-myristoylation has been recognized as a cotranslational protein modification. Recently, it was demonstrated that protein N-myristoylation could occur posttranslationally, as in the case of the pro-apoptotic protein BID and cytoskeletal actin. Our previous study showed that the N-terminal nine residues of the C-terminal caspase cleavage product of human gelsolin, an actin-regulatory protein, efficiently direct the protein N-myristoylation. In this study, to analyze the posttranslational N-myristoylation of gelsolin during apoptosis, metabolic labeling of gelsolin and its caspase cleavage products expressed in COS-1 cells with [H-3] myristic acid was performed. It was found that the C-terminal caspase cleavage product of human gelsolin (tGelsolin) was efficiently N-myristoylated. When COS-1 cells transiently transfected with gelsolin cDNA were treated with etoposide or staurosporine, apoptosis-inducing agents, N-myristoylated tGelsolin was generated, as demonstrated by in vivo metabolic labeling. The generation of posttranslationally N-myristoylated tGelsolin during apoptosis was also observed on endogenous gelsolin expressed in HeLa cells. Immunofluorescence staining and subcellular fractionation experiment revealed that exogenously expressed tGelsolin did not localize to mitochondria but rather was diffusely distributed in the cytoplasm. To study the role of this modification in the anti-apoptotic activity of tGelsolin, we constructed the bicistronic expression plasmid tGelsolin IRES-EGFP capable of overexpressing tGelsolin concomitantly with EGFP. Overexpression of N-myristoylated tGelsolin in COS-1 cells using this plasmid significantly inhibited etoposide-induced apoptosis, whereas overexpression of the non-myristoylated tGelsolinG2A mutant did not cause resistance to apoptosis. These results indicate that posttranslational N-myristoylation of tGelsolin does not direct mitochondrial targeting, but this modification is involved in the anti-apoptotic activity of tGelsolin.	Yamaguchi Univ, Dept Biol Chem, Fac Agr, Yamaguchi 7538515, Japan	Yamaguchi University	Utsumi, T (corresponding author), Yamaguchi Univ, Dept Biol Chem, Fac Agr, Yamaguchi 7538515, Japan.	utsumi@yamaguchi-u.ac.jp						Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; COOPER JA, 1988, J CELL BIOL, V106, P1229, DOI 10.1083/jcb.106.4.1229; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Geng YJ, 1998, EUR J CELL BIOL, V77, P294, DOI 10.1016/S0171-9335(98)80088-5; Harms C, 2004, MOL CELL NEUROSCI, V25, P69, DOI 10.1016/j.mcn.2003.09.012; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; McGough AM, 2003, FEBS LETT, V552, P75, DOI 10.1016/S0014-5793(03)00932-3; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; Qiao HJ, 2005, NEUROBIOL AGING, V26, P849, DOI 10.1016/j.neurobiolaging.2004.08.003; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Utsumi T, 2003, FEBS LETT, V539, P37, DOI 10.1016/S0014-5793(03)00180-7; Utsumi T, 2001, J BIOL CHEM, V276, P10505, DOI 10.1074/jbc.M006134200; Utsumi T, 1998, ARCH BIOCHEM BIOPHYS, V349, P216, DOI 10.1006/abbi.1997.0468; UTSUMI T, 1995, MOL CELL BIOL, V15, P6389; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	31	64	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14288	14295		10.1074/jbc.M510338200	http://dx.doi.org/10.1074/jbc.M510338200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16556605	hybrid			2022-12-25	WOS:000237512300054
J	Spinelli, S; Campanacci, V; Blangy, S; Moineau, S; Tegoni, M; Cambillau, C				Spinelli, Silvia; Campanacci, Valerie; Blangy, Stephanie; Moineau, Sylvain; Tegoni, Mariella; Cambillau, Christian			Modular structure of the receptor binding proteins of Lactococcus lactis phages - The RBP structure of the temperate phage TP901-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ADENOVIRUS FIBER; ACID BACTERIA; BETA-HELIX; CELL-WALL; BACTERIOPHAGES; IDENTIFICATION; CHEESE; ATTACHMENT; EVOLUTION	Lactococcus lactis is a Gram-positive bacterium widely used by the dairy industry. Several industrial L. lactis strains are sensitive to various distinct bacteriophages. Most of them belong to the Siphoviridae family and comprise several species, among which the 936 and P335 are prominent. Members of these two phage species recognize their hosts through the interaction of their receptor-binding protein (RBP) with external cell wall saccharidices of the host, the "receptors." We report here the 1.65 angstrom resolution crystal structure of the RBP from phage TP901-1, a member of the P335 species. This RBP of 163 amino acids is a homotrimer comprising three domains: a helical N terminus, an interlaced beta-prism, and a beta-barrel, the head domain (residues 64-163), which binds a glycerol molecule. Fluorescence quenching experiments indicated that the RBP exhibits high affinity for glycerol, muramyl-dipeptide, and other saccharides in solution. The structural comparison of this RBP with that of lactococcal phage p2 RBP, a member of the 936 species (Spinelli, S., Desmyter, A., Verrips, C. T., de Haard, J.W., Moineau, S., and Cambillau, C. (2006) Nat. Struct. Mol. Biol. 13, 85-89) suggests a large extent of modularity in RBPs of lactococcal phages.	CNRS, Architectrure & Fonct Macromol Biol, UMR 6098, F-13288 Marseille 09, France; Univ Aix Marseille 1, F-13288 Marseille 09, France; Univ Aix Marseille 2, F-13288 Marseille 09, France; Univ Laval, Grp Rech Ecol Buccale, Fac Med Dent, Quebec City, PQ G1K 7P4, Canada; Univ Laval, Felix Herelle Reference Ctr Bacterial Viruses, Quebec City, PQ G1K 7P4, Canada; Univ Laval, Dept Biochim & Microbiol, Fac Sci & Genie, Quebec City, PQ G1K 7P4, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Laval University; Laval University; Laval University	Cambillau, C (corresponding author), CNRS, Architectrure & Fonct Macromol Biol, UMR 6098, Campus Luminy,Case 932, F-13288 Marseille 09, France.	cambillau@afmb.univ-mrs.fr	Moineau, Sylvain/I-7231-2019; Moineau, Sylvain/N-3578-2013	Moineau, Sylvain/0000-0002-2832-5101; Campanacci, Valerie/0000-0001-6407-6395				Bamford DH, 2002, THEOR POPUL BIOL, V61, P461, DOI 10.1006/tpbi.2002.1591; Bissonnette F, 2000, J DAIRY SCI, V83, P620, DOI 10.3168/jds.S0022-0302(00)74921-6; Brondsted L, 2001, VIROLOGY, V283, P93, DOI 10.1006/viro.2001.0871; Burmeister WP, 2004, J VIROL, V78, P7727, DOI 10.1128/JVI.78.14.7727-7736.2004; Chappell JD, 2002, EMBO J, V21, P1, DOI 10.1093/emboj/21.1.1; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; De Haard HJW, 2005, J BACTERIOL, V187, P4531, DOI 10.1128/JB.187.13.4531-4541.2005; Delcour J, 1999, ANTON LEEUW INT J G, V76, P159, DOI 10.1023/A:1002089722581; Deveau H, 2002, APPL ENVIRON MICROB, V68, P4364, DOI 10.1128/AEM.68.9.4364-4369.2002; Dupont K, 2004, APPL ENVIRON MICROB, V70, P5818, DOI 10.1128/AEM.70.10.5818-5824.2004; Dupont K, 2004, APPL ENVIRON MICROB, V70, P5825, DOI 10.1128/AEM.70.10.5825-5832.2004; Geller BL, 2005, J DAIRY SCI, V88, P900, DOI 10.3168/jds.S0022-0302(05)72756-9; JOSEPHSEN J, 1988, MILCHWISSENSCHAFT, V43, P219; JOSEPHSEN J, 1998, LACTIC ACID BACTERIA, P385; LASKOWSKI R, 1993, J APPL CRYSTALLOGR, V26, P91; Ledeboer AM, 2002, J DAIRY SCI, V85, P1376, DOI 10.3168/jds.S0022-0302(02)74204-5; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mitraki A, 2002, J STRUCT BIOL, V137, P236, DOI 10.1006/jsbi.2002.4447; MOINEAU S, 1993, APPL ENVIRON MICROB, V59, P197, DOI 10.1128/AEM.59.1.197-202.1993; MOINEAU S, 1992, CAN J MICROBIOL, V38, P875, DOI 10.1139/m92-143; Moineau S, 1996, J DAIRY SCI, V79, P2104, DOI 10.3168/jds.S0022-0302(96)76584-0; Moineau S, 2002, ASM NEWS, V68, P388; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ROUSSEL A, 1991, TURBO FRODO GRAPHICS; Schibli DJ, 2004, MOL MEMBR BIOL, V21, P361, DOI 10.1080/09687860400017784; Smith NL, 2005, P NATL ACAD SCI USA, V102, P17652, DOI 10.1073/pnas.0504782102; Spinelli S, 2006, NAT STRUCT MOL BIOL, V13, P85, DOI 10.1038/nsmb1029; Sulzenbacher G, 2002, ACTA CRYSTALLOGR D, V58, P2109, DOI 10.1107/S0907444902013938; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; Tremblay DM, 2006, J BACTERIOL, V188, P2400, DOI 10.1128/JB.188.7.2400-2410.2006; VALYASEVI R, 1990, APPL ENVIRON MICROB, V56, P1882, DOI 10.1128/AEM.56.6.1882-1889.1990; VALYASEVI R, 1994, J DAIRY SCI, V77, P1, DOI 10.3168/jds.S0022-0302(94)76921-6; van Raaij MJ, 2001, J MOL BIOL, V314, P1137, DOI 10.1006/jmbi.2000.5204; Vegge CS, 2006, J BACTERIOL, V188, P55, DOI 10.1128/JB.188.1.55-63.2006; Vegge CS, 2005, J BACTERIOL, V187, P4187, DOI 10.1128/JB.187.12.4187-4197.2005; Walhout AJM, 2000, METHOD ENZYMOL, V328, P575, DOI 10.1016/S0076-6879(00)28419-X; Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110	40	98	100	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14256	14262		10.1074/jbc.M600666200	http://dx.doi.org/10.1074/jbc.M600666200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16549427	hybrid			2022-12-25	WOS:000237512300050
J	Ullers, RS; Houben, ENG; Brunner, J; Oudega, B; Harms, N; Luirink, J				Ullers, Ronald S.; Houben, Edith N. G.; Brunner, Josef; Oudega, Bauke; Harms, Nellie; Luirink, Joen			Sequence-specific interactions of nascent Escherichia coli polypeptides with trigger factor and signal recognition particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; PRESECRETORY PROTEINS; SEC-TRANSLOCASE; RIBOSOME; YIDC; SITE; CHAPERONE; INSERTION; PEPTIDE; BINDS	As nascent polypeptides exit the ribosomal tunnel they immediately associate with chaperones, folding catalysts, and targeting factors. These interactions are decisive for the future conformation and destination of the protein that is being synthesized. Using Escherichia coli as a model organism, we have systematically analyzed how the earliest contacts of nascent polypeptides with cytosolic factors depend on the nature and future destination of the emerging sequence using a photo cross-linking approach. Together, the data suggest that the chaperone trigger factor is adjacent to emerging sequences by default, consistent with both its placement near the nascent chain exit site and its cellular abundance. The signal recognition particle (SRP) effectively competes the contact with TF when a signal anchor (SA) sequence of a nascent inner membrane protein appears outside the ribosome. The SRP remains in contact with the SA and downstream sequences during further synthesis of similar to 30 amino acids. The contact with trigger factor is then restored unless another transmembrane segment reinitiates SRP binding. Importantly and in contrast to published data, the SRP appears perfectly capable of distinguishing SA sequences from signal sequences in secretory proteins at this early stage in biogenesis.	Free Univ Amsterdam, Inst Cell & Mol Biol, Dept Mol Microbiol, NL-1081 HV Amsterdam, Netherlands; ETH, Inst Biochem, CH-8093 Zurich, Switzerland	Vrije Universiteit Amsterdam; Swiss Federal Institutes of Technology Domain; ETH Zurich	Luirink, J (corresponding author), Free Univ Amsterdam, Inst Cell & Mol Biol, Dept Mol Microbiol, NL-1081 HV Amsterdam, Netherlands.	joen.luirink@falw.vu.nl	Houben, Edith N.G./B-2110-2015; Luirink, Joen/AAB-8658-2021	Houben, Edith N.G./0000-0002-8805-2002; Luirink, J./0000-0001-8431-0804				Albanese V, 2002, NAT STRUCT BIOL, V9, P716, DOI 10.1038/nsb1002-716; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Bernstein KD, 2001, J BACTERIOL, V183, P2187, DOI 10.1128/JB.183.7.2187-2197.2001; Buskiewicz I, 2004, P NATL ACAD SCI USA, V101, P7902, DOI 10.1073/pnas.0402231101; Craig EA, 2003, CURR OPIN MICROBIOL, V6, P157, DOI 10.1016/S1369-5274(03)00030-4; Dalbey RE, 2004, BBA-MOL CELL RES, V1694, P37, DOI 10.1016/j.bbamcr.2004.03.009; de Gier JWL, 2003, EMBO REP, V4, P939, DOI 10.1038/sj.embor.embor921; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; Etchells SA, 2004, NAT STRUCT MOL BIOL, V11, P391, DOI 10.1038/nsmb0504-391; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; Halic M, 2005, CURR OPIN STRUC BIOL, V15, P116, DOI 10.1016/j.sbi.2005.01.013; Halic M, 2004, NATURE, V427, P808, DOI 10.1038/nature02342; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Houben ENG, 2005, J CELL BIOL, V170, P27, DOI 10.1083/jcb.200503035; Houben ENG, 2004, EMBO REP, V5, P970, DOI 10.1038/sj.embor.7400261; Houben ENG, 2002, J BIOL CHEM, V277, P35880, DOI 10.1074/jbc.M205556200; JENSEN CG, 1994, J BACTERIOL, V176, P7148, DOI 10.1128/JB.176.23.7148-7154.1994; Jong WSP, 2004, EUR J BIOCHEM, V271, P4779, DOI 10.1111/j.1432-1033.2004.04442.x; Kebir MO, 2002, BIOCHEMISTRY-US, V41, P5573, DOI 10.1021/bi015798t; Kramer G, 2004, J BIOL CHEM, V279, P14165, DOI 10.1074/jbc.M313635200; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Kuroiwa T, 1996, J BIOL CHEM, V271, P6423, DOI 10.1074/jbc.271.11.6423; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; LEE JI, 1992, J BIOL CHEM, V267, P938; LIEBKE HH, 1987, J BACTERIOL, V169, P1174, DOI 10.1128/jb.169.3.1174-1181.1987; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; Raine A, 2004, BIOCHIMIE, V86, P495, DOI 10.1016/j.biochi.2004.05.004; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Ullers RS, 2004, P NATL ACAD SCI USA, V101, P7583, DOI 10.1073/pnas.0402398101; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; Woolhead CA, 2004, CELL, V116, P725, DOI 10.1016/S0092-8674(04)00169-2; Ying BW, 2005, J BIOL CHEM, V280, P12035, DOI 10.1074/jbc.M500364200; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492	47	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13999	14005		10.1074/jbc.M600638200	http://dx.doi.org/10.1074/jbc.M600638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551615	Green Published, hybrid			2022-12-25	WOS:000237512300022
J	Andrews, BJ; Lehman, JA; Turchi, JJ				Andrews, BJ; Lehman, JA; Turchi, JJ			Kinetic analysis of the Ku-DNA binding activity reveals a redox-dependent alteration in protein structure that stimulates dissociation of the Ku-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; KINASE CATALYTIC SUBUNIT; INDUCED OXIDATIVE STRESS; CYSTEINE RESIDUES; MAMMALIAN-CELLS; REPAIR PROTEINS; STOPPED-FLOW; END; PK; DAMAGE	Ku is a heterodimeric protein comprising 70- and 80-kDa subunits that participate in the non- homologous end-joining (NHEJ) repair pathway for rejoining DNA double strand breaks. We have analyzed the pre- steady state binding of Ku with various DNA duplex substrates and identified a redox- sensitive Ku- DNA interaction. Pre-steady state analysis of Ku DNA binding was monitored via intrinsic Ku quenching upon binding DNA and revealed that, under fully reduced conditions, binding occurred in a single- step process. Reactions performed under limited reduction revealed a two- step binding process, whereas under fully oxidized conditions, we were unable to detect quenching of Ku fluorescence upon binding DNA. The differential quenching observed under the different redox conditions could not be attributed to two Ku molecules binding to a single substrate or Ku sliding inward on the substrate. Although only modest differences in Ku DNA binding activity were observed in the stoichiometric anisotropy and electrophoretic mobility shift assay studies, as a function of redox conditions, a dramatic difference in the rate of Ku dissociation from DNA was observed. This effect was also induced by diamide treatment of Ku and could be abrogated by dithiothreitol treatment, demonstrating a reversible redox effect on the stability of the Ku-DNA complex. The redox-dependent alteration in Ku- DNA interactions is manifested by a redox-dependent alteration in Ku structure, which was confirmed by limited proteolysis and mass spectrometry analyses. The results support a model for the interaction of Ku with DNA that is regulated by redox status and is achieved by altering the dissociation of the Ku- DNA complex.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Wright State Univ, Dept Biomed Sci, Dayton, OH 45435 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University System of Ohio; Wright State University Dayton	Turchi, JJ (corresponding author), Indiana Univ, Inst Canc Res, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.	jturchi@iupui.edu	Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NCI NIH HHS [R01 CA082741, R01 CA082741-05, CA82741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal A, 2001, MOL CELL BIOCHEM, V223, P71, DOI 10.1023/A:1017900810837; Agrawal A, 2001, MOL CELL BIOCHEM, V224, P9, DOI 10.1023/A:1011990704575; Andrews BJ, 2004, MOL CANCER THER, V3, P385; Arosio D, 2004, J BIOL CHEM, V279, P42826, DOI 10.1074/jbc.M406529200; Arosio D, 2002, J BIOL CHEM, V277, P9741, DOI 10.1074/jbc.M111916200; Ayene IS, 2002, J BIOL CHEM, V277, P9929, DOI 10.1074/jbc.M111366200; Ayene IS, 2000, INT J RADIAT BIOL, V76, P1523; Bacsi A, 2005, FREE RADICAL BIO MED, V39, P1650, DOI 10.1016/j.freeradbiomed.2005.08.013; Bianchi A, 1999, J BIOL CHEM, V274, P35284; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Boldogh I, 2003, TOXICOLOGY, V193, P137, DOI 10.1016/j.tox.2003.08.013; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Iliakis G, 2004, CYTOGENET GENOME RES, V104, P14, DOI 10.1159/000077461; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P6032, DOI 10.1021/bi020122z; MIMORI T, 1986, J BIOL CHEM, V261, P375; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; Pawelczak KS, 2005, NUCLEIC ACIDS RES, V33, P152, DOI 10.1093/nar/gki157; Poinsignon C, 2004, EUR J IMMUNOL, V34, P3146, DOI 10.1002/eji.200425455; Ramsden DA, 1998, EMBO J, V17, P609, DOI 10.1093/emboj/17.2.609; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Song JY, 2003, J BIOL CHEM, V278, P36676, DOI 10.1074/jbc.M303692200; Turchi JJ, 2000, NUCLEIC ACIDS RES, V28, P4634, DOI 10.1093/nar/28.23.4634; Turchi JJ, 1996, J BIOL CHEM, V271, P13861, DOI 10.1074/jbc.271.23.13861; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang HC, 2001, NUCLEIC ACIDS RES, V29, P1653, DOI 10.1093/nar/29.8.1653; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034; ZHANG WW, 1993, BIOCHEM J, V293, P769, DOI 10.1042/bj2930769	36	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13596	13603		10.1074/jbc.M512787200	http://dx.doi.org/10.1074/jbc.M512787200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537541	hybrid, Green Accepted			2022-12-25	WOS:000237336600069
J	Brondijk, THC; van Boxel, GI; Mather, OC; Quirk, PG; White, SA; Jackson, JB				Brondijk, THC; van Boxel, GI; Mather, OC; Quirk, PG; White, SA; Jackson, JB			The role of invariant amino acid residues at the hydride transfer site of proton-translocating transhydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; MOBILE-LOOP REGION; RHODOSPIRILLUM-RUBRUM; DOMAIN-I; ESCHERICHIA-COLI; NAD(H)-BINDING COMPONENT; NADP(H)-BINDING DOMAINS; CONFORMATIONAL DYNAMICS; CATALYTIC-PROPERTIES; CRYSTAL-STRUCTURE	Transhydrogenase couples proton translocation across a membrane to hydride transfer between NADH and NADP(+). Previous x-ray structures of complexes of the nucleotide-binding components of transhydrogenase ("dI(2)dIII(1)" complexes) indicate that the dihydronicotinamide ring of NADH can move from a distal position relative to the nicotinamide ring of NADP(+) to a proximal position. The movement might be responsible for gating hydride transfer during proton translocation. We have mutated three invariant amino acids, Arg-127, Asp-135, and Ser-138, in the NAD( H)-binding site of Rhodospirillum rubrum transhydrogenase. In each mutant, turnover by the intact enzyme is strongly inhibited. Stopped-flow experiments using dI(2)dIII(1) complexes show that inhibition results from a block in the steps associated with hydride transfer. Mutation of Asp-135 and Ser-138 had no effect on the binding affinity of either NAD(+) or NADH, but mutation of Arg-127 led to much weaker binding of NADH and slightly weaker binding of NAD(+). X-ray structures of dI(2)dIII(1) complexes carrying the mutations showed that their effects were restricted to the locality of the bound NAD( H). The results are consistent with the suggestion that in wild-type protein movement of the Arg-127 side chain, and its hydrogen bonding to Asp-135 and Ser-138, stabilizes the dihydronicotinamide of NADH in the proximal position for hydride transfer.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Jackson, JB (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	j.b.jackson@bham.ac.uk	Brondijk, Harma/AAD-6485-2019	Brondijk, Harma/0000-0002-0234-673X; White, Scott/0000-0002-0202-6154	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AMBARTSOUMIAN G, 1994, MICROBIOL-UK, V140, P1737, DOI 10.1099/13500872-140-7-1737; Arkblad EL, 2005, FREE RADICAL BIO MED, V38, P1518, DOI 10.1016/j.freeradbiomed.2005.02.012; Bizouarn T, 1996, EUR J BIOCHEM, V239, P737, DOI 10.1111/j.1432-1033.1996.0737u.x; BIZOUARN T, 1995, BBA-BIOENERGETICS, V1229, P49, DOI 10.1016/0005-2728(94)00186-9; Bizouarn T, 1996, J BIOL CHEM, V271, P10103, DOI 10.1074/jbc.271.17.10103; Broos J, 2003, J BIOL CHEM, V278, P47578, DOI 10.1074/jbc.M309287200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckley PA, 2000, STRUCTURE, V8, P809, DOI 10.1016/S0969-2126(00)00171-4; CLAYTON RK, 1963, BIOCHIM BIOPHYS ACTA, V75, P312, DOI 10.1016/0006-3002(63)90618-8; Cotton NPJ, 2001, STRUCTURE, V9, P165, DOI 10.1016/S0969-2126(01)00571-8; CUNNINGHAM IJ, 1992, BIOCHIM BIOPHYS ACTA, V1100, P332, DOI 10.1016/0167-4838(92)90490-5; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; Diggle C, 1996, J BIOL CHEM, V271, P10109, DOI 10.1074/jbc.271.17.10109; Evans W, 1997, CHEM BRIT, V33, P22; FISHER RR, 1971, J BIOL CHEM, V246, P4679; Fjellstrom O, 1999, BIOCHEMISTRY-US, V38, P415, DOI 10.1021/bi9817111; Fjellstrom O, 1997, BIOCHEMISTRY-US, V36, P11331, DOI 10.1021/bi970958f; Grimley RL, 1997, BIOCHEMISTRY-US, V36, P14762, DOI 10.1021/bi971832l; Gupta S, 1998, BBA-BIOENERGETICS, V1409, P25, DOI 10.1016/S0005-2728(98)00146-7; Hickman JW, 2002, J BACTERIOL, V184, P400, DOI 10.1128/JB.184.2.400-409.2002; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; Jackson JB, 2005, RSC BIOMOLEC SCI, P376; Jackson JB, 2003, FEBS LETT, V545, P18, DOI 10.1016/S0014-5793(03)00388-0; Jeeves M, 1999, J BIOMOL NMR, V13, P305, DOI 10.1023/A:1008300609352; Johansson T, 2005, J MOL BIOL, V352, P299, DOI 10.1016/j.jmb.2005.07.022; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCCP4 ESF EADB, V226; LITTLE JW, 1972, ANAL BIOCHEM, V48, P217, DOI 10.1016/0003-2697(72)90184-4; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Mather OC, 2004, BIOCHEMISTRY-US, V43, P10952, DOI 10.1021/bi0497594; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Peake SJ, 1999, BBA-BIOENERGETICS, V1413, P81, DOI 10.1016/S0005-2728(99)00084-5; Pinheiro TJT, 2001, J BIOL CHEM, V276, P44757, DOI 10.1074/jbc.M109227200; Prasad GS, 1999, NAT STRUCT BIOL, V6, P1126; Prasad GS, 2002, BIOCHEMISTRY-US, V41, P12745, DOI 10.1021/bi020251f; Quirk PG, 1999, BBA-BIOENERGETICS, V1412, P139, DOI 10.1016/S0005-2728(99)00057-2; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; Singh A, 2003, J BIOL CHEM, V278, P33208, DOI 10.1074/jbc.M303061200; Sundaresan V, 2005, J MOL BIOL, V346, P617, DOI 10.1016/j.jmb.2004.11.070; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; van Boxel GI, 2003, BIOCHEMISTRY-US, V42, P1217, DOI 10.1021/bi027032e; Venning JD, 2000, J BIOL CHEM, V275, P19490, DOI 10.1074/jbc.M000577200; Venning JD, 1997, J BIOL CHEM, V272, P27535, DOI 10.1074/jbc.272.44.27535; Venning JD, 1998, EUR J BIOCHEM, V257, P202, DOI 10.1046/j.1432-1327.1998.2570202.x; Venning JD, 2001, J BIOL CHEM, V276, P30678, DOI 10.1074/jbc.M104429200; White SA, 2000, STRUCT FOLD DES, V8, P1, DOI 10.1016/S0969-2126(00)00075-7; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P28165; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9	54	11	14	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13345	13354		10.1074/jbc.M513230200	http://dx.doi.org/10.1074/jbc.M513230200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533815	hybrid			2022-12-25	WOS:000237336600040
J	Chou, CY; Jen, WP; Hsieh, YH; Shiao, MS; Chang, GG				Chou, CY; Jen, WP; Hsieh, YH; Shiao, MS; Chang, GG			Structural and functional variations in human apolipoprotein E3 and E4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIZE-DISTRIBUTION ANALYSIS; RECEPTOR-BINDING DOMAIN; ALZHEIMERS-DISEASE; LIPID INTERACTION; A-I; PROTEIN INTERACTIONS; SECONDARY STRUCTURE; NEURONAL CELLS; ASSOCIATION; MODEL	There are three major apolipoprotein E ( apoE) isoforms. Although APOE-epsilon 3 is considered a longevity gene, APOE-epsilon 4 is a dual risk factor to atherosclerosis and Alzheimer disease. We have expressed full-length and N- and C-terminal truncated apoE3 and apoE4 tailored to eliminate helix and domain interactions to unveil structural and functional disturbances. The N- terminal truncated apoE4-( 72 - 299) and C-terminal truncated apoE4-( 1 - 231) showed more complicated or aggregated species than those of the corresponding apoE3 counterparts. This isoformic structural variation did not exist in the presence of dihexanoylphosphatidylcholine. The C-terminal truncated apoE-( 1 - 191) and apoE-( 1 - 231) proteins greatly lost lipid binding ability as illustrated by the dimyristoylphosphatidylcholine turbidity clearance. The low density lipoprotein ( LDL) receptor binding ability, determined by a competition binding assay of H-3-LDL to the LDL receptor of HepG2 cells, showed that apoE4 proteins with N- terminal ( apoE4-( 72 - 299)), C-terminal ( apoE4-( 1 - 231)), or complete C-terminal truncation ( apoE4-( 1 - 191)) maintained greater receptor binding abilities than their apoE3 counterparts. The cholesterol-lowering abilities of apoE3-( 72 - 299) and apoE3-( 1 - 231) in apoE- deficient mice were decreased significantly. The structural preference of apoE4 to remain functional in solution may explain the enhanced opportunity of apoE4 isoform to display its pathophysiologic functions in atherosclerosis and Alzheimer disease.	Natl Yang Ming Univ, Fac Life Sci, Inst Biochem, Struct Biol Program, Taipei 112, Taiwan; Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Chang, GG (corresponding author), Natl Yang Ming Univ, Fac Life Sci, Inst Biochem, Struct Biol Program, 155 Li Nong St,Sec 2, Taipei 112, Taiwan.	ggchang@ym.edu.tw		Chou, Chi-Yuan/0000-0002-3400-171X				AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Braman J, 1996, Methods Mol Biol, V57, P31; BURNS RA, 1980, BIOCHEMISTRY-US, V19, P3100, DOI 10.1021/bi00554a041; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102; Chou CY, 2005, BIOPHYS J, V88, P455, DOI 10.1529/biophysj.104.046813; Choy N, 2003, J MOL BIOL, V334, P527, DOI 10.1016/j.jmb.2003.09.059; de la Torre JC, 2002, J ALZHEIMERS DIS, V4, P497, DOI 10.3233/jad-2002-4606; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; DYER CA, 1991, J BIOL CHEM, V266, P22803; Fan DP, 2004, BIOCHEMISTRY-US, V43, P5055, DOI 10.1021/bi035958w; Farkas MH, 2004, J LIPID RES, V45, P1546, DOI 10.1194/jlr.M400104-JLR200; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; Greenow K, 2005, J MOL MED, V83, P329, DOI 10.1007/s00109-004-0631-3; GREGG RE, 1988, CLIN CHEM, V34, pB28; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; Hatters DM, 2005, J BIOL CHEM, V280, P34288, DOI 10.1074/jbc.M506044200; Hoff J, 2000, LAB ANIMAL, V29, P47; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; Kiss RS, 2003, J BIOL CHEM, V278, P21952, DOI 10.1074/jbc.M302676200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREMPLER F, 1987, J CLIN INVEST, V80, P401, DOI 10.1172/JCI113086; Lane RM, 2005, J LIPID RES, V46, P949, DOI 10.1194/jlr.M400486-JLR200; Li XP, 2003, BIOCHEMISTRY-US, V42, P10406, DOI 10.1021/bi027093c; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; LUNDBERG BB, 1985, BIOCHEM J, V228, P219, DOI 10.1042/bj2280219; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; Perugini MA, 2000, J BIOL CHEM, V275, P36758, DOI 10.1074/jbc.M005565200; Peters-Libeu CA, 2006, J BIOL CHEM, V281, P1073, DOI 10.1074/jbc.M510851200; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Saito H, 2003, J BIOL CHEM, V278, P40723, DOI 10.1074/jbc.M304814200; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; Schneeweis LA, 2005, BIOCHEMISTRY-US, V44, P12525, DOI 10.1021/bi050872j; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schuck P, 2005, ANALYTICAL ULTRACENTRIFUGATION: TECHNIQUES AND METHODS, P26; Segall ML, 2002, J LIPID RES, V43, P1688, DOI 10.1194/jlr.M200157-JLR200; SEGREST JP, 1992, J LIPID RES, V33, P141; Song S, 2003, MOL CELL, V12, P553, DOI 10.1016/j.molcel.2003.08.005; Song SM, 2004, TRENDS MOL MED, V10, P565, DOI 10.1016/j.molmed.2004.09.005; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; TAUSK RJM, 1974, BIOPHYS CHEM, V2, P175, DOI 10.1016/0301-4622(74)80004-9; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WILSON C, 1994, STRUCTURE, V2, P713, DOI 10.1016/S0969-2126(00)00072-1; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Xu Q, 2004, J BIOL CHEM, V279, P25511, DOI 10.1074/jbc.M311256200; Ye SM, 2005, P NATL ACAD SCI USA, V102, P18700, DOI 10.1073/pnas.0508693102; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	63	38	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13333	13344		10.1074/jbc.M511077200	http://dx.doi.org/10.1074/jbc.M511077200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16540478	hybrid			2022-12-25	WOS:000237336600039
J	Herold, MJ; Zeitz, J; Pelzer, C; Kraus, C; Peters, A; Wohlleben, G; Berberich, I				Herold, MJ; Zeitz, J; Pelzer, C; Kraus, C; Peters, A; Wohlleben, G; Berberich, I			The stability and anti-apoptotic function of A1 are controlled by its C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; NF-KAPPA-B; CELL-DEATH; BH3-ONLY PROTEINS; UBIQUITIN LIGASE; DOWN-REGULATION; BETA-TRCP; DEGRADATION; EXPRESSION; BAX	Most Bcl-2 family members can localize to intracellular membranes via hydrophobic sequences within their C-terminal portion. We found that the C terminus of the anti-apoptotic family member A1 did not function as a membrane anchor. Instead, this stretch of the protein rendered A1 highly unstable by mediating its polyubiquitination and rapid proteasomal degradation. Moreover, the domain did not only function independently of its position within the A1 protein but when transfered could even destabilize unrelated proteins like enhanced green fluorescent protein and caspase-3. A1 was, however, much more stable in the presence of the Bcl-2 homology-only protein BimEL, suggesting that direct interaction of A1 with pro-apoptotic members of the Bcl-2 family strongly reduces its rate of turnover. We further show that the C-terminal end of A1 also contributes to the anti-apoptotic capacity of the protein. In conclusion, our data demonstrate that the C terminus serves a dual function by controlling the stability of A1 and by amplifying the capacity of the protein to protect cells against apoptosis.	Univ Wurzburg, Inst Immunol & Virol, D-97078 Wurzburg, Germany	University of Wurzburg	Berberich, I (corresponding author), Univ Wurzburg, Inst Immunol & Virol, Versbacher Str 7, D-97078 Wurzburg, Germany.	berberich.i@uni-wuerzburg.de	Herold, Marco J/C-8039-2013	Herold, Marco J/0000-0001-7539-7581				Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; BERBERICH I, 1992, EUR J IMMUNOL, V22, P525, DOI 10.1002/eji.1830220235; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOI SS, 1995, ONCOGENE, V11, P1693; Chuang PI, 2002, BLOOD, V99, P3350, DOI 10.1182/blood.V99.9.3350; Clybouw C, 2005, J IMMUNOL, V175, P2968, DOI 10.4049/jimmunol.175.5.2968; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Fischer SE, 2004, J EXP MED, V200, P905, DOI 10.1084/jem.20040402; Gonzalez J, 2003, BLOOD, V101, P2679, DOI 10.1182/blood-2002-04-1229; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kucharczak JF, 2005, CELL DEATH DIFFER, V12, P1225, DOI 10.1038/sj.cdd.4401684; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; LIN EY, 1993, J IMMUNOL, V151, P1979; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873; Melino G, 2005, CELL DEATH DIFFER, V12, P1155, DOI 10.1038/sj.cdd.4401740; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Schinzel A, 2004, BBA-MOL CELL RES, V1644, P95, DOI 10.1016/j.bbamcr.2003.09.006; Schliephake DE, 1996, EUR J IMMUNOL, V26, P268, DOI 10.1002/eji.1830260142; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Somogyi RD, 2001, CELL DEATH DIFFER, V8, P785, DOI 10.1038/sj.cdd.4400879; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Strasser A, 2000, ANN NY ACAD SCI, V917, P541; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yang WS, 2005, J CELL BIOCHEM, V94, P1234, DOI 10.1002/jcb.20381; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	47	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13663	13671		10.1074/jbc.M600266200	http://dx.doi.org/10.1074/jbc.M600266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551634	hybrid			2022-12-25	WOS:000237336600077
J	Krut, O; Wiegmann, K; Kashkar, H; Yazdanpanah, B; Kronke, M				Krut, O; Wiegmann, K; Kashkar, H; Yazdanpanah, B; Kronke, M			Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SPHINGOMYELINASE; CERAMIDE PRODUCTION; PHOSPHOLIPASE-C; MEMBRANE; PREDICTION; APOPTOSIS; RECEPTOR; ELEGANS; DISEASE; MOUSE	Two genes encoding neutral sphingomyelinases- 1 and - 2 ( sphingomyelin phosphodiesterases- 2 and - 3) have been recently identified that hydrolyze sphingomyelin to phosphorylcholine and ceramide. Data bank searches using a peptide sequence derived from a previously purified bovine neutral sphingomyelinase ( nSMase) allowed us to identify a cDNA encoding a novel human sphingomyelinase, nSMase3, that shows only a little homology to nSMase1 and - 2. nSMase3 was biochemically characterized by overexpression in a yeast strain, JK9 - 3d Delta Isc1p, lacking endogenous SMase activity. Similar to nSMase2, nSMase3 is Mg2+- dependent and shows optimal activity at pH7, which is enhanced in the presence of phosphatidylserine and inhibited by scyphostatin. nSMase3 is ubiquitously expressed as a 4.6- kb mRNA species. nSMase3 lacks an N- terminal signal peptide, yet contains a 23- amino- acid transmembrane domain close to the C terminus, which is indicative for the family of C- tail- anchored integral membrane proteins. Cellular localization studies with hemagglutinin- tagged nSMase3 demonstrated colocal-ization with markers of the endoplasmic reticulum as well as with Golgi markers. Tumor necrosis factor stimulates rapid activation of nSMase3 in MCF7 cells with peak activity at 1.5 min, which was impaired by expression of dominant negative FAN.	Univ Cologne, Inst Med Microbiol Immunol & Hyg, Ctr Mol Med, D-50935 Cologne, Germany	University of Cologne	Kronke, M (corresponding author), Univ Cologne, Inst Med Microbiol Immunol & Hyg, Ctr Mol Med, Goldenfelsstr 19-21, D-50935 Cologne, Germany.	M.Kroenke@uni-koeln.de						Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aubin I, 2005, NAT GENET, V37, P803, DOI 10.1038/ng1603; Bernardo K, 2000, J BIOL CHEM, V275, P7641, DOI 10.1074/jbc.275.11.7641; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; Borgese N, 2003, J CELL BIOL, V161, P1013, DOI 10.1083/jcb.200303069; CAMPADELLI G, 1993, P NATL ACAD SCI USA, V90, P2798, DOI 10.1073/pnas.90.7.2798; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Jung M, 1999, AM J HUM GENET, V65, P1068, DOI 10.1086/302580; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KOOY J, 1992, J BIOL CHEM, V267, P20255; Kreder D, 1999, EMBO J, V18, P2472, DOI 10.1093/emboj/18.9.2472; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nara F, 1999, J ANTIBIOT, V52, P525, DOI 10.7164/antibiotics.52.525; Pajukanta P, 2000, AM J HUM GENET, V67, P1481, DOI 10.1086/316902; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Sambrook J, 2001, MOL CLONING LAB MANU; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Stoffel A, 2004, P NATL ACAD SCI USA, V101, P9079, DOI 10.1073/pnas.0402415101; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tonnetti L, 1999, J EXP MED, V189, P1581, DOI 10.1084/jem.189.10.1581; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Zumbansen M, 2002, MOL CELL BIOL, V22, P3633, DOI 10.1128/MCB.22.11.3633-3638.2002	42	102	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13784	13793		10.1074/jbc.M511306200	http://dx.doi.org/10.1074/jbc.M511306200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16517606	hybrid			2022-12-25	WOS:000237336600089
J	Lemasson, I; Polakowski, NJ; Laybourn, PJ; Nyborg, JK				Lemasson, I; Polakowski, NJ; Laybourn, PJ; Nyborg, JK			Tax-dependent displacement of nucleosomes during transcriptional activation of human T-cell leukemia virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; TRANSACTIVATION IN-VITRO; BINDING PROTEIN CREB; RNA-POLYMERASE-II; REGULATORY SEQUENCES; COACTIVATOR CBP; GENE-EXPRESSION; CHROMATIN; PROMOTER; ELONGATION	The human T-cell leukemia virus type 1 (HTLV-1) is integrated into the host cell DNA and assembled into nucleosomes. Within the repressive chromatin environment, the virally encoded Tax protein mediates the recruitment of the coactivators CREB-binding protein/p300 to the HTLV-1 promoter, located within the long terminal repeats (LTRs) of the provirus. These proteins carry acetyltransferase activity that is essential for strong transcriptional activation of the virus in the context of chromatin. Consistent with this, the amino-terminal tails of nucleosomal histones at the viral promoter are acetylated in Tax-expressing cells. We have developed a system in which we transfect Tax into cells carrying integrated copies of the HTLV-1 LTR driving the luciferase gene to analyze changes in "activating" histone modifications at the LTR. Unexpectedly, Tax transactivation led to an apparent reduction of these modifications at the HTLV-1 promoter and downstream region that correlates with a similar reduction in histone H3 and linker histone H1. Micrococcal nuclease protection analysis showed that less LTR-luciferase DNA is nucleosomal in Tax-expressing cells. Furthermore, nucleosome depletion correlated with RNA polymerase II recruitment and loss of SWI/SNF. The M47 Tax mutant, deficient in HTLV-1 transcriptional activation, was also defective for nucleosome depletion. Although this mutant formed complexes with CREB and p300 at the HTLV-1 promoter in vivo, it was unable to mediate RNA polymerase II recruitment or SWI/SNF displacement. These results support a model in which nucleosomes are depleted from the LTR and transcribed region during Tax-mediated transcriptional activation and correlate RNA polymerase II recruitment with nucleosome depletion.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Laybourn, PJ (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	Paul.Laybourn@colostate.edu	Lemasson, Isabelle/N-1355-2013	polakowski, Nicholas/0000-0003-4949-5799	NCI NIH HHS [CA55035, CA87540, R01 CA055035-13, R01 CA055035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087540, R01CA055035, R55CA055035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Azran Inbal, 2004, Retrovirology, V1, P20; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Boeger H, 2005, FEBS LETT, V579, P899, DOI 10.1016/j.febslet.2004.11.027; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Fragoso G, 1997, METHODS, V11, P246, DOI 10.1006/meth.1996.0411; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Georges SA, 2003, MOL CELL BIOL, V23, P3392, DOI 10.1128/MCB.23.10.3392-3404.2003; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; GESSAIN A, 1985, LANCET, V2, P407; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; Hager GL, 1999, METHOD ENZYMOL, V304, P626; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; Kristjuhan A, 2004, EMBO J, V23, P4243, DOI 10.1038/sj.emboj.7600433; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lenzmeier BA, 1999, J MOL BIOL, V291, P731, DOI 10.1006/jmbi.1999.2969; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Nagaich AK, 2004, MOL CELL, V14, P163, DOI 10.1016/S1097-2765(04)00178-9; Okada M, 2002, J VIROL, V76, P12564, DOI 10.1128/JVI.76.24.12564-12573.2002; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Schwabish MA, 2004, MOL CELL BIOL, V24, P10111, DOI 10.1128/MCB.24.23.10111-10117.2004; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; van den Hoff M J, 1995, Methods Mol Biol, V48, P185; Vicent GP, 2004, MOL CELL, V16, P439, DOI 10.1016/j.molcel.2004.10.025; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; Zhao J, 2005, MOL CELL BIOL, V25, P8985, DOI 10.1128/MCB.25.20.8985-8999.2005	50	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13075	13082		10.1074/jbc.M512193200	http://dx.doi.org/10.1074/jbc.M512193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547351	hybrid			2022-12-25	WOS:000237336600011
J	Li, HX; Kobayashi, M; Blonska, M; You, Y; Lin, X				Li, HX; Kobayashi, M; Blonska, M; You, Y; Lin, X			Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-RECEPTOR; LIPID RAFTS; KINASE RIP; TAK1; RECRUITMENT; PATHWAY; COMPLEX; MEKK3; TAB2; IKK	Stimulation of cells with tumor necrosis factor (TNF alpha) triggers a recruitment of various signaling molecules, such as RIP, to the TNF alpha receptor 1 complex, leading to activation of NF-K B. Previous studies indicate that RIP plays an essential role for TNF alpha- induced NF-KB activation, but the molecular mechanism by which RIP mediates TNF alpha signals to activate NF-KB is not fully defined. Earlier studies suggest that RIP undergoes a ligand- dependent ubiquitination. However, it remains to be determined whether the ubiquitination of RIP is required for TNF alpha-induced NF-KB activation. In this study, we have identified Lys(377) of RIP as the functional ubiquitination site, because mutating this residue to arginine completely abolished RIP-mediated NF-K B activation. The K377R mutation of RIP cannot undergo ligand-dependent ubiquitination and fails to recruit its downstream signaling components into the TNF alpha receptor 1 complex. Together, our studies provide the first genetic evidence that the ubiquitination of RIP is required for TNF alpha-induced NF-KB activation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; SUNY Buffalo, Grad Program Biochem, Buffalo, NY 14214 USA	University of Texas System; UTMD Anderson Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Lin, X (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA.	xllin@mdanderson.org	Blonska, Marzenna/U-7751-2019	Blonska, Marzenna/0000-0001-5237-8732	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065899, R56GM065899] Funding Source: NIH RePORTER; NIAID NIH HHS [AI058048] Funding Source: Medline; NIGMS NIH HHS [GM065899] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Blonska M, 2004, MOL CELL BIOL, V24, P10757, DOI 10.1128/MCB.24.24.10757-10765.2004; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Morlon A, 2005, HUM MOL GENET, V14, P3751, DOI 10.1093/hmg/ddi405; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	25	209	226	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13636	13643		10.1074/jbc.M600620200	http://dx.doi.org/10.1074/jbc.M600620200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543241	hybrid			2022-12-25	WOS:000237336600074
J	Sivan, SS; Tsitron, E; Wachtel, E; Roughley, PJ; Sakkee, N; van der Ham, F; DeGroot, J; Roberts, S; Maroudas, A				Sivan, SS; Tsitron, E; Wachtel, E; Roughley, PJ; Sakkee, N; van der Ham, F; DeGroot, J; Roberts, S; Maroudas, A			Aggrecan turnover in human intervertebral disc as determined by the racemization of aspartic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; AGE-RELATED ACCUMULATION; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; HYALURONATE; PRODUCTS; PROTEINS; COLLAGEN	We have used the racemization of aspartic acid as a marker for the "molecular age" of aggrecan components of the human intervertebral disc matrix (aggregating and non-aggregating proteoglycans as well as the different buoyant density fractions of aggrecan). By measuring the D/L-Asp ratio of the various aggrecan species as a function of age and using the values of the racemization constant, k(i), found earlier for aggrecan in articular cartilage, we were able to establish directly the relative residence time of these molecules in human intervertebral disc matrix. For A1 preparations taken from normal tissue, turnover rates of 0.059 +/- 0.01 and 0.063 +/- 0.01/year correspond to half-life values of 12 +/- 2.0 and 11.23 +/- 1.9 years for nucleus pulposus and annulus fibrosus, respectively; the turnover rates of 0.084 +/- 0.022 and 0.092 +/- 0.034/year for degenerate tissue correspond to half-life values of 8.77 +/- 2.2 and 8.41 +/- 2.8 years, suggesting increased rate of removal of small aggrecan fragments. For the large monomer, fraction A1D1, turnover is 0.13 +/- 0.04/year, corresponding to a half-life of 5.56 +/- 1.58 years, similar to 3.4 years in human articular cartilage. For the binding region (A1D6), turnover is 0.033 +/- 0.0012/year, corresponding to a half-life of 21.53 +/- 0.6 years, similar to 23.5 years in articular cartilage. A1 preparations from nucleus pulposus contain a lower proportion of aggregating proteoglycans as compared with annulus fibrosus, suggesting increased proteolytic modification in the nucleus pulposus. D/L-Asp values in aggregating and non-aggregating proteoglycans of a 24-year-old individual show similar results, suggesting that the non-aggregating molecules are synthesized initially as aggregating proteoglycans, which thereafter undergo cleavage and detachment from hyaluronan.	Technion Israel Inst Technol, Julius Silver Inst Biomed Sci, Fac Biomed Engn, Dept Biomed Engn, IL-32000 Haifa, Israel; Weizmann Inst Sci, Fac Chem, IL-76100 Rehovot, Israel; Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; TNO, Qual Life, Business Unit Biomed Res, NL-2301 CE Leiden, Netherlands; Robert Jones & Agnes Hunt Orthopaed Hosp, Ctr Spinal Studies, Oswestry SY10 7AG, Shrops, England	Technion Israel Institute of Technology; Weizmann Institute of Science; McGill University; Netherlands Organization Applied Science Research; Keele University	Sivan, SS (corresponding author), Technion Israel Inst Technol, Julius Silver Inst Biomed Sci, Fac Biomed Engn, Dept Biomed Engn, IL-32000 Haifa, Israel.	sarit@bm.technion.ac.il	DeGroot, Jeroen/C-4585-2012	Sivan, Sarit/0000-0002-6074-8032				ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; BADA JL, 1984, METHOD ENZYMOL, V106, P98; BAYLISS MT, 1978, BIOCHEM J, V176, P683, DOI 10.1042/bj1760683; BAYLISS MT, 1985, BIOCHEM J, V232, P111, DOI 10.1042/bj2320111; BAYLISS MT, 1990, BIOCHEM SOC T, V18, P799, DOI 10.1042/bst0180799; BAYLISS MT, 1990, METHODS CARTILAGE RE, P220; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; HARDINGHAM TE, 1976, BIOCHEM J, V159, P143, DOI 10.1042/bj1590143; HEINEGARD D, 1977, J BIOL CHEM, V252, P1980; HELFMAN PM, 1976, NATURE, V262, P279, DOI 10.1038/262279b0; HELFMAN PM, 1975, P NATL ACAD SCI USA, V72, P2891, DOI 10.1073/pnas.72.8.2891; HIRSCH C., 1953, ACTA ORTHOPAED SCAND, V22, P184; MAN EH, 1983, SCIENCE, V220, P1407, DOI 10.1126/science.6857259; Maroudas A, 1998, ARCH BIOCHEM BIOPHYS, V350, P61, DOI 10.1006/abbi.1997.0492; MAROUDAS A, 1975, J ANAT, V120, P113; MAROUDAS A, 1992, CONNECT TISSUE RES, V28, P161, DOI 10.3109/03008209209015033; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; MELROSE J, 1994, MATRIX BIOL, V14, P61, DOI 10.1016/0945-053X(94)90030-2; Ohtani S, 1998, J FORENSIC SCI, V43, P949; PFEIFFER H, 1995, INT J LEGAL MED, V108, P19, DOI 10.1007/BF01845611; POWELL JT, 1992, ATHEROSCLEROSIS, V97, P201, DOI 10.1016/0021-9150(92)90132-Z; ROUGHLEY PJ, 2006, IN PRESS EUR SPINE J; Sztrolovics R, 2002, BIOCHEM J, V362, P473, DOI 10.1042/0264-6021:3620473; Verzijl N, 2000, BIOCHEM J, V350, P381, DOI 10.1042/0264-6021:3500381; Verzijl N, 2001, MATRIX BIOL, V20, P409, DOI 10.1016/S0945-053X(01)00158-5; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200	27	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13009	13014		10.1074/jbc.M600296200	http://dx.doi.org/10.1074/jbc.M600296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16537531	hybrid, Green Published			2022-12-25	WOS:000237336600003
J	Moreland, JG; Davis, AP; Bailey, G; Nauseef, WM; Lamb, FS				Moreland, JG; Davis, AP; Bailey, G; Nauseef, WM; Lamb, FS			Anion channels, including ClC-3, are required for normal neutrophil oxidative function, phagocytosis, and transendothelial migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CHLORIDE CHANNELS; PLASMA-MEMBRANE; OXIDASE; ACTIVATION; EXPRESSION; EFFLUX; CL; IDENTIFICATION; GRANULOCYTES; MODULATION	NADPH oxidase activity, phagocytosis, and cell migration are essential functions of polymorphonuclear leukocytes (PMNs) in host defense. The cytoskeletal reorganization necessary to perform these functions has been extensively studied, but the role of cell volume regulation, which is likely dependent upon anion channels, has not been defined. Mice lacking the anion channel ClC-3 (Clcn3((-/-))) died from presumed sepsis following intravascular catheter placement, whereas Clcn3((+/+)) littermates survived. We hypothesized that ClC-3 has a critical role in host defense and reasoned that PMN function would be compromised in these mice. Clcn3((-/-)) PMNs displayed markedly reduced NADPH oxidase activity in response to opsonized zymosan and modestly reduced activity after phorbol 12-myristate 13-acetate. Human PMNs treated with the anion channel inhibitors niflumic acid or 5-nitro-2-(3-phenylpropylamino)benzoic acid had a very similar defect. ClC-3 protein was detected in the secretory vesicles and secondary granules of resting PMNs and was up-regulated to the phagosomal membrane. Clcn3((-/-)) PMNs and human PMNs lacking normal anion channel function both exhibited reduced uptake of opsonized zymosan at 1, 5, and 10 min in a synchronized phagocytosis assay. Niflumic acid-treated PMNs also had impaired transendothelial migration in vitro, whereas migration in vivo was not altered in Clcn3((-/-)) PMNs. Selective inhibition of the swelling-activated chloride channel with tamoxifen profoundly reduced PMN migration but had no effect on NADPH oxidase activity. In summary, PMNs lacking normal anion channel function exhibited reduced NADPH oxidase activity, diminished phagocytosis, and impaired migration. ClC-3 was specifically involved in the respiratory burst and phagocytosis.	Univ Iowa, Dept Pediat, Div Pediat Crit Care, Iowa City, IA 52242 USA; Univ Iowa, Div Crit Care, Iowa City, IA 52242 USA; Univ Iowa, Inflammat Program, Iowa City, IA 52242 USA; Univ Iowa, Dept Med, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Moreland, JG (corresponding author), Univ Iowa, Dept Pediat, Div Pediat Crit Care, 200 Hawkins Dr, Iowa City, IA 52242 USA.	jessica-moreland@uiowa.edu		Nauseef, William/0000-0003-4032-757X; Lamb, Fred/0000-0003-2955-5133	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD041922] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062483, R56HL062483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI034879, R01AI034879] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-62483] Funding Source: Medline; NIAID NIH HHS [AI34879] Funding Source: Medline; NICHD NIH HHS [T32 HD041922, T32 HD041922-04] Funding Source: Medline; NIEHS NIH HHS [ES00378] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Affairs(US Department of Veterans Affairs); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); BLRD VA		Allen LAH, 1999, BLOOD, V93, P3521, DOI 10.1182/blood.V93.10.3521.410k21_3521_3530; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; de Tassigny AD, 2003, FUND CLIN PHARMACOL, V17, P539, DOI 10.1046/j.1472-8206.2003.00197.x; DeLeo FR, 1999, J IMMUNOL, V163, P6732; Dickerson LW, 2002, BRAIN RES, V958, P227, DOI 10.1016/S0006-8993(02)03519-9; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Garcia-Duran M, 1999, CIRC RES, V85, P1020; Geiszt M, 1997, J BIOL CHEM, V272, P26471, DOI 10.1074/jbc.272.42.26471; HELLEBERG L, 1981, CLIN PHARMACOKINET, V6, P245, DOI 10.2165/00003088-198106040-00001; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; Jankowski A, 1999, J BIOL CHEM, V274, P26098, DOI 10.1074/jbc.274.37.26098; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jiang BH, 2002, LIFE SCI, V70, P1383, DOI 10.1016/S0024-3205(01)01517-X; Kobayashi T, 1998, J CELL SCI, V111, P81; KORCHAK HM, 1980, P NATL ACAD SCI-BIOL, V77, P2721, DOI 10.1073/pnas.77.5.2721; KRAUSE KH, 1990, J CLIN INVEST, V85, P491, DOI 10.1172/JCI114464; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; MAKERT M, 1988, J LAB CLIN MED, V111, P57; Menegazzi R, 1996, J CELL BIOL, V135, P511, DOI 10.1083/jcb.135.2.511; Moreland JG, 2004, J IMMUNOL, V172, P426, DOI 10.4049/jimmunol.172.1.426; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; Parij N, 1998, EUR J PHARMACOL, V352, P299, DOI 10.1016/S0014-2999(98)00370-7; Perez-Cornejo P, 2004, J IMMUNOL, V172, P6988, DOI 10.4049/jimmunol.172.11.6988; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; Ransom CB, 2001, J NEUROSCI, V21, P7674, DOI 10.1523/JNEUROSCI.21-19-07674.2001; REENWOOD IA, 1998, AM J PHYSIOL, V275, pH1524; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; ROCHARVEILLER M, 1995, INFLAMM RES, V44, P198, DOI 10.1007/BF01782258; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SENGELOV H, 1992, J BIOL CHEM, V267, P14912; SHIMIZU Y, 1993, BIOCHEM PHARMACOL, V45, P1743; SIMCHOWITZ L, 1986, J GEN PHYSIOL, V88, P167, DOI 10.1085/jgp.88.2.167; Soroceanu L, 1999, J NEUROSCI, V19, P5942, DOI 10.1523/JNEUROSCI.19-14-05942.1999; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; STODDARD JS, 1993, AM J PHYSIOL, V265, pC156, DOI 10.1152/ajpcell.1993.265.1.C156; Varela D, 2004, J BIOL CHEM, V279, P13301, DOI 10.1074/jbc.C400020200; Wang Bor-Sen, 2000, Proceedings of the National Science Council Republic of China Part B Life Sciences, V24, P178; Wheeler M, 2000, FASEB J, V14, P476, DOI 10.1096/fasebj.14.3.476; WINERBOURN CC, 2004, JPN J INFECT DIS, V57, pS31	45	121	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12277	12288		10.1074/jbc.M511030200	http://dx.doi.org/10.1074/jbc.M511030200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522634	hybrid			2022-12-25	WOS:000237134700012
J	Wang, J; Okamoto, Y; Morishita, J; Tsuboi, K; Miyatake, A; Ueda, N				Wang, J; Okamoto, Y; Morishita, J; Tsuboi, K; Miyatake, A; Ueda, N			Functional analysis of the purified anandamide-generating phospholipase D as a member of the metallo-beta-lactamase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACYLETHANOLAMINE PHOSPHOLIPIDS; CANNABINOID-RECEPTOR-LIGAND; CRYSTAL-STRUCTURE; ACYLATED GLYCEROPHOSPHOLIPIDS; ENZYMATIC-SYNTHESIS; ACTIVE-SITE; BINDING; PHOSPHODIESTERASE; IDENTIFICATION; BIOSYNTHESIS	In animal tissues, bioactive N-acylethanolamines including the endocannabinoid anandamide are formed from their corresponding N-acylphosphatidylethanolamines (NAPEs) by the catalysis of a specific phospholipase D (NAPE-PLD) that belongs to the metallo-beta-lactamase family. Despite its potential physiological importance, NAPE-PLD has not yet been characterized with a purified enzyme preparation. In the present study we expressed a recombinant NAPE-PLD in Escherichia coli and highly purified it. The purified enzyme was remarkably activated in a dose-dependent manner by millimolar concentrations of Mg2+ as well as Ca2+ and, hence, appeared to be constitutively active. The enzyme showed extremely high specificity for NAPEs among various glycerophospholipids but did not reveal obvious selectivity for different long chain or medium chain N-acyl species of NAPEs. These results suggested the ability of NAPE-PLD to degrade different NAPEs without damaging other membrane phospholipids. Metal analysis revealed the presence of catalytically important zinc in NAPE-PLD. In addition, site-directed mutagenesis studies were addressed to several histidine and aspartic acid residues of NAPE-PLD that are highly conserved within the metallo-beta-lactamase family. Single mutations of Asp-147, His-185, His-187, Asp-189, His-190, His-253, Asp-284, and His-321 caused abolishment or remarkable reduction of the catalytic activity. Moreover, when six cysteine residues were individually mutated to serine, only C224S showed a considerably reduced activity. The activities of L207F and H380R found as single nucleotide polymorphisms were also low. Thus, NAPE-PLD appeared to function through a mechanism similar to those of the well characterized members of this family but play a unique role in the lipid metabolism of animal tissues.	Kagawa Univ, Sch Med, Dept Biochem, Miki, Kagawa 7610793, Japan; Kagawa Univ, Life Sci Res Ctr, Miki, Kagawa 7610793, Japan; China Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Shenyang 110001, Peoples R China	Kagawa University; Kagawa University; China Medical University	Ueda, N (corresponding author), Kagawa Univ, Sch Med, Dept Biochem, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	nueda@med.kagawa-u.ac.jp	OKAMOTO, Yasuo/J-8438-2015					APPLEBUR.ML, 1970, J BIOL CHEM, V245, P4968; Aravind L, 1999, In Silico Biol, V1, P69; Bates PA, 2001, PROTEINS, P39; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; Caramelo JJ, 2003, BIOCHEM J, V374, P109, DOI 10.1042/BJ20021840; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; COMFURIUS P, 1990, J LIPID RES, V31, P1719; Curtiss NP, 2005, GENOMICS, V85, P600, DOI 10.1016/j.ygeno.2005.01.013; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; de la Sierra-Gallay IL, 2005, NATURE, V433, P657, DOI 10.1038/nature03284; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Garau G, 2005, J BIOL CHEM, V280, P28591, DOI 10.1074/jbc.M502744200; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Guo Y, 2005, J BIOL CHEM, V280, P23429, DOI 10.1074/jbc.C500168200; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Haruta S, 2000, ANTIMICROB AGENTS CH, V44, P2304, DOI 10.1128/AAC.44.9.2304-2309.2000; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Ishii R, 2005, J BIOL CHEM, V280, P14138, DOI 10.1074/jbc.M500355200; Kim MH, 2005, P NATL ACAD SCI USA, V102, P17606, DOI 10.1073/pnas.0504996102; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LIU J, 2005, 2005 S CANN INT CANN, P119; Liu Q, 2002, CHEM PHYS LIPIDS, V115, P77, DOI 10.1016/S0009-3084(02)00015-4; Maccarrone M, 2005, J CELL SCI, V118, P4393, DOI 10.1242/jcs.02536; Maccarrone M, 2002, BIOCHEM J, V366, P137, DOI 10.1042/BJ20020438; Martin SF, 2000, ANAL BIOCHEM, V278, P106, DOI 10.1006/abio.1999.4420; Materon IC, 2004, J MOL BIOL, V344, P653, DOI 10.1016/j.jmb.2004.09.074; Materon IC, 2001, PROTEIN SCI, V10, P2556, DOI 10.1110/ps.ps.40884; McFarland MJ, 2004, PHARMACOL THERAPEUT, V104, P117, DOI 10.1016/j.pharmthera.2004.07.008; Morishita J, 2005, J NEUROCHEM, V94, P753, DOI 10.1111/j.1471-4159.2005.03234.x; Movahed P, 2005, J BIOL CHEM, V280, P38496, DOI 10.1074/jbc.M507429200; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NATARAJAN V, 1984, J NEUROCHEM, V42, P1613, DOI 10.1111/j.1471-4159.1984.tb12750.x; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Okamoto Y, 2005, BIOCHEM J, V389, P241, DOI 10.1042/BJ20041790; Okamoto Y, 2002, J BIOL CHEM, V277, P46470, DOI 10.1074/jbc.M207779200; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Petersen G, 1999, FEBS LETT, V455, P41, DOI 10.1016/S0014-5793(99)00861-3; PIEPER U, 2004, NUCLEIC ACIDS RES, V2, P217; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Rohman M, 2000, PROTEIN EXPRES PURIF, V20, P45, DOI 10.1006/prep.2000.1271; ROZA M, 1973, BIOCHIM BIOPHYS ACTA, V327, P24, DOI 10.1016/0005-2744(73)90099-5; Sasaki T, 1997, LIFE SCI, V61, P1803, DOI 10.1016/S0024-3205(97)00804-7; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Schmid HHO, 2002, PROSTAG LEUKOTR ESS, V66, P363, DOI 10.1054/plef.2001.0348; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1986, CHEM PHYS LIPIDS, V41, P195, DOI 10.1016/0009-3084(86)90022-8; Spath B, 2005, J BIOL CHEM, V280, P35440, DOI 10.1074/jbc.M506418200; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; Sun YX, 2004, BIOCHEM J, V380, P749, DOI 10.1042/BJ20040031; Terrazzino S, 2004, FASEB J, V18, P1580, DOI 10.1096/fj.03-1080fje; Ueda N, 2005, CURR MED CHEM, V12, P1413, DOI 10.2174/0929867054020918; Ueda N, 2001, BBA-MOL CELL BIOL L, V1532, P121, DOI 10.1016/S1388-1981(01)00120-2; van der Stelt M, 2004, EUR J BIOCHEM, V271, P1827, DOI 10.1111/j.1432-1033.2004.04081.x; Vogel A, 2004, BIOCHEMISTRY-US, V43, P10379, DOI 10.1021/bi049703+; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Yang HY, 2002, PROTEIN SCI, V11, P2958, DOI 10.1110/ps.0225302	69	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12325	12335		10.1074/jbc.M512359200	http://dx.doi.org/10.1074/jbc.M512359200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527816	hybrid			2022-12-25	WOS:000237134700017
J	Boisvert-Adamo, K; Aplin, AE				Boisvert-Adamo, K.; Aplin, A. E.			B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis	ONCOGENE			English	Article						adhesion; apoptosis; collagen; ERK1/2; fibronectin; melanoma	GLYCOGEN-SYNTHASE KINASE-3; ONCOGENIC MUTATIONS; BRAF MUTATIONS; NEVUS CELLS; SURVIVAL; PATHWAY; ACTIVATION; APOPTOSIS; AKT; GROWTH	A hallmark feature of cancer is resistance to anoikis, apoptosis induced when cells either lose contact with or encounter an inappropriate extracellular matrix. Melanoma is inherently associated with a high degree of resistance to apoptosis. Mutations in B-RAF are prevalent in melanoma and promote constitutive MEK-ERK1/2 signaling and cell transformation. Acquisition of B-RAF mutations correlates with vertical phase growth when melanoma cells invade into the dermis, a collagen-rich environment that also contains fibronectin matrix. In addition, alterations in phosphoinositide-3 kinase (PI-3 kinase) signaling that lead to activation of AKT are detected in advanced melanomas. Here we show that knockdown of B-RAF expression by siRNA or pharmacological inhibition of MEK rendered melanoma cells susceptible to anoikis. Furthermore, adhesion to fibronectin but not collagen protected melanoma cells from anoikis through a PI-3 kinase-dependent pathway. Therefore, melanoma cells require either B-RAF or PI-3 kinase activation for protection from anoikis. Notably, AKT signaling in melanoma cells is substrate specific. These findings demonstrate that melanoma cells utilize multiple signaling pathways to provide resistance to apoptosis.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MC-165,47 New Scotland Ave, Albany, NY 12208 USA.	aplina@mail.amc.edu			NIGMS NIH HHS [GM067893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alanko T, 2000, J INVEST DERMATOL, V115, P286, DOI 10.1046/j.1523-1747.2000.00045.x; Alanko T, 1999, J INVEST DERMATOL, V113, P111, DOI 10.1046/j.1523-1747.1999.00636.x; Alonso SR, 2004, AM J PATHOL, V164, P193, DOI 10.1016/S0002-9440(10)63110-0; Bataille V, 2003, EUR J CANCER, V39, P1341, DOI 10.1016/S0959-8049(03)00313-7; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies MA, 1998, CANCER RES, V58, P5285; DEL PL, 1997, SCIENCE, V278, P687; Dong JL, 2003, CANCER RES, V63, P3883; Eisenmann KM, 2003, CANCER RES, V63, P8330; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Gaggioli C, 2005, ONCOGENE, V24, P1423, DOI 10.1038/sj.onc.1208318; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gill M, 2005, J AM ACAD DERMATOL, V53, P108, DOI 10.1016/j.jaad.2005.04.013; Guldberg P, 1997, CANCER RES, V57, P3660; Hingorani SR, 2003, CANCER RES, V63, P5198; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Marshman E, 2003, J CELL SCI, V116, P675, DOI 10.1242/jcs.00263; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; REGINATO MJ, 2003, NAT CELL BIOL, V6, P6; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stahl JM, 2003, CANCER RES, V63, P2881; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433	54	53	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4848	4856		10.1038/sj.onc.1209493	http://dx.doi.org/10.1038/sj.onc.1209493			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16547495				2022-12-25	WOS:000239687100003
J	Yang, H; Zhang, Y; Zhao, R; Wen, YY; Fournier, K; Wu, HB; Yang, HY; Diaz, J; Laronga, C; Lee, MH				Yang, H.; Zhang, Y.; Zhao, R.; Wen, Y. -Y; Fournier, K.; Wu, H. -B; Yang, H. -Y; Diaz, J.; Laronga, C.; Lee, M. -H			Negative cell cycle regulator 14-3-3 sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt	ONCOGENE			English	Article						p27; 14-3-3; Akt; tumor suppression	FORKHEAD TRANSCRIPTION FACTOR; DEPENDENT KINASE INHIBITOR; BREAST-CANCER; CYTOPLASMIC LOCALIZATION; PROTEIN-KINASE; DNA-DAMAGE; PHOSPHORYLATION; P27(KIP1); GROWTH; BRCA1	The 14-3-3 sigma (sigma) protein is a human cancer marker downregulated in various tumors, but its function has not been fully established. 14-3-3 sigma is a negative regulator of cell cycle when overexpressed, but it is not clear whether 14-3-3 sigma regulates cyclin-dependent kinase inhibitor p27(kip1) to negatively affect cell cycle progression. Protein kinase B/Akt is a crucial regulator of oncogenic signal and can phosphorylate p27(Kip1) to enhance p27(kip1)degradation, thereby promoting cell growth. Here, we show that 14-3-3 sigma-mediated cell cycle arrest concurred with p27(kip1) upregulation and Akt inactivation. We show that 14-3-3 sigma blocks Akt-mediated acceleration of P27(kip1) turnover rate. 14-3-3 sigma inhibits Akt-mediated p27(kip1) phosphorylation that targets p27(kip1) for nuclear export and degradation. 14-3-3 sigma inhibits cell survival and tumorigenicity of Akt-activating breast cancer cell. Low expression of 14-3-3 sigma in human primary breast cancers correlates with cytoplasmic location of p27(kip1). These data provide an insight into 14-3-3 sigma activity and rational cancer gene therapy by identifying 14-3-3 sigma as a positive regulator of p27 and as a potential anticancer agent.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Program Genes & Dev, Grad Sch Biomed Sci, Houston, TX USA; Eastern Virginia Med Sch, Dept Surg, Norfolk, VA 23501 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Biol Program, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci Houston, Program Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Eastern Virginia Medical School; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 79, Houston, TX 77030 USA.	mhlee@mdanderson.org		Lee, Mong-Hong/0000-0001-8675-8215	NCI NIH HHS [R01CA089266, CA16672, R01 CA089266, R56 CA089266] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R56CA089266, R01CA089266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; ALBERTSEN HM, 1994, NAT GENET, V7, P472, DOI 10.1038/ng0894-472; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Newman L, 2001, MOL CARCINOGEN, V30, P169, DOI 10.1002/mc.1025; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YANG H, 2006, IN PRESS MOL CANC TH; YANG H, 2006, IN PRESS CANC RES; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yang HY, 2001, ONCOGENE, V20, P3695, DOI 10.1038/sj.onc.1204472; YANG HY, 2006, IN PRESS J CELL BIOC; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhang YJ, 2004, ONCOGENE, V23, P7132, DOI 10.1038/sj.onc.1207918; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	39	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4585	4594		10.1038/sj.onc.1209481	http://dx.doi.org/10.1038/sj.onc.1209481			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16532026				2022-12-25	WOS:000239457500008
J	Kim, YR; Kim, JS; Lee, SH; Lee, WR; Sohn, JN; Chung, YC; Shim, HK; Lee, SC; Kwon, MH; Kim, YS				Kim, Young-Rim; Kim, Jeong-Sun; Lee, Seung-Hyun; Lee, Woo-Ram; Sohn, Jong-Nam; Chung, Yu-Chul; Shim, Hye-Kyung; Lee, Suk-Chan; Kwon, Myung-Hee; Kim, Yong-Sung			Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded DNAs without sequence specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FV; AUTOANTIBODY; RECOGNITION; FAB; MODULATION; EXPRESSION; CLEAVAGE; FRAGMENT; MOUSE; SERA	Anti-DNA antibodies (Abs) are of biomedical interest because they are associated with autoimmune diseases in human and mice. Previously we isolated an anti-DNA monoclonal Ab 3D8 from an autoimmune-prone MRL-lpr/lpr mouse. Here we have characterized DNA binding kinetics and hydrolyzing activities of the recombinant single chain variable fragment ( scFv) and the single variable domains of heavy chain (VH) and light chain (VL) using various single-stranded (ss) and double-stranded (ds) DNA substrates. All the Abs bound to both ds- and ssDNAs without significant preferential sequence specificity showing scFv higher affinities (K-D = similar to 17-74 n(M)) than VH (K-D = similar to 2.4-8.4 mu(M)) and VL (K-D = similar to 3.2-72 mu(M)), and efficiently hydrolyzed both ds- and ssDNAs without sequence specificity in a Mg2+-dependent manner, except for the poor activity of 3D8 scFv for ss-(dT)(40). Elucidated crystal structure-based His to Ala mutations on the complementarity determining regions of VH (His-H35 -> Ala) and/or VL (His-L94 -> Ala) of 3D8 scFv significantly inhibited the catalytic activities, indicating that the His residues are involved in the catalytic mechanism of 3D8 scFv. However, the DNA hydrolyzing activities of single domain VH and VL were not affected by the mutations, indicative of their different catalytic mechanisms from that of 3D8 scFv. Our results demonstrate single domain Abs with DNase activities for the first time, which might provide new insights into substrate recognition and catalytic mechanisms of anti-DNA Abs.	Chonnam Natl Univ, Dept Chem, Kwangju 500757, South Korea; Ajou Univ, Sch Med, Dept Microbiol, Suwon 443749, South Korea; Ajou Univ, Dept Mol Sci & Technol, Suwon 443749, South Korea; Sungkyunkwan Univ, Dept Genet Engn, Suwon 440746, South Korea	Chonnam National University; Ajou University; Ajou University; Sungkyunkwan University (SKKU)	Kim, JS (corresponding author), Chonnam Natl Univ, Dept Chem, 300 Yongbong Dong, Kwangju 500757, South Korea.	jsunkim@chonnam.ac.kr; kwonmh@ajou.ac.kr; kimys@ajou.ac.kr		Kim, Yong-Sung/0000-0003-2673-1509				Ay J, 2000, J MOL BIOL, V301, P239, DOI 10.1006/jmbi.2000.3971; Baranovskii AG, 2001, IMMUNOL LETT, V76, P163, DOI 10.1016/S0165-2478(01)00185-7; BARRY MM, 1993, MOL IMMUNOL, V30, P833, DOI 10.1016/0161-5890(93)90006-W; BRIGIDO MM, 1993, J IMMUNOL, V150, P469; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cerutti ML, 2001, J BIOL CHEM, V276, P12769, DOI 10.1074/jbc.M100260200; Chen Y, 1999, J IMMUNOL, V162, P4663; CLARK P, 1974, BIOCHEMISTRY-US, V13, P5098, DOI 10.1021/bi00722a007; Cleary J, 2003, BIOCHEMISTRY-US, V42, P30, DOI 10.1021/bi0203942; Di Pietro SM, 2003, BIOCHEMISTRY-US, V42, P6218, DOI 10.1021/bi026866u; Dubrovskaya VV, 2003, BIOCHEMISTRY-MOSCOW+, V68, P1081, DOI 10.1023/A:1026350426842; Eivazova ER, 2000, IMMUNOLOGY, V101, P371, DOI 10.1046/j.1365-2567.2000.00119.x; Gololobov GV, 1997, MOL IMMUNOL, V34, P1083, DOI 10.1016/S0161-5890(97)00129-6; GOLOLOBOV GV, 1995, P NATL ACAD SCI USA, V92, P254, DOI 10.1073/pnas.92.1.254; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Jang YJ, 2003, CELL MOL LIFE SCI, V60, P309, DOI 10.1007/s000180300026; Jang YJ, 2001, MOL IMMUNOL, V38, P383, DOI 10.1016/S0161-5890(01)00066-9; Jin HL, 2004, PROTEIN SCI, V13, P3222, DOI 10.1110/ps.04921704; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNOWICZ E, 1973, BIOCHIM BIOPHYS ACTA, V312, P72, DOI 10.1016/0005-2787(73)90053-1; Kanyshkova TG, 1997, FEBS LETT, V416, P23, DOI 10.1016/S0014-5793(97)01163-0; Komissarov AA, 1999, BIOCHEMISTRY-US, V38, P14631, DOI 10.1021/bi991347l; KUBOTA T, 1986, IMMUNOL LETT, V14, P53, DOI 10.1016/0165-2478(86)90020-9; Kumar S, 2001, J MOL BIOL, V308, P527, DOI 10.1006/jmbi.2001.4534; Kwon MH, 2002, IMMUNOL INVEST, V31, P205, DOI 10.1081/IMM-120016241; Lee HW, 2005, BIOCHEM BIOPH RES CO, V330, P1205, DOI 10.1016/j.bbrc.2005.03.101; Marion TN, 1997, METHODS, V11, P3, DOI 10.1006/meth.1996.0381; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mouratou B, 2002, J IMMUNOL METHODS, V269, P147, DOI 10.1016/S0022-1759(02)00231-4; Nevinsky GA, 2002, J IMMUNOL METHODS, V269, P235, DOI 10.1016/S0022-1759(02)00234-X; Nevinsky GA, 2000, APPL BIOCHEM BIOTECH, V83, P115, DOI 10.1385/ABAB:83:1-3:115; NEVINSKY GA, 2005, NATURAL CATALYTIC AN; O'Connor KC, 2001, J MOL RECOGNIT, V14, P18, DOI 10.1002/1099-1352(200101/02)14:1<18::AID-JMR515>3.0.CO;2-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAUL S, 1995, J BIOL CHEM, V270, P15257, DOI 10.1074/jbc.270.25.15257; POLYMENIS M, 1995, J IMMUNOL, V154, P2198; RADIC MZ, 1993, J IMMUNOL, V150, P4966; Schuermann JP, 2005, J MOL BIOL, V347, P965, DOI 10.1016/j.jmb.2005.02.008; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; Stevens SY, 1999, BIOCHEMISTRY-US, V38, P560, DOI 10.1021/bi981899o; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0	42	86	100	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15287	15295		10.1074/jbc.M600937200	http://dx.doi.org/10.1074/jbc.M600937200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16551636	hybrid			2022-12-25	WOS:000237922200032
J	Pieri, L; Bucciantini, M; Nosi, D; Formigli, L; Savistchenko, J; Melki, R; Stefani, M				Pieri, Laura; Bucciantini, Monica; Nosi, Daniele; Formigli, Lucia; Savistchenko, Jimmy; Melki, Ronald; Stefani, Massimo			The yeast prion Ure2p native-like assemblies are toxic to mammalian cells regardless of their aggregation state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE AMYLOID OLIGOMERS; PHOSPHATIDYLSERINE-CONTAINING MEMBRANES; PROTEIN MISFOLDING DISEASES; SACCHAROMYCES-CEREVISIAE; IN-VITRO; ALZHEIMERS-DISEASE; COMMON MECHANISM; STRUCTURAL-CHARACTERIZATION; CRYSTAL-STRUCTURE; TUMOR-CELLS	The yeast prion Ure2p assembles in vitro into oligomers and fibrils retaining the alpha-helix content and binding properties of the soluble protein. Here we show that the different forms of Ure2p native-like assemblies ( dimers, oligomers, and fibrils) are similarly toxic to murine H-END cells when added to the culture medium. Interestingly, the amyloid fibrils obtained by heat treatment of the toxic native-like fibrils appear harmless. Moreover, the Ure2p C-terminal domain, lacking the N-terminal segment necessary for aggregation but containing the glutathione binding site, is not cytotoxic. This finding strongly supports the idea that Ure2p toxicity depends on the structural properties of the flexible N-terminal prion domain and can therefore be considered as an inherent feature of the protein, unrelated to its aggregation state but rather associated with a basic toxic fold shared by all of the Ure2p native-like assemblies. Indeed, the latter are able to interact with the cell surface, leading to alteration of calcium homeostasis, membrane permeabilization, and oxidative stress, whereas the heat-treated amyloid fibrils do not. Our results support the idea of a general mechanism of toxicity of any protein/peptide aggregate endowed with structural features, making it able to interact with cell membranes and to destabilize them. This evidence extends the widely accepted view that the toxicity by protein aggregates is restricted to amyloid prefibrillar aggregates and provides new insights into the mechanism by which native-like oligomers compromise cell viability.	Univ Florence, Dept Biochem Sci, I-50134 Florence, Italy; Univ Florence, Interuniv Ctr Study Mol Basis Neurodegenerat Dis, I-50134 Florence, Italy; Univ Florence, Dept Anat Histol & Forens Med, I-50134 Florence, Italy; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	University of Florence; University of Florence; University of Florence; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Melki, R (corresponding author), Univ Florence, Dept Biochem Sci, Viale Morgagni 50, I-50134 Florence, Italy.	melki@lebs.cnrs-gif.fr; stefani@scibio.unifi.it	Savistchenko, Jimmy/A-6448-2011	STEFANI, MASSIMO/0000-0002-4490-1922; bucciantini, monica/0000-0002-5243-9301; , Laura/0000-0003-0779-9014				Abe K, 1996, J NEUROCHEM, V67, P2074; Arispe N, 2002, FASEB J, V16, P1526, DOI 10.1096/fj.02-0829com; Bai M, 2004, J BIOL CHEM, V279, P50025, DOI 10.1074/jbc.M406612200; Baxa U, 2004, J MOL BIOL, V339, P259, DOI 10.1016/j.jmb.2004.03.033; Baxa U, 2003, J BIOL CHEM, V278, P43717, DOI 10.1074/jbc.M306004200; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2004, BIOCHEMISTRY-US, V43, P5022, DOI 10.1021/bi049828e; Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; Bucciantini M, 2004, FASEB J, V18, P437, DOI 10.1096/fj.04-3086fje; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carulla N, 2005, NATURE, V436, P554, DOI 10.1038/nature03986; Cecchi C, 2005, J CELL SCI, V118, P3459, DOI 10.1242/jcs.02473; Choi J, 2005, INVEST OPHTH VIS SCI, V46, P214, DOI 10.1167/iovs.04-0765; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hirakura Y, 2001, AMYLOID, V8, P94, DOI 10.3109/13506120109007350; Hotze EM, 2002, J BIOL CHEM, V277, P11597, DOI 10.1074/jbc.M111039200; Ji SR, 2002, J BIOL CHEM, V277, P6273, DOI 10.1074/jbc.M104146200; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Kagan BL, 2004, J MEMBRANE BIOL, V202, P1, DOI 10.1007/s00232-004-0709-4; Kajava AV, 2004, P NATL ACAD SCI USA, V101, P7885, DOI 10.1073/pnas.0402427101; KANSKI J, 2001, BIOCHIM BIOPHYS ACTA, V1586, P190; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kourie JI, 2002, CLIN EXP PHARMACOL P, V29, P741, DOI 10.1046/j.1440-1681.2002.03737.x; Kranenburg O, 2003, FEBS LETT, V539, P149, DOI 10.1016/S0014-5793(03)00218-7; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee G, 2002, PEPTIDES, V23, P1249, DOI 10.1016/S0196-9781(02)00060-8; Leliveld SR, 2003, EUR J BIOCHEM, V270, P3619, DOI 10.1046/j.1432-1033.2003.03750.x; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V12, P283; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Mattson MP, 1999, METHOD ENZYMOL, V309, P733; Mihara H, 1998, BIOPOLYMERS, V47, P83, DOI 10.1002/(SICI)1097-0282(1998)47:1<83::AID-BIP9>3.0.CO;2-T; Milhavet O, 2002, BRAIN RES REV, V38, P328, DOI 10.1016/S0165-0173(01)00150-3; Miyata S, 2001, J BIOL CHEM, V276, P13778, DOI 10.1074/jbc.M011527200; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Sousa MM, 2001, AM J PATHOL, V159, P1993; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Svanborg C, 2003, ADV CANCER RES, V88, P1; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; Valeva A, 2001, J BIOL CHEM, V276, P14835, DOI 10.1074/jbc.M100301200; Wang LM, 2002, P NATL ACAD SCI USA, V99, P15947, DOI 10.1073/pnas.252508399; Wickner RB, 2000, J STRUCT BIOL, V130, P310, DOI 10.1006/jsbi.2000.4250; Wickner RB, 1996, ANNU REV GENET, V30, P109, DOI 10.1146/annurev.genet.30.1.109; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Yip CM, 2001, J MOL BIOL, V311, P723, DOI 10.1006/jmbi.2001.4881; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119; Zhang YH, 2003, EXP CELL RES, V289, P36, DOI 10.1016/S0014-4827(03)00188-5; Zhao HX, 2005, BIOCHEMISTRY-US, V44, P2857, DOI 10.1021/bi048510j; Zhao HX, 2004, BIOCHEMISTRY-US, V43, P10302, DOI 10.1021/bi049002c; Zurdo J, 2001, J AM CHEM SOC, V123, P8141, DOI 10.1021/ja016229b	65	42	42	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15337	15344		10.1074/jbc.M511647200	http://dx.doi.org/10.1074/jbc.M511647200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16571726	hybrid			2022-12-25	WOS:000237922200038
J	Srinivasan, R; Mager, GM; Ward, RM; Mayer, J; Svaren, J				Srinivasan, Rajini; Mager, Gennifer M.; Ward, Rebecca M.; Mayer, Joshua; Svaren, John			NAB2 represses transcription by interacting with the CHD4 subunit of the nucleosome remodeling and deacetylase (NuRD) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL NERVOUS-SYSTEM; NEGATIVE FEEDBACK LOOP; PROSTATE-CANCER CELLS; FINGER GENE KROX20; EGR1 TARGET GENES; HISTONE DEACETYLASE; COREPRESSOR NAB2; DEVELOPING HINDBRAIN; NGFI-A; SEGMENTAL EXPRESSION	Early growth response (EGR) transactivators act as critical regulators of several physiological processes, including peripheral nerve myelination and progression of prostate cancer. The NAB1 and NAB2 (NGFI-A/EGR1-binding protein) transcriptional corepressors directly interact with three EGR family members (Egr1/NGFIA/zif268, Egr2/Krox20, and Egr3) and repress activation of their target promoters. To understand the molecular mechanisms underlying NAB repression, we found that EGR activity is modulated by at least two repression domains within NAB2, one of which uniquely requires interaction with the CHD4(chromodomain helicase DNA-binding protein 4) subunit of the NuRD ( nucleosome remodeling and deacetylase) chromatin remodeling complex. Both NAB proteins can bind either CHD3 or CHD4, indicating that the interaction is conserved among these two protein families. Furthermore, we show that repression of the endogenous Rad gene by NAB2 involves interaction with CHD4 and demonstrate colocalization of NAB2 and CHD4 on the Rad promoter in myelinating Schwann cells. Finally, we show that interaction with CHD4 is regulated by alternative splicing of the NAB2 mRNA.	Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Pharmacol Training Program, Madison, WI 53706 USA; Univ Wisconsin, Cellular & Mol Biol Training Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Svaren, J (corresponding author), Univ Wisconsin, Sch Vet Med, 2015 Linden Dr, Madison, WI 53706 USA.	jpsvaren@wisc.edu	Svaren, John/A-1605-2010; Mayer, Joshua/D-1862-2011	Svaren, John/0000-0003-2963-7921; Mayer, Joshua/0000-0002-4294-4603	NICHD NIH HHS [HD41590, P30 HD03352] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003352] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041590] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Baron V, 2003, ONCOGENE, V22, P4194, DOI 10.1038/sj.onc.1206560; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bouazoune K, 2002, EMBO J, V21, P2430, DOI 10.1093/emboj/21.10.2430; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Buitrago M, 2005, NAT MED, V11, P837, DOI 10.1038/nm1272; Choo Y, 1997, J MOL BIOL, V273, P525, DOI 10.1006/jmbi.1997.1339; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Eid MA, 1998, CANCER RES, V58, P2461; Elfring LK, 1998, GENETICS, V148, P251; Feng Q, 2003, CURR TOP MICROBIOL, V274, P269; Feng Q, 2001, GENE DEV, V15, P827; FIELDS S, 1989, NATURE, V20; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hong W, 2005, EMBO J, V24, P2367, DOI 10.1038/sj.emboj.7600703; Houston P, 2001, BIOCHEM BIOPH RES CO, V283, P480, DOI 10.1006/bbrc.2001.4810; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; Kumbrink J, 2005, J BIOL CHEM, V280, P42785, DOI 10.1074/jbc.M511079200; Le N, 2005, NAT NEUROSCI, V8, P932, DOI 10.1038/nn1490; Le N, 2005, P NATL ACAD SCI USA, V102, P2596, DOI 10.1073/pnas.0407836102; LeBlanc SE, 2006, J BIOL CHEM, V281, P5453, DOI 10.1074/jbc.M512159200; Levi G, 1996, DEVELOPMENT, V122, P113; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lucerna M, 2003, J BIOL CHEM, V278, P11433, DOI 10.1074/jbc.M204937200; Mechta-Grigoriou F, 2000, DEVELOPMENT, V127, P119; Murawsky CM, 2001, EMBO REP, V2, P1089, DOI 10.1093/embo-reports/kve252; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; Nonchev S, 1996, DEVELOPMENT, V122, P543; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Seitanidou T, 1997, MECH DEVELOP, V65, P31, DOI 10.1016/S0925-4773(97)00051-8; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Theil T, 1998, DEVELOPMENT, V125, P443; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Verheijen MHG, 2003, GENE DEV, V17, P2450, DOI 10.1101/gad.1116203; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Warner LE, 1999, HUM MOL GENET, V8, P1245, DOI 10.1093/hmg/8.7.1245; Warner LE, 1998, NAT GENET, V18, P382, DOI 10.1038/ng0498-382; Williams CJ, 2004, IMMUNITY, V20, P719, DOI 10.1016/j.immuni.2004.05.005; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	63	85	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15129	15137		10.1074/jbc.M600775200	http://dx.doi.org/10.1074/jbc.M600775200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574654	hybrid			2022-12-25	WOS:000237922200015
J	Wang, RS; Wang, BP; He, WX; Zheng, H				Wang, Runsheng; Wang, Baiping; He, Wanxia; Zheng, Hui			Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT HUMAN PRESENILIN-1; PRECURSOR-PROTEIN; GAMMA-SECRETASE; TRANSGENIC MICE; TRANSMEMBRANE DOMAIN; INTRACELLULAR DOMAIN; CLEAVAGE; NOTCH; DEPOSITION; VULNERABILITY	Mutations in presenilin 1 (PS1) lead to dominant inheritance of early onset familial Alzheimer disease ( FAD). These mutations are known to alter the gamma-secretase cleavage of the amyloid precursor protein, resulting in increased ratio of A beta 42/A beta 40 and accelerated amyloid plaque pathology in transgenic mouse models. To investigate the factors that drive the A beta 42/A beta 40 ratio and amyloid pathogenesis and to investigate the possible interactions between wildtype and FAD mutant PS1, which are co-expressed in transgenic animals, we expressed the PS1 M146V knock-in allele either on wild-type PS1 (PS1(M146V/+)) or PS1 null (PS1(M146V/-)) background and crossed these alleles with the Tg2576 APP transgenic mice. Introduction of the PS1 M146V mutation on Tg2576 background resulted in earlier onset of plaque pathology. Surprisingly, removing the wild-type PS1 in the presence of the PS1 M146V mutation (PS1(M146V/-)) greatly exacerbated the amyloid burden; and this was attributed to a reduction of gamma-secretase activity rather than an increase in A beta 42. Our findings establish a protective role of the wild-type PS1 against the FAD mutation-induced amyloid pathology through a partial loss-of-function mechanism.	Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA	Baylor College of Medicine; Baylor College of Medicine; Cleveland Clinic Foundation	Zheng, H (corresponding author), Baylor Coll Med, Huffington Ctr Aging, 1 Baylor Plaza,M320, Houston, TX 77030 USA.	huiz@bcm.tmc.edu			NIA NIH HHS [T32 AG000183, AG20670, AG21141] Funding Source: Medline; NINDS NIH HHS [NS40039] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021141, R01AG020670, T32AG000183] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dewachter I, 2002, J NEUROSCI, V22, P3445; Dineley KT, 2002, J BIOL CHEM, V277, P22768, DOI 10.1074/jbc.M200164200; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Jankowsky JL, 2004, NEUROBIOL AGING, V25, P885, DOI 10.1016/j.neurobiolaging.2003.09.008; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saura CA, 2005, J NEUROSCI, V25, P6755, DOI 10.1523/JNEUROSCI.1247-05.2005; Siman R, 2000, J NEUROSCI, V20, P8717; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Wang R, 2004, NEUROSCIENCE, V126, P305, DOI 10.1016/j.neuroscience.2004.03.048; Wang RS, 2006, P NATL ACAD SCI USA, V103, P353, DOI 10.1073/pnas.0509822102; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wiley JC, 2005, J NEUROCHEM, V94, P1189, DOI 10.1111/j.1471-4159.2005.03266.x; Wilquet V, 2004, CURR OPIN NEUROBIOL, V14, P582, DOI 10.1016/j.conb.2004.08.001; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia XF, 2002, P NATL ACAD SCI USA, V99, P8760, DOI 10.1073/pnas.132045399; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zhao GJ, 2005, J BIOL CHEM, V280, P37689, DOI 10.1074/jbc.M507993200	42	57	61	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15330	15336		10.1074/jbc.M512574200	http://dx.doi.org/10.1074/jbc.M512574200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574645	hybrid			2022-12-25	WOS:000237922200037
J	Hizli, AA; Black, AR; Pysz, MA; Black, JD				Hizli, A. Asli; Black, Adrian R.; Pysz, Marybeth A.; Black, Jennifer D.			Protein kinase C alpha signaling inhibits cyclin D1 translation in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE ARREST; APC LOSS; D1; INITIATION; PROLIFERATION; EXPRESSION; GROWTH; PHOSPHORYLATION; DIFFERENTIATION; RECRUITMENT	Cyclin D1 is a key regulator of cell proliferation, acting as a mitogen sensor and linking extracellular signaling to the cell cycle machinery. Strict control of cyclin D1 levels is critical for maintenance of tissue homeostasis. We have reported previously that protein kinase C alpha (PKC alpha), a negative regulator of cell growth in the intestinal epithelium, promotes rapid down-regulation of cyclin D1 ( Frey, M. R., Clark, J.A., Leontieva, O., Uronis, J.M., Black, A. R., and Black, J.D. (2000) J. Cell Biol. 151, 763-778). The current study explores the mechanisms underlying PKC alpha-induced loss of cyclin D1 protein in non-transformed intestinal epithelial cells. Our findings exclude several mechanisms previously implicated in down-regulation of cyclin D1 during cell cycle exit/differentiation, including alterations in cyclin D1 mRNA expression and protein turnover. Instead, we identify PKC alpha as a novel repressor of cyclin D1 translation, acting at the level of cap-dependent initiation. Inhibition of cyclin D1 translation initiation is mediated by PKC alpha-induced hypophosphorylation/activation of the translational suppressor 4E-BP1, association of 4E-BP1 with the mRNA cap-binding protein eIF4E, and sequestration of cyclin D1 mRNA in 4E-BP1-associated complexes. Together, these post-transcriptional effects ensure rapid disappearance of the potent mitogenic molecule cyclin D1 during PKC alpha-induced cell cycle withdrawal in the intestinal epithelium.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Black, JD (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton Sts, Buffalo, NY 14263 USA.	jennifer.black@roswellpark.org		HIZLI DENIZ, AYSEN ASLI/0000-0003-0490-7737	NCI NIH HHS [CA 113048, CA 16056] Funding Source: Medline; NIDDK NIH HHS [DK 54909, DK 60632] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, F32CA113048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054909, R56DK060632, R01DK060632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aeder SE, 2004, ONCOGENE, V23, P9062, DOI 10.1038/sj.onc.1208093; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Campo PA, 2002, CELL GROWTH DIFFER, V13, P409; Caron S, 2004, MOL CELL BIOL, V24, P4920, DOI 10.1128/MCB.24.11.4920-4928.2004; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; Clark JA, 2004, J BIOL CHEM, V279, P9233, DOI 10.1074/jbc.M312268200; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Detjen KM, 2000, J CELL SCI, V113, P3025; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; FILMUS J, 1994, ONCOGENE, V9, P3627; Fisher TS, 2004, NAT STRUCT MOL BIOL, V11, P1198, DOI 10.1038/nsmb854; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Frey MR, 1997, J BIOL CHEM, V272, P9424; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Guo Y, 2005, ONCOGENE, V24, P1032, DOI 10.1038/sj.onc.1208299; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Jiang H, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-2; JIANG YH, 1995, CELL GROWTH DIFFER, V6, P1381; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Miyamoto S, 2000, BBA-GENE STRUCT EXPR, V1494, P28, DOI 10.1016/S0167-4781(00)00208-6; Neill GW, 2003, CANCER RES, V63, P4692; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sakaguchi M, 2004, J CELL BIOL, V164, P979, DOI 10.1083/jcb.200312041; Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Tibudan SS, 2002, J INVEST DERMATOL, V119, P1282, DOI 10.1046/j.1523-1747.2002.19625.x; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Zhang T, 1997, CANCER RES, V57, P169; Zhu YM, 2005, CANCER RES, V65, P4520, DOI 10.1158/0008-5472.CAN-04-4506	53	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14596	14603		10.1074/jbc.M601959200	http://dx.doi.org/10.1074/jbc.M601959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16556598	hybrid			2022-12-25	WOS:000237671300011
J	Li, XQ; Lu, Y; Jin, WD; Liang, K; Mills, GB; Fan, Z				Li, XQ; Lu, Y; Jin, WD; Liang, K; Mills, GB; Fan, Z			Autophosphorylation of Akt at Threonine 72 and Serine 246 - A potential mechanism of regulation of Akt kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CANCER CELLS; ACTIVATION; DOMAIN; PHOSPHORYLATES; RESISTANCE; AKT/PKB; INSULIN; B/AKT	Activation of the serine/ threonine protein kinase Akt is a multistep process. We here propose that the kinase activity of Akt is regulated via autophosphorylation in trans at two putative sites ( threonine 72 and serine 246) that lie in the characteristic Akt substrate motif ( RXRXX( S/ T)). Incubation of Akt immunoprecipitated from transfected cells with a pre- activated Akt recombinant protein and gamma- P-32- labeled ATP led to marked incorporation of radioactivity in wild- type Akt but not Akt/ T72A/ S246A mutant. Western blot analysis using a phosphorylated Akt substrate- specific antibody of Akt immunoprecipitated from transfected cells confirmed the autophosphorylation of wild- type Akt but not Akt/ T72A/ S246A mutant in insulin- like growth factor- 1 ( IGF- 1)- stimulated cells. Autophosphorylation of Akt on Thr- 72 and Ser- 246 appeared to require prior phosphorylation of Akt on Thr- 308 and Ser- 473. Compared with wild- type Akt, Akt/ T72A/ S246A mutant exhibited markedly reduced basal Akt kinase activity and response to cellular stimulation by insulin-like growth factor- 1, and also conferred less cellular resistance to doxorubicin- induced apoptosis. The findings from these pilot studies suggest that Akt regulates its kinase activity through autophosphorylation. Further investigation of this potential novel regulatory mechanism by which Akt performs its cellular functions is warranted.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 036, Houston, TX 77030 USA.	zfan@mdanderson.org						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alkan S, 2002, BLOOD, V99, P2278, DOI 10.1182/blood-2001-01-0317; Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brognard J, 2001, CANCER RES, V61, P3986; Carter Michael D, 2004, J Biomol Tech, V15, P257; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Coffer PJ, 1998, BIOCHEM J, V335, P1; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Liu B, 2000, BRIT J CANCER, V82, P1991; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Perugini RA, 2000, J SURG RES, V90, P39, DOI 10.1006/jsre.2000.5833; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Ringel MD, 2001, CANCER RES, V61, P6105; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sun M, 2001, CANCER RES, V61, P5985; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271	30	23	23	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13837	13843		10.1074/jbc.M602060200	http://dx.doi.org/10.1074/jbc.M602060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16549426	hybrid			2022-12-25	WOS:000237336600094
J	Cipriano, DJ; Wood, KS; Bi, YM; Dunn, SD				Cipriano, DJ; Wood, KS; Bi, YM; Dunn, SD			Mutations in the dimerization domain of the b subunit from the Escherichia coli ATP synthase - Deletions disrupt function but not enzyme assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED COILS; 2ND STALK; F1F0-ATPASE; PROTEINS; SECTOR; ENERGY; ALPHA; DIMER; F1	The b subunit dimer of Escherichia coli ATP synthase serves essential roles as an assembly factor for the enzyme and as a stator during rotational catalysis. To investigate the functional importance of its coiled coil dimerization domain, a series of internal deletions including each individual residue between Lys-100 and Ala-105 (b(Delta K100)-b(Delta A105)), b(Delta K100-A103), and b(Delta K100-Q106) as well as a control b(K100A) missense mutation were prepared. All of the mutants supported assembly of ATP synthase, but all single-residue deletions failed to support growth on acetate, indicating a severe defect in oxidative phosphorylation, and b(Delta K100-Q106) displayed moderately reduced growth. The membrane-bound ATPase activities of these strains showed a related reduction in sensitivity to dicyclohexylcarbodiimide, indicative of uncoupling. Analysis of dimerization of the soluble constructs of b(Delta K100) and the multiple-residue deletions by sedimentation equilibrium revealed reduced dimerization compared with wild type for all deletions, with b(Delta K100-Q106) most severely affected. In cross-linking studies it was found that F-1-ATPase can mediate the dimerization of some soluble b constructs but did not mediate dimerization of b(Delta K100) and b(Delta K100-Q106); these two forms also were defective in F-1 binding analyses. We conclude that defective dimerization of soluble b constructs severely affects F-1 binding in vitro, yet allows assembly of ATP synthase in vivo. The highly uncoupled nature of enzymes with single-residue deletions in b indicates that the b subunit serves an active function in energy coupling rather than just holding on to the F-1 sector. This function is proposed to depend on proper, specific interactions between the b subunits and F-1.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Dunn, SD (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	sdunn@uwo.ca	Dunn, Stanley/D-3418-2013					Bhatt D, 2005, J BIOENERG BIOMEMBR, V37, P67, DOI 10.1007/s10863-005-4129-7; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cherepanov DA, 1999, FEBS LETT, V449, P1, DOI 10.1016/S0014-5793(99)00386-5; Cipriano DJ, 2006, J BIOL CHEM, V281, P501, DOI 10.1074/jbc.M509986200; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; DUNCAN TM, 2003, ENZYMES, V23, P203; Dunn S. D., 2004, HDB ATPASES, P311; Dunn SD, 2001, BIOCHEMISTRY-US, V40, P187, DOI 10.1021/bi001821j; DUNN SD, 1992, J BIOL CHEM, V267, P7630; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Futai M., 2004, HDB ATPASES BIOCH CE, P237; Gruber M, 2003, TRENDS BIOCHEM SCI, V28, P679, DOI 10.1016/j.tibs.2003.10.008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lupas AN, 2005, ADV PROTEIN CHEM, V70, P37, DOI 10.1016/S0065-3233(04)70003-0; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; MESELSON M, 1968, NATURE, V217, P1110, DOI 10.1038/2171110a0; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Revington M, 2002, PROTEIN SCI, V11, P1227, DOI 10.1110/ps.3200102; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Sorgen PL, 1999, J BIOL CHEM, V274, P36261, DOI 10.1074/jbc.274.51.36261; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1	36	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12408	12413		10.1074/jbc.M513368200	http://dx.doi.org/10.1074/jbc.M513368200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531410	hybrid			2022-12-25	WOS:000237134700026
J	Hekim, C; Leinonen, J; Narvanen, A; Koistinen, H; Zhu, L; Koivunen, E; Vaisanen, V; Stenman, UH				Hekim, C; Leinonen, J; Narvanen, A; Koistinen, H; Zhu, L; Koivunen, E; Vaisanen, V; Stenman, UH			Novel peptide inhibitors of human kallikrein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; HUMAN-GLANDULAR-KALLIKREIN; SUBSTRATE-SPECIFICITY; BINDING PEPTIDES; MESSENGER-RNA; CELL-ADHESION; CANCER; HK2; EXPRESSION; PLASMINOGEN	Human kallikrein 2 (hK2) is a serine protease produced by the secretory epithelial cells in the prostate. Because hK2 activates several factors participating in proteolytic cascades that may mediate metastasis of prostate cancer, modulation of the activity of hK2 is a potential way of preventing tumor growth and metastasis. Furthermore, specific ligands for hK2 are potentially useful for targeting and imaging of prostate cancer and for assay development. We have used enzymatically active recombinant hK2 captured by a monoclonal antibody exposing the active site of the enzyme to screen phage display peptide libraries. Using libraries expressing 10 or 11 amino acids long linear peptides, we identified six different peptides binding to hK2. Three of these were shown to be specific and efficient inhibitors of the enzymatic activity of hK2 toward a peptide substrate. Furthermore, the peptides inhibited the activation of the proform of prostate-specific antigen by hK2. Amino acid substitution analyses revealed that motifs of six amino acids were required for the inhibitory activity. These peptides are potentially useful for treatment and targeting of prostate cancer.	Univ Helsinki, Cent Hosp, Dept Clin Chem, Biomedicum, FIN-00290 Helsinki, Finland; Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland; Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Univ Turku, Dept Biotechnol, FIN-20520 Turku, Finland	University of Helsinki; Helsinki University Central Hospital; University of Eastern Finland; University of Helsinki; University of Turku	Stenman, UH (corresponding author), Univ Helsinki, Cent Hosp, Dept Clin Chem, POB 700, Helsinki 00029, Finland.	ulf-hakan.stenman@hus.fi	Koistinen, Hannu/AGU-1279-2022; Narvanen, Ale/A-6002-2009	Koistinen, Hannu/0000-0003-0926-3109; Koivunen, Erkki/0000-0002-6443-9595				Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bangma CH, 1997, J UROLOGY, V157, P2191, DOI 10.1016/S0022-5347(01)64712-8; Boerman OC, 2000, SEMIN NUCL MED, V30, P195, DOI 10.1053/snuc.2000.7441; Bourgeois L, 1997, J BIOL CHEM, V272, P29590, DOI 10.1074/jbc.272.47.29590; Catalona WJ, 2000, UROLOGY, V55, P791, DOI 10.1016/S0090-4295(99)00602-0; CHAPDELAINE P, 1988, FEBS LETT, V236, P205, DOI 10.1016/0014-5793(88)80315-6; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Clements JA, 2004, CRIT REV CL LAB SCI, V41, P265, DOI 10.1080/10408360490471931; Cloutier SM, 2004, EUR J BIOCHEM, V271, P607, DOI 10.1111/j.1432-1033.2003.03963.x; Cloutier SM, 2002, EUR J BIOCHEM, V269, P2747, DOI 10.1046/j.1432-1033.2002.02960.x; Darson MF, 1999, UROLOGY, V53, P939, DOI 10.1016/S0090-4295(98)00637-2; Darson MF, 1997, UROLOGY, V49, P857, DOI 10.1016/S0090-4295(97)00108-8; Denmeade SR, 1997, CANCER RES, V57, P4924; Denmeade SR, 1998, CANCER RES, V58, P2537; Fortier AH, 1999, J NATL CANCER I, V91, P1635, DOI 10.1093/jnci/91.19.1635; Frenette G, 1997, INT J CANCER, V71, P897, DOI 10.1002/(SICI)1097-0215(19970529)71:5<897::AID-IJC31>3.0.CO;2-2; Heidtmann HH, 1999, BRIT J CANCER, V81, P1269, DOI 10.1038/sj.bjc.6692167; HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2; Koivunen E, 1999, J NUCL MED, V40, P883; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Kwiatkowski MK, 1998, UROLOGY, V52, P360, DOI 10.1016/S0090-4295(98)00245-3; Leinonen J, 2002, CLIN CHEM, V48, P2208; Lintula S, 2005, PROSTATE, V63, P324, DOI 10.1002/pros.20194; Liu S, 1999, CHEM REV, V99, P2235, DOI 10.1021/cr980436l; Lovgren J, 1999, EUR J BIOCHEM, V266, P1050, DOI 10.1046/j.1432-1327.1999.00946.x; Lovgren J, 1997, BIOCHEM BIOPH RES CO, V238, P549, DOI 10.1006/bbrc.1997.7333; Mikolajczyk SD, 1999, INT J CANCER, V81, P438, DOI 10.1002/(SICI)1097-0215(19990505)81:3<438::AID-IJC18>3.3.CO;2-L; Mikolajczyk SD, 1998, PROSTATE, V34, P44; Morpurgo M, 2002, BIOCONJUGATE CHEM, V13, P1238, DOI 10.1021/bc0100511; MORRIS BJ, 1989, CLIN EXP PHARMACOL P, V16, P345, DOI 10.1111/j.1440-1681.1989.tb01570.x; Nagakawa O, 2001, INT J UROL, V8, P65, DOI 10.1046/j.1442-2042.2001.00250.x; Nam RK, 2000, J CLIN ONCOL, V18, P1036, DOI 10.1200/JCO.2000.18.5.1036; Ruoslahti E, 2000, ANNU REV IMMUNOL, V18, P813, DOI 10.1146/annurev.immunol.18.1.813; Stege R, 2000, CLIN CANCER RES, V6, P160; Stenman UH, 1999, TUMOR BIOL, V20, P1, DOI 10.1159/000056523; Stenman UH, 2005, SCAND J UROL NEPHROL, V39, P64, DOI 10.1080/03008880510030941; STENMAN UH, 1991, CANCER RES, V51, P222; VEBER DF, 1972, J AM CHEM SOC, V94, P5456, DOI 10.1021/ja00770a600; WANG MC, 1979, INVEST UROL, V17, P159; Wu P, 2000, EUR J BIOCHEM, V267, P6212, DOI 10.1046/j.1432-1327.2000.01696.x; Wu P, 2004, PROSTATE, V58, P345, DOI 10.1002/pros.10337; Wu P, 2004, CLIN CHEM, V50, P125, DOI 10.1373/clinchem.2003.026146; ZHANG WM, 1995, CLIN CHEM, V41, P1567	47	39	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12555	12560		10.1074/jbc.M600014200	http://dx.doi.org/10.1074/jbc.M600014200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527822	hybrid			2022-12-25	WOS:000237134700044
J	McCabe, M; Low, JA; Imperiale, MJ; Day, ML				McCabe, M; Low, JA; Imperiale, MJ; Day, ML			Human polyomavirus BKV transcriptionally activates DNA methyltransferase 1 through the pRb/E2F pathway	ONCOGENE			English	Article						virus; DNA methylation; DNMT1; E2F; kidney	LARGE-T-ANTIGEN; DE-NOVO METHYLATION; ABERRANT METHYLATION; GENE-EXPRESSION; HUMAN-PAPILLOMAVIRUS; TRANSFORMED-CELLS; SIMIAN VIRUS-40; DOWN-REGULATION; TUMOR-ANTIGEN; CADHERIN GENE	Many DNA tumor virus oncogenes are capable of activating and highjacking the host cell's DNA replication machinery for its own reproduction purposes through targeting and inactivation of the retinoblastoma pocket protein family. Pocket proteins function to regulate cell cycle progression and DNA synthesis through inhibitory interactions with the E2F transcription factors. The interaction of viral oncogenes with the pocket proteins is crucial for their transforming activity. We recently demonstrated that the DNA methyltransferase 1 (DNMT1) gene is an E2F target gene that is transcriptionally activated in cells lacking the retinoblastoma gene (Rb-/-). Overexpression of DNMT1 is implicated in tumor suppressor gene hypermethylation which is associated with tumorigenesis. Given that viral oncogenes potently stimulate E2F activity, we hypothesized that viral infection might activate DNMT1 and thereby promote transformation. Herein, we demonstrate that DNMT1 is strongly activated by the human polyomavirus BKV large T antigen (TAg) and adenovirus E1a. Viral oncogene mutants incapable of binding the pocket proteins are ineffective at activating DNMT1 compared to their wildtype counterparts. Additionally, mutation of the E2F sites within the DNMT1 promoters dramatically abrogates transcriptional activation. These data suggest that viral induction of DNMT1 through modulation of the pRB/E2F pathway may be involved in viral transformation.	Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Day, ML (corresponding author), Univ Michigan, Dept Urol, 6219 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mday@umich.edu			NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061488] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09676] Funding Source: Medline; NIAID NIH HHS [AI060584] Funding Source: Medline; NIDDK NIH HHS [DK61488] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200; AZZI A, 1994, BONE MARROW TRANSPL, V14, P235; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; Biniszkiewicz D, 2002, MOL CELL BIOL, V22, P2124, DOI 10.1128/MCB.22.7.2124-2135.2002; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; BOUCHARD J, 1990, ANTIMICROB AGENTS CH, V34, P206, DOI 10.1128/AAC.34.2.206; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CRAWFORD L, 1982, J VIROL, V41, P709, DOI 10.1128/JVI.41.2.709-709.1982; Das D, 2004, ONCOGENE, V23, P7031, DOI 10.1038/sj.onc.1207920; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; El-Osta A, 2000, GENE EXPRESSION, V9, P63; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOORHA R, 1984, VIROLOGY, V138, P94, DOI 10.1016/0042-6822(84)90150-8; GUNTHERT U, 1976, P NATL ACAD SCI USA, V73, P3923, DOI 10.1073/pnas.73.11.3923; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; HELLER H, 1995, P NATL ACAD SCI USA, V92, P5515, DOI 10.1073/pnas.92.12.5515; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hohlweg U, 2003, VIRUS RES, V98, P45, DOI 10.1016/j.virusres.2003.08.012; Humes HD, 2002, AM J KIDNEY DIS, V39, P1078, DOI 10.1053/ajkd.2002.32792; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jarrard DF, 1997, CLIN CANCER RES, V3, P2121; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSONTHOMPSON M, 1988, IN VITRO CELL DEV B, V24, P1114; KAYE AM, 1967, J MOL BIOL, V24, P475, DOI 10.1016/0022-2836(67)90233-1; Khalili K, 2003, ONCOGENE, V22, P5181, DOI 10.1038/sj.onc.1206559; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; Low J, 2004, VIROLOGY, V323, P182, DOI 10.1016/j.virol.2004.03.027; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; Mikovits JA, 1998, MOL CELL BIOL, V18, P5166, DOI 10.1128/MCB.18.9.5166; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; NAKSHATRI H, 1988, J VIROL, V62, P4613, DOI 10.1128/JVI.62.12.4613-4621.1988; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; Peterson EJ, 2003, CANCER RES, V63, P6579; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; Remus R, 1999, J VIROL, V73, P1010, DOI 10.1128/JVI.73.2.1010-1022.1999; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Santin AD, 2005, VIROLOGY, V331, P269, DOI 10.1016/j.virol.2004.09.045; Shivapurkar N, 2004, CANCER RES, V64, P3757, DOI 10.1158/0008-5472.CAN-03-3307; SINCLAIR AJ, 1995, J VIROL, V69, P1292, DOI 10.1128/JVI.69.2.1292-1295.1995; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; SUTTER D, 1980, P NATL ACAD SCI-BIOL, V77, P253, DOI 10.1073/pnas.77.1.253; Suzuki M, 2005, ONCOGENE, V24, P1302, DOI 10.1038/sj.onc.1208263; Syrjanen SM, 1999, ANN MED, V31, P175, DOI 10.3109/07853899909115976; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2001, CANCER RES, V61, P5727; Trabanelli C, 1998, VIROLOGY, V243, P492, DOI 10.1006/viro.1998.9080; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Vilchez RA, 2004, CLIN MICROBIOL REV, V17, P495, DOI [10.1128/CMR.17.3.495-508.2004, 10.1128/cmr.17.3.495-508.2004]; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	71	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2727	2735		10.1038/sj.onc.1209266	http://dx.doi.org/10.1038/sj.onc.1209266			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16547506				2022-12-25	WOS:000237272900004
J	Deindl, E; Zaruba, MM; Brunner, S; Huber, B; Mehl, U; Assmann, G; Hoefer, IE; Mueller-Hoecker, J; Franz, WM				Deindl, Elisabeth; Zaruba, Marc-Michael; Brunner, Stefan; Huber, Bruno; Mehl, Ursula; Assmann, Gerald; Hoefer, Imo E.; Mueller-Hoecker, Josef; Franz, Wolfgang-Michael			G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis	FASEB JOURNAL			English	Article						granulocyte-colony stimulating factor; bone marrow derived cells; intercellular adhesion molecule-1	COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; GRANULOCYTE-COLONY; PROGENITOR CELLS; ENDOTHELIAL-CELLS; MOBILIZATION; REPAIR; TRANSPLANTATION; REGENERATION; MONOCYTES	Granulocyte-colony stimulating factor (G-CSF) has been shown to improve cardiac function after myocardial infarction (MI) by bone marrow cell mobilization and by protecting cardiomyocytes from apoptotic cell death. However, its role in collateral artery growth (arteriogenesis) has not been elucidated. Here, we investigated the effect of G-CSF on arteriolar growth and cardiac function in a murine MI model. Mice were treated with G-CSF (100 mu g/kg/day) directly after MI for 5 consecutive days. G-CSF application resulted in a significant increase of circulating mononuclear cells expressing stem cell markers. Arterioles in the border zone of infarcted myocardium showed an increased expression of ICAM-1 accompanied by an accumulation of bone marrow derived cells and a pronounced proliferation of endothelial and smooth muscle cells. Histology of G-CSF treated mice revealed a lower amount of granulation tissue (67.8 vs. 84.4%) associated with a subsequent reduction in free LV wall thinning and scar extension (23.1 vs. 30.8% of LV). Furthermore, G-CSF treated animals showed a significant improvement of post-MI survival (68.8 vs. 46.2%). Pressure-volume relations revealed a partially restored myocardial function at day 30 (EF: 32.5 vs. 17.2%). Our results demonstrate that G-CSF administration after MI stimulates arteriogenesis and attenuates ischemic cardiomyopathy after MI.	Univ Munich, Klinikum Grosshadern, Dept Med 1, D-81377 Munich, Germany; Univ Munich, Inst Pathol, D-8000 Munich, Germany; UMC, Dept Expt Cardiol, Utrecht, Netherlands	University of Munich; University of Munich	Franz, WM (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Med 1, Marchioninistr 15, D-81377 Munich, Germany.	wolfgang.franz@med.uni-muenchen.de	Deindl, Elisabeth/A-2511-2013; Zaruba, Marc-Michael/AAI-8571-2020	Zaruba, Marc-Michael/0000-0003-1074-5463				ARAI AE, 1992, CIRC RES, V70, P1137, DOI 10.1161/01.RES.70.6.1137; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; BRAUNWALD E, 1991, AM J CARDIOL, V68, pD1; Buschmann IR, 2001, ATHEROSCLEROSIS, V159, P343, DOI 10.1016/S0021-9150(01)00637-2; Buschmann IR, 2003, CIRCULATION, V108, P610, DOI 10.1161/01.CIR.0000074209.17561.99; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Carstanjen D, 2002, TRANSFUSION, V42, P588, DOI 10.1046/j.1537-2995.2002.00088.x; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; Deindl E, 2004, ARTERIOGENESIS, P115; Deindl E, 2003, FASEB J, V17, P1174, DOI 10.1096/fj.02-0800fje; Deten A, 2005, CARDIOVASC RES, V65, P52, DOI 10.1016/j.cardiores.2004.11.009; Fuste B, 2004, HAEMATOLOGICA, V89, P578; Georgakopoulos D, 1998, AM J PHYSIOL-HEART C, V274, pH1416, DOI 10.1152/ajpheart.1998.274.4.H1416; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Heil M, 2002, AM J PHYSIOL-HEART C, V283, pH2411, DOI 10.1152/ajpheart.01098.2001; Herold J, 2004, HUM GENE THER, V15, P1, DOI 10.1089/10430340460732517; Hill JM, 2005, J AM COLL CARDIOL, V46, P1643, DOI 10.1016/j.jacc.2005.01.067; Hoefer IE, 2005, ATHEROSCLEROSIS, V181, P285, DOI 10.1016/j.atherosclerosis.2005.01.047; Hoefer IE, 2004, CIRC RES, V94, P1179, DOI 10.1161/01.RES.0000126922.18222.F0; Ince H, 2005, CIRCULATION, V112, P3097, DOI 10.1161/CIRCULATIONAHA.105.541433; JORGENSEN E, 2005, INT J CARDIOL; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kong DL, 2004, CIRCULATION, V110, P2039, DOI 10.1161/01.CIR.0000143161.01901.BD; Kuethe F, 2004, DEUT MED WOCHENSCHR, V129, P424, DOI 10.1055/s-2004-820062; Minatoguchi S, 2004, CIRCULATION, V109, P2572, DOI 10.1161/01.CIR.0000129770.93985.3E; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Norol F, 2003, BLOOD, V102, P4361, DOI 10.1182/blood-2003-03-0685; Ohtsuka M, 2004, FASEB J, V18, P851, DOI 10.1096/fj.03-0637fje; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Peter FW, 1999, BURNS, V25, P477, DOI 10.1016/S0305-4179(99)00036-4; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; Schneeloch E, 2004, P NATL ACAD SCI USA, V101, P12730, DOI 10.1073/pnas.0404880101; SCHWARZ F, 1982, AM J CARDIOL, V50, P933, DOI 10.1016/0002-9149(82)90398-8; Seiler C, 2001, CIRCULATION, V104, P2012, DOI 10.1161/hc4201.097835; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Sugano Y, 2005, CARDIOVASC RES, V65, P446, DOI 10.1016/j.cardiores.2004.10.008; Tanaka J, 2002, INT J HEMATOL, V75, P489, DOI 10.1007/BF02982111; Valgimigli M, 2005, EUR HEART J, V26, P1838, DOI 10.1093/eurheartj/ehi289; Vargel I, 2002, ANN PLAS SURG, V49, P646, DOI 10.1097/00000637-200212000-00015; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Yang F, 2002, EXP PHYSIOL, V87, P547, DOI 10.1113/eph8702385; Zbinden S, 2005, J AM COLL CARDIOL, V46, P1636, DOI 10.1016/j.jacc.2005.01.068; Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C	47	130	136	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					956	+		10.1096/fj.05-4763fje	http://dx.doi.org/10.1096/fj.05-4763fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571777				2022-12-25	WOS:000240157700020
J	Ren, YJ; Barnwell, LF; Alexander, JC; Lubin, FD; Adelman, JP; Pfaffinger, PJ; Schrader, LA; Anderson, AE				Ren, YJ; Barnwell, LF; Alexander, JC; Lubin, FD; Adelman, JP; Pfaffinger, PJ; Schrader, LA; Anderson, AE			Regulation of surface localization of the small conductance Ca2+-activated potassium channel, Sk2, through direct phosphorylation by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL PYRAMIDAL NEURONS; RAT SUPRAOPTIC NUCLEUS; K+-CHANNEL; SYNAPTIC PLASTICITY; PLASMA-MEMBRANE; CYCLIC-AMP; TRAFFICKING; EXPRESSION; KV4.2; BRAIN	Small conductance, Ca2+-activated voltage-independent potassium channels (SK channels) are widely expressed in diverse tissues; however, little is known about the molecular regulation of SK channel subunits. Direct alteration of ion channel subunits by kinases is a candidate mechanism for functional modulation of these channels. We find that activation of cyclic AMP-dependent protein kinase (PKA) with forskolin ( 50 mu M) causes a dramatic decrease in surface localization of the SK2 channel subunit expressed in COS7 cells due to direct phosphorylation of the SK2 channel subunit. PKA phosphorylation studies using the intracellular domains of the SK2 channel subunit expressed as glutathione S-transferase fusion protein constructs showed that both the amino-terminal and carboxyl-terminal regions are PKA substrates in vitro. Mutational analysis identified a single PKA phosphorylation site within the amino-terminal of the SK2 subunit at serine 136. Mutagenesis and mass spectrometry studies identified four PKA phosphorylation sites: Ser(465) ( minor site) and three amino acid residues Ser(568), Ser(569), and Ser(570) ( major sites) within the carboxyl-terminal region. A mutated SK2 channel subunit, with the three contiguous serines mutated to alanines to block phosphorylation at these sites, shows no decrease in surface expression after PKA stimulation. Thus, our findings suggest that PKA phosphorylation of these three sites is necessary for PKA-mediated reorganization of SK2 surface expression.	Baylor Univ, Dept Pediat, Cain Fdn Labs, Feigin Ctr 955, Houston, TX 77030 USA; Baylor Univ, Dept Neurol, Houston, TX 77030 USA; Baylor Univ, Dept Neurosci, Houston, TX 77030 USA; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA	Baylor University; Baylor University; Baylor University; Oregon Health & Science University	Anderson, AE (corresponding author), Baylor Univ, Dept Pediat, Cain Fdn Labs, Feigin Ctr 955, 1102 Bates St,MC 3-6365, Houston, TX 77030 USA.	annea@bcm.tmc.edu	Schrader, Laura/ABH-4854-2020	Schrader, Laura/0000-0003-3355-1194				ADAMS J, 1999, SOC NEUR ABSTR, V25, P541; Adams JP, 2000, J NEUROCHEM, V75, P2277, DOI 10.1046/j.1471-4159.2000.0752277.x; Anderson AE, 2000, J BIOL CHEM, V275, P5337, DOI 10.1074/jbc.275.8.5337; Armstrong WE, 2005, J COMP NEUROL, V491, P175, DOI 10.1002/cne.20679; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bond CT, 2004, J NEUROSCI, V24, P5301, DOI 10.1523/JNEUROSCI.0182-04.2004; Bond CT, 1999, ANN NY ACAD SCI, V868, P370, DOI 10.1111/j.1749-6632.1999.tb11298.x; Cai X, 2004, NEURON, V44, P351, DOI 10.1016/j.neuron.2004.09.026; Cingolani LA, 2002, J NEUROSCI, V22, P4456, DOI 10.1523/JNEUROSCI.22-11-04456.2002; Cloues RK, 2003, J NEUROSCI, V23, P1593; Faber ESL, 2005, NAT NEUROSCI, V8, P635, DOI 10.1038/nn1450; Gallo G, 2002, J NEUROSCI, V22, P5016, DOI 10.1523/JNEUROSCI.22-12-05016.2002; Grunnet M, 2004, J NEUROSCI RES, V78, P845, DOI 10.1002/jnr.20318; Hammond RS, 2006, J NEUROSCI, V26, P1844, DOI 10.1523/JNEUROSCI.4106-05.2006; Haug T, 2000, J NEUROPHYSIOL, V83, P2071, DOI 10.1152/jn.2000.83.4.2071; Heusser K, 2005, CURR OPIN NEUROBIOL, V15, P364, DOI 10.1016/j.conb.2005.04.001; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Khawaled R, 1999, PFLUG ARCH EUR J PHY, V438, P314, DOI 10.1007/s004240050915; Klocker N, 2001, MOL CELL NEUROSCI, V17, P514, DOI 10.1006/mcne.2000.0956; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Kramar EA, 2004, J NEUROSCI, V24, P5151, DOI 10.1523/JNEUROSCI.0800-04.2004; Lee AL, 2003, J NEUROCHEM, V86, P1079, DOI 10.1046/j.1471-4159.2003.01880.x; Lee WS, 2003, J BIOL CHEM, V278, P25940, DOI 10.1074/jbc.M302091200; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P245, DOI 10.1113/jphysiol.1986.sp016007; Markstein R, 1999, N-S ARCH PHARMACOL, V359, P454, DOI 10.1007/PL00005375; Misonou H, 2004, NAT NEUROSCI, V7, P711, DOI 10.1038/nn1260; Ngo-Anh TJ, 2005, NAT NEUROSCI, V8, P642, DOI 10.1038/nn1449; O'Connell AD, 2005, P NATL ACAD SCI USA, V102, P9954, DOI 10.1073/pnas.0504332102; Perrotti N, 2001, J BIOL CHEM, V276, P9406, DOI 10.1074/jbc.M007052200; Sailer CA, 2002, J NEUROSCI, V22, P9698; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P468, DOI 10.1152/jn.1988.59.2.468; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Stackman RW, 2002, J NEUROSCI, V22, P10163; Stern JE, 1997, J PHYSIOL-LONDON, V500, P497, DOI 10.1113/jphysiol.1997.sp022036; Stocker M, 1999, P NATL ACAD SCI USA, V96, P4662, DOI 10.1073/pnas.96.8.4662; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; STORM JF, 1990, PROG BRAIN RES, V83, P161; Strassmaier T, 2005, J BIOL CHEM, V280, P21231, DOI 10.1074/jbc.M413125200; Viard P, 2004, NAT NEUROSCI, V7, P939, DOI 10.1038/nn1300; Wagner EJ, 2001, J PHARMACOL EXP THER, V299, P21; YOO D, 2005, J BIOL CHEM; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou JS, 2002, CIRC RES, V91, P540, DOI 10.1161/01.RES.0000033598.00903.27	46	77	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11769	11779		10.1074/jbc.M513125200	http://dx.doi.org/10.1074/jbc.M513125200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513649	hybrid			2022-12-25	WOS:000236988100042
J	Wei, L; Sandbulte, MR; Thomas, PG; Webby, RJ; Homayouni, R; Pfeffer, LM				Wei, L; Sandbulte, MR; Thomas, PG; Webby, RJ; Homayouni, R; Pfeffer, LM			NF kappa B negatively regulates interferon-induced gene expression and anti-influenza activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-SURVIVAL; MX PROTEINS; VIRUS; ACTIVATION; RESISTANCE; BETA	Interferons (IFNs) are antiviral cytokines that selectively regulate gene expression through several signaling pathways including nuclear factor kappa B (NF kappa B). To investigate the specific role of NF kappa B in IFN signaling, we performed gene expression profiling after IFN treatment of embryonic fibroblasts derived from normal mice or mice with targeted deletion of NF kappa B p50 and p65 genes. Interestingly, several antiviral and immunomodulatory genes were induced higher by IFN in NF kappa B knock-out cells. Chromatin immunoprecipitation experiments demonstrated that NF kappa B was basally bound to the promoters of these genes, while IFN treatment resulted in the recruitment of STAT1 and STAT2 to these promoters. However, in NF kappa B knock-out cells IFN induced STAT binding as well as the binding of the IFN regulatory factor-1 (IRF1) to the IFN-stimulated gene (ISG) promoters. IRF1 binding closely correlated with enhanced gene induction. Moreover, NF kappa B suppressed both antiviral and immunomodulatory actions of IFN against influenza virus. Our results identify a novel negative regulatory role of NF kappa B in IFN-induced gene expression and biological activities and suggest that modulating NF kappa B activity may provide a new avenue for enhancing the therapeutic effectiveness of IFN.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Neurol, Memphis, TN 38163 USA; Univ Tennessee, Inst Canc, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Pfeffer, LM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, 930 Madison Ave,Rm 530, Memphis, TN 38163 USA.	lpfeffer@utmem.edu	Homayouni, Ramin/U-2837-2019; Thomas, Paul G./H-1063-2018; Webby, Richard J/N-5657-2018; Wei, Lai/D-1088-2014; Homayouni, Ramin/B-3547-2009	Homayouni, Ramin/0000-0003-0186-5076; Thomas, Paul G./0000-0001-7955-0256; Homayouni, Ramin/0000-0003-0186-5076; Sandbulte, Matthew/0000-0001-6693-674X; Pfeffer, Lawrence/0000-0003-2809-1234	NCI NIH HHS [R01 CA073753, CA73753] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SL, 1999, VIROLOGY, V256, P8, DOI 10.1006/viro.1999.9614; Arduini RM, 2004, PROTEIN EXPRES PURIF, V34, P229, DOI 10.1016/j.pep.2003.11.004; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Belz GT, 2000, J VIROL, V74, P3486, DOI 10.1128/JVI.74.8.3486-3493.2000; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Govorkova EA, 2004, ANTIMICROB AGENTS CH, V48, P4855, DOI 10.1128/AAC.48.12.4855-4863.2004; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Lee SH, 2002, GENOME RES, V12, P527, DOI 10.1101/gr.20102; Nimmerjahn F, 2004, J GEN VIROL, V85, P2347, DOI 10.1099/vir.0.79958-0; Pfeffer LM, 2004, J BIOL CHEM, V279, P31304, DOI 10.1074/jbc.M308975200; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; Ploegh H L, 2000, Nutr Rev, V58, pS25; PLOEGH HL, 2000, NUTR REV, V58, pS63; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Taylor GA, 2004, NAT REV IMMUNOL, V4, P100, DOI 10.1038/nri1270; Uger RA, 1997, J IMMUNOL, V158, P685; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; Zhang Y, 2005, J BIOL CHEM, V280, P34306, DOI 10.1074/jbc.M503263200	26	88	100	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11678	11684		10.1074/jbc.M513286200	http://dx.doi.org/10.1074/jbc.M513286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16517601	Green Accepted, hybrid			2022-12-25	WOS:000236988100031
J	Massimi, P; Narayan, N; Cuenda, A; Banks, L				Massimi, P.; Narayan, N.; Cuenda, A.; Banks, L.			Phosphorylation of the discs large tumour suppressor protein controls its membrane localisation and enhances its susceptibility to HPV E6-induced degradation	ONCOGENE			English	Article						Dlg; HPV; JNK; proteasome	PAPILLOMAVIRUS E6 PROTEINS; PROTEASOME-MEDIATED DEGRADATION; HIGH-RISK; HUMAN HOMOLOG; ADENOVIRUS E4-ORF1; CELL POLARITY; ACTIN MOTOR; MYOSIN-VI; ONCOPROTEINS; EXPRESSION	The Discs Large (Dlg) protein is intimately involved in regulating cell polarity and cell proliferation, and is targeted by the high-risk Human Papillomavirus (HPV) E6 proteins for proteasome-mediated degradation. We show here that exposure of cells to osmotic shock induces the hyperphosphorylation of Dlg and its concomitant accumulation within the cell membrane at sites of cell contact, a process that requires an intact actin. lament network. In addition, hyperphosphorylation of Dlg also renders it more susceptible to degradation induced by the HPV-18 E6 oncoprotein. Mutational analysis of Dlg identifies a region within the first 185 amino acids as being important for this, with phosphorylation on residue S158 being responsible for its enhanced targeting by the E6 oncoprotein. Using specific kinase inhibitors, we show that Jun N-terminal kinase (JNK) is in part responsible for this phosphorylation, and for the subsequent Dlg accumulation at sites of cell contact. These results further support the notion of a complex phosphorylation-dependent regulation of Dlg, both with respect to its precise cellular localisation and to its susceptibility to proteasome-mediated degradation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland; Univ Extremadura, Fac Vet, Dipartimento Bioquim & Biol Mol, Caceres, Spain	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Dundee; Universidad de Extremadura	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org						Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Buss F, 2002, TRAFFIC, V3, P851, DOI 10.1034/j.1600-0854.2002.31201.x; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mantovani F, 2001, J CELL SCI, V114, P4285; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	32	49	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4276	4285		10.1038/sj.onc.1209457	http://dx.doi.org/10.1038/sj.onc.1209457			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16532034				2022-12-25	WOS:000239240100003
J	Patel, HV; Vyas, KA; Mattoo, RL; Southworth, M; Perler, FB; Comb, D; Roseman, S				Patel, Himatkumar V.; Vyas, Kavita A.; Mattoo, Roshan L.; Southworth, Maurice; Perler, Francine B.; Comb, Donald; Roseman, Saul			Properties of the C-terminal domain of enzyme I of the Escherichia coli phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR-TRANSPORT; BACTERIAL PHOSPHOENOLPYRUVATE; SALMONELLA-TYPHIMURIUM; PHOSPHORYL TRANSFER; CRYSTAL-STRUCTURE; PROTEIN HPR; COMPLEX; VITRO; SITE; ULTRACENTRIFUGATION	The bacterial phosphoenolpyruvate (PEP):glycose phosphotransferase system (PTS) mediates uptake/phosphorylation of sugars. The transport of all PTS sugars requires Enzyme I (EI) and a phosphocarrier histidine protein of the PTS (HPr). The PTS is stringently regulated, and a potential mechanism is the monomer/dimer transition of EI, because only the dimer accepts the phosphoryl group from PEP. EI monomer consists of two major domains, at the N and C termini (EI-N and EI-C, respectively). EI-N accepts the phosphoryl group from phospho-HPr but not PEP. However, it is phosphorylated by PEP(Mg2+) when complemented with EI-C. Here we report that the phosphotransfer rate increases similar to 25-fold when HPr is added to a mixture of EI-N, EI-C, and PEP(Mg2+). A model to explain this effect is offered. Sedimentation equilibrium results show that the association constant for dimerization of EI-C monomers is 260-fold greater than the K-a for native EI. The ligands have no detectable effect on the secondary structure of the dimer (far UV CD) but have profound effects on the tertiary structure as determined by near UV CD spectroscopy, thermal denaturation, sedimentation equilibrium and velocity, and intrinsic fluorescence of the 2 Trp residues. The binding of PEP requires Mg2+. For example, there is no effect of PEP on the T-m, an increase of 7 degrees C in the presence of Mg2+, and similar to 14 degrees C when both are present. Interestingly, the dissociation constants for each of the ligands from EI-C are approximately the same as the kinetic (K-m) constants for the ligands in the complete PTS sugar phosphorylation assays.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; New England Biolabs Inc, Ipswich, MA 01938 USA	Johns Hopkins University; New England Biolabs	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	roseman@jhu.edu	Vyas, Kavita/GRJ-4578-2022		NIGMS NIH HHS [GM 38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038759, R01GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON B, 1971, J BIOL CHEM, V246, P7023; Brokx SJ, 2000, BIOCHEMISTRY-US, V39, P3624, DOI 10.1021/bi991250z; CHAUVIN F, 1994, J BIOL CHEM, V269, P20270; Chauvin F, 1996, RES MICROBIOL, V147, P471, DOI 10.1016/0923-2508(96)84001-0; Chauvin F, 1996, P NATL ACAD SCI USA, V93, P7028, DOI 10.1073/pnas.93.14.7028; Dam J, 2004, METHOD ENZYMOL, V384, P185; Fersht A., 1985, ENZYME STRUCTURE MEC; Fomenkov A, 1998, P NATL ACAD SCI USA, V95, P8491, DOI 10.1073/pnas.95.15.8491; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Ginsburg A, 2002, ARCH BIOCHEM BIOPHYS, V397, P273, DOI 10.1006/abbi.2001.2603; HAN MK, 1987, ANAL BIOCHEM, V161, P479, DOI 10.1016/0003-2697(87)90477-5; HAN MK, 1990, J BIOL CHEM, V265, P1985; Herzberg O, 1996, P NATL ACAD SCI USA, V93, P2652, DOI 10.1073/pnas.93.7.2652; Herzberg O, 2002, BIOCHEMISTRY-US, V41, P780, DOI 10.1021/bi011799+; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Liao DI, 1996, STRUCTURE, V4, P861, DOI 10.1016/S0969-2126(96)00092-5; LICALSI C, 1991, J BIOL CHEM, V266, P19519; Meadow ND, 1996, J BIOL CHEM, V271, P33440, DOI 10.1074/jbc.271.52.33440; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Meadow ND, 2005, BIOCHEMISTRY-US, V44, P12790, DOI 10.1021/bi0502846; Miller BG, 2002, ANNU REV BIOCHEM, V71, P847, DOI 10.1146/annurev.biochem.71.110601.135446; Oberholzer AE, 2005, J MOL BIOL, V346, P521, DOI 10.1016/j.jmb.2004.11.077; Patel HV, 2006, J BIOL CHEM, V281, P17570, DOI 10.1074/jbc.M508965200; Perler FB, 2002, NUCLEIC ACIDS RES, V30, P383, DOI 10.1093/nar/30.1.383; Peterkofsky A, 2001, J MOL MICROB BIOTECH, V3, P347; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; Saier MH, 2001, J MOL MICROB BIOTECH, V3, P325; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; WAYGOOD EB, 1982, METHOD ENZYMOL, V90, P423; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WEIGEL N, 1982, J BIOL CHEM, V257, P4477	36	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	2006	281	26					17579	17587		10.1074/jbc.M508966200	http://dx.doi.org/10.1074/jbc.M508966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	055ZO	16547354	hybrid			2022-12-25	WOS:000238490300007
J	Bornhovd, C; Vogel, F; Neupert, W; Reichert, AS				Bornhoevd, Carsten; Vogel, Frank; Neupert, Walter; Reichert, Andreas S.			Mitochondrial membrane potential is dependent on the oligomeric state of F1F0-ATP synthase supracomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; YEAST SACCHAROMYCES-CEREVISIAE; RED FIBERS MERRF; ATP SYNTHASE; MYOCLONUS EPILEPSY; INHIBITOR PROTEIN; HUMAN-CELLS; SUBUNIT-E; MORPHOLOGY; MUTATION	The F1F0-ATP synthase in mitochondria, in addition to its function in energy transduction, has a structural role in determining cristae morphology. This depends on its ability to form dimeric and higher oligomeric supracomplexes. Here we show that mutants of the dimer-specific subunits e and g, which destabilize dimeric and oligomeric F1F0-ATP synthase supracomplexes, have a decreased mitochondrial membrane potential Delta Psi. The degree of destabilization correlated with the reduction of the membrane potential. The enzymatic activities of F1F0-ATP synthase and cytochrome c oxidase, maximal respiration rate, coupling of oxidative phosphorylation, and tubular mitochondrial morphology were not affected or only to a minor extent. In mutants lacking one or two coiled-coil domains of subunit e, the reduction of the mitochondrial membrane potential was not due to loss of mitochondrial DNA, a reduced capacity of oxidative phosphorylation, or to altered cristae morphology. We propose a role for the supracomplexes of the F1F0-ATP synthase in organizing microdomains within the inner membrane, ensuring optimal bioenergetic competence of mitochondria.	Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Reichert, AS (corresponding author), Univ Munich, Adolf Butenandt Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	Andreas.Reichert@med.uni-muenchen.de	Reichert, Andreas/A-4090-2012	Reichert, Andreas/0000-0001-9340-3113				Antonicka H, 1999, BIOCHEM J, V342, P537, DOI 10.1042/0264-6021:3420537; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 2003, EUR J BIOCHEM, V270, P1875, DOI 10.1046/j.1432-1033.2003.03557.x; Boyle GM, 1999, EUR J BIOCHEM, V262, P315, DOI 10.1046/j.1432-1327.1999.00345.x; Cabezon E, 2000, J BIOL CHEM, V275, P28353, DOI 10.1074/jbc.C000427200; Dienhart M, 2002, J BIOL CHEM, V277, P39289, DOI 10.1074/jbc.M205720200; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Everard-Gigot V, 2005, EUKARYOT CELL, V4, P346, DOI 10.1128/EC.4.2.346-355.2005; Giraud MF, 2002, BBA-BIOENERGETICS, V1555, P174, DOI 10.1016/S0005-2728(02)00274-8; Herlan M, 2004, J CELL BIOL, V165, P167, DOI 10.1083/jcb.200403022; Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LARSSON NG, 1992, AM J HUM GENET, V51, P1201; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; LETELLIER T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P58, DOI 10.1016/0005-2728(93)90189-M; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Soubannier V, 2002, J BIOL CHEM, V277, P10739, DOI 10.1074/jbc.M111882200; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L	27	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13990	13998		10.1074/jbc.M512334200	http://dx.doi.org/10.1074/jbc.M512334200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551625	hybrid			2022-12-25	WOS:000237512300021
J	de Saro, FJL; Marinus, MG; Modrich, P; O'Donnell, M				Lopez de Saro, Francisco J.; Marinus, Martin G.; Modrich, Paul; O'Donnell, Mike			The beta sliding clamp binds to multiple sites within MutL and MutS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA MISMATCH REPAIR; POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI MUTS; REPLICATION FIDELITY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN MUTS; PCNA; STRAND	The MutL and MutS proteins are the central components of the DNA repair machinery that corrects mismatches generated by DNA polymerases during synthesis. We find that MutL interacts directly with the beta sliding clamp, a ring-shaped dimeric protein that confers processivity to DNA polymerases by tethering them to their substrates. Interestingly, the interaction of MutL with beta only occurs in the presence of single-stranded DNA. We find that the interaction occurs via a loop in MutL near the ATP-binding site. The binding site of MutL on beta locates to the hydrophobic pocket between domains two and three of the clamp. Site-specific replacement of two residues in MutL diminished interaction with beta without disrupting MutL function with helicase II. In vivo studies reveal that this mutant MutL is no longer functional in mismatch repair. In addition, the human MLH1 has a close match to the proliferating cell nuclear antigen clamp binding motif in the region that corresponds to the beta interaction site in Escherichia coli MutL, and a peptide corresponding to this site binds proliferating cell nuclear antigen. The current report also examines in detail the interaction of beta with MutS. We find that two distinct regions of MutS interact with beta. One is located near the C terminus and the other is close to the N terminus, within the mismatch binding domain. Complementation studies using genes encoding different MutS mutants reveal that the N-terminal beta interaction motif on MutS is essential for activity in vivo, but the C-terminal interaction site for beta is not. In light of these results, we propose roles for the beta clamp in orchestrating the sequence of events that lead to mismatch repair in the cell.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Rockefeller University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Duke University; Howard Hughes Medical Institute	de Saro, FJL (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	fjlopez@cbm.uam.es		Modrich, Paul/0000-0001-8708-9885; O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [R01 GM063790-04, GM38839, GM63790, GM23719] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R01GM063790, R37GM023719, R37GM038839, R01GM023719] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bjornson KP, 2003, J BIOL CHEM, V278, P34667, DOI 10.1074/jbc.M305513200; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Calmann MA, 2005, J BACTERIOL, V187, P6577, DOI 10.1128/JB.187.18.6577-6579.2005; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chen C, 1999, MOL CELL BIOL, V19, P7801; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Constantin N, 2005, J BIOL CHEM, V280, P39752, DOI 10.1074/jbc.M509701200; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; de Saro FJL, 2003, EMBO J, V22, P6408, DOI 10.1093/emboj/cdg603; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; Dohrmann PR, 2005, J MOL BIOL, V350, P228, DOI 10.1016/j.jmb.2005.04.065; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Fijalkowska IJ, 1998, P NATL ACAD SCI USA, V95, P10020, DOI 10.1073/pnas.95.17.10020; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Fujii S, 2004, EMBO J, V23, P4342, DOI 10.1038/sj.emboj.7600438; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guarne A, 2004, EMBO J, V23, P4134, DOI 10.1038/sj.emboj.7600412; Guarne A, 2001, EMBO J, V20, P5521, DOI 10.1093/emboj/20.19.5521; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Indiani C, 2005, MOL CELL, V19, P805, DOI 10.1016/j.molcel.2005.08.011; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lau PJ, 2003, J BIOL CHEM, V278, P14, DOI 10.1074/jbc.C200627200; Lau PJ, 2002, MOL CELL BIOL, V22, P6669, DOI 10.1128/MCB.22.19.6669-6680.2002; Lee SD, 2006, J MOL BIOL, V355, P175, DOI 10.1016/j.jmb.2005.10.059; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Murphy KC, 2000, GENE, V246, P321, DOI 10.1016/S0378-1119(00)00071-8; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; Pavlov YI, 2002, MOL CELL, V10, P207, DOI 10.1016/S1097-2765(02)00567-1; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; Smith BT, 2001, MOL CELL, V8, P1197, DOI 10.1016/S1097-2765(01)00402-6; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wang HX, 2004, EMBO J, V23, P2126, DOI 10.1038/sj.emboj.7600153; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wijffels G, 2004, BIOCHEMISTRY-US, V43, P5661, DOI 10.1021/bi036229j; Yang W, 2000, COLD SPRING HARB SYM, V65, P225, DOI 10.1101/sqb.2000.65.225	59	66	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14340	14349		10.1074/jbc.M601264200	http://dx.doi.org/10.1074/jbc.M601264200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16546997	hybrid			2022-12-25	WOS:000237512300060
J	Del Borgo, MP; Hughes, RA; Bathgate, RAD; Lin, F; Kawamura, K; Wade, JD				Del Borgo, MP; Hughes, RA; Bathgate, RAD; Lin, F; Kawamura, K; Wade, JD			Analogs of insulin-like peptide 3 (INSL3) B-chain are LGR8 antagonists in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXIN FAMILY PEPTIDES; RECEPTOR-BINDING SITE; INSULIN-LIKE PEPTIDE; CIRCULAR-DICHROISM; PHAGE DISPLAY; CELL-SURVIVAL; CRYPTORCHIDISM; CONFORMATION; TESTIS; GROWTH	Insulin-like peptide 3 (INSL3) is a member of the insulin superfamily that plays an important role in mediating testes descent during fetal development. More recently, it has also been demonstrated to initiate oocyte maturation and suppress male germ cell apoptosis. These actions are mediated via a specific G-protein-coupled receptor, LGR8. Little is known regarding the structure and function relationship of INSL3, although it is believed that the principal receptor binding site resides within its B-chain. We subsequently observed that the linear B-chain alone (INSL3B-(1-31)) bound to LGR8 and was able to antagonise INSL3 stimulated cAMP accumulation in HEK-293T cells expressing LGR8. Sequentially N- and C-terminally shortened linear analogs were prepared by solid phase synthesis and subsequent assay showed that the minimum length required for binding was residues 11-27. It was also observed that increased binding affinity correlated with a corresponding increase in alpha-helical content as measured by circular dichroism spectroscopy. Molecular modeling studies suggested that judicious placement of a conformational constraint within this peptide would increase its alpha-helix content and result in increased structural similarity to the B-chain within native INSL3. Consequently, intramolecularly disulfide-linked analogs of the B-chain showed a potentiation of INSL3 antagonistic activity, as well as exhibiting increased proteolytic stability, as assessed in rat serum in vitro. Administration of one of these peptides into the testes of rats resulted in a substantial decrease in testis weight probably due to the inhibition of germ cell survival, suggesting that INSL3 antagonists may have potential as novel contraceptive agents.	Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia; Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Stanford University	Wade, JD (corresponding author), Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia.	j.wade@hfi.unimelb.edu.au	Bathgate, Ross/ABE-6471-2020	Bathgate, Ross/0000-0001-6301-861X; Wade, John/0000-0002-1352-6568				Adham IM, 2002, MOL ENDOCRINOL, V16, P244, DOI 10.1210/me.16.2.244; Bathgate RA, 2006, PHARMACOL REV, V58, P7, DOI 10.1124/pr.58.1.9; Bathgate RA, 2005, ANN NY ACAD SCI, V1041, P61, DOI 10.1196/annals.1282.010; BATHGATE RAD, 2005, PHYSL REPROD, P679; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; Bullesbach EE, 2005, J BIOL CHEM, V280, P14051, DOI 10.1074/jbc.M500030200; Bullesbach EE, 2005, J BIOL CHEM, V280, P14586, DOI 10.1074/jbc.M414443200; Bullesbach EE, 2004, BIOCHEMISTRY-US, V43, P8021, DOI 10.1021/bi049601j; Bullesbach EE, 1999, BIOCHEMISTRY-US, V38, P3073, DOI 10.1021/bi982687u; Claasz AA, 2002, EUR J BIOCHEM, V269, P6287, DOI 10.1046/j.1432-1033.2002.03348.x; Dawson NF, 1999, J PEPT RES, V53, P542, DOI 10.1034/j.1399-3011.1999.00060.x; Del Borgo MP, 2005, J PEPT SCI, V11, P564, DOI 10.1002/psc.652; Deshayes K, 2002, CHEM BIOL, V9, P495, DOI 10.1016/S1074-5521(02)00129-1; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; Fu P, 2004, J PEPT RES, V63, P91, DOI 10.1111/j.1399-3011.2003.00118.x; Gorlov IP, 2002, HUM MOL GENET, V11, P2309, DOI 10.1093/hmg/11.19.2309; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Halls ML, 2005, J PHARMACOL EXP THER, V313, P677, DOI 10.1124/jpet.104.080655; Hombach-Klonisch S, 2003, INT J ONCOL, V22, P993; Horvat S, 1999, SPECTROCHIM ACTA A, V55, P2347, DOI 10.1016/S1386-1425(99)00132-8; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Kamischke A, 2004, TRENDS PHARMACOL SCI, V25, P49, DOI 10.1016/j.tips.2003.11.009; Kawamura K, 2004, P NATL ACAD SCI USA, V101, P7323, DOI 10.1073/pnas.0307061101; Kubota Y, 2002, MOL HUM REPROD, V8, P900, DOI 10.1093/molehr/8.10.900; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; Lim HN, 2001, EUR J ENDOCRINOL, V144, P129, DOI 10.1530/eje.0.1440129; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; Maruyama K, 1999, PEPTIDES, V20, P881, DOI 10.1016/S0196-9781(99)00076-5; McGee EA, 2000, ENDOCR REV, V21, P200, DOI 10.1210/er.21.2.200; Muda M, 2005, MOL HUM REPROD, V11, P591, DOI 10.1093/molehr/gah205; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; Rosengren KJ, 2006, J BIOL CHEM, V281, P5845, DOI 10.1074/jbc.M511210200; Scott DJ, 2005, ANN NY ACAD SCI, V1041, P13, DOI 10.1196/annals.1282.003; Skelton NJ, 2001, BIOCHEMISTRY-US, V40, P8487, DOI 10.1021/bi0103866; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; Tan YY, 1999, BRIT J PHARMACOL, V127, P91, DOI 10.1038/sj.bjp.0702517; TAPANAINEN JS, 1993, MOL ENDOCRINOL, V7, P643, DOI 10.1210/me.7.5.643; Tugyi R, 2005, J PEPT SCI, V11, P642, DOI 10.1002/psc.669; Wilkinson TN, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-14; Yan Y, 2005, ANN NY ACAD SCI, V1041, P35, DOI 10.1196/annals.1282.007; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	43	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13068	13074		10.1074/jbc.M600472200	http://dx.doi.org/10.1074/jbc.M600472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547350	hybrid			2022-12-25	WOS:000237336600010
J	Kizuka, Y; Matsui, T; Takematsu, H; Kozutsumi, Y; Kawasaki, T; Oka, S				Kizuka, Y; Matsui, T; Takematsu, H; Kozutsumi, Y; Kawasaki, T; Oka, S			Physical and functional association of glucuronyltransferases and sulfotransferase involved in HNK-1 biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE EPITOPE HNK-1; MYELIN GLYCOPROTEIN P0; PROTEIN LINKAGE REGION; MOLECULAR-CLONING; GOLGI-APPARATUS; NERVOUS-SYSTEM; COMPLEX-FORMATION; MICE DEFICIENT; RAT-BRAIN; N-GLYCANS	HNK-1 carbohydrate expressed predominantly in the nervous system is considered to be involved in cell migration, recognition, adhesion, and synaptic plasticity. Human natural killer-1 (HNK-1) carbohydrate has a unique structure consisting of a sulfated trisaccharide (HSO(3)(-)3GlcA beta 1-3Gal-1-4GlcNAc-) and is sequentially biosynthesized by one of two glucuronyltransferases (GlcAT-P or GlcAT-S) and a sulfotransferase (HNK-1ST). Considering that almost all the HNK-1 carbohydrate structures so far determined in the nervous system are sulfated, we hypothesized that GlcAT-P or GlcAT-S functionally associates with HNK-1ST, which results in efficient sequential biosynthesis of HNK-1 carbohydrate. In this study, we demonstrated that both GlcAT-P and GlcAT-S were co-immunoprecipitated with HNK-1ST with a transient expression system in Chinese hamster ovary cells. Immunofluorescence staining revealed that these enzymes are mainly co-localized in the Golgi apparatus. To determine which domain is involved in this interaction, we prepared the C- terminal catalytic domains of GlcAT-P, GlcAT-S, and HNK-1ST, and we then performed pulldown assays with the purified enzymes. As a result, we obtained evidence that mutual catalytic domains of GlcAT-P or GlcAT-S and HNK-1ST are important and sufficient for formation of an enzyme complex. With an in vitro assay system, the activity of HNK-1ST increased about 2-fold in the presence of GlcAT- P or GlcAT-S compared with that in its absence. These results suggest that the function of this enzyme complex is relevant to the efficient sequential biosynthesis of the HNK-1 carbohydrate.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Lab Membrane Biochem & Biophys, Kyoto 6068501, Japan; Ritsumeikan Univ, Res Ctr Glycobiotechnol, Shiga 5258577, Japan	Kyoto University; Kyoto University; Ritsumeikan University	Oka, S (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Kyoto 6068501, Japan.	shogo@pharm.kyoto-u.ac.jp		Kizuka, Yasuhiko/0000-0002-3181-9743				Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; de Graffenried CL, 2004, CURR OPIN CELL BIOL, V16, P356, DOI 10.1016/j.ceb.2004.06.007; Gallego RG, 2001, J BIOL CHEM, V276, P30834, DOI 10.1074/jbc.M101013200; Giraudo CG, 2003, J BIOL CHEM, V278, P40262, DOI 10.1074/jbc.M305455200; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; Kakuda S, 2005, GLYCOBIOLOGY, V15, P203, DOI 10.1093/glycob/cwi001; Kakuda S, 2004, J BIOL CHEM, V279, P22693, DOI 10.1074/jbc.M400622200; Kakuda S, 2004, PROTEIN EXPRES PURIF, V35, P111, DOI 10.1016/j.pep.2003.12.021; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Liedtke S, 2001, GLYCOBIOLOGY, V11, P373, DOI 10.1093/glycob/11.5.373; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Mitsumoto Y, 2000, GENOMICS, V65, P166, DOI 10.1006/geno.2000.6152; Nilsson T, 1996, J CELL SCI, V109, P1975; OKA S, 1992, J BIOL CHEM, V267, P22711; Okuda T, 2000, J BIOL CHEM, V275, P40605, DOI 10.1074/jbc.M007983200; PANGALOS MN, 1995, J BIOL CHEM, V270, P10388, DOI 10.1074/jbc.270.18.10388; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; Seko A, 2005, GLYCOBIOLOGY, V15, P943, DOI 10.1093/glycob/cwi082; Senn C, 2002, MOL CELL NEUROSCI, V20, P712, DOI 10.1006/mcne.2002.1142; Sprong H, 2003, MOL BIOL CELL, V14, DOI 10.1091/mbc.E03-03-0130; Tagawa H, 2005, J BIOL CHEM, V280, P23876, DOI 10.1074/jbc.M501728200; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Terayama K, 1998, J BIOL CHEM, V273, P30295, DOI 10.1074/jbc.273.46.30295; Tone Y, 1999, FEBS LETT, V459, P415, DOI 10.1016/S0014-5793(99)01287-9; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; Wakabayashi H, 1999, J BIOL CHEM, V274, P5436, DOI 10.1074/jbc.274.9.5436; Yamamoto S, 2002, J BIOL CHEM, V277, P27227, DOI 10.1074/jbc.C200296200; Yamamoto S, 2002, J BIOCHEM, V131, P337, DOI 10.1093/oxfordjournals.jbchem.a003108; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; YOSHIHARA Y, 1991, J CELL BIOL, V115, P731, DOI 10.1083/jcb.115.3.731	32	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13644	13651		10.1074/jbc.M601453200	http://dx.doi.org/10.1074/jbc.M601453200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543228	hybrid			2022-12-25	WOS:000237336600075
J	Chen, ZJ; Hague, C; Hall, RA; Minneman, KP				Chen, ZJ; Hague, C; Hall, RA; Minneman, KP			Syntrophins regulate alpha(1D)-adrenergic receptors through a PDZ domain-mediated interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; NITRIC-OXIDE SYNTHASE; ALPHA(1)-ADRENOCEPTOR SUBTYPES; ALPHA(1B)-ADRENERGIC RECEPTOR; TRANSGLUTAMINASE ACTIVITY; SARCOLEMMAL LOCALIZATION; DEPENDENT EXPRESSION; DYSTROPHIN COMPLEX; SODIUM-CHANNELS; PROTEIN	To find novel cytoplasmic binding partners of the alpha(1D)-adrenergic receptor (AR), a yeast two-hybrid screen using the alpha(1D)-AR C terminus as bait was performed on a human brain cDNA library. alpha-Syntrophin, a protein containing one PDZ domain and two pleckstrin homology domains, was isolated in this screen as an alpha(1D)-AR-interacting protein. alpha-Syntrophin specifically recognized the C terminus of alpha(1D)- but not alpha(1A)- or alpha(1B)-ARs. In blot overlay assays, the PDZ domains of syntrophin isoforms alpha, beta 1, and beta 2 but not gamma 1 or gamma 2 showed strong selective interactions with the alpha(1D)-AR C-tail fusion protein. In transfected human embryonic kidney 293 cells, full-length alpha(1D)- but not alpha(1A)- or alpha(1B)-ARs co-immunoprecipitated with syntrophins, and the importance of the receptor C terminus for the alpha(1D)-AR/syntrophin interaction was confirmed using chimeric receptors. Mutation of the PDZ-interacting motif at the alpha(1D)-AR C terminus markedly decreased inositol phosphate formation stimulated by norepinephrine but not carbachol in transfected HEK293 cells. This mutation also dramatically decreased alpha(1D)-AR binding and protein expression. In addition, stable overexpression of alpha-syntrophin significantly increased alpha(1D)-AR protein expression and binding but did not affect those with a mutated PDZ-interacting motif, suggesting that syntrophin plays an important role in maintaining receptor stability by directly interacting with the receptor PDZ-interacting motif. This direct interaction may provide new information about the regulation of alpha(1D)-AR signaling and the role of syntrophins in modulating G protein-coupled receptor function.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Minneman, KP (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.	kminneman@pharm.emory.edu		Hall, Randy/0000-0002-8318-8728				Adams ME, 2004, J NEUROSCI, V24, P10302, DOI 10.1523/JNEUROSCI.3408-04.2004; Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; Albrecht DE, 2002, NEUROSIGNALS, V11, P123, DOI 10.1159/000065053; Balasubramanian S, 2004, J BIOL CHEM, V279, P18840, DOI 10.1074/jbc.M313470200; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Chalothorn D, 2002, MOL PHARMACOL, V61, P1008, DOI 10.1124/mol.61.5.1008; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Chen ZJ, 2004, J BIOL CHEM, V279, P35326, DOI 10.1074/jbc.M403703200; Chockalingam PS, 1999, BIOCHEMISTRY-US, V38, P5596, DOI 10.1021/bi982564+; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; Gee SH, 1998, J NEUROSCI, V18, P128; Hague C, 2005, J BIOL CHEM, V280, P27289, DOI 10.1074/jbc.M502365200; Hague C, 2004, J BIOL CHEM, V279, P15541, DOI 10.1074/jbc.M314014200; Hague C, 2004, J PHARMACOL EXP THER, V309, P388, DOI 10.1124/jpet.103.060509; Hague C, 2003, LIFE SCI, V74, P411, DOI 10.1016/j.lfs.2003.07.008; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Hogan A, 2004, J BIOL CHEM, V279, P53717, DOI 10.1074/jbc.M410654200; Iwata Y, 2005, MOL CELL BIOCHEM, V268, P59, DOI 10.1007/s11010-005-2998-z; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Oak SA, 2001, BIOCHEMISTRY-US, V40, P11270, DOI 10.1021/bi010490n; Ort T, 2001, EMBO J, V20, P4013, DOI 10.1093/emboj/20.15.4013; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Piluso G, 2000, J BIOL CHEM, V275, P15851, DOI 10.1074/jbc.M000439200; Pupo AS, 2003, EUR J PHARMACOL, V462, P1, DOI 10.1016/S0014-2999(03)01292-5; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Tanoue A, 2002, LIFE SCI, V71, P2207, DOI 10.1016/S0024-3205(02)02012-X; Thomas GD, 2003, CIRC RES, V92, P554, DOI 10.1161/01.RES.0000061570.83105.52; Uberti MA, 2005, J PHARMACOL EXP THER, V313, P16, DOI 10.1124/jpet.104.079541; Uberti MA, 2003, MOL PHARMACOL, V64, P1379, DOI 10.1124/mol.64.6.1379; Vicentic A, 2002, J PHARMACOL EXP THER, V302, P58, DOI 10.1124/jpet.302.1.58; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Wiedemann U, 2004, J MOL BIOL, V343, P703, DOI 10.1016/j.jmb.2004.08.064; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; Zhong HY, 1999, EUR J PHARMACOL, V375, P261, DOI 10.1016/S0014-2999(99)00222-8	40	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12414	12420		10.1074/jbc.M508651200	http://dx.doi.org/10.1074/jbc.M508651200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16533813	hybrid			2022-12-25	WOS:000237134700027
J	Hu, PQ; Berkowitz, P; Madden, VJ; Rubenstein, DS				Hu, PQ; Berkowitz, P; Madden, VJ; Rubenstein, DS			Stabilization of plakoglobin and enhanced keratinocyte cell-cell adhesion by intracellular O-glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; GLCNAC TRANSFERASE; TETRATRICOPEPTIDE REPEATS; ADHERENS JUNCTIONS; CYTOSOLIC PROTEINS; PEMPHIGUS-VULGARIS; NUCLEAR; PHOSPHORYLATION; DESMOSOMES; MEMBRANE	O-Glycosylation modifies and regulates a variety of intracellular proteins. Plakoglobin, which functions in both cell-cell adhesion and signal transduction, is modified by O-glycosylation; however, the significance is unknown. To investigate the functional consequence of plakoglobin O-glycosylation, we cloned and overexpressed in keratinocytes murine O-GlcNAc transferase (mOGT). Over expression of mOGT in murine keratinocytes resulted in (i) glycosylation of plakoglobin and (ii) increased levels of plakoglobin due to post-translational stabilization of plakoglobin. Additionally, overexpression of mOGT in keratinocytes correlated with increased staining for cell-cell adhesion proteins and greater cell-cell adhesion. These observations suggest that O-glycosylation functions to regulate the post-translational stability of plakoglobin and keratinocyte cell-cell adhesion.	Univ N Carolina, Dept Dermatol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Rubenstein, DS (corresponding author), Univ N Carolina, Dept Dermatol, Sch Med, Suite 3100 Thurston Bowles CB 7287, Chapel Hill, NC 27599 USA.	druben@med.unc.edu	Ariel, Pablo/AGJ-4118-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049427] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI49427] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berkowitz P, 2005, J BIOL CHEM, V280, P23778, DOI 10.1074/jbc.M501365200; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Haltiwanger RS, 1997, J BIOL CHEM, V272, P8752, DOI 10.1074/jbc.272.13.8752; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hanover JA, 2003, ARCH BIOCHEM BIOPHYS, V409, P287, DOI 10.1016/S0003-9861(02)00578-7; Hatsell S, 2003, J BIOL CHEM, V278, P37745, DOI 10.1074/jbc.M301346200; Hu PQ, 2003, J INVEST DERMATOL, V121, P242, DOI 10.1046/j.1523-1747.2003.12376.x; Hu PQ, 2001, J INVEST DERMATOL, V117, P1059, DOI 10.1046/j.0022-202x.2001.01523.x; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; Ishii K, 2005, J INVEST DERMATOL, V124, P939, DOI 10.1111/j.0022-202X.2005.23714.x; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; LEWIS JE, 1994, J INVEST DERMATOL, V102, P870, DOI 10.1111/1523-1747.ep12382690; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Lubas WA, 1997, J BIOL CHEM, V272, P9316; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	21	29	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12786	12791		10.1074/jbc.M511702200	http://dx.doi.org/10.1074/jbc.M511702200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16510446	hybrid, Green Published			2022-12-25	WOS:000237134700072
J	Sims, JK; Houston, SI; Magazinnik, T; Rice, JC				Sims, JK; Houston, SI; Magazinnik, T; Rice, JC			A trans-tail histone code defined by monomethylated H4 Lys-20 and H3 Lys-9 demarcates distinct regions of silent chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-LYSINE; MAMMALIAN CHROMATIN; HETEROCHROMATIN; METHYLTRANSFERASE; UBIQUITINATION; TRANSCRIPTION; EXPRESSION; PR-SET7; SET8; H2B	The specific post-translational modifications of the histone proteins are associated with specific DNA-templated processes, such as transcriptional activation or repression. To investigate the biological role(s) of histone H4 lysine 20 (H4 Lys-20) methylation, we created a novel panel of antibodies that specifically detected mono-, di-, or trimethylated H4 Lys-20. We report that the different methylated forms of H4 Lys-20 are compartmentalized within visually distinct, transcriptionally silent regions in the mammalian nucleus. Interestingly, direct comparison of methylated H4 Lys-20 with the different methylated states of histone H3 lysine 9 (H3 Lys-9) revealed significant overlap and exclusion between the specific groups of methyl modifications. Trimethylated H4 Lys-20 and H3 Lys-9 were both selectively enriched within pericentric heterochromatin. Similarly, monomethylated H4 Lys-20 and H3 Lys-9 partitioned together and the dimethylated forms partitioned together within the chromosome arms; however, the mono- and dimethylated modifications were virtually exclusive. These findings strongly suggest that the combinatorial presence or absence of the different methylated states of H4 Lys-20 and H3 Lys-9 define particular types of silent chromatin. Consistent with this, detailed analysis of monomethylated H4 Lys-20 and H3 Lys-9 revealed that both were preferentially and selectively enriched within the same nucleosome particle in vivo. Collectively, these findings define a novel trans-tail histone code involving monomethylated H4 Lys-20 and H3 Lys-9 that act cooperatively to mark distinct regions of silent chromatin within the mammalian epigenome.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California	Rice, JC (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Kenneth Norris Jr Comprehens Canc Ctr, 1501 San Pablo St,ZNI 225,MC 2821, Los Angeles, CA 90033 USA.	juddrice@usc.edu	Rice, Judd C/B-7806-2009		NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER; NCI NIH HHS [2 CA 014089-31] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Biron VL, 2004, DEV BIOL, V276, P337, DOI 10.1016/j.ydbio.2004.08.038; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Couture JF, 2005, GENE DEV, V19, P1455, DOI 10.1101/gad.1318405; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hennig W, 1999, CHROMOSOMA, V108, P1, DOI 10.1007/s004120050346; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Julien E, 2004, MOL CELL, V14, P713, DOI 10.1016/j.molcel.2004.06.008; Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; MURRAY K, 1964, BIOCHEMISTRY-US, V3, P10, DOI 10.1021/bi00889a003; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Perez-Burgos L, 2004, METHOD ENZYMOL, V376, P234; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Stadler F, 2005, J NEUROCHEM, V94, P324, DOI 10.1111/j.1471-4159.2005.03190.x; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sullivan BA, 2004, NAT STRUCT MOL BIOL, V11, P1076, DOI 10.1038/nsmb845; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Van Holde KE, 1988, SPRINGER SERIES MOL; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Xiao B, 2005, GENE DEV, V19, P1444, DOI 10.1101/gad.1315905; Yin YL, 2005, J BIOL CHEM, V280, P30025, DOI 10.1074/jbc.M501691200; Zhang KL, 2003, J CHROMATOGR B, V783, P173, DOI 10.1016/S1570-0232(02)00631-1	40	89	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12760	12766		10.1074/jbc.M513462200	http://dx.doi.org/10.1074/jbc.M513462200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517599	hybrid			2022-12-25	WOS:000237134700069
J	Wieczorek, A; McHenry, CS				Wieczorek, A; McHenry, CS			The NH2-terminal php domain of the alpha subunit of the Escherichia coli replicase binds the epsilon proofreading subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; STRUCTURAL BASIS; EXONUCLEASE ACTIVITY; ACTIVE-SITE; IDENTIFICATION; PURIFICATION; HOLOENZYME; REPAIR; ACID; GENE	The alpha subunit of the replicase of all bacteria contains a php domain, initially identified by its similarity to histidinol phosphatase but of otherwise unknown function (Aravind, L., and Koonin, E. V. ( 1998) Nucleic Acids Res. 26, 3746 - 3752). Deletion of 60 residues from the NH2 terminus of the alpha php domain destroys epsilon binding. The minimal 255-residue php domain, estimated by sequence alignment with homolog YcdX, is insufficient for is an element of binding. However, a 320-residue segment including sequences that immediately precede the polymerase domain binds is an element of with the same affinity as the 1160-residue full-length alpha subunit. A subset of mutations of a conserved acidic residue (Asp(43) in Escherichia coli alpha) present in the php domain of all bacterial replicases resulted in defects in is an element of binding. Using sequence alignments, we show that the prototypical Gram(+) Pol C, which contains the polymerase and proofreading activities within the same polypeptide chain, has an is an element of-like sequence inserted in a surface loop near the center of the homologous YcdX protein. These findings suggest that the php domain serves as a platform to enable coordination of proofreading and polymerase activities during chromosomal replication.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McHenry, CS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave,B-121, Denver, CO 80262 USA.	Charles.McHenry@uchsc.edu			NIGMS NIH HHS [GM060273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060273] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P3746, DOI 10.1093/nar/26.16.3746; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Bailey MF, 2004, J MOL BIOL, V336, P673, DOI 10.1016/j.jmb.2003.11.023; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; Coleman JE, 1998, CURR OPIN CHEM BIOL, V2, P222, DOI 10.1016/S1367-5931(98)80064-1; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; COX EC, 1982, GENETICS, V100, P7; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; de Saro FJL, 2003, EMBO J, V22, P6408, DOI 10.1093/emboj/cdg603; DIFRANCESCO R, 1984, J BIOL CHEM, V259, P5567; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Dohrmann PR, 2005, J MOL BIOL, V350, P228, DOI 10.1016/j.jmb.2005.04.065; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; GRIEP MA, 1990, J BIOL CHEM, V265, P20356; Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4; Jin YH, 2005, MOL CELL BIOL, V25, P461, DOI 10.1128/MCB.25.1.461-471.2005; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim DR, 1996, J BIOL CHEM, V271, P20699, DOI 10.1074/jbc.271.34.20699; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Lecointe F, 2004, MOL MICROBIOL, V53, P1721, DOI 10.1111/j.1365-2958.2004.04233.x; Lehtinen DA, 2004, BIOCHEM J, V384, P337, DOI 10.1042/BJ20040660; LOW RL, 1976, J BIOL CHEM, V251, P1311; Mah TF, 2000, GENE DEV, V14, P2664, DOI 10.1101/gad.822900; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; OLSON MW, 1992, J BIOL CHEM, V267, P23136; Perrino FW, 1999, BIOCHEMISTRY-US, V38, P16001, DOI 10.1021/bi991429+; Pham PT, 1998, J BIOL CHEM, V273, P23575, DOI 10.1074/jbc.273.36.23575; Pritchard AE, 1999, J MOL BIOL, V285, P1067, DOI 10.1006/jmbi.1998.2352; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; Shao XG, 2000, NUCLEIC ACIDS RES, V28, P2643, DOI 10.1093/nar/28.14.2643; Taft-Benz SA, 1999, J BACTERIOL, V181, P2963, DOI 10.1128/JB.181.9.2963-2965.1999; Teplyakov A, 2003, PROTEINS, V51, P315, DOI 10.1002/prot.10352; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506	46	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12561	12567		10.1074/jbc.M513844200	http://dx.doi.org/10.1074/jbc.M513844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517598	hybrid			2022-12-25	WOS:000237134700045
J	Stoldt, VR; Schnorr, O; Schulze-Osthoff, K; Scharf, RE				Stoldt, Volker R.; Schnorr, Oliver; Schulze-Osthoff, Klaus; Scharf, Rudiger E.			Transforming growth factor-beta 1 enhances the antifibrinolytic and prothrombotic state of growing endothelial cells in a cell cycle-specific manner	FASEB JOURNAL			English	Article						tissue repair; homeostasis; angiogenesis; plasminogen activator inhibitor; human umbilical vein endothelial cells	TRANSFORMING-GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR INHIBITOR-1; GENE DEFICIENT MICE; DIRECT BINDING; BETA; STIMULATION; MODULATION; EXPRESSION; THROMBOSIS; FIBROSIS	Cell cycle-dependent modulation of protein expression may influence the balance of antithrombotic and prothrombotic properties of endothelial cells. In the present study, we examined the regulation of prothrombotic and antithrombotic molecules by transforming growth factor-beta 1 (TGF-beta 1) during distinct phases of the cell cycle in human umbilical vein endothelial cells. In the absence of TGF-beta 1, the expression of thrombomodulin, the plasminogen activators u-PA and t-PA, and their inhibitor PAI-1 was significantly increased in the S/G2 compared to the G(1) phase. Treatment of endothelial cells with TGF-beta 1, however, resulted in elevated expression of PAI-1 specifically in the S/G2 phase, while t-PA and u-PA increased to the same extent in both the G1 and S/G2 phase. These findings demonstrate that the expression of a subset of hemostatically relevant proteins is regulated during endothelial cell cycle and that TGF-beta 1 can differentially modulate cell cycle-controlled protein expression.	Univ Dusseldorf, Dept Hemostasis & Transfus Med, Lab Vasc Biol, Med Ctr, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Ctr, Ctr Biol & Med Res, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Med Ctr, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Stoldt, VR (corresponding author), Univ Dusseldorf, Dept Hemostasis & Transfus Med, Lab Vasc Biol, Med Ctr, Bldg 12-49-00,Rm 9,Moorenstr 5, D-40225 Dusseldorf, Germany.	stoldt@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; Boehm JR, 1999, J CELL PHYSIOL, V181, P96, DOI 10.1002/(SICI)1097-4652(199910)181:1<96::AID-JCP10>3.0.CO;2-I; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Cines DB, 1998, BLOOD, V91, P3527; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; ERICKSON LA, 1990, NATURE, V346, P74, DOI 10.1038/346074a0; Fay WP, 1997, BLOOD, V90, P204; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; Hou BD, 2004, J BIOL CHEM, V279, P18127, DOI 10.1074/jbc.M310438200; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Le Breton M, 2005, BIOCHIMIE, V87, P805, DOI 10.1016/j.biochi.2005.04.014; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; OHJI T, 1995, THROMB HAEMOSTASIS, V73, P812; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V176, P633, DOI 10.1016/S0006-291X(05)80231-1; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; StaianoCoico L, 1996, EXP CELL RES, V227, P123, DOI 10.1006/excr.1996.0257; Tietze L, 1998, THROMB HAEMOSTASIS, V79, P362; Wu KK, 1996, ANNU REV MED, V47, P315	27	3	4	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					965	+		10.1096/fj.04-3032fje	http://dx.doi.org/10.1096/fj.04-3032fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571780				2022-12-25	WOS:000240157700023
J	Wang, YM; Li, G				Wang, YM; Li, G			ING3 promotes UV-induced apoptosis via Fas/caspase-8 pathway in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; CUTANEOUS MELANOMA; DOWN-REGULATION; DNA-REPAIR; P53; EXPRESSION; INDUCTION; FAMILY; ACETYLATION; CANCER	The novel ING tumor-suppressor family proteins (ING1-5) have been discovered during the past decade and are recognized as the regulators of transcription, cell cycle checkpoints, DNA repair, apoptosis, cellular senescence, angiogenesis, and nuclear phosphoinositide signaling. ING proteins contain a few conserved domains, including plant homeodomain motif, nuclear localization signal, and potential chromatin regulatory domain, suggesting that the ING family proteins may share common biological functions. ING3 has been shown to modulate p53-mediated transcription, cell cycle control, and apoptosis, possibly by modulating the NuA4 complex histone acetyltransferase activity. Because ING1b and ING2 have been shown to be involved in cellular stress responses such as nucleotide excision repair and apoptosis after UV irradiation, we investigated whether ING3 also mediated UV-induced apoptosis. We found that ING3 expression was rapidly induced by UV irradiation at both mRNA and protein levels. Using the stable clones of melanoma cells overexpressing ING3, we showed that overexpression of ING3 significantly promoted UV-induced apoptosis. Unlike its homologues ING1b and ING2, ING3-increased apoptosis was independent of functional p53. Furthermore, ING3 did not affect the expression of mitochondrial proteins but increased the cleavage of Bid and caspases-8, -9, and -3. Moreover, ING3-mediated apoptosis was blocked by inhibition of caspase-8 or Fas activation. In addition, ING3 up-regulated Fas expression at both mRNA and protein levels. Knock down of ING3 decreased UV-induced apoptosis remarkably. These data indicate that ING3 plays an important role in cellular response to UV irradiation by enhancing UV-induced apoptosis through the activation of Fas/caspase-8 pathway.	Univ British Columbia, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver Coastal Hlth Res Inst, Vancouver, BC BCV6H 3Z6, Canada	University of British Columbia; Vancouver Coastal Health Research Institute	Li, G (corresponding author), Univ British Columbia, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver Coastal Hlth Res Inst, 2660 Oak St, Vancouver, BC BCV6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011					Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Ceruti JM, 2005, ONCOGENE, V24, P4065, DOI 10.1038/sj.onc.1208570; Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610; Cheung KJ, 2001, CANCER RES, V61, P4974; Chin MY, 2005, EXP CELL RES, V304, P531, DOI 10.1016/j.yexcr.2004.11.023; Dauda M M, 2005, Niger Postgrad Med J, V12, P125; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; GICHREST BA, 1999, NEW ENGL J MED, V340, P1341; Girnita L, 2000, CANCER RES, V60, P5278; Gong W, 2005, INT J BIOCHEM CELL B, V37, P1054, DOI 10.1016/j.biocel.2004.09.008; GONZANI O, 2003, CELL, V114, P99; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; Gunduz M, 2005, GENE, V356, P109, DOI 10.1016/j.gene.2005.02.014; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Li G, 1998, MELANOMA RES, V8, P17, DOI 10.1097/00008390-199802000-00004; Li G, 2000, J INVEST DERMATOL, V114, P514, DOI 10.1046/j.1523-1747.2000.00867.x; Luu Y, 2003, ANTICANCER RES, V23, P99; NAFATA S, 1999, ANNU REV GENET, V33, P29; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rager EL, 2005, AM FAM PHYSICIAN, V72, P269; Sabel MS, 2003, ONCOLOGIST, V8, P451, DOI 10.1634/theoncologist.8-5-451; Scott M, 2001, J CELL SCI, V114, P3455; Shi XB, 2005, J CELL BIOCHEM, V96, P1127, DOI 10.1002/jcb.20625; Shiseki M, 2003, CANCER RES, V63, P2373; Stratton Michael R, 2004, J Drugs Dermatol, V3, P573; Takahashi M, 2004, ONCOL REP, V12, P811; Thompson JF, 2005, LANCET, V365, P687, DOI 10.1016/S0140-6736(05)17951-3; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; Tsang FC, 2003, FEBS LETT, V553, P277, DOI 10.1016/S0014-5793(03)01024-X; Tsao H, 2005, DERMATOL CLIN, V23, P323, DOI 10.1016/j.det.2004.09.005; VANELSAS A, 1997, MELANOMA RES S, V2, pS107; Wang J, 2006, CANCER RES, V66, P1906, DOI 10.1158/0008-5472.CAN-05-3444; Wei Jian-Bao, 2005, Ai Zheng, V24, P141; Wellbrock C, 2005, CURR BIOL, V15, P1629, DOI 10.1016/j.cub.2005.08.036; Yamashita T, 2001, J INVEST DERMATOL, V117, P914, DOI 10.1046/j.0022-202x.2001.01464.x; Yu GZ, 2004, WORLD J GASTROENTERO, V10, P3597, DOI 10.3748/wjg.v10.i24.3597; ZOLZER F, 1995, RADIOTHER ONCOL, V37, P20, DOI 10.1016/0167-8140(95)01618-Q	53	75	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11887	11893		10.1074/jbc.M511309200	http://dx.doi.org/10.1074/jbc.M511309200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16520380	hybrid			2022-12-25	WOS:000236988100056
J	Lindgren, D; Liedberg, F; Andersson, A; Chebil, G; Gudjonsson, S; Borg, A; Mansson, W; Fioretos, T; Hoglund, M				Lindgren, D; Liedberg, F; Andersson, A; Chebil, G; Gudjonsson, S; Borg, A; Mansson, W; Fioretos, T; Hoglund, M			Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q	ONCOGENE			English	Article						expression profiling; FGFR3; chromosome 9; urothelial carcinoma; bladder cancer	TRANSITIONAL-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR-3; GENE-EXPRESSION; URINARY-BLADDER; MICROARRAY DATA; CANCER; IDENTIFICATION; PAPILLARY; PATHWAYS; PROGRESSION	We used gene expression pro. ling, mutation analyses of FGFR3 and TP53, and LOH analyses of chromosome 9 and the TP53 region on chromosome arm 17p, to molecularly characterize 75 Ta and T1 bladder carcinomas. We identified four major cellular processes related to cell cycle, protein synthesis, immune response, and extra cellular components that contribute to the expressional heterogeneity of early-stage urothelial cell carcinoma ( UCC). Activating FGFR3 mutations were found at the highest frequency in G1 tumors ( 80%), and showed a strong correlation with FGFR3 expression. In contrast, G3 tumors displayed mutations in less than 10% of the cases and a low level of FGFR3 expression. Even though LOH on chromosome 9 was not associated with any specific expression pattern, our data indicate that loss of chromosome 9 is associated with tumor development rather than initiation. The combined analyses suggest the existence of two types of UCC tumors, one which is characterized by FGFR3 mutation or expression, high expression of protein synthesis genes, and low expression of cell cycle genes. Furthermore, the presented data underscore FGFR3 receptor involvement in urothelial cell transformation as the presence of FGFR3 mutations has a major impact on the global gene expression pro. le of bladder carcinomas.	Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Urol, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden; Helsingborg Hosp AB, Dept Pathol & Cytol, Helsingborg, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Helsingborgs Hospital	Lindgren, D (corresponding author), Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden.	david.lindgren@med.lu.se	Gudjonsson, S./K-6878-2015	Gudjonsson, S./0000-0002-5147-595X; Fioretos, Thoas/0000-0002-3235-6154; Hoglund, Mattias/0000-0001-9283-4421; Hagstrom-Andersson, Anna/0000-0002-2904-1311				Bakkar AA, 2003, CANCER RES, V63, P8108; Baud E, 1999, INT J ONCOL, V14, P441; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409; Brausi M, 2002, EUR UROL, V41, P523, DOI 10.1016/S0302-2838(02)00068-4; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Cordon-Cardo C, 1998, CANCER SURV, V32, P115; Duggan B, 2004, CURR OPIN UROL, V14, P277, DOI 10.1097/00042307-200409000-00006; Dyrskjot L, 2003, NAT GENET, V33, P90, DOI 10.1038/ng1061; Dyrskjot L, 2005, CLIN CANCER RES, V11, P4029, DOI 10.1158/1078-0432.CCR-04-2095; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Hafner C, 2002, INT J CANCER, V101, P1, DOI 10.1002/ijc.10544; Haukaas S, 1999, BJU INT, V83, P957; Herr HW, 2000, J UROLOGY, V163, P60, DOI 10.1016/S0022-5347(05)67972-4; Heyer LJ, 1999, GENOME RES, V9, P1106, DOI 10.1101/gr.9.11.1106; Hoglund M, 2001, CANCER RES, V61, P8241; Kim JH, 2005, LAB INVEST, V85, P532, DOI 10.1038/labinvest.3700250; Knowles MA, 1999, ELECTROPHORESIS, V20, P269, DOI 10.1002/(SICI)1522-2683(19990201)20:2<269::AID-ELPS269>3.3.CO;2-Z; Modlich O, 2004, CLIN CANCER RES, V10, P3410, DOI 10.1158/1078-0432.CCR-03-0134; Mor O, 2003, ONCOGENE, V22, P7702, DOI 10.1038/sj.onc.1207039; Mostofi F, 1999, HISTOLOGICAL TYPING; PROUT GR, 1992, J UROLOGY, V148, P1413, DOI 10.1016/S0022-5347(17)36924-0; Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1; Saal LH, 2002, GENOME BIOL, V3; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sanchez-Carbayo M, 2003, AM J PATHOL, V163, P505, DOI 10.1016/S0002-9440(10)63679-6; Sobin, 2009, UICC TNM CLASSIFICAT; SPRUCK CH, 1994, CANCER RES, V54, P784; Thykjaer T, 2001, CANCER RES, V61, P2492; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vajo Z, 2000, ENDOCR REV, V21, P23, DOI 10.1210/er.21.1.23; van Rhijn BSW, 2004, CANCER RES, V64, P1911, DOI 10.1158/0008-5472.CAN-03-2421; van Rhijn BWG, 2003, J CLIN ONCOL, V21, P1912, DOI 10.1200/JCO.2003.05.073; van Rhijn BWG, 2002, EUR J HUM GENET, V10, P819, DOI 10.1038/sj.ejhg.5200883; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wild PJ, 2005, CLIN CANCER RES, V11, P4415, DOI 10.1158/1078-0432.CCR-05-0259; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	39	106	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2685	2696		10.1038/sj.onc.1209249	http://dx.doi.org/10.1038/sj.onc.1209249			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16532037				2022-12-25	WOS:000237099400013
J	Bossolasco, M; Veillette, F; Bertrand, R; Mes-Masson, AM				Bossolasco, M.; Veillette, F.; Bertrand, R.; Mes-Masson, A. -M			Human TDE1, a TDE1/TMS family member, inhibits apoptosis in vitro and stimulates in vivo tumorigenesis	ONCOGENE			English	Article						TDE1; apoptosis; transformation; tumorigenesis	ANTIGEN TRANSGENIC MICE; SUBCELLULAR-LOCALIZATION; PROTEIN FAMILY; CELL-LINES; EXPRESSION; IDENTIFICATION; GENE; CULTURE; CANCER; TISSUE	We have previously described hTDE1, the human homologue of the recently described TDE1/TMS family of proteins whose members have been identified in several species. Although a defined biochemical activity has yet to be assigned to TDE1/TMS family members, previous results point to the overexpression of family members in tumor cell lines or tissues. To define whether hTDE1 may directly impact on neoplastic transformation, we derived and characterized stable Rat-1 transfectants that constitutively express hTDE1 at the plasma membrane. Expression of hTDE1 in Rat-1 transfectants had a significant effect on cell contact inhibition in vitro as judged by a focus formation assay. In addition, by monitoring caspase-3 activity and Hoechst staining, we determined that hTDE1 overexpression partially protects cells from serum starvation- and etoposide-induced apoptosis. Finally, hTDE1 Rat-1-expressing clones accelerated the formation of tumors in a nude mouse assay. Our results suggest that hTDE1 contributes directly to oncogenesis in vivo that may in part be explained by its effect on apoptosis in vitro.	CHUM, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Mes-Masson, AM (corresponding author), CHUM, ICM, Hop Notre Dame de Bon Secours, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.	anne-marie.mes-masson@umontreal.ca		Mes-Masson, Anne-Marie/0000-0002-6498-266X				Aoki S, 2002, J NEUROSCI, V22, P10751; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; Bossolasco M, 1999, MOL CARCINOGEN, V26, P189, DOI 10.1002/(SICI)1098-2744(199911)26:3<189::AID-MC8>3.0.CO;2-T; CHALIFOUR LE, 1990, ONCOGENE, V5, P1719; CHALIFOUR LE, 1992, MOL CARCINOGEN, V5, P178, DOI 10.1002/mc.2940050304; Corn PG, 2002, BIOESSAYS, V24, P83, DOI 10.1002/bies.10036; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Ferrigno P, 1999, METHOD CELL BIOL, V58, P107; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Grossman TR, 2000, J EXP BIOL, V203, P447; Inuzuka M, 2005, J BIOL CHEM, V280, P35776, DOI 10.1074/jbc.M505712200; Krueger WHH, 1997, J NEUROCHEM, V69, P1343; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; LEBEL M, 1994, DNA SEQUENCE, V5, P31, DOI 10.3109/10425179409039702; Nowell PC, 2002, SEMIN CANCER BIOL, V12, P261, DOI 10.1016/S1044-579X(02)00012-3; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; Pearce DA, 2000, J NEUROSCI RES, V59, P19, DOI 10.1002/(SICI)1097-4547(20000101)59:1<19::AID-JNR3>3.0.CO;2-Y; Player A, 2003, INT J CANCER, V107, P238, DOI 10.1002/ijc.11391; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; Rodriguez-Bigas MA, 2003, HOLLAND FREI CANC ME; Ronot X, 2000, CYTOMETRY, V41, P19, DOI 10.1002/1097-0320(20000901)41:1<19::AID-CYTO3>3.0.CO;2-X; Royle SJ, 2003, BIOESSAYS, V25, P39, DOI 10.1002/bies.10200; Shigeta M, 2003, J CELL BIOL, V163, P165, DOI 10.1083/jcb.200301075; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; TEMIN HM, 1958, VIROLOGY, V6, P669, DOI 10.1016/0042-6822(58)90114-4; Xu J, 2003, MOL BIOL REP, V30, P47, DOI 10.1023/A:1022250428015	28	20	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4549	4558		10.1038/sj.onc.1209488	http://dx.doi.org/10.1038/sj.onc.1209488			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16547497				2022-12-25	WOS:000239457500005
J	Ishimura, A; Lee, HS; Bong, YS; Saucier, C; Mood, K; Park, E; Daar, IO				Ishimura, A.; Lee, H-S; Bong, Y-S; Saucier, C.; Mood, K.; Park, E. K.; Daar, I. O.			Oncogenic Met receptor induces ectopic structures in Xenopus embryos	ONCOGENE			English	Article						Met receptor; Xenopus; tyrosine kinase signaling	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; GRB2 BINDING-SITE; TYROSINE KINASE; MESODERM INDUCTION; C-MET; NEURAL CREST; MAP KINASE; CELL-TRANSFORMATION	When aberrantly expressed or activated, the Met receptor tyrosine kinase is involved in tumor invasiveness and metastasis. In this study, we have used the Xenopus embryonic system to de. ne the role of various Met proximal-binding partners and downstream signaling pathways in regulating an induced morphogenetic event. We show that expression of an oncogenic derivative of the Met receptor (Tpr-Met) induces ectopic morphogenetic structures during Xenopus embryogenesis. Using variant forms of Tpr-Met that are engineered to recruit a specific signaling molecule of choice, we demonstrate that the sole recruitment of either the Grb2 or the Shc adaptor protein is sufficient to induce ectopic structures and anterior reduction, while the recruitment of PI-3Kinase (PI-3K) is necessary but not sufficient for this effect. In contrast, the recruitment of PLC gamma can initiate the induction, but fails to maintain or elongate supernumerary structures. Finally, evidence indicates that the Ras/Raf/MAPK pathway is necessary, but not sufficient to induce these structures. This study also emphasizes the importance of examining signaling molecules in the regulatory context that is provided by receptor/effector interactions when assessing a role in cell growth and differentiation.	NCI, Frederick Canc Res & Dev Ctr, Lab Prot Dynam & Signaling, Frederick, MD 21702 USA; McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; McGill University	Daar, IO (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Lab Prot Dynam & Signaling, Bldg 560,Room 22-3, Frederick, MD 21702 USA.	daar@ncifcrf.gov	Saucier, Caroline/Q-9250-2019; Lee, Hyun-Shik/G-3555-2011	Saucier, Caroline/0000-0001-7678-9886; Daar, Ira/0000-0003-2657-526X	NATIONAL CANCER INSTITUTE [Z01BC010006, ZIABC010006] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aoki S, 1997, BIOCHEM BIOPH RES CO, V234, P8, DOI 10.1006/bbrc.1997.6567; Atabey N, 2001, J BIOL CHEM, V276, P14308, DOI 10.1074/jbc.M010202200; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BELLUSCI S, 1994, ONCOGENE, V9, P1091; Berthou S, 2004, ONCOGENE, V23, P5387, DOI 10.1038/sj.onc.1207691; Brewster R, 2000, DEVELOPMENT, V127, P4395; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Carballada R, 2001, DEVELOPMENT, V128, P35; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Chen YL, 1999, MECH DEVELOP, V80, P67, DOI 10.1016/S0925-4773(98)00194-4; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Chong LD, 2000, MOL CELL BIOL, V20, P724, DOI 10.1128/MCB.20.2.724-734.2000; Christen B, 2003, DEV DYNAM, V226, P349, DOI 10.1002/dvdy.10231; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Christensen JG, 2003, CANCER RES, V63, P7345; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; Coltella N, 2003, FASEB J, V17, P1162, DOI 10.1096/fj.02-0576fje; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Dupont H, 1999, EUR J BIOCHEM, V265, P530, DOI 10.1046/j.1432-1327.1999.00689.x; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Gupta RW, 1998, ONCOGENE, V17, P2155, DOI 10.1038/sj.onc.1202158; GURDON JB, 1984, CELL, V38, P691, DOI 10.1016/0092-8674(84)90264-2; Hama J, 2001, MECH DEVELOP, V109, P195, DOI 10.1016/S0925-4773(01)00524-X; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JACOBSON M, 1986, DEV BIOL, V116, P524, DOI 10.1016/0012-1606(86)90153-3; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, ONCOGENE, V13, P853; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kim P, 1997, DEV BIOL, V187, P1, DOI 10.1006/dbio.1997.8572; Koibuchi N, 2004, BLOOD, V103, P3320, DOI 10.1182/blood-2003-02-0352; LABONNE C, 1994, DEVELOPMENT, V120, P463; LABONNE C, 1995, DEVELOPMENT, V121, P1475; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; LIU C, 1992, ONCOGENE, V7, P181; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Lombardo A, 2001, MECH DEVELOP, V106, P191, DOI 10.1016/S0925-4773(01)00438-5; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; Maeda R, 2001, ONCOGENE, V20, P1329, DOI 10.1038/sj.onc.1204250; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maulik G, 2002, CLIN CANCER RES, V8, P620; MAYOR R, 1995, DEVELOPMENT, V121, P767; Mood K, 2006, J CELL PHYSIOL, V207, P271, DOI 10.1002/jcp.20564; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Park EK, 2004, MOL BIOL CELL, V15, P1647, DOI 10.1091/mbc.E03-09-0674; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Pownall ME, 1996, DEVELOPMENT, V122, P3881; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RONG S, 1994, COLD SPRING HARB SYM, V59, P629, DOI 10.1101/SQB.1994.059.01.072; RONG S, 1993, CANCER RES, V53, P5355; SATO SM, 1991, DEVELOPMENT, V112, P747; Sattler M, 2003, CANCER RES, V63, P5462; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Schmidt L, 1998, CANCER RES, V58, P1719; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; SIVE HL, 2000, EARLY DEV XENOPUS LA, P143; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; STERN CD, 1990, DEVELOPMENT, V110, P1271; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Tada M, 1997, DEVELOPMENT, V124, P2225; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; To CTT, 1998, ONCOL REP, V5, P1013; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; Tsarfaty I, 1999, ANAL QUANT CYTOL, V21, P397; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weinstein DC, 1998, NATURE, V394, P904, DOI 10.1038/29808; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yasuo H, 2001, INT J DEV BIOL, V45, P229; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	93	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4286	4299		10.1038/sj.onc.1209463	http://dx.doi.org/10.1038/sj.onc.1209463			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518409				2022-12-25	WOS:000239240100004
J	Ling, X; Wang, Y; Dietrich, MF; Andreeff, M; Arlinghaus, RB				Ling, X.; Wang, Y.; Dietrich, M. F.; Andreeff, M.; Arlinghaus, R. B.			Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice	ONCOGENE			English	Article						vaccination; murine leukemia; membrane-bound GM-CSF; lentivirus	DENDRITIC CELLS; TUMOR-CELLS; BALB/C MICE; GENERATION; CANCER; PROGENITORS; VACCINES; IMMUNITY; EGFP; CML	The fundamental basis for immunotherapy of leukemia is that leukemic cells express specific antigens that are not expressed by normal hematopoietic cells. However, the host immune system appears to be tolerant to leukemia cells. To overcome this tolerance, we vaccinated immuno-competent mice with murine leukemia cells (WEHI-3B and BCR-ABL+ 32D cells) transduced with a specifically constructed transmembrane form of granulocyte macrophage colony-stimulating factor ( tmGM-CSF). The transduced cells expressed tmGM-CSF on the cell-surface. To determine whether tmGM-CSF-expressing WEHI-3B leukemia cells would prevent leukemia formation as a vaccine, immunocompetent mice ( BALB/c and C3H/HEJ) were immunized with lethally irradiated murine leukemia cells expressing cell-surface tmGM-CSF before challenging mice with murine leukemia cells. Two immunocompetent mouse models were investigated, either WEHI-3B cells in BALB/c mice or BCR-ABL+ 32D cells in C3H/HEJ mouse. The results showed that 100% of WEHI-3B/tmGM-CSF-vaccinated BALB/c mice and about 65% of 32D+ BCR-ABL/tmGM-CSF-vaccinated C3H/HEJ mice were protected from leukemia after leukemia cell challenge, whereas all non-vaccinated mice succumbed to leukemia. Spleen and marrow cell suspensions from vaccinated mice challenged with WEHI-3B cells lacked detectable GFP+ WEHI-3B cells at 82 days post-challenge. A significant delay of death was observed in C3H/HEJ mice challenged with the very aggressive DA-1 cell line expressing BCR-ABL. Vaccination of mice with WEHI-3B/CD40L cells protected 80% of the mice from the WEHI-3B challenge. Notably, 60% of the WEHI-3B/BALB/c mice were also protected from leukemia when WEHI-3B/tmGM-CSF vaccination was carried out after the leukemia challenge. In order to determine whether cellular immunity is involved in this vaccine-mediated protection, either CD4+ or CD8+ T cells were depleted from mice after the WEHI-3B/tmGM-CSF vaccination. The results indicate that CD8+ T-cells mediated the protective immune response provided by the irradiated tmGM-CSF-expressing WEHI-3B cells. In addition, vaccination of nude mice did not provide protection from WEHI-3B leukemia induction. Importantly, 80% of non-vaccinated mice were also protected from a WEHI-3B cell challenge after receiving spleen cells from vaccinated mice 1 day before challenge with leukemia cells. These results indicate that overexpression of tmGM-CSF on the leukemia cell-surface can enhance the recognition of leukemic cells by CD8+ T cells, and can either prevent or significantly delay leukemia induction. These findings suggest that injection of irradiated leukemia cells expressing cell-surface-bound GM-CSF has the potential as an immunological approach to treat leukemia.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bone Marrow Transplant, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rarlingh@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [5P30 CA16672-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acres B, 2004, CURR OPIN MOL THER, V6, P40; BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; Bitton RJ, 2004, CURR OPIN MOL THER, V6, P17; Bleier JI, 2004, J IMMUNOL, V172, P7408, DOI 10.4049/jimmunol.172.12.7408; Butturini A, 1995, Cancer Treat Res, V76, P299; DALCY GQ, 1990, SCIENCE, V16, P824; de Vos S, 1998, LEUKEMIA, V12, P401, DOI 10.1038/sj.leu.2400940; Denaro M, 2001, GENE THER, V8, P1814, DOI 10.1038/sj.gt.3301601; Dong R, 2003, BLOOD, V101, P3560, DOI 10.1182/blood-2002-06-1841; Fujimura T, 2004, IMMUNOL LETT, V93, P17, DOI 10.1016/j.imlet.2004.01.013; Galea-Lauri J, 2002, IMMUNOLOGY, V107, P20, DOI 10.1046/j.1365-2567.2002.01497.x; Gambotto A, 2000, GENE THER, V7, P2036, DOI 10.1038/sj.gt.3301335; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hoo WS, 1999, J IMMUNOL, V162, P7343; Larregina A, 1996, IMMUNOLOGY, V87, P317, DOI 10.1046/j.1365-2567.1996.451513.x; Ling XY, 2003, CANCER RES, V63, P298; MATULONIS UA, 1995, BLOOD, V85, P2507, DOI 10.1182/blood.V85.9.2507.bloodjournal8592507; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; O'Keefe Christine L, 2004, Hematology, V9, P189, DOI 10.1080/10245330410001701530; Platzbecker U, 2004, LEUKEMIA LYMPHOMA, V45, P447, DOI 10.1080/10428190310001615684; Pulendran B, 2004, EUR J IMMUNOL, V34, P66, DOI 10.1002/eji.200324567; Rojas R, 2003, LEUKEMIA RES, V27, P351, DOI 10.1016/S0145-2126(02)00180-7; Saudemont A, 2005, BLOOD, V105, P2428, DOI 10.1182/blood-2004-09-3458; Saudemont A, 2002, LEUKEMIA, V16, P1637, DOI 10.1038/sj.leu.2402590; STRIPECKE R, 2001, GENE THER, V6, P1305; Vereecque R, 1999, LEUKEMIA RES, V23, P415; Yei S, 2002, GENE THER, V9, P1302, DOI 10.1038/sj.gt.3301803; Zhao RCH, 1997, BLOOD, V90, P4687, DOI 10.1182/blood.V90.12.4687.4687_4687_4698	30	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4483	4490		10.1038/sj.onc.1209477	http://dx.doi.org/10.1038/sj.onc.1209477			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547503				2022-12-25	WOS:000239326000011
J	Mitra, SK; Lim, ST; Chi, A; Schlaepfer, DD				Mitra, S. K.; Lim, S-T; Chi, A.; Schlaepfer, D. D.			Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model	ONCOGENE			English	Article						FAK; FRNK; shRNA; uPA; invasion; metastasis	CELL MOTILITY; GROWTH-FACTOR; FAK EXPRESSION; CANCER CELLS; MIGRATION; INVASION; SRC; PROMOTES; APOPTOSIS; DEATH	Expression of focal adhesion kinase (FAK) is elevated in malignant breast cancer, yet the role of intrinsic FAK activity in promoting tumor progression remains undefined. Here, we have inhibited FAK activity or expression in murine 4T1 breast carcinoma cells via dominant-negative focal adhesion kinase-related non-kinase (FRNK) or anti-FAK short hairpin RNA (shRNA) expression, respectively. Neither FRNK nor FAK shRNA (similar to 80% reduced FAK levels) affected 4T1 proliferation in culture, whereas reduced FAK activity or expression blocked 4T1 cell invasion through Matrigel and resulted in 2-3-fold lower urokinase plasminogen activator (uPA) expression. Control 4T1 cells implanted into mammary fat pads of BALB/c mice exhibited spontaneous metastasis to the lungs, to the peritoneal cavity, and resulted in 90% lethality within 21 days. Whereas FAK shRNA-expressing 4T1 cells formed tumors in mice with low levels of apoptosis, when mammary-injected, these cells did not exhibit lung metastasis after 21 days and caused only 40% lethality up to 60 days. Transient re-expression of wildtype but not kinase-dead FAK in 4T1 FAK shRNA cells promoted uPA production and mammary to lung metastasis within 7 days. In fact, stable human uPA overexpression in 4T1 FAK shRNA cells promoted Matrigel invasion and lung metastasis equal to 4T1 controls. Conversely, treatment with plasminogen activator inhibitor-1 or neutralizing antibody to uPA blocked Matrigel invasion of 4T1 control cells. These studies provide the first direct proof that FAK catalytic activity can facilitate metastatic breast cancer progression by regulating uPA expression.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM 21,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dschlaep@scripps.edu		Lim, Steve/0000-0003-0323-8607	NATIONAL CANCER INSTITUTE [R29CA075240, R01CA087038, R01CA102310, R01CA075240] Funding Source: NIH RePORTER; NCI NIH HHS [CA75240, CA87038, CA102310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Duxbury MS, 2003, BIOCHEM BIOPH RES CO, V311, P786, DOI 10.1016/j.bbrc.2003.10.060; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; Han EKH, 2004, ANTICANCER RES, V24, P3899; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hauck CR, 2002, J BIOL CHEM, V277, P12487, DOI 10.1074/jbc.C100760200; Hauck CR, 2001, CANCER RES, V61, P7079; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Hess AR, 2005, CANCER RES, V65, P9851, DOI 10.1158/0008-5472.CAN-05-2172; Hsia DA, 2005, MOL CELL BIOL, V25, P9700, DOI 10.1128/MCB.25.21.9700-9712.2005; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Itoh S, 2004, CLIN CANCER RES, V10, P2812, DOI 10.1158/1078-0432.CCR-1046-03; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Lightfoot HM, 2004, BREAST CANCER RES TR, V88, P109, DOI 10.1007/s10549-004-1022-8; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Miyazaki T, 2003, BRIT J CANCER, V89, P140, DOI 10.1038/sj.bjc.6601050; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Oktay MH, 2003, HUM PATHOL, V34, P240, DOI 10.1053/hupa.2003.40; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Recher C, 2004, CANCER RES, V64, P3191, DOI 10.1158/0008-5472.CAN-03-3005; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; Watermann DO, 2005, BRIT J CANCER, V93, P694, DOI 10.1038/sj.bjc.6602744; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; YU H, 1990, CANCER RES, V50, P7623	48	81	88	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4429	4440		10.1038/sj.onc.1209482	http://dx.doi.org/10.1038/sj.onc.1209482			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547501				2022-12-25	WOS:000239326000006
J	Schiller, M; Bohm, M; Dennler, S; Ehrchen, JM; Mauviel, A				Schiller, M.; Boehm, M.; Dennler, S.; Ehrchen, J. M.; Mauviel, A.			Mitogen- and stress-activated protein kinase 1 is critical for interleukin-1-induced, CREB-mediated, c-fos gene expression in keratinocytes	ONCOGENE			English	Article						cAMP; c-fos; CREB; PKA; MAP kinases; interleukin-1	KINASE SIGNALING CASCADES; SERUM RESPONSE ELEMENT; PROTEIN-KINASE; MAP KINASE; METALLOPROTEINASE EXPRESSION; TRANSGENIC MICE; TRANSCRIPTION; INDUCTION; AP-1; CELLS	c-fos, which encodes a transcription factor of the AP-1 family, is a prototypical immediate-early gene induced by a number of proinflammatory cytokines including interleukin-1 (IL-1), the latter being an important regulator of skin homeostasis. Using the human keratinocyte cell line HaCaT as an in vitro model, we dissected the molecular pathways leading to IL-1-induced c-fos gene induction. Phosphorylation of the transcription factor cAMP response element binding protein (CREB) at Ser133 was found to be essential for IL-1-induced c-fos gene induction and was closely paralleled by protein kinase A (PKA) activation. In contrast to other cell types, the cyclooxy-genase/prostaglandin pathway, known to activate the cAMP/PKA cascade, plays little, if any, role in c-fos expression downstream of the IL-1 receptor in keratinocytes. Simultaneous activation of several of the mitogen-activated protein kinase (MAPK) cascades occurred in response to IL-1, but each differentially contributed to c-fos induction by IL-1, with the p38/MAPK being the most crucial of all, the extracellular signal-regulated kinase pathway contributing in an additive manner and the Jun N-terminal kinase pathway playing little, if any, role. We also demonstrate that p38-dependent activation of mitogen- and stress-activated kinase 1 (MSK1), a CREB kinase, is a key step for c-fos gene activation by IL-1. Finally, we identify MSK1 as playing a positive role in the control of cell proliferation of both HaCaT keratinocytes and the A431 human epidermoid carcinoma line.	Hop St Louis, INSERM, U697, F-75010 Paris, France; Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol, Dept Dermatol, Munster, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Munster	Mauviel, A (corresponding author), Hop St Louis, INSERM, U697, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	alain.mauviel@stlouis.inserm.fr	MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Braddock M, 2004, NAT REV DRUG DISCOV, V3, P1, DOI 10.1038/nrd1342; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Dayer JM, 2003, RHEUMATOLOGY, V42, P3, DOI 10.1093/rheumatology/keg326; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kumar S, 2001, J CELL PHYSIOL, V187, P294, DOI 10.1002/jcp.1082; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUGER TA, 1990, J INVEST DERMATOL, V95, pS100, DOI 10.1111/1523-1747.ep12874944; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Podolsky DK, 1997, J GASTROENTEROL, V32, P122, DOI 10.1007/BF01213309; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Schuck S, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-6; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; Strniskova M, 2002, GEN PHYSIOL BIOPHYS, V21, P231; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; WANG ZQ, 1995, CANCER RES, V55, P6244; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3	38	37	41	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4449	4457		10.1038/sj.onc.1209479	http://dx.doi.org/10.1038/sj.onc.1209479			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16532028				2022-12-25	WOS:000239326000008
J	Bellve, KD; Leonard, D; Standley, C; Lifshitz, LM; Tuft, RA; Hayakawa, A; Corvera, S; Fogarty, KE				Bellve, Karl D.; Leonard, Deborah; Standley, Clive; Lifshitz, Lawrence M.; Tuft, Richard A.; Hayakawa, Akira; Corvera, Silvia; Fogarty, Kevin E.			Plasma membrane domains specialized for clathrinmediated endocytosis in primary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFLECTION FLUORESCENCE MICROSCOPY; MEDIATED ENDOCYTOSIS; COATED PITS; POPULATION; VESICLES; BIOLOGY; INSULIN; COMPLEX; GLUT4; CARGO	Clathrin assembly at the plasma membrane is a fundamental process required for endocytosis. In cultured cells, most of the clathrin is localized to large patches that display little lateral mobility. The functional role of these regions is not clear, and it has been thought that they may represent artifacts of cell adhesion of cultured cells. Here we have analyzed clathrin organization in primary adipose cells isolated from mice, which are nonadherent and fully differentiated. The majority of clathrin on the plasma membrane of these cells (> 60%) was found in large clathrin patches that displayed virtually no lateral mobility and persisted for many minutes, and a smaller amount was found in small spots that appeared and disappeared rapidly. Direct visualization of transferrin revealed that it bound onto large arrays of clathrin, internalizing through vesicles that emerge from these domains. High resolution imaging (50 images/s) revealed fluorescence intensity fluctuations consistent with the formation and detachment of coated vesicles from within large patches. These results reveal that large clathrin assemblies are active regions of endocytosis in mammalian cells and highlight the importance of understanding the mechanistic basis for this organization.	Univ Massachusetts, Sch Med, Program Mol Med, Dept Physiol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Interdisciplinary Grad Program, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Corvera, S (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Dept Physiol, 373 Plantat St, Worcester, MA 01605 USA.	silvia.corvera@umassmed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK060564] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK60564] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Beaumont V, 2003, BIOCHEM SOC T, V31, P819, DOI 10.1042/BST0310819; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Keyel PA, 2004, J BIOL CHEM, V279, P13190, DOI 10.1074/jbc.M312717200; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Lifshitz L. M., 1994, Proceedings of the IEEE Workshop on Biomedical Image Analysis (Cat. No.94TH0624-7), P166, DOI 10.1109/BIA.1994.315854; Lizunov VA, 2005, J CELL BIOL, V169, P481, DOI 10.1083/jcb.200412069; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Merrifield CJ, 2005, CELL, V121, P593, DOI 10.1016/j.cell.2005.03.015; Moskowitz HS, 2005, MOL BIOL CELL, V16, P1769, DOI 10.1091/mbc.E04-08-0739; Rappoport J, 2004, TRAFFIC, V5, P327, DOI 10.1111/j.1600-0854.2004.00187.x; Rappoport JZ, 2003, TRAFFIC, V4, P460, DOI 10.1034/j.1600-0854.2003.00100.x; Rappoport JZ, 2003, J CELL SCI, V116, P847, DOI 10.1242/jcs.00289; Rappoport JZ, 2005, TRAFFIC, V6, P539, DOI 10.1111/j.1600-0854.2005.00280.x; Rappoport JZ, 2003, J BIOL CHEM, V278, P47357, DOI 10.1074/jbc.C300390200; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001	21	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16139	16146		10.1074/jbc.M511370200	http://dx.doi.org/10.1074/jbc.M511370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16537543	hybrid			2022-12-25	WOS:000237996000067
J	Liu, XB; Bandyopadhyay, B; Nakamoto, T; Singh, B; Liedtke, W; Melvin, JE; Ambudkar, I				Liu, Xibao; Bandyopadhyay, Bidhan; Nakamoto, Tetsuji; Singh, Brij; Liedtke, Wolfgang; Melvin, James E.; Ambudkar, Indu			A role for AQP5 in activation of TRPV4 by hypotonicity - Concerted involvement of AQP5 and TRPV4 in regulation of cell volume recovery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION CHANNEL; TRANSLOCATION; MEMBRANE; CALCIUM; ACINAR; IDENTIFICATION; LOCALIZATION; AQUAPORIN-5; CURRENTS; INSULIN	Regulation of cell volume in response to changes in osmolarity is critical for cell function and survival. However, the molecular basis of osmosensation and regulation of cell volume are not clearly understood. We have examined the mechanism of regulatory volume decrease ( RVD) in salivary gland cells and report a novel association between osmosensing TRPV4 ( transient receptor potential vanalloid 4) and AQP5 ( aquaporin 5), which is required for regulating water permeability and cell volume. Exposure of salivary gland cells and acini to hypotonicity elicited an increase in cell volume and activation of RVD. Hypotonicity also activated Ca2+ entry, which was required for subsequent RVD. Ca2+ entry was associated with a distinct nonselective cation current that was activated by 4 alpha PDD and inhibited by ruthenium red, suggesting involvement of TRPV4. Consistent with this, endogenous TRPV4 was detected in cells and in the apical region of acini along AQP5. Importantly, acinar cells from mice lacking either TRPV4 or AQP5 displayed greatly reduced Ca2+ entry and loss of RVD in response to hypotonicity, although the extent of cell swelling was similar. Expression of N terminus-deleted AQP5 suppressed TRPV4 activation and RVD but not cell swelling. Furthermore, hypotonicity increased the association and surface expression of AQP5 and TRPV4. Both these effects and RVD were reduced by actin depolymerization. These data demonstrate that ( i) activation of TRPV4 by hypotonicity depends on AQP5, not on cell swelling per se, and ( ii) TRPV4 and AQP5 concertedly control regulatory volume decrease. These data suggest a potentially important role for TRPV4 in salivary gland function.	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; Univ Rochester, Ctr Oral Biol, Rochester, NY 14642 USA; Univ N Dakota, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA; Duke Univ, Med Ctr, Ctr Translat Neurosci, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Rochester; University of North Dakota Grand Forks; Duke University	Ambudkar, I (corresponding author), NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10 Rm 1N-113, Bethesda, MD 20892 USA.	indu.ambudkar@nih.gov	Liedtke, Wolfgang B/G-4633-2011; Bandyopadhyay, Bidhan/AAC-6828-2022; Liedtke, Wolfgang/GNH-1878-2022	Bandyopadhyay, Bidhan/0000-0003-2364-8945; Singh, Brij/0000-0003-0535-5997	NIDCR NIH HHS [DE013823] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438, R01DE013823] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ambudkar IS, 2000, CRIT REV ORAL BIOL M, V11, P4, DOI 10.1177/10454411000110010301; Andrade YN, 2005, J CELL BIOL, V168, P869, DOI 10.1083/jcb.200409070; Arniges M, 2004, J BIOL CHEM, V279, P54062, DOI 10.1074/jbc.M409708200; Becker D, 2005, J CELL SCI, V118, P2435, DOI 10.1242/jcs.02372; Boels K, 2001, J CELL SCI, V114, P3599; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; Chung MK, 2003, J BIOL CHEM, V278, P32037, DOI 10.1074/jbc.M303251200; Cohen DM, 2005, AM J PHYSIOL-CELL PH, V288, pC483, DOI 10.1152/ajpcell.00452.2004; Earley S, 2005, CIRC RES, V97, P1270, DOI 10.1161/01.RES.0000194321.60300.d6; Gresz V, 2001, AM J PHYSIOL-GASTR L, V281, pG247, DOI 10.1152/ajpgi.2001.281.1.G247; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V265, P94, DOI 10.1006/bbrc.1999.1630; Ishikawa Y, 2005, AM J PHYSIOL-CELL PH, V289, pC1303, DOI 10.1152/ajpcell.00211.2005; Jakab M, 2002, CELL PHYSIOL BIOCHEM, V12, P235, DOI 10.1159/000067895; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469; Krane CM, 2001, J BIOL CHEM, V276, P23413, DOI 10.1074/jbc.M008760200; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P13698, DOI 10.1073/pnas.1735416100; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2005, J PHYSIOL-LONDON, V567, P53, DOI 10.1113/jphysiol.2005.088963; Liu X, 2004, J MEMBRANE BIOL, V200, P93, DOI 10.1007/s00232-004-0698-3; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Melvin JE, 2005, ANNU REV PHYSIOL, V67, P445, DOI 10.1146/annurev.physiol.67.041703.084745; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Okada Y, 2001, COMP BIOCHEM PHYS A, V130, P377, DOI 10.1016/S1095-6433(01)00424-X; Strange K, 2004, ADV PHYSIOL EDUC, V28, P155, DOI 10.1152/advan.00034.2004; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suzuki M, 2003, J BIOL CHEM, V278, P51448, DOI 10.1074/jbc.M308212200; Tinel H, 2000, CELL PHYSIOL BIOCHEM, V10, P297, DOI 10.1159/000016375; Tran SD, 2005, TISSUE ENG, V11, P172, DOI 10.1089/ten.2005.11.172; Van Buren JJ, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-17; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Vriens J, 2005, CIRC RES, V97, P908, DOI 10.1161/01.RES.0000187474.47805.30; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Wellner RB, 2005, TISSUE ENG, V11, P1449, DOI 10.1089/ten.2005.11.1449; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442	39	175	192	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15485	15495		10.1074/jbc.M600549200	http://dx.doi.org/10.1074/jbc.M600549200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16571723	hybrid			2022-12-25	WOS:000237922200055
J	Shen, L; Guo, JJ; Santos-Berrios, C; Wu, MX				Shen, Li; Guo, Jinjin; Santos-Berrios, Cynthia; Wu, Mei X.			Distinct domains for anti- and pro-apoptotic activities of IEX-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; MITOCHONDRIAL HYPERPOLARIZATION; CELL-DEATH; EXPRESSION; PROTEIN; GROWTH; LIFE; IDENTIFICATION; RADIATION; SEQUENCE	IEX-1 (immediate early response gene X-1) is a stress-inducible gene. Its overexpression can suppress or enhance apoptosis dependent on the nature of stress, yet the polypeptide does not possess any of the functional domains that are homologous to those present in well characterized effectors or inhibitors of apoptosis. This study using sequence-targeting mutagenesis reveals a transmembrane-like integrated region of the protein to be critical for both pro-apoptotic and anti-apoptotic functions. Substitution of the key hydrophobic residues with hydrophilic ones within this region impairs the capacity IEX-1 to positively and negatively regulate apoptosis. Mutations at N-linked glycosylation and phosphorylation sites or truncation of the C terminus of IEX-1 also abrogated its potential to promote cell survival. However, distinguished from the transmembrane-like domain, these mutants preserved pro-apoptotic activity of IEX-1 fully. On the contrary, mutation of nuclear localization sequence, despite its importance in apoptosis, did not impede IEX1-mediated cell survival. Strikingly, all the mutants that lose their anti-apoptotic ability are unable to prevent acute increases in production of intracellular reactive oxygen species (ROS) at the initial onset of apoptosis, whereas those mutants that can sustain anti-death function also control acute ROS production as sufficiently as wild-type IEX-1. These findings suggest a critical role of IEX-1 in regulation of intracellular ROS homeostasis, providing new insight into the mechanism underlying IEX-1-mediated cell survival.	Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Wu, MX (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Edwards 222,50 Blossom St, Boston, MA 02114 USA.	mwu2@partners.org			NIAID NIH HHS [AI050822] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050822] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CHARLES CH, 1993, ONCOGENE, V8, P797; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Domachowske JB, 2000, J INFECT DIS, V181, P824, DOI 10.1086/315319; Feldmann KA, 2001, HISTOCHEM CELL BIOL, V115, P489; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Gonzalez S, 2005, CANCER RES, V65, P2186, DOI 10.1158/0008-5472.CAN-04-3047; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Huang YH, 2002, ONCOGENE, V21, P6819, DOI 10.1038/sj.onc.1205854; Im HJ, 2002, ONCOGENE, V21, P3706, DOI 10.1038/sj.onc.1205450; Kadenbach B, 2004, BBA-BIOENERGETICS, V1655, P400, DOI 10.1016/j.bbabio.2003.06.005; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kruse ML, 2005, J BIOL CHEM, V280, P24849, DOI 10.1074/jbc.M501571200; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; Kumar R, 2004, BIOCHEM BIOPH RES CO, V323, P1293, DOI 10.1016/j.bbrc.2004.09.006; Landmesser U, 2003, J CLIN INVEST, V111, P1201, DOI 10.1172/JCI200314172; Ledesma A., 2002, GENOME BIOL, V3, p3015.1, DOI DOI 10.1186/gb-2002-3-12-reviews3015; Matarrese P, 2003, J IMMUNOL, V170, P6006, DOI 10.4049/jimmunol.170.12.6006; Mittal A, 2006, J IMMUNOL, V176, P2183, DOI 10.4049/jimmunol.176.4.2183; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Patsos G, 2005, BIOCHEM SOC T, V33, P721, DOI 10.1042/BST0330721; Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001; Perry SW, 2005, J IMMUNOL, V174, P4333, DOI 10.4049/jimmunol.174.7.4333; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Ricci JE, 2003, CELL DEATH DIFFER, V10, P488, DOI 10.1038/sj.cdd.4401225; Sanchez-Alcazar JA, 2000, CELL DEATH DIFFER, V7, P1090, DOI 10.1038/sj.cdd.4400740; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schleiff E, 2000, J CELL SCI, V113, P2267; Sommer SL, 2006, J APPL PHYSIOL, V100, P707, DOI 10.1152/japplphysiol.00306.2005; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699; Zhang YJ, 2003, ONCOGENE, V22, P6845, DOI 10.1038/sj.onc.1206707	41	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15304	15311		10.1074/jbc.M600054200	http://dx.doi.org/10.1074/jbc.M600054200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16567805	hybrid			2022-12-25	WOS:000237922200034
J	Citri, A; Harari, D; Shohat, G; Ramakrishnan, P; Gan, J; Lavi, S; Eisenstein, M; Kimchi, A; Wallach, D; Pietrokovski, S; Yarden, Y				Citri, Ami; Harari, Daniel; Shohat, Galit; Ramakrishnan, Parameswaran; Gan, Judith; Lavi, Sara; Eisenstein, Miriam; Kimchi, Adi; Wallach, David; Pietrokovski, Shmuel; Yarden, Yosef			Hsp90 recognizes a common surface on client kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7-AMINO ACID SEQUENCE; HIGH-AFFINITY BINDING; SHOCK-PROTEIN 90; SIGNAL-TRANSDUCTION; MOLECULAR CHAPERONES; TYROSINE KINASES; AMINO-TERMINUS; CO-CHAPERONE; DEGRADATION; DOMAIN	Hsp90 is a highly abundant chaperone whose clientele includes hundreds of cellular proteins, many of which are central players in key signal transduction pathways and the majority of which are protein kinases. In light of the variety of Hsp90 clientele, the mechanism of selectivity of the chaperone toward its client proteins is a major open question. Focusing on human kinases, we have demonstrated that the chaperone recognizes a common surface in the amino-terminal lobe of kinases from diverse families, including two newly identified clients, NF kappa B-inducing kinase and death-associated protein kinase, and the oncoprotein HER2/ErbB-2. Surface electrostatics determine the interaction with the Hsp90 chaperone complex such that introduction of a negative charge within this region disrupts recognition. Compiling information on the Hsp90 dependence of 105 protein kinases, including 16 kinases whose relationship to Hsp90 is first examined in this study, reveals that surface features, rather than a contiguous amino acid sequence, define the capacity of the Hsp90 chaperone machine to recognize client kinases. Analyzing Hsp90 regulation of two major signaling cascades, the mitogen-activated protein kinase and phosphatidylinositol 3-kinase, leads us to propose that the selectivity of the chaperone to specific kinases is functional, namely that Hsp90 controls kinases that function as hubs integrating multiple inputs. These lessons bear significance to pharmacological attempts to target the chaperone in human pathologies, such as cancer.	Weizmann Inst Sci, Dept Biol Regulat, IL-97100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-97100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-97100 Rehovot, Israel; Ben Gurion Univ Negev, Bioinformat Support Unit, IL-84105 Beer Sheva, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Ben Gurion University	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, IL-97100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Citri, Ami/R-8973-2019; YARDEN, YOSEF/K-1467-2012; Ramakrishnan, Parameswaran/AAB-9083-2020	Citri, Ami/0000-0002-9914-0278; Ramakrishnan, Parameswaran/0000-0002-1314-827X; Shohat-Ophir, Galit/0000-0003-1246-1827; Pietrokovski, Shmuel/0000-0001-8573-5863	NCI NIH HHS [CA72981] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; An WG, 2000, CELL GROWTH DIFFER, V11, P355; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Brugge J S, 1983, Prog Clin Biol Res, V119, P135; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Citri A, 2004, EMBO REP, V5, P1165, DOI 10.1038/sj.embor.7400300; Citri A, 2004, CELL CYCLE, V3, P51; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; GILSON MK, 1987, NATURE, V330, P84, DOI 10.1038/330084a0; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; HENIKOFF S, 1995, GENE, V163, P17; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; Kaul S, 2002, J BIOL CHEM, V277, P36223, DOI 10.1074/jbc.M206748200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matsuda S, 1999, J BIOL CHEM, V274, P34515, DOI 10.1074/jbc.274.49.34515; Millson SH, 2005, EUKARYOT CELL, V4, P849, DOI 10.1128/EC.4.5.849-860.2005; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Nollen EAA, 2002, J CELL SCI, V115, P2809; Nony P, 2003, ONCOGENE, V22, P9165, DOI 10.1038/sj.onc.1207179; Pietrokovski S, 1996, NUCLEIC ACIDS RES, V24, P3836, DOI 10.1093/nar/24.19.3836; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prince T, 2004, J BIOL CHEM, V279, P39975, DOI 10.1074/jbc.M406882200; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Riggs DL, 2004, CRIT REV BIOCHEM MOL, V39, P279, DOI 10.1080/10409230490892513; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Scroggins BT, 2003, BIOCHEMISTRY-US, V42, P12550, DOI 10.1021/bi035001t; Shao JY, 2003, J BIOL CHEM, V278, P38117, DOI 10.1074/jbc.C300330200; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Smith DF, 1998, BIOL CHEM, V379, P283; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Tikhomirov O, 2003, CANCER RES, V63, P39; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; Xu WP, 2005, NAT STRUCT MOL BIOL, V12, P120, DOI 10.1038/nsmb885; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yun BG, 2005, EXP CELL RES, V307, P212, DOI 10.1016/j.yexcr.2005.03.003; Zhang H, 2004, J BIOL CHEM, V279, P19457, DOI 10.1074/jbc.M311377200; Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9; Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024; Zheng FF, 2000, CANCER RES, V60, P2090	53	178	185	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14361	14369		10.1074/jbc.M512613200	http://dx.doi.org/10.1074/jbc.M512613200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16551624	hybrid			2022-12-25	WOS:000237512300062
J	Danielsson, R; Suorsa, M; Paakkarinen, V; Albertsson, PA; Styring, S; Aro, EM; Mamedov, F				Danielsson, Ravi; Suorsa, Marjaana; Paakkarinen, Virpi; Albertsson, Per-Ake; Styring, Stenbjorn; Aro, Eva-Mari; Mamedov, Fikret			Dimeric and monomeric organization of photosystem II - Distribution of five distinct complexes in the different domains of the thylakoid membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; PROTEIN COMPLEXES; PROTEOMIC APPROACH; SUPRAMOLECULAR ORGANIZATION; PHOTOSYNTHETIC OXIDATION; FUNCTIONAL-PROPERTIES; CYTOCHROME B(559); CRYSTAL-STRUCTURE; REACTION CENTERS; DIFFERENT PARTS	The supramolecular organization of photosystem II (PSII) was characterized in distinct domains of the thylakoid membrane, the grana core, the grana margins, the stroma lamellae, and the so-called Y100 fraction. PSII supercomplexes, PSII core dimers, PSII core monomers, PSII core monomers lacking the CP43 subunit, and PSII reaction centers were resolved and quantified by blue native PAGE, SDS-PAGE for the second dimension, and immunoanalysis of the D1 protein. Dimeric PSII (PSII supercomplexes and PSII core dimers) dominate in the core part of the thylakoid granum, whereas the monomeric PSII prevails in the stroma lamellae. Considerable amounts of PSII monomers lacking the CP43 protein and PSII reaction centers (D1-D2-cytochrome b(559) complex) were found in the stroma lamellae. Our quantitative picture of the supramolecular composition of PSII, which is totally different between different domains of the thylakoid membrane, is discussed with respect to the function of PSII in each fraction. Steady state electron transfer, flash-induced fluorescence decay, and EPR analysis revealed that nearly all of the dimeric forms represent oxygen-evolving PSII centers. PSII core monomers were heterogeneous, and a large fraction did not evolve oxygen. PSII monomers without the CP43 protein and PSII reaction centers showed no oxygen-evolving activity.	Uppsala Univ, Dept Photochem & Mol Sci, S-75236 Uppsala, Sweden; Lund Univ, Dept Biochem, Ctr Chem & Chem Engn, S-22100 Lund, Sweden; Univ Turku, Dept Biol, FI-20014 Turku, Finland	Uppsala University; Lund University; University of Turku	Mamedov, F (corresponding author), Uppsala Univ, Dept Photochem & Mol Sci, S-75236 Uppsala, Sweden.	fikret.mamedov@fotomol.uu.se	Aro, Eva-Mari/Q-8664-2017; Mamedov, Fikret/A-1761-2016; Styring, Stenbjörn/L-8414-2016	Aro, Eva-Mari/0000-0002-2922-1435; Mamedov, Fikret/0000-0002-6218-3039; Styring, Stenbjörn/0000-0002-2803-9244; Suorsa, Marjaana/0000-0002-3821-0607				Albertsson P-A, 2000, RECENT RES DEV BIOEN, V1, P143; ALBERTSSON PA, 1994, METHOD ENZYMOL, V228, P469; Albertsson PA, 1995, PHOTOSYNTH RES, V46, P141, DOI 10.1007/BF00020424; Albertsson PA, 2001, TRENDS PLANT SCI, V6, P349, DOI 10.1016/S1360-1385(01)02021-0; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; ANDERSSON B, 1982, FEBS LETT, V146, P13, DOI 10.1016/0014-5793(82)80695-9; Andersson B, 2001, ADV PHOTOSYNTH, V11, P377; ANDREASSON E, 1988, BIOCHIM BIOPHYS ACTA, V936, P339, DOI 10.1016/0005-2728(88)90010-2; [Anonymous], 2002, PHOTOSYNTHETICA; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Aro EM, 2005, J EXP BOT, V56, P347, DOI 10.1093/jxb/eri041; Barber J, 2002, CURR OPIN STRUC BIOL, V12, P523, DOI 10.1016/S0959-440X(02)00357-3; BARBER J, 1998, PHYSIOL PLANTARUM, V100, P817; BASSI R, 1995, EUR J BIOCHEM, V233, P709, DOI 10.1111/j.1432-1033.1995.709_3.x; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Bianchetti M, 1998, J BIOL CHEM, V273, P16128, DOI 10.1074/jbc.273.26.16128; Boekema EJ, 2000, BIOCHEMISTRY-US, V39, P12907, DOI 10.1021/bi0009183; Boekema EJ, 2000, J MOL BIOL, V301, P1123, DOI 10.1006/jmbi.2000.4037; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; Boussac A, 2000, BBA-BIOENERGETICS, V1457, P145, DOI 10.1016/S0005-2728(00)00073-6; Boussac A, 1996, BIOCHEMISTRY-US, V35, P6984, DOI 10.1021/bi960636w; BRICKER TM, 1996, OXYGENIC PHOTOSYNTHE, P113; BRITT DR, 1996, OXYGENIC PHOTOSYNTHE, P137; CASEY JL, 1984, BIOCHIM BIOPHYS ACTA, V767, P21, DOI 10.1016/0005-2728(84)90075-6; Ciambella C, 2005, PROTEOMICS, V5, P746, DOI 10.1002/pmic.200401129; Danielsson R, 2004, BBA-BIOENERGETICS, V1608, P53, DOI 10.1016/j.bbabio.2003.10.005; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; Dekker JP, 2002, PHOTOSYNTH RES, V72, P203, DOI 10.1023/A:1016188818591; DEPAULA JC, 1985, BIOCHEMISTRY-US, V24, P8114, DOI 10.1021/bi00348a042; Diner BA, 2002, ANNU REV PLANT BIOL, V53, P551, DOI 10.1146/annurev.arplant.53.100301.135238; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Goussias C, 2002, PHILOS T R SOC B, V357, P1369, DOI 10.1098/rstb.2002.1134; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; HARRISON MA, 1992, PLANT CELL PHYSIOL, V33, P627; Heinemeyer J, 2004, PHYTOCHEMISTRY, V65, P1683, DOI 10.1016/j.phytochem.2004.04.022; HENRYSSON T, 1990, PHOTOSYNTH RES, V25, P107, DOI 10.1007/BF00035459; Herranen M, 2004, PLANT PHYSIOL, V134, P470, DOI 10.1104/pp.103.032326; Jahns P, 1997, BBA-BIOENERGETICS, V1318, P1, DOI 10.1016/S0005-2728(96)00133-8; KAMINSKAYA O, 1999, BIOCHEMISTRY-US, V38, P10578; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kettunen R, 1996, PLANT PHYSIOL, V111, P1183, DOI 10.1104/pp.111.4.1183; Kim EH, 2005, BBA-BIOENERGETICS, V1708, P187, DOI 10.1016/j.bbabio.2005.03.011; Kirchhoff H, 2004, BIOCHEMISTRY-US, V43, P9204, DOI 10.1021/bi0494626; Kruse O, 2000, J BIOL CHEM, V275, P6509, DOI 10.1074/jbc.275.9.6509; Kruse O, 1997, FEBS LETT, V408, P276, DOI 10.1016/S0014-5793(97)00439-0; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavergne J, 1996, OXYGENIC PHOTOSYNTHE, P265; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; Magnuson A, 1999, BBA-BIOENERGETICS, V1411, P180, DOI 10.1016/S0005-2728(99)00044-4; Mamedov F, 2000, BIOCHEMISTRY-US, V39, P10478, DOI 10.1021/bi992877k; Mamedov F, 2003, PHYSIOL PLANTARUM, V119, P328, DOI 10.1034/j.1399-3054.2003.00187.x; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; Mustardy L, 2003, TRENDS PLANT SCI, V8, P117, DOI 10.1016/S1360-1385(03)00015-3; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NUGENT JHA, 1989, FEBS LETT, V255, P53, DOI 10.1016/0014-5793(89)81059-2; PETER GF, 1991, J BIOL CHEM, V266, P16745; Rexroth S, 2003, ELECTROPHORESIS, V24, P2814, DOI 10.1002/elps.200305543; Rokka A, 2005, BIOCHEM J, V388, P159, DOI 10.1042/BJ20042098; Rova M, 1998, BIOCHEMISTRY-US, V37, P11039, DOI 10.1021/bi980381h; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SHIPTON CA, 1991, P NATL ACAD SCI USA, V88, P6691, DOI 10.1073/pnas.88.15.6691; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; Suorsa M, 2004, EUR J BIOCHEM, V271, P96, DOI 10.1046/j.1432-1033.2003.03906.x; SVENSSON P, 1991, BIOCHIM BIOPHYS ACTA, V1060, P45, DOI 10.1016/S0005-2728(05)80117-3; VANMIEGHEM FJE, 1991, BIOCHIM BIOPHYS ACTA, V1058, P379, DOI 10.1016/S0005-2728(05)80134-3; WOLLENBERGER L, 1994, BBA-BIOENERGETICS, V1184, P93, DOI 10.1016/0005-2728(94)90158-9; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122; ZIMMERMANN JL, 1986, BIOCHEMISTRY-US, V25, P4609, DOI 10.1021/bi00364a023; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	73	108	112	2	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14241	14249		10.1074/jbc.M600634200	http://dx.doi.org/10.1074/jbc.M600634200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16537530	hybrid			2022-12-25	WOS:000237512300048
J	Soulat, D; Jault, JM; Duclos, B; Geourjon, C; Cozzone, AJ; Grangeasse, C				Soulat, Didier; Jault, Jean-Michel; Duclos, Bertrand; Geourjon, Christophe; Cozzone, Alain J.; Grangeasse, Christophe			Staphylococcus aureus operates protein-tyrosine phosphorylation through a specific mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM ACINETOBACTER-JOHNSONII; GROUP-1 CAPSULAR POLYSACCHARIDES; DIVISION SITE SELECTION; ESCHERICHIA-COLI; STREPTOCOCCUS-PNEUMONIAE; MIND ATPASE; NUCLEOTIDE-BINDING; KINASE; WZC; BIOSYNTHESIS	Protein phosphorylation on tyrosine has been originally characterized in animal systems and has been shown to be involved in several fundamental processes including signal transduction, growth control, and malignancy. It has been later demonstrated to occur also in a number of bacteria, and recent data suggest that it may participate in the control of bacterial pathogenicity. In this work, we provide evidence that the Gram-positive human pathogen Staphylococcus aureus harbors a protein-tyrosine kinase activity. This activity is borne by a protein, termed Cap5B2, whose phosphorylating capacity is expressed only in the presence of a stimulatory protein, either Cap5A1 or Cap5A2, that enhances its affinity for the phosphoryl donor ATP. In fact, the last 27/29 amino acids of the C-terminal domain of either polypeptide are sufficient for stimulating Cap5B2 activity. The stimulation of Cap5B2 by Cap5A1 involves essentially three amino acid residues in a helix of Cap5A1 (Asp202, Glu203, and Asp205) and three residues in a helix (helix 7) of Cap5B2 (Glu190, Lys192, and Lys193), thus suggesting helix-helix interaction between these two proteins. This type of helix-helix interaction resembles the interaction required for the activation of MinD ATPase by MinE protein in the process of septum-site determination, MinD sharing sequence similarity with Cap5B2. Such activation mechanism is described here in a Gram-positive bacterial tyrosine kinase, and differs from the activation mechanism previously proposed for Gram- negative bacteria. Therefore, it appears that S. aureus, and possibly other Gram- positive bacteria, utilizes a specific molecular mechanism for triggering protein-tyrosine kinase activity.	Univ Lyon, CNRS, Inst Biol & Chem Prot, F-69367 Lyon 07, France; Univ Grenoble 1, CNRS, CEA, Lab Mol & Cellular Biophys, F-38054 Grenoble, France; Univ Vienna, Max F Perutz Labs, Inst Microbiol & Immunobiol, A-1030 Vienna, Austria	Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Grangeasse, C (corresponding author), Univ Lyon, CNRS, Inst Biol & Chem Prot, 7 Passage Vercors, F-69367 Lyon 07, France.	c.grangeasse@ibcp.fr	jault, jean-michel/G-2086-2012	jault, jean-michel/0000-0003-1743-2777; Grangeasse, Christophe/0000-0002-5484-4589; Soulat, Didier/0000-0002-3688-5846				Bender MH, 2003, J BACTERIOL, V185, P6057, DOI 10.1128/JB.185.20.6057-6066.2003; Bilwes AM, 2001, NAT STRUCT BIOL, V8, P353, DOI 10.1038/86243; Cozzone AJ, 2004, ARCH MICROBIOL, V181, P171, DOI 10.1007/s00203-003-0640-6; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Doublet P, 1999, FEBS LETT, V445, P137, DOI 10.1016/S0014-5793(99)00111-8; Geourjon C, 2001, PROTEIN SCI, V10, P788, DOI 10.1110/ps.30001; GEOURJON C, 1995, J MOL GRAPHICS, V13, P199; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grangeasse C, 2002, J BIOL CHEM, V277, P7127, DOI 10.1074/jbc.M110880200; Grangeasse C, 1999, IUBMB LIFE, V48, P339; Guermeur Y, 1999, BIOINFORMATICS, V15, P413, DOI 10.1093/bioinformatics/15.5.413; Hayashi I, 2001, EMBO J, V20, P1819, DOI 10.1093/emboj/20.8.1819; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ilan O, 1999, EMBO J, V18, P3241, DOI 10.1093/emboj/18.12.3241; Jault JM, 2000, J BIOL CHEM, V275, P1773, DOI 10.1074/jbc.275.3.1773; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Ma LY, 2004, MOL MICROBIOL, V54, P99, DOI 10.1111/j.1365-2958.2004.04265.x; Ma LY, 2003, J BACTERIOL, V185, P4948, DOI 10.1128/JB.185.16.4948-4955.2003; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; Mijakovic I, 2003, EMBO J, V22, P4709, DOI 10.1093/emboj/cdg458; Molle V, 2003, BIOCHEMISTRY-US, V42, P15300, DOI 10.1021/bi035150b; Morona JK, 2000, MOL MICROBIOL, V35, P1431, DOI 10.1046/j.1365-2958.2000.01808.x; Morona JK, 2003, J BACTERIOL, V185, P3009, DOI 10.1128/JB.185.10.3009-3019.2003; Nakar D, 2003, J BACTERIOL, V185, P1001, DOI 10.1128/JB.185.3.1001-1009.2003; Niemeyer D, 2001, J BACTERIOL, V183, P5163, DOI 10.1128/JB.183.17.5163-5170.2001; Oudot C, 1999, EUR J BIOCHEM, V262, P224, DOI 10.1046/j.1432-1327.1999.00395.x; Paiment A, 2002, J BACTERIOL, V184, P6437, DOI 10.1128/JB.184.23.6437-6447.2002; Vincent C, 1999, J BACTERIOL, V181, P3472, DOI 10.1128/JB.181.11.3472-3477.1999; Vincent C, 2000, J MOL BIOL, V304, P311, DOI 10.1006/jmbi.2000.4217; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Whitfield C, 2003, CARBOHYD RES, V338, P2491, DOI 10.1016/j.carres.2003.08.010; Wugeditsch T, 2001, J BIOL CHEM, V276, P2361, DOI 10.1074/jbc.M009092200; Zhou HJ, 2005, J BACTERIOL, V187, P629, DOI 10.1128/JB.187.2.629-638.2005	33	50	54	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14048	14056		10.1074/jbc.M513600200	http://dx.doi.org/10.1074/jbc.M513600200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16565080	hybrid			2022-12-25	WOS:000237512300027
J	Rishi, AK; Zhang, LY; Yu, YJ; Jiang, Y; Nautiyal, J; Wali, A; Fontana, JA; Levi, E; Majumdar, APN				Rishi, AK; Zhang, LY; Yu, YJ; Jiang, Y; Nautiyal, J; Wali, A; Fontana, JA; Levi, E; Majumdar, APN			Cell cycle- and apoptosis-regulatory protein-1 is involved in apoptosis signaling by epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; HUMAN BREAST-CANCER; TYROSINE KINASE; TRANSDUCTION PATHWAYS; RETINOID CD437; STRESS; ACTIVATION; INHIBITORS; MEDIATORS; NETWORK	CARP-1, a novel apoptosis inducer, regulates apoptosis signaling by diverse agents, including adriamycin and growth factors. Epidermal growth factor receptor ( EGFR)-related protein ( ERRP), a pan-ErbB inhibitor, inhibits EGFR and stimulates apoptosis. Treatments of cells with ERRP or Iressa ( an EGFR tyrosine kinase inhibitor) results in elevated CARP-1 levels, whereas antisense-dependent depletion of CARP-1 causes inhibition of apoptosis by ERRP. CARP-1 is a tyrosine-phosphorylated protein, and ERRP treatments cause elevated tyrosine phosphorylation of CARP-1. CARP-1 contains multiple, nonoverlapping apoptosis-inducing subdomains; one such subdomain is present within amino acids 1 - 198. Wild-type or CARP-1-( 1 - 198) proteins that have substitution of tyrosine 192 to phenylalanine abrogate apoptosis by ERRP. In addition, apoptosis mediated by wild type or CARP-1-( 1 198), and not CARP-1-( 1 - 198(Y192F)), results in activation of caspase-9 and increased phosphorylation of p38 MAPK. However, the expression of dominant-negative forms of p38 MAPK activators MKK3 or MKK6 proteins inhibits apoptosis induced by both the full-length and truncated ( amino acids 1 - 198) proteins. Together, data demonstrate that tyrosine 192 of CARP-1 is a target of apoptosis signaling, and CARP-1, in turn, promotes apoptosis by activating p38 MAPK and caspase-9.	VA Med Ctr, Detroit, MI 48201 USA; Wayne State Univ, Dept Internal Med, Detroit, MI 48201 USA; Wayne State Univ, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Rishi, AK (corresponding author), VA Med Ctr, Rm B4334,4646 John R, Detroit, MI 48201 USA.	Rishia@Karmanos.org		Fontana, Joseph/0000-0003-3829-3358; Levi, Edi/0000-0003-1809-2866	NCI NIH HHS [R01 CA109370] Funding Source: Medline; NIA NIH HHS [R01 AG 14343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Casalini P, 2004, J CELL PHYSIOL, V200, P343, DOI 10.1002/jcp.20007; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KRISCHBAUM MH, 2000, J CELL BIOCH S, V34, P52; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Liang JY, 1999, PROSTATE, V38, P228; Lohrisch C, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.29713; Marciniak DJ, 2004, MOL CANCER THER, V3, P1615; Marciniak DJ, 2003, GASTROENTEROLOGY, V124, P1337, DOI 10.1016/S0016-5085(03)00264-6; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rae JM, 2004, BREAST CANCER RES TR, V83, P99, DOI 10.1023/B:BREA.0000010702.10130.29; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; REED JC, 2004, SCI STKE 2004, P9; Rishi AK, 2003, J BIOL CHEM, V278, P33422, DOI 10.1074/jbc.M303173200; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; SHAO ZM, 1995, ONCOGENE, V11, P493; Tikhomirov O, 2004, J BIOL CHEM, V279, P12988, DOI 10.1074/jbc.M311655200; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Xu H, 2005, MOL CANCER THER, V4, P435; Yu YJ, 2001, AM J PHYSIOL-CELL PH, V280, pC1083, DOI 10.1152/ajpcell.2001.280.5.C1083	33	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13188	13198		10.1074/jbc.M512279200	http://dx.doi.org/10.1074/jbc.M512279200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543231	hybrid			2022-12-25	WOS:000237336600024
J	Begg, GE; Holman, SR; Stokes, PH; Matthews, JM; Graham, RM; Iismaa, SE				Begg, GE; Holman, SR; Stokes, PH; Matthews, JM; Graham, RM; Iismaa, SE			Mutation of a critical arginine in the GTP-binding site of transglutaminase 2 disinhibits intracellular cross-linking activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE; PHOSPHOLIPASE C-DELTA-1; STRUCTURAL BASIS; CORE DOMAIN; PROTEIN; RECEPTOR; CALCIUM; G(H); G(H)/TRANSGLUTAMINASE; IDENTIFICATION	Transglutaminase type 2 (TG2; also known as Gh) is a multifunctional protein involved in diverse cellular processes. It has two well characterized enzyme activities: receptor-stimulated signaling that requires GTP binding and calcium-activated transamidation or cross-linking that is inhibited by GTP. In addition to the GDP binding residues identified from the human TG2 crystal structure (Liu, S., Cerione, R. A., and Clardy, J. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 2743 - 2747), we have previously implicated Ser(171) in GTP binding, as binding is lost with glutamate substitution (Iismaa, S. E., Wu, M.-J., Nanda, N., Church, W. B., and Graham, R. M. ( 2000) J. Biol. Chem. 275, 18259 - 18265). Here, we have shown that alanine substitution of homologous residues in rat TG2 ( Phe(174) in the core domain or Arg(476), Arg(478), or Arg(579) in barrel 1) does not affect TG activity but reduces or abolishes GTP binding and GTP gamma S inhibition of TG activity in vitro, indicating that these residues are important in GTP binding. Alanine substitution of Ser(171) does not impair GTP binding, indicating this residue does not interact directly with GTP. Arg(579) is particularly important for GTP binding, as isothermal titration calorimetry demonstrated a 100-fold reduction in GTP binding affinity by the R579A mutant. Unlike wild-type TG2 or its S171E or F174A mutants, which are sensitive to both trypsin and mu-calpain digestion, R579A is inherently more resistant to mu-calpain, but not trypsin, digestion, indicating reduced accessibility and/or flexibility of this mutant in the region of the calpain cleavage site(s). Basal TG activity of intact R579A stable SH-SY5Y neuroblastoma cell transfectants was slightly increased relative to wild-type transfectants and, in contrast to the TG activity of the latter, was further stimulated by muscarinic receptor-activated calcium mobilization. Thus, loss of GTP binding sensitizes TG2 to intracellular calcium concentrations. These findings are consistent with the notion that intracellularly, under physiological conditions, TG2 is maintained largely as a latent enzyme, its calcium-activated cross-linking activity being suppressed allosterically by guanine nucleotide binding.	Victor Chang Cardiac Res Inst, Mol Cardiol Program, Darlinghurst, NSW 2010, Australia; Univ Sydney, Sydney, NSW 2006, Australia	Victor Chang Cardiac Research Institute; University of Sydney	Iismaa, SE (corresponding author), Victor Chang Cardiac Res Inst, Mol Cardiol Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	s.iismaa@victorchang.unsw.edu.au	Matthews, Jacqueline/A-7322-2013; Iismaa, Siiri/C-9300-2013; Iismaa, Siiri/A-9924-2008	Iismaa, Siiri/0000-0003-2409-7356; Matthews, Jacqueline/0000-0001-8518-3472				Ahvazi B, 2004, J BIOL CHEM, V279, P7180, DOI 10.1074/jbc.M312310200; Akimov SS, 2001, J CELL SCI, V114, P2989; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BERGAMINI CM, 1993, BIOCHEM J, V291, P37, DOI 10.1042/bj2910037; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Candi E, 2004, BIOCHEM J, V381, P313, DOI 10.1042/BJ20031474; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Dupuis M, 2004, J BIOL CHEM, V279, P19257, DOI 10.1074/jbc.M314299200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hartigan JA, 1999, J BIOL CHEM, V274, P21395, DOI 10.1074/jbc.274.30.21395; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; Iismaa SE, 2000, J BIOL CHEM, V275, P18259, DOI 10.1074/jbc.M000583200; Iismaa SE, 2003, P NATL ACAD SCI USA, V100, P12636, DOI 10.1073/pnas.1635052100; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; IM MJ, 1990, J BIOL CHEM, V265, P18952; Jeon JH, 2002, BIOCHEM BIOPH RES CO, V294, P818, DOI 10.1016/S0006-291X(02)00582-X; Lai TS, 1997, J BIOL CHEM, V272, P16295, DOI 10.1074/jbc.272.26.16295; Lai TS, 2001, BIOCHEMISTRY-US, V40, P4904, DOI 10.1021/bi002321t; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mishra S, 2006, BIOCHEM BIOPH RES CO, V339, P726, DOI 10.1016/j.bbrc.2005.11.071; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; MISHRA S, 2006, J BIOL CHEM; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; Murthy SNP, 2002, P NATL ACAD SCI USA, V99, P2738, DOI 10.1073/pnas.052715799; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Park ES, 1998, BIOCHEM J, V331, P283, DOI 10.1042/bj3310283; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200; Vezza R, 1999, J BIOL CHEM, V274, P12774, DOI 10.1074/jbc.274.18.12774; Zhang JW, 1999, BIOCHEM J, V343, P541, DOI 10.1042/0264-6021:3430541; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; Zhang JW, 1998, J NEUROCHEM, V71, P240; Zhang ZB, 2003, CIRC RES, V92, P1153, DOI 10.1161/01.RES.0000071749.22027.45	38	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12603	12609		10.1074/jbc.M600146200	http://dx.doi.org/10.1074/jbc.M600146200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16522628	hybrid			2022-12-25	WOS:000237134700050
J	Ratner, AJ; Hippe, KR; Aguilar, JL; Bender, MH; Nelson, AL; Weiser, JN				Ratner, AJ; Hippe, KR; Aguilar, JL; Bender, MH; Nelson, AL; Weiser, JN			Epithelial cells are sensitive detectors of bacterial pore-forming toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; STREPTOCOCCUS-PNEUMONIAE; HUMAN NEUTROPHILS; IN-VITRO; SIGNALING PATHWAYS; ANTHROLYSIN-O; MURINE MODEL; PNEUMOLYSIN; INFECTION	Epithelial cells act as an interface between human mucosal surfaces and the surrounding environment. As a result, they are responsible for the initiation of local immune responses, which may be crucial for prevention of invasive infection. Here we show that epithelial cells detect the presence of bacterial pore-forming toxins ( including pneumolysin from Streptococcus pneumoniae, alpha-hemolysin from Staphylococcus aureus, streptolysin O from Streptococcus pyogenes, and anthrolysin O from Bacillus anthracis) at nanomolar concentrations, far below those required to cause cytolysis. Phosphorylation of p38 MAPK appears to be a conserved response of epithelial cells to subcytolytic concentrations of bacterial pore-forming toxins, and this activity is inhibited by the addition of high molecular weight osmolytes to the extracellular medium. By sensing osmotic stress caused by the insertion of a sublethal number of pores into their membranes, epithelial cells may act as an early warning system to commence an immune response, while the local density of toxin-producing bacteria remains low. Osmosensing may thus represent a novel innate immune response to a common bacterial virulence strategy.	Univ Penn, Dept Microbiol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Ratner, AJ (corresponding author), Univ Penn, Dept Microbiol, Sch Med, Johnson Pavil 401A, Philadelphia, PA 19104 USA.	ratner@mail.med.upenn.edu		Weiser, Jeffrey/0000-0001-7168-8090; Ratner, Adam/0000-0003-1761-794X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI065450, R21AI054647, R21AI044231, R01AI044231, R01AI038446] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI038446, R01 AI044231, AI065450, AI044231, R21 AI054647, R21 AI044231, AI054647, K08 AI065450, AI038446] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BERRY AM, 1989, INFECT IMMUN, V57, P2037, DOI 10.1128/IAI.57.7.2037-2042.1989; Braun JS, 2002, J CLIN INVEST, V109, P19; Burns D., 2003, BACTERIAL PROTEIN TO; Chung WO, 2004, INFECT IMMUN, V72, P352, DOI 10.1128/IAI.72.1.352-358.2004; Cockeran R, 2002, J INFECT DIS, V186, P562, DOI 10.1086/341563; Cockeran R, 2001, INFECT IMMUN, V69, P3494, DOI 10.1128/IAI.69.5.3494-3496.2001; Cockeran R, 2001, J INFECT DIS, V183, P604, DOI 10.1086/318536; Fickl H, 2005, CLIN EXP IMMUNOL, V140, P274, DOI 10.1111/j.1365-2249.2005.02757.x; Huffman DL, 2004, P NATL ACAD SCI USA, V101, P10995, DOI 10.1073/pnas.0404073101; Kernodle DS, 1997, INFECT IMMUN, V65, P179, DOI 10.1128/IAI.65.1.179-184.1997; Korchev YE, 1998, BIOCHEM J, V329, P571; KORCHEV YE, 1992, J MEMBRANE BIOL, V127, P195; Limbago B, 2000, INFECT IMMUN, V68, P6384, DOI 10.1128/IAI.68.11.6384-6390.2000; Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100; Maloney JA, 1999, AM J PHYSIOL-CELL PH, V276, pC221, DOI 10.1152/ajpcell.1999.276.1.C221; Monier RM, 2002, J INFECT DIS, V185, P921, DOI 10.1086/339483; Nonnenmacher C, 2003, INFECT IMMUN, V71, P850, DOI 10.1128/IAI.71.2.850-856.2003; Okahashi N, 2003, INFECT IMMUN, V71, P948, DOI 10.1128/IAI.71.2.948-955.2003; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Park JM, 2004, J EXP MED, V200, P1647, DOI 10.1084/jem.20041215; Ratner AJ, 2005, P NATL ACAD SCI USA, V102, P3429, DOI 10.1073/pnas.0500599102; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; Schmeck B, 2004, J BIOL CHEM, V279, P53241, DOI 10.1074/jbc.M313702200; Shannon JG, 2003, INFECT IMMUN, V71, P3183, DOI 10.1128/IAI.71.6.3183-3189.2003; Srivastava A, 2005, INFECT IMMUN, V73, P6479, DOI 10.1128/IAI.73.10.6479-6487.2005; Stringaris AK, 2002, NEUROBIOL DIS, V11, P355, DOI 10.1006/nbdi.2002.0561; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; van den Blink B, 2001, J IMMUNOL, V166, P582, DOI 10.4049/jimmunol.166.1.582; van Rossum AMC, 2005, INFECT IMMUN, V73, P7718, DOI 10.1128/IAI.73.11.7718-7726.2005; Walev I, 2001, FASEB J, V15, P237, DOI 10.1096/fj.01-0572fje	32	140	142	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12994	12998		10.1074/jbc.M511431200	http://dx.doi.org/10.1074/jbc.M511431200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520379	Green Accepted, hybrid			2022-12-25	WOS:000237134700095
J	Yin, MB; Li, ZR; Toth, K; Cao, S; Durrani, FA; Hapke, G; Bhattacharya, A; Azrak, RG; Frank, C; Rustum, YM				Yin, MB; Li, ZR; Toth, K; Cao, S; Durrani, FA; Hapke, G; Bhattacharya, A; Azrak, RG; Frank, C; Rustum, YM			Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1 alpha expression, resulting in reduced angiogenesis	ONCOGENE			English	Article						MSC; irinotecan; COX-2; iNOS; HIF-1 alpha; angiogenesis	NF-KAPPA-B; SQUAMOUS-CELL CARCINOMA; COLON-CANCER CELLS; GENE-EXPRESSION; COLORECTAL-CANCER; ENDOTHELIAL-CELLS; MAMMARY-CANCER; NECK-CANCER; MOUSE SKIN; HUMAN HEAD	Until recently, the use of Se-methylselenocysteine ( MSC) as selective modulator of the antitumor activity and selectivity of anticancer drugs including irinotecan, a topoisomerase I poison, had not been evaluated. Therapeutic synergy between MSC and irinotecan was demonstrated by our laboratory in mice bearing human squamous cell carcinoma of the head and neck tumors. In FaDu xenografts, a poorly differentiated tumor-expressing mutant p53, the cure rate was increased from 30% with irinotecan alone to 100% with the combination of irinotecan and MSC. Cellular exposure to cytotoxic concentration of SN-38, the active metabolite of irinotecan (0.1 mu M) alone and in combination with noncytotoxic concentration of MSC (10 mu M) did not result in additional enhancement of chk2 phosphorylation and downregulation of specific DNA replication-associated proteins, cdc6, MCM2, cdc25A, nor increase in PARP cleavage, caspase activation and the 30-300 kb DNA fragmentation induced by SN-38 treatment. MSC did not alter significantly markers associated with apoptosis, nor potentiate irinotecan-induced apoptosis. These results indicate that apoptosis is unlikely to be one of the main mechanism associated with the observed in vivo therapeutic synergy. In contrast, significant downregulation of cyclooxygenase-2 (COX-2) expression and activity was observed in the cells exposed to SN-38 in combination with MSC compared to SN-38 alone. Moreover, the inhibition of PGE(2) production was also observed in the cells treated with the combination as compared with SN-38 alone. Analysis of tumor tissues at 24 h after treatment with synergistic modality of irinotecan and MSC revealed significant downregulation of COX-2, inducible nitric oxide synthase (iNOS) and hypoxia-induced factor-1 alpha expression (HIF 1 alpha). Moreover, decreased micro-vessel density was observed after irinotecan treatment with the addition of MSC. These results suggest that observed therapeutic synergy correlates with the inhibition of neoangiogenesis through the downregulation of COX-2, iNOS and HIF-1 alpha expression.	Roswell Pk Canc Inst, Dept Canc Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Rustum, YM (corresponding author), Roswell Pk Canc Inst, Dept Canc Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	youcef.rustum@roswellpark.org			NCI NIH HHS [CA16056, CA65761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA065761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn KS, 2005, LIFE SCI, V76, P2315, DOI 10.1016/j.lfs.2004.10.042; Apostolou S, 2004, ONCOGENE, V23, P5032, DOI 10.1038/sj.onc.1207683; Azrak RG, 2004, CLIN CANCER RES, V10, P1121, DOI 10.1158/1078-0432.CCR-0913-3; Bhattacharya A, 2004, CLIN CANCER RES, V10, P8005, DOI 10.1158/1078-0432.CCR-04-1306; Bing RJ, 2001, CLIN CANCER RES, V7, P3385; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Cao SS, 2004, CLIN CANCER RES, V10, P2561, DOI 10.1158/1078-0432.CCR-03-0268; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Chapple KS, 2002, J PATHOL, V198, P435, DOI 10.1002/path.1223; Chen YC, 2000, BIOCHEM PHARMACOL, V59, P1445, DOI 10.1016/S0006-2952(00)00255-0; Cherukuri DR, 2005, CANCER BIOL THER, V4, P175; Chun KS, 2004, CARCINOGENESIS, V25, P445, DOI 10.1093/carcin/bgh021; Cianchi F, 2004, CLIN CANCER RES, V10, P2694, DOI 10.1158/1078-0432.CCR-03-0192; Cianchi F, 2001, GASTROENTEROLOGY, V121, P1339, DOI 10.1053/gast.2001.29691; Cianchi F, 2003, AM J PATHOL, V162, P793, DOI 10.1016/S0002-9440(10)63876-X; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gallo O, 2002, BIOCHEM BIOPH RES CO, V299, P517, DOI 10.1016/S0006-291X(02)02683-9; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; GIACCIA AJ, 1991, MUTAT RES, V263, P69, DOI 10.1016/0165-7992(91)90062-9; Guo B, 2000, CLIN CANCER RES, V6, P718; Hussain SP, 2004, CANCER RES, V64, P6849, DOI 10.1158/0008-5472.CAN-04-2201; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Ip C, 1999, ANTICANCER RES, V19, P2875; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Jiang C, 1999, MOL CARCINOGEN, V26, P213, DOI 10.1002/(SICI)1098-2744(199912)26:4<213::AID-MC1>3.0.CO;2-Z; Jones MK, 1999, NAT MED, V5, P1418; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kisley LR, 2002, CANCER RES, V62, P6850; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Lu JX, 2001, NUTR CANCER, V40, P64, DOI 10.1207/S15327914NC401_12; Lu JX, 2001, ADV EXP MED BIOL, V492, P131; Masferrer JL, 2000, CANCER RES, V60, P1306; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MEDINA D, 1988, PATHOL IMMUNOPATH R, V7, P187, DOI 10.1159/000157115; Merchan JR, 2005, INT J CANCER, V113, P490, DOI 10.1002/ijc.20595; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Park SW, 2003, INT J CANCER, V107, P729, DOI 10.1002/ijc.11498; Pichiule P, 2004, J BIOL CHEM, V279, P12171, DOI 10.1074/jbc.M305146200; Rajnakova A, 2001, CANCER LETT, V172, P177, DOI 10.1016/S0304-3835(01)00645-0; Rapisarda A, 2004, CANCER RES, V64, P6845, DOI 10.1158/0008-5472.CAN-04-2116; Reid ME, 2002, CANCER EPIDEM BIOMAR, V11, P1285; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Wei DY, 2004, CANCER RES, V64, P2030, DOI 10.1158/0008-5472.CAN-03-1945; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Yin MB, 2004, MOL PHARMACOL, V66, P153, DOI 10.1124/mol.66.1.153; Zhou N, 2003, J BIOL CHEM, V278, P29532, DOI 10.1074/jbc.M301877200; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	57	32	35	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2509	2519		10.1038/sj.onc.1209073	http://dx.doi.org/10.1038/sj.onc.1209073			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16518418				2022-12-25	WOS:000236948000009
J	Roderfeld, M; Weiskirchen, R; Wagner, S; Berres, ML; Henkel, C; Grotzinger, J; Gressner, AM; Matern, S; Roeb, E				Roderfeld, Martin; Weiskirchen, Ralf; Wagner, Sandra; Berres, Marie-Luise; Henkel, Corinna; Groetzinger, Joachim; Gressner, Axel M.; Matern, Siegfried; Roeb, Elke			Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice	FASEB JOURNAL			English	Article						liver; fibrosis; MMP-9; TIMP-1; hepatic stellate cells	ESTABLISHED LIVER FIBROSIS; TISSUE INHIBITOR; GENE-EXPRESSION; STELLATE CELLS; RNA EXPRESSION; TGF-BETA; METALLOPROTEINASE-1; RAT; COLLAGENASE; APOPTOSIS	Tissue inhibitor of metalloproteinases-1 (TIMP-1) plays a crucial role in the pathogenesis of hepatic fibrosis and thus may represent an important therapeutic target in the design of anti-fibrotic strategies for chronic liver disease. We present an innovative therapy based on the assignment of inactivated enzymes acting as scavengers for TIMP-1. Hepatic fibrosis was induced in BALB/c mice by repetitive intraperitoneal CCl4 injection. The animals were treated with proteolytic inactive matrix metalloproteinase-9 mutants (E402Q, H401A, E402H/H411E) using adenovirus-mediated gene transfer. Application of these MMP-9 mutants inhibited fibrogenesis, which was indicated by decreasing portal and periportal accumulation of collagen. Total hydroxyproline of liver tissue, the morphometric stage of fibrosis as well as mRNA expression of marker proteins for hepatic fibrosis in livers of E402Q- and H401A-treated mice were significantly reduced. MMP-9 mutants suppressed transdifferentiation of hepatic stellate cells to the myofibroblast like phenotype in vitro and in vivo. Moreover, adenoviral application of the mutants MMP-9-H401A and -E402Q led to increased apoptosis of activated hepatic stellate cells, thought to be the main promoters of hepatic fibrosis. Application of MMP-9 mutants as TIMP-1 scavengers may provide a new therapeutic strategy for hepatic fibrosis.	Univ Giessen, Dept Internal Med 2, D-35385 Giessen, Germany; Univ Kiel, Inst Biochem, D-2300 Kiel, Germany; RWTH Univ Hosp Aachen, Dept Internal Med 3, Aachen, Germany; RWTH Univ Hosp Aachen, Inst Clin Chem & Pathobiochem, Aachen, Germany	Justus Liebig University Giessen; University of Kiel; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Roeb, E (corresponding author), Univ Giessen, Dept Internal Med 2, Paul Maimberg Str 5, D-35385 Giessen, Germany.	elke.roeb@innere.med.uni-giessen.de	Weiskirchen, Ralf/O-1734-2018; , Martin/AHD-5202-2022; Berres, Marie-Luise/AAN-5351-2021	Weiskirchen, Ralf/0000-0003-3888-0931; , Martin/0000-0002-3232-1277; 				Abriss B, 2003, J HEPATOL, V38, P169, DOI 10.1016/S0168-8278(02)00361-6; Arthur MJP, 1998, J GASTROEN HEPATOL, V13, pS33; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Farci P, 2004, GASTROENTEROLOGY, V126, P1740, DOI 10.1053/j.gastro.2004.03.017; Flisiak R, 2002, HEPATO-GASTROENTEROL, V49, P1369; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; FRIEDMAN SL, 2002, SCI MED, V8, P194; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Herbst H, 1997, AM J PATHOL, V150, P1647; Herrmann J, 2004, ARCH VIROL, V149, P1611, DOI 10.1007/s00705-004-0300-4; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Iimuro Y, 2003, GASTROENTEROLOGY, V124, P445, DOI 10.1053/gast.2003.50063; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Iredale JP, 2004, GASTROENTEROLOGY, V126, P1199, DOI 10.1053/j.gastro.2004.01.060; Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1002/hep.510240129; IREDALE JP, 1995, CLIN SCI, V89, P75, DOI 10.1042/cs0890075; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Issa R, 2004, GASTROENTEROLOGY, V126, P1795, DOI 10.1053/j.gastro.2004.03.009; JAMALL IS, 1981, ANAL BIOCHEM, V112, P70, DOI 10.1016/0003-2697(81)90261-X; Janoschek N, 2004, BIOCHEM BIOPH RES CO, V316, P1107, DOI 10.1016/j.bbrc.2004.02.147; Jiang W, 2005, CHINESE MED J-PEKING, V118, P192; Kasahara A, 1997, J HEPATOL, V26, P574, DOI 10.1016/S0168-8278(97)80423-0; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KORDULA T, 1992, FEBS LETT, V313, P143, DOI 10.1016/0014-5793(92)81431-K; Kuyvenhoven JP, 2003, THROMB HAEMOSTASIS, V89, P718, DOI 10.1055/s-0037-1613578; Levy C, 2004, AM J GASTROENTEROL, V99, P269, DOI 10.1111/j.1572-0241.2004.04094.x; Liu WB, 2003, WORLD J GASTROENTERO, V9, P316, DOI 10.3748/wjg.v9.i2.316; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; Morelli AE, 2000, J VIROL, V74, P9617, DOI 10.1128/JVI.74.20.9617-9628.2000; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; Nie QH, 2001, WORLD J GASTROENTERO, V7, P363; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Parsons CJ, 2004, HEPATOLOGY, V40, P1106, DOI 10.1002/hep.20425; PETERSON VS, 1995, POLITICAL EXPRESSION, V1, P1; Richards CD, 1997, J IMMUNOL, V159, P2431; Roeb E, 2000, FASEB J, V14, P1671; ROEB E, 1994, FEBS LETT, V349, P45, DOI 10.1016/0014-5793(94)00636-9; ROEB E, 1993, HEPATOLOGY, V18, P1437, DOI 10.1016/0270-9139(93)90236-G; Roeb E, 1997, J HEPATOL, V27, P535, DOI 10.1016/S0168-8278(97)80359-5; Roeb E, 2002, J BIOL CHEM, V277, P50326, DOI 10.1074/jbc.M207446200; SCHAFER S, 1987, HEPATOLOGY, V7, P680, DOI 10.1002/hep.1840070411; Schuppan D, 2001, HEPATOLOGY, V33, P483, DOI 10.1053/jhep.2001.22340; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Siller-Lopez F, 2004, GASTROENTEROLOGY, V126, P1122, DOI 10.1053/j.gastro.2003.12.045; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WALDROP FS, 1982, HISTOCHEMISTRY, V74, P487, DOI 10.1007/BF00496662; Weber LWD, 2003, CRIT REV TOXICOL, V33, P105, DOI 10.1080/713611034; WEISKIRCHEN R, 2000, BMC CELL BIOL, V1; Yoshiji H, 2000, HEPATOLOGY, V32, P1248, DOI 10.1053/jhep.2000.20521; Yoshiji H, 2002, HEPATOLOGY, V36, P850, DOI 10.1053/jhep.2002.35625; Yu Q, 2000, GENE DEV, V14, P163; Zhou XY, 2004, J BIOL CHEM, V279, P23996, DOI 10.1074/jbc.M311668200	60	115	136	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2006	20	3					444	454		10.1096/fj.05-4828com	http://dx.doi.org/10.1096/fj.05-4828com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	074LY	16507762				2022-12-25	WOS:000239815100008
J	Kondratov, RV; Shamanna, RK; Kondratova, AA; Gorbacheva, VY; Antoch, MP				Kondratov, RV; Shamanna, RK; Kondratova, AA; Gorbacheva, VY; Antoch, MP			Dual role of the CLOCK/BMAL1 circadian complex in transcriptional regulation	FASEB JOURNAL			English	Article						transcriptional activation; stress response	SUDDEN CARDIAC DEATH; CLOCK PROTEIN; SENSITIVITY; MOUSE; PATHWAYS; MAMMALS; GENES	The basic helix-loop-helix (bHLH)-PAS domain containing transcription factors CLOCK and BMAL1 are two major components of the circadian molecular oscillator. It is known that the CLOCK/BMAL1 complex positively regulates the activity of E-box containing promoters. Here we demonstrate that the CLOCK/BMAL1 complex can also suppress the activity of some promoters upon its interaction with CRYPTOCHROME ( CRY). Such a dual function of the circadian transcriptional complex provides a mechanistic explanation for the unpredicted pattern of circadian gene expression in the tissues of Bmal1 null mice. We speculate that the switch from transcriptional activation to transcriptional repression may provide a highly efficient mechanism for circadian control of gene expression. We also show that CLOCK/BMAL1 can interfere with promoter regulation by other, non-circadian, transcription factors including N-MYC and ETS, leading to attenuation or abrogation of transcription of CLOCK/BMAL1-controlled stress-induced genes. We propose that, based upon these results, both circadian repression and activation of the transcription of different target genes are required for circadian responses to various external stimuli, including genotoxic stress induced by anticancer treatment.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Kondratov, RV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	kondrar@ccf.org; antochm@ccf.org	Kanagal-Shamanna, Rashmi/K-1258-2019	Kanagal-Shamanna, Rashmi/0000-0001-7829-5249; Antoch, mantoch/0000-0003-3001-8511; Kondratov, Roman/0000-0003-3449-745X	NCI NIH HHS [CA102522] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102522] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antoch MP, 2005, CELL CYCLE, V4, P901, DOI 10.4161/cc.4.7.1792; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gorbacheva VY, 2005, P NATL ACAD SCI USA, V102, P3407, DOI 10.1073/pnas.0409897102; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kondratov RV, 2003, GENE DEV, V17, P1921, DOI 10.1101/gad.1099503; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lis Christopher G, 2003, Integr Cancer Ther, V2, P105, DOI 10.1177/1534735403002002002; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Panda S, 2004, J BIOL RHYTHM, V19, P374, DOI 10.1177/0748730404269008; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Smolensky MH, 1999, CHRONOBIOL INT, V16, P539, DOI 10.3109/07420529908998728; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; WILLICH SN, 1992, AM J CARDIOL, V70, P65, DOI 10.1016/0002-9149(92)91391-G; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301	26	89	93	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					530	+		10.1096/fj.05-5321fje	http://dx.doi.org/10.1096/fj.05-5321fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16507766				2022-12-25	WOS:000235996000006
J	Ito, K; Oji, Y; Tatsumi, N; Shimizu, S; Kanai, Y; Nakazawa, T; Asada, M; Jomgeow, T; Aoyagi, S; Nakano, Y; Tamaki, H; Sakaguchi, N; T Shirakata,; Nishida, S; Kawakami, M; Tsuboi, A; Oka, Y; Tsujimoto, Y; Sugiyama, H				Ito, K.; Oji, Y.; Tatsumi, N.; Shimizu, S.; Kanai, Y.; Nakazawa, T.; Asada, M.; Jomgeow, T.; Aoyagi, S.; Nakano, Y.; Tamaki, H.; Sakaguchi, N.; T Shirakata; Nishida, S.; Kawakami, M.; Tsuboi, A.; Oka, Y.; Tsujimoto, Y.; Sugiyama, H.			Antiapoptotic function of 17AA(+) WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway	ONCOGENE			English	Article						Wilms' tumor gene; WT1; anti-apoptosis; 17AA(+) WT1 isoform	PROMOTER ACTIVITY; EXPRESSION; SUPPRESSOR; OVEREXPRESSION; DIFFERENTIATION; PROLIFERATION; INVOLVEMENT; INHIBITION; REPRESSION; PRODUCT	The WT1 gene is overexpressed in human primary leukemia and a wide variety of solid cancers. The WT1 gene is alternatively spliced at two sites, yielding four isoforms: 17AA(+) KTS(+), 17AA(+) KTS(-), 17AA(-) KTS(+), and 17AA(-) KTS(-). Here, we showed that 17AA(+) WT1-specific siRNA induced apoptosis in three WT1-expressing leukemia cell lines (K562, HL-60, and Kasumi-1), but not in WT1-nonexpressing lymphoma cell line (Daudi). 17AA(+) WT1-specific siRNA activated caspase- 3 and - 9 in the intrinsic apoptosis pathway but not caspase- 8 in the extrinsic one. On the other hand, 17AA(-) WT1-specific siRNA did not induce apoptosis in the three WT1-expressing cell lines. The apoptosis was associated with activation of proapoptotic Bax, which was activated upstream of the mitochondria. Constitutive expression of 17AA(+) WT1 isoforms inhibited apoptosis of K562 leukemia cells induced by apoptosis-inducing agents, etoposide and doxorubicin, through the protection of mitochondrial membrane damages, and DNA-binding zinc-finger region of 17AA(+) WT1 isoform was essential for the antiapoptotic functions. We further studied the gene(s) whose expression was altered by the expression of 17AA(+) WT1 isoforms and showed that the expression of proapoptotic Bak was decreased by the expression of 17AA(+) KTS(-) WT1 isoform. Taken together, these results indicated that 17AA(+) WT1 isoforms played antiapoptotic roles at some points upstream of the mitochondria in the intrinsic apoptosis pathway.	Osaka Univ, Dept Funct Diagnost Sci, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Biomed Informat, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Med Genet, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Mol Med, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Canc Immunotherapy, Grad Sch Med, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University	Sugiyama, H (corresponding author), Osaka Univ, Dept Funct Diagnost Sci, Grad Sch Med, 1-7 Yamada Oka, Suita, Osaka 5650871, Japan.	sugiyama@sahs.med.osaka-u.ac.jp	Nakazawa, Tsutomu/ABF-2907-2020	Nakazawa, Tsutomu/0000-0003-4286-9356				Algar EM, 1996, ONCOGENE, V12, P1005; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Davies JA, 2004, HUM MOL GENET, V13, P235, DOI 10.1093/hmg/ddh015; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Englert C, 1997, CANCER RES, V57, P1429; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GOODYER P, 1995, ONCOGENE, V10, P1125; Harada Y, 1999, MOL UROL, V3, P357; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hubinger G, 2001, EXP HEMATOL, V29, P1226, DOI 10.1016/S0301-472X(01)00719-6; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Li H, 2003, INT J HEMATOL, V77, P463, DOI 10.1007/BF02986614; Loeb DM, 2001, CANCER RES, V61, P921; Loeb DM, 2003, LEUKEMIA, V17, P965, DOI 10.1038/sj.leu.2402906; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Niksic M, 2004, HUM MOL GENET, V13, P463, DOI 10.1093/hmg/ddh040; Oji Y, 1999, JPN J CANCER RES, V90, P194, DOI 10.1111/j.1349-7006.1999.tb00733.x; Oji Y, 2002, INT J CANCER, V100, P297, DOI 10.1002/ijc.10476; Oji Y, 2004, CANCER SCI, V95, P822, DOI 10.1111/j.1349-7006.2004.tb02188.x; Oji Y, 2004, ANTICANCER RES, V24, P3103; Oji Y, 2004, CANCER SCI, V95, P583, DOI 10.1111/j.1349-7006.2004.tb02490.x; Oji Y, 2003, CANCER SCI, V94, P712, DOI 10.1111/j.1349-7006.2003.tb01507.x; Oji Y, 2003, CANCER SCI, V94, P606, DOI 10.1111/j.1349-7006.2003.tb01490.x; Oji Y, 2003, CANCER SCI, V94, P523, DOI 10.1111/j.1349-7006.2003.tb01477.x; Osaka M, 1997, INT J CANCER, V72, P696, DOI 10.1002/(SICI)1097-0215(19970807)72:4<696::AID-IJC23>3.0.CO;2-8; Reynolds PA, 2003, GENE DEV, V17, P2094, DOI 10.1101/gad.1110703; Shimizu S, 1996, ONCOGENE, V12, P2251; Siehl JM, 2004, ANN HEMATOL, V83, P745, DOI 10.1007/s00277-004-0941-0; Sugiyama H, 2001, INT J HEMATOL, V73, P177, DOI 10.1007/BF02981935; Tsuboi A, 1999, LEUKEMIA RES, V23, P499, DOI 10.1016/S0145-2126(99)00037-5; Tuna M, 2005, ONCOGENE, V24, P1648, DOI 10.1038/sj.onc.1208345; Ueda T, 2003, CANCER SCI, V94, P271, DOI 10.1111/j.1349-7006.2003.tb01432.x; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Yamagami T, 1998, LEUKEMIA RES, V22, P383, DOI 10.1016/S0145-2126(97)00176-8; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878	42	83	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4217	4229		10.1038/sj.onc.1209455	http://dx.doi.org/10.1038/sj.onc.1209455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16518414				2022-12-25	WOS:000239004800009
J	Balakrishnan, A; Patel, B; Sieber, SA; Chen, D; Pachikara, N; Zhong, GM; Cravatt, BF; Fan, HZ				Balakrishnan, Amit; Patel, Bhairavi; Sieber, Stephan A.; Chen, Ding; Pachikara, Niseema; Zhong, Guangming; Cravatt, Benjamin F.; Fan, Huizhou			Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA CONVERTING-ENZYME; POLYPEPTIDE DEFORMYLASE; GENOME SEQUENCE; PNEUMONIAE; CELLS; ACTINONIN; PSITTACI; PROTEIN; COLI	Chlamydia trachomatis is an obligate intracellular bacterium responsible for a number of human diseases. The mechanism underlying the intracellular parasitology of Chlamydiae remains poorly understood. In searching for host factors required for chlamydial infection, we discovered that C. trachomatis growth was effectively inhibited with GM6001 and TAPI-0, two compounds known as specific inhibitors of matrix metalloproteases. The inhibition was independent of chlamydial entry of the cell, suggesting that the loss of extracellular metalloprotease activities of the host cell is unlikely to be the mechanism for the growth suppression. Nucleotide sequences of candidate metalloprotease genes remained unchanged in a chlamydial variant designated GR10, which had been selected for resistance to the inhibitors. Nevertheless, GR10 displayed a single base mutation in the presumable promoter region of the gene for peptide deformylase (PDF), a metal-dependent enzyme that removes the N-formyl group from newly synthesized bacterial proteins. The mutation correlated with an increased PDF expression level and resistance to actinonin, a known PDF inhibitor with antibacterial activity, as compared with the parental strain. Recombinant chlamydial PDF was covalently labeled with a hydroxamate-based molecular probe designated AspR1, which was developed for the detection of metalloproteases. The AspR1 labeling of the chlamydial PDF became significantly less efficient in the presence of excessive amounts of GM6001 and TAPI-0. Finally, the PDF enzyme activity was efficiently inhibited with GM6001 and TAPI-0. Taken together, our results suggest that the metalloprotease inhibitors suppress chlamydial growth by targeting the bacterial PDF. These findings have important biochemical and medical implications.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Phys & Biophys, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Piscataway, NJ 08854 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Texas System; University of Texas Health San Antonio; Scripps Research Institute	Fan, HZ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Phys & Biophys, 683 Hoes Lane, Piscataway, NJ 08854 USA.	fanhu@umdnj.edu	Fan, Huizhou/E-5835-2012; Sieber, Stephan/C-1172-2010	FAN, HUIZHOU/0000-0002-4903-926X	NIAID NIH HHS [1R21 AI 064441] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI064441] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAPECCHI MR, 1966, P NATL ACAD SCI USA, V55, P1517, DOI 10.1073/pnas.55.6.1517; Chen D, 2005, EXPERT OPIN INV DRUG, V14, P1107, DOI 10.1517/13543784.14.9.1107; Chen DZ, 2000, BIOCHEMISTRY-US, V39, P1256, DOI 10.1021/bi992245y; FAHR MJ, 1995, J BACTERIOL, V177, P4252, DOI 10.1128/jb.177.15.4252-4260.1995; FAN HZ, 1991, J BACTERIOL, V173, P6670, DOI 10.1128/jb.173.21.6670-6677.1991; Fan HZ, 2003, J BIOL CHEM, V278, P18617, DOI 10.1074/jbc.M300331200; FAN HZ, 1992, J CLIN INVEST, V90, P1803, DOI 10.1172/JCI116055; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Giglione C, 2000, MOL MICROBIOL, V36, P1197, DOI 10.1046/j.1365-2958.2000.01908.x; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; Greene W, 2004, INFECT IMMUN, V72, P451, DOI 10.1128/IAI.72.1.451-460.2004; HATCH TP, 1975, J BACTERIOL, V122, P393, DOI 10.1128/JB.122.2.393-400.1975; Jones RN, 2004, J ANTIMICROB CHEMOTH, V53, P804, DOI 10.1093/jac/dkh184; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; Kuo CC, 1997, J VASC SURG, V26, P29, DOI 10.1016/S0741-5214(97)70143-5; Levy DE, 1998, J MED CHEM, V41, P199, DOI 10.1021/jm970494j; Li XJ, 2004, J BIOL CHEM, V279, P27365, DOI 10.1074/jbc.M401690200; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; MAZEL D, 1994, EMBO J, V13, P914, DOI 10.1002/j.1460-2075.1994.tb06335.x; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; Rajagopalan PTR, 1997, BIOCHEMISTRY-US, V36, P13910, DOI 10.1021/bi971155v; Read TD, 2003, NUCLEIC ACIDS RES, V31, P2134, DOI 10.1093/nar/gkg321; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; SCHACTER J, 1999, CHLAMYDIA INTRACELLU; Schaumburg CS, 2003, NUCLEIC ACIDS RES, V31, P551, DOI 10.1093/nar/gkg150; Speers AE, 2003, J AM CHEM SOC, V125, P4686, DOI 10.1021/ja034490h; Speers AE, 2004, CHEM BIOL, V11, P535, DOI 10.1016/j.chembiol.2004.03.012; Steele-Mortimer O, 2002, CELL MICROBIOL, V4, P43, DOI 10.1046/j.1462-5822.2002.00170.x; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; TOYE B, 1990, INFECT IMMUN, V58, P3909, DOI 10.1128/IAI.58.12.3909-3913.1990; Van Aller GS, 2005, BIOCHEMISTRY-US, V44, P253, DOI 10.1021/bi048632b; Ward ME, 1988, MICOBIOLOGY CHLAMYDI, P71; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325; Xiao YM, 2004, INFECT IMMUN, V72, P5470, DOI 10.1128/IAI.72.9.5470-5474.2004	36	43	46	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16691	16699		10.1074/jbc.M513648200	http://dx.doi.org/10.1074/jbc.M513648200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16565079	hybrid			2022-12-25	WOS:000238165700063
J	Honnappa, S; Jahnke, W; Seelig, J; Steinmetz, MO				Honnappa, Srinivas; Jahnke, Wolfgang; Seelig, Joachim; Steinmetz, Michel O.			Control of intrinsically disordered stathmin by multisite phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-DESTABILIZING ACTIVITY; IN-VITRO; TUBULIN; PROTEINS; BINDING; OP18/STATHMIN; DYNAMICS; SPINDLE; PREDICTION; INCREASES	Stathmin is an intrinsically disordered protein implicated in the regulation of microtubule dynamics and in the development of cancer. The microtubule destabilizing activity of stathmin is down-regulated by phosphorylation of four serine residues, Ser(16), Ser(25), Ser(38), and Ser(63). Here we have used calorimetric and spectroscopic methods, including nuclear magnetic resonance to analyze the properties of seven stathmin phosphoisoforms to bind tubulin and inhibit microtubule formation. We found that stathmin phosphorylation results in a substantial loss in hydration entropy upon tubulin-stathmin complex formation. Remarkably, a linear correlation between the free energy change of complex formation and the microtubule inhibition activities of stathmin phosphoisoforms was observed. This finding provides a biophysical basis for understanding the mechanism by which local stathmin activity gradients important for promoting localized microtubule growth are established. We further found that phosphorylation of Ser16 and Ser63 disrupts the formation of a tubulin-interacting beta-hairpin and a helical segment, respectively, explaining the dominant role of these residues in regulating cell cycle progression. The insight into the tubulin-stathmin interaction offers a molecular basis for understanding the nature and the factors that control intrinsically disordered protein systems in general.	Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Novartis Pharma AG, NIBR, Discovery Technol, CH-4002 Basel, Switzerland; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Novartis; University of Basel	Steinmetz, MO (corresponding author), Paul Scherrer Inst, CH-5232 Villigen, Switzerland.	michel.steinmetz@psi.ch	Steinmetz, Michel O/AAA-3349-2022	Steinmetz, Michel O/0000-0001-6157-3687				Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Clement MJ, 2005, BIOCHEMISTRY-US, V44, P14616, DOI 10.1021/bi0512492; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Curmi PA, 1999, CELL STRUCT FUNCT, V24, P345; DI PG, 1997, FEBS LETT, V416, P149; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; Gigant B, 2005, NATURE, V435, P519, DOI 10.1038/nature03566; Honnappa S, 2003, J BIOL CHEM, V278, P38926, DOI 10.1074/jbc.M305546200; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; Iancu C, 2001, J CELL SCI, V114, P909; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Kuntziger T, 2001, J BIOL CHEM, V276, P22979, DOI 10.1074/jbc.M101466200; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; Liu ZH, 2005, CANCER RES, V65, P1647, DOI 10.1158/0008-5472.CAN-04-1754; Luque I, 1998, METHOD ENZYMOL, V295, P100; Manna T, 2006, J BIOL CHEM, V281, P2071, DOI 10.1074/jbc.M510661200; Niethammer P, 2004, SCIENCE, V303, P1862, DOI 10.1126/science.1094108; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; Rubin CI, 2004, J CELL BIOCHEM, V93, P242, DOI 10.1002/jcb.20187; Shumyatsky GP, 2005, CELL, V123, P697, DOI 10.1016/j.cell.2005.08.038; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Tholey A, 1999, BIOPHYS J, V76, P76, DOI 10.1016/S0006-3495(99)77179-1; Tompa P, 2005, TRENDS BIOCHEM SCI, V30, P484, DOI 10.1016/j.tibs.2005.07.008; Uversky VN, 2005, J MOL RECOGNIT, V18, P343, DOI 10.1002/jmr.747; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200	40	39	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2006	281	23					16078	16083		10.1074/jbc.M513524200	http://dx.doi.org/10.1074/jbc.M513524200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	049DM	16554300	Green Published, hybrid			2022-12-25	WOS:000237996000060
J	Okuyama, H; Krishnamachary, B; Zhou, YF; Nagasawa, H; Bosch-Marce, M; Semenza, GL				Okuyama, Hiroaki; Krishnamachary, Balaji; Zhou, Yi Fu; Nagasawa, Hideko; Bosch-Marce, Marta; Semenza, Gregg L.			Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; STEM-CELLS; FACTOR-I; TRANSCRIPTIONAL REGULATION; MYOCARDIAL-INFARCTION; PROGENITOR CELLS; GENE-EXPRESSION; FACTOR 1-ALPHA; HIF-ALPHA; HIF-1-ALPHA	Bone marrow-derived cells are recruited to sites of ischemia, where they promote tissue vascularization. This response is dependent upon the expression of vascular endothelial growth factor ( VEGF) receptor 1 ( VEGFR1), which mediates cell migration in response to VEGF or placental growth factor ( PLGF). In this study, we found that exposure of cultured mouse bone marrow-derived mesenchymal stromal cells ( MSC) to hypoxia or an adenovirus encoding a constitutively active form of hypoxia-inducible factor 1 ( HIF-1) induced VEGFR1 mRNA and protein expression and promoted ex vivo migration in response to VEGF or PLGF. MSCin which HIF-1 activity was inhibited by a dominant negative or RNA interference approach expressed markedly reduced levels of VEGFR1 and failed to migrate or activate AKT in response to VEGF or PLGF. Thus, loss-of-function and gain-of-function approaches demonstrated that HIF-1 activity is necessary and sufficient for basal and hypoxia-induced VEGFR1 expression in bone marrow-derived MSC.	Johns Hopkins Univ, Sch Med, Vasc Biol Program, Inst Cell Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Semenza, GL (corresponding author), Broadway Res Bldg,Suite 671,733 N Broadway, Baltimore, MD 21205 USA.	gsemenza@jhmi.edu			NHLBI NIH HHS [R01-HL53338, P01-HL65608] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL065608, R03HL053338] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aicher A, 2005, HYPERTENSION, V45, P321, DOI 10.1161/01.HYP.0000154789.28695.ea; Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102; Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21-3-337; Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200; Calvani M, 2006, BLOOD, V107, P2705, DOI 10.1182/blood-2005-09-3541; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldser D, 1999, CANCER RES, V59, P3915; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fiedler J, 2005, BIOCHEM BIOPH RES CO, V334, P561, DOI 10.1016/j.bbrc.2005.06.116; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Hirschi KK, 2002, GENE THER, V9, P648, DOI 10.1038/sj.gt.3301722; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Li TS, 2002, AM J PHYSIOL-HEART C, V283, pH468, DOI 10.1152/ajpheart.00261.2002; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Mouquet F, 2005, CIRC RES, V97, P1090, DOI 10.1161/01.RES.0000194330.66545.f5; Nagaya N, 2004, AM J PHYSIOL-HEART C, V287, pH2670, DOI 10.1152/ajpheart.01071.2003; ODA T, 2006, IN PRESS AM J PHYSL; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; Patel TH, 2005, CARDIOVASC RES, V68, P144, DOI 10.1016/j.cardiores.2005.05.002; Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Resar JR, 2005, CHEST, V128, P787, DOI 10.1378/chest.128.2.787; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Silva GV, 2005, CIRCULATION, V111, P150, DOI 10.1161/01.CIR.0000151812.86142.45; Sowter HM, 2003, CANCER RES, V63, P6130; Stoeltzing O, 2004, JNCI-J NATL CANCER I, V96, P946, DOI 10.1093/jnci/djh168; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takeda N, 2004, CIRC RES, V95, P146, DOI 10.1161/01.RES.0000134920.10128.b4; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Yu AY, 1998, AM J PHYSIOL-LUNG C, V275, pL818, DOI 10.1152/ajplung.1998.275.4.L818; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhong H, 1999, CANCER RES, V59, P5830	63	132	150	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15554	15563		10.1074/jbc.M602003200	http://dx.doi.org/10.1074/jbc.M602003200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574650	hybrid			2022-12-25	WOS:000237922200062
J	Tzeng, SL; Cheng, YW; Li, CH; Lin, YS; Hsu, HC; Kang, JJ				Tzeng, Shu-Ling; Cheng, Yu-Wen; Li, Ching-Hao; Lin, Young-Sun; Hsu, Hey-Chi; Kang, Jaw-Jou			Physiological and functional interactions between Tcf4 and Daxx in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA PROTEIN PML; BETA-CATENIN; CYCLIN D1; TRANSCRIPTIONAL ACTIVATION; COLORECTAL-CANCER; BINDING PROTEIN; EXPRESSION; COMPLEX; APOPTOSIS; GENE	Daxx, a human cell death-associated protein, was isolated as a Tcf4-interacting protein, using a yeast two-hybrid screen. Co-immunoprecipitation in HEK-293T cells and yeast two-hybrid screen in Y190 cells were performed to identify the interaction between Tcf4 with Daxx and to map the binding regions of Tcf4. In the nucleus, Daxx reduced DNA binding activity of Tcf4 and repressed Tcf4 transcriptional activity. Overexpression of Daxx altered the expression of genes downstream of Tcf4, including cyclin D1 and Hath-1, and induced G(1) phase arrest in colon cancer cells. A reduction in Daxx protein expression was also observed in colon adenocarcinoma tissue when compared with normal colon tissue. This evidence suggests a possible physiological function of Daxx, via interaction with Tcf4, to regulate proliferation and differentiation of colon cells.	Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Pathol, Taipei, Taiwan; Taipei Med Univ, Sch Pharm, Taipei, Taiwan; Dev Ctr Biotechnol, Taipei 10051, Taiwan	National Taiwan University; National Taiwan University; Taipei Medical University	Kang, JJ (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, 1 Jen Ai Rd,Sect 1, Taipei, Taiwan.	jjkang@ha.mc.ntu.edu.tw		KANG, JAW-JOU/0000-0002-6350-3997				Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bartkova J, 2001, GASTROENTEROLOGY, V120, P1680, DOI 10.1053/gast.2001.24880; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Ben-Arie N, 2000, DEVELOPMENT, V127, P1039; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Cuff M, 2005, GASTROENTEROLOGY, V128, P676, DOI 10.1053/j.gastro.2004.12.003; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Fujie H, 2001, HEPATOL RES, V20, P39, DOI 10.1016/S1386-6346(00)00116-9; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; Helms AW, 1998, DEVELOPMENT, V125, P919; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; Isaka F, 1999, EUR J NEUROSCI, V11, P2582, DOI 10.1046/j.1460-9568.1999.00699.x; Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jung C, 2005, BRIT J CANCER, V92, P2233, DOI 10.1038/sj.bjc.6602631; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; Kiriakidou M, 1997, DNA CELL BIOL, V16, P1289, DOI 10.1089/dna.1997.16.1289; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Leow CC, 2004, CANCER RES, V64, P6050, DOI 10.1158/0008-5472.CAN-04-0290; Li CH, 2005, J BIOL CHEM, V280, P26193, DOI 10.1074/jbc.M501371200; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; Lin DY, 2003, J BIOL CHEM, V278, P15958, DOI 10.1074/jbc.M300387200; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muromoto R, 2004, J IMMUNOL, V172, P2985, DOI 10.4049/jimmunol.172.5.2985; Obradovic D, 2004, MOL PHARMACOL, V65, P761, DOI 10.1124/mol.65.3.761; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pluta AF, 1998, J CELL SCI, V111, P2029; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tang J, 2004, J BIOL CHEM, V279, P20369, DOI 10.1074/jbc.M401321200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Tsai HL, 1996, J BIOL CHEM, V271, P3534; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	53	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15405	15411		10.1074/jbc.M601807200	http://dx.doi.org/10.1074/jbc.M601807200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16569639	hybrid			2022-12-25	WOS:000237922200046
J	Xie, B; Zhou, G; Chan, SY; Shapiro, E; Kong, XP; Wu, XR; Sun, TT; Costello, CE				Xie, Bo; Zhou, Ge; Chan, Shiu-Yung; Shapiro, Ellen; Kong, Xiang-Peng; Wu, Xue-Ru; Sun, Tung-Tien; Costello, Catherine E.			Distinct glycan structures of uroplakins Ia and Ib - Structural basis for the selective binding of FimH adhesin to uroplakin Ia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; ASYMMETRIC UNIT MEMBRANE; URINARY-BLADDER; MASS-SPECTROMETRY; DIFFERENTIAL BINDING; UROTHELIAL RECEPTOR; TYPE-1 FIMBRIAE; PROTEIN; OLIGOSACCHARIDES; EPITHELIUM	Although it has been shown that mouse uroplakin (UP) Ia, a major glycoprotein of urothelial apical surface, can serve as the receptor for the FimH lectin adhesin of type 1-fimbriated Escherichia coli, the organism that causes a great majority of urinary tract infections, the glycan structure of this native receptor was unknown. Using a sensitive approach that combines in-gel glycosidase and protease digestions, permethylation of released glycans, and mass spectrometry, we have elucidated for the first time the native glycoform structures of the mouse UPIa receptor and those of its non-binding homolog, UPIb, and have determined the glycosylation site occupancy. UPIa presents a high level of terminally exposed mannose residues ( located on Man(6)GlcNAc(2) to Man(9) GlcNAc(2)) that are capable of specifically interacting with FimH. We have shown that this property is conserved not only in the mouse uroplakins but also in cattle and, even more importantly, in human UPIa, thus establishing the concept that UPIa is a major urothelial receptor in humans and other mammals for the mannose-specific FimH variant. In contrast, our results indicate that most terminally exposed glycans of mouse UPIb are non-mannose residues, thus explaining the failure of FimH to bind to this UPIb. In cattle, on the other hand, complex carbohydrates constituted only about 20% of the UPIb N-linked glycans. Human UPIa contained exclusively high mannose glycans, and human UPIb contained only complex glycans. The drastically different carbohydrate processing of the UPIa and UPIb proteins, two closely related members of the tetraspanin family, may reflect differences in their folding and masking due to their interactions with their associated proteins, UPII and UPIIIa, respectively. Results from this study shed light on the molecular pathogenesis of urinary tract infections and may aid in the design of glyco-mimetic inhibitors for preventing and treating this	Boston Univ, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Dept Biophys, Boston, MA 02118 USA; NYU, Sch Med, Dept Urol Biochem, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	Boston University; Boston University; New York University; New York University; New York University	Sun, TT (corresponding author), Boston Univ, Dept Biochem, 670 Albany St,Rm 511, Boston, MA 02118 USA.	cecmsms@bu.edu	Sun, Tung-Tien/J-4425-2015	Sun, Tung-Tien/0000-0002-6841-1063; Wu, Xue-Ru/0000-0001-6058-6291; Kong, Xiang-Peng/0000-0001-5773-2681; Costello, Catherine/0000-0003-1594-5122	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015942, P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056903, R01DK039753, P01DK052206] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR 10888, S10 RR 15942] Funding Source: Medline; NIDDK NIH HHS [R01 DK 39753, P01 DK 52206, R01 DK056903] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; Anderson GG, 2003, SCIENCE, V301, P105, DOI 10.1126/science.1084550; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Bouckaert J, 2005, MOL MICROBIOL, V55, P441, DOI 10.1111/j.1365-2958.2004.04415.x; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Cavallone D, 2004, J BIOL CHEM, V279, P216, DOI 10.1074/jbc.M308821200; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Ciucanu I, 2003, J AM CHEM SOC, V125, P16213, DOI 10.1021/ja035660t; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; Dell A, 2001, SCIENCE, V291, P2351, DOI 10.1126/science.1058890; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Durand G, 2000, CLIN CHEM, V46, P795; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; FIRON N, 1984, INFECT IMMUN, V43, P1088, DOI 10.1128/IAI.43.3.1088-1090.1984; Geerlings SE, 2002, DIABETES CARE, V25, P1405, DOI 10.2337/diacare.25.8.1405; GILLECECASTRO BL, 1990, METHOD ENZYMOL, V193, P689, DOI 10.1016/0076-6879(90)93445-Q; Harvey DJ, 2000, J MASS SPECTROM, V35, P1178, DOI 10.1002/1096-9888(200010)35:10<1178::AID-JMS46>3.0.CO;2-F; HARVEY DJ, 1993, RAPID COMMUN MASS SP, V7, P614, DOI 10.1002/rcm.1290070712; Hasty DL, 2005, COLONIZATION OF MUCOSAL SURFACES, P351; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HICKS RM, 1969, NATURE, V224, P1304, DOI 10.1038/2241304a0; HICKS RM, 1965, J CELL BIOL, V26, P25, DOI 10.1083/jcb.26.1.25; Hu CCA, 2005, MOL BIOL CELL, V16, P3937, DOI 10.1091/mbc.E05-02-0136; Hung CS, 2002, MOL MICROBIOL, V44, P903, DOI 10.1046/j.1365-2958.2002.02915.x; Jenkins N, 1996, NAT BIOTECHNOL, V14, P975, DOI 10.1038/nbt0896-975; JONES CH, 1995, P NATL ACAD SCI USA, V92, P2081, DOI 10.1073/pnas.92.6.2081; Jones J, 2005, BBA-GEN SUBJECTS, V1726, P121, DOI 10.1016/j.bbagen.2005.07.003; Kachar B, 1999, J MOL BIOL, V285, P595, DOI 10.1006/jmbi.1998.2304; Klemm P, 1996, ADV EXP MED BIOL, V408, P193; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSS LG, 1969, LAB INVEST, V21, P154; LIN JH, 1994, J BIOL CHEM, V269, P1775; Lindhorst TK, 1998, GLYCOCONJUGATE J, V15, P605, DOI 10.1023/A:1006920027641; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; Min GW, 2003, J CELL SCI, V116, P4087, DOI 10.1242/jcs.00811; Min GW, 2002, J MOL BIOL, V317, P697, DOI 10.1006/jmbi.2002.5442; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Mulvey MA, 2000, P NATL ACAD SCI USA, V97, P8829, DOI 10.1073/pnas.97.16.8829; Naven TJP, 1996, RAPID COMMUN MASS SP, V10, P1361, DOI 10.1002/(SICI)1097-0231(199608)10:11<1361::AID-RCM642>3.0.CO;2-A; NEESER JR, 1986, INFECT IMMUN, V52, P428, DOI 10.1128/IAI.52.2.428-436.1986; OHANLEY P, 1985, J CLIN INVEST, V75, P347, DOI 10.1172/JCI111707; Oostergetel GT, 2001, J MOL BIOL, V314, P245, DOI 10.1006/jmbi.2001.5128; Pan YT, 1997, INFECT IMMUN, V65, P4199, DOI 10.1128/IAI.65.10.4199-4206.1997; Reinhold VN, 1996, METHOD ENZYMOL, V271, P377; RICHTER WJ, 1990, METHOD ENZYMOL, V193, P607, DOI 10.1016/0076-6879(90)93441-M; Rudd PM, 1997, CRIT REV BIOCHEM MOL, V32, P1, DOI 10.3109/10409239709085144; Rudd PM, 1997, CURR OPIN BIOTECH, V8, P488, DOI 10.1016/S0958-1669(97)80073-0; Schilling JD, 2001, J INFECT DIS, V183, pS36, DOI 10.1086/318855; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; Sokurenko EV, 1997, J BIOL CHEM, V272, P17880, DOI 10.1074/jbc.272.28.17880; Sokurenko EV, 1998, P NATL ACAD SCI USA, V95, P8922, DOI 10.1073/pnas.95.15.8922; TAYLOR KA, 1984, J ULTRA MOL STRUCT R, V87, P23, DOI 10.1016/S0022-5320(84)90113-8; TRIMBLE RB, 1978, J BIOL CHEM, V253, P4508; Tu LY, 2002, MOL BIOL CELL, V13, P4221, DOI 10.1091/mbc.E02-04-0211; Vetsch M, 2002, J MOL BIOL, V322, P827, DOI 10.1016/S0022-2836(02)00845-8; WALZ T, 1995, J MOL BIOL, V248, P887, DOI 10.1006/jmbi.1995.0269; WU XR, 1993, J CELL SCI, V106, P31; WU XR, 1995, J BIOL CHEM, V270, P29752; Wu XR, 1996, P NATL ACAD SCI USA, V93, P9630, DOI 10.1073/pnas.93.18.9630; WU XR, 1994, J BIOL CHEM, V269, P13716; WU XR, 1990, J BIOL CHEM, V265, P19170; YU J, 1990, J CELL BIOL, V111, P1207, DOI 10.1083/jcb.111.3.1207; YU J, 1994, J CELL BIOL, V125, P171, DOI 10.1083/jcb.125.1.171; Zhou G, 2001, J CELL SCI, V114, P4095	67	97	100	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14644	14653		10.1074/jbc.M600877200	http://dx.doi.org/10.1074/jbc.M600877200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16567801	hybrid			2022-12-25	WOS:000237671300016
J	Kim, S; Xu, X; Hecht, A; Boyer, TG				Kim, Seokjoong; Xu, Xuan; Hecht, Andreas; Boyer, Thomas G.			Mediator is a transducer of Wnt/beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BETA-CATENIN; TRANSCRIPTION FACTOR; NEGATIVE REGULATOR; DEPENDENT TRANSCRIPTION; COACTIVATOR COMPLEX; TRAP220 COMPONENT; NUCLEAR RECEPTORS; CYCLIN D1; TARGET	Signal transduction within the canonical Wnt/beta-catenin pathway drives development and carcinogenesis through programmed or unprogrammed changes in gene transcription. Although the upstream events linked to signal-induced activation of beta-catenin in the cytoplasm have been deciphered in considerable detail, much less is known regarding the mechanism by which beta-catenin stimulates target gene transcription in the nucleus. Here, we show that beta-catenin physically and functionally targets the MED12 subunit in Mediator to activate transcription. The beta-catenin transactivation domain bound directly to isolated MED12 and intact Mediator both in vitro and in vivo, and Mediator was recruited to Wnt-responsive genes in a beta-catenin-dependent manner. Disruption of the beta-catenin/MED12 interaction through dominant-negative interference- or RNA interference- mediated MED12 suppression inhibited beta-catenin transactivation in response to Wnt signaling. This study thus identifies the MED12 interface within Mediator as a new component and a potential therapeutic target in the Wnt/beta-catenin pathway.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; Univ Freiburg, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Freiburg	Boyer, TG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	boyer@uthscsa.edu		Hecht, Andreas/0000-0003-2262-2575	NATIONAL CANCER INSTITUTE [R01CA098301] Funding Source: NIH RePORTER; NCI NIH HHS [CA-098301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bjorklund S, 2005, TRENDS BIOCHEM SCI, V30, P240, DOI 10.1016/j.tibs.2005.03.008; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Bourbon HM, 2004, MOL CELL, V14, P553, DOI 10.1016/j.molcel.2004.05.011; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Cantin GT, 2003, P NATL ACAD SCI USA, V100, P12003, DOI 10.1073/pnas.2035253100; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Gwack Y, 2003, MOL CELL BIOL, V23, P2055, DOI 10.1128/MCB.23.6.2055-2067.2003; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Janody F, 2003, DEVELOPMENT, V130, P3691, DOI 10.1242/dev.00607; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kato Y, 2002, NATURE, V418, P641, DOI 10.1038/nature00969; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kornberg RD, 2005, TRENDS BIOCHEM SCI, V30, P235, DOI 10.1016/j.tibs.2005.03.011; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Kuras L, 2003, P NATL ACAD SCI USA, V100, P13887, DOI 10.1073/pnas.2036346100; Lau JF, 2003, MOL CELL BIOL, V23, P620, DOI 10.1128/MCB.23.2.620-628.2003; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Liu Y, 2004, MOL CELL BIOL, V24, P1721, DOI 10.1128/MCB.24.4.1721-1735.2004; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Malik S, 2005, TRENDS BIOCHEM SCI, V30, P256, DOI 10.1016/j.tibs.2005.03.009; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Mittler G, 2001, EMBO REP, V2, P808, DOI 10.1093/embo-reports/kve186; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Park JM, 2001, MOL CELL, V8, P9, DOI 10.1016/S1097-2765(01)00296-9; Park JM, 2000, MOL CELL BIOL, V20, P8709, DOI 10.1128/MCB.20.23.8709-8719.2000; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Polakis P, 2000, GENE DEV, V14, P1837; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Samuelsen CO, 2003, P NATL ACAD SCI USA, V100, P6422, DOI 10.1073/pnas.1030497100; Shibamoto S, 1998, GENES CELLS, V3, P659; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tan W, 2004, J BIOL CHEM, V279, P55153, DOI 10.1074/jbc.M410926200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Treisman JE, 2001, DEVELOPMENT, V128, P603; Valenta T, 2003, NUCLEIC ACIDS RES, V31, P2369, DOI 10.1093/nar/gkg346; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang G, 2005, MOL CELL, V17, P683, DOI 10.1016/j.molcel.2005.02.010; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yang FJ, 2004, P NATL ACAD SCI USA, V101, P2339, DOI 10.1073/pnas.0308676100; Yoda A, 2005, DEVELOPMENT, V132, P1885, DOI 10.1242/dev.01776; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang H, 2000, GENE DEV, V14, P2161, DOI 10.1101/gad.814700; Zhang H, 2001, DEVELOPMENT, V128, P767; Zhou RJ, 2002, NUCLEIC ACIDS RES, V30, P3245, DOI 10.1093/nar/gkf443	85	229	236	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14066	14075		10.1074/jbc.M602696200	http://dx.doi.org/10.1074/jbc.M602696200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16565090	hybrid			2022-12-25	WOS:000237512300029
J	Nakajima, H; Watanabe, N; Shibata, F; Kitamura, T; Ikeda, Y; Handa, M				Nakajima, Hideaki; Watanabe, Naohide; Shibata, Fumi; Kitamura, Toshio; Ikeda, Yasuo; Handa, Makoto			N-terminal Region of CCAAT/Enhancer-binding Protein epsilon Is Critical for Cell Cycle Arrest, Apoptosis, and Functional Maturation during Myeloid Differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; C/EBP-ALPHA; MICE LACKING; PROLIFERATION; TRANSCRIPTION; GROWTH; P21; GRANULOPOIESIS; HYPERPLASIA; DEGRADATION	CCAAT/enhancer-binding protein epsilon (C/EBP epsilon) plays a critical role in terminal myeloid differentiation. Differentiation is an integrated process of cell cycle arrest, morphological change, functional maturation, and apoptosis. However, the molecular networks underlying these events in C/EBP epsilon-induced differentiation remain poorly understood. To reveal these mechanisms, we performed a detailed molecular analysis of C/EBP epsilon-induced differentiation using an inducible form of C/EBP epsilon. The activation of C/EBP epsilon induced growth arrest, morphological differentiation, the expression of CD11b and secondary granule proteins, and apoptosis in myeloid cell lines. Unlike C/EBP alpha, C/EBP epsilon dramatically up-regulated p27 with a concomitant down-regulation of cdk4/6 and cyclin D2/A/E. Moreover, the anti-apoptotic proteins Bcl-2 and Bcl-x were down-regulated, whereas pro-apoptotic protein Bax remained unchanged. Using a variety of mutants, we revealed that these events were all regulated by the N-terminal activation domain of C/EBP epsilon. Interestingly, some of the differentiation processes such as the induction of secondary granule protein genes were clearly inhibited by c-Myc; however, inhibition of apoptosis by Bcl-x did not affect the entire differentiation processes. These data indicate the N terminus of C/EBP epsilon to be solely responsible for most aspects of myeloid differentiation, and these events were differentially affected by c-Myc.	[Nakajima, Hideaki] Univ Tokyo, Inst Med Sci, Ctr Excellence, Minato Ku, Tokyo 1088639, Japan; [Ikeda, Yasuo] Keio Univ, Sch Med, Dept Internal Med, Div Hematol, Tokyo 1608582, Japan; [Watanabe, Naohide; Handa, Makoto] Keio Univ, Sch Med, Dept Transfus & Cell Therapy, Tokyo 1608582, Japan; [Shibata, Fumi; Kitamura, Toshio] Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy, Tokyo 1088639, Japan	University of Tokyo; Keio University; Keio University; University of Tokyo	Nakajima, H (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Excellence, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.	hnakajim@ims.u-tokyo.ac.jp	Handa, Makoto/B-1121-2014; Kitamura, Toshio/AAA-2071-2021		Ministry of Education, Science, Sports and Culture of Japan; Naito Foundation	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Naito Foundation(Naito Memorial Foundation)	This work was supported in part by grants from the Ministry of Education, Science, Sports and Culture of Japan and the Naito Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Dinauer Mary C., 2000, Hematology Am Soc Hematol Educ Program, P303; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gery S, 2004, BLOOD, V103, P828, DOI 10.1182/blood-2003-01-0159; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lekstrom-Himes J, 1999, BLOOD, V93, P3096; Lekstrom-Himes JA, 2001, STEM CELLS, V19, P125, DOI 10.1634/stemcells.19-2-125; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; Nakajima H, 2001, EMBO J, V20, P6836, DOI 10.1093/emboj/20.23.6836; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Verbeek W, 1999, BLOOD, V94, P3141, DOI 10.1182/blood.V94.9.3141.421k41_3141_3150; Verbeek W, 2001, LEUKEMIA, V15, P103, DOI 10.1038/sj.leu.2401995; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Williamson EA, 1998, J BIOL CHEM, V273, P14796, DOI 10.1074/jbc.273.24.14796; Yamanaka R, 1998, INT J MOL MED, V1, P213; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	34	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14494	14502		10.1074/jbc.M600575200	http://dx.doi.org/10.1074/jbc.M600575200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16531405	hybrid			2022-12-25	WOS:000207179300008
J	Raduner, S; Majewska, A; Chen, JZ; Xie, XQ; Hamon, J; Faller, B; Altmann, KH; Gertsch, J				Raduner, Stefan; Majewska, Adriana; Chen, Jian-Zhong; Xie, Xiang-Qun; Hamon, Jacques; Faller, Bernard; Altmann, Karl-Heinz; Gertsch, Juerg			Alkylamides from Echinacea are a new class of cannabinomimetics - Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANNABINOID CB2 RECEPTOR; GENE-EXPRESSION; ENDOCANNABINOID SYSTEM; IMMUNE MODULATION; SELECTIVE LIGANDS; PHOSPHOLIPASE-C; DOUBLE-BLIND; COMMON COLD; HL-60 CELLS; SR 144528	Alkylamides (alkamides) from Echinacea modulate tumor necrosis factor alpha mRNA expression in human monocytes/ macrophages via the cannabinoid type 2 (CB2) receptor (Gertsch, J., Schoop, R., Kuenzle, U., and Suter, A. (2004) FEBS Lett. 577, 563-569). Here we show that the alkylamides dodeca-2E,4E,8Z,10Z- tetraenoic acid isobutylamide (A1) and dodeca-2E, 4E-dienoic acid isobutylamide (A2) bind to the CB2 receptor more strongly than the endogenous cannabinoids. The K-i values of A1 and A2 (CB2 similar to 60 nM; CB1 > 1500 nM) were determined by displacement of the synthetic high affinity cannabinoid ligand [H-3] CP-55,940. Molecular modeling suggests that alkylamides bind in the solvent-accessible cavity in CB2, directed by H-bonding and pi-pi interactions. In a screen with 49 other pharmacologically relevant receptors, it could be shown that A1 and A2 specifically bind to CB2 and CB1. A1 and A2 elevated total intracellular Ca2+ in CB2-positive but not in CB2-negative promyelocytic HL60 cells, an effect that was inhibited by the CB2 antagonist SR144528. At 50 nM, A1, A2, and the endogenous cannabinoid anandamide (CB2 K-i > 200 nM) up-regulated constitutive interleukin (IL)-6 expression in human whole blood in a seemingly CB2-dependent manner. A1, A2, anandamide, the CB2 antagonist SR144528 (Ki < 10 nM), and also the non-CB2-binding alkylamide undeca-2E-ene,8,10-diynoic acid isobutylamide all significantly inhibited lipopolysaccharide-induced tumor necrosis factor alpha, IL-1 beta, and IL-12p70 expression (5-500 nM) in a CB2-independent manner. Alkylamides and anandamide also showed weak differential effects on anti-CD3- versus anti-CD28-stimulated cytokine expression in human whole blood. Overall, alkylamides, anandamide, and SR144528 potently inhibited lipopolysaccharide-induced inflammation in human whole blood and exerted modulatory effects on cytokine expression, but these effects are not exclusively related to CB2 binding.	ETH, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland; Univ Houston, Coll Pharm, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA; Novartis Inst BioMed Res, CH-4002 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Houston System; University of Houston; Novartis	Gertsch, J (corresponding author), ETH, Dept Chem & Appl Biosci, Wolfgang Pauli Str 10, CH-8093 Zurich, Switzerland.	juerg.gertsch@pharma.ethz.ch		Gertsch, Jurg/0000-0003-0978-1555				Barnes J, 2005, J PHARM PHARMACOL, V57, P929, DOI 10.1211/0022357056127; BAUER R, 1988, PHYTOCHEMISTRY, V27, P2339, DOI 10.1016/0031-9422(88)80156-0; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Brinkeborn RM, 1999, PHYTOMEDICINE, V6, P1; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Carlisle SJ, 2002, INT IMMUNOPHARMACOL, V2, P69, DOI 10.1016/S1567-5769(01)00147-3; Chen JZ, 2005, LIFE SCI, V76, P2053, DOI 10.1016/j.lfs.2004.08.041; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Croxford JL, 2005, J NEUROIMMUNOL, V166, P3, DOI 10.1016/j.jneuroim.2005.04.023; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; De Petrocellis L, 2004, BRIT J PHARMACOL, V141, P765, DOI 10.1038/sj.bjp.0705666; Demuth DG, 2006, LIFE SCI, V78, P549, DOI 10.1016/j.lfs.2005.05.055; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Feng WK, 2003, BIOCHEM PHARMACOL, V65, P1077, DOI 10.1016/S0006-2952(03)00005-4; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Gertsch J, 2004, FEBS LETT, V577, P563, DOI 10.1016/j.febslet.2004.10.064; Goel V, 2004, J CLIN PHARM THER, V29, P75, DOI 10.1111/j.1365-2710.2003.00542.x; Gouldson P, 2000, EUR J PHARMACOL, V401, P17, DOI 10.1016/S0014-2999(00)00439-8; Jbilo O, 1999, FEBS LETT, V448, P273, DOI 10.1016/S0014-5793(99)00380-4; Jones SA, 2005, J IMMUNOL, V175, P3463, DOI 10.4049/jimmunol.175.6.3463; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; Kaplan BLF, 2005, J LEUKOCYTE BIOL, V77, P966, DOI 10.1189/jlb.1104652; Kaplan BLF, 2003, J PHARMACOL EXP THER, V306, P1077, DOI 10.1124/jpet.103.051961; Kishimoto S, 2004, J BIOCHEM, V135, P517, DOI 10.1093/jb/mvh063; KLEIN TW, 1993, J PHARMACOL EXP THER, V267, P635; Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Lograno MD, 2004, EUR J PHARMACOL, V494, P55, DOI 10.1016/j.ejphar.2004.04.039; LUNN CA, 2005, PHARM EXP THER, V316, P780; Makriyannis A, 2005, PROSTAG OTH LIPID M, V77, P210, DOI 10.1016/j.prostaglandins.2004.01.010; Matias I, 2002, EUR J BIOCHEM, V269, P3771, DOI 10.1046/j.1432-1033.2002.03078.x; Matthias A, 2005, LIFE SCI, V77, P2018, DOI 10.1016/j.lfs.2005.04.009; McAllister SD, 2003, J MED CHEM, V46, P5139, DOI 10.1021/jm0302647; McAllister SD, 2002, BIOCHEM PHARMACOL, V63, P2121, DOI 10.1016/S0006-2952(02)01031-6; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Molina-Holgado F, 1998, FEBS LETT, V433, P139, DOI 10.1016/S0014-5793(98)00851-5; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Oka S, 2005, J BIOL CHEM, V280, P18488, DOI 10.1074/jbc.M413260200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAROLARO D, 2002, CHEM PHYS LIPIDS, V108, P169; Percival SS, 2000, BIOCHEM PHARMACOL, V60, P155, DOI 10.1016/S0006-2952(99)00413-X; Quartilho A, 2003, ANESTHESIOLOGY, V99, P955, DOI 10.1097/00000542-200310000-00031; Raitio KH, 2005, CURR MED CHEM, V12, P1217, DOI 10.2174/0929867053764617; Randolph RK, 2003, EXP BIOL MED, V228, P1051, DOI 10.1177/153537020322800910; Rao GK, 2004, J LEUKOCYTE BIOL, V75, P884, DOI 10.1189/jlb.1203638; Rhee Man-Hee, 2002, J Vet Sci, V3, P179; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Sarfaraz S, 2005, CANCER RES, V65, P1635, DOI 10.1158/0008-5472.CAN-04-3410; Schatz AR, 1997, TOXICOL APPL PHARM, V142, P278, DOI 10.1006/taap.1996.8034; Shire D, 1996, J BIOL CHEM, V271, P6941, DOI 10.1074/jbc.271.12.6941; Shoemaker JL, 2005, J PHARMACOL EXP THER, V315, P828, DOI 10.1124/jpet.105.089474; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; Skapenko A, 2001, J IMMUNOL, V166, P4283, DOI 10.4049/jimmunol.166.7.4283; Song ZH, 1999, MOL PHARMACOL, V56, P834; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; Turner RB, 2005, NEW ENGL J MED, V353, P341, DOI 10.1056/NEJMoa044441; Woelkart K, 2005, PLANTA MED, V71, P701, DOI 10.1055/s-2005-871290; Woelkart K, 2005, J CLIN PHARMACOL, V45, P683, DOI 10.1177/0091270004273493; Xie XQ, 2003, PROTEINS, V53, P307, DOI 10.1002/prot.10511; Zoratti C, 2003, BRIT J PHARMACOL, V140, P1351, DOI 10.1038/sj.bjp.0705529	65	196	207	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14192	14206		10.1074/jbc.M601074200	http://dx.doi.org/10.1074/jbc.M601074200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16547349	hybrid			2022-12-25	WOS:000237512300043
J	Lu, M; Gong, XG; Lu, YW; Guo, JJ; Wang, CH; Pan, YJ				Lu, M; Gong, XG; Lu, YW; Guo, JJ; Wang, CH; Pan, YJ			Molecular cloning and functional characterization of a cell-permeable superoxide dismutase targeted to lung adenocarcinoma cells - Inhibition cell proliferation through the Akt/p27(kip1) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; OXIDATIVE STRESS; ANGIOTENSIN-II; BETA-CAROTENE; BINDING; GLUTATHIONE; APOPTOSIS; DNA; OVEREXPRESSION; MITOCHONDRIA	In clinical oncology, many trials with superoxide dismutase (SOD) have failed to demonstrate antitumor ability and in many cases even caused deleterious effects because of low tumor-targeting ability. In the current research, the Nostoc commune Fe-SOD coding sequence was amplified from genomic DNA. In addition, the single chain variable fragment (ScFv) was constructed from the cDNA of an LC-1 hybridoma cell line secreting anti-lung adenocarcinoma monoclonal antibody. After modification, the SOD and ScFv were fused and co-expressed, and the resulting fusion protein produced SOD and LC-1 antibody activity. Tracing SOD-ScFv by fluorescein isothiocyanate and superoxide anions (O-2(-)) in SPC-A-1 cells showed that the fusion protein could recognize and enter SPC-A-1 cells to eliminate O-2(-). The lower oxidative stress resulting from the decrease in cellular O-2(-). delayed the cell cycle at G1 and significantly slowed SPC-A-1 cell growth in association with the dephosphorylation of the serine-threonine protein kinase Akt and expression of p27(kip1). The tumor-targeting fusion protein resulting from this research overcomes two disadvantages of SODs previously used in the clinical setting, the inability to target tumor cells or permeate the cell membrane. These findings lay the groundwork for development of an efficient antitumor drug targeted by the ScFv.	Zhejiang Univ, Inst Biochem, Hangzhou 310027, Peoples R China; Zhejiang Univ, Inst Chem Biol & Pharmaceut Chem, Hangzhou 310027, Peoples R China	Zhejiang University; Zhejiang University	Gong, XG (corresponding author), Zhejiang Univ, Inst Biochem, Hangzhou 310027, Peoples R China.	gongxg@zju.edu.cn; panyuanjiang@zju.edu.cn	lu, min/E-5407-2014					Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BRAVARD A, 1994, INT J CANCER, V59, P843, DOI 10.1002/ijc.2910590622; Delanian S, 2001, RADIOTHER ONCOL, V58, P325, DOI 10.1016/S0167-8140(00)00332-7; Deng TL, 2005, BIOCHEM BIOPH RES CO, V338, P748, DOI 10.1016/j.bbrc.2005.10.010; Fujimura M, 1999, J NEUROSCI, V19, P3414; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; GE XR, 1989, ACTA BIOL EXP SINICA, V22, P359; Grunwaldt G, 2002, J PHOTOCH PHOTOBIO B, V67, P177, DOI 10.1016/S1011-1344(02)00323-8; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Hruszkewycz A M, 1988, Basic Life Sci, V49, P449; JEFFREY SA, 2004, J BIOL CHEM, V48, P50420; Jubeh TT, 2005, MOL PHARMACEUT, V2, P2, DOI 10.1021/mp0499095; Kim CS, 1997, NUCLEIC ACIDS RES, V25, P1085, DOI 10.1093/nar/25.5.1085; Kim YC, 1999, GENE, V239, P129, DOI 10.1016/S0378-1119(99)00369-8; Kimura S, 2005, HYPERTENSION, V45, P438, DOI 10.1161/01.HYP.0000157169.27818.ae; KODAMA M, 1987, ARCH BIOCHEM BIOPHYS, V258, P574, DOI 10.1016/0003-9861(87)90379-1; Lam EWN, 1997, CANCER RES, V57, P5550; Lang CH, 1999, AM J PHYSIOL-GASTR L, V276, pG719, DOI 10.1152/ajpgi.1999.276.3.G719; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lim JH, 1997, FEBS LETT, V406, P142, DOI 10.1016/S0014-5793(97)00262-7; Lindsay MP, 2000, J CEREAL SCI, V31, P321, DOI 10.1006/jcrs.2000.0309; Lu Min, 2005, J Zhejiang Univ Sci B, V6, P832, DOI 10.1631/jzus.2005.B0832; Mahadevan B, 2001, CARCINOGENESIS, V22, P161, DOI 10.1093/carcin/22.1.161; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Mitchinson MJ, 1999, LANCET, V353, P381, DOI 10.1016/S0140-6736(05)74955-2; Nutt LK, 2005, CANCER BIOL THER, V4, P459; Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724; ORWAR O, 1995, ANAL CHEM, V67, P4261, DOI 10.1021/ac00119a010; OYANAGUI Y, 1991, BIOCHEM PHARMACOL, V42, P991, DOI 10.1016/0006-2952(91)90280-I; Palozza P, 2001, FREE RADICAL BIO MED, V30, P1000, DOI 10.1016/S0891-5849(01)00488-9; Paz-Miguel JE, 1999, J IMMUNOL, V163, P5399; Pervaiz S, 1999, FEBS LETT, V459, P343, DOI 10.1016/S0014-5793(99)01258-2; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; Rengel RG, 2005, EUR J PHARM BIOPHARM, V60, P47, DOI 10.1016/j.ejpb.2004.12.002; Sawada GA, 1996, CYTOMETRY, V25, P254, DOI 10.1002/(SICI)1097-0320(19961101)25:3<254::AID-CYTO6>3.3.CO;2-3; Scanlon JM, 1998, J NEUROCHEM, V71, P2392; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHWARZ M, 1984, CARCINOGENESIS, V5, P1663, DOI 10.1093/carcin/5.12.1663; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Shi DY, 2003, FEBS LETT, V542, P60, DOI 10.1016/S0014-5793(03)00338-7; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; UNDARESAN M, 1995, SCIENCE, V270, P296; Venkataraman S, 2005, ONCOGENE, V24, P77, DOI 10.1038/sj.onc.1208145; WEFERS H, 1983, EUR J BIOCHEM, V137, P29, DOI 10.1111/j.1432-1033.1983.tb07791.x; WU YN, 1994, J CELL BIOL, V125, P743, DOI 10.1083/jcb.125.4.743; XIE W, 1996, ACTA BIOL EXP SINICA, V29, P207; Zhang Y, 2002, CANCER RES, V62, P1205; Zimmerman MC, 2005, HYPERTENSION, V45, P717, DOI 10.1161/01.HYP.0000153463.22621.5e	55	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13620	13627		10.1074/jbc.M600523200	http://dx.doi.org/10.1074/jbc.M600523200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551617	hybrid			2022-12-25	WOS:000237336600072
J	Yanofsky, SD; Shen, ES; Holden, F; Whitehorn, E; Aguilar, B; Tate, E; Holmes, CP; Scheuerman, R; MacLean, D; Wu, MM; Frail, DE; Lopez, FJ; Winneker, R; Arey, BJ; Barrett, RW				Yanofsky, SD; Shen, ES; Holden, F; Whitehorn, E; Aguilar, B; Tate, E; Holmes, CP; Scheuerman, R; MacLean, D; Wu, MM; Frail, DE; Lopez, FJ; Winneker, R; Arey, BJ; Barrett, RW			Allosteric activation of the follicle-stimulating hormone (FSH) receptor by selective, nonpeptide agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINATORIAL ORGANIC-SYNTHESIS; EXTRACELLULAR DOMAIN CHIMERAS; LUCIFERASE REPORTER GENE; THYROTROPIN RECEPTOR; AMINO-ACIDS; IN-VIVO; BINDING; ANTAGONIST; SECRETION; DISCOVERY	The pituitary glycoprotein hormones, luteinizing hormone and follicle-stimulating hormone ( FSH), act through their cognate receptors to initiate a series of coordinated physiological events that results in germ cell maturation. Given the importance of FSH in regulating folliculogenesis and fertility, the development of FSH mimetics has been sought to treat infertility. Currently, purified and recombinant human FSH are the only FSH receptor ( FSH-R) agonists available for infertility treatment. By screening unbiased combinatorial chemistry libraries, using a cAMP-responsive luciferase reporter assay, we discovered thiazolidinone agonists ( EC50's = 20 mu M) of the human FSH-R. Subsequent analog library screening and parallel synthesis optimization resulted in the identification of a potent agonist ( EC50 = 2 nM) with full efficacy compared with FSH that was FSH-R-selective and -dependent. The compound mediated progesterone production in Y1 cells transfected with the human FSH-R ( EC50 = 980 nM) and estradiol production from primary rat ovarian granulosa cells ( EC50 = 10.5 nM). This and related compounds did not compete with FSH for binding to the FSH-R. Use of human FSH/thyroid-stimulating hormone ( TSH) receptor chimeras suggested a novel mechanism for receptor activation through a binding site independent of the natural hormone binding site. This study is the first report of a high affinity small molecule agonist that activates a glycoprotein hormone receptor through an allosteric mechanism. The small molecule FSH receptor agonists described here could lead to an oral alternative to the current parenteral FSH treatments used clinically to induce ovarian stimulation for both in vivo and in vitro fertilization therapy.	Affymax Inc, Palo Alto, CA 94304 USA; Wyeth Pharmaceut, Womens Hlth & Musculoskeletal Biol, Collegeville, PA 19426 USA	Pfizer	Yanofsky, SD (corresponding author), 3781 Nathan Way, Palo Alto, CA 94303 USA.	syanofsky@sbcglobal.net						AITTOMAKI K, 1995, CELL, V82, P959, DOI 10.1016/0092-8674(95)90275-9; ALBANESE C, 1994, MOL CELL ENDOCRINOL, V101, P211, DOI 10.1016/0303-7207(94)90237-2; Arey BJ, 1997, MOL ENDOCRINOL, V11, P517, DOI 10.1210/me.11.5.517; Arey BJ, 2005, ENDOCRINOLOGY, V146, P2015, DOI 10.1210/en.2004-1318; Arey BJ, 2002, ENDOCRINOLOGY, V143, P3822, DOI 10.1210/en.2002-220372; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Chappel S, 1998, HUM REPROD, V13, P18, DOI 10.1093/humrep/13.suppl_3.18; CHRISTOPHE S, 1993, BIOCHEM BIOPH RES CO, V196, P402, DOI 10.1006/bbrc.1993.2263; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; Dierich A, 1998, P NATL ACAD SCI USA, V95, P13612, DOI 10.1073/pnas.95.23.13612; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; George SE, 1998, BIOCHEM PHARMACOL, V56, P25, DOI 10.1016/S0006-2952(98)00014-8; George SE, 1997, J NEUROCHEM, V69, P1278; GORDON EM, 1995, CURR OPIN BIOTECH, V6, P624, DOI 10.1016/0958-1669(95)80103-0; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Guo T, 2004, BIOORG MED CHEM LETT, V14, P1713, DOI 10.1016/j.bmcl.2004.01.042; Guo T, 2004, BIOORG MED CHEM LETT, V14, P1717, DOI 10.1016/j.bmcl.2004.01.043; HOLMES CP, 1995, J ORG CHEM, V60, P7328, DOI 10.1021/jo00127a044; HOLMES CP, 1995, J ORG CHEM, V60, P2318, DOI 10.1021/jo00113a004; HSUEH AJW, 1989, RECENT PROG HORM RES, V45, P209; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; JI IH, 1995, J BIOL CHEM, V270, P15970, DOI 10.1074/jbc.270.27.15970; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; Koller KJ, 1997, ANAL BIOCHEM, V250, P51, DOI 10.1006/abio.1997.2190; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; Maclean D, 2004, J COMB CHEM, V6, P196, DOI 10.1021/cc0300154; May LT, 2003, CURR OPIN PHARMACOL, V3, P551, DOI 10.1016/S1471-4892(03)00107-3; McDonnell J, 1998, BRIT J PHARMACOL, V125, P717, DOI 10.1038/sj.bjp.0702139; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1150, DOI 10.1016/S0006-291X(05)80906-4; Ni ZJ, 1996, J MED CHEM, V39, P1601, DOI 10.1021/jm960043j; Sohn J, 2002, J BIOL CHEM, V277, P50165, DOI 10.1074/jbc.M207646200; Stevis PE, 1999, ENDOCRINE, V10, P153, DOI 10.1385/ENDO:10:2:153; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; VASSART G, 1991, TRENDS ENDOCRIN MET, V2, P151, DOI 10.1016/1043-2760(91)90006-9; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974	39	60	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13226	13233		10.1074/jbc.M600601200	http://dx.doi.org/10.1074/jbc.M600601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16540466	hybrid			2022-12-25	WOS:000237336600028
J	Harada, K; Okiyoneda, T; Hashimoto, Y; Ueno, K; Nakamura, K; Yamahira, K; Sugahara, T; Shuto, T; Wada, I; Suico, MA; Kai, H				Harada, K; Okiyoneda, T; Hashimoto, Y; Ueno, K; Nakamura, K; Yamahira, K; Sugahara, T; Shuto, T; Wada, I; Suico, MA; Kai, H			Calreticulin negatively regulates the cell surface expression of cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; CFTR; DEGRADATION; DELTA-F508; PROTEASOME; CALNEXIN; CHAPERONE; GOLGI	Cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent Cl- channel at the plasma membrane, and its malfunction results in cystic fibrosis, the most common lethal genetic disease in Caucasians. Quality control of CFTR is strictly regulated by several molecular chaperones. Here we show that calreticulin (CRT), which is a lectin-like chaperone in the endoplasmic reticulum (ER), negatively regulates the cell surface CFTR. RNA interference- based CRT knockdown induced the increase of CFTR expression. Consistently, this effect was observed in vivo. CRT heterozygous (CRT+/-) mice had a higher endogenous expression of CFTR than the wild-type mice. Moreover, CRT overexpression induced cell surface expression of CRT, and it significantly decreased the cell surface expression and function of CFTR. CRT overexpression destabilized the cell surface CFTR by enhancing endocytosis, leading to proteasomal degradation. Deletion of the carboxyl domain of CRT, which results in its ER export, increased the negative effect and enhanced the interaction with CFTR. Thus, CRT in the post-ER compartments may act as a negative regulator of the cell surface CFTR.	Kumamoto Univ, Fac Med & Pharmaceut Sci, Dept Mol Med, Kumamoto 8620973, Japan; Kumamoto Univ, Fac Med & Pharmaceut Sci, Dept Pediat, Kumamoto 8620973, Japan; Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima 9601295, Japan	Kumamoto University; Kumamoto University; Fukushima Medical University	Kai, H (corresponding author), Kumamoto Univ, Fac Med & Pharmaceut Sci, Dept Mol Med, Kumamoto 8620973, Japan.	hirokai@gpo.kumamoto-u.ac.jp		, Kimitoshi/0000-0003-4903-2428; Okiyoneda, Tsukasa/0000-0002-5175-2224; Wada, Ikuo/0000-0001-5668-6994				Alberti S, 2004, MOL BIOL CELL, V15, P4003, DOI 10.1091/mbc.E04-04-0293; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Berwin B, 2003, EMBO J, V22, P6127, DOI 10.1093/emboj/cdg572; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Cantin AM, 2006, AM J PHYSIOL-CELL PH, V290, pC262, DOI 10.1152/ajpcell.00070.2005; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Flores-Diaz M, 2004, J BIOL CHEM, V279, P21724, DOI 10.1074/jbc.M312791200; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Ihara Y, 2005, BIOCHEM BIOPH RES CO, V329, P1343, DOI 10.1016/j.bbrc.2005.02.112; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Lukacs GL, 1997, BIOCHEM J, V328, P353; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; Nagaya H, 2002, MOL BIOL CELL, V13, P302, DOI 10.1091/mbc.01-05-0255; Okiyoneda T, 2004, J PHARMACOL SCI, V95, P471, DOI 10.1254/jphs.SC0040081; Okiyoneda T, 2004, MOL BIOL CELL, V15, P563, DOI 10.1091/mbc.E03-06-0379; Okiyoneda T, 2002, FEBS LETT, V526, P87, DOI 10.1016/S0014-5793(02)03134-4; PIND S, 1994, J BIOL CHEM, V269, P12784; Popescu CI, 2005, J BIOL CHEM, V280, P13833, DOI 10.1074/jbc.M413087200; Ribeiro CMP, 2005, J BIOL CHEM, V280, P10202, DOI 10.1074/jbc.M410317200; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rizvi SM, 2004, MOL CELL, V15, P913, DOI 10.1016/j.molcel.2004.09.001; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	44	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12841	12848		10.1074/jbc.M512975200	http://dx.doi.org/10.1074/jbc.M512975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527813	hybrid			2022-12-25	WOS:000237134700079
J	Li, HT; Liu, XP; Cui, HM; Chen, YR; Chen, YR; Cardounel, AJ; Zweier, JL				Li, HT; Liu, XP; Cui, HM; Chen, YR; Chen, YR; Cardounel, AJ; Zweier, JL			Characterization of the mechanism of cytochrome p450 reductase-cytochrome p450-mediated nitric oxide and nitrosothiol generation from organic nitrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERYL TRINITRATE BIOTRANSFORMATION; AORTIC GUANYLYL CYCLASE; XANTHINE-OXIDASE; DIPHENYLENEIODONIUM SULFATE; S-NITROSOTHIOLS; C REDUCTASE; GLUTATHIONE TRANSFERASE; PHARMACOLOGICAL ACTIONS; FLAVOPROTEIN INHIBITOR; BIOLOGICAL-SYSTEMS	Mammalian cytochrome P450 reductase (CPR) and cytochrome P450 (CP) play important roles in organic nitrate bioactivation; however, the mechanism by which they convert organic nitrate to NO remains unknown. Questions remain regarding the initial precursor of NO that serves to link organic nitrate to the activation of soluble guanylyl cyclase (sGC). To characterize the mechanism of CPR-CP-mediated organic nitrate bioactivation, EPR, chemiluminescence NO analyzer, NO electrode, and immunoassay studies were performed. With rat hepatic microsomes or purified CPR, the presence of NADPH triggered organic nitrate reduction to NO2-. The CPR flavin site inhibitor diphenyleneiodonium inhibited this NO2- generation, whereas the CP inhibitor clotrimazole did not. However, clotrimazole greatly inhibited NO2--dependent NO generation. Therefore, CPR catalyzes organic nitrate reduction, producing nitrite, whereas CP can mediate further nitrite reduction to NO. Nitrite-dependent NO generation contributed < 10% of the CPR-CP-mediated NO generation from organic nitrates; thus, NO2- is not the main precursor of NO. CPR-CP-mediated NO generation was largely thiol-dependent. Studies suggested that organic nitrite (R-O-NO) was produced from organic nitrate reduction by CPR. Further reaction of organic nitrite with free or microsome-associated thiols led to NO or nitrosothiol generation and thus stimulated the activation of sGC. Thus, organic nitrite is the initial product in the process of CRP-CP-mediated organic nitrate activation and is the precursor of NO and nitrosothiols, serving as the link between organic nitrate and sGC activation.	Ohio State Univ, Coll Med, Davis Heart & Lung Res Inst 110G, Ctr Biomed EPR Spect & Imaging, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Div Cardiovasc Med, Dept Internal Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Zweier, JL (corresponding author), Ohio State Univ, Coll Med, Davis Heart & Lung Res Inst 110G, Ctr Biomed EPR Spect & Imaging, 473 W 12th Ave, Columbus, OH 43210 USA.	jay.zweier@osumc.edu	Liu, Xiaoping/A-4516-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, P01HL065608, R01HL063744, R29HL038324, R01HL083237] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL083237, HL65608, HL63744, HL38324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BENNETT BM, 1992, J PHARMACOL EXP THER, V261, P716; BENNETT BM, 1994, TRENDS PHARMACOL SCI, V15, P245, DOI 10.1016/0165-6147(94)90319-0; BORNFELDT KE, 1987, PHARMACOL TOXICOL, V60, P110, DOI 10.1111/j.1600-0773.1987.tb01507.x; BURGER IH, 1971, BIOCHEM J, V123, pP9; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; DELAFORGE M, 1993, CHEM-BIOL INTERACT, V86, P103, DOI 10.1016/0009-2797(93)90115-F; Doel JJ, 2001, BBA-GEN SUBJECTS, V1527, P81, DOI 10.1016/S0304-4165(01)00148-9; Dohr O, 2001, P NATL ACAD SCI USA, V98, P81, DOI 10.1073/pnas.98.1.81; DUTHU GS, 1979, DRUG METAB DISPOS, V7, P263; FEELISCH M, 1992, BIOCHEM PHARMACOL, V44, P1149, DOI 10.1016/0006-2952(92)90379-W; Feelisch M, 1999, MOL PHARMACOL, V56, P243, DOI 10.1124/mol.56.2.243; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Grosser N, 2000, BIOCHEM BIOPH RES CO, V274, P255, DOI 10.1006/bbrc.2000.3121; HORECKER BL, 1950, ARCH BIOCHEM, V29, P232; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; Ji YB, 1996, BIOCHEM J, V313, P377, DOI 10.1042/bj3130377; KOWALUK EA, 1993, DRUG METAB DISPOS, V21, P967; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; Lee WI, 2003, NITRIC OXIDE-BIOL CH, V8, P103, DOI 10.1016/S1089-8603(02)00183-0; Li HT, 2004, J BIOL CHEM, V279, P16939, DOI 10.1074/jbc.M314336200; Li HT, 2005, J BIOL CHEM, V280, P16594, DOI 10.1074/jbc.M411905200; Li HT, 2003, BIOCHEMISTRY-US, V42, P1150, DOI 10.1021/bi026385a; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; LIU ZG, 1993, J PHARMACOL EXP THER, V264, P1432; LIU ZG, 1992, EUR J PHARMACOL, V211, P129, DOI 10.1016/0014-2999(92)90275-9; MCDONALD BJ, 1994, CAN J PHYSIOL PHARM, V72, P1513, DOI 10.1139/y94-217; MCDONALD BJ, 1993, BIOCHEM PHARMACOL, V45, P268, DOI 10.1016/0006-2952(93)90403-J; MCDONALD BJ, 1990, CAN J PHYSIOL PHARM, V68, P1552, DOI 10.1139/y90-236; MCGUIRE JJ, 1994, J PHARMACOL EXP THER, V271, P708; McGuire JJ, 1998, BIOCHEM PHARMACOL, V56, P881, DOI 10.1016/S0006-2952(98)00216-0; Meah Y, 2001, P NATL ACAD SCI USA, V98, P8560, DOI 10.1073/pnas.151249098; MELLION BT, 1983, MOL PHARMACOL, V23, P653; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MEYER DJ, 1994, FEBS LETT, V351, P427, DOI 10.1016/0014-5793(94)00904-X; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; Nohl H, 2000, ACTA BIOCHIM POL, V47, P913, DOI 10.18388/abp.2000_3946; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; RAIKHMAN L M, 1971, Biofizika, V16, P1135; Ratz JD, 2000, J PHARMACOL EXP THER, V293, P569; Ratz JD, 1999, BRIT J PHARMACOL, V126, P61, DOI 10.1038/sj.bjp.0702268; Reutov VP, 1998, BIOCHEMISTRY-MOSCOW+, V63, P874; ROMANIN C, 1988, J MOL CELL CARDIOL, V20, P389, DOI 10.1016/S0022-2828(88)80130-5; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; SCHNEEWEISS A, 1990, ADV NITRATE THERAPY, P155; SERVENT D, 1989, BIOCHEM BIOPH RES CO, V163, P1210, DOI 10.1016/0006-291X(89)91106-6; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; Tiravanti E, 2004, J BIOL CHEM, V279, P11065, DOI 10.1074/jbc.M311908200; Vanin AF, 2000, BBA-GEN SUBJECTS, V1474, P365, DOI 10.1016/S0304-4165(00)00033-7; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; Wong PSY, 1999, DRUG METAB DISPOS, V27, P502; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; Yuan R, 1997, J PHARMACOL EXP THER, V281, P1499; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	60	61	63	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12546	12554		10.1074/jbc.M511803200	http://dx.doi.org/10.1074/jbc.M511803200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527817	hybrid			2022-12-25	WOS:000237134700043
J	Peterson, YK; Kelly, P; Weinbaum, CA; Casey, PJ				Peterson, YK; Kelly, P; Weinbaum, CA; Casey, PJ			A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-RNA REPLICATION; RHO-GTPASES; FARNESYLTRANSFERASE INHIBITORS; CANCER; CELLS; GERANYLGERANYLATION; PRENYLATION; FARNESYL; RAS; APOPTOSIS	Inhibiting protein prenylation is an attractive means to modulate cellular processes controlled by a variety of signaling proteins, including oncogenic proteins such as Ras and Rho GTPases. The largest class of prenylated proteins contain a so-called CaaX motif at their carboxyl termini and are subject to a maturation process initiated by the attachment of an isoprenoid lipid by either protein farnesyltransferase ( FTase) or protein geranylgeranyltransferase type I ( GGTase-I). Inhibitors of FTase, termed FTIs, have been the subject of intensive development in the past decade and have shown efficacy in clinical trials. Although GGTase-I inhibitors (GGTIs) have received less attention, accumulating evidence suggests GGTIs may augment therapies using FTIs and could be useful to treat a myriad of additional disease states. Here we describe the characterization of a selective, highly potent, and cell-active GGTase-I inhibitor, GGTI-DU40. Kinetic analysis revealed that inhibition by GGTI-DU40 is competitive with the protein substrate and uncompetitive with the isoprenoid substrate; the K-i for the inhibition is 0.8 nM. GGTI-DU40 is highly selective for GGTase-I both in vitro and in living cells. Studies indicate GGTI-DU40 blocks prenylation of a number of geranylgeranylated CaaX proteins. Treatment of MDAMB-231 breast cancer cells with GGTI-DU40 inhibited thrombin-induced cell rounding via a process that involves inhibition of Rho proteins without significantly effecting parallel mobilization of calcium via G beta gamma. These studies establish GGTI-DU40 as a prime tool for interrogating biologies associated with protein geranylgeranylation and define a novel structure for this emerging class of experimental therapeutics.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aznar S, 2004, CANCER LETT, V206, P181, DOI 10.1016/j.canlet.2003.08.035; Baron Rudi A., 2004, BMC Biochemistry, V5, P19, DOI 10.1186/1471-2091-5-19; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; Carrico D, 2005, BIOORGAN MED CHEM, V13, P677, DOI 10.1016/j.bmc.2004.10.053; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Doll RJ, 2004, CURR OPIN DRUG DISC, V7, P478; Einav S, 2003, J ANTIMICROB CHEMOTH, V52, P883, DOI 10.1093/jac/dkg490; Fiordalisi JJ, 2003, J BIOL CHEM, V278, P41718, DOI 10.1074/jbc.M305733200; Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02-1014fje; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Karp J. E., 2004, Annals of Hematology, V83, pS87; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Meigs TE, 2005, J BIOL CHEM, V280, P18049, DOI 10.1074/jbc.M500445200; Meigs TE, 2002, J BIOL CHEM, V277, P24594, DOI 10.1074/jbc.M201984200; Morgan MA, 2003, LEUKEMIA, V17, P1508, DOI 10.1038/sj.leu.2403022; Park HJ, 2002, CIRC RES, V91, P143, DOI 10.1161/01.RES.0000028149.15986.4C; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Rao S, 2004, J CLIN ONCOL, V22, P3950, DOI 10.1200/JCO.2004.10.037; Reid TS, 2004, J MOL BIOL, V343, P417, DOI 10.1016/j.jmb.2004.08.056; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Sivakumar B, 2004, JAMA-J AM MED ASSOC, V292, P972, DOI 10.1001/jama.292.8.972; Smith V, 2002, CLIN CANCER RES, V8, P2002; Stark WW, 1998, AM J PHYSIOL-LUNG C, V275, pL55, DOI 10.1152/ajplung.1998.275.1.L55; Sun JZ, 2003, CANCER RES, V63, P8922; Thissen JA, 1996, ANAL BIOCHEM, V243, P80, DOI 10.1006/abio.1996.0484; Vasudevan A, 1999, J MED CHEM, V42, P1333, DOI 10.1021/jm9900873; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Walters CE, 2002, J IMMUNOL, V168, P4087, DOI 10.4049/jimmunol.168.8.4087; Wang CF, 2005, MOL CELL, V18, P425, DOI 10.1016/j.molcel.2005.04.004; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Ye J, 2003, P NATL ACAD SCI USA, V100, P15865, DOI 10.1073/pnas.2237238100; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	50	56	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12445	12450		10.1074/jbc.M600168200	http://dx.doi.org/10.1074/jbc.M600168200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517596	hybrid			2022-12-25	WOS:000237134700031
J	Rosen, KM; Veereshwarayya, V; Moussa, CEH; Fu, QH; Goldberg, MS; Schlossmacher, MG; Shen, J; Querfurth, HW				Rosen, KM; Veereshwarayya, V; Moussa, CEH; Fu, QH; Goldberg, MS; Schlossmacher, MG; Shen, J; Querfurth, HW			Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY MYOSITIS; ENDOPLASMIC-RETICULUM STRESS; PRECURSOR PROTEIN; ALPHA-SYNUCLEIN; OXIDATIVE DAMAGE; GENE; ALZHEIMERS; DISEASE; PROTEASOME; UBIQUITIN	Mutations in the ubiquitin ligase-encoding Parkin gene have been implicated in the pathogenesis of autosomal recessive Parkinson disease. Outside of the central nervous system, Parkin is prominently expressed in skeletal muscle. We have found accumulations of Parkin protein in skeletal muscle biopsies taken from patients with inclusion body myositis, a degenerative disorder in which intramyofiber accumulations of the beta-amyloid peptide are pathognomonic. In comparing primary cultures of skeletal muscle derived from parkin knock-out and wild-type mice, we have found the absence of parkin to result in greater sensitivity to mitochondrial stressors rotenone and carbonyl cyanide 3-chlorophenylhydrazone, without any alteration in sensitivity to calcium ionophore or hydrogen peroxide. Utilizing viral expression constructs coding for the Alzheimer disease and inclusion body myositis-linked beta-amyloid precursor protein and for its metabolic byproducts A beta 42 and C100, we found that parkin knock-out muscle cells are also more sensitive to the toxic effects of intracellular A beta. We also constructed a lentiviral system to overexpress wild-type Parkin and have shown that boosting the levels of parkin expression in normal skeletal muscle cultures provides substantial protection against both mitochondrial toxins and overexpressed beta-amyloid. Correspondingly, exogenous Parkin significantly lowered A beta levels. These data support the hypothesis that in myocytes parkin has dual properties in the maintenance of skeletal muscle mitochondrial homeostasis and in the regulation of A beta levels.	Tufts Univ, Dept Neurol, Caritas St Elizabeths Med Ctr, Sch Med, Boston, MA 02135 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA	St. Elizabeth's Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Rosen, KM (corresponding author), Tufts Univ, Dept Neurol, Caritas St Elizabeths Med Ctr, Sch Med, 736 Cambridge St, Boston, MA 02135 USA.	kenneth_rosen@cchcs.org; henry.querfurth@tufts.edu	Goldberg, Matthew/T-7827-2019	Goldberg, Matthew/0000-0002-5172-9841; Schlossmacher, Michael/0000-0002-0394-0300	NINDS NIH HHS [NS041373] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041373] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; ASKANAS V, 1991, NEUROSCI LETT, V130, P73, DOI 10.1016/0304-3940(91)90230-Q; Askanas V, 2002, CURR OPIN NEUROL, V15, P525, DOI 10.1097/00019052-200210000-00002; Askanas V, 1996, P NATL ACAD SCI USA, V93, P1314, DOI 10.1073/pnas.93.3.1314; Askanas V, 1997, NEUROREPORT, V8, P2155, DOI 10.1097/00001756-199707070-00012; Askanas Valerie, 1995, Current Opinion in Rheumatology, V7, P486, DOI 10.1097/00002281-199511000-00005; Beal MF, 2004, J BIOENERG BIOMEMBR, V36, P381, DOI 10.1023/B:JOBB.0000041772.74810.92; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Carpenter S, 1996, J NEUROPATH EXP NEUR, V55, P1105, DOI 10.1097/00005072-199611000-00001; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; Dachsel JC, 2005, FEBS LETT, V579, P3913, DOI 10.1016/j.febslet.2005.06.003; Dalakas Marinos C., 2001, Current Opinion in Pharmacology, V1, P300, DOI 10.1016/S1471-4892(01)00053-4; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Fratta P, 2005, AM J PATHOL, V167, P517, DOI 10.1016/S0002-9440(10)62994-X; Fukuchi K, 1998, AM J PATHOL, V153, P1687, DOI 10.1016/S0002-9440(10)65682-9; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Greene JC, 2005, HUM MOL GENET, V14, P799, DOI 10.1093/hmg/ddi074; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Johnstone EM, 1996, BIOCHEM BIOPH RES CO, V220, P710, DOI 10.1006/bbrc.1996.0469; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Ko HS, 2005, J NEUROSCI, V25, P7968, DOI 10.1523/JNEUROSCI.2172-05.2005; LaVoie MJ, 2005, NAT MED, V11, P1214, DOI 10.1038/nm1314; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; Mattson MP, 2002, INT REV NEUROBIOL, V53, P387; MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J; McFerrin J, 1998, NEUROREPORT, V9, P3201, DOI 10.1097/00001756-199810050-00013; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Nunan J, 2003, J NEUROSCI RES, V74, P378, DOI 10.1002/jnr.10646; Nunan J, 2001, EUR J BIOCHEM, V268, P5329, DOI 10.1046/j.0014-2956.2001.02465.x; Ohyagi Y, 2000, NEUROREPORT, V11, P167, DOI 10.1097/00001756-200001170-00033; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Pesah Y, 2004, DEVELOPMENT, V131, P2183, DOI 10.1242/dev.01095; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Pramstaller PP, 2005, ANN NEUROL, V58, P411, DOI 10.1002/ana.20587; Querfurth HW, 2001, MOL CELL NEUROSCI, V17, P793, DOI 10.1006/mcne.2001.0972; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Skovronsky DM, 2000, BIOCHEMISTRY-US, V39, P810, DOI 10.1021/bi991728z; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Sugarman MC, 2006, NEUROBIOL AGING, V27, P423, DOI 10.1016/j.neurobiolaging.2005.02.011; Sugarman MC, 2002, P NATL ACAD SCI USA, V99, P6334, DOI 10.1073/pnas.082545599; Vattemi G, 2004, AM J PATHOL, V164, P1, DOI 10.1016/S0002-9440(10)63089-1; Vattemi G, 2001, LANCET, V358, P1962, DOI 10.1016/S0140-6736(01)06969-0; Ved R, 2005, J BIOL CHEM, V280, P42655, DOI 10.1074/jbc.M505910200; von Coelln R, 2004, CELL TISSUE RES, V318, P175, DOI 10.1007/s00441-004-0924-4; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; West AB, 2002, HUM MOL GENET, V11, P2787, DOI 10.1093/hmg/11.22.2787; Wilczynski GM, 2000, AM J PATHOL, V156, P1835, DOI 10.1016/S0002-9440(10)65056-0; Winklhofer KF, 2003, J BIOL CHEM, V278, P47199, DOI 10.1074/jbc.M306769200; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	59	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12809	12816		10.1074/jbc.M512649200	http://dx.doi.org/10.1074/jbc.M512649200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517603	hybrid			2022-12-25	WOS:000237134700075
J	Totzke, G; Essmann, F; Pohlmann, S; Lindenblatt, C; Janicke, RU; Schulze-Osthoff, K				Totzke, G; Essmann, F; Pohlmann, S; Lindenblatt, C; Janicke, RU; Schulze-Osthoff, K			A novel member of the I kappa B family, human I kappa B-zeta, inhibits transactivation of p65 and its DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOPROTEIN BCL-3; GENE-EXPRESSION; INDUCED APOPTOSIS; TUMOR-CELLS; CYCLIN D1; PROTEIN; RECEPTOR; ALPHA; ACTIVATION; PHOSPHORYLATION	A novel member of the I kappa B family, human I kappa B-zeta, was identified by a differential screening approach of apoptosis-sensitive and -resistant tumor cells. The protein consists of 6 ankyrin repeats at its COOH terminus and shares about 30% identity with other I kappa B members. I kappa B-zeta associates with both the p65 and p50 subunit of NF-kappa B and inhibits the transcriptional activity as well as the DNA binding of the transcription factor. Interestingly, I kappa B-zeta is localized in the nucleus where it aggregates in matrix-associated deacetylase bodies, indicating that I kappa B-zeta regulates nuclear NF-kappa B activity rather than its nuclear translocation from the cytoplasm. I kappa B-zeta expression itself was regulated by NF-kappa B, suggesting that its activity is controlled in a negative feedback loop. Unlike classical I kappa B proteins, I kappa B-zeta was not degraded upon cell stimulation. Treatment with tumor necrosis factor-alpha, interleukin-1 beta, and lipopolysaccharide induced a strong induction of I kappa B-zeta transcripts. Expression of I kappa B-zeta was detected in different tissues including lung, liver, and in leukocytes but not in the brain. Suppression of endogenous I kappa B-zeta by RNA interference rendered cells more resistant to apoptosis, whereas overexpression of I kappa B-zeta was sufficient to induce cell death. Our results, therefore, suggest that I kappa B-zeta functions as an additional regulator of NF-kappa B activity and, hence, provides another control level for the activation of NF-kappa B-dependent target genes.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013; Essmann, Frank/ABG-7409-2020	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Essmann, Frank/0000-0003-4369-8456				ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Engels IH, 2005, MOL CELL BIOL, V25, P2808, DOI 10.1128/MCB.25.7.2808-2818.2005; Eto A, 2003, BIOCHEM BIOPH RES CO, V301, P495, DOI 10.1016/S0006-291X(02)03082-6; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore TD, 1996, ONCOGENE, V13, P1367; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Haruta H, 2001, J BIOL CHEM, V276, P12485, DOI 10.1074/jbc.C100075200; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hirotani T, 2005, J IMMUNOL, V174, P3650, DOI 10.4049/jimmunol.174.6.3650; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; KO Y, 1995, MOL CELL PROBE, V9, P215, DOI 10.1016/S0890-8508(95)90070-5; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Motoyama M, 2005, J BIOL CHEM, V280, P7444, DOI 10.1074/jbc.M412738200; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Stier S, 2000, FEBS LETT, V467, P299, DOI 10.1016/S0014-5793(00)01177-7; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Totzke G, 2003, ONCOGENE, V22, P8021, DOI 10.1038/sj.onc.1206837; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wu C, 2003, J BIOL CHEM, V278, P31980, DOI 10.1074/jbc.M304278200; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yamazaki S, 2005, J BIOL CHEM, V280, P1678, DOI 10.1074/jbc.M409983200	56	78	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12645	12654		10.1074/jbc.M511956200	http://dx.doi.org/10.1074/jbc.M511956200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16513645	hybrid			2022-12-25	WOS:000237134700055
J	Qin, HW; Wilson, CA; Lee, SJ; Benveniste, EN				Qin, Hongwei; Wilson, Cynthia A.; Lee, Sun Jung; Benveniste, Etty N.			IFN-beta-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia	FASEB JOURNAL			English	Article						macrophages; microglia	CYTOKINE SIGNALING SOCS; NF-KAPPA-B; IMMUNE-SYSTEM; TRANSCRIPTION; GAMMA; TRANSDUCTION; ACTIVATION; SUPPRESSOR; INDUCTION; INHIBITOR	Costimulation between T cells and antigenpresenting cells is required for adaptive immune responses. CD40, a costimulatory molecule, is expressed in macrophages and microglia. The aberrant expression of CD40 is involved in human diseases including multiple sclerosis, rheumatoid arthritis, and Alzheimer's disease. CD40 expression is induced by a variety of stimuli, including IFN-gamma and lipopolysaccharide (LPS). In this study, we describe the molecular basis by which IFN-beta, a cytokine with immunomodulatory properties, regulates CD40 gene expression. IFN-beta induces CD40 expression in macrophages and microglia at the transcriptional level, and GAS elements in the CD40 promoter are required for IFN-beta-induced CD40 promoter activity. The critical role of signal transducers and activators of transcription-1 alpha (STAT-1 alpha) in this response was confirmed by utilizing primary microglia from STAT-1 alpha deficient mice. IFN-beta induces suppressor of cytokine signaling-1 (SOCS-1) gene expression, which inhibits cytokine signaling by inhibiting activation of STAT proteins. The ectopic expression of SOCS-1 abrogates IFN-beta-mediated STAT-1 alpha activation and inhibits IFN-beta-induced CD40 expression. IFN-beta-induced recruitment of STAT-1 alpha and RNA Pol II and permissive histone modifications on the CD40 promoter are also inhibited by SOCS-1 overexpression. These novel results indicate that IFN-beta-induced SOCS-1 plays an important role in the negative regulation of IFN-beta-induced CD40 gene expression.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Benveniste, EN (corresponding author), Univ Alabama, Dept Cell Biol, 1918 Univ Blvd,MCLM 395, Birmingham, AL 35294 USA.	tika@uab.edu			NIADDK NIH HHS [AM20614] Funding Source: Medline; NIAMS NIH HHS [AR-48311] Funding Source: Medline; NINDS NIH HHS [NS-45290, NS-36765] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036765, R01NS045290] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Bartholome EJ, 2001, J INTERF CYTOK RES, V21, P495, DOI 10.1089/10799900152434367; Belardelli F, 2002, CYTOKINE GROWTH F R, V13, P119, DOI 10.1016/S1359-6101(01)00022-3; Benveniste EN, 2004, BRAIN BEHAV IMMUN, V18, P7, DOI 10.1016/j.bbi.2003.09.001; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Comabella M, 2002, J NEUROIMMUNOL, V126, P205, DOI 10.1016/S0165-5728(02)00064-4; Cooney RN, 2002, SHOCK, V17, P83, DOI 10.1097/00024382-200202000-00001; Dhib-Jalbut S, 1997, MULT SCLER J, V3, P397, DOI 10.1177/135245859700300609; Diehl S, 2000, IMMUNITY, V13, P805, DOI 10.1016/S1074-7613(00)00078-9; Ding YZ, 2003, J IMMUNOL, V170, P1383, DOI 10.4049/jimmunol.170.3.1383; Elliott J, 2004, TRENDS IMMUNOL, V25, P434, DOI 10.1016/j.it.2004.05.012; Floris S, 2002, J NEUROIMMUNOL, V127, P69, DOI 10.1016/S0165-5728(02)00098-X; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Hebenstreit D, 2003, J IMMUNOL, V171, P5901, DOI 10.4049/jimmunol.171.11.5901; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Ilangumaran S, 2004, SEMIN IMMUNOL, V16, P351, DOI 10.1016/j.smim.2004.08.015; Jegalian AG, 2002, J BIOL CHEM, V277, P2345, DOI 10.1074/jbc.M105575200; Johnston JA, 2003, NAT IMMUNOL, V4, P507, DOI 10.1038/ni0603-507; Jones J, 2005, VIROLOGY, V331, P106, DOI 10.1016/j.virol.2004.10.013; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Karaghiosoff M, 2003, NAT IMMUNOL, V4, P471, DOI 10.1038/ni910; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kim MO, 2002, J NEUROCHEM, V81, P1361, DOI 10.1046/j.1471-4159.2002.00949.x; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lin RT, 1999, MOL CELL BIOL, V19, P959; Losman JA, 1999, J IMMUNOL, V162, P3770; LU HT, 1995, J EXP MED, V182, P1517, DOI 10.1084/jem.182.5.1517; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Mostecki J, 2005, J BIOL CHEM, V280, P2596, DOI 10.1074/jbc.M408938200; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Nguyen VT, 2002, J BIOL CHEM, V277, P13796, DOI 10.1074/jbc.M111906200; NORRIS JG, 1993, J NEUROIMMUNOL, V45, P137; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Qin HW, 2005, BLOOD, V106, P3114, DOI 10.1182/blood-2005-02-0759; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Shrikant P, 1996, J IMMUNOL, V156, P1307; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Sporri B, 2001, BLOOD, V97, P221, DOI 10.1182/blood.V97.1.221; Stevenson NJ, 2004, J IMMUNOL, V173, P3243, DOI 10.4049/jimmunol.173.5.3243; Teige I, 2003, J IMMUNOL, V170, P4776, DOI 10.4049/jimmunol.170.9.4776; Travagli J, 2004, J BIOL CHEM, V279, P35183, DOI 10.1074/jbc.M403223200; WANG RK, 2000, P SOC PHOTO-OPT INS, V1, P12; Wesemann DR, 2004, NAT IMMUNOL, V5, P199, DOI 10.1038/ni1025; Wesemann DR, 2002, J IMMUNOL, V169, P2354, DOI 10.4049/jimmunol.169.5.2354; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200	51	63	66	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2006	20	7					985	+		10.1096/fj.05-5493fje	http://dx.doi.org/10.1096/fj.05-5493fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	079EG	16571771				2022-12-25	WOS:000240157700030
J	Sutherland, CM; Moretti, PAB; Hewitt, NM; Bagley, CJ; Vadas, MA; Pitson, SM				Sutherland, CM; Moretti, PAB; Hewitt, NM; Bagley, CJ; Vadas, MA; Pitson, SM			The calmodulin-binding site of sphingosine kinase and its role in agonist-dependent translocation of sphingosine kinase 1 to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; TARGET RECOGNITION; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; HUMAN MACROPHAGES; CELL-MIGRATION; ACTIVATION; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; RECEPTOR	Sphingosine kinases catalyze the formation of sphingosine 1-phosphate, a bioactive lipid involved in many aspects of cellular regulation, including the fundamental biological processes of cell growth and survival. A diverse range of cell agonists induce activation of human sphingosine kinase 1 (hSK1) and, commonly, its translocation to the plasma membrane. Although the activation of hSK1 in response to at least some agonists occurs directly via its phosphorylation at Ser(225) by ERK1/2, many aspects governing the regulation of this phosphorylation and subsequent translocation remain unknown. Here, in an attempt to understand some of these processes, we have examined the known interaction of hSK1 with calmodulin (CaM). By using a combination of limited proteolysis, peptide interaction analysis, and site-directed mutagenesis, we have identified that the CaM-binding site of hSK1 resides in the region spanned by residues 191 - 206. Specifically, Phe(197) and Leu(198) are critically involved in the interaction because a version of hSK1 incorporating mutations of both Phe(197) --> Ala and Leu(198) --> Gln failed to bind CaM. We have also shown for the first time that human sphingosine kinase 2 (hSK2) binds CaM, and does so via a CaM binding region that is conserved with hSK1 because comparable mutations in hSK2 also ablate CaM binding to this protein. By using the CaM-binding-deficient version of hSK1, we have begun to elucidate the role of CaM in hSK1 regulation by demonstrating that disruption of the CaM-binding site ablates agonist-induced translocation of hSK1 from the cytoplasm to the plasma membrane, while having no effect on hSK1 phosphorylation and catalytic activation.	Inst Med & Vet Sci, Div Human Immunol, Hanson Inst, Adelaide, SA 5000, Australia; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5000, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide	Pitson, SM (corresponding author), Inst Med & Vet Sci, Div Human Immunol, Hanson Inst, Frome Rd, Adelaide, SA 5000, Australia.	stuart.pitson@imvs.sa.gov.au	Vadas, Mathew/R-1378-2019; Pitson, Stuart/B-9342-2009	Pitson, Stuart/0000-0002-9527-2740				Baumruker T, 2005, IMMUNOL LETT, V96, P175, DOI 10.1016/j.imlet.2004.09.001; Bhattacharya S, 2004, BBA-MOL CELL RES, V1742, P69, DOI 10.1016/j.bbamcr.2004.09.002; Blom T, 2005, CELL SIGNAL, V17, P827, DOI 10.1016/j.cellsig.2004.11.022; Censarek P, 2002, BIOCHEMISTRY-US, V41, P8598, DOI 10.1021/bi025681k; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; Edsall L, 2000, METHOD ENZYMOL, V312, P9; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Li CJ, 1999, J CELL SCI, V112, P1567; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Mastrandrea LD, 2005, DIABETES, V54, P1429, DOI 10.2337/diabetes.54.5.1429; Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Pitson SM, 2001, FEBS LETT, V509, P169; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Roberts JL, 2004, ANAL BIOCHEM, V331, P122, DOI 10.1016/j.ab.2004.03.030; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Sienaert I, 2002, BIOCHEM J, V365, P269, DOI 10.1042/BJ20020144; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Stahelin RV, 2005, J BIOL CHEM, V280, P43030, DOI 10.1074/jbc.M507574200; Thompson CR, 2005, J IMMUNOL, V174, P3551, DOI 10.4049/jimmunol.174.6.3551; Thorogate R, 2004, J CELL SCI, V117, P5923, DOI 10.1242/jcs.01510; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yamniuk AP, 2004, MOL BIOTECHNOL, V27, P33, DOI 10.1385/MB:27:1:33; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Yokota S, 2004, FEBS LETT, V578, P106, DOI 10.1016/j.febslet.2004.10.081; Young KW, 2003, CELL CALCIUM, V33, P119, DOI 10.1016/S0143-4160(02)00205-1; Yus-Najera E, 2002, J BIOL CHEM, V277, P28545, DOI 10.1074/jbc.M204130200; Zhang HW, 2003, J BIOL CHEM, V278, P8348, DOI 10.1074/jbc.M209565200	52	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11693	11701		10.1074/jbc.M601042200	http://dx.doi.org/10.1074/jbc.M601042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16522638	hybrid			2022-12-25	WOS:000236988100033
J	Cemazar, M; Daly, NL; Haggblad, S; Lo, KP; Yulyaningsih, E; Craik, DJ				Cemazar, M; Daly, NL; Haggblad, S; Lo, KP; Yulyaningsih, E; Craik, DJ			Knots in rings - The circular knotted protein momordica cochinchinensis trypsin inhibitor-II folds via a stable two-disulfide intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTINE KNOT; THERMODYNAMIC STABILITY; EETI-II; MOTIF; PRINCIPLES; DIVERSITY; PATHWAYS; FAMILY; PLANT	The aim of this work was to elucidate the oxidative folding mechanism of the macrocyclic cystine knot protein MCoTI-II. We aimed to investigate how the six-cysteine residues distributed on the circular backbone of the reduced unfolded peptide recognize their correct partner and join up to form a complex cystine-knotted topology. To answer this question, we studied the oxidative folding of the naturally occurring peptide using a range of spectroscopic methods. For both oxidative folding and reductive unfolding, the same disulfide intermediate species was prevalent and was characterized to be a native-like two-disulfide intermediate in which the Cys(1)-Cys(18) disulfide bond was absent. Overall, the folding pathway of this head-to-tail cyclized protein was found to be similar to that of linear cystine knot proteins from the squash family of trypsin inhibitors. However, the pathway differs in an important way from that of the cyclotide kalata B1, in that the equivalent two-disulfide intermediate in that case is not a direct precursor of the native protein. The size of the embedded ring within the cystine knot motif appears to play a crucial role in the folding pathway. Larger rings contribute to the independence of disulfides and favor an on-pathway native-like intermediate that has a smaller energy barrier to cross to form the native fold. The fact that macrocyclic proteins are readily able to fold to a complex knotted structure in vitro in the absence of chaperones makes them suitable as protein engineering scaffolds that have remarkable stability.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Australian Res Council Special Res Ctr Funct & Ap, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Craik, David/B-1695-2010; /A-6021-2011; Daly, Norelle L/D-4302-2013	Craik, David/0000-0003-0007-6796; /0000-0003-2110-2017; Daly, Norelle L/0000-0002-4697-6602				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Cemazar M, 2004, J BIOL CHEM, V279, P16697, DOI 10.1074/jbc.M312328200; Cemazar M, 2003, P NATL ACAD SCI USA, V100, P5754, DOI 10.1073/pnas.2225470100; Chang JY, 2001, J BIOL CHEM, V276, P4845, DOI 10.1074/jbc.M005160200; Chang JY, 2000, J BIOL CHEM, V275, P8287, DOI 10.1074/jbc.275.12.8287; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Chang JY, 2000, J BIOL CHEM, V275, P14205, DOI 10.1074/jbc.275.19.14205; Clark RJ, 2006, BIOCHEM J, V394, P85, DOI 10.1042/BJ20051691; Colgrave ML, 2004, BIOCHEMISTRY-US, V43, P5965, DOI 10.1021/bi049711q; CRAIK D, 2006, IN PRESS CURR OPIN D; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2005, PROTEIN PEPTIDE LETT, V12, P147, DOI 10.2174/0929866053005863; Craik DJ, 2004, CURR PROTEIN PEPT SC, V5, P297, DOI 10.2174/1389203043379512; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; CREIGHTON TE, 1974, J MOL BIOL, V87, P579, DOI 10.1016/0022-2836(74)90105-3; Daly NL, 2003, LETT PEPT SCI, V10, P523, DOI 10.1007/BF02442584; Daly NL, 2003, J BIOL CHEM, V278, P6314, DOI 10.1074/jbc.M210492200; Darling RJ, 2000, J BIOL CHEM, V275, P15413, DOI 10.1074/jbc.275.20.15413; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; Felizmenio-Quimio ME, 2001, J BIOL CHEM, V276, P22875, DOI 10.1074/jbc.M101666200; Gran L, 2000, J ETHNOPHARMACOL, V70, P197, DOI 10.1016/S0378-8741(99)00175-0; Heitz A, 2001, BIOCHEMISTRY-US, V40, P7973, DOI 10.1021/bi0106639; HEITZ A, 1995, EUR J BIOCHEM, V233, P837, DOI 10.1111/j.1432-1033.1995.837_3.x; Helland R, 1999, ACTA CRYSTALLOGR D, V55, P139, DOI 10.1107/S090744499801052X; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Kratzner R, 2005, ACTA CRYSTALLOGR D, V61, P1255, DOI 10.1107/S0907444905021207; LENGUYEN D, 1993, PROTEIN SCI, V2, P165; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; Muller YA, 2002, J BIOL CHEM, V277, P43410, DOI 10.1074/jbc.M206438200; Mulvenna JP, 2006, NUCLEIC ACIDS RES, V34, pD192, DOI 10.1093/nar/gkj005; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Stefani M, 2004, BBA-MOL BASIS DIS, V1739, P5, DOI 10.1016/j.bbadis.2004.08.004; Thaimattam R, 2002, ACTA CRYSTALLOGR D, V58, P1448, DOI 10.1107/S0907444902011769; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; van den Berg B, 1999, J MOL BIOL, V290, P781, DOI 10.1006/jmbi.1999.2915; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; Wedemeyer WJ, 2002, BIOCHEMISTRY-US, V41, P1483, DOI 10.1021/bi011893q; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	38	41	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8224	8232		10.1074/jbc.M513399200	http://dx.doi.org/10.1074/jbc.M513399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16547012	hybrid			2022-12-25	WOS:000236031000062
J	Niizuma, H; Nakamura, Y; Ozaki, T; Nakanishi, H; Ohira, M; Isogai, E; Kageyama, H; Imaizumi, M; Nakagawara, A				Niizuma, H.; Nakamura, Y.; Ozaki, T.; Nakanishi, H.; Ohira, M.; Isogai, E.; Kageyama, H.; Imaizumi, M.; Nakagawara, A.			Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma	ONCOGENE			English	Article						apoptosis; Bcl-2; neuroblastoma; retinoic acid	NEURONAL DIFFERENTIATION; NEURAL DIFFERENTIATION; SIGNALING PATHWAY; EXPRESSION; PROTEIN; CHEMOTHERAPY; ACTIVATION; FAMILY; LINE; BAX	Retinoic acid (RA) has been shown to induce neuronal differentiation and/or apoptosis, and is widely used as a chemotherapeutic agent for treating the patients with neuroblastoma. However, the therapeutic effect of RA is still limited. To unveil the molecular mechanism(s) inducing differentiation and apoptosis in neuroblastoma cells, we compared CHP134 and NB-39-nu cell lines, in which all-trans-RA (ATRA) induces apoptosis, with LAN-5 and RTBM1 cell lines, in which it induces neuronal differentiation. Here, we found that Bcl-2 was strongly downregulated in CHP134 and NB-39-nu cells, whereas it was abundantly expressed in LA-N-5 and RTBM1 cells. ATRA-mediated apoptosis in CHP134 and NB-39-nu cells was associated with a significant activation of caspase-9 and caspase-3 as well as cytoplasmic release of cytochrome c from mitochondria in a p53-independent manner. Enforced expression of Bcl-2 significantly inhibited ATRA-mediated apoptosis in CHP134 cells. In addition, treatment of RTBM1 cells with a Bcl-2 inhibitor, HA14-1, enhanced apoptotic response induced by ATRA. Of note, two out of 10 sporadic neuroblastomas expressed bcl-2 at undetectable levels and underwent cell death in response to ATRA in primary cultures. Thus, our present results suggest that overexpression of Bcl-2 is one of the key mechanisms to give neuroblastoma cells the resistance against ATRA-mediated apoptosis. This may provide a new therapeutic strategy against the ATRA-resistant and aggressive neuroblastomas by combining treatment with ATRA and a Bcl-2 inhibitor.	Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Tohoku Univ, Sch Med, Dept Pediat, Aoba Ku, Sendai, Miyagi 980, Japan; Miyagi Childrens Hosp, Dept Hematol & Oncol, Aoba Ku, Sendai, Miyagi, Japan	Chiba Cancer Center; Tohoku University	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Niizuma, Hidetaka/L-9023-2019					Abel F, 2005, EUR J CANCER, V41, P635, DOI 10.1016/j.ejca.2004.12.021; Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; DOLE M, 1994, CANCER RES, V54, P3253; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Gallo G, 2003, ANTICANCER RES, V23, P777; Kim R, 2004, CANCER-AM CANCER SOC, V101, P2491, DOI 10.1002/cncr.20696; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; Maden M, 2001, INT REV CYTOL, V209, P1; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; McCaffery PJ, 2003, EUR J NEUROSCI, V18, P457, DOI 10.1046/j.1460-9568.2003.02765.x; Melino G, 1997, J NEURO-ONCOL, V31, P65, DOI 10.1023/A:1005733430435; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nagai J, 2004, CANCER RES, V64, P7910, DOI 10.1158/0008-5472.CAN-04-1178; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 1997, CANCER RES, V57, P4578; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakagawara A, 1998, Hum Cell, V11, P115; Nakamura Y, 2003, BIOCHEM BIOPH RES CO, V307, P206, DOI 10.1016/S0006-291X(03)01138-0; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; RAMANI P, 1994, J PATHOL, V172, P273, DOI 10.1002/path.1711720308; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Schor NF, 1999, J NEURO-ONCOL, V41, P159, DOI 10.1023/A:1006171406740; Shi LY, 2005, NEUROSCI LETT, V375, P7, DOI 10.1016/j.neulet.2004.10.082; Takada N, 2001, MED PEDIATR ONCOL, V36, P122, DOI 10.1002/1096-911X(20010101)36:1<122::AID-MPO1029>3.0.CO;2-R; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; van Noesel MM, 2003, GENE CHROMOSOME CANC, V38, P226, DOI 10.1002/gcc.10278; VILLABLANCA JG, 1995, J CLIN ONCOL, V13, P894, DOI 10.1200/JCO.1995.13.4.894; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124	46	59	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5046	5055		10.1038/sj.onc.1209515	http://dx.doi.org/10.1038/sj.onc.1209515			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568081				2022-12-25	WOS:000239921300010
J	Shulewitz, M; Soloviev, I; Wu, T; Koeppen, H; Polakis, P; Sakanaka, C				Shulewitz, M.; Soloviev, I.; Wu, T.; Koeppen, H.; Polakis, P.; Sakanaka, C.			Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer	ONCOGENE			English	Article						Wnt; TCF-4; Sfrp1; breast cancer	BETA-CATENIN; COLORECTAL-CANCER; PROGNOSTIC MARKER; CYCLIN D1; EXPRESSION; TRANSCRIPTION; GENE; CELLS; PROTEIN; APC	Mutations in Wnt pathway genes are rare in human breast cancer, yet activation of the pathway is evident from the misolocalization of beta-catenin. We searched for relationships in the expression of Wnt pathway genes and found that both secreted frizzled related protein 1 (Sfrp1) and TCF-4 transcripts were all highly downregulated in a common subset of breast cancers relative to normal breast tissue. Sfrp1 has been previously characterized as a Wnt inhibitor, and we found that interfering with its expression in the human mammary epithelial cell line MCF10A activated Wnt signaling. Reduction of TCF-4 levels in breast cancer was surprising as it is a transcription factor that is responsive to Wnt signaling. Therefore, we investigated a possible inhibitory role for TCF-4 in human breast cells as well as further characterizing Sfrp1. We identified CD24 as a Wnt target in MCF10A cells and used its expression a marker of Wnt signaling. Interfering with either Sfrp1 or TCF-4 in this cell line enhanced CD24 expression. Furthermore, removal of TCF/LEF binding sites in a CD24-luciferase reporter resulted in elevated reporter gene expression. Our results indicate that both Sfrp1 and TCF-4 repress Wnt signaling in breast tissue and their downregulation contributes to the activation of Wnt signaling.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Sakanaka, C (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,MS40, San Francisco, CA 94080 USA.	chies@gene.com						Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Bukholm IK, 2000, J PATHOL, V190, P15; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Dorsky RI, 2003, DEVELOPMENT, V130, P1937, DOI 10.1242/dev.00402; Duval A, 2000, CANCER RES, V60, P3872; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Kim CH, 2000, NATURE, V407, P913, DOI 10.1038/35038097; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Kristiansen G, 2003, CLIN CANCER RES, V9, P4906; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; Merrill BJ, 2004, DEVELOPMENT, V131, P263, DOI 10.1242/dev.00935; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PIRRUCCELLO SJ, 1986, J IMMUNOL, V136, P3779; Polakis P, 2000, GENE DEV, V14, P1837; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; SOULE HD, 1990, CANCER RES, V50, P6075; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Thorpe CJ, 2004, DEVELOPMENT, V131, P2899, DOI 10.1242/dev.01171; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035	48	81	87	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4361	4369		10.1038/sj.onc.1209470	http://dx.doi.org/10.1038/sj.onc.1209470			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16532032				2022-12-25	WOS:000239240100011
J	Bergo, VB; Ntefidou, M; Trivedi, VD; Amsden, JJ; Kralj, JM; Rothschild, KJ; Spudich, JL				Bergo, Vladislav B.; Ntefidou, Maria; Trivedi, Vishwa D.; Amsden, Jason J.; Kralj, Joel M.; Rothschild, Kenneth J.; Spudich, John L.			Conformational changes in the photocycle of Anabaena sensory rhodopsin - Absence of the Schiff base counterion protonation signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOCHEMICAL-REACTION CYCLE; TIME-RESOLVED FTIR; BACTERIORHODOPSIN MUTANTS; VIBRATIONAL SPECTROSCOPY; DIFFERENCE SPECTROSCOPY; RAMAN-SPECTROSCOPY; STRUCTURAL-CHANGES; LIGHT; CHROMOPHORE; PHARAONIS	Anabaena sensory rhodopsin (ASR) is a novel microbial rhodopsin recently discovered in the freshwater cyanobacterium Anabaena sp. PCC7120. This protein most likely functions as a photosensory receptor as do the related haloarchaeal sensory rhodopsins. However, unlike the archaeal pigments, which are tightly bound to their cognate membrane-embedded transducers, ASR interacts with a soluble cytoplasmic protein analogous to transducers of animal vertebrate rhodopsins. In this study, infrared spectroscopy was used to examine the molecular mechanism of photoactivation in ASR. Light adaptation of the pigment leads to a phototransformation of an all-trans/15-anti to 13-cis/15-syn retinylidene-containing species very similar in chromophore structural changes to those caused by dark adaptation in bacteriorhodopsin. Following 532 nm laser-pulsed excitation, the protein exhibits predominantly an all-trans retinylidene photocycle containing a deprotonated Schiff base species similar to those of other microbial rhodopsins such as bacteriorhodopsin, sensory rhodopsin II, and Neurospora rhodopsin. However, no changes are observed in the Schiff base counterion Asp-75, which remains unprotonated throughout the photocycle. This result along with other evidence indicates that the Schiff base proton release mechanism differs significantly from that of other known microbial rhodopsins, possibly because of the absence of a second carboxylate group at the ASR photoactive site. Several conformational changes are detected during the ASR photocycle including in the transmembrane helices E and G as indicated by hydrogen-bonding alterations of their native cysteine residues. In addition, similarly to animal vertebrate rhodopsin, perturbations of the polar head groups of lipid molecules are detected.	Boston Univ, Dept Phys, Lab Mol Biophys, Boston, MA 02215 USA; Univ Texas, Sch Med, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Boston University; University of Texas System	Rothschild, KJ (corresponding author), Boston Univ, Dept Phys, Lab Mol Biophys, 590 Commonwealth Ave, Boston, MA 02215 USA.	kjr@bu.edu	Rothschild, Kenneth J/P-6177-2018	Rothschild, Kenneth J/0000-0002-2847-6671	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027750, R01GM069969] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATON B, 1977, BIOCHEMISTRY-US, V16, P2995, DOI 10.1021/bi00632a029; Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079-6107(00)00021-3; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Bergo V, 2000, BIOCHEMISTRY-US, V39, P2823, DOI 10.1021/bi991676d; Bergo V, 2004, BIOCHEMISTRY-US, V43, P9075, DOI 10.1021/bi0361968; Bergo V, 2003, J BIOL CHEM, V278, P36556, DOI 10.1074/jbc.M303719200; Bergo V, 2002, PHOTOCHEM PHOTOBIOL, V76, P341, DOI 10.1562/0031-8655(2002)076<0341:AFTISO>2.0.CO;2; Bieszke JA, 1999, P NATL ACAD SCI USA, V96, P8034, DOI 10.1073/pnas.96.14.8034; BOUSCHE O, 1992, PHOTOCHEM PHOTOBIOL, V56, P1085, DOI 10.1111/j.1751-1097.1992.tb09732.x; BOUSCHE O, 1991, J BIOL CHEM, V266, P11063; BOUSCHE O, 1991, BIOCHEMISTRY-US, V30, P5395, DOI 10.1021/bi00236a010; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; Brown LS, 2001, J BIOL CHEM, V276, P32495, DOI 10.1074/jbc.M102652200; DEGRIP WJ, 1988, PHOTOCHEM PHOTOBIOL, V48, P497, DOI 10.1111/j.1751-1097.1988.tb02852.x; Dioumaev AK, 2002, BIOCHEMISTRY-US, V41, P5348, DOI 10.1021/bi025563x; Dioumaev AK, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1269, DOI 10.1023/A:1013135419529; DOLLINGER G, 1986, BIOCHEMISTRY-US, V25, P6524, DOI 10.1021/bi00369a028; EISENSTEIN L, 1987, J AM CHEM SOC, V109, P6860, DOI 10.1021/ja00256a055; Engelhard M, 1996, FEBS LETT, V395, P195, DOI 10.1016/0014-5793(96)01041-1; Furutani Y, 2005, BIOCHEMISTRY-US, V44, P12287, DOI 10.1021/bi050841o; Furutani Y, 2005, BIOCHEMISTRY-US, V44, P2909, DOI 10.1021/bi047893i; Furutani Y, 2004, BIOCHEMISTRY-US, V43, P5204, DOI 10.1021/bi036316b; Gerwert K, 1999, BIOL CHEM, V380, P931, DOI 10.1515/BC.1999.115; GERWERT K, 1986, EMBO J, V5, P805, DOI 10.1002/j.1460-2075.1986.tb04285.x; Hein M, 2003, BIOPHYS J, V84, P1208, DOI 10.1016/S0006-3495(03)74935-2; Isele J, 2000, BIOPHYS J, V79, P3063, DOI 10.1016/S0006-3495(00)76541-6; Jung KH, 2003, MOL MICROBIOL, V47, P1513, DOI 10.1046/j.1365-2958.2003.03395.x; LI HM, 1992, J AM CHEM SOC, V114, P7463, DOI 10.1021/ja00045a019; PARKER FS, 1983, APPL INFRARED RAMAN; RATH P, 1993, BIOCHEMISTRY-US, V32, P2272, DOI 10.1021/bi00060a020; RATH P, 1994, BIOCHEMISTRY-US, V33, P5600, DOI 10.1021/bi00184a032; RATH P, 1994, BIOPHYS J, V66, P2085, DOI 10.1016/S0006-3495(94)81003-3; ROEPE PD, 1988, J BIOL CHEM, V263, P5110; ROTHSCHILD KJ, 1982, P NATL ACAD SCI-BIOL, V79, P4045, DOI 10.1073/pnas.79.13.4045; ROTHSCHILD KJ, 1981, BIOCHEM BIOPH RES CO, V103, P483, DOI 10.1016/0006-291X(81)90478-2; ROTHSCHILD KJ, 1988, BIOCHEMISTRY-US, V27, P2420, DOI 10.1021/bi00407a026; Sineshchekov OA, 2004, PHOTOCH PHOTOBIO SCI, V3, P548, DOI 10.1039/b316207a; Sineshchekov OA, 2002, P NATL ACAD SCI USA, V99, P8689, DOI 10.1073/pnas.122243399; Sineshchevkov OA, 2005, J BIOL CHEM, V280, P14663, DOI 10.1074/jbc.m501416200; SMITH SO, 1987, J PHYS CHEM-US, V91, P804, DOI 10.1021/j100288a011; SMITH SO, 1987, J AM CHEM SOC, V109, P3108, DOI 10.1021/ja00244a038; SMITH SO, 1983, BIOCHEMISTRY-US, V22, P6141, DOI 10.1021/bi00295a016; Spudich JL, 2002, CURR OPIN STRUC BIOL, V12, P540, DOI 10.1016/S0959-440X(02)00359-7; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Vogeley L, 2004, SCIENCE, V306, P1390, DOI 10.1126/science.1103943; Waschuk SA, 2005, P NATL ACAD SCI USA, V102, P6879, DOI 10.1073/pnas.0409659102; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Zhu JY, 1997, PHOTOCHEM PHOTOBIOL, V66, P788, DOI 10.1111/j.1751-1097.1997.tb03225.x	50	40	40	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15208	15214		10.1074/jbc.M600033200	http://dx.doi.org/10.1074/jbc.M600033200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16537532	hybrid			2022-12-25	WOS:000237922200024
J	Michl, P; Knobel, B; Downward, J				Michl, Patrick; Knobel, Beate; Downward, Julian			CUTL1 is phosphorylated by protein kinase A, modulating its effects on cell proliferation and motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; CYCLIC-AMP; TRANSCRIPTION FACTOR; DNA-BINDING; ALPHA-6-BETA-4 INTEGRIN; GENE-TRANSCRIPTION; INTRACELLULAR CAMP; LAMELLAE FORMATION; PANCREATIC-CANCER; CARCINOMA-CELLS	CUTL1, also known as CDP ( CCAAT Displacement Protein), Cut, or Cux-1, is a homeodomain transcription factor known to play an essential role in development and cell cycle progression. Previously, we identified CUTL1 as modulator of cell motility and invasiveness. Here we report that protein kinase A (PKA), known to inhibit tumor progression in various tumor types, directly phosphorylates CUTL1 at serine 1215 in NIH3T3 fibroblasts. The PKA-induced phosphorylation results in decreased DNA binding affinity of CUTL1 and diminished CUTL1- mediated cell cycle progression and cell motility. Furthermore, the expression of several CUTL1 target genes involved in proliferation and migration, such as DNA polymerase A and DKK2, was modulated by PKA-induced phosphorylation. These data identify CUTL1 as a novel target of PKA through which this protein kinase can modulate tumor cell motility and tumor progression.	Canc Res UK, London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; Univ Ulm Klinikum, Abt Innere Med 1, D-89081 Ulm, Germany	Cancer Research UK; Ulm University	Downward, J (corresponding author), Canc Res UK, London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	downward@cancer.org.uk	Michl, Patrick/HDN-4172-2022; Michl, Patrick/AAG-3987-2021; Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Chen TC, 1998, LAB INVEST, V78, P165; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Edin ML, 2001, EXP CELL RES, V270, P214, DOI 10.1006/excr.2001.5345; Ellenrieder V, 2002, EMBO J, V21, P2451, DOI 10.1093/emboj/21.10.2451; Ellis T, 2001, GENE DEV, V15, P2307, DOI 10.1101/gad.200101; Farrow B, 2003, SURGERY, V134, P197, DOI 10.1067/msy.2003.220; Goulet B, 2004, CELL CYCLE, V3, P986; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Goulet B, 2002, CANCER RES, V62, P6625; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; Howcroft TK, 1997, ANAL BIOCHEM, V244, P22, DOI 10.1006/abio.1996.9868; Kuiperij HB, 2005, ONCOGENE, V24, P2087, DOI 10.1038/sj.onc.1208450; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Ledford AW, 2002, DEV BIOL, V245, P157, DOI 10.1006/dbio.2002.0636; Luong MX, 2002, MOL CELL BIOL, V22, P1424, DOI 10.1128/MCB.22.5.1424-1437.2002; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Michl P, 2003, CANCER RES, V63, P6265; Murata K, 2001, CLIN EXP METASTAS, V18, P599, DOI 10.1023/A:1011926116777; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Santaguida M, 2001, J BIOL CHEM, V276, P45780, DOI 10.1074/jbc.M107978200; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Sinclair AM, 2001, BLOOD, V98, P3658, DOI 10.1182/blood.V98.13.3658; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; TANAKA K, 1995, CANCER RES, V55, P2927; Tavares AT, 2000, DEVELOPMENT, V127, P5133; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Truscott M, 2003, MOL CELL BIOL, V23, P3013, DOI 10.1128/MCB.23.8.3013-3028.2003; van Gurp MF, 1999, CANCER RES, V59, P5980; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Weissinger EM, 2004, BRIT J CANCER, V91, P186, DOI 10.1038/sj.bjc.6601909; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yamanaka Y, 2002, CANCER LETT, V176, P143, DOI 10.1016/S0304-3835(01)00764-9; Zeng WR, 1999, ONCOGENE, V18, P2015, DOI 10.1038/sj.onc.1202519; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200; Zhang LZ, 2004, J BIOL CHEM, V279, P20858, DOI 10.1074/jbc.M310643200	50	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15138	15144		10.1074/jbc.M600908200	http://dx.doi.org/10.1074/jbc.M600908200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574653	hybrid			2022-12-25	WOS:000237922200016
J	Rath, A; Melnyk, RA; Deber, CM				Rath, Arianna; Melnyk, Roman A.; Deber, Charles M.			Evidence for assembly of small multidrug resistance proteins by a "two-faced" transmembrane helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER EMRE; ESCHERICHIA-COLI; OLIGOMERIC STRUCTURE; SEGMENT; ASSOCIATION; RETENTION; PEPTIDES; PACKING; EFFLUX; DRIVE	Clinically significant bacterial resistance to drugs and cytotoxic compounds can be conferred by the energy-dependent efflux of toxicants, catalyzed by proteins embedded in the bacterial cell membrane. One such group of proteins, the small multidrug resistance family, are drug/proton antiporters that must oligomerize to function, a process that requires the assembly of at least two inactive monomers by intermolecular association of their four transmembrane helices. Here, we have used peptides that correspond to each of the four wild type transmembrane helices of the Halobacterium salinarum protein Hsmr and a corresponding library of mutant peptides to determine the interactive surfaces that likely contribute to protein oligomerization. Hsmr peptides were examined for strong ( sodium dodecyl sulfate-resistant) and weaker( perfluorooctanoate-resistant) helix-helix interactions, in conjunction with circular dichroism, fluorescence energy transfer measurements, and molecular modeling. The results are compatible with a scheme in which two faces of helix four permit self-assembly via a higher affinity asymmetric pairing and a lower affinity symmetric interaction, resulting in a discrete tetramer. Our finding that two surfaces of helix four can contribute to the stability of small multidrug resistance protein assembly provides a molecular basis for the design of therapeutics that target this antibiotic resistance mechanism.	Hosp Sick Children, Div Struct Biol & Biochem, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Deber, CM (corresponding author), Hosp Sick Children, Div Struct Biol & Biochem, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	deber@sickkids.ca	Melnyk, Roman/GQA-9908-2022					ADAIR BD, 1994, BIOCHEMISTRY-US, V33, P5539, DOI 10.1021/bi00184a024; Amblard Muriel, 2005, V298, P3; Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Deber CM, 2001, PROTEIN SCI, V10, P212, DOI 10.1110/ps.30301; Elbaz Y, 2004, P NATL ACAD SCI USA, V101, P1519, DOI 10.1073/pnas.0306533101; Fleming KG, 2001, PROTEINS, V45, P313, DOI 10.1002/prot.1151; GANS PJ, 1991, BIOPOLYMERS, V31, P1605, DOI 10.1002/bip.360311315; Gottschalk KE, 2004, BIOPHYS J, V86, P3335, DOI 10.1529/biophysj.103.034546; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Johnson RM, 2004, BIOCHEMISTRY-US, V43, P14361, DOI 10.1021/bi0492760; Liu Y, 2002, GENOME BIOL, V3; Ma C, 2004, P NATL ACAD SCI USA, V101, P2852, DOI 10.1073/pnas.0400137101; Melnyk RA, 2001, BIOCHEMISTRY-US, V40, P11106, DOI 10.1021/bi010642e; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ninio S, 2004, FEBS LETT, V562, P193, DOI 10.1016/S0014-5793(04)00240-6; Ninio S, 2003, J BIOL CHEM, V278, P12000, DOI 10.1074/jbc.M213119200; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Partridge AW, 2003, J BIOL CHEM, V278, P22056, DOI 10.1074/jbc.M210685200; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Pornillos O, 2005, SCIENCE, V310, P1950, DOI 10.1126/science.1119776; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Schwaiger M, 1998, EUR J BIOCHEM, V254, P610, DOI 10.1046/j.1432-1327.1998.2540610.x; Soskine M, 2002, P NATL ACAD SCI USA, V99, P12043, DOI 10.1073/pnas.192392899; Tate CG, 2003, J MOL BIOL, V332, P229, DOI 10.1016/S0022-2836(03)00895-7; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; Therien AG, 2002, J BIOL CHEM, V277, P6067, DOI 10.1074/jbc.M110264200; Ubarretxena-Belandia I, 2004, FEBS LETT, V564, P234, DOI 10.1016/S0014-5793(04)00228-5; Ubarretxena-Belandia I, 2003, EMBO J, V22, P6175, DOI 10.1093/emboj/cdg611; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; Wang C, 2000, J BIOL CHEM, V275, P16155, DOI 10.1074/jbc.M000723200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	36	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2006	281	22					15546	15553		10.1074/jbc.M600434200	http://dx.doi.org/10.1074/jbc.M600434200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	048BI	16574656	hybrid			2022-12-25	WOS:000237922200061
J	Bohm, C; Seibel, NM; Henkel, B; Steiner, H; Haass, C; Hampe, W				Boehm, Christopher; Seibel, Nicole M.; Henkel, Birgit; Steiner, Harald; Haass, Christian; Hampe, Wolfgang			SorLA signaling by regulated intramembrane proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; RECEPTOR-RELATED PROTEIN; HEAD-ACTIVATOR RECEPTOR; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; NEUROTENSIN RECEPTOR-3/SORTILIN; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; SORTING RECEPTOR; MOSAIC RECEPTOR	The single-transmembrane receptor SorLA/LR11 contains binding domains typical for lipoprotein receptors and a VPS10 domain, which binds the neuropeptide head-activator. This undecapeptide enhances proliferation of neuronal precursor cells in a SorLA-dependent manner. Using specific inhibitors we found previously that head activator activates shedding of SorLA by the metalloprotease TACE close to the transmembrane domain releasing the large extracellular part of the receptor. Here we show that the remaining COOH-terminal membrane fragment of SorLA is processed by gamma-secretase. Inhibition of gamma-secretase by specific inhibitors or overexpression of dominant negative presenilin mutants and knock out of the presenilin genes led to accumulation of the SorLA membrane fragment and also of full-length SorLA in the membrane. In an in vitro assay we observed the gamma-secretase-dependent release of the two soluble cleavage products, the SorLA cytoplasmic domain and the SorLA gamma-peptide. These processing steps are reminiscent of a novel signaling pathway that has been described for the notch receptor. Here, the notch cytoplasmic domain is released into the cytoplasm by the gamma-secretase and migrates to the nucleus where it acts as a transcriptional regulator. In parallel we found that a fusion protein of the released cytoplasmic tail of SorLA with EGFP located to the nucleus only if the nuclear localization signal of SorLA was intact. In a reporter gene assay the cytoplasmic domain of SorLA acted as a transcriptional activator indicating that SorLA might directly regulate transcription after activation by gamma-secretase.	Univ Hamburg, Med Ctr, Ctr Expt Med, Dept Biochem & Mol Biol 2 Mol Cell Biol, D-20246 Hamburg, Germany; Univ Munich, Lab Alzheimers & Parkinsons Dis Res, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Hamburg; University of Munich	Hampe, W (corresponding author), Univ Klinikum Eppendorf, Inst Biochem & Molekulabiol 2, Martinistr 52, D-20246 Hamburg, Germany.	hampe@uke.uni-hamburg.de						Andersen OM, 2005, P NATL ACAD SCI USA, V102, P13461, DOI 10.1073/pnas.0503689102; Berezovska O, 2001, J BIOL CHEM, V276, P30018, DOI 10.1074/jbc.M008268200; Boels K, 2001, J CELL SCI, V114, P3599; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Dicou E, 2004, J NEUROSCI RES, V78, P92, DOI 10.1002/jnr.20231; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2002, J BIOL CHEM, V277, P13389, DOI 10.1074/jbc.M111571200; Franke I, 1997, EUR J BIOCHEM, V244, P940, DOI 10.1111/j.1432-1033.1997.00940.x; Gliemann J, 2004, BIOCHEM J, V381, P203, DOI 10.1042/BJ20040149; Guo L, 2002, MOL CELL PROTEOMICS, V1, P30, DOI 10.1074/mcp.M100020-MCP200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Hampe W, 1999, DEVELOPMENT, V126, P4077; Hampe W, 2000, J CELL SCI, V113, P4475; Hampe W, 1996, EUR J BIOCHEM, V235, P814, DOI 10.1111/j.1432-1033.1996.t01-1-00814.x; Hampe Wolfgang, 1999, Results and Problems in Cell Differentiation, V26, P323; Hermans-Borgmeyer I, 1998, MECH DEVELOP, V70, P65, DOI 10.1016/S0925-4773(97)00177-9; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Jacobsen L, 2002, FEBS LETT, V511, P155, DOI 10.1016/S0014-5793(01)03299-9; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; Kanaki T, 1999, ARTERIOSCL THROM VAS, V19, P2687, DOI 10.1161/01.ATV.19.11.2687; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lintzel J, 2002, BIOL CHEM, V383, P1727, DOI 10.1515/BC.2002.193; Lleo A, 2005, J BIOL CHEM, V280, P27303, DOI 10.1074/jbc.M413969200; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Martin S, 2002, GASTROENTEROLOGY, V123, P1135, DOI 10.1053/gast.2002.36000; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Medina M, 2003, CELL SIGNAL, V15, P829, DOI 10.1016/S0898-6568(03)00041-X; Nagano O, 2004, CANCER SCI, V95, P930, DOI 10.1111/j.1349-7006.2004.tb03179.x; Navarro V, 2002, BIOCHEM BIOPH RES CO, V298, P760, DOI 10.1016/S0006-291X(02)02564-0; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nilsson J, 2005, PROTEINS, V60, P606, DOI 10.1002/prot.20583; Offe K, 2006, J NEUROSCI, V26, P1596, DOI 10.1523/JNEUROSCI.4946-05.2006; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Scherzer CR, 2004, ARCH NEUROL-CHICAGO, V61, P1200, DOI 10.1001/archneur.61.8.1200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Spoelgen R, 2006, J NEUROSCI, V26, P418, DOI 10.1523/JNEUROSCI.3882-05.2006; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner Harald, 2004, Current Alzheimer Research, V1, P175, DOI 10.2174/1567205043332081; Taira K, 2001, ARTERIOSCL THROM VAS, V21, P1501, DOI 10.1161/hq0901.094500; Westergaard UB, 2004, J BIOL CHEM, V279, P50221, DOI 10.1074/jbc.M408873200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; Zhu YJ, 2004, CIRC RES, V94, P752, DOI 10.1161/01.RES.0000120862.79154.0F	55	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14547	14553		10.1074/jbc.M601660200	http://dx.doi.org/10.1074/jbc.M601660200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16531402	hybrid			2022-12-25	WOS:000237671300005
J	Hawtin, SR				Hawtin, Stuart R.			Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V-1a receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; WILD-TYPE; NONPEPTIDE ANTAGONIST; MEMBRANE TRAFFICKING; POTENTIAL TREATMENT; QUALITY-CONTROL; HIGHLY POTENT; HIGH-AFFINITY; N-TERMINUS; MUTANTS	Pharmacological chaperones represent a new class of ligand with the potential to facilitate the delivery of misfolded, but still active, G-protein-coupled receptors to the cell surface. Using transfected HEK 293T cells, treatment with a nonpeptide antagonist, SR49059, dramatically increased (similar to 60- old) the surface expression of a misfolded, nonfunctional and intracellularly localized vasopressin V-1a receptor (V1aR) mutant (D148A). This rescue of surface expression (111 +/- 7%) was almost identical to wild type assessed by confocal microscopy and quantitative enzyme-linked immunosorbent assaybased techniques. Recovery was not specific to D148A, since other surface-impaired mutations, D148N and D148E, and wild type were also increased following SR49059 exposure. However, surface delivery was specific to SR49059, since V1aR-selective peptide ligands or unrelated ligands were unable to mimic this action, suggesting that SR49059 acts intracellularly. SR49059-mediated surface rescue was time-, mutant-, and concentration-dependent but not directly related to its binding affinity. Maximal recovery was achieved following 12 h of treatment and did not involve de novo receptor synthesis or a consequence of preventing endogenous constitutive activity and/or internalization. Once at the surface, all mutants displayed enhanced signaling ability, and D148A was able to undergo agonist-mediated internalization. SR49059 was not effectively removed from the receptor, since signaling (EC50) of both wild type and D148A was reduced similar to 40-fold. This is the first report of a pharmacological chaperone ligand to act on misfolded mutant V(1a)Rs. This work provides an excellent model to understand the mechanistic action of an important new class of drug that may have potential in the treatment of diseases caused by inherited mutations.	Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham	Hawtin, SR (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Sch Biomed Sci, Nottingham NG7 2UH, England.	Stuart.Hawtin@nottingham.ac.uk						Bernier V, 2004, TRENDS ENDOCRIN MET, V15, P222, DOI 10.1016/j.tem.2004.05.003; Bernier V, 2004, MOL ENDOCRINOL, V18, P2074, DOI 10.1210/me.2004-0080; Bernier V, 2006, J AM SOC NEPHROL, V17, P232, DOI 10.1681/ASN.2005080854; Brothers SP, 2004, MOL ENDOCRINOL, V18, P1787, DOI 10.1210/me.2004-0091; Chaipatikul V, 2003, MOL PHARMACOL, V64, P32, DOI 10.1124/mol.64.1.32; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cotte N, 2000, EUR J BIOCHEM, V267, P4253, DOI 10.1046/j.1432-1033.2000.01472.x; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fan J, 2005, MOL ENDOCRINOL, V19, P2579, DOI 10.1210/me.2004-0301; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; Hawtin SR, 2005, MOL ENDOCRINOL, V19, P2871, DOI 10.1210/me.2005-0148; Hawtin SR, 2005, MOL PHARMACOL, V68, P1172, DOI 10.1124/mol.105.013359; Hawtin SR, 2003, EUR J BIOCHEM, V270, P4681, DOI 10.1046/j.1432-1033.2003.03865.x; Hawtin SR, 2002, MOL ENDOCRINOL, V16, P600, DOI 10.1210/me.16.3.600; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Hawtin SR, 2001, BIOCHEM J, V357, P73, DOI 10.1042/0264-6021:3570073; Hawtin Stuart R., 1997, Biochemical Society Transactions, V25, p437S; Hermosilla R, 2004, TRAFFIC, V5, P993, DOI 10.1111/j.1600-0854.2004.00239.x; Janovick JA, 2003, J PHARMACOL EXP THER, V305, P608, DOI 10.1124/jpet.102.048454; Janovick JA, 2002, J CLIN ENDOCR METAB, V87, P3255, DOI 10.1210/jc.87.7.3255; Knollman PE, 2005, J BIOL CHEM, V280, P24506, DOI 10.1074/jbc.M501978200; KRISTIANSEN K, 2003, PHARMACOL THERAPEUT, V103, P21; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; McClellan AJ, 2005, NAT CELL BIOL, V7, P736, DOI 10.1038/ncb0805-736; Mizrachi D, 2004, MOL ENDOCRINOL, V18, P1768, DOI 10.1210/me.2003-0406; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; Morello JP, 2001, ANNU REV PHYSIOL, V63, P607, DOI 10.1146/annurev.physiol.63.1.607; Morello JP, 2001, BIOCHEMISTRY-US, V40, P6766, DOI 10.1021/bi002699r; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Nebenfuhr A, 2002, PLANT PHYSIOL, V130, P1102, DOI 10.1104/pp.011569; Nijenhuis WAJ, 2003, J BIOL CHEM, V278, P22939, DOI 10.1074/jbc.M211326200; Noorwez SM, 2004, J BIOL CHEM, V279, P16278, DOI 10.1074/jbc.M312101200; Pankevych H, 2003, J BIOL CHEM, V278, P30283, DOI 10.1074/jbc.M212918200; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Rozell TG, 1998, ENDOCRINOLOGY, V139, P1588, DOI 10.1210/en.139.4.1588; SCHMIDT A, 1991, FEBS LETT, V282, P77, DOI 10.1016/0014-5793(91)80448-C; Serradeil-Le Gal C, 2002, J PHARMACOL EXP THER, V300, P1122; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; SerradeilLeGal C, 1996, J CLIN INVEST, V98, P2729, DOI 10.1172/JCI119098; Shryock JC, 1998, MOL PHARMACOL, V53, P886; Smit MJ, 1996, P NATL ACAD SCI USA, V93, P6802, DOI 10.1073/pnas.93.13.6802; Smith DF, 1998, PHARMACOL REV, V50, P493; Tahtaoui C, 2003, J BIOL CHEM, V278, P40010, DOI 10.1074/jbc.M301128200; Tan CM, 2004, ANNU REV PHARMACOL, V44, P559, DOI 10.1146/annurev.pharmtox.44.101802.121558; Thibonnier M, 2001, ANNU REV PHARMACOL, V41, P175, DOI 10.1146/annurev.pharmtox.41.1.175; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Welch WJ, 2004, SEMIN CELL DEV BIOL, V15, P31, DOI 10.1016/j.semcdb.2003.12.011; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Wuller S, 2004, J BIOL CHEM, V279, P47254, DOI 10.1074/jbc.M408154200	50	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14604	14614		10.1074/jbc.M511610200	http://dx.doi.org/10.1074/jbc.M511610200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16565083	hybrid			2022-12-25	WOS:000237671300012
J	Kang, HJ; Kim, HJ; Kim, SK; Barouki, R; Cho, CH; Khanna, KK; Rosen, EM; Bae, I				Kang, Hyo Jin; Kim, Hee Jeong; Kim, Sang Keun; Barouki, Robert; Cho, Chi-Heum; Khanna, Kum Kum; Rosen, Eliot M.; Bae, Insoo			BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; CR6-INTERACTING FACTOR-1 INTERACTS; PLANAR AROMATIC-COMPOUNDS; GADD45 FAMILY PROTEINS; ESTROGEN-RECEPTOR; NUCLEAR TRANSLOCATOR; TRANSCRIPTIONAL COACTIVATORS; SUSCEPTIBILITY GENE; CYTOCHROME P4501A1; ANDROGEN RECEPTOR	Previously, we have reported that BRCA1 regulates the expression of various classes of genes, including genes involved in xenobiotic stress responses (Bae, I., Fan, S., Meng, Q., Rih, J. K., Kim, H. J., Kang, H. J., Xu, J., Goldberg, I. D., Jaiswal, A. K., and Rosen, E. M. (2004) Cancer Res. 64, 7893-7909). In the present study, we have investigated the effects of BRCA1 on xenobiotic stress-inducible gene expression. In response to aryl hydrocarbon receptor (AhR) ligands, cytoplasmic AhR becomes activated and then translocates to the nucleus where it forms a complex with the aryl hydrocarbon receptor nuclear translocator (ARNT). Subsequently, the AhR(.)ARNT complex binds to the enhancer or promoter of genes containing a xenobiotic stress-responsive element and regulates the expression of multiple target genes including cytochrome P450 subfamily polypeptide 1 (CYP1A1). In this study, we have found that endogenous and overexpressed exogenous wild-type BRCA1 affect xenobiotic stress-induced CYP1A1 gene expression. Using a standard chromatin immunoprecipitation assay, we have demonstrated that BRCA1 is recruited to the promoter regions of CYP1A1 and CYP1B1 along with ARNT and/or AhR following xenobiotic exposure. Our findings suggest that BRCA1 may be physiologically important for mounting a normal response to xenobiotic insults and that it may function as a coactivator for ARNT activity. Using immunoprecipitation, Western blotting, and glutathione S-transferase capture assays, a xenobiotic-independent interaction between BRCA1 and ARNT has been identified, although it is not yet known whether this is a direct or indirect interaction. We have also found that the inducibility of CYP1A1 and CYP1B1 transcripts following xenobiotic stress was significantly attenuated in BRCA1 knockdown cells. This reduced inducibility is associated with an altered stability of ARNT and was almost completely reversed in cells transfected with an ARNT expression vector. Finally, we have found that xenobiotic (TCDD) treatments of breast cancer cells containing reduced levels of BRCA1 cause the transcription factor ARNT to become unstable.	Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul 151742, South Korea; Univ Paris 05, INSERM, U490, F-75270 Paris 06, France; Keimyung Univ, Sch Med, Dept Obstet & Gynecol, Taegu, South Korea; Post Off Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia	Georgetown University; Seoul National University (SNU); Seoul National University (SNU); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Keimyung University; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Bae, I (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, 3970 Reservoir Rd, Washington, DC 20057 USA.	ib42@georgetown.edu	Khanna, Kum Kum/I-1747-2013	Khanna, Kum Kum/0000-0001-8650-5381	NATIONAL CANCER INSTITUTE [R01CA080000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES014440] Funding Source: NIH RePORTER; NCI NIH HHS [CA 080000] Funding Source: Medline; NIEHS NIH HHS [ES 014440-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANERSON SF, 1998, NAT GENET, V19, P254; Bae I, 2004, CANCER RES, V64, P7893, DOI 10.1158/0008-5472.CAN-04-1119; Beischlag TV, 2004, J BIOL CHEM, V279, P54620, DOI 10.1074/jbc.M410456200; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bradshaw TD, 2004, CURR MED CHEM, V11, P1009, DOI 10.2174/0929867043455530; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Cho IJ, 2003, J BIOL CHEM, V278, P44103, DOI 10.1074/jbc.M307597200; Chung HK, 2003, J BIOL CHEM, V278, P28079, DOI 10.1074/jbc.M212835200; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Emi Y, 1996, J BIOL CHEM, V271, P3952, DOI 10.1074/jbc.271.7.3952; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hu YF, 2000, J BIOL CHEM, V275, P40910, DOI 10.1074/jbc.C000607200; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Kobayashi A, 1997, J BIOCHEM, V122, P703; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Morel Y, 1999, MOL CELL BIOL, V19, P6825; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Park JJ, 2000, CANCER RES, V60, P5946; Park KC, 2005, MOL ENDOCRINOL, V19, P12, DOI 10.1210/me.2004-0107; Perdew GH, 1996, BIOCHEM MOL BIOL INT, V39, P589; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; THOMSEN JS, 1994, CARCINOGENESIS, V15, P933, DOI 10.1093/carcin/15.5.933; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Q, 2001, ONCOGENE, V20, P4640, DOI 10.1038/sj.onc.1204625; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yi YW, 2000, BIOCHEM BIOPH RES CO, V272, P193; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	52	42	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14654	14662		10.1074/jbc.M601613200	http://dx.doi.org/10.1074/jbc.M601613200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16567799	Green Published, hybrid			2022-12-25	WOS:000237671300017
J	Milburn, CC; Lamble, HJ; Theodossis, A; Bull, SD; Hough, DW; Danson, MJ; Taylor, GL				Milburn, Christine C.; Lamble, Henry J.; Theodossis, Alex; Bull, Steven D.; Hough, David W.; Danson, Michael J.; Taylor, Garry L.			The structural basis of substrate promiscuity in glucose dehydrogenase from the hyperthermophilic archaeon Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTNER-DOUDOROFF PATHWAY; DIRECT LINEAR PLOT; X-RAY ANALYSIS; ALCOHOL-DEHYDROGENASE; DINUCLEOTIDE BINDING; GLYCOLYTIC PATHWAYS; CRYSTAL-STRUCTURE; ENZYME; GLUCONATE; CRYSTALLIZATION	The hyperthermophilic archaeon Sulfolobus solfataricus grows optimally above 80 degrees C and utilizes an unusual, promiscuous, non-phosphorylative Entner-Doudoroff pathway to metabolize both glucose and galactose. The first enzyme in this pathway, glucose dehydrogenase, catalyzes the oxidation of glucose to gluconate, but has been shown to have activity with a broad range of sugar substrates, including glucose, galactose, xylose, and L-arabinose, with a requirement for the glucose stereo configuration at the C2 and C3 positions. Here we report the crystal structure of the apo form of glucose dehydrogenase to a resolution of 1.8 angstrom and a complex with its required cofactor, NADP(+), to a resolution of 2.3 angstrom. A T41A mutation was engineered to enable the trapping of substrate in the crystal. Complexes of the enzyme with D-glucose and D-xylose are presented to resolutions of 1.6 and 1.5 angstrom, respectively, that provide evidence of selectivity for the beta-anomeric, pyranose form of the substrate, and indicate that this is the productive substrate form. The nature of the promiscuity of glucose dehydrogenase is also elucidated, and a physiological role for this enzyme in xylose metabolism is suggested. Finally, the structure suggests that the mechanism of sugar oxidation by this enzyme may be similar to that described for human sorbitol dehydrogenase.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Bath, Dept Chem, Bath BA2 7AY, Avon, England; Univ Bath, Ctr Extremophile Res, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of St Andrews; University of Bath; University of Bath	Taylor, GL (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.	glt2@st-andrews.ac.uk	Theodossis, Alexander/A-1091-2009; Taylor, Garry/G-3017-2014	Taylor, Garry/0000-0001-9486-566X				Ahmed H, 2005, BIOCHEM J, V390, P529, DOI 10.1042/BJ20041711; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beis K, 2003, J AM CHEM SOC, V125, P11872, DOI 10.1021/ja035796r; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUDGEN N, 1986, FEBS LETT, V196, P207, DOI 10.1016/0014-5793(86)80247-2; CORNISHB.A, 1974, BIOCHEM J, V139, P721, DOI 10.1042/bj1390721; DEROSA M, 1984, BIOCHEM J, V224, P407, DOI 10.1042/bj2240407; Edwards KJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P173, DOI 10.1006/abbi.1996.0158; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; EKLUND H, 1985, BIOCHEMISTRY-US, V24, P8005, DOI 10.1021/bi00348a025; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; EKLUND H, 1982, J BIOL CHEM, V257, P4349; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; ELSHAFEI AM, 1989, ACTA BIOTECHNOL, V9, P485, DOI 10.1002/abio.370090523; ELZAINY TA, 1973, J BACTERIOL, V114, P457, DOI 10.1128/JB.114.1.457-459.1973; Esclapez J, 2005, ACTA CRYSTALLOGR F, V61, P743, DOI 10.1107/S1744309105019949; Ferrer J, 2001, ACTA CRYSTALLOGR D, V57, P1887, DOI 10.1107/S0907444901015189; GIARDINA P, 1986, BIOCHEM J, V239, P517, DOI 10.1042/bj2390517; GROGAN DW, 1989, J BACTERIOL, V171, P6710, DOI 10.1128/jb.171.12.6710-6719.1989; JEFFERY J, 1984, EMBO J, V3, P357, DOI 10.1002/j.1460-2075.1984.tb01811.x; Johansson K, 2001, CHEM-BIOL INTERACT, V130, P351, DOI 10.1016/S0009-2797(00)00260-X; JOHN J, 1994, STRUCTURE, V2, P385, DOI 10.1016/S0969-2126(00)00040-X; Johnsen U, 2004, J BACTERIOL, V186, P6198, DOI 10.1128/JB.186.18.6198-6207.2004; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORNVALL H, 1987, EUR J BIOCHEM, V167, P195, DOI 10.1111/j.1432-1033.1987.tb13323.x; Kim SH, 2005, BIOCHEM J, V387, P271, DOI 10.1042/BJ20041053; Lamble FJ, 2004, FEBS LETT, V576, P133, DOI 10.1016/j.febslet.2004.08.074; Lamble HJ, 2005, FEBS LETT, V579, P6865, DOI 10.1016/j.febslet.2005.11.028; Lamble HJ, 2003, J BIOL CHEM, V278, P34066, DOI 10.1074/jbc.M305818200; LESLIE AGW, 1992, JNT CCP4 ESF EAMCB N, V26, P27; LI H, 1994, BIOCHEMISTRY-US, V33, P11734, DOI 10.1021/bi00205a009; Meijers R, 2001, J BIOL CHEM, V276, P9316, DOI 10.1074/jbc.M010870200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pauly TA, 2003, STRUCTURE, V11, P1071, DOI 10.1016/S0969-2126(03)00167-9; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; RYDE U, 1995, PROTEIN SCI, V4, P1124, DOI 10.1002/pro.5560040611; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; SIEBERS B, 1993, FEMS MICROBIOL LETT, V111, P1; Soderberg Tim, 2005, Archaea, V1, P347, DOI 10.1155/2005/314760; Theodossis A, 2004, J BIOL CHEM, V279, P43886, DOI 10.1074/jbc.M407702200; Theodossis A, 2005, ACTA CRYSTALLOGR F, V61, P112, DOI 10.1107/S174430910403101X; Verhees CH, 2003, BIOCHEM J, V375, P231, DOI 10.1042/BJ20021472; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012	46	43	46	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14796	14804		10.1074/jbc.M601334200	http://dx.doi.org/10.1074/jbc.M601334200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16556607	hybrid			2022-12-25	WOS:000237671300033
J	Roy, A; Fung, YK; Liu, XJ; Pahan, K				Roy, Avik; Fung, Yiu K.; Liu, Xiaojuan; Pahan, Kalipada			Up-regulation of microglial CD11b expression by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; MULTIPLE-SCLEROSIS; AMEBOID MICROGLIA; HUMAN ASTROGLIA; SYNTHASE; CELLS; ACTIVATION	Increased expression of CD11b, the beta-integrin marker of microglia, represents microglial activation during neurodegenerative inflammation. However, the molecular mechanism behind increased microglial CD11b expression is poorly understood. The present study was undertaken to explore the role of nitric oxide ( NO) in the expression of CD11b in microglial cells. Bacterial lipopolysaccharide ( LPS) induced the production of NO and increased the expression of CD11b in mouse BV-2 microglial cells and primary microglia. Either a scavenger of NO ( PTIO) or an inhibitor of inducible nitric-oxide synthase ( L-NIL) blocked this increase in microglial CD11b expression. Furthermore, co-microinjection of PTIO with LPS was also able to suppress LPS-mediated expression of CD11b and loss of dopaminergic neuronal fibers and neurotransmitters in striatum in vivo. Similarly, other inducers of NO production such as interferon-gamma, interleukin-1 beta, human immunodeficiency virus type-1 gp120, and double-stranded RNA( poly( IC)) also increased the expression of CD11b in microglia through NO. The role of NO in the expression of CD11b was corroborated further by the expression of microglial CD11b by GSNO, an NO donor. Because NO transduces many intracellular signals via guanylate cyclase ( GC), we investigated the role of GC, cyclic GMP ( cGMP), and cGMP-activated protein kinase ( PKG) in microglial expression of CD11b. Inhibition of LPS- and GSNO-mediated upregulation of CD11b either by NS2028 ( a specific inhibitor of GC) or by KT5823 and Rp-8-bromo-cGMP ( specific inhibitors of PKG), and increase in CD11b expression either by 8-bromo-cGMP or by MY-5445 ( a specific inhibitor of cGMP phosphodiesterase) alone suggest that NO increases microglial expression of CD11b via GC-cGMP-PKG. In addition, GSNO induced the activation of cAMP response element-binding protein ( CREB) via PKG that was involved in the up-regulation of CD11b. This study illustrates a novel biological role of NO in regulating the expression of CD11b in microglia through GC-cGMP-PKG-CREB pathway that may participate in the pathogenesis of devastating neurodegenerative disorders.	Univ Nebraska, Med Ctr, Dept Oral Biol, Sect Neurosci, Lincoln, NE 68583 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, Sect Neurosci, 40th & Holdrege, Lincoln, NE 68583 USA.	kpahan@unmc.edu			NINDS NIH HHS [NS 48923, NS 39940, R01 NS039940, R01 NS039940-05A1, R21 NS048923, R21 NS048923-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS048923, R01NS039940] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Auch CJ, 2004, FEBS LETT, V563, P223, DOI 10.1016/S0014-5793(04)00302-3; Barcia C, 2004, GLIA, V46, P402, DOI 10.1002/glia.20015; Bredt DS, 2003, MOL PHARMACOL, V63, P1206, DOI 10.1124/mol.63.6.1206; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Chan SHH, 2004, MOL PHARMACOL, V65, P319, DOI 10.1124/mol.65.2.319; Dasgupta S, 2004, J IMMUNOL, V173, P1344, DOI 10.4049/jimmunol.173.2.1344; Dasgupta S, 2003, J BIOL CHEM, V278, P22424, DOI 10.1074/jbc.M301789200; Dasgupta S, 2002, J BIOL CHEM, V277, P39327, DOI 10.1074/jbc.M111841200; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; DAWSON VL, 1993, P NATL ACAD SCI USA, V90, P3256, DOI 10.1073/pnas.90.8.3256; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hawkins RD, 1998, PROG BRAIN RES, V118, P155; Hill KE, 2004, J NEUROIMMUNOL, V151, P171, DOI 10.1016/j.jneuroim.2004.02.005; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jana A, 2004, J NEUROSCI, V24, P9531, DOI 10.1523/JNEUROSCI.3085-04.2004; Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200; Jouvert P, 2004, J NEUROSCI, V24, P10716, DOI 10.1523/JNEUROSCI.1398-04.2004; Kim HS, 2004, J NEUROIMMUNOL, V151, P85, DOI 10.1016/j.jneuroim.2004.02.006; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; Monfort P, 2002, J NEUROSCI, V22, P10116; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; RADI R, 1991, J BIOL CHEM, V266, P4244; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Saha RN, 2003, J NEUROCHEM, V86, P1057, DOI 10.1046/j.1471-4159.2003.01942.x; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Schwarz M, 2002, THROMB RES, V107, P121, DOI 10.1016/S0049-3848(02)00207-4; Stewart VC, 2003, FREE RADICAL BIO MED, V34, P287, DOI 10.1016/S0891-5849(02)01327-8; Stoner NC, 2001, SURGERY, V130, P236, DOI 10.1067/msy.2001.115903; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002	41	68	75	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 26	2006	281	21					14971	14980		10.1074/jbc.M600236200	http://dx.doi.org/10.1074/jbc.M600236200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	044KN	16551637	Green Accepted, hybrid			2022-12-25	WOS:000237671300050
J	Babu, G; Waterfield, M; Chang, M; Wu, XF; Sun, SC				Babu, Geetha; Waterfield, Michael; Chang, Mikyoung; Wu, Xuefeng; Sun, Shao-Cong			Deregulated activation of oncoprotein kinase Tpl2/Cot in HTLV-I-transformed T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; VIRUS TYPE-I; TYPE-1 TAX INDUCTION; NUCLEAR-FACTOR; COT ONCOGENE; MAP KINASE; IKK-ALPHA; LEUKEMIA; PROTEIN; EXPRESSION	Protein kinase Tpl2/Cot is encoded by a protooncogene that is cis-activated by retroviral insertion in murine T cell lymphomas. It has remained unclear whether this oncoprotein kinase is mutated or post-translationally activated in human cancer cells. We have shown here that Tpl2/Cot is constitutively activated in human leukemia cell lines transformed by the human T cell leukemia virus type I (HTLV-I). The kinase activity of Tpl2/Cot is normally suppressed through its physical interaction with an inhibitor, the NF-kappa B1 precursor protein p105. Interestingly, a large pool of Tpl2/Cot is liberated from p105 and exhibits constitutive kinase activity in HTLV-I-transformed T cells. In contrast to its labile property in normal cells, the pathologically activated Tpl2/Cot is remarkably stable. Further, whereas the physiological activation of Tpl2/Cot involves its long isoform, the HTLV-activated Tpl2/Cot is predominantly the short isoform. We have also shown that the HTLV-I-encoded Tax protein is able to activate Tpl2/Cot in transfected cells. Finally, Tpl2/Cot participates in the activation of NF-kappa B1 by Tax. These findings indicate that deregulated activation of Tpl2/Cot may occur in human cancer cells.	Penn State Univ, Coll Med, Milton S Hershey Med Ctr, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Milton S Hershey Med Ctr, Dept Microbiol & Immunol, Hershey, PA 17033 USA.	sxs70@psu.edu			NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057555] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA68471] Funding Source: Medline; NIAID NIH HHS [R01 AI057555] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKI M, 1991, ONCOGENE, V6, P1515; BALWIN AS, 1996, ANNU REV IMMUNOL, V14, P649; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Castro AC, 2003, BIOORG MED CHEM LETT, V13, P2419, DOI 10.1016/S0960-894X(03)00408-6; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Cho J, 2005, J BIOL CHEM, V280, P20442, DOI 10.1074/jbc.M413554200; Christoforidou AV, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-34; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GAZDAR AF, 1980, BLOOD, V55, P409; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Good L, 1997, J BIOL CHEM, V272, P1425, DOI 10.1074/jbc.272.3.1425; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KOEFFLER HP, 1984, BLOOD, V64, P482; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; MAGGIRWAR SB, 1995, ONCOGENE, V11, P993; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MIYOSHI I, 1981, GANN, V72, P978; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Ruland J, 2003, IMMUNOL REV, V193, P93, DOI 10.1034/j.1600-065X.2003.00049.x; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sharma S, 1996, P NATL ACAD SCI USA, V93, P11842, DOI 10.1073/pnas.93.21.11842; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Xu X, 1996, ONCOGENE, V13, P135; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	63	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14041	14047		10.1074/jbc.M512375200	http://dx.doi.org/10.1074/jbc.M512375200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16565081	hybrid			2022-12-25	WOS:000237512300026
J	Ho, HH; Ivashkiv, LB				Ho, Hao H.; Ivashkiv, Lionel B.			Role of STAT3 in type I interferon responses - Negative regulation of STAT1-dependent inflammatory gene activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; CELLS; ALPHA; GAMMA; MICE; EXPRESSION; IL-10; SOCS3; MACROPHAGES	Type I interferons (IFN alpha/beta) induce antiviral responses and have immunomodulatory effects that can either promote or suppress immunity and inflammation. In myeloid cells IFN alpha/beta activates signal transducers and activators of transcription STAT1, STAT2, and STAT3. STAT1 and STAT2 mediate the antiviral and inflammatory effects of IFN alpha/beta, but the function of IFN alpha/beta-activated STAT3 is not known. We investigated the role of STAT3 in type I IFN signaling in myeloid cells by modulating STAT3 expression and the intensity of STAT3 activation using overexpression and RNA interference and determining the effects on downstream signaling and gene expression. IFN alpha-activated STAT3 inhibited STAT1-dependent gene activation, thereby down-regulating IFN alpha-mediated induction of inflammatory mediators such as the chemokines CXCL9 (Mig) and CXCL10 (IP-10). At the same time, IFN alpha-activated STAT3 supported ISGF-3-dependent induction of antiviral genes. STAT3 did not suppress STAT1 tyrosine phosphorylation or nuclear translocation but instead sequestered STAT1 and suppressed the formation of DNA-binding STAT1 homodimers. These results identify a regulatory function for STAT3 in attenuating the inflammatory properties of type I IFNs and provide a mechanism of suppression of STAT1 function that differs from previously described suppression of tyrosine phosphorylation. The results suggest that changes in the relative expression and activation of STAT1 and STAT3 that occur during immune responses determine the nature of cellular responses to type I IFNs.	Hosp Special Surg, Dept Med, Arthritis & Tissue Degenerat Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Grad Program Immunol, New York, NY 10031 USA	Cornell University	Ivashkiv, LB (corresponding author), Hosp Special Surg, Dept Med, Arthritis & Tissue Degenerat Program, 535 E 70th St, New York, NY 10021 USA.	ivashkivl@hss.edu						Antoniv TT, 2005, IMMUNOBIOLOGY, V210, P87, DOI 10.1016/j.imbio.2005.05.003; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brierley MM, 2002, J INTERF CYTOK RES, V22, P835, DOI 10.1089/107999002760274845; Caraglia M, 2005, J CELL PHYSIOL, V202, P323, DOI 10.1002/jcp.20137; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Crow MK, 2003, AUTOIMMUNITY, V36, P481, DOI 10.1080/08916930310001625952; Durbin JE, 2000, J IMMUNOL, V164, P4220, DOI 10.4049/jimmunol.164.8.4220; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Gil MP, 2006, BLOOD, V107, P987, DOI 10.1182/blood-2005-07-2834; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Gimeno R, 2005, MOL CELL BIOL, V25, P5456, DOI 10.1128/MCB.25.13.5456-5465.2005; Herrero C, 2003, J IMMUNOL, V171, P5034, DOI 10.4049/jimmunol.171.10.5034; Hu XY, 2005, J IMMUNOL, V175, P3637, DOI 10.4049/jimmunol.175.6.3637; Hu XY, 2002, NAT IMMUNOL, V3, P859, DOI 10.1038/ni828; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Illa I, 1997, AM J PATHOL, V151, P81; Johnston JA, 2003, NAT IMMUNOL, V4, P507, DOI 10.1038/ni0603-507; Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254-003-0012-2; Katakura K, 2005, J CLIN INVEST, V115, P695, DOI 10.1172/JCI200522996; Khabar KSA, 2004, J MOL BIOL, V342, P833, DOI 10.1016/j.jmb.2004.07.065; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kraan TCTMV, 2003, ARTHRITIS RHEUM-US, V48, P2132, DOI 10.1002/art.11096; Kuroiwa T, 2003, CLIN IMMUNOL, V106, P65, DOI 10.1016/S1521-6616(02)00022-0; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Mahboubi K, 2002, J BIOL CHEM, V277, P8012, DOI 10.1074/jbc.M107542200; Maritano D, 2004, NAT IMMUNOL, V5, P401, DOI 10.1038/ni1052; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Moss EG, 2003, NAT CELL BIOL, V5, P771, DOI 10.1038/ncb0903-771; Murray PJ, 2005, P NATL ACAD SCI USA, V102, P8686, DOI 10.1073/pnas.0500419102; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; Nishibori T, 2004, J EXP MED, V199, P25, DOI 10.1084/jem.20020509; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; SENGUPTA TK, 1995, J EXP MED, V181, P1015, DOI 10.1084/jem.181.3.1015; Sharif MN, 2004, J IMMUNOL, V172, P6476, DOI 10.4049/jimmunol.172.10.6476; Shen XN, 2000, FEBS LETT, V480, P132, DOI 10.1016/S0014-5793(00)01905-0; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takaoka A, 2003, CANCER SCI, V94, P405, DOI 10.1111/j.1349-7006.2003.tb01455.x; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tanabe Y, 2005, J IMMUNOL, V174, P609, DOI 10.4049/jimmunol.174.2.609; Tassiulas I, 2004, NAT IMMUNOL, V5, P1181, DOI 10.1038/ni1126; Wong LH, 1998, J IMMUNOL, V160, P5475; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang J, 2005, CANCER RES, V65, P939; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	56	223	229	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14111	14118		10.1074/jbc.M511797200	http://dx.doi.org/10.1074/jbc.M511797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16571725	hybrid			2022-12-25	WOS:000237512300034
J	Guyot, B; Murai, K; Fujiwara, Y; Valverde-Garduno, V; Hammett, M; Wells, S; Dear, N; Orkin, SH; Porcher, C; Vyas, P				Guyot, B; Murai, K; Fujiwara, Y; Valverde-Garduno, V; Hammett, M; Wells, S; Dear, N; Orkin, SH; Porcher, C; Vyas, P			Characterization of a megakaryocyte-specific enhancer of the key hemopoietic transcription factor GATA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; GENE-EXPRESSION; CELL-LINE; DIFFERENTIATION; ELEMENT; GROWTH; FLI-1; PROLIFERATION; MATURATION; REGULATOR	Specification and differentiation of the megakaryocyte and erythroid lineages from a common bipotential progenitor provides a well studied model to dissect binary cell fate decisions. To understand how the distinct megakaryocyte- and erythroid- specific gene programs arise, we have examined the transcriptional regulation of the megakaryocyte erythroid transcription factor GATA1. Hemopoietic-specific mouse ( m) GATA1 expression requires the mGata1 enhancer mHS- 3.5. Within mHS- 3.5, the 3 ' 179 bp of mHS- 3.5 are required for megakaryocyte but not red cell expression. Here, we show mHS- 3.5 binds key hemopoietic transcription factors in vivo and is required to maintain histone acetylation at the mGata1 locus in primary megakaryocytes. Analysis of GATA1- LacZ reporter gene expression in transgenic mice shows that a 25- bp element within the 3 '- 179 bp in mHS- 3.5 is critical for megakaryocyte expression. In vitro three DNA binding activities A, B, and C bind to the core of the 25- bp element, and these binding sites are conserved through evolution. Activity A is the zinc finger transcription factor ZBP89 that also binds to other cis elements in the mGata1 locus. Activity B is of particular interest as it is present in primary megakaryocytes but not red cells. Furthermore, mutation analysis in transgenic mice reveals activity B is required for megakaryocyte- specific enhancer function. Bioinformatic analysis shows sequence corresponding to the binding site for activity B is a previously unrecognized motif, present in the cis elements of the Fli1 gene, another important megakaryocyte- specific transcription factor. In summary, we have identified a motif and a DNA binding activity likely to be important in directing a megakaryocyte gene expression program that is distinct from that in red cells.	John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England	University of Oxford	Vyas, P (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	paresh.vyas@molecular-medicine.oxford.ac.uk	Vyas, Paresh/B-5708-2009; Porcher, Catherine/D-7026-2016	Vyas, Paresh/0000-0003-3931-0914; Guyot, Boris/0000-0002-4512-7123; Valverde-Garduno, Veronica/0000-0003-1490-2905	MRC [MC_U137961146, MC_U137961142] Funding Source: UKRI; Medical Research Council [MC_U137961142, MC_U137961146] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; Boopathi E, 2004, J BIOL CHEM, V279, P35242, DOI 10.1074/jbc.M403160200; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Eisbacher M, 2003, MOL CELL BIOL, V23, P3427, DOI 10.1128/MCB.23.10.3427-3441.2003; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Guyot B, 2004, BLOOD, V104, P89, DOI 10.1182/blood-2004-01-0108; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Hisa T, 2004, EMBO J, V23, P450, DOI 10.1038/sj.emboj.7600038; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; ISHIDA Y, 1993, EXP HEMATOL, V21, P289; Iwasaki H, 2003, IMMUNITY, V19, P451, DOI 10.1016/S1074-7613(03)00242-5; Jackers P, 2004, J BIOL CHEM, V279, P52183, DOI 10.1074/jbc.M407489200; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kobayashi M, 2001, DEVELOPMENT, V128, P2341; Kuhl C, 2005, MOL CELL BIOL, V25, P8592, DOI 10.1128/MCB.25.19.8592-8606.2005; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Nishimura S, 2000, MOL CELL BIOL, V20, P713, DOI 10.1128/MCB.20.2.713-723.2000; Okada Y, 2003, BLOOD, V101, P4748, DOI 10.1182/blood-2002-02-0380; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; Park H, 2003, BLOOD, V101, P894, DOI 10.1182/blood-2002-03-0680; Ronchi Antonella, 1997, Genes and Function, V1, P245; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Starck J, 1999, MOL CELL BIOL, V19, P121; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Valverde-Garduno V, 2004, BLOOD, V104, P3106, DOI 10.1182/blood-2004-04-1333; Villeval JL, 1997, BLOOD, V90, P4369; Vyas P, 1999, DEVELOPMENT, V126, P2799; Vyas P, 1999, BLOOD, V93, P2867; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; Woo AJ, 2005, BLOOD, V106, p244A; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yamada A, 2001, J BIOL CHEM, V276, P18082, DOI 10.1074/jbc.M008387200	43	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13733	13742		10.1074/jbc.M602052200	http://dx.doi.org/10.1074/jbc.M602052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16551635	hybrid			2022-12-25	WOS:000237336600084
J	Ho, DT; Bardwell, AJ; Grewal, S; Iverson, C; Bardwell, L				Ho, DT; Bardwell, AJ; Grewal, S; Iverson, C; Bardwell, L			Interacting JNK-docking sites in MKK7 promote binding and activation of JNK mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; HIGH-AFFINITY INTERACTION; MAP KINASES; SIGNAL-TRANSDUCTION; DOPAMINERGIC-NEURONS; MPTP MODEL; STRESS; SPECIFICITY; PHOSPHORYLATION; PATHWAY	D-sites are a class of MAPK-docking sites that have been found in many MAPK regulators and substrates. A single functional, high affinity D-site has been identified near the N terminus of each of the MAPK kinases ( MKKs orMEKs) MEK1, MEK2, MKK3, MKK4, and MKK6. Here we demonstrated that MKK7 recognizes its target JNK by a novel mechanism involving a partially cooperative interaction of three low affinity D-sites in the N-terminal domain of MKK7. Mutations of the conserved residues within any one of the three docking sites ( D1, D2, and D3) disrupted the ability of the N-terminal domain of MKK7 beta to bind JNK1 by about 50 - 70%. Moreover, mutation of any two of the three D-sites reduced binding by about 80 - 90%, and mutation of all three reduced binding by 95%. Full-length MKK7 containing combined D1/D2 mutations was compromised for binding to JNK1 and exhibited reduced JNK1 kinase activity when compared with wild-type MKK7. Peptide versions of the D-sites from MKK4 or the JIP-1 scaffold protein inhibited MKK7-JNK binding, suggesting that all three JNK regulators bind to the same region of JNK. Moreover, peptide versions of any of the three D-sites of MKK7 inhibited the ability of JNK1 and JNK2 to phosphorylate their transcription factor substrates c-Jun and ATF2, suggesting that D-site-containing substrates also compete with MKK7 for docking to JNK. Finally, MKK7-derived D-site peptides exhibited selective inhibition of JNK1 versus ERK2. We conclude that MKK7 contains three JNK-docking sites that interact to selectively bind JNK and contribute to JNK signal transmission and specificity.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Bardwell, L (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.	bardwell@uci.edu	Bardwell, Lee/I-8284-2019	Bardwell, Lee/0000-0002-2393-8363; Grewal, Seema/0000-0001-6372-8590	NIGMS NIH HHS [GM60366, R01 GM060366-06, R01 GM060366] Funding Source: Medline; NLM NIH HHS [T15 LM007443, LM07443] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060366] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Bardwell AJ, 2004, BIOCHEM J, V378, P569, DOI 10.1042/BJ20031382; Bardwell AJ, 2003, BIOCHEM J, V370, P1077, DOI 10.1042/BJ20021806; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Barsyte-Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200; Bhattacharyya RP, 2006, SCIENCE, V311, P822, DOI 10.1126/science.1120941; Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Flatauer LJ, 2005, MOL CELL BIOL, V25, P1793, DOI 10.1128/MCB.25.5.1793-1803.2005; Grewal S, 2006, CELL SIGNAL, V18, P123, DOI 10.1016/j.cellsig.2005.04.001; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; Komarova NL, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100031; Kusari AB, 2004, J CELL BIOL, V164, P267, DOI 10.1083/jcb.200310021; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Mooney LM, 2004, J BIOL CHEM, V279, P11843, DOI 10.1074/jbc.M311841200; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Sasaki T, 2001, J EXP MED, V194, P757, DOI 10.1084/jem.194.6.757; Schwartz MA, 2004, ANNU REV GENET, V38, P725, DOI 10.1146/annurev.genet.39.073003.112634; Seyfried J, 2005, MOL CELL BIOL, V25, P9820, DOI 10.1128/MCB.25.22.9820-9828.2005; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Wada T, 2004, NAT CELL BIOL, V6, P215, DOI 10.1038/ncb1098; Waetzig V, 2005, TRENDS PHARMACOL SCI, V26, P455, DOI 10.1016/j.tips.2005.07.006; Wang WY, 2004, NEUROSCI RES, V48, P195, DOI 10.1016/j.neures.2003.10.012; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yoshida H, 2004, J NEUROCHEM, V90, P352, DOI 10.1111/j.1471-4159.2004.02479.x	59	58	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13169	13179		10.1074/jbc.M601010200	http://dx.doi.org/10.1074/jbc.M601010200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533805	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000237336600022
J	Lohkamp, B; Andersen, B; Piskur, J; Dobritzsch, D				Lohkamp, B; Andersen, B; Piskur, J; Dobritzsch, D			The crystal structures of dihydropyrimidinases reaffirm the close relationship between cyclic amidohydrolases and explain their substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY-DIFFRACTION ANALYSIS; D-HYDANTOINASE; ACTIVE-SITE; 5,6-DIHYDROPYRIMIDINE AMIDOHYDROLASE; MOLECULAR-STRUCTURE; BETA-ALANINE; PURIFICATION; PROTEIN; ENZYMES; MECHANISM	In eukaryotes, dihydropyrimidinase catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Here we describe the three- dimensional structures of dihydropyrimidinase from two eukaryotes, the yeast Saccharomyces kluyveri and the slime mold Dictyostelium discoideum, determined and refined to 2.4 and 2.05 angstrom, respectively. Both enzymes have a ( beta/ alpha)(8)- barrel structural core embedding the catalytic di- zinc center, which is accompanied by a smaller beta- sandwich domain. Despite loop- forming insertions in the sequence of the yeast enzyme, the overall structures and architectures of the active sites of the dihydropyrimidinases are strikingly similar to each other, as well as to those of hydantoinases, dihydroorotases, and other members of the amidohydrolase superfamily of enzymes. However, formation of the physiologically relevant tetramer shows subtle but nonetheless significant differences. The extension of one of the sheets of the beta- sandwich domain across a subunit- subunit interface in yeast dihydropyrimidinase underlines its closer evolutionary relationship to hydantoinases, whereas the slime mold enzyme shows higher similarity to the noncatalytic collapsin- response mediator proteins involved in neuron development. Catalysis is expected to follow a dihydroorotase- like mechanism but in the opposite direction and with a different substrate. Complexes with dihydrouracil and N- carbamyl- beta- alanine obtained for the yeast dihydropyrimidinase reveal the mode of substrate and product binding and allow conclusions about what determines substrate specificity, stereoselectivity, and the reaction direction among cyclic amidohydrolases.	Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Lund Univ, Dept Cell & Organism Biol, S-22362 Lund, Sweden	Karolinska Institutet; Lund University	Dobritzsch, D (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Tomtebodavagen 6, SE-17177 Stockholm, Sweden.	Doreen.Dobritzsch@ki.se	Dobritzsch, Doreen/H-7334-2018	Lohkamp, Bernhard/0000-0002-5646-2090; Andersen, Birgit/0000-0002-9696-1708				Abendroth J, 2002, J MOL BIOL, V320, P143, DOI 10.1016/S0022-2836(02)00422-9; Abendroth J, 2002, BIOCHEMISTRY-US, V41, P8589, DOI 10.1021/bi0157722; Altenbuchner J, 2001, CURR OPIN BIOTECH, V12, P559, DOI 10.1016/S0958-1669(01)00263-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS KP, 1983, ARCH BIOCHEM BIOPHYS, V226, P469, DOI 10.1016/0003-9861(83)90316-8; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; CECERE F, 1975, FEBS LETT, V57, P192, DOI 10.1016/0014-5793(75)80714-9; Cheon YH, 2004, BIOCHEMISTRY-US, V43, P7413, DOI 10.1021/bi036330o; Cheon YH, 2003, J MOL CATAL B-ENZYM, V26, P217, DOI 10.1016/j.molcatb.2003.06.005; Cheon YH, 2002, BIOCHEMISTRY-US, V41, P9410, DOI 10.1021/bi0201567; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Deo RC, 2004, EMBO J, V23, P9, DOI 10.1038/sj.emboj.7600021; Dobritzsch D, 2005, ACTA CRYSTALLOGR F, V61, P359, DOI 10.1107/S174430910500610X; DUDLEY KH, 1974, DRUG METAB DISPOS, V2, P103; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gojkovic Z, 2000, J MOL BIOL, V295, P1073, DOI 10.1006/jmbi.1999.3393; Gojkovic Z, 2003, NUCLEIC ACIDS RES, V31, P1683, DOI 10.1093/nar/gkg258; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; HASINOFF BB, 1993, DRUG METAB DISPOS, V21, P883; HEGGIE GD, 1987, CANCER RES, V47, P2203; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JAHNKE K, 1993, BIOCHEMISTRY-US, V32, P5160, DOI 10.1021/bi00070a027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAUTZ J, 1989, EUR J BIOCHEM, V181, P431, DOI 10.1111/j.1432-1033.1989.tb14743.x; KIKUGAWA M, 1994, EUR J BIOCHEM, V219, P393, DOI 10.1111/j.1432-1033.1994.tb19951.x; Kim GJ, 1998, BIOCHEM J, V330, P295, DOI 10.1042/bj3300295; Kim GJ, 1998, BIOCHEM BIOPH RES CO, V243, P96, DOI 10.1006/bbrc.1997.8037; Kishan KVR, 2005, J MOL BIOL, V347, P95, DOI 10.1016/j.jmb.2005.01.025; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lohkamp B, 2006, ACTA CRYSTALLOGR F, V62, P36, DOI 10.1107/S174430910503976X; Lohkamp B., 2005, CCP4 NEWSLETTER, V42; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; Marti-Arbona R, 2005, BIOORG CHEM, V33, P448, DOI 10.1016/j.bioorg.2005.10.002; Marti-Arbona R, 2005, BIOCHEMISTRY-US, V44, P7115, DOI 10.1021/bi050008r; May O, 1998, BIOL CHEM, V379, P743; May O, 1998, J BIOTECHNOL, V61, P1, DOI 10.1016/S0168-1656(98)00005-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ogawa J, 1997, J MOL CATAL B-ENZYM, V2, P163, DOI 10.1016/S1381-1177(96)00020-3; Porter TN, 2004, BIOCHEMISTRY-US, V43, P16285, DOI 10.1021/bi048308g; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; SANDBERG M, 1981, J NEUROCHEM, V37, P1353, DOI 10.1111/j.1471-4159.1981.tb04691.x; Seibert CM, 2005, BIOCHEMISTRY-US, V44, P6383, DOI 10.1021/bi047326v; Sharma R, 1997, BIOCHEM BIOPH RES CO, V234, P485, DOI 10.1006/bbrc.1997.6659; Shim H, 2000, BIOCHEMISTRY-US, V39, P7357, DOI 10.1021/bi000291o; Sumi S, 1998, AM J MED GENET, V78, P336, DOI 10.1002/(SICI)1096-8628(19980724)78:4<336::AID-AJMG6>3.0.CO;2-J; Syldatk C, 1999, APPL MICROBIOL BIOT, V51, P293, DOI 10.1007/s002530051395; Takemoto T, 2000, GENE, V261, P259, DOI 10.1016/S0378-1119(00)00494-7; Thoden JB, 2001, BIOCHEMISTRY-US, V40, P6989, DOI 10.1021/bi010682i; TRAUT TW, 1984, BIOCHEMISTRY-US, V23, P2533, DOI 10.1021/bi00306a033; Traut TW, 1996, PROG NUCLEIC ACID RE, V53, P1, DOI 10.1016/S0079-6603(08)60142-7; van Kuilenburg ABP, 2003, CLIN CANCER RES, V9, P4363; vanGennip AH, 1997, J INHERIT METAB DIS, V20, P339, DOI 10.1023/A:1005309423960; WALLACH DP, 1957, J BIOL CHEM, V226, P277; WASTERNACK C, 1980, PHARMACOL THERAPEUT, V8, P629, DOI 10.1016/0163-7258(80)90079-0; Xu Z, 2003, J BACTERIOL, V185, P4038, DOI 10.1128/JB.185.14.4038-4049.2003; Zameitat E, 2004, FEBS LETT, V568, P129, DOI 10.1016/j.febslet.2004.05.017	65	45	47	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13762	13776		10.1074/jbc.M513266200	http://dx.doi.org/10.1074/jbc.M513266200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16517602	hybrid			2022-12-25	WOS:000237336600087
J	Choe, Y; Leonetti, F; Greenbaum, DC; Lecaille, F; Bogyo, M; Bromme, D; Ellman, JA; Craik, CS				Choe, Y; Leonetti, F; Greenbaum, DC; Lecaille, F; Bogyo, M; Bromme, D; Ellman, JA; Craik, CS			Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-V; (ACYLOXY)METHYL KETONES; INHIBITOR DESIGN; ACTIVE-SITE; EXPRESSION; LOCALIZATION; PAPAIN; DEGRADATION; OSTEOCLASTS; DEFINITION	The substrate specificities of papain-like cysteine proteases ( clan CA, family C1) papain, bromelain, and human cathepsins L, V, K, S, F, B, and five proteases of parasitic origin were studied using a completely diversified positional scanning synthetic combinatorial library. A bifunctional coumarin fluorophore was used that facilitated synthesis of the library and individual peptide substrates. The library has a total of 160,000 tetrapeptide substrate sequences completely randomizing each of the P1, P2, P3, and P4 positions with 20 amino acids. A microtiter plate assay format permitted a rapid determination of the specificity profile of each enzyme. Individual peptide substrates were then synthesized and tested for a quantitative determination of the specificity of the human cathepsins. Despite the conserved three-dimensional structure and similar substrate specificity of the enzymes studied, distinct amino acid preferences that differentiate each enzyme were identified. The specificities of cathepsins K and S partially match the cleavage site sequences in their physiological substrates. Capitalizing on its unique preference for proline and glycine at the P2 and P3 positions, respectively, selective substrates and a substrate-based inhibitor were developed for cathepsin K. A cluster analysis of the proteases based on the complete specificity profile provided a functional characterization distinct from standard sequence analysis. This approach provides useful information for developing selective chemical probes to study protease-related pathologies and physiologies.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley; Icahn School of Medicine at Mount Sinai	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Box 2280, San Francisco, CA 94143 USA.	craik@cgl.ucsf.edu	Ellman, Jonathan A/C-7732-2013; Lecaille, Fabien/GRY-5313-2022	Lecaille, Fabien/0000-0003-1060-4222; Leonetti, Francesco/0000-0003-2043-7464; Bogyo, Matthew/0000-0003-3753-4412	NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048669, R01AR046182] Funding Source: NIH RePORTER; NCI NIH HHS [CA72006] Funding Source: Medline; NIAID NIH HHS [AI35707] Funding Source: Medline; NIAMS NIH HHS [AR46182, AR48669] Funding Source: Medline; NIGMS NIH HHS [GM54051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; BARRETT AJ, 2004, HDB PROTEOLYTIC ENZY, P1105; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; BROMME D, 1994, BIOL CHEM H-S, V375, P343, DOI 10.1515/bchm3.1994.375.5.343; Bromme D, 1996, PROTEIN SCI, V5, P789; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 2002, CURR PHARM DESIGN, V8, P1639, DOI 10.2174/1381612023394179; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; BUNIN BA, 1998, COMBINATORIAL INDEX, P6; Caffrey CR, 2001, MOL BIOCHEM PARASIT, V118, P61, DOI 10.1016/S0166-6851(01)00368-1; Cotrin SS, 2004, ANAL BIOCHEM, V335, P244, DOI 10.1016/j.ab.2004.09.012; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Harris JL, 2001, J BIOL CHEM, V276, P34941, DOI 10.1074/jbc.M102997200; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727; Lecaille F, 2002, CHEM REV, V102, P4459, DOI 10.1021/cr0101656; Maly DJ, 2002, J ORG CHEM, V67, P910, DOI 10.1021/jo016140o; Marnett AB, 2005, TRENDS BIOTECHNOL, V23, P59, DOI 10.1016/j.tibtech.2004.12.010; McGrath ME, 1998, PROTEIN SCI, V7, P1294, DOI 10.1002/pro.5560070604; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; Puzer L, 2004, ARCH BIOCHEM BIOPHYS, V430, P274, DOI 10.1016/j.abb.2004.07.006; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Rosenthal PJ, 2004, INT J PARASITOL, V34, P1489, DOI 10.1016/j.ijpara.2004.10.003; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Salter JP, 2002, J BIOL CHEM, V277, P24618, DOI 10.1074/jbc.M202364200; SMITH SM, 1989, J BIOL CHEM, V264, P20487; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turk D, 1998, BIOL CHEM, V379, P137, DOI 10.1515/bchm.1998.379.2.137; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; WAGNER BM, 1994, J MED CHEM, V37, P1833, DOI 10.1021/jm00038a012; Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084; Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013	38	304	332	3	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12824	12832		10.1074/jbc.M513331200	http://dx.doi.org/10.1074/jbc.M513331200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520377	hybrid			2022-12-25	WOS:000237134700077
J	Cobine, PA; Pierrel, F; Leary, SC; Sasarman, F; Horng, YC; Shoubridge, EA; Winge, DR				Cobine, PA; Pierrel, F; Leary, SC; Sasarman, F; Horng, YC; Shoubridge, EA; Winge, DR			The P174L mutation in human Sco1 severely compromises Cox17-dependent metallation but does not impair copper binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; YEAST; GENE; COX17; CARDIOMYOPATHY; DEFICIENCY; ONSET; SITES	Sco1 is a metallochaperone that is required for copper delivery to the Cu-A site in the CoxII subunit of cytochrome c oxidase. The only known missense mutation in human Sco1, a P174L substitution in the copper-binding domain, is associated with a fatal neonatal hepatopathy; however, the molecular basis for dysfunction of the protein is unknown. Immortalized fibroblasts from a SCO1 patient show a severe deficiency in cytochrome c oxidase activity that was partially rescued by overexpression of P174L Sco1. The mutant protein retained the ability to bind Cu(I) and Cu(II) normally when expressed in bacteria, but Cox17-mediated copper transfer was severely compromised both in vitro and in a yeast cytoplasmic assay. The corresponding P153L substitution in yeast Sco1 was impaired in suppressing the phenotype of cells harboring the weakly functional C57Y allele of Cox17; however, it was functional in sco1 Delta yeast when the wild-type COX17 gene was present. Pulse-chase labeling of mitochondrial translation products in SCO1 patient fibroblasts showed no change in the rate of CoxII translation, but there was a specific and rapid turnover of CoxII protein in the chase. These data indicate that the P174L mutation attenuates a transient interaction with Cox17 that is necessary for copper transfer. They further suggest that defective Cox17-mediated copper metallation of Sco1, as well as the subsequent failure of Cu-A site maturation, is the basis for the inefficient assembly of the cytochrome c oxidase complex in SCO1 patients.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; McGill University; McGill University	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	eric@ericpc.mni.mcgill.ca; dennis.winge@hsc.utah.edu	Cobine, Paul A/G-3107-2011; Cobine, Paul/AAH-6619-2020; Leary, Scot/B-3036-2012; Horng, Yih-Chern/I-6682-2018; Winge, Dennis/G-3611-2010; PIERREL, Fabien/M-6016-2014	Cobine, Paul A/0000-0001-6012-0985; Cobine, Paul/0000-0001-6012-0985; Horng, Yih-Chern/0000-0001-9558-3189; PIERREL, Fabien/0000-0003-2083-3002	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03817] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489; Barros MH, 2004, J BIOL CHEM, V279, P31943, DOI 10.1074/jbc.M405014200; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Horng YC, 2005, J BIOL CHEM, V280, P34113, DOI 10.1074/jbc.M506801200; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; Jaksch M, 2001, NEUROLOGY, V57, P1440, DOI 10.1212/WNL.57.8.1440; Leary SC, 2004, HUM MOL GENET, V13, P1839, DOI 10.1093/hmg/ddh197; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Papadopoulou LC, 1999, NAT GENET, V23, P333; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; Paret C, 2000, BIOCHEM BIOPH RES CO, V279, P341, DOI 10.1006/bbrc.2000.3949; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Valnot I, 2000, AM J HUM GENET, V67, P1104; Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245; Williams JC, 2005, J BIOL CHEM, V280, P15202, DOI 10.1074/jbc.M410705200; Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	23	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12270	12276		10.1074/jbc.M600496200	http://dx.doi.org/10.1074/jbc.M600496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520371	Green Submitted, hybrid			2022-12-25	WOS:000237134700011
J	Song, H; Lee, MY; Kinsey, SP; Weber, DJ; Blaustein, MP				Song, H; Lee, MY; Kinsey, SP; Weber, DJ; Blaustein, MP			An N-terminal sequence targets and tethers Na+ pump alpha 2 subunits to specialized plasma membrane microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-ATPASE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; NA,K-ATPASE ISOZYMES; CATALYTIC SUBUNIT; OUABAIN AFFINITY; ANKYRIN-BINDING; NA/CA EXCHANGER; SMOOTH-MUSCLE; CALCIUM-PUMP	Sodium pumps (alpha B dimers) with the alpha 1 isoform of the catalytic (alpha) subunit are expressed in all cells. Additionally, most cells express Na+ pumps with a second alpha isoform. For example, astrocytes and arterial myocytes also express Na+ pumps with the alpha 2 isoform. The alpha 2 pumps localize to plasma membrane ( PM) microdomains overlying "junctional" sarco-/endoplasmic reticulum (S/ER), but the alpha 1 pumps are more uniformly distributed. To study alpha 2 targeting, we expressed alpha 1/alpha 2 and alpha 2/alpha 1 chimeras and 1-90 and 1-120 amino acid N-terminal peptides in primary cultured mouse astrocytes. Immunocytochemistry revealed that alpha 2/alpha 1 ( but not alpha 1/alpha 2) chimeras markedly reduced native alpha 2 (i.e. were "dominant negatives"). N-terminal (1-120 and 1-90 amino acids) alpha 2 ( and alpha 3), but not alpha 1 peptides also targeted to the PM-S/ER junctions and were dominant negative for native alpha 2 in astrocytes and arterial myocytes. Thus alpha 2 and alpha 3 have the same targeting sequence. Ca2+ (fura-2) signals in astrocytes expressing the 1-90 alpha 2 peptide were comparable to signals in cells from alpha 2 null mutants (i.e. functionally dominant negative): 1 mu M ATP-evoked Ca2+ transients were augmented, and 100 nM ouabain-induced amplification was abolished. Amino acid substitutions in the 1-120 alpha 1 and alpha 2 constructs, and in full-length alpha 1, revealed that Leu-27 and Ala-35 are essential for targeting/tethering the constructs to PM-S/ER junctions.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Blaustein, MP (corresponding author), Univ Maryland, Sch Med, Dept Physiol, 655 W Baltimore St, Baltimore, MD 21201 USA.	mblaustein@som.umaryland.edu	Weber, David J/B-5349-2011	Weber, David J/0000-0002-8824-1110	NHLBI NIH HHS [HL-45215] Funding Source: Medline; NIGMS NIH HHS [GM-58888, R01 GM058888] Funding Source: Medline; NINDS NIH HHS [NS-16106] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016106] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Al-Khalili L, 2004, J BIOL CHEM, V279, P25211, DOI 10.1074/jbc.M402152200; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Blaustein MP, 2002, ANN NY ACAD SCI, V976, P356; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; Dostanic I, 2005, AM J PHYSIOL-HEART C, V288, pH477, DOI 10.1152/ajpheart.00083.2004; Dunbar LA, 2000, EUR J CELL BIOL, V79, P557, DOI 10.1078/0171-9335-00079; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; Golovina VA, 1996, GLIA, V16, P296; Golovina VA, 2003, AM J PHYSIOL-CELL PH, V284, pC475, DOI 10.1152/ajpcell.00383.2002; HENKART M, 1976, J CELL BIOL, V70, P338, DOI 10.1083/jcb.70.2.338; HENSLEY CB, 1992, AM J PHYSIOL, V262, pC484, DOI 10.1152/ajpcell.1992.262.2.C484; James PF, 1999, MOL CELL, V3, P555, DOI 10.1016/S1097-2765(00)80349-4; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Juhaszova M, 1997, ANN NY ACAD SCI, V834, P524, DOI 10.1111/j.1749-6632.1997.tb52310.x; Juhaszova M, 1997, P NATL ACAD SCI USA, V94, P1800, DOI 10.1073/pnas.94.5.1800; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; LEE MY, 2005, J GEN PHYSIOL, V126, pA69; Lencesova L, 2004, J BIOL CHEM, V279, P2885, DOI 10.1074/jbc.M310365200; LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327; MCGRAIL KM, 1991, J NEUROSCI, V11, P381, DOI 10.1523/jneurosci.11-02-00381.1991; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J CELL SCI, V115, P1565; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; Peng L, 1997, J NEUROSCI, V17, P3488; PRESSLEY TA, 1992, AM J PHYSIOL, V262, pC743, DOI 10.1152/ajpcell.1992.262.3.C743; Shelly DA, 2004, AM J PHYSIOL-CELL PH, V286, pC813, DOI 10.1152/ajpcell.00389.2003; SLODZINSKI MK, 1995, AM J PHYSIOL-CELL PH, V269, pC1340, DOI 10.1152/ajpcell.1995.269.5.C1340; Staton TJ, 2005, FASEB J, V19, pA1619; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Tallini YN, 2006, P NATL ACAD SCI USA, V103, P4753, DOI 10.1073/pnas.0509378103; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; Woo AL, 2000, J BIOL CHEM, V275, P20693, DOI 10.1074/jbc.M002323200; Zhang J, 2005, J PHYSIOL-LONDON, V569, P243, DOI 10.1113/jphysiol.2005.091801; Zhang ZS, 1998, J BIOL CHEM, V273, P18681, DOI 10.1074/jbc.273.30.18681	42	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12929	12940		10.1074/jbc.M507450200	http://dx.doi.org/10.1074/jbc.M507450200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16524882	hybrid			2022-12-25	WOS:000237134700088
J	Tan, YV; Couvineau, A; Murail, S; Ceraudo, E; Neumann, JM; Lacapere, JJ; Laburthe, M				Tan, YV; Couvineau, A; Murail, S; Ceraudo, E; Neumann, JM; Lacapere, JJ; Laburthe, M			Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor - Photoaffinity, NMR, and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CRYSTAL-STRUCTURE; VIP RECEPTOR; AMINO-ACIDS; DOMAINS; RESIDUES; BINDING; FAMILY; IDENTIFICATION; PHARMACOLOGY	The neuropeptide vasoactive intestinal peptide (VIP) strongly impacts on human pathophysiology and does so through interaction with class II G protein-coupled receptors named VIP pituitary adenylate cyclase-activating peptide (PACAP) receptors (VPACs). The molecular nature of VIP binding to receptors remains elusive. In this work, we have docked VIP in the human VPAC1 receptor by the following approach. (i) VIP probes containing photolabile residues in positions 6, 22, and 24 of VIP were used to photolabel the receptor. After receptor cleavage and Edman sequencing of labeled receptor fragments, it was shown that Phe(6), Tyr(22), and Asn(24) of VIP are in contact with Asp(107), Gly(116), and Cys(122) in the N-terminal ectodomain (N-ted) of the receptor, respectively. (ii) The structure of VIP was determined by NMR showing a central alpha helix, a disordered N-terminal His(1)-Phe(6) segment and a 3(10) Ser(25)-Asn(28) helix termination. (iii) A three-dimensional model of the N-ted of hVPAC1 was constructed by using the NMR structure of the N-ted of corticotropin-releasing factor receptor 2 beta as a template. As expected, the fold is identified as a short consensus repeat with two antiparallel beta sheets and is stabilized by three disulfide bonds. (iv) Taking into account the constraints provided by photoaffinity, VIP was docked into the hVPAC1 receptor N-ted. The 6-28 fragment of VIP nicely lies in the N-ted C-terminal part, but the N terminus region of VIP is free for interacting with the receptor transmembrane region. The data provide a structural rationale to the proposed two-step activation mechanism of VPAC receptor and more generally of class II G protein-coupled receptors.	Fac Med Bichat, INSERM, U773, Ctr Rech Biomed Bichat Beaujon, F-75018 Paris, France; Univ Paris 07, F-75018 Paris, France; Ctr Etud Saclay, CNRS, Unite Rech 2096, Dept Biol Joliot Curie,CEA Dept Sci Biol, F-91191 Gif Sur Yvette, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Laburthe, M (corresponding author), Fac Med Bichat, INSERM, U773, Ctr Rech Biomed Bichat Beaujon, CRB3,16 Rue Henir Huchard, F-75018 Paris, France.	laburthe@bichat.inserm.fr	LABURTHE, Marc/C-1875-2012; couvineau, alain/G-3641-2013; couvineau, alain/T-3466-2019; Murail, Samuel/AAC-3897-2019	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168; Murail, Samuel/0000-0002-3842-5333				BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chorev M, 2002, RECEPTOR CHANNEL, V8, P219, DOI 10.1080/10606820213685; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; Couvineau A, 2003, J BIOL CHEM, V278, P24759, DOI 10.1074/jbc.M301916200; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FRY DC, 1989, BIOCHEMISTRY-US, V28, P2399, DOI 10.1021/bi00432a010; Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043-2760(01)00409-X; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; Grace CRR, 2004, P NATL ACAD SCI USA, V101, P12836, DOI 10.1073/pnas.0404702101; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Hawrot E, 1998, FEBS LETT, V432, P103, DOI 10.1016/S0014-5793(98)00794-7; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; Laburthe M, 2002, RECEPTOR CHANNEL, V8, P137, DOI 10.1080/10606820290005191; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; Lins L, 2001, J BIOL CHEM, V276, P10153, DOI 10.1074/jbc.M009730200; Nicole P, 2000, J BIOL CHEM, V275, P24003, DOI 10.1074/jbc.M002325200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; Sexton PM, 2002, RECEPTOR CHANNEL, V8, P135, DOI 10.1080/10606820290005056; Solano RM, 2001, J BIOL CHEM, V276, P1084, DOI 10.1074/jbc.M007686200; Tan YV, 2004, J BIOL CHEM, V279, P38889, DOI 10.1074/jbc.M404460200; Tan YV, 2003, J BIOL CHEM, V278, P36531, DOI 10.1074/jbc.M304770200; THERIAULT Y, 1991, BIOPOLYMERS, V31, P459, DOI 10.1002/bip.360310411; TURNER JT, 1986, PEPTIDES, V7, P849, DOI 10.1016/0196-9781(86)90105-1; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3	32	56	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12792	12798		10.1074/jbc.M513305200	http://dx.doi.org/10.1074/jbc.M513305200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520374	hybrid			2022-12-25	WOS:000237134700073
J	Bellais, S; Arthur, M; Dubost, L; Hugonnet, JE; Gutmann, L; van Heijenoort, J; Legrand, R; Brouard, JP; Rice, L; Mainardi, JL				Bellais, S; Arthur, M; Dubost, L; Hugonnet, JE; Gutmann, L; van Heijenoort, J; Legrand, R; Brouard, JP; Rice, L; Mainardi, JL			Asl(fm), the D-aspartate ligase responsible for the addition of D-aspartic acid onto the peptidoglycan precursor of Enterococcus faecium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CELL-WALLS; CARBAMOYL-PHOSPHATE SYNTHETASE; BETA-LACTAM RESISTANCE; D-ALANINE LIGASE; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; STREPTOCOCCUS-PNEUMONIAE; PEPTIDE SYNTHETASES; CRYSTAL-STRUCTURE; VIRIDESCENS FEMX	D-Aspartate ligase has remained the last unidentified peptide bond-forming enzyme in the peptidoglycan assembly pathway of Gram-positive bacteria. Here we show that a two-gene cluster of Enterococcus faecium encodes aspartate racemase ( Rac(fm)) and ligase ( Asl(fm)) for incorporation of D-Asp into the side chain of the peptidoglycan precursor. Aslfm was identified as a new member of the ATP-grasp protein superfamily, which includes a diverse set of enzymes catalyzing ATP-dependent carboxylate-amine ligation reactions. Aslfm specifically ligated the beta-carboxylate of D-Asp to the epsilon-amino group of L-Lys in the nucleotide precursor UDP-N-acetylmuramyl-pentapeptide. D-iso-Asparagine was not a substrate of Aslfm, indicating that the presence of this amino acid in the peptidoglycan of E. faecium results from amidation of the alpha-carboxyl of D-Asp after its addition to the precursor. Heterospecific expression of the genes encoding Rac(fm) and Asl(fm) in Enterococcus faecalis led to production of stem peptides substituted by D-Asp instead of L-Ala(2), providing evidence for the in vivo specificity and function of these enzymes. Strikingly, sequencing of the cross-bridges revealed that substitution of L-Ala(2) by D-Asp is tolerated by the D,D-transpeptidase activity of the penicillin-binding proteins both in the acceptor and in the donor substrates. The Asl(fm) ligase appears as an attractive target for the development of narrow spectrum antibiotics active against multiresistant E. faecium.	Univ Paris 06, Univ Paris Descartes, Ctr Rech Biomed Cordeliers,Fac Med, LRMA,INSERM,U655, F-75270 Paris 06, France; Museum Natl Hist Nat, USM0502, CNRS,UMR8041, Plateforme Spectrometrie Masse & Proteom,Dept Rec, F-75005 Paris, France; Univ Paris 05, Fac Med, Hop Europeen Georges Pompidou, AP HP, F-75908 Paris 15, France; Univ Paris 11, Enveloppes Bacteriennes & Antibiot, CNRS, UMR 8619, F-91405 Orsay, France; Aventis Pharma France, F-93235 Romainville, France; Louis Stokes Cleveland Vet Affairs Med Ctr, Med Serv, Cleveland, OH 44106 USA; Louis Stokes Cleveland Vet Affairs Med Ctr, Res Serv, Cleveland, OH 44106 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis; Sanofi France; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Mainardi, JL (corresponding author), Univ Paris 06, Univ Paris Descartes, Ctr Rech Biomed Cordeliers,Fac Med, LRMA,INSERM,U655, 15 Rue Ecole Med, F-75270 Paris 06, France.	jlmainar@bhdc.jussieu.fr	MAINARDI, Jean-Luc/E-2714-2014; HUGONNET, Jean-Emmanuel/ABC-7914-2021; HUGONNET, Jean-Emmanuel/H-3581-2014; Arthur, Michel/G-3680-2013	MAINARDI, Jean-Luc/0000-0002-4159-0129; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; Arthur, Michel/0000-0003-1007-636X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045626] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI45626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Arbeloa A, 2004, J BIOL CHEM, V279, P41546, DOI 10.1074/jbc.M407149200; ARTHUR M, 1994, ANTIMICROB AGENTS CH, V38, P1899, DOI 10.1128/AAC.38.9.1899; Ashiuchi M, 1999, BIOSCI BIOTECH BIOCH, V63, P792, DOI 10.1271/bbb.63.792; Benson TE, 2002, STRUCTURE, V10, P1107, DOI 10.1016/S0969-2126(02)00807-9; Biarrotte-Sorin S, 2004, STRUCTURE, V12, P257, DOI 10.1016/j.str.2004.01.006; BillotKlein D, 1997, J BACTERIOL, V179, P4684, DOI 10.1128/jb.179.15.4684-4688.1997; Bouhss A, 1997, BIOCHEMISTRY-US, V36, P11556, DOI 10.1021/bi970797f; Bouhss A, 2002, J BIOL CHEM, V277, P45935, DOI 10.1074/jbc.M207449200; DUKTAMALEN S, 1992, GENE, V112, P53; FAN C, 1995, P NATL ACAD SCI USA, V92, P1172, DOI 10.1073/pnas.92.4.1172; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; Filipe SR, 2000, J BIOL CHEM, V275, P27768; Filipe SR, 2002, P NATL ACAD SCI USA, V99, P1550, DOI 10.1073/pnas.032671699; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Hegde SS, 2003, J BIOL CHEM, V278, P22861, DOI 10.1074/jbc.M301565200; Kopp U, 1996, MICROB DRUG RESIST, V2, P29, DOI 10.1089/mdr.1996.2.29; Kothe M, 1997, P NATL ACAD SCI USA, V94, P12348, DOI 10.1073/pnas.94.23.12348; Liu LJ, 2002, J MOL BIOL, V319, P479, DOI 10.1016/S0022-2836(02)00296-6; Mainardi JL, 2005, J BIOL CHEM, V280, P38146, DOI 10.1074/jbc.M507384200; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; MenginLecreulx D, 1996, J BACTERIOL, V178, P5347, DOI 10.1128/jb.178.18.5347-5352.1996; Murray BE, 2000, NEW ENGL J MED, V342, P710, DOI 10.1056/NEJM200003093421007; Naas T, 2005, J CLIN MICROBIOL, V43, P3642, DOI 10.1128/JCM.43.8.3642-3649.2005; PLAPP R, 1970, J BIOL CHEM, V245, P3667; Rohrer S, 1999, P NATL ACAD SCI USA, V96, P9351, DOI 10.1073/pnas.96.16.9351; Rohrer S, 2003, ANTIMICROB AGENTS CH, V47, P837, DOI 10.1128/AAC.47.3.837-846.2003; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; STAUDENBAUER W, 1972, J BIOL CHEM, V247, P5095; STAUDENBAUER W, 1972, J BIOL CHEM, V247, P5289; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; WILLIAMSON R, 1985, J GEN MICROBIOL, V131, P1933; Yamashita T, 2004, EUR J BIOCHEM, V271, P4798, DOI 10.1111/j.1432-1033.2004.04445.x; YOHDA M, 1991, BIOCHIM BIOPHYS ACTA, V1089, P234, DOI 10.1016/0167-4781(91)90013-C; Yohda M, 1996, J BIOL CHEM, V271, P22017, DOI 10.1074/jbc.271.36.22017	37	70	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11586	11594		10.1074/jbc.M600114200	http://dx.doi.org/10.1074/jbc.M600114200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16510449	hybrid			2022-12-25	WOS:000236988100021
J	Hong, Y; Nagamune, K; Morita, YS; Nakatani, F; Ashida, H; Maeda, Y; Kinoshita, T				Hong, Y; Nagamune, K; Morita, YS; Nakatani, F; Ashida, H; Maeda, Y; Kinoshita, T			Removal or maintenance of inositol-linked acyl chain in glycosylphosphatidylinositol is critical in trypanosome life cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN SLEEPING SICKNESS; VARIANT SURFACE GLYCOPROTEINS; RNA INTERFERENCE; STRUCTURAL-CHARACTERIZATION; DEVELOPMENTAL VARIATION; INDUCIBLE EXPRESSION; ANCHORED PROTEINS; LEISHMANIA-MAJOR; MEMBRANE ANCHORS; GPI BIOSYNTHESIS	The protozoan parasite Trypanosoma brucei is coated by glycosylphosphatidylinositol ( GPI)-anchored proteins. During GPI biosynthesis, inositol in phosphatidylinositol becomes acylated. Inositol is deacylated prior to attachment to variant surface glycoproteins in the bloodstream form, whereas it remains acylated in procyclins in the procyclic form. We have cloned a T. brucei GPI inositol deacylase ( GPIdeAc2). In accordance with the acylation/deacylation profile, the level of GPIdeAc2 mRNA was 6-fold higher in the bloodstream form than in the procyclic form. Knockdown of GPIdeAc2 in the bloodstream form caused accumulation of an inositol-acylated GPI, a decreased VSG expression on the cell surface and slower growth, indicating that inositol-deacylation is essential for the growth of the bloodstream form. Overexpression of GPIdeAc2 in the procyclic form caused an accumulation of GPI biosynthetic intermediates lacking inositol-linked acyl chain and decreased cell surface procyclins because of release into the culture medium, indicating that overexpression of GPIdeAc2 is deleterious to the surface coat of the procyclic form. Therefore, the GPI inositol deacylase activity must be tightly regulated in trypanosome life cycle.	Osaka Univ, Microbial Dis Res Inst, Dept Immunoregulat, Suita, Osaka 5650871, Japan	Osaka University	Kinoshita, T (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Immunoregulat, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	tkinoshi@biken.osaka-u.ac.jp	Ashida, Hisashi/HCI-0293-2022; Kinoshita, Taroh/C-7353-2009	Ashida, Hisashi/0000-0001-5844-4075; Morita, Yasu/0000-0002-4514-9242				Alibu VP, 2005, MOL BIOCHEM PARASIT, V139, P75, DOI 10.1016/j.molbiopara.2004.10.002; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; Chang TH, 2002, J BIOL CHEM, V277, P50176, DOI 10.1074/jbc.M208374200; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; Doerrler WT, 1996, J BIOL CHEM, V271, P27031, DOI 10.1074/jbc.271.43.27031; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; Ferguson MAJ, 2000, P NATL ACAD SCI USA, V97, P10673, DOI 10.1073/pnas.97.20.10673; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1992, J BIOL CHEM, V267, P5324; Guther MLS, 2003, BIOCHEMISTRY-US, V42, P14532, DOI 10.1021/bi034869g; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; Guther MLS, 2001, EMBO J, V20, P4923, DOI 10.1093/emboj/20.17.4923; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; MENON AK, 1990, J BIOL CHEM, V265, P9033; Morita YS, 2000, J BIOL CHEM, V275, P14147, DOI 10.1074/jbc.275.19.14147; Nagamune K, 2004, J EXP MED, V199, P1445, DOI 10.1084/jem.20030635; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; Roditi I, 2002, TRENDS MICROBIOL, V10, P128, DOI 10.1016/S0966-842X(02)02309-0; Ruepp S, 1997, J CELL BIOL, V137, P1369, DOI 10.1083/jcb.137.6.1369; SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567; Sheader K, 2005, P NATL ACAD SCI USA, V102, P8716, DOI 10.1073/pnas.0501886102; Smith TK, 2004, EMBO J, V23, P4701, DOI 10.1038/sj.emboj.7600456; Tanaka S, 2004, J BIOL CHEM, V279, P14256, DOI 10.1074/jbc.M313755200; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; Vassella E, 2003, MOL BIOL CELL, V14, P1308, DOI 10.1091/mbc.E02-10-0694; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	36	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11595	11602		10.1074/jbc.M513061200	http://dx.doi.org/10.1074/jbc.M513061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16510441	hybrid			2022-12-25	WOS:000236988100022
J	Piltti, K; Kerosuo, L; Hakanen, J; Eriksson, M; Angers-Loustau, A; Leppa, S; Salminen, M; Sariola, H; Wartiovaara, K				Piltti, K.; Kerosuo, L.; Hakanen, J.; Eriksson, M.; Angers-Loustau, A.; Leppa, S.; Salminen, M.; Sariola, H.; Wartiovaara, K.			E6/E7 oncogenes increase and tumor suppressors decrease the proportion of self-renewing neural progenitor cells	ONCOGENE			English	Article						oncogene; tumor suppressor; progenitor; self-renewal	HUMAN-PAPILLOMAVIRUS TYPE-16; STEM-CELL; E7 GENE; RETINOBLASTOMA PROTEIN; SIGNALING PATHWAY; EPITHELIAL-CELLS; PRECURSOR CELLS; LARGE-T; PROMOTES; KINASE	Many if not most tissues need a controlled number of stem cells to maintain normal function. Cancer can be seen as a process of disturbed tissue homeostasis, in which too many cells have or acquire too primitive identity. Here we measured how oncogenes and tumour suppressors affect the differentiation capacity, proportion and characteristics of progenitor cells in a model tissue. Neural progenitor cells (NPCs) were exposed to human papilloma virus E6, E7 or E6/E7 oncogenes, which degrade tumour suppressors p53 and pRb family members, respectively. E6/E7-expressing or p53(-/-) NPCs were able to differentiate, but simultaneously retained high capacity for self-renewal, proliferation, ability to remain multi-potent in conditions promoting differentiation and showed delayed cell cycle exit. These functions were mediated through p53 and pRb family, and involved MEK-ERK signalling. Decreased amount of p53 increased self-renewal and proliferation, whereas pRb affected only proliferation. Our results suggest that the oncogenes increase whereas p53 and pRb family tumour suppressors decrease the number and proportion of progenitor cells. These findings provide one explanation how oncogenes and tumour suppressors control tissue homeostasis and highlight their importance in stem cell self-renewal, linked both to cancer and life-long tissue turnover.	Univ Helsinki, Dept Biol, Inst Biomed, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, HUCH Lab Diagnost, Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Wartiovaara, K (corresponding author), Univ Helsinki, Dept Biol, Inst Biomed, POB 63, FIN-00014 Helsinki, Finland.	kirmo.wartiovaara@helsinki.fi	Hakanen, Janne/O-2166-2016	Hakanen, Janne/0000-0002-7501-2917; Salminen, Marjo/0000-0003-0696-6845; Piltti, Katja/0000-0002-9773-0442; Leppa, Sirpa/0000-0002-8265-511X; Angers-Loustau, Alexandre/0000-0003-1425-4143				Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Boyer SN, 1996, CANCER RES, V56, P4620; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; Chakrabarti O, 2004, J VIROL, V78, P5934, DOI 10.1128/JVI.78.11.5934-5945.2004; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Coursen JD, 1997, EXP CELL RES, V235, P245, DOI 10.1006/excr.1997.3670; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Dazy S, 2003, ONCOGENE, V22, P9205, DOI 10.1038/sj.onc.1207049; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; Farah MH, 2000, DEVELOPMENT, V127, P693; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Miller MW, 2003, BRAIN RES, V965, P57, DOI 10.1016/S0006-8993(02)04119-7; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Popsueva A, 2003, J CELL BIOL, V161, P119, DOI 10.1083/jcb.200212174; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Singh SK, 2003, CANCER RES, V63, P5821; SLACK RS, 1993, ONCOGENE, V8, P1585; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; TeKippe M, 2003, EXP HEMATOL, V31, P521, DOI 10.1016/S0301-472X(03)00072-9; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Toma JG, 2000, J NEUROSCI, V20, P7648; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van Houten VMM, 2001, INT J CANCER, V93, P232, DOI 10.1002/ijc.1313; Vanderluit JL, 2004, J CELL BIOL, V166, P853, DOI 10.1083/jcb.200403156; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	45	16	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4880	4889		10.1038/sj.onc.1209492	http://dx.doi.org/10.1038/sj.onc.1209492			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16532024				2022-12-25	WOS:000239687100006
J	Cohen, Z; Bacharach, E; Lavi, S				Cohen, Z.; Bacharach, E.; Lavi, S.			Mouse major satellite DNA is prone to eccDNA formation via DNA Ligase IV-dependent pathway	ONCOGENE			English	Article						eccDNA; spcDNA; genomic instability; major satellite DNA; DNA Ligase IV	EXTRACHROMOSOMAL CIRCULAR DNAS; MAMMALIAN-CELLS; GENOMIC INSTABILITY; RECOMBINATION; CIRCLES; MOLECULES; SPCDNA; DROSOPHILA; TELOMERES; SEQUENCES	Elevated levels of extrachromosomal circular DNA (eccDNA or spcDNA) are closely associated with genomic instability and aging. Despite extensive studies, the mechanism of its generation in mammalian cells is unknown. We report here that mouse major satellite DNA (MSD) is prone to eccDNA formation and that the resulting molecules are multimeres of the basic repeat. Extrachromosomal circular major satellite (ECMS) DNA constitutes the majority of eccDNA in B16 mouse melanoma cells and is highly abundant in other mouse cells. Production of these molecules is enhanced in proliferating cells, suggesting that processes associated with DNA replication are involved in their appearance. Using siRNA technique we show that DNA Ligase IV is engaged in ECMS synthesis. Based on our findings we propose a novel two-step model for eccDNA formation in mammalian cells.	Tel Aviv Univ, Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Lavi, S (corresponding author), Tel Aviv Univ, Fac Life Sci, Dept Cell Res & Immunol, POB 39040, IL-69978 Tel Aviv, Israel.	lavisara@post.tau.ac.il		Bacharach, Eran/0000-0001-8341-2833; Cohen, Zoya/0000-0002-1284-3035				ASSUM G, 1993, HUM GENET, V91, P489; Autiero M, 2002, INT J CANCER, V99, P370, DOI 10.1002/ijc.10368; BERTELSEN AH, 1982, BIOCHEMISTRY-US, V21, P2076, DOI 10.1021/bi00538a015; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; CHATTERJEE B, 1989, J MOL BIOL, V210, P303, DOI 10.1016/0022-2836(89)90332-X; Cohen S, 1997, ONCOGENE, V14, P977, DOI 10.1038/sj.onc.1200917; Cohen S, 2003, GENOME RES, V13, P1133, DOI 10.1101/gr.907603; Cohen S, 1996, MOL CELL BIOL, V16, P2002; Cohen S, 1999, MOL CELL BIOL, V19, P6682; Cohen S, 2001, NUCLEIC ACIDS RES, V29, P2542, DOI 10.1093/nar/29.12.2542; DEGROOTE F, 1989, CHROMOSOMA, V89, P201; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; GAUBATZ JW, 1990, MUTAT RES, V237, P29, DOI 10.1016/0921-8734(90)90029-Q; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KIYAMA R, 1987, J MOL BIOL, V193, P591, DOI 10.1016/0022-2836(87)90342-1; KUNISADA T, 1985, MECH AGEING DEV, V29, P89, DOI 10.1016/0047-6374(85)90050-8; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MOTEJLEK K, 1993, MUTAT RES, V293, P205, DOI 10.1016/0921-8777(93)90071-N; NEHLS M, 1995, TRENDS GENET, V11, P39, DOI 10.1016/S0168-9525(00)88990-8; Ohki R, 1995, NUCLEIC ACIDS RES, V23, P4971, DOI 10.1093/nar/23.24.4971; Park PU, 1999, MOL CELL BIOL, V19, P3848; PONT G, 1988, NUCLEIC ACIDS RES, V16, P8817, DOI 10.1093/nar/16.18.8817; Regev A, 1998, ONCOGENE, V17, P3455, DOI 10.1038/sj.onc.1202250; Sambrook J., 2002, MOL CLONING LAB MANU; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; Silver L.M., 1995, MOUSE GENETICS CONCE; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Takeuchi Y, 2003, GENE DEV, V17, P1497, DOI 10.1101/gad.1085403; VANLOON N, 1994, NUCLEIC ACIDS RES, V13, P2447; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Zhong Q, 2002, CANCER RES, V62, P3966	34	36	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4515	4524		10.1038/sj.onc.1209485	http://dx.doi.org/10.1038/sj.onc.1209485			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16547499				2022-12-25	WOS:000239457500002
J	Dixit, VD; Weeraratna, AT; Yang, HW; Bertak, D; Cooper-Jenkins, A; Riggins, GJ; Eberhart, CG; Taub, DD				Dixit, Vishwa Deep; Weeraratna, Ashani T.; Yang, Hyunwon; Bertak, Dorothy; Cooper-Jenkins, Anthony; Riggins, Gregory J.; Eberhart, Charles G.; Taub, Dennis D.			Ghrelin and the growth hormone secretagogue receptor constitute a novel autocrine pathway in astrocytoma motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DES-ACYL GHRELIN; PROTEIN-KINASE-C; BIOLOGICAL-ACTIVITY; MESSENGER-RNA; EXPRESSION; ACTIVATION; IDENTIFICATION; CANCER; GLIOMA; CELLS	Originally thought of as a stomach-derived endocrine peptide acting via its receptors in the central nervous system to stimulate food intake and growth hormone expression, ghrelin and its receptor ( growth hormone secretagogue receptor (GHS-R)) are widely expressed in a number of organ systems, including cancer cells. However, the direct functional role of ghrelin and its receptor in tumors of central nervous system origin remains to be defined. Here, we demonstrate that the human astrocytoma cell lines U-118, U-87, CCF-STTG1, and SW1088 express 6-, 11-, 15-, and 29-fold higher levels of GHS-R compared with primary normal human astrocytes. The ligation of GHS-R by ghrelin on these cells resulted in an increase in intracellular calcium mobilization, protein kinase C activation, actin polymerization, matrix metalloproteinase-2 activity, and astrocytoma motility. In addition, ghrelin led to actin polymerization and membrane ruffling on cells, with the specific co-localization of the small GTPase Rac1 with GHS-R on the leading edge of the astrocytoma cells and imparting the tumor cells with a motile phenotype. Disruption of the endogenous ghrelin/GHS-R pathway by RNA interference resulted in diminished motility, matrix metalloproteinase activity, and Rac expression, whereas tumor cells stably overexpressing GHS-R exhibited increased cell motility. The relevance of ghrelin and GHS-R expression was verified in clinically relevant tissues from 20 patients with oligodendrogliomas and grade II-IV astrocytomas. Analysis of a central nervous system tumor tissue microarray revealed that strong GHS-R and ghrelin expression was significantly more common in high grade tumors compared with low grade ones. Together, these findings suggest a novel role for the ghrelin/ GHS-R axis in astrocytoma cell migration and invasiveness of cancers of central nervous system origin.	NIA, Clin Immunol Sect, Immunol Lab, NIH,Intramural Res Program, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins University	Taub, DD (corresponding author), NIA, Clin Immunol Sect, Immunol Lab, NIH,Intramural Res Program, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	Taubd@grc.nia.nih.gov			NATIONAL INSTITUTE ON AGING [Z01AG000758, Z01AG000766] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AG000758-10] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Albini A, 1998, Pathol Oncol Res, V4, P230; Ariyasu H, 2005, ENDOCRINOLOGY, V146, P355, DOI 10.1210/en.2004-0629; Baessler A, 2005, DIABETES, V54, P259, DOI 10.2337/diabetes.54.1.259; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Banks WA, 2002, J PHARMACOL EXP THER, V302, P822, DOI 10.1124/jpet.102.034827; Barlier A, 1999, J NEUROENDOCRINOL, V11, P491; Boon K, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-39; Burton E C, 2000, Curr Treat Options Oncol, V1, P459, DOI 10.1007/s11864-000-0073-2; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; CARLINI VP, 1999, BIOCHEM BIOPH RES CO, V299, P739; Caron E, 2003, NAT CELL BIOL, V5, P185, DOI 10.1038/ncb0303-185; Cassoni P, 2004, EUR J ENDOCRINOL, V150, P173, DOI 10.1530/eje.0.1500173; Cassoni P, 2001, J CLIN ENDOCR METAB, V86, P1738, DOI 10.1210/jc.86.4.1738; Chen CY, 2005, GASTROENTEROLOGY, V129, P8, DOI 10.1053/j.gastro.2005.04.015; Corbetta S, 2003, J CLIN ENDOCR METAB, V88, P3117, DOI 10.1210/jc.2002-021842; da Rocha AB, 2002, ONCOLOGIST, V7, P17, DOI 10.1634/theoncologist.7-1-17; De Vriese C, 2005, ENDOCRINOLOGY, V146, P1514, DOI 10.1210/en.2004-0964; Dixit VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JCI200421134; Dupont J, 2003, HORM METAB RES, V35, P740; Duxbury MS, 2003, BIOCHEM BIOPH RES CO, V309, P464, DOI 10.1016/j.bbrc.2003.08.024; Garcia JM, 2005, J CLIN ENDOCR METAB, V90, P2920, DOI 10.1210/jc.2004-1788; Gaytan F, 2005, J CLIN ENDOCR METAB, V90, P1798, DOI 10.1210/jc.2004-1532; Gaytan F, 2004, J CLIN ENDOCR METAB, V89, P400, DOI 10.1210/jc.2003-031375; Ghe C, 2002, ENDOCRINOLOGY, V143, P484, DOI 10.1210/en.143.2.484; Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988; Granado M, 2005, AM J PHYSIOL-ENDOC M, V288, pE486, DOI 10.1152/ajpendo.00196.2004; Hirano H, 1999, Neuro Oncol, V1, P109, DOI 10.1093/neuonc/1.2.109; Hosoda H, 2003, J BIOL CHEM, V278, P64, DOI 10.1074/jbc.M205366200; Inui A, 2001, NAT REV NEUROSCI, V2, P551, DOI 10.1038/35086018; Jaffe AB, 2003, SCIENCE, V302, P1690, DOI 10.1126/science.1092874; Jeffery PL, 2003, CYTOKINE GROWTH F R, V14, P113, DOI 10.1016/S1359-6101(02)00089-8; Kanamoto N, 2001, J CLIN ENDOCR METAB, V86, P4984, DOI 10.1210/jc.86.10.4984; Kari F W, 1999, J Nutr Health Aging, V3, P92; Kiaris H, 1999, P NATL ACAD SCI USA, V96, P226, DOI 10.1073/pnas.96.1.226; Kim K, 2001, CLIN ENDOCRINOL, V54, P759, DOI 10.1046/j.1365-2265.2001.01286.x; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; Li WG, 2004, CIRCULATION, V109, P2221, DOI 10.1161/01.CIR.0000127956.43874.F2; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Mukherjee P, 2004, CLIN CANCER RES, V10, P5622, DOI 10.1158/1078-0432.CCR-04-0308; Murata M, 2002, J BIOL CHEM, V277, P5667, DOI 10.1074/jbc.M103898200; Nagaya N, 2004, CIRCULATION, V110, P3674, DOI 10.1161/01.CIR.0000149746.62908.BB; Pola S, 2003, J BIOL CHEM, V278, P40601, DOI 10.1074/jbc.M306510200; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; Skinner MM, 1998, J CLIN ENDOCR METAB, V83, P4314, DOI 10.1210/jc.83.12.4314; Sliva D, 2002, BIOCHEM BIOPH RES CO, V290, P552, DOI 10.1006/bbrc.2001.6225; Smith RG, 1999, TRENDS ENDOCRIN MET, V10, P128, DOI 10.1016/S1043-2760(98)00132-5; Strickler R, 2000, Clin J Oncol Nurs, V4, P153; Sun YX, 2004, P NATL ACAD SCI USA, V101, P4679, DOI 10.1073/pnas.0305930101; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Tsolakis AV, 2004, J CLIN ENDOCR METAB, V89, P3739, DOI 10.1210/jc.2003-032118; Ukkola O, 2001, J CLIN ENDOCR METAB, V86, P3996, DOI 10.1210/jc.86.8.3996; Volante M, 2003, AM J PATHOL, V162, P645, DOI 10.1016/S0002-9440(10)63858-8; Ware ML, 2003, HISTOL HISTOPATHOL, V18, P207, DOI 10.14670/HH-18.207; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; Zhang WZ, 2004, J PHYSIOL-LONDON, V559, P729, DOI 10.1113/jphysiol.2004.064121; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	67	62	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2006	281	24					16681	16690		10.1074/jbc.M600223200	http://dx.doi.org/10.1074/jbc.M600223200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	051MR	16527811	Green Accepted, hybrid			2022-12-25	WOS:000238165700062
J	Mizukami, Y; Fujiki, K; Duerr, EM; Gala, M; Jo, WS; Zhang, XB; Chung, DC				Mizukami, Yusuke; Fujiki, Kotoyo; Duerr, Eva-Maria; Gala, Manish; Jo, Won-Seok; Zhang, Xiaobo; Chung, Daniel C.			Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR ANGIOGENESIS; INDUCIBLE FACTOR-1; COLORECTAL-CANCER; SIGNALING PATHWAY; FACTOR EXPRESSION; UP-REGULATION; IN-VIVO; RAS; ACTIVATION; CELLS	The induction of vascular endothelial growth factor (VEGF) is an essential feature of tumor angiogenesis. Hypoxia is a potent stimulator of VEGF expression, and hypoxia-inducible factor-1 (HIF-1) is considered to be critical for this induction. However, we have previously demonstrated that induction of VEGF by hypoxia was preserved when HIF-1 alpha was silenced. We sought to better define the molecular basis of this HIF-1-independent regulation. In colon cancer cells, hypoxia stimulated multiple K-ras effector pathways including phosphatidylinositol 3-kinase. VEGF promoter deletion studies identified a novel promoter region between -418 and -223 bp that was responsive to hypoxia in a PI3K/Rho/ROCK-dependent manner. Electrophoretic mobility shift assays identified a fragment between -300 and -251 bp that demonstrated a unique shift only in hypoxic conditions. Inhibition of PI3K or ROCK blocked the formation of this complex. A binding site for c-Myc, a target of ROCK, was identified at -271 bp. A role for c-Myc in the hypoxic induction of VEGF was demonstrated by site-directed mutagenesis of the VEGF promoter and silencing of c-Myc by small interfering RNA. Collectively, these findings suggest an alternative mechanism for the hypoxic induction of VEGF in colon cancer that does not depend upon HIF-1 alpha but instead requires the activation of PI3K/Rho/ROCK and c-Myc.			Chung, DC (corresponding author), Harvard Univ, Sch Med, GRJ-825,55 Fruit St, Boston, MA 02114 USA.	chung.daniel@mgh.harvard.edu	Mizukami, Yusuke/AAU-1767-2021; Mizukami, Yusuke/AAB-1777-2019	Mizukami, Yusuke/0000-0002-1068-7024; 	NCI NIH HHS [CA92594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barr LF, 2000, CANCER RES, V60, P143; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chen EY, 2001, CANCER RES, V61, P2429; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kaluz S, 2003, CANCER RES, V63, P917; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Knies-Bamforth UE, 2004, CANCER RES, V64, P6563, DOI 10.1158/0008-5472.CAN-03-3176; KOONG AC, 1994, CANCER RES, V54, P5273; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lynch M, 2005, MOL CELL BIOL, V25, P6436, DOI 10.1128/MCB.25.15.6436-6453.2005; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mezquita P, 2005, ONCOGENE, V24, P889, DOI 10.1038/sj.onc.1208251; Minet E, 2001, EXP CELL RES, V265, P114, DOI 10.1006/excr.2001.5180; Mizukami Y, 2004, CANCER RES, V64, P1765, DOI 10.1158/0008-5472.CAN-03-3017; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; von Marschall Z, 2001, GUT, V48, P87, DOI 10.1136/gut.48.1.87; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Williams NS, 2003, CLIN CANCER RES, V9, P931; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Zhang XB, 2001, CANCER RES, V61, P6050	42	78	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					13957	13963		10.1074/jbc.M511763200	http://dx.doi.org/10.1074/jbc.M511763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16543245	hybrid			2022-12-25	WOS:000237512300017
J	Nelson, KK; Subbaram, S; Connor, KM; Dasgupta, J; Ha, XF; Meng, TC; Tonks, NK; Melendez, JA				Nelson, Kristin K.; Subbaram, Sita; Connor, Kip M.; Dasgupta, Jaya; Ha, Xiao-Fang; Meng, Tzu-Ching; Tonks, Nicholas K.; Melendez, J. Andres			Redox-dependent matrix metalloproteinase-1 expression is regulated by JNK through ets and AP-1 promoter motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SINGLE NUCLEOTIDE POLYMORPHISM; MANGANESE SUPEROXIDE-DISMUTASE; TRANSCRIPTION FACTOR FAMILY; N-TERMINAL KINASE; FACTOR-KAPPA-B; GENE-EXPRESSION; C-JUN; DIFFERENTIAL REGULATION; HISTONE MODIFICATIONS	Reactive oxygen species have been shown to play an important role in the regulation of distinct signaling cascades, many of which act upon the production of matrix metalloproteinases (MMP). Using a series of redox-engineered cell lines we have previously demonstrated that MMP-1 expression is sensitive to the alterations in the steady state production of H2O2 ( Ranganathan, A. C., Nelson, K. K., Rodriguez, A. M., Kim, K. H., Tower, G. B., Rutter, J. L., Brinckerhoff, C. E., Epstein, C. J., Huang, T. T., Jeffrey, J. J., and Melendez, J. A. ( 2001) J. Biol. Chem. 276, 14264-14270). In the present study, we investigate the molecular mechanisms involved in the H2O2-mediated induction of MMP-1. Mutational analysis of an MMP-1 promoter indicates that both the single nucleotide polymorphism creating an Ets binding site at -1607 and a proximal AP-1 site at -1602 are required for maximal H2O2-dependent transcription. The redox-sensitive MMP-1 protein expression requires activation of both ERK1/2 and JNK pathways. Importantly, JNK signaling is largely responsible for the H2O2 sensitivity of the MMP-1 promoter, whereas ERK1/2 contributes to both its basal and H2O2 dependence. H2O2 control of Ets-1 expression was ERK1/2-dependent whereas that of c-Jun requires both ERK1/2 and JNK signaling. Chromatin immunoprecipitation assays indicate that binding of the histone acetyltransferase, p300, and the transcription factors Ets-1 and c-Jun to the MMP-1 promoter is redox sensitive. The redox sensitivity of MMP-1 expression is also associated with an increase in the abundance of oxidatively inactivated protein-tyrosine phosphatases. Targeted cytosolic or mitochondrial scavenging of H2O2 prevented all of the aforementioned signals. These studies provide substantial insight into the mechanisms underlying the redox-dependent control of MMP-1 and may lead to the development of novel targeted antioxidant-based inhibitory therapies for controlling MMP-1 expression during degenerative disease processes.	Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; Acad Sinica, Inst Biol Chem, Taipei 105, Taiwan; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Albany Medical College; Academia Sinica - Taiwan; Cold Spring Harbor Laboratory	Melendez, JA (corresponding author), Albany Med Coll, Ctr Immunol & Microbial Dis, MC 151,47 New Scotland Ave, Albany, NY 12208 USA.	melenda@mail.amc.edu	Meng, Tzu-Ching/G-5426-2019	Meng, Tzu-Ching/0000-0001-7693-2021; Melendez, Juan/0000-0001-8021-3097; Connor, Kip/0000-0002-2048-9080	NATIONAL CANCER INSTITUTE [K22CA095011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI049822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055989] Funding Source: NIH RePORTER; NCI NIH HHS [CA77068, CA095011] Funding Source: Medline; NIAID NIH HHS [AI49822] Funding Source: Medline; NIGMS NIH HHS [GM55989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argiles JM, 1997, FASEB J, V11, P743, DOI 10.1096/fasebj.11.10.9271359; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Baker EA, 2000, BRIT J SURG, V87, P1215, DOI 10.1046/j.1365-2168.2000.01531.x; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Buttice G, 1996, ONCOGENE, V13, P2297; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; Connor KM, 2005, J BIOL CHEM, V280, P16916, DOI 10.1074/jbc.M410690200; Doehn U, 2004, BIOCHEM J, V382, P425, DOI 10.1042/BJ20040948; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Gao CQ, 2003, CARDIOVASC RES, V57, P426; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hart CA, 2002, BRIT J CANCER, V86, P1136, DOI 10.1038/sj/bjc/6600207; Hinoda Y, 2002, INT J CANCER, V102, P526, DOI 10.1002/ijc.10750; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim A, 2005, FREE RADICAL BIO MED, V39, P1128, DOI 10.1016/j.freeradbiomed.2005.06.007; Konorev EA, 2002, FREE RADICAL BIO MED, V33, P988, DOI 10.1016/S0891-5849(02)00989-9; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Kuruganti PA, 2002, J NEURO-ONCOL, V56, P109, DOI 10.1023/A:1014530309082; Ma ZD, 2004, J BIOL CHEM, V279, P46326, DOI 10.1074/jbc.M405438200; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Martens JHA, 2003, MOL CELL BIOL, V23, P1808, DOI 10.1128/MCB.23.5.1808-1816.2003; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Nelson KK, 2003, CLIN CANCER RES, V9, P424; Nikkola J, 2001, MELANOMA RES, V11, P157, DOI 10.1097/00008390-200104000-00011; Noll WW, 2001, AM J PATHOL, V158, P691, DOI 10.1016/S0002-9440(10)64011-4; Park MJ, 2002, CANCER RES, V62, P6318; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Polte T, 2004, FREE RADICAL BIO MED, V36, P1566, DOI 10.1016/j.freeradbiomed.2004.04.003; Ranganathan AC, 2001, J BIOL CHEM, V276, P14264, DOI 10.1074/jbc.M100199200; Reddy SPM, 2002, AM J PHYSIOL-LUNG C, V283, pL1161, DOI 10.1152/ajplung.00140.2002; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; Rutter JL, 1998, CANCER RES, V58, P5321; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sanij E, 2001, BIOCHEM BIOPH RES CO, V287, P1003, DOI 10.1006/bbrc.2001.5680; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shen BC, 2003, CANCER RES, V63, P6537; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Tower GB, 2003, EUR J BIOCHEM, V270, P4216, DOI 10.1046/j.1432-1033.2003.03821.x; Tower GB, 2002, BBA-MOL BASIS DIS, V1586, P265, DOI 10.1016/S0925-4439(01)00105-3; Vincenti MP, 2001, J CLIN INVEST, V108, P181; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wood GA, 2001, EXP BIOL MED, V226, P799, DOI 10.1177/153537020222600813; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Ye S, 2001, CANCER RES, V61, P1296; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhu Y, 2001, CANCER RES, V61, P7825	59	61	63	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14100	14110		10.1074/jbc.M601820200	http://dx.doi.org/10.1074/jbc.M601820200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	042FC	16569638	hybrid			2022-12-25	WOS:000237512300033
J	Hong, JH; Moon, SJ; Byun, HM; Kim, MS; Jo, H; Bae, YS; Lee, SI; Bootman, MD; Roderick, HL; Shin, DM; Seo, JT				Hong, JH; Moon, SJ; Byun, HM; Kim, MS; Jo, H; Bae, YS; Lee, SI; Bootman, MD; Roderick, HL; Shin, DM; Seo, JT			Critical role of phospholipase C gamma 1 in the generation of H2O2-evoked [Ca2+](i) oscillations in cultured rat cortical astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; HYDROGEN-PEROXIDE; REACTIVE-OXYGEN; INTRACELLULAR CA2+; OXIDATIVE STRESS; CALCIUM-RELEASE; EGF RECEPTOR; C-GAMMA; ACTIVATION	Reactive oxygen species, such as the superoxide anion, H2O2, and the hydroxyl radical, have been considered as cytotoxic by-products of cellular metabolism. However, recent studies have provided evidence that H2O2 serves as a signaling molecule modulating various physiological functions. Here we investigated the effect of H2O2 on the regulation of intracellular Ca2+ signaling in rat cortical astrocytes. H2O2 triggered the generation of oscillations of intracellular Ca2+ concentration ([Ca2+](i)) in a concentration-dependent manner over the range 10-100 mu M. The H2O2-induced [Ca2+](i) oscillations persisted in the absence of extracellular Ca2+ and were prevented by depletion of intracellular Ca2+ stores with thapsigargin. The H2O2-induced [Ca2+](i) oscillations were not inhibited by pretreatment with ryanodine but were prevented by 2-aminoethoxydiphenyl borate and caffeine, known antagonists of inositol 1,4,5-trisphosphate receptors. H2O2 activated phospholipase C (PLC) gamma 1 in a dose-dependent manner, and U73122, an inhibitor of PLC, completely abolished the H2O2-induced [Ca2+](i) oscillations. In addition, RNA interference against PLC gamma 1 and the expression of the inositol 1,4,5-trisphosphate-sequestering "sponge" prevented the generation of [Ca2+](i) oscillations. H2O2-induced [Ca2+](i) oscillations and PLC gamma 1 phosphorylation were inhibited by pretreatment with dithiothreitol, a sulfhydryl-reducing agent. Finally, epidermal growth factor induced H2O2 production, PLC gamma 1 activation, and [Ca2+](i) increases, which were attenuated by N-acetylcysteine and diphenyleneiodonium and by the overexpression of peroxiredoxin type II. Therefore, we conclude that low concentrations of exogenously applied H2O2 generate [Ca2+](i) oscillations by activating PLC gamma 1 through sulfhydryl oxidation-dependent mechanisms. Furthermore, we show that this mechanism underlies the modulatory effect of endogenously produced H2O2 on epidermal growth factor-induced Ca2+ signaling in rat cortical astrocytes.	Yonsei Univ, Coll Dent, Dept Oral Biol, Brain Korea Project Med Sci 21,Oral Sci Res Ctr, Seoul 120752, South Korea; Ewha Womans Univ, Ctr Cell Signalling Res, Div Mol Life Sci, Seoul 120750, South Korea; Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	Yonsei University; Yonsei University Health System; Ewha Womans University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	Shin, DM (corresponding author), Yonsei Univ, Coll Dent, Dept Oral Biol, Brain Korea Project Med Sci 21,Oral Sci Res Ctr, Seoul 120752, South Korea.	dmshin@yumc.yonsei.ac.kr; jeong@yumc.yonsei.ac.kr	Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451; Shin, Dong Min/0000-0001-6042-0435; Moon, Seok Jun/0000-0001-7282-2888	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C116, BBS/E/B/00001116] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Akaishi T, 2004, NEUROSCI LETT, V356, P25, DOI 10.1016/j.neulet.2003.11.012; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; Bultynck G, 2004, BIOCHEM J, V381, P87, DOI 10.1042/BJ20040072; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Gamaley IA, 1999, INT REV CYTOL, V188, P203; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hansson E, 2003, FASEB J, V17, P341, DOI 10.1096/fj.02-0429rev; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hu QH, 2000, J BIOL CHEM, V275, P15749, DOI 10.1074/jbc.M000381200; Hu QH, 2002, J BIOL CHEM, V277, P32546, DOI 10.1074/jbc.M201550200; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Lee IH, 2004, J BIOL CHEM, V279, P26645, DOI 10.1074/jbc.M311525200; Lee ZW, 2000, CELL SIGNAL, V12, P91, DOI 10.1016/S0898-6568(99)00069-8; Levison SW, 2000, GLIA, V32, P328, DOI 10.1002/1098-1136(200012)32:3<328::AID-GLIA110>3.0.CO;2-7; Liu Q, 2005, CELL BIOCHEM FUNCT, V23, P93, DOI 10.1002/cbf.1171; Meissner G, 2004, CIRC RES, V94, P418, DOI 10.1161/01.RES.0000122072.43826.98; Missiaen L, 2001, CELL CALCIUM, V29, P111, DOI 10.1054/ceca.2000.0163; Newman EA, 2003, TRENDS NEUROSCI, V26, P536, DOI 10.1016/S0166-2236(03)00237-6; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Pariente JA, 2001, J MEMBRANE BIOL, V179, P27, DOI 10.1007/s002320010034; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; Pignatelli P, 1998, BLOOD, V91, P484, DOI 10.1182/blood.V91.2.484.484_484_490; Putney JW, 2001, J CELL SCI, V114, P2223; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; Rabchevsky AG, 1998, J NEUROSCI, V18, P10541, DOI 10.1523/jneurosci.18-24-10541.1998; Redondo PC, 2004, BIOCHEM PHARMACOL, V67, P491, DOI 10.1016/j.bcp.2003.09.031; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; Servitja JM, 2000, J NEUROCHEM, V75, P788, DOI 10.1046/j.1471-4159.2000.0750788.x; Smith MA, 2003, J PHYSIOL-LONDON, V547, P417, DOI 10.1113/jphysiol.2002.034561; Sneyd J, 2004, P NATL ACAD SCI USA, V101, P1392, DOI 10.1073/pnas.0303472101; Sobey CG, 1997, STROKE, V28, P2290, DOI 10.1161/01.STR.28.11.2290; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; Tokmakov AA, 2002, CELL CALCIUM, V32, P11, DOI 10.1016/S0143-4160(02)00078-7; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; Vanlingen S, 2001, BIOCHEM PHARMACOL, V61, P803, DOI 10.1016/S0006-2952(01)00540-8; Varela D, 2004, J BIOL CHEM, V279, P13301, DOI 10.1074/jbc.C400020200; Wang XF, 2000, J NEUROCHEM, V74, P1434, DOI 10.1046/j.1471-4159.2000.0741434.x; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200	58	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13057	13067		10.1074/jbc.M601726200	http://dx.doi.org/10.1074/jbc.M601726200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543237	Green Published, hybrid			2022-12-25	WOS:000237336600009
J	Kim, SH; Song, JH; Choi, BG; Kim, HJ; Kim, TS				Kim, SH; Song, JH; Choi, BG; Kim, HJ; Kim, TS			Chemical modification of santonin into a diacetoxy acetal form confers the ability to induce differentiation of human promyelocytic leukemia cells via the down-regulation of NF-kappa B DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RETINOIC ACID; HL-60 CELLS; TERMINAL DIFFERENTIATION; SESQUITERPENE LACTONE; D-3-INDUCED DIFFERENTIATION; ERYTHROID-DIFFERENTIATION; IN-VITRO; ACTIVATION; PARTHENOLIDE	Many sesquiterpene lactone compounds either induce or enhance the cell differentiation of human leukemia cells. However, we reported in a previous study that santonin, a eudesmanolide sesquiterpene lactone, exerts no effects on the differentiation of leukemia cells. In this report, to evaluate the possibility of chemically modifying santonin into its derivatives with differentiation inducing activity, we synthesized a series of santonin derivatives, and determined their effects on cellular differentiation in the human promyelocytic leukemia HL-60 cell system. A diacetoxy acetal derivative of santonin (DAAS) was found to induce significant HL-60 cell differentiation in a dose-dependent manner, whereas santonin in its original form did not. The HL-60 cells were differentiated into a granulocytic lineage when exposed to DAAS. In addition, the observed induction in cell differentiation closely correlated with the levels of NF-kappa B DNA binding activity inhibited by DAAS. Both Western blot analyses and kinase inhibitor studies determined that protein kinase C, ERK, and phosphatidylinositol 3-kinase were upstream components of the DAAS-mediated inhibition of NF-kappa B binding activity in HL-60 leukemia cells. The results of this study indicate that santonin can, indeed, be chemically modified into a derivative with differentiation inducing abilities, and suggest that DAAS might prove useful in the treatment of neoplastic diseases.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Chonnam Natl Univ, Coll Pharm, Res Inst Drug Dev, Kwangju 500757, South Korea; Chonnam Natl Univ Hosp, Genome Res Ctr Hematopoiet Dis, Kwangju 500757, South Korea	Korea University; Chonnam National University; Chonnam National University; Chonnam National University Hospital	Kim, TS (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	tskim@korea.ac.kr		Kim, Seung Hyun/0000-0001-5527-6846				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALHARBI MM, 1994, JPN J PHARMACOL, V64, P135, DOI 10.1254/jjp.64.135; ANDO M, 1987, J ORG CHEM, V52, P4782; BEERE HM, 1993, ANTI-CANCER DRUG DES, V8, P299; Bertagnolo V, 1999, CANCER RES, V59, P542; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Cai JY, 2004, ARCH BIOCHEM BIOPHYS, V424, P119, DOI 10.1016/j.abb.2004.02.012; CALABRESSE C, 1993, BIOCHEM BIOPH RES CO, V195, P31, DOI 10.1006/bbrc.1993.2005; Caponigro F, 1997, ANTI-CANCER DRUG, V8, P26, DOI 10.1097/00001813-199701000-00003; Coligan J, 1995, CURRENT PROTOCOLS IM; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HALL IH, 1988, ANTICANCER RES, V8, P33; Hehner SP, 1999, J IMMUNOL, V163, P5617; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; Kang SN, 2002, BRIT J PHARMACOL, V135, P1235, DOI 10.1038/sj.bjp.0704573; KANSAS GS, 1990, BLOOD, V76, P2483; KATO K, 1971, TETRAHEDRON, V27, P5987, DOI 10.1016/S0040-4020(01)91763-6; Kim SH, 2005, EUR J PHARMACOL, V511, P89, DOI 10.1016/j.ejphar.2005.02.008; Kim SH, 2002, BIOCHEM PHARMACOL, V64, P1233, DOI 10.1016/S0006-2952(02)01292-3; Kim TS, 2001, BRIT J PHARMACOL, V134, P571, DOI 10.1038/sj.bjp.0704298; KOMADA F, 1991, CANCER RES, V51, P4271; Konopleva M, 2002, BLOOD, V99, P326, DOI 10.1182/blood.V99.1.326; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Makishima M, 1998, BLOOD, V91, P4715, DOI 10.1182/blood.V91.12.4715.412k07_4715_4726; Marcinkowska E, 1997, BIOCHEM BIOPH RES CO, V241, P419, DOI 10.1006/bbrc.1997.7832; MARTIN ML, 1988, J ETHNOPHARMACOL, V23, P285, DOI 10.1016/0378-8741(88)90007-4; Mata-Greenwood E, 2001, J NAT PROD, V64, P1509, DOI 10.1021/np010212p; Ohnishi M, 1997, JPN J CANCER RES, V88, P111, DOI 10.1111/j.1349-7006.1997.tb00355.x; PEREZSOUTO N, 1992, J CHROMATOGR, V593, P209, DOI 10.1016/0021-9673(92)80288-6; Ross JJ, 1999, PLANTA MED, V65, P126, DOI 10.1055/s-1999-13972; ROSSI C, 1986, J PHARM SCI, V75, P784, DOI 10.1002/jps.2600750812; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; Sharma HW, 1996, ANTICANCER RES, V16, P589; Singh B, 2001, FOLIA MICROBIOL, V46, P137, DOI 10.1007/BF02873592; Sokoloski JA, 1998, CANCER LETT, V125, P157, DOI 10.1016/S0304-3835(97)00505-3; Szanto A, 2005, MOL PHARMACOL, V67, P1935, DOI 10.1124/mol.104.006445; TANAKA H, 1983, BIOCHEM BIOPH RES CO, V117, P86, DOI 10.1016/0006-291X(83)91544-9; Tsiftsoglou AS, 2003, PHARMACOL THERAPEUT, V100, P257, DOI 10.1016/j.pharmthera.2003.09.002; VANDERSCHOOT CE, 1989, ACTA HAEMATOL, V78, P32; Woessmann W, 2001, EXP CELL RES, V264, P193, DOI 10.1006/excr.2000.5124; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WU XZ, 1989, LEUKEMIA RES, V13, P869, DOI 10.1016/0145-2126(89)90039-8; Yen A, 2004, MOL PHARMACOL, V66, P1727, DOI 10.1124/mol.104.003475; ZAKARIA H, 1999, J EXP MED, V190, P1583	45	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13117	13125		10.1074/jbc.M510944200	http://dx.doi.org/10.1074/jbc.M510944200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16554308	hybrid			2022-12-25	WOS:000237336600016
J	Korkhov, VM; Holy, M; Freissmuth, M; Sitte, HH				Korkhov, VM; Holy, M; Freissmuth, M; Sitte, HH			The conserved glutamate (Glu(136)) in transmembrane domain 2 of the serotonin transporter is required for the conformational switch in the transport cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE TRANSPORTER; AMINOBUTYRIC-ACID TRANSPORTER-1; ENERGY-TRANSFER MICROSCOPY; RAT GABA TRANSPORTER-1; OLIGOMER FORMATION; NEUROTRANSMITTER TRANSPORTERS; PLATELET 5-HYDROXYTRYPTAMINE; SURFACE EXPRESSION; ESCHERICHIA-COLI; COCAINE BINDING	The alternate access model provides the theoretical framework for understanding how transporters translocate hydrophilic substrates across the lipid bilayer. The model postulates at least two conformations of a transporter, an outward and an inward facing conformation, which seal the translocation pathway to the interior and exterior of the cell, respectively. It is not clear how the conformational switch is triggered in neurotransmitter/ sodium symporters, but Na+ is likely to play an essential role. Here, we focused on Glu(136) of the serotonin transporter ( SERT); this residue is conserved in transmembrane domain 2 of neurotransmitter/ sodium symporters and related proteins. Three substitutions were introduced, resulting in SERT- E136D, SERT- E136Q, and SERT- E136A, which were all correctly inserted into the plasma membrane. SERT-E136Q and SERT- E136A failed to support substrate influx into cells, whereas SERT- E136D did so at a reduced rate. Binding experiments with the inhibitor 2 beta- [H-3] carbomethoxy- 3 beta- ( 4- iodophenyl) tropane (beta- [H-3] CIT) supported the conjecture that the mutant transporters preferentially adopted the inward facing conformation: beta- [H-3] CIT interacted with SERT in a manner consistent with binding to the outward facing state. Accordingly, the Na+- induced acceleration of beta- [H-3] CIT association was most pronounced in wildtype SERT, followed bySERT- E136D > SERT- E136Q > SERT- E136A. Similarly, SERT- E136Q supported substrate efflux in a manner indistinguishable from wild- type SERT, whereas SERT- E136A was inactive. Thus, in the absence of Glu136, the conformational equilibrium of SERT is shifted progressively ( SERT- E136D > SERT- E136Q > SERT- E136A) to the inward facing conformation.	Med Univ Vienna, Ctr Biomol Med & Pharmacol, Inst Pharmacol, A-1090 Vienna, Austria	Medical University of Vienna	Freissmuth, M (corresponding author), Med Univ Vienna, Ctr Biomol Med & Pharmacol, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@meduniwien.ac.at	Sitte, Harald/O-7025-2019; Sitte, Harald/N-2681-2013	Sitte, Harald/0000-0002-1339-7444; Sitte, Harald/0000-0002-1339-7444; Freissmuth, Michael/0000-0001-9398-1765; Korkhov, Volodymyr/0000-0002-0962-9433				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Adams SV, 2003, BIOPHYS J, V85, P1548, DOI 10.1016/S0006-3495(03)74587-1; Adams SV, 2002, BIOPHYS J, V83, P3268, DOI 10.1016/S0006-3495(02)75328-9; ANDROUTSELLISTH, 2003, J BIOL CHEM, V278, P12073; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; Chen NH, 2001, J NEUROCHEM, V77, P1116, DOI 10.1046/j.1471-4159.2001.00312.x; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; Farhan H, 2004, J BIOL CHEM, V279, P28553, DOI 10.1074/jbc.M307325200; Galli A, 1997, J NEUROSCI, V17, P3401; Hahn MK, 2003, J NEUROSCI, V23, P4470; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Just H, 2004, J BIOL CHEM, V279, P6650, DOI 10.1074/jbc.M306092200; KESHET GI, 1995, FEBS LETT, V371, P39, DOI 10.1016/0014-5793(95)00859-8; Korkhov VM, 2004, J BIOL CHEM, V279, P55728, DOI 10.1074/jbc.M409449200; Loland CJ, 2004, J BIOL CHEM, V279, P3228, DOI 10.1074/jbc.M304755200; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; NELSON PJ, 1979, J BIOL CHEM, V254, P84; Petersen CI, 1999, NAT NEUROSCI, V2, P605, DOI 10.1038/10158; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Rudnick Gary, 2002, P25; Sato Y, 2004, J BIOL CHEM, V279, P22926, DOI 10.1074/jbc.M312194200; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Scholze P, 2000, J PHARMACOL EXP THER, V293, P870; Seal RP, 1999, ANNU REV PHARMACOL, V39, P431, DOI 10.1146/annurev.pharmtox.39.1.431; Sen N, 2005, NEUROPHARMACOLOGY, V49, P780, DOI 10.1016/j.neuropharm.2005.08.014; Sitte HH, 2004, MOL INTERV, V4, P38, DOI 10.1124/mi.4.1.38; Sitte HH, 2003, EUR J PHARMACOL, V479, P229, DOI 10.1016/j.ejphar.2003.08.072; Sitte HH, 2001, MOL PHARMACOL, V59, P1129, DOI 10.1124/mol.59.5.1129; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; Sucic S, 2002, J NEUROCHEM, V81, P344, DOI 10.1046/j.1471-4159.2002.00826.x; Sur C, 1998, J NEUROCHEM, V70, P2545; TALVENHEIMO J, 1979, J BIOL CHEM, V254, P4631; TALVENHEIMO J, 1983, J BIOL CHEM, V258, P6115; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; WALL SC, 1993, MOL PHARMACOL, V43, P264; Wuller S, 2004, J BIOL CHEM, V279, P47254, DOI 10.1074/jbc.M408154200; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978	43	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13439	13448		10.1074/jbc.M511382200	http://dx.doi.org/10.1074/jbc.M511382200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16527819	hybrid			2022-12-25	WOS:000237336600051
J	Lansky, IB; Lukat-Rodgers, GS; Block, D; Rodgers, KR; Ratliff, M; Wilks, A				Lansky, IB; Lukat-Rodgers, GS; Block, D; Rodgers, KR; Ratliff, M; Wilks, A			The cytoplasmic heme-binding protein (PhuS) from the heme uptake system of Pseudomonas aeruginosa is an intracellular heme-trafficking protein to the delta-regioselective heme oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; AXIAL LIGAND MUTANTS; SHIGELLA-DYSENTERIAE; RESONANCE RAMAN; CORYNEBACTERIUM-DIPHTHERIAE; HORSERADISH-PEROXIDASE; SIGNAL-TRANSDUCTION; DEPENDENT SYSTEMS; COUPLED OXIDATION; TRANSPORT-SYSTEM	The uptake and utilization of heme as an iron source is a receptor-mediated process in bacterial pathogens and involves a number of proteins required for internalization and degradation of heme. In the following report we provide the first in-depth spectroscopic and functional characterization of a cytoplasmic heme-binding protein PhuS from the opportunistic pathogen Pseudomonas aeruginosa. Spectroscopic characterization of the heme-PhuS complex at neutral pH indicates that the heme is predominantly six-coordinate low spin. However, the resonance Raman spectra and global fit analysis of the UV-visible spectra show that at all pH values between 6 and 10 three distinct species are present to varying degrees. The distribution of the heme across multiple spin states and coordination number highlights the flexibility of the heme environment. We provide further evidence that the cytoplasmic heme- binding proteins, contrary to previous reports, are not heme oxygenases. The degradation of the heme-PhuS complex in the presence of a reducing agent is a result of H2O2 formed by direct reduction of molecular oxygen and does not yield biliverdin. In contrast, the heme-PhuS complex is an intracellular heme trafficking protein that specifically transfers heme to the previously characterized iron- regulated heme oxygenase pa-HO. Surface plasmon resonance experiments confirm that the transfer of heme is driven by a specific protein- protein interaction. This data taken together with the spectroscopic characterization is consistent with a protein that functions to shuttle heme within the cell.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; N Dakota State Univ, Dept Chem Biochem & Mol Biol, Fargo, ND 58105 USA	University System of Maryland; University of Maryland Baltimore; North Dakota State University Fargo	Wilks, A (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 Penn St, Baltimore, MD 21201 USA.	awilks@rx.umaryland.edu			NCRR NIH HHS [P20 RR015566, P20 RR15556] Funding Source: Medline; NIAID NIH HHS [AI-48551] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015566] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048551] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ANTONINI E, 1971, FRONTIERS BIOL HEMOG, V21; ASHER SA, 1979, BIOCHEMISTRY-US, V18, P5377, DOI 10.1021/bi00591a019; Avila L, 2003, J AM CHEM SOC, V125, P4103, DOI 10.1021/ja029311v; Avila L, 2000, J AM CHEM SOC, V122, P7618, DOI 10.1021/ja001137s; Boffi A, 1999, BIOPHYS J, V77, P1143, DOI 10.1016/S0006-3495(99)76965-1; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; CHEN L, 1995, MOL MICROBIOL, V18, P295, DOI 10.1111/j.1365-2958.1995.mmi_18020295.x; Das TK, 1999, J BIOL CHEM, V274, P2916, DOI 10.1074/jbc.274.5.2916; Das TK, 1999, INORG CHEM, V38, P1952, DOI 10.1021/ic990049+; De Montellano PRO, 2001, ADV INORG CHEM, V51, P359; de Montellano PRO, 2000, CURR OPIN CHEM BIOL, V4, P221; Drazek ES, 2000, MOL MICROBIOL, V36, P68, DOI 10.1046/j.1365-2958.2000.01818.x; Eakanunkul S, 2005, BIOCHEMISTRY-US, V44, P13179, DOI 10.1021/bi050422r; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; FUHROP JH, 1975, PROPHYRINS METALLOPO; HENDERSON DP, 1993, MOL MICROBIOL, V7, P461, DOI 10.1111/j.1365-2958.1993.tb01137.x; Hornung JM, 1996, MOL MICROBIOL, V20, P725, DOI 10.1111/j.1365-2958.1996.tb02512.x; Howes BD, 1997, BIOCHEMISTRY-US, V36, P1532, DOI 10.1021/bi962502o; LETOFFE S, 1994, J BACTERIOL, V176, P5372; Letoffe S, 1998, MOL MICROBIOL, V28, P1223, DOI 10.1046/j.1365-2958.1998.00885.x; Lukat-Rodgers GS, 1998, BIOCHEMISTRY-US, V37, P13543, DOI 10.1021/bi981439v; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; Mey AR, 2001, MOL MICROBIOL, V42, P835, DOI 10.1046/j.1365-2958.2001.02683.x; MILLS M, 1995, J BACTERIOL, V177, P3004, DOI 10.1128/jb.177.11.3004-3009.1995; O'Malley SM, 1999, J BACTERIOL, V181, P3594; Ochsner UA, 2000, MICROBIOL-UK, V146, P185, DOI 10.1099/00221287-146-1-185; Palma M, 2003, ARCH MICROBIOL, V180, P374, DOI 10.1007/s00203-003-0602-z; PENA MMO, 1995, J BIOL CHEM, V270, P22478, DOI 10.1074/jbc.270.38.22478; Ratliff M, 2001, J BACTERIOL, V183, P6394, DOI 10.1128/JB.183.21.6394-6403.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEA CM, 1991, MOL MICROBIOL, V5, P1415, DOI 10.1111/j.1365-2958.1991.tb00788.x; Sigman JA, 2001, J AM CHEM SOC, V123, P6945, DOI 10.1021/ja015776u; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Smulevich G, 1996, BIOCHEMISTRY-US, V35, P10576, DOI 10.1021/bi9605898; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; STOJILJKOVIC I, 1992, EMBO J, V11, P4359, DOI 10.1002/j.1460-2075.1992.tb05535.x; Suits MDL, 2005, P NATL ACAD SCI USA, V102, P16955, DOI 10.1073/pnas.0504289102; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; Tasler R, 2005, FEBS J, V272, P1927, DOI 10.1111/j.1742-4658.2005.04623.x; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; Wegele R, 2004, J BIOL CHEM, V279, P45791, DOI 10.1074/jbc.M408303200; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; Wilks A, 2002, ANTIOXID REDOX SIGN, V4, P603, DOI 10.1089/15230860260220102; Wilks A, 2001, ARCH BIOCHEM BIOPHYS, V387, P137, DOI 10.1006/abbi.2000.2250; Wyckoff EE, 1998, MOL MICROBIOL, V28, P1139, DOI 10.1046/j.1365-2958.1998.00873.x; Wyckoff EE, 2005, J BACTERIOL, V187, P5658, DOI 10.1128/JB.187.16.5658-5664.2005; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	51	79	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13652	13662		10.1074/jbc.M600824200	http://dx.doi.org/10.1074/jbc.M600824200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16533806	hybrid			2022-12-25	WOS:000237336600076
J	O'Brien, DP; Israel, DA; Krishna, U; Romero-Gallo, J; Nedrud, J; Medof, ME; Lin, F; Redline, R; Lublin, DM; Nowicki, BJ; Franco, AT; Ogden, S; Williams, AD; Polk, DB; Peek, RM				O'Brien, DP; Israel, DA; Krishna, U; Romero-Gallo, J; Nedrud, J; Medof, ME; Lin, F; Redline, R; Lublin, DM; Nowicki, BJ; Franco, AT; Ogden, S; Williams, AD; Polk, DB; Peek, RM			The role of decay-accelerating factor as a receptor for Helicobacter pylori and a mediator of gastric inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHERING ESCHERICHIA-COLI; EPITHELIAL-CELLS; CAGA PROTEIN; IV SECRETION; FACTOR CD55; TRANSEPITHELIAL MIGRATION; TYROSINE PHOSPHORYLATION; GASTROINTESTINAL-TRACT; AFA/DR ADHESINS; IN-VITRO	Persistent gastritis induced by Helicobacter pylori is the strongest known risk factor for peptic ulcer disease and distal gastric adenocarcinoma, a process for which adherence of H. pylori to gastric epithelial cells is critical. Decay-accelerating factor ( DAF), a protein that protects epithelial cells from complement-mediated lysis, also functions as a receptor for several microbial pathogens. In this study, we investigated whether H. pylori utilizes DAF as a receptor and the role of DAF within H. pylori-infected gastric mucosa. In vitro studies showed that H. pylori adhered avidly to Chinese hamster ovary cells expressing human DAF but not to vector controls. In H. pylori, disruption of the virulence factors vacA, cagA, and cagE did not alter adherence, but deletion of DAF complement control protein ( CCP) domains 1 - 4 or the heavily O-glycosylated serinethreonine-rich COOH-terminal domain reduced binding. In cultured gastric epithelial cells, H. pylori induced transcriptional upregulation of DAF, and genetic deficiency of DAF attenuated the development of inflammation among H. pylori-infected mice. These results indicate that DAF may regulate H. pylori-epithelial cell interactions relevant to pathogenesis.	Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Canc Biol, Nashville, TN 37232 USA; Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Meharry Med Coll, Dept Obstet & Gynecol, Nashville, TN 37208 USA; Meharry Med Coll, Dept Biomed Sci, Nashville, TN 37208 USA; Meharry Med Coll, Div Microbial Pathogenesis & Immune Response, Nashville, TN 37208 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Case Western Reserve University; Washington University (WUSTL); Meharry Medical College; Meharry Medical College; Meharry Medical College; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Peek, RM (corresponding author), Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Med, 2215 Garland Ave,1030C MRB 4, Nashville, TN 37232 USA.	richard.peek@vanderbilt.edu		Franco, Aime/0000-0002-1677-5228	NATIONAL CANCER INSTITUTE [R01CA077955, R29CA077955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS052471] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77955] Funding Source: Medline; NIDDK NIH HHS [DK-58587] Funding Source: Medline; NINDS NIH HHS [R01 NS052471-04, R01 NS052471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aras RA, 2003, J EXP MED, V198, P1349, DOI 10.1084/jem.20030381; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; Berstad AE, 1998, GUT, V42, P522, DOI 10.1136/gut.42.4.522; Betis F, 2003, INFECT IMMUN, V71, P1774, DOI 10.1128/IAI.71.4.1774-1783.2003; Betis F, 2003, INFECT IMMUN, V71, P1068, DOI 10.1128/IAI.71.3.1068-1074.2003; Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102; Camorlinga-Ponce M, 2004, J CLIN PATHOL, V57, P822, DOI 10.1136/jcp.2004.017087; CLARKSON NA, 1995, J VIROL, V69, P5497, DOI 10.1128/JVI.69.9.5497-5501.1995; Cover TL, 2003, CANCER RES, V63, P951; COYNE KE, 1992, J IMMUNOL, V149, P2906; Crawford HC, 2003, GASTROENTEROLOGY, V125, P1125, DOI 10.1016/S0016-5085(03)01206-X; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Fujikawa A, 2003, NAT GENET, V33, P375, DOI 10.1038/ng1112; Garhart CA, 2002, INFECT IMMUN, V70, P3529, DOI 10.1128/IAI.70.7.3529-3538.2002; Gerhard M, 1999, P NATL ACAD SCI USA, V96, P12778, DOI 10.1073/pnas.96.22.12778; Gobert AP, 2001, P NATL ACAD SCI USA, V98, P13844, DOI 10.1073/pnas.241443798; Guignot J, 2000, INFECT IMMUN, V68, P3554, DOI 10.1128/IAI.68.6.3554-3563.2000; Gupta RA, 2001, J BIOL CHEM, V276, P31059, DOI 10.1074/jbc.M104141200; Hasan RJ, 2002, INFECT IMMUN, V70, P4485, DOI 10.1128/IAI.70.8.4485-4493.2002; He YN, 2002, P NATL ACAD SCI USA, V99, P10325, DOI 10.1073/pnas.152161599; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Israel DA, 2001, J CLIN INVEST, V107, P611, DOI 10.1172/JCI11450; Karnauchow TM, 1998, J VIROL, V72, P9380, DOI 10.1128/JVI.72.11.9380-9383.1998; Kiso T, 2002, HISTOPATHOLOGY, V40, P339, DOI 10.1046/j.1365-2559.2002.01350.x; Lawrence DW, 2003, J EXP MED, V198, P999, DOI 10.1084/jem.20030380; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Lin F, 2001, IMMUNOLOGY, V104, P215, DOI 10.1046/j.1365-2567.2001.01287.x; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; MARTINO TA, 1994, CIRC RES, V74, P182, DOI 10.1161/01.RES.74.2.182; Moss SF, 2003, CURR OPIN INFECT DIS, V16, P445, DOI 10.1097/00001432-200310000-00011; NOWICKI B, 1993, J EXP MED, V178, P2115, DOI 10.1084/jem.178.6.2115; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Oh JD, 2005, P NATL ACAD SCI USA, V102, P5186, DOI 10.1073/pnas.0407657102; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peek RM, 1999, CANCER RES, V59, P6124; Peek RM, 1998, P ASSOC AM PHYSICIAN, V110, P531; PHAM T, 1995, INFECT IMMUN, V63, P1663, DOI 10.1128/IAI.63.5.1663-1668.1995; Rautemaa R, 2001, GASTROENTEROLOGY, V120, P470, DOI 10.1053/gast.2001.21197; Sasaki M, 1998, HISTOPATHOLOGY, V33, P554; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Selvarangan R, 2000, INFECT IMMUN, V68, P1391, DOI 10.1128/IAI.68.3.1391-1399.2000; Servin AL, 2005, CLIN MICROBIOL REV, V18, P264, DOI 10.1128/CMR.18.2.264-292.2005; Shafren DR, 1998, J VIROL, V72, P9407, DOI 10.1128/JVI.72.11.9407-9412.1998; Shafren DR, 1998, J IMMUNOL, V160, P2318; Solnick JV, 2004, P NATL ACAD SCI USA, V101, P2106, DOI 10.1073/pnas.0308573100; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Syder AJ, 2003, P NATL ACAD SCI USA, V100, P3467, DOI 10.1073/pnas.0230380100; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; YOUSEF GE, 1988, LANCET, V1, P146	53	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13317	13323		10.1074/jbc.M601805200	http://dx.doi.org/10.1074/jbc.M601805200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16543227	hybrid			2022-12-25	WOS:000237336600037
J	Scott, PG; Dodd, CM; Bergmann, EM; Sheehan, JK; Bishop, PN				Scott, PG; Dodd, CM; Bergmann, EM; Sheehan, JK; Bishop, PN			Crystal structure of the biglycan dimer and evidence that dimerization is essential for folding and stability of class I small leucine-rich repeat proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; DERMATAN SULFATE PROTEOGLYCANS; SKIN PROTEODERMATAN SULFATE; GROWTH-FACTOR-BETA; TARGETED DISRUPTION; CORE PROTEIN; DECORIN; COLLAGEN; BONE; FIBROMODULIN	Biglycan and decorin are two closely related proteoglycans whose protein cores contain leucine-rich repeats flanked by disulfides. We have previously shown that decorin is dimeric both in solution and in crystal structures. In this study we determined whether biglycan dimerizes and investigated the role of dimerization in the folding and stability of these proteoglycans. We used light scattering to show that biglycan is dimeric in solution and solved the crystal structure of the glycoprotein core of biglycan at 3.40-A resolution. This structure reveals that biglycan dimerizes in the same way as decorin, i.e. by apposition of the concave inner surfaces of the leucine-rich repeat domains. We demonstrate that low concentrations of guanidinium chloride denature biglycan and decorin but that the denaturation is completely reversible following removal of the guanidinium chloride, as assessed by circular dichroism spectroscopy. Furthermore, the rate of refolding is dependent on protein concentration, demonstrating that it is not a unimolecular process. Upon heating, decorin shows a single structural transition at a T-m of 45 - 46 degrees C but refolds completely upon cooling to 25 degrees C. This property of decorin enabled us to show both by calorimetry and light scattering that dimer to monomer transition coincided with unfolding and monomer to dimer transition coincided with refolding; thus these processes are inextricably linked. We further conclude that folded monomeric biglycan or decorin cannot exist in solution. This implies novel interrelated functions for the parallel beta sheet faces of these leucine-rich repeat proteoglycans, including dimerization and stabilization of protein folding.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Alberta Synchrotron Inst, Res Transit Facil, Edmonton, AB T6G 2H7, Canada; Univ Manchester, Wellcome Trust Ctr CellMatrix Res, Fac Life Sci, Manchester M13 9PL, Lancs, England; Univ Manchester, Sch Med, Acad Unit Eye & Vis Sci, Manchester M13 9PL, Lancs, England	University of Alberta; University of Alberta; University of Manchester; University of Manchester	Scott, PG (corresponding author), Univ Alberta, Dept Biochem, 474 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	Paul.Scott@ualberta.ca		Bishop, Paul/0000-0001-7937-7932	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; Hakkinen L, 2000, LAB INVEST, V80, P1869, DOI 10.1038/labinvest.3780197; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Holton J, 2004, P NATL ACAD SCI USA, V101, P1537, DOI 10.1073/pnas.0306241101; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Krishnan P, 1999, J BIOL CHEM, V274, P10945, DOI 10.1074/jbc.274.16.10945; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Le Goff MM, 2003, J BIOL CHEM, V278, P45280, DOI 10.1074/jbc.M303117200; LIU J, 1994, J BIOL CHEM, V269, P28366; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Matsushima N, 2000, PROTEINS, V38, P210, DOI 10.1002/(SICI)1097-0134(20000201)38:2<210::AID-PROT9>3.0.CO;2-1; MCEWAN PA, 2006, IN PRESS J STRUCT BI; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MECHANIC G, 1979, SKELETAL RES EXPT AP, P227; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; Pace C N, 1986, Methods Enzymol, V131, P266; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCOTT JE, 1985, BIOSCIENCE REP, V5, P71, DOI 10.1007/BF01117443; SCOTT JE, 1993, DERMATAN SULPHATE PR, P165; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; Scott PG, 2003, J BIOL CHEM, V278, P18353, DOI 10.1074/jbc.M211936200; Scott PG, 1997, BBA-GEN SUBJECTS, V1336, P254, DOI 10.1016/S0304-4165(97)00040-8; SCOTT PG, 1993, DERMATAN SULPHATE PR, P81; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZANGRANDO D, 1989, BIOPOLYMERS, V28, P1295, DOI 10.1002/bip.360280710; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9; Zhu JX, 2005, J BIOL CHEM, V280, P32468, DOI 10.1074/jbc.M503833200	44	66	75	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13324	13332		10.1074/jbc.M513470200	http://dx.doi.org/10.1074/jbc.M513470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16547006	hybrid			2022-12-25	WOS:000237336600038
J	Wang, YQ; Tian, GL; Cowan, NJ; Cabral, F				Wang, YQ; Tian, GL; Cowan, NJ; Cabral, F			Mutations affecting beta-tubulin folding and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ALPHA/BETA-TUBULIN; COFACTOR-A; RESISTANCE; MICROTUBULES; PROTEINS; CHAPERONIN; PREFOLDIN; ISOTYPES; ACTIN	Revertants of a colcemid-resistant Chinese hamster ovary cell line with an altered (D45Y) beta-tubulin have allowed the identification of four cis-acting mutations (L187R, Y398C, a 12-amino acid in-frame deletion, and a C-terminal truncation) that act by destabilizing the mutant tubulin and preventing it from incorporating into microtubules. These unstable beta-tubulins fail to form heterodimers and are predominantly found in association with the chaperonin CCT, suggesting that they cannot undergo productive folding. In agreement with these in vivo observations, we show that the defective beta-tubulins do not stably interact with cofactors involved in the tubulin folding pathway and, hence, fail to exchange with beta-tubulin in purified alpha beta heterodimers. Treatment of cells with MG132 causes an accumulation of the aberrant tubulins, indicating that improperly folded beta-tubulin is degraded by the proteasome. Rapid degradation of the mutant tubulin does not elicit compensatory changes in wild-type tubulin synthesis or assembly. Instead, loss of beta-tubulin from the mutant allele causes a 30-40% decrease in cellular tubulin content with no obvious effect on cell growth or survival.	Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; NYU, Ctr Med, Dept Biochem, New York, NY 10016 USA	University of Texas System; New York University	Cabral, F (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, 6431 Fannin St, Houston, TX 77030 USA.	fcabral@uth.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA085935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047234] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA085935-07, CA85935, R01 CA085935-06A1, R01 CA085935] Funding Source: Medline; NIDDK NIH HHS [DK47234, R01 DK047234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P252, DOI 10.1016/0167-4781(91)90112-Y; Barlow SB, 2002, J CELL SCI, V115, P3469; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; BOGGS B, 1987, MOL CELL BIOL, V7, P2700, DOI 10.1128/MCB.7.8.2700; BOGGS BA, 1988, J BIOL CHEM, V263, P14566; CABRAL F, 1982, MOL CELL BIOL, V2, P720, DOI 10.1128/MCB.2.6.720; CABRAL F, 1980, CELL, V20, P29, DOI 10.1016/0092-8674(80)90231-7; Cabral F, 1979, Methods Enzymol, V56, P602; Cabral F., 2000, DRUG RESIST UPDATE, V3, P1; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; Cowan NJ, 2002, ADV PROTEIN CHEM, V59, P73; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Guasch A, 2002, J MOL BIOL, V318, P1139, DOI 10.1016/S0022-2836(02)00185-7; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hari M, 2003, MOL CANCER THER, V2, P597; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Luduena RF, 1998, INT REV CYTOL, V178, P207; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Nolasco S, 2005, FEBS LETT, V579, P3515, DOI 10.1016/j.febslet.2005.05.022; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Ren Y, 2003, J NEUROSCI, V23, P3316; SAWADA T, 1989, J BIOL CHEM, V264, P3013; SPIEGELMAN BM, 1977, CELL, V12, P587, DOI 10.1016/0092-8674(77)90259-8; Spiess C, 2004, TRENDS CELL BIOL, V14, P598, DOI 10.1016/j.tcb.2004.09.015; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Tian GL, 1999, J BIOL CHEM, V274, P24054, DOI 10.1074/jbc.274.34.24054; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URSIC D, 1994, MOL BIOL CELL, V5, P1065, DOI 10.1091/mbc.5.10.1065; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wang YQ, 2005, BBA-MOL CELL RES, V1744, P245, DOI 10.1016/j.bbamcr.2004.12.003; Wang YQ, 2004, BIOCHEMISTRY-US, V43, P8965, DOI 10.1021/bi049637b	38	22	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	2006	281	19					13628	13635		10.1074/jbc.M513730200	http://dx.doi.org/10.1074/jbc.M513730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	039VV	16554299	Green Accepted, hybrid			2022-12-25	WOS:000237336600073
J	Killoran, MP; Keck, JL				Killoran, MP; Keck, JL			Three HRDC domains differentially modulate Deinococcus radiodurans RecQ DNA helicase biochemical activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECQ; PILIN ANTIGENIC VARIATION; CRYSTAL-STRUCTURE; GENETIC-RECOMBINATION; STRAND EXCHANGE; BINDING PROTEIN; REPAIR; PATHWAY; GENOME; WERNER	RecQ helicases are key genome maintenance enzymes that function in DNA replication, recombination, and repair. In contrast to nearly every other identified RecQ family member, the RecQ helicase from the radioresistant bacterium Deinococcus radiodurans encodes three "Helicase and RNaseDC-terminal" (HRDC) domains at its C terminus. HRDC domains have been implicated in structure-specific nucleic acid binding with roles in targeting RecQ proteins to particular DNA structures; however, only RecQ proteins with single HRDC domains have been examined to date. We demonstrate that the HRDC domains can be proteolytically removed from the D. radiodurans RecQ (DrRecQ) C terminus, consistent with each forming a structural domain. Using this observation as a guide, we produced a panel of recombinant DrRecQ variants lacking combinations of its HRDC domains to investigate their biochemical functions. The N-terminal-most HRDC domain is shown to be critical for high affinity DNA binding and for efficient unwinding of DNA in some contexts. In contrast, the more C-terminal HRDC domains attenuate the DNA binding affinity and DNA-dependent ATP hydrolysis rate of the enzyme and play more complex roles in structure-specific DNA unwinding. Our results indicate that the multiple DrRecQ HRDC domains have evolved to encode DNA binding and regulatory functions in the enzyme.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Biomol Chem, Med Sci Ctr 550, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Keck, JL (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Biomol Chem, Med Sci Ctr 550, 1300 Univ Ave, Madison, WI 53706 USA.	jlkeck@wisc.edu		Keck, James/0000-0002-5961-0220	NIGMS NIH HHS [GM067085, R01 GM067085, GM068061] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067085, R01GM068061] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; Bennett RJ, 2004, CRIT REV BIOCHEM MOL, V39, P79, DOI 10.1080/10409230490460756; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bernstein DA, 2005, STRUCTURE, V13, P1173, DOI 10.1016/j.str.2005.04.018; Bernstein DA, 2004, P NATL ACAD SCI USA, V101, P8575, DOI 10.1073/pnas.0401331101; Bernstein DA, 2003, NUCLEIC ACIDS RES, V31, P2778, DOI 10.1093/nar/gkg376; Cox MM, 2005, NAT REV MICROBIOL, V3, P882, DOI 10.1038/nrmicro1264; Earl AM, 2002, J BACTERIOL, V184, P6216, DOI 10.1128/JB.184.22.6216-6224.2002; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Eggington JM, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-2; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Hegde SP, 1996, P NATL ACAD SCI USA, V93, P14468, DOI 10.1073/pnas.93.25.14468; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; Hu JS, 2005, P NATL ACAD SCI USA, V102, P18379, DOI 10.1073/pnas.0509380102; Ivancic-Bace I, 2005, J BACTERIOL, V187, P1350, DOI 10.1128/JB.187.4.1350-1356.2005; Janscak P, 2003, J MOL BIOL, V330, P29, DOI 10.1016/S0022-2836(03)00534-5; Kim JI, 2002, P NATL ACAD SCI USA, V99, P7917, DOI 10.1073/pnas.122218499; Kim JI, 2002, J BACTERIOL, V184, P1649, DOI 10.1128/JB.184.6.1649-1660.2002; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitayama S, 2000, MUTAT RES-DNA REPAIR, V461, P179, DOI 10.1016/S0921-8777(00)00044-6; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Lee BI, 2004, EMBO J, V23, P2029, DOI 10.1038/sj.emboj.7600222; Leiros I, 2005, EMBO J, V24, P906, DOI 10.1038/sj.emboj.7600582; Liu JL, 2004, J BIOL CHEM, V279, P42794, DOI 10.1074/jbc.M405008200; Liu Z, 1999, STRUCTURE, V7, P1557, DOI 10.1016/S0969-2126(00)88346-X; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; Makharashvili N, 2004, STRUCTURE, V12, P1881, DOI 10.1016/j.str.2004.08.006; Mehr IJ, 1998, MOL MICROBIOL, V30, P697, DOI 10.1046/j.1365-2958.1998.01089.x; Misra HS, 2006, MOL MICROBIOL, V59, P1308, DOI 10.1111/j.1365-2958.2005.05005.x; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Mullen JR, 2001, GENETICS, V157, P103; Mullen JR, 2000, GENETICS, V154, P1101; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Putnam CD, 2005, DNA REPAIR, V4, P1410, DOI 10.1016/j.dnarep.2005.08.007; Rajan R, 2004, J MOL BIOL, V344, P951, DOI 10.1016/j.jmb.2004.09.087; Sambrook J, 2001, MOL CLONING LAB MANU; Serkin CD, 1998, J BACTERIOL, V180, P1955, DOI 10.1128/JB.180.7.1955-1958.1998; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Wu L, 2005, EMBO J, V24, P2679, DOI 10.1038/sj.emboj.7600740; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	50	30	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12849	12857		10.1074/jbc.M600097200	http://dx.doi.org/10.1074/jbc.M600097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16531400	hybrid			2022-12-25	WOS:000237134700080
J	Klein, S; Franco, M; Chardin, P; Luton, F				Klein, S; Franco, M; Chardin, P; Luton, F			Role of the Arf6 GDP/GTP cycle and Arf6 GTPase-activating proteins in actin remodeling and intracellular transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR-1; TRANSITION-STATE ANALOG; EFFECTOR DOMAIN MUTANT; PLASMA-MEMBRANE; NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-D; CYTOSKELETON ORGANIZATION; CHOLERA-TOXIN; GAP; COMPLEX	We have analyzed both biochemically and functionally a series of Arf6 mutants, providing new insights into the molecular mode of action of the small G protein Arf6. First, by comparing a fast-cycling mutant (Arf6(T157N)) and a GTPase-deficient mutant (Arf6(Q67L)), we established the necessity for completion of the Arf6 GDP/GTP cycle for recycling of major histocompatibility complex molecules to the plasma membrane. Second, we found that aluminum fluoride (AlFx), known for inducing membrane protrusion in cells expressing exogenous wild-type Arf6, stabilized a functional wild-type Arf6 center dot AlFx center dot GTPase-activating protein (GAP) complex in vitro and in vivo. We also found that the tandem mutation Q37E/S38I prevented the binding of two Arf GAPs, but not the effector ARHGAP10, and blocked the formation of membrane protrusion and actin reorganization. Together, our results with AlFx and Arf6(Q37E/S38I) demonstrate the critical role of the Arf6 GAPs as effectors for Arf6-regulated actin cytoskeleton remodeling. Finally, competition experiments conducted in vivo suggest the existence of a membrane receptor for GDP-bound Arf6.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Luton, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, 660,Route Lucioles, F-06560 Valbonne, France.	luton@ipmc.cnrs.fr	Franco, Michel/ABH-4993-2020; FRANCO, michel/AAA-9735-2021; Luton, Frederic/N-7673-2017	Franco, Michel/0000-0003-1853-8661; 				Al-Awar O, 2000, MOL CELL BIOL, V20, P5998, DOI 10.1128/MCB.20.16.5998-6007.2000; Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Dubois T, 2005, NAT CELL BIOL, V7, P353, DOI 10.1038/ncb1244; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Gaschet J, 1999, J BIOL CHEM, V274, P20040, DOI 10.1074/jbc.274.28.20040; Haas AK, 2005, NAT CELL BIOL, V7, P887, DOI 10.1038/ncb1290; Hashimoto S, 2004, J BIOL CHEM, V279, P37677, DOI 10.1074/jbc.M404196200; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Honda A, 2005, J CELL BIOL, V168, P1039, DOI 10.1083/jcb.200409138; Jackson TR, 2000, J CELL BIOL, V151, P627, DOI 10.1083/jcb.151.3.627; Jones DH, 1999, BIOCHEM J, V341, P185, DOI 10.1042/0264-6021:3410185; Jovanovic OA, 2006, MOL BIOL CELL, V17, P327, DOI 10.1091/mbc.E05-06-0523; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Klein S, 2005, FEBS LETT, V579, P5741, DOI 10.1016/j.febslet.2005.09.055; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Liang JO, 1997, J BIOL CHEM, V272, P33001, DOI 10.1074/jbc.272.52.33001; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; Marshansky V, 1997, ELECTROPHORESIS, V18, P538, DOI 10.1002/elps.1150180334; Martinu L, 2004, MOL CELL BIOL, V24, P9752, DOI 10.1128/MCB.24.22.9752-9762.2004; Menetrey J, 2000, NAT STRUCT BIOL, V7, P466; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Nie ZZ, 2002, J BIOL CHEM, V277, P48965, DOI 10.1074/jbc.M202969200; Niedergang F, 2003, J CELL BIOL, V161, P1143, DOI 10.1083/jcb.200210069; Pasqualato S, 2001, EMBO REP, V2, P234, DOI 10.1093/embo-reports/kve043; Powelka AM, 2004, TRAFFIC, V5, P20, DOI 10.1111/j.1600-0854.2004.00150.x; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Randazzo PA, 2004, CELL SIGNAL, V16, P401, DOI 10.1016/j.cellsig.2003.09.012; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Sabe H, 2003, J BIOCHEM, V134, P485, DOI 10.1093/jb/mvg181; Santy LC, 2002, J BIOL CHEM, V277, P40185, DOI 10.1074/jbc.C200481200; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; STAM NJ, 1986, J IMMUNOL, V137, P2299; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Venkateswarlu K, 2004, J BIOL CHEM, V279, P6205, DOI 10.1074/jbc.C300482200; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Yang JS, 2002, J CELL BIOL, V159, P69, DOI 10.1083/jcb.200206015; Zhang CJ, 1998, J BIOL CHEM, V273, P19792, DOI 10.1074/jbc.273.31.19792; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	59	46	48	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12352	12361		10.1074/jbc.M601021200	http://dx.doi.org/10.1074/jbc.M601021200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16527809	hybrid			2022-12-25	WOS:000237134700020
J	Michael, IP; Pampalakis, G; Mikolajczyk, SD; Malm, J; Sotiropoulou, G; Diamandis, EP				Michael, IP; Pampalakis, G; Mikolajczyk, SD; Malm, J; Sotiropoulou, G; Diamandis, EP			Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLANDULAR KALLIKREIN; SERINE-PROTEASE; OVARIAN-CANCER; SEMENOGELIN-I; GENE FAMILY; SUBSTRATE-SPECIFICITY; BLOOD-COAGULATION; STRATUM-CORNEUM; PRO-PSA; PREDOMINANT PROTEIN	Human tissue kallikreins (hKs) are a family of fifteen serine proteases. Several lines of evidence suggest that hKs participate in proteolytic cascade pathways. Human kallikrein 5 (hK5) has trypsin-like activity, is able to self-activate, and is co-expressed in various tissues with other hKs. In this study, we examined the ability of hK5 to activate other hKs. By using synthetic heptapeptides that encompass the activation site of each kallikrein and recombinant pro-hKs, we demonstrated that hK5 is able to activate pro-hK2 and pro-hK3. We then showed that, following their activation, hK5 can internally cleave and deactivate hK2 and hK3. Given the predominant expression of hK2 and hK3 in the prostate, we examined the pathophysiological role of hK5 in this tissue. We studied the regulation of hK5 activity by cations (Zn2+, Ca2+, Mg2+, Na+, and K+) and citrate and showed that Zn2+ can efficiently inhibit hK5 activity at levels well below its normal concentration in the prostate. We also show that hK5 can degrade semenogelins I and II, the major components of the seminal clot. Semenogelins can reverse the inhibition of hK5 by Zn2+, providing a novel regulatory mechanism of its serine protease activity. hK5 is also able to internally cleave insulin-like growth factor-binding proteins 1, 2, 3, 4, and 5, but not 6, suggesting that it might be involved in prostate cancer progression through growth factor regulation. Our results uncover a kallikrein proteolytic cascade pathway in the prostate that participates in seminal clot liquefaction and probably in prostate cancer progression.	Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Beckman Coulter Inc, San Diego, CA 92121 USA; Univ Patras, Sch Hlth Sci, Dept Pharm, Patras 26500, Greece; Malmo Univ Hosp, Dept Lab Med, Univ Lund, Sect Clin Chem, SE-20502 Malmo, Sweden	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Beckman Coulter Inc.; University of Patras; Lund University; Skane University Hospital	Diamandis, EP (corresponding author), Mt Sinai Hosp, Dept Pathol & Lab Med, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	ediamandis@mtsinai.on.ca	Michael, Iacovos P/C-8695-2016	Michael, Iacovos P/0000-0001-7674-1233; Diamandis, Eleftherios/0000-0002-1589-820X				Bangma CH, 1997, J UROLOGY, V157, P544, DOI 10.1016/S0022-5347(01)65197-8; Bernett MJ, 2002, J BIOL CHEM, V277, P24562, DOI 10.1074/jbc.M202392200; BOOTH BA, 1996, AM J PHYSIOL, V271, P465; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Borgono CA, 2004, MOL CANCER RES, V2, P257; Brattsand M, 2005, J INVEST DERMATOL, V124, P198, DOI 10.1111/j.0022-202X.2004.23547.x; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; Bunn RC, 2003, TRENDS ENDOCRIN MET, V14, P176, DOI 10.1016/S1043-2760(03)00049-3; Chen ZX, 1997, J UROLOGY, V157, P2166, DOI 10.1016/S0022-5347(01)64704-9; CHRISTENSSON A, 1990, EUR J BIOCHEM, V194, P755, DOI 10.1111/j.1432-1033.1990.tb19466.x; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; Costello LC, 2004, PROSTATE CANCER P D, V7, P111, DOI 10.1038/sj.pcan.4500712; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAVIE EW, 1986, COLD SPRING HARB SYM, V51, P509, DOI 10.1101/SQB.1986.051.01.062; Denmeade SR, 2001, PROSTATE, V48, P122, DOI 10.1002/pros.1088; Diamandis EP, 2003, TUMOR BIOL, V24, P299, DOI 10.1159/000076462; Diamandis EP, 1998, TRENDS ENDOCRIN MET, V9, P310, DOI 10.1016/S1043-2760(98)00082-4; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Diamandis EP, 2002, CLIN CHEM, V48, P1198; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; HANSSON L, 1994, J BIOL CHEM, V269, P19420; Henricks WH, 1998, AM J CLIN PATHOL, V109, P533, DOI 10.1093/ajcp/109.5.533; Hsieh MC, 2000, BBA-PROTEIN STRUCT M, V1481, P75, DOI 10.1016/S0167-4838(00)00116-3; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Jonsson M, 2005, BIOCHEM J, V387, P447, DOI 10.1042/BJ20041424; KAVANAGH JP, 1985, J REPROD FERTIL, V75, P35; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim H, 2001, BRIT J CANCER, V84, P643, DOI 10.1054/bjoc.2000.1649; Kumar A, 1997, CANCER RES, V57, P3111; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; LILJA H, 1985, SCAND J CLIN LAB INV, V45, P635, DOI 10.3109/00365518509155271; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Lovgren J, 1999, EUR J BIOCHEM, V262, P781, DOI 10.1046/j.1432-1327.1999.00433.x; Lovgren J, 1999, EUR J BIOCHEM, V266, P1050, DOI 10.1046/j.1432-1327.1999.00946.x; Lovgren J, 1997, BIOCHEM BIOPH RES CO, V238, P549, DOI 10.1006/bbrc.1997.7333; Magklara A, 2003, BIOCHEM BIOPH RES CO, V307, P948, DOI 10.1016/S0006-291X(03)01271-3; Malm J, 1996, EUR J BIOCHEM, V238, P48, DOI 10.1111/j.1432-1033.1996.0048q.x; Malm J, 2000, PROSTATE, V45, P132, DOI 10.1002/1097-0045(20001001)45:2<132::AID-PROS7>3.0.CO;2-3; Matsumura M, 2005, PROSTATE, V62, P1, DOI 10.1002/pros.20101; Meyer A, 1997, INT J CANCER, V74, P630, DOI 10.1002/(SICI)1097-0215(19971219)74:6<630::AID-IJC13>3.0.CO;2-9; Michael IP, 2005, J BIOL CHEM, V280, P14628, DOI 10.1074/jbc.M408132200; Mikolajczyk SD, 1997, EUR J BIOCHEM, V246, P440, DOI 10.1111/j.1432-1033.1997.00440.x; NAITO K, 1991, J BIOL CHEM, V266, P7353; Obiezu CV, 2005, CANCER LETT, V224, P1, DOI 10.1016/j.canlet.2004.09.024; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; Pollak M, 1998, CANCER METAST REV, V17, P383, DOI 10.1023/A:1006154108619; Rehault S, 2001, EUR J BIOCHEM, V268, P2960, DOI 10.1046/j.1432-1327.2001.02185.x; Rishi I, 2003, APPL IMMUNOHISTO M M, V11, P253; Robert M, 1997, BIOCHEMISTRY-US, V36, P3811, DOI 10.1021/bi9626158; Robert M, 1999, CELL MOL LIFE SCI, V55, P944, DOI 10.1007/s000180050346; Rosenzweig SA, 2004, GROWTH HORM IGF RES, V14, P329, DOI 10.1016/j.ghir.2004.02.003; SENSABAUGH GF, 1990, J UROLOGY, V144, P1523, DOI 10.1016/S0022-5347(17)39790-2; Sotiropoulou G, 2003, ONCOL RES, V13, P381; Takayama TK, 2001, BIOCHEMISTRY-US, V40, P15341, DOI 10.1021/bi015775e; Takayama TK, 1997, J BIOL CHEM, V272, P21582, DOI 10.1074/jbc.272.34.21582; Takayama TK, 2001, BIOCHEMISTRY-US, V40, P1679, DOI 10.1021/bi002129r; WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166; Yousef GM, 2002, BIOL CHEM, V383, P1045, DOI 10.1515/BC.2002.113; Yousef GM, 2003, CANCER RES, V63, P3958; Yousef GM, 2003, CANCER RES, V63, P2223; Yousef GM, 2002, UROLOGY, V60, P714, DOI 10.1016/S0090-4295(02)01811-3; Yousef GM, 2002, PROSTATE, V51, P126, DOI 10.1002/pros.10067; Yousef GM, 2002, CLIN CHEM, V48, P1241; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zaichick V. Ye., 1997, International Urology and Nephrology, V29, P565, DOI 10.1007/BF02552202; Zaichick V. Ye, 1996, International Urology and Nephrology, V28, P687, DOI 10.1007/BF02552165; Zheng B, 1998, ENDOCRINOLOGY, V139, P1708, DOI 10.1210/endo.139.4.5945	69	99	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12743	12750		10.1074/jbc.M600326200	http://dx.doi.org/10.1074/jbc.M600326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16517595	hybrid			2022-12-25	WOS:000237134700067
J	Row, PE; Prior, IA; McCullough, J; Clague, MJ; Urbe, S				Row, PE; Prior, IA; McCullough, J; Clague, MJ; Urbe, S			The ubiquitin isopeptidase UBPY regulates endosomal ubiquitin dynamics and is essential for receptor down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; MEDIATES UBIQUITINATION; DEUBIQUITINATING ENZYME; BINDS UBIQUITIN; PROTEIN; HRS; COMPLEX; DOMAIN; MET; PATHWAY	UBPY is a ubiquitin-specific protease that can deubiquitinate monoubiquitinated receptor tyrosine kinases, as well as process Lys-48- and Lys-63-linked polyubiquitin to lower denomination forms in vitro. Catalytically inactive UBPY localizes to endosomes, which accumulate ubiquitinated proteins. We have explored the sequelae of short interfering RNA-mediated knockdown of UBPY. Global levels of ubiquitinated protein increase and ubiquitin accumulates on endosomes, although free ubiquitin levels are unchanged. UBPY-depleted cells have more and larger multivesicular endosomal structures that are frequently associated through extended contact areas, characterized by regularly spaced, electron-dense, bridging profiles. Degradation of acutely stimulated receptor tyrosine kinases, epidermal growth factor receptor and Met, is strongly inhibited in UBPY knockdown cells suggesting that UBPY function is essential for growth factor receptor down-regulation. In contrast, stability of the UBPY binding partner STAM is dramatically compromised in UBPY knockdown cells. The cellular functions of UBPY are complex but clearly distinct from those of the Lys-63-ubiquitin- specific protease, AMSH, with which it shares a binding site on the SH3 domain of STAM.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Urbe, S (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	urbe@liv.ac.uk	Clague, Michael J/A-7199-2008	Clague, Michael J/0000-0003-3355-9479; McCullough, John/0000-0001-6836-4394; Prior, Ian/0000-0002-4055-5161; Urbe, Sylvie/0000-0003-4735-9814	Wellcome Trust [074766] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bowers K, 2004, TRAFFIC, V5, P194, DOI 10.1111/j.1600-0854.2004.00169.x; Bowers K, 2006, J BIOL CHEM, V281, P5094, DOI 10.1074/jbc.M508632200; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Dupre S, 2004, BBA-MOL CELL RES, V1695, P89, DOI 10.1016/j.bbamcr.2004.09.024; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hartmann-Petersen R, 2003, FEBS LETT, V535, P77, DOI 10.1016/S0014-5793(02)03874-7; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Kanazawa C, 2003, BIOCHEM BIOPH RES CO, V309, P848, DOI 10.1016/j.bbrc.2003.08.078; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Katzmann DJ, 2004, MOL BIOL CELL, V15, P468, DOI 10.1091/mbc.E03-07-0473; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Luhtala N, 2004, J CELL BIOL, V166, P717, DOI 10.1083/jcb.200403139; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Row PE, 2005, BIOCHEM J, V389, P629, DOI 10.1042/BJ20050067; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759	39	188	191	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12618	12624		10.1074/jbc.M512615200	http://dx.doi.org/10.1074/jbc.M512615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16520378	hybrid			2022-12-25	WOS:000237134700052
J	Garcia, AD; Otero, J; Lebowitz, J; Schuck, P; Moss, B				Garcia, AD; Otero, J; Lebowitz, J; Schuck, P; Moss, B			Quaternary structure and cleavage specificity of a poxvirus Holliday junction resolvase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS-DNA; SIZE-DISTRIBUTION ANALYSIS; ESCHERICHIA-COLI; IN-VITRO; LINEAR MINICHROMOSOMES; CONCATEMER JUNCTIONS; RUVC PROTEIN; ANALYTICAL ULTRACENTRIFUGATION; SACCHAROMYCES-CEREVISIAE; HAIRPIN TERMINI	Recently, poxviruses were found to encode a protein with signature motifs present in the RuvC family of Holliday junction ( HJ) resolvases, which have a key role in homologous recombination in bacteria. The vaccinia virus homolog A22 specifically cleaved synthetic HJ DNA in vitro and was required for the in vivo resolution of viral DNA concatemers into unit-length genomes with hairpin telomeres. It was of interest to further characterize a poxvirus resolvase in view of the low sequence similarity with RuvC, the absence of virus-encoded RuvA and RuvB to interact with, and the different functions of the viral and bacterial resolvases. Because purified A22 aggregated severely, studies were carried out with maltose-binding protein fused to A22 as well as to RuvC. Using gel filtration, chemical cross-linking, analytical ultracentrifugation, and light scattering, we demonstrated that A22 and RuvC are homodimers in solution. Furthermore, the dimeric form of the resolvase associated with HJ DNA, presumably facilitating the symmetrical cleavage of such structures. Like RuvC, A22 symmetrically cleaved fixed HJ junctions as well as junctions allowing strand mobility. Unlike RuvC and other members of the family, however, the poxvirus enzyme exhibited little cleavage sequence specificity. Structural and enzymatic similarities of poxvirus, bacterial, and fungal mitochondrial HJ resolvases are consistent with their predicted evolutionary relationship based on sequence analysis. The absence of a homologous resolvase in mammalian cells makes these microbial enzymes excellent potential therapeutic targets.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; NIH, Div Bioengn & Phys Sci, Off Res Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	Moss, B (corresponding author), NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.	bmoss@nih.gov	Schuck, Peter/AAA-6888-2020	Schuck, Peter/0000-0002-8859-6966; Moss, Bernard/0000-0002-2154-8564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000307, ZIAAI000307] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485, Z01OD011081] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BAROUDY BM, 1982, COLD SPRING HARB SYM, V47, P723, DOI 10.1101/SQB.1983.047.01.083; BAROUDY BM, 1982, CELL, V28, P315, DOI 10.1016/0092-8674(82)90349-X; COLINAS RJ, 1990, VIROLOGY, V179, P267, DOI 10.1016/0042-6822(90)90295-3; Da Fonseca F, 2003, P NATL ACAD SCI USA, V100, P11291, DOI 10.1073/pnas.1534874100; DELANGE AM, 1987, J VIROL, V61, P1957, DOI 10.1128/JVI.61.6.1957-1963.1987; DELANGE AM, 1989, J VIROL, V63, P2437, DOI 10.1128/JVI.63.6.2437-2444.1989; DELANGE AM, 1986, J VIROL, V59, P249, DOI 10.1128/JVI.59.2.249-259.1986; DICKIE P, 1987, J MOL BIOL, V196, P541, DOI 10.1016/0022-2836(87)90031-3; Eggleston AK, 2000, J BIOL CHEM, V275, P26467, DOI 10.1074/jbc.M001496200; Garcia AD, 2000, P NATL ACAD SCI USA, V97, P8926, DOI 10.1073/pnas.150238697; Garcia AD, 2001, J VIROL, V75, P6460, DOI 10.1128/JVI.75.14.6460-6471.2001; GARON CF, 1978, P NATL ACAD SCI USA, V75, P4863, DOI 10.1073/pnas.75.10.4863; GESHELIN P, 1974, J MOL BIOL, V88, P785, DOI 10.1016/0022-2836(74)90399-4; Giraud-Panis MJE, 1998, J MOL BIOL, V278, P117, DOI 10.1006/jmbi.1998.1681; HU FQ, 1991, VIROLOGY, V181, P716, DOI 10.1016/0042-6822(91)90905-Q; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KERR SM, 1991, VIROLOGY, V180, P625, DOI 10.1016/0042-6822(91)90076-N; KERR SM, 1989, NUCLEIC ACIDS RES, V17, P9039, DOI 10.1093/nar/17.22.9039; KERR SM, 1991, EMBO J, V10, P4343, DOI 10.1002/j.1460-2075.1991.tb05012.x; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MERCHLINSKY M, 1989, J VIROL, V63, P1595, DOI 10.1128/JVI.63.4.1595-1603.1989; MERCHLINSKY M, 1988, J MOL BIOL, V199, P399, DOI 10.1016/0022-2836(88)90613-4; MERCHLINSKY M, 1990, J VIROL, V64, P3437, DOI 10.1128/JVI.64.7.3437-3446.1990; MERCHLINSKY M, 1989, J VIROL, V63, P4354, DOI 10.1128/JVI.63.10.4354-4361.1989; MERCHLINSKY M, 1986, CELL, V45, P879, DOI 10.1016/0092-8674(86)90562-3; MERCHLINSKY M, 1990, J VIROL, V64, P5029, DOI 10.1128/JVI.64.10.5029-5035.1990; MOSS B, 1996, POXVIRIDAE VIRUSES T, P2637; MOYER RW, 1981, CELL, V27, P391, DOI 10.1016/0092-8674(81)90422-0; Palaniyar N, 1999, J MOL BIOL, V287, P9, DOI 10.1006/jmbi.1999.2586; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; Schofield MJ, 1998, BIOCHEMISTRY-US, V37, P7733, DOI 10.1021/bi980399s; Schuck P, 1999, BIOPHYS J, V76, P2288, DOI 10.1016/S0006-3495(99)77384-4; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; Shah R, 1997, EMBO J, V16, P1464, DOI 10.1093/emboj/16.6.1464; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; Sharples GJ, 2001, MOL MICROBIOL, V39, P823, DOI 10.1046/j.1365-2958.2001.02284.x; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STUART D, 1992, J VIROL, V66, P1551, DOI 10.1128/JVI.66.3.1551-1563.1992; STUART D, 1991, J VIROL, V65, P61, DOI 10.1128/JVI.65.1.61-70.1991; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166; White MF, 1997, MOL CELL BIOL, V17, P6465, DOI 10.1128/MCB.17.11.6465	50	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11618	11626		10.1074/jbc.M600182200	http://dx.doi.org/10.1074/jbc.M600182200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16513635	hybrid			2022-12-25	WOS:000236988100025
